<SEC-DOCUMENT>0000059478-23-000082.txt : 20230222
<SEC-HEADER>0000059478-23-000082.hdr.sgml : 20230222
<ACCEPTANCE-DATETIME>20230222102653
ACCESSION NUMBER:		0000059478-23-000082
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		128
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230222
DATE AS OF CHANGE:		20230222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		23650996

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lly-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:ccabaa9f-f08b-4cef-8cc5-6b16fc2f1828,g:814ba434-7768-4150-bd97-753155d7ed58,d:909b702f7db044078a8e3e150503788d--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:lly="http://www.lilly.com/20221231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lly-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF80L2ZyYWc6MzZmZjcyNGU3NzkzNDAxYzljM2Y3NjAwZmE3ZTE0N2EvdGFibGU6N2Q0MWE4NDJlNzdlNGQ0ZWIzOGMxMzVmYjY0OTMxOWUvdGFibGVyYW5nZTo3ZDQxYTg0MmU3N2U0ZDRlYjM4YzEzNWZiNjQ5MzE5ZV8yLTEtMS0xLTE5NzE4Mg_94f5edce-4a9e-42e5-9535-c905ae220709">true</ix:nonNumeric><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF80L2ZyYWc6MzZmZjcyNGU3NzkzNDAxYzljM2Y3NjAwZmE3ZTE0N2EvdGFibGU6N2Q0MWE4NDJlNzdlNGQ0ZWIzOGMxMzVmYjY0OTMxOWUvdGFibGVyYW5nZTo3ZDQxYTg0MmU3N2U0ZDRlYjM4YzEzNWZiNjQ5MzE5ZV8zLTEtMS0xLTE5NzE4Mg_5e0da8b0-fc23-40bc-ad47-1179c84d6439">false</ix:nonNumeric><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF80L2ZyYWc6MzZmZjcyNGU3NzkzNDAxYzljM2Y3NjAwZmE3ZTE0N2EvdGFibGU6N2Q0MWE4NDJlNzdlNGQ0ZWIzOGMxMzVmYjY0OTMxOWUvdGFibGVyYW5nZTo3ZDQxYTg0MmU3N2U0ZDRlYjM4YzEzNWZiNjQ5MzE5ZV80LTEtMS0xLTE5NzE4Mg_b65041eb-e118-45a7-980b-7293f10dc0cd">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF80L2ZyYWc6MzZmZjcyNGU3NzkzNDAxYzljM2Y3NjAwZmE3ZTE0N2EvdGFibGU6N2Q0MWE4NDJlNzdlNGQ0ZWIzOGMxMzVmYjY0OTMxOWUvdGFibGVyYW5nZTo3ZDQxYTg0MmU3N2U0ZDRlYjM4YzEzNWZiNjQ5MzE5ZV81LTEtMS0xLTE5NzE4Mg_8508add8-21af-4214-a234-82fb7a576251">2022</ix:nonNumeric><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF80L2ZyYWc6MzZmZjcyNGU3NzkzNDAxYzljM2Y3NjAwZmE3ZTE0N2EvdGFibGU6N2Q0MWE4NDJlNzdlNGQ0ZWIzOGMxMzVmYjY0OTMxOWUvdGFibGVyYW5nZTo3ZDQxYTg0MmU3N2U0ZDRlYjM4YzEzNWZiNjQ5MzE5ZV82LTEtMS0xLTE5NzE4Mg_5d103170-3e9a-40cf-a7d2-1f22e6311b16">FY</ix:nonNumeric><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF80L2ZyYWc6MzZmZjcyNGU3NzkzNDAxYzljM2Y3NjAwZmE3ZTE0N2EvdGFibGU6N2Q0MWE4NDJlNzdlNGQ0ZWIzOGMxMzVmYjY0OTMxOWUvdGFibGVyYW5nZTo3ZDQxYTg0MmU3N2U0ZDRlYjM4YzEzNWZiNjQ5MzE5ZV83LTEtMS0xLTE5NzE4Mg_5921cbcd-8fb8-4ea5-a83b-349fe25e0d20">0000059478</ix:nonNumeric><ix:nonNumeric contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" name="us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2XzIxOTkwMjMyNTgzMTA_a65ace08-5ec6-44b7-98e1-20a4af3312ff">http://fasb.org/us-gaap/2022#RestructuringSettlementAndImpairmentProvisions</ix:nonNumeric><ix:nonNumeric contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" name="us-gaap:ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2XzIxOTkwMjMyNTgzMTA_b860e1a5-db44-4847-b689-049eb53e6544">http://fasb.org/us-gaap/2022#RestructuringSettlementAndImpairmentProvisions</ix:nonNumeric><ix:nonNumeric contextRef="i6b274ca23e0b42b29ed5c9770e8e2696_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzQ4OTk_d5717d76-4a43-4c49-bf30-1707e388a603">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ic6e3f53705dc4d19ba4af718a25d24c1_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzI3Mg_0bc998e4-b996-4544-9f0f-ef94e39f535f">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="ife049f03c96e47288db50605b1356b32_I20221231" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzktMC0xLTEtMTk3MTgy_8ddc8d02-9a67-4865-bc1c-83f42fdd1643">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lly-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0123f42da8014c4e80a496f4ec156d49_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6faa5dfbefd43faba61396886103e54_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7506ecec16a548918d36c633b7d2886f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74727aae65ec420f8d2a7d3f2fc82caa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b6679d8bf73400fb57c1d771b743b9f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd78f7ed1d134dcf8be4669929f8630d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ec7aad2a8d0401f82a878dda7a7a03e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icee8de005b2e49f9879377e478c0b2db_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625BritishPoundDenominatedNotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbdd41c0af48472b8577f5e8157441c2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62b9486903fe42cd82d7869cb7d772c4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bfa6ff0f0fa4248813d3e66ff3abdab_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if754bc01888f45ac8d951c81d205bc32_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i57c62c4ea2844c0e9a340732ae328cbc_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ife049f03c96e47288db50605b1356b32_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i356b319ab866417988ad019b9794d8cb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9021134b4fbc4e258ea850eb3c4c4c7b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a2f5f0abb434012bb2af32c10ddc89c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6870f7c27b5d40b09b8227c732a66406_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89c86fcc6d9848e19d2dcbf04813b652_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cfd19befed844bdbd1e65f027b7a2ec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b11cb527104470694b7931c221de577_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6964671a05464b22a4eb74dbbd4d79e7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i774298166b774d40bff6c0588b2f3c56_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b0c0c02225844c6b4ea5018b890387d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i375d8504588144e3bb7b25036361f87c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19f9560e8da24c70a901e8c074917400_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16cfc9ba4c614087a5a71a8d2a07e024_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia61f75ab6b7546e7a580ad9a5b93f8d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a274dc2077148a0b820a07f6dfed9f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7559b91ac864734b64c8cb3e513830a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf02933ba36a42cfbfedca3bc4a05dea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfab23ce152040e39f298e6d61067c78_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ae7226bbaa54a2bbab2e5672eb2325b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4862d64d1a0c4143be7faa33eecd5fae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if05c4645dada4161887047e966e0cacc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief070a1731ef4d1cbff5877950a5d572_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i641baa148fc94939a4e053beaf2b5f97_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44b2a1ce17cf4dcf80f4b720f9b9853c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a1511cc032b4cc28578302f22e2c378_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18e2767e0827495582d56de8c7445b9d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id08bbbd0c60b41d489ec1b27da14ee41_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5849b31083f849e0a1279866ce821c8d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d74411eaba3495eb1fb5b40272b8e0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f874e14a4254206a744a4d998b3e21e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9397c716ecc8492dbfa355270ffb58b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8898e7952db94e61a40bdb19eaf218e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4292c3a6efd4496b3c10175cfb14871_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64797ebd6cf24a2b83d33c497b3a79cc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03cb5dfdc26c46d3b41f02d740b93582_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadf0599f6d15415f8e902c9d74e9a82f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25b818086dc044f0bd310156d54327e0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib71f55d1f6214dbc90efad0d6e0c1bb4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i611da2eb6b9c4c8bb17a1786b533ae67_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i178450cc0eef447cab2a5bd78e323b88_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37f9e6a906424b848ddbd2a24ab91d95_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71b32db201354064b5cb0802d4c538dd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42001d8086bb49dda45b041109c50d00_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a6bea1aa20b446397b350ac2671efab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54accb4bb2b648519e8a5ddd0145dcb3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79b34353006b49229fc2d875ac767766_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68cf5a8007734a98a36e143a7305b0b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib66e8131e7a64596bd768a5869bc86ab_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ie555d2f92f6542cc95e629676af2b0dc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99575cf533c942e98caf27205363dccd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78dd629925fb4ae4a5093b5fc180b030_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08fdadf5ca3249bb9c4fb62f22fd5774_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09ca7f6b539b42c9bf6134ac1b709820_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c9c826fd2b347378c7aa9dfe51568b7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadec1e1743a24bc4aa16803f33246e23_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6618dd5b6c274f07b8f2d7da01455ae9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46e71ff65ed94973b8d1406f4b8985bd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3cb0bc9a28341368653294b04baaed1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c4252adafce48d88948c0f7b97ac340_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fd0e5a16356409e8036bedd277f4b6c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85cc049a60e14b52a4c0ca5ac603af8d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i688f1fee1d614afdae131948a26e41be_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99ecb99c796447d88385d69144bcd82c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3df9d79b482447198c448522c1b720b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0918ef1c05fb4f68ab4e15f2a8283a12_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbf827440e1c44ed9d4fa7f91748f0b5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4e5c7fafd8141999915cd2f615aaeb8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91192a23f0104c96a6b1188f603bb21a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a5b41d1ce604fd1b7157e4bb21a41c7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79ee633bf3254f18873fa97220a9dff2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibed6c41cdbc8431bac939f81410f22c9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i908ec847fcf64bb7913cbcb485ad4d96_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8129ef6df6f431e977d79c1b651ea70_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d1a32c39d7543c5bda93421375a60d8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4677e27f1be4111b8e4c3d118b419a1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ac4e905749940e0acc95a2b2b4d06c1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1429058ec4bd4a89b6ef2f638439c0e5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90ebccca38314b2b893a86d4df3e24ed_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i940a532a79364120a9f3635e0d2abcec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ee509ded6c2446891ec496e86228071_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i353b4ca1ec8545e29d12179593b5f304_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c31d4c6617549a6926ef9edc6b8d19d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0a89f71ff7840b2aee585821fdc79bb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6129a4ae188436e997eb164885bd944_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba2beed36c49496f8c05407dbded623c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf3a669814bf4e739636b5862a5a79d3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42a13a96ce9d4498957d2c9c70ac693b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie734d147b3a94c178e55911be7120159_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83a6a8aae9224f21a121e9d9db314173_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5838c7dc2be042b2a3ab858cf9b880e6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbedbb47344e4f2cb3b8765fa2aff470_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ed9fab22d754adeb11fb4fe998cb3a6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63f062d00a9b498abb19bb45e988b8a2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c28332273c24b679e3f1bb73cf7cc58_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c493cb7f8944bb2b545e0e6d00775bc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i625ee4d76d334362b8de4352af1b773d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia873c39e36f34f9880aa324b4f3c6b89_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5019cb5a09214868a6ffd5c421748740_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf887a499d9b4c1f9b06d18769bf3a1d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf2974bb2f68427da48e46d951d464e4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64eacb976de14569ac6ff1899c6605de_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6306f16596f249559125fb3a670c3326_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7b5bde978fc4056b0f67115cb95bdc1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a2a0156508b46d6a429156a9e507b0a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e04de56005e49cf9693a8f1a4d921b6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a158eedd1b1481995dd35bc68fea4dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie94ce0194f2a42f986e5b3f0d5e00c05_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9763e7d353848e4a659a5f54585d4a3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87c4deaeae714216a5ee408c78d2cf02_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie572e122731f4d66b7d209d9d838c85f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb2c52e8eea34a75a5e2f2b51206fa4b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb4fc43fe5434bd9b22e62377d8e4f20_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b43b7a7eb4a42ea96b75af06d3894fc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8fe6893994d4f3da2aed48164588249_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08d12e8f58234c72a009dbbd89e1ef87_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2045052682ee483d9ecaaf59cf44fdb5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i725c992052d041e192d4ee9a85e23fe8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6b37c5bfb894eb683d061c2663d2135_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0093b813b28435d89b38aaa707cb59a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i815000e020f14a53a097e53a2b56cf06_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d08de0a5b1a48e693777db50fe7ee4e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebb55033007f414c8fa01ecddd9bf258_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i436f39f0114a4a5b9a126d5a84fad158_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf01e8c322a64b3cb59c38b35cf69a28_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic463dd1900c549c09de91b07ab6ca276_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bc3a2798eef4b98bf1cda7f51dbb961_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34b6a251be9e4777827eee958db02629_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfa9bb0a325b4912942a0407bfd24c96_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7e2990f5e8845a191e0fb00304c2103_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cc3f43284394154b2281bd30b634ec5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96f6b8a0775b4507983b982add0eaa15_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i475b2a44ffaa4b3ab01390955fe7fb4e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e84d0c1a5604dc399d2032784a2c381_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1d59b98a2b84f41bcf716a679809aef_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47bf0038a1cf485685beffa18825039e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbe5cf54b9584a46ba3abe1a6a45520b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77bb27eccc6e416b96871a23917489a6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99feddef0f9d4b61ae8c11159fdbbed6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3881ed56ede64167839562a909065542_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4da626bf5e3e4942861f067702818432_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d4ae7d53fa74012826220f9d9aefec0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e5fa2fc32ec4622803f8565f86727be_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc6ab3bc43384429a45007709c2c734c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d903025752047dc8b7cdd55eb19a7ed_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb7822de8b36448bbb44fa84bf3d26b2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1dfa84e409446888abbc37fbcf675ba_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ec671c462234f09b93b6aebd0b48663_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ea2a5bdd3934abbababa751cef82703_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia800ee3300054be0a311fc0ded6756a4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i050aca7ad92848f7bce2d263075706f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedf81083b171427593695e6bf008b9ca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38d43d13cc4649cdb4b312a0c6e19672_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4403e2fd87d64f338b43367544717790_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5e9ce589b3341e59b661221502733d3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if37fae77f3fd48b39b0930752704bc6a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eceda29c176407a87bd531353a1c6e8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia87e1143e93f432785a964577b99cef5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20f5d0530c744df690ab8c031e4207b2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i760024cf4c2b4368ae467fa2e123ad6a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d7597d5af254ee68dee4515242f8889_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8399f74b1bdf46aeb1528d1b339e6322_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0ea5b089cf44e24b8e07841f4632655_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf3ddbf27f6d4e1f91bb0bb812805861_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib32eab706ca94218a617e1064dbc8ab2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4223c4a3b6f241dfb2bdcc2730d74722_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1e350402b214cd6a481e96fcc09dc2d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6e79e5873c04265ae9f72597e7f8655_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i657624079cc0470f8c99a900c86bb61e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8d7a484c7774a6fafe5d1a16b52d73c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bd0bb01de3b4defa7e5a43ea90f78fa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89ca17c8c8fa4a3c97af54a9338d556b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie11d2b1d901b4c59b9940a3eec5fac7e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bbf7ffff8d940379635573118d0f46d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb60edeed6364e088d8dbb6b15046831_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae608dbd9c8b41bba6dbf7a3b438fbf1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3072b728afd41dda5c1bc25d9a2f756_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4a1e442fced4165a82ae4740cb22603_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68b90bf218ec4f59bc626928cee0157a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0f6cf7efc0d4c7fa84a45bd8424a737_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17d469e38c5249c1b559efdd08d0b75f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8250de8fcc304ad3ba9fd98d5ffe1067_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaab72e5a9431446392b87064073da439_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaefaac168c674bd8bbaf0ba59c09b345_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8f82cf734df4f228c6ca91846be4abc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8b87668f0c34cfe8c41218fb3f7c47d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i140a6b9bf6b14209800b8ed52032d8f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9daf68a25164d62b1bb8bf1e3e52307_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1cc6ca8f8f148fbbce02f358ee33e7b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cbe097595924436a04ba8cc2a5d2e99_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib156c3b2d1414c94bf4093abcc3dafc8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33fca98fda4a48f79d860f14183ce7e3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie34501579b964c8abb3704d789d36cdb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77f2f9e5632a4e7c9163699499944509_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60c850a7c7894db69b4a040b6d233af0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d17a977fd83415c9e00512147086a44_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad01c8f917b44cacad101857ae82b796_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i027e5de11b114136913aecf0144ddbc2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0fafe92cc1347b5bc9f75c189771831_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8037b2d8309d4fb482c5ec2dedc8a023_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05b4f558633e4ea782159ade55b154e9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic41b44053bbf475aa1692687a86d75c8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a7fe42f8eac44919bbccc5a618cf3f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i785953ac34004786aaaaf3b2c864ba77_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32f96b235c0b43198bae6d8ec75f0a44_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife00cbd3aa774f1faba1231e784a9643_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib74ddbdf3df74b23b09907d3377b3d56_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bfddc1069524fcd8b6e480aa1ef27c3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6538ec30c43840a99b5e15dc4bcc8131_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b4a05b525764d80b2afbc012254fe88_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75c9e82d787c47c0bdb7e1e3d16ce5f4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if30607cf1ea84cf498de520dba0098c7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i698cd7cf5e334be397e08d1f53f737ab_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09c32552bbc74587b3fe07cd98986a93_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83ddfe09bcd8407bab751faee3cfa0bf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i322d3171da864966aedc55c9b681518f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5621221cf9f34eef9b9959e16714579c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0247f0ebdb344b409d4ad90e21eedad1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib15d3cae66954118a6d0296e4d23df93_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if841f2a4ceaf4fe58f4697466e041316_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8429e0edc9214436aaddaab1bcaeb6b9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e963233c54e48a888c15bcf4c23ffde_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cfffcec45ae40fb8465dac10b22a976_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7501982382a4a88bbc9f7e3e3e85161_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dd637301dfb459db236d29c1bcf0177_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77b859afefa6475bbb5c098a0f192a8d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i061bb5f86557438ea2fcf07c86b17b69_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45698e97012941fdb7ec2890f67c1c66_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24ef4fbd510845ce85f4028d457ed43c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2762e4d8c5664efd8b887ca758f9b9c4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74331b3977d84386b77d2682b2d47eb2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8f45af4cef54b1ca2871b3cd9a01e27_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b7a565db26f4dbaaefe0953a8a80479_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia31a0ff6d06240dda20f93d85ba7a1b0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if85eef2cfec74cb1a86907d6bcafb6ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i958d4fe65ef3466d9c1b806dc825fd05_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71acdff4e8334d96837f9b23f9643937_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff78a5e546e044469bcb8ddfffc41863_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02714f6a0b344ffaabb940f97f9422bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a75711b53cf4bd4854c933fc91f0554_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0deffb51001949c4bd36158c98e3df90_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12173600f90244fa8c910b03b4b7685b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a9c8e37f3254306908fbf67a57a962f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c655ff0b6734b1b895917ead0f1d0bc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib57a805732c14379adc9748655cc8c8a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5231cf59d554630ab8ee2ab6a543866_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06358e5e2c9543f9b4d8af95e8fbee1a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie66a1354c46c40fd8326cd7ee4fa99c1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e3a4aa6df1d471499e619affd59a81c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2d92d62baf647fba64657e6da2c5cc7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0743faca88f49c9a9a69941934ee01a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb29b5e537384747850aedf57eea8ac5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if04be40612da46cd8c72bcf49f6acda6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6d44e44e5ef4e85b17fd98791ed3f74_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a19b43d72264c28838a978d205164c4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i864722d9b52d4c70b0ca7b1f3f30b98b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id79c2882668a445497ebd9d63d0e6b0f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c2193c6723347899232bf1d50d961c5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie596f23aada14611bc47697f70b8e788_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb22934230f849698cd861bdcfad137e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1be2a9f3e7684d60a8f1c56366cb8f4f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26f622dfdd764d8da1a4d607b1b94085_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd3aa04d3e924b2ebf2ea8e693f3b76c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bfc2608a4d84b308f03c62f86081700_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24ac34b561704aaf9cdc8cf15d9421c4_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="right"><xbrli:measure>lly:right</xbrli:measure></xbrli:unit><xbrli:context id="iceb5a7f2472e4bb0a0f8c4fe22cd2d24_I20221201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic28ae7a6137047c1a086087e77b37fc7_D20221201-20221201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bbccb3f78b34d48a0c51e4a8de0644e_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeb47b42169c4a378f20a2bb7a0d88f6_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79e8bd3a88dd451697bfede1f38f914c_I20210122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i592f678cd37f48ac8b0d09a457ed8878_D20210122-20210122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-22</xbrli:startDate><xbrli:endDate>2021-01-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i911ffcfb85b543048b73c602e046f88a_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57500d6d00fa48b2a37e2a728d955386_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22bda1e261ac4b2488c77f767678e525_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:BioMarinPharmaceuticalIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb08a5c1f49e4f2990ebe8463033cbeb_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:FoghornTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0973cb0fd694b219690663eb984716f_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:RigelPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81d67d91f47b4d55acc7e70b5b593208_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PrecisionBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4554cea5b47540518c88b975dda8a988_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76b78baacb0a4d53bbd37d9f5f91b297_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PetraPharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdaaf6c7f8004c49b4ff53eb161a0b68_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:DisarmTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib72f8530223f4b8b9206e3912e939d05_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3307f82bfdc14dd5a7869a1f5a407fe3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6382df2fed0453f9d14c9ca82bc5c85_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b54345933e846e39cc3f792be5b88ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i191cd21724a847a1ab7b4f35246862d4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i485f72de6db64da1bfe2334d8014678b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93deb0a502fc4527a3920971ba7c2c0f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95a63cfe221f41ebba6cd651af9ddf9b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ea327d1c37d4bfca7f2723b4565f151_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb1a49e986754a4593a59e0e5166de8d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac449f4acefe4dc984d41cb41455bae6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib09d7cfc9f57482cacbac86586144b4f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i540e1253ab844a0bbc43a8cfb3ee0920_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadfe8a33be5c4ba7afa22a73eed9d5ef_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c91f4e2d9c840879cf9a65000a09847_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81b687c200704d14b8cd74e649ddccdc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1f7f5218520412cb6fd499f49c829c4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69ac6765ad604943bedfef80dbb59046_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0b97a2e15744cdfa799e948994a62f0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb5d7e7fe6df47d69da986515824156b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39d7234845174224b663942a5c72f5c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36f40f8db5514b028a508fdf20bcd89f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f3dc4d892d343b49ec303ecaf36d9bd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc949a713d77433c984ccf27f4feda59_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cb32af28a4d439d8eae4393101c3901_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5000c09e5ee64486a770c6f98d826b1f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i841f858d8d814afcbb33413461967380_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1b1742cf89b4c1fb470b6fea7034191_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11abecbd539d44bca9891ae6f43a6b9d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i340330379c1b4d17a5d1893688ec0953_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7796b711e49341dab27420fbab5beae5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88b5d5e3acab4840b3a4b0c187d24ff5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2046b6b3eed4ac6b751298dc54b230f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85739ca7c6b04f86b9f0f4e04dac3933_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c6d39fa7dff407a9bb5b5c2e98c8f37_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if819ebce2b824e4f956b1fc03a244870_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d41b93e38c04495a8c9e35a8f93a51b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a6cadf85ae74e19b0b4b3d94566c950_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib29cb4f6b7524096a38ea003c862f821_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e73f160e8f04f4eaddf6e0c2226046d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cc4f4f8668840918ffb5f33a50164aa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83db6edf74c94f7dbe7af9c3b57e71cd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96a991509ebf43809a439058ce22fa7e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf3de48b5cde4b74bd86492c49a3cfff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab0fa37d1d26458698fec203c6de3170_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b78ecf596654f379406da98609085ad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e65c1e9f8314c05bb18488e182dcdc8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c6b6db44fad4227b0e7923dd144dad5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i267eeb3d4c4544ed98a8e040d42e3659_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie08ea2826b404bb1b32d7612d132d1fc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4360dfda4bcd4ae8aacb3842d8b38544_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecdb9bef83534c1ca768e9eb267d15fb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd68026d385248dc99ec6cebbbcf4fe0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8623252cacd94e8eacc974d3c5bb281a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3b93d9016f347f7a42304dbc2662cbf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7745ed8eaec4896a79398bf44e3ee0c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2c6931fe5d44a29a69a4915f25c3aa3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e449ba54e0f4910991f72fc6586c372_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i202f70807f944a99b3c4a8546c4c57b6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96434fbfa57540c3bf2a773a2c2ff46e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc245c7e9eab4641886b085a802fcb71_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic744f4b830ac467eb5deba8b1de59644_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09eaf08a82294887bec59eec2190dd1e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0b4fd6680c24327b70dbadbcdab8d00_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c609093db884ac09f9b0f30051477e4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3257f473d8d344f2a056bb2771c42f6e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43ea231ef1224a80971a531780a87b35_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31f61c2016124d9faff9cfc9175c8e0b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa948220bcab4ce3b0bd4520c7b48b28_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica209a2bd9434d09b84c0795cb110ef9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecb3faf84ac344d18fad6aa15881f6ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87a3049207dd433897dc2049c4a35614_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97d710d13dea404c9c76ca03cfd32cae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fb8d947138d48f4ba4234d90a755569_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id93e165c23a14eb4848c3cfac9842a39_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide566100c19446ef9e02ffe6729e317a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i206922eb76584eceb418d0469c699ef1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a592b428bb4466ca49b8ab98ac79c2f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie77fee34bd8143b9865e1a7ce56ae13b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cb09673cd4d4a51aeae0a4b4fad802f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idec2713ca1764f9984742765f2a3f5f6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ef264a2971a4d6d9632968955a88874_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67745cb3a266420caea7e92585afd798_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1d701e8a7d846deb5dfed51dc19420e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e3bd9c97de44684a6f54ff2b763dce6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6543e2dc57fc4942a80a5c4b47c6a4d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbf3bc2cf6f14b3e986aed5486e859be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c7e6db0a0f342f38f0da6050795d81e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70d18d4fe82d4e3799255211fdb7c961_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e527334606a4f5cb5eb429d7720b579_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21be69bc53c046e5bc04d738798632b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00463fe56920430aa066d2ecd7dce5ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc6345dbf99e4b10a664854739c10ab7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09d53a5267d54e38ab69be8d99e1a128_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i791959b335d9411682c43bc9a3d30863_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1424fba935ab49b1bca8d99d589337e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i995cc780a15a4e11a297abb46a4670e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if923bd42b75741279230d2a8db22bf73_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie18586de026d4b76ac4be48157ae8d1d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i630ee0edbef7428faf2976f9c169689f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66776fea49f94b9a845efebd8dc9043a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dd7f0aa7ba940b4871022bad3341f93_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefd7992238674ff3901e725d12b4b20f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40df2b9b5ee34ab0aa3950d2139dfd76_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea1803ebd97a4e4f87e68572966755b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0d644ad67b64ed896bb8c35759604a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i065e0d87c04c401fae0f22c40bf7957c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id97791b6d6d4420180779511ef340d85_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9a5c2ba711e441db5517f030cff4003_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i114748072ce44e029035eb08efa37d1f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i825718d9a8af4d88a0b8aa9db37556e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83265c7960c34844bb2725361d24deba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i869fd0d7109b41d4815c68ea3a46ebac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8bae18362b342449e21722305a0c0ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67b95f772703429a8a0357ffd550d665_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id72a1c59b3e84bdabceb3740c94a39b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia286896d0b5e4e60be5600fdf1b2b12e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5351b4419e648ebbac325c9a8f25776_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97a76897f7614783bbc3b95171430289_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08786343c67b4a868c5253051cd773cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0f4d070f3f34eacab1aaebe39cae662_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4762367938c14cfca0c24d191f73550c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e291e2320cd48a3aa360f816a7fed28_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib49d1436b4674f92b884ce9b352c35d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68ab827622544f9ea9120e5ce5dd8bab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7a8b848d1d8427c890edfad8cc5f8cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc8331fd4f1147f4992919b2c03cbd9c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7cfbaeb1387403689ac26389c2117c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6613a24a2ca74795845a7f065003a508_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86203110a3b4409f801853ea6da76a28_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05a9e0f210644523adfae49f8876648c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1ea8deb8e384d8cb4e5f60294c5ed92_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19b69bc057c7444085abf4374f69f116_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedff9c53d09a4160b981746e70812997_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b78813a7f544e37b44ae5f03d274d1e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7159491c93374658b5b5847e6ac5edf6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9001871d7424666bd9d0957d8242b6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab54aa3b8b47409280b75c28d3043c2f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1028e48517574b909d8fcf57e1818f87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39ef4f84d9484b978fdf61e96ab0edaa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie250a0992fc5431f969a7964f8245fdc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUsdSellEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i7e9395f4903c4d1e8256befb608125af_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyEuroSellUsDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ea07b15fab64564acb30e6db85e870e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSDollarSellChineseYuanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cny"><xbrli:measure>iso4217:CNY</xbrli:measure></xbrli:unit><xbrli:context id="i94c6020cd3ae44f998a4fa76cd815d56_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyJapaneseYenSellUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:context id="iceee439d84744b8d804526bc0f2adeab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSdollarSellJapaneseYenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e20eef33fbc4dec93f944ed6836a620_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyGBPSellUSDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i61a09d5cb8a14ccea8468a476ea53884_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuySwissFrancSellUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="chf"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit><xbrli:context id="ibf02b938757d412587be87a02a84f028_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd3cce905838492e986c48f76166193c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4778e0d847b8442d93aeec9ae0fcc5af_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapUSDollarsToEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cef174a144b4c2b89d92be601c8cc4f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapSwissFrancsToU.S.DollarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6c65f3c28a542199950c644aa1cf261_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SellEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f3aff17db1c4acb85c8851f9450065d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SellChineseYuanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia85b3dcb7d4541c7aad67c44e3261dea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21e6e625c3cb4498ba3bf6924f8d2408_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7662cc39cfe4433b0594d699b335670_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6798f46f87f74360b20909f04395afc3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbbe46ca06b34c009dcda97ccf3beb64_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if399b1d939d243708da92494b6325f95_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cdf044d78494e7694b33040bfab47e7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e9fe4a4a4094271b4b30ac4a4625c89_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i912fb880c8bf46f58edb6cd6fdf00e0d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i971ee4b6404c4ed885962afd497cc6c4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af19dae3f054b648cdca7471fa01367_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fa81b5097b2466db639a8a9b4205905_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a1804ba514d421fa041c53b09e064df_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i544fc2f9696049b4b7cbe0345f8fde19_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i526dbe18caa14f808c563a07c118fdec_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ad852d92b9f48d787f3e17319eca10c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb73f5b531de4d949faf24baf79a438d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i813ae3ce219c4fb99714b7ffced341ac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a07487d016f4962ae2b2023e270baed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie637e63779d34f95ab0e1211537d3d90_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3222ddf3a8ac4302b584f8b59946a14b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic146904e7a5d4de8860196733919670c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ace96eae50846258f2aa585eca6aab7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie36116f601d041c795e77b729ac2bd12_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ecf981515d64142ae2c545ec8473910_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5197ef213a4645978df5f719742ae403_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50e4a751923845029648d84b7970c686_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife02be8abfd44063a559e3b91d3451e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96ba97b94ac14d2785bd7fa84c035ba6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f476c609f70478db4f2ecd35dc8eb68_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22c86b90cca74ee28587fd7b463de73e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8155874edc7f4d55bd1452edf423993c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36992cb2187547dfa9f7e206d125f62d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2840be8f4a94f848fa12213edee040f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8790eb3b0704b11bbbdffca311b63b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36c4a0d2b7e245eabd1f07bf17e8efea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c71c6fa987a4120a284c9b9145e27e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b33940746b24ac0b52755c11e6154f0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5b2741087f34d8badb76a8ebcb2b3fd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b1936dd4cad4f59a9112c82012622aa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic11c3f50a6ad41aaaa6ec682a1a2bf69_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32517cdb203a46dbb43f88560fafdc6e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i233ef483a0f64f039b86216aee108bfa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a806ed2d9564a57a182b6ed0c5fe28f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ea6da8b55e34d8189b756c1edd72ca2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52cdc2ce968e46748102e49a49b2747c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5626e89be6054126b0e88da30ec22edb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76ad9553f0574ea0869f164b30ead95a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie253e8109f6b4b66b779831838983108_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eb0b46018c54f5c946184e340c3804d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5172caf5b4c745e49a779865e4df8b6d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e87bdf692d44f63b49e30cb351f8be1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2277951e04244daea0a2517c6b972ce4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i177a13f9ceb04b04ac9f5de0f3c10743_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1960642f8dbc465babdbb93b28ddece6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia14954f687c6405ab00a4364d579fd9a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i588da95a877d48e8954f17fe68f586a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96d7fb6d960d43a18ef69089fff51e0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0180c6864ed746a8b3d870461649834a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia760ea075df24dcfa76244f5eb52e815_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id945978cb9e34780a08b5b17c28c3dae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i377eee7df67949f38f58d5844a15b18c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4ba21050cbf4b33a8dce7b1f2a8fba8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15f875e3e2144b5391ee55f902226825_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b5c16eeb8a64c579a2fa0a33daa5b36_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i314c0f6b364b4833a2bf7dc6a7d484ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64c6a536ce224bd0a7d1bacbad4b9f82_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85bddc6b22b045908bcc27ca039aa3f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i233603743e32403cba2427b98f94cd71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb4bb153c0824966869a2e351056f2e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cd010e314334386addf3e1c41d3fba9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc2482a53a724280953dce9975c1774d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2d3bf8b263f4308af9996212c4ea414_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia46188499bcd4b979e789d0ac42002c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i863c16ddfefc491d81ad6914ccd53e60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80d6f9b361384095856711315cacf141_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefe9492781434d5eb9e61902a0768540_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aabc6919dd54de293fd5ab586ac3010_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19ce6f75fe844b619eed1f83ac0c0e45_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i039334735ea6463da706b51515b478f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i024cb51bbd8f473892a3c8c4eb2d1047_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ffb9e56119443489f2dea0c32378917_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc9330205fa247e0a9d3b8796fe79d3e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10d20920da5045eaa6a64364e50740b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78739e5e4dd447ee99f90605c73e27ac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1a89a2666b74590bf74ff22f798d881_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b274ca23e0b42b29ed5c9770e8e2696_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb1db2575cf945c4b53c0b1c6bcbffc0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84043b4b737545c9b8356075843761af_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc25faf9338644178cb1e8c7d5454052_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6e3f53705dc4d19ba4af718a25d24c1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c90a1dfddcc4a0b8f2e9d9ade98f0f7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdc99a357f5645e68fea63babcf6e1a1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:UNITEDSTATESAndPUERTORICOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23db86fa8b8e464f9ab3b7f022c25c05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:UNITEDSTATESAndPUERTORICOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eff6ba2e6fb4744acc735827cfe6e99_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idef4bb393b97493c912842acdbb55c84_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf3c5f0215ae42afafbd93e42ab13afc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cd853d454b54902b5326960dc6dae46_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7296a85c804344a4b823ccbd1579e425_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A235NotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74a66519f1704bd5891f02b44669f2ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A235NotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafbbc254a62f477095aad8da1c3c29cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A30NotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49ed564e316641a190e2ea5bc0d13358_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A30NotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cb67bf176ed48d699fda531feb23c5c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A10EuroDenominatedNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieee67ef519a14645b909c395101668dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A10EuroDenominatedNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic91bf59cc87d4b018a72edb84c344f75_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A015SwissFrancDenominatedNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c45ef9bd50d43fd98a3d77dab23bf12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A015SwissFrancDenominatedNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61abf79406074265841d9e59afd0b927_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A7125NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab38c12183ba4ea08deb88ed706456ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A7125NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b3c6352b0e54655905b05316d9d6f6e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A275NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7460ec1a2ce645628f9b4950c383a2e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A275NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if91ad0b4d0f445169909fc587ad4be66_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625EuroDenominatedNotesDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia43db658a17f4423b0dfd76ce053a30a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625EuroDenominatedNotesDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26c8536d6b204e03856812446168bceb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A55NotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i674e9d0712e3435bb2d0ecdf73d1e2f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A55NotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f1a3b951bfe4ef2a9d50583c4bbd77c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A31NotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e1618d7d24c48259896e1e2026a0aed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A31NotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87bad62899d149bdaac599617b653af1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A045SwissFrancDenominatedNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i933751a82f6445a3b8dcbd93c8fc716a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A045SwissFrancDenominatedNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08a6834348314addb7e7dc8a7a6dfac1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia61b26c361d64e2b848451ac3c78f961_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie374eb8422b44d6781dd2c7369a9bbe9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A42YenDenominatedNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53bdc5a3a83441b19c9683bb0db20458_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A42YenDenominatedNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19faddcfa3a6449f9e5d54d4c7cc0a5d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A2125EuroDenominatedNotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20625f40121146dbbad262af55cd252c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A2125EuroDenominatedNotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aa8cf85cde34e54833cd650ef5410b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A625EuroDenominatedNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7f6d19c2b7d422585182914ccfc57a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A625EuroDenominatedNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8db52983c5fb45929449da08901ec208_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4811598343304ab1a6ac92a4d4384082_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i525c05f6af404e8e88124f226b94e2ce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A56YenDenominatedNotesDue2034Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58706ae52cd04d5787f689decd555c79_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A56YenDenominatedNotesDue2034Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62868cd48e734ea186f9dbc3ddc52276_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A677NotesDue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i039f506220b44e9b92088ddadae4d438_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A677NotesDue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia861290fae084d9dad2fa74b54a93f61_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A555NotesDue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0f1ac1cc9084ecbb7ec146e7a0ecf59_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A555NotesDue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08e38bce3a2645658e249867cecec63c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A595NotesDue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1a7b88a64384880b61cf8aa84d05774_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A595NotesDue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0343f767507d45eeae7ccb730acb9974_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3875NotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9ce6e78973845499d30563930a6453b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3875NotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieed40c2fbef84f74b11d5910f62ad4eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625BritishPoundDenominatedNotesDue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f3c74be38f245b8b6ed35611a69d273_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625BritishPoundDenominatedNotesDue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54e0e0101a7841daae4f2106284daf1d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A465NotesDue2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d2c94e9725b44148fcdb6193e2870fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A465NotesDue2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeb8b7e9ed7a49e49e94f6af00648190_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A37NotesDue2045Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea58f3bd452e4a36842dd6ec45db98a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A37NotesDue2045Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea465f0f6ff843b3ae0b1c8b37cd87ef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2047Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59316aeff65f444fa246fc62593bfeef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2047Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41a65a471c734c42a6d546c096e16d1b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd3a46888e13415cb278b164998a5c33_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfc0c52db55940be9c4b62d052da668e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A17EuroDenominatedNotesDue2049Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeb85aea19744a2ab1f156a41e098a53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A17EuroDenominatedNotesDue2049Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdba7d3f60f347eca7dbb1d8296ddcdc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A97YenDenominatedNotesDue2049Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c07500c2b6f4b61a48ebb178947c8db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A97YenDenominatedNotesDue2049Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06e56a449d7e46f5a50fe0e1d8d8f32b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i867cfd6e85ca49dc8bc5f47a7e85af14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e986ddd3ce54fd1b852b00b58b6aa8c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fbb357599024d59874aed080c948903_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60c6d92c70bb4827b8d11ed6c2927a17_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ed86b00b5854fb5ad549409205591d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedd1c12277a041ab81c0a54878416b3c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A25NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id73e022a19034845867e9f0ce636e37e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A25NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58f74fa5874e4bab94a1ead5e6fd1e49_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fffe809d4dc437bbf367bdf220199fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbbad28b34b342babe4bf7cc2a5134cb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb7eeafef488487ca857290e624770bd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c779efd9f6c4ddea6602f310141dc09_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b321af1dafc43ccbaeaa9699581dab7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57ce917b0f0c422ca61e881f3f692344_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a5e0b9bc64e491cb66aa141907b7e5c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i451dcfd995634628a4d966f35c25b82c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625BritishPoundDenominatedNotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b24bd1f49ea4586a8301239a10ac27e_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c474d66fd4941be8ee1af7f8bc945a2_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i341d1442ad9c4796ad0ad6233bebae92_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied580748898946bdaf1108b103303bdd_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b7e5b5013ea482e858c341d9431d76f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9ac3bd2cc2c4fb7844518c2ea52b6ed_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e29d24af5de402499fe4ebe60451143_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdbadac98c4141e0b7b6c55a77240061_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6441fa6a78ef4e12b30986772baa1b26_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06c599f0bde9445fa16d1cc4feb31a6f_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A25NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a93a3c5ae824553bbd8a41bbef49dbb_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0163626092d4db6b26a6af6487a4108_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:SeniorNotesDueMay2050AndSeptember2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34e736a6ca514f689eb35288b8ec7b70_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id89b274231544b368ef56d599d8e67f0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e110f0e24e249d59282a44ccaa3721e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie786c6b1fada4a3dbc69ad548931dec2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03b05f63c9574af38cc3b218f3d7f04c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i171e2f5cc14f445bbc2e02aa39c75b98_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide30b7bea6124a16bed5fd85591c653f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34c6e2fee53c4d53a400e54ee5da855d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:RelativeValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9f12c5407404719932a1a7e44769cdb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:RelativeValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4ee98787c674df09daac84147aa1690_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:RelativeValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5945a2c316d46c8a331422ade10498d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:RelativeValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia611d9892499421694f697dc5c368ddb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c55e65384854a888970465b0818f479_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27e6f36ed2b84f35a058e35522e9b351_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbf91d3e9e6846ab8570536827522ece_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf5b57373be441b6bfebc18bd3f1612c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">lly:May2021ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15d3684123a54cc4bc7e71a64f370060_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">lly:May2021ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89d3a6dd2c454e45a2881b0daf36f171_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:CarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibac57721c29548ee93eb53c76de5151c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:ExpirationBy2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e25213daac34fafad0267f51e54ab7e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:ExpirationBetween2028And2042Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i652bcd633d9e4b988a731c9c680da3b1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b497353dce84fff8af5126132c7d5aa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aaea1c0c5f449f78c245961a000b0ae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e1fc18a41da4a52b4f290bd30b05e25_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:ExpirationBy2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38c21f98a7ad430e92e87e091c5eebdb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:NoExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i057f9a4808af4123bcdfdc6c3301e04b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d98baaa405f4230aa08556aee4f87ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i125b075ff711498b8733b378408d98e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if520336c52c54904ba5808790e7ec324_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c073455f233450ea6806f68e460a7bc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97e3f341714546fea22d7415bf7423fc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad4ae6cfb47049b5bd782e22f164d8b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a0874db15724bfb8216d84461801c57_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia316b6b7c534488da162855e12856aee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if80d17ed3d7341139c95e570648359b1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a731db9bce5491f98e9d3db25b05e57_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01910d1722ed432eac20033caa81d3e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib43d57949131458885d98c8a93ecc8ff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9058615b4dac4d84a46d1a194938b1d0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1210e6088eb043d5b57234e2c04d5495_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i304ba8d5a46e4918b1388a3aa5a0d641_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d88291b946e4fada2d92e7be0e6c4ca_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08f9dd15c5264811a0adf0cd5ddbcd70_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf36ffdc2a634608b0576bc6c10d74a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie67f316541574a54a1c5e224c4068a84_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8597a970d914e7eac33966ec50e2e45_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aa3bc29c31c46e9841c05765cc07cbb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f741744892048f79ba678614ab460e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id53867d3f4f742a7a401891b83a35ccf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8d9e90e67b644c1b7eb36d3e839d86c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63893449a2d84076a10449b426a8a463_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcb0e523afe1433d98caca75025ecee4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09007bccf7314e778accdfc89455e47b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if606ee97c9704abab603056e8b0edf59_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabe7285b3fc24407971675b7ceb932de_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3749025b65a24fee9b938b61605247bd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i646d525b330b4affbcc9bcbad3171961_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5111829abe1472899906644ebdadd1d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7453fa11715a4896b1ff0f0ff5f09c00_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i512f904a58b2427780f61c85d1dd6a60_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e8af31081da45808fbffb31cff06d39_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97fa38adcb92459287110b63f86477a0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia76c0aca32f2426babb3ee042aaa4e38_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60107ebc9335412ca6f1bd84bb68da84_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3068b14ed0e644b6a479187e62d04177_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0de112ae15004511bf9407f3cf72d975_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09a2d55b1e1c44d2871d456003ef7230_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic04e46f294ce4c0fb14fa8b921ae66cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c1c27297ae64abdb64c978fa594cbaa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba64a2ba2ee54c4d8ce53c70040e9ff0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib078fa49932d485e98c330eba8129f3c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b15966785264fd6be87c35ad8b78710_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if24ea8f19b4a4e008be14e1cb7ea857b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea985983bda74c2b82efe6e81f782028_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6bce240b92c4b78a32086372012e86c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9076ad0d4db44a508631c37b130697de_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfe24bf9e81d43ec9e96c7d669380b3c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i686e8ff5c4a8496da94e3e68008b4845_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i343ea5fd96b643009c59bf6456fe7731_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6e300f5e5754a95992494e35bb4fad2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i580abbf76b7b4f58b638cef09a78edb0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbf22e6860aa4abdaf439b706e4a6866_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc86bd5686bc4e3badb3c7e166fac6f4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0ff8e7d4cbb47789b98e55ac9b9b579_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57b56107f1e043c1a3ad9569212ecacb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebe855aa68c84719bddaf01cf7d20e04_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b0a212192da4a3395f2bbeacd3c312f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f2751d7d37f4b76ad3b2e86c47f4de3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b541896dac543b49b5eb351edb80e69_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5150947e1ab4960a30b20610ac83cff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c5b75e2b27940d7bb2d6260640d34c3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5a9db5d280b4dc4bfdd26c9e650a29c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bcf9c01534f47bea99586f19a3f1740_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00e53324a4a84c8dae1e489c5b3ca7f8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dd2dddf24274ba4b7eaca5d40b7c7db_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id68a32c29c1344a8a0b3ed2942d12fcb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aecc4a27cff4b94aaf8df6b2ede03a1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86e7e8e7c42c482380a28afa9ecf2c76_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b8f63f573404294a870cfa838208b7e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe30650bfb8d48aca6dbadae71597e65_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7950f077c83c4b968114ecde2e2b0bd4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66c5b68aaa0a4c93bc23b9644ce7ffac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17d44c14ec1b4c2eac9a8389f7430791_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0ee3659217840abbe55a716b6c7657a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27a0f7402b7543f39f6f976686d8a1b5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91fb865ecf4145fdb3d535b6bf576475_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27650537dca947bd9b29fafaf84048a2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9cc9944568941598d1e56273115b999_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icea19db21d1f4850ad503d0164f02ee0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01671d18379a4457892b23355b0f63c3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76954bb677604e0f941a30448e281a31_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id11b13c420a14cce9b018741905d1215_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e95f60a2ff14f7a97e13a88c47f23f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i214c74f186244036ad65d031acecd8f4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61594b0a985e418eb0de58c665ee7a9b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb8608c8404a41bc91d4b199b497742a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i482b293366b34226b38b20258e4f2ad2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic00e07bcbece4f109e90289df0b99c67_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i943b1859aecd4fa38530943834fb212b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfe4715993be47369f1c27e1cf4db3cb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b1abf4ee53847788edba9a69ea4a81f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i538c50f08a0144988c39feeb3a4731aa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib62a4aeb2d014482b292e1b7aa806e54_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b7b4fe31ce54233aefaaf027ce7e8ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2a5ae8949b04000ac5560edc4d7e9f2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfdcf6378ed942a7996ee1a9da26e09d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied4d313aab9b4f8e8034b9f72db4c6fc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2c2d4e821d048eeaf50b62f405c3e71_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ff6377b237b439999bb2d77c5a32fec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee337558500947b7a15e1c6d6b59308a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c54b0e2a7354d1ebf52c04c3b53f6d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib132a0af29334d8a89770179f4a4c6e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20851fdc53e743b38af1e76d003c6b3a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52ee54330e824cfdbed0febda5250fe6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d7d1ea05ba24b2f993e48849a306d14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48bf8cce218249108f768811cdf3855e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c05e60f32ed4c1ca1330ed0411bd74e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1829f3c584ad46e09fa69d3bdf4dc092_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic042d55e713d42e19343e9d8183251f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c88f62a561a44a69856cba4e6223aaf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebf3bab110174c6a97b925581b28f022_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c0f80e4c70a4dd7a7f479eb93de4798_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8694353f6b5944bcbe80d4ab90db02f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6900b09ea625493ca6b4be8dd33fd73a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bce15f7824346e9b1c4801a21ba7d71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3a21ae3393e41d2ba9480eaa0b21d70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if383bbdeabc347c3a143b1392643d685_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia372a081047f4dbf909c87201c2dd657_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cccb32003004700acd3e2d5c3acc3ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b6be538722f49cd8981ecd65c3e7940_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i436b8c7264ce4c04bb05b44bfd87ca82_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f1e4df3ea5b421eb52a4e93ecf681d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6ac3978756e4b5fb17fbea6da4f990d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9c29a065a0846b9ac55a37fa94c8241_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92b5f5e714014f79bfda8cdf1d9b2a7c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6c67444f0284e208beac9c4be9a2f0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dee72abed824f43841304219403a584_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a95086891b14aaf917d8c2716ac3e3d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42734379ac9542d89b7f72f1422d85f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cef80ce2abe42448dfd3c31b2730530_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i082bf7a8d7da4db2b649a2e7f798417f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i295f7348ee104256b1ad8f7695918565_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide75442ca7484565b7ece117ea2f7059_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b695768bf7d42a3bcd05424e7e3f801_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieda949f586eb474d94003b25eeb0028d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied3619ec524f4266a7e63df4bffc201d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5cc405af174407082725f9ad493bde7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54dba7ed180b415fabfb7905a989ee6f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0af2032243144ef284ce6407829b4dee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i901ab2be4c854280b4098c1694160fde_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3f5f72c269e4e2f8f39b493b30dee70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6e5fa70dfa147419df6887b95a1c72a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb10e0158e6e4678aba453d3e46e07c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30a6b7ac42614433b9f0fa273ce3a0bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9017de5b93e24421b9baf62ead566064_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cfc4ac7e4a54ac497e9a40c408806fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibad8ae81108d443a8d7b7c73c118e1b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3788338e5f754c888353b212dd5956a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0015f68641264909839363808c4359b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i348b81fae8ab42de8c1879ac0c79e30c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia56272ad45124bdc80feb1442c60a30d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i757f940abbe04ca0bc0b713ee02d015c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i345e2321a45e415d986e9e3fbe0a8b1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i402b1f58d5d94b2e89c8d64936db028d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f6287de46e54474b2e7b025101c06f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifda53d5c5113486194c825c985c42f46_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i227d6a2f64bb432583256bb6d486f599_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie71f4ed1e3434f8687ea6d6c4e0184d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41aac4ca412c41fabad0761de653d3e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibacb732d9a3e42ecb1b0d3672103ab48_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd0e7a73c5654d22b1fb7d1f44eec75b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i143d17ad6d23439bbe5839cb7f2fa3d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82b433b6c64f411cbf07c20ec03e6cc0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ecc36ab470d4e41be47e03d24ef4065_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id86c9caf6218488d8edebac267e948ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbf66898d55a4866946d2c1b7d0808c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0d702f1019341bc888bc0e964569748_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa4a4b71cd744411915501b9954c7190_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i689b0515d1e94c50807ae2688713eb9a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7475b438e64f45c889b5836a9b35767c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fba731405fa40f08f44c49bbce45751_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad19a6d6a32c4de3b7b3d6e7f1edf524_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie71ccfe9ea594f9b9006353fffcd6bd2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58114e11cdf547b081755beebbfc89d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55c8b439a98248178a88acf2e2f0d064_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8d28a152a83416bace6b87dcae9c074_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bb519b30c624115a193843ede27be5e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if209ba23a08741c5a788dd9694d2de32_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29dcd560ceb84008813877608a70d4fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i043b55ba16e04186b3221ade43979e4b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3a21e55d8164183ac65c36e858f86e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i905bdea6d6d74e49ba3fae3f028d50c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25b644c98bfd4c39b72d7a1615c8880e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib73e985ef58a4760a5c29be61384bb88_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8bcd2b4b6ca476fadb8cce5fd37f874_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5e89110b5ca48398995bbf99899d921_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b9ad2ac337a4df9a8bc5ff2950a967b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5967fb68324426389a6dc239fcdd98d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i463ba1a48ccc4e9c9cb4282e58cd05a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i299c48115d8542b08f12325d39cefe4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27dc976858f044bdbd3ba64895aeb4cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6462a3f459994819a179b58529f573e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic623b25c46754468b1e9528796093989_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a1d3b46d2544213bc3eb41e5d6e128c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5ef3078b94645859a7ca03beed57c99_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf76714ef18e4ce6b454dfc623ac6be7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0dae23a26dd4790bdef9addc65290ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i560967994b3c4feaa52141c4dad6145c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00b75991e2e34b09b2420ae55e962bf3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied91fc6d6fdd4a9db5f172426ce099f6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>lly:patent</xbrli:measure></xbrli:unit><xbrli:context id="iaead771b48fe47589b2c796815693940_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63382dd666fe46d0b3e154a58b6cfe75_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31efe8055d7c4c549c6b4e3589629dce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>lly:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i62bc7ea2d50e4f44a034b2205030f1c9_D20090301-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>lly:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="idb638f2256714679a5c385f7893d6fbf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="site"><xbrli:measure>lly:site</xbrli:measure></xbrli:unit><xbrli:context id="i69662148bb09444d89587f00392b3075_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="brl"><xbrli:measure>iso4217:BRL</xbrli:measure></xbrli:unit><xbrli:context id="ie6e063495e83471dbc258b40a141debf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad23c8f46fec4d02b0a1bcb29a2373cb_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63ea09a048414de7b321b1ada8f7b0a4_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5a9f8356a0c4d9ca2c89e981a149cb5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogHumulinAndForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc973a7f9e3144daaacecbbb0e56d8b2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i782d346d63cd4661b107c0a82f9e4b82_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7be554abe40648b39a94f657bb20d919_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc3cb8d5258a4da9a5d7c9e511159aa3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06509abf85c548088ad01601353119b6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9a8c569328a4f30be03a86aa6c30d95_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i551c81f2cb044ba38f8c330455e4e04c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17390e21b41d40f786eda486ba1ce2c7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05873b0c5a3d432cb9d95359fb5df095_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifce42ff1cd2e4bbd9d84d0fa5ad5830e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f5a08b9d5ec477b89e3e3d1f861d631_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5108cbcfc4b74ce7b92ac3b0def03d6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa5d7c8469594718ad1fc73143d3d064_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3316d423843f422793957a50410a8a36_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7653b13d4d7a4b1ea53ccf1f2894f8e0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d8b6b1d95db4e629430b1a90c83d5ed_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57369029d5994ec1a83968149ccf0c57_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i223571c60a5b423f8ffc9ccfbe85991b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i556ef38e7ad6431685ad87cfb8474525_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66b44aaa3e8a45e08cb1bf413d8b0659_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17c04e1ff996458393a87969564ad1fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i972702fe45444acb9e6640afa709e559_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i555a212b77e94fec899486cbaa76fc01_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2aa5e5ddf4514d70abb39fde1aef3c0c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c2f066479d04e8a991d5d71e2aa8bac_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66b74eb9d22141c790775d44d424fc2f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6f1b84d8e0044fba3da52e09503d7ef_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3ab662330354f1d9f630d917b2b9226_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie36998435f274cd5b1ef204d97105cbd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia343b309a27649efbcdc14994affb7a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i463002f84e9c4e7ba72e5b39ba3391e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib916975408c44e2c89551e919105a31d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fb8bb210d8244f89d422fb23165a4e3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i023d933f184447ddac5d72ebf87e0336_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i472a66eae4d2427ba823727867f6c0f9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84dd851668914a6db57dd7071efd43cf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i514b258fa8244695bafee3af86f5baa4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9961583d4b548ebbcb37171c99e617d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i344999926eb8490985eec925cad19570_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d7c5f720a834207b54353c4bd105eba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18678afeadcd4e3d83ea294339141d26_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b856402e0234773bcad0e3fc79b8715_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia960d127a0284a50a7e9041cfc5cc3ff_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib01471a2ae8e487caadc07f6eb55dd21_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3a0343f9166479e970860fc345fb4c5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a4ec401a8f24eeda71c72518a06d67d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefbc11fe7e2b4373988b6e83dcf18945_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i909b702f7db044078a8e3e150503788d_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">United States</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities and Exchange Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDg2_7c4e1473-b1dc-4385-b35a-0cc0990d5f51">10-K</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Annual report pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">for the fiscal year ended <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8yMDE_eb823fe3-d2af-4acf-b240-5d7f447b8c15"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8yMDE_4ddb4333-b91e-49b5-98ec-1d85e5c7e51b">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDky_7fbb660b-d6b3-4b21-8996-b28bb2285669">001-06351</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8yMzc_742da120-e287-476f-bb22-4faafced49bd">ELI LILLY AND COMPANY</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.432%"><tr><td style="width:1.0%"></td><td style="width:7.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6Y2I5ZTY4NjM0ZWVlNGM4NmEwMTViMTJmM2I5MTVjY2MvdGFibGVyYW5nZTpjYjllNjg2MzRlZWU0Yzg2YTAxNWIxMmYzYjkxNWNjY18wLTItMS0xLTE5NzE4Mg_139530b5-20f0-4e1a-9e48-ea56c5259be1">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6Y2I5ZTY4NjM0ZWVlNGM4NmEwMTViMTJmM2I5MTVjY2MvdGFibGVyYW5nZTpjYjllNjg2MzRlZWU0Yzg2YTAxNWIxMmYzYjkxNWNjY18wLTUtMS0xLTE5NzE4Mg_0ac9597b-5e55-4a13-bfa2-b7f2663037cc">35-0470950</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identification No.)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDgy_f1c7c32a-1953-4549-9ac7-ba5c1b28c4da">Lilly Corporate Center</ix:nonNumeric>, <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDg3_01e3a314-b046-4361-9920-a4fb8be01a03">Indianapolis</ix:nonNumeric>, <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDgz_55d80609-766f-4d53-997d-8048de520e34">Indiana</ix:nonNumeric> <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDg0_7dbbc5d2-ef2d-452f-b7a2-10c74d61802d">46285</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address and zip code of principal executive offices)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code (<ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl80NTY_13a1bb1a-269d-4066-880f-82c460c32f7f">317</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDgw_54f69473-524c-4960-8915-df79852421da">276-2000</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Exchange Act:</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Each Exchange On Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0123f42da8014c4e80a496f4ec156d49_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18xLTAtMS0xLTE5NzE4Mg_efb0814b-fb2b-42ae-85e8-dd1fac7cfdf9">Common Stock (no par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0123f42da8014c4e80a496f4ec156d49_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18xLTEtMS0xLTE5NzE4Mg_1a0cc0e7-3343-4557-b5b6-b78e856353a5">LLY</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0123f42da8014c4e80a496f4ec156d49_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18xLTItMS0xLTE5NzE4Mg_75fc2004-f0ea-4512-ad4c-0e7c0b7665d6">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia6faa5dfbefd43faba61396886103e54_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18yLTAtMS0xLTE5NzE4Mg_5ed422b2-eacb-4260-822b-7cc9f79d6946">7 1/8% Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia6faa5dfbefd43faba61396886103e54_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18yLTEtMS0xLTE5NzE4Mg_9be41701-6dd0-4b7d-b516-5a67adc3b4b6">LLY25</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia6faa5dfbefd43faba61396886103e54_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18yLTItMS0xLTE5NzE4Mg_008aa05f-2712-476b-8a31-affbe9360c10">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7506ecec16a548918d36c633b7d2886f_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18zLTAtMS0xLTE5NzE4Mg_9d81ceb6-b630-47e5-a669-9a761e4c995d">1.625% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7506ecec16a548918d36c633b7d2886f_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18zLTEtMS0xLTE5NzE4Mg_d0048868-0af1-4e56-b0be-7b6c1576cee5">LLY26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7506ecec16a548918d36c633b7d2886f_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18zLTItMS0xLTE5NzE4Mg_575de243-02b9-4d34-89fc-ea97cdec2784">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i74727aae65ec420f8d2a7d3f2fc82caa_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM180LTAtMS0xLTE5NzE4Mg_62872ec8-0f63-4ca7-8ff3-d3e154fd1b0b">2.125% Notes due 2030</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i74727aae65ec420f8d2a7d3f2fc82caa_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM180LTEtMS0xLTE5NzE4Mg_531186ef-3044-481d-81f4-4ae9511c785c">LLY30</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i74727aae65ec420f8d2a7d3f2fc82caa_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM180LTItMS0xLTE5NzE4Mg_55ab3908-810c-46f4-94ec-4e25f8dd6944">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8b6679d8bf73400fb57c1d771b743b9f_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM181LTAtMS0xLTE5NzE4Mg_6f1c0955-4657-41d6-bf97-6ae1abf1eaad">0.625% Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8b6679d8bf73400fb57c1d771b743b9f_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM181LTEtMS0xLTE5NzE4Mg_c61bb1be-3b13-48b2-968a-e0a43714c94c">LLY31</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8b6679d8bf73400fb57c1d771b743b9f_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM181LTItMS0xLTE5NzE4Mg_92e3c32b-242a-4e54-be00-8273b7251340">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idd78f7ed1d134dcf8be4669929f8630d_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM182LTAtMS0xLTE5NzE4Mg_b79e3a2c-08f3-4bfe-ae51-8248ffed3853">0.500% Notes due 2033</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idd78f7ed1d134dcf8be4669929f8630d_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM182LTEtMS0xLTE5NzE4Mg_7dbd0608-37de-4287-8a76-ee0daa236be4">LLY33</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idd78f7ed1d134dcf8be4669929f8630d_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM182LTItMS0xLTE5NzE4Mg_9939fd7a-8e28-44d2-b76a-3c1fe5d3552f">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1ec7aad2a8d0401f82a878dda7a7a03e_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM183LTAtMS0xLTE5NzE4Mg_5541671a-b4c3-4ede-b288-3ee67ac4bca2">6.77%&#160;Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1ec7aad2a8d0401f82a878dda7a7a03e_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM183LTEtMS0xLTE5NzE4Mg_daac9a7b-0a64-41a1-afa2-f1afaca08723">LLY36</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1ec7aad2a8d0401f82a878dda7a7a03e_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM183LTItMS0xLTE5NzE4Mg_a0c75165-318d-4b02-baf9-815e52e6efa2">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icee8de005b2e49f9879377e478c0b2db_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM184LTAtMS0xLTE5NzE4Mg_815d01d5-6b0c-4f45-b5da-6ddf5fb83ee4">1.625% Notes due 2043</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icee8de005b2e49f9879377e478c0b2db_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM184LTEtMS0xLTE5NzE4Mg_b77057b6-de5d-4c5a-ad6a-7cf6b28532e1">LLY43</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icee8de005b2e49f9879377e478c0b2db_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM184LTItMS0xLTE5NzE4Mg_6d8130cf-a6a3-4af7-b4ac-a49736743585">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifbdd41c0af48472b8577f5e8157441c2_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM185LTAtMS0xLTE5NzE4Mg_bf7aaed3-0286-496d-8687-63b8dcc39a27">1.700% Notes due 2049</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifbdd41c0af48472b8577f5e8157441c2_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM185LTEtMS0xLTE5NzE4Mg_9b321e6c-a71b-4a87-ae63-6983aed649a5">LLY49A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifbdd41c0af48472b8577f5e8157441c2_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM185LTItMS0xLTE5NzE4Mg_6219bbe6-0ed5-452b-8d9c-e6269aeda1fa">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i62b9486903fe42cd82d7869cb7d772c4_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18xMC0wLTEtMS0xOTcxODI_daf5536a-cbe5-40ca-9efe-f3c406ff49ff">1.125% Notes due 2051</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i62b9486903fe42cd82d7869cb7d772c4_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18xMC0xLTEtMS0xOTcxODI_75bdfb34-fe0a-4b93-93fd-424a48942f9d">LLY51</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i62b9486903fe42cd82d7869cb7d772c4_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18xMC0yLTEtMS0xOTcxODI_0e321fb6-edbf-4b6c-b59d-292f5b04cbf1">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0bfa6ff0f0fa4248813d3e66ff3abdab_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18xMS0wLTEtMS0xOTcxODI_6d1d824a-c9a1-444f-bab6-92121f632bfc">1.375% Notes due 2061</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0bfa6ff0f0fa4248813d3e66ff3abdab_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18xMS0xLTEtMS0xOTcxODI_aa42d788-aa4c-4eed-9e27-9ebc286cb169">LLY61</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0bfa6ff0f0fa4248813d3e66ff3abdab_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18xMS0yLTEtMS0xOTcxODI_efc5f1bb-e2c1-4018-82f5-d3202adec84a">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Exchange Act: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">None</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDgx_b3ca633c-bb9a-4777-b432-07ca701bf0ad">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> No  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Exchange Act. Yes&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDkw_84ff9eec-a147-444e-a745-e7bab3ff9952">No</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDkx_92898ba8-2c8e-49ab-8234-d22d077fd3c1">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> No  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDg4_cc2ccda4-d26e-4423-8530-b2a87151ee7d">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.937%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6Y2NiZmRiNzRhZDczNGM1ZjgzNTY0ZGFiMDEwYTNjODgvdGFibGVyYW5nZTpjY2JmZGI3NGFkNzM0YzVmODM1NjRkYWIwMTBhM2M4OF8wLTAtMS0xLTE5NzE4Mg_8d82d2ef-0148-4aff-b10b-6f6431cfacec">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6Y2NiZmRiNzRhZDczNGM1ZjgzNTY0ZGFiMDEwYTNjODgvdGFibGVyYW5nZTpjY2JmZGI3NGFkNzM0YzVmODM1NjRkYWIwMTBhM2M4OF8xLTctMS0xLTE5NzE4Mg_0d08907b-107e-4e5f-9abe-1e0cc460b465">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6Y2NiZmRiNzRhZDczNGM1ZjgzNTY0ZGFiMDEwYTNjODgvdGFibGVyYW5nZTpjY2JmZGI3NGFkNzM0YzVmODM1NjRkYWIwMTBhM2M4OF8yLTctMS0xLTE5NzE4Mg_ae936fb4-f956-4e99-9a33-dbf5dc34a94c">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDg1_185f1884-740e-42bb-8e18-22e44a7a327c">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). &#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDkz_e4243202-fdda-49e5-a49d-906f32d18655">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Aggregate market value of the common equity held by non-affiliates computed by reference to the price at which the common equity was last sold as of the last business day of the Registrant's most recently completed second fiscal quarter: approximately $<ix:nonFraction unitRef="usd" contextRef="if754bc01888f45ac8d951c81d205bc32_I20220630" decimals="-6" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8yODYz_3a783d28-be6e-44b0-b8dd-cd492941fbcf">274,342,000,000</ix:nonFraction>.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of shares of common stock outstanding as of February&#160;17, 2023: <ix:nonFraction unitRef="shares" contextRef="i57c62c4ea2844c0e9a340732ae328cbc_I20230217" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8yOTIy_923cc5f5-b8aa-4c9f-a793-7b5a495876dd">950,296,118</ix:nonFraction></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDg5_192fcec3-2fce-4f4a-8490-ffdff269e715" escape="true">Portions of the Registrant's Proxy Statement for the 2023 Annual Meeting of Shareholders have been incorporated by reference into Part III of this report.</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eli Lilly and Company</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Year Ended December&#160;31, 2022 </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:8.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_13">Part I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_16">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_16">Business</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_19">Item 1A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_19">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_22">Item 1B.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_22">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_25">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_25">Properties</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_25">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_28">Item 3.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_28">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_31">Item 4.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_31">34</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_34">Part II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_37">Item 5.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_37">Market for the Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_37">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_43">Item 6.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_43">[Reserved]</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_43">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_46">Item 7.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_46">Management's Discussion and Analysis of Results of Operations and Financial Condition</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_46">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_70">Item 7A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_70">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_70">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_73">Item 8.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_73">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_73">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_157">Item 9.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_157">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_157">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_160">Item 9A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_160">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_160">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_163">Item 9B.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_163">Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_163">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_166">Item 9C.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_166">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_166">113</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_169">Part III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_172">Item 10.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_172">Directors, Executive Officers, and Corporate Governance</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_172">114</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_175">Item 11.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_175">Executive Compensation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_175">114</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_178">Item 12.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_178">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_178">115</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_181">Item 13.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_181">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_181">115</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_184">Item 14.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_184">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_184">115</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_187">Item 15.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_187">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_187">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_196">Item 16.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_196">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i909b702f7db044078a8e3e150503788d_196">117</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. In particular, information appearing under "Business," "Risk Factors," and "Management's Discussion and Analysis of Results of Operations and Financial Condition" includes forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts, and generally can be identified by the use of words such as "may," "believe," "will," "expect," "project," "estimate," "intend," "anticipate," "plan," "continue," or similar expressions or future or conditional verbs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements inherently involve many risks and uncertainties that could cause actual results to differ materially from those expressed in forward-looking statements. Where, in any forward-looking statement, we express an expectation or belief as to future results or events, it is based on management's current plans and expectations, expressed in good faith and believed to have a reasonable basis. However, we can give no assurance that any such expectation or belief will result or will be achieved or accomplished. Investors therefore should not place undue reliance on forward-looking statements. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated:</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact and outcome of acquisitions and business development transactions and related integration costs;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expiration of intellectual property protection for certain of our products and competition from generic and/or biosimilar products;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in patent law or regulations related to data package exclusivity;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive developments affecting current products and our pipeline;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market uptake of recently launched products;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">information technology system inadequacies, breaches, or operating failures;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our information technology systems, networks, and facilities, or those of third parties with whom we share our data;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of global macroeconomic conditions, trade disruptions, disputes, unrest, war, regional dependencies, or other costs, uncertainties and risks related to engaging in business globally; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected safety or efficacy concerns associated with our products;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, or regulatory actions related to our facilities;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">dependence on certain products for a significant percentage of our total revenue and an increasingly consolidated supply chain;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reliance on third-party relationships and outsourcing arrangements;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of public health outbreaks, epidemics, or pandemics, such as the COVID-19 pandemic;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory changes or other developments;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory actions regarding operations and products; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">devaluations in foreign currency exchange rates or changes in interest rates and inflation;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in tax law, tax rates, or events that differ from our assumptions related to tax positions; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">asset impairments and restructuring charges;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory compliance problems or government investigations; and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors should also carefully read the factors described under Item 1A, "Risk Factors" in this Annual Report on Form 10-K for a description of certain risks that could, among other things, cause our actual results to differ from those expressed in forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above and under Item 1A, "Risk Factors" to be a complete statement of all potential risks and uncertainties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All forward-looking statements speak only as of the date of this Annual Report and are expressly qualified in their entirety by the risk factors and cautionary statements included in this Annual Report. Except as is required by law, we expressly disclaim any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this Annual Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Part I</span></div><div id="i909b702f7db044078a8e3e150503788d_16"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Business</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company (referred to as the company, Lilly, we, or us) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover, develop, manufacture, and market products in a single business segment&#8212;human pharmaceutical products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our purpose is to unite caring with discovery to create medicines that make life better for people around the world. Most of the products that we sell today were discovered or developed by our own scientists, and our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture and distribute our products through facilities in the United States (U.S.), including Puerto Rico, and 7 other countries. Our products are sold in approximately 110 countries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products include:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diabetes products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in collaboration with Boehringer Ingelheim, a long-acting human insulin analog for the treatment of diabetes.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humalog Mix 75/25,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humalog U-100,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humalog U-200,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humalog Mix 50/50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">insulin lispro,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">insulin lispro protamine</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> insulin lispro mix 75/25, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">human insulin analogs for the treatment of diabetes. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Humulin 70/30, Humulin N, Humulin R, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humulin U-500</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">human insulins of recombinant DNA origin for the treatment of diabetes.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in collaboration with Boehringer Ingelheim, for the treatment of type 2 diabetes; to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease; and to reduce the risk of cardiovascular death and hospitalizations for heart failure in adults.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Mounjaro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, for the treatment of adults with type 2 diabetes in combination with diet and exercise to improve glycemic control.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Trulicit</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of type 2 diabetes in adults and pediatric patients 10 years of age and older, and to reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Oncology products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the first-line treatment, in combination with two other agents, of advanced non-small cell lung cancer (NSCLC) for patients with non-squamous cell histology and no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations; for the first-line treatment, in combination with another agent, of advanced non-squamous NSCLC; for the second-line treatment of advanced non-squamous NSCLC; as monotherapy for the maintenance treatment of advanced non-squamous NSCLC in patients whose disease has not progressed immediately following chemotherapy treatment; and in combination with another agent for the treatment of malignant pleural mesothelioma.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for use as monotherapy or in combination with another agent as a second-line treatment of advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma; in combination with another agent as a second-line treatment of metastatic NSCLC; in combination with another agent as a second-line treatment of metastatic colorectal cancer; as a monotherapy as a second-line treatment of hepatocellular carcinoma; and in combination with another agent as a first-line treatment of adult patients with metastatic NSCLC with activating epidermal growth factor receptor mutations. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, indicated both as monotherapy and in combination with another agent for the treatment of certain types of colorectal cancers; and as monotherapy, in combination with chemotherapy, or in combination with radiation therapy for the treatment of certain types of head and neck cancers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Jaypirca</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Retevmo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of metastatic NSCLC with a rearranged during transfection (RET) gene fusion in adult patients; for the treatment of advanced metastatic medullary thyroid cancer with a RET mutation who require systemic therapy in adult and pediatric patients; for the treatment of advanced or metastatic thyroid cancer with a RET gene fusion in adult and pediatric patients who require systemic therapy and are radioactive iodine-refractory; and for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in collaboration with Innovent Biologics, Inc., for the treatment of relapsed or refractory classic Hodgkin's lymphoma; for the first-line treatment of non-squamous NSCLC in combination with Alimta and another agent; for the first-line treatment of squamous NSCLC in combination with two other agents; for the first-line treatment of hepatocellular carcinoma in combination with another agent; for the first-line treatment of esophageal squamous cell carcinoma in combination with certain other agents; and for the first-line treatment of gastric cancer in combination with two other agents, each in China.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for use as monotherapy or in combination with endocrine therapy for the treatment of HR+, HER2- metastatic breast cancer and in combination with endocrine therapy for treatment of HR+, HER2-, node positive, early breast cancer at high risk of recurrence and a Ki-67 score at least 20 percent, as determined by a U.S. Food and Drug Administration (FDA) approved test.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Immunology products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in collaboration with Incyte Corporation, for the treatment of adults with moderately-to-severely active rheumatoid arthritis, moderate to severe atopic dermatitis, and severe alopecia areata, and for the treatment of hospitalized adults with COVID-19 who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of adults and pediatric patients aged 6 years or older with moderate-to-severe plaque psoriasis, adults with active psoriatic arthritis, adults with ankylosing spondylitis, and adults with active non-radiographic axial spondyloarthritis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neuroscience products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain due to chronic low back pain or chronic pain due to osteoarthritis.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for migraine prevention and the treatment of episodic cluster headache in adults.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other products and therapies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Bamlanivimab </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> etesevimab</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, administered together, for the treatment of mild-to-moderate COVID-19 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in adults and pediatric patients from birth to 12 years old with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death (Emergency Use Authorization (EUA) granted in 2021). In May 2022, the FDA announced that bamlanivimab and etesevimab are not currently authorized for emergency use for any U.S. region.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Bebtelovimab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older and weighing at least 40 kilograms) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate (EUA granted in 2022). In November 2022, the FDA announced that bebtelovimab is not currently authorized for emergency use for any U.S. region.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of erectile dysfunction and benign prostatic hyperplasia.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing and Distribution</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell most of our products worldwide. We adapt our marketing methods and product emphasis in various countries to meet local customer needs and comply with local regulations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We promote our major products in the U.S. through sales representatives who engage with physicians and other healthcare professionals. We also educate healthcare providers about our products in various other ways, including promoting in online channels, distributing literature and samples of certain products to physicians, and exhibiting at medical meetings. In addition, we advertise certain products directly to consumers in the U.S., and we maintain websites and other media channels with information about our major products. We supplement our employee sales force with contract sales organizations to leverage our resources and reach additional patients in need.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. We enter into arrangements with these organizations providing for discounts or rebates on our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., most of our products are distributed through wholesalers that serve pharmacies, physicians and other healthcare professionals, and hospitals. In 2022, 2021, and 2020, three wholesale distributors in the U.S.&#8212;McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health, Inc.&#8212;each accounted for a significant percentage of our consolidated revenue. No other customer accounted for more than 10&#160;percent of our consolidated revenue in any of these years. For additional information, see Item 8, "Financial Statements and Supplementary Data&#8212;Note 2: Revenue."</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outside the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products we market and distribution of our products vary from country to country. Outside the U.S., we promote our products to healthcare providers through sales representatives and other channels. In most countries in which we operate, we maintain our own sales organizations, but in some countries we market our products through third parties, some of which we have engaged through distribution and promotion arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing Collaborations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products are marketed in arrangements with other pharmaceutical companies. For example, we and Boehringer Ingelheim have a global agreement to develop and commercialize a portfolio of diabetes products, including Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jardiance, Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> XR, and Basaglar. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see Item 8, "Financial Statements and Supplementary Data&#8212;Note 4: Collaborations and Other Arrangements."</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products compete globally with many other pharmaceutical products in highly competitive markets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Important competitive factors include effectiveness, safety, and ease of use; formulary placement, price, payer coverage and reimbursement rates, and demonstrated cost-effectiveness; regulatory approvals; marketing effectiveness; and research and development of new products, processes, modalities, and uses. Most new products or uses that we introduce must compete with other branded, biosimilar, or generic products already on the market or that are later developed by competitors. When competitors introduce new products, uses, or delivery systems with therapeutic or cost advantages, including by developing new modalities, our products become subject to decreased sales volumes, progressive price reductions, or both. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our long-term competitive success depends on discovering and developing (either alone or in collaboration with others) or acquiring innovative, cost-effective products that provide improved outcomes for patients and deliver value to payers, and continuously improving the productivity of our operations in a highly competitive environment. There can be no assurance that our efforts will result in commercially successful products, and it is possible that our products will be, or will become, uncompetitive from time to time as a result of products or uses developed by our competitors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Pharmaceuticals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the biggest competitive challenges we face is from generic pharmaceuticals. In the U.S., Europe, Japan, and other jurisdictions, the regulatory approval process for pharmaceuticals (other than biological products (biologics)) exempts generics from costly and time-consuming clinical trials to demonstrate their safety and efficacy, allowing generic manufacturers to rely on the safety and efficacy of the innovator product. As a result, generic manufacturers generally invest far fewer resources than we do for our branded products in research and development and can price their products significantly lower than our branded products. Accordingly, when a branded non-biologic pharmaceutical loses its market exclusivity, it normally faces intense price competition from generic forms of the product, which can result in the loss of a significant portion of the product's revenue in a very short period of time. Moreover, governments in some countries leverage generic entrants to drive price concessions through the utilization of volume-based procurement bidding and other measures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, public and private payers typically encourage the use of generics as alternatives to brand-name drugs in their healthcare programs. Laws in the U.S. generally allow, and in many cases require, pharmacists to substitute generic drugs that have been rated under government procedures to be essentially equivalent to a brand-name drug. Where substitution is mandatory, it must be made unless the prescribing physician expressly forbids it. In certain countries outside the U.S., intellectual property protection is weak, and we must compete with generic or counterfeit versions of our products relatively shortly after launch. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Biosimilars</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of our products and potential new medicines in our clinical-stage pipeline are biologics. In the U.S., the FDA regulates biologics under the Federal Food, Drug and Cosmetic Act, the Public Health Service Act, and implementing regulations. Competition for Lilly's biologics may be affected by the approval of follow-on biologics, also known as biosimilars. A biosimilar is a subsequent version of an approved innovator biologic that, due to its analytical and clinical similarity to the innovator biologic, may be approved based on an abbreviated data package that relies in part on the full testing required of the innovator biologic. Approval by the FDA ultimately depends on many factors, including a showing that the biosimilar is "highly similar" to the original product and has no clinically meaningful differences from the original product in terms of safety, purity, and potency.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Globally, most governments have developed abbreviated regulatory pathways to approve biosimilars as follow-ons to innovator-developed biologics, including the Biologics Price Competition and Innovation Act of 2009 (the BPCIA) in the U.S. A number of biosimilars have been licensed under the BPCIA, as well as in Europe and Japan. The patent and regulatory exclusivity for the existing innovator biologic generally must expire in a given market before biosimilars may enter that market. In addition, the extent to which a biosimilar, once approved, will be substituted for the innovator biologic in a way that is similar to traditional generic substitution for non-biologic products is not yet entirely clear, and will depend on a number of regulatory and marketplace factors that are still developing. In the U.S., currently only a biosimilar product that is determined to be "interchangeable" by the FDA will be considered substitutable for the original biologic product without the intervention of the healthcare provider who prescribed the original biologic product. The FDA requirements for interchangeability are evolving but the FDA has issued several "interchangeable" designations for biosimilar products, including for competitive insulin products, and is expected to continue doing so in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory interpretation of important aspects of the laws regulating biosimilars continues to evolve and, therefore, the impact of these laws on our business remains subject to substantial uncertainty. Biosimilars may present both competitive challenges and opportunities. While competitors have developed biosimilars that compete with our products, we have developed, and may continue to develop, our own biosimilars. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Private Sector Dynamics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. private sector, consolidation and integration among healthcare organizations significantly affects the competitive marketplace for pharmaceuticals. Health plans, managed care organizations, pharmacy benefit managers, wholesalers, and other supply chain stakeholders have been consolidating into fewer, larger entities, thus enhancing their market power and importance. Private third-party insurers, as well as governments, typically maintain formularies that specify coverage (the conditions under which drugs are included on a plan's formulary) and reimbursement (the associated out-of-pocket cost to the consumer) to control costs by negotiating discounts or rebates in exchange for formulary inclusion and placement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formulary placement can lead to reduced usage of a drug for the relevant patient population due to coverage restrictions, such as prior authorizations and formulary exclusions, or due to reimbursement limitations that result in higher consumer out-of-pocket cost, such as non-preferred co-pay tiers, increased co-insurance levels, and higher deductibles. Consequently, pharmaceutical companies face increased pressure in negotiations, and compete fiercely for formulary placement, not only on the basis of product attributes such as efficacy, safety profile, or patient ease of use, but also by providing rebates or other concessions. As payers and pharmaceutical companies continue to negotiate formulary placement and rebates, value-based agreements, where rebates may be based on achievement (or not) of specified outcomes, are another tool that has become increasingly prevalent. Cost is an increasingly important factor in formulary decisions, particularly in treatment areas in which the payer has taken the position that multiple branded products are therapeutically comparable. These pressures have negatively affected, and could continue to negatively affect, our consolidated results of operations. In addition to formulary placement, changes in insurance designs continue to drive greater consumer cost-sharing through high deductible plans and higher co-insurance or co-pays. For additional information on pricing and reimbursement for our pharmaceutical products, see "&#8212;Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access&#8212;U.S."</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents, Trademarks, and Other Intellectual Property Rights</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property protection is critical to our ability to successfully commercialize our life sciences innovations and invest in the search for new medicines and uses. We own, have applied for, or are licensed under, a large number of patents in the U.S. and many other countries relating to products, product uses, formulations, and manufacturing processes. In addition, as discussed below, for some products we have effective intellectual property protection in the form of data protection under pharmaceutical regulatory laws.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent protection anticipated to be of most relevance to pharmaceuticals is provided by national patents claiming the active ingredient (the compound patent) for our products, particularly those in major markets such as the U.S., major European countries, and Japan. These patents may be issued based upon the filing of international patent applications, usually filed under the Patent Cooperation Treaty (PCT). Patent applications covering compounds are generally filed during the discovery phase of the drug discovery process, which is described in the "Research and Development" section below. In general, national patents in each relevant country are available for a period of 20 years from the filing date of the PCT application, which is often years prior to the launch of a commercial product. Further patent term adjustments and restorations may extend the original patent term:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patent term adjustment is a statutory right available to all U.S. patent applicants to provide relief in the event that a patent grant is delayed during examination by the U.S. Patent and Trademark Office (USPTO).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patent term restoration is a statutory right provided to U.S. patent holders that claim inventions subject to review by the FDA. To compensate for a portion of the time invested in clinical trials and the FDA review process, a single patent for a pharmaceutical product may be eligible for patent term restoration. Patent term restoration is determined by a formula that cannot be calculated until product approval due to the uncertainty of the duration of clinical trials and the time it takes the FDA to review an application. There is a five-year cap on any restoration, and no patent's expiration date may be extended beyond 14 years from FDA approval. Some countries outside the U.S. similarly offer forms of patent term restoration for patents claiming inventions subject to a local review by a regulatory agency. For example, Supplementary Protection Certificates are available to extend the life of a European patent up to an additional five years (subject to a 15-year cap from European Medicines Agency (EMA) approval). Also, in Japan, South Korea, Australia, and other jurisdictions, patent terms can be extended up to five years, depending on the length of regulatory review and other factors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss of effective patent protection for pharmaceuticals, especially for non-biologic products, typically results in the loss of effective market exclusivity for the product, often leading to a severe and rapid decline in revenues for the product. However, in some cases the innovator company may retain exclusivity despite approval of the generic, biosimilar, or other follow-on versions of a new medicine beyond the expiration of the compound patent through manufacturing trade secrets, later-expiring patents on manufacturing processes, methods of use or formulations, or data protection that may be available under pharmaceutical regulatory laws. Changes to the laws and regulations governing these protections could result in earlier loss of effective market exclusivity. The primary forms of data protection are as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory authorities in major markets generally grant data package protection for a period of years following new drug approvals in recognition of the substantial investment required to complete clinical trials. Data package protection prohibits other manufacturers from submitting regulatory applications for marketing approval in reliance on the innovator company's regulatory submission data for the drug. The base period of data package protection depends on the country. For example, the period is generally five years in the U.S. (12 years for new biologics as described below), effectively 10 years in Europe, and eight years in Japan. The period begins on the date of product approval and runs concurrently with the patent term for any relevant patent.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the BPCIA, the FDA has the authority to approve biosimilars. A competitor seeking approval of a biosimilar must file an application to show its molecule is highly similar to an approved innovator biologic and include a certain amount of safety and efficacy data that the FDA will consider on a case-by-case basis. Under the data protection provisions of this law, the FDA cannot approve a biosimilar application until 12 years after initial marketing approval of the innovator biologic, subject to certain conditions. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the U.S., the FDA has the authority to grant additional data protection for approved drugs where the sponsor conducts specified testing in pediatric or adolescent populations within a specified time period. If granted, this "pediatric exclusivity" provides an additional six months of exclusivity, which is added to the term of data protection and, for products other than biologics, to the term of any relevant patents, to the extent these protections have not already expired. While the term of the pediatric exclusivity begins upon the expiration of the relevant patent, pediatric exclusivity is a regulatory exclusivity&#8212;i.e., a bar to generic or biosimilar approval, not a patent right.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the U.S. orphan drug law, a specific use of a drug or biologic can receive "orphan" designation if it is intended to treat a disease or condition affecting fewer than 200,000 people in the U.S., or affecting more than 200,000&#160;people but not reasonably expected to recover its development and marketing costs through U.S. sales. Among other benefits, orphan designation entitles the particular use of the drug to seven years of market exclusivity, meaning that the FDA cannot (with limited exceptions) approve another marketing application for the same drug for the same indication until expiration of the seven-year period. Unlike pediatric exclusivity, the orphan exclusivity period is independent of and runs in parallel with any applicable patents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the major markets, the adequacy and effectiveness of intellectual property protection for pharmaceuticals varies widely, and in a number of these markets we are unable to patent our products or to enforce the patents that we receive for our products. Under the Trade-Related Aspects of Intellectual Property (TRIPs) Agreement administered by the World Trade Organization, more than 140 countries have agreed to provide non-discriminatory protection for most pharmaceutical inventions and to assure that adequate and effective rights are available to patent owners. Certain developing countries limit protection for biopharmaceutical products under their interpretation of "flexibilities" allowed under the TRIPs Agreement. Thus, some types of patents, such as those on new uses of compounds or new forms of molecules, are not available in certain developing countries. Further, many developing countries, and some developed countries, do not provide effective data package protection even though it is specified in the TRIPs Agreement. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Intellectual Property Portfolio</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider intellectual property protection for certain products, processes, uses, and formulations&#8212;particularly with respect to those products discussed below&#8212;to be important to our operations. In addition to the patents and data protection identified below, we may hold patents on manufacturing processes, formulations, devices, or uses that extend exclusivity beyond the dates shown below. For approved products, dates include, where applicable, pending or granted patent term extensions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most relevant U.S. patent protection or data protection and associated expiry dates for our major or recently launched patent-protected marketed products are as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cyramza is protected by a compound patent and biologics data protection (2026).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Emgality is protected by a compound patent (2033) and biologics data protection (2030).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jardiance, and the related combination product Glyxambi, is protected by a compound patent (2028).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jaypirca is protected by a compound patent (2037) and by data protection (2028). </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mounjaro is protected by a compound patent (2036) and by data protection (2027).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Olumiant is protected by a compound patent (2032). </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Retevmo is protected by a compound patent (2037) and by data protection (2025).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reyvow</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by a compound patent (2030).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Taltz is protected by a compound patent (2030) and by biologics data protection (2028).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trulicity is protected by a compound patent (2027) and by biologics data protection (2027).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Verzenio is protected by a compound patent (2031).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., important patent protection or data protection includes: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Baqsimi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by data protection in Japan (2026).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cyramza is protected by a compound patent (2028) and by data protection (2024) in major European countries, and by a compound patent (2026) and by data protection (2023) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Emgality is protected by a compound patent (2033) and by data protection (2028) in major European countries, and by a compound patent (2035) and by data protection (2029) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jardiance is protected by a compound patent in major European countries (2029) and Japan (2030).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mounjaro is protected by a compound patent in major European countries (2037) and Japan (2040).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Olumiant is protected by a compound patent (2032) and by data protection (2027) in major European countries, and by a compound patent (2033) and by data protection (2025) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Retevmo is protected by a compound patent (2037) and by data protection (2031) in major European countries, and by a compound patent (2038) and by data protection (2029) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reyvow is protected by data protection (2032) in major European countries, and a compound patent (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and by data protection (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2032</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Taltz is protected by a compound patent (2031) and data protection (2027) in major European countries and a compound patent (2030) and data protection (2024) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trulicity is protected by a compound patent (2029) and by data protection (2024) in major European countries and by a compound patent (2029) and by data protection (2023) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Verzenio is protected by a compound patent (2033) and data protection (2028) in major European countries and by a compound patent (2034) and data protection (2026) in Japan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following product candidates are the most relevant currently under regulatory review. Upon approval, we expect relevant compound patent and data protections to apply:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Donanemab has been submitted for regulatory review in the U.S. for the treatment of early Alzheimer's disease. In January 2023, the FDA issued a complete response letter for our accelerated approval submission. Phase III trials are ongoing.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lebrikizumab has been submitted for regulatory review in the U.S. and Europe for the treatment of atopic dermatitis.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mirikizumab has been submitted for regulatory review in the U.S., Europe, and Japan for the treatment of ulcerative colitis.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide, we sell all of our major products under trademarks consisting of our product names, logos, and unique product appearances (e.g., the appearance of our Trulicity autoinjector) that we consider in the aggregate to be important to our operations. Trademark protection varies throughout the world, with protection continuing in some countries as long as the mark is used, and in other countries as long as it is registered. Registrations are normally for fixed but renewable terms. Trademark protection typically extends beyond the patent and data protection for a product. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Licenses and Collaborations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our major products are not subject to significant license and collaboration agreements. For information on our license and collaboration agreements, see Item 8, "Financial Statements and Supplementary Data&#8212;Note 4: Collaborations and Other Arrangements." </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Challenges </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, authorizes the FDA to approve generic versions of innovative pharmaceuticals (other than biologics, which are discussed below in more detail) when the generic manufacturer has not conducted safety and efficacy studies but files an Abbreviated New Drug Application (ANDA). In an ANDA, the generic manufacturer must demonstrate only "pharmaceutical equivalence" and "bioequivalence" between the generic version and the New Drug Application (NDA)-approved-drug, not safety and efficacy. Establishing pharmaceutical equivalence and bioequivalence is generally straightforward and inexpensive for the generic company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Absent a patent challenge, the FDA cannot approve an ANDA until after certain of the innovator's patents expire. However, after the innovator has marketed its product for four years, a generic manufacturer may file an ANDA alleging that one or more of the patents listed in the innovator's NDA are invalid or not infringed. This allegation is commonly known as a "Paragraph IV certification." If the innovator responds by filing suit against the generic manufacturer, the FDA is then prohibited from approving the generic company's application for a 30-month period (which can be shortened or extended by the trial court judge hearing the patent challenge). If one or more of the NDA-listed patents are challenged, the first filer(s) of a Paragraph IV certification may be entitled to a 180-day period of market exclusivity over all other generic manufacturers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic manufacturers use Paragraph IV certifications extensively to challenge patents on innovative pharmaceuticals. In addition, generic companies have shown willingness to launch "at risk," i.e., after receiving ANDA approval but before final resolution of their patent challenge.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BPCIA, the FDA cannot approve an application for a biosimilar product until data protection expires, 12 years after initial marketing approval of the innovator biologic, and an application may not be submitted until four years following the date the innovator biologic was first approved. However, the BPCIA does provide a mechanism for a prospective biosimilar competitor to challenge the validity of an innovator's patents as early as four years after initial marketing approval of the innovator biologic. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent litigation scheme under the BPCIA, and the BPCIA itself, is complex and continues to be interpreted and implemented by the FDA, as well as by courts. Courts have held that biosimilar applicants are not required to engage in the BPCIA patent litigation scheme and patent holders retain the right to bring suit under normal patent law procedures if a biosimilar applicant attempts to commercialize a product prior to patent expiration. Further, in the U.S., the increased likelihood of generic and biosimilar challenges to innovators' intellectual property has increased the risk of loss of innovators' market exclusivity. See also "&#8212;Competition&#8212;Biosimilars." In addition, there is a procedure in U.S. patent law, known as inter partes review (IPR), which allows any member of the public to file a petition with the USPTO seeking the review of any issued U.S. patent for validity. IPRs are conducted before Administrative Patent Judges in the USPTO using a lower standard of proof than used in federal district court. In addition, the challenged patents are not accorded the presumption of validity as they are in federal district court. Generic drug companies and even some investment firms have engaged in the IPR process in attempts to invalidate our patents. The use of IPR proceedings after the institution of litigation pursuant to the BPCIA or Hatch-Waxman Act is currently a topic of debate among legislators. We have also observed, and may continue to observe, changes at the Patent Trial and Appeal Board (PTAB), including with respect to the PTAB's policy to discretionarily deny an otherwise meritorious petition for IPR in light of a concurrent district court proceeding. See Item 1A, "Risk Factors&#8212;Risks Related to Our Business&#8212;Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected."</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., the legal doctrines and processes by which pharmaceutical patents can be challenged vary widely. In recent years, we have experienced an increase in patent challenges from generic manufacturers in many countries outside the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information on administrative challenges and litigation involving our intellectual property rights, see Item 8, "Financial Statements and Supplementary Data&#8212;Note 16: Contingencies." </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation of Our Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are regulated extensively by numerous national, state, and local agencies. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulation of Products </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lengthy process of laboratory and clinical testing, data analysis, manufacturing development, and regulatory review necessary for governmental approvals of our products is extremely costly and can significantly delay product introductions and revenue generation. In addition, our operations are subject to complex federal, state, local, and foreign laws and regulations concerning relationships with healthcare providers and suppliers, the environment, occupational health and safety, data privacy, and other matters. Evolving regulatory priorities have intensified governmental scrutiny of our operations, including with respect to current Good Manufacturing Practices (cGMP), quality assurance, and similar regulations. Compliance with the laws and regulations affecting the manufacture and sale of current products and the discovery, development, and introduction of new products and uses will continue to require substantial effort, expense, and capital investment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of particular importance to our business is regulation by the FDA in the U.S. Pursuant to laws and regulations that include the Federal Food, Drug, and Cosmetic Act, the FDA has jurisdiction over all of our products and devices in the U.S. and administers requirements covering the testing, safety, effectiveness, manufacturing, quality control, distribution, labeling, marketing, promotion, advertising, dissemination of information, and post-marketing surveillance of those products and devices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval, our products remain subject to regulation by various agencies in connection with labeling, import, export, storage, recordkeeping, advertising, promotion, and safety reporting. We conduct extensive post-marketing surveillance of the safety of the products we sell. The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after a product reaches the market. The FDA also strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Pharmaceutical products may be promoted only for approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., our products and operations are subject to similar regulatory requirements, notably by the EMA in Europe, the Ministry of Health, Labor and Welfare in Japan, and the National Medical Products Administration in China. Specific regulatory requirements vary from country to country. Regulatory and compliance requirements, as well as approval processes outside the U.S., may differ from those in the U.S. and may involve additional costs, uncertainties, and risks.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory agencies outside the U.S. extensively regulate all aspects of manufacturing quality for pharmaceuticals under their cGMP regulations. We make substantial investments of capital and operating expenses to implement comprehensive, company-wide quality systems and controls in our manufacturing, product development, and process development operations in an effort to maintain sustained compliance with cGMP and other regulations. However, in the event we fail to adhere to these requirements, we become subject to potential government investigations, regulatory and legal actions, product recalls and seizures, fines and penalties, interruption of production leading to product shortages, import bans or denials of import certifications, delays or denials in new product approvals or line extensions or supplemental approvals of current products pending resolution of the issues, and reputational harm, any of which would adversely affect our business. Certain of our products are manufactured by third parties, and their failure to comply with these regulations could adversely affect us, including through failure to supply product to us or delays in approvals of new products or indications. Any determination by the FDA or other regulatory authorities of manufacturing or other deficiencies could adversely affect our business and reputation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to a variety of federal, state, local, and foreign environmental, health and safety, and other laws and regulations that may affect our research, development or production efforts. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emergency Use Authorizations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Secretary of Health and Human Services may issue an EUA to authorize unapproved medical products, or unapproved uses of approved medical products, to be manufactured, marketed, and sold in the context of an actual or potential emergency that has been designated by the government. An EUA terminates when the emergency determination underlying the EUA terminates, and EUAs can be revoked under other circumstances, the timing of which may occur unexpectedly or be difficult to predict.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., the emergency use of medical products is subject to regulatory processes and requirements that vary and differ from those in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has been designated as a national emergency in the U.S. On the basis of such determination, the FDA granted EUAs for bamlanivimab and etesevimab administered together, certain COVID-19-related uses of baricitinib, and bebtelovimab, and similar actions have been taken by other regulators in certain jurisdictions outside the U.S. However, the FDA has revised, and may in the future further revise, these EUAs in response to the changing conditions of the COVID-19 pandemic, such as the prevalence of variants against which our antibodies have varying degrees of efficacy. In May and November 2022, respectively, the FDA announced that bamlanivimab and etesevimab are, and bebtelovimab is, not currently authorized for emergency use for any U.S. region.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Laws and Regulations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketing, promotional, and pricing practices of pharmaceutical manufacturers, as well as the manner in which manufacturers interact with purchasers, prescribers, and patients, are subject to various other U.S. federal and state laws, as well as analogous foreign laws and regulations, including the federal anti-kickback statute, the False Claims Act, and state laws governing kickbacks, false claims, unfair trade practices, and consumer protection. These laws are administered by, among others, the Department of Justice, the Office of Inspector General of the Department of Health and Human Services, the Federal Trade Commission, the Office of Personnel Management, and state attorneys general. State, federal, and foreign governments, agencies, and other regulatory bodies are active in their oversight, enforcement activities, and coordination with respect to pharmaceutical companies, which has resulted in intensified scrutiny, litigation costs, corporate criminal sanctions, and substantial civil settlements in the pharmaceutical industry. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Foreign Corrupt Practices Act of 1977 (FCPA) prohibits certain individuals and entities, including U.S. publicly traded companies, from promising, offering, or giving anything of value to foreign officials with the corrupt intent of influencing the foreign official for the purpose of helping the company obtain or retain business or gain any improper advantage. The FCPA also imposes specific recordkeeping and internal controls requirements on U.S. publicly traded companies. As noted above, our business is heavily regulated and therefore involves significant interaction with officials outside the U.S. Additionally, in many countries outside the U.S., healthcare providers who prescribe pharmaceuticals are employed by the government and purchasers of pharmaceuticals are government entities; therefore, our interactions with these prescribers and purchasers are subject to regulation under the FCPA. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the U.S. application and enforcement of the FCPA, the various jurisdictions in which we operate and supply our products have laws and regulations aimed at preventing and penalizing corrupt and anticompetitive behavior. In recent years, several jurisdictions have enhanced their laws and regulations in this area, increased their enforcement activities, and/or increased the level of cross-border coordination and information sharing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are, and could in the future become, subject to administrative and legal proceedings and actions, which could include claims for civil penalties (including treble damages under the False Claims Act), criminal sanctions, and administrative remedies, including exclusion from U.S. federal and other healthcare programs. It is possible that an adverse outcome in future actions could have a material adverse impact on our consolidated results of operations, liquidity, and financial position in any given period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to a variety of federal, state, local, and foreign environmental, health and safety, and other laws and regulations that may affect our research, development, or production efforts. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There continues to be considerable public and government scrutiny of pharmaceutical pricing. In addition, U.S. government actions to reduce federal spending on entitlement programs, including Medicare and Medicaid, may affect payment for our products or services associated with the provision of our products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the U.S. government enacted the Inflation Reduction Act of 2022 (IRA). Among other measures, the IRA will require the U.S. Department of Health and Human Services to effectively set prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D. Generally, these government prices apply nine (medicines approved under an NDA) or thirteen (medicines approved under a Biologics License Application) years following initial FDA approval and will be capped at a statutory ceiling price that is likely to represent a significant discount from average prices to wholesalers and direct purchasers. It is too soon to tell how the U.S. government will set these prices as the law specifies a ceiling price, but not a minimum or floor price. One or more of our significant products may be selected, which would have the effect of accelerating revenue erosion prior to patent expiry. The effect of reducing prices and reimbursement for certain of our products would significantly impact our business and consolidated results of operations. The establishment of payment limits or other restrictions by drug affordability review boards and other state level actors would similarly impact us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other IRA provisions provide for rebate obligations on drug manufacturers that increase prices of Medicare Part B and Part D medicines at a rate greater than the rate of inflation and Part D benefit redesign that includes replacing the Part D coverage gap discount program with a new manufacturer discounting program. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties, which could be significant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA takes effect progressively starting in 2023, with the first government-set prices effective in 2026. The IRA may meaningfully influence our business strategies and those of our competitors. In particular, the nine-year timeline to set prices for medicines approved under an NDA may reduce the attractiveness of investment in small molecule innovation. The implications to us of a competitor&#8217;s product being selected for price setting are also uncertain. Provisions of the IRA may be subject to legal challenges or other reformation, and the full impact of the IRA on our business and the pharmaceutical industry remains uncertain.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Heightened governmental scrutiny over the manner in which drug manufacturers price their marketed products has also resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Restrictive or unfavorable pricing, coverage, or reimbursement determinations for our medicines or product candidates by governments, regulatory agencies, courts, or private payers could also adversely impact our business and financial results. For example, in April 2022, the Centers for Medicare &amp; Medicaid Services issued the Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer&#8217;s Disease national coverage determination (the Alzheimer's Monoclonal Antibody NCD) limiting coverage of FDA-approved monoclonal antibodies that target amyloid for the treatment of Alzheimer's disease for people with Medicare only if they are enrolled in qualifying clinical trials. In its current form, the Alzheimer&#8217;s Monoclonal Antibody NCD would result in significantly reduced coverage for, and negatively impact, our product candidate donanemab, and may negatively impact our business and financial results. Additional policies, regulations, legislation, or enforcement, including those proposed or pursued by the U.S. Congress, the current U.S. presidential administration, and regulatory authorities worldwide, could intensify these efforts and adversely impact our business and consolidated results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., we are required to provide rebates to the federal government and state governments on their purchases of our pharmaceuticals under various federal and state healthcare programs, including state Medicaid and Medicaid Managed Care programs (minimum of 23.1 percent plus adjustments for price increases above the consumer price index over time) and discounts to private entities who treat patients in certain types of healthcare facilities intended to serve low-income and uninsured patients (known as 340B covered entities). Additionally, an annual fee is imposed on pharmaceutical manufacturers and importers that sell branded prescription drugs to specified government programs. Since 2019, the Bipartisan Budget Act has required manufacturers of brand-name drugs, biologics, and biosimilars to provide a discount of 70 percent of the cost of branded prescription drugs for Medicare Part D participants who are in the "doughnut hole" (the coverage gap in Medicare prescription drug coverage). Beginning in October 2024, under the IRA the 70 percent discount will be replaced by a 10 percent discount for all Medicare Part D beneficiaries that have met their deductible and incurred out of pocket drug costs below a $2,000 threshold and a 20 percent discount for beneficiaries that have incurred out of pocket drug costs above the $2,000 threshold.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates are also negotiated in the private sector. We pay rebates to private payers that provide prescription drug benefits to seniors covered by Medicare and to private payers that provide prescription drug benefits to their customers. These rebates are affected by the introduction of competitive products and generics in the same class. Our approach to the rebates we offer to private payers that provide prescription drug benefits to seniors covered by Medicare may be impacted by the 2020 regulatory amendments to the anti-kickback statute's discount safe harbor, which have currently been stayed until at least January 1, 2032. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of risks related to how we price our products, see Item 1A, "Risk Factors&#8212;Risks Related to Our Business&#8212;We face litigation and investigations related to our products, how we price our products, and how we commercialize our products; we could face large numbers of claims in the future, which could adversely affect our business, and we are self-insured for such matters."</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outside the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Globally, public and private payers are increasingly restricting access to pharmaceuticals based on assessments of comparative effectiveness and value, including through the establishment of formal health technology assessment processes. In addition, third-party organizations, including professional associations, academic institutions, and non-profit entities associated with payers, conduct and publish comparative effectiveness and cost/benefit analyses on medicines, the impact of which are uncertain. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In most international markets, we operate in an environment of government-mandated cost-containment programs, which may include price controls, international reference pricing (to other countries' prices), discounts and rebates, therapeutic reference pricing (to other, often generic, pharmaceutical choices), restrictions on physician prescription levels, and mandatory generic substitution. In October 2022, the German Parliament passed cost cutting reforms and these reforms were followed by activation of a clawback mechanism in France and implementation of increased mandatory rebates in the United Kingdom. These changes may be followed in 2023 by biopharmaceutical-focused austerity measures in more countries in Europe and in other markets. Reforms, including those that may stem from periods of economic downturn or uncertainty, or as a result of high inflation, emergence or escalation of, and responses to, war or unrest (including the Russia-Ukraine war), or government budgeting priorities (including as exacerbated by the COVID-19 pandemic), may continue to result in added pressure on pricing and reimbursement for our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the extent to which our business may be affected by these or other potential future legislative, regulatory, or payer developments. However, in general we expect to see continued focus on regulating pricing, resulting in additional state, federal, and international legislative and regulatory developments that could have further negative effects on pricing and reimbursement for our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 7, "Management's Discussion and Analysis&#8212;Executive Overview&#8212;Other Matters&#8212;Trends Affecting Pharmaceutical Pricing, Reimbursement, and Access" for additional information regarding recent legislative, administrative, and other pricing initiatives and their impact on our results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment to research and development dates back more than 140 years. We invest heavily in research and development because we believe it is critical to our long-term competitiveness. At the end of 2022, we employed approximately 9,000 people in pharmaceutical research and development activities, including a substantial number of physicians, scientists holding graduate or postgraduate degrees, and highly skilled technical personnel. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal pharmaceutical research focuses primarily on the areas of obesity &amp; diabetes, immunology, neuroscience, and oncology. At the outset of the COVID-19 pandemic, we also focused on researching and developing potential treatments for COVID-19. In addition to discovering and developing new medicines, we seek to expand the value of existing products through new uses, formulations, and therapeutic approaches that provide additional value to patients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To supplement our internal efforts, we collaborate with others, including academic institutions and research-based pharmaceutical and biotechnology companies. We use the services of physicians, hospitals, medical schools, and other research organizations worldwide to conduct clinical trials to establish the safety and effectiveness of our medicines. We also invest in external research and technologies that we believe complement and strengthen our own efforts. These investments can take many forms, including, among others, licensing arrangements, co-development agreements, co-promotion arrangements, joint ventures, acquisitions, and equity investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical development is time-consuming, expensive, and risky. Very few of the candidates discovered by researchers ultimately become approved medicines. The process from discovery to regulatory approval can take over a decade. Candidates can fail at any stage of the process, and even late-stage candidates sometimes fail to receive regulatory approval or achieve commercial success. The following describes in more detail the research and development process for pharmaceutical products:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phases of New Drug Development</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10pt">Discovery Phase</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the discovery phase, scientists identify, design, and synthesize promising candidates by analyzing their effect on biological targets thought to play a role in disease. Targets are often unproven and only candidates that have the desired effect on the target and meet other design criteria move to the next phase of development, which includes the initiation of studies in animals to support regulatory and safety requirements for clinical research in humans. The discovery phase can take years and the probability of any one candidate becoming a medicine is extremely low.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Early Development Phase</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early development includes initial testing for safety and efficacy and early analyses of manufacturing requirements. Safety testing is initially performed in laboratory tests and animals, as necessary. In general, the first human tests (often referred to as Phase I) are conducted in small groups of subjects to assess safety and evaluate the potential dosing range. Subsequently, larger populations of patients are studied (Phase II) to identify initial signs of efficacy while continuing to assess safety. In parallel, scientists work to identify safe, effective, and economical manufacturing processes. Long-term animal studies continue to test for potential safety issues. Of the candidates that enter the early development phase, approximately 10 percent move to the late development phase. The early development phase varies but can take several years to complete.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Late Development Phase</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Late phase development projects (typically Phase III) have met initial safety requirements and shown initial evidence of efficacy in earlier studies. As a result, these candidates generally have a higher likelihood of success and trials include larger patient populations to demonstrate safety and efficacy in the disease. These studies are designed to demonstrate the benefit and risk of the potential new medicine and may be compared to competitive therapies, placebo, or both. Phase III studies are generally conducted globally and are designed to support regulatory filings for marketing approval. The duration of Phase III testing varies by disease and may take two to four years.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Submission Phase</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a potential new medicine is submitted to regulatory agencies, the time to final marketing approval can vary from several months to several years, depending on the disease state, the strength and complexity of available data, the degree of unmet need, and the time required for the regulatory agency(ies) to evaluate the submission, which can depend on prioritization by regulators and other factors. There is no guarantee that a potential medicine will receive marketing approval, or that decisions on marketing approvals or indications will be consistent across geographic areas.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our investments in research, both internally and in collaboration with others, have resulted in a robust pipeline of potential new medicines and new treatment indications in all stages of development. We have a number of</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> new medicine </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates in clinical development or under regulatory review, and we have a larger number of projects in the discovery phase. See Item 7, "Management's Discussion and Analysis&#8212;Executive Overview&#8212;Late-Stage Pipeline," for more information on our late-stage product candidates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Raw Materials and Product Supply</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we obtain certain raw or intermediate materials primarily from only one source. We generally seek to maintain sufficient inventory to supply the market until an alternative source of supply can be implemented, in the event one of these suppliers becomes unable to provide the materials or product. However, various developments have led, and may in the future lead, to interruption or shortages in supply until we establish new sources, implement alternative processes, bring new manufacturing facilities online, or pause or discontinue product sales in one or more markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our revenue comes from products produced predominantly in our own facilities. Our principal active ingredient manufacturing occurs at sites we own in the U.S., including Puerto Rico, and Ireland. Finishing operations, including formulation, filling, assembling, delivery device manufacturing, and packaging, take place at a number of sites throughout the world. We utilize third parties for certain active ingredient manufacturing and finishing operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our supply chain (including our own facilities, contracted arrangements, and inventory) in a way that is intended to allow us to meet substantially all expected product demand while maintaining flexibility to reallocate manufacturing capacity to improve efficiency and respond to changes in supply and demand. To maintain supply of our products, we use a variety of techniques, including comprehensive quality systems, inventory management, and back-up sites.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, pharmaceutical production processes are complex, highly regulated, and vary widely from product to product. Shifting or adding manufacturing capacity can be a very lengthy process requiring significant capital expenditures, process modifications, and regulatory approvals. Accordingly, developments such as unplanned plant shutdowns, manufacturing or quality assurance difficulties at one of our facilities or contracted facilities, failure or refusal of a supplier or contract manufacturer to supply contracted quantities, increases in demand on a supplier, or difficulties in predicting or variability in demand for our products and those of our competitors have led, and may in the future lead, to interruption or higher costs in the supply of certain products, product shortages, or pauses or discontinuations of product sales in one or more markets. Further, global transportation and logistics challenges, cost inflation, and tight labor markets, have caused, and in the future may cause, delays in and/or increased costs related to distribution of our medicines, the construction or acquisition of manufacturing capacity, procurement activity, and supplier or contract manufacturer arrangements. For more information on the additional risks we face in connection with any difficulties, disruptions, and shortages in the manufacturing, distribution, and sale of our products, see Item 1A, "Risk Factors&#8212;Risks Related to Our Business&#8212;Manufacturing, quality, or supply chain difficulties, disruptions, or shortages could lead to product supply problems."</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, cost inflation, the strain on global transportation, logistics, and labor markets (including as exacerbated by the COVID-19 pandemic and the emergence or escalation of, and responses to, war or unrest, including the Russia-Ukraine war), global economic downturns or uncertainty, and an increase in overall demand in our industry for certain products and materials have had, and may continue to have, a number of impacts on our business, including increased costs and disruptions in the supply of our medicines. For more information, see Item 1A, "Risk Factors&#8212;Risks Related to Our Business&#8212;Public health outbreaks, epidemics, or pandemics, such as the COVID-19 pandemic, have adversely impacted and may in the future adversely impact our business and operations." and Item 7, "Management's Discussion and Analysis&#8212;Executive Overview&#8212;Other Matters&#8212;COVID-19 Pandemic."</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality Assurance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in great measure on customer confidence in the quality of our products and in the integrity of the data that support their safety and effectiveness. Product quality requires a total commitment to quality in all parts of our operations, including research and development, purchasing, facilities planning, manufacturing, distribution, and dissemination of information about our medicines. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality of production processes involves strict control of ingredients, equipment, facilities, manufacturing methods, packaging materials, and labeling. We perform tests at various stages of production processes and on the final product in an effort to ensure that the product meets all applicable regulatory requirements and our internal standards. These tests may involve chemical and physical chemical analyses, microbiological testing, testing in animals, or a combination thereof. Additional assurance of quality is provided by quality assurance groups that audit and monitor all aspects of quality related to pharmaceutical manufacturing procedures and systems in company operations and at third-party suppliers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers of the Company</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information regarding our current executive officers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of office for each executive officer expires on the date of the annual meeting of the board of directors, to be held on May 1, 2023 in connection with the company's annual meeting of shareholders, or on the date his or her successor is chosen and qualified. No director or executive officer has a "family relationship" with any other director or executive officer of the company, as that term is defined for purposes of this disclosure requirement. There is no understanding between any executive officer or director and any other person pursuant to which the executive officer was selected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.597%"><tr><td style="width:1.0%"></td><td style="width:16.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Titles and Business Experience</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">David Ricks</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chair, President, and Chief Executive Officer (CEO) (since 2017). Previously, Mr. Ricks held various leadership roles with Lilly, including senior vice president and president, Lilly Bio-Medicines. Mr. Ricks has 26 years of service with Lilly.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anat Ashkenazi </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Executive Vice President and Chief Financial Officer (since 2021). Previously, Ms. Ashkenazi held various leadership roles with Lilly, including senior vice president, controller and chief financial officer, Lilly Research Laboratories, and vice president, finance and chief financial officer, Lilly Diabetes and Lilly global manufacturing and quality. Ms. Ashkenazi has 21 years of service with Lilly. </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eric Dozier</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Executive Vice President, Human Resources and Diversity (since 2022). Previously, Mr. Dozier held various leadership roles with Lilly, including senior vice president, chief commercial officer for Loxo@Lilly, and vice president, global ethics and compliance officer. Mr. Dozier has 25 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anat Hakim</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Executive Vice President, General Counsel and Secretary (since 2020). Prior to joining Lilly, Ms. Hakim was senior vice president, general counsel and secretary of WellCare Health Plans, Inc. (WellCare) from 2016 to 2018, and executive vice president, general counsel and secretary of WellCare from 2018 to 2020. Prior to joining WellCare, she served as divisional vice president and associate general counsel of intellectual property litigation at Abbott Laboratories from 2010 to 2013 and divisional vice president and associate general counsel of litigation from 2013 to 2016. Ms. Hakim has three years of service with Lilly.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Edgardo Hernandez</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Executive Vice President and President, Manufacturing Operations (since 2021). Previously, Mr. Hernandez held various leadership roles with Lilly, including senior vice president, global parenteral drug product, delivery devices and regional manufacturing, and vice president, Fegersheim operations. Mr. Hernandez has </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patrik Jonsson</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Executive Vice President and President, Lilly Immunology, Lilly USA, and Chief Customer Officer (since 2021). Previously, Mr. Jonsson held various leadership roles with Lilly, including senior vice president and president, Lilly USA, and chief customer officer, senior vice president and president, Lilly Bio-Medicines and president and general manager, Lilly Japan. Mr. Jonsson has 32 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Michael Mason </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Executive Vice President and President, Lilly Diabetes (since 2020). Previously, Mr. Mason held various leadership roles with Lilly, including senior vice president, connected care and insulins and vice president of U.S. Diabetes. Mr. Mason has 33 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Johna Norton</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Executive Vice President, Global Quality (since 2017). Previously, Ms. Norton held various leadership roles with Lilly, including vice president, global quality assurance API manufacturing and product research and development. Ms. Norton has 32 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leigh Ann Pusey</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Executive Vice President, Corporate Affairs and Communications (since 2017). Prior to joining Lilly, Ms. Pusey was president and chief executive officer of the American Insurance Association from 2009 to 2017. Ms. Pusey has five years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diogo Rau</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Executive Vice President and Chief Information and Digital Officer (since 2021). Prior to joining Lilly, Mr. Rau was senior director of information systems and technology for retail and online stores of Apple Inc. from 2011 to 2021. Prior to his tenure at Apple, he served as a partner at McKinsey &amp; Company. Mr. Rau has two years of service with Lilly.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Daniel Skovronsky, M.D., Ph.D.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Executive Vice President, Chief Scientific and Medical Officer, and President, Lilly Research Laboratories (since 2021). Previously, Dr. Skovronsky held various leadership roles with Lilly, including senior vice president, chief scientific officer, and president, Lilly Research Laboratories, and senior vice president, clinical and product development. Dr. Skovronsky has 12 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jacob Van Naarden</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Executive Vice President, CEO, Loxo@Lilly, and President, Lilly Oncology (since 2021). Previously, Mr. Van Naarden served as Chief Executive Officer-Loxo Oncology at Lilly, and Chief Operating Officer-Loxo Oncology at Lilly. Mr. Van Naarden joined Lilly in 2019 when the company acquired Loxo Oncology, Inc., where he was the chief operating officer. In previous roles, Mr. Van Naarden worked in various biotechnology investing, operating, and advisory capacities, including positions with HealthCor Management, Aisling Capital, and Goldman Sachs. Mr. Van Naarden has four years of service with Lilly.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alonzo Weems</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Executive Vice President, Enterprise Risk Management, and Chief Ethics and Compliance Officer (since 2021). Previously, Mr. Weems held various leadership roles with Lilly, including vice president and deputy general counsel for corporate legal functions, general counsel for Lilly USA, and general counsel for biomedicines and diabetes. Mr. Weems has </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anne White</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Executive Vice President and President, Lilly Neuroscience (since 2021). Previously, Ms. White held various leadership roles with Lilly, including senior vice president and president, Lilly Oncology, vice president of Portfolio Management, Chorus, and Next Generation Research and Development. Ms. White has 27 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ilya Yuffa</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Executive Vice President and President, Lilly International (since 2021). Previously, Mr. Yuffa held various leadership roles with Lilly, including senior vice president and president, Lilly Bio-Medicines, vice president of U.S. Diabetes, general manager of Italy Hub, and vice president, global ethics and compliance officer since 2014. Mr. Yuffa has 26 years of service with Lilly.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our core values&#8212;integrity, excellence, and respect for people&#8212;shape our approach to attracting, retaining, engaging, and developing a highly skilled and ethical workforce, which is critical to executing our strategy. We believe the strength of our workforce significantly contributes to our financial performance and enables us to make life better for people around the world. For instance, most of the products we sell today were discovered or developed by our own scientists, and our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines. We believe that fostering a positive culture that values the contributions of our talented colleagues helps drive our success.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to creating a safe, supportive, ethical, and rewarding work environment through strategic focus on our human capital management process, fairness and nondiscrimination in our employment practices, robust training and development opportunities, and competitive pay and benefits. We believe our dedication to promoting diversity, equity, and inclusion (DEI) within our company reflects our values and is a key driver of business success and growth. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly conduct anonymous employee surveys to seek feedback from our workforce on a variety of topics. These results are reviewed and analyzed by our leaders to identify opportunities to adjust our policies and benefits to improve our employees' experience. As a result of our efforts, we believe that we have a highly performing, cohesive workforce and that our employee relations are good.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of 2022, we employed approximately 39,000 people, including approximately 21,000 employees outside the U.S. Our employees include approximately 9,000 people engaged in research and development activities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategy and Oversight</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to build diverse and inclusive teams, our CEO and executive committee set expectations for inclusive leadership and hold leaders accountable for achieving results. Because dedication to human capital management is also a core component of our corporate governance, our board of directors regularly engages with management and facilitates a system of reporting designed to monitor human capital management initiatives and progress as part of the overarching framework that guides how we attract, retain, engage, and develop a workforce that aligns with our values and mission. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diversity, Equity, and Inclusion</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to fairness and nondiscrimination in our employment practices, and we deeply value diverse backgrounds, skills, and global perspectives. To fulfill our purpose, we believe we must look at challenges from multiple viewpoints and understand the diverse experiences of the patients who depend on us. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that fostering DEI begins with understanding. For example, our </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Journeys </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research has yielded important insights about the experiences of women, Black/African American, Latinx, Asian, and LGBTQ+ employees at Lilly. The results of this research are reviewed by our senior leadership, and we deploy actions and activities in response to these insights to improve our workplace and corporate culture.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, as part of our DEI and community initiatives, Lilly and the Lilly Foundation launched the Racial Justice Commitment, with Lilly pledging 25,000 volunteer hours and the Lilly Foundation committing $25 million over five years to help decrease the burden of racial injustice and its effects on communities of color. The Racial Justice Commitment aims to drive change across five areas: internal people development, health equity, social impact, diversity partners, and family sustaining jobs, through the use of financial and people resources. From 2020 through 2022, we have made progress in these efforts, including nearly tripling our spending with Black-owned businesses, committing over $98 million in minority-led venture capital firms, serving over 30,000 volunteer hours to advance racial justice initiatives, and expanding our Skills First Program at Lilly for individuals without four-year college degrees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2017, we have committed to increasing women, Black/African American, Latinx, and Asian representation in leadership roles, and we actively monitor our progress. From the end of 2018 through the end of 2022, we increased the percentage of women in management globally from 42 percent to 49 percent. For minority group members (MGM) in the U.S. over the same period, we increased management representation from 19 percent to 25 percent. Across all levels of our workforce, from the end of 2018 through the end of 2022, we have seen increased representation for MGMs in the U.S. and women globally. Our focus on DEI is also evident at our executive committee and board of directors. Five of 15 current members (approximately 33 percent) of our executive committee (which includes our CEO) are women and three are MGMs. In addition, as of the filing of this report, the company's 13-member board of directors includes five women and six members who are MGMs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our efforts in DEI and workplace benefits have garnered numerous recognitions, including, in 2022, Top 50 Companies for Diversity by DiversityInc., Top Companies for Board of Directors by DiversityInc., Top Companies for Supplier Diversity by DiversityInc., Top Companies for ESG by DiversityInc., America's Best Employers for Women by Forbes, Perfect Score on the Human Rights Campaign Foundation Corporate Equality Index, World's Most Ethical Companies by Ethisphere, Perfect Score on Disability Equity Index Best Places to Work by Disability:IN, Pharmaceutical Innovation Index, Zero Project Award for Access Lilly, and Top Companies for Executive Women, Best Companies for Multicultural Women, Best Companies for Dads, 70 percent and Higher Inclusion Index by Seramount.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Development</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe attracting and retaining the best, diverse talent begins with the hiring process. We therefore require hiring managers to consider a diverse pool of candidates and we strive to provide a diverse panel of interviewers for open positions. We believe that hiring in this way helps ensure that people from all backgrounds have equal opportunity to advance their careers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2022, we launched </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discover</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a 12-month new employee onboarding program with multiple touchpoints designed to foster integration into Lilly, to accelerate learning in their new roles and to create connections to further a sense of belonging at Lilly. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discover</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was shaped in part by external benchmarking, feedback from employees, and learnings from onboarding remotely during the COVID-19 pandemic.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer training to enable our employees to perform their duties in our highly regulated industry. We also strive to cultivate a culture that promotes ongoing learning by encouraging employees to seek further education and growth experiences, helping them build rewarding careers. We have introduced online programming to facilitate access to our learning and development offerings in addition to our in-person programs. Many training courses are designed to improve accessibility for people with disabilities and other unique needs. Across Lilly, we are continuously working to design learning experiences to be more inclusive and effective. In addition, we have implemented development tools and resources for all employees, improved our talent programs and processes to provide broader access to information, and increased transparency regarding career development and advancement at Lilly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee resource groups (ERGs) are another important component of developing talent at Lilly. We currently have 11 ERGs representing groups including women, MGMs, LGBTQ+ individuals, veterans, and people with disabilities. ERGs offer our diverse workforce opportunities to build relationships, engage with senior leaders, advance our caring community, and offer unique insights and perspectives to improve our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have continued our efforts to create an inclusive workplace with the goal of ensuring that all employees feel safe to speak up and share their ideas at work. Our Make it Safe to Thrive education and awareness program is designed to help employees and leaders understand how individual psychological safety can be created and enhanced and includes live and online training. In late 2022, we introduced a new version of Make it Safe to Thrive for leaders that continues to focus on psychological safety and creating an inclusive environment. Leaders are provided the opportunity to work through challenging conversations and situations currently being navigated in the workplace.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly is committed to fostering a culture of diversity and respect in the workplace&#8212;an environment free of discrimination, harassment, or retaliation of any kind. In 2022, as part of our annual review of The Red Book and related policies and procedures, we revised the Global Conduct in the Workplace procedure to continue to help ensure that we maintain a respectful, safe, inclusive, and professional workplace.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Health and Safety</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to foster a healthy, vibrant work environment, which includes keeping our employees safe. We seek to create a companywide culture where best-in-class safety practices are consistently followed. To do this, we assess and continuously attempt to improve our companywide safety performance to promote the well-being of employees and to help safeguard communities where we operate. As the COVID-19 pandemic has evolved, we have continued to take various measures (as necessary) to protect and support the health and safety of our employees globally. We believe a holistic approach and dedication to safety helps us be our best as we deliver on our company purpose to improve lives around the world.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information Available on Our Website</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our company website is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">www.lilly.com</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the information accessible on or through our website is incorporated into this Annual Report on Form 10-K. We make available through the website, free of charge, our company filings with the SEC as soon as reasonably practicable after we electronically file them with, or furnish them to, the SEC. These include our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, proxy statements, registration statements, and any amendments to those documents. The link to our SEC filings is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">investor.lilly.com/financial-information/sec-filings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paper copies of the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that are filed with the SEC are available without charge upon written request to:</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ELI LILLY AND COMPANY</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c/o General Counsel and Secretary</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly Corporate Center</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indianapolis, Indiana 46285</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the "Governance" section of our website includes our corporate governance guidelines, board of directors and committee information (including committee charters), and our articles of incorporation and bylaws. The link to our corporate governance information is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">lilly.com/leadership/governance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We routinely post important information for investors in the &#8220;Investors&#8221; section of our website, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">www.lilly.com</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We may use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the &#8220;Investors&#8221; section of our website, in addition to following our press releases, filings with the SEC, public conference calls, presentations, and webcasts. We may also use social media channels to communicate with investors and the public about our business, products and other matters, and those communications could be deemed to be material information. The information contained on, or that may be accessed through, our website or social media channels, is not incorporated by reference into, and is not a part of, this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:2pt">Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the other information contained in this Annual Report on Form 10-K, the following risk factors should be considered carefully in evaluating our company. It is possible that our business, financial condition, liquidity, cash flows, or results of operations could be materially adversely affected by any of these risks. Certain of these risks could also adversely affect the company's reputation. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could also adversely affect our business and reputation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Pharmaceutical research and development is very costly and highly uncertain; we may not succeed in developing, licensing, or acquiring commercially successful products sufficient in number or value to replace revenues of products that have lost or will lose intellectual property protection or are displaced by competing products or therapies.&#160;</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many difficulties and uncertainties inherent in pharmaceutical research and development, the introduction of new products, and business development activities to enhance our product pipeline. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a high rate of failure inherent in new drug discovery and development. To bring a drug from the discovery phase to market can take over a decade and often costs in excess of $2 billion. Failure can occur at any point in the process, including in later stages after substantial investment. As a result, most funds invested in research programs will not generate financial returns. New product candidates that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain or maintain necessary regulatory approvals or payer reimbursement or coverage, the application of pricing controls, limited scope of approved uses, label changes, changes in the relevant treatment standards or the availability of new or better competitive products, difficulty or excessive costs to manufacture, or infringement of the patents or intellectual property rights of others. Regulatory agencies establish high hurdles for the efficacy and safety of new products and indications. Delays, uncertainties, unpredictabilities, and inconsistencies in drug approval processes across markets and agencies can result in delays in product launches, lost market opportunity, potential impairment of inventories, and other negative impacts. In addition, it can be very difficult to predict revenue growth rates of or variability in demand for new products and indications.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot state with certainty when or whether our products now under development will be approved or launched; whether, if initially granted, such approval will be maintained; whether we will be able to develop, license, or otherwise acquire additional product candidates or products; or whether our products, once launched, will be commercially successful. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must maintain a continuous flow of successful new products and successful new indications or line extensions for existing products, both through our internal efforts and our business development activities, sufficient both to cover our substantial research and development costs and to replace revenues that are lost as profitable products become subject to pricing controls, lose intellectual property exclusivity, or are displaced by competing products or therapies. Failure to do so in the short-term or long-term would have a material adverse effect on our business, results of operations, cash flows, and financial position.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage in various forms of business development activities to enhance our product pipeline, including licensing arrangements, co-development agreements, co-promotion arrangements, joint ventures, acquisitions, and equity investments. There are substantial risks associated with identifying successful business development targets and consummating related transactions. Increased focus on business combinations in our industry, including by the Federal Trade Commission and competition authorities in Europe and other jurisdictions, and heightened competition for attractive targets has and could continue to delay, jeopardize or increase the costs of our business development activities. In addition, failures or difficulties in integrating or retaining new personnel or the operations of the businesses, products, or assets we acquire (including related technology, commercial operations, compliance programs, information security, manufacturing, distribution, and general business operations and procedures) may affect our ability to realize the expected benefits of business development transactions and may result in our incurrence of substantial asset impairment or restructuring charges. We also may fail to generate the expected revenue and pipeline enhancement from business development activities due to developments outside our control, including unsuccessful clinical trials, issues related to the quality, integrity, or broad applicability of data, regulatory impediments, and commercialization challenges. Accordingly, business </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development transactions may not be completed in a timely manner (if at all), may not result in successful development outcomes or successful commercialization of any product, and may give rise to legal proceedings or regulatory scrutiny.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1, "Business&#8212;Research and Development&#8212;Phases of New Drug Development" and Item 7, "Management's Discussion and Analysis&#8212;Executive Overview&#8212;Late-Stage Pipeline," for more details about our current product pipeline. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">We depend on products with intellectual property protection for most of our revenues, cash flows, and earnings; the loss of effective intellectual property protection for certain of our products has resulted, and in the future is likely to continue to result, in rapid and severe declines in revenues for those products.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of their lifecycles, our products lose significant patent protection and/or data protection in the U.S., as well as in key jurisdictions outside the U.S., after a specified period of time. Some products also lose patent protection as a result of successful third-party challenges. We have faced, and remain exposed to, generic competition following the expiration or loss of such intellectual property protection. For example, following the expiration of patent exclusivity for Alimta in Europe and Japan in June 2021, we have faced generic competition that has rapidly and severely eroded revenue from prior levels, and we expect such competition will continue to erode revenue from current levels in these markets. In addition, as a result of the entry of multiple generics in the U.S. following the expiration of patent and pediatric exclusivity for Alimta in in the first half of 2022, we began facing, and expect to continue to face, generic competition that has rapidly and severely eroded revenue from prior levels, and we expect will continue to erode revenue from current levels.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain other significant products no longer have effective exclusivity through patent protection or data protection. For non-biologic products, loss of exclusivity (whether by expiration of legal rights or by termination thereof as a consequence of litigation) typically results in the entry of one or more generic competitors, leading to a rapid and severe decline in revenues, especially in the U.S. For biologics (such as Humalog, Humulin, Erbitux, Cyramza, Trulicity, Taltz, and Emgality), loss of exclusivity may or may not result in the near-term entry of competitor versions (i.e., biosimilars) due to many factors, including development timelines, manufacturing challenges, and/or uncertainties regarding the regulatory pathways for approval of the competitor versions. Generic pharmaceutical companies could also introduce a generic product before resolution of any related patent litigation.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that the patents we are seeking will be granted or that the patents we hold will be found valid and enforceable if challenged. Moreover, patents relating to particular products, uses, formulations, or processes do not preclude other manufacturers from employing alternative processes or marketing alternative products or formulations that compete with our patented products. In addition, competitors or other third parties may assert claims that our activities infringe patents or other intellectual property rights held by them, or allege a third-party right of ownership in our existing intellectual property. See Item&#160;7, "Management's Discussion and Analysis&#8212;Executive Overview&#8212;Other Matters&#8212;Patent Matters," and Item 1, "Business&#8212;Patents, Trademarks, and Other Intellectual Property Rights," for more details. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines. Without strong intellectual property protection, we would be unable to generate the returns necessary to support our significant investments in research and development, as well as the other expenditures required to bring new drugs and indications to the market. Intellectual property protection varies throughout the world and is subject to change over time, depending on local laws and regulations. Changes to such laws, regulations, and enforcement practices could reduce protections for our innovative products and indications. For example, potential reforms to pharmaceutical legislation in the European Union may threaten the predictability and length of certain pharmaceutical intellectual property incentives. Changes proposed by the USPTO to limit the number of, and differences between, patents obtained could also affect the scope of patent protection for our products in the U.S. Also in the U.S., in addition to the process for challenging patents set forth in the BPCIA, which applies to biologic products, the Hatch-Waxman Act provides generic companies substantial incentives to seek to invalidate our patents covering pharmaceutical products. As a result, we expect that our U.S. patents on major pharmaceutical products, including biologics, will continue to be routinely challenged in litigation </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and may not be upheld. In addition, a separate IPR process currently allows competitors to seek invalidation of patents at the USPTO without the protections of the BPCIA or Hatch-Waxman Act. The use of IPR proceedings after the institution of litigation pursuant to the BPCIA or Hatch-Waxman Act is currently a topic of debate among legislators and the future ability of our competitors to use IPR proceedings as an alternative to Hatch-Waxman Act or BPCIA litigation procedures to challenge our patents remains uncertain. Recently, the USPTO issued an interim procedure regarding the use of discretionary denials of IPR proceedings when there is parallel district court litigation. However, it is not clear how this interim procedure could affect the ability of our competitors to institute IPR proceedings after institution of litigation. If our patents are challenged through this expedited review process, even if we prevail in demonstrating the validity of our patent, our win provides limited precedential value at the PTAB and no precedential value in federal district court, meaning the same patent can be challenged by other competitors. We face many generic manufacturer challenges to our patents outside the U.S. as well. The entry of generic competitors typically results in rapid and severe declines in revenues. In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property rights held by them. If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay significant damages for past infringement or royalties on future sales. In addition, intellectual property protection in certain jurisdictions outside the U.S. is weak and we face additional risks to our intellectual property rights, including competition with generic or counterfeit versions of our products relatively shortly after launch. See Item 1, "Business&#8212;Patents, Trademarks, and Other Intellectual Property Rights," and Item 8, "Financial Statements and Supplementary Data&#8212;Note 16: Contingencies," for more details.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">We and our products face intense competition from multinational pharmaceutical companies, biotechnology companies, and lower-cost generic and biosimilar manufacturers, and such competition could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete with a large number of multinational pharmaceutical companies, biotechnology companies, and generic pharmaceutical companies and, in many cases, our products compete against the leading products of one or more of our competitors. To compete successfully, we must continue to deliver to the market innovative, cost-effective products that meet important medical needs. Our product revenues can be adversely affected by the introduction by competitors of branded products that are perceived as superior by the marketplace, by generic or biosimilar versions of our branded products, and by generic or biosimilar versions of other products in the same therapeutic class as our branded products. Our revenues can also be adversely affected by treatment innovations, including new modalities, that eliminate or minimize the need for treatment with our drugs.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation of generic and biosimilar products varies around the world and such regulation is complex and subject to ongoing interpretation and implementation by regulatory agencies and courts. Particularly for biosimilars, health authority guidelines and legislative actions could make it less burdensome for competitor products to enter the market and further incentivize uptake of biosimilars. In the U.S., the FDA has issued several "interchangeability" designations for biosimilar products, and is expected to continue doing so in the future. These designations could &#8211; subject to state law requirements &#8211; enable pharmacies to substitute biosimilars for innovator biological products. Given the importance of biologic products to our clinical-stage pipeline, such regulation could have a material adverse effect on our business. See Item 1, "Business&#8212;Competition" and "Business&#8212;Research and Development," for more details.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on our ability to attract, engage, and retain highly qualified and skilled personnel in order to compete effectively. To continue to commercialize our products, and advance the research, development, and commercialization of additional modalities, indications, and product candidates, we have expanded, and will likely need to further expand, our workforce, including in the areas of manufacturing, clinical trials management, regulatory affairs, and sales and marketing, both in and outside the U.S. We continue to face intense competition for qualified individuals from numerous multinational pharmaceutical companies, biotechnology companies, academic and other research institutions, as well as employers near our manufacturing and other facilities, which has and may continue to increase our labor costs. Our ability to attract and retain talent in our increasingly competitive environment may be further complicated by evolving employment trends, including as related to increased preferences for remote or flexible work arrangements; public health outbreaks, epidemics, or pandemics, such as the COVID-19 pandemic; political, social, civil, or cultural unrest; emergence or escalation of, and responses to, war and unrest; or the threat of or perceived potential for any of the foregoing events. Our failure to compete effectively for talent could negatively affect sales of our current and any future </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved products, and could result in material financial, legal, commercial, or reputational harm to our business.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Failure, inadequacy, breach of, or unauthorized access to, our IT systems or those of our third-party service providers, unauthorized access to our confidential information, or violations of data protection laws, could each result in material harm to our business and reputation.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A great deal of confidential information owned by us or our business partners or other third parties is stored in our information systems, networks, and facilities or those of third parties. This includes valuable trade secrets and intellectual property, clinical trial information, corporate strategic plans, marketing plans, customer information, and personally identifiable information, such as employee and patient information (collectively, confidential information). We also rely, to a large extent, on the efficient and uninterrupted operation of complex information technology systems, infrastructure, and hardware (together, IT systems), some of which are within our control and some of which are within the control of third parties, to accumulate, process, store, and transmit large amounts of confidential information and other data. We are subject to a variety of continuously evolving and developing laws and regulations around the world related to privacy, data protection, and data security. Maintaining the security, confidentiality, integrity, and availability of our IT systems and confidential information is vital to our business. Our failure, or the failure of our third-party service providers, to protect and maintain the security, confidentiality, integrity, and availability of our (or their) IT systems and our confidential information and other data could significantly harm our reputation as well as result in significant costs, including those related to fines, litigation, and obligations to comply with applicable data breach laws.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IT systems are vulnerable to system inadequacies, operating failures, service interruptions or failures, security breaches, malicious intrusions, or cyber-attacks from a variety of sources, which may remain undetected for significant periods of time. Such vulnerabilities, inadequacies, or failures are in many cases more acute for IT systems associated with recently acquired businesses, and we may be unable to address such vulnerabilities, inadequacies, or failures immediately after acquiring a business. As a result, our newly acquired businesses could be more vulnerable to potential interruptions, breaches, intrusions, or attacks. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks are growing in their frequency, sophistication, and intensity, and are becoming increasingly difficult to detect, mitigate, or prevent. Cyber-attacks come in many forms, including the deployment of harmful malware, exploitation of vulnerabilities (including those of third-party software or systems), denial-of-service attacks, the use of social engineering, and other means to compromise the confidentiality, integrity, and availability of our IT systems, confidential information, and other data. Breaches resulting in the compromise, disruption, degradation, manipulation, loss, theft, destruction, or unauthorized disclosure or use of confidential information, or the unauthorized access to, disruption of, or interference with our IT systems, products and services, can occur in a variety of ways, including negligent or wrongful conduct by employees or others with permitted access to our systems and information, or wrongful conduct by hackers, competitors, certain governments or nation-states, or other current or former company personnel. Our third-party partners, including third-party providers of data hosting or cloud services, as well as suppliers, distributors, alliances, and other third parties with whom we may share data, face similar risks, which could affect us directly or indirectly. Unassociated third parties present further risks, including by propagating misinformation related to our products, business, and industry. The healthcare industry has been and continues to be a target for cyber-attacks, and the number of threats has increased over time. Numerous federal agencies that monitor and regulate internet and cyber-crime have issued guidance, alerts and directives warning of software vulnerabilities that require immediate patching, malicious actors targeting healthcare-related systems and nation-state sponsored hacking designed to steal valuable information.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure, inadequacy, or breach of our IT systems or business processes, the compromise, disruption, degradation, manipulation, loss, theft, destruction, or unauthorized access to, disclosure or use of, confidential information, or the unauthorized access to, disruption of, or interference with our products and services that rely on IT systems or business processes, could impair our ability to secure and maintain intellectual property rights; result in a product manufacturing interruption or failure, or in the interruption or failure of products or services that rely on IT systems or business processes; damage our operations, customer relationships, or reputation; undermine integration activities or otherwise delay the launch of acquired products; result in unfavorable clinical trial results by virtue of incorrect or unreliable data; and/or cause us to lose trade secrets or other competitive advantages. Unauthorized disclosure of personally identifiable information could expose us to significant sanctions for violations of data privacy laws and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations around the world and could damage public trust in our company. In addition, IT system security in jurisdictions outside the U.S. is weaker and may result in additional costs, uncertainties, and risks. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, system inadequacies, operating failures, unauthorized access, service interruptions or failures, security breaches, malicious intrusions, cyber-attacks, and the compromise, disruption, degradation, manipulation, loss, theft, destruction, or unauthorized disclosure or use of confidential information have not had a material impact on our consolidated results of operations. We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business, or reputational losses that may result from an interruption or breach of our IT systems. We continue to implement measures in an effort to protect, detect, respond to, and minimize or prevent these risks and to enhance the resiliency of our IT systems; however, these measures may not be successful and we may fail to detect or remediate security breaches, malicious intrusions, cyber-attacks, or other compromises of our systems. Any of these events could result in material financial, legal, commercial, or reputational harm to our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Economic downturns or international trade and other global disruptions or disputes could adversely affect our business and operating results.&#160;</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic slowdowns could lead to decreased utilization of our products, affecting our sales. Declining tax revenues and increased government spending on other programs attributable to economic downturns increase the pressure on governments to reduce healthcare spending, leading to increased control of drug prices or lower utilization. Additionally, some customers, including governments or other entities reliant upon government funding, may be unable to pay for our products fully or in a timely manner. Also, if our customers, suppliers, or collaboration partners experience financial difficulties, we could experience slower customer collections, greater bad debt expense, and performance defaults by suppliers or collaboration partners. Similarly significant economic downturns could limit our ability to access capital markets.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, significant portions of our business are conducted in Europe (including the United Kingdom), Asia (including China), and other international geographies. Trade and other global disputes and interruptions in international relationships, including related to tariffs, trade protection measures, import or export licensing requirements, the imposition of trade sanctions or similar restrictions by the U.S. or other governments, unrest or war, as well as public health outbreaks, epidemics, or pandemics, such as the COVID-19 pandemic, affect our ability to do business. For example, tensions between the U.S. and China have led to a series of tariffs and sanctions being imposed by the U.S. on imports from China mainland, as well as other business restrictions. As a further example, the financial impact of higher energy prices, defense spending, and inflation due, in part, to the Russia-Ukraine war and resulting geopolitical and economic disruptions, particularly following the COVID-19 pandemic, has further exacerbated financial pressures on governments with single-payer or government funded healthcare systems, leading to increased impetus for increases in rebates, clawbacks, and other reforms to reimbursement systems, particularly in Europe. These and similar events have adversely affected, and may continue to adversely affect, us, our business partners, and our customers. For more details, see Item 1, "Business&#8212;Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access."&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Pharmaceutical products can develop unexpected safety or efficacy concerns, which could have a material adverse effect on our revenues, income, and reputation.&#160;</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical products receive regulatory approval based on data obtained in controlled clinical trials of limited duration. After approval, the products are used for longer periods of time by much larger numbers of patients. Accordingly, we and others (including regulatory agencies and private payers) collect extensive information on the efficacy and safety of our marketed products by continuously monitoring the use of our products in the marketplace. In addition, we or others may conduct post-marketing clinical studies on efficacy and safety of our marketed products. New safety or efficacy data from both market surveillance and post-marketing clinical studies may result in product label changes or other measures that could reduce the product's market acceptance and result in declining sales. Serious safety or efficacy issues that arise after product approval have, and could in the future, result in voluntary or mandatory product recalls or withdrawals from the market. Safety issues have, and could in the future, result in costly product liability claims. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">We face litigation and investigations related to our products, how we price our products, and how we commercialize our products; we could face large numbers of claims in the future, which could adversely affect our business, and we are self-insured for such matters. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a substantial number of claims involving various current and historical products, litigation and investigations. These claims relate to how we commercialize and/or how we price our products, including relating to our 340B drug pricing program, as well as contractual matters and other disputes. See Item&#160;8, "Financial Statements and Supplementary Data&#8212;Note 16: Contingencies" for more information on our current product liability litigation, as well as pricing and other litigation, investigations, and inquiries. Because of the nature of pharmaceutical products, we are, and could in the future become, subject to large numbers of product liability claims for our previous, current, or future products, or to further litigation or investigations, including related to pricing or other commercial practices. Such matters could affect our results of operations or require us to recognize substantial charges to resolve and, if involving marketed products, could adversely affect sales of the product and our consolidated results of operations in any given period. Due to a very restrictive market for liability insurance, we are self-insured for litigation liability losses for all of our currently marketed products, as well as for litigation or investigations related to our pricing practices or other similar matters. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Manufacturing, quality, or supply chain difficulties, disruptions, or shortages could lead to product supply problems.&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical manufacturing is complex and highly regulated. Manufacturing or quality assurance difficulties at our facilities or those of our contractors and suppliers, the failure or refusal of a supplier or contract manufacturer to supply contracted quantities, or increases in demand on a supplier could result in delays and disruptions in the manufacturing, distribution, and sale of our products and/or product shortages, leading to lost revenue. In select cases, supply constraints may also lead to pauses, discontinuations or other product availability issues in one or more markets, which could have a material adverse effect on our consolidated results of operations and cash flows. Further, cost inflation and global transportation and logistics challenges, as well as tight labor markets, have caused, and in the future may cause, delays in, and/or increase costs related to, distribution of our medicines, the construction or other acquisition of manufacturing capacity, procurement activity, and supplier or contract manufacturer arrangements. Such difficulties, disruptions, or challenges could result from quality, oversight, or regulatory compliance problems; natural disasters (including increased instances of natural disasters or other events that may be due to climate change), public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic); periods of global economic downturn or uncertainty; emergence or escalation of, and responses to, war or unrest (including the Russia-Ukraine war); equipment, mechanical, data, or IT system vulnerabilities, such as system inadequacies, inadequate controls or procedures, operating failures, service interruptions or failures, security breaches, malicious intrusions, or cyber-attacks from a variety of sources; labor shortages; contractual disputes with our suppliers and contract manufacturers; or inability to obtain single-source or other raw or intermediate materials. Regional dependencies may in some cases accentuate risks related to manufacturing and supply. For example, we, and the pharmaceutical industry generally, depend on China-based partners for integral chemical synthesis, reagents, starting materials, and ingredients.</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Difficulties in predicting or variability in demand for our products and those of our competitors and the very long lead times necessary for the expansion and regulatory qualification of pharmaceutical manufacturing capacity have resulted, and in the future may result, in difficulty meeting demand for, or disruptions, shortages, and higher costs in the supply of, our products. For example, we have experienced challenges in meeting demand for our incretin products, partially due to the limited availability of competitor therapies. Despite our ongoing efforts to meet significant expected demand by obtaining additional internal and contracted manufacturing capacity, there can be no assurances that such capacity increases will be realized as expected. Delays or challenges in operationalizing additional manufacturing capacity would limit our ability to capitalize on expected demand. Conversely, unexpected contingencies that limit demand for our incretin products would undermine our ability to realize the full benefit of significant capital expenditures that we have incurred, and expect to continue to incur, to augment manufacturing capacity and may also subject us to contractual payment obligations. The foregoing risks and uncertainties could negatively impact our consolidated results of operations and reputation. See Item 1, "Business&#8212;Raw Materials and Product Supply," and Item 7, "Management's Discussion and Analysis&#8212;Financial Condition and Liquidity" for more details.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">We derive a significant percentage of our total revenue from relatively few products and sell our products through increasingly consolidated supply chain stakeholders, which may subject us to, or exacerbate, various risks. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derived direct product and/or alliance revenues of more than $1 billion for each of Trulicity, Verzenio, Taltz, Jardiance (including Glyxambi, Synjardy, and Trijardy XR), Humalog (including Insulin Lispro), our COVID-19 antibodies, and Humulin that collectively accounted for 69 percent of our total revenues in 2022. In particular, Trulicity accounted for 26 percent of our total revenues in 2022 and we expect GLP-1s, including Mounjaro, which we launched in 2022, to represent a significant and growing portion of our business. Loss of patent protection, changes in prescription rates, material product liability litigation, unexpected side effects or safety concerns, significant changes in demand, regulatory proceedings, negative publicity affecting doctor or patient confidence, pressure from existing or new competitive products, changes in labeling, pricing, and access pressures, or supply shortages or disruptions for these products or any of our other major products could materially impact our results of operations.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the U.S., most of our products are distributed through wholesalers and if one of these significant wholesalers should encounter financial or other difficulties, it might decrease the amount of business the wholesaler does with us or we might be unable to timely collect the amounts that the wholesaler owes us, which could negatively impact our results of operations. See Item 1, &#8220;Business&#8212;Marketing and Distribution,&#8221; for more details. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the negotiating power of health plans, managed care organizations, pharmacy benefit managers, and other supply chain stakeholders has increased due to consolidation, regulatory, and other market impacts, and they, along with governments, increasingly employ formularies to control costs and encourage utilization of certain drugs, including through the use of formulary inclusion, or favorable formulary placement. Such stakeholders have also increasingly imposed utilization management tools favoring the use of generic products. As these practices expand, including due to potential further consolidation of U.S. private third-party payers, we may face difficulty in obtaining or maintaining timely or adequate pricing or formulary placement of our products. We expect that consolidation of supply chain stakeholders will continue to increase competitive and pricing pressures on pharmaceutical manufacturers. For additional information on pricing and reimbursement for our pharmaceutical products, see "U.S. Private Sector Dynamics" and "Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access&#8212;U.S."</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Reliance on third-party relationships and outsourcing arrangements could adversely affect our business. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties, including suppliers, distributors, alliances, and collaborations with other pharmaceutical and biotechnology companies, and third-party service providers, for selected aspects of product and clinical development, manufacturing, commercialization, hosting of, and support for, IT systems, product distribution, and certain financial transactional processes. As examples, we outsource the day-to-day management and oversight of some of our clinical trials to contract research organizations and the distribution of our products through logistics providers.&#160;Outsourcing involves many risks, including the risk that the third parties may not perform to our standards or legal requirements, including applicable requirements for diversity in clinical trials; may not produce reliable results; may not perform in a timely manner; may not maintain the confidentiality, integrity, and availability of confidential and proprietary information relating to us, our clinical trial subjects, or patients; may experience disruption or fail to perform due to IT system vulnerabilities, breaches, cyber-attacks, or inadequate controls or procedures; may be unable to satisfy their commitments to us in which case we may not be able to achieve acceptable alternative sourcing; or may fail to perform at all. The foregoing risks may be heightened in jurisdictions outside the U.S., where we may have fewer alternative providers as well as face additional costs, uncertainties, and risks. Failure of third parties to meet their contractual, regulatory, confidentiality, privacy, security, or other obligations to us, our clinical trial subjects, and our patients could have a material adverse effect on our business. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Public health outbreaks, epidemics, or pandemics, such as the COVID-19 pandemic, have adversely impacted and may in the future adversely impact our business and operations. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual or threatened public health outbreaks, epidemics, or pandemics, such as the COVID-19 pandemic, have adversely impacted and may in the future adversely impact our business and operations. The </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 pandemic has adversely impacted and may continue to adversely impact our business and operations across markets to varying and fluctuating degrees, including as a result of:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost inflation and strain on global transportation, manufacturing, and labor markets, which have negatively impacted development, manufacturing, supply, distribution, and sales of our medicines, including through increased costs to provide, and in some cases disruptions in supply or shortages of, our medicines.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fewer in-person interactions among patients and healthcare providers and our employees with healthcare professionals in certain markets. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pricing pressures, rebates, clawbacks, and other changes in reimbursement policies and programs resulting, in part, from the financial strain of the COVID-19 pandemic on government-funded healthcare systems around the world.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks related to our COVID-19 therapies, including heightened regulatory scrutiny of our manufacturing practices, quality assurance, and similar regulations; restrictions on administration that limit widespread and timely access to our therapies, and risks related to handling, return, and/or refund of product after delivery by us; concerns related to expedited authorization of restricted distribution of products with less than typical safety and efficacy data; and fluctuations in, or elimination of, demand for our COVID-19 therapies, including based on the availability of superior or competitive therapies, preventative measures such as vaccines and antiviral medicines, mutations of the virus impacting effectiveness, revocations or restrictions on EUAs, reaching endemic status in different jurisdictions, reduced government and payer funding for COVID-19 therapies, the unpredictable nature of pandemics, and other developments. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other risks related to the COVID-19 pandemic and other actual or threatened public health outbreaks, epidemics, or pandemics could affect other aspects of our business or intensify other risks inherent in our business. The degree to which the COVID-19 pandemic could continue to affect us and other actual or threatened public health outbreaks, epidemics, or pandemics could affect us, will depend on developments that are highly uncertain and beyond our knowledge or control, including the duration and severity of the public health threat, the actions taken to reduce its transmission, the introduction and spread of new variants, the degree and extent of government restrictions on economic activity, government spending, and access to healthcare, and the speed with which, and extent to which, economic and operating conditions recover. Should the COVID-19 pandemic, or any other actual or threatened public health outbreak, epidemic, or pandemic, as well as any associated or resulting cost of inflation, supply chain disruption, labor market impact, recession, depression, or other negative contingency, continue for a prolonged period, these risks could be exacerbated, causing further impact on our business and operations.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Our business is subject to increasing government price controls and other public and private restrictions on pricing, reimbursement, and access for our drugs, which could have a material adverse effect on our results of operations, reputation or business.&#160;</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public and private payers continue to take aggressive steps to control their expenditures for pharmaceuticals by placing restrictions on pricing and reimbursement for, and patient access to, our medicines. These pressures have negatively affected, and could continue to negatively affect, our consolidated results of operations. Governments and private payers worldwide have intensified their scrutiny of, and actions intended to address, pricing, reimbursement, and access to pharmaceutical products. Additional policies, regulations, legislation, or enforcement, including as a result of the regulatory priorities of the current U.S. presidential administration and regulatory authorities worldwide, could adversely impact our business and consolidated results of operations. In particular, if one or more of our significant products are selected under the IRA, the resulting price reduction and reimbursement could negatively impact our business and consolidated results of operations. For more details, see Item 1, "Business&#8212;Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access."</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, restrictive or unfavorable pricing, coverage, or reimbursement determinations for our medicines or product candidates by governments, regulatory agencies, courts, or private payers, such as the Alzheimer&#8217;s Monoclonal Antibody NCD, may adversely impact our business and financial results. We </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continue to experience additional pricing pressures, rebates, clawbacks, and other changes in reimbursement policies and programs resulting from the financial strain of the COVID-19 pandemic, periods of global economic downturn or uncertainty, and the emergence or escalation of, and responses to, war or unrest (including the Russia-Ukraine war).</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more details, see Item 1, "Business&#8212;Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access," Item&#160;7, "Management's Discussion and Analysis&#8212;Executive Overview&#8212;Other Matters&#8212;Trends Affecting Pharmaceutical Pricing, Reimbursement, and Access," and Item 8, "Financial Statements and Supplementary Data&#8212;Note 16: Contingencies."</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Changes in foreign currency rates, interest rate risks, or inflation affect our results of operations.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global company, we face foreign currency risk exposure from fluctuating currency exchange rates, interest rate risk from our exposure to floating and variable interest rates, and inflation risk from existing and expected rates of inflation in the U.S. and other jurisdictions, each of which impacts our results of operations. In recent periods, significant fluctuations in currency rates and inflation have had a significant negative impact on our results of operations. We are a net receiver of foreign currencies and our results of operations may continue to be adversely impacted if the U.S. dollar remains strong compared to foreign currencies. Further, in the event of an extreme devaluation of local currency in a particular market in which we operate, the price of our products could become unsustainable in the relevant market. Inflationary pressures in recent periods have also negatively impacted us and may continue to negatively impact us in various ways, including cost inflation, higher labor costs, and other higher expenses, with some of these higher expenses due in part to policy actions intended to curb inflation. See Item 7, "Management's Discussion and Analysis&#8212;Financial Condition and Liquidity" and Item 8, "Financial Statements and Supplementary Data&#8212;Note 1: Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards," for more details.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">We are subject to evolving and complex tax laws, which may result in additional liabilities and affect our results of operations.&#160;</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in the U.S. and numerous other jurisdictions, and in the course of our business, we make judgments about the expected tax treatment of various transactions and events. Changes in tax laws, regulations, administrative practices, principles, and interpretations, as well as events that differ from our expectations, have affected and may adversely affect our effective tax rates, cash flows, and/or results of operations. Significant uncertainty currently exists regarding tax proposals introduced by the current U.S. administration and Congress, including modifications to certain aspects of the Tax Cuts and Jobs Act of 2017, such as the potential repeal or deferral of the provision requiring capitalization of research and development expenses. In addition, tax authorities in the U.S. and other jurisdictions in which we do business routinely examine our tax returns and are intensifying their scrutiny and examinations of profit allocations among jurisdictions, which could unfavorably impact our results of operations. Further, actions taken with respect to tax-related matters by associations such as the Organisation for Economic Co-operation and Development and the European Commission could influence tax laws in countries in which we operate. Modifications to key elements of the current U.S. or international tax framework could have a significant impact on our effective tax rate, results of operations, and cash flows. See Item 7, "Management's Discussion and Analysis&#8212;Executive Overview&#8212;Other Matters&#8212;Tax Matters" and Item 8, "Financial Statements and Supplementary Data&#8212;Note 14: Income Taxes," for more details.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Regulatory compliance problems could be damaging to the company.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketing, promotional, and pricing practices of pharmaceutical manufacturers, as well as the manner in which manufacturers interact with purchasers, prescribers, and patients, are subject to extensive scrutiny and regulation. Many companies, including us, are and have been subject to investigations and claims related to these practices asserted by federal, state, and foreign governmental authorities, private payers, and consumers. These investigations and claims have resulted in substantial expense and other significant consequences to us. We are, and could in the future become, subject to such investigations and claims, the outcomes of which include criminal charges and fines, penalties, or other monetary or non-monetary remedies, including exclusion from U.S. federal and other healthcare programs. Such investigations and claims have intensified and may continue to intensify as a result of the regulatory priorities of each particular U.S. presidential administration and other regulatory authorities worldwide. In addition, regulatory issues concerning compliance with cGMP, quality assurance, evolving standards, and increased scrutiny around excipients and potential impurities such as nitrosamines, and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">similar regulations and standards (and comparable foreign regulations and standards) for our products can lead to regulatory and legal actions, product recalls and seizures, fines and penalties, interruption of production leading to product shortages, import bans or denials of import certifications, delays or denials in new product approvals or line extensions or supplemental approvals of current products pending resolution of the issues, and reputational harm, any of which would adversely affect our business. Regulatory compliance and processes in jurisdictions outside the U.S. may also be less predictable and result in additional costs, uncertainties, and risks. See Item 1, "Business&#8212;Government Regulation of Our Operations," for more details. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, there is an increased focus by foreign, federal, state, and local regulatory and legislative bodies regarding environmental policies relating to climate change, regulating greenhouse gas emissions, carbon taxes, emissions trading schemes, sustainable manufacturing, human rights and equity matters, and disclosure regarding the foregoing, many of which may be ambiguous, inconsistent, dynamic or conflicting. We expect to experience increased restrictions and compliance costs, legal costs, and expenses related to such new or changing legal or regulatory requirements. Moreover, compliance with any such legal or regulatory requirements would require us to devote substantial time and attention to these matters. In addition, we may still be subject to penalties or potential litigation if such laws and regulations are interpreted or applied in a manner inconsistent with our practices.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are subject to increased negative attention from the media, stockholders, activists, and other stakeholders on climate change, social, and sustainability matters. The perception that we have failed to act in a socially responsible manner, whether or not valid, results in adverse publicity that can negatively affect our business and reputation, as well as result in increased scrutiny from legislators and regulatory authorities. Moreover, from time to time we establish and publicly announce goals and commitments, including to reduce our impact on the environment. Our ability to achieve any stated environmental, social or governance goal, target or objective is subject to numerous factors and conditions, many of which are outside our control. Examples of such factors include evolving regulatory requirements affecting sustainability standards or disclosures or imposing different requirements, the availability of requisite financing, and the availability of suppliers that can meet our sustainability and other goals. If we fail to achieve, are perceived to have failed or been delayed in achieving, or improperly report our progress toward achieving these goals and commitments, it could negatively affect our reputation or investor confidence, and expose us to enforcement actions and litigation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 1B.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:2pt">Unresolved Staff Comments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_25"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Properties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal domestic and international executive offices are located in Indianapolis. At December&#160;31, 2022, we owned nine production, distribution, and corporate administrative sites in the United States (U.S.), including Puerto Rico. These facilities contain an aggregate of approximately 8.1 million square feet of floor area dedicated to production, distribution, and administration. Major production sites include Indianapolis, Indiana; Carolina, Puerto Rico; and Branchburg, New Jersey. In 2023, we expect production to commence at an additional approximately 0.4 million square foot facility in Durham, North Carolina, with other production facilities and expansions of production facilities expected to come online in future periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own production and distribution sites in seven countries outside the U.S., containing an aggregate of approximately 4.6&#160;million square feet of floor area. Major production sites include facilities in Ireland, France, Spain, Italy, and China.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., our research and development facilities contain an aggregate of approximately 4.5 million square feet of floor area, primarily consisting of owned facilities located in Indianapolis and smaller leased sites primarily in San Diego, California; San Francisco, California; and New York, New York. Outside the U.S., we own a small research and development facility in Spain and lease a small site in Singapore.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that none of our properties is subject to any encumbrance, easement, or other restriction that would detract materially from its value or impair its use in the operation of the business. The buildings we own are of varying ages and in good condition.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_28"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various currently pending legal actions, government investigations, and environmental proceedings. Information pertaining to legal proceedings is described in Item 8, "Financial Statements and Supplementary Data - Note 16: Contingencies," and incorporated by reference herein. </span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_31"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Mine Safety Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Part II</span></div><div id="i909b702f7db044078a8e3e150503788d_37"></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 5.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Market for the Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to the principal market for our common stock, dividends, and related stockholder matters is described in Item 7, "Management's Discussion and Analysis of Results of Operations and Financial Condition" and Item 12, "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters." This information is incorporated herein by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 17, 2023, there were approximately 19,868 holders of record of our common stock based on information provided by EQ Shareowner Services, our transfer agent. Our common stock is listed under the ticker symbol LLY on the New York Stock Exchange (NYSE). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to repurchases of our equity securities during the fourth quarter ended December&#160;31, 2022:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>(in&#160;thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Price&#160;Paid<br/>per Share</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of&#160;Shares<br/>Purchased as Part of<br/>Publicly Announced<br/>Plans or Programs<br/>(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate&#160;Dollar&#160;Value<br/>of&#160;Shares&#160;that&#160;May&#160;Yet&#160;Be<br/>Purchased Under the<br/>Plans or Programs<br/>(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2022</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 46pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,250.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 46pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,250.0</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2022</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 46pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,250.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 46pt 0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2022, we did not repurchase any shares under our $5.00 billion share repurchase program authorized in May 2021.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PERFORMANCE GRAPH</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the return on Lilly stock with that of the Standard&#160;&amp; Poor's (S&amp;P) 500 Stock Index and our peer group for the years 2018 through 2022. The graph assumes that, on the last business day of 2017, a person invested $100 each in Lilly stock, the S&amp;P 500 Stock Index, and the peer group's collective common stock. The graph measures total shareholder return, which takes into account both stock price and dividends. It assumes that dividends paid by a company are immediately reinvested in that company's stock. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Value of $100 Invested on Last Business Day of 2017 Comparison of Five-Year Cumulative Total Shareholder Return Among Lilly, S&amp;P 500 Stock Index, and Peer Group</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div><span><br/></span></div><div style="text-align:center"><img src="lly-20221231_g1.jpg" alt="lly-20221231_g1.jpg" style="height:434px;margin-bottom:5pt;vertical-align:text-bottom;width:623px"/></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.598%"><tr><td style="width:1.0%"></td><td style="width:16.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:2.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lilly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peer&#160;Group</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">S&amp;P&#160;500</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec-17</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec-18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec-19</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.13&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.15&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.72&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec-20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec-21</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355.08&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.56&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.58&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec-22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">We constructed the peer group as the industry index for this graph. It is comprised of the following companies in the pharmaceutical and biotechnology industries: AbbVie Inc.; Amgen Inc.; AstraZeneca PLC; Biogen Inc.; Bristol-Myers Squibb Company; Gilead Sciences Inc.; GlaxoSmithKline plc; Johnson&#160;&amp; Johnson; Merck&#160;&amp; Co., Inc.; Novartis AG; Novo Nordisk A/S; Pfizer Inc.; Roche Holding AG; Sanofi S.A.; and Takeda Pharmaceutical Company Limited. The peer group used for performance benchmarking aligns with the peer group used for executive compensation purposes for 2022.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 6. [Reserved]</span></div><div style="margin-top:9pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_46"></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 7.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Management's Discussion and Analysis of Results of Operations and Financial Condition</span></div><div id="i909b702f7db044078a8e3e150503788d_49"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Tables present dollars in millions, except per-share data)</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management's discussion and analysis of results of operations and financial condition is intended to assist the reader in understanding and assessing significant changes and trends related to our company's results of operations and financial position. This discussion and analysis should be read in conjunction with Item 8, "Financial Statements and Supplementary Data." Certain statements in this Item 7 constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" and Item&#160;1A, "Risk Factors," may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_52"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXECUTIVE OVERVIEW</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This section provides an overview of our financial results, late-stage pipeline developments, and other matters affecting our company and the pharmaceutical industry. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Results</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our key operating results:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:55.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.413%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,541.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,318.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,911.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,005.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin as a percent of revenue</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,190.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,930.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling, and administrative</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,440.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,431.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (IPR&amp;D) and development milestones</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">908.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring, and other special charges</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">244.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">320.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,244.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,581.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased in 2022 driven by increased volume, largely offset by lower realized prices and the unfavorable impact of foreign exchange rates. Research and development expenses increased in 2022, driven primarily by higher development expenses for late-stage assets, partially offset by lower development expenses for COVID-19 antibodies and the favorable impact of foreign exchange rates. Marketing, selling, and administrative expenses in 2022 remained relatively flat compared to 2021 as increased costs associated with launches of new products and indications were offset by the favorable impact of foreign exchange rates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following highlighted items affect comparisons of our 2022 and 2021 financial results:</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D and Development Milestones (Note 3 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized $908.5 million of acquired IPR&amp;D and development milestones that included the buy-out of substantially all future obligations that were contingent upon the occurrence of certain events linked to the success of our mutant-selective PI3k&#945; inhibitor and a purchase of a Priority Review Voucher. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Impairment, Restructuring, and Other Special Charges (Note 5 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized charges of $244.6 million primarily related to an intangible asset impairment for GBA1 Gene Therapy (PR001) due to changes in estimated launch timing.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other-Net, (Income) Expense (Note 18 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized $410.7 million of net investment losses on equity securities. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 2021 </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Sales (See Note 6 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized a net inventory impairment charge related to our COVID-19 antibodies of $339.7&#160;million. As part of our response to the COVID-19 pandemic, and at the request of the United States (U.S.) and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic evolved during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to demand from U.S. and international governments, including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D and Development Milestones (Note 3 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized $970.1 million of acquired IPR&amp;D and development milestones that included charges resulting from business development transactions with Foghorn Therapeutics Inc. (Foghorn), Rigel Pharmaceuticals, Inc. (Rigel), and Precision Biosciences, Inc. (Precision). </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Impairment, Restructuring, and Other Special Charges (Note 5 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized charges of $316.1 million primarily related to an impairment of a contract-based intangible asset from our acquisition of Loxo Oncology, Inc. (Loxo), an intangible asset impairment resulting from the sale of the rights to Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as acquisition and integration costs associated with the acquisition of Prevail Therapeutics Inc. (Prevail). </span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other-Net, (Income) Expense (Note 18 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized a debt extinguishment loss of $405.2 million related to the repurchase of debt. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized $176.9 million of net investment gains on equity securities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Late-Stage Pipeline</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. We currently have approximately 45 new medicine candidates in clinical development or under regulatory review, and a larger number of projects in the discovery phase.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following certain new molecular entities (NMEs) are currently in Phase II or Phase III clinical trials or have been submitted for regulatory review or have received regulatory approval in the U.S., Europe, or Japan. The following table reflects the status of certain NMEs, including certain other developments, up to the time of the filing of this Annual Report on Form 10-K:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.575%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status </span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diabetes</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basal Insulin-Fc</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 1 and 2 diabetes</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials initiated in 2022 and 2023. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANGPTL3 siRNA</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in 2022.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LP(a) Inhibitor</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in 2022.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LP(a) siRNA</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in 2022.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orforglipron</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials were recently completed.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 2 diabetes</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retatrutide </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials were recently completed. </span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 2 diabetes</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lebrikizumab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted in the U.S. and Europe in 2022. Phase III trials are ongoing. </span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mirikizumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ulcerative colitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted in the U.S., Europe, and Japan in 2022.</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crohn's Disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BTLA MAB Agonist</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic lupus erythematosus</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in 2022.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CXCR1/2 Ligands Monoclonal Antibody</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hidradenitis suppurativa</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Peresolimab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rheumatoid arthritis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rezpegaldesleukin </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic lupus erythematosus</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.575%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status </span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Neuroscience</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:75pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donanemab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Complete Response Letter</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span id="i7633fa60997c49d1a52f1211b4cbd624_23-3-1-1-231105"></span><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Submitted in the U.S. in 2022 under the accelerated approval pathway. In January 2023, the FDA issued a complete response letter for the accelerated approval submission. Phase III trials are ongoing.</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remternetug</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial initiated in 2022.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solanezumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GBA1 Gene Therapy (PR001)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parkinson's disease </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase II trial is ongoing. </span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GRN Gene Therapy (PR006)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frontotemporal dementia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase II trial is ongoing. </span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">O-GlcNAcase Inh</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">P2X7 Inhibitor</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials initiated in 2022.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SSTR4 Agonist</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRPA1 Antagonist</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:35pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pirtobrutinib</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Jaypirca</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mantle cell lymphoma</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDA granted accelerated approval</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in the U.S. in January 2023. Phase III trial is ongoing. </span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic lymphocytic leukemia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B-cell malignancies</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selpercatinib (Retevmo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lung cancer</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thyroid cancer</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imlunestrant</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjuvant Breast Cancer</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial initiated in 2022.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:35pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ER+HER2- metastatic breast cancer</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Almirall, S.A. in Europe. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Breakthrough Therapy designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fast Track designation is designed to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Continued approval may be contingent on verification and description of clinical benefit in confirmatory Phase III trials.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pipeline also contains several new indication line extension (NILEX) products. The following certain NILEX products for use in the indication described are currently in Phase II or Phase III clinical trials or have been submitted for regulatory review or have received regulatory approval in the U.S., Europe, or Japan. The following table reflects the status of certain NILEX products, including certain other developments, up to the time of the filing of this Annual Report on Form 10-K:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diabetes</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Empagliflozin (Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic kidney disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Submitted in the U.S. and Europe in January 2023.</span></div></td></tr><tr style="height:35pt"><td colspan="3" rowspan="4" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tirzepatide (Mounjaro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submission initiated</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in 2022. Initiated a rolling submission in the U.S. in 2022. Phase III trials are ongoing. </span></div></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart failure with preserved ejection fraction</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing.</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obstructive sleep apnea</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial initiated in 2022. Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in 2022.</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonalcoholic steatohepatitis </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing. </span></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Abemaciclib (Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prostate cancer</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase III</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing.</span></div></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Boehringer Ingelheim. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fast Track designation is designed to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many difficulties and uncertainties inherent in pharmaceutical research and development and the introduction of new products, as well as a high rate of failure inherent in new drug discovery and development. To bring a drug from the discovery phase to market can take over a decade and often costs in excess of $2 billion. Failure can occur at any point in the process, including in later stages after substantial investment. As a result, most funds invested in research programs will not generate financial returns. New product candidates that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain or maintain necessary regulatory approvals or payer reimbursement or coverage, the application of pricing controls, limited scope of approved uses, label changes, changes in the relevant treatment standards or the availability of new or better competitive products, difficulty or excessive costs to manufacture, or infringement of the patents or intellectual property rights of others. Regulatory agencies establish high hurdles for the efficacy and safety of new products and indications. Delays, uncertainties, unpredictabilities, and inconsistencies in drug approval processes across markets and agencies can result in delays in product launches and lost market opportunity. In addition, it can be very difficult to predict revenue growth rates of or variability in demand for new products and indications. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage research and development spending across our portfolio of potential new medicines. A delay in, or termination of, any one project will not necessarily cause a significant change in our total research and development spending. Due to the risks and uncertainties involved in the research and development process, we cannot reliably estimate the nature, timing, and costs of the efforts necessary to complete the development of our research and development projects, nor can we reliably estimate the future potential revenue that will be generated from any successful research and development project. Each project represents only a portion of the overall pipeline, and none is individually material to our consolidated research and development expense. While we do accumulate certain research and development costs on a project level for internal reporting purposes, we must make significant cost estimations and allocations, some of which rely on data that are neither reproducible nor validated through accepted control mechanisms. Therefore, we do not have sufficiently reliable data to report on total research and development costs by project, by preclinical versus clinical spend, or by therapeutic category. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on patents or other forms of intellectual property protection for most of our revenue, cash flows, and earnings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the expiration of patent exclusivity for Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe and Japan in June 2021, we have faced generic competition that has rapidly and severely eroded revenue from prior levels, and we expect such competition will continue to erode revenues from current levels in these markets. In addition, as a result of the entry of multiple generics in the U.S. following the expiration of patent and pediatric exclusivity in the first half of 2022, we began facing, and expect to continue to face, generic competition that has rapidly and severely eroded revenue from prior levels, and we expect will continue to erode revenue from current levels. This decline in revenue will continue to impact period-over-period financial results comparisons, particularly during the first half of 2023. See Note 16 to the consolidated financial statements for a description of legal proceedings currently pending regarding certain of our patents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compound patents for Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin lispro) have expired in the U.S. and major international markets, and we have also introduced lower-priced versions of Humalog as part of our insulin access and affordability solutions. A competitor has a similar version of insulin lispro in the U.S. and in certain European markets. Due to the impact of competition and pricing pressure in the U.S. and certain international markets, we expect that lower revenue for Humalog due to realized price decline will continue over time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trends Affecting Pharmaceutical Pricing, Reimbursement, and Access</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reforms, including those that may stem from periods of economic downturn or uncertainty, or as a result of high inflation, emergence or escalation of, and responses to, war or unrest (including the Russia-Ukraine war), or government budgeting priorities (including as exacerbated by the COVID-19 pandemic), may continue to result in added pressure on pricing and reimbursement for our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global concern over access to and affordability of pharmaceutical products continues to drive regulatory and legislative debate and action, as well as worldwide cost containment efforts by governmental authorities. Such measures include the use of mandated discounts, price reporting requirements, mandated reference prices, restrictive formularies, changes to available intellectual property protections, as well as other efforts. In August 2022, the U.S. government enacted the Inflation Reduction Act of 2022 (IRA). Among other measures, the IRA will require the U.S. Department of Health and Human Services to effectively set prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D. Generally, these government prices apply nine (medicines approved under a New Drug Application) or thirteen (medicines approved under a Biologics License Application) years following initial FDA approval and will be capped at a statutory ceiling price that is likely to represent a significant discount from average prices to wholesalers and direct purchasers. It is too soon to tell how the U.S. government will set these prices as the law specifies a ceiling price, but not a minimum or floor price. One or more of our significant products may be selected, which would have the effect of accelerating revenue erosion prior to patent expiry. The effect of reducing prices and reimbursement for certain of our products would significantly impact our business and consolidated results of operations. The establishment of payment limits or other restrictions by drug affordability review boards and other state level actors would similarly impact us.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other IRA provisions provide for rebate obligations on drug manufacturers that increase prices of Medicare Part B and Part D medicines at a rate greater than the rate of inflation and Part D benefit redesign that includes replacing the Part D coverage gap discount program with a new manufacturer discounting program. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties, which could be significant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA takes effect progressively starting in 2023, with the first government-set prices effective in 2026. The IRA may meaningfully influence our business strategies and those of our competitors. In particular, the nine-year timeline to set prices for medicines approved under a new drug application may reduce the attractiveness of investment in small molecule innovation. The implications to us of a competitor's product being selected for price setting are also uncertain. Provisions of the IRA may be subject to legal challenges or other reformation, and the full impact of the IRA on our business and the pharmaceutical industry remains uncertain. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional policies, regulations, legislation, or enforcement, including those proposed and/or pursued by the U.S. Congress, the current U.S. presidential administration, and regulatory authorities worldwide, could adversely impact our business and consolidated results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidation and integration of private payors and pharmacy benefit managers in the U.S. has also significantly impacted the market for pharmaceuticals by increasing payor leverage in negotiating manufacturer price or rebate concessions and pharmacy reimbursement rates. Furthermore, restrictive or unfavorable pricing, coverage, or reimbursement determinations for our medicines or product candidates by governments, regulatory agencies, courts, or private payers, such as the Centers for Medicare &amp; Medicaid Services' national coverage determination for monoclonal antibodies for the treatment of Alzheimer's Disease, may adversely impact our business and consolidated results of operations. We expect that these actions may intensify and could particularly affect certain products, such as insulin, as governments manage and emerge from the COVID-19 pandemic, which could adversely affect our business. In addition, we are engaged in litigation and investigations related to our 340B program and access to insulin that, if resolved adversely to us, could negatively impact our business and consolidated results of operations. It is not currently possible to predict the overall potential adverse impact to us or the general pharmaceutical industry of continued cost containment efforts worldwide. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, regulatory issues concerning compliance with current Good Manufacturing Practices, quality assurance, evolving standards, and increased scrutiny around excipients and potential impurities such as nitrosamines, and similar regulations and standards (and comparable foreign regulations and standards) for our products can lead to regulatory and legal actions, product recalls and seizures, fines and penalties, interruption of production leading to product shortages, import bans or denials of import certifications, delays or denials in new product approvals or line extensions or supplemental approvals of current products pending resolution of the issues, and reputational harm, any of which would adversely affect our business. Moreover, increased focus on business combinations across industries and jurisdictions can lead to impediments to the completion of business combinations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1, "Business&#8212;Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access" and Note 16 to the consolidated financial statements for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have faced challenges, and expect to continue to face challenges, meeting strong demand for our incretin products, including due to the limited and fluctuating availability of competitor therapies. In the U.S., given very strong uptake of Mounjaro following its launch in the U.S. for type 2 diabetes in the second quarter of 2022, and as demand for Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has remained strong, we have experienced intermittent delays in fulfilling certain U.S. orders for these products. Outside the U.S., we have implemented certain actions to minimize the impact on existing Trulicity patients, but we expect to continue to experience intermittent disruptions in our supply of Trulicity in international markets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate tight supplies of our incretin products will persist until additional manufacturing capacity is operationalized. We expect additional internal and contracted manufacturing capacity will become fully operational around the world in the next several years, with significant expansion in 2023, as part of our ongoing efforts to meet the significant demand for our incretin medicines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes and various other taxes in the U.S. and in many foreign jurisdictions; therefore, changes in both domestic and international tax laws or regulations have affected and may affect our effective tax rate, results of operations, and cash flows. In 2017, the U.S. enacted the Tax Cuts and Jobs Act (the 2017 Tax Act), which contained a provision that requires capitalization and amortization of research and development expenses for tax purposes starting in 2022. Previously, these expenses could be deducted in the year incurred. The implementation of this provision increased our cash payments of income taxes by approximately $1.20 billion in 2022. While the implementation of this provision will continue to increase our cash payments of income taxes, the increase will moderately decrease from 2022 levels over the five-year amortization period.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and countries around the world are actively proposing and enacting tax law changes. Further, actions taken with respect to tax-related matters by associations such as the Organisation for Economic Co-operation and Development and the European Commission could influence tax laws in countries in which we operate. Tax authorities in the U.S. and other jurisdictions in which we do business routinely examine our tax returns and are intensifying their scrutiny and examinations of profit allocations among jurisdictions. Changes to existing U.S. and foreign tax laws and increased scrutiny by tax authorities in the U.S. and other jurisdictions could adversely impact our future consolidated results of operations and cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Rates and Other Impacts</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global company, we face foreign currency risk exposure from fluctuating currency exchange rates, primarily the U.S. dollar against the euro, Japanese yen, and Chinese yuan. While we seek to manage a portion of these exposures through hedging and other risk management techniques, significant fluctuations in currency rates can have a material impact, either positive or negative, on our consolidated results of operations in any given period. During the year ended December&#160;31, 2022, revenue was unfavorably impacted by 3 percent due to foreign exchange rates. While there is uncertainty in the future movements in foreign exchange rates, fluctuations in these rates have, and we currently expect in the near-term future will, adversely impact our consolidated results of operations and cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, cost inflation, the strain on global transportation, logistics, and labor markets (including as exacerbated by the COVID-19 pandemic and the emergence or escalation of, and responses to, war or unrest, including the Russia-Ukraine war), global economic downturns or uncertainty, and an increase in overall demand in our industry for certain products and materials have had, and may continue to have, a number of impacts on our business, including increased costs and disruptions in the supply of our medicines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest in external research and technologies that we believe complement and strengthen our own efforts. These investments can take many forms, including acquisitions, collaborations, investments, and licensing arrangements. We view our business development activity as a way to enhance our pipeline and strengthen our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 to the consolidated financial statements for further discussion regarding our recent acquisitions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the COVID-19 pandemic evolves, we remain focused on protecting the health, safety, and well-being of our employees; supporting the medical system and our communities; and affordability of and access to our medicines. At the outset of the COVID-19 pandemic, we also focused on researching, developing, and supplying COVID-19 therapies, although we do not currently expect significant further revenue attributable to treatments for COVID-19. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has adversely impacted and may continue to adversely impact our business and operations across markets to varying and fluctuating degrees, including as a result of cost inflation and strain on the global transportation, manufacturing, and labor markets, fewer in-person interactions among patients and healthcare providers and our employees with healthcare professionals in certain markets, pricing pressures, rebates, clawbacks, and other changes in reimbursement policies resulting from the financial strain of the COVID-19 pandemic on government-funded healthcare systems, and risks related to our COVID-19 therapies. The degree to which the COVID-19 pandemic could continue to affect us will depend on developments that are highly uncertain and beyond our knowledge or control. For additional information, see Item 1A, "Risk Factors&#8212;Risk Related to Our Business&#8212;Public health outbreaks, epidemics, or pandemics, such as the COVID-19 pandemic, have adversely impacted and may in the future adversely impact our business and operations." </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A, "Risk Factors" for additional information on risk factors that could impact our business and operations.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">RESULTS OF OPERATIONS</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Results&#8212;2022 </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity by region:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,190.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,811.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,351.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,507.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,541.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,318.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are components of the change in revenue compared with the prior year:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:50.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.975%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volume</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Price</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange rates</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent change</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. the increase in volume in 2022 was primarily driven by Trulicity, Verzenio, Jardiance, Mounjaro, and Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by decreased volume for Alimta, following the entry of multiple generics in the first half of 2022. In the U.S. the decrease in realized prices was primarily driven by Humalog, due to a list price reduction of insulin lispro injection and unfavorable segment mix, and Trulicity and Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, due to unfavorable segment mix and higher contracted rebates. In addition, the decrease in realized prices of Humalog was partially offset by changes to estimates for rebates and discounts in 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S. the increase in volume in 2022 was primarily driven by Verzenio, Trulicity, Jardiance, Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Taltz, partially offset by a decrease in volume due to generic competition for Alimta and Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and decreased utilization of COVID-19 antibodies. The decrease in realized prices outside the U.S. was primarily driven by the impact of government pricing in China from National Reimbursement Drug List (NRDL) formulary for certain products, particularly Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Verzenio, and volume-based procurement (VBP) for Humalog. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity in 2022 compared with 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:35.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside&#160;U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trulicity</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,688.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,750.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,439.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,471.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verzenio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,653.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">830.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,483.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taltz</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,724.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">757.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,482.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,212.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,194.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">871.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,066.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,490.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,191.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">868.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,060.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,453.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,008.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,023.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,239.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">730.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">289.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,019.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">351.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">620.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">971.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alimta</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">543.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">384.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">927.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">148.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">682.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">830.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">470.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">289.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">760.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">462.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">188.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">650.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">367.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">245.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">613.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">552.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">587.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">500.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">566.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mounjaro</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">366.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">115.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">482.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">306.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">293.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">293.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cymbalta</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">249.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">283.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">687.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">974.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,662.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,190.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,351.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,541.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,318.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - Not meaningful</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to Emergency Use Authorizations (EUAs) or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib that were made pursuant to EUA or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Trulicity increased 16 percent in the U.S., driven by increased demand, partially offset by lower realized prices due to unfavorable segment mix and higher contracted rebates. Revenue outside the U.S. increased 12 percent, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates and, to a lesser extent, lower realized prices. We experienced intermittent delays in fulfilling certain U.S. Trulicity orders during the second half of 2022. Actions to manage strong demand across our incretin portfolio, including measures to minimize existing patient impact in international markets, also affected volume in 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Verzenio increased 98 percent in the U.S., primarily driven by increased demand. Revenue outside the U.S. increased 61 percent, driven by increased demand, partially offset by lower realized prices primarily due to the impact of the NRDL formulary in China and the unfavorable impact of foreign exchange rates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Taltz increased 12 percent in the U.S., driven by increased demand, partially offset by lower realized prices. Revenue outside the U.S. increased 13 percent, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates and lower realized prices. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Jardiance increased 48 percent in the U.S., primarily driven by increased demand. Revenue outside the U.S. increased 28 percent, primarily driven by increased demand, partially offset by the unfavorable impact of foreign exchange rates. See Note 4 to the consolidated financial statements for information regarding our collaboration with Boehringer Ingelheim involving Jardiance.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Humalog decreased 10 percent in the U.S., primarily driven by lower realized prices due to a list price reduction of insulin lispro injection and unfavorable segment mix, partially offset by changes to estimates for rebates and discounts in 2021. Revenue outside the U.S. decreased 23 percent, primarily driven by lower realized prices due to the impact of VBP in China and the unfavorable impact of foreign exchange rates. Due to the impact of competition and pricing pressure in the U.S. and certain international markets, we expect that lower revenue for Humalog due to realized price decline will continue over time. See "&#8212;Executive Overview&#8212;Other Matters&#8212;Patent Matters" for additional information. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of COVID-19 antibodies was $2.01&#160;billion in the U.S. during the year ended December&#160;31, 2022, primarily due to bebtelovimab supplied to the U.S. government. COVID-19 antibodies are not currently authorized for emergency use in the U.S. We do not currently expect significant further revenue attributable to the treatment of COVID-19. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Alimta decreased 56 percent in the U.S., primarily driven by decreased demand due to the entry of multiple generics in the first half of 2022. Revenue outside the U.S. decreased 54 percent, primarily driven by decreased demand due to generic competition. Following the expiration of patent exclusivity for Alimta in Europe and Japan in June 2021, we have faced generic competition that has rapidly and severely eroded revenue from prior levels, and we expect such competition will continue to erode revenues from current levels in these markets. In addition, as a result of the entry of multiple generics in the U.S. following the expiration of patent and pediatric exclusivity in the first half of 2022, we began facing, and expect to continue to face, generic competition that has rapidly and severely eroded revenue from prior levels, and we expect will continue to erode revenue from current levels. See "&#8212;Executive Overview&#8212;Other Matters&#8212;Patent Matters" for additional information. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross Margin, Costs, and Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin as a percent of revenue was 76.8 percent in 2022, an increase of 2.6 percentage points compared with 2021, primarily driven by a net inventory impairment charge related to our COVID-19 antibodies recognized in 2021 and the unfavorable effect of foreign exchange rates on international inventories sold in 2021. Additionally, in 2022, favorable product mix, including the impact of lower sales of COVID-19 antibodies and Olumiant for the treatment of COVID-19, were offset by lower realized prices and increased expenses due to inflation and logistics costs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased 4 percent to $7.19 billion in 2022, driven primarily by higher development expenses for late-stage assets, partially offset by lower development expenses for COVID-19 antibodies and the favorable impact of foreign exchange rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing, selling, and administrative expenses remained relatively flat at $6.44 billion in 2022, as increased costs associated with launches of new products and indications were offset by the favorable impact of foreign exchange rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have undertaken compensatory actions to improve retention and address wage inflation, which will increase compensation costs and impact our consolidated results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized acquired IPR&amp;D and development milestones of $908.5 million in 2022 that included the buy-out of substantially all future obligations that were contingent upon the occurrence of certain events linked to the success of our mutant-selective PI3k&#945; inhibitor and a purchase of a Priority Review Voucher. We recognized acquired IPR&amp;D and development milestones of $970.1 million in 2021 that included charges resulting from business development transactions with Foghorn, Rigel, and Precision. See Note 3 to the consolidated financial statements for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized asset impairment, restructuring, and other special charges of $244.6 million in 2022, primarily related to an intangible asset impairment for GBA1 Gene Therapy (PR001) due to changes in estimated launch timing. We recognized asset impairment, restructuring, and other special charges of $316.1 million in 2021, primarily related to an impairment of a contract-based intangible asset from our acquisition of Loxo, an intangible asset impairment resulting from the sale of the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8212;net, (income) expense was expense of $320.9 million in 2022, primarily driven by net investment losses on equity securities. Other&#8212;net, (income) expense was expense of $201.6 million in 2021, primarily driven by a debt extinguishment loss of $405.2 million related to the repurchase of debt, partially offset by net investment gains on equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate was 8.3 percent in 2022, reflecting the favorable tax impact of the implementation of a provision in the 2017 Tax Act that requires capitalization and amortization of research and development expenses for tax purposes starting in 2022, partially offset by the tax impact of the mix of earnings in higher tax jurisdictions. Our effective tax rate was 9.3 percent in 2021, reflecting the favorable tax impacts of acquired IPR&amp;D and development milestone charges, net investment gains on equity securities, and a net discrete tax benefit.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Results&#8212;2021 </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our results of operations pertaining to 2021 and 2020 see Item 7, "Management's Discussion and Analysis of Results of Operations and Financial Condition" in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2021.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">FINANCIAL CONDITION AND LIQUIDITY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our available cash and cash equivalents, together with our ability to generate operating cash flow and our access to short-term and long-term borrowings, are sufficient to fund our existing and planned capital requirements, which include: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">working capital requirements, including related to employee payroll, clinical trials, manufacturing materials, and taxes;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capital expenditures;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">share repurchases and dividends;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">repayment of outstanding short-term and long-term borrowings; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contributions to our defined benefit pension and retiree health benefit plans;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">milestone and royalty payments; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential business development activities, including acquisitions, collaborations, investments, and licensing arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management continuously evaluates our liquidity and capital resources, including our access to external capital, to ensure we can adequately and efficiently finance our capital requirements. As of December&#160;31, 2022, our material cash requirements primarily related to purchases of goods and services to produce our products and conduct our operations, capital expenditures, dividends, repayment of outstanding borrowings, milestone and royalty payments, the remaining obligations for the one-time repatriation transition tax (also known as the 'Toll Tax') from the 2017 Tax Act, leases, unfunded commitments to invest in venture capital funds, and retirement benefits (see Notes 11, 4, 14, 10, 7, and 15 to the consolidated financial statements). We anticipate our cash requirements related to ordinary course purchases of goods and services will be consistent with our past levels relative to revenues.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we committed to invest over several years more than $2 billion in two new facilities in Lebanon, Indiana to manufacture existing and future products, more than $1 billion in a new facility in Concord, North Carolina to manufacture parenteral (injectable) products and devices, and more than 400 million euro in a new facility in Limerick, Ireland to expand our manufacturing network for biologic active ingredients. In early 2023, we committed to invest an additional $450 million to expand manufacturing capacity at Research Triangle Park facility in Durham, North Carolina for additional parenteral filling, device assembly, and packaging capacity. These investments, and other capital investments that support our operations, will result in higher capital expenditures for the next several years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Tax Act contained a provision that requires us to capitalize and amortize research and development expenses for tax purposes starting in 2022, whereas previously we could fully deduct these expenses in the year incurred. The implementation of this provision increased our cash payments of income taxes by approximately $1.20 billion in 2022. While the implementation of this provision will continue to increase our cash payments of income taxes, the increase will moderately decrease from 2022 levels over the five-year amortization period. See "&#8212;Executive Overview&#8212;Other Matters&#8212;Tax Matters" for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents decreased to $2.07 billion as of December&#160;31, 2022, compared with $3.82 billion at December&#160;31, 2021. Net cash provided by operating activities was $7.08&#160;billion in 2022, compared with $7.26&#160;billion in 2021. Refer to the consolidated statements of cash flows for additional information on the significant sources and uses of cash for the years ended December&#160;31, 2022 and 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our cash and cash equivalents, we held total investments of $3.05 billion and $3.30 billion as of December&#160;31, 2022 and 2021, respectively. See Note 7 to the consolidated financial statements for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we acquired all shares of Akouos, Inc. (Akouos) for a purchase price that included $12.50 per share in cash (or an aggregate of $327.2&#160;million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Akouos shareholders up to an additional $3.00 per share in cash (or an aggregate of approximately $122&#160;million) payable, subject to certain terms and conditions, upon the achievement of certain specified milestones. This acquisition was funded through cash on hand. See Note 3 to the consolidated financial statements for additional information. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, total debt was $16.24 billion, a decrease of $646.1 million compared with $16.88&#160;billion at December&#160;31, 2021. See Note 11 to the consolidated financial statements for additional information. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had a total of $7.33 billion of unused committed bank credit facilities, $7.00&#160;billion of which is available to support our commercial paper program. See Note 11 to the consolidated financial statements for additional information. We believe that amounts accessible through existing commercial paper markets should be adequate to fund short-term borrowing needs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends of $3.92 per share and $3.40 per share were paid in 2022 and 2021, respectively. The quarterly dividend was increased to $1.13 per share effective for the dividend to be paid in the first quarter of 2023, resulting in an indicated annual rate for 2023 of $4.52 per share.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures were $1.85 billion during 2022, compared to $1.31 billion in 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we repurchased $1.50 billion of shares under our $5.00&#160;billion share repurchase program authorized in May 2021. As of December&#160;31, 2022, we had $3.25 billion remaining under this program. See Note 13 to the consolidated financial statements for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "&#8212;Executive Overview&#8212;Other Matters&#8212;Patent Matters" for information regarding recent losses of patent protection.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both domestically and abroad, we continue to monitor the potential impacts of the economic environment; the creditworthiness of our wholesalers and other customers, including foreign government-backed agencies and suppliers; the uncertain impact of healthcare legislation; and various international government funding levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our operations are exposed to fluctuations in interest rates, currency values, and fair values of equity securities. These fluctuations impact the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of this risk management program is to limit the impact on earnings of fluctuations in interest and currency exchange rates. All derivative activities are for purposes other than trading.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary interest rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest rate exposures, we strive to achieve an acceptable balance between fixed and floating rate debt positions and may enter into interest rate derivatives to help maintain that balance. As of December&#160;31, 2022, substantially all of our total long-term debt carries interest at a fixed rate. We have converted approximately 10 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. Based on our overall interest rate exposure at December&#160;31, 2022 and 2021, including derivatives and other interest rate risk-sensitive instruments, a hypothetical 10 percent change in interest rates applied to the fair value of the instruments as of December&#160;31, 2022 and 2021, respectively, would not have a material impact on earnings, cash flows, or fair values of interest rate risk-sensitive instruments over a one-year period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency risk exposure results from fluctuating currency exchange rates, primarily the U.S. dollar against the euro, Japanese yen, and Chinese yuan. We face foreign currency exchange exposures when we enter into transactions arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. We also face currency exposure that arises from translating the results of our global operations to the U.S. dollar at exchange rates that have fluctuated from the beginning of the period. We&#160;may enter into foreign currency forward or option derivative contracts to reduce the effect of fluctuating currency exchange rates (primarily the euro, the Japanese yen, and Chinese yuan). Our corporate risk-management policy outlines the minimum and maximum hedge coverage of such exposures. Gains and losses on these derivative contracts offset, in part, the impact of currency fluctuations on the existing assets and liabilities. We periodically analyze the fair values of the outstanding foreign currency derivative contracts to determine their sensitivity to changes in foreign exchange rates. A hypothetical 10 percent change in exchange rates (primarily against the U.S. dollar) applied to the fair values of our outstanding foreign currency derivative contracts as of December&#160;31, 2022 and 2021, would not have a material impact on earnings, cash flows, or financial position over a one-year period. This sensitivity analysis does not consider the impact that hypothetical changes in exchange rates would have on the underlying foreign currency denominated transactions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fair value risk exposure relates primarily to our public equity investments and to equity investments that do not have readily determinable fair values. As of December&#160;31, 2022 and 2021, our carrying values of these investments were $1.16 billion and $1.83 billion, respectively. A hypothetical 20 percent change in fair value of the equity instruments would have impacted other-net, (income) expense by $232.4 million and $365.6 million as of December&#160;31, 2022 and 2021, respectively. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources. We acquire and collaborate on potential products still in development and enter into research and development arrangements with third parties that often require milestone and royalty payments to the third party contingent upon the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required contingent upon the successful achievement of an important point in the development life cycle of the pharmaceutical product (e.g., approval for marketing by the appropriate regulatory agency or upon the achievement of certain sales levels). If required by the arrangement, we may make royalty payments based upon a percentage of the sales of the product in the event that regulatory approval for marketing is obtained. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individually, these arrangements are generally not material in any one annual reporting period. However, if milestones for multiple products covered by these arrangements were reached in the same reporting period, the aggregate expense or aggregate milestone payments made could be material to our results of operations or cash flows, respectively, in that period. See Note 4 to the consolidated financial statements for additional information. These arrangements often give us the discretion to unilaterally terminate development of the product, which would allow us to avoid making the contingent payments; however, we are unlikely to cease development if the compound successfully achieves milestone objectives. We view these payments as positive because they signify that the product is successfully moving through development and is now generating or is more likely to generate cash flows from sales of products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we expand our manufacturing capacity in order to meet existing and expected demand of our incretin products, we have entered, and expect to continue to enter, into various agreements for contract manufacturing and for supply of materials. The executed agreements could, under certain circumstances, require us to pay up to approximately $4.5 billion if we do not purchase specified amounts of goods or services over the durations of the agreements, which generally range from 2 to 8 years.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">APPLICATION OF CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing our financial statements in accordance with accounting principles generally accepted in the U.S., we must often make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. Some of those judgments can be subjective and complex, and consequently actual results could differ from those estimates. For any given individual estimate or assumption we make, it is possible that other people applying reasonable judgment to the same facts and circumstances could develop different estimates. We believe that, given current facts and circumstances, it is unlikely that applying any such other reasonable judgment would cause a material adverse effect on our consolidated results of operations, financial position, or liquidity for the periods presented in this report. Our most critical accounting estimates have been discussed with our audit committee and are described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition and Sales Return, Rebate, and Discount Accruals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. For product sales to customers, provisions for returns, rebates and discounts are established in the same period the related product sales are recognized. To determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates. The largest of our sales rebate and discount amounts include rebates associated with sales covered by managed care, Medicare, Medicaid, and chargeback programs, as well as reductions in revenue related to our patient assistance programs, in the U.S. In determining the appropriate accrual amount, we consider our historical rebate payments for these programs, as well as patient assistance program costs, by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2 to the consolidated financial statements for further information on revenue recognition and sales return, rebate, and discount accruals.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from collaborations and other arrangements will include our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statement Impact</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our accruals for sales returns, rebates, and discounts are reasonable and appropriate based on current facts and circumstances. Our rebate and discount liabilities are included in sales rebates and discounts on our consolidated balance sheet. Our sales return liability is included in other current liabilities and other noncurrent liabilities on our consolidated balance sheet. As of December&#160;31, 2022, a 5 percent change in our consolidated sales return, rebate, and discount liability would result in a change in revenue of approximately $464&#160;million. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The portion of our consolidated sales return, rebate, and discount liability resulting from sales of our products in the U.S. was approximately 90 percent as of December&#160;31, 2022 and 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a roll-forward of our most significant U.S. sales return, rebate, and discount liability balances, including managed care, Medicare, Medicaid, chargeback, and patient assistance programs:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:75.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.185%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales return, rebate, and discount liabilities, beginning of year</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,161.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,400.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of net sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,398.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,106.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(26,345.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,344.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales return, rebate, and discount liabilities, end of year</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,214.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,161.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjustments of the estimates for these returns, rebates, and discounts to actual results were less than 1 percent of consolidated revenue for each of the years presented.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase in reduction of net sales in 2022 was primarily driven by our incretin products due to increase in our patient assistance programs and in volume of rebates for managed care, Medicare and Medicaid programs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Liabilities and Other Contingencies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation liabilities and other contingencies are, by their nature, uncertain and based upon complex judgments and probabilities. The factors we consider in developing our litigation liability reserves and other contingent liability amounts include the merits and jurisdiction of the litigation, the nature and the number of other similar current and past matters, the nature of the product and the current assessment of the science subject to the litigation, as applicable, and the likelihood of settlement and current state of settlement discussions, if any. In addition, we accrue for certain liability claims incurred, but not filed, to the extent we can formulate a reasonable estimate of their costs based primarily on historical claims experience and data regarding product usage. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also consider the insurance coverage we have to diminish the exposure for periods covered by insurance. In assessing our insurance coverage, we consider the policy coverage limits and exclusions, the potential for denial of coverage by the insurance company, the financial condition of the insurers, and the possibility of and length of time for collection. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently marketed products. In addition to insurance coverage, we consider any third-party indemnification to which we are entitled or under which we are obligated. With respect to our third-party indemnification rights, these considerations include the nature of the indemnification, the financial condition of the indemnifying party, and the possibility of and length of time for collection.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The litigation accruals and environmental liabilities and the related estimated insurance recoverables have been reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine whether acquisitions or licensing transactions should be accounted for as a business combination or as an asset acquisition, we make certain judgments, which include assessing whether the acquired set of activities and assets would meet the definition of a business under the relevant accounting rules. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the acquired set of activities and assets meets the definition of a business, assets acquired and liabilities assumed are required to be recorded at their respective fair values on our consolidated balance sheet as of the acquisition date. The excess of the purchase price over the fair value of the acquired net assets, where applicable, is recorded as goodwill. If the acquired set of activities and assets does not meet the definition of a business, the transaction is recorded as an acquisition of assets and, therefore, any acquired IPR&amp;D that does not have an alternative future use is charged to acquired IPR&amp;D and development milestones on our consolidated statement of operations at the acquisition date, and goodwill is not recorded. See Note 3 to the consolidated financial statements for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The judgments made in determining estimated fair values assigned to assets acquired and liabilities assumed in a business combination, as well as estimated asset lives, can materially affect our consolidated results of operations. The fair values of intangible assets, including acquired IPR&amp;D, are determined using information available near the acquisition date based on estimates and assumptions that are deemed reasonable by management. Significant estimates and assumptions include, but are not limited to, probability of technical success, revenue projections, and discount rate. Depending on the facts and circumstances, we may deem it necessary to engage an independent valuation expert to assist in valuing significant assets and liabilities. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of identifiable intangible assets are primarily determined using an "income method," as described in Note 8 to the consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of any contingent consideration liability that results from a business combination is primarily determined using a discounted cash flow analysis, as described in Note 7 to the consolidated financial statements. Estimating the fair value of contingent consideration requires the use of significant estimates and judgments, including, but not limited to, probability of technical success and the discount rate.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statement Impact</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, a 5 percent change in the contingent consideration liabilities would result in a change in income before income taxes of $5.5 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Indefinite-Lived and Long-Lived Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review the carrying value of long-lived assets (both intangible and tangible) for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset (or asset group) may not be recoverable. We identify impairment by comparing the projected undiscounted cash flows to be generated by the asset (or asset group) to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value, and the cost basis is adjusted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and indefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the intangible asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several methods may be used to determine the estimated fair value of acquired IPR&amp;D, all of which require multiple assumptions. We utilize the "income method," as described in Note 8 to the consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For acquired IPR&amp;D assets, the risk of failure has been factored into the fair value measure and there can be no certainty that these assets ultimately will yield a successful product, as discussed previously in "&#8212;Executive Overview&#8212;Late-Stage Pipeline." The nature of the pharmaceutical business is high-risk and requires that we invest in a large number of projects to maintain a successful portfolio of approved products. As such, it is likely that some acquired IPR&amp;D assets will become impaired in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates of future cash flows, based on what we believe to be reasonable and supportable assumptions and projections, require management's judgment. Actual results could vary materially from these estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefits Assumptions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit pension plan and retiree health benefit plan costs include assumptions for the discount rate, expected return on plan assets, and retirement age. These assumptions have a significant effect on the amounts reported. In addition to the analysis below, see Note 15 to the consolidated financial statements for additional information regarding our retirement benefits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annually, we evaluate the discount rate and the expected return on plan assets in our defined benefit pension and retiree health benefit plans. We use an actuarially determined, plan-specific yield curve of high quality, fixed income debt instruments to determine the discount rates. In evaluating the expected return on plan assets, we consider many factors, with a primary analysis of current and projected market conditions, asset returns and asset allocations (approximately 70 percent of which are growth investments), and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the discount rates and expected return on plan assets of other companies, where applicable. In evaluating our expected retirement age assumption, we consider the retirement ages of our past employees eligible for pension and medical benefits together with our expectations of future retirement ages.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annually, we determine the fair value of the plan assets in our defined benefit pension and retiree health benefit plans. Approximately 50 percent of our plan assets are in hedge funds and private equity-like investment funds (collectively, alternative assets). We value these alternative investments using significant unobservable inputs or using the net asset value reported by the counterparty, adjusted as necessary. Inputs include underlying net asset values, discounted cash flows valuations, comparable market valuations, and adjustments for currency, credit, liquidity and other risks.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statement Impact</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the 2022 discount rate for the U.S. defined benefit pension and retiree health benefit plans (U.S. plans) were to change by a quarter percentage point, income before income taxes would change by $23.8 million. If the 2022 expected return on plan assets for U.S. plans were to change by a quarter percentage point, income before income taxes would change by $33.5 million. If our assumption regarding the 2022 expected age of future retirees for U.S. plans were adjusted by one year, our income before income taxes would be affected by $46.3 million. The U.S. plans, including Puerto Rico, represent approximately 85 percent of each of the total projected benefit obligation and total plan assets at December&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to the fair value of plan assets are not recognized in pension and retiree health benefit expense in the year that the adjustments occur. Such changes are deferred, along with other actuarial gains and losses, and are amortized into expense over the expected remaining service life of employees.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file tax returns based upon our interpretation of tax laws and regulations, and we record estimates in our financial statements based upon these interpretations at the applicable tax rates in the jurisdictions in which we operate. Our tax returns are routinely subject to examination by taxing authorities, which could result in future tax, interest, and penalty assessments. Inherent uncertainties also exist in estimates of many tax positions due to the complexity of tax laws. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution. The amount of unrecognized tax benefits is adjusted for changes in facts and circumstances such as changes to existing tax law, the issuance of regulations by taxing authorities, new information obtained during a tax examination, or resolution of a tax examination. We believe our estimates for uncertain tax positions are both appropriate and sufficient to pay assessments that may result from examinations of our tax returns. We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded valuation allowances against certain of our deferred tax assets, primarily those that have been generated from net operating losses, tax credits, and other tax carryforwards and carrybacks in certain taxing jurisdictions. In evaluating whether we would more likely than not recover these deferred tax assets, we have not assumed future taxable income in the jurisdictions associated with these carryforwards where history does not support such an assumption. Implementation of tax planning strategies to recover these deferred tax assets or to generate future taxable income in these jurisdictions could lead to the reversal of all or a portion of these valuation allowances and a reduction of income tax expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statement Impact</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, a 5 percent change in the amount of uncertain tax positions and the valuation allowance would result in a change in net income of $85.0 million and $38.8 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_67"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">LEGAL AND REGULATORY MATTERS </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to certain legal proceedings can be found in Note 16 to the consolidated financial statements and is incorporated here by reference.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_70"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 7A.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:2pt">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You can find quantitative and qualitative disclosures about market risk (e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> interest rate risk) at Item&#160;7, "Management's Discussion and Analysis - Financial Condition and Liquidity." That information is incorporated by reference herein.</span></div><div style="margin-top:5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 8.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Financial Statements and Supplementary Data</span></div><div id="i909b702f7db044078a8e3e150503788d_76"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Statements of Operations</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:37.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ELI LILLY AND COMPANY AND SUBSIDIARIES<br/>(Dollars in millions and shares in thousands, except per-share data)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue (Note 2)</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMS00LTEtMS0xOTcxODI_2a3d8417-cd94-4487-b5d9-1d4a254620bf">28,541.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMS02LTEtMS0xOTcxODI_a1db985c-6b79-4b2a-b6ac-10fdcd4cb895">28,318.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMS04LTEtMS0xOTcxODI_9d4a671c-7a6f-48fa-809b-0cf0f41fc94c">24,539.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, expenses, and other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMy00LTEtMS0xOTcxODI_e5ee7537-0002-4cf0-9b2e-d015aff381f0">6,629.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMy02LTEtMS0xOTcxODI_dbec22c9-4bbb-4f02-8bfb-62b5e2e0a5d0">7,312.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMy04LTEtMS0xOTcxODI_d22fba28-c936-4adb-b0e7-946af6261f95">5,483.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNC00LTEtMS0xOTcxODI_b0de80ef-3cd0-4d59-9381-15cffaee2379">7,190.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNC02LTEtMS0xOTcxODI_845edef5-3208-46a7-928e-9b40fc851b55">6,930.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNC04LTEtMS0xOTcxODI_4e54d8e8-bbba-47da-ab26-658f59ff0805">5,976.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling, and administrative</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNS00LTEtMS0xOTcxODI_0ca1d9a4-ae67-4364-a8c8-24fd48ffffa0">6,440.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNS02LTEtMS0xOTcxODI_2a3d0d6f-9e17-4ada-934a-1c7996e0ec9c">6,431.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNS04LTEtMS0xOTcxODI_a55f4050-5f92-4322-9a3b-c21acb09e5fc">6,121.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development and development milestones (Note 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNi00LTEtMS0xOTcxODI_baff4a8b-830f-4c11-904c-efb0462138b4">908.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNi02LTEtMS0xOTcxODI_ebd203ce-4a32-42a7-9b6f-96612aa2e9ae">970.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNi04LTEtMS0xOTcxODI_a24ad2dc-1d0d-4d4e-bf67-0bf3b4988841">769.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring, and other special charges <br/>(Note 5)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNy00LTEtMS0xOTcxODI_aeddbb38-4085-4fe3-a128-b3cb38bcd829">244.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNy02LTEtMS0xOTcxODI_eebd5d7b-7f9e-48dd-807e-e830680bf8c5">316.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNy04LTEtMS0xOTcxODI_737c3c0a-7eb4-49dd-9427-594000d6db21">131.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense (Note 18)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfOC00LTEtMS0xOTcxODI_bd070b80-bc64-4053-94af-852a7763058b">320.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfOC02LTEtMS0xOTcxODI_6f33b035-3620-47b0-bdc0-69c1a89d0a3c">201.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfOC04LTEtMS0xOTcxODI_b229d220-ea87-4324-a48f-1abcfb80dfd1">1,171.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="lly:CostOfSalesOperatingExpensesAndOtherNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfOS00LTEtMS0xOTcxODI_a8dd7d06-2c2b-4c36-8e5d-4d69ead65bf8">21,735.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="lly:CostOfSalesOperatingExpensesAndOtherNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfOS02LTEtMS0xOTcxODI_8945d183-94ce-4cde-9cd5-d01eba369617">22,162.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="lly:CostOfSalesOperatingExpensesAndOtherNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfOS04LTEtMS0xOTcxODI_7557c30b-dc4b-410e-9987-629c86cc5eb5">17,309.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTAtNC0xLTEtMTk3MTgy_a1467945-7b09-4830-b35b-4b09ce08af65">6,806.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTAtNi0xLTEtMTk3MTgy_68b9d782-4280-40bf-b5b1-e83088676b41">6,155.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTAtOC0xLTEtMTk3MTgy_ff6b94fb-3111-4150-96cf-ced45afdf375">7,229.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes (Note 14)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTEtNC0xLTEtMTk3MTgy_a15aa45f-a185-4381-8024-4d87f0fff1b4">561.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTEtNi0xLTEtMTk3MTgy_a5945d4e-a638-482e-b692-bb66192f5c92">573.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTEtOC0xLTEtMTk3MTgy_eb3380e3-3ad9-412c-923e-31d1f69abccf">1,036.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTQtNC0xLTEtMTk3MTgy_21a4af03-c8dd-4245-87b5-eae635fb6d2f">6,244.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTQtNi0xLTEtMTk3MTgy_1fa38700-fa84-4919-b383-0f1500d0250e">5,581.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTQtOC0xLTEtMTk3MTgy_8cc89653-1e63-4c06-a0cf-ad668a87cee6">6,193.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="9" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTktNC0xLTEtMTk3MTgy_57b2ab7d-397e-4875-bc6e-bb056af5b963">6.93</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTktNi0xLTEtMTk3MTgy_6a7e0b59-a5fa-45b8-9241-142c93580deb">6.15</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTktOC0xLTEtMTk3MTgy_d9b6a1c3-18f7-4a47-96dd-eefc73be459e">6.82</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMjMtNC0xLTEtMTk3MTgy_11c9bcd5-ea8c-4607-8fde-30413a136dfb">6.90</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMjMtNi0xLTEtMTk3MTgy_878b97d0-34a6-4f32-836a-98eef08bc822">6.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMjMtOC0xLTEtMTk3MTgy_0cb71c06-51ee-4354-a108-23213fa1eb45">6.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="9" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in calculation of earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMjYtNC0xLTEtMTk3MTgy_82b9cec2-7b44-4d33-8e9e-3bebdf8854f8">901,736</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMjYtNi0xLTEtMTk3MTgy_874e2854-3124-47d4-bfcd-e2fed9d682eb">906,963</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMjYtOC0xLTEtMTk3MTgy_17a1eb1a-7259-43d0-9830-9d919865152b">907,634</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMjctNC0xLTEtMTk3MTgy_d137c619-e224-40a8-91fc-05af250251e9">904,619</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMjctNi0xLTEtMTk3MTgy_ef08873d-b8c3-4abd-9cd7-9fbe6c6b0ceb">911,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMjctOC0xLTEtMTk3MTgy_3fb076a1-86e6-42d8-8497-0a466b140f38">912,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Statements of Comprehensive Income (Loss)</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ELI LILLY AND COMPANY AND SUBSIDIARIES<br/>(Dollars in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfMS00LTEtMS0xOTcxODI_4ce7a97b-84bf-4f6b-8266-4c29830194f8">6,244.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfMS02LTEtMS0xOTcxODI_5c1e4cdf-1e6a-444a-a376-5f5a7ab744c8">5,581.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfMS04LTEtMS0xOTcxODI_40f2856f-b3be-45ce-9a3b-902348d7a2c7">6,193.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in foreign currency translation gains (losses)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfMy00LTEtMS0xOTcxODI_3b83e774-b9a0-4909-8378-69db592c432f">248.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfMy02LTEtMS0xOTcxODI_7214dca8-3327-44de-9e7e-8b36700e5184">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfMy04LTEtMS0xOTcxODI_c8720a99-3463-4cf7-8393-772b519eb5dd">122.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in net unrealized gains (losses) on securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNC00LTEtMS0xOTcxODI_d702b24e-826a-476b-bad6-027d6ed079f8">53.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNC02LTEtMS0xOTcxODI_a1f49844-f71c-476d-92cf-b7ddeff478fe">15.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNC04LTEtMS0xOTcxODI_b193e578-bfa7-4662-8453-ecf7a636f39a">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in defined benefit pension and retiree health benefit plans (Note 15)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNS00LTEtMS0xOTcxODI_25267950-7ba3-4e30-97f5-bbdd4da45c3d">616.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNS02LTEtMS0xOTcxODI_d807d762-62bd-44ec-9182-6f7f5d322bbe">2,699.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNS04LTEtMS0xOTcxODI_c1385818-3867-4adc-9da7-ed465d5e4306">157.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in effective portion of cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNi00LTEtMS0xOTcxODI_526b3ba2-e337-48e7-b521-a9e33fbe669d">432.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNi02LTEtMS0xOTcxODI_234f269f-f7c4-435a-883d-03f977e00ed3">151.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNi04LTEtMS0xOTcxODI_71b1cc80-87bf-4034-8f48-79e136a2c9a0">152.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before income taxes</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNy00LTEtMS0xOTcxODI_275c9a42-9615-4bdb-ab73-e20d438b6e82">748.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNy02LTEtMS0xOTcxODI_2eb81990-42cf-45c6-8a28-56a44f146430">2,848.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNy04LTEtMS0xOTcxODI_c8e19113-2495-41d8-aec8-f5d86fa26f31">173.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) for income taxes related to other comprehensive income (loss) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfOC00LTEtMS0xOTcxODI_33a1ea6d-d39f-4123-b8db-e7548b4e0d83">250.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfOC02LTEtMS0xOTcxODI_2877e434-a0e4-46f5-8759-6982d8d8cd33">695.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfOC04LTEtMS0xOTcxODI_7c9e988e-584b-40ed-9b53-c7f831c0b683">200.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax (Note 17)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfOS00LTEtMS0xOTcxODI_edf8fead-674e-4378-95ba-6368fe31ec3c">498.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfOS02LTEtMS0xOTcxODI_bbf9c8e4-da5f-49dd-b720-07fffbb116ec">2,153.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfOS04LTEtMS0xOTcxODI_20cd51a5-ed17-48c2-a73c-54379c492736">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfMTItNC0xLTEtMTk3MTgy_e03ebbcd-102f-47dd-b562-1753bcfe79c6">6,743.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfMTItNi0xLTEtMTk3MTgy_893e1c1e-dc68-4312-8b63-480dad561de9">7,735.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfMTItOC0xLTEtMTk3MTgy_d869620e-f909-4f13-a5b4-6e0e0cf48e88">6,220.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ELI LILLY AND COMPANY AND SUBSIDIARIES<br/>(Dollars in millions, shares in thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents (Note 7)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMy00LTEtMS0xOTcxODI_ee847f79-31d3-43d6-bf83-f421d1047787">2,067.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMy02LTEtMS0xOTcxODI_83acf139-c535-4792-a654-2876d49b2982">3,818.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNC00LTEtMS0xOTcxODI_b70fecba-f024-44a9-ae90-f994ca8f78ed">144.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNC02LTEtMS0xOTcxODI_c607d822-3282-4426-8728-61c2cfaf9a4a">90.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowances of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNS0wLTEtMS0xOTcxODIvdGV4dHJlZ2lvbjpjMjFjOTZhYTdiOWM0YjgxOGYzZTdhODYwMmVjYmYwYl80Nw_e3b0069d-a448-4bd1-ab5e-142f9320d857">16.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2022)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;and $<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNS0wLTEtMS0xOTcxODIvdGV4dHJlZ2lvbjpjMjFjOTZhYTdiOWM0YjgxOGYzZTdhODYwMmVjYmYwYl81OQ_70c63f9e-9abe-492c-9664-7e4f6ee1a9e0">22.5</ix:nonFraction> (2021)</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNS00LTEtMS0xOTcxODI_4d23613d-0f59-4daa-a33b-655e886be397">6,896.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNS02LTEtMS0xOTcxODI_6a9f0bb3-2a26-4f5c-8b4a-914235a0de9c">6,672.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:OtherReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNi00LTEtMS0xOTcxODI_c72a8ed4-d20a-4953-8f1c-7b2f459b8032">1,662.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:OtherReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNi02LTEtMS0xOTcxODI_3a5c317a-a772-47bd-88a8-a1b8c4b83e17">1,454.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories (Note 6)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNy00LTEtMS0xOTcxODI_2c5eaa6b-6fb8-49a2-a416-342dfc4fca86">4,309.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNy02LTEtMS0xOTcxODI_d4d778d8-07aa-4ae9-a85c-4cd1af0cb55b">3,886.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfOC00LTEtMS0xOTcxODI_98617a57-3b2c-4801-be6a-a30fbae4c9a3">2,954.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfOC02LTEtMS0xOTcxODI_9ec25993-c6f5-492f-9291-b8ebcf064cc9">2,530.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTAtNC0xLTEtMTk3MTgy_b41d6e72-8dd6-4b2e-b8c3-08f82b3670a0">18,034.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTAtNi0xLTEtMTk3MTgy_260815c2-af1d-4e25-85db-3ab660d3e5f6">18,452.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTEtNC0xLTEtMTk3MTgy_9d5a2328-c54b-44ac-9e20-95d8bf64403a">2,901.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTEtNi0xLTEtMTk3MTgy_d0a79f9f-1bba-4e5e-9461-677e6767c7c8">3,212.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill (Note 8)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTItNC0xLTEtMTk3MTgy_3babf8b4-e566-4fe9-8a6e-17fbe9c913bd">4,073.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTItNi0xLTEtMTk3MTgy_a91cb7bc-d99c-49fe-b4ae-9438c28e2024">3,892.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles, net (Note 8)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTMtNC0xLTEtMTk3MTgy_7a24eeac-9cd7-49dd-8a10-f0abc9ae4582">7,206.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTMtNi0xLTEtMTk3MTgy_53b82931-cda6-4c7e-97c1-fa86817d5fe9">7,691.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (Note 14)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTQtNC0xLTEtMTk3MTgy_fa9e0455-96ab-4ec0-aac4-470108d18d26">2,792.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTQtNi0xLTEtMTk3MTgy_78f1766b-85a7-4d8c-82f9-cf08cd22d2db">2,489.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net (Note 9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTUtNC0xLTEtMTk3MTgy_5a4c1e38-2103-4563-bcdb-fef6b28f60da">10,144.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTUtNi0xLTEtMTk3MTgy_707a1920-48a9-4342-87d1-65cebdf79881">8,985.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTctNC0xLTEtMTk3MTgy_dd4a4903-1092-410a-b9a0-410f2210c1f8">4,337.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTctNi0xLTEtMTk3MTgy_36ae6317-47ff-4d27-91c5-e04ae03efd8a">4,082.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTktNC0xLTEtMTk3MTgy_7d556992-bba1-4d4f-936c-de44ee1e4f7b">49,489.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTktNi0xLTEtMTk3MTgy_2148a1c4-6272-42b1-9d6c-4d9c6a8e0f03">48,806.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings and current maturities of long-term debt (Note 11)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjItNC0xLTEtMTk3MTgy_7b26f788-7115-445a-97df-8ae1061a99c6">1,501.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjItNi0xLTEtMTk3MTgy_d7cd3c52-f90a-44dc-aeb7-16117ea7fe59">1,538.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjMtNC0xLTEtMTk3MTgy_490c8b87-5efc-4249-8d9e-a72415556c6d">1,930.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjMtNi0xLTEtMTk3MTgy_98d2baf6-97d0-45cf-8c44-e17e25561348">1,670.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjQtNC0xLTEtMTk3MTgy_6c03b281-3652-4928-8a38-87391e82c4bc">1,059.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjQtNi0xLTEtMTk3MTgy_91da9fa5-967d-4f98-bba9-61965ab7febb">958.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="lly:SalesRebatesAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjUtNC0xLTEtMTk3MTgy_107ea4cc-42b5-48a0-8d33-fcbdfd2237f0">8,784.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="lly:SalesRebatesAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjUtNi0xLTEtMTk3MTgy_72c3c5f5-2c82-4a28-8b39-e8b1ae7ca62c">6,845.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjYtNC0xLTEtMTk3MTgy_c8fbe7a5-6527-4887-8e3a-c2f05b7d05d1">1,017.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjYtNi0xLTEtMTk3MTgy_9cd3d134-8be0-4d76-9554-b45d8d2f85d1">885.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable (Note 14)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjctNC0xLTEtMTk3MTgy_dd010223-1acf-42a0-9eb6-5c7c329ac1e3">475.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjctNi0xLTEtMTk3MTgy_c0c73f5e-4606-4e30-b743-7b52b16e27a7">126.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjgtNC0xLTEtMTk3MTgy_d4aff757-d574-40ee-886f-682253b1143c">2,370.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjgtNi0xLTEtMTk3MTgy_266ea945-4e1f-419e-81df-1c059b49e8d6">3,027.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzAtNC0xLTEtMTk3MTgy_52db124b-0be2-44df-8648-dcbe5d93468c">17,138.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzAtNi0xLTEtMTk3MTgy_e193368e-5107-449e-8d8a-b83d9cc719df">15,052.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzItNC0xLTEtMTk3MTgy_44ec558b-da5e-4954-bbe9-a310f62c9380">14,737.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzItNi0xLTEtMTk3MTgy_c915af09-ecdc-428c-a5f0-3baf9af75c59">15,346.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits (Note 15)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzMtNC0xLTEtMTk3MTgy_324eb94a-0df5-401a-8a7c-f8fa8e433402">1,305.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzMtNi0xLTEtMTk3MTgy_eac11c3c-6370-4157-a704-7a088295bd86">1,954.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term income taxes payable (Note 14)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzQtNC0xLTEtMTk3MTgy_17078785-3f1d-4111-9ff6-b6def04ff9fc">3,709.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzQtNi0xLTEtMTk3MTgy_c5fa92be-5181-423d-b63d-1af5f82a28b6">3,920.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities (Note 14)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzUtNC0xLTEtMTk3MTgy_d37b3ced-a4c7-4ca0-887f-5217d80db6bc">87.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzUtNi0xLTEtMTk3MTgy_b1218330-23db-45e2-a52d-866e93067c17">1,733.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzYtNC0xLTEtMTk3MTgy_b66051ff-ce11-4c9f-bd93-38ec4f049a4f">1,736.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzYtNi0xLTEtMTk3MTgy_5e6f6b3a-c47a-407c-95fc-3b0b31fe577c">1,644.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other liabilities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzgtNC0xLTEtMTk3MTgy_500b6a9f-f993-434a-a591-923e3f04925b">21,576.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzgtNi0xLTEtMTk3MTgy_a641fd98-0f93-4ab9-837c-f9299de9a758">24,598.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Commitments and Contingencies (Note 16)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzktNC0xLTEtMTk3MTgy_ad39234a-3e85-4b24-886d-41da88e1611d"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzktNi0xLTEtMTk3MTgy_3e84cc2e-f539-4761-a6c5-637dfb9fa44c"></ix:nonFraction></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Eli Lilly and Company Shareholders' Equity (Notes 12 and 13)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#8212;no par value</span></div><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorized shares: <ix:nonFraction unitRef="shares" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDEtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246YzBhOGZlYzBhYzY0NGM1Zjg2M2VhN2M0YzJhZDJjZTRfNDk_89455235-6bfa-4eec-803c-b933365c37d5"><ix:nonFraction unitRef="shares" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDEtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246YzBhOGZlYzBhYzY0NGM1Zjg2M2VhN2M0YzJhZDJjZTRfNDk_ba9d0f51-c507-44f5-9ef3-366735c064e9">3,200,000</ix:nonFraction></ix:nonFraction></span></div><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued shares: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDEtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246YzBhOGZlYzBhYzY0NGM1Zjg2M2VhN2M0YzJhZDJjZTRfNjc_c91326ce-0ae8-4684-ae15-dfcb126e39ba">950,632</ix:nonFraction> (2022)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;and <ix:nonFraction unitRef="shares" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDEtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246YzBhOGZlYzBhYzY0NGM1Zjg2M2VhN2M0YzJhZDJjZTRfODE_be250d77-9c8f-449e-aa82-d79b4c7c2ec2">954,116</ix:nonFraction> (2021)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDEtNC0xLTEtMTk3MTgy_31fabd41-34a2-439f-a0a7-15821feb647c">594.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDEtNi0xLTEtMTk3MTgy_ff4d5030-62a7-49df-98c9-1c81e82f99fa">596.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDItNC0xLTEtMTk3MTgy_9e47888a-01c3-418a-9398-f9244c78d1ff">6,921.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDItNi0xLTEtMTk3MTgy_2c347ab7-aef9-40ac-ae18-e14c761094dc">6,833.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDMtNC0xLTEtMTk3MTgy_f7f24e58-d7d0-49da-beba-bf386d8549d8">10,042.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDMtNi0xLTEtMTk3MTgy_48ba4f6b-f4b9-4cc5-88a9-76d073c5de9d">8,958.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit trust</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDQtNC0xLTEtMTk3MTgy_eeb48956-8f75-44a2-9da1-654defaf8220">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDQtNi0xLTEtMTk3MTgy_b2243ca5-161c-4977-8f1c-bbcc1c4907c0">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss (Note 17)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDUtNC0xLTEtMTk3MTgy_e170d053-369d-4580-8525-231e1057736b">3,844.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDUtNi0xLTEtMTk3MTgy_dc9162f0-1b72-4970-ae9c-dcff3363a44e">4,343.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of common stock in treasury</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:TreasuryStockCommonValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDYtNC0xLTEtMTk3MTgy_f722b83c-4b3d-4dcc-b51c-485f0a898e37">50.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:TreasuryStockCommonValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDYtNi0xLTEtMTk3MTgy_f0c8cf0a-909e-4c8d-85ab-79d5595b053c">52.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Eli Lilly and Company shareholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDctNC0xLTEtMTk3MTgy_fdc76c7d-c5e8-4b08-aeb3-49d93deb8901">10,649.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDctNi0xLTEtMTk3MTgy_2f1123d2-6fd4-49a6-9a39-c4e42ce2448b">8,979.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDgtNC0xLTEtMTk3MTgy_179f42b9-b98c-471b-a6ef-d4ecf00eff21">125.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDgtNi0xLTEtMTk3MTgy_01997221-cec2-4bb3-bd11-aed4da0bb6cf">175.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDktNC0xLTEtMTk3MTgy_66ab7bc1-8fbb-4f1d-8d3c-85ec33501507">10,775.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDktNi0xLTEtMTk3MTgy_7433fec5-97bd-4d0e-8d39-ecb96aae2bff">9,154.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNTAtNC0xLTEtMTk3MTgy_a255c79e-c9ee-4ded-974d-879992cc88f9">49,489.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNTAtNi0xLTEtMTk3MTgy_4d6228fa-69f6-44e8-a54b-fb1ee23c7cbf">48,806.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Statements of Shareholders' Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Equity of Eli Lilly and Company Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">ELI LILLY AND COMPANY AND SUBSIDIARIES<br/>(Dollars in millions, except per-share data, and shares in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Employee Benefit Trust</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock in Treasury</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Noncontrolling Interest</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at January 1, 2020</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i356b319ab866417988ad019b9794d8cb_I20191231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMy0xLTEtMS0xOTcxODI_c0300d13-6917-45a2-8965-34c492012a90">958,056</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i356b319ab866417988ad019b9794d8cb_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMy0zLTEtMS0xOTcxODI_0e2141cc-ad35-4ff1-affe-5de8b01e1570">598.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9021134b4fbc4e258ea850eb3c4c4c7b_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMy01LTEtMS0xOTcxODI_5e9f3623-c4b5-454b-bac2-0261b08c59e0">6,685.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2f5f0abb434012bb2af32c10ddc89c_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMy03LTEtMS0xOTcxODI_30f170ad-ac60-42ab-8770-a350c38b3a68">4,920.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6870f7c27b5d40b09b8227c732a66406_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMy05LTEtMS0xOTcxODI_531bb3fd-6080-451d-a4f8-04e84d876974">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89c86fcc6d9848e19d2dcbf04813b652_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMy0xMS0xLTEtMTk3MTgy_51311629-38ab-4595-8ca4-092f94375bad">6,523.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cfd19befed844bdbd1e65f027b7a2ec_I20191231" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMy0xMy0xLTEtMTk3MTgy_b597b73c-7827-4a41-99f1-e5b7af4c4ecb">530</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cfd19befed844bdbd1e65f027b7a2ec_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMy0xNS0xLTEtMTk3MTgy_3b8c3dfb-14ea-4233-989c-b5f898c9515f">60.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b11cb527104470694b7931c221de577_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMy0xNy0xLTEtMTk3MTgy_214c116d-a4d2-4004-a6f1-8cfaf8a029a7">92.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6964671a05464b22a4eb74dbbd4d79e7_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNC03LTEtMS0xOTcxODI_bf4c1f6d-ff7c-47d2-901d-1a480a38d73b">6,193.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i774298166b774d40bff6c0588b2f3c56_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNC0xNy0xLTEtMTk3MTgy_aa095316-3967-40ad-acdf-13bebb60aa1b">126.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b0c0c02225844c6b4ea5018b890387d_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNS0xMS0xLTEtMTk3MTgy_1c27b239-d860-4975-a021-76519f9b5be6">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash dividends declared per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNi0wLTEtMS0xOTcxODIvdGV4dHJlZ2lvbjo4M2Q4YTI1YmEwMWQ0OTVjOWUzODBhYjFiZjRkMGJiMF8zOQ_6e32d87b-40ce-4404-9b95-98f068ae2478">3.07</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6964671a05464b22a4eb74dbbd4d79e7_D20200101-20201231" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNi03LTEtMS0xOTcxODI_8e8dfa9e-a6b4-497e-a768-b8fb410598a7">2,786.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retirement of treasury shares</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i375d8504588144e3bb7b25036361f87c_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNy0xLTEtMS0xOTcxODI_4b4a6cad-59db-40a6-825b-bbe8c887994f">3,627</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i375d8504588144e3bb7b25036361f87c_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNy0zLTEtMS0xOTcxODI_71f538e3-fcd4-4c5c-bea9-0c2501f48d9e">2.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6964671a05464b22a4eb74dbbd4d79e7_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNy03LTEtMS0xOTcxODI_f9ea041d-652d-487f-8bd0-aa0743d23521">497.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i19f9560e8da24c70a901e8c074917400_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNy0xMy0xLTEtMTk3MTgy_310c2cfa-b007-46ef-a49b-0c383127c31a">3,627</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f9560e8da24c70a901e8c074917400_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNy0xNS0xLTEtMTk3MTgy_8aef3499-bfcb-4870-8fa2-ab00bc2a6b48">500.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19f9560e8da24c70a901e8c074917400_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfOC0xMy0xLTEtMTk3MTgy_5a2daed6-4261-40e0-993b-2c5862a77bee">3,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19f9560e8da24c70a901e8c074917400_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfOC0xNS0xLTEtMTk3MTgy_e4a75118-d4cc-4dd3-894f-b63001afffb7">500.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i375d8504588144e3bb7b25036361f87c_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfOS0xLTEtMS0xOTcxODI_5b709857-c603-4421-8212-7eda383abdca">2,648</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375d8504588144e3bb7b25036361f87c_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfOS0zLTEtMS0xOTcxODI_ef0047c2-dc5b-4638-9302-8df3a047b5c0">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cfc9ba4c614087a5a71a8d2a07e024_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfOS01LTEtMS0xOTcxODI_f5b5f78c-ddb0-494a-b3fc-e3d083e127a0">212.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i19f9560e8da24c70a901e8c074917400_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfOS0xMy0xLTEtMTk3MTgy_450d1c96-c87d-452a-870d-12c423fe3778">43</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f9560e8da24c70a901e8c074917400_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfOS0xNS0xLTEtMTk3MTgy_d032176a-4d4d-49ae-903f-321ffb691f77">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cfc9ba4c614087a5a71a8d2a07e024_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTAtNS0xLTEtMTk3MTgy_a9e25c2e-c92c-42a7-8271-c4ed5d64d2ce">308.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cfc9ba4c614087a5a71a8d2a07e024_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTMtNS0xLTEtMTk3MTgy_367ac503-5e55-4f63-a65f-77acc63228c1">2.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i774298166b774d40bff6c0588b2f3c56_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTMtMTctMS0xLTE5NzE4Mg_6c72293d-3c06-44da-8795-7c1831e38ef5">35.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia61f75ab6b7546e7a580ad9a5b93f8d2_I20201231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTQtMS0xLTEtMTk3MTgy_22151b19-599b-441b-8301-7f83026e47f3">957,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia61f75ab6b7546e7a580ad9a5b93f8d2_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTQtMy0xLTEtMTk3MTgy_abc0005c-0577-4069-a83c-00f3dc7f5ba3">598.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a274dc2077148a0b820a07f6dfed9f8_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTQtNS0xLTEtMTk3MTgy_96470cc3-a851-45e2-a494-55166e0e438f">6,778.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7559b91ac864734b64c8cb3e513830a_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTQtNy0xLTEtMTk3MTgy_3581a59b-4989-407f-8fd1-8b65b8eee524">7,830.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf02933ba36a42cfbfedca3bc4a05dea_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTQtOS0xLTEtMTk3MTgy_d06fdb25-acb3-4958-a11e-715692873d8d">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfab23ce152040e39f298e6d61067c78_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTQtMTEtMS0xLTE5NzE4Mg_c9f20d58-19b0-4a2c-83c4-9ed976faac88">6,496.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ae7226bbaa54a2bbab2e5672eb2325b_I20201231" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTQtMTMtMS0xLTE5NzE4Mg_e56330f3-2431-4e85-b1d9-f41353e2b691">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ae7226bbaa54a2bbab2e5672eb2325b_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTQtMTUtMS0xLTE5NzE4Mg_549e06c3-1f4c-4617-b6a3-48173a774c45">55.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4862d64d1a0c4143be7faa33eecd5fae_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTQtMTctMS0xLTE5NzE4Mg_4b32b67e-1e34-4f89-b4b7-3d5c99895796">183.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income </span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05c4645dada4161887047e966e0cacc_D20210101-20211231" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTUtNy0xLTEtMTk3MTgy_17de5c0a-bcca-4b48-bccd-21ac9939ad9f">5,581.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief070a1731ef4d1cbff5877950a5d572_D20210101-20211231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTUtMTctMS0xLTE5NzE4Mg_abc9733f-d059-46ed-b614-d85b14c49b33">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i641baa148fc94939a4e053beaf2b5f97_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTYtMTEtMS0xLTE5NzE4Mg_2f99c01c-1d9a-453b-8f0f-74ecaf7f6381">2,153.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash dividends declared per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTctMC0xLTEtMTk3MTgyL3RleHRyZWdpb246MGJmNzY4YmFmZWE4NDkzMjlkMmIyYmVlYTEwNjZiNzFfMzk_8ed24ef9-1058-4a81-b421-7a3ebf942bbd">3.53</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if05c4645dada4161887047e966e0cacc_D20210101-20211231" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTctNy0xLTEtMTk3MTgy_855e14bf-9db7-4031-84a7-c5af67bd5f36">3,201.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retirement of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i44b2a1ce17cf4dcf80f4b720f9b9853c_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTgtMS0xLTEtMTk3MTgy_d63190d1-67ee-4768-8485-9c0fc33ebf81">5,412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44b2a1ce17cf4dcf80f4b720f9b9853c_D20210101-20211231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTgtMy0xLTEtMTk3MTgy_f52978b2-4299-4293-b5d0-bbc05320e7a5">3.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if05c4645dada4161887047e966e0cacc_D20210101-20211231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTgtNy0xLTEtMTk3MTgy_16996918-fc51-44dd-baeb-b67e6b835779">1,246.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1a1511cc032b4cc28578302f22e2c378_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTgtMTMtMS0xLTE5NzE4Mg_8522d1de-b019-4395-b634-42366bf22e15">5,412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a1511cc032b4cc28578302f22e2c378_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTgtMTUtMS0xLTE5NzE4Mg_1ce90fcf-870d-4010-bd4f-18a3af31f6bc">1,250.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a1511cc032b4cc28578302f22e2c378_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTktMTMtMS0xLTE5NzE4Mg_faf15ea2-b07f-459a-9f8d-03168c59ee63">5,412</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a1511cc032b4cc28578302f22e2c378_D20210101-20211231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTktMTUtMS0xLTE5NzE4Mg_5d18817e-f102-45e5-975d-8b2d7e6b0983">1,250.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44b2a1ce17cf4dcf80f4b720f9b9853c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjAtMS0xLTEtMTk3MTgy_bba0662f-fadc-4bb9-aa29-b25944a58f0a">2,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b2a1ce17cf4dcf80f4b720f9b9853c_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjAtMy0xLTEtMTk3MTgy_f806a4cf-d63a-4773-8fe7-3151f38097eb">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18e2767e0827495582d56de8c7445b9d_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjAtNS0xLTEtMTk3MTgy_1fc41105-6817-438f-96da-05565b215657">287.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1a1511cc032b4cc28578302f22e2c378_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjAtMTMtMS0xLTE5NzE4Mg_a893c4c3-2f8c-405d-a683-15ae67e01354">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a1511cc032b4cc28578302f22e2c378_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjAtMTUtMS0xLTE5NzE4Mg_6cb72473-4807-4953-b106-0316bb6dca13">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18e2767e0827495582d56de8c7445b9d_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjEtNS0xLTEtMTk3MTgy_d0c74c53-36b4-4d1a-9e82-f51260274b85">342.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i18e2767e0827495582d56de8c7445b9d_D20210101-20211231" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjQtNS0xLTEtMTk3MTgy_9ce124dc-6179-4367-a3d2-8de924e689bc"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if05c4645dada4161887047e966e0cacc_D20210101-20211231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjQtNy0xLTEtMTk3MTgy_1b4630dc-608e-4db8-9ad4-afb26cf1e715">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief070a1731ef4d1cbff5877950a5d572_D20210101-20211231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjQtMTctMS0xLTE5NzE4Mg_de8c7a87-576d-4a6d-b883-83413866e007">11.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id08bbbd0c60b41d489ec1b27da14ee41_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjUtMS0xLTEtMTk3MTgy_2826aeef-55d3-4bdb-ba69-787aec22432b">954,116</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08bbbd0c60b41d489ec1b27da14ee41_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjUtMy0xLTEtMTk3MTgy_cda4327e-ecc6-4776-8e13-ac2af321a701">596.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5849b31083f849e0a1279866ce821c8d_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjUtNS0xLTEtMTk3MTgy_514510a4-e022-4bde-b734-ec139ee1c952">6,833.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d74411eaba3495eb1fb5b40272b8e0b_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjUtNy0xLTEtMTk3MTgy_e180a134-1eef-406e-b815-e03884d7894e">8,958.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f874e14a4254206a744a4d998b3e21e_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjUtOS0xLTEtMTk3MTgy_f5844005-a1af-4e87-82ba-da5c3d2e15a9">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9397c716ecc8492dbfa355270ffb58b6_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjUtMTEtMS0xLTE5NzE4Mg_db3def59-ab7c-4131-80a5-472242a9bb66">4,343.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8898e7952db94e61a40bdb19eaf218e7_I20211231" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjUtMTMtMS0xLTE5NzE4Mg_74087450-5530-44d4-8e02-40ea367dbcb9">463</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8898e7952db94e61a40bdb19eaf218e7_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjUtMTUtMS0xLTE5NzE4Mg_52c4af6b-02b3-49d1-a9be-a8c5ff312dec">52.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4292c3a6efd4496b3c10175cfb14871_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjUtMTctMS0xLTE5NzE4Mg_2f9914b9-a1b5-4391-b5ca-63086ea7082e">175.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64797ebd6cf24a2b83d33c497b3a79cc_D20220101-20221231" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjYtNy0xLTEtMTk3MTgy_19b483c9-2c23-4cc7-af45-d3c7fa2c7233">6,244.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03cb5dfdc26c46d3b41f02d740b93582_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjYtMTctMS0xLTE5NzE4Mg_b758d3e4-f45b-462b-a2a6-1aaffa1d6ede">20.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf0599f6d15415f8e902c9d74e9a82f_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjctMTEtMS0xLTE5NzE4Mg_4d34163e-5192-4a27-895c-f61683192557">498.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash dividends declared per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjgtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246ZWYxZTgxYjljOGE1NDcwZDhhOTJjZGJiMmY1ZmJkZDZfMzk_3df4b3a4-a7fd-4a11-8857-a1ed3c3018fb">4.07</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64797ebd6cf24a2b83d33c497b3a79cc_D20220101-20221231" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjgtNy0xLTEtMTk3MTgy_4fc7efd8-bdbf-4981-b85e-b5eb24a1cc3e">3,667.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retirement of treasury shares</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i25b818086dc044f0bd310156d54327e0_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjktMS0xLTEtMTk3MTgy_6ea23331-0387-4774-8f6e-3a2e2c3df64e">5,607</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25b818086dc044f0bd310156d54327e0_D20220101-20221231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjktMy0xLTEtMTk3MTgy_a3b9111d-4546-4902-a533-8c3030b1aaf4">3.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64797ebd6cf24a2b83d33c497b3a79cc_D20220101-20221231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjktNy0xLTEtMTk3MTgy_d4c9a130-f684-4d48-a505-504c21e5754a">1,496.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib71f55d1f6214dbc90efad0d6e0c1bb4_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjktMTMtMS0xLTE5NzE4Mg_ce521660-80bf-4cb3-a843-80c6dfc3069b">5,607</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib71f55d1f6214dbc90efad0d6e0c1bb4_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjktMTUtMS0xLTE5NzE4Mg_1f21c611-cac5-41b6-86b8-5af54ab92548">1,500.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib71f55d1f6214dbc90efad0d6e0c1bb4_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzAtMTMtMS0xLTE5NzE4Mg_1d413793-88f4-4c9f-9595-c60968c70ef9">5,607</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib71f55d1f6214dbc90efad0d6e0c1bb4_D20220101-20221231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzAtMTUtMS0xLTE5NzE4Mg_8dbc8553-71fc-46dd-abdb-d966a2ef57c5">1,500.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25b818086dc044f0bd310156d54327e0_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzEtMS0xLTEtMTk3MTgy_1eab3179-2761-44c8-8ea1-27c7218ed240">2,123</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b818086dc044f0bd310156d54327e0_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzEtMy0xLTEtMTk3MTgy_8cedbd68-7185-4db6-a2da-6591d05b7598">1.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i611da2eb6b9c4c8bb17a1786b533ae67_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzEtNS0xLTEtMTk3MTgy_26eb1967-6641-46d5-941e-aeb8a9068d7b">283.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib71f55d1f6214dbc90efad0d6e0c1bb4_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzEtMTMtMS0xLTE5NzE4Mg_ed4b8196-eb5a-4881-b824-c767ad9468d9">13</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib71f55d1f6214dbc90efad0d6e0c1bb4_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzEtMTUtMS0xLTE5NzE4Mg_863188cb-7bc4-4955-97a6-c2aed9ad499d">2.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i611da2eb6b9c4c8bb17a1786b533ae67_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzItNS0xLTEtMTk3MTgy_3d7682bd-925c-48d5-acb2-73c521c23a6d">371.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64797ebd6cf24a2b83d33c497b3a79cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzUtNy0xLTEtMTk3MTgy_b21543fc-5089-4c08-9025-6780289f2d52">3.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03cb5dfdc26c46d3b41f02d740b93582_D20220101-20221231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzUtMTctMS0xLTE5NzE4Mg_bff138f0-222f-4adb-a114-a9b2c2f55ae4">29.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i178450cc0eef447cab2a5bd78e323b88_I20221231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzYtMS0xLTEtMTk3MTgy_1cd96021-a1a4-4cd1-9fd4-e5b0b0e8530b">950,632</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178450cc0eef447cab2a5bd78e323b88_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzYtMy0xLTEtMTk3MTgy_dd57e38d-051c-45c5-999d-b169e600e0cd">594.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37f9e6a906424b848ddbd2a24ab91d95_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzYtNS0xLTEtMTk3MTgy_2f433e3c-e5a5-4436-a669-be12c6dbf63e">6,921.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71b32db201354064b5cb0802d4c538dd_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzYtNy0xLTEtMTk3MTgy_a6409c07-45b8-4118-aa67-6575094c5c84">10,042.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42001d8086bb49dda45b041109c50d00_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzYtOS0xLTEtMTk3MTgy_94725afc-df06-49ea-b88e-52dd144aac6a">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a6bea1aa20b446397b350ac2671efab_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzYtMTEtMS0xLTE5NzE4Mg_4a914708-8fa4-47cb-ad9b-d96d156cb1e5">3,844.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54accb4bb2b648519e8a5ddd0145dcb3_I20221231" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzYtMTMtMS0xLTE5NzE4Mg_f70837ee-660e-4715-9cd9-b5d0b0825ef5">450</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54accb4bb2b648519e8a5ddd0145dcb3_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzYtMTUtMS0xLTE5NzE4Mg_6dfc8e3e-efbd-48aa-bb0e-0a6153eb2f8f">50.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79b34353006b49229fc2d875ac767766_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzYtMTctMS0xLTE5NzE4Mg_72184bf3-e972-4b4d-bb10-40a6cf6f7d41">125.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.537%"><tr><td style="width:1.0%"></td><td style="width:40.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.221%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ELI LILLY AND COMPANY AND SUBSIDIARIES<br/>(Dollars in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMi00LTEtMS0xOTcxODI_4ce7a97b-84bf-4f6b-8266-4c29830194f8">6,244.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMi02LTEtMS0xOTcxODI_5c1e4cdf-1e6a-444a-a376-5f5a7ab744c8">5,581.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMi04LTEtMS0xOTcxODI_40f2856f-b3be-45ce-9a3b-902348d7a2c7">6,193.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNi00LTEtMS0xOTcxODI_b634928a-15b2-45c5-bcb9-18a7a3c3507a">1,522.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNi02LTEtMS0xOTcxODI_49622885-f497-4b0e-9b9b-050f9ddd54f5">1,547.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNi04LTEtMS0xOTcxODI_7a7654a7-66e5-4b04-a3cc-288e0278f2a8">1,323.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment loss (Note 11)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNy00LTEtMS0xOTcxODI_133c9294-82a2-4acb-9bff-0bc2d3766187">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNy02LTEtMS0xOTcxODI_3581fbc7-34df-468e-8f47-2e2f13259e19">405.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNy04LTEtMS0xOTcxODI_60d20df6-d36d-4aba-a24e-3953e3b41e0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfOC00LTEtMS0xOTcxODI_55a01b8f-f210-43ed-8425-a1c22c408888">2,185.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfOC02LTEtMS0xOTcxODI_b91e7a07-e85e-45c8-b5d1-61787df241a3">802.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfOC04LTEtMS0xOTcxODI_d6afe109-c718-43cf-a80d-d6f74bc46fe2">134.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfOS00LTEtMS0xOTcxODI_6a967c18-76cb-4dcc-ac11-b9a2ed20fbae">371.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfOS02LTEtMS0xOTcxODI_c2224ec1-4417-4030-b371-2b19f077e912">342.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfOS04LTEtMS0xOTcxODI_e19997f6-6ae0-49f4-aeb3-3fcceac4f268">308.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment (gains) losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTAtNC0xLTEtMTk3MTgy_57fbecaf-98b0-4142-ad83-c111c811d2a3">420.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTAtNi0xLTEtMTk3MTgy_c7ac88db-bf4d-4000-874e-a852e2cd3221">178.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTAtOC0xLTEtMTk3MTgy_b4cd1694-68d3-4c96-9feb-47e39aba361d">1,438.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (Note 3)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTEtNC0xLTEtMTk3MTgy_411f469e-e259-48db-a79f-a955f3716447">420.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTEtNi0xLTEtMTk3MTgy_3f378f71-9551-4499-9591-4dd7e7a1c1f1">874.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTEtOC0xLTEtMTk3MTgy_76248d0a-670f-4b43-99d0-990df28a2368">660.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash operating activities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTItNC0xLTEtMTk3MTgy_71a45564-5542-4df7-8fb8-83b62ea20baf">304.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTItNi0xLTEtMTk3MTgy_f0696134-3d53-4adb-9a45-af3edbe8ee34">511.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTItOC0xLTEtMTk3MTgy_a8676b8e-445e-4f31-85a0-0f7eaf13519b">333.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net of acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables&#8212;(increase) decrease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTQtNC0xLTEtMTk3MTgy_27ed8481-1074-4b5d-a600-a488a87e732b">299.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTQtNi0xLTEtMTk3MTgy_c9d742bf-3a5d-458a-9c02-ea0e58091fbe">1,278.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTQtOC0xLTEtMTk3MTgy_74214f29-257e-4a52-8822-272440b64bac">1,350.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories&#8212;(increase) decrease</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTUtNC0xLTEtMTk3MTgy_f8bf0200-73a8-4615-938d-14b3de9f836c">599.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTUtNi0xLTEtMTk3MTgy_cf2457c0-7ca1-4edd-9911-981b4f70c545">235.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTUtOC0xLTEtMTk3MTgy_997f0726-4af5-499b-b3b9-4f340f9475ad">533.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets&#8212;(increase) decrease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTYtNC0xLTEtMTk3MTgy_33f490e1-aacc-4b9b-8583-4bcbd472cd03">793.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTYtNi0xLTEtMTk3MTgy_7afe1e70-5ca0-44f7-b8ff-dbe9e4130479">1,515.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTYtOC0xLTEtMTk3MTgy_600ed8e5-ac04-4a39-8985-a4b91dc4c346">457.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable&#8212;increase (decrease)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTctNC0xLTEtMTk3MTgy_b5b354be-2c92-4ff3-a311-f569841006c2">346.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTctNi0xLTEtMTk3MTgy_4e87e763-8796-43a3-8aa0-4fce591ec83f">359.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTctOC0xLTEtMTk3MTgy_380cdc5c-9991-4aa2-b8eb-a09b7db804f7">322.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities&#8212;increase (decrease)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTgtNC0xLTEtMTk3MTgy_6be0c96a-2d73-4132-b808-921cbbc14e46">1,331.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTgtNi0xLTEtMTk3MTgy_043a7497-3b08-4b49-a105-783d876a217b">664.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTgtOC0xLTEtMTk3MTgy_3b213220-7a42-4167-a518-ceebb860a599">1,271.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Provided by Operating Activities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTktNC0xLTEtMTk3MTgy_3ab28726-3aa0-49cc-85ff-bd10cc236677">7,084.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTktNi0xLTEtMTk3MTgy_6df45312-9559-4dd3-9c49-71d81c296c19">7,260.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTktOC0xLTEtMTk3MTgy_35d88e97-7b35-4307-ae85-d3ad7c079eff">6,499.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjEtNC0xLTEtMTk3MTgy_467e7fa3-e75e-4d2b-aaa0-0b1762e553bc">1,854.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjEtNi0xLTEtMTk3MTgy_f397cddf-9a25-4860-a8da-9c6cd1c5b4a9">1,309.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjEtOC0xLTEtMTk3MTgy_1515322e-b8f6-489f-a41f-bad7cefebb6d">1,387.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjItNC0xLTEtMTk3MTgy_631bf1eb-65f8-4de8-8b40-78b03bd73b12">121.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjItNi0xLTEtMTk3MTgy_6e166bf8-fe24-4c17-85bf-071997b3dd28">47.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjItOC0xLTEtMTk3MTgy_4838f6a6-cc6c-46e4-b009-100758e81f91">129.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjMtNC0xLTEtMTk3MTgy_a2f8b1cf-5efe-400a-87a9-6f51d58d6a9e">107.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjMtNi0xLTEtMTk3MTgy_4b299cdf-e7e2-456a-b7d4-01f5094f7b4c">83.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjMtOC0xLTEtMTk3MTgy_c7e5c567-367c-427b-a1c3-f0983a77fcf2">11.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of noncurrent investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjQtNC0xLTEtMTk3MTgy_d0cd0b51-b8d6-40bb-8125-31cb3ff926eb">342.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjQtNi0xLTEtMTk3MTgy_dc109c14-d82e-4dbb-b4c6-e625abeba269">800.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjQtOC0xLTEtMTk3MTgy_7b4a82a7-cd3a-46d2-9498-812466091314">757.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of noncurrent investments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjUtNC0xLTEtMTk3MTgy_42fd1a6c-1db7-4afe-91ae-e53ae69a28bf">600.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjUtNi0xLTEtMTk3MTgy_a32c465e-009f-4d60-b7ea-600c259d2ea0">929.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjUtOC0xLTEtMTk3MTgy_c283b0f7-6a46-48b0-bc8b-2ae6f391f728">358.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of in-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="lly:PurchasedInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjYtNC0xLTEtMTk3MTgy_bd8b5b68-f332-47a7-9b8e-77521e5ab58c">629.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="lly:PurchasedInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjYtNi0xLTEtMTk3MTgy_766c712c-e832-402a-9df9-76231612889b">563.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="lly:PurchasedInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjYtOC0xLTEtMTk3MTgy_1607dca7-0329-4779-8e39-7c0bda81cd76">641.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisitions, net of cash acquired (Note 3)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjctNC0xLTEtMTk3MTgy_30125d49-1d11-448a-9990-3e6fd617304f">327.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjctNi0xLTEtMTk3MTgy_49cd8754-5326-4b39-b7b9-a2699351ba6b">747.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjctOC0xLTEtMTk3MTgy_ead3da49-4038-4428-b634-b3a61688bc87">849.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investing activities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzAtNC0xLTEtMTk3MTgy_e338f6fc-041c-4f40-9448-0787c8733d62">206.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzAtNi0xLTEtMTk3MTgy_e2306603-d481-4018-a698-37d58dd53bdb">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzAtOC0xLTEtMTk3MTgy_ec2d8e50-c41d-4cbf-a92b-2ff7fd83325d">102.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Used for Investing Activities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzEtNC0xLTEtMTk3MTgy_d262cc75-d341-406d-b659-5039ab78d49a">3,261.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzEtNi0xLTEtMTk3MTgy_3b3548ae-33db-46de-9c82-1afa23c0422a">2,762.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzEtOC0xLTEtMTk3MTgy_e78e43a5-d065-4c66-9cad-e12aa91e1636">2,258.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzMtNC0xLTEtMTk3MTgy_d123b66f-b5de-4670-b222-494150e5dada">3,535.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzMtNi0xLTEtMTk3MTgy_ce23fb8a-2f8c-4a09-9078-40aadbbae8d3">3,086.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzMtOC0xLTEtMTk3MTgy_a5b0860f-b791-4a93-ab51-1026514dd0b9">2,687.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in short-term borrowings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzQtNC0xLTEtMTk3MTgy_3c4a8e42-a118-46f9-a280-ff08998faeaf">1,498.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzQtNi0xLTEtMTk3MTgy_19adaba4-84e3-4cb2-b58c-5b8c434c21fc">4.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzQtOC0xLTEtMTk3MTgy_c561c68d-504f-476f-8869-47aff226183b">1,494.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzUtNC0xLTEtMTk3MTgy_8b17d5f5-f94d-4ac5-b3aa-c635b4449ff5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzUtNi0xLTEtMTk3MTgy_b6ab0654-450d-423b-abcc-72abcfeadc46">2,410.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzUtOC0xLTEtMTk3MTgy_4f82ec99-6b0d-47a8-b0e3-be6629b26f46">2,062.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzYtNC0xLTEtMTk3MTgy_3547da0b-f5c1-4541-9ff9-b35c2857cd2c">1,560.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzYtNi0xLTEtMTk3MTgy_a88ad3ed-2a71-442f-933b-103659052d1b">1,905.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzYtOC0xLTEtMTk3MTgy_c20bec0f-17ea-428e-9343-71b4bd589e96">276.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of common stock</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzctNC0xLTEtMTk3MTgy_e4b16ec3-8b9d-4bca-97da-86cd65509149">1,500.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzctNi0xLTEtMTk3MTgy_86985f03-bb99-45aa-841d-a06152ba1033">1,250.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzctOC0xLTEtMTk3MTgy_c610d8a9-f75d-4fe9-8be7-285e45874ba3">500.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other financing activities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzktNC0xLTEtMTk3MTgy_03a22323-c032-4986-b95c-1d1adc6936b2">308.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzktNi0xLTEtMTk3MTgy_c25fc339-d319-454a-aa68-428136b85f57">295.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzktOC0xLTEtMTk3MTgy_5bd8a726-958d-47e4-904d-3ab4dc33058f">241.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Used for Financing Activities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDAtNC0xLTEtMTk3MTgy_3d736c61-c2a6-410b-93fa-45bfc95849c4">5,406.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDAtNi0xLTEtMTk3MTgy_4c9242f0-7a93-4939-ab20-97559b41f74a">4,131.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDAtOC0xLTEtMTk3MTgy_1615661d-8a58-4e3c-a6b1-7a9a14e63252">3,137.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDEtNC0xLTEtMTk3MTgy_10301f87-0079-4cfe-a2ae-f95314d436c7">167.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDEtNi0xLTEtMTk3MTgy_d958eae0-2964-49c5-a0ba-0d24c3526bd1">205.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDEtOC0xLTEtMTk3MTgy_4ac5deed-9095-453a-9d1b-04bec83fa145">216.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDItNC0xLTEtMTk3MTgy_a57a0298-4b7f-49aa-8177-50fc3503c59c">1,751.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDItNi0xLTEtMTk3MTgy_9c4f98cb-2f02-48b8-8734-bd374b104c3f">161.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDItOC0xLTEtMTk3MTgy_c7254469-b2fa-4da0-8880-1d26fd911456">1,319.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDMtNC0xLTEtMTk3MTgy_9c10fa64-9b7b-410d-a32a-6368217f82b8">3,818.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68cf5a8007734a98a36e143a7305b0b7_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDMtNi0xLTEtMTk3MTgy_69df54ca-6c7c-4762-8490-219ac6f2ac2c">3,657.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib66e8131e7a64596bd768a5869bc86ab_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDMtOC0xLTEtMTk3MTgy_9f0a4e8d-1c1b-4786-a87a-28d6ac596e5c">2,337.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and Cash Equivalents at End of Year</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDQtNC0xLTEtMTk3MTgy_2af6b2c1-b996-46f6-8266-4c240f4dc281">2,067.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDQtNi0xLTEtMTk3MTgy_2d11fa94-87fe-42aa-aebb-a9fd4d007c71">3,818.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68cf5a8007734a98a36e143a7305b0b7_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDQtOC0xLTEtMTk3MTgy_b78845d9-8a67-4e99-b96c-bbde2d5cc173">3,657.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Tables present dollars in millions, except per-share data)</span></div><div id="i909b702f7db044078a8e3e150503788d_94"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;1:&#160;<ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNTQ0MA_45eab13d-16c3-4ae8-92b5-44fd00e59202" continuedAt="id340afd5a37f4ab0adbcaf15da8f20b2" escape="true">Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards</ix:nonNumeric></span></div><ix:continuation id="id340afd5a37f4ab0adbcaf15da8f20b2" continuedAt="i627f532389524f7fafcd5e52b04e97e4"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include Eli Lilly and Company and all subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). We consider majority voting interests, as well as effective economic or other control over an entity when deciding whether or not to consolidate an entity. We generally do not have control by means other than voting interests. Where our ownership of consolidated subsidiaries is less than 100 percent, the noncontrolling shareholders' interests are reflected as a separate component of equity. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing of this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNTQ2OQ_ede03294-8a2e-4368-aa1d-8aa8565eb789" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D) and Development Milestones</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including but not limited to, compensation and benefits, facilities and overhead expense, clinical trial expense and fees paid to contract research organizations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D and development milestones include the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use. Additionally, milestone payment obligations related to these transactions that are incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNTQ3MA_c199fd87-f9a0-4493-8cbe-00d3cbbaded3" continuedAt="ie241d3de03ef4768a18f4f2cada699ff" escape="true">Earnings Per Share (EPS)</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie241d3de03ef4768a18f4f2cada699ff">All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis. We calculate basic EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i627f532389524f7fafcd5e52b04e97e4"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNTQ2MQ_9cc01501-830e-4806-a0a8-92993f9ac52e" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNTQ3Mg_1075e5fd-bfc9-46b1-97e0-0dd3e7385cd8" continuedAt="i03cc71a31ad24914ae363c32fbda452a" escape="true">Advertising Expenses</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i03cc71a31ad24914ae363c32fbda452a">Costs associated with advertising are expensed as incurred and are included in marketing, selling, and administrative expenses.</ix:continuation> Advertising expenses, comprised primarily of television, radio, print media, and internet advertising, totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNDU3NA_09bd9a04-eeff-4579-ad84-dd8a7b181cf2">1.0</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNDU3OA_06e9c0b9-dc42-4ccc-a54a-efaa22c85090">1.2</ix:nonFraction> billion, and $<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNDU4Ng_069f52df-2e53-4c03-a0fc-84d9ac6e41e7">1.1</ix:nonFraction> billion in 2022, 2021, and 2020, respectively, which was less than <ix:nonFraction unitRef="number" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="2" name="lly:AdvertisingExpensePercentageOfRevenue" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNDY0Mg_1696a1bc-c285-4c4d-9393-599338472e87"><ix:nonFraction unitRef="number" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="2" name="lly:AdvertisingExpensePercentageOfRevenue" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNDY0Mg_45dc5ab0-054a-4f9c-b7b2-bdda65dfe740"><ix:nonFraction unitRef="number" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="2" name="lly:AdvertisingExpensePercentageOfRevenue" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNDY0Mg_58dd2fb0-244b-4bc0-b2be-98e522cc544c">5</ix:nonFraction></ix:nonFraction></ix:nonFraction> percent of revenue each year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Significant Accounting Policies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other significant accounting policies are described in the remaining appropriate notes to the consolidated financial statements.</span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNTQ1Mg_8e2564ee-5ef3-4df7-9c73-99593b62af8a" continuedAt="i1209fed9dbe540f1bf7de89c3a1c7ba4" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Implementation of New Financial Accounting Standards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update (ASU) 2021-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes annual disclosure requirements for companies that analogize to a grant or contribution accounting model for government assistance transactions. We adopted the standard as of January 1, 2022. The adoption did not impact our financial statement disclosures. </span></div></ix:nonNumeric><div style="margin-top:6pt"><ix:continuation id="i1209fed9dbe540f1bf7de89c3a1c7ba4" continuedAt="ia8a2c2e92d1b41f783b4883718c739aa"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform</span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia8a2c2e92d1b41f783b4883718c739aa">, as further modified by ASU 2021-01 and ASU 2022-06, provides for temporary optional expedients and exceptions in applying current GAAP to contracts, hedging relationships, and other transactions affected by the transition from the use of the London Interbank Offered Rate (LIBOR) to an alternative reference rate. The standard is currently applicable to contracts entered into before January 1, 2025. We adopted the standard in the first quarter of 2022. The adoption did not have a material impact on our consolidated financial statements</ix:continuation>.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_97"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;2:&#160;<ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMTM0OTM_ae7ac4ca-3a13-4aa5-817f-e68c1cc10ff4" continuedAt="ib06a25cfffa0442aa42685e154a906fe" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="ib06a25cfffa0442aa42685e154a906fe" continuedAt="i6eb3e7c16869464ca19021e7a9765867"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMTM0OTg_d25c79ae-cd38-4a3c-a201-6138c648eb18" continuedAt="i18e98d1133fb466f8f42030346dfdaee" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated statements of operations:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie555d2f92f6542cc95e629676af2b0dc_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjJiMDE5MDNmMDk5YjRkYWNiYzcxMGQ1Yzg5Njg3ZTdiL3RhYmxlcmFuZ2U6MmIwMTkwM2YwOTliNGRhY2JjNzEwZDVjODk2ODdlN2JfMS0xLTEtMS0xOTcxODI_df666909-8fe9-4d7d-aa18-1fbf19533674">25,462.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99575cf533c942e98caf27205363dccd_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjJiMDE5MDNmMDk5YjRkYWNiYzcxMGQ1Yzg5Njg3ZTdiL3RhYmxlcmFuZ2U6MmIwMTkwM2YwOTliNGRhY2JjNzEwZDVjODk2ODdlN2JfMS0zLTEtMS0xOTcxODI_891d7356-acdf-4340-bd7f-f3b0af7b1b10">25,957.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78dd629925fb4ae4a5093b5fc180b030_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjJiMDE5MDNmMDk5YjRkYWNiYzcxMGQ1Yzg5Njg3ZTdiL3RhYmxlcmFuZ2U6MmIwMTkwM2YwOTliNGRhY2JjNzEwZDVjODk2ODdlN2JfMS01LTEtMS0xOTcxODI_1a33ed50-ba5b-469b-9265-91d598b6aea9">22,694.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08fdadf5ca3249bb9c4fb62f22fd5774_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjJiMDE5MDNmMDk5YjRkYWNiYzcxMGQ1Yzg5Njg3ZTdiL3RhYmxlcmFuZ2U6MmIwMTkwM2YwOTliNGRhY2JjNzEwZDVjODk2ODdlN2JfMi0xLTEtMS0xOTcxODI_74dba910-bba1-4b0c-ad45-1b09b5cd1f26">3,078.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ca7f6b539b42c9bf6134ac1b709820_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjJiMDE5MDNmMDk5YjRkYWNiYzcxMGQ1Yzg5Njg3ZTdiL3RhYmxlcmFuZ2U6MmIwMTkwM2YwOTliNGRhY2JjNzEwZDVjODk2ODdlN2JfMi0zLTEtMS0xOTcxODI_a5ad2c23-106f-469c-8733-7c13d4936ec8">2,360.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c9c826fd2b347378c7aa9dfe51568b7_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjJiMDE5MDNmMDk5YjRkYWNiYzcxMGQ1Yzg5Njg3ZTdiL3RhYmxlcmFuZ2U6MmIwMTkwM2YwOTliNGRhY2JjNzEwZDVjODk2ODdlN2JfMi01LTEtMS0xOTcxODI_7d96a95f-b0db-49b6-9ed9-5aca8f487011">1,845.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjJiMDE5MDNmMDk5YjRkYWNiYzcxMGQ1Yzg5Njg3ZTdiL3RhYmxlcmFuZ2U6MmIwMTkwM2YwOTliNGRhY2JjNzEwZDVjODk2ODdlN2JfMy0xLTEtMS0xOTcxODI_0905ad92-23b4-42b2-81e4-d48fb2dc405d">28,541.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjJiMDE5MDNmMDk5YjRkYWNiYzcxMGQ1Yzg5Njg3ZTdiL3RhYmxlcmFuZ2U6MmIwMTkwM2YwOTliNGRhY2JjNzEwZDVjODk2ODdlN2JfMy0zLTEtMS0xOTcxODI_72f13fd6-b8fa-4b8e-b239-21ada5f47e5b">28,318.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjJiMDE5MDNmMDk5YjRkYWNiYzcxMGQ1Yzg5Njg3ZTdiL3RhYmxlcmFuZ2U6MmIwMTkwM2YwOTliNGRhY2JjNzEwZDVjODk2ODdlN2JfMy01LTEtMS0xOTcxODI_19604575-ee79-44db-9df8-ef603490b718">24,539.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $<ix:nonFraction unitRef="usd" contextRef="iadec1e1743a24bc4aa16803f33246e23_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjI3_b5c017c8-0bbd-4919-8fcd-ea88b946f916">163.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6618dd5b6c274f07b8f2d7da01455ae9_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjMx_bd8d8f9f-8c5d-488d-96cf-68d41eb36719">175.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i46e71ff65ed94973b8d1406f4b8985bd_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjM5_42b48b39-cd41-46fd-a093-70e8d71735e2">135.6</ix:nonFraction> million during the years ended December 31, 2022, 2021, and 2020, respectively.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaborations, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i6eb3e7c16869464ca19021e7a9765867" continuedAt="i89cab2bf5dae4669a5f2121a32fadd6d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="lly:RevenuefromContractPaymentTermMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMTQ3Nw_2c64cac3-16eb-4807-b2d5-0b9b99668200">30</ix:nonNumeric> to <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="lly:RevenuefromContractPaymentTermMaximum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMTM0ODA_2f0c8a45-91d4-4865-8d49-aac22d21e114">70</ix:nonNumeric> days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="lly:RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMTc0NA_dc8a115d-d1a3-47ee-9dba-ab80fdb34ecd">one year</ix:nonNumeric> or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates, discounts, and returns are established in the same period the related product sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our products are sold to wholesalers that serve pharmacies, physicians and other healthcare professionals, and hospitals. For the years ended December&#160;31, 2022, 2021, and 2020, our three largest wholesalers each accounted for between <ix:nonFraction unitRef="number" contextRef="ia3cb0bc9a28341368653294b04baaed1_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjY5NA_43db9614-1a89-4e69-b7a1-25453d295d40"><ix:nonFraction unitRef="number" contextRef="i3c4252adafce48d88948c0f7b97ac340_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjY5NA_8193be13-fa1e-44e8-9571-5e700e6703bd"><ix:nonFraction unitRef="number" contextRef="i9fd0e5a16356409e8036bedd277f4b6c_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjY5NA_c4010d9e-87dc-4135-aaf6-67cd2c20ddde">16</ix:nonFraction></ix:nonFraction></ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="i85cc049a60e14b52a4c0ca5ac603af8d_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjcwMQ_3545db78-8925-43cc-9b9e-b8279331b0cb"><ix:nonFraction unitRef="number" contextRef="i688f1fee1d614afdae131948a26e41be_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjcwMQ_52541d19-581c-4d9b-af6f-7b1fba1ca965"><ix:nonFraction unitRef="number" contextRef="i99ecb99c796447d88385d69144bcd82c_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjcwMQ_8b3fb7eb-2fa8-42a8-b99f-84981b4181fe">21</ix:nonFraction></ix:nonFraction></ix:nonFraction> percent of consolidated revenue. Further, they each accounted for between <ix:nonFraction unitRef="number" contextRef="ic3df9d79b482447198c448522c1b720b_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjc3MA_c07baf1a-f138-46ae-b490-4838c1cd422c"><ix:nonFraction unitRef="number" contextRef="i0918ef1c05fb4f68ab4e15f2a8283a12_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjc3MA_f16e19a6-21d3-41a1-9ebd-baeb25b0dcd9">18</ix:nonFraction></ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="ibbf827440e1c44ed9d4fa7f91748f0b5_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjc3Nw_1f37b45d-9c72-42d5-8c3b-d73670e228ee"><ix:nonFraction unitRef="number" contextRef="ie4e5c7fafd8141999915cd2f615aaeb8_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjc3Nw_2537637b-072d-463c-8e83-1272140ac78d">29</ix:nonFraction></ix:nonFraction> percent of accounts receivable as of December&#160;31, 2022 and 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates, discounts, and returns. The following describe the most significant of these judgments:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sales Rebates and Discounts - Background and Uncertainties</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We initially invoice our customers at contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medicaid, chargebacks, long-term care, hospital, patient assistance programs, and various other programs. We estimate these accruals using an expected value approach.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The largest of our sales rebate and discount amounts include rebates associated with sales covered by managed care, Medicare, Medicaid, and chargeback programs, as well as reductions in revenue related to our patient assistance programs, in the U.S. In determining the appropriate accrual amount, we consider our historical rebate payments for these programs, as well as patient assistance program costs, by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing. Although we accrue a liability for revenue reductions related to these programs at the time we record the sale, the reduction related to that sale is typically paid up to <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="lly:RevenuePerformanceObligationSalesRebatePaymentPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfNDgwNw_e17cc6f2-7209-4257-a263-67d78c125ed2">six months</ix:nonNumeric> later. Because of this time lag, in any particular period our net product revenue may incorporate revisions of accruals for several periods.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. An estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i89cab2bf5dae4669a5f2121a32fadd6d" continuedAt="ib1a43c00d16e48ed815e8274b10fa912"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sales Returns - Background and Uncertainties</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">When product sales occur, to determine the appropriate transaction price for our sales, we estimate a reserve for future product returns related to those sales using an expected value approach. This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="lly:RevenuePerformanceObligationSalesReturnsProductExpirationDate" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfNTc1NQ_93075510-e2e4-41af-8afc-277a32bdade6">24</ix:nonNumeric> months after the initial sale of a product to our customer), and estimated levels of inventory in the wholesale and retail channels, as well as any other specifically identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and discontinuations, or a changing competitive environment. We maintain a returns policy that allows most U.S. customers to return most of our products for dating issues within a specified period prior to and subsequent to the product's expiration date. Following the loss of exclusivity for a patent-dependent product, we expect to experience an elevated level of product returns as product inventory remaining in the wholesale and retail channels expires. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions. We record the return amounts as a deduction to arrive at our net product revenue. Once the product is returned, it is destroyed; we do not record a right of return asset. Our returns policies outside the U.S. are generally more restrictive than in the U.S. as returns are not allowed for reasons other than failure to meet product specifications in many countries. Our reserve for future product returns for product sales outside the U.S. is not material.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As a part of our process to estimate a reserve for product returns, we regularly review the supply levels of our significant products at the major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain U.S. wholesaler inventory levels at an average of approximately <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="lly:RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfNzUyNQ_7bcb11b7-5862-4974-883c-0e98588715cc">one month</ix:nonNumeric> or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements provides us with data on inventory levels at our wholesalers; however, our data on inventory levels in the retail channel is more limited. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Actual U.S. product returns have been less than <ix:nonFraction unitRef="number" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="2" name="lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfODIwNA_3e1ea2b2-e284-431e-8111-49924abd40ab"><ix:nonFraction unitRef="number" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="2" name="lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfODIwNA_7fbd4ef0-69d9-499c-95c0-acaa780e79f8"><ix:nonFraction unitRef="number" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="2" name="lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfODIwNA_9403c054-0e5b-4723-868f-e1a2e332776c">2</ix:nonFraction></ix:nonFraction></ix:nonFraction> percent of our U.S. revenue during each of the past three years and have not fluctuated significantly as a percentage of revenue, although fluctuations are more likely in periods following loss of patent exclusivity for major products in the U.S. market. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Adjustments to Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to increase revenue, recognized as a result of changes in estimates for our most significant U.S. sales returns, rebates, and discounts liability balances for products shipped in previous periods, were less than <ix:nonFraction unitRef="number" contextRef="i91192a23f0104c96a6b1188f603bb21a_D20220101-20221231" decimals="2" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfOTM0NTg0ODg1MDIxMw_4d32b876-513b-4162-b387-3dcc85c63b94"><ix:nonFraction unitRef="number" contextRef="i1a5b41d1ce604fd1b7157e4bb21a41c7_D20200101-20201231" decimals="2" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfOTM0NTg0ODg1MDIxMw_5ec7076b-c863-4a9a-bc53-60d784e42800"><ix:nonFraction unitRef="number" contextRef="i79ee633bf3254f18873fa97220a9dff2_D20210101-20211231" decimals="2" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfOTM0NTg0ODg1MDIxMw_88862a80-8382-4145-94f9-6532b790c6e9">1</ix:nonFraction></ix:nonFraction></ix:nonFraction> percent of U.S. revenue during each of the years ended December 31, 2022, 2021, and 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration and Other Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize several types of revenue from our collaborations and other arrangements, which we discuss in general terms immediately below and more specifically in Note 4 for each of our material collaborations and other arrangements. Our collaborations and other arrangements are not contracts with customers but are evaluated to determine whether any aspects of the arrangements are contracts with customers. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue related to products we sell pursuant to these arrangements is included in net product revenue, while other sources of revenue (e.g., royalties and profit sharing from our partner) are included in collaboration and other revenue.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty revenue from licensees and certain of our collaboration partners, which is based on sales to third-parties of licensed products and technology, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This royalty revenue is included in collaboration and other revenue.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="ib1a43c00d16e48ed815e8274b10fa912" continuedAt="ief63a997058340b48c4f1327dbdc730a"><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For arrangements involving multiple goods or services (e.g., research and development, marketing and selling, manufacturing, and distribution), each required good or service is evaluated to determine whether it is distinct. If a good or service does not qualify as distinct, it is combined with the other non-distinct goods or services within the arrangement and these combined goods or services are treated as a single performance obligation for accounting purposes. The arrangement's transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation. For arrangements that involve variable consideration where we have sold intellectual property, we recognize revenue based on estimates of the amount of consideration we believe we will be entitled to receive from the other party, subject to a constraint. These estimates are adjusted to reflect the actual amounts to be collected when those facts and circumstances become known.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development will not receive regulatory approval, we generally do not recognize any contingent payments that would be due to us upon or after regulatory approval. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contract Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. </span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMTM0ODE_58a1ee1c-f3ea-4330-940a-8321b088ea06" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjg3ZWE5MGEwODAwMzQ1MjNiNzMwNGM1YWNmY2VjNTcyL3RhYmxlcmFuZ2U6ODdlYTkwYTA4MDAzNDUyM2I3MzA0YzVhY2ZjZWM1NzJfMS0xLTEtMS0xOTcxODI_241101dc-b65b-48d0-bcd9-01271b85863c">219.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjg3ZWE5MGEwODAwMzQ1MjNiNzMwNGM1YWNmY2VjNTcyL3RhYmxlcmFuZ2U6ODdlYTkwYTA4MDAzNDUyM2I3MzA0YzVhY2ZjZWM1NzJfMS0zLTEtMS0xOTcxODI_9ddeee92-dd67-419d-b126-8d073ef9f4ac">262.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract liabilities balances disclosed above as of December&#160;31, 2022 and 2021 were primarily related to the remaining license period of symbolic intellectual property and obligations to perform research and development activities or supply product for a defined period of time.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021, and 2020, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="ief63a997058340b48c4f1327dbdc730a" continuedAt="ia0faef1580ba48cfb3a8157503270fe3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><ix:continuation id="i18e98d1133fb466f8f42030346dfdaee" continuedAt="icc3f1cfa9730482bb8a2b2a96ff5ddd7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.537%"><tr><td style="width:1.0%"></td><td style="width:10.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="12" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed6c41cdbc8431bac939f81410f22c9_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNi0zLTEtMS0xOTcxODI_94312414-5196-489d-b3e0-99624f210c1c">5,688.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i908ec847fcf64bb7913cbcb485ad4d96_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNi01LTEtMS0xOTcxODI_cfe6cb50-6a2e-4856-a11f-a158b3905336">4,914.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8129ef6df6f431e977d79c1b651ea70_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNi03LTEtMS0xOTcxODI_99c12c94-4932-4a6a-ab6f-28f767a8836c">3,835.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d1a32c39d7543c5bda93421375a60d8_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNi05LTEtMS0xOTcxODI_239cdf73-1621-4fac-84b8-e3ac863100ec">1,750.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4677e27f1be4111b8e4c3d118b419a1_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNi0xMS0xLTEtMTk3MTgy_a5491261-6a30-439e-b010-2a38993e34ba">1,557.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ac4e905749940e0acc95a2b2b4d06c1_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNi0xMy0xLTEtMTk3MTgy_5a9e11b6-37d6-4454-afe3-20b90e174ffd">1,232.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1429058ec4bd4a89b6ef2f638439c0e5_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy0zLTEtMS0yMjY3NzQ_7096107c-b07c-4001-aab4-d1436b403cdf">1,194.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90ebccca38314b2b893a86d4df3e24ed_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy01LTEtMS0yMjY3NzQ_fd57aff2-1be3-470d-b91f-b9ce4d8e098c">807.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940a532a79364120a9f3635e0d2abcec_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy03LTEtMS0yMjY3NzQ_b35a41a4-3a29-44ef-89d3-aeb3d2ff0ded">620.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee509ded6c2446891ec496e86228071_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy05LTEtMS0yMjY3NzQ_5e78d97c-4576-477b-a9aa-ab33a3d10122">871.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i353b4ca1ec8545e29d12179593b5f304_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy0xMS0xLTEtMjI2Nzc0_6a1dbee3-21ca-487e-8b1c-0a076cb818b7">683.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c31d4c6617549a6926ef9edc6b8d19d_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy0xMy0xLTEtMjI2Nzc0_9a1a89a8-426a-4048-ae61-fed01c48395a">533.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (2)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0a89f71ff7840b2aee585821fdc79bb_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy0zLTEtMS0xOTcxODI_ad33dc25-5a8b-4a8e-93b2-64f5a5b700df">1,191.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6129a4ae188436e997eb164885bd944_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy01LTEtMS0xOTcxODI_b6db9d85-df7f-47e0-9195-978b2dda0033">1,320.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2beed36c49496f8c05407dbded623c_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy03LTEtMS0xOTcxODI_59470cb5-f139-49da-ab05-ac70b7efbb6c">1,485.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf3a669814bf4e739636b5862a5a79d3_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy05LTEtMS0xOTcxODI_501dec96-74ae-4b74-9b98-a822df38cd3f">868.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42a13a96ce9d4498957d2c9c70ac693b_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy0xMS0xLTEtMTk3MTgy_557c769e-9503-46c3-80b6-01b736576619">1,132.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie734d147b3a94c178e55911be7120159_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy0xMy0xLTEtMTk3MTgy_7183b1e0-fe34-43cf-9522-bdf1bc29e43b">1,140.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83a6a8aae9224f21a121e9d9db314173_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfOS0zLTEtMS0xOTcxODI_0c98da31-dcf0-47d8-8f3e-70ca97c453bc">730.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5838c7dc2be042b2a3ab858cf9b880e6_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfOS01LTEtMS0xOTcxODI_9374c8ff-6505-4fd7-b78a-e2b231bfee18">832.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbedbb47344e4f2cb3b8765fa2aff470_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfOS03LTEtMS0xOTcxODI_3b066e48-2f72-48ea-8ff3-8b6449a6b474">866.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ed9fab22d754adeb11fb4fe998cb3a6_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfOS05LTEtMS0xOTcxODI_aca050da-082a-4a61-96d6-c8b5a0ff5bff">289.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63f062d00a9b498abb19bb45e988b8a2_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfOS0xMS0xLTEtMTk3MTgy_54a46399-e307-4c61-9318-0d10e907a2f7">389.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c28332273c24b679e3f1bb73cf7cc58_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfOS0xMy0xLTEtMTk3MTgy_fc9fe3c2-a568-4342-bac6-4b085a10a416">393.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c493cb7f8944bb2b545e0e6d00775bc_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTAtMy0xLTEtMTk3MTgy_dd61e482-8184-433a-9322-3d2fba72da00">470.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625ee4d76d334362b8de4352af1b773d_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTAtNS0xLTEtMTk3MTgy_e1852d96-03ef-4bfd-b844-96ec25c8b65b">588.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia873c39e36f34f9880aa324b4f3c6b89_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTAtNy0xLTEtMTk3MTgy_2b6c5d93-c5f8-44b4-a8db-e2a4877ac8fb">842.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5019cb5a09214868a6ffd5c421748740_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTAtOS0xLTEtMTk3MTgy_ea7d6f44-7fd1-4972-bda8-ca894ba641e4">289.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf887a499d9b4c1f9b06d18769bf3a1d_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTAtMTEtMS0xLTE5NzE4Mg_684db544-232e-403c-97f2-2acd0ad9f434">304.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf2974bb2f68427da48e46d951d464e4_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTAtMTMtMS0xLTE5NzE4Mg_2db3e10b-1d37-420c-aaf6-220dcfc89c9f">282.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Mounjaro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eacb976de14569ac6ff1899c6605de_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTEtMy0xLTEtMTk5ODY4_854f3a37-80cc-4536-9491-b3b06aef3d60">366.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6306f16596f249559125fb3a670c3326_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTEtNS0xLTEtMTk5ODg2_46598a54-419a-4938-9529-3cce70fcc81f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7b5bde978fc4056b0f67115cb95bdc1_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTEtNy0xLTEtMTk5ODkz_2a928dad-ab2a-4f1e-9482-6a48fe58f27c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a2a0156508b46d6a429156a9e507b0a_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTEtOS0xLTEtMTk5ODgz_58482d00-a02d-4a19-85e1-504453430be3">115.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e04de56005e49cf9693a8f1a4d921b6_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTEtMTEtMS0xLTE5OTkwMA_d1a5a942-7aeb-48a6-9ac7-c7805c5c39a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a158eedd1b1481995dd35bc68fea4dc_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTEtMTMtMS0xLTE5OTkwNw_8540bf16-4ba4-4005-a6d6-1931b9a641bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other diabetes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie94ce0194f2a42f986e5b3f0d5e00c05_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTItMy0xLTEtMTk3MTgy_0d6d9603-909f-4dc2-851c-4d2e97b4e92e">268.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9763e7d353848e4a659a5f54585d4a3_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTItNS0xLTEtMTk3MTgy_8f4e432d-30e3-40d3-8830-0e6a155a7340">255.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87c4deaeae714216a5ee408c78d2cf02_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTItNy0xLTEtMTk3MTgy_be8267ac-0551-41ee-ba0a-34d0289f6ab6">258.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie572e122731f4d66b7d209d9d838c85f_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTItOS0xLTEtMTk3MTgy_61829540-4ae7-4988-8aae-a23709ad5452">367.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2c52e8eea34a75a5e2f2b51206fa4b_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTItMTEtMS0xLTE5NzE4Mg_4b5bb6f3-d8fc-4c68-adf3-341ac72bed9a">401.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb4fc43fe5434bd9b22e62377d8e4f20_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTItMTMtMS0xLTE5NzE4Mg_1695099e-07e7-4caf-8e46-e08291751618">344.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total diabetes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b43b7a7eb4a42ea96b75af06d3894fc_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTMtMy0xLTEtMTk3MTgy_83cf771f-9e3f-4a14-a08b-f814c0b89ede">9,911.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8fe6893994d4f3da2aed48164588249_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTMtNS0xLTEtMTk3MTgy_afcb6b07-cdee-444b-9a69-571a9b7b8db7">8,719.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08d12e8f58234c72a009dbbd89e1ef87_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTMtNy0xLTEtMTk3MTgy_4b5bcfca-43eb-476d-9cfd-11edff7561f2">7,909.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2045052682ee483d9ecaaf59cf44fdb5_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTMtOS0xLTEtMTk3MTgy_b79ac0f9-b894-48b4-b103-de5cd6964b26">4,553.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i725c992052d041e192d4ee9a85e23fe8_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTMtMTEtMS0xLTE5NzE4Mg_d6645576-2350-4c73-a793-3199ae103050">4,468.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6b37c5bfb894eb683d061c2663d2135_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTMtMTMtMS0xLTE5NzE4Mg_02b5aa4a-238c-405d-8666-abe09fcf9bdc">3,925.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0093b813b28435d89b38aaa707cb59a_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctMy0xLTEtMjI2Nzgz_1f83c8e6-59e6-4666-9954-ae58c01faf24">1,653.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i815000e020f14a53a097e53a2b56cf06_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctNS0xLTEtMjI2Nzgz_84ad6e4d-6bed-41a1-9b16-c48bbc4b7115">834.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d08de0a5b1a48e693777db50fe7ee4e_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctNy0xLTEtMjI2Nzgz_0c4937e5-9b79-44d8-8d98-0a5e87352154">618.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb55033007f414c8fa01ecddd9bf258_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctOS0xLTEtMjI2Nzgz_3297a357-6b33-4623-897f-d2818b641b96">830.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436f39f0114a4a5b9a126d5a84fad158_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctMTEtMS0xLTIyNjc4Mw_1fe95ee0-05fe-4643-97fb-0788e95cc5ff">515.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf01e8c322a64b3cb59c38b35cf69a28_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctMTMtMS0xLTIyNjc4Mw_fb3bb46b-f45c-44da-a916-bf007db577e8">294.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic463dd1900c549c09de91b07ab6ca276_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTgtMy0xLTEtMjI2ODU3_6980f285-4f8c-496d-b8b0-4eebc03be1ad">351.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bc3a2798eef4b98bf1cda7f51dbb961_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTgtNS0xLTEtMjI2ODU3_ac35ad60-a664-488e-8799-7bece6d2792d">358.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34b6a251be9e4777827eee958db02629_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTgtNy0xLTEtMjI2ODU3_b40190b7-92ad-4163-b440-f18ebb109a59">381.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa9bb0a325b4912942a0407bfd24c96_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTgtOS0xLTEtMjI2ODU3_d1a1124b-5c2c-4b63-a1c8-fb081942b042">620.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7e2990f5e8845a191e0fb00304c2103_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTgtMTEtMS0xLTIyNjg1Nw_2df13f49-b4ba-449d-bed2-c84f06f4d6b2">674.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cc3f43284394154b2281bd30b634ec5_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTgtMTMtMS0xLTIyNjg1Nw_dda791d8-99dd-47ec-8100-1569e6e3b543">650.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f6b8a0775b4507983b982add0eaa15_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTYtMy0xLTEtMTk3MTgy_fcac69ef-50f5-427a-92f7-c9549cb2e827">543.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475b2a44ffaa4b3ab01390955fe7fb4e_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTYtNS0xLTEtMTk3MTgy_5752c991-61ab-4138-b65a-8c2458130030">1,233.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e84d0c1a5604dc399d2032784a2c381_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTYtNy0xLTEtMTk3MTgy_34822df9-fcf3-4eeb-b7d0-16cea4547094">1,265.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d59b98a2b84f41bcf716a679809aef_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTYtOS0xLTEtMTk3MTgy_ae481d61-fd78-4733-a968-0f1a4ad249fb">384.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47bf0038a1cf485685beffa18825039e_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTYtMTEtMS0xLTE5NzE4Mg_69217c74-e500-434e-b4ca-8db6a1620c6b">827.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe5cf54b9584a46ba3abe1a6a45520b_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTYtMTMtMS0xLTE5NzE4Mg_99ec412f-1835-4805-a228-f7e53e842993">1,064.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77bb27eccc6e416b96871a23917489a6_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctMy0xLTEtMTk3MTgy_ce371e18-ca05-40a9-b0c9-7b2768f23bb6">500.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99feddef0f9d4b61ae8c11159fdbbed6_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctNS0xLTEtMTk3MTgy_e405843e-a1fa-4584-ba1d-b4991257f99a">481.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3881ed56ede64167839562a909065542_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctNy0xLTEtMTk3MTgy_8ea6e459-e253-4d29-993e-e8c4468994ee">480.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4da626bf5e3e4942861f067702818432_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctOS0xLTEtMTk3MTgy_5912613d-907f-4e34-a12d-17e167b3b550">66.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4ae7d53fa74012826220f9d9aefec0_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctMTEtMS0xLTE5NzE4Mg_8189764f-3796-41a9-98c8-78baa48fae5f">66.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5fa2fc32ec4622803f8565f86727be_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctMTMtMS0xLTE5NzE4Mg_6a0ab5c0-212c-4e97-ad8c-9e1eb0485ca6">56.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6ab3bc43384429a45007709c2c734c_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjAtMy0xLTEtMTk3MTgy_a6a7ddb1-2160-4e52-8168-59519ba99554">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d903025752047dc8b7cdd55eb19a7ed_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjAtNS0xLTEtMTk3MTgy_baaa318e-dcde-493a-9f00-e2505f2aa804">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb7822de8b36448bbb44fa84bf3d26b2_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjAtNy0xLTEtMTk3MTgy_405dc2a5-0025-4036-9f16-cc86ebfb3b7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1dfa84e409446888abbc37fbcf675ba_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjAtOS0xLTEtMTk3MTgy_b3fca4f8-b69c-4853-9093-6e02df82f504">293.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ec671c462234f09b93b6aebd0b48663_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjAtMTEtMS0xLTE5NzE4Mg_bd75c9f1-430a-49ee-85cb-75dc83d8647f">418.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ea2a5bdd3934abbababa751cef82703_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjAtMTMtMS0xLTE5NzE4Mg_4c0ee359-04f3-4885-9ce2-60f6b1eb883f">308.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other oncology</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia800ee3300054be0a311fc0ded6756a4_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjEtMy0xLTEtMTk3MTgy_900ca234-18d5-4111-9c87-a76b1911aa49">169.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050aca7ad92848f7bce2d263075706f3_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjEtNS0xLTEtMTk3MTgy_68843427-fa53-422a-8edd-12c8bd937563">120.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedf81083b171427593695e6bf008b9ca_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjEtNy0xLTEtMTk3MTgy_a56a533a-4fc5-49dd-869c-ea1a375d1d4e">46.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d43d13cc4649cdb4b312a0c6e19672_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjEtOS0xLTEtMTk3MTgy_c8ba3591-dbea-4fd7-913e-06db78cee4f3">254.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4403e2fd87d64f338b43367544717790_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjEtMTEtMS0xLTE5NzE4Mg_badb9849-6413-4e0f-80c1-e10a0e5307c6">210.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5e9ce589b3341e59b661221502733d3_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjEtMTMtMS0xLTE5NzE4Mg_e892dabd-bd7a-4234-aa3a-617fdb529aeb">152.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if37fae77f3fd48b39b0930752704bc6a_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjItMy0xLTEtMTk3MTgy_8b393641-6497-434e-81af-50f88facfc05">3,218.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eceda29c176407a87bd531353a1c6e8_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjItNS0xLTEtMTk3MTgy_f53655cc-f0a8-4aac-8cf1-802dc6c000da">3,028.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia87e1143e93f432785a964577b99cef5_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjItNy0xLTEtMTk3MTgy_1c3158a3-4bcc-4736-bcdc-d0568dc5828a">2,792.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f5d0530c744df690ab8c031e4207b2_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjItOS0xLTEtMTk3MTgy_91b5dfff-730a-488a-9dbb-b0b53224a63b">2,448.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i760024cf4c2b4368ae467fa2e123ad6a_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjItMTEtMS0xLTE5NzE4Mg_2604e57f-8403-4cde-91f8-6a5d49f9b3f7">2,712.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d7597d5af254ee68dee4515242f8889_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjItMTMtMS0xLTE5NzE4Mg_e7e4dfec-c4cc-4367-8bbd-8c930892fd82">2,527.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8399f74b1bdf46aeb1528d1b339e6322_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjUtMy0xLTEtMTk3MTgy_021e4026-3346-442e-be20-4fe6754804e1">1,724.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ea5b089cf44e24b8e07841f4632655_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjUtNS0xLTEtMTk3MTgy_8ec1c3e6-c51f-4b01-aa1b-9debdd97489f">1,542.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf3ddbf27f6d4e1f91bb0bb812805861_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjUtNy0xLTEtMTk3MTgy_edceff95-626f-4d9c-85c9-1e461a63c533">1,288.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32eab706ca94218a617e1064dbc8ab2_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjUtOS0xLTEtMTk3MTgy_67aa3f19-edb4-414f-99db-9cc6570d4f40">757.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4223c4a3b6f241dfb2bdcc2730d74722_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjUtMTEtMS0xLTE5NzE4Mg_9156164f-5285-48ba-9fa1-5413fecdc435">670.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e350402b214cd6a481e96fcc09dc2d_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjUtMTMtMS0xLTE5NzE4Mg_c29dc61c-955c-4326-a87a-1fc32dc68e66">500.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (3)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e79e5873c04265ae9f72597e7f8655_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjYtMy0xLTEtMTk3MTgy_d4c54ddf-0832-4676-8611-719c688f43a9">148.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657624079cc0470f8c99a900c86bb61e_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjYtNS0xLTEtMTk3MTgy_4863bb6a-f989-41b4-9fb9-d66856967dc9">324.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8d7a484c7774a6fafe5d1a16b52d73c_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjYtNy0xLTEtMTk3MTgy_eb648e0d-1bf3-4e54-8140-9ec9c3760c6b">63.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd0bb01de3b4defa7e5a43ea90f78fa_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjYtOS0xLTEtMTk3MTgy_97395605-b966-4216-9aea-e5d946f44d6d">682.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ca17c8c8fa4a3c97af54a9338d556b_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjYtMTEtMS0xLTE5NzE4Mg_9e7d4539-6521-4d93-a42c-02f5471b2431">791.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie11d2b1d901b4c59b9940a3eec5fac7e_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjYtMTMtMS0xLTE5NzE4Mg_6fa18873-a236-4cce-a821-c6fc80af5991">575.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other immunology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bbf7ffff8d940379635573118d0f46d_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjctMy0xLTEtMTk3MTgy_b31f94e4-591b-4036-9ed9-db36ad823264">20.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb60edeed6364e088d8dbb6b15046831_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjctNS0xLTEtMTk3MTgy_69ab9ed0-9038-4c51-97fe-73593e7fd0a6">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae608dbd9c8b41bba6dbf7a3b438fbf1_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjctNy0xLTEtMTk3MTgy_dc40747b-e075-4e0d-8990-8a8a355a0585">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3072b728afd41dda5c1bc25d9a2f756_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjctOS0xLTEtMTk3MTgy_4afbf275-6bb2-4b7c-9666-90f6d8fd2910">12.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4a1e442fced4165a82ae4740cb22603_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjctMTEtMS0xLTE5NzE4Mg_ef7a4e3f-58db-46de-bc1c-5959b3a2542d">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68b90bf218ec4f59bc626928cee0157a_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjctMTMtMS0xLTE5NzE4Mg_28fc5d5a-87fc-41a4-abbe-6af1a46a9f19">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total immunology</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f6cf7efc0d4c7fa84a45bd8424a737_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjgtMy0xLTEtMTk3MTgy_b437ca48-20ec-46f5-ae98-1f77c5c2d9fc">1,892.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d469e38c5249c1b559efdd08d0b75f_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjgtNS0xLTEtMTk3MTgy_20e7f68d-9d69-4a64-9a36-39b49f4fab8f">1,881.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8250de8fcc304ad3ba9fd98d5ffe1067_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjgtNy0xLTEtMTk3MTgy_3e6433c4-71ad-494d-b573-da77e44cc67e">1,372.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaab72e5a9431446392b87064073da439_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjgtOS0xLTEtMTk3MTgy_7e4ed3f4-8a8a-43b1-b02b-37314daf6403">1,451.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaefaac168c674bd8bbaf0ba59c09b345_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjgtMTEtMS0xLTE5NzE4Mg_1cb78c09-03fa-4dca-9351-96f2ad3ab611">1,479.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8f82cf734df4f228c6ca91846be4abc_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjgtMTMtMS0xLTE5NzE4Mg_0559da85-2bf2-4ce2-bb27-6ecec7c11b09">1,089.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8b87668f0c34cfe8c41218fb3f7c47d_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzItMy0xLTEtMjI2ODA0_38558c06-831d-4973-85e6-f87fe832f08e">462.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140a6b9bf6b14209800b8ed52032d8f3_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzItNS0xLTEtMjI2ODA0_0f402bf1-e7dc-4ec0-9d9e-bec7eccba4c8">434.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9daf68a25164d62b1bb8bf1e3e52307_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzItNy0xLTEtMjI2ODA0_d178d34b-60eb-4ac2-ab35-f45d51ee88a0">325.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1cc6ca8f8f148fbbce02f358ee33e7b_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzItOS0xLTEtMjI2ODA0_b6024a06-4d5f-4a4d-8fc6-1fdb293f3a69">188.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cbe097595924436a04ba8cc2a5d2e99_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzItMTEtMS0xLTIyNjgwNA_489e887c-c7c7-451c-ab97-4e5febd50ef2">142.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib156c3b2d1414c94bf4093abcc3dafc8_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzItMTMtMS0xLTIyNjgwNA_d983c3c3-a7e9-4f1c-9db6-440107b01e10">37.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33fca98fda4a48f79d860f14183ce7e3_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzMtMy0xLTEtMjI2ODY5_ad20474a-e4ee-482c-8cf6-0f83b96c5e13">30.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie34501579b964c8abb3704d789d36cdb_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzMtNS0xLTEtMjI2ODY5_ed56d070-8f63-42be-baec-9ae8b2f12e2b">39.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77f2f9e5632a4e7c9163699499944509_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzMtNy0xLTEtMjI2ODY5_fc71ac6f-6867-4547-a719-8aa9b2f9d9dc">46.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c850a7c7894db69b4a040b6d233af0_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzMtOS0xLTEtMjI2ODY5_3c73512a-0eff-4b1a-97b3-0c70b49e2423">306.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d17a977fd83415c9e00512147086a44_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzMtMTEtMS0xLTIyNjg2OQ_64d66fbd-274b-4978-9f2f-22a8d68e9c08">390.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad01c8f917b44cacad101857ae82b796_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzMtMTMtMS0xLTIyNjg2OQ_aa942874-f11f-41d8-93be-d7b18f282da6">360.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027e5de11b114136913aecf0144ddbc2_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzEtMy0xLTEtMTk3MTgy_5ba2b260-a7ba-449f-9bda-70d44f2cf143">33.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0fafe92cc1347b5bc9f75c189771831_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzEtNS0xLTEtMTk3MTgy_86e2a4dd-0d18-4483-a353-c110783fea26">38.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8037b2d8309d4fb482c5ec2dedc8a023_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzEtNy0xLTEtMTk3MTgy_a43966b7-c1ed-403f-8b4a-d4548d8b98d5">42.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b4f558633e4ea782159ade55b154e9_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzEtOS0xLTEtMTk3MTgy_d4606c5a-b8a7-4e0a-9b83-077a8bb91d80">249.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic41b44053bbf475aa1692687a86d75c8_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzEtMTEtMS0xLTE5NzE4Mg_88586230-96bd-44f3-94cc-3e431b31400b">542.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a7fe42f8eac44919bbccc5a618cf3f4_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzEtMTMtMS0xLTE5NzE4Mg_e6c8e308-b0ae-45f8-9fe9-3b0ef37ee9a6">725.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i785953ac34004786aaaaf3b2c864ba77_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzUtMy0xLTEtMTk3MTgy_f7e8411e-5961-4d1d-ab3f-5dd363baf7df">85.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32f96b235c0b43198bae6d8ec75f0a44_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzUtNS0xLTEtMTk3MTgy_317d1e49-ba68-42b2-a274-a89e319e25f1">102.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife00cbd3aa774f1faba1231e784a9643_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzUtNy0xLTEtMTk3MTgy_6267d01f-280b-48e3-bb5f-b2af70fe3082">73.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib74ddbdf3df74b23b09907d3377b3d56_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzUtOS0xLTEtMTk3MTgy_b6aad4cf-9b7e-4fe1-9553-305973b5a4a5">189.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bfddc1069524fcd8b6e480aa1ef27c3_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzUtMTEtMS0xLTE5NzE4Mg_ce23bbe0-9a0d-4b92-aa78-1410e6ae566e">207.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6538ec30c43840a99b5e15dc4bcc8131_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzUtMTMtMS0xLTE5NzE4Mg_b144a51a-599d-4547-b1e5-7a5081da5f80">220.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total neuroscience</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b4a05b525764d80b2afbc012254fe88_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzYtMy0xLTEtMTk3MTgy_e7a03a22-2fea-4754-89d7-fa0b2901d17b">612.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75c9e82d787c47c0bdb7e1e3d16ce5f4_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzYtNS0xLTEtMTk3MTgy_0c14698d-4849-4268-bdc2-0720a8a0b953">614.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30607cf1ea84cf498de520dba0098c7_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzYtNy0xLTEtMTk3MTgy_a35699fe-7194-4ae0-8e85-e038641e7367">487.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i698cd7cf5e334be397e08d1f53f737ab_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzYtOS0xLTEtMTk3MTgy_cc5b84a9-4df0-4461-a65a-ae2d4ccd1df0">933.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09c32552bbc74587b3fe07cd98986a93_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzYtMTEtMS0xLTE5NzE4Mg_836d0f24-9a92-4086-a786-65fc40c0b0d6">1,283.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83ddfe09bcd8407bab751faee3cfa0bf_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzYtMTMtMS0xLTE5NzE4Mg_cddc5605-2c4d-4b1d-9f6e-1f65d2a78ad6">1,344.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i322d3171da864966aedc55c9b681518f_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzktMy0xLTEtMTk3MTgy_50483c8e-2563-4b9e-8e69-cd75d114644e">2,008.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5621221cf9f34eef9b9959e16714579c_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzktNS0xLTEtMTk3MTgy_ea76f048-e653-4bf7-b6c2-3dbfb732cc25">1,978.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0247f0ebdb344b409d4ad90e21eedad1_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzktNy0xLTEtMTk3MTgy_09727e58-8c97-4abd-916d-97560a2f1877">850.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib15d3cae66954118a6d0296e4d23df93_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzktOS0xLTEtMTk3MTgy_dfe8ea67-ab36-4596-840d-ce161bc42110">14.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if841f2a4ceaf4fe58f4697466e041316_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzktMTEtMS0xLTE5NzE4Mg_6f5a9cc9-1a86-40c1-bc4d-2dea19f04e73">261.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8429e0edc9214436aaddaab1bcaeb6b9_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzktMTMtMS0xLTE5NzE4Mg_354b1880-b7d2-4c2b-991f-8b6752a94909">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e963233c54e48a888c15bcf4c23ffde_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDAtMy0xLTEtMTk3MTgy_6c70a4e4-d3ef-4621-b60a-5c74928127cb">367.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cfffcec45ae40fb8465dac10b22a976_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDAtNS0xLTEtMTk3MTgy_eb25351e-8835-40b0-828a-612a16e3169d">441.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7501982382a4a88bbc9f7e3e3e85161_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDAtNy0xLTEtMTk3MTgy_4bdf4e06-4328-44f8-acb6-986cf7efec36">510.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd637301dfb459db236d29c1bcf0177_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDAtOS0xLTEtMTk3MTgy_1376dd9b-ac8a-47c9-a68e-a9e1af214d8f">245.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77b859afefa6475bbb5c098a0f192a8d_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDAtMTEtMS0xLTE5NzE4Mg_f3a71b53-6b20-4ea7-8eec-ee39af9dc573">360.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i061bb5f86557438ea2fcf07c86b17b69_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDAtMTMtMS0xLTE5NzE4Mg_96be0d57-d537-4c3e-a32f-a6d14adff813">536.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45698e97012941fdb7ec2890f67c1c66_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDEtMy0xLTEtMTk3MTgy_a913a711-4955-465f-9849-b171e1502d8d">35.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24ef4fbd510845ce85f4028d457ed43c_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDEtNS0xLTEtMTk3MTgy_a468fa4a-7b4d-40f8-b779-64c0e59cfa76">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2762e4d8c5664efd8b887ca758f9b9c4_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDEtNy0xLTEtMTk3MTgy_9d83a7fe-ad61-43f0-a578-cc78be3cf06a">61.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74331b3977d84386b77d2682b2d47eb2_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDEtOS0xLTEtMTk3MTgy_03fd1776-ad3a-4c58-81d5-6f06b93bb5cc">552.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f45af4cef54b1ca2871b3cd9a01e27_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDEtMTEtMS0xLTE5NzE4Mg_9bc177bf-6204-4407-9a37-f45fddeb918c">707.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b7a565db26f4dbaaefe0953a8a80479_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDEtMTMtMS0xLTE5NzE4Mg_0a1ba50f-6ccf-4065-9dac-88aeb27abe4c">545.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia31a0ff6d06240dda20f93d85ba7a1b0_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDItMy0xLTEtMTk3MTgy_5c55aeeb-bd0b-473a-a778-474363f44c47">144.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if85eef2cfec74cb1a86907d6bcafb6ee_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDItNS0xLTEtMTk3MTgy_7a019406-e447-4a0a-a1d9-702354cf0f22">136.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958d4fe65ef3466d9c1b806dc825fd05_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDItNy0xLTEtMTk3MTgy_723d955f-979e-439e-b8f2-bc2a17ae24e8">246.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71acdff4e8334d96837f9b23f9643937_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDItOS0xLTEtMTk3MTgy_7660c17c-ba0d-4abd-b768-269bd25db63e">151.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff78a5e546e044469bcb8ddfffc41863_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDItMTEtMS0xLTE5NzE4Mg_9f594548-26dc-430f-9960-3852b1bd3f1b">233.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02714f6a0b344ffaabb940f97f9422bb_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDItMTMtMS0xLTE5NzE4Mg_b5da919c-b859-41da-b98b-9d3f1cacfed2">321.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a75711b53cf4bd4854c933fc91f0554_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDMtMy0xLTEtMTk3MTgy_acbef196-a51b-4e16-9678-88491961903b">2,555.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0deffb51001949c4bd36158c98e3df90_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDMtNS0xLTEtMTk3MTgy_c056888d-b7d8-44ac-8238-a54853e16707">2,566.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12173600f90244fa8c910b03b4b7685b_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDMtNy0xLTEtMTk3MTgy_160313a9-895a-4469-a05f-8d53755987b9">1,668.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a9c8e37f3254306908fbf67a57a962f_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDMtOS0xLTEtMTk3MTgy_644c5838-d3d3-4026-8788-26c5eeadc767">964.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c655ff0b6734b1b895917ead0f1d0bc_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDMtMTEtMS0xLTE5NzE4Mg_aef00de7-5a83-4e51-92d4-a5f2d863ee22">1,563.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57a805732c14379adc9748655cc8c8a_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDMtMTMtMS0xLTE5NzE4Mg_94fb0266-5ce8-4832-baca-747340d04f0d">1,424.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5231cf59d554630ab8ee2ab6a543866_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDUtMy0xLTEtMTk3MTgy_93a09734-a6ca-4945-82d2-d662569f6fb8">18,190.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06358e5e2c9543f9b4d8af95e8fbee1a_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDUtNS0xLTEtMTk3MTgy_6c3eaf64-f90a-4581-ad5d-02e5290b55c9">16,811.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66a1354c46c40fd8326cd7ee4fa99c1_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDUtNy0xLTEtMTk3MTgy_803b7228-2959-4276-a179-199752c1e15d">14,229.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e3a4aa6df1d471499e619affd59a81c_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDUtOS0xLTEtMTk3MTgy_0287b396-4867-46cd-8420-3f333adc6800">10,351.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2d92d62baf647fba64657e6da2c5cc7_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDUtMTEtMS0xLTE5NzE4Mg_0c781e11-4bd1-44ec-942f-8e67bf71ec26">11,507.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0743faca88f49c9a9a69941934ee01a_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDUtMTMtMS0xLTE5NzE4Mg_fa42fe24-821e-4fac-a7ad-4573b7d9bc92">10,310.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Humalog revenue includes insulin lispro.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations. </span></div></ix:continuation></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="ia0faef1580ba48cfb3a8157503270fe3"><ix:continuation id="icc3f1cfa9730482bb8a2b2a96ff5ddd7" continuedAt="ic68bb9b2d07e491fa5bb31b25118f6a3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:38.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5231cf59d554630ab8ee2ab6a543866_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfMy00LTEtMS0xOTcxODI_6b2d9420-e3a6-4f91-8940-0b4897cfec31">18,190.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06358e5e2c9543f9b4d8af95e8fbee1a_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfMy02LTEtMS0xOTcxODI_484d8235-27dd-445d-ba24-2d18b9c48dd1">16,811.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66a1354c46c40fd8326cd7ee4fa99c1_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfMy04LTEtMS0xOTcxODI_7364a0ee-3de7-4f12-ad20-7e1c9e59b6ff">14,229.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb29b5e537384747850aedf57eea8ac5_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNC00LTEtMS0xOTcxODI_120f7b65-c959-43f6-837c-96931e036d5a">4,299.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if04be40612da46cd8c72bcf49f6acda6_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNC02LTEtMS0xOTcxODI_007a0ff8-b550-4ab2-96bf-dde658f6a45c">4,776.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d44e44e5ef4e85b17fd98791ed3f74_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNC04LTEtMS0xOTcxODI_701a9a8d-a94d-45dd-ba85-606800831aa1">4,187.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a19b43d72264c28838a978d205164c4_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNS00LTEtMS0xOTcxODI_d30da061-3ad6-435b-a2b0-0695d162f532">1,747.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864722d9b52d4c70b0ca7b1f3f30b98b_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNS02LTEtMS0xOTcxODI_d0b7acb2-d932-4d03-812c-ac1e5d66db1e">2,367.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id79c2882668a445497ebd9d63d0e6b0f_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNS04LTEtMS0xOTcxODI_7cef5753-3fd0-4018-947c-32259bb29594">2,583.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2193c6723347899232bf1d50d961c5_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNi00LTEtMS0xOTcxODI_95edcf13-d44f-4b31-a06b-9cf2865b7dca">1,452.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie596f23aada14611bc47697f70b8e788_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNi02LTEtMS0xOTcxODI_3dae45c8-6d74-48be-a41f-0ae778e89ffe">1,661.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb22934230f849698cd861bdcfad137e_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNi04LTEtMS0xOTcxODI_e1111e59-069c-4ab9-8894-71c6b2fec5df">1,116.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be2a9f3e7684d60a8f1c56366cb8f4f_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNy00LTEtMS0xOTcxODI_a2052cfe-3655-4006-ba6b-339a51d8b975">2,852.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f622dfdd764d8da1a4d607b1b94085_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNy02LTEtMS0xOTcxODI_537fbe91-27cf-477b-b875-b5c86bf40472">2,702.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd3aa04d3e924b2ebf2ea8e693f3b76c_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNy04LTEtMS0xOTcxODI_79df88f6-ea97-4df3-8d0c-5b75c1ff87e1">2,422.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfOC00LTEtMS0xOTcxODI_e046e779-4760-49bf-a3f7-07494a5551cc">28,541.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfOC02LTEtMS0xOTcxODI_0f06ecb0-6861-48de-be26-1deeee3829b5">28,318.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfOC04LTEtMS0xOTcxODI_01c2231f-bc2d-4044-b3b7-b4ed1cb4a56a">24,539.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div></ix:continuation><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="ic68bb9b2d07e491fa5bb31b25118f6a3" continuedAt="i29d08954992543628bd39d09111738a1">(1) </ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i29d08954992543628bd39d09111738a1">Revenue is attributed to the countries based on the location of the customer</ix:continuation>.</span></div></ix:continuation><div style="margin-top:6pt;padding-left:9pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_100"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;3:&#160;<ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:AssetAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzcwNTg_4398cc7b-f107-4d6d-b98e-9c3383274053" continuedAt="id724c36eb7b94871b2fa50714be07ad4" escape="true"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzcwNTg_ca790005-364d-4504-850e-2109a462180c" continuedAt="ib1806014550d491d846a68988c8c226d" escape="true">Acquisitions</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="id724c36eb7b94871b2fa50714be07ad4" continuedAt="i607150c540c046fabfb594caa24b4305"><ix:continuation id="ib1806014550d491d846a68988c8c226d" continuedAt="if7d1f2c99e8f4ee38681a3ee07775876"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage in various forms of business development activities to enhance our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements. In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, January 2021, and February 2020, we completed the acquisitions of Akouos, Inc. (Akouos), Prevail Therapeutics Inc. (Prevail), and Dermira, Inc. (Dermira), respectively. These transactions, as further discussed below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzcwNTA_7cfe8fcd-1105-497a-824b-1257a99da86a" continuedAt="i1364321a198642d08870449e5d1802b9" escape="true">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development in 2022, 2021, and 2020, which are further discussed below in Asset Acquisitions. <ix:continuation id="i1364321a198642d08870449e5d1802b9">Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed if the compound has no alternative future use.</ix:continuation> Milestone payment obligations incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs. We recognized acquired IPR&amp;D and development milestone charges of $<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzE4Mjg_ec16c415-6a2e-43bf-a821-e1e07ab64ccc">908.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzE4MzI_0793e8ec-3df7-4d4b-b9a4-001e835251a6">970.1</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzE4NDA_18df601b-28f8-41be-ab32-7c7dfa9de9a6">769.8</ix:nonFraction>&#160;million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions of Businesses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Akouos Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we acquired all shares of Akouos for a purchase price that included $<ix:nonFraction unitRef="usdPerShare" contextRef="i2bfc2608a4d84b308f03c62f86081700_I20221231" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzU0OTc1NTgyNDQxNg_e1600f39-d36a-4be7-b922-e3ce9382d40c">12.50</ix:nonFraction> per share in cash (or an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i24ac34b561704aaf9cdc8cf15d9421c4_D20221201-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzU0OTc1NTgzMDM2OA_979dadb4-ef43-4e98-8216-57e3ccb4d0bc">327.2</ix:nonFraction>&#160;million, net of cash acquired) plus <ix:nonFraction unitRef="right" contextRef="i24ac34b561704aaf9cdc8cf15d9421c4_D20221201-20221231" decimals="INF" name="lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzU0OTc1NTgyNDUwMA_0a3ea3e0-99ea-4e7b-987a-c9a8e3b27494">one</ix:nonFraction> non-tradable contingent value right (CVR) per share. The CVR entitles the Akouos shareholders up to an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="i2bfc2608a4d84b308f03c62f86081700_I20221231" decimals="INF" name="lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzU0OTc1NTgyNDU5MQ_bc1b0d10-91db-42f1-a61f-67d47a41c37f">3.00</ix:nonFraction> per share in cash (or an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="i2bfc2608a4d84b308f03c62f86081700_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzU0OTc1NTgzMzM3NQ_10b86a93-e68e-4922-b105-9bab3056ad5b">122</ix:nonFraction>&#160;million) payable, subject to certain terms and conditions, upon the achievement of certain specified milestones. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired potential gene therapy treatments for hearing loss and other inner ear conditions. The lead gene therapies in clinical development that we acquired included GJB2 (which encodes connexin 26) for a common form of monogenic deafness and hearing loss; AK-OTOF for hearing loss due to mutations in the otoferlin gene; AK-CLRN1 for Usher Type 3A, an autosomal recessive disorder characterized by progressive loss of both hearing and vision; and AK-antiVEGF for vestibular schwannoma.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i607150c540c046fabfb594caa24b4305" continuedAt="i58e2781b1511428baf4aa7cd3cc7e878"><ix:continuation id="if7d1f2c99e8f4ee38681a3ee07775876" continuedAt="i3483f0dcdc1743649c88eef8604899a9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our access to Akouos information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzI3NDg3NzkwODM0ODY_0255a792-35ae-4b0b-b504-338e2ea2cc6b" continuedAt="ib669509c2f9a4388b31bbc349e2b074b" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at December 1, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb5a7f2472e4bb0a0f8c4fe22cd2d24_I20221201" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTo4ZmJjZmI2NjFmZjM0YzFkOWUzYWEzZThhZjMwNjlkMi90YWJsZXJhbmdlOjhmYmNmYjY2MWZmMzRjMWQ5ZTNhYTNlOGFmMzA2OWQyXzEtMS0xLTEtMjE5ODIx_31e8e7a5-49f8-402f-8a61-68bb260a37d2">153.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb5a7f2472e4bb0a0f8c4fe22cd2d24_I20221201" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTo4ZmJjZmI2NjFmZjM0YzFkOWUzYWEzZThhZjMwNjlkMi90YWJsZXJhbmdlOjhmYmNmYjY2MWZmMzRjMWQ5ZTNhYTNlOGFmMzA2OWQyXzItMS0xLTEtMjE5ODIx_a12c8988-b5c7-442f-a1d5-0dc200111b0b">184.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb5a7f2472e4bb0a0f8c4fe22cd2d24_I20221201" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTo4ZmJjZmI2NjFmZjM0YzFkOWUzYWEzZThhZjMwNjlkMi90YWJsZXJhbmdlOjhmYmNmYjY2MWZmMzRjMWQ5ZTNhYTNlOGFmMzA2OWQyXzMtMS0xLTEtMjE5ODIx_4b4a14ef-9dfb-4097-9c3f-671e9c6e12d0">181.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb5a7f2472e4bb0a0f8c4fe22cd2d24_I20221201" decimals="-5" name="lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTo4ZmJjZmI2NjFmZjM0YzFkOWUzYWEzZThhZjMwNjlkMi90YWJsZXJhbmdlOjhmYmNmYjY2MWZmMzRjMWQ5ZTNhYTNlOGFmMzA2OWQyXzUtMS0xLTEtMjE5ODIx_8ad8b21b-cfc9-4da9-ba89-9ba9f3c5e5d5">28.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb5a7f2472e4bb0a0f8c4fe22cd2d24_I20221201" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTo4ZmJjZmI2NjFmZjM0YzFkOWUzYWEzZThhZjMwNjlkMi90YWJsZXJhbmdlOjhmYmNmYjY2MWZmMzRjMWQ5ZTNhYTNlOGFmMzA2OWQyXzYtMS0xLTEtMjE5ODIx_e79774be-8378-4aba-a5bd-389c2b8d6320">547.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic28ae7a6137047c1a086087e77b37fc7_D20221201-20221201" decimals="-5" name="us-gaap:CashAcquiredFromAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTo4ZmJjZmI2NjFmZjM0YzFkOWUzYWEzZThhZjMwNjlkMi90YWJsZXJhbmdlOjhmYmNmYjY2MWZmMzRjMWQ5ZTNhYTNlOGFmMzA2OWQyXzgtMS0xLTEtMjIwMTIy_1bb1ebff-4f38-4db7-86c9-0b87ce2a2673">153.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iceb5a7f2472e4bb0a0f8c4fe22cd2d24_I20221201" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTo4ZmJjZmI2NjFmZjM0YzFkOWUzYWEzZThhZjMwNjlkMi90YWJsZXJhbmdlOjhmYmNmYjY2MWZmMzRjMWQ5ZTNhYTNlOGFmMzA2OWQyXzktMS0xLTEtMjIwMTIy_c20c04b7-ab5d-4f22-bd6a-a3f9ea505e69">66.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24ac34b561704aaf9cdc8cf15d9421c4_D20221201-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTo4ZmJjZmI2NjFmZjM0YzFkOWUzYWEzZThhZjMwNjlkMi90YWJsZXJhbmdlOjhmYmNmYjY2MWZmMzRjMWQ5ZTNhYTNlOGFmMzA2OWQyXzEwLTEtMS0xLTIyMDEyMg_979dadb4-ef43-4e98-8216-57e3ccb4d0bc">327.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to GJB2.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Akouos and is not deductible for tax purposes. </span></div></ix:nonNumeric><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="ib669509c2f9a4388b31bbc349e2b074b" continuedAt="i7b8dd47952c0407ab2bf2c2101bd851c">(3) </ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i7b8dd47952c0407ab2bf2c2101bd851c" continuedAt="ibd4fc372fef9483bb596216f2b2d022d">See Note 7 for a discussion on the estimation of the CVR liability.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations attributable to Akouos for the year ended December&#160;31, 2022 were immaterial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2022 and 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Prevail Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $<ix:nonFraction unitRef="usdPerShare" contextRef="i9bbccb3f78b34d48a0c51e4a8de0644e_I20210131" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzMyOTg1MzQ4OTI1ODU_f4692da5-d274-4266-beec-6be360ca9d2d">22.50</ix:nonFraction> per share in cash (or an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ibeb47b42169c4a378f20a2bb7a0d88f6_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzMyOTg1MzQ4OTI1Njk_b8d5f3e8-0ef4-40f5-b1c9-7fd13fef94d8">747.4</ix:nonFraction>&#160;million, net of cash acquired) plus <ix:nonFraction unitRef="right" contextRef="ibeb47b42169c4a378f20a2bb7a0d88f6_D20210101-20210131" decimals="INF" name="lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzU0OTc1NTgxNDgxODA_50c37e7d-5b08-4f67-8c3f-3485d04436d1">one</ix:nonFraction> non-tradable CVR per share. The CVR entitles Prevail stockholders up to an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="i9bbccb3f78b34d48a0c51e4a8de0644e_I20210131" decimals="INF" name="lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzMyOTg1MzQ4OTI1OTU_18209a9e-70b9-4892-9596-d8351bfdca4d">4.00</ix:nonFraction> per share in cash (or an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="i9bbccb3f78b34d48a0c51e4a8de0644e_I20210131" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzMyOTg1MzQ4OTI2MTQ_fc0f5f45-4586-4f43-9772-e5876852a196">160</ix:nonFraction>&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately <ix:nonFraction unitRef="usdPerShare" contextRef="i9bbccb3f78b34d48a0c51e4a8de0644e_I20210131" decimals="3" name="lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzU0OTc1NTgxNDgxODk_c7d041a4-5936-4ed0-892b-586d6d9baa43">8.3</ix:nonFraction> cents per month until December 1, 2028, at which point the CVR will expire without payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition established a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i58e2781b1511428baf4aa7cd3cc7e878" continuedAt="i2234e5baf02c4c09b416d38430a9f5da"><ix:continuation id="i3483f0dcdc1743649c88eef8604899a9" continuedAt="ib013968e8b804d1a9c4e96cbe3dc5e53"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><ix:continuation id="ibd4fc372fef9483bb596216f2b2d022d" continuedAt="i0d1e95b454de4e13ae4b386756e23781"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e8bd3a88dd451697bfede1f38f914c_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTphMzZhYjkwYzg3Yzg0ZWMwYWVkZWUyYTI1YWMwYWMzMy90YWJsZXJhbmdlOmEzNmFiOTBjODdjODRlYzBhZWRlZTJhMjVhYzBhYzMzXzEtMS0xLTEtMTk3MTgy_495cd62d-0830-4cb4-8255-89db4941e53b">90.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e8bd3a88dd451697bfede1f38f914c_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTphMzZhYjkwYzg3Yzg0ZWMwYWVkZWUyYTI1YWMwYWMzMy90YWJsZXJhbmdlOmEzNmFiOTBjODdjODRlYzBhZWRlZTJhMjVhYzBhYzMzXzItMS0xLTEtMTk3MTgy_744289e9-55e5-4a11-ae8e-1c9db6cbc8f3">824.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e8bd3a88dd451697bfede1f38f914c_I20210122" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTphMzZhYjkwYzg3Yzg0ZWMwYWVkZWUyYTI1YWMwYWMzMy90YWJsZXJhbmdlOmEzNmFiOTBjODdjODRlYzBhZWRlZTJhMjVhYzBhYzMzXzMtMS0xLTEtMTk3MTgy_15a64fa9-6a27-426e-8c3f-9b7ef93f0e9d">126.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79e8bd3a88dd451697bfede1f38f914c_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTphMzZhYjkwYzg3Yzg0ZWMwYWVkZWUyYTI1YWMwYWMzMy90YWJsZXJhbmdlOmEzNmFiOTBjODdjODRlYzBhZWRlZTJhMjVhYzBhYzMzXzQtMS0xLTEtMTk3MTgy_5a7552e9-966d-45a0-ba3c-0e38352b15be">106.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79e8bd3a88dd451697bfede1f38f914c_I20210122" decimals="-5" sign="-" name="lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTphMzZhYjkwYzg3Yzg0ZWMwYWVkZWUyYTI1YWMwYWMzMy90YWJsZXJhbmdlOmEzNmFiOTBjODdjODRlYzBhZWRlZTJhMjVhYzBhYzMzXzUtMS0xLTEtMTk3MTgy_e314d002-1e7a-4fc1-a3c5-3e8712496980">31.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e8bd3a88dd451697bfede1f38f914c_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTphMzZhYjkwYzg3Yzg0ZWMwYWVkZWUyYTI1YWMwYWMzMy90YWJsZXJhbmdlOmEzNmFiOTBjODdjODRlYzBhZWRlZTJhMjVhYzBhYzMzXzYtMS0xLTEtMTk3MTgy_68e7e61a-5120-40cd-a9c6-40cc34e319d9">903.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i592f678cd37f48ac8b0d09a457ed8878_D20210122-20210122" decimals="-5" name="us-gaap:CashAcquiredFromAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTphMzZhYjkwYzg3Yzg0ZWMwYWVkZWUyYTI1YWMwYWMzMy90YWJsZXJhbmdlOmEzNmFiOTBjODdjODRlYzBhZWRlZTJhMjVhYzBhYzMzXzgtMS0xLTEtMTk3MTgy_c44c2918-6383-447d-9bd3-3bac74dc786f">90.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79e8bd3a88dd451697bfede1f38f914c_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTphMzZhYjkwYzg3Yzg0ZWMwYWVkZWUyYTI1YWMwYWMzMy90YWJsZXJhbmdlOmEzNmFiOTBjODdjODRlYzBhZWRlZTJhMjVhYzBhYzMzXzktMS0xLTEtMTk3MTgy_adfbcf02-4e06-4ac1-8565-c2b7b205406e">65.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i592f678cd37f48ac8b0d09a457ed8878_D20210122-20210122" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTphMzZhYjkwYzg3Yzg0ZWMwYWVkZWUyYTI1YWMwYWMzMy90YWJsZXJhbmdlOmEzNmFiOTBjODdjODRlYzBhZWRlZTJhMjVhYzBhYzMzXzEwLTEtMS0xLTE5NzE4Mg_854590e6-cf1c-4772-8e0d-f09c4f535a79">747.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001. In the third quarter of 2022, we impaired the intangible asset related to PR001. See Note 5 for additional information.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div></ix:continuation><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i0d1e95b454de4e13ae4b386756e23781" continuedAt="ibf87c19190404961b549baadc851247a">(3) </ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="ibf87c19190404961b549baadc851247a">See Note 7 for a discussion on the estimation of the CVR liability.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations attributable to Prevail for the years ended December&#160;31, 2022 and 2021 were immaterial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Dermira Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we acquired all shares of Dermira for a purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="i911ffcfb85b543048b73c602e046f88a_D20200201-20200229" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzQ0NjM_05652d90-75ea-4428-b2c7-32ad14fb6a38">849.3</ix:nonFraction> million, net of cash acquired. Under terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. We also acquired Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the year ended December 31, 2021, we sold the rights to Qbrexza. See Note 5 for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $<ix:nonFraction unitRef="usd" contextRef="i57500d6d00fa48b2a37e2a728d955386_I20200229" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzUxOTQ_e27a538d-b9c5-4ad7-9b7b-5569e3771e53">86.8</ix:nonFraction> million, other intangibles of $<ix:nonFraction unitRef="usd" contextRef="i57500d6d00fa48b2a37e2a728d955386_I20200229" decimals="-7" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzUyMTk_a06c11b7-f100-4a14-945e-4812f8d08de9">1.20</ix:nonFraction> billion primarily related to lebrikizumab, deferred income tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="i57500d6d00fa48b2a37e2a728d955386_I20200229" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzUyOTI_4e5824ec-72d8-4d1b-a466-9c4be4a85759">49.5</ix:nonFraction> million, and long-term debt of $<ix:nonFraction unitRef="usd" contextRef="i57500d6d00fa48b2a37e2a728d955386_I20200229" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzUzMTg_adbfabb4-f088-4a28-86ef-b3cd1cfa93d3">375.5</ix:nonFraction> million. After the acquisition, we repaid $<ix:nonFraction unitRef="usd" contextRef="i911ffcfb85b543048b73c602e046f88a_D20200201-20200229" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzUzNTU_cd679f3a-b3bf-47b1-9726-65afe747c115">276.2</ix:nonFraction>&#160;million of long-term debt assumed as part of our acquisition of Dermira.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue attributable to assets acquired in the Dermira acquisition did not have a material impact on our consolidated statement of operations for the years ended December&#160;31, 2022, 2021, and 2020. We are unable to provide the results of operations for the years ended December&#160;31, 2022, 2021, and 2020 attributable to Dermira as those operations were substantially integrated into our legacy business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included because this acquisition did not have a material impact on our consolidated statements of operations for the year ended December 31, 2020.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i2234e5baf02c4c09b416d38430a9f5da" continuedAt="ieaf5ba9d20bc48cc83ca9fe9b739d728"><ix:continuation id="ib013968e8b804d1a9c4e96cbe3dc5e53" continuedAt="i34d19f5838f8493db19d62ea08d5ce19"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzcwMzk_332fa35c-e980-4722-acb8-60910c07911e" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant asset acquisitions during 2022, 2021, and 2020.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.718%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s),Therapy, or Asset</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority Review Voucher</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22bda1e261ac4b2488c77f767678e525_D20220201-20220228" decimals="-5" name="lly:PaymentsForAssetAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTpmNzNmNDBlNjdkMTM0NzE4OGQ4N2YxMTVlNTBhNDUwOC90YWJsZXJhbmdlOmY3M2Y0MGU2N2QxMzQ3MTg4ZDg3ZjExNWU1MGE0NTA4XzEtNi0xLTEtMjA3MDEx_72e24e57-96f1-4102-9f89-2b9ee994dded">110.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foghorn Therapeutics Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new oncology medicines</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb08a5c1f49e4f2990ebe8463033cbeb_D20211201-20211231" decimals="-5" name="lly:PaymentsForAssetAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTpmNzNmNDBlNjdkMTM0NzE4OGQ4N2YxMTVlNTBhNDUwOC90YWJsZXJhbmdlOmY3M2Y0MGU2N2QxMzQ3MTg4ZDg3ZjExNWU1MGE0NTA4XzMtNi0xLTEtMTk3MTgy_4080adc9-71ec-46df-a6de-c3b09f7c6f4c">316.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0973cb0fd694b219690663eb984716f_D20210301-20210331" decimals="-5" name="lly:PaymentsForAssetAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTpmNzNmNDBlNjdkMTM0NzE4OGQ4N2YxMTVlNTBhNDUwOC90YWJsZXJhbmdlOmY3M2Y0MGU2N2QxMzQ3MTg4ZDg3ZjExNWU1MGE0NTA4XzQtNi0xLTEtMTk3MTgy_13c4194b-6a64-4455-b62b-86a45b72139f">125.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81d67d91f47b4d55acc7e70b5b593208_D20210101-20210131" decimals="-5" name="lly:PaymentsForAssetAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTpmNzNmNDBlNjdkMTM0NzE4OGQ4N2YxMTVlNTBhNDUwOC90YWJsZXJhbmdlOmY3M2Y0MGU2N2QxMzQ3MTg4ZDg3ZjExNWU1MGE0NTA4XzUtNi0xLTEtMTk3MTgy_dfae80eb-39f4-4e88-8f82-62f682c35ca2">107.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Innovent Biologics, Inc. (Innovent)</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine, for geographies outside of China</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4554cea5b47540518c88b975dda8a988_D20201001-20201031" decimals="-5" name="lly:PaymentsForAssetAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTpmNzNmNDBlNjdkMTM0NzE4OGQ4N2YxMTVlNTBhNDUwOC90YWJsZXJhbmdlOmY3M2Y0MGU2N2QxMzQ3MTg4ZDg3ZjExNWU1MGE0NTA4XzctNi0xLTEtMTk3MTgy_5f16e5cd-530c-4d19-9604-b462732b19fa">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Petra Pharma Corporation (Petra)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutant-selective PI3K</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#945;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> inhibitor that could lead to potential new medicine</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76b78baacb0a4d53bbd37d9f5f91b297_D20200501-20200531" decimals="-5" name="lly:PaymentsForAssetAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTpmNzNmNDBlNjdkMTM0NzE4OGQ4N2YxMTVlNTBhNDUwOC90YWJsZXJhbmdlOmY3M2Y0MGU2N2QxMzQ3MTg4ZDg3ZjExNWU1MGE0NTA4XzgtNi0xLTEtMTk3MTgy_50b23889-6397-4a0d-b615-a2b779bd8a90">174.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disarm Therapeutics, Inc. </span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disease-modifying therapeutics program for patients with axonal degeneration</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdaaf6c7f8004c49b4ff53eb161a0b68_D20201001-20201031" decimals="-5" name="lly:PaymentsForAssetAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTpmNzNmNDBlNjdkMTM0NzE4OGQ4N2YxMTVlNTBhNDUwOC90YWJsZXJhbmdlOmY3M2Y0MGU2N2QxMzQ3MTg4ZDg3ZjExNWU1MGE0NTA4XzktNi0xLTEtMTk3MTgy_8f803053-7919-459d-aa6c-3b02acf49140">126.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In 2022, we terminated our license for sintilimab injection for geographies outside of China and reverted rights to Innovent.</span></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="margin-top:6pt"><ix:continuation id="ieaf5ba9d20bc48cc83ca9fe9b739d728" continuedAt="i8b967acb091249f9b8420396be10464c"><ix:continuation id="i34d19f5838f8493db19d62ea08d5ce19" continuedAt="ib48bfba20af7458f8475aa2cdff0701e"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Petra, we were required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3K</span><span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#945;</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8b967acb091249f9b8420396be10464c"><ix:continuation id="ib48bfba20af7458f8475aa2cdff0701e"> inhibitor. In 2022, we entered into agreements with substantially all Petra shareholders to acquire their rights to receive any future milestone payments in exchange for a one-time payment. As a result of these agreements, we recognized a charge of $<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="lly:PaymentsForAssetAcquisitions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzY3NDM_43c625ab-b34e-4462-a294-c8596d62c02a">333.8</ix:nonFraction>&#160;million as a development milestone in 2022. Any remaining contingent milestones payments linked to the success of the mutant-selective PI3K&#945; are not expected to be material. We did not recognize other significant development milestones during the years ended December&#160;31, 2022, 2021, and 2020.</ix:continuation></ix:continuation> </span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_103"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;4:&#160;<ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzExMzQ5_99af30bf-dd25-4c40-a0aa-f72f21b834e4" continuedAt="i8ae1f8b9e5a547559e9568da8a8ca09c" escape="true">Collaborations and Other Arrangements</ix:nonNumeric></span></div><ix:continuation id="i8ae1f8b9e5a547559e9568da8a8ca09c" continuedAt="i2689ad99d1124a77bf262238e5c8e456"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i2689ad99d1124a77bf262238e5c8e456" continuedAt="i6cb8fbc18cab42d5bf4c5ced8b59bf23"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Boehringer Ingelheim Diabetes Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim's oral diabetes products: Jardiance, Glyxambi, Synjardy, Trijardy XR, Trajenta, and Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as our basal insulin, Basaglar. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Jardiance, Trajenta, and Basaglar in the U.S., Europe, and Japan, milestone payments made for Jardiance and Trajenta were capitalized as intangible assets and are being amortized to cost of sales, and milestone payments received for Basaglar were recorded as contract liabilities and are being amortized to collaboration and other revenue. The milestones pertaining to Jardiance and Trajenta are being amortized through their respective term under the collaboration, which, depending on country or region, is determined based on the latest to occur of (a) a defined number of years following launch date, (b) the expiration of the compound patent, or (c) the expiration of marketing authorization exclusivity. The milestones pertaining to Basaglar are being amortized through 2029. <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzExMzUx_5c08aabb-ea05-4a02-b04d-568c8597604d" continuedAt="ibfc1d68a4a044624801ddfdc89b2ef6c" escape="true">The table below summarizes the net milestones capitalized with respect to the Jardiance and Trajenta families of products and the net milestones deferred with respect to Basaglar as of December 31: </ix:nonNumeric></span></div><ix:continuation id="ibfc1d68a4a044624801ddfdc89b2ef6c" continuedAt="i62b16457042a416c89d462b72fe9d599"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones Capitalized (Deferred)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib72f8530223f4b8b9206e3912e939d05_I20221231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTpjZGIwOTU4YThlYTk0NzY5YmExYTk2NGU2OTVjODRlOS90YWJsZXJhbmdlOmNkYjA5NThhOGVhOTQ3NjliYTFhOTY0ZTY5NWM4NGU5XzItMS0xLTEtMTk3MTgy_2d634a23-cff3-47fa-95cd-e380b2448060">116.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3307f82bfdc14dd5a7869a1f5a407fe3_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTpjZGIwOTU4YThlYTk0NzY5YmExYTk2NGU2OTVjODRlOS90YWJsZXJhbmdlOmNkYjA5NThhOGVhOTQ3NjliYTFhOTY0ZTY5NWM4NGU5XzItMi0xLTEtMTk3MTgy_8b891805-515e-4b3b-9e9d-d091fdc2c628">136.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6382df2fed0453f9d14c9ca82bc5c85_I20221231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTpjZGIwOTU4YThlYTk0NzY5YmExYTk2NGU2OTVjODRlOS90YWJsZXJhbmdlOmNkYjA5NThhOGVhOTQ3NjliYTFhOTY0ZTY5NWM4NGU5XzMtMS0xLTEtMTk3MTgy_0cd6a12e-0ee0-4eab-91ba-8222fd4a1ad1">63.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b54345933e846e39cc3f792be5b88ff_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTpjZGIwOTU4YThlYTk0NzY5YmExYTk2NGU2OTVjODRlOS90YWJsZXJhbmdlOmNkYjA5NThhOGVhOTQ3NjliYTFhOTY0ZTY5NWM4NGU5XzMtMi0xLTEtMTk3MTgy_854c6456-6478-4f0a-a5ff-13d99796e388">88.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i191cd21724a847a1ab7b4f35246862d4_I20221231" decimals="-5" sign="-" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTpjZGIwOTU4YThlYTk0NzY5YmExYTk2NGU2OTVjODRlOS90YWJsZXJhbmdlOmNkYjA5NThhOGVhOTQ3NjliYTFhOTY0ZTY5NWM4NGU5XzQtMS0xLTEtMTk3MTgy_cab1f512-a2b0-4185-8430-e9969b5b289c">130.6</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i485f72de6db64da1bfe2334d8014678b_I20211231" decimals="-5" sign="-" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTpjZGIwOTU4YThlYTk0NzY5YmExYTk2NGU2OTVjODRlOS90YWJsZXJhbmdlOmNkYjA5NThhOGVhOTQ3NjliYTFhOTY0ZTY5NWM4NGU5XzQtMi0xLTEtMTk3MTgy_3b17fee3-b123-4bc5-b5fd-bc9b79b520d7">149.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Jardiance product family, we and Boehringer Ingelheim share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. The royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.</span></div><ix:continuation id="i62b16457042a416c89d462b72fe9d599" continuedAt="i0af81b831035426abca78fd4679bef0b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to Basaglar:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93deb0a502fc4527a3920971ba7c2c0f_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo3NWE0YjdlYjAxNGQ0MGRmYWEwNzFjNzE3MDBhZDFhMS90YWJsZXJhbmdlOjc1YTRiN2ViMDE0ZDQwZGZhYTA3MWM3MTcwMGFkMWExXzEtMS0xLTEtMTk3MTgy_4b5e2bfb-9398-4d4a-a49f-4829230692e5">2,066.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a63cfe221f41ebba6cd651af9ddf9b_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo3NWE0YjdlYjAxNGQ0MGRmYWEwNzFjNzE3MDBhZDFhMS90YWJsZXJhbmdlOjc1YTRiN2ViMDE0ZDQwZGZhYTA3MWM3MTcwMGFkMWExXzEtMy0xLTEtMTk3MTgy_c528d5e4-eae6-45e4-990a-b7d7035bf139">1,490.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ea327d1c37d4bfca7f2723b4565f151_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo3NWE0YjdlYjAxNGQ0MGRmYWEwNzFjNzE3MDBhZDFhMS90YWJsZXJhbmdlOjc1YTRiN2ViMDE0ZDQwZGZhYTA3MWM3MTcwMGFkMWExXzEtNS0xLTEtMTk3MTgy_471235b2-9f02-476f-ac60-200412d8465b">1,153.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb1a49e986754a4593a59e0e5166de8d_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo3NWE0YjdlYjAxNGQ0MGRmYWEwNzFjNzE3MDBhZDFhMS90YWJsZXJhbmdlOjc1YTRiN2ViMDE0ZDQwZGZhYTA3MWM3MTcwMGFkMWExXzItMS0xLTEtMTk3MTgy_92fd2a6c-ecd7-4551-80fc-4a3875123a09">760.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac449f4acefe4dc984d41cb41455bae6_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo3NWE0YjdlYjAxNGQ0MGRmYWEwNzFjNzE3MDBhZDFhMS90YWJsZXJhbmdlOjc1YTRiN2ViMDE0ZDQwZGZhYTA3MWM3MTcwMGFkMWExXzItMy0xLTEtMTk3MTgy_b6355e75-d24a-492b-bbb4-2e197495f70d">892.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib09d7cfc9f57482cacbac86586144b4f_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo3NWE0YjdlYjAxNGQ0MGRmYWEwNzFjNzE3MDBhZDFhMS90YWJsZXJhbmdlOjc1YTRiN2ViMDE0ZDQwZGZhYTA3MWM3MTcwMGFkMWExXzItNS0xLTEtMTk3MTgy_bb36314d-2638-41fe-a258-3bd8740e2f6b">1,124.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i540e1253ab844a0bbc43a8cfb3ee0920_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo3NWE0YjdlYjAxNGQ0MGRmYWEwNzFjNzE3MDBhZDFhMS90YWJsZXJhbmdlOjc1YTRiN2ViMDE0ZDQwZGZhYTA3MWM3MTcwMGFkMWExXzMtMS0xLTEtMTk3MTgy_bd09b64c-d8f3-41a1-97da-0ab32087aa08">383.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadfe8a33be5c4ba7afa22a73eed9d5ef_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo3NWE0YjdlYjAxNGQ0MGRmYWEwNzFjNzE3MDBhZDFhMS90YWJsZXJhbmdlOjc1YTRiN2ViMDE0ZDQwZGZhYTA3MWM3MTcwMGFkMWExXzMtMy0xLTEtMTk3MTgy_a5354597-140f-4de0-8894-40d7b69e2ee7">372.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c91f4e2d9c840879cf9a65000a09847_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo3NWE0YjdlYjAxNGQ0MGRmYWEwNzFjNzE3MDBhZDFhMS90YWJsZXJhbmdlOjc1YTRiN2ViMDE0ZDQwZGZhYTA3MWM3MTcwMGFkMWExXzMtNS0xLTEtMTk3MTgy_11291c4e-c78f-46b8-8f6e-c50454536c5c">358.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Olumiant</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to baricitinib, which is branded and trademarked as Olumiant, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases and COVID-19. Incyte has the right to receive tiered, double digit royalty payments on worldwide net sales with rates ranging up to <ix:nonFraction unitRef="number" contextRef="i81b687c200704d14b8cd74e649ddccdc_D20220101-20221231" decimals="2" name="lly:CollaborativeArrangementRightsAndObligationsPercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzQ3MTA_837d4d2c-9488-4380-92ad-d4712c5d7d60">20</ix:nonFraction> percent. Incyte has the right to receive an additional royalty ranging up to the low teens on worldwide net sales for the treatment of COVID-19 that exceed a specified aggregate worldwide net sales threshold. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i6cb8fbc18cab42d5bf4c5ced8b59bf23" continuedAt="i3697491654514ccdbca9f848b958e118"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, as well as achievement of a sales-based milestone, milestone payments of $<ix:nonFraction unitRef="usd" contextRef="id1f7f5218520412cb6fd499f49c829c4_I20221231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzUyMTY_248195d1-fc75-4b8e-be7b-78ac0eea0d86">330.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i69ac6765ad604943bedfef80dbb59046_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzUyMjM_cd17625b-9b4d-4b0c-a20f-3432136058c5">260.0</ix:nonFraction> million were capitalized as intangible assets as of December&#160;31, 2022 and 2021, respectively, and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, Incyte is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ib0b97a2e15744cdfa799e948994a62f0_I20221231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzU1NjY_e440443b-f2f5-4270-9da5-ddc942b4f3b6">100.0</ix:nonFraction>&#160;million of additional payments from us in potential sales-based milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Olumiant, including sales of baricitinib that were made pursuant to EUA or similar regulatory authorizations, to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. <ix:continuation id="i0af81b831035426abca78fd4679bef0b" continuedAt="iba06434f3a3740d8868e7ea1744fcb7b">The following table summarizes our net product revenue recognized with respect to Olumiant:</ix:continuation></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="iba06434f3a3740d8868e7ea1744fcb7b" continuedAt="i1bf18649124b4711a62bbf42b4a0cbae"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d7e7fe6df47d69da986515824156b_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTplZjEwZmZmYWYzYWI0ZmNiYjc5YmI4ZjQzMzhkYjRiNy90YWJsZXJhbmdlOmVmMTBmZmZhZjNhYjRmY2JiNzliYjhmNDMzOGRiNGI3XzEtMS0xLTEtMTk3MTgy_952ee925-ad92-44f4-b590-f426a6e7ce4e">830.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39d7234845174224b663942a5c72f5c7_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTplZjEwZmZmYWYzYWI0ZmNiYjc5YmI4ZjQzMzhkYjRiNy90YWJsZXJhbmdlOmVmMTBmZmZhZjNhYjRmY2JiNzliYjhmNDMzOGRiNGI3XzEtMy0xLTEtMTk3MTgy_41409a0c-de71-4742-8756-cbf4e27bce72">1,115.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36f40f8db5514b028a508fdf20bcd89f_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTplZjEwZmZmYWYzYWI0ZmNiYjc5YmI4ZjQzMzhkYjRiNy90YWJsZXJhbmdlOmVmMTBmZmZhZjNhYjRmY2JiNzliYjhmNDMzOGRiNGI3XzEtNS0xLTEtMTk3MTgy_9a7c2f73-3762-4824-97dc-88eaee054f54">638.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Antibodies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with AbCellera Biologics Inc. (AbCellera) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab and bebtelovimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on worldwide net sales of bamlanivimab and bebtelovimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a license and collaboration agreement with Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of mainland China and the Special Administrative Regions of Hong Kong and Macau. Junshi Biosciences received royalty payments in the mid-teens on our net sales of etesevimab. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to EUAs or similar regulatory authorizations, we recognized $<ix:nonFraction unitRef="usd" contextRef="i6f3dc4d892d343b49ec303ecaf36d9bd_D20220101-20221231" decimals="-7" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzk4OTU2MDQ2NzA1NTQ_c0f92bb4-f7c6-44f6-9cad-366bb68f7bde">2.02</ix:nonFraction>&#160;billion, $<ix:nonFraction unitRef="usd" contextRef="icc949a713d77433c984ccf27f4feda59_D20210101-20211231" decimals="-7" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzk4OTU2MDQ2NzA1NTk_66c5bcae-af40-4a60-9b43-33478076e541">2.24</ix:nonFraction>&#160;billion, and $<ix:nonFraction unitRef="usd" contextRef="i7cb32af28a4d439d8eae4393101c3901_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzk4OTU2MDQ2NzA1Njg_38e2a9d8-c8ba-48cf-b70e-cba76770c264">871.2</ix:nonFraction>&#160;million of net product revenue associated with our sales of our COVID-19 antibodies during the years ended December&#160;31, 2022, 2021, and 2020, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tyvyt</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Innovent to jointly develop and commercialize sintilimab injection in China, where it is branded and trademarked as Tyvyt. We record our sales of Tyvyt to third parties as net product revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We report as collaboration and other revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. <ix:continuation id="i1bf18649124b4711a62bbf42b4a0cbae" continuedAt="ied0b77ccdf5f4a57b85c202bf895ab0d">The following table summarizes our revenue recognized in China with respect to Tyvyt: </ix:continuation></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="ied0b77ccdf5f4a57b85c202bf895ab0d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5000c09e5ee64486a770c6f98d826b1f_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo4N2JmYjlhY2ZhNzU0YTg4YTVhM2U3NzNhNmJhYThkYS90YWJsZXJhbmdlOjg3YmZiOWFjZmE3NTRhODhhNWEzZTc3M2E2YmFhOGRhXzEtMS0xLTEtMTk3MTgy_fad8a89c-4c72-476c-b6f6-21b986aa9a64">293.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841f858d8d814afcbb33413461967380_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo4N2JmYjlhY2ZhNzU0YTg4YTVhM2U3NzNhNmJhYThkYS90YWJsZXJhbmdlOjg3YmZiOWFjZmE3NTRhODhhNWEzZTc3M2E2YmFhOGRhXzEtMi0xLTEtMTk3MTgy_90d0f724-8acb-4144-975a-ea1501d9d4bf">418.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1b1742cf89b4c1fb470b6fea7034191_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo4N2JmYjlhY2ZhNzU0YTg4YTVhM2U3NzNhNmJhYThkYS90YWJsZXJhbmdlOjg3YmZiOWFjZmE3NTRhODhhNWEzZTc3M2E2YmFhOGRhXzEtMy0xLTEtMTk3MTgy_bde4d42c-1350-4a9e-88b5-945bd5bb8303">308.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lebrikizumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively, Roche), which provides us the worldwide development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future worldwide net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of December&#160;31, 2022, Roche is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i11abecbd539d44bca9891ae6f43a6b9d_I20221231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzEwMjAz_8d76170d-79ae-42b6-beb2-ff2d3f747dc1">165.0</ix:nonFraction> million of additional payments from us contingent upon the achievement of success-based regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i340330379c1b4d17a5d1893688ec0953_I20221231" decimals="-7" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzEwMzA3_ac1cbdcc-976a-4bc2-9c7a-73d5a7afb1d0">1.03</ix:nonFraction> billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab. During the year ended December&#160;31, 2022, milestone payments to Roche were not material.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3697491654514ccdbca9f848b958e118">We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of December&#160;31, 2022, we are eligible to receive additional payments of $<ix:nonFraction unitRef="usd" contextRef="i7796b711e49341dab27420fbab5beae5_I20221231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzEwOTYz_9781c61e-bdea-45ee-a2dd-071254ff149a">65.0</ix:nonFraction> million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i88b5d5e3acab4840b3a4b0c187d24ff5_I20221231" decimals="-7" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzExMDYx_3f6856b5-4ae9-4d1d-933f-95eaa004fd1e">1.25</ix:nonFraction>&#160;billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab. There were no remaining contract liabilities as of December&#160;31, 2022. As of December 31, 2021 and 2020, contract liabilities were not material. During the years ended December&#160;31, 2022, 2021, and 2020, collaboration and other revenue recognized was not material.</ix:continuation> </span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_106"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;5:&#160;<ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2Xzk1OA_96d514fd-e38d-4b5a-b886-6dcf05049cb8" continuedAt="iccbf81ca3de645e7b894ad27b6e2d117" escape="true">Asset Impairment, Restructuring, and Other Special Charges</ix:nonNumeric></span></div><ix:continuation id="iccbf81ca3de645e7b894ad27b6e2d117" continuedAt="i1609a3629e9e4eb6968e883bdfed378f"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2Xzk2MA_159221ca-1853-46de-8630-f188884bb1d7" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2XzIxOTkwMjMyNTgzMTA_a65ace08-5ec6-44b7-98e1-20a4af3312ff"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2XzIxOTkwMjMyNTgzMTA_b860e1a5-db44-4847-b689-049eb53e6544">asset impairment, restructuring, and other special charges</span></span> in our consolidated statements of operations are described below: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment (gain) and other special charges</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90YWJsZTo2MmE0MDU4ZmU4ZjE0MmZmYjdlOGMxYWQ1ZWQ5MTljOC90YWJsZXJhbmdlOjYyYTQwNThmZThmMTQyZmZiN2U4YzFhZDVlZDkxOWM4XzEtMS0xLTEtMjAwMDM0_a0a05dc3-3954-44c6-ad71-d76d97f01990">221.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90YWJsZTo2MmE0MDU4ZmU4ZjE0MmZmYjdlOGMxYWQ1ZWQ5MTljOC90YWJsZXJhbmdlOjYyYTQwNThmZThmMTQyZmZiN2U4YzFhZDVlZDkxOWM4XzEtMy0xLTEtMjAwMDM0_62b39e3b-d4f6-4327-93d3-0f13e9542152">303.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90YWJsZTo2MmE0MDU4ZmU4ZjE0MmZmYjdlOGMxYWQ1ZWQ5MTljOC90YWJsZXJhbmdlOjYyYTQwNThmZThmMTQyZmZiN2U4YzFhZDVlZDkxOWM4XzEtNS0xLTEtMjAwMDM0_e84f0738-b638-4e0d-9a48-7bd42236743b">20.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90YWJsZTo2MmE0MDU4ZmU4ZjE0MmZmYjdlOGMxYWQ1ZWQ5MTljOC90YWJsZXJhbmdlOjYyYTQwNThmZThmMTQyZmZiN2U4YzFhZDVlZDkxOWM4XzEtMS0xLTEtMTk3MTgy_ac3e556e-f0f9-4062-9242-2405929c765f">23.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90YWJsZTo2MmE0MDU4ZmU4ZjE0MmZmYjdlOGMxYWQ1ZWQ5MTljOC90YWJsZXJhbmdlOjYyYTQwNThmZThmMTQyZmZiN2U4YzFhZDVlZDkxOWM4XzEtMy0xLTEtMTk3MTgy_97620614-692c-44e9-b85b-0b664304cf3d">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90YWJsZTo2MmE0MDU4ZmU4ZjE0MmZmYjdlOGMxYWQ1ZWQ5MTljOC90YWJsZXJhbmdlOjYyYTQwNThmZThmMTQyZmZiN2U4YzFhZDVlZDkxOWM4XzEtNS0xLTEtMTk3MTgy_fd9ca0dd-7090-4d35-a5d6-dce0df8ac16a">151.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90YWJsZTo2MmE0MDU4ZmU4ZjE0MmZmYjdlOGMxYWQ1ZWQ5MTljOC90YWJsZXJhbmdlOjYyYTQwNThmZThmMTQyZmZiN2U4YzFhZDVlZDkxOWM4XzQtMS0xLTEtMTk3MTgy_e63f92ab-a72b-44d4-8e45-5682dc26b5b1">244.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90YWJsZTo2MmE0MDU4ZmU4ZjE0MmZmYjdlOGMxYWQ1ZWQ5MTljOC90YWJsZXJhbmdlOjYyYTQwNThmZThmMTQyZmZiN2U4YzFhZDVlZDkxOWM4XzQtMy0xLTEtMTk3MTgy_14603f0a-0ad8-4dfb-9823-d0d61aae7216">316.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90YWJsZTo2MmE0MDU4ZmU4ZjE0MmZmYjdlOGMxYWQ1ZWQ5MTljOC90YWJsZXJhbmdlOjYyYTQwNThmZThmMTQyZmZiN2U4YzFhZDVlZDkxOWM4XzQtNS0xLTEtMTk3MTgy_b233c668-0420-4e59-915d-1eab2e7894f3">131.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairment, restructuring, and other special charges recognized during the year ended December&#160;31, 2022 were primarily related to an intangible asset impairment for GBA1 Gene Therapy (PR001), acquired in the Prevail acquisition, as a result of changes in key assumptions used in the valuation due to delays in estimated launch timing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2XzU0OTc1NTgxNTg3NQ_2e6454b9-b438-4774-8e73-3a501259a57f">128.0</ix:nonFraction> million of intangible asset impairment as a result of the decision by Bayer AG to discontinue the development of a Phase I molecule related to a contract-based intangible asset from our acquisition of Loxo Oncology, Inc. Additionally, we recognized $<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2XzU0OTc1NTgxNjEwNg_bf9c30ba-2fdb-403d-a500-58e2ff95e003">108.1</ix:nonFraction> million of intangible asset impairment from the sale of the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. </span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1609a3629e9e4eb6968e883bdfed378f">Severance costs recognized during the year ended December 31, 2020 were incurred as a result of actions taken worldwide to reduce our cost structure.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;6:&#160;<ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90ZXh0cmVnaW9uOjFkNGMwMTFmNzc3YjQxMDg4MzM0NmIzYTE2MjI4ZmVjXzEzNzY_f37ecf10-5303-4dfa-9a2b-5b6aca519459" continuedAt="ie4163b46194645138788a0130deb8a02" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="ie4163b46194645138788a0130deb8a02" continuedAt="ia60076be47a0492d98edf18af23d44ba"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90ZXh0cmVnaW9uOjFkNGMwMTFmNzc3YjQxMDg4MzM0NmIzYTE2MjI4ZmVjXzEzNjI_7a2bb54f-bcb3-472d-903d-ffea09ea3a9a" escape="true">We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.</ix:nonNumeric> Inventories measured using LIFO must be valued at the lower of cost or market. Inventories measured using FIFO must be valued at the lower of cost or net realizable value. </span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90ZXh0cmVnaW9uOjFkNGMwMTFmNzc3YjQxMDg4MzM0NmIzYTE2MjI4ZmVjXzEzNjQ_7f4e6c85-4d58-4f45-9116-22822a7e9328" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories at December&#160;31 consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzEtMS0xLTEtMTk3MTgy_6b501efb-2902-4765-b2c6-688413cb9c90">901.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzEtMy0xLTEtMTk3MTgy_cb768152-1a34-4a0d-b1a1-54f5af271f52">761.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzItMS0xLTEtMTk3MTgy_cb8f65d4-0d3b-43db-87f8-0407fed3b9e8">2,597.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzItMy0xLTEtMTk3MTgy_0b4cd1a2-e969-4788-a064-18e85ef6d1c2">2,372.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzMtMS0xLTEtMTk3MTgy_09d7c756-e91c-4785-b31b-44590d390bd3">801.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzMtMy0xLTEtMTk3MTgy_dd501953-7853-42b4-a46a-cdd3bfe77684">717.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates replacement cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzQtMS0xLTEtMTk3MTgy_7baa7cf8-2c3e-4f4a-bb23-cc2519525206">4,300.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzQtMy0xLTEtMTk3MTgy_38bf78cb-b750-4f60-9098-14d2a8912ce3">3,851.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase to LIFO cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" sign="-" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzUtMS0xLTEtMTk3MTgy_46311f4b-ee62-4ce5-91fe-ff4337683045">8.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" sign="-" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzUtMy0xLTEtMTk3MTgy_1967d702-976a-4234-bcb7-459b031b0906">34.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzYtMS0xLTEtMTk3MTgy_1c5b249f-0931-4a6f-89ca-9526e1da7566">4,309.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzYtMy0xLTEtMTk3MTgy_88d6b486-b3a2-4c5b-bf20-3d1f2ac92bde">3,886.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories valued under the LIFO method comprised $<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-7" name="us-gaap:LIFOInventoryAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90ZXh0cmVnaW9uOjFkNGMwMTFmNzc3YjQxMDg4MzM0NmIzYTE2MjI4ZmVjXzUzOA_63bb7967-2269-4801-945a-7f62600878a0">1.23</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-7" name="us-gaap:LIFOInventoryAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90ZXh0cmVnaW9uOjFkNGMwMTFmNzc3YjQxMDg4MzM0NmIzYTE2MjI4ZmVjXzU0NQ_177c6b53-380d-4d3a-a6c6-097671656959">1.36</ix:nonFraction> billion of total inventories at December&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia60076be47a0492d98edf18af23d44ba" continuedAt="i114ec4263f64405a8e47338b81033a10">We recognized a net inventory impairment charge related to our COVID-19 antibodies of $<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90ZXh0cmVnaW9uOjFkNGMwMTFmNzc3YjQxMDg4MzM0NmIzYTE2MjI4ZmVjXzY4Mw_bdccb9ef-d514-4f85-b066-fc7be96d7733">339.7</ix:nonFraction> million during the year ended December 31, 2021 in cost of sales in our consolidated statements of operations. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic evolved during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to demand from U.S. and international governments,</ix:continuation></span><span style="color:#212121;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i114ec4263f64405a8e47338b81033a10"> including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies.</ix:continuation> </span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_112"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;7:&#160;<ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE0ODk0_217ee481-4ebd-4af2-a681-59094e472e43" continuedAt="i096fb69827624aa5a0374a3efe74bcf4" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i096fb69827624aa5a0374a3efe74bcf4" continuedAt="i222f2c6e5b1e44c7aae06c0f4c046162"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments in Equity and Debt Securities</span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzI3NDg3NzkxMDIxNTM_c5ae80f8-6bbb-45c4-968e-059b17a5ee9c" continuedAt="ie30230a7305a41d4aeea5cfb8560bb36" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie30230a7305a41d4aeea5cfb8560bb36" continuedAt="i88bb749a49d14856920c95d7a78380c6">We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors.</ix:continuation> Adjustments recorded for the years ended December&#160;31, 2022, 2021, and 2020 were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net gains (losses) recognized in our consolidated statements of operations for equity securities were $(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzEwNDQ1MzYwNDg0Nzk0_4d26cfa4-3112-4d7d-bf28-b77fc80b7526">410.7</ix:nonFraction>)&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzEwNDQ1MzYwNDg0Nzk5_a54cbcef-9999-4eff-aab0-ef2c42dc8416">176.9</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-7" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzEwNDQ1MzYwNDg0ODA4_7e2d904c-41a9-4bea-87d9-8b264f4c4064">1.44</ix:nonFraction>&#160;billion for the years ended December&#160;31, 2022, 2021, and 2020, respectively. The net gains (losses) recognized for the years ended December&#160;31, 2022, 2021, and 2020 on equity securities sold during the respective periods were not material.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i222f2c6e5b1e44c7aae06c0f4c046162" continuedAt="iff945955334b4ce5b40be24ed6e89eba"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had approximately $<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-6" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzEwNDQ1MzYwNDg1MTk2_a8e233b2-541a-4f11-95e8-7c32b22c8dfc">957</ix:nonFraction>&#160;million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzEwNDQ1MzYwNDg1MzE2_fcbd0ed2-ecef-4c7b-af0f-9a64e4cb7cf4">10</ix:nonNumeric> years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i88bb749a49d14856920c95d7a78380c6">We record our available-for-sale debt securities at fair value, with changes in fair value reported as a component of accumulated other comprehensive income (loss). We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.</ix:continuation> Impairment and credit losses related to available-for-sale securities were not material for the years ended December&#160;31, 2022, 2021, and 2020.</span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzI3NDg3NzkxMDIxNTE_1cab454c-f496-4e7c-b41c-237722c00285" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December&#160;31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.552%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More Than 10 Years</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpjMWIzYjNjZDY4NTM0NWEyODE5ZTVmODU2MWIxZGEyMC90YWJsZXJhbmdlOmMxYjNiM2NkNjg1MzQ1YTI4MTllNWY4NTYxYjFkYTIwXzItMS0xLTEtMjM4OTAy_4d3e8cab-dabd-441d-88dc-bfcb3eddd1a4">646.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpjMWIzYjNjZDY4NTM0NWEyODE5ZTVmODU2MWIxZGEyMC90YWJsZXJhbmdlOmMxYjNiM2NkNjg1MzQ1YTI4MTllNWY4NTYxYjFkYTIwXzItMy0xLTEtMjM4OTAy_60604cd7-5a74-4fd8-a2a7-321a52be0a5a">86.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpjMWIzYjNjZDY4NTM0NWEyODE5ZTVmODU2MWIxZGEyMC90YWJsZXJhbmdlOmMxYjNiM2NkNjg1MzQ1YTI4MTllNWY4NTYxYjFkYTIwXzItNS0xLTEtMjM4OTAy_e73e008a-ffe9-44d6-986c-bb488c12e680">242.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpjMWIzYjNjZDY4NTM0NWEyODE5ZTVmODU2MWIxZGEyMC90YWJsZXJhbmdlOmMxYjNiM2NkNjg1MzQ1YTI4MTllNWY4NTYxYjFkYTIwXzItNy0xLTEtMjM4OTAy_bcf4bf14-27cb-4408-a4f6-5493397c615b">104.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpjMWIzYjNjZDY4NTM0NWEyODE5ZTVmODU2MWIxZGEyMC90YWJsZXJhbmdlOmMxYjNiM2NkNjg1MzQ1YTI4MTllNWY4NTYxYjFkYTIwXzItOS0xLTEtMjM4OTAy_f1d79d72-fe3c-46d9-9ff7-2d1d44c26106">214.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzI3NDg3NzkxMDIxNDY_4c9ee139-aab5-49f0-a0e4-9f10b7260fba" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpiYWNjYWZkZmU0M2U0OGE0OGU3NzdlMzk3YmEwMjA3My90YWJsZXJhbmdlOmJhY2NhZmRmZTQzZTQ4YTQ4ZTc3N2UzOTdiYTAyMDczXzEtMS0xLTEtMjM4OTI4_b286ab98-73ea-4d4a-96bf-fcdb98d324d0">0.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpiYWNjYWZkZmU0M2U0OGE0OGU3NzdlMzk3YmEwMjA3My90YWJsZXJhbmdlOmJhY2NhZmRmZTQzZTQ4YTQ4ZTc3N2UzOTdiYTAyMDczXzEtMy0xLTEtMjM4OTI4_8cabdfc7-82b3-4b9b-abb2-052183494658">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpiYWNjYWZkZmU0M2U0OGE0OGU3NzdlMzk3YmEwMjA3My90YWJsZXJhbmdlOmJhY2NhZmRmZTQzZTQ4YTQ4ZTc3N2UzOTdiYTAyMDczXzItMS0xLTEtMjM4OTI4_5d23ec36-7444-41d1-9a63-84fd058be4a2">49.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpiYWNjYWZkZmU0M2U0OGE0OGU3NzdlMzk3YmEwMjA3My90YWJsZXJhbmdlOmJhY2NhZmRmZTQzZTQ4YTQ4ZTc3N2UzOTdiYTAyMDczXzItMy0xLTEtMjM4OTI4_9bc7a656-7691-4917-b3b1-373bde48e92b">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpiYWNjYWZkZmU0M2U0OGE0OGU3NzdlMzk3YmEwMjA3My90YWJsZXJhbmdlOmJhY2NhZmRmZTQzZTQ4YTQ4ZTc3N2UzOTdiYTAyMDczXzMtMS0xLTEtMjM4OTI4_54926f19-04b7-4578-9c5e-082f21143dac">46.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpiYWNjYWZkZmU0M2U0OGE0OGU3NzdlMzk3YmEwMjA3My90YWJsZXJhbmdlOmJhY2NhZmRmZTQzZTQ4YTQ4ZTc3N2UzOTdiYTAyMDczXzMtMy0xLTEtMjM4OTI4_7af09b3a-43c8-41ee-82a6-c4fae66093a5">250.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpiYWNjYWZkZmU0M2U0OGE0OGU3NzdlMzk3YmEwMjA3My90YWJsZXJhbmdlOmJhY2NhZmRmZTQzZTQ4YTQ4ZTc3N2UzOTdiYTAyMDczXzQtMS0xLTEtMjM4OTI4_ee849c50-5cca-485b-bda5-4d9f64881aaa">568.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpiYWNjYWZkZmU0M2U0OGE0OGU3NzdlMzk3YmEwMjA3My90YWJsZXJhbmdlOmJhY2NhZmRmZTQzZTQ4YTQ4ZTc3N2UzOTdiYTAyMDczXzQtMy0xLTEtMjM4OTI4_eccce1f0-7adc-4bba-aa07-fcbd940cdec0">290.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately <ix:nonFraction unitRef="number" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="2" name="us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzEwNDQ1MzYwNDg4Mjkw_9226ad24-646f-4ca6-abeb-a3f1e9aafa9c">99</ix:nonFraction> percent of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of December&#160;31, 2022, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of a material default on interest or principal payments for our debt securities.</span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzI3NDg3NzkxMDIxNDc_45ada370-5cc7-4db1-a3a1-beecb80aa980" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo3MDYyMmI3NWE3YzQ0NzBjYjI4ZWRhYjllZjg4YTFlZi90YWJsZXJhbmdlOjcwNjIyYjc1YTdjNDQ3MGNiMjhlZGFiOWVmODhhMWVmXzEtMS0xLTEtMjM4OTY4_add78c4e-7c4c-4b49-bd17-8bb2f3a08756">132.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo3MDYyMmI3NWE3YzQ0NzBjYjI4ZWRhYjllZjg4YTFlZi90YWJsZXJhbmdlOjcwNjIyYjc1YTdjNDQ3MGNiMjhlZGFiOWVmODhhMWVmXzEtMy0xLTEtMjM4OTY4_7ac6cc21-a664-4ae8-a20a-ca73d3dc0a36">174.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo3MDYyMmI3NWE3YzQ0NzBjYjI4ZWRhYjllZjg4YTFlZi90YWJsZXJhbmdlOjcwNjIyYjc1YTdjNDQ3MGNiMjhlZGFiOWVmODhhMWVmXzEtNS0xLTEtMjM4OTY4_bab3918c-531a-4633-8176-89f9160ffcf0">264.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo3MDYyMmI3NWE3YzQ0NzBjYjI4ZWRhYjllZjg4YTFlZi90YWJsZXJhbmdlOjcwNjIyYjc1YTdjNDQ3MGNiMjhlZGFiOWVmODhhMWVmXzItMS0xLTEtMjM4OTY4_4fa8c3e7-8e9e-4240-8ffc-d5f63aed0467">0.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo3MDYyMmI3NWE3YzQ0NzBjYjI4ZWRhYjllZjg4YTFlZi90YWJsZXJhbmdlOjcwNjIyYjc1YTdjNDQ3MGNiMjhlZGFiOWVmODhhMWVmXzItMy0xLTEtMjM4OTY4_543e1dd2-3c05-4809-b4d4-250d5b492643">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo3MDYyMmI3NWE3YzQ0NzBjYjI4ZWRhYjllZjg4YTFlZi90YWJsZXJhbmdlOjcwNjIyYjc1YTdjNDQ3MGNiMjhlZGFiOWVmODhhMWVmXzItNS0xLTEtMjM4OTY4_6a76d4e5-e209-4a2a-9bab-a5923700110e">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo3MDYyMmI3NWE3YzQ0NzBjYjI4ZWRhYjllZjg4YTFlZi90YWJsZXJhbmdlOjcwNjIyYjc1YTdjNDQ3MGNiMjhlZGFiOWVmODhhMWVmXzMtMS0xLTEtMjM4OTY4_0a487e58-9768-4ec8-8b26-805c085480d3">9.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo3MDYyMmI3NWE3YzQ0NzBjYjI4ZWRhYjllZjg4YTFlZi90YWJsZXJhbmdlOjcwNjIyYjc1YTdjNDQ3MGNiMjhlZGFiOWVmODhhMWVmXzMtMy0xLTEtMjM4OTY4_d4a04d86-8793-4419-9ad2-80c73591ddf7">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo3MDYyMmI3NWE3YzQ0NzBjYjI4ZWRhYjllZjg4YTFlZi90YWJsZXJhbmdlOjcwNjIyYjc1YTdjNDQ3MGNiMjhlZGFiOWVmODhhMWVmXzMtNS0xLTEtMjM4OTY4_ac97b495-0a7d-46af-9e58-baef8ec02402">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="iff945955334b4ce5b40be24ed6e89eba" continuedAt="i155b916853ee46e98b8fb49b160139a9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value of Investments</span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzI3NDg3NzkxMDIxNDk_02aaedbe-4618-4701-a0a2-faa3a07060af" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain fair value information at December&#160;31, 2022 and 2021 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2046b6b3eed4ac6b751298dc54b230f_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMtMS0xLTEtMjM5MDA5_038dfb46-de2d-4de8-9470-bc4f701390a9">657.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85739ca7c6b04f86b9f0f4e04dac3933_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMtMy0xLTEtMjM5MDA5_eedfadb4-b476-4ab0-b782-3a5fd2a9d00e">657.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6d39fa7dff407a9bb5b5c2e98c8f37_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMtNS0xLTEtMjM5MDA5_c83c4800-5a91-4c4a-9bcf-6f596cc6ff27">650.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if819ebce2b824e4f956b1fc03a244870_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMtNy0xLTEtMjM5MDA5_3732709c-171b-42ed-8176-29600b839caf">7.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d41b93e38c04495a8c9e35a8f93a51b_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMtOS0xLTEtMjM5MDA5_06c9d063-1651-40a6-9132-4a57fba10b0f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a6cadf85ae74e19b0b4b3d94566c950_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMtMTEtMS0xLTI0MDExNw_a6c4f31c-5d56-4ec7-aa5d-3f5739fff86d">657.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib29cb4f6b7524096a38ea003c862f821_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzUtMS0xLTEtMjM5MDA5_247f38f8-440f-41b8-adaf-da46a4f3bf32">30.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e73f160e8f04f4eaddf6e0c2226046d_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzUtMy0xLTEtMjM5MDA5_0b6fdf83-3a75-405d-933d-33809d85b0e3">31.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc4f4f8668840918ffb5f33a50164aa_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzUtNS0xLTEtMjM5MDA5_55326e24-3a4b-47a4-baa5-f6d5f187ab7c">30.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83db6edf74c94f7dbe7af9c3b57e71cd_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzUtNy0xLTEtMjM5MDA5_2db2839c-d3c7-4c0f-9222-b56cf138ff2e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a991509ebf43809a439058ce22fa7e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzUtOS0xLTEtMjM5MDA5_bd2fdb07-62d9-4e06-8186-bb129ea2afa1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf3de48b5cde4b74bd86492c49a3cfff_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzUtMTEtMS0xLTI0MDA4Nw_7108f670-79e8-41b2-94a9-1473fed0706b">30.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0fa37d1d26458698fec203c6de3170_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzYtMS0xLTEtMjM5MDA5_a460b6c9-7784-4acc-96cc-086ea2382cfc">53.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b78ecf596654f379406da98609085ad_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzYtMy0xLTEtMjM5MDA5_90e608cd-81db-4889-95e8-6d2fce26db08">53.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e65c1e9f8314c05bb18488e182dcdc8_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzYtNS0xLTEtMjM5MDA5_92cbd92e-248b-437b-bd45-a954d60cbf45">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c6b6db44fad4227b0e7923dd144dad5_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzYtNy0xLTEtMjM5MDA5_ff15922a-3d3e-41b1-908c-c05f4698df2b">53.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i267eeb3d4c4544ed98a8e040d42e3659_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzYtOS0xLTEtMjM5MDA5_b3de3371-23bf-4140-8544-67d950797cb1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie08ea2826b404bb1b32d7612d132d1fc_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzYtMTEtMS0xLTI0MDA4Nw_bdf2b07f-d849-4f17-949c-0e4e510ca995">53.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4360dfda4bcd4ae8aacb3842d8b38544_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzgtMS0xLTEtMjM5MDA5_6cde02f3-f889-4e55-8117-bfd10e148961">2.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecdb9bef83534c1ca768e9eb267d15fb_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzgtMy0xLTEtMjM5MDA5_dbc4be71-37b8-4cd9-aade-2326c263415b">2.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd68026d385248dc99ec6cebbbcf4fe0_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzgtNS0xLTEtMjM5MDA5_ce7e7de8-bdef-4b01-be95-f795c1494830">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8623252cacd94e8eacc974d3c5bb281a_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzgtNy0xLTEtMjM5MDA5_31f544c4-72aa-4770-adac-1113c787b706">2.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3b93d9016f347f7a42304dbc2662cbf_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzgtOS0xLTEtMjM5MDA5_65b3ac40-d45d-4bc3-af93-9d98d6a33608">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7745ed8eaec4896a79398bf44e3ee0c_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzgtMTEtMS0xLTI0MDA4Nw_48882939-9050-4c8a-b127-368031666322">2.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2c6931fe5d44a29a69a4915f25c3aa3_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzktMS0xLTEtMjM5MDA5_3d9d44cd-8204-4a59-b1cc-3343a43d1dae">58.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e449ba54e0f4910991f72fc6586c372_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzktMy0xLTEtMjM5MDA5_2fa21e01-3bdf-4360-a355-6e3e486e3e09">58.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202f70807f944a99b3c4a8546c4c57b6_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzktNS0xLTEtMjM5MDA5_12e40e64-0596-46ea-beb8-9a386615b0cf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96434fbfa57540c3bf2a773a2c2ff46e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzktNy0xLTEtMjM5MDA5_3ba808c7-cfae-403d-9a46-6d5b5359c814">39.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc245c7e9eab4641886b085a802fcb71_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzktOS0xLTEtMjM5MDA5_0e560cf8-fa4f-4033-88f6-1abd008cd7fa">19.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic744f4b830ac467eb5deba8b1de59644_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzktMTEtMS0xLTI0MDA4Nw_344d708a-fc66-4731-bac8-54f5761e37b5">58.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2046b6b3eed4ac6b751298dc54b230f_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzExLTEtMS0xLTI0MDA5OQ_9142e6d9-941b-4920-8cfe-874a4881809b">144.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="36" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib29cb4f6b7524096a38ea003c862f821_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzEzLTEtMS0xLTIzOTAwOQ_91b3656c-2784-4693-9f65-c37916d236e1">146.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e73f160e8f04f4eaddf6e0c2226046d_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzEzLTMtMS0xLTIzOTAwOQ_89c8609f-75b5-4f6b-be1a-93d2f0239cf7">163.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc4f4f8668840918ffb5f33a50164aa_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzEzLTUtMS0xLTIzOTAwOQ_040771c2-e4a7-4f0f-898c-ad1ebcf865d7">146.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83db6edf74c94f7dbe7af9c3b57e71cd_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzEzLTctMS0xLTIzOTAwOQ_e187c918-ab64-4a16-b3e3-0e70c4a2a5fe">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a991509ebf43809a439058ce22fa7e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzEzLTktMS0xLTIzOTAwOQ_f7f1f87d-96d7-4c7a-affe-30083870f1ca">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf3de48b5cde4b74bd86492c49a3cfff_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzEzLTExLTEtMS0yNDAwODk_a9b6f765-47d4-42ac-9e6b-38e91e675281">146.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0fa37d1d26458698fec203c6de3170_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE0LTEtMS0xLTI0MDA5Nw_ab239393-4206-41ae-bd08-c6367e3f547d">213.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b78ecf596654f379406da98609085ad_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE0LTMtMS0xLTIzOTAwOQ_e772789b-491f-4c9a-887a-2250bd287e85">235.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e65c1e9f8314c05bb18488e182dcdc8_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE0LTUtMS0xLTIzOTAwOQ_e285f747-314e-4368-9f52-43171b268d24">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c6b6db44fad4227b0e7923dd144dad5_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE0LTctMS0xLTIzOTAwOQ_248b5824-43b5-45a0-a823-dcc5c72731fd">213.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i267eeb3d4c4544ed98a8e040d42e3659_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE0LTktMS0xLTIzOTAwOQ_101dae74-9859-4e5c-ad88-4a1d74007116">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie08ea2826b404bb1b32d7612d132d1fc_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE0LTExLTEtMS0yNDAwODk_0c4c0b47-9a36-4bb2-a8f0-4a3df4652da0">213.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09eaf08a82294887bec59eec2190dd1e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE1LTEtMS0xLTI0MDA5Nw_b2bea4fc-d436-4148-83b0-cbff436763f8">149.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b4fd6680c24327b70dbadbcdab8d00_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE1LTMtMS0xLTIzOTAwOQ_f57407fe-0e9f-470b-8d38-87682e09ea10">161.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c609093db884ac09f9b0f30051477e4_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE1LTUtMS0xLTIzOTAwOQ_66fd1757-87a1-4aad-986c-d32d3e563364">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3257f473d8d344f2a056bb2771c42f6e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE1LTctMS0xLTIzOTAwOQ_8a1568f2-e30b-4a82-8fe0-3fad5f09c541">149.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43ea231ef1224a80971a531780a87b35_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE1LTktMS0xLTIzOTAwOQ_73518ae5-cc09-4514-8cb6-572fdd4ba2b9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31f61c2016124d9faff9cfc9175c8e0b_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE1LTExLTEtMS0yNDAwODk_04806c82-0de5-442a-bedd-bd9d7744d2d1">149.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4360dfda4bcd4ae8aacb3842d8b38544_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE2LTEtMS0xLTI0MDA5Nw_59fe0337-18bb-4a3d-9e06-44b5370a8e1f">50.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecdb9bef83534c1ca768e9eb267d15fb_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE2LTMtMS0xLTIzOTAwOQ_476def96-66bd-4e5c-a360-187b9138bc3c">52.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd68026d385248dc99ec6cebbbcf4fe0_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE2LTUtMS0xLTIzOTAwOQ_31bd7a28-4781-4862-9d5d-740a84ef7c13">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8623252cacd94e8eacc974d3c5bb281a_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE2LTctMS0xLTIzOTAwOQ_2a2425ae-b81b-4472-bf2d-18dbfa92afea">50.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3b93d9016f347f7a42304dbc2662cbf_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE2LTktMS0xLTIzOTAwOQ_b2f64e30-edf5-4438-8e0d-a5f343c7babc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7745ed8eaec4896a79398bf44e3ee0c_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE2LTExLTEtMS0yNDAwODk_78856eb6-45d3-410a-9de7-5cd4e15105b4">50.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa948220bcab4ce3b0bd4520c7b48b28_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE3LTEtMS0xLTI0MDA5Nw_10724dd6-adfa-4dba-b478-97241182296f">398.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica209a2bd9434d09b84c0795cb110ef9_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE3LTMtMS0xLTIzOTAwOQ_25f10434-f9f6-42e5-abb6-abc8b7ef71d3">34.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb3faf84ac344d18fad6aa15881f6ed_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE3LTUtMS0xLTIzOTAwOQ_a8ffaa65-643d-4293-bf77-756ba274df3e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a3049207dd433897dc2049c4a35614_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE3LTctMS0xLTIzOTAwOQ_efc40c3f-577f-4d85-b29c-88c72f631982">311.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97d710d13dea404c9c76ca03cfd32cae_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE3LTktMS0xLTIzOTAwOQ_aa178eec-6f19-4cf6-843b-8cc0e9c1afb6">87.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb8d947138d48f4ba4234d90a755569_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE3LTExLTEtMS0yNDAwODk_69334b73-38df-4a8e-9e72-7dd62b19a228">398.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id93e165c23a14eb4848c3cfac9842a39_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE4LTEtMS0xLTI0MDA5Nw_282c59b7-eff8-41d9-9b0a-7268dec07556">683.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide566100c19446ef9e02ffe6729e317a_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE4LTMtMS0xLTIzOTAwOQ_d0915346-999f-4321-bc40-4f5a15ed847e">484.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206922eb76584eceb418d0469c699ef1_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE4LTUtMS0xLTIzOTAwOQ_1cbc5394-c177-4952-bf55-1f1685a110cf">683.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a592b428bb4466ca49b8ab98ac79c2f_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE4LTctMS0xLTIzOTAwOQ_49aca476-2fe5-4788-87a4-2edcb079737f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie77fee34bd8143b9865e1a7ce56ae13b_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE4LTktMS0xLTIzOTAwOQ_43c90ccb-2233-4c35-888d-9ea47062a017">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cb09673cd4d4a51aeae0a4b4fad802f_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE4LTExLTEtMS0yNDAwODk_b19e51f7-3f21-449f-8ddf-5c51514e9ec4">683.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2046b6b3eed4ac6b751298dc54b230f_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE5LTEtMS0xLTIzOTAwOQ_0fe80eb9-efb2-40ec-8788-4bf558d8c6fb">478.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec2713ca1764f9984742765f2a3f5f6_I20221231" decimals="-5" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzIwLTEtMS0xLTIzOTAwOQ_739aa598-7920-4af7-98e3-31892858ad5f">781.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2046b6b3eed4ac6b751298dc54b230f_I20221231" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzIxLTEtMS0xLTI0MDEwMQ_29a07017-5111-4128-b1df-c3c2f2f01650">2,901.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ef264a2971a4d6d9632968955a88874_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI0LTEtMS0xLTIzOTAwOQ_abf6ffb9-5f71-4065-a9aa-9bdfdda884cc">2,379.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67745cb3a266420caea7e92585afd798_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI0LTMtMS0xLTIzOTAwOQ_71cdd9a4-04be-406b-9e11-219e4d6a5b0d">2,379.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1d701e8a7d846deb5dfed51dc19420e_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI0LTUtMS0xLTIzOTAwOQ_bd582689-a88b-47cc-9ae9-bb4f2224202e">2,361.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3bd9c97de44684a6f54ff2b763dce6_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI0LTctMS0xLTIzOTAwOQ_37fce205-cc4b-4c50-a04d-b41693bbfe94">18.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6543e2dc57fc4942a80a5c4b47c6a4d6_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI0LTktMS0xLTIzOTAwOQ_7c569454-c10d-4dff-9536-744d58e9a7d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbf3bc2cf6f14b3e986aed5486e859be_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI0LTExLTEtMS0yNDAwOTE_f4720f54-e7d9-4656-917d-067410a463f8">2,379.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c7e6db0a0f342f38f0da6050795d81e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI2LTEtMS0xLTI0MDEwMw_23d0775f-0041-4c4f-9894-c32bbb95497b">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d18d4fe82d4e3799255211fdb7c961_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI2LTMtMS0xLTIzOTAwOQ_058a9c48-90a5-4d7d-9593-71112736784a">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e527334606a4f5cb5eb429d7720b579_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI2LTUtMS0xLTIzOTAwOQ_aff2e97a-0968-4eda-a478-895bdbe1287e">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21be69bc53c046e5bc04d738798632b0_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI2LTctMS0xLTIzOTAwOQ_4ed4014f-9710-40fc-a4c0-2a0dfd4627bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00463fe56920430aa066d2ecd7dce5ec_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI2LTktMS0xLTIzOTAwOQ_aec61647-cbd4-43fe-8f0e-3fb4fba7ae7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6345dbf99e4b10a664854739c10ab7_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI2LTExLTEtMS0yNDAwOTM_bda8ac20-de01-4864-ac99-ad34448ff8f2">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09d53a5267d54e38ab69be8d99e1a128_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI3LTEtMS0xLTIzOTAwOQ_bc48954c-512f-4e82-a074-ca8573e19b3a">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i791959b335d9411682c43bc9a3d30863_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI3LTMtMS0xLTIzOTAwOQ_50b8110c-172c-4df6-83d5-d2089dff730e">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1424fba935ab49b1bca8d99d589337e3_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI3LTUtMS0xLTIzOTAwOQ_b89c7c74-01eb-489b-8e7d-19022794fdc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i995cc780a15a4e11a297abb46a4670e5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI3LTctMS0xLTIzOTAwOQ_e0c1f280-72e8-4c82-8f62-2ad52729f27d">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if923bd42b75741279230d2a8db22bf73_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI3LTktMS0xLTIzOTAwOQ_fe431c13-264a-4364-a4b4-2507cd7bc537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie18586de026d4b76ac4be48157ae8d1d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI3LTExLTEtMS0yNDAwOTM_26cd8cc7-fc9f-46bb-84c7-59db9458608f">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i630ee0edbef7428faf2976f9c169689f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI4LTEtMS0xLTIzOTAwOQ_25d367f7-b8b8-4ca7-b3ac-b8b6a82c8355">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66776fea49f94b9a845efebd8dc9043a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI4LTMtMS0xLTIzOTAwOQ_6208fb3a-964c-4249-b806-b5641cba298d">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd7f0aa7ba940b4871022bad3341f93_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI4LTUtMS0xLTIzOTAwOQ_ebf454ca-de53-4c8f-9b08-d7c4fbbfe5c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefd7992238674ff3901e725d12b4b20f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI4LTctMS0xLTIzOTAwOQ_87c32c50-abb2-491a-8f1c-065feacb9593">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40df2b9b5ee34ab0aa3950d2139dfd76_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI4LTktMS0xLTIzOTAwOQ_667a253b-2478-4dc7-adb7-8cbc897d5d60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea1803ebd97a4e4f87e68572966755b4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI4LTExLTEtMS0yNDAwOTM_283feab5-644f-4b56-b735-a6ef07046aff">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0d644ad67b64ed896bb8c35759604a5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI5LTEtMS0xLTIzOTAwOQ_d01c0d70-2b18-4af3-8963-1637d0a969ae">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065e0d87c04c401fae0f22c40bf7957c_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI5LTMtMS0xLTIzOTAwOQ_2a081c01-45a9-4b1d-ad0c-447cf6974863">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id97791b6d6d4420180779511ef340d85_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI5LTUtMS0xLTIzOTAwOQ_e5c274bf-b436-4f84-965b-d8ee41f3ee6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a5c2ba711e441db5517f030cff4003_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI5LTctMS0xLTIzOTAwOQ_84f5fe0e-4068-446e-a45b-27055757dc79">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i114748072ce44e029035eb08efa37d1f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI5LTktMS0xLTIzOTAwOQ_134eea15-e525-4af8-b634-7f49b7e1ef4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i825718d9a8af4d88a0b8aa9db37556e2_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI5LTExLTEtMS0yNDAwOTM_3a23d765-f618-4364-b3d1-0ee59357adeb">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83265c7960c34844bb2725361d24deba_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMwLTEtMS0xLTIzOTAwOQ_68165e13-8030-44a5-b381-99d62ed83f5e">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i869fd0d7109b41d4815c68ea3a46ebac_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMwLTMtMS0xLTIzOTAwOQ_a9e8f73a-f414-4f38-8723-7b491d8dd5a1">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8bae18362b342449e21722305a0c0ea_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMwLTUtMS0xLTIzOTAwOQ_b68e994c-5569-434f-a4b3-2045cba7baa1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b95f772703429a8a0357ffd550d665_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMwLTctMS0xLTIzOTAwOQ_5a905724-9553-435b-8aed-5f6573104bd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id72a1c59b3e84bdabceb3740c94a39b2_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMwLTktMS0xLTIzOTAwOQ_ad8e1120-8b47-4e99-a1ec-24acdb36b016">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia286896d0b5e4e60be5600fdf1b2b12e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMwLTExLTEtMS0yNDAwOTM_959f08a3-6923-4c64-adf4-650d06f7d458">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ef264a2971a4d6d9632968955a88874_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMyLTEtMS0xLTI0MDEwNQ_7d82a997-d410-4581-85c8-7c06d6f3bef2">90.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c7e6db0a0f342f38f0da6050795d81e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM0LTEtMS0xLTI0MDEwNw_c461d79d-8563-483b-9792-4f265dbddf89">137.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d18d4fe82d4e3799255211fdb7c961_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM0LTMtMS0xLTIzOTAwOQ_31d164b4-45e4-4e79-af0f-90e4fc838b36">136.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e527334606a4f5cb5eb429d7720b579_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM0LTUtMS0xLTIzOTAwOQ_aa5e04da-370c-4d1e-809f-1f52c6dc79c7">137.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21be69bc53c046e5bc04d738798632b0_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM0LTctMS0xLTIzOTAwOQ_ca0bf682-15ec-4da5-8da1-bf89e9dfc6de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00463fe56920430aa066d2ecd7dce5ec_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM0LTktMS0xLTIzOTAwOQ_094c2850-1d37-40f6-ab0c-70af9ba9ce95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6345dbf99e4b10a664854739c10ab7_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM0LTExLTEtMS0yNDAwOTU_d94b7ead-bfff-45c8-a96c-7e747839a2f0">137.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09d53a5267d54e38ab69be8d99e1a128_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM1LTEtMS0xLTI0MDEwNw_43f5e70c-194d-4253-a566-635401922fb4">235.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i791959b335d9411682c43bc9a3d30863_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM1LTMtMS0xLTIzOTAwOQ_7c4c5770-5606-4406-8595-0da51c36bf21">232.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1424fba935ab49b1bca8d99d589337e3_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM1LTUtMS0xLTIzOTAwOQ_ce4fe385-f3e5-4bf8-9393-42c94992a902">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i995cc780a15a4e11a297abb46a4670e5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM1LTctMS0xLTIzOTAwOQ_a73013dc-6679-49e4-8607-bcb22ce7c3ce">235.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if923bd42b75741279230d2a8db22bf73_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM1LTktMS0xLTIzOTAwOQ_3b463239-b226-4bb0-909e-b8432addd5b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie18586de026d4b76ac4be48157ae8d1d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM1LTExLTEtMS0yNDAwOTU_e92d604e-c0e9-40c5-bd5e-549485b9b122">235.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i630ee0edbef7428faf2976f9c169689f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM2LTEtMS0xLTI0MDEwNw_1ebccbeb-902b-4115-a7be-187fb194d1d8">109.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66776fea49f94b9a845efebd8dc9043a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM2LTMtMS0xLTIzOTAwOQ_78bcfa28-2e40-4c6e-b686-6676cc4f5dce">108.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd7f0aa7ba940b4871022bad3341f93_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM2LTUtMS0xLTIzOTAwOQ_818ef264-e94f-4163-ae94-26559ab95b1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefd7992238674ff3901e725d12b4b20f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM2LTctMS0xLTIzOTAwOQ_54fe9376-18b3-46e9-9e1b-177cba98596c">109.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40df2b9b5ee34ab0aa3950d2139dfd76_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM2LTktMS0xLTIzOTAwOQ_9b27edfb-e2d6-44f8-9f0d-f5eb4b0564b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea1803ebd97a4e4f87e68572966755b4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM2LTExLTEtMS0yNDAwOTU_b7e4892e-00d8-4066-a713-1985dbe6dd2b">109.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0d644ad67b64ed896bb8c35759604a5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM3LTEtMS0xLTI0MDEwNw_bdd0e7b4-333e-4a09-af9c-9296a6e09799">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065e0d87c04c401fae0f22c40bf7957c_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM3LTMtMS0xLTIzOTAwOQ_ece92a70-0051-451c-b615-37baec668032">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id97791b6d6d4420180779511ef340d85_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM3LTUtMS0xLTIzOTAwOQ_39b78827-3ce3-4bf8-8099-c0e2cca61e0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a5c2ba711e441db5517f030cff4003_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM3LTctMS0xLTIzOTAwOQ_a771235d-05a2-4004-b58c-122149120575">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i114748072ce44e029035eb08efa37d1f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM3LTktMS0xLTIzOTAwOQ_ad2568dd-ef02-41d9-bfd9-9655099e81d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i825718d9a8af4d88a0b8aa9db37556e2_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM3LTExLTEtMS0yNDAwOTU_c98c9de8-f622-4df6-9862-2c206e778a1f">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5351b4419e648ebbac325c9a8f25776_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM4LTEtMS0xLTI0MDEwNw_c9fb5c06-fca2-4d2c-8906-3871a3d1f5de">108.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a76897f7614783bbc3b95171430289_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM4LTMtMS0xLTIzOTAwOQ_0beb6541-cb76-4917-a1f5-dd350f8aa8a8">22.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08786343c67b4a868c5253051cd773cb_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM4LTUtMS0xLTIzOTAwOQ_88692e76-9c04-434d-b68b-24f845f9454a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0f4d070f3f34eacab1aaebe39cae662_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM4LTctMS0xLTIzOTAwOQ_98363d8f-5932-440d-bdab-edd4291ad11b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4762367938c14cfca0c24d191f73550c_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM4LTktMS0xLTIzOTAwOQ_3605aaaf-c0bc-4925-a3ef-ce97b1f15597">108.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e291e2320cd48a3aa360f816a7fed28_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM4LTExLTEtMS0yNDAwOTU_90829edb-8c06-4845-bdd9-9c3d347be5d6">108.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib49d1436b4674f92b884ce9b352c35d1_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM5LTEtMS0xLTI0MDEwNw_e05a2864-77ad-4c00-8461-f2d9ff6ca0c2">1,279.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68ab827622544f9ea9120e5ce5dd8bab_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM5LTMtMS0xLTIzOTAwOQ_38110a80-eabd-47ca-80c7-04eb8b10966b">487.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a8b848d1d8427c890edfad8cc5f8cf_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM5LTUtMS0xLTIzOTAwOQ_21f14278-5e58-40b1-af8e-b09b69daceb9">1,279.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8331fd4f1147f4992919b2c03cbd9c_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM5LTctMS0xLTIzOTAwOQ_1b80b552-0a3e-409f-aa83-ca6836166876">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cfbaeb1387403689ac26389c2117c8_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM5LTktMS0xLTIzOTAwOQ_e6a15d41-4da4-4a52-a913-4942f700c15a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6613a24a2ca74795845a7f065003a508_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM5LTExLTEtMS0yNDAwOTU_c5382d00-62a1-4d2e-ab69-5357c8678a2f">1,279.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ef264a2971a4d6d9632968955a88874_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzQwLTEtMS0xLTIzOTAwOQ_da2a9448-b42d-4f99-8d50-6e85f01fed48">548.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86203110a3b4409f801853ea6da76a28_I20211231" decimals="-5" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzQxLTEtMS0xLTIzOTAwOQ_bb83ed00-347f-49df-8bac-d65e5358d855">771.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ef264a2971a4d6d9632968955a88874_I20211231" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzQyLTEtMS0xLTI0MDEwOA_d72331f4-28b9-4eb9-b834-114a457f7ad7">3,212.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i155b916853ee46e98b8fb49b160139a9" continuedAt="iee0dc22d789a46f99181036066a82732"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. Fair values are not readily available for certain equity investments measured under the measurement alternative.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Debt</span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzI3NDg3NzkxMDIxNDg_4e9589bb-28ce-48a5-8666-6480c6314169" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain fair value information at December&#160;31, 2022 and 2021 for our short-term and long-term debt:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:37.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term commercial paper borrowings</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05a9e0f210644523adfae49f8876648c_I20221231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzMtMS0xLTEtMjM5MDkz_e967ba24-face-44a0-8dec-9b1bbbf289ac">1,498.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ea8deb8e384d8cb4e5f60294c5ed92_I20221231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzMtMy0xLTEtMjM5MDkz_1f27587f-e794-465f-b943-d2a18dd7a397">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19b69bc057c7444085abf4374f69f116_I20221231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzMtNS0xLTEtMjM5MDkz_b77d5000-2d92-4b4b-95b6-bcdc53491ab0">1,492.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedff9c53d09a4160b981746e70812997_I20221231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzMtNy0xLTEtMjM5MDkz_83f391f0-dce0-4bf2-9b7a-e43dfbf3dbd2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b78813a7f544e37b44ae5f03d274d1e_I20221231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzMtOS0xLTEtMjM5MDkz_8badb64c-1769-4d52-bf1e-63744b4949a3">1,492.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7159491c93374658b5b5847e6ac5edf6_I20211231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzQtMS0xLTEtMjM5MDkz_6024933f-6275-4cda-8c8f-a0f5b61ed509">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9001871d7424666bd9d0957d8242b6b_I20211231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzQtMy0xLTEtMjM5MDkz_7eebe48a-e007-481a-909e-e5ddb46c7c8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab54aa3b8b47409280b75c28d3043c2f_I20211231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzQtNS0xLTEtMjM5MDkz_7c45d7fb-906f-4fac-a33f-5b45b1a62da3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1028e48517574b909d8fcf57e1818f87_I20211231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzQtNy0xLTEtMjM5MDkz_ee9176cf-d809-45ac-95b7-0cfc3ab32e7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39ef4f84d9484b978fdf61e96ab0edaa_I20211231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzQtOS0xLTEtMjM5MDkz_67133c1c-6713-4346-b352-0b29ec93b1db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2046b6b3eed4ac6b751298dc54b230f_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzYtMS0xLTEtMjM5MDkz_07d80d4c-0ed0-4ff4-beb6-2ac0042c2427">14,740.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6d39fa7dff407a9bb5b5c2e98c8f37_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzYtMy0xLTEtMjM5MDkz_6779885f-6fda-419d-ba99-3b788017e10f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if819ebce2b824e4f956b1fc03a244870_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzYtNS0xLTEtMjM5MDkz_f95ae30d-585b-4d5f-832c-3cd25475750c">12,329.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d41b93e38c04495a8c9e35a8f93a51b_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzYtNy0xLTEtMjM5MDkz_9508e2bd-cbdd-4d56-a4bd-81ff50cb2483">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a6cadf85ae74e19b0b4b3d94566c950_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzYtOS0xLTEtMjM5MDkz_82d8d8ac-dd67-4769-a3d1-5380bf579817">12,329.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ef264a2971a4d6d9632968955a88874_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzctMS0xLTEtMjM5MDkz_b7261875-8dab-4dc2-aeea-20a078542e60">16,884.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1d701e8a7d846deb5dfed51dc19420e_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzctMy0xLTEtMjM5MDkz_f0325c5d-a072-4d5b-a7e3-ab6e79046294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3bd9c97de44684a6f54ff2b763dce6_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzctNS0xLTEtMjM5MDkz_cc9a720d-54b5-4756-8af2-0c7c8d9c446a">18,157.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6543e2dc57fc4942a80a5c4b47c6a4d6_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzctNy0xLTEtMjM5MDkz_39eda0fb-c067-4c36-b6be-a0b0d8279f09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbf3bc2cf6f14b3e986aed5486e859be_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzctOS0xLTEtMjM5MDkz_2c9b3cb5-cfff-405f-ade2-1c560dd22c14">18,157.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Management and Related Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE0ODY5_dd567325-5086-4c66-b89c-f909b41e439b" escape="true">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions.&#160;We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their investment grade credit ratings.</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE5NzkxMjA5MzMxMjc1_4bc036f3-392d-4f02-90ef-40b3ca0af179">422.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE5NzkxMjA5MzMxMjgz_65bafaa3-caf0-468c-b3b4-550696d74d8f">550.5</ix:nonFraction> million&#160;of accounts receivable as of December&#160;31, 2022 and 2021, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated results of operations for the years ended December&#160;31, 2022, 2021, and 2020 were not material.</span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE0ODUx_610af501-11f7-44b5-a2bf-03451ca588ce" continuedAt="i44c5f698dcd948cfbe69eb05c8859969" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive income (loss) (see Note 17) and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive income (loss) (see Note 17). Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="iee0dc22d789a46f99181036066a82732" continuedAt="ib5b995b4468e4ae4872bcbf6f6e702df"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i44c5f698dcd948cfbe69eb05c8859969" continuedAt="i5882d499d64f498cbae7318ae5d64431">We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, Chinese yuan, Japanese yen, and Swiss franc). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments.</ix:continuation> Forward contracts generally have maturities not exceeding <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:AverageRemainingMaturityOfForeignCurrencyDerivatives1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzQyNDY_b17963e4-e33b-41c3-8e45-ef043016dd36">12</ix:nonNumeric> months. <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzI3NDg3NzkwODYxMDA_f4deba9f-f124-4e6e-9f7b-cadd3e20d10c" continuedAt="i7b20b1d5eb3d4f38beeb4ee94cb61afd" escape="true">At December&#160;31, 2022, we had outstanding foreign currency forward commitments as follows, all of which have settlement dates within <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzQ3NjI_f1698e55-14db-4571-a1a6-41c94a8c660d">180</ix:nonNumeric> days:</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i7b20b1d5eb3d4f38beeb4ee94cb61afd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.487%"><tr><td style="width:1.0%"></td><td style="width:23.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchase</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sell</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie250a0992fc5431f969a7964f8245fdc_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzEtMC0xLTEtMjMzNzI4_b81f7fc1-67d4-4c6e-9069-131645d8eeaf">2,516.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="ie250a0992fc5431f969a7964f8245fdc_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzEtMi0xLTEtMjMzNzMy_654b549b-5d25-46b8-86e3-d108498b7125">2,369.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i7e9395f4903c4d1e8256befb608125af_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzItMC0xLTEtMjMzNjc4_82d6b93c-b1bf-473d-bf76-4cce3432e768">3,371.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e9395f4903c4d1e8256befb608125af_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzItMi0xLTEtMjMzNjkw_96c046b2-de00-4a2b-98a7-9c85c4d9ed04">3,575.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ea07b15fab64564acb30e6db85e870e_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzMtMC0xLTEtMjMzNzQw_05eb8a81-9569-410c-b5e3-d32d802b99b2">199.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chinese yuan</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="i3ea07b15fab64564acb30e6db85e870e_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzMtMi0xLTEtMjMzNzQ4_3e2c2a08-aa40-4001-9d41-8f2b80d11425">1,396.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="jpy" contextRef="i94c6020cd3ae44f998a4fa76cd815d56_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzQtMC0xLTEtMjMzNzUy_97654e94-fb8a-460e-a548-a7ac1550373e">14,139.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94c6020cd3ae44f998a4fa76cd815d56_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzQtMi0xLTEtMjMzNzYw_ef7ef507-97c1-43dd-8a5f-df0be7df894c">105.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceee439d84744b8d804526bc0f2adeab_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzUtMC0xLTEtMjMzNzcw_901ab0f8-44cd-4682-a03f-35737561635b">90.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="jpy" contextRef="iceee439d84744b8d804526bc0f2adeab_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzUtMi0xLTEtMjMzNzc2_57df1571-14a9-4acf-8cc9-66a3ea12392a">12,212.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British pounds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="i0e20eef33fbc4dec93f944ed6836a620_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzYtMC0xLTEtMjMzNzgw_b40c0de6-3abb-4d4a-b4e4-b4b7470f03aa">207.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e20eef33fbc4dec93f944ed6836a620_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzYtMi0xLTEtMjMzNzg0_b59c722a-ac46-4b17-b4f8-29e370d1a00e">254.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="chf" contextRef="i61a09d5cb8a14ccea8468a476ea53884_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzktMC0xLTEtMjM4MTQ5_c1e11e3c-7451-468a-acf8-944238a07626">101.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61a09d5cb8a14ccea8468a476ea53884_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzktMy0xLTEtMjM4MTU4_bf8a73cb-6cb4-4511-b763-d6ea9cfab7e5">109.3</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange risk is also managed through the use of foreign currency debt, cross-currency interest rate swaps, and foreign currency forward contracts. Our foreign currency-denominated notes had carrying amounts of $<ix:nonFraction unitRef="usd" contextRef="ibf02b938757d412587be87a02a84f028_I20221231" decimals="-7" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzQ5OTk_f63c1f66-354b-45b1-adac-995e188b94fd">6.83</ix:nonFraction> billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ifd3cce905838492e986c48f76166193c_I20211231" decimals="-7" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzUwMDY_055b5f54-33e7-4878-9b13-54e48228d6a9">7.90</ix:nonFraction>&#160;billion as of December&#160;31, 2022 and 2021, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-7" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzUwNDk_16255cc8-7149-4ebc-8e08-7aa2549c984c">5.45</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-7" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzUwNTY_a4d7b7d5-ac3e-4361-94c3-502cca17ffd9">5.79</ix:nonFraction>&#160;billion have been designated as, and are effective as, economic hedges of net investments in certain of our foreign operations as of December&#160;31, 2022 and 2021, respectively. At December&#160;31, 2022, we had outstanding cross currency swaps with notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i4778e0d847b8442d93aeec9ae0fcc5af_I20221231" decimals="-7" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzUyODE_ed6ad4bd-cdf6-483e-b2ae-8ddb250173ac">1.02</ix:nonFraction> billion swapping U.S. dollars to euro and $<ix:nonFraction unitRef="usd" contextRef="i5cef174a144b4c2b89d92be601c8cc4f_I20221231" decimals="-7" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzUzMTg_17001ad5-3e41-4aff-9f2c-80c7c739fad2">1.00</ix:nonFraction>&#160;billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed-rate debt to foreign-denominated fixed rate debt, have also been designated as, and are effective as, economic hedges of net investments. At December&#160;31, 2022, we had outstanding foreign currency forward contracts to sell <ix:nonFraction unitRef="eur" contextRef="if6c65f3c28a542199950c644aa1cf261_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE2NDkyNjc0NTcwMjM_db0d6aaf-d3bd-4f42-a811-e9de76094172">325.0</ix:nonFraction> million euro and to sell <ix:nonFraction unitRef="cny" contextRef="i8f3aff17db1c4acb85c8851f9450065d_I20221231" decimals="-7" name="us-gaap:DerivativeAssetNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzEwNDQ1MzYwNDc5ODQw_0309fa9c-057a-4930-9cb9-043e92ce790c">1.82</ix:nonFraction> billion Chinese yuan, with settlement dates ranging through 2023, which have been designated as, and are effective as, economic hedges of net investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5882d499d64f498cbae7318ae5d64431" continuedAt="if50201a5115b415a80aa15754861d0aa">In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. </ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if50201a5115b415a80aa15754861d0aa" continuedAt="i9f7ec9e2ae1b4cf1a51fb8b8e5b432d3">Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows.</ix:continuation> At December&#160;31, 2022, substantially all of our total long-term debt is at a fixed rate. We have converted approximately <ix:nonFraction unitRef="number" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="2" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzcwOTE_d58138e3-5363-465b-93fa-813fb6fe7387">10</ix:nonFraction> percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="ib5b995b4468e4ae4872bcbf6f6e702df" continuedAt="i4c8683347df74a96a9271fc657ec2491"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9f7ec9e2ae1b4cf1a51fb8b8e5b432d3">We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss) (see Note 17) and, upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt.</ix:continuation> As of December&#160;31, 2022, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $<ix:nonFraction unitRef="usd" contextRef="ia85b3dcb7d4541c7aad67c44e3261dea_I20221231" decimals="-7" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzc4MDA_a8f3150d-f5a7-44d9-bafd-399424aca3d2">1.85</ix:nonFraction>&#160;billion, which have settlement dates ranging between 2023 and 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">The Effect of Risk Management Instruments on the Consolidated Statements of Operations</span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE0ODc2_8c6f02fc-a071-4fdb-a4ab-7d1cc9b9e697" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21e6e625c3cb4498ba3bf6924f8d2408_D20220101-20221231" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzItMS0xLTEtMTk3MTgy_9b20d986-0ab6-498b-a371-bb5915cd6944">209.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7662cc39cfe4433b0594d699b335670_D20210101-20211231" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzItMy0xLTEtMTk3MTgy_652668da-cedd-4c9f-8b6a-6bce84735b59">78.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6798f46f87f74360b20909f04395afc3_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzItNS0xLTEtMTk3MTgy_f30b0b8c-8a13-4142-ae6b-20590ec3fd25">86.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbbe46ca06b34c009dcda97ccf3beb64_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzMtMS0xLTEtMTk3MTgy_5103bf7d-fa51-4d1f-9247-fe7b882f435c">209.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if399b1d939d243708da92494b6325f95_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzMtMy0xLTEtMTk3MTgy_30b32fa4-4537-4991-8b52-44256b9df424">78.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cdf044d78494e7694b33040bfab47e7_D20200101-20201231" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzMtNS0xLTEtMTk3MTgy_3f222806-0984-4bd1-bfdb-42c59148ac95">86.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbbe46ca06b34c009dcda97ccf3beb64_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzUtMS0xLTEtMTk3MTgy_29b26d7b-d68e-4646-8d5e-53b61628cfaf">16.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if399b1d939d243708da92494b6325f95_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzUtMy0xLTEtMTk3MTgy_c265f261-db6f-4f4d-b3d1-0c6d60f77470">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cdf044d78494e7694b33040bfab47e7_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzUtNS0xLTEtMTk3MTgy_c4c4b201-a8ad-4824-a437-6533482bef8b">16.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e9fe4a4a4094271b4b30ac4a4625c89_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzYtMS0xLTEtMTk3MTgy_84404e29-810c-4d8a-8630-d4560666cd16">8.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i912fb880c8bf46f58edb6cd6fdf00e0d_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzYtMy0xLTEtMTk3MTgy_35ad745c-aeb7-4aa9-9b12-ef4d6f03791f">41.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i971ee4b6404c4ed885962afd497cc6c4_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzYtNS0xLTEtMTk3MTgy_53b74e84-3f61-44a9-8402-9be2cae14aae">102.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7af19dae3f054b648cdca7471fa01367_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzctMS0xLTEtMTk3MTgy_682e6fe0-fade-4838-bb80-f9af3ff59824">191.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fa81b5097b2466db639a8a9b4205905_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzctMy0xLTEtMTk3MTgy_1679aaa4-e111-423d-ace6-5d8566d1c50a">204.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a1804ba514d421fa041c53b09e064df_D20200101-20201231" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzctNS0xLTEtMTk3MTgy_0af58a56-d789-4784-884c-e5c5402873bd">123.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzgtMS0xLTEtMTk3MTgy_0d9daa5d-43da-401b-8978-34c79b93981d">216.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzgtMy0xLTEtMTk3MTgy_ccd29b01-bd20-4aac-8768-54022b44356d">263.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzgtNS0xLTEtMTk3MTgy_6694996a-6dc5-43b5-a9b7-abad58e521c2">209.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021, and 2020, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE0ODQ0_82b80dcf-507b-4363-9544-a4b82dc4682d" escape="true"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE0ODQ0_ef31cb34-ce64-419a-8db1-8134028b9837" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544fc2f9696049b4b7cbe0345f8fde19_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzItMS0xLTEtMTk3MTgy_8a7bb25b-4a42-4a3e-8106-ad4898aa4949">324.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526dbe18caa14f808c563a07c118fdec_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzItMy0xLTEtMTk3MTgy_5921bbcc-ca77-4758-92f6-8a548ddf3172">435.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ad852d92b9f48d787f3e17319eca10c_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzItNS0xLTEtMTk3MTgy_45f21306-7aaa-419d-8c0f-82b71e145bed">404.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb73f5b531de4d949faf24baf79a438d_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzMtMS0xLTEtMTk3MTgy_aff14e8f-b952-4a5e-8109-ebe58ff38c83">52.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i813ae3ce219c4fb99714b7ffced341ac_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzMtMy0xLTEtMTk3MTgy_5389a8d5-a68b-46fa-ada4-6199b9b2e932">213.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a07487d016f4962ae2b2023e270baed_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzMtNS0xLTEtMTk3MTgy_c40bb61a-d282-400c-9371-dfa707041002">207.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie637e63779d34f95ab0e1211537d3d90_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzQtMS0xLTEtMjMyMDM0_4e60d0af-a7ff-4d5d-a961-f8cd0562239a">15.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3222ddf3a8ac4302b584f8b59946a14b_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzQtMy0xLTEtMjMyMDcy_5c118fa0-b5f4-4f81-bb31-a6f3470905a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic146904e7a5d4de8860196733919670c_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzQtNS0xLTEtMjMyMTIz_7be1b604-2d6c-4112-addd-e54293015bf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ace96eae50846258f2aa585eca6aab7_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzUtMS0xLTEtMTk3MTgy_a20c4231-b08a-464b-8b3d-963c7e92747e">391.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36116f601d041c795e77b729ac2bd12_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzUtMy0xLTEtMTk3MTgy_b3a9a56a-82fc-474a-af81-cb87de9f32b6">97.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ecf981515d64142ae2c545ec8473910_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzUtNS0xLTEtMTk3MTgy_0905c32b-fb27-44dd-9d6e-8db300af0756">110.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb73f5b531de4d949faf24baf79a438d_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzYtMS0xLTEtMTk3MTgy_670596db-b608-4e29-bfa5-b5eaf1c8862d">29.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i813ae3ce219c4fb99714b7ffced341ac_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzYtMy0xLTEtMTk3MTgy_19473864-0cb9-43a5-8c91-750c3b944b47">42.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a07487d016f4962ae2b2023e270baed_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzYtNS0xLTEtMTk3MTgy_e9446d68-5bb0-4d53-948a-6565b6916f79">53.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the next 12 months, we expect to reclassify $<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" sign="-" name="us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzg1NDY_b6e6069a-805e-40a8-904d-282822cdda5c">16.8</ix:nonFraction> million of pretax net losses on cash flow hedges from accumulated other comprehensive income (loss) to other&#8211;net, (income) expense. During the years ended December&#160;31, 2022, 2021, and 2020, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i4c8683347df74a96a9271fc657ec2491" continuedAt="i9e510f824c79436ca5a70edc40a2594b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value of Risk-Management Instruments</span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE0ODMz_53aaae84-7268-4589-bffa-22e207b8c0fd" continuedAt="i08a38b41d15c4f0f8c916ce8c4278a02" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain fair value information at December&#160;31, 2022 and 2021 for risk-management assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:40.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.890%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.890%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.890%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.890%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.898%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5197ef213a4645978df5f719742ae403_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzctMS0xLTEtMTk3MTgy_f21d50f2-99d6-493d-b84b-f85c69f4b547">134.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e4a751923845029648d84b7970c686_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzctMy0xLTEtMTk3MTgy_2550955a-1c69-4562-9c5e-fa592a50cc08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife02be8abfd44063a559e3b91d3451e8_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzctNS0xLTEtMTk3MTgy_8e49c9cd-0111-43ae-af87-13e679348d7a">134.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ba97b94ac14d2785bd7fa84c035ba6_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzctNy0xLTEtMTk3MTgy_d1bddf79-4db1-4df2-88a7-3b921899076a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f476c609f70478db4f2ecd35dc8eb68_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzctOS0xLTEtMTk3MTgy_ac40938d-62ac-49bf-af42-9b84e3bc0b7f">134.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22c86b90cca74ee28587fd7b463de73e_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzktMS0xLTEtMTk3MTgy_df904694-1456-417b-b689-61e0ea991cac">162.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8155874edc7f4d55bd1452edf423993c_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzktMy0xLTEtMTk3MTgy_ef796c2f-cf50-4b11-964c-b4dc0541117d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36992cb2187547dfa9f7e206d125f62d_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzktNS0xLTEtMTk3MTgy_f409d366-efe9-4d6d-81c5-fd112f42ec11">162.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2840be8f4a94f848fa12213edee040f_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzktNy0xLTEtMTk3MTgy_0350c810-2fc0-49d4-af1d-1a49848ca5f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8790eb3b0704b11bbbdffca311b63b8_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzktOS0xLTEtMTk3MTgy_eca9bdbe-3a44-4c55-90ed-bb48b787ba71">162.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22c86b90cca74ee28587fd7b463de73e_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEwLTEtMS0xLTE5NzE4Mg_fad954fe-3840-470d-943a-ac7baaf0a188">246.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8155874edc7f4d55bd1452edf423993c_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEwLTMtMS0xLTE5NzE4Mg_e998b429-d1f5-47a4-bff1-1508cf78d041">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36992cb2187547dfa9f7e206d125f62d_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEwLTUtMS0xLTE5NzE4Mg_a2b24393-2470-4821-a0fc-c4db09003fd5">246.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2840be8f4a94f848fa12213edee040f_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEwLTctMS0xLTE5NzE4Mg_b18751f0-5752-4a0b-a6ea-08d22af9e419">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8790eb3b0704b11bbbdffca311b63b8_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEwLTktMS0xLTE5NzE4Mg_5674efe5-ed5f-4f08-bcb7-f7691cc701bf">246.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36c4a0d2b7e245eabd1f07bf17e8efea_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEzLTEtMS0xLTE5NzE4Mg_013d0fa9-7724-48aa-9fd3-24437344b185">67.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c71c6fa987a4120a284c9b9145e27e7_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEzLTMtMS0xLTE5NzE4Mg_278d17df-6d82-4061-b338-3e43b60b7709">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b33940746b24ac0b52755c11e6154f0_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEzLTUtMS0xLTE5NzE4Mg_959b114f-eddd-4e36-af66-18020bd8e64b">67.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5b2741087f34d8badb76a8ebcb2b3fd_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEzLTctMS0xLTE5NzE4Mg_7546dbb9-ca61-49cd-bd07-b936d6055953">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1936dd4cad4f59a9112c82012622aa_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEzLTktMS0xLTE5NzE4Mg_2cafc658-0c6b-4eca-a912-7f4dd43c1d69">67.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic11c3f50a6ad41aaaa6ec682a1a2bf69_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzE5LTEtMS0xLTE5NzE4Mg_b5c7f65b-f516-4bb1-b66e-57dd6ab7c9d2">53.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32517cdb203a46dbb43f88560fafdc6e_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzE5LTMtMS0xLTE5NzE4Mg_b90c1c37-f2e5-4a06-a2ef-f1f2de9a68ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233ef483a0f64f039b86216aee108bfa_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzE5LTUtMS0xLTE5NzE4Mg_65e05760-da86-4a46-9e67-6dc6982e3eab">53.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a806ed2d9564a57a182b6ed0c5fe28f_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzE5LTctMS0xLTE5NzE4Mg_5f4e6dbc-dd01-455f-8b59-a1f8953fb3f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ea6da8b55e34d8189b756c1edd72ca2_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzE5LTktMS0xLTE5NzE4Mg_c304611e-d914-491f-9c2c-1fac09bd57b9">53.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52cdc2ce968e46748102e49a49b2747c_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTEtMS0xLTIzMzAxNQ_f0247580-9f0e-4c98-ba4f-b089f0e62626">38.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5626e89be6054126b0e88da30ec22edb_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTMtMS0xLTIzMzAyOA_1b9de234-0843-457a-858e-64333f86ce79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76ad9553f0574ea0869f164b30ead95a_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTUtMS0xLTIzNDQzOA_9c0a7f7f-09ea-40c7-afa1-9462c961422e">38.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie253e8109f6b4b66b779831838983108_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTctMS0xLTIzMzAzOQ_348ea872-c381-45a4-b3b1-03b277febd44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4eb0b46018c54f5c946184e340c3804d_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTktMS0xLTIzMzA1MQ_574d598e-32b9-41d5-9a21-107670f64248">38.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5172caf5b4c745e49a779865e4df8b6d_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTEtMS0xLTE5NzE4Mg_9d38c164-dccd-4381-b0d5-35ff77071f40">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e87bdf692d44f63b49e30cb351f8be1_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTMtMS0xLTE5NzE4Mg_12628ad2-bafd-4ab0-aeee-29bb10c6f457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277951e04244daea0a2517c6b972ce4_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTUtMS0xLTE5NzE4Mg_8f2a1b92-8ebc-41fe-9934-b212366b0201">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i177a13f9ceb04b04ac9f5de0f3c10743_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTctMS0xLTE5NzE4Mg_04190d2b-271b-41bc-8ba3-1994b39e1daf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1960642f8dbc465babdbb93b28ddece6_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTktMS0xLTE5NzE4Mg_ec777679-b73f-4107-9ce2-6df9c53a788d">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5172caf5b4c745e49a779865e4df8b6d_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI0LTEtMS0xLTE5NzE4Mg_bc2ec4db-8c1c-409e-8613-b1e186de781d">21.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e87bdf692d44f63b49e30cb351f8be1_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI0LTMtMS0xLTE5NzE4Mg_a4cb39fe-70f7-428d-aa56-ca431e92b950">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2277951e04244daea0a2517c6b972ce4_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI0LTUtMS0xLTE5NzE4Mg_211102cd-d158-40e6-9b6f-3f86f8c89cb2">21.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i177a13f9ceb04b04ac9f5de0f3c10743_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI0LTctMS0xLTE5NzE4Mg_cf225677-4b64-4bac-af66-6d2f00af09da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1960642f8dbc465babdbb93b28ddece6_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI0LTktMS0xLTE5NzE4Mg_c76f1d41-1f7c-491e-a8ad-a0326151e1f9">21.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2046b6b3eed4ac6b751298dc54b230f_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI2LTEtMS0xLTE5NzE4Mg_4cf1971a-1e1e-46f6-9abe-76bc528e27e1">39.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6d39fa7dff407a9bb5b5c2e98c8f37_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI2LTMtMS0xLTE5NzE4Mg_8452d57b-6ad0-45e3-bef9-2edd93ae7644">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if819ebce2b824e4f956b1fc03a244870_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI2LTUtMS0xLTE5NzE4Mg_8fa3a85b-32b9-4966-8b8d-8192392e9ef3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d41b93e38c04495a8c9e35a8f93a51b_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI2LTctMS0xLTE5NzE4Mg_134c7548-6da4-44ef-816b-4b8262abfebd">39.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a6cadf85ae74e19b0b4b3d94566c950_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI2LTktMS0xLTE5NzE4Mg_663fbc79-1e86-4c0f-b962-1404b9b8103f">39.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2046b6b3eed4ac6b751298dc54b230f_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI3LTEtMS0xLTE5NzE4Mg_36a4548d-287f-4a7c-8cd4-a75788da5968">70.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6d39fa7dff407a9bb5b5c2e98c8f37_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI3LTMtMS0xLTE5NzE4Mg_9ca62ba5-a52f-4049-b851-f561e85f6f8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if819ebce2b824e4f956b1fc03a244870_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI3LTUtMS0xLTE5NzE4Mg_98dfd8c6-32c4-4756-8ec5-11805a1aa1ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d41b93e38c04495a8c9e35a8f93a51b_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI3LTctMS0xLTE5NzE4Mg_bef4defb-f3ac-411d-bc6f-24b91d91ddbf">70.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a6cadf85ae74e19b0b4b3d94566c950_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI3LTktMS0xLTE5NzE4Mg_03e26590-de5d-4348-95e8-64aebc90231d">70.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i9e510f824c79436ca5a70edc40a2594b" continuedAt="i352843eadc1d4f7088d287555893a9f0"><div style="margin-top:6pt"><ix:continuation id="i08a38b41d15c4f0f8c916ce8c4278a02"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:40.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.890%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.890%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.890%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.890%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.898%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia14954f687c6405ab00a4364d579fd9a_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMyLTEtMS0xLTE5NzE4Mg_22320a5c-eb0b-42ef-a4c3-218a0af5fcae">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i588da95a877d48e8954f17fe68f586a7_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMyLTMtMS0xLTE5NzE4Mg_ce09f582-5386-4c1b-95dd-57ab177144d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d7fb6d960d43a18ef69089fff51e0e_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMyLTUtMS0xLTE5NzE4Mg_38159d67-e2cb-4aac-8db3-09f4608ce077">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0180c6864ed746a8b3d870461649834a_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMyLTctMS0xLTE5NzE4Mg_89bbf48f-9769-4447-aaf8-0007fb78c5d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia760ea075df24dcfa76244f5eb52e815_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMyLTktMS0xLTE5NzE4Mg_4c4925c0-3e8c-48fe-baf1-7b4d604f4894">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia14954f687c6405ab00a4364d579fd9a_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMzLTEtMS0xLTE5NzE4Mg_d942b0dc-b34e-48df-968b-9f95ec4ae240">78.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i588da95a877d48e8954f17fe68f586a7_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMzLTMtMS0xLTE5NzE4Mg_27a6f7d2-a148-4763-8b7b-a94d4a286179">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d7fb6d960d43a18ef69089fff51e0e_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMzLTUtMS0xLTE5NzE4Mg_ae7fd521-e40c-4fb6-9d85-80f920bd482a">78.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0180c6864ed746a8b3d870461649834a_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMzLTctMS0xLTE5NzE4Mg_e898817c-9429-412d-bdbb-038d37be23b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia760ea075df24dcfa76244f5eb52e815_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMzLTktMS0xLTE5NzE4Mg_c57f0b72-b3c0-4c0f-b264-28c7daeee5f6">78.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia14954f687c6405ab00a4364d579fd9a_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM1LTEtMS0xLTE5NzE4Mg_b650ab53-eace-4675-a6c9-97d22dbea44f">7.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i588da95a877d48e8954f17fe68f586a7_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM1LTMtMS0xLTE5NzE4Mg_0524a34c-0326-4c38-8a15-f27219561238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96d7fb6d960d43a18ef69089fff51e0e_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM1LTUtMS0xLTE5NzE4Mg_35b6d254-7b77-4094-ad5d-c2dbf7c3d403">7.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0180c6864ed746a8b3d870461649834a_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM1LTctMS0xLTE5NzE4Mg_7b593424-0948-4fa2-8d2f-02cd1c3372a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia760ea075df24dcfa76244f5eb52e815_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM1LTktMS0xLTE5NzE4Mg_18608297-c8eb-4937-8ab9-8a831a39f740">7.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id945978cb9e34780a08b5b17c28c3dae_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM3LTEtMS0xLTE5NzE4Mg_76e4041f-75d0-474a-87e7-9ef4f37e83db">49.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i377eee7df67949f38f58d5844a15b18c_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM3LTMtMS0xLTE5NzE4Mg_5c130887-bd04-49f2-9444-8e4cfafb0dbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4ba21050cbf4b33a8dce7b1f2a8fba8_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM3LTUtMS0xLTE5NzE4Mg_91301aee-7777-44ef-8427-fb699668c6ef">49.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f875e3e2144b5391ee55f902226825_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM3LTctMS0xLTE5NzE4Mg_c2d726b6-a8bb-4184-9ac4-2b8f79a3257e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5c16eeb8a64c579a2fa0a33daa5b36_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM3LTktMS0xLTE5NzE4Mg_757d9be9-b2cc-4b4a-a4aa-98d573ba7a24">49.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id945978cb9e34780a08b5b17c28c3dae_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM4LTEtMS0xLTE5NzE4Mg_4edd3857-dada-4824-8f80-103b9796f4eb">31.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i377eee7df67949f38f58d5844a15b18c_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM4LTMtMS0xLTE5NzE4Mg_f543cdb6-16ee-4537-83c4-4c7dc9e2cad3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4ba21050cbf4b33a8dce7b1f2a8fba8_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM4LTUtMS0xLTE5NzE4Mg_d718ac06-3c9c-4839-947c-93925250642f">31.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f875e3e2144b5391ee55f902226825_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM4LTctMS0xLTE5NzE4Mg_909c2a17-8d71-4205-b25b-f2290016a195">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b5c16eeb8a64c579a2fa0a33daa5b36_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM4LTktMS0xLTE5NzE4Mg_0e45fa6b-c969-4140-9be8-8535cd1c8a35">31.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314c0f6b364b4833a2bf7dc6a7d484ef_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQxLTEtMS0xLTE5NzE4Mg_44a65ae8-a404-4bbd-a286-163ffab487f6">31.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c6a536ce224bd0a7d1bacbad4b9f82_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQxLTMtMS0xLTE5NzE4Mg_775335ea-f161-4240-9217-5a3c9ac9f1c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85bddc6b22b045908bcc27ca039aa3f2_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQxLTUtMS0xLTE5NzE4Mg_1c9e7b10-cb06-41a1-8cff-b35a73f1da24">31.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233603743e32403cba2427b98f94cd71_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQxLTctMS0xLTE5NzE4Mg_b18fb8b3-281c-44a4-bdb2-2b1834a78d46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb4bb153c0824966869a2e351056f2e3_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQxLTktMS0xLTE5NzE4Mg_36a2a9bc-fe36-484e-960e-fcd4957f5ba2">31.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i314c0f6b364b4833a2bf7dc6a7d484ef_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQyLTEtMS0xLTE5NzE4Mg_430b7d51-1f24-42c9-934d-15a5b39ed4ba">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c6a536ce224bd0a7d1bacbad4b9f82_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQyLTMtMS0xLTE5NzE4Mg_955dee60-e9ab-4d08-984b-d7e065df420c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85bddc6b22b045908bcc27ca039aa3f2_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQyLTUtMS0xLTE5NzE4Mg_bd0db6bd-5d20-44df-ad40-0be935d68705">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233603743e32403cba2427b98f94cd71_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQyLTctMS0xLTE5NzE4Mg_3a804252-6ffb-41ed-b7a8-72c1ccf06046">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb4bb153c0824966869a2e351056f2e3_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQyLTktMS0xLTE5NzE4Mg_94320972-ad2a-4ec7-9064-69e95983b7b9">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cd010e314334386addf3e1c41d3fba9_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ1LTEtMS0xLTE5NzE4Mg_57a252cb-8392-433e-8445-47ca66394d28">33.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2482a53a724280953dce9975c1774d_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ1LTMtMS0xLTE5NzE4Mg_d8265275-e1e3-498f-805c-a0dfd5df8f44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d3bf8b263f4308af9996212c4ea414_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ1LTUtMS0xLTE5NzE4Mg_828a30c5-f545-4d92-ad72-700b594c9e6b">33.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia46188499bcd4b979e789d0ac42002c4_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ1LTctMS0xLTE5NzE4Mg_8d63572c-4033-4699-b53d-89e77af4bc17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863c16ddfefc491d81ad6914ccd53e60_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ1LTktMS0xLTE5NzE4Mg_0bde5a6a-d649-4856-8885-39c068dde619">33.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cd010e314334386addf3e1c41d3fba9_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ2LTEtMS0xLTE5NzE4Mg_9a2efa6a-7472-43ce-8195-a4244ad94bfe">1.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2482a53a724280953dce9975c1774d_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ2LTMtMS0xLTE5NzE4Mg_4f19fc34-066c-429a-9740-48bf3e26fbf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2d3bf8b263f4308af9996212c4ea414_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ2LTUtMS0xLTE5NzE4Mg_b0b57416-9d9e-448a-9e1d-e8a3c8203ba1">1.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia46188499bcd4b979e789d0ac42002c4_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ2LTctMS0xLTE5NzE4Mg_3fff9f4c-addb-4d44-9597-c2e5271dd221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i863c16ddfefc491d81ad6914ccd53e60_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ2LTktMS0xLTE5NzE4Mg_e3d2b7c7-4214-4c00-94f8-7a4cd9ff28af">1.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80d6f9b361384095856711315cacf141_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ4LTEtMS0xLTE5NzE4Mg_50cfb1c7-5344-44cd-81dd-658e35ea1172">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe9492781434d5eb9e61902a0768540_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ4LTMtMS0xLTE5NzE4Mg_c2636e80-a9f8-4608-9043-14ee99ae52f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aabc6919dd54de293fd5ab586ac3010_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ4LTUtMS0xLTE5NzE4Mg_1ec81589-6e32-4620-98ab-102a6c0c3f4d">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ce6f75fe844b619eed1f83ac0c0e45_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ4LTctMS0xLTE5NzE4Mg_0e5e4bca-209a-44e5-85ac-2a23d41113ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i039334735ea6463da706b51515b478f3_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ4LTktMS0xLTE5NzE4Mg_695a8ed8-4dbb-4d22-a794-8095cedc0025">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80d6f9b361384095856711315cacf141_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ5LTEtMS0xLTE5NzE4Mg_a848b475-591a-4f93-ad50-a78f0639e89e">35.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe9492781434d5eb9e61902a0768540_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ5LTMtMS0xLTE5NzE4Mg_05870226-5fc9-4a0c-91b5-dff3914cd32b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7aabc6919dd54de293fd5ab586ac3010_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ5LTUtMS0xLTE5NzE4Mg_cb16cbb3-e3b3-4848-9edc-b575259751c7">35.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ce6f75fe844b619eed1f83ac0c0e45_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ5LTctMS0xLTE5NzE4Mg_68ad1152-b744-4f8c-95a9-ab69b6f0a515">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i039334735ea6463da706b51515b478f3_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ5LTktMS0xLTE5NzE4Mg_ba085289-9eae-486d-84fb-77ef36b2035e">35.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ef264a2971a4d6d9632968955a88874_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzUxLTEtMS0xLTE5NzE4Mg_719ab64a-2e4b-4ac0-854c-dfaf2dc8a61b">70.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1d701e8a7d846deb5dfed51dc19420e_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzUxLTMtMS0xLTE5NzE4Mg_b9dccd67-ad75-4966-96c7-fbfc6d87e377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3bd9c97de44684a6f54ff2b763dce6_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzUxLTUtMS0xLTE5NzE4Mg_31739321-303f-49f7-9738-d9115f3412a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6543e2dc57fc4942a80a5c4b47c6a4d6_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzUxLTctMS0xLTE5NzE4Mg_4b892d09-59b8-4f3a-af47-9c1af21aa1c4">70.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbf3bc2cf6f14b3e986aed5486e859be_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzUxLTktMS0xLTE5NzE4Mg_481d3d27-e9eb-4e6e-a26d-7f877fab5d9e">70.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i352843eadc1d4f7088d287555893a9f0">Contingent consideration liabilities relate to our liabilities arising in connection with the CVRs issued as a result of both the Akouos and Prevail acquisitions. The fair values of the CVR liabilities were estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payments associated with the agreed upon regulatory milestones based on probabilities of technical success, timing of the potential milestone events for the compounds, and estimated discount rates. See Note 3 for additional information related to the CVR arrangements for both Akouos and Prevail.</ix:continuation> </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;8: <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzUyODM_4567e14b-7e07-499b-b0f7-ef1d430df9d4" continuedAt="i844412009f224eb4a7d4e40e3926d736" escape="true">Goodwill and Other Intangibles</ix:nonNumeric></span></div><ix:continuation id="i844412009f224eb4a7d4e40e3926d736" continuedAt="i92bdc94c1f4e4d93acdb6764a68c3577"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzUyOTA_967d66f8-83da-4ada-a70e-80bd3ac68e52" continuedAt="if2fd1655c88f4c16bf568a5b421e6e69" escape="true">Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value to its carrying value is performed to determine the amount of any impairment.</ix:nonNumeric> The change in goodwill during 2022 was primarily related to our acquisition of Akouos. See Note 3 for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzgwNQ_355e4ed1-8def-4cea-8ed3-2705c3fabd7f"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzgwNQ_e07b8e03-c189-4e46-97ce-27c285a275b4"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzgwNQ_e8dcbf67-23d3-49e1-87b5-82a06ea1c6ba">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairments occurred with respect to the carrying value of goodwill for the years ended December&#160;31, 2022, 2021, and 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Intangibles</span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzUyOTg_a86b533a-bbc6-4036-a870-285ddcf31196" escape="true"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzUzMDA_5f287e23-29bd-4d24-8608-a64598dad796" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of intangible assets other than goodwill at December&#160;31 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:26.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024cb51bbd8f473892a3c8c4eb2d1047_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzMtMS0xLTEtMTk3MTgy_26903894-b94f-477d-8b64-be42592464b8">7,922.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i024cb51bbd8f473892a3c8c4eb2d1047_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzMtMy0xLTEtMTk3MTgy_9f8c1d8f-5428-40fe-8f77-5923bf4ac9f3">2,589.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024cb51bbd8f473892a3c8c4eb2d1047_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzMtNS0xLTEtMTk3MTgy_754be984-3487-4928-b215-fa4809838d05">5,332.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffb9e56119443489f2dea0c32378917_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzMtNy0xLTEtMTk3MTgy_65305e4d-15f5-457b-8457-dfee59316973">7,987.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ffb9e56119443489f2dea0c32378917_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzMtOS0xLTEtMTk3MTgy_9ed4fea3-f426-4b1d-96bb-e73ce6a27702">2,229.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffb9e56119443489f2dea0c32378917_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzMtMTEtMS0xLTE5NzE4Mg_81fb981f-3fe4-4bf4-9f72-2fcf79f25b19">5,758.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc9330205fa247e0a9d3b8796fe79d3e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzQtMS0xLTEtMTk3MTgy_a181a3b2-d0ee-444b-bf4a-bc113e3e2c15">35.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc9330205fa247e0a9d3b8796fe79d3e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzQtMy0xLTEtMTk3MTgy_4cd31321-c45a-4f7c-b84d-933499a79cc5">32.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc9330205fa247e0a9d3b8796fe79d3e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzQtNS0xLTEtMTk3MTgy_0dc5b8c8-32cf-4f88-9f77-fa4d13e8662c">2.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10d20920da5045eaa6a64364e50740b4_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzQtNy0xLTEtMTk3MTgy_478960dd-01c8-4cbe-a69b-33a528020fc7">69.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10d20920da5045eaa6a64364e50740b4_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzQtOS0xLTEtMTk3MTgy_9ab252bf-d108-473a-ba4b-41ef8bdb954f">60.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10d20920da5045eaa6a64364e50740b4_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzQtMTEtMS0xLTE5NzE4Mg_c07248dc-4260-4e92-9eb3-100cc3b61530">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzUtMS0xLTEtMTk3MTgy_dd785514-c5df-404e-acb6-996a6ce207c0">7,957.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzUtMy0xLTEtMTk3MTgy_f2a6b6a2-8c45-4395-8a00-aab4fe4bb283">2,622.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzUtNS0xLTEtMTk3MTgy_715fb403-083a-4aa2-97d1-762c1df9d3f7">5,334.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzUtNy0xLTEtMTk3MTgy_bc9d744e-50ae-4da6-8924-1a09c5044c21">8,056.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzUtOS0xLTEtMTk3MTgy_dc0a0d79-1530-4791-b2a2-ab988a7dc3ac">2,289.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzUtMTEtMS0xLTE5NzE4Mg_962aa05e-c53f-4e4d-8c70-1b8b0d10baf2">5,766.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78739e5e4dd447ee99f90605c73e27ac_I20221231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzctMS0xLTEtMTk3MTgy_174ff15c-19c6-4c08-bfc1-c0316756b3c3">1,871.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78739e5e4dd447ee99f90605c73e27ac_I20221231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzctNS0xLTEtMTk3MTgy_cd45fc31-c217-4d31-892f-c0d162a8d101">1,871.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1a89a2666b74590bf74ff22f798d881_I20211231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzctNy0xLTEtMTk3MTgy_d37f81f2-0b09-4c81-b121-8bef75e043d6">1,925.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1a89a2666b74590bf74ff22f798d881_I20211231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzctMTEtMS0xLTE5NzE4Mg_fcb1d036-50d8-43db-b1bd-9429c5c8c81a">1,925.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzgtMS0xLTEtMTk3MTgy_3ec36b40-2e18-4b84-b99d-452bb1fc6b57">9,829.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzgtMy0xLTEtMTk3MTgy_4019a388-9b30-4602-9287-33e0a6373a4b">2,622.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzgtNS0xLTEtMTk3MTgy_86524af3-a505-4616-a775-0fc40d9181c6">7,206.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzgtNy0xLTEtMTk3MTgy_4d8f17a4-8573-4fe7-b059-7f0f97100cfe">9,981.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzgtOS0xLTEtMTk3MTgy_82e66b7e-7fac-4054-84dc-7b9b142e7bc0">2,289.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzgtMTEtMS0xLTE5NzE4Mg_0254dccb-1170-4848-819a-f527583227a4">7,691.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction (U.S., Europe, and Japan) and capitalized milestone payments. <ix:continuation id="if2fd1655c88f4c16bf568a5b421e6e69" continuedAt="i8a603549ed6b449085bf07f0037d8e0c">For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.</ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other finite-lived intangible assets consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies, and customer relationships from business combinations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D consists of the fair values of acquired IPR&amp;D projects acquired in business combination, adjusted for subsequent impairments, if any. <ix:continuation id="i8a603549ed6b449085bf07f0037d8e0c" continuedAt="ied9e586203834ee884fcc28de4c8ca97">The costs of acquired IPR&amp;D projects acquired directly in a transaction other than a business combination are capitalized as other intangible assets if the projects have an alternative future use; otherwise, they are expensed immediately. See Note 3 for significant acquired IPR&amp;D projects that had no alternative future use. </ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ied9e586203834ee884fcc28de4c8ca97" continuedAt="i27ec202b1a7045e884203e40faac6719">Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the "income method," which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, analyst expectations, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&amp;D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i92bdc94c1f4e4d93acdb6764a68c3577"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in acquired IPR&amp;D intangibles in 2022 is due to the impairment of an intangible asset for GBA1 Gene Therapy (PR001). See Note 5 for additional information. This decrease was partially offset by acquired IPR&amp;D assets recognized from the acquisition of Akouos. See Note 3 for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I<ix:continuation id="i27ec202b1a7045e884203e40faac6719">ndefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&amp;D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives are capitalized and are amortized primarily to cost of sales over their estimated useful lives, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzQ4OTk_d5717d76-4a43-4c49-bf30-1707e388a603">one</span> to <ix:nonNumeric contextRef="ibb1db2575cf945c4b53c0b1c6bcbffc0_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzQ5MDU_a01fc102-7262-4504-9ef5-2606c0ad5321">20</ix:nonNumeric> years. As of December&#160;31, 2022, the remaining weighted-average amortization period for finite-lived intangible assets was approximately <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzUwMjM_0b14d0ef-34e3-477f-81d9-04cdbdee4075">13</ix:nonNumeric> years. </span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzUyNjY_58c7bc5e-2fac-4217-b1e4-aeb48f9fb567" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to finite-lived intangible assets was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTo3OGYxODQxZDBhMmI0MThiYjg5MzM4YTUzYjZjNmYyMi90YWJsZXJhbmdlOjc4ZjE4NDFkMGEyYjQxOGJiODkzMzhhNTNiNmM2ZjIyXzEtMS0xLTEtMTk3MTgy_4cfc7499-63b6-46f2-aa3d-70bf61ede714">579.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTo3OGYxODQxZDBhMmI0MThiYjg5MzM4YTUzYjZjNmYyMi90YWJsZXJhbmdlOjc4ZjE4NDFkMGEyYjQxOGJiODkzMzhhNTNiNmM2ZjIyXzEtMy0xLTEtMTk3MTgy_49cfbfb8-7808-4065-9b8a-07640c98b7de">628.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTo3OGYxODQxZDBhMmI0MThiYjg5MzM4YTUzYjZjNmYyMi90YWJsZXJhbmdlOjc4ZjE4NDFkMGEyYjQxOGJiODkzMzhhNTNiNmM2ZjIyXzEtNS0xLTEtMTk3MTgy_142ac77b-742d-4cd6-ab93-3992b1a3af0c">428.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzUyNzE_6d80c9fb-396c-47ba-be09-3c48c4894226" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December&#160;31, 2022 is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.517%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated amortization expense</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTozYTRiZmU1M2E3N2E0YmRkOTUyOTExOGVlODkwYzYxYS90YWJsZXJhbmdlOjNhNGJmZTUzYTc3YTRiZGQ5NTI5MTE4ZWU4OTBjNjFhXzEtMS0xLTEtMTk3MTgy_6e0c8267-afc3-4664-8cbd-5004ad756ca7">497.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTozYTRiZmU1M2E3N2E0YmRkOTUyOTExOGVlODkwYzYxYS90YWJsZXJhbmdlOjNhNGJmZTUzYTc3YTRiZGQ5NTI5MTE4ZWU4OTBjNjFhXzEtMy0xLTEtMTk3MTgy_f2ac92a6-3b86-4e1e-89a6-7ab86097d48b">447.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTozYTRiZmU1M2E3N2E0YmRkOTUyOTExOGVlODkwYzYxYS90YWJsZXJhbmdlOjNhNGJmZTUzYTc3YTRiZGQ5NTI5MTE4ZWU4OTBjNjFhXzEtNS0xLTEtMTk3MTgy_05c016ff-6e26-4ed1-a127-1dce32e45c43">435.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTozYTRiZmU1M2E3N2E0YmRkOTUyOTExOGVlODkwYzYxYS90YWJsZXJhbmdlOjNhNGJmZTUzYTc3YTRiZGQ5NTI5MTE4ZWU4OTBjNjFhXzEtNy0xLTEtMTk3MTgy_dd1e7f67-e36f-48b0-9fac-3c5226453e12">424.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTozYTRiZmU1M2E3N2E0YmRkOTUyOTExOGVlODkwYzYxYS90YWJsZXJhbmdlOjNhNGJmZTUzYTc3YTRiZGQ5NTI5MTE4ZWU4OTBjNjFhXzEtOS0xLTEtMTk3MTgy_8e601a4a-c9b2-426d-a973-648b951be9af">422.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;9: <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzEyMTE_e3f3dc55-b8b8-4e20-bd7c-3b9e8775921b" continuedAt="i5ea43933e1ba453fa256a43004eb5dbf" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i5ea43933e1ba453fa256a43004eb5dbf"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzEyMzA_a3da989a-b164-44d0-9008-0b9b3c1feba6" escape="true">Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (<ix:nonNumeric contextRef="i84043b4b737545c9b8356075843761af_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzI0NQ_180e6339-b271-4267-8e9b-4a9a48237f26">12</ix:nonNumeric> to <ix:nonNumeric contextRef="ibc25faf9338644178cb1e8c7d5454052_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzI1MQ_27bdcc96-0394-4fbe-9e3e-5fc566d30d26">50</ix:nonNumeric> years for buildings and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzI3Mg_0bc998e4-b996-4544-9f0f-ef94e39f535f">three</span> to <ix:nonNumeric contextRef="i3c90a1dfddcc4a0b8f2e9d9ade98f0f7_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzI3OA_47e8c6e9-2736-40fe-8ee4-ba883b7c3069">25</ix:nonNumeric> years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value, and the cost basis is adjusted.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzEyMjg_2b207ebf-2710-4c56-ad34-5a368ff45ca1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, property and equipment consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:73.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzEtMS0xLTEtMTk3MTgy_4cf58ab2-6856-4145-a2a5-020174eb6054">256.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzEtMy0xLTEtMTk3MTgy_bd52c9b2-898c-48c8-b2d4-4b7285c70d72">258.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzItMS0xLTEtMTk3MTgy_0bf0199e-0d41-4407-8b0e-cdcd1402999e">7,915.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzItMy0xLTEtMTk3MTgy_74741860-6587-40dd-84b6-03d942672bf1">7,588.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:MachineryAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzMtMS0xLTEtMTk3MTgy_14ddeaa3-acbb-4dc4-a126-735469181198">9,406.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:MachineryAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzMtMy0xLTEtMTk3MTgy_0e32f5ff-85bb-4a00-b4a6-35715e03e28e">8,937.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzUtMS0xLTEtMTk3MTgy_b2de8852-f4b8-4625-8c97-c8b73f5f1430">2,798.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzUtMy0xLTEtMTk3MTgy_037ed67b-9280-47eb-a2d1-fd9c624c9654">2,177.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzYtMS0xLTEtMTk3MTgy_94048c34-6298-4ef4-ba22-1fa234687620">20,377.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzYtMy0xLTEtMTk3MTgy_befc2bb0-3d34-4b53-b78c-c4a86bb1896a">18,961.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzctMS0xLTEtMTk3MTgy_a86f6cde-06c4-47f7-8fcf-4498a7f646d7">10,233.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzctMy0xLTEtMTk3MTgy_7cdb5523-b609-4935-9045-2277ff3749ea">9,976.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzgtMS0xLTEtMTk3MTgy_cefde9a9-9ac6-4e9a-99b5-696bbe88f969">10,144.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzgtMy0xLTEtMTk3MTgy_7e446048-6228-445c-baf1-9c9f40ebc58f">8,985.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToyYzc4YmY1Yzg4OWY0MGIyYTU5OTljYzVhMDlhOTU2YS90YWJsZXJhbmdlOjJjNzhiZjVjODg5ZjQwYjJhNTk5OWNjNWEwOWE5NTZhXzEtMS0xLTEtMTk3MTgy_559f6c0c-26a7-4d98-a5bd-9ae2fcfbfaee">816.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToyYzc4YmY1Yzg4OWY0MGIyYTU5OTljYzVhMDlhOTU2YS90YWJsZXJhbmdlOjJjNzhiZjVjODg5ZjQwYjJhNTk5OWNjNWEwOWE5NTZhXzEtMy0xLTEtMTk3MTgy_b67bfe7c-b7e6-4489-bd02-eae908d2fdb7">787.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToyYzc4YmY1Yzg4OWY0MGIyYTU5OTljYzVhMDlhOTU2YS90YWJsZXJhbmdlOjJjNzhiZjVjODg5ZjQwYjJhNTk5OWNjNWEwOWE5NTZhXzEtNS0xLTEtMTk3MTgy_21e0f655-9fb3-4658-ba30-7e2b7c71de06">765.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized interest costs were not material for the years ended December&#160;31, 2022, 2021, and 2020. </span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzEyMTQ_00501e11-3fc0-487b-8ee4-85679fd0cff5" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-lived assets by geographical area:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc99a357f5645e68fea63babcf6e1a1_I20221231" decimals="-5" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToxNTcyNzgzNGM3NmQ0N2Y3YjFkNGEzNmIwNTQ5MjEzYy90YWJsZXJhbmdlOjE1NzI3ODM0Yzc2ZDQ3ZjdiMWQ0YTM2YjA1NDkyMTNjXzMtNC0xLTEtMTk3MTgy_29ff120f-4520-46f7-bb28-fdef241f8be4">7,709.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23db86fa8b8e464f9ab3b7f022c25c05_I20211231" decimals="-5" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToxNTcyNzgzNGM3NmQ0N2Y3YjFkNGEzNmIwNTQ5MjEzYy90YWJsZXJhbmdlOjE1NzI3ODM0Yzc2ZDQ3ZjdiMWQ0YTM2YjA1NDkyMTNjXzMtNi0xLTEtMTk3MTgy_ebb82039-9a29-4363-ae89-4a8b39220455">6,620.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eff6ba2e6fb4744acc735827cfe6e99_I20221231" decimals="-5" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToxNTcyNzgzNGM3NmQ0N2Y3YjFkNGEzNmIwNTQ5MjEzYy90YWJsZXJhbmdlOjE1NzI3ODM0Yzc2ZDQ3ZjdiMWQ0YTM2YjA1NDkyMTNjXzQtNC0xLTEtMTk3MTgy_a2e84165-0282-46f3-b977-1b80cd8225b5">1,898.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef4bb393b97493c912842acdbb55c84_I20211231" decimals="-5" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToxNTcyNzgzNGM3NmQ0N2Y3YjFkNGEzNmIwNTQ5MjEzYy90YWJsZXJhbmdlOjE1NzI3ODM0Yzc2ZDQ3ZjdiMWQ0YTM2YjA1NDkyMTNjXzQtNi0xLTEtMTk3MTgy_bcf69752-8eea-4a6c-85a1-10cdb1aa92e7">1,702.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf3c5f0215ae42afafbd93e42ab13afc_I20221231" decimals="-5" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToxNTcyNzgzNGM3NmQ0N2Y3YjFkNGEzNmIwNTQ5MjEzYy90YWJsZXJhbmdlOjE1NzI3ODM0Yzc2ZDQ3ZjdiMWQ0YTM2YjA1NDkyMTNjXzUtNC0xLTEtMTk3MTgy_e6fcec8c-e66e-4c2a-a027-4e2b36b69d51">1,625.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd853d454b54902b5326960dc6dae46_I20211231" decimals="-5" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToxNTcyNzgzNGM3NmQ0N2Y3YjFkNGEzNmIwNTQ5MjEzYy90YWJsZXJhbmdlOjE1NzI3ODM0Yzc2ZDQ3ZjdiMWQ0YTM2YjA1NDkyMTNjXzUtNi0xLTEtMTk3MTgy_4c23bd07-6646-4f46-8411-832790656e82">1,691.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToxNTcyNzgzNGM3NmQ0N2Y3YjFkNGEzNmIwNTQ5MjEzYy90YWJsZXJhbmdlOjE1NzI3ODM0Yzc2ZDQ3ZjdiMWQ0YTM2YjA1NDkyMTNjXzYtNC0xLTEtMTk3MTgy_a38cc748-c66a-40f7-ad31-47efddbdfd62">11,234.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToxNTcyNzgzNGM3NmQ0N2Y3YjFkNGEzNmIwNTQ5MjEzYy90YWJsZXJhbmdlOjE1NzI3ODM0Yzc2ZDQ3ZjdiMWQ0YTM2YjA1NDkyMTNjXzYtNi0xLTEtMTk3MTgy_3b1da8de-6d63-4d65-a279-c277d641c53a">10,013.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment, net, operating lease assets, and certain other noncurrent assets.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;10:&#160;<ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90ZXh0cmVnaW9uOmI1YjQwYjYwY2UzODQwZTJhZDNkM2FhNjU0MDBhYjQwXzI2MDU_2c46d43f-4297-4068-8e8d-826d226f232e" continuedAt="i2380c143ef304e28ade77af2717aeeb7" escape="true"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90ZXh0cmVnaW9uOmI1YjQwYjYwY2UzODQwZTJhZDNkM2FhNjU0MDBhYjQwXzI2MDY_c2e88960-8e3f-479e-93bb-cfa6fdf61897" continuedAt="ic9cb839eb2b84fa788e6c4de3435a3a3" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i2380c143ef304e28ade77af2717aeeb7"><ix:continuation id="ic9cb839eb2b84fa788e6c4de3435a3a3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. We have leases with terms up to <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="lly:LesseeLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90ZXh0cmVnaW9uOmI1YjQwYjYwY2UzODQwZTJhZDNkM2FhNjU0MDBhYjQwXzEwOQ_7d44893b-8ba7-4992-a653-9a6758bf99b9">14</ix:nonNumeric> years primarily for corporate offices, research and development facilities, vehicles, and equipment, including some of which have options to extend and/or early-terminate the leases. We determine the lease term by assuming the exercise of any renewal and/or early-termination options that are reasonably assured.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets are presented as other noncurrent assets in our consolidated balance sheets, and the current and long-term portions of operating lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, in our consolidated balance sheets. Short-term leases, which are deemed at inception to have a lease term of 12 months or less, are not recorded on the consolidated balance sheets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets represent our right to use an underlying asset for the lease term, and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for operating lease assets, which is recognized on a straight-line basis over the lease term, was $<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90ZXh0cmVnaW9uOmI1YjQwYjYwY2UzODQwZTJhZDNkM2FhNjU0MDBhYjQwXzE1Mjg_f397636a-5e68-4478-857a-933aea376ae9">148.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90ZXh0cmVnaW9uOmI1YjQwYjYwY2UzODQwZTJhZDNkM2FhNjU0MDBhYjQwXzE1MzI_3559d2b1-395e-4bcc-b110-2be4c42374ea">159.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90ZXh0cmVnaW9uOmI1YjQwYjYwY2UzODQwZTJhZDNkM2FhNjU0MDBhYjQwXzE1NDA_dff59e22-d547-400b-a814-607a9688192a">154.6</ix:nonFraction> million during the years ended December&#160;31, 2022, 2021, and 2020, respectively. Variable lease payments, which represent non-lease components such as maintenance, insurance and taxes, and which vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the payment obligation is incurred and were not material during the years ended December&#160;31, 2022, 2021, and 2020. Short-term lease expense was not material during the years ended December&#160;31, 2022, 2021, and 2020.</span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90ZXh0cmVnaW9uOmI1YjQwYjYwY2UzODQwZTJhZDNkM2FhNjU0MDBhYjQwXzI2MDM_417dcc33-6dc8-499c-9487-fc5e30dbd950" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases as of December&#160;31, 2022 and 2021 was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.801%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.950%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ife049f03c96e47288db50605b1356b32_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZToxYmEzNWNhODhlOWE0NmZhODExZjE0YmU5ZGI2ZWI1Ni90YWJsZXJhbmdlOjFiYTM1Y2E4OGU5YTQ2ZmE4MTFmMTRiZTlkYjZlYjU2XzEtMi0xLTEtMTk3MTgy_63f12642-4ecc-421e-ba67-a602497c6c3a">7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZToxYmEzNWNhODhlOWE0NmZhODExZjE0YmU5ZGI2ZWI1Ni90YWJsZXJhbmdlOjFiYTM1Y2E4OGU5YTQ2ZmE4MTFmMTRiZTlkYjZlYjU2XzEtMy0xLTEtMTk3MTgy_95456dfa-c39d-4d22-b2ad-6b2ea87ab79e">7</ix:nonNumeric> years</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZToxYmEzNWNhODhlOWE0NmZhODExZjE0YmU5ZGI2ZWI1Ni90YWJsZXJhbmdlOjFiYTM1Y2E4OGU5YTQ2ZmE4MTFmMTRiZTlkYjZlYjU2XzItMi0xLTEtMTk3MTgy_58dc5418-99c9-4521-9295-8fc9fcca7714">3.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZToxYmEzNWNhODhlOWE0NmZhODExZjE0YmU5ZGI2ZWI1Ni90YWJsZXJhbmdlOjFiYTM1Y2E4OGU5YTQ2ZmE4MTFmMTRiZTlkYjZlYjU2XzItMy0xLTEtMTk3MTgy_5c046b4c-8657-4b9b-b2cd-561b38014339">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2022, 2021, and 2020 was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTpiMjM1ZTk2YWRmZTY0NGJlOTE3YmNkODg5MDI4MDRkZS90YWJsZXJhbmdlOmIyMzVlOTZhZGZlNjQ0YmU5MTdiY2Q4ODkwMjgwNGRlXzEtMi0xLTEtMTk3MTgy_ae84b250-b1d9-433f-92c5-bced8679fa40">149.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTpiMjM1ZTk2YWRmZTY0NGJlOTE3YmNkODg5MDI4MDRkZS90YWJsZXJhbmdlOmIyMzVlOTZhZGZlNjQ0YmU5MTdiY2Q4ODkwMjgwNGRlXzEtMy0xLTEtMTk3MTgy_058b5dec-5da4-49ae-ae76-933c5f5faea5">156.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTpiMjM1ZTk2YWRmZTY0NGJlOTE3YmNkODg5MDI4MDRkZS90YWJsZXJhbmdlOmIyMzVlOTZhZGZlNjQ0YmU5MTdiY2Q4ODkwMjgwNGRlXzEtNC0xLTEtMTk3MTgy_91302d8e-ae57-4fd6-8a5b-e1aadff80bd6">160.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTpiMjM1ZTk2YWRmZTY0NGJlOTE3YmNkODg5MDI4MDRkZS90YWJsZXJhbmdlOmIyMzVlOTZhZGZlNjQ0YmU5MTdiY2Q4ODkwMjgwNGRlXzItMi0xLTEtMTk3MTgy_6c91456a-b3a7-4f9d-a2b3-e160156c9d4d">155.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTpiMjM1ZTk2YWRmZTY0NGJlOTE3YmNkODg5MDI4MDRkZS90YWJsZXJhbmdlOmIyMzVlOTZhZGZlNjQ0YmU5MTdiY2Q4ODkwMjgwNGRlXzItMy0xLTEtMTk3MTgy_10b17b7b-95d1-4ec2-9493-2befa4d696fb">163.5</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTpiMjM1ZTk2YWRmZTY0NGJlOTE3YmNkODg5MDI4MDRkZS90YWJsZXJhbmdlOmIyMzVlOTZhZGZlNjQ0YmU5MTdiY2Q4ODkwMjgwNGRlXzItNC0xLTEtMTk3MTgy_1bc9822e-25c3-45c7-8686-b058098f80d6">136.7</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90ZXh0cmVnaW9uOmI1YjQwYjYwY2UzODQwZTJhZDNkM2FhNjU0MDBhYjQwXzI2MDQ_50bef635-2270-4641-8131-c288c3707d4b" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2022 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.740%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzEtMS0xLTEtMTk3MTgy_2a3a2506-16e1-4b63-85b2-76474f1029e0">154.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzItMS0xLTEtMTk3MTgy_5e9608cd-f671-4dbc-8670-59f554e3ef3e">131.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzMtMS0xLTEtMTk3MTgy_e199f799-e2d9-432f-bea0-bb9f73d1b419">115.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzQtMS0xLTEtMTk3MTgy_02a088bd-c829-4f1b-b7d7-1fbf6193d280">96.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzUtMS0xLTEtMTk3MTgy_5a80117a-b075-4c27-8d80-82dd10bd3af8">76.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzYtMS0xLTEtMTk3MTgy_dd1c1a3a-91b3-4f52-93e5-0c167ffff807">250.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzctMS0xLTEtMTk3MTgy_a4abc1b1-699a-4758-958d-3d0f8a5a08c3">823.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzgtMS0xLTEtMTk3MTgy_9c78d3ce-4c9b-419b-b4fb-52717323876f">95.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzktMC0xLTEtMTk3MTgy_8ddc8d02-9a67-4865-bc1c-83f42fdd1643">Total</span></span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzktMS0xLTEtMTk3MTgy_2e47a54f-61fa-4c4c-8cb8-cc5c9657f896">728.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases are included in property and equipment, short-term borrowings and current maturities of long-term debt, and long-term debt in our consolidated balance sheets. Finance leases are not material to our consolidated financial statements.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11: <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzQwNDk_261a1a80-bd3b-4cc2-99ab-12f0030fa369" continuedAt="ic26aa4074810427584a650255045a23d" escape="true">Borrowings</ix:nonNumeric></span></div><ix:continuation id="ic26aa4074810427584a650255045a23d" continuedAt="idfabe8f488954bd4a8357b4f74a14720"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzQwNDg_9f36b7cc-25e4-4082-8d5f-5b8e2635972c" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt at December&#160;31 consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term commercial paper borrowings</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzEtMS0xLTEtMjI3MTEw_ae4acb3f-57ff-4b26-8a40-3994cc496fd5">1,498.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzEtMy0xLTEtMjI3MTE4_844e244c-a60b-4366-8505-a3cacca206ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term notes </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzEtMS0xLTEtMTk3MTgy_7ac852a6-0b0c-4524-a57a-f6e064923be9">14,815.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzEtMy0xLTEtMTk3MTgy_1c29cd9d-f769-4e01-8743-ba4177abf964">16,741.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:OtherNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzItMS0xLTEtMTk3MTgy_613099e9-9363-4e22-933a-e31d8daa9f02">6.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:OtherNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzItMy0xLTEtMTk3MTgy_3983d56c-1395-44fe-9de8-f81868b07f5c">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzMtMS0xLTEtMTk3MTgy_847dd41b-207f-4325-a0b5-5c87f97d0f10">77.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzMtMy0xLTEtMTk3MTgy_f55fee16-5215-494c-854c-1c7b1c867b6a">84.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment on hedged long-term notes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" sign="-" name="lly:LongTermDebtFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzQtMS0xLTEtMTk3MTgy_b908fdde-f977-4583-b289-aa23f3c7c34f">4.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="lly:LongTermDebtFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzQtMy0xLTEtMTk3MTgy_f115236f-14cc-4b28-8cf1-8d4126991d38">216.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzUtMS0xLTEtMTk3MTgy_e4d00767-e7a5-4881-8a3b-7ea1fd92907a">16,238.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzUtMy0xLTEtMTk3MTgy_3ba8112b-0064-408c-98c5-5322641adfd2">16,884.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzYtMS0xLTEtMTk3MTgy_0e173ce0-c2af-4131-b7bf-693cd5dedc79">1,501.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzYtMy0xLTEtMTk3MTgy_7497226a-e2f3-4cca-bbdf-64a882846b52">1,538.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzctMS0xLTEtMTk3MTgy_e3177802-aad3-4105-b855-3e60e77bcd28">14,737.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzctMy0xLTEtMTk3MTgy_3bda07fa-f87a-4aee-bb16-23885b4b6c44">15,346.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average effective borrowing rate on short-term commercial paper borrowings at December 31, 2022 was <ix:nonFraction unitRef="number" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="2" name="us-gaap:ShortTermDebtWeightedAverageInterestRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzEwNDQ1MzYwNDY4ODU1_fcb05a4d-a50b-45e1-9cba-f4a6fe6bce0c">4.20</ix:nonFraction> percent.</span></div></ix:continuation><div style="margin-top:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="idfabe8f488954bd4a8357b4f74a14720" continuedAt="i4d4e34ad153243eb924eeb2769c08224"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzQwNjU_4c547a22-2194-4aad-ae03-bbe34fa336dd" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-term notes at December 31:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.640%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.179%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i7296a85c804344a4b823ccbd1579e425_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246ZjQ4YmM1NjViZTk3NGMwZTlhYmYzZjNiNzc5ZmM1MjBfNA_4c93b603-f2d2-4065-bfc4-3deafc3e68c9">2.35</ix:nonFraction>% notes due 2022</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7296a85c804344a4b823ccbd1579e425_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEtMS0xLTEtMTk3MTgy_5c93e4bd-a7e3-41a9-86e2-bd6d921d3c44">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a66519f1704bd5891f02b44669f2ef_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEtMy0xLTEtMTk3MTgy_d2102aa8-591e-444a-b5d4-9bc7d7be4b58">750.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="iafbbc254a62f477095aad8da1c3c29cc_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzItMC0xLTEtMTk3MTgyL3RleHRyZWdpb246Y2IxYmFkZTI4YzYyNDUyNjgyOWNkOGZlNzBlYTU1MzRfNA_b34c7395-9593-472b-b0cd-566f2537aa0d">3.00</ix:nonFraction>% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="iafbbc254a62f477095aad8da1c3c29cc_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzItMS0xLTEtMTk3MTgy_33223693-9076-4985-b399-3653d057d175">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ed564e316641a190e2ea5bc0d13358_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzItMy0xLTEtMTk3MTgy_2d4ef707-1f60-41d9-b610-1b2cab83fa6a">99.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i5cb67bf176ed48d699fda531feb23c5c_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246ZDRhZTUxZjdjNzJkNDg4MmFmOTBiMGQ2NDczNTJkOGRfNA_3f778f31-3883-4e40-9dc9-f8873bc37f5a">1.00</ix:nonFraction>% euro denominated notes due 2022</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i5cb67bf176ed48d699fda531feb23c5c_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMtMS0xLTEtMTk3MTgy_466e2f06-6ff1-43c5-98ee-9921fb19e00c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ieee67ef519a14645b909c395101668dd_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMtMy0xLTEtMTk3MTgy_d551860a-5110-4754-a7cf-7077e3e756c8">678.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ic91bf59cc87d4b018a72edb84c344f75_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzQtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246MjM1NWRjMTQ3ZGQ4NDk4MDkxODJhYjVjMmMyNDJhYjdfNA_56160b17-6742-47a8-a43e-d445ede21899">0.15</ix:nonFraction>% Swiss franc denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ic91bf59cc87d4b018a72edb84c344f75_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzQtMS0xLTEtMTk3MTgy_a9630d96-17f8-49c7-8abb-7fee711bd216">649.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i5c45ef9bd50d43fd98a3d77dab23bf12_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzQtMy0xLTEtMTk3MTgy_9d9e9993-4b88-4959-8c5f-283560ecd4d8">654.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i61abf79406074265841d9e59afd0b927_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzUtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246NzcxODM1OGJhY2I1NDI4NGE5YmIyZWVhYzI3MGJkNDhfNA_62a742b7-c6b1-4a5e-9f81-ef194f0bc8f7">7.125</ix:nonFraction>% notes due 2025</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i61abf79406074265841d9e59afd0b927_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzUtMS0xLTEtMTk3MTgy_a2163d7b-0c29-4837-a611-b096aa9347ff">217.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="iab38c12183ba4ea08deb88ed706456ce_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzUtMy0xLTEtMTk3MTgy_f4e1c80a-9da0-4e37-b03b-ad604170c8bc">217.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i1b3c6352b0e54655905b05316d9d6f6e_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzYtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246OTkwYTI0ZGE2OTIyNDE0MWEyMGU4MTFlZGZlMTFjM2ZfNA_b7c8acbf-396e-4840-b886-cf3f0c215c95">2.75</ix:nonFraction>% notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1b3c6352b0e54655905b05316d9d6f6e_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzYtMS0xLTEtMTk3MTgy_666f24fa-0311-401f-bdbe-b9ecc28daec1">560.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i7460ec1a2ce645628f9b4950c383a2e7_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzYtMy0xLTEtMTk3MTgy_ddfa33bb-426b-4477-bda2-e6493f6bdf29">560.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="if91ad0b4d0f445169909fc587ad4be66_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzctMC0xLTEtMTk3MTgyL3RleHRyZWdpb246Y2VlZTdiYjkzOWRiNDA5OWFkODM5NjcxZjFmMjllMjBfNA_4cfa37a7-e18b-4c7a-ba97-64f2466905a2">1.625</ix:nonFraction>% euro denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if91ad0b4d0f445169909fc587ad4be66_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzctMS0xLTEtMTk3MTgy_8f3c8618-16a1-443e-9c33-880f25bf0dd5">799.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ia43db658a17f4423b0dfd76ce053a30a_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzctMy0xLTEtMTk3MTgy_c61a1afd-7984-4810-a357-02eb20bc8d77">847.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i26c8536d6b204e03856812446168bceb_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzgtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246ZmEzZGY3Y2Q4MDJiNGU5ODgyNmZhMDJkMDg3OTYwZTFfNA_7bbbfa6e-a72b-489b-a0cc-1b55878cca8b">5.5</ix:nonFraction>% notes due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i26c8536d6b204e03856812446168bceb_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzgtMS0xLTEtMTk3MTgy_e6dfdaee-71ed-4070-a1b7-a13dee31ee2c">364.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i674e9d0712e3435bb2d0ecdf73d1e2f6_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzgtMy0xLTEtMTk3MTgy_9a515630-7d23-403a-a11c-043d6d3a0a5f">364.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i8f1a3b951bfe4ef2a9d50583c4bbd77c_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzktMC0xLTEtMTk3MTgyL3RleHRyZWdpb246MmM1ZjQxN2M3Y2U4NGRkZGFiZTNiNzE3NDdlNDQ4MWFfNA_3f9eed45-a9df-4d37-a06e-4d36af819ead">3.1</ix:nonFraction>% notes due 2027</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i8f1a3b951bfe4ef2a9d50583c4bbd77c_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzktMS0xLTEtMTk3MTgy_752ebdb6-eb8f-4eca-b345-a661b2e97a9b">401.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0e1618d7d24c48259896e1e2026a0aed_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzktMy0xLTEtMTk3MTgy_f0c04859-d2a9-4b3c-8b0c-e2f29cd7047d">401.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i87bad62899d149bdaac599617b653af1_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEwLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjhmMTJlYWI1ZTI5ODRjZWY5MTA1OTI2MjJjZDI5ZDY4XzQ_f40845fc-4c31-438b-bd03-6828e665f239">0.45</ix:nonFraction>% Swiss franc denominated notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i87bad62899d149bdaac599617b653af1_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEwLTEtMS0xLTE5NzE4Mg_8db9e6a0-7f75-47d6-99de-b94f4d29cf1a">433.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i933751a82f6445a3b8dcbd93c8fc716a_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEwLTMtMS0xLTE5NzE4Mg_a8643cf2-56b3-4405-a962-1f0a6cc6ca19">436.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i08a6834348314addb7e7dc8a7a6dfac1_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzExLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOmYzZmQ2ZmMwYjM0NzQzNTQ4OTFmNzczMDlhNjFlY2Q3XzQ_e2981395-9ea6-4646-bfa0-9b68e07cc356">3.375</ix:nonFraction>% notes due 2029</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i08a6834348314addb7e7dc8a7a6dfac1_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzExLTEtMS0xLTE5NzE4Mg_8adca5db-e579-432f-8ef9-e6836a4e5621">930.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ia61b26c361d64e2b848451ac3c78f961_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzExLTMtMS0xLTE5NzE4Mg_c82c338b-4924-4e09-b333-28e107be9c69">930.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ie374eb8422b44d6781dd2c7369a9bbe9_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEyLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjUxMWM0N2Y0NzE4NDQ2YWViOGU0ODA0MjU1ZDhmMjE1XzQ_ec5a2b1c-d0c7-4620-a0fc-f4a135c4fc0e">0.42</ix:nonFraction>% Japanese yen denominated notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ie374eb8422b44d6781dd2c7369a9bbe9_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEyLTEtMS0xLTE5NzE4Mg_2a593397-3fab-46a4-bb1a-2a143197bd72">172.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i53bdc5a3a83441b19c9683bb0db20458_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEyLTMtMS0xLTE5NzE4Mg_966e89cd-0862-4f5e-83bd-9d5703960c78">199.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i19faddcfa3a6449f9e5d54d4c7cc0a5d_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEzLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjllZTNmYzAyOWQ2ZDQ2MTFiMTM5MzgxN2ZiODJlOTFhXzQ_5f4a0977-ab77-4acd-b4a3-7fc86768e8ca">2.125</ix:nonFraction>% euro denominated notes due 2030</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i19faddcfa3a6449f9e5d54d4c7cc0a5d_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEzLTEtMS0xLTE5NzE4Mg_503f44d3-7577-4ea7-82ce-bf6835c4529b">799.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i20625f40121146dbbad262af55cd252c_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEzLTMtMS0xLTE5NzE4Mg_89dfded8-2b0f-4e02-80a6-1b4713a93ceb">847.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i0aa8cf85cde34e54833cd650ef5410b8_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE0LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjMzNjVkMTAyYWFkNzQ1OTNhZDAxODY3NzI0NjkzYjczXzQ_c720d1f7-08b1-4bf5-8531-8f090315b8ae">0.625</ix:nonFraction>% euro denominated notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0aa8cf85cde34e54833cd650ef5410b8_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE0LTEtMS0xLTE5NzE4Mg_5f0d5da9-585b-4f56-ad39-74956e24924c">639.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ie7f6d19c2b7d422585182914ccfc57a8_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE0LTMtMS0xLTE5NzE4Mg_91628567-1472-416d-aa39-bb49681e758b">678.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i8db52983c5fb45929449da08901ec208_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE1LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOmZkZTJiY2QxNDkzZTQ4YWE5ZmEyZDBiMDAwNjVlZTc5XzQ_49e7b165-8e8e-4938-87eb-dbdc7b29f74b">0.50</ix:nonFraction>% euro denominated notes due 2033</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i8db52983c5fb45929449da08901ec208_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE1LTEtMS0xLTE5NzE4Mg_03df2aa8-d532-4a21-8a6a-963c606ee226">639.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4811598343304ab1a6ac92a4d4384082_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE1LTMtMS0xLTE5NzE4Mg_2b256a63-4081-42b1-8113-796d31545a33">678.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i525c05f6af404e8e88124f226b94e2ce_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE2LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjU0N2M5MjA2MDkzNzQxYWU4YTRiMjZhZmU3YWZhZGUxXzQ_069bb0d5-a27d-4ca2-942d-6753af0d0421">0.56</ix:nonFraction>% Japanese yen denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i525c05f6af404e8e88124f226b94e2ce_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE2LTEtMS0xLTE5NzE4Mg_0fcaad78-efa9-4859-bd60-e98b6dec4466">69.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i58706ae52cd04d5787f689decd555c79_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE2LTMtMS0xLTE5NzE4Mg_6d7d6fdf-6e33-4532-8633-0503c4ba7b69">80.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i62868cd48e734ea186f9dbc3ddc52276_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE3LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjk2ODc1MGQzODk5ZjQxMGQ5NWJmNzBkODllMWU5NTYyXzQ_6f78b4a7-5390-4f83-a881-6f29730faa29">6.77</ix:nonFraction>% notes due 2036</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i62868cd48e734ea186f9dbc3ddc52276_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE3LTEtMS0xLTE5NzE4Mg_7da5f73f-93f5-41de-b967-8055f6d06db2">158.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i039f506220b44e9b92088ddadae4d438_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE3LTMtMS0xLTE5NzE4Mg_9cbcbb21-1ab1-4060-a571-ec428b644609">158.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ia861290fae084d9dad2fa74b54a93f61_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE4LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjJlMDU2YzYyZTY4YjQxZWI4YWMzYTgxNmEyNWMyYjU3XzQ_0051ce5a-cf9a-4459-8404-6099c36fb130">5.55</ix:nonFraction>% notes due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ia861290fae084d9dad2fa74b54a93f61_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE4LTEtMS0xLTE5NzE4Mg_fdb263af-474c-4572-a89f-812e9ebff26d">444.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if0f1ac1cc9084ecbb7ec146e7a0ecf59_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE4LTMtMS0xLTE5NzE4Mg_7f6ec94f-282a-431b-8b40-21b84ea18c09">444.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i08e38bce3a2645658e249867cecec63c_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE5LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjlhMDhiOGQ0YTI0ZDQ0MTZhMzIxNTAzZjEyN2I4MDIxXzQ_deb029cf-dc2c-4305-b09b-265a4083d13d">5.95</ix:nonFraction>% notes due 2037</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i08e38bce3a2645658e249867cecec63c_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE5LTEtMS0xLTE5NzE4Mg_5415b42c-97fe-409d-bee7-7fce072c000e">266.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ic1a7b88a64384880b61cf8aa84d05774_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE5LTMtMS0xLTE5NzE4Mg_d145b5ac-50d2-44e4-ba3d-38629d6643ff">266.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i0343f767507d45eeae7ccb730acb9974_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIwLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjQwY2M4NWYwNTFkMTQxMGFhNWI4YWVmZTg2Mzc5MTFhXzQ_0097eeef-dca2-4cfb-9e35-0c261ebe064e">3.875</ix:nonFraction>% notes due 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0343f767507d45eeae7ccb730acb9974_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIwLTEtMS0xLTE5NzE4Mg_c5c0eb30-2848-446e-ac18-ab8d0e78e31b">240.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="id9ce6e78973845499d30563930a6453b_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIwLTMtMS0xLTE5NzE4Mg_73123ec0-afac-4f2e-bf3c-c9fbde0b189d">240.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ieed40c2fbef84f74b11d5910f62ad4eb_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIxLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjI2NTMwNDYwYTU4ZTQwMzhiMmRkMmMzNTI4YmUzOTA1XzQ_5f6ac0f5-5aff-4e12-8dbe-077e599f1272">1.625</ix:nonFraction>% British pound denominated notes due 2043</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ieed40c2fbef84f74b11d5910f62ad4eb_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIxLTEtMS0xLTE5NzE4Mg_84d6929f-c4ba-4ad9-bbde-e357b93efc6f">301.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0f3c74be38f245b8b6ed35611a69d273_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIxLTMtMS0xLTE5NzE4Mg_1fe797da-29e5-4963-a1d6-487291f18e1f">337.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i54e0e0101a7841daae4f2106284daf1d_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIyLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjM1OTYwOTVjZmIyZjRlOThhODg4YjcyMzE1NWI1YjZiXzQ_72c1eadd-914f-49ca-b4e7-07b7a582de39">4.65</ix:nonFraction>% notes due 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i54e0e0101a7841daae4f2106284daf1d_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIyLTEtMS0xLTE5NzE4Mg_94f6818f-b9e5-46c4-b279-6295a32482ea">38.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1d2c94e9725b44148fcdb6193e2870fd_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIyLTMtMS0xLTE5NzE4Mg_72b3b554-9a75-42e8-9cb2-0e8b5cac9c76">38.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ieeb8b7e9ed7a49e49e94f6af00648190_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIzLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjJjMWU0OWMxYTEyYzQ0MzhhZGJlNWU3NzNmNTBlZjJkXzQ_c3f66044-420f-4842-861c-1cb1c63cb8f2">3.7</ix:nonFraction>% notes due 2045</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ieeb8b7e9ed7a49e49e94f6af00648190_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIzLTEtMS0xLTE5NzE4Mg_8b003bd7-ce88-49f1-a6ee-99f81ada9197">386.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="iea58f3bd452e4a36842dd6ec45db98a3_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIzLTMtMS0xLTE5NzE4Mg_f931d5ad-2c2f-421a-9199-56dc667696ab">386.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="iea465f0f6ff843b3ae0b1c8b37cd87ef_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI0LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjA5NGQzZTRiOGJhNTQ5ZTRiOGNjMmI1NGEwNGM2YjQyXzQ_60ade5be-4e1f-4aed-985c-161c82b40490">3.95</ix:nonFraction>% notes due 2047</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="iea465f0f6ff843b3ae0b1c8b37cd87ef_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI0LTEtMS0xLTE5NzE4Mg_cc39c20a-3aee-40b8-8be5-df802c47a664">347.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i59316aeff65f444fa246fc62593bfeef_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI0LTMtMS0xLTE5NzE4Mg_0c750e1a-4115-485e-9e77-6df034d59d77">347.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i41a65a471c734c42a6d546c096e16d1b_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI1LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjU5NDlkMGQxMzZlNjQ5YTRhMDIzNTcwYTJiNzZlZjJhXzQ_1a41cea0-8f74-4bb4-b9a8-fd4baffa69ab">3.95</ix:nonFraction>% notes due 2049</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i41a65a471c734c42a6d546c096e16d1b_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI1LTEtMS0xLTE5NzE4Mg_80d7f9eb-df01-4b9e-9765-6f4862d9a505">958.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="icd3a46888e13415cb278b164998a5c33_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI1LTMtMS0xLTE5NzE4Mg_5d5e00c0-5820-4fa5-afd8-2f3f389ef217">958.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ibfc0c52db55940be9c4b62d052da668e_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI2LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOmRmN2Q0YzMzYmVhZTQ1ZWI5NTkzNTRhNWVmODUyZjViXzQ_0fee0d7d-f0e0-43e5-8d1d-d4030132fccf">1.70</ix:nonFraction>% euro denominated notes due 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibfc0c52db55940be9c4b62d052da668e_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI2LTEtMS0xLTE5NzE4Mg_46fce806-ed6c-42b2-8aa8-176d8ebc17b5">1,065.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibeb85aea19744a2ab1f156a41e098a53_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI2LTMtMS0xLTE5NzE4Mg_2eefaeeb-24b2-4b3e-a4d1-83208265d993">1,130.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="icdba7d3f60f347eca7dbb1d8296ddcdc_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI3LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOmQyZDExZTA3NGRkMjQwYzQ4ZGQxMjY3ZjM2YjBlNzJjXzQ_39472108-5679-4d92-99cd-57c5bcc6397a">0.97</ix:nonFraction>% Japanese yen denominated notes due 2049</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="icdba7d3f60f347eca7dbb1d8296ddcdc_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI3LTEtMS0xLTE5NzE4Mg_aed4592d-f968-428f-b601-a6a5e5d2af27">57.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4c07500c2b6f4b61a48ebb178947c8db_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI3LTMtMS0xLTE5NzE4Mg_061d8e2d-fb99-44c9-bf14-a1c1d1edab6b">66.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i06e56a449d7e46f5a50fe0e1d8d8f32b_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI4LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjEzYzIyZmZiZjI0YjQzZjBiYzdhZGQ1ZTYzMDNmNmRjXzQ_a851de54-f391-4dea-8d84-5710cc9ac03c">2.25</ix:nonFraction>% notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i06e56a449d7e46f5a50fe0e1d8d8f32b_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI4LTEtMS0xLTE5NzE4Mg_7da5c66a-6946-4a2b-b7d6-2a9c8fa2947f">1,250.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867cfd6e85ca49dc8bc5f47a7e85af14_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI4LTMtMS0xLTE5NzE4Mg_f1a3462f-6952-4c38-a2a7-f0e4084f1296">1,250.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i7e986ddd3ce54fd1b852b00b58b6aa8c_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMwLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjhkODVhNmQ5MzI1ZTQxYmJhZThhMTc1NzM4M2FjMzVmXzQ_f8270979-de0a-4f40-8e85-dab83ff707f5">1.125</ix:nonFraction>% euro denominated notes due 2051</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i7e986ddd3ce54fd1b852b00b58b6aa8c_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMwLTEtMS0xLTE5NzE4Mg_4c020fa7-bf3d-41cf-849c-e6b6cd3cbd07">532.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0fbb357599024d59874aed080c948903_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMwLTMtMS0xLTE5NzE4Mg_a1868b21-7e4e-491d-a011-8de5e745783f">565.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i60c6d92c70bb4827b8d11ed6c2927a17_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMxLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjQyNTU4Mzk0MWJhNjRiODg5MmY3MGM3MmUwZjg0YWFlXzQ_167ef358-ff2e-4713-9f01-79d5685a1c50">4.15</ix:nonFraction>% notes due 2059</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i60c6d92c70bb4827b8d11ed6c2927a17_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMxLTEtMS0xLTE5NzE4Mg_1856d58c-d5e9-4977-a241-51f7bbcdc32f">591.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i7ed86b00b5854fb5ad549409205591d0_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMxLTMtMS0xLTE5NzE4Mg_dc51500b-f497-434a-bc88-a38f069335cc">591.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="iedd1c12277a041ab81c0a54878416b3c_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMyLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjRlNDVhMzdmMDA4YjRkODE4ZDdhMmMwNjQ3ZmEzYWExXzQ_76e7dbf4-f8c9-4085-84bc-fc73dcc5829b">2.50</ix:nonFraction>% notes due 2060</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="iedd1c12277a041ab81c0a54878416b3c_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMyLTEtMS0xLTE5NzE4Mg_5d2505c3-4002-4cc3-9e73-29d6b7b5d8a5">850.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73e022a19034845867e9f0ce636e37e_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMyLTMtMS0xLTE5NzE4Mg_1e41ee1e-1ef5-436b-99ee-6289ba928dd2">850.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i58f74fa5874e4bab94a1ead5e6fd1e49_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMzLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjM2MmExZjM1MzM4NjQ0NjU4Zjg2MjNhN2ZiOTZhNTlhXzQ_956d6364-5bae-435a-a9ee-980046efd846">1.375</ix:nonFraction>% euro denominated notes due 2061</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i58f74fa5874e4bab94a1ead5e6fd1e49_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMzLTEtMS0xLTE5NzE4Mg_d21f61ac-41c3-4d02-8276-fbef44033dbb">746.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i9fffe809d4dc437bbf367bdf220199fd_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMzLTMtMS0xLTE5NzE4Mg_7d0f3722-4fd5-4401-bbec-b9628643d459">791.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unamortized note discounts</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzM0LTEtMS0xLTE5NzE4Mg_4ce98b37-da56-4daf-83fd-c4300ac08b51">96.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzM0LTMtMS0xLTE5NzE4Mg_97d60952-4b5f-44e1-9215-b78a03ad37ae">105.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total long-term notes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzM1LTEtMS0xLTE5NzE4Mg_7e959628-b45d-4791-8572-9c3966f59a28">14,815.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzM1LTMtMS0xLTE5NzE4Mg_d1f7af3b-18fe-43b0-bf5e-157e62c0800f">16,741.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average effective borrowing rate for each issuance of the long term-notes approximates the stated interest rate. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had a total of $<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-7" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI5NA_ad756664-f0d8-43fa-b32c-61bdf88055b1">7.33</ix:nonFraction> billion of unused committed bank credit facilities, which consisted primarily of a $<ix:nonFraction unitRef="usd" contextRef="icbbad28b34b342babe4bf7cc2a5134cb_I20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzM3Mg_354d5f2b-d1b0-4552-be15-39870fc0e669">3.00</ix:nonFraction> billion credit facility that expires in December 2026 and a $<ix:nonFraction unitRef="usd" contextRef="ieb7eeafef488487ca857290e624770bd_I20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzQyNw_fada4e91-5b86-4c4b-86d2-528f52b03ddb">4.00</ix:nonFraction>&#160;billion <ix:nonNumeric contextRef="i0c779efd9f6c4ddea6602f310141dc09_D20220101-20221231" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzQzMA_adfc6e22-48d2-4a6e-a2f6-deeb6cfde601">364</ix:nonNumeric>-day facility that expires in September 2023, both of which are available to support our commercial paper program. We have not drawn against the $<ix:nonFraction unitRef="usd" contextRef="icbbad28b34b342babe4bf7cc2a5134cb_I20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzU3Ng_354d5f2b-d1b0-4552-be15-39870fc0e669">3.00</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ieb7eeafef488487ca857290e624770bd_I20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzU4Mw_fada4e91-5b86-4c4b-86d2-528f52b03ddb">4.00</ix:nonFraction> billion facilities as of December&#160;31, 2022. Of the remaining committed bank credit facilities, the outstanding balances as of December&#160;31, 2022 and 2021 were not material. Compensating balances and commitment fees are not material, and there are no conditions that are probable of occurring under which the lines may be withdrawn. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we issued euro-denominated notes consisting of &#8364;<ix:nonFraction unitRef="eur" contextRef="i0b321af1dafc43ccbaeaa9699581dab7_I20210930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM1MDk_d976b6a1-5e65-415f-9ad2-c2582807a9e7">600.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i0b321af1dafc43ccbaeaa9699581dab7_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzU0OTc1NTgxNDMxNzk_b55646a4-5a23-4e76-90bd-8d5a59c3954c">0.50</ix:nonFraction> percent fixed-rate notes due in September 2033, with interest to be paid annually. The net proceeds from the offering have been, and will continue to be, used to fund, in whole or in part, eligible projects designed to advance one or more of our environmental, social, and governance objectives.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i4d4e34ad153243eb924eeb2769c08224"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we issued euro-denominated notes consisting of &#8364;<ix:nonFraction unitRef="eur" contextRef="i57ce917b0f0c422ca61e881f3f692344_I20210930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM1MjU_8273f2fd-887c-4cb1-9023-0f8d29862b9a">500.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i57ce917b0f0c422ca61e881f3f692344_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzU0OTc1NTgxNDMxODY_48ca812b-0123-44b8-b0ef-b2d18bcdda55">1.125</ix:nonFraction> percent fixed-rate notes due in September 2051 and &#8364;<ix:nonFraction unitRef="eur" contextRef="i4a5e0b9bc64e491cb66aa141907b7e5c_I20210930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM1NDE_6da02cc4-97e3-401b-b3db-7aac1e36832c">700.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i4a5e0b9bc64e491cb66aa141907b7e5c_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzU0OTc1NTgxNDMxOTQ_8d5e6ece-2bad-42b5-b66b-aba7a0e6aad6">1.375</ix:nonFraction> percent fixed-rate notes due in September 2061, with interest to be paid annually, and British pound-denominated notes consisting of &#163;<ix:nonFraction unitRef="gbp" contextRef="i451dcfd995634628a4d966f35c25b82c_I20210930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM1NTc_2c31c06c-f548-4c56-9f9d-37853b7836a2">250.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i451dcfd995634628a4d966f35c25b82c_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzU0OTc1NTgxNDMyMDI_d12b45a1-f270-4784-93ee-0bb39b781e20">1.625</ix:nonFraction> percent fixed-rate notes due in September 2043, with interest to be paid annually. We paid $<ix:nonFraction unitRef="usd" contextRef="i0b24bd1f49ea4586a8301239a10ac27e_D20210901-20210930" decimals="-7" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM1NzM_8d568e0e-86f1-481b-a280-5cf580678c55">1.91</ix:nonFraction>&#160;billion of the net cash proceeds from the offering to purchase and redeem certain higher interest rate U.S. dollar-denominated notes with an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i0b24bd1f49ea4586a8301239a10ac27e_D20210901-20210930" decimals="-7" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM1ODg_2be794d1-b274-4da8-924b-cd95c8ba67dd">1.50</ix:nonFraction>&#160;billion, resulting in a debt extinguishment loss of $<ix:nonFraction unitRef="usd" contextRef="i0b24bd1f49ea4586a8301239a10ac27e_D20210901-20210930" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM2MDM_6c955590-d26e-4b31-a0a1-ba3ca8279096">405.2</ix:nonFraction>&#160;million. This loss was included in other-net, (income) expense in our consolidated statement of operations for the year ended December 31, 2021. The $<ix:nonFraction unitRef="usd" contextRef="i0b24bd1f49ea4586a8301239a10ac27e_D20210901-20210930" decimals="-7" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM2MTk_c9e2adee-16c8-4b9d-b0fa-647fd963674e">1.50</ix:nonFraction>&#160;billion principal amount of higher interest rate U.S. dollar-denominated notes that were redeemed primarily included $<ix:nonFraction unitRef="usd" contextRef="i7c474d66fd4941be8ee1af7f8bc945a2_D20210901-20210930" decimals="-5" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM2MzQ_c29426cd-935e-499d-b9df-cc4cd3e61c64">541.8</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i341d1442ad9c4796ad0ad6233bebae92_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzU0OTc1NTgxNDMyMTA_3c57eb18-6f5c-4dd4-a914-cd7caf866433">3.95</ix:nonFraction> percent notes due 2049, $<ix:nonFraction unitRef="usd" contextRef="ied580748898946bdaf1108b103303bdd_D20210901-20210930" decimals="-5" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM2NTA_92f175c5-df18-4800-bd86-7ed59f8a6601">408.7</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i3b7e5b5013ea482e858c341d9431d76f_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzU0OTc1NTgxNDMyMTc_5cfcece4-5cbd-45e9-93e7-f045b8bdb35f">4.15</ix:nonFraction> percent notes due 2059, and $<ix:nonFraction unitRef="usd" contextRef="ie9ac3bd2cc2c4fb7844518c2ea52b6ed_D20210901-20210930" decimals="-5" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM2NjY_4e280ac3-ef45-4c4a-84ba-9673c83e6094">219.4</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i8e29d24af5de402499fe4ebe60451143_I20210930" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzU0OTc1NTgxNDMyMjQ_bbe231bd-e8bf-4f74-82fc-bc18187488a6">3.375</ix:nonFraction> percent notes due 2029. We used the remaining net proceeds from the offering to prefund certain 2022 debt maturities and for general corporate purposes. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we issued $<ix:nonFraction unitRef="usd" contextRef="ifdbadac98c4141e0b7b6c55a77240061_I20200531" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI0ODk_d00c60e9-5ccc-4fba-bec8-e6452bc30de4">1.00</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="ifdbadac98c4141e0b7b6c55a77240061_I20200531" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI0OTU_9eb3c138-582a-4efa-9ed3-a0143492ab3c">2.25</ix:nonFraction> percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $<ix:nonFraction unitRef="usd" contextRef="i6441fa6a78ef4e12b30986772baa1b26_D20200501-20200531" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI2MjM_4d415174-0f62-475e-bf2c-ff938a166d11">988.6</ix:nonFraction> million for general corporate purposes, including the repayment of outstanding commercial paper. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we issued $<ix:nonFraction unitRef="usd" contextRef="i06c599f0bde9445fa16d1cc4feb31a6f_I20200831" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDI_80eefbaa-16e8-4d6d-b91b-e07b016c56a2">850.0</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="i06c599f0bde9445fa16d1cc4feb31a6f_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg_10708b2c-ea22-48ba-852d-2bc0078a68de">2.50</ix:nonFraction> percent fixed-rate notes due in September 2060 and an additional $<ix:nonFraction unitRef="usd" contextRef="i8a93a3c5ae824553bbd8a41bbef49dbb_I20200831" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI4MDg_a55a9bff-00fd-4dbe-bf6f-b1bb4b71cffe">250.0</ix:nonFraction> million of our <ix:nonFraction unitRef="number" contextRef="i8a93a3c5ae824553bbd8a41bbef49dbb_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI4MTg_61744cdc-a78e-4619-a054-5119a73e8b00">2.25</ix:nonFraction> percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $<ix:nonFraction unitRef="usd" contextRef="ic0163626092d4db6b26a6af6487a4108_D20200801-20200831" decimals="-7" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI5NDY_4d6a7adb-c0d0-4357-9335-01274e55272f">1.07</ix:nonFraction> billion for general corporate purposes, including the repayment of outstanding commercial paper. </span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzQwMzk_d10a860f-5b2a-43df-8630-fcf9cbab2bb1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amounts of maturities on long-term debt for the next five years are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:49.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities on long-term debt</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpmZDI5ZDVmYmUwMjA0NTRjYjQ0YjE0ZWI2YzNiNTUxMi90YWJsZXJhbmdlOmZkMjlkNWZiZTAyMDQ1NGNiNDRiMTRlYjZjM2I1NTEyXzEtMS0xLTEtMTk3MTgy_2107ddb9-8f6e-4581-a9c3-7f4f279198a5">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpmZDI5ZDVmYmUwMjA0NTRjYjQ0YjE0ZWI2YzNiNTUxMi90YWJsZXJhbmdlOmZkMjlkNWZiZTAyMDQ1NGNiNDRiMTRlYjZjM2I1NTEyXzEtMy0xLTEtMTk3MTgy_d10e9ed8-4607-410c-9097-9483f3260dc2">649.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpmZDI5ZDVmYmUwMjA0NTRjYjQ0YjE0ZWI2YzNiNTUxMi90YWJsZXJhbmdlOmZkMjlkNWZiZTAyMDQ1NGNiNDRiMTRlYjZjM2I1NTEyXzEtNS0xLTEtMTk3MTgy_6199602d-5db8-4e0c-9a2a-ec95fa748080">778.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpmZDI5ZDVmYmUwMjA0NTRjYjQ0YjE0ZWI2YzNiNTUxMi90YWJsZXJhbmdlOmZkMjlkNWZiZTAyMDQ1NGNiNDRiMTRlYjZjM2I1NTEyXzEtNy0xLTEtMTk3MTgy_985ab90e-bcbd-4ba4-98c3-77a9090bcb6c">799.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpmZDI5ZDVmYmUwMjA0NTRjYjQ0YjE0ZWI2YzNiNTUxMi90YWJsZXJhbmdlOmZkMjlkNWZiZTAyMDQ1NGNiNDRiMTRlYjZjM2I1NTEyXzEtOS0xLTEtMTk3MTgy_7f207c14-1e75-40fe-815c-a7be555a9f92">765.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have converted approximately <ix:nonFraction unitRef="number" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="2" name="lly:DescriptionOfDerivativeActivityVolumePercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzMxNjc_6c4b2274-94f5-469d-9585-960b6ee02716">10</ix:nonFraction> percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. The weighted-average effective borrowing rates based on long-term debt obligations and interest rates at December&#160;31, 2022 and 2021, including the effects of interest rate swaps for hedged debt obligations, were <ix:nonFraction unitRef="number" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzM0NTc_2a6e0056-c529-4bdd-a48c-6f10d9d8ded0">2.87</ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzM0NjQ_c3bd99f0-2e18-444a-8050-415a36fabf3f">2.27</ix:nonFraction> percent, respectively.</span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="lly:ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzQwNDc_dd2564e6-d7b1-46a1-ae0a-db0afee3e57a" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments for interest on borrowings</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo4ZDVlNmNkNGQ4NDc0YmE4OTdmMGFiMzM1NjBhNDFhYy90YWJsZXJhbmdlOjhkNWU2Y2Q0ZDg0NzRiYTg5N2YwYWIzMzU2MGE0MWFjXzEtMS0xLTEtMTk3MTgy_18193880-e7af-4a12-a4a0-86bd5a6dc51b">323.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo4ZDVlNmNkNGQ4NDc0YmE4OTdmMGFiMzM1NjBhNDFhYy90YWJsZXJhbmdlOjhkNWU2Y2Q0ZDg0NzRiYTg5N2YwYWIzMzU2MGE0MWFjXzEtMy0xLTEtMTk3MTgy_fce81304-bc37-4eab-b60a-cfd223478749">338.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo4ZDVlNmNkNGQ4NDc0YmE4OTdmMGFiMzM1NjBhNDFhYy90YWJsZXJhbmdlOjhkNWU2Y2Q0ZDg0NzRiYTg5N2YwYWIzMzU2MGE0MWFjXzEtNS0xLTEtMTk3MTgy_2795e774-5f24-432e-aa97-0093ff83c2f6">345.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the requirements of derivatives and hedging guidance, the portion of our fixed-rate debt obligations that is hedged as a fair value hedge is reflected in the consolidated balance sheets as an amount equal to the sum of the debt's carrying value plus the fair value adjustment representing changes in fair value of the hedged debt attributable to movements in market interest rates subsequent to the inception of the hedge.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_127"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12: <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU1ODA_5141af1b-e8b1-4744-96a7-f8beeda1297b" continuedAt="if2a3d98cafe048bcacdb99ad15b3ade2" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="if2a3d98cafe048bcacdb99ad15b3ade2" continuedAt="i0734d938de1d425fb19c10a576e554f8"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock-based compensation expense consists of performance awards (PAs), shareholder value awards (SVAs), relative value awards (RVAs), and restricted stock units (RSUs). <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU1NTU_4d81b789-fc9d-4180-ad7c-418b102c2504" escape="true">We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, RVA, and RSU shares.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU1NDU_38f8c5c3-c1f1-432a-bf45-e92a23bf0dea" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense and the related tax benefits were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo1MzFkYTU5NzhjM2M0NmRmYjYyYmRiNGZkMWUxM2E3OC90YWJsZXJhbmdlOjUzMWRhNTk3OGMzYzQ2ZGZiNjJiZGI0ZmQxZTEzYTc4XzEtMS0xLTEtMTk3MTgy_455b81db-4837-40ea-a0de-1081012db7b9">371.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo1MzFkYTU5NzhjM2M0NmRmYjYyYmRiNGZkMWUxM2E3OC90YWJsZXJhbmdlOjUzMWRhNTk3OGMzYzQ2ZGZiNjJiZGI0ZmQxZTEzYTc4XzEtMy0xLTEtMTk3MTgy_83473a63-605d-41f7-bbf6-f042e394ab56">342.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo1MzFkYTU5NzhjM2M0NmRmYjYyYmRiNGZkMWUxM2E3OC90YWJsZXJhbmdlOjUzMWRhNTk3OGMzYzQ2ZGZiNjJiZGI0ZmQxZTEzYTc4XzEtNS0xLTEtMTk3MTgy_1945d8de-28aa-4a77-a8da-0ab098e9d83f">308.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo1MzFkYTU5NzhjM2M0NmRmYjYyYmRiNGZkMWUxM2E3OC90YWJsZXJhbmdlOjUzMWRhNTk3OGMzYzQ2ZGZiNjJiZGI0ZmQxZTEzYTc4XzItMS0xLTEtMTk3MTgy_4a0ba434-1859-4816-8058-7226777e1a00">77.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo1MzFkYTU5NzhjM2M0NmRmYjYyYmRiNGZkMWUxM2E3OC90YWJsZXJhbmdlOjUzMWRhNTk3OGMzYzQ2ZGZiNjJiZGI0ZmQxZTEzYTc4XzItMy0xLTEtMTk3MTgy_0ac609ba-c006-4b4c-abb4-a7bde9b5d688">72.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo1MzFkYTU5NzhjM2M0NmRmYjYyYmRiNGZkMWUxM2E3OC90YWJsZXJhbmdlOjUzMWRhNTk3OGMzYzQ2ZGZiNjJiZGI0ZmQxZTEzYTc4XzItNS0xLTEtMTk3MTgy_7616b937-8233-49c9-809a-ac7a1d5c5cf5">64.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, stock-based compensation awards may be granted under the 2002 Lilly Stock Plan for not more than <ix:nonFraction unitRef="shares" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzY5Ng_303b8ab7-7d81-4188-a5df-79ff0a6c378f">50.0</ix:nonFraction> million additional shares. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i0734d938de1d425fb19c10a576e554f8" continuedAt="i100100eb81e048f9b0048608ae1c3f2f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Award Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain pre-established earnings-per-share targets over a <ix:nonNumeric contextRef="i34e736a6ca514f689eb35288b8ec7b70_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU1Njc_8482784a-3cfe-46ab-ac0f-5661292c5b9b">two-year</ix:nonNumeric> period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period. The fair values of PAs granted for the years ended December&#160;31, 2022, 2021, and 2020 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i34e736a6ca514f689eb35288b8ec7b70_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzEyMTk_0f76021d-450d-4709-8b67-9f79a15bfc73">234.93</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="id89b274231544b368ef56d599d8e67f0_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzEyMjM_66b84c07-f7ed-48ff-94cb-68fc7b9e3601">198.57</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i9e110f0e24e249d59282a44ccaa3721e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzEyMzE_32f50dae-7fcf-4909-bed2-7fa5083a90b1">137.33</ix:nonFraction>, respectively. The number of shares ultimately issued for the PA program is dependent upon the EPS achieved during the vesting period. Pursuant to this program, approximately <ix:nonFraction unitRef="shares" contextRef="i34e736a6ca514f689eb35288b8ec7b70_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzE0MDk_cd2722c8-ac71-454e-8cc9-56781351acbf">0.7</ix:nonFraction> million shares, <ix:nonFraction unitRef="shares" contextRef="id89b274231544b368ef56d599d8e67f0_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzE0MjA_72bc02c0-e974-4f27-98a2-ec6a646798cd">0.7</ix:nonFraction> million shares, and <ix:nonFraction unitRef="shares" contextRef="i9e110f0e24e249d59282a44ccaa3721e_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzE0MzU_ad461756-6ce4-4de6-a130-f62edeebfd6d">1.1</ix:nonFraction>&#160;million shares were issued during the years ended December&#160;31, 2022, 2021, and 2020, respectively. Approximately <ix:nonFraction unitRef="shares" contextRef="i34e736a6ca514f689eb35288b8ec7b70_D20220101-20221231" decimals="-5" name="lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzE1MjQ_91934331-0344-468f-8c87-e275e66aa059">0.5</ix:nonFraction> million shares are expected to be issued in 2023. As of December&#160;31, 2022, the total remaining unrecognized compensation cost related to nonvested PAs was $<ix:nonFraction unitRef="usd" contextRef="ie786c6b1fada4a3dbc69ad548931dec2_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzE2NTc_401ad042-25b2-4600-a64d-248c9c7651ea">38.4</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of <ix:nonNumeric contextRef="i34e736a6ca514f689eb35288b8ec7b70_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzE3NDk_613aed05-c25c-4322-995b-5cab9b23f84b">12</ix:nonNumeric> months.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Value Award Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SVAs are granted to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on our stock price at the end of the <ix:nonNumeric contextRef="i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU1NDY_ef981db4-3297-4800-8439-b99cc4cf5317">three-year</ix:nonNumeric> vesting period compared to pre-established target stock prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="lly:SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU1NDc_cd5003e3-837d-4bbf-b1fa-9e8d8c1d9c19" continuedAt="i9127953b86e9447c9fd67f5387467f63" escape="true">The weighted-average fair values of the SVA units granted during the years ended December&#160;31, 2022, 2021, and 2020 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzI4MTg_41411bfd-7bc1-4f22-a943-b3a44555f6c0">203.88</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i03b05f63c9574af38cc3b218f3d7f04c_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzI4MjI_5404dac9-4039-4ce5-a359-931424154104">230.19</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i171e2f5cc14f445bbc2e02aa39c75b98_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzI4MzA_cf67c3c5-5e2e-487d-818a-29e94ef954d4">139.14</ix:nonFraction>, respectively, determined using the following assumptions:</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="i9127953b86e9447c9fd67f5387467f63" continuedAt="ia5c4447b17e047f5b492bd601cb74f40"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2M2MyNjA4NDJmZGI0NWRmOWRkOWUwZTVhMTVkOWUzNC90YWJsZXJhbmdlOjYzYzI2MDg0MmZkYjQ1ZGY5ZGQ5ZTBlNWExNWQ5ZTM0XzEtMS0xLTEtMTk3MTgy_431ec3fd-c8e4-4254-b397-1dd1cd9e469b">1.60</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03b05f63c9574af38cc3b218f3d7f04c_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2M2MyNjA4NDJmZGI0NWRmOWRkOWUwZTVhMTVkOWUzNC90YWJsZXJhbmdlOjYzYzI2MDg0MmZkYjQ1ZGY5ZGQ5ZTBlNWExNWQ5ZTM0XzEtMy0xLTEtMTk3MTgy_112ee0f8-101e-456b-8d93-d6e88909eb3e">2.50</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i171e2f5cc14f445bbc2e02aa39c75b98_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2M2MyNjA4NDJmZGI0NWRmOWRkOWUwZTVhMTVkOWUzNC90YWJsZXJhbmdlOjYzYzI2MDg0MmZkYjQ1ZGY5ZGQ5ZTBlNWExNWQ5ZTM0XzEtNS0xLTEtMTk3MTgy_daf78c68-2359-4438-90e9-04f92b21bfa4">2.50</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2M2MyNjA4NDJmZGI0NWRmOWRkOWUwZTVhMTVkOWUzNC90YWJsZXJhbmdlOjYzYzI2MDg0MmZkYjQ1ZGY5ZGQ5ZTBlNWExNWQ5ZTM0XzItMS0xLTEtMTk3MTgy_682c66b8-9cea-4df9-b8ce-2e337d038d61">1.57</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03b05f63c9574af38cc3b218f3d7f04c_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2M2MyNjA4NDJmZGI0NWRmOWRkOWUwZTVhMTVkOWUzNC90YWJsZXJhbmdlOjYzYzI2MDg0MmZkYjQ1ZGY5ZGQ5ZTBlNWExNWQ5ZTM0XzItMy0xLTEtMTk3MTgy_cf08521a-96b0-482d-8508-b94cad3e0d19">0.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i171e2f5cc14f445bbc2e02aa39c75b98_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2M2MyNjA4NDJmZGI0NWRmOWRkOWUwZTVhMTVkOWUzNC90YWJsZXJhbmdlOjYzYzI2MDg0MmZkYjQ1ZGY5ZGQ5ZTBlNWExNWQ5ZTM0XzItNS0xLTEtMTk3MTgy_867c038a-f980-4c9f-8106-41470b2e7951">1.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2M2MyNjA4NDJmZGI0NWRmOWRkOWUwZTVhMTVkOWUzNC90YWJsZXJhbmdlOjYzYzI2MDg0MmZkYjQ1ZGY5ZGQ5ZTBlNWExNWQ5ZTM0XzMtMS0xLTEtMTk3MTgy_5545dd84-be84-42bd-b821-fe62340b84b5">32.99</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03b05f63c9574af38cc3b218f3d7f04c_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2M2MyNjA4NDJmZGI0NWRmOWRkOWUwZTVhMTVkOWUzNC90YWJsZXJhbmdlOjYzYzI2MDg0MmZkYjQ1ZGY5ZGQ5ZTBlNWExNWQ5ZTM0XzMtMy0xLTEtMTk3MTgy_38e6f49e-11d8-4909-a3ba-26165c0c3a6d">31.42</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i171e2f5cc14f445bbc2e02aa39c75b98_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2M2MyNjA4NDJmZGI0NWRmOWRkOWUwZTVhMTVkOWUzNC90YWJsZXJhbmdlOjYzYzI2MDg0MmZkYjQ1ZGY5ZGQ5ZTBlNWExNWQ5ZTM0XzMtNS0xLTEtMTk3MTgy_8e532a67-b791-4372-b06a-77eeff14fa46">20.90</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this program, approximately <ix:nonFraction unitRef="shares" contextRef="i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzI5MzQ_6d0e7261-e6bf-4a57-bc65-b3bb870ca3e7">0.5</ix:nonFraction> million shares, <ix:nonFraction unitRef="shares" contextRef="i03b05f63c9574af38cc3b218f3d7f04c_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzI5NDU_bf0ad94d-9a79-45a9-9a7d-46f3bfd1aba7">1.0</ix:nonFraction> million shares, and <ix:nonFraction unitRef="shares" contextRef="i171e2f5cc14f445bbc2e02aa39c75b98_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzI5NjA_3f72a3f5-cc0e-49f6-ad8f-9f49599eac0b">0.8</ix:nonFraction> million shares were issued during the years ended December&#160;31, 2022, 2021, and 2020, respectively. Approximately <ix:nonFraction unitRef="shares" contextRef="i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231" decimals="-5" name="lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzMwNDk_895546e3-1c8f-4099-8ebd-8f5e753ed9bd">0.3</ix:nonFraction>&#160;million shares are expected to be issued in 2023. As of December&#160;31, 2022, the total remaining unrecognized compensation cost related to nonvested SVAs was $<ix:nonFraction unitRef="usd" contextRef="ide30b7bea6124a16bed5fd85591c653f_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzMxODM_861109a5-40fe-4d52-b23e-75b4de0b4e20">43.3</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of <ix:nonNumeric contextRef="i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzMyNzU_fa108418-48e8-4288-b35c-7cdd6d17e5f9">21</ix:nonNumeric> months.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Relative Value Award Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RVAs are granted to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on the growth of our stock price at the end of the <ix:nonNumeric contextRef="i34c6e2fee53c4d53a400e54ee5da855d_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU1NTI_4d4d217c-a901-400b-999b-eba4d01b507e">three-year</ix:nonNumeric> vesting period compared to our peers. We measure the fair value of the RVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price and our peers' stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. <ix:continuation id="ia5c4447b17e047f5b492bd601cb74f40" continuedAt="i577ee2df78f8424680d8b4919c0c9054">The weighted-average fair value of the RVA units granted during the years ended December&#160;31, 2022, 2021 and 2020 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i34c6e2fee53c4d53a400e54ee5da855d_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzQzNjk_7d4bbcf3-fe04-4027-940b-1ecff65e0fb0">230.00</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ie9f12c5407404719932a1a7e44769cdb_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzQzNzY_20decb91-f49a-4a94-920f-98d4fc49b0c0">286.71</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="ie4ee98787c674df09daac84147aa1690_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU0OTc1NTgxOTg2OA_7ea14d3b-a499-4459-95d9-19dda3d44fed">179.90</ix:nonFraction>, respectively, determined using the following assumptions:</ix:continuation></span></div><div style="margin-top:6pt"><ix:continuation id="i577ee2df78f8424680d8b4919c0c9054"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34c6e2fee53c4d53a400e54ee5da855d_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2MmJmNzJmOTQ3ZTc0NGI1ODgzYmY0MzQ1MDk3ZDY2Yy90YWJsZXJhbmdlOjYyYmY3MmY5NDdlNzQ0YjU4ODNiZjQzNDUwOTdkNjZjXzEtMS0xLTEtMTk3MTgy_03d7b4e8-de74-46b9-aee1-d6105c4715f3">1.60</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie9f12c5407404719932a1a7e44769cdb_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2MmJmNzJmOTQ3ZTc0NGI1ODgzYmY0MzQ1MDk3ZDY2Yy90YWJsZXJhbmdlOjYyYmY3MmY5NDdlNzQ0YjU4ODNiZjQzNDUwOTdkNjZjXzEtMi0xLTEtMTk3MTgy_ce4712aa-20b5-47d4-9319-9d8fa7235a61">2.50</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4ee98787c674df09daac84147aa1690_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2MmJmNzJmOTQ3ZTc0NGI1ODgzYmY0MzQ1MDk3ZDY2Yy90YWJsZXJhbmdlOjYyYmY3MmY5NDdlNzQ0YjU4ODNiZjQzNDUwOTdkNjZjXzEtMy0xLTEtMjIyNTg5_4a94eb76-3612-4ae7-a82d-be2a8b0f95f6">2.50</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34c6e2fee53c4d53a400e54ee5da855d_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2MmJmNzJmOTQ3ZTc0NGI1ODgzYmY0MzQ1MDk3ZDY2Yy90YWJsZXJhbmdlOjYyYmY3MmY5NDdlNzQ0YjU4ODNiZjQzNDUwOTdkNjZjXzItMS0xLTEtMTk3MTgy_53f0bcd8-5c0d-423f-89e0-40af55348985">1.57</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie9f12c5407404719932a1a7e44769cdb_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2MmJmNzJmOTQ3ZTc0NGI1ODgzYmY0MzQ1MDk3ZDY2Yy90YWJsZXJhbmdlOjYyYmY3MmY5NDdlNzQ0YjU4ODNiZjQzNDUwOTdkNjZjXzItMi0xLTEtMTk3MTgy_f152d5be-b261-422c-8ee3-f3b9fc133ab4">0.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4ee98787c674df09daac84147aa1690_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2MmJmNzJmOTQ3ZTc0NGI1ODgzYmY0MzQ1MDk3ZDY2Yy90YWJsZXJhbmdlOjYyYmY3MmY5NDdlNzQ0YjU4ODNiZjQzNDUwOTdkNjZjXzItMy0xLTEtMjIyNTg5_66dfa5b1-43c0-4d66-8437-00ec59e05405">1.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34c6e2fee53c4d53a400e54ee5da855d_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2MmJmNzJmOTQ3ZTc0NGI1ODgzYmY0MzQ1MDk3ZDY2Yy90YWJsZXJhbmdlOjYyYmY3MmY5NDdlNzQ0YjU4ODNiZjQzNDUwOTdkNjZjXzMtMS0xLTEtMTk3MTgy_77a3af2b-6639-451a-979e-4d68fa16d25d">32.86</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie9f12c5407404719932a1a7e44769cdb_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2MmJmNzJmOTQ3ZTc0NGI1ODgzYmY0MzQ1MDk3ZDY2Yy90YWJsZXJhbmdlOjYyYmY3MmY5NDdlNzQ0YjU4ODNiZjQzNDUwOTdkNjZjXzMtMi0xLTEtMTk3MTgy_165dd012-9f98-4a3b-962a-a1b8c4091b10">30.95</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4ee98787c674df09daac84147aa1690_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2MmJmNzJmOTQ3ZTc0NGI1ODgzYmY0MzQ1MDk3ZDY2Yy90YWJsZXJhbmdlOjYyYmY3MmY5NDdlNzQ0YjU4ODNiZjQzNDUwOTdkNjZjXzMtMy0xLTEtMjIyNTg5_c57785ed-4363-4a2b-bac5-843bd5885722">19.89</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="shares" contextRef="i34c6e2fee53c4d53a400e54ee5da855d_D20220101-20221231" decimals="-5" name="lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU0OTc1NTgxOTg4Mw_0c7a9d55-25f6-41b7-bb9d-e93fa777031e">0.1</ix:nonFraction> million shares are expected to be issued in 2023. As of December&#160;31, 2022, the total remaining unrecognized compensation cost related to nonvested RVAs was $<ix:nonFraction unitRef="usd" contextRef="if5945a2c316d46c8a331422ade10498d_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzQ1MzE_44e2bd9e-7b1b-406d-ae74-5492bf12d540">17.5</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of <ix:nonNumeric contextRef="i34c6e2fee53c4d53a400e54ee5da855d_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzQ2MjM_0e5ff744-8d1b-4536-b384-d92190004058">22</ix:nonNumeric> months.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i100100eb81e048f9b0048608ae1c3f2f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically <ix:nonNumeric contextRef="ia611d9892499421694f697dc5c368ddb_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzQ5MDk_a0bbebba-00ab-478a-838c-c10fff1e6309">three years</ix:nonNumeric>. The weighted-average fair values of RSU awards granted during the years ended December&#160;31, 2022, 2021, and 2020 were $<ix:nonFraction unitRef="usdPerShare" contextRef="ia611d9892499421694f697dc5c368ddb_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzQ5OTQ_2a640fc7-10a8-477d-9ad9-877cb53bb373">239.88</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i4c55e65384854a888970465b0818f479_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzQ5OTg_5b3d284c-e1f7-4f86-8f59-5cb5779d6409">196.30</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i27e6f36ed2b84f35a058e35522e9b351_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzUwMDY_f2de9144-5494-4d49-b6a8-c298253a89ef">135.42</ix:nonFraction>, respectively. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures. Pursuant to this program, <ix:nonFraction unitRef="shares" contextRef="ia611d9892499421694f697dc5c368ddb_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzUxNjE_e88b0e78-beb2-4369-a154-d7e8b47bc58d">1.0</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="i4c55e65384854a888970465b0818f479_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzUxNjU_6e475141-3f15-480f-894c-70abdc4a2a8f">0.7</ix:nonFraction> million, and <ix:nonFraction unitRef="shares" contextRef="i27e6f36ed2b84f35a058e35522e9b351_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzUxNzM_54cee153-7255-41eb-b91b-a74aff2b15de">1.1</ix:nonFraction> million shares were granted and approximately <ix:nonFraction unitRef="shares" contextRef="ia611d9892499421694f697dc5c368ddb_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzUyMTQ_02c81532-a5d1-47f9-986d-843e9215de95">0.8</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="i4c55e65384854a888970465b0818f479_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzUyMTg_fd839e99-69ce-4c99-8238-769821a6e2d1">0.6</ix:nonFraction> million, and <ix:nonFraction unitRef="shares" contextRef="i27e6f36ed2b84f35a058e35522e9b351_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzUyMjY_8636bd95-cde8-4710-acdf-57c0fa571522">0.6</ix:nonFraction> million shares were issued during the years ended December&#160;31, 2022, 2021, and 2020, respectively. Approximately <ix:nonFraction unitRef="shares" contextRef="ia611d9892499421694f697dc5c368ddb_D20220101-20221231" decimals="-5" name="lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzUzMTU_6eed11f0-32e5-4322-be1f-0e84eb07fb75">0.6</ix:nonFraction> million shares are expected to be issued in 2023. As of December&#160;31, 2022, the total remaining unrecognized compensation cost related to nonvested RSUs was $<ix:nonFraction unitRef="usd" contextRef="ifbf91d3e9e6846ab8570536827522ece_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU0NDk_01fdaafa-94a4-4535-b59e-2b2d542eb852">221.6</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of <ix:nonNumeric contextRef="ia611d9892499421694f697dc5c368ddb_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU1NDE_5359f1c6-95bd-4890-b59b-633ce1200623">25</ix:nonNumeric> months.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_130"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;13:&#160;<ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzEyMDQ_1202f42a-4620-4fb4-9f85-9b8d070be124" continuedAt="i4a3b83f2ae4941f99c2c2ce123bb8c71" escape="true">Shareholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i4a3b83f2ae4941f99c2c2ce123bb8c71"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, 2021, and 2020, we repurchased $<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-7" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzY5_7c62b1e3-9f2a-43fa-b17b-9700080ad39e">1.50</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-7" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2Xzcz_7348dae8-ea46-4f0c-9cd1-fccb641b220b">1.25</ix:nonFraction> billion, and $<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2Xzgx_5cb8229a-1797-4d28-8066-c0792d6f1e9b">500.0</ix:nonFraction> million, respectively, of shares associated with our share repurchase programs. As of December&#160;31, 2022, we had $<ix:nonFraction unitRef="usd" contextRef="icf5b57373be441b6bfebc18bd3f1612c_I20221231" decimals="-7" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzQzNw_af914655-3eb4-4f4b-9ba4-9348d863fa9c">3.25</ix:nonFraction> billion remaining under our $<ix:nonFraction unitRef="usd" contextRef="i15d3684123a54cc4bc7e71a64f370060_I20210531" decimals="-7" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzQ2MA_e17e9664-e40c-4c70-ac40-5756d0751e81">5.00</ix:nonFraction> billion share repurchase program that our board authorized in May 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="shares" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzQ5OA_4f6debf6-67e2-4644-828a-7a7b7941d681">5.0</ix:nonFraction> million authorized shares of preferred stock. As of December&#160;31, 2022 and 2021, <ix:nonFraction unitRef="shares" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzU1Ng_3686d610-d539-4bb0-a401-137e384b0c4c"><ix:nonFraction unitRef="shares" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzU1Ng_7c1be781-c32d-4a9c-89b4-7d0066045362">no</ix:nonFraction></ix:nonFraction> preferred stock was issued.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an employee benefit trust that held <ix:nonFraction unitRef="shares" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:CommonStockSharesHeldInEmployeeTrustShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzYzMQ_288b0258-1955-4100-bd3f-50f160ded5ba"><ix:nonFraction unitRef="shares" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:CommonStockSharesHeldInEmployeeTrustShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzYzMQ_b8ba7ef8-8e3c-47a3-8634-b9eb8e9b98ac">50.0</ix:nonFraction></ix:nonFraction> million shares of our common stock at both December&#160;31, 2022 and 2021, to provide a source of funds to assist us in meeting our obligations under various employee benefit plans. The cost basis of the shares held in the trust was $<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-7" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzgzOA_8c5277a3-22b8-4b08-a646-c208d3ae664e"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-7" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzgzOA_caf06539-d285-4855-a2b9-543e1cf737fa">3.01</ix:nonFraction></ix:nonFraction>&#160;billion at both December&#160;31, 2022 and 2021, and is shown as a reduction of shareholders' equity. Any dividend transactions between us and the trust are eliminated. Stock held by the trust is not considered outstanding in the computation of EPS. The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended December&#160;31, 2022, 2021, and 2020.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_133"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;14:&#160;<ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU1MzM_6d2ae9ba-16ab-4058-8350-8ef72d1d0599" continuedAt="i41a6f6f93eda4305b4cca5c29c90ebd6" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i41a6f6f93eda4305b4cca5c29c90ebd6" continuedAt="i56e049653dc94ceab690a01458da565c"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU1NzE_22248e20-87b9-4fda-9bf0-6e05f4a3c2d5" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Deferred taxes related to global intangible low-taxed income (GILTI) are also recognized for the future tax effects of temporary differences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position, based on its technical merits, will be sustained upon examination by the taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU1NDg_2dd83102-dcb2-4c3f-90d3-2dafe21a109f" continuedAt="i8fadaac345af4513ab13851a35e5272d" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is the composition of income tax expense:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzItMS0xLTEtMTk3MTgy_a5f0e905-3702-4bf0-865b-add720741159">2,153.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzItMy0xLTEtMTk3MTgy_3d774e5d-d390-4e64-9f07-314e05625191">938.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzItNS0xLTEtMTk3MTgy_a54da064-a06b-44d2-a810-0506e833486d">567.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzMtMS0xLTEtMTk3MTgy_b5604c23-3a17-4b69-9152-39e933d236a0">547.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzMtMy0xLTEtMTk3MTgy_2f79366e-c49c-48f7-8dba-1dc9dc6dfa76">466.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzMtNS0xLTEtMTk3MTgy_96099319-7e3f-49c2-90ee-4045be265fbd">650.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzQtMS0xLTEtMTk3MTgy_168b1a83-269d-4030-b00a-ced018f5321c">45.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzQtMy0xLTEtMTk3MTgy_5a2266fa-bdf4-4d24-b6d7-0c5330d85acd">28.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzQtNS0xLTEtMTk3MTgy_b1cd9c45-e259-472a-b114-4f6b8ca74e60">47.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzUtMS0xLTEtMTk3MTgy_a8f54d4c-526f-4a7d-b8f8-cfd0be662f67">2,746.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzUtMy0xLTEtMTk3MTgy_78425f85-d8c0-4f3b-842a-e1f87fa50cb9">1,376.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzUtNS0xLTEtMTk3MTgy_0d830a03-ac4b-4e7f-8262-ec3b4d760fed">1,170.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzctMS0xLTEtMTk3MTgy_be25a59c-2795-4a14-954c-4d34b1a8f09d">1,992.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzctMy0xLTEtMTk3MTgy_4b6fa837-b2bf-4957-8f16-cd22406d2d71">977.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzctNS0xLTEtMTk3MTgy_1e79ca39-f776-4cf6-b040-9f860b67cf43">97.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzgtMS0xLTEtMTk3MTgy_6bfd15b5-41ed-48a7-b207-6e89eaa21ea5">78.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzgtMy0xLTEtMTk3MTgy_546383f4-6f43-499e-b6f0-fbb1936a799e">174.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzgtNS0xLTEtMTk3MTgy_27a1baa1-05dd-4468-a7dc-e2c1924cd78f">16.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzktMS0xLTEtMTk3MTgy_9b325236-7a88-487c-b134-4e662e7cdaa9">114.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzktMy0xLTEtMTk3MTgy_c0eaf899-9a1c-4e6c-91c5-bf0ff60a5d8f">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzktNS0xLTEtMTk3MTgy_d8665afc-90e9-4bf9-880b-7aa6f90173c0">20.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzEwLTEtMS0xLTE5NzE4Mg_ea0ee63d-3e0d-4392-a2a1-74a08967d78b">2,185.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzEwLTMtMS0xLTE5NzE4Mg_6e0e04bf-a86e-45d2-b05f-298bda7a3156">802.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzEwLTUtMS0xLTE5NzE4Mg_e7b35468-58a0-4849-a458-6967a43a6de1">134.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzExLTEtMS0xLTE5NzE4Mg_dcf711c3-6d29-4c15-bf5c-f5712ad6d393">561.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzExLTMtMS0xLTE5NzE4Mg_339f0b33-87ad-4d9b-b2d3-9127445c753b">573.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzExLTUtMS0xLTE5NzE4Mg_74a60db4-cd2e-4e8c-83e4-e1037f5d5316">1,036.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i8fadaac345af4513ab13851a35e5272d" continuedAt="ie2376a56401941c788e514fd9bf4d21f">(1)</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="ie2376a56401941c788e514fd9bf4d21f"> The 2022, 2021, and 2020 current tax expense includes $<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0Xzg1NQ_e45b8059-7722-46e7-a5c0-d6270a026393">189.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0Xzg1OQ_2bcd7aae-99f7-4548-88a6-8d0f2093a362">64.7</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0Xzg2Nw_ffdc30c1-ce5d-4e10-8674-81021b87c59f">144.4</ix:nonFraction> million of tax benefit, respectively, from utilization of net operating loss and other tax carryforwards.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i56e049653dc94ceab690a01458da565c" continuedAt="ie79dd19206914be4a3c3bfc9ba211766"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU1NzI_720dd04f-bd22-4481-ad00-0ddb3f0560ac" escape="true"><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities as of December&#160;31 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzItMS0xLTEtMTk3MTgy_6d38977f-fcf5-45db-b5d0-53d7ee746dc1">2,071.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzItMy0xLTEtMTk3MTgy_1d31ab87-0aa4-44b2-a298-ddd20ae52c4d">2,347.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzMtMS0xLTEtMTk3MTgy_b912f230-7f9c-4f7f-ad11-7191d712c71e">427.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzMtMy0xLTEtMTk3MTgy_3e792e1f-2183-4b7c-b20c-7e70eeeb6ef5">634.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzQtMS0xLTEtMTk3MTgy_eb64902f-b205-434a-9f01-b775706a770e">477.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzQtMy0xLTEtMTk3MTgy_e9d59c69-9217-4c1e-89c1-6685e14bcfc3">463.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss and other tax carryforwards and carrybacks</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzUtMS0xLTEtMTk3MTgy_1fb4563b-ba91-48a4-8315-e2370436c7b4">626.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzUtMy0xLTEtMTk3MTgy_de0cee6d-bba6-462f-ac7f-59a3ab633075">645.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="lly:DeferredTaxAssetsSalesRebatesAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzYtMS0xLTEtMTk3MTgy_48804023-3f8e-49bb-b44e-482f6912714b">1,312.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="lly:DeferredTaxAssetsSalesRebatesAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzYtMy0xLTEtMTk3MTgy_c6526476-df14-435a-ac6d-5231e1666589">832.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Correlative tax adjustments</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="lly:DeferredTaxAssetsCorrectiveTaxAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzctMS0xLTEtMTk3MTgy_e2e3f656-e32a-46e8-b965-277eaaf83084">752.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="lly:DeferredTaxAssetsCorrectiveTaxAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzctMy0xLTEtMTk3MTgy_b0f508df-8929-4c91-904f-d24d5c1412d7">560.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax redeterminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="lly:DeferredTaxAssetsForeignTaxRedeterminations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzgtMS0xLTEtMTk3MTgy_c5b81b75-f773-415f-82d5-7dff5a309e33">267.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="lly:DeferredTaxAssetsForeignTaxRedeterminations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzgtMy0xLTEtMTk3MTgy_913db604-841f-4990-a197-2ccf81629358">274.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="lly:DeferredTaxAssetsOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzktMS0xLTEtMTk3MTgy_5cc01c6f-20fe-4c34-8574-e61aefbd891c">147.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="lly:DeferredTaxAssetsOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzktMy0xLTEtMTk3MTgy_63ae331d-72fa-4ce7-91bb-d38f36bff6a9">150.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzEwLTEtMS0xLTE5NzE4Mg_3bf8a658-33d1-451f-8792-8d57b99143e6">1,615.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzEwLTMtMS0xLTE5NzE4Mg_55ca09c0-959a-4ae8-9ebd-03ef8cfb06d8">275.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzExLTEtMS0xLTE5NzE4Mg_650e92c0-4996-498a-a085-fd734fb4ab76">361.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzExLTMtMS0xLTE5NzE4Mg_91624683-0def-461e-93e1-6b5d16db6926">477.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzEyLTEtMS0xLTE5NzE4Mg_f0c55a64-c50c-4fe0-9f1a-03ffcb59766d">8,059.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzEyLTMtMS0xLTE5NzE4Mg_1aa6cbf8-10e4-4cdc-b36e-4ad2f4eb5bf4">6,662.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowances</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzEzLTEtMS0xLTE5NzE4Mg_53dbcffd-c6e9-4cb4-8575-45f490fa1cb6">775.1</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzEzLTMtMS0xLTE5NzE4Mg_b88b000e-7740-4c75-9caf-caf957b65fb0">875.6</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE0LTEtMS0xLTE5NzE4Mg_f87ecfff-68bd-463c-9477-4e40970aeb32">7,284.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE0LTMtMS0xLTE5NzE4Mg_b5e7ea97-c3e9-42c4-b5e1-e8a2bd45da6e">5,786.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings of foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE2LTEtMS0xLTE5NzE4Mg_182244f6-eb0b-4baa-924b-4d985b54e26c">1,226.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE2LTMtMS0xLTE5NzE4Mg_01cb2149-9602-4f4f-9306-e67dbca9c67e">1,583.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE3LTEtMS0xLTE5NzE4Mg_0bd45d45-9234-4780-8869-8ff0e7a95af4">1,387.9</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE3LTMtMS0xLTE5NzE4Mg_330f02ba-dfc5-4496-8454-130d79f63793">1,516.1</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE4LTEtMS0xLTE5NzE4Mg_66a3ffbd-fbda-4a8b-bfc0-2a123478e016">639.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE4LTMtMS0xLTE5NzE4Mg_325381c8-e020-47c6-9140-0c0ac8801d4e">596.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid employee benefits</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE5LTEtMS0xLTE5NzE4Mg_9c51bd7a-d025-4bf2-a53a-5cf3ede2cbfa">546.5</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE5LTMtMS0xLTE5NzE4Mg_576a2b2a-6598-4c03-b469-69e4dd751fd2">560.6</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzIwLTEtMS0xLTE5NzE4Mg_0524af9b-8c45-4688-a91a-8e546f9f1f90">433.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzIwLTMtMS0xLTE5NzE4Mg_3a9086f1-1a92-4ddc-9ad8-b3e7adef61a9">338.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial instruments</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzIxLTEtMS0xLTE5NzE4Mg_40794f76-34af-4865-823d-ece226c4b1e8">215.0</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzIxLTMtMS0xLTE5NzE4Mg_17faf3cc-4849-4006-b949-47052a04ff78">303.0</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzIyLTEtMS0xLTE5NzE4Mg_4f9b54a8-f448-4288-8811-b857e6861660">130.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzIyLTMtMS0xLTE5NzE4Mg_bd93d91e-d432-4d04-a408-12d30cbcc84d">132.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzIzLTEtMS0xLTE5NzE4Mg_7f81c4e9-d286-43aa-9c11-3cccf0f75d29">4,579.1</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzIzLTMtMS0xLTE5NzE4Mg_a410edf4-ef91-423e-9101-87fe41f8d86c">5,030.7</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets - net</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzI0LTEtMS0xLTE5NzE4Mg_b817d386-9849-4ab1-82fe-cda7cf8695f4">2,705.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzI0LTMtMS0xLTE5NzE4Mg_fb6bcb1a-2bc3-4fd5-a3c4-ff489d3a9237">755.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred tax asset and related valuation allowance amounts for U.S. federal, international, and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, based on filed tax returns we have tax credit carryforwards and carrybacks of $<ix:nonFraction unitRef="usd" contextRef="i89d3a6dd2c454e45a2881b0daf36f171_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE0MDA_3d929d8a-00e5-4cf7-a371-ea65dc3afe17">873.6</ix:nonFraction>&#160;million available to reduce future income taxes; $<ix:nonFraction unitRef="usd" contextRef="ibac57721c29548ee93eb53c76de5151c_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE0NDQ_cab12370-e9f7-4d1f-a93c-e3724ce3d9bd">148.8</ix:nonFraction> million, if unused, will expire by 2026, and $<ix:nonFraction unitRef="usd" contextRef="i2e25213daac34fafad0267f51e54ab7e_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE0ODI_462e4f31-6052-4fa1-85b2-6c6df7d100cf">27.1</ix:nonFraction>&#160;million, if unused, will expire between 2028 and 2042. The remaining portion of the tax credit carryforwards is related to federal tax credits of $<ix:nonFraction unitRef="usd" contextRef="i652bcd633d9e4b988a731c9c680da3b1_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE2MTk_96bbdc32-3312-445d-ba45-3b510da3477d">68.6</ix:nonFraction> million, international tax credits of $<ix:nonFraction unitRef="usd" contextRef="i6b497353dce84fff8af5126132c7d5aa_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE2NTI_73af7c48-b134-4920-a4f3-5ac1f4278c87">118.6</ix:nonFraction>&#160;million, and state tax credits of $<ix:nonFraction unitRef="usd" contextRef="i8aaea1c0c5f449f78c245961a000b0ae_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE2ODE_bdbc433e-012d-4d4d-be57-b34cdf88c657">510.5</ix:nonFraction> million, all of which are fully reserved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, based on filed tax returns we had net operating losses and other carryforwards for international and U.S. federal income tax purposes of $<ix:nonFraction unitRef="usd" contextRef="i89d3a6dd2c454e45a2881b0daf36f171_I20221231" decimals="-7" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE4NjI_934023a6-bb9f-4025-80af-d9330f8edfb5">2.52</ix:nonFraction> billion: $<ix:nonFraction unitRef="usd" contextRef="i8e1fc18a41da4a52b4f290bd30b05e25_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE4NjY_89abe4f0-e347-4781-bb30-19e07e97903f">319.1</ix:nonFraction> million will expire by 2027; $<ix:nonFraction unitRef="usd" contextRef="i2e25213daac34fafad0267f51e54ab7e_I20221231" decimals="-7" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE4ODg_979e4db7-b534-4b7a-ac91-8628550a815d">1.44</ix:nonFraction>&#160;billion will expire between 2028 and 2042; and $<ix:nonFraction unitRef="usd" contextRef="i38c21f98a7ad430e92e87e091c5eebdb_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE5MjY_c3383049-a2eb-4270-851f-1d278fcde702">762.0</ix:nonFraction> million of the carryforwards will never expire. Net operating losses and other carryforwards for international and U.S. federal income tax purposes are partially reserved. Deferred tax assets related to state net operating losses and other carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i8aaea1c0c5f449f78c245961a000b0ae_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzIxNzg_01550da2-39f9-427e-91b9-33ef35e12990">246.2</ix:nonFraction>&#160;million are fully reserved as of December&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, prepaid expenses and other current assets included prepaid taxes of $<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-7" name="us-gaap:PrepaidTaxes" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU0OTc1NTgyMzgxMA_ab91e71e-da44-4982-af7e-8b160db9ecc1">2.37</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-7" name="us-gaap:PrepaidTaxes" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU0OTc1NTgyMzgxOA_42b92e87-c80f-4b86-bb38-6d1d34f714ed">1.98</ix:nonFraction> billion, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic and Puerto Rican companies contributed approximately <ix:nonFraction unitRef="number" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="2" name="lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzIyNzI_99427c49-c42f-4658-b709-2c4707949bd2">33</ix:nonFraction> percent, <ix:nonFraction unitRef="number" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="2" name="lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzIyNzY_cb80d4f3-cf94-44b9-8251-a29fda313b4c">28</ix:nonFraction> percent, and <ix:nonFraction unitRef="number" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="2" name="lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzIyODQ_33935269-e08e-4c6c-9953-85fae98d9859">39</ix:nonFraction> percent for the years ended December&#160;31, 2022, 2021, and 2020, respectively, to consolidated income before income taxes. We have a subsidiary operating in Puerto Rico under a tax incentive grant effective through the end of 2031, which was amended in 2022 to apply the alternate tax regime established by recently enacted Puerto Rico legislation starting in 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="ie79dd19206914be4a3c3bfc9ba211766" continuedAt="id6cabdd8bdf44e878e89d08e2c549007"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Substantially all of the unremitted earnings of our foreign subsidiaries are considered not to be indefinitely reinvested for continued use in our foreign operations. At December&#160;31, 2022 and 2021, we accrued an immaterial amount of foreign withholding taxes and state income taxes that would be owed upon future distributions of unremitted earnings of our foreign subsidiaries that are not indefinitely reinvested. For the amount considered to be indefinitely reinvested, it is not practicable to determine the amount of the related deferred income tax liability due to the complexities in the tax laws and assumptions we would have to make.</span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="lly:ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU1NjU_d19ca330-a5a2-4be8-8868-b3315319a2f8" continuedAt="ie89769597f684622879b6c2796be032a" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments of U.S. federal, state, and foreign income taxes, net of refunds, were as follows: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments of income taxes</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTphYmNjNWU3MmJhYTc0Y2M0OWI5N2RhN2EwMmQzZTVlYS90YWJsZXJhbmdlOmFiY2M1ZTcyYmFhNzRjYzQ5Yjk3ZGE3YTAyZDNlNWVhXzEtMS0xLTEtMTk3MTgy_5fc0ff95-a88c-4208-b7ac-1b9e5ca3a11e">2,672.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTphYmNjNWU3MmJhYTc0Y2M0OWI5N2RhN2EwMmQzZTVlYS90YWJsZXJhbmdlOmFiY2M1ZTcyYmFhNzRjYzQ5Yjk3ZGE3YTAyZDNlNWVhXzEtMy0xLTEtMTk3MTgy_75e055b4-19bf-4f2d-b942-9e70041d1b46">1,598.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTphYmNjNWU3MmJhYTc0Y2M0OWI5N2RhN2EwMmQzZTVlYS90YWJsZXJhbmdlOmFiY2M1ZTcyYmFhNzRjYzQ5Yjk3ZGE3YTAyZDNlNWVhXzEtNS0xLTEtMTk3MTgy_c24d53c8-4f63-437c-90ca-120d16613389">954.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Tax Cuts and Job Act (2017 Tax Act) was signed into law. The 2017 Tax Act included significant changes to the U.S. corporate income tax system, including a one-time repatriation transition tax (also known as the 'Toll Tax') on unremitted foreign earnings. The 2017 Tax Act provided an election to taxpayers subject to the Toll Tax to make payments over an eight-year period beginning in 2018 through 2025. <ix:continuation id="ie89769597f684622879b6c2796be032a" continuedAt="i1da2687e2ba549869a4a5eacc074dc1d">Having made this election, our future cash payments relating to the Toll Tax as of December&#160;31, 2022 are as follows:</ix:continuation></span></div><div style="margin-top:6pt"><ix:continuation id="i1da2687e2ba549869a4a5eacc074dc1d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.253%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 1 Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-3 Years</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Tax Act Toll Tax</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="lly:TaxCutAndJobsActTollTaxToBePaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTowMTQ3NmI5M2QzMDI0YTBmYTljN2E2NDhhNWRmNzEzMC90YWJsZXJhbmdlOjAxNDc2YjkzZDMwMjRhMGZhOWM3YTY0OGE1ZGY3MTMwXzEtMS0xLTEtMTk3MTgy_c8d380d6-65fa-4601-bc33-0d35b38617f5">1,895.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="lly:TaxCutAndJobsActTollTaxToBePaidWithinOneYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTowMTQ3NmI5M2QzMDI0YTBmYTljN2E2NDhhNWRmNzEzMC90YWJsZXJhbmdlOjAxNDc2YjkzZDMwMjRhMGZhOWM3YTY0OGE1ZGY3MTMwXzEtMi0xLTEtMTk3MTgy_26cc5c14-0df6-4506-83ec-760346cf7436">475.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="lly:TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTowMTQ3NmI5M2QzMDI0YTBmYTljN2E2NDhhNWRmNzEzMC90YWJsZXJhbmdlOjAxNDc2YjkzZDMwMjRhMGZhOWM3YTY0OGE1ZGY3MTMwXzEtMy0xLTEtMTk3MTgy_a32bdca8-fe8c-4538-b600-5caa6be0d089">1,420.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we have additional noncurrent income tax payables of $<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-7" name="lly:AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzM4MTQ_25abd790-52b5-42cd-821b-6f759ba99978">2.28</ix:nonFraction>&#160;billion unrelated to the Toll Tax; we cannot reasonably estimate the timing of future cash outflows associated with these liabilities. </span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU1Mzg_06922e5c-362b-45ff-8d5e-661b50ca79ed" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a reconciliation of the consolidated income tax expense applying the U.S. federal statutory rate to income before income taxes to reported consolidated income tax expense: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at the U.S. federal statutory tax rate</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzEtMS0xLTEtMTk3MTgy_7d543451-d616-4f8f-ab10-c03e40e8d013">1,429.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzEtMy0xLTEtMTk3MTgy_e2fa7bea-3b34-4314-b9cf-13f563da3b46">1,292.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzEtNS0xLTEtMTk3MTgy_1558863d-394d-42d9-b729-5296aec13ef5">1,518.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add (deduct):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations, including Puerto Rico</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzMtMS0xLTEtMTk3MTgy_92192ea9-eddf-44ce-880e-bcee11fe83f8">299.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzMtMy0xLTEtMTk3MTgy_fcc5fcd6-714d-49cf-8a54-419227d787fb">447.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzMtNS0xLTEtMTk3MTgy_850113f7-70ea-4a16-b2d5-9effba0627a3">297.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzQtMS0xLTEtMTk3MTgy_84f07be6-3772-439b-8a5e-40a20c717462">155.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzQtMy0xLTEtMTk3MTgy_92c59063-8367-4ffc-814c-60c9b7cf3047">100.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzQtNS0xLTEtMTk3MTgy_f8d8b566-112f-43ea-a458-6a7e1dfddc34">97.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzUtMS0xLTEtMTk3MTgy_32a389f7-56e7-45ea-9b15-1526c3b823b2">287.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzUtMy0xLTEtMTk3MTgy_4bbd0679-f3fe-443d-ab70-6698a230bb9f">86.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzUtNS0xLTEtMTk3MTgy_30c0c2bb-1314-4de8-b062-9c57b51242d2">71.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance release</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzctMS0xLTEtMjM5ODg4_24e4aef5-1004-45db-ad97-a979cf7912c5">116.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzctMy0xLTEtMjM5ODk1_ac5938ea-d0e1-4711-b72b-06828c4824ec">19.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzctNS0xLTEtMjM5OTAy_e21432ad-fcf6-488e-91a6-36bd288a3d31">10.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzctMS0xLTEtMTk3MTgy_8fc96519-1d6f-475a-8726-d297f9c154d0">9.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzctMy0xLTEtMTk3MTgy_1a4932fe-a480-4ee4-a26c-a770ed2b898d">65.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzctNS0xLTEtMTk3MTgy_a5482f00-5a64-4d38-8a25-edd594eb5949">5.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzgtMS0xLTEtMTk3MTgy_7a139c4b-37c4-4675-85ce-f4d31712e244">561.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzgtMy0xLTEtMTk3MTgy_96616586-ee43-4d10-abb9-6dea0f8e715d">573.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzgtNS0xLTEtMTk3MTgy_4737c0d1-dbe6-45fa-889b-091fbf2c12d3">1,036.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes the impact of Puerto Rico Excise Tax, GILTI tax, and other U.S. taxation of foreign income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU1NzQ_b5ae453e-78c7-43b1-b583-2f5deaa8dbd0" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January&#160;1</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzEtMS0xLTEtMTk3MTgy_06fc302e-710f-4d61-892c-9ad279ee819a">2,798.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68cf5a8007734a98a36e143a7305b0b7_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzEtMy0xLTEtMTk3MTgy_255caf34-ae26-4f8f-a1d7-0378242e39cf">2,551.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib66e8131e7a64596bd768a5869bc86ab_I20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzEtNS0xLTEtMTk3MTgy_ab0ea722-fc64-47f8-9db4-e3c05cd72337">2,108.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzItMS0xLTEtMTk3MTgy_dee4533e-3db5-4eb6-8d8f-23a6938f0acf">274.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzItMy0xLTEtMTk3MTgy_a5168d71-0de1-48a4-8e9f-bd88f8c4548f">310.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzItNS0xLTEtMTk3MTgy_db2dbfcc-24ba-4e35-9964-04854c20f747">225.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzMtMS0xLTEtMTk3MTgy_84231711-613f-4c34-bb80-5e2b5890da6b">34.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzMtMy0xLTEtMTk3MTgy_571f3959-62fe-4023-8b43-7705421b50d8">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzMtNS0xLTEtMTk3MTgy_99000abf-333e-43e8-98bb-b5f4666fd866">310.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzQtMS0xLTEtMTk3MTgy_2404f3c0-9f29-4f21-959e-f44bee8b3d04">10.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzQtMy0xLTEtMTk3MTgy_d9faa5ab-9328-404c-b479-1cb4495bad37">8.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzQtNS0xLTEtMTk3MTgy_6bbcc308-5434-44d7-8226-30b96d9520c5">52.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzUtMS0xLTEtMTk3MTgy_70eb96d1-1457-4f64-a782-ebd6204b6491">44.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzUtMy0xLTEtMTk3MTgy_282130b9-7b6f-4898-85b1-bbd0520d72d1">38.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzUtNS0xLTEtMTk3MTgy_0f006587-ca6c-4c9f-9b07-af675ccdf61e">72.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapses of statutes of limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzYtMS0xLTEtMTk3MTgy_c46d1bd6-5af8-40fc-8411-36ee6aa98146">11.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzYtMy0xLTEtMTk3MTgy_ef3630fa-172b-4407-a802-221ae543b288">49.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzYtNS0xLTEtMTk3MTgy_40e09f24-041e-4a07-8b24-dc458a9c5aad">41.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes related to the impact of foreign currency translation</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzctMS0xLTEtMTk3MTgy_5f8938af-bdbf-4c6d-be6e-d51499ea0f5d">52.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzctMy0xLTEtMTk3MTgy_877f7599-6bb2-4611-8212-68436dab7a7b">66.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzctNS0xLTEtMTk3MTgy_d14148a4-1c43-4250-b5a8-dc0cb7545cbe">73.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzgtMS0xLTEtMTk3MTgy_41adf140-e882-4ae3-a964-8368617429d3">2,987.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzgtMy0xLTEtMTk3MTgy_05a493c6-5af3-4257-be55-2c30dc98a0e0">2,798.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68cf5a8007734a98a36e143a7305b0b7_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzgtNS0xLTEtMTk3MTgy_1334f348-feae-4338-8090-f2f0d3f4f1e7">2,551.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was $<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-7" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzQ0NDk_92bc419f-1a36-43b9-b462-5a50531e5d0f"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-7" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzQ0NDk_b0001d6b-2219-48ce-9efe-3b27c4586c6b">1.70</ix:nonFraction></ix:nonFraction>&#160;billion at both December&#160;31, 2022 and 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file U.S. federal, foreign, and various state and local income tax returns. We are no longer subject to U.S. federal income tax examination for years before 2016. In most major foreign and state jurisdictions, we are no longer subject to income tax examination for years before 2012.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="id6cabdd8bdf44e878e89d08e2c549007"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. examination of tax years 2016-2018 began in 2019 and remains ongoing. While it is reasonably possible that the Internal Revenue Service examination of these tax years could conclude within the next 12 months, final resolution of certain matters is dependent upon several factors, including the potential for formal administrative proceedings. As a result, an estimate of the range of reasonably possible changes in unrecognized tax benefits cannot be made. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to unrecognized tax benefits are recognized in income tax expense and were not material for the years ended December&#160;31, 2022, 2021, and 2020. Our accrued interest and penalties related to unrecognized tax benefits were $<ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU0OTc1NTgyMzQ2Nw_7a75d364-0423-4189-b205-25b7f91150a5">271.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU0OTc1NTgyMzQ4NA_7b005001-e2d7-495d-8e11-ad27a0b5bc9f">220.1</ix:nonFraction>&#160;million at December&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_136"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15:&#160;<ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMTU4_be67f1be-9b56-401c-9b6b-eba600c67bea" continuedAt="i007ece0d2e8446be9ddceb09aa10ade6" escape="true">Retirement Benefits</ix:nonNumeric></span></div><ix:continuation id="i007ece0d2e8446be9ddceb09aa10ade6" continuedAt="iade34ce8929448ca91b2ff7babbb7741"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMTE1_b989eb21-4492-49b3-9bf1-3f0f36da7497" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a measurement date of December&#160;31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December&#160;31 for our defined benefit pension and retiree health benefit plans, which were as follows: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzMtMS0xLTEtMTk3MTgy_bf1ee576-2f15-4bdb-91e7-73d23ca8837d">17,565.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057f9a4808af4123bcdfdc6c3301e04b_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzMtMy0xLTEtMTk3MTgy_88fe8271-2a2a-4e19-946a-21754016d5fb">18,225.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzMtNS0xLTEtMTk3MTgy_4e4bb330-726c-4ee8-9c1a-88e092db4f59">1,663.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i125b075ff711498b8733b378408d98e3_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzMtNy0xLTEtMTk3MTgy_50fffef4-7cfe-497e-bd8a-19a4daf0aa46">1,753.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzQtMS0xLTEtMTk3MTgy_12d6bfaa-b6d8-4e3c-a02d-655480e8fc6d">351.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzQtMy0xLTEtMTk3MTgy_b1a6a6e1-24d5-457b-b0ca-111209e8d20c">369.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzQtNS0xLTEtMTk3MTgy_739aaee5-c226-4975-ab13-7a80d0257b59">46.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzQtNy0xLTEtMTk3MTgy_5d2fe00d-66d1-4dc5-92ed-02836f516415">49.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzUtMS0xLTEtMTk3MTgy_4f5fbed7-141e-4341-b274-516ea3adc153">398.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzUtMy0xLTEtMTk3MTgy_9e6b9c29-5bcc-442c-9ddc-dfb22a508ca4">337.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzUtNS0xLTEtMTk3MTgy_9c1c4fa1-2068-42e2-9338-4d69ec88c886">37.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzUtNy0xLTEtMTk3MTgy_bcd3a7a6-5054-4200-aae9-75e83aef647e">32.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzYtMS0xLTEtMTk3MTgy_7e60f945-7d8f-44b2-b5ef-49260b1c472d">4,158.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzYtMy0xLTEtMTk3MTgy_6e1d5dde-3e08-405d-8176-4573c2a31686">564.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzYtNS0xLTEtMTk3MTgy_32538041-6430-4e26-956a-b28f6df817e4">395.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzYtNy0xLTEtMTk3MTgy_bfe9e08d-1926-4728-b7db-6b77979159af">86.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzctMS0xLTEtMTk3MTgy_57afa707-3d4d-449b-88d2-65884adb7b08">608.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzctMy0xLTEtMTk3MTgy_5558f15f-2ef7-4b74-8cfe-8f13fa25312b">630.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzctNS0xLTEtMTk3MTgy_93b026d1-8c50-422b-9aa8-08da69ac7dfe">86.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzctNy0xLTEtMTk3MTgy_668488d3-db28-494c-9675-b38b74e4420d">79.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other adjustments</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzEwLTEtMS0xLTE5NzE4Mg_1c5cbcce-7728-4729-93ad-7e3a91c01d37">325.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzEwLTMtMS0xLTE5NzE4Mg_60d6aa91-d0a8-42d0-a1b0-91299ef33938">173.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzEwLTUtMS0xLTE5NzE4Mg_64bfde20-6e5b-4d07-89c1-1e2a12cf5bb8">6.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzEwLTctMS0xLTE5NzE4Mg_0bc800e4-4b31-43e2-b70e-97bad9f12b5d">6.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at end of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzExLTEtMS0xLTE5NzE4Mg_8a82db2b-d2d8-422f-80d1-9034a733323a">13,222.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzExLTMtMS0xLTE5NzE4Mg_8314bc8e-45dc-4869-a8c0-d2a7c681fb95">17,565.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzExLTUtMS0xLTE5NzE4Mg_702c6e5a-316f-4fa2-8d23-ae8d367846ff">1,258.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzExLTctMS0xLTE5NzE4Mg_950e4d5d-def4-42c8-816b-16d50948a226">1,663.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMDcx_605d959a-66c1-4443-9b1e-5a425d5aeb54" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzEtMS0xLTEtMTk3MTgy_57b46ef3-7b15-4eaa-ad10-e36cd6d68de2">16,416.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057f9a4808af4123bcdfdc6c3301e04b_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzEtMy0xLTEtMTk3MTgy_5d5f9649-08c8-431e-86d6-01145d5ea1a3">14,579.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzEtNS0xLTEtMTk3MTgy_021f9a18-13f0-4213-af86-905411484764">3,361.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i125b075ff711498b8733b378408d98e3_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzEtNy0xLTEtMTk3MTgy_848f1d75-94fc-490d-b114-02b53fa5b255">3,227.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzItMS0xLTEtMTk3MTgy_592f3b4b-5486-4cd6-a4b2-969f8ce8d013">2,388.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzItMy0xLTEtMTk3MTgy_884cbff1-58fa-4d03-aef8-813d3c07b2df">2,458.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzItNS0xLTEtMTk3MTgy_7c0dd02b-fb2a-4469-88df-e1dffa0eb50e">796.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzItNy0xLTEtMTk3MTgy_9a2880e2-1b0f-432b-81d1-80a32d149abf">202.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzMtMS0xLTEtMTk3MTgy_a0c287f4-f079-4162-8e98-bc952781263d">118.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzMtMy0xLTEtMTk3MTgy_98227f36-b9d4-4414-89f5-619ca6b067ef">131.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzMtNS0xLTEtMTk3MTgy_dd219a68-5d49-4e94-8618-90c50c3d3c91">13.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzMtNy0xLTEtMTk3MTgy_b3e7966c-537f-4615-8ed3-79b5068864f9">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzQtMS0xLTEtMTk3MTgy_f2a28af4-0ad7-41d1-813b-a2c8e513ecea">608.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzQtMy0xLTEtMTk3MTgy_39039af2-176a-47f8-a0b5-a63ab2d43f98">630.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzQtNS0xLTEtMTk3MTgy_1a4ffa21-cc1c-40e4-891a-a6459d3c88ec">86.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzQtNy0xLTEtMTk3MTgy_fd4d1f1b-d9e2-4f2d-926d-558d9bbf3f5a">79.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzUtMS0xLTEtMTk3MTgy_52d8e39b-b876-4dc3-b15a-6db748409aed">341.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzUtMy0xLTEtMTk3MTgy_6327fb4e-02a3-4297-b8f1-6ade485b611d">122.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzUtNS0xLTEtMTk3MTgy_c330b8ba-f767-40b4-bee1-b160f7a2069d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzUtNy0xLTEtMTk3MTgy_f81bcc07-31b4-42de-8e98-9cd7b2bbd1c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzYtMS0xLTEtMTk3MTgy_db506cc4-7cbc-4072-8660-382ea6868950">13,195.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzYtMy0xLTEtMTk3MTgy_785bb8cf-d801-4677-af8b-0b9b265b4994">16,416.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzYtNS0xLTEtMTk3MTgy_ae664107-8ec5-406d-a3e4-d6c4ac8e10de">2,492.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzYtNy0xLTEtMTk3MTgy_024cc0b4-312b-43ac-81dd-590cd0af86f2">3,361.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfNetFundedStatusTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMDg3_0b030c04-03a5-430f-9558-bbce09586650" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzAtMS0xLTEtMTk3MTgy_99cb8e11-7d01-4e36-b4d7-ddae04b0de05">26.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzAtMy0xLTEtMTk3MTgy_d7e1f5e9-b01d-4fa3-ac54-ba05788f62a5">1,149.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzAtNS0xLTEtMTk3MTgy_32e0c9cc-64bb-4235-9574-c2b85e6b992f">1,233.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzAtNy0xLTEtMTk3MTgy_0a4d1fe7-4cf8-4e47-ac8d-290a3caf1145">1,697.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzEtMS0xLTEtMTk3MTgy_2f5da981-b136-41c7-aae8-9fafabb5488d">2,687.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzEtMy0xLTEtMTk3MTgy_a9895707-883c-4101-adde-385e3b2dc4e7">3,908.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzEtNS0xLTEtMTk3MTgy_9c4d3dac-4aed-4761-bda4-c451934de1dd">54.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzEtNy0xLTEtMTk3MTgy_bb32eb12-bcb6-4a20-941c-91fcc91c1b92">497.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized prior service (benefit) cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzItMS0xLTEtMTk3MTgy_7cabf8b6-e8a0-4ee0-a71c-f35b050b3905">8.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzItMy0xLTEtMTk3MTgy_46efde27-fa7d-4be1-bed2-71e3eb9b6865">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzItNS0xLTEtMTk3MTgy_09461acc-1963-47bd-af09-0897956f2fdc">62.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzItNy0xLTEtMTk3MTgy_38467099-bdf9-4270-8f84-39e27252cd27">117.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzMtMS0xLTEtMTk3MTgy_4e1a05d1-a9a1-4efc-aa2d-8a0dfb76e428">2,669.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzMtMy0xLTEtMTk3MTgy_0786c1bd-ed63-4a34-b9c7-43bf960dea79">2,770.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzMtNS0xLTEtMTk3MTgy_db66744d-9afb-454a-b410-4b431670fbec">1,226.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzMtNy0xLTEtMTk3MTgy_01483b3e-fb2a-4bac-9718-6a1ca28b4e65">1,082.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMDc1_f8e4856f-8564-46a4-afcf-1b98968bad9a" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in the consolidated balance sheet consisted&#160;of:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzEtMS0xLTEtMTk3MTgy_5cc1ce73-d503-4159-8670-faed970f4fd8">1,208.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzEtMy0xLTEtMTk3MTgy_daf72767-1a6c-45b0-ba9c-691a8a27f69f">668.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzEtNS0xLTEtMTk3MTgy_772199c6-bb2f-4719-af16-9d9774aa60ed">1,383.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzEtNy0xLTEtMTk3MTgy_7ade8e2c-d207-406f-b38a-1398e6a4fbbb">1,910.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzItMS0xLTEtMTk3MTgy_1554b65d-f6c9-443b-84fa-4565bf1b7113">70.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzItMy0xLTEtMTk3MTgy_98ab0e4c-538f-43e3-a82d-8a7cb75959e2">68.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzItNS0xLTEtMTk3MTgy_bc798faa-8149-481a-a9f7-b228f2fd3bdb">8.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzItNy0xLTEtMTk3MTgy_b5d8e3e2-717a-4391-bd71-f480fdd2701b">7.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzMtMS0xLTEtMTk3MTgy_83061b7f-1ad6-4964-bc5c-a388ac12203d">1,163.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzMtMy0xLTEtMTk3MTgy_116d1570-bcbb-45cd-8155-9c99b2c655b0">1,749.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzMtNS0xLTEtMTk3MTgy_432b4137-544f-4f73-b786-2d4be3769f51">141.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzMtNy0xLTEtMTk3MTgy_22ed7b4a-f3e8-41a5-a6b0-e5b8d090948b">204.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (income) loss before income taxes</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzQtMS0xLTEtMTk3MTgy_070946e5-c1bf-4a47-9430-ca115f1b2e1f">2,695.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzQtMy0xLTEtMTk3MTgy_41ec182f-5df1-439e-8c03-e8b66f72a222">3,919.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzQtNS0xLTEtMTk3MTgy_c8bc7d40-d90a-4b67-9465-ce8078a68d0a">7.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzQtNy0xLTEtMTk3MTgy_592297e2-9f89-47c1-a3ff-6153a88c6e22">614.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzUtMS0xLTEtMTk3MTgy_72c48e17-ac61-4af4-a834-62e65adb4f94">2,669.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzUtMy0xLTEtMTk3MTgy_176b78cb-77a9-4157-bc5d-6a557507782d">2,770.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzUtNS0xLTEtMTk3MTgy_4a548e7f-7346-4a3c-84aa-e4b969c1db27">1,226.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzUtNy0xLTEtMTk3MTgy_15c31197-d86b-49c2-89e5-ad845929b965">1,082.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized net actuarial (gain) loss and unrecognized prior service (benefit) cost have not yet been recognized in net periodic pension costs and were included in accumulated other comprehensive loss at December&#160;31, 2022 and 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="iade34ce8929448ca91b2ff7babbb7741" continuedAt="ifea7aafbdd0f4c0ea40fc832f74e76f3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-7" sign="-" name="us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzU1Mw_dc91daff-f323-4021-affd-b650eb4b0a84">4.75</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzU0OTc1NTgyNTU1NA_8e4f4607-c726-4a40-8633-e5d45c9a4a3a">750.4</ix:nonFraction>&#160;million declines in benefit obligation in 2022 and 2021, respectively, were both driven primarily by increases in the discount rates.</span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMTU1_ad8a4d6a-f62e-4d11-96e9-95f232bc2dc1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents our weighted-average assumptions as of December&#160;31:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate for benefit obligation</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzItMS0xLTEtMTk3MTgy_84e161e8-4e9e-4dd6-aafb-7119be178831">5.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzItMy0xLTEtMTk3MTgy_cb613400-f6d5-47ed-92cf-0caa3ea0d9af">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i057f9a4808af4123bcdfdc6c3301e04b_I20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzItNS0xLTEtMTk3MTgy_1b4329eb-87cd-402d-9485-0566e124dc75">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzItNy0xLTEtMTk3MTgy_508748df-a890-44d5-8104-6ffb020eb9be">5.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzItOS0xLTEtMTk3MTgy_3212120a-92f5-49c7-9c26-98a551580c5d">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i125b075ff711498b8733b378408d98e3_I20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzItMTEtMS0xLTE5NzE4Mg_9b92a764-3c45-4fbe-a357-99c16b9a4e30">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate for net benefit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzMtMS0xLTEtMTk3MTgy_7c60c45e-f379-4579-a8ee-17c6fabcffde">2.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzMtMy0xLTEtMTk3MTgy_056c9228-1b9a-4fa4-85db-9676e0ef7bf1">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzMtNS0xLTEtMTk3MTgy_e1b08405-acf1-4287-93b6-f77b6b050fed">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzMtNy0xLTEtMTk3MTgy_66a3e20d-7ff2-428f-81e0-0dfae58dcd44">3.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzMtOS0xLTEtMTk3MTgy_f3f7733f-2b10-4897-bca6-c711d6035022">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzMtMTEtMS0xLTE5NzE4Mg_b3cf5f09-d534-4d54-aab3-b67692b066ff">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase for benefit obligation</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzQtMS0xLTEtMTk3MTgy_4bfaab60-a44c-435c-8942-1ee27324f6bc">4.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzQtMy0xLTEtMTk3MTgy_caab7a89-4c1e-4c35-8963-221ba8f3c4aa">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i057f9a4808af4123bcdfdc6c3301e04b_I20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzQtNS0xLTEtMTk3MTgy_192be767-d891-4ecd-b6ab-74686980c23b">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase for net benefit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzUtMS0xLTEtMTk3MTgy_98e97432-88c1-46e6-8b15-5920f9d81b22">3.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzUtMy0xLTEtMTk3MTgy_05a4de09-6179-4057-b232-343cf11a30a4">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzUtNS0xLTEtMTk3MTgy_6f7da3a2-b115-4eee-a30d-c43d96a1975d">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets for net benefit costs</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzYtMS0xLTEtMTk3MTgy_fa50eaa7-d80f-422f-bac5-894df9c33fb4">8.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzYtMy0xLTEtMTk3MTgy_8bd77c48-0894-4a7b-b11e-1dd8ae241a4f">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzYtNS0xLTEtMTk3MTgy_679b995c-efa6-4a5d-a319-83cb108e3bf9">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzYtNy0xLTEtMTk3MTgy_ee260a60-bc7a-4e59-9be9-1fdf4b4e13ad">7.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzYtOS0xLTEtMTk3MTgy_633b7fc2-f558-455a-b4d9-b53b3d1cf43b">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzYtMTEtMS0xLTE5NzE4Mg_a40ecdf6-c376-43e7-8631-9e3285809d4d">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We annually evaluate the expected return on plan assets in our defined benefit pension and retiree health benefit plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the design of our retiree health benefit plans, healthcare-cost trend rates do not have a material impact on our financial condition or results of operations.</span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMTU3_d3e7271a-a53e-4e41-a112-c777101d2fe8" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028-2032</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension plans</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzEtMS0xLTEtMTk3MTgy_6d0d05c2-081a-4466-9a0d-276f81b96dea">648.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzEtMy0xLTEtMTk3MTgy_f9073af4-b9e7-402b-b6c1-a6bc69236d9d">664.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzEtNS0xLTEtMTk3MTgy_b80e52bc-2a34-471b-aa8c-7519282b19b7">682.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzEtNy0xLTEtMTk3MTgy_39ad17bd-fed8-4288-a49c-9c2df5eb596c">705.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzEtOS0xLTEtMTk3MTgy_53d000f9-7fb0-4cb1-bf2d-83bfc5332f92">732.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzEtMTEtMS0xLTE5NzE4Mg_0d22029f-11a6-41d8-a7b5-061d10ea491b">4,079.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retiree health benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzItMS0xLTEtMTk3MTgy_7356fb87-5ce6-4bf1-a53a-ac1088308b7a">89.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzItMy0xLTEtMTk3MTgy_14d4d1b6-cf38-453c-b0ec-504350b26312">91.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzItNS0xLTEtMTk3MTgy_18b93a23-60cd-44de-9d47-937947c58158">92.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzItNy0xLTEtMTk3MTgy_8c1370fe-4122-46e9-b219-846b015061bb">92.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzItOS0xLTEtMTk3MTgy_8635af79-1867-4a2d-92cd-a3b587cf24d2">93.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzItMTEtMS0xLTE5NzE4Mg_200eacd9-8c4a-402d-b666-3a45f3d660fa">468.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMTQz_e0bab24a-46c0-4680-91d9-6a437ba6e3e1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyZDM3MDNmNTNjYzk0NzhjYjdhYTE3N2Y1N2MzN2IwYS90YWJsZXJhbmdlOjJkMzcwM2Y1M2NjOTQ3OGNiN2FhMTc3ZjU3YzM3YjBhXzEtMS0xLTEtMTk3MTgy_8200f237-7e4a-4fce-a171-c1717a7cfb7e">2,211.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyZDM3MDNmNTNjYzk0NzhjYjdhYTE3N2Y1N2MzN2IwYS90YWJsZXJhbmdlOjJkMzcwM2Y1M2NjOTQ3OGNiN2FhMTc3ZjU3YzM3YjBhXzEtMy0xLTEtMTk3MTgy_cf5ba576-66e3-4fe1-b7c4-f43a892407e5">3,360.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife049f03c96e47288db50605b1356b32_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyZDM3MDNmNTNjYzk0NzhjYjdhYTE3N2Y1N2MzN2IwYS90YWJsZXJhbmdlOjJkMzcwM2Y1M2NjOTQ3OGNiN2FhMTc3ZjU3YzM3YjBhXzItMS0xLTEtMTk3MTgy_de6cb23c-4f2b-478f-94b9-f44e79d2aa5f">977.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyZDM3MDNmNTNjYzk0NzhjYjdhYTE3N2Y1N2MzN2IwYS90YWJsZXJhbmdlOjJkMzcwM2Y1M2NjOTQ3OGNiN2FhMTc3ZjU3YzM3YjBhXzItMy0xLTEtMTk3MTgy_93a9aa5e-fa4f-4dd4-abd0-6f76f7081dd1">1,542.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMDc2_c503ca8f-3505-44cd-9f33-043b1f1682af" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health <br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpjOWFjMTc5ZjU2OTg0MDM0YmZmYjZkYmNlYjk3MDRlZC90YWJsZXJhbmdlOmM5YWMxNzlmNTY5ODQwMzRiZmZiNmRiY2ViOTcwNGVkXzItMS0xLTEtMTk3MTgy_f2fb5161-ac19-4d4f-a81b-f4c208e3a87b">1,721.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpjOWFjMTc5ZjU2OTg0MDM0YmZmYjZkYmNlYjk3MDRlZC90YWJsZXJhbmdlOmM5YWMxNzlmNTY5ODQwMzRiZmZiNmRiY2ViOTcwNGVkXzItMy0xLTEtMTk3MTgy_baeee77b-a77e-4c93-b594-649c7f431728">2,532.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpjOWFjMTc5ZjU2OTg0MDM0YmZmYjZkYmNlYjk3MDRlZC90YWJsZXJhbmdlOmM5YWMxNzlmNTY5ODQwMzRiZmZiNmRiY2ViOTcwNGVkXzItNS0xLTEtMTk3MTgy_17e044f3-0acf-4f85-93c1-0159a7902c16">149.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpjOWFjMTc5ZjU2OTg0MDM0YmZmYjZkYmNlYjk3MDRlZC90YWJsZXJhbmdlOmM5YWMxNzlmNTY5ODQwMzRiZmZiNmRiY2ViOTcwNGVkXzItNy0xLTEtMTk3MTgy_f86ba389-cceb-4455-8a3a-fcb96915e274">212.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpjOWFjMTc5ZjU2OTg0MDM0YmZmYjZkYmNlYjk3MDRlZC90YWJsZXJhbmdlOmM5YWMxNzlmNTY5ODQwMzRiZmZiNmRiY2ViOTcwNGVkXzMtMS0xLTEtMTk3MTgy_686476c1-50c3-4093-b02f-d1e1e4fefcb9">652.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpjOWFjMTc5ZjU2OTg0MDM0YmZmYjZkYmNlYjk3MDRlZC90YWJsZXJhbmdlOmM5YWMxNzlmNTY5ODQwMzRiZmZiNmRiY2ViOTcwNGVkXzMtMy0xLTEtMTk3MTgy_33babdc0-d984-4b75-8e1a-119a6163be6a">973.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpjOWFjMTc5ZjU2OTg0MDM0YmZmYjZkYmNlYjk3MDRlZC90YWJsZXJhbmdlOmM5YWMxNzlmNTY5ODQwMzRiZmZiNmRiY2ViOTcwNGVkXzMtNS0xLTEtMTk3MTgy_87f79d9b-94fe-4789-97a4-da160b018d56">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpjOWFjMTc5ZjU2OTg0MDM0YmZmYjZkYmNlYjk3MDRlZC90YWJsZXJhbmdlOmM5YWMxNzlmNTY5ODQwMzRiZmZiNmRiY2ViOTcwNGVkXzMtNy0xLTEtMTk3MTgy_eb7b04f3-b5f2-4957-93ab-c302f0e3ba82">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total accumulated benefit obligation for our defined benefit pension plans was $<ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-7" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzIwNDE_de75ac97-6ca7-48bd-9a40-43ee5e73c5a2">12.01</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231" decimals="-7" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzIwNDg_3cb42574-efb1-463e-b386-4e7233b94d4f">16.44</ix:nonFraction>&#160;billion at December&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="ifea7aafbdd0f4c0ea40fc832f74e76f3" continuedAt="if3392e82c9c04e8dad757cbc389133ca"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMDQ3_6735bc00-4662-4193-9658-d7ffe70aa7a7" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit expense included the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"></td><td style="width:38.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic (benefit) cost:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzMtMS0xLTEtMTk3MTgy_5112051b-2529-4bab-b8ec-c1e8cbd644ff">351.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzMtMy0xLTEtMTk3MTgy_e981b6d0-a7b7-43a8-aa8b-c765821e8a4e">369.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzMtNS0xLTEtMTk3MTgy_87a462bf-e3ac-42de-8388-df9548d1d91a">325.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzMtNy0xLTEtMTk3MTgy_1dc937e1-c2b7-4567-b33d-b617c56efb23">46.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzMtOS0xLTEtMTk3MTgy_d3af3d2c-3d30-4f42-9b1e-0b557f6fc9b9">49.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzMtMTEtMS0xLTE5NzE4Mg_62c28252-e348-4deb-b679-467df92b53ae">40.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzQtMS0xLTEtMTk3MTgy_665b236c-db44-4bf4-8756-84591929e725">398.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzQtMy0xLTEtMTk3MTgy_94764ae4-84ae-453a-a536-eec6f28830f0">337.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzQtNS0xLTEtMTk3MTgy_c7cfc875-b85e-4c73-a4d8-494d004b77cc">425.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzQtNy0xLTEtMTk3MTgy_821e9cf9-4a15-42c6-9184-af758f2811f8">37.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzQtOS0xLTEtMTk3MTgy_48d08a41-9542-4ec5-91be-2614cd49bc4f">32.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzQtMTEtMS0xLTE5NzE4Mg_27df2783-55d1-4f47-ad90-7a0a9c82343a">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzUtMS0xLTEtMTk3MTgy_442cfb84-5bdf-424d-92c2-b1a37b18c119">947.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzUtMy0xLTEtMTk3MTgy_cda9660e-240f-493f-b6f6-73e8c0f2b9b1">949.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzUtNS0xLTEtMTk3MTgy_70e3e81d-daa7-4049-96ce-e2868252d364">901.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzUtNy0xLTEtMTk3MTgy_0854147d-1fbf-42db-a81c-83dedf53b3fb">152.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzUtOS0xLTEtMTk3MTgy_4c1ccacb-281b-41c8-8188-f9b47508606d">146.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzUtMTEtMS0xLTE5NzE4Mg_cd0006a3-8a31-4f6b-a8f7-92b8cb652151">158.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (benefit) cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzYtMS0xLTEtMTk3MTgy_d508050a-c385-428e-88b4-df7c6cc4cf39">2.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzYtMy0xLTEtMTk3MTgy_a8eb3858-9086-486e-8b8a-e4b4b671242f">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzYtNS0xLTEtMTk3MTgy_40980402-6a9c-4290-a5a4-fe16fca8ad0b">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzYtNy0xLTEtMTk3MTgy_0f60dbd3-069a-44e6-9344-ad8aaf2d257c">54.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzYtOS0xLTEtMTk3MTgy_542c5d2d-0e21-4044-b587-5bd80a59ae9e">59.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzYtMTEtMS0xLTE5NzE4Mg_fa7d99de-6cea-4fd4-8f3d-ee47f4798dc3">59.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzctMS0xLTEtMTk3MTgy_8c0d4181-87a9-4a41-ac0b-3239bdf89ff0">342.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzctMy0xLTEtMTk3MTgy_ebb44f1a-6d03-4adb-abb0-a585361c7873">487.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzctNS0xLTEtMTk3MTgy_cc9f20f4-9641-431f-ba85-08a8b32b0a79">396.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzctNy0xLTEtMTk3MTgy_5d70ee0f-89cc-41b0-8532-6ea6b01f7325">0.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzctOS0xLTEtMTk3MTgy_ad5e9d29-82eb-4a72-811a-ca0927f2e442">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzctMTEtMS0xLTE5NzE4Mg_864a3318-7e5e-4172-9837-f4671aeac84a">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzEwLTEtMS0xLTE5NzE4Mg_8d022bf3-effc-452c-b125-302c1f3dcad3">147.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzEwLTMtMS0xLTE5NzE4Mg_669272d5-7331-431f-9503-f4dfb81d8b05">249.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzEwLTUtMS0xLTE5NzE4Mg_fcf16dd2-86a1-4c9a-a13e-8e1fbbcaa47a">250.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzEwLTctMS0xLTE5NzE4Mg_3c98f622-62a8-44c8-bd81-2098f5f13007">121.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzEwLTktMS0xLTE5NzE4Mg_0e244011-e93e-47c7-8e50-b239983d54df">120.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzEwLTExLTEtMS0xOTcxODI_343bd133-b113-403e-9202-bc5b8eda7e83">136.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMTUy_98eb5e00-9f47-471c-9648-dc3a3f004c60" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents the amounts recognized in other comprehensive income (loss) for the years ended December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, and 2020:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.313%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.313%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.313%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.313%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.313%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined&#160;Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree&#160;Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss) arising during period</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzItMS0xLTEtMTk3MTgy_69c36391-0535-42ef-8f7b-9653722acf7e">823.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzItMy0xLTEtMTk3MTgy_90b2710b-57d3-4a98-88ea-8d0dbdf6d302">2,072.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzItNS0xLTEtMTk3MTgy_3723285c-2493-41e6-a76b-4d0481419089">663.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzItNy0xLTEtMTk3MTgy_a212655f-1cae-485e-aa71-ceaf115ff040">552.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzItOS0xLTEtMTk3MTgy_15bee6a3-59a7-40a2-b8f1-fb52f1f27671">142.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzItMTEtMS0xLTE5NzE4Mg_bc5d2271-2a90-4015-9047-a518d6affbb4">238.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzMtMS0xLTEtMTk3MTgy_9fac0324-249f-4bee-9bf1-561d61ecc7bb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzMtMy0xLTEtMTk3MTgy_7eb6de69-6c40-430f-b6c5-ac2b736954ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzMtNS0xLTEtMTk3MTgy_b249df60-e113-4994-adc8-594749a542e4">2.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzMtNy0xLTEtMTk3MTgy_db74c448-1a17-41f2-9a23-495c7f1efbc1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzMtOS0xLTEtMTk3MTgy_835c19db-36b3-4624-b28d-bc8161b6161c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzMtMTEtMS0xLTE5NzE4Mg_24325698-37ee-4fc3-90c6-95e5454bbd92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (benefit) cost included in net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzUtMS0xLTEtMTk3MTgy_ff6ed148-b0cc-470e-8618-3f5753db80a9">2.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzUtMy0xLTEtMTk3MTgy_de08ac5d-0bfa-4e94-9ad0-0470ef9d2187">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzUtNS0xLTEtMTk3MTgy_7b617932-cf02-4d16-a0ae-d258f15e3c22">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzUtNy0xLTEtMTk3MTgy_3829730e-63ce-4697-970f-54104f2953d9">54.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzUtOS0xLTEtMTk3MTgy_f9109c02-727c-49ef-a66b-9481ef41b4da">59.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzUtMTEtMS0xLTE5NzE4Mg_c1d4ea08-9d9f-4b7b-aa96-6cc0e2934ff4">59.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial (gain) loss included in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzYtMS0xLTEtMTk3MTgy_e6bbc0d5-db14-4e28-80f7-9e5fdad2e52b">342.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzYtMy0xLTEtMTk3MTgy_3d99b073-caae-45fb-ab28-21abbd68c453">487.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzYtNS0xLTEtMTk3MTgy_bcf6b2e0-0d68-4394-98f6-caef90a91b6e">396.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzYtNy0xLTEtMTk3MTgy_c07e0156-457d-4519-b1ac-0547befd0e29">0.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzYtOS0xLTEtMTk3MTgy_58bb94fd-2940-485c-996e-07176629934d">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzYtMTEtMS0xLTE5NzE4Mg_dcac6bd7-5b63-4c02-8d15-93828b555901">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzctMS0xLTEtMTk3MTgy_f5862a0f-d902-4a46-b1ca-c44f9f6febe9">55.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzctMy0xLTEtMTk3MTgy_dd66066d-de68-49ed-a343-da8e3d510f1f">47.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzctNS0xLTEtMTk3MTgy_912331f1-2577-499d-a7ab-3b9dccf396a0">71.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzctNy0xLTEtMTk3MTgy_a2ff6f0b-6bda-4f49-8501-58a477684d37">0.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzctOS0xLTEtMTk3MTgy_375ae293-1dac-4828-86a0-c387ba2210f5">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzctMTEtMS0xLTE5NzE4Mg_2e8aabb9-dc24-4e40-b6a9-3a96597462db">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss) during period</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzgtMS0xLTEtMTk3MTgy_1f925bc7-40d6-4117-af34-ef13d138f276">1,223.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzgtMy0xLTEtMTk3MTgy_2a6c2800-a8fd-4929-b8f8-01b92cffd37e">2,611.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzgtNS0xLTEtMTk3MTgy_0ca86bb6-3e38-4cdb-b0f6-687f41701b97">335.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzgtNy0xLTEtMTk3MTgy_5ae8d82a-1602-4e04-85d3-f17a92ec1d3c">607.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzgtOS0xLTEtMTk3MTgy_1eebfa4e-efa5-4c97-9d8d-a58e8f8f8a86">88.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzgtMTEtMS0xLTE5NzE4Mg_9dccab36-5a03-4ee5-a153-cd1a7592362f">178.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have defined contribution savings plans that cover our eligible employees worldwide. The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plans are based on employee contributions and the level of our match. Expenses under the plans totaled $<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzI2NTE_5250c117-0ad1-4d83-9cdc-109df079077d">170.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzI2NTU_cb8a3fa4-80c7-464c-961f-6c16b6f71af1">167.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzI2NjM_08a1c945-6629-49f3-9689-2d6ebe8829b1">164.3</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide certain other postemployment benefits primarily related to disability benefits and accrue for the related cost over the service lives of employees. Expenses associated with these benefit plans for the years ended December&#160;31, 2022, 2021, and 2020 were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Benefit Plan Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. U.S. and Puerto Rico plans represent approximately <ix:nonFraction unitRef="number" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="2" name="lly:DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzMyMDI_9b5bc269-bcd1-421f-92f9-db14034465a6">85</ix:nonFraction> percent of our global investments. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control, and limit concentrations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our portfolio to minimize concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="if3392e82c9c04e8dad757cbc389133ca" continuedAt="ibebb7b338f0a4ea8a1a62016ae7e38dc"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global benefit plans may enter into contractual arrangements (derivatives) to implement the local investment policy or manage particular portfolio risks. Derivatives are principally used to increase or decrease exposure to a particular public equity, fixed income, commodity, or currency market more rapidly or less expensively than could be accomplished through the use of the cash markets. The plans utilize both exchange-traded and over-the-counter instruments. The maximum exposure to either a market or counterparty credit loss is limited to the carrying value of the receivable, and is managed within contractual limits. We expect all of our counterparties to meet their obligations. The gross values of these derivative receivables and payables are not material to the global asset portfolio, and their values are reflected within the tables below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The defined benefit pension and retiree health benefit plan allocation for the U.S. and Puerto Rico currently comprises approximately <ix:nonFraction unitRef="number" contextRef="iad4ae6cfb47049b5bd782e22f164d8b3_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzQ4OTc_c3105c6d-d27a-4381-9b0d-8d343c2f061b">75</ix:nonFraction> percent growth investments and <ix:nonFraction unitRef="number" contextRef="i8a0874db15724bfb8216d84461801c57_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzQ5MjM_624252f1-14a4-4363-ae13-313892039c0c">25</ix:nonFraction> percent fixed-income investments. The growth investment allocation encompasses U.S. and international public equity securities, hedge funds, private equity-like investments, and real estate. These portfolio allocations are intended to reduce overall risk by providing diversification, while seeking moderate to high returns over the long term.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public equity securities are well diversified and invested in U.S. and international small-to-large companies across various asset managers and styles. The remaining portion of the growth portfolio is invested in private alternative investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed-income investments primarily consist of fixed-income securities in U.S. treasuries and agencies, emerging market debt obligations, corporate bonds, bank loans, mortgage-backed securities, commercial mortgage-backed obligations, and any related repurchase agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hedge funds are privately owned institutional investment funds that generally have moderate liquidity. Hedge funds seek specified levels of absolute return regardless of overall market conditions, and generally have low correlations to public equity and debt markets. Hedge funds often invest substantially in financial market instruments (stocks, bonds, commodities, currencies, derivatives, etc.) using a very broad range of trading activities to manage portfolio risks. Hedge fund strategies focus primarily on security selection and seek to be neutral with respect to market moves. Common groupings of hedge fund strategies include relative value, tactical, and event driven. Relative value strategies include arbitrage, when the same asset can simultaneously be bought and sold at different prices, achieving an immediate profit. Tactical strategies often take long and short positions to reduce or eliminate overall market risks while seeking a particular investment opportunity. Event strategy opportunities can evolve from specific company announcements such as mergers and acquisitions, and typically have little correlation to overall market directional movements. Our hedge fund investments are made through limited partnership interests in fund-of-funds structures and directly into hedge funds. Plan holdings in hedge funds are valued based on net asset values (NAVs) calculated by each fund or general partner, as applicable, and we have the ability to redeem these investments at NAV.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private equity-like investment funds typically have low liquidity and are made through long-term partnerships or joint ventures that invest in pools of capital invested in primarily non-publicly traded entities. Underlying investments include venture capital (early stage investing), buyout, special situations, private debt, and private real estate investments. Private equity management firms typically acquire and then reorganize private companies to create increased long term value. Private equity-like funds usually have a limited life of approximately 10-15 years, and require a minimum investment commitment from their limited partners. Our private equity-like investments are made both directly into funds and through fund-of-funds structures to ensure broad diversification of management styles and assets across the portfolio. Plan holdings in private equity-like investments are valued using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual audited financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Real estate is composed of public holdings. Real estate investments in registered investment companies that trade on an exchange are classified as Level 1 on the fair value hierarchy. Real estate investments in funds measured at fair value on the basis of NAV provided by the fund manager are classified as such. These NAVs are developed with inputs including discounted cash flow, independent appraisal, and market comparable analyses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets include cash and cash equivalents and mark-to-market value of derivatives.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="ibebb7b338f0a4ea8a1a62016ae7e38dc" continuedAt="i7be1a5fdee294f15bb6c2c1166bcecbf"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash value of the trust-owned insurance contract is primarily invested in investment-grade publicly traded equity and fixed-income securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than hedge funds, private equity-like investments, and a portion of the real estate holdings, which are discussed above, we determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses.</span></div><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMDU0_517ce730-0299-4e38-a230-f04380de83a1" continuedAt="i0a2ea746e14441a586607f43e7124dc9" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2022 by asset category were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:30.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices in Active Markets&#160;for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Observable&#160;<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investments Valued at Net Asset Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia316b6b7c534488da162855e12856aee_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzQtMS0xLTEtMTk3MTgy_1769a1fb-6ab5-48fd-b817-56267cef6191">1,132.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if80d17ed3d7341139c95e570648359b1_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzQtMy0xLTEtMTk3MTgy_99c73b70-c8de-4df8-ad1c-16caf6f68e9a">396.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a731db9bce5491f98e9d3db25b05e57_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzQtNS0xLTEtMTk3MTgy_e20417e2-4075-44eb-819c-a40e55957fbe">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01910d1722ed432eac20033caa81d3e8_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzQtNy0xLTEtMTk3MTgy_f17f439d-9910-4c8d-a422-4f9423affbff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib43d57949131458885d98c8a93ecc8ff_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzQtOS0xLTEtMTk3MTgy_596f8cb4-6494-4903-b1f1-fc7b05a37af1">735.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9058615b4dac4d84a46d1a194938b1d0_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzUtMS0xLTEtMTk3MTgy_f8d44f48-2430-42a1-9391-7d0fc3dff3c1">1,177.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1210e6088eb043d5b57234e2c04d5495_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzUtMy0xLTEtMTk3MTgy_0a3d50da-b253-4cfb-b840-a5935a14e20a">369.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i304ba8d5a46e4918b1388a3aa5a0d641_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzUtNS0xLTEtMTk3MTgy_e3797b6b-96a9-4fd2-a4b9-81377e9a9c2d">300.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d88291b946e4fada2d92e7be0e6c4ca_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzUtNy0xLTEtMTk3MTgy_e92831e4-f7aa-4505-ae71-fc255b45c923">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08f9dd15c5264811a0adf0cd5ddbcd70_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzUtOS0xLTEtMTk3MTgy_2b47f7db-8b14-4c6a-8cc5-76c7a9547082">506.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf36ffdc2a634608b0576bc6c10d74a6_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzctMS0xLTEtMTk3MTgy_0ca04451-c765-4bd4-8893-962acd87a60f">2,445.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67f316541574a54a1c5e224c4068a84_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzctMy0xLTEtMTk3MTgy_48e6034a-94ef-4b44-ac86-3e041a333876">19.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8597a970d914e7eac33966ec50e2e45_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzctNS0xLTEtMTk3MTgy_938947cd-0dc8-453b-86e8-f6d62955ad48">2,058.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa3bc29c31c46e9841c05765cc07cbb_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzctNy0xLTEtMTk3MTgy_8e49e0cd-8c50-4e86-bffe-5cba4f1fdef0">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f741744892048f79ba678614ab460e9_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzctOS0xLTEtMTk3MTgy_e8e7bb4c-38e6-4f7f-a571-168bd2281db2">367.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets - repurchase agreements</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id53867d3f4f742a7a401891b83a35ccf_I20221231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzgtMS0xLTEtMTk3MTgy_e15bb315-fbab-4dc5-86d1-60a63e9b6dc3">706.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8d9e90e67b644c1b7eb36d3e839d86c_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzgtMy0xLTEtMTk3MTgy_8efdfed4-8803-4887-a73d-1d9467a52db0">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63893449a2d84076a10449b426a8a463_I20221231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzgtNS0xLTEtMTk3MTgy_b493a43e-26ba-4442-b06c-950d01877c9e">713.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcb0e523afe1433d98caca75025ecee4_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzgtNy0xLTEtMTk3MTgy_8834a856-ce29-4f46-9f6e-ed5c09a9cc24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09007bccf7314e778accdfc89455e47b_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzgtOS0xLTEtMTk3MTgy_1d9e0988-418f-4d03-ab1d-00a03e8b9ee5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if606ee97c9704abab603056e8b0edf59_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzktMS0xLTEtMTk3MTgy_a2e5bb37-3c0d-40f1-9e31-26e0fba4e912">273.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabe7285b3fc24407971675b7ceb932de_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzktMy0xLTEtMTk3MTgy_2c5c0998-28cb-4e34-abdc-983062e789f5">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3749025b65a24fee9b938b61605247bd_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzktNS0xLTEtMTk3MTgy_48ae59d5-302e-481a-bbe1-cffb43ef34a1">32.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646d525b330b4affbcc9bcbad3171961_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzktNy0xLTEtMTk3MTgy_f14969f2-b52b-445a-9876-96c6a46217ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5111829abe1472899906644ebdadd1d_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzktOS0xLTEtMTk3MTgy_a243138e-436e-4e52-b28c-d57a9952708e">230.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7453fa11715a4896b1ff0f0ff5f09c00_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzExLTEtMS0xLTE5NzE4Mg_4004b510-b65e-4ce8-b69f-5fecc49a5bcd">3,249.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512f904a58b2427780f61c85d1dd6a60_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzExLTMtMS0xLTE5NzE4Mg_e3af4710-fb46-4511-96f9-818adc3f3a1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8af31081da45808fbffb31cff06d39_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzExLTUtMS0xLTE5NzE4Mg_1055ee6e-165b-4e71-9839-e84f847e1c47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97fa38adcb92459287110b63f86477a0_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzExLTctMS0xLTE5NzE4Mg_cdb33fa4-7cd3-42f4-8135-2144f8f9f3e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia76c0aca32f2426babb3ee042aaa4e38_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzExLTktMS0xLTE5NzE4Mg_2a9cb174-13a7-4836-a546-dcceca186a75">3,249.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60107ebc9335412ca6f1bd84bb68da84_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEyLTEtMS0xLTE5NzE4Mg_3ca7acf0-867c-4951-ab0e-3f62fbeb9adc">4,014.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3068b14ed0e644b6a479187e62d04177_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEyLTMtMS0xLTE5NzE4Mg_f21b4ee7-90aa-4d49-9a02-935ba5c6fce7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de112ae15004511bf9407f3cf72d975_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEyLTUtMS0xLTE5NzE4Mg_83bd14d3-73ef-4851-bd67-e945dbdc3731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09a2d55b1e1c44d2871d456003ef7230_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEyLTctMS0xLTE5NzE4Mg_29355369-c068-4a28-981b-2d5cb2a4d82c">25.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic04e46f294ce4c0fb14fa8b921ae66cc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEyLTktMS0xLTE5NzE4Mg_cd97584c-52a0-4859-854c-2aadf2eafc29">3,988.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1c27297ae64abdb64c978fa594cbaa_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEzLTEtMS0xLTE5NzE4Mg_8bcb3f71-2e65-413e-bf46-2f2ad6dffff9">349.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba64a2ba2ee54c4d8ce53c70040e9ff0_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEzLTMtMS0xLTE5NzE4Mg_8433fd1c-c48c-442d-9f70-057193518868">234.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib078fa49932d485e98c330eba8129f3c_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEzLTUtMS0xLTE5NzE4Mg_929ef952-fef3-46b8-b922-a7960591a93c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b15966785264fd6be87c35ad8b78710_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEzLTctMS0xLTE5NzE4Mg_db0ee76d-750d-4336-964c-097fc9d57d72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if24ea8f19b4a4e008be14e1cb7ea857b_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEzLTktMS0xLTE5NzE4Mg_16e60e70-f892-4b60-8804-ccc651305fbe">114.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea985983bda74c2b82efe6e81f782028_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE0LTEtMS0xLTE5NzE4Mg_86c869f8-8085-45c1-8792-54b1c0e8eea0">1,261.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6bce240b92c4b78a32086372012e86c_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE0LTMtMS0xLTE5NzE4Mg_3e0ccbe3-3b0b-473c-97f3-e31dc8b77a57">251.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9076ad0d4db44a508631c37b130697de_I20221231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE0LTUtMS0xLTE5NzE4Mg_4be98402-6826-402f-862e-d4fb225c2711">131.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe24bf9e81d43ec9e96c7d669380b3c_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE0LTctMS0xLTE5NzE4Mg_55a0a9d4-57d8-44bc-9a8c-9b9da6f8f3e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i686e8ff5c4a8496da94e3e68008b4845_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE0LTktMS0xLTE5NzE4Mg_66fbbe6f-fd3b-4c3f-99f9-861d22a61366">1,142.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE1LTEtMS0xLTE5NzE4Mg_64b8ae80-b764-438b-a83c-fda7660acef1">13,195.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343ea5fd96b643009c59bf6456fe7731_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE1LTMtMS0xLTE5NzE4Mg_81938a17-b8fd-476d-92a0-070064bb8b28">1,288.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6e300f5e5754a95992494e35bb4fad2_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE1LTUtMS0xLTE5NzE4Mg_1cb9b91b-404e-422c-9962-7b0b2fc0864e">1,546.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i580abbf76b7b4f58b638cef09a78edb0_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE1LTctMS0xLTE5NzE4Mg_5af5cb8f-b757-48f8-a849-a4fd60c848a7">25.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbf22e6860aa4abdaf439b706e4a6866_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE1LTktMS0xLTE5NzE4Mg_0852fe88-ff81-4017-87df-37a773cf309d">10,335.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc86bd5686bc4e3badb3c7e166fac6f4_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE5LTEtMS0xLTE5NzE4Mg_1d2d2bf7-958f-44f0-8c15-657c2050dd06">104.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0ff8e7d4cbb47789b98e55ac9b9b579_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE5LTMtMS0xLTE5NzE4Mg_d8c04639-d70a-4e74-8c9e-e19e51bebac2">35.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57b56107f1e043c1a3ad9569212ecacb_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE5LTUtMS0xLTE5NzE4Mg_00a8bfe0-530d-44e2-8c43-1c20091f7ce2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebe855aa68c84719bddaf01cf7d20e04_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE5LTctMS0xLTE5NzE4Mg_e9d9d184-9da8-423c-834c-0512c3f2bafc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b0a212192da4a3395f2bbeacd3c312f_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE5LTktMS0xLTE5NzE4Mg_30d2aa65-d372-4eb7-9326-92fc95e17e6b">68.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2751d7d37f4b76ad3b2e86c47f4de3_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIwLTEtMS0xLTE5NzE4Mg_6cc3b3e1-a270-45d8-a2c7-3dd208fd52bf">72.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b541896dac543b49b5eb351edb80e69_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIwLTMtMS0xLTE5NzE4Mg_0344aeaa-846d-4d07-9469-c9b3e22451f6">31.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5150947e1ab4960a30b20610ac83cff_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIwLTUtMS0xLTE5NzE4Mg_7e6b9baa-ff3a-474b-840d-fd1deabac743">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5b75e2b27940d7bb2d6260640d34c3_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIwLTctMS0xLTE5NzE4Mg_f1cd789f-a54c-4142-89d5-2635c3feb375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5a9db5d280b4dc4bfdd26c9e650a29c_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIwLTktMS0xLTE5NzE4Mg_5dacfa23-b486-4dd2-b35c-d9dd3186dd92">40.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bcf9c01534f47bea99586f19a3f1740_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIyLTEtMS0xLTE5NzE4Mg_bdfbd529-3c11-4196-bd30-d0a717662213">63.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00e53324a4a84c8dae1e489c5b3ca7f8_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIyLTMtMS0xLTE5NzE4Mg_34ec97e2-0af2-4724-a2d4-e9001f185fa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dd2dddf24274ba4b7eaca5d40b7c7db_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIyLTUtMS0xLTE5NzE4Mg_3510fee7-8839-4095-9fb4-fded06504310">63.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id68a32c29c1344a8a0b3ed2942d12fcb_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIyLTctMS0xLTE5NzE4Mg_57753d67-701b-4687-afd6-96afd20f6700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aecc4a27cff4b94aaf8df6b2ede03a1_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIyLTktMS0xLTE5NzE4Mg_5e0f6599-f19f-4ac7-aa17-8e4bcef6808b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86e7e8e7c42c482380a28afa9ecf2c76_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIzLTEtMS0xLTE5NzE4Mg_9d3e2969-78cd-4e28-abfa-708a74d405d4">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b8f63f573404294a870cfa838208b7e_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIzLTMtMS0xLTE5NzE4Mg_091da482-57e7-486b-a13c-993bfbf4e210">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe30650bfb8d48aca6dbadae71597e65_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIzLTUtMS0xLTE5NzE4Mg_71d1ee0f-3a0f-4f71-b014-01c7a2f8d003">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7950f077c83c4b968114ecde2e2b0bd4_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIzLTctMS0xLTE5NzE4Mg_33343593-3239-4743-8ad9-453f103aa901">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c5b68aaa0a4c93bc23b9644ce7ffac_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIzLTktMS0xLTE5NzE4Mg_ae3c3695-2fc0-4727-b265-1613285826ca">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d44c14ec1b4c2eac9a8389f7430791_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI1LTEtMS0xLTE5NzE4Mg_7b93a22b-2f3e-4f06-85ce-758b71a6a29e">294.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ee3659217840abbe55a716b6c7657a_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI1LTMtMS0xLTE5NzE4Mg_46af7eb7-29a5-403c-9083-bac6eeab0901">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27a0f7402b7543f39f6f976686d8a1b5_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI1LTUtMS0xLTE5NzE4Mg_72566147-3405-4cef-8d8d-b34d47b3ee39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fb865ecf4145fdb3d535b6bf576475_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI1LTctMS0xLTE5NzE4Mg_8e1e02b2-26ef-461d-a266-5c9fb8e6afde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27650537dca947bd9b29fafaf84048a2_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI1LTktMS0xLTE5NzE4Mg_aefc68b5-0082-4332-a6d3-aceb953988a0">294.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9cc9944568941598d1e56273115b999_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI2LTEtMS0xLTE5NzE4Mg_a81e23be-ee7c-4554-83ac-58abda3f044c">332.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea19db21d1f4850ad503d0164f02ee0_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI2LTMtMS0xLTE5NzE4Mg_da74579a-0c25-435f-bc54-aa0d8cd1abd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01671d18379a4457892b23355b0f63c3_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI2LTUtMS0xLTE5NzE4Mg_6cf72a87-6e34-458a-9edf-9446862b6d39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76954bb677604e0f941a30448e281a31_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI2LTctMS0xLTE5NzE4Mg_0e78e8c2-4660-49f1-a81d-83f925f399f5">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id11b13c420a14cce9b018741905d1215_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI2LTktMS0xLTE5NzE4Mg_5b39c22f-d254-4ce8-93b8-9caf570b8b5a">330.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash value of trust owned insurance contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95f60a2ff14f7a97e13a88c47f23f9_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI3LTEtMS0xLTE5NzE4Mg_9c2c5284-33f8-45f0-8a27-cbe9c1cfd917">1,470.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214c74f186244036ad65d031acecd8f4_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI3LTMtMS0xLTE5NzE4Mg_8781c1e3-e57c-4346-b4de-be2b1f18737a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61594b0a985e418eb0de58c665ee7a9b_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI3LTUtMS0xLTE5NzE4Mg_a8860a7b-7e92-46df-b664-7f2616a7a469">1,470.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8608c8404a41bc91d4b199b497742a_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI3LTctMS0xLTE5NzE4Mg_fce98fde-0d78-4ce4-986a-72115568bab5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i482b293366b34226b38b20258e4f2ad2_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI3LTktMS0xLTE5NzE4Mg_2c214d6b-f85a-442c-aeba-b351eddd77ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic00e07bcbece4f109e90289df0b99c67_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI4LTEtMS0xLTE5NzE4Mg_d37b144d-27a3-4ccb-b1b6-2718c58ad2f4">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i943b1859aecd4fa38530943834fb212b_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI4LTMtMS0xLTE5NzE4Mg_33f4032c-65f8-43ff-b10b-2119a10ca6c9">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe4715993be47369f1c27e1cf4db3cb_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI4LTUtMS0xLTE5NzE4Mg_a8100393-8411-4761-946d-8929a91b7944">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1abf4ee53847788edba9a69ea4a81f_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI4LTctMS0xLTE5NzE4Mg_a0292649-8e02-4188-9c66-b1754b31cdee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i538c50f08a0144988c39feeb3a4731aa_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI4LTktMS0xLTE5NzE4Mg_fc1e5eed-7c44-4f98-acce-d81c1b695a0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib62a4aeb2d014482b292e1b7aa806e54_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI5LTEtMS0xLTE5NzE4Mg_e52ca385-bf12-43f0-b38e-b09f5010dd3b">112.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b7b4fe31ce54233aefaaf027ce7e8ed_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI5LTMtMS0xLTE5NzE4Mg_7e961e6b-9178-4b7f-bbc5-56ea4f709a3a">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2a5ae8949b04000ac5560edc4d7e9f2_I20221231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI5LTUtMS0xLTE5NzE4Mg_eb91436c-ac70-4e5b-8ab1-eb2b474efabd">19.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfdcf6378ed942a7996ee1a9da26e09d_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI5LTctMS0xLTE5NzE4Mg_e7e2202a-df65-412c-92cd-fac8aeb50ee0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied4d313aab9b4f8e8034b9f72db4c6fc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI5LTktMS0xLTE5NzE4Mg_9abc11a2-4421-4d27-b373-9b5e246722e2">107.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzMwLTEtMS0xLTE5NzE4Mg_51edcbae-9318-4763-ad36-1ba967f97d57">2,492.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2c2d4e821d048eeaf50b62f405c3e71_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzMwLTMtMS0xLTE5NzE4Mg_d14d1f0f-a1d2-477d-a9cf-c87d437f3919">113.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ff6377b237b439999bb2d77c5a32fec_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzMwLTUtMS0xLTE5NzE4Mg_4b372dba-d0fa-4386-95e5-c708ccf296ac">1,514.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee337558500947b7a15e1c6d6b59308a_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzMwLTctMS0xLTE5NzE4Mg_7ad8ba04-19a5-44aa-906e-450a1d28b19d">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c54b0e2a7354d1ebf52c04c3b53f6d5_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzMwLTktMS0xLTE5NzE4Mg_6c1789fa-eac7-4a89-b811-0f125cee19b1">862.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December&#160;31, 2022. The activity in the Level 3 investments during the year ended December&#160;31, 2022 was not material.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i7be1a5fdee294f15bb6c2c1166bcecbf"><ix:continuation id="i0a2ea746e14441a586607f43e7124dc9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2021 by asset category were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:30.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices in Active Markets&#160;for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investments Valued at Net Asset Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib132a0af29334d8a89770179f4a4c6e3_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzQtMS0xLTEtMTk3MTgy_3fe780fd-2e0e-4e9b-95a1-11b61f8a7cb4">1,325.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20851fdc53e743b38af1e76d003c6b3a_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzQtMy0xLTEtMTk3MTgy_d75ad22b-65ae-4cef-8a8a-d3364695b710">430.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ee54330e824cfdbed0febda5250fe6_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzQtNS0xLTEtMTk3MTgy_cdef854e-18cd-4426-a5d4-8208f95c3272">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d7d1ea05ba24b2f993e48849a306d14_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzQtNy0xLTEtMTk3MTgy_796397b2-b7f1-4306-9495-5ac5b6f121a5">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bf8cce218249108f768811cdf3855e_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzQtOS0xLTEtMTk3MTgy_0f4851df-d7e3-4b10-acdc-948f6d516328">893.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c05e60f32ed4c1ca1330ed0411bd74e_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzUtMS0xLTEtMTk3MTgy_ebde7f83-9c18-47b2-89e8-a90d36438bfc">2,722.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1829f3c584ad46e09fa69d3bdf4dc092_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzUtMy0xLTEtMTk3MTgy_ad19cc14-767c-4b02-93fb-e81417438d45">815.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic042d55e713d42e19343e9d8183251f0_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzUtNS0xLTEtMTk3MTgy_53629ea2-70a5-44c2-b32a-7b17b7515644">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c88f62a561a44a69856cba4e6223aaf_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzUtNy0xLTEtMTk3MTgy_2f369900-e757-4f63-8f73-82ac954751d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebf3bab110174c6a97b925581b28f022_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzUtOS0xLTEtMTk3MTgy_3493dbb8-5a12-4234-a29e-f7bd821f335a">1,907.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c0f80e4c70a4dd7a7f479eb93de4798_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzctMS0xLTEtMTk3MTgy_e031ce60-fc44-415e-9192-010f7fb3d788">4,496.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8694353f6b5944bcbe80d4ab90db02f5_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzctMy0xLTEtMTk3MTgy_f282a80d-3dab-4733-af4b-15c1d92318c5">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6900b09ea625493ca6b4be8dd33fd73a_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzctNS0xLTEtMTk3MTgy_df90c52d-936b-4671-a11c-0d2a651f4540">3,356.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bce15f7824346e9b1c4801a21ba7d71_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzctNy0xLTEtMTk3MTgy_6becca8b-ea97-4017-96b0-ba1908aa59a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3a21ae3393e41d2ba9480eaa0b21d70_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzctOS0xLTEtMTk3MTgy_4c97157f-753e-4e42-b084-afd0349f1780">1,136.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets - repurchase agreements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if383bbdeabc347c3a143b1392643d685_I20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzgtMS0xLTEtMTk3MTgy_126fba34-b3d5-49c4-b2c9-3654df5cdf5a">1,376.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia372a081047f4dbf909c87201c2dd657_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzgtMy0xLTEtMTk3MTgy_6b0119de-cfe7-4ac6-9f90-7cd9f20827d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cccb32003004700acd3e2d5c3acc3ba_I20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzgtNS0xLTEtMTk3MTgy_d03e4c90-12ec-4a58-b1a6-1f84fe33742e">1,376.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6be538722f49cd8981ecd65c3e7940_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzgtNy0xLTEtMTk3MTgy_fa77c56b-b903-4048-bd52-edbfdaa79f0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436b8c7264ce4c04bb05b44bfd87ca82_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzgtOS0xLTEtMTk3MTgy_1d1f323e-03d3-47f1-a818-d2004a51a12a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f1e4df3ea5b421eb52a4e93ecf681d3_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzktMS0xLTEtMTk3MTgy_cb0a37b3-0ceb-4178-a810-b2a8327a5027">611.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6ac3978756e4b5fb17fbea6da4f990d_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzktMy0xLTEtMTk3MTgy_6a6976b4-4fbf-455b-bf82-3bab644efe97">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9c29a065a0846b9ac55a37fa94c8241_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzktNS0xLTEtMTk3MTgy_a10ee009-1efe-4ef0-8267-86bf3d44d82c">250.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92b5f5e714014f79bfda8cdf1d9b2a7c_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzktNy0xLTEtMTk3MTgy_341e084a-6d2f-432f-834c-609cacd6b5b5">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6c67444f0284e208beac9c4be9a2f0f_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzktOS0xLTEtMTk3MTgy_d7328384-9104-4283-877e-69e41c47f60f">349.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dee72abed824f43841304219403a584_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzExLTEtMS0xLTE5NzE4Mg_7f0e3504-b8a2-4de6-a6b5-660f1b880c99">3,046.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a95086891b14aaf917d8c2716ac3e3d_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzExLTMtMS0xLTE5NzE4Mg_5568f292-77e6-4ae2-8321-8b1a468c7ad7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42734379ac9542d89b7f72f1422d85f6_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzExLTUtMS0xLTE5NzE4Mg_17493d82-789e-4b96-90be-b450e0fa9c7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cef80ce2abe42448dfd3c31b2730530_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzExLTctMS0xLTE5NzE4Mg_593a7f83-1401-4315-ab2e-8b1a0aaee63c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i082bf7a8d7da4db2b649a2e7f798417f_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzExLTktMS0xLTE5NzE4Mg_75568ad1-9bda-4af0-8fa3-a79e1196662e">3,046.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i295f7348ee104256b1ad8f7695918565_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEyLTEtMS0xLTE5NzE4Mg_2a85b399-dd12-4ed4-9c90-802b23cf4989">3,816.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide75442ca7484565b7ece117ea2f7059_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEyLTMtMS0xLTE5NzE4Mg_3e349d59-5731-4864-a3f8-e089e3b47a1f">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b695768bf7d42a3bcd05424e7e3f801_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEyLTUtMS0xLTE5NzE4Mg_b2f98595-3450-4fcf-b194-3ad99afd6452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieda949f586eb474d94003b25eeb0028d_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEyLTctMS0xLTE5NzE4Mg_b6785422-35fe-4b66-8589-79e572addf05">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3619ec524f4266a7e63df4bffc201d_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEyLTktMS0xLTE5NzE4Mg_49d8fe16-aadb-4731-a980-4fd35b8b3e3a">3,808.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5cc405af174407082725f9ad493bde7_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEzLTEtMS0xLTE5NzE4Mg_d13f2a85-1663-40e5-a11e-8106ece03350">630.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54dba7ed180b415fabfb7905a989ee6f_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEzLTMtMS0xLTE5NzE4Mg_614b0c15-d63d-49a4-9893-1bae06e2855a">363.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0af2032243144ef284ce6407829b4dee_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEzLTUtMS0xLTE5NzE4Mg_7c23cb90-9314-4652-a837-829db632cfcd">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901ab2be4c854280b4098c1694160fde_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEzLTctMS0xLTE5NzE4Mg_7565a871-a8bd-4f5f-9717-4a46411d6b67">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f5f72c269e4e2f8f39b493b30dee70_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEzLTktMS0xLTE5NzE4Mg_2b7d0cc1-da56-4506-8e11-fb4c4c9c2b41">248.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e5fa70dfa147419df6887b95a1c72a_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE0LTEtMS0xLTE5NzE4Mg_ace2b56a-6110-46ca-bae9-ac5ef3362e05">1,143.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb10e0158e6e4678aba453d3e46e07c5_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE0LTMtMS0xLTE5NzE4Mg_fa91d45e-01e1-4cd0-9875-6d30f0832b8d">103.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a6b7ac42614433b9f0fa273ce3a0bb_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE0LTUtMS0xLTE5NzE4Mg_69d24538-8f26-42be-83d0-71565f5df0be">263.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9017de5b93e24421b9baf62ead566064_I20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE0LTctMS0xLTE5NzE4Mg_29429a27-948d-43ab-8acd-e8c8d15937b5">2.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cfc4ac7e4a54ac497e9a40c408806fb_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE0LTktMS0xLTE5NzE4Mg_a1f929d3-3283-4821-9471-cd8b23da17ec">779.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE1LTEtMS0xLTE5NzE4Mg_d0e68794-4c7c-420a-abe9-ef4286822360">16,416.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibad8ae81108d443a8d7b7c73c118e1b6_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE1LTMtMS0xLTE5NzE4Mg_4d4133cf-5c0a-4e6b-ae20-a87dadd2a192">1,728.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3788338e5f754c888353b212dd5956a7_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE1LTUtMS0xLTE5NzE4Mg_fd08c701-0e4d-4f3f-a313-6861f6893c87">2,501.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0015f68641264909839363808c4359b0_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE1LTctMS0xLTE5NzE4Mg_1e219a7d-1152-4f92-a5b8-5b0ca8a7fbd8">15.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i348b81fae8ab42de8c1879ac0c79e30c_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE1LTktMS0xLTE5NzE4Mg_82985532-b234-4aef-b634-ac5d56067a85">12,170.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia56272ad45124bdc80feb1442c60a30d_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE5LTEtMS0xLTE5NzE4Mg_63354b14-e088-463a-87d7-201d8310d6ed">124.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i757f940abbe04ca0bc0b713ee02d015c_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE5LTMtMS0xLTE5NzE4Mg_8138290e-5ca3-48f2-a0ed-6a2cf1df8fdc">40.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i345e2321a45e415d986e9e3fbe0a8b1e_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE5LTUtMS0xLTE5NzE4Mg_d26ac0f3-e226-41d9-a522-2e31e506bcd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402b1f58d5d94b2e89c8d64936db028d_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE5LTctMS0xLTE5NzE4Mg_87b5a7ad-ff57-4d80-bd47-a60e4c0a37be">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f6287de46e54474b2e7b025101c06f2_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE5LTktMS0xLTE5NzE4Mg_5210aafd-7195-4fc5-9973-9c8531f8279d">83.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifda53d5c5113486194c825c985c42f46_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIwLTEtMS0xLTE5NzE4Mg_010758f1-1c7b-4776-9363-90f03f228012">180.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227d6a2f64bb432583256bb6d486f599_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIwLTMtMS0xLTE5NzE4Mg_b642f53c-189e-4465-82a6-a4d264371b36">47.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie71f4ed1e3434f8687ea6d6c4e0184d1_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIwLTUtMS0xLTE5NzE4Mg_194e77db-86ec-4213-b990-18065ac2cc19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41aac4ca412c41fabad0761de653d3e6_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIwLTctMS0xLTE5NzE4Mg_a0b0f469-6874-48ac-a205-1ce07ef903c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibacb732d9a3e42ecb1b0d3672103ab48_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIwLTktMS0xLTE5NzE4Mg_f2d488f3-cb7a-404f-b4f5-042269bea422">132.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd0e7a73c5654d22b1fb7d1f44eec75b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIyLTEtMS0xLTE5NzE4Mg_a5df6ba9-7da6-437b-9d8b-23d13e451f0e">102.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i143d17ad6d23439bbe5839cb7f2fa3d1_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIyLTMtMS0xLTE5NzE4Mg_3c30742a-4f2e-4f86-9616-510c49e7cd47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b433b6c64f411cbf07c20ec03e6cc0_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIyLTUtMS0xLTE5NzE4Mg_e1b682c0-080e-4ced-9391-f2ba9448b892">80.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ecc36ab470d4e41be47e03d24ef4065_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIyLTctMS0xLTE5NzE4Mg_f9d47b1c-d5df-4b62-bc55-a0028f75690d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id86c9caf6218488d8edebac267e948ff_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIyLTktMS0xLTE5NzE4Mg_0e90c6ac-00a8-47fc-8365-014975541632">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbf66898d55a4866946d2c1b7d0808c5_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIzLTEtMS0xLTE5NzE4Mg_1aa51f98-f12b-4b33-9e80-6c12fbf65ec2">51.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d702f1019341bc888bc0e964569748_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIzLTMtMS0xLTE5NzE4Mg_ce29da36-aa60-4da3-9f68-ab4b6c7d3a61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa4a4b71cd744411915501b9954c7190_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIzLTUtMS0xLTE5NzE4Mg_df3afdcd-1c36-40ba-b98b-4456a00f3762">23.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i689b0515d1e94c50807ae2688713eb9a_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIzLTctMS0xLTE5NzE4Mg_10c282a1-76cb-4e77-9f2c-f595569bf59b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7475b438e64f45c889b5836a9b35767c_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIzLTktMS0xLTE5NzE4Mg_3fb5097f-1a75-4037-9f5f-90ece1d0cec6">27.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fba731405fa40f08f44c49bbce45751_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI1LTEtMS0xLTE5NzE4Mg_6adc1fd6-7bd5-4669-97fc-75baa0ac5d49">275.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad19a6d6a32c4de3b7b3d6e7f1edf524_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI1LTMtMS0xLTE5NzE4Mg_574519dc-4022-4742-ae66-ca5d7d6ec4cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie71ccfe9ea594f9b9006353fffcd6bd2_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI1LTUtMS0xLTE5NzE4Mg_b3cd12ae-0067-48f1-b074-6460e5529d2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58114e11cdf547b081755beebbfc89d2_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI1LTctMS0xLTE5NzE4Mg_b12cba7f-2546-4c88-bd58-f0a1ef794846">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c8b439a98248178a88acf2e2f0d064_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI1LTktMS0xLTE5NzE4Mg_54808306-4818-4f23-96e3-191c52c7b69f">275.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d28a152a83416bace6b87dcae9c074_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI2LTEtMS0xLTE5NzE4Mg_9c0b2662-fe1a-4e5e-a053-76bee3fb5417">317.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bb519b30c624115a193843ede27be5e_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI2LTMtMS0xLTE5NzE4Mg_9b147cd3-0e63-4be8-b348-6d28d1f60db8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if209ba23a08741c5a788dd9694d2de32_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI2LTUtMS0xLTE5NzE4Mg_0bec0b03-bf14-4b29-b331-52492661a95c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29dcd560ceb84008813877608a70d4fd_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI2LTctMS0xLTE5NzE4Mg_f4af29cc-1e08-4f6a-9f43-fc89cebc0519">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i043b55ba16e04186b3221ade43979e4b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI2LTktMS0xLTE5NzE4Mg_2a901b00-3f0c-4fa5-a1ed-77132865b882">317.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash value of trust owned insurance contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a21e55d8164183ac65c36e858f86e8_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI3LTEtMS0xLTE5NzE4Mg_d089eda3-bfc6-4dd1-ac4e-167ec9cb2296">2,166.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905bdea6d6d74e49ba3fae3f028d50c6_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI3LTMtMS0xLTE5NzE4Mg_88a1dfc7-13d0-4e87-9a08-fb3a9ae35d73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b644c98bfd4c39b72d7a1615c8880e_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI3LTUtMS0xLTE5NzE4Mg_36acf94b-831c-494a-a7cd-293b71df1727">2,166.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73e985ef58a4760a5c29be61384bb88_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI3LTctMS0xLTE5NzE4Mg_57d5b0fe-64e5-4f74-b429-e1471ca99f9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8bcd2b4b6ca476fadb8cce5fd37f874_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI3LTktMS0xLTE5NzE4Mg_b39f9353-46b1-43c7-bf91-48c63dd00b87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5e89110b5ca48398995bbf99899d921_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI4LTEtMS0xLTE5NzE4Mg_76eb7acb-9346-41df-aeb2-66c0edc49c76">36.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b9ad2ac337a4df9a8bc5ff2950a967b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI4LTMtMS0xLTE5NzE4Mg_26dcaec5-9ae3-430e-8d9f-3e84e505a0ac">34.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5967fb68324426389a6dc239fcdd98d_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI4LTUtMS0xLTE5NzE4Mg_b46cd5f5-1553-4eb5-b983-8854b7fa5a45">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i463ba1a48ccc4e9c9cb4282e58cd05a6_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI4LTctMS0xLTE5NzE4Mg_cb192205-3b00-4be0-8777-c3f5ce13d489">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i299c48115d8542b08f12325d39cefe4e_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI4LTktMS0xLTE5NzE4Mg_f15c6cc8-807d-4b1e-b115-59150e17d0e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27dc976858f044bdbd3ba64895aeb4cd_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI5LTEtMS0xLTE5NzE4Mg_ea9015e8-8ec6-4bcf-95ee-eaa0293b8858">106.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6462a3f459994819a179b58529f573e1_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI5LTMtMS0xLTE5NzE4Mg_0ec8e6f2-2b8a-440b-a20c-a03cfafe3a42">24.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic623b25c46754468b1e9528796093989_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI5LTUtMS0xLTE5NzE4Mg_5b22c3d8-6dc4-4f8a-9a35-aed2e420a5ed">18.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a1d3b46d2544213bc3eb41e5d6e128c_I20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI5LTctMS0xLTE5NzE4Mg_ce0a8f0d-111b-4eb1-98b7-bd29c5c76fd3">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5ef3078b94645859a7ca03beed57c99_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI5LTktMS0xLTE5NzE4Mg_2b49af37-1df7-4650-b8c9-8fbc30829088">63.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzMwLTEtMS0xLTE5NzE4Mg_7e61c481-6b01-4092-8112-90a4b289319e">3,361.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf76714ef18e4ce6b454dfc623ac6be7_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzMwLTMtMS0xLTE5NzE4Mg_24480fe2-ab71-4102-ab6a-d5b16ad7781e">147.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0dae23a26dd4790bdef9addc65290ef_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzMwLTUtMS0xLTE5NzE4Mg_e4e355e6-7dd8-4aaa-bce2-6cf367e11636">2,290.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i560967994b3c4feaa52141c4dad6145c_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzMwLTctMS0xLTE5NzE4Mg_ac40aef6-fd7c-4b4e-9c7c-a68c737d3efc">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b75991e2e34b09b2420ae55e962bf3_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzMwLTktMS0xLTE5NzE4Mg_cbe3103b-97dc-4636-bc13-303b24b521f5">922.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December&#160;31, 2021. The activity in the Level 3 investments during the year ended December&#160;31, 2021 was not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we expect to contribute approximately $<ix:nonFraction unitRef="usd" contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzEwODU5_561c9f06-606c-4081-ab0b-3257f0c572cb">30</ix:nonFraction> million to our defined benefit pension plans to satisfy minimum funding requirements for the year. We do not currently expect to make material discretionary contributions in 2023.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16: <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzI1NTM2_0e166893-9527-4f68-a946-3f7f10e9e112" continuedAt="i51d26d4402d64d14b5d0dd0df8ed09bd" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="i51d26d4402d64d14b5d0dd0df8ed09bd" continuedAt="i86dce5d5050e4536884b4ec679ca53e5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the final outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzI3NDg3NzkxMDIyODU_1b004409-7007-489a-babd-a885bc6b8147" continuedAt="id5f2d23a2bd0479c9d04605f875a6400" escape="true">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id5f2d23a2bd0479c9d04605f875a6400">Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Alimta European Patent Litigation</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Alimta (pemetrexed)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was protected by a patent through June 2021. A number of legal proceedings that were initiated prior to patent expiration are ongoing</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Emgality Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a named defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts seeking a ruling that various claims in <ix:nonFraction unitRef="patent" contextRef="ied91fc6d6fdd4a9db5f172426ce099f6_I20221231" decimals="INF" name="lly:LossContingencyNumberOfPatents" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzMyNzE_a0dae407-b1e4-4a4e-bd66-43f914c05863">three</ix:nonFraction> different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following a trial, in November 2022, a jury returned a verdict in favor of Teva. The parties have filed post-trial motions on which the court will rule and then enter final judgment in the case. We intend to appeal the jury verdict if necessary. Pursuant to agreement by the parties, the award, if any, will not become due until completion of the appeal process. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we were named as a defendant in a second litigation filed by Teva in the U.S. District Court for the District of Massachusetts seeking a ruling that <ix:nonFraction unitRef="patent" contextRef="iaead771b48fe47589b2c796815693940_I20210630" decimals="INF" name="lly:LossContingencyNumberOfPatents" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzM2MjI_985d6f3a-ba63-4f27-bcd8-17f39d105443">two</ix:nonFraction> of Teva's patents, which are directed toward use of the active ingredient in Emgality to treat migraine, would be infringed by our continued sales of Emgality. We challenged these <ix:nonFraction unitRef="patent" contextRef="i63382dd666fe46d0b3e154a58b6cfe75_I20221031" decimals="INF" name="lly:LossContingencyNumberOfPatents" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzE2NDkyNjc0NjcyNDg_650adb53-f904-4df1-b751-5e41bd5a2e38">two</ix:nonFraction> patents by filing requests for Inter Partes Review with the Patent Trial and Appeal Board (PTAB) and in October 2022, the PTAB granted our requests.The corresponding district court litigation is stayed while this PTAB proceeding is ongoing.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i86dce5d5050e4536884b4ec679ca53e5" continuedAt="ib2db8d44fe6048ffa045bcd18ce33ec1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Boehringer Ingelheim, our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court for the District of Delaware alleging infringement arising from submissions of Abbreviated New Drug Applications (ANDA) by a number of generic companies seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, the generic companies' ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. This litigation has been stayed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Taltz Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in May 2020, Lilly and Novartis Pharma AG (Novartis) had been litigating the validity and alleged infringement by Taltz of certain patents Novartis acquired from Genentech, Inc. (Genentech). As of October 2022, we had pending cases in Ireland, Italy, Switzerland, and the Netherlands where Novartis sought injunctions to stop Taltz commercialization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we entered into a cashless (no-payment) settlement and mutual release agreement with Novartis, which resolved such disputes. Without any admission of liability or wrongdoing, we and Novartis have agreed to mutual releases for past claims and mutual covenants not to sue the other in relation to Taltz and the patents Novartis purchased from Genentech. This matter is closed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Zyprexa Canada Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the mid-2000s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trademark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgment, thereby dismissing Apotex's case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021. In August 2022, the Court dismissed the appeal and in October 2022, Apotex appealed the decision. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Byetta&#174; Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in over <ix:nonFraction unitRef="lawsuit" contextRef="i31efe8055d7c4c549c6b4e3589629dce_I20221231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzcxODU_d33f24bd-c122-4f2c-b2e9-1ef020026dfc">500</ix:nonFraction> Byetta product liability lawsuits in the U.S. that were first initiated in March 2009 and involved over <ix:nonFraction unitRef="plaintiff" contextRef="i62bc7ea2d50e4f44a034b2205030f1c9_D20090301-20221231" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzcyOTI_56cdc529-f48f-4007-b154-72062a75aca3">800</ix:nonFraction> plaintiffs. These lawsuits have been filed in various state and federal jurisdictions, including California state court (coordinated in Los Angeles County Superior Court), and various federal courts, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. The majority of these suits contained allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer). All of the MDL and state court lawsuits have been dismissed as of January 2023 and we consider these matters closed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Proceedings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than <ix:nonFraction unitRef="site" contextRef="idb638f2256714679a5c385f7893d6fbf_I20221231" decimals="0" name="lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzk0MDI_bcd2b420-e6cf-48b4-84a5-7f38184da0e2">10</ix:nonFraction> sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="ib2db8d44fe6048ffa045bcd18ce33ec1" continuedAt="i8941c32ce50842e3a857608066f52111"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">340B Litigation and Investigations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies and HHS's Administrative Dispute Resolution regulations. We seek a declaratory judgment that the defendants violated the Administrative Procedure Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government's enforcement of the administrative dispute resolution process against us. In May 2021, HRSA notified us that it determined that our policy was contrary to the 340B statute. In response, in May 2021, we amended our complaint to bring claims related to HRSA's determination and filed a motion for preliminary injunction and temporary restraining order requesting that the U.S. District Court for the Southern District of Indiana enjoin defendants from taking any action against us relating to the 340B drug pricing program until after the court issues a final judgment on the aforementioned litigation. In May 2021, the court denied our motion for a temporary restraining order but deferred resolution of our motion for preliminary injunction. In June 2021, the defendants withdrew the HHS December 30, 2020 advisory opinion. In July 2021, the court held oral argument on the parties' cross motions for summary judgment, the defendants' motion to dismiss, and our motion for preliminary injunction related to HRSA's May 2021 enforcement letter. In October 2021, the court denied the defendants' motion to dismiss, and granted in part and denied in part the parties' cross motions for summary judgment. Both parties filed notices of appeal related to the court's summary judgment order. In October 2022, the U.S. Court of Appeals for the Seventh Circuit held oral argument. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administrative Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government's enforcement of this administrative dispute resolution process against us. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we, along with Sanofi-Aventis U.S., LLC (Sanofi), Novo Nordisk Inc. (Novo Nordisk), and AstraZeneca Pharmaceuticals LP, were named as a defendant in a purported class action lawsuit filed in the U.S. District Court for the Western District of New York by Mosaic Health, Inc. alleging antitrust and unjust enrichment claims related to the defendants' 340B distribution programs. We, with Sanofi and Novo Nordisk, filed a motion to dismiss the lawsuit, which was granted in September 2022. In October 2022, the plaintiffs filed a motion for leave to amend their complaint. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a civil investigative subpoena in February 2021 from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Branchburg Manufacturing Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received a subpoena from the U.S. Department of Justice requesting the production of certain documents relating to our manufacturing site in Branchburg, New Jersey. We are cooperating with the subpoena.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i8941c32ce50842e3a857608066f52111" continuedAt="ie6e8f59176534752a01bd63bb4449a58"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Brazil Litigation &#8211; Cosmopolis Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Labor Attorney Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a Public Civil Action brought by the Labor Public Attorney (LPA) for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, (the Labor Court) alleging possible harm to employees and former employees caused by alleged exposure to soil and groundwater contaminants at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the Labor Court judge ruled against Lilly Brasil, ordering it to undertake several remedial and compensatory actions including health coverage for a class of individuals and certain of their children. In July 2018, the appeals court (TRT) generally affirmed our appeal of the Labor Court's ruling, which included a liquidated award of <ix:nonFraction unitRef="brl" contextRef="i69662148bb09444d89587f00392b3075_D20180701-20180731" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzE0MjEy_2660306c-6228-459d-9d3f-8d23cce1e25f">300</ix:nonFraction> million Brazilian reais, which, when adjusted for inflation and the addition of pre and post judgment interest using the current Central Bank of Brazil's special system of clearance and custody rate, is approximately <ix:nonFraction unitRef="brl" contextRef="ie6e063495e83471dbc258b40a141debf_D20220101-20221231" decimals="-9" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt-sec:numwordsen" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzE0NDIz_9f350f2c-581d-4a18-9cc1-18899682a631">one</ix:nonFraction> billion Brazilian reais (approximately $<ix:nonFraction unitRef="usd" contextRef="ie6e063495e83471dbc258b40a141debf_D20220101-20221231" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzU0OTc1NTg1OTQ2Mg_29127f2b-232b-44f6-b8f0-01f46269db02">184</ix:nonFraction>&#160;million as of December&#160;31, 2022). In August 2019, Lilly Brasil filed an appeal to the superior labor court (TST) and in June 2021, the TRT published its decision on the admissibility of Lilly Brasil's appeal, allowing the majority of the elements, which were allowed to proceed in June 2021; elements not proceeding are subject to an interlocutory appeal to the TST that was filed in June 2021. In September 2019, the TRT stayed a number of elements of its trial court decision pending the determination of Lilly Brasil's appeal to the TST.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019 and September 2020, the LPA filed applications in the Labor Court for enforcement of certain remedies granted by the TRT in its July 2018 decision, requested restrictions on Lilly Brasil&#8217;s assets in Brazil, and required Lilly Brasil and Antibi&#243;ticos do Brasil Ltda. (ABL) to submit a list of potential beneficiaries of the Public Civil Action. In July 2019, the Labor Court issued a ruling requiring a freeze of Lilly Brasil&#8217;s immovable property or, alternatively, a security deposit or lien of <ix:nonFraction unitRef="brl" contextRef="iad23c8f46fec4d02b0a1bcb29a2373cb_D20190701-20190731" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzE1NDkz_b5c21ca0-ba7f-4bd3-9ccc-15038e951c94">500</ix:nonFraction> million Brazilian reais, which ruling was subsequently limited in scope and the security was reduced to <ix:nonFraction unitRef="brl" contextRef="i63ea09a048414de7b321b1ada8f7b0a4_D20210601-20210630" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzE1NTkx_9be7e67d-cd1b-4411-a485-6545804b38f4">100</ix:nonFraction> million Brazilian reais. ABL and LPA appealed the June 2021 Labor Court ruling to the TST, which appeal is under review. The Labor Court is currently assessing the status of Lilly Brasil&#8217;s and ABL&#8217;s compliance with such portion of the July 2018 TRT decision and an inspection in the industrial plant is expected. These matters are ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Individual Former Employee Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly Brasil is also named in various pending lawsuits filed in the Labor Court by individual former employees making related claims. These individual lawsuits are at various stages in the litigation process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Puerto Rico Tax Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2013, the Municipality of Carolina in Puerto Rico (Municipality) filed a lawsuit against us alleging noncompliance with respect to a contract with the Municipality and seeking a declaratory judgment. In December 2020, the Puerto Rico Appellate Court (AP) reversed the summary judgment previously granted by the Court of First Instance (CFI) in our favor, dismissing the Municipality's complaint in its entirety. The AP remanded the case to the CFI for trial on the merits. The trial began in May 2022; however, the Municipality filed a new motion requesting the CFI to award damages. The request was denied by the CFI in our favor and the Municipality filed for revision at the AP, which we opposed, staying the case. In February 2023, the AP denied the Municipality's motion for revision. This matter is ongoing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Average Manufacturer Price Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, we, along with another pharmaceutical manufacturer, were named as co-defendants in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Following a trial in August 2022, the jury returned a verdict in favor of the plaintiff. The case is proceeding with post-trial motions after which the court will enter final judgment in the case. This matter is ongoing.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="ie6e8f59176534752a01bd63bb4449a58" continuedAt="i60764f062447404b9e8faf9b85b277ca"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Health Choice Alliance </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="ie5a9f8356a0c4d9ca2c89e981a149cb5_I20221231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzE3NTk5_97fbf8f0-ab84-439f-a41c-fcb6e67dfdec">two</ix:nonFraction> lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively, for certain patient support programs related to our products Humalog, Humulin, and Forteo. The Texas state court action has been stayed. The New Jersey state court action was dismissed with prejudice pending an ongoing appeal before the Appellate Division of the New Jersey Superior Court. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pricing Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, along with Sanofi, Novo Nordisk, and in some matters certain pharmacy benefit managers, have been named in lawsuits related to insulin pricing that assert various theories, including consumer protection, fraud, false advertising, unjust enrichment, civil conspiracy, federal and state RICO statutes, deceptive trade practices, and unfair competition claims. These lawsuits include In re. Insulin Pricing Litigation, a putative consumer class action (U.S. District Court for the District of New Jersey, 2017); </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (U.S. District Court for the District of New Jersey, 2018); </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a putative class action brought by direct purchasers of insulin (U.S. District Court for the District of New Jersey, 2020), and suits brought by the State of Minnesota (U.S. District Court for the District of New Jersey, 2018), State of Kentucky (Franklin County Circuit Court, 2019), State of Mississippi (U.S. District Court for the Southern District of Mississippi, 2021), State of Arkansas (U.S. District Court for the Eastern District of Arkansas, 2022), County of Albany, New York (U.S. District Court for the Northern District of New York, 2022), State of Montana (U.S. District Court for the District of Montana, 2022), State of Kansas (U.S. District Court for the District of Kansas, 2022), State of Illinois (U.S. District Court for the Northern District of Illinois, 2022), State of California (Los Angeles County Superior Court, 2023), Jackson County, Missouri in a putative class action on behalf of Missouri counties and municipalities (Jackson County Circuit Court, 2023), and the Government of Puerto Rico (Court of First Instance Superior Court, San Juan, 2023). These lawsuits are at various stages in the litigation process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investigations, Subpoenas, and Inquiries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the pricing and sale of our insulin and other products, we have been subject to various investigations and received subpoenas, civil investigative demand requests, information requests, interrogatories, and other inquiries from various governmental entities. These include subpoenas from the New York and Vermont Attorney General Offices, civil investigative demands from the Washington, New Mexico, Colorado, Louisiana, Texas and Ohio Attorney General Offices, the U.S. Department of Justice and the U.S. Federal Trade Commission, as well as information requests from the Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada Attorney General Offices. In January 2022, the Michigan Attorney General filed a petition in Michigan state court seeking authorization to investigate Lilly for potential violations of the Michigan Consumer Protection Act (MCPA), and a complaint seeking a declaratory judgment that the Attorney General has authority to investigate Lilly's sale of insulin under the MCPA. The court authorized the proposed investigation and the issuance of civil investigative subpoenas. In April 2022, the parties entered into a stipulation providing that the State of Michigan will not issue any civil investigative subpoena to us under the MCPA until the declaratory judgment action is resolved. In July 2022, the court dismissed the case in its entirety. The Michigan Attorney General filed a notice of appeal to the Michigan Court of Appeals, which remains pending. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a request in January 2019 from the House of Representatives' Committee on Oversight and Reform seeking commercial information and business records related to the pricing of insulin products, among other issues. We also received similar requests from the Senate Finance Committee and the Senate Committee on Health, Education, Labor, and Pensions, and separate requests from the House Committee on Energy and Commerce majority and minority members. In January 2021, the Senate Finance Committee released a report summarizing the findings of its investigation. In December 2021 the House of Representatives' Committee on Oversight and Reform majority and minority staffs released separate reports with findings from their investigations into drug pricing, including of insulin products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are cooperating with all of the aforementioned investigations, subpoenas, and inquiries.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i60764f062447404b9e8faf9b85b277ca"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Research Corporation Technologies, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. In October 2021, the court issued a summary judgment decision finding in favor of RCT on certain issues, including with respect to a disputed royalty. Both parties filed motions for reconsideration, which were denied. We filed supplemental summary judgment motions. In November 2022, the court stayed proceedings so the parties can pursue mediation. A trial date has not been set. Potential damages payable under the litigation, if finally awarded after an appeal, could be material but are not currently reasonably estimable. This matter is ongoing.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_142"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17:&#160;<ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90ZXh0cmVnaW9uOjdhMzRhYzM1NTIxZjRmZmJhY2M2MTc3ZDA5ZDM5ZjlkXzEwOTM_aeeed69a-98b9-4206-b3aa-447ef0d765ed" continuedAt="i73a2bd249a9342e09c211c832f6fbd0d" escape="true">Other Comprehensive Income (Loss)</ix:nonNumeric></span></div><ix:continuation id="i73a2bd249a9342e09c211c832f6fbd0d" continuedAt="i84194df5da614eb580b357e0f359249d"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90ZXh0cmVnaW9uOjdhMzRhYzM1NTIxZjRmZmJhY2M2MTc3ZDA5ZDM5ZjlkXzEwNzc_0a95d0e0-c817-4beb-8831-e7aaf0064872" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to each component of other comprehensive income (loss):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.405%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2020</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc973a7f9e3144daaacecbbb0e56d8b2_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzItMS0xLTEtMTk3MTgy_6c76b9fb-2380-4e2a-8259-66d7a13dc9a7">1,678.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782d346d63cd4661b107c0a82f9e4b82_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzItMy0xLTEtMTk3MTgy_e695553f-db2c-4f2e-8f7f-0dfa05ced034">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7be554abe40648b39a94f657bb20d919_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzItNS0xLTEtMTk3MTgy_0cf9275d-721a-4e2c-97a3-f0065e7b1f5e">4,638.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc3cb8d5258a4da9a5d7c9e511159aa3_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzItNy0xLTEtMTk3MTgy_08ae0302-fba2-4231-b231-f530de2c08bd">211.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06509abf85c548088ad01601353119b6_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzItMTEtMS0xLTE5NzE4Mg_7a797447-a909-4330-93ff-67a41851be76">6,523.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a8c569328a4f30be03a86aa6c30d95_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzQtMS0xLTEtMTk3MTgy_a5281a5f-ccfd-4f0c-8595-8859d209e420">250.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551c81f2cb044ba38f8c330455e4e04c_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzQtMy0xLTEtMTk3MTgy_e26cc947-2d13-4a2a-9eaa-2eb8bbbdbe7b">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17390e21b41d40f786eda486ba1ce2c7_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzQtNS0xLTEtMTk3MTgy_4aff6a2e-0db2-4a4c-9900-9d51fcc065ec">379.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05873b0c5a3d432cb9d95359fb5df095_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzQtNy0xLTEtMTk3MTgy_585f6049-0087-40d3-a554-50db167da6cb">133.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzQtMTEtMS0xLTE5NzE4Mg_e6fa710d-ee22-43ef-961f-486f6f7aeea9">256.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a8c569328a4f30be03a86aa6c30d95_D20200101-20201231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzUtMS0xLTEtMTk3MTgy_dab1cdbb-5e9c-44d2-9f80-1e3374debfbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551c81f2cb044ba38f8c330455e4e04c_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzUtMy0xLTEtMTk3MTgy_9ee00f16-7878-4b87-a968-9d92ef886a69">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17390e21b41d40f786eda486ba1ce2c7_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzUtNS0xLTEtMTk3MTgy_84e055e8-2f68-4988-bd31-dba6e44c762b">267.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05873b0c5a3d432cb9d95359fb5df095_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzUtNy0xLTEtMTk3MTgy_218d95ec-b18b-4be4-a87e-5069d2b810a6">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzUtMTEtMS0xLTE5NzE4Mg_88c9dd1c-a162-46bd-a2d3-393728e9958c">283.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a8c569328a4f30be03a86aa6c30d95_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzYtMS0xLTEtMTk3MTgy_abfb0712-7faf-4c10-a361-52b3e967db5e">250.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551c81f2cb044ba38f8c330455e4e04c_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzYtMy0xLTEtMTk3MTgy_95852712-5b41-4973-b08f-18d7a604c335">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17390e21b41d40f786eda486ba1ce2c7_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzYtNS0xLTEtMTk3MTgy_c6094f81-5e43-431e-a32f-afef7bfa1ee9">112.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05873b0c5a3d432cb9d95359fb5df095_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzYtNy0xLTEtMTk3MTgy_f657a8e9-a514-48a1-a909-606f154dddb9">120.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzYtMTEtMS0xLTE5NzE4Mg_15ba3802-9ce2-4eca-bf9b-0c2f472ed8a5">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifce42ff1cd2e4bbd9d84d0fa5ad5830e_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEwLTEtMS0xLTE5NzE4Mg_c055097b-5d4e-4ddd-87f9-bf562e397ce9">1,427.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5a08b9d5ec477b89e3e3d1f861d631_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEwLTMtMS0xLTE5NzE4Mg_d3b0dcc3-887d-451a-ad7b-2578495e3057">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5108cbcfc4b74ce7b92ac3b0def03d6d_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEwLTUtMS0xLTE5NzE4Mg_a3456d95-cdc1-458a-af10-24fba16255b2">4,751.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa5d7c8469594718ad1fc73143d3d064_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEwLTctMS0xLTE5NzE4Mg_ba5d6688-516d-4f63-90f0-75bf71c291e7">332.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3316d423843f422793957a50410a8a36_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEwLTExLTEtMS0xOTcxODI_6d70de1e-58a0-49ea-a875-9528780cb836">6,496.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7653b13d4d7a4b1ea53ccf1f2894f8e0_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEzLTEtMS0xLTE5NzE4Mg_d4a86c15-9c37-4d91-83e0-ab8914fff14d">122.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d8b6b1d95db4e629430b1a90c83d5ed_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEzLTMtMS0xLTE5NzE4Mg_7e8819e9-28a2-429a-afcc-59550ce97778">11.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57369029d5994ec1a83968149ccf0c57_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEzLTUtMS0xLTE5NzE4Mg_a0554c8d-cee1-4285-9795-a9f7aaa50206">1,823.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i223571c60a5b423f8ffc9ccfbe85991b_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEzLTctMS0xLTE5NzE4Mg_45f704f2-cf84-4e7e-b994-f4ad711fe54a">106.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEzLTExLTEtMS0xOTcxODI_c4ad5661-ae85-4d6a-b96c-d539e8e6c1d1">1,795.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7653b13d4d7a4b1ea53ccf1f2894f8e0_D20210101-20211231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE0LTEtMS0xLTE5NzE4Mg_86249107-a270-443d-9d8d-b6dda2e0a780">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d8b6b1d95db4e629430b1a90c83d5ed_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE0LTMtMS0xLTE5NzE4Mg_d39d4729-22c1-4655-86c4-3714cf66980f">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57369029d5994ec1a83968149ccf0c57_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE0LTUtMS0xLTE5NzE4Mg_6204d94a-a43c-4d60-b397-225df2659b50">344.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i223571c60a5b423f8ffc9ccfbe85991b_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE0LTctMS0xLTE5NzE4Mg_be585922-10c4-42ff-a8fb-556196fa5dc1">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE0LTExLTEtMS0xOTcxODI_0f0219ca-8136-4328-9820-1b38bc67a64d">357.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7653b13d4d7a4b1ea53ccf1f2894f8e0_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE1LTEtMS0xLTE5NzE4Mg_e9ea8fa4-fa95-42ea-a146-32f49b4f0f94">122.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d8b6b1d95db4e629430b1a90c83d5ed_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE1LTMtMS0xLTE5NzE4Mg_65dd5f98-5dfe-4764-9e21-05260f77aede">11.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57369029d5994ec1a83968149ccf0c57_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE1LTUtMS0xLTE5NzE4Mg_6af384e7-8d10-4829-8db7-52652ee9ffbb">2,167.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i223571c60a5b423f8ffc9ccfbe85991b_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE1LTctMS0xLTE5NzE4Mg_316c9c0c-99e0-4336-8018-69ca7b50430f">119.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE1LTExLTEtMS0xOTcxODI_1f453bfc-a8d9-4ada-ac42-10ff971726c1">2,153.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i556ef38e7ad6431685ad87cfb8474525_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE3LTEtMS0xLTE5NzE4Mg_028ce19c-9e7c-4ba8-bf58-059c296710f4">1,550.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b44aaa3e8a45e08cb1bf413d8b0659_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE3LTMtMS0xLTE5NzE4Mg_82e0f518-4dac-48ca-8b76-f16b8596b34c">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17c04e1ff996458393a87969564ad1fc_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE3LTUtMS0xLTE5NzE4Mg_0e6acf46-f501-43b5-9913-74ea15e1194a">2,583.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i972702fe45444acb9e6640afa709e559_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE3LTctMS0xLTE5NzE4Mg_36459c6f-ce99-4300-aafe-71b5a2eb17aa">213.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i555a212b77e94fec899486cbaa76fc01_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE3LTExLTEtMS0xOTcxODI_732cb8d2-446c-46ed-a925-9f5b8a652caf">4,343.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2aa5e5ddf4514d70abb39fde1aef3c0c_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE5LTEtMS0xLTE5NzE4Mg_96484811-d050-4da2-8247-0331c8c378eb">324.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c2f066479d04e8a991d5d71e2aa8bac_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE5LTMtMS0xLTE5NzE4Mg_632c3bad-4027-43f5-96e7-2083f0bc5c7f">52.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b74eb9d22141c790775d44d424fc2f_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE5LTUtMS0xLTE5NzE4Mg_d09b379a-d390-4b04-84d3-2f9064e3dddb">291.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6f1b84d8e0044fba3da52e09503d7ef_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE5LTctMS0xLTE5NzE4Mg_5f5963ba-d589-4f11-9849-a3188487f03b">332.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE5LTExLTEtMS0xOTcxODI_37f1a871-1a54-4754-872b-06482443285b">247.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aa5e5ddf4514d70abb39fde1aef3c0c_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIwLTEtMS0xLTE5NzE4Mg_8519654e-3378-4608-9d91-1b35892d6970">0.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2f066479d04e8a991d5d71e2aa8bac_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIwLTMtMS0xLTE5NzE4Mg_e6a9c7b2-2b23-4d84-b508-10c31a5d1213">11.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b74eb9d22141c790775d44d424fc2f_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIwLTUtMS0xLTE5NzE4Mg_6d187392-82d4-4979-828a-525ca6db2cbe">229.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6f1b84d8e0044fba3da52e09503d7ef_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIwLTctMS0xLTE5NzE4Mg_721bd12a-629d-49a8-80f0-7713d19e79bb">9.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIwLTExLTEtMS0xOTcxODI_b14214f3-759e-4e10-abcf-2fa99d40740f">250.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2aa5e5ddf4514d70abb39fde1aef3c0c_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIxLTEtMS0xLTE5NzE4Mg_a2f135ee-3c6f-4fe3-961b-408fd008e100">324.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c2f066479d04e8a991d5d71e2aa8bac_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIxLTMtMS0xLTE5NzE4Mg_46d755ad-c50d-4ada-a14b-3128f7ef0fea">40.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b74eb9d22141c790775d44d424fc2f_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIxLTUtMS0xLTE5NzE4Mg_fe564505-d03f-43fd-be06-6fe84ae1be42">521.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6f1b84d8e0044fba3da52e09503d7ef_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIxLTctMS0xLTE5NzE4Mg_066dcf29-9084-4e09-9beb-a62df3685d9c">342.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIxLTExLTEtMS0xOTcxODI_e75150a6-3719-4af6-b6c6-e7e24dfe1717">498.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance at December 31, 2022</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3ab662330354f1d9f630d917b2b9226_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIzLTEtMS0xLTE5NzE4Mg_a5a82191-03fa-4abc-8c4a-e91ee8341a13">1,874.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36998435f274cd5b1ef204d97105cbd_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIzLTMtMS0xLTE5NzE4Mg_29327494-0343-45bb-939d-5680860773ab">37.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia343b309a27649efbcdc14994affb7a6_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIzLTUtMS0xLTE5NzE4Mg_4668156c-b9bd-4acc-a75a-86d493dba333">2,062.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i463002f84e9c4e7ba72e5b39ba3391e7_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIzLTctMS0xLTE5NzE4Mg_77b6471a-f848-4a75-8206-d344538e680a">129.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib916975408c44e2c89551e919105a31d_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIzLTExLTEtMS0xOTcxODI_44f45736-1f10-4b6e-ab7a-9be44be528d0">3,844.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2aa5e5ddf4514d70abb39fde1aef3c0c_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzEtMS0xLTEtMTk3MTgy_98946bd5-4ba4-43ea-9b30-ad031815bff3">75.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7653b13d4d7a4b1ea53ccf1f2894f8e0_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzEtMy0xLTEtMTk3MTgy_0e55065c-de55-443c-be81-9379fb1826d6">136.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a8c569328a4f30be03a86aa6c30d95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzEtNS0xLTEtMTk3MTgy_88e146b3-9e33-4fc0-a2af-428630e1e3b2">128.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2f066479d04e8a991d5d71e2aa8bac_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzItMS0xLTEtMTk3MTgy_032c327b-3eca-4f87-8bbf-c672736fbeeb">12.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d8b6b1d95db4e629430b1a90c83d5ed_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzItMy0xLTEtMTk3MTgy_db5c552a-820a-458f-9fb6-ff9429d6c7a7">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i551c81f2cb044ba38f8c330455e4e04c_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzItNS0xLTEtMTk3MTgy_c82e23eb-7c00-4451-b3b9-d6c2ff373f64">4.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66b74eb9d22141c790775d44d424fc2f_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzMtMS0xLTEtMTk3MTgy_ae3958b9-6557-4335-bd9e-202cd44d2934">95.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57369029d5994ec1a83968149ccf0c57_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzMtMy0xLTEtMTk3MTgy_108d4222-2734-4d6c-99c0-c63a5716e92f">532.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17390e21b41d40f786eda486ba1ce2c7_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzMtNS0xLTEtMTk3MTgy_08439e0a-1b3c-42ec-9711-76716bcd0af6">44.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6f1b84d8e0044fba3da52e09503d7ef_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzQtMS0xLTEtMTk3MTgy_23a08ab4-552a-4a82-b9d7-1dffec48d580">90.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i223571c60a5b423f8ffc9ccfbe85991b_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzQtMy0xLTEtMTk3MTgy_edc92e1d-4e22-458c-8365-a5352b38746a">31.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05873b0c5a3d432cb9d95359fb5df095_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzQtNS0xLTEtMTk3MTgy_b502da06-7d32-473a-9546-ccd5f6b49731">32.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzUtMS0xLTEtMTk3MTgy_2998a4fd-393b-43fe-be55-8d8811982aba">250.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzUtMy0xLTEtMTk3MTgy_689140d7-2582-4226-ada8-77bc777ff11e">695.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzUtNS0xLTEtMTk3MTgy_f2c4e9ee-1b7c-40ca-8a35-95159a41f328">200.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 7), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated statements of operations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i84194df5da614eb580b357e0f359249d"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90ZXh0cmVnaW9uOjdhMzRhYzM1NTIxZjRmZmJhY2M2MTc3ZDA5ZDM5ZjlkXzEwNzM_c7846259-1d68-49a4-8b76-7e6c53e6df59" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.230%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other <br/>Comprehensive Loss Components</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Statements of Operations</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fb8bb210d8244f89d422fb23165a4e3_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzMtMS0xLTEtMTk3MTgy_f73304af-c996-4db6-8ad9-a737caed5b10">52.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i023d933f184447ddac5d72ebf87e0336_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzMtMy0xLTEtMTk3MTgy_8b3c569e-80ba-4c3f-a31e-2df9ab8d5885">55.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i472a66eae4d2427ba823727867f6c0f9_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzMtNS0xLTEtMTk3MTgy_3cf4534d-7e4e-4893-bbcf-dc7566482409">55.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84dd851668914a6db57dd7071efd43cf_D20220101-20221231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzQtMS0xLTEtMTk3MTgy_23ce4b39-5a24-4cc9-ae03-0bd200290a64">343.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i514b258fa8244695bafee3af86f5baa4_D20210101-20211231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzQtMy0xLTEtMTk3MTgy_71826d29-fac3-4610-9b8d-83e29c54251d">490.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9961583d4b548ebbcb37171c99e617d_D20200101-20201231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzQtNS0xLTEtMTk3MTgy_cf6a8100-1167-4df8-8e38-780474724bcf">393.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i344999926eb8490985eec925cad19570_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzUtMS0xLTEtMTk3MTgy_04d368d9-9693-4395-bc53-483f62c41dba">290.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7c5f720a834207b54353c4bd105eba_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzUtMy0xLTEtMTk3MTgy_7866748c-2ea4-45fd-bbb2-3474abfa3107">435.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18678afeadcd4e3d83ea294339141d26_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzUtNS0xLTEtMTk3MTgy_c208e4ff-2ed6-4b88-b29d-b0747c492873">338.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i344999926eb8490985eec925cad19570_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzYtMS0xLTEtMTk3MTgy_1d2d1ecb-177b-45bd-96ce-82107c69a0b1">61.1</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d7c5f720a834207b54353c4bd105eba_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzYtMy0xLTEtMTk3MTgy_666482a3-dee9-4113-80b3-f3452ee2d6f6">91.5</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18678afeadcd4e3d83ea294339141d26_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzYtNS0xLTEtMTk3MTgy_016bb354-7ff2-4b35-b7b8-00cc581e54f1">71.0</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i344999926eb8490985eec925cad19570_D20220101-20221231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzctMS0xLTEtMTk3MTgy_1f383320-441d-4953-864b-ee777e32ea02">229.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7c5f720a834207b54353c4bd105eba_D20210101-20211231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzctMy0xLTEtMTk3MTgy_edeeda4c-d507-463c-909b-aeed2fb96168">344.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18678afeadcd4e3d83ea294339141d26_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzctNS0xLTEtMTk3MTgy_c552122f-4e9c-48ac-934a-38a2ee908dd5">267.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b856402e0234773bcad0e3fc79b8715_D20220101-20221231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzktMS0xLTEtMTk3MTgy_dcb9c177-28f1-4bd9-817b-fbcc089686ab">21.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia960d127a0284a50a7e9041cfc5cc3ff_D20210101-20211231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzktMy0xLTEtMTk3MTgy_7314f096-574d-47ce-9291-ef11ae72e29d">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib01471a2ae8e487caadc07f6eb55dd21_D20200101-20201231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzktNS0xLTEtMTk3MTgy_2851bea4-4ec5-4f4a-bace-d9bc3896222c">16.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a0343f9166479e970860fc345fb4c5_D20220101-20221231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzEyLTEtMS0xLTE5NzE4Mg_ce5d27a1-8cec-4f56-8091-bfc570f427a4">250.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a4ec401a8f24eeda71c72518a06d67d_D20210101-20211231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzEyLTMtMS0xLTE5NzE4Mg_39affce1-d377-4f3b-86c0-522de3725d66">357.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefbc11fe7e2b4373988b6e83dcf18945_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzEyLTUtMS0xLTE5NzE4Mg_81f452e0-0d12-4344-9fff-46e41595da22">283.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_145"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 18:&#160;<ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90ZXh0cmVnaW9uOjZmNWEzYzJjYTM2NTQ2ZDFhNzRmZTZkZTFkZWRlZDZlXzk5_2dee57ff-0eae-4595-a098-0d843b15f84e" continuedAt="ice4deed31a5345f094b45c2ddc66fa77" escape="true">Other&#8211;Net, (Income) Expense</ix:nonNumeric></span></div><ix:continuation id="ice4deed31a5345f094b45c2ddc66fa77"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90ZXh0cmVnaW9uOjZmNWEzYzJjYTM2NTQ2ZDFhNzRmZTZkZTFkZWRlZDZlXzEwMg_8ae14efc-5dfa-4d10-b071-0b0882f450e8" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzEtMS0xLTEtMTk3MTgy_753a56d9-3634-4a4d-9294-d0412294897a">331.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzEtMy0xLTEtMTk3MTgy_6a386a27-cb9c-4eab-b37d-13a0a00097b8">339.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzEtNS0xLTEtMTk3MTgy_a69beaf1-e4a9-445e-8c61-b8a722bfa586">359.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzItMS0xLTEtMTk3MTgy_8c837135-1bb6-404c-9b51-85265c771796">62.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzItMy0xLTEtMTk3MTgy_a2d864e4-17d6-42be-98ad-bd58e26635a3">25.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzItNS0xLTEtMTk3MTgy_8dba20b7-31c6-42bf-8753-c13b35676af9">33.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment (gains) losses on equity securities (Note 7)</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzMtMS0xLTEtMTk3MTgy_9552f222-c655-4f7a-83cb-31912d57cef9">410.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzMtMy0xLTEtMTk3MTgy_30c351bf-3c4a-4302-898e-615e97d82620">176.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzMtNS0xLTEtMTk3MTgy_3e44f26d-065b-4a9c-975d-7d991cd0ac9b">1,442.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment loss (Note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzQtMS0xLTEtMTk3MTgy_9b59edee-6a17-4561-bd3d-b4bbdf8b3169">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzQtMy0xLTEtMTk3MTgy_96d772e1-8c81-4067-89e4-988474312348">405.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzQtNS0xLTEtMTk3MTgy_e68387c1-98e7-4a6d-a7a8-0b05ef09589c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzYtMS0xLTEtMTk3MTgy_00d5eece-8559-4d91-8765-7d7fee01fce3">372.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzYtMy0xLTEtMTk3MTgy_ea278574-9582-48fc-b30f-90da43fa2020">289.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzYtNS0xLTEtMTk3MTgy_ad281757-096a-47c9-b5f7-691c86163026">251.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzctMS0xLTEtMTk3MTgy_17e95600-da3f-4720-a5a8-72d67f6a6abb">14.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzctMy0xLTEtMTk3MTgy_742f85a8-ba51-4f8a-801a-3bac81837bc9">51.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzctNS0xLTEtMTk3MTgy_5823e245-3113-40c6-8f24-554bc6abf8c2">195.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzgtMS0xLTEtMTk3MTgy_82a7c708-983b-424d-aba5-680bf57fa323">320.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzgtMy0xLTEtMTk3MTgy_633422de-f95b-4be3-bba9-c86dc2c9751c">201.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzgtNS0xLTEtMTk3MTgy_844213a2-7366-44ae-81c9-28cdf5b354ea">1,171.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_148"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Management's Reports</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Report for Financial Statements&#8212;Eli Lilly and Company and Subsidiaries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of Eli Lilly and Company and subsidiaries is responsible for the accuracy, integrity, and fair presentation of the financial statements. The statements have been prepared in accordance with generally accepted accounting principles in the United States and include amounts based on judgments and estimates by management. In management's opinion, the consolidated financial statements present fairly our financial position, results of operations, and cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the system of internal accounting controls, we maintain a code of conduct (known as "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Red Book"</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) that applies to all employees worldwide, requiring proper overall business conduct, avoidance of conflicts of interest, compliance with laws, and confidentiality of proprietary information. All employees must take training annually on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Red Book</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and are required to report suspected violations. A hotline number is available on our lilly.com website and on the internal LillyNow website to enable reporting of suspected violations anonymously. Employees who report suspected violations are protected from discrimination or retaliation by the company. In addition to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Red Book</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the chief executive officer and all financial management must sign a financial code of ethics, which further reinforces their ethical and fiduciary responsibilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been audited by Ernst&#160;&amp; Young LLP, an independent registered public accounting firm (PCAOB ID: <ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDgvZnJhZzo4YWEwYjY1ZTg2NDE0MDQ5YWM1ZWZmMjU4YzQ5NzI2OS90ZXh0cmVnaW9uOjhhYTBiNjVlODY0MTQwNDlhYzVlZmYyNThjNDk3MjY5XzE1ODM_4a0f09f2-d247-4711-8977-296f2d67bde9">42</ix:nonNumeric>). Their responsibility is to examine our consolidated financial statements in accordance with generally accepted auditing standards of the Public Company Accounting Oversight Board (United&#160;States). Ernst&#160;&amp; Young's opinion with respect to the fairness of the presentation of the statements is included in Item&#160;8 of our Annual Report on Form 10-K. Ernst&#160;&amp; Young reports directly to the audit committee of the board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee includes five nonemployee members of the board of directors, all of whom are independent from our company. The committee charter, which is available on our website, outlines the members' roles and responsibilities. It is the audit committee's responsibility to appoint an independent registered public accounting firm subject to shareholder ratification, pre-approve both audit and non-audit services performed by the independent registered public accounting firm, and review the reports submitted by the firm. The audit committee meets several times during the year with management, the internal auditors, and the independent public accounting firm to discuss audit activities, internal controls, and financial reporting matters, including reviews of our externally published financial results. The internal auditors and the independent registered public accounting firm have full and free access to the committee.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dedicated to ensuring that we maintain the high standards of financial accounting and reporting that we have established. We are committed to providing financial information that is transparent, timely, complete, relevant, and accurate. Our culture demands integrity and an unyielding commitment to strong internal practices and policies. Finally, we have the highest confidence in our financial reporting, our underlying system of internal controls, and our people, who are objective in their responsibilities, operate under a code of conduct and are subject to the highest level of ethical standards.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Report on Internal Control Over Financial Reporting&#8212;Eli Lilly and Company and Subsidiaries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of Eli Lilly and Company and subsidiaries is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules&#160;13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. We have global financial policies that govern critical areas, including internal controls, financial accounting and reporting, fiduciary accountability, and safeguarding of corporate assets. Our internal accounting control systems are designed to provide reasonable assurance that assets are safeguarded, that transactions are executed in accordance with management's authorization and are properly recorded, and that accounting records are adequate for preparation of financial statements and other financial information. A staff of internal auditors regularly monitors, on a worldwide basis, the adequacy and effectiveness of internal accounting controls. The general auditor reports directly to the audit committee of the board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in "Internal Control&#8212;Integrated Framework" (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our evaluation under this framework, we concluded that our internal control over financial reporting was effective as of December&#160;31, 2022. However, because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of internal control over financial reporting as of December&#160;31, 2022 has been audited by Ernst&#160;&amp; Young LLP, an independent registered public accounting firm, as stated in their attestation report, which appears herein. Their responsibility is to evaluate whether internal control over financial reporting was designed and operating effectively.</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.919%"><tr><td style="width:1.0%"></td><td style="width:48.353%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.892%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Ricks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chair, President, and Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President&#160;and Chief Financial Officer</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;22, 2023 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_151"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Report of Independent Registered Public Accounting Firm </span></div><div style="margin-top:0.05pt"><span><br/></span></div><div style="margin-top:0.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Shareholders of Eli Lilly and Company</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the accompanying consolidated balance sheets of Eli Lilly and Company and subsidiaries (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive income (loss), shareholders' equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control &#8212; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 22, 2023 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"></td><td style="width:16.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Medicaid, Managed Care, and Medicare sales rebate accruals</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2 to the consolidated financial statements under the caption "Net Product Revenue," the Company establishes provisions for sales rebate and discounts in the same period as the related sales occur. At December 31, 2022 the Company had $8,784.1 million in sales rebate and discount accruals. A large portion of these accruals are rebates associated with sales in the United States for which payment for purchase of the product is covered by Medicaid, Managed Care, and Medicare. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the Medicaid, Managed Care, and Medicare sales rebate and discount liabilities is challenging because of the subjectivity of certain assumptions required to estimate the rebate liabilities. In calculating the appropriate accrual amount, the Company considers historical Medicaid, Managed Care, and Medicare rebate payments by product as a percentage of their historical sales as well as any significant changes in sales trends, the lag in payment timing, an evaluation of the current Medicaid and Medicare laws and interpretations, the percentage of products that are sold via Medicaid, Managed Care, and Medicare, and product pricing. For Medicaid, there is significant complexity associated with calculating the legislated Medicaid rebates. Management utilizes employees with legislative experience and knowledge in developing assumptions used to calculate Medicaid rebates. Similarly, for Managed Care and Medicare, given variability in prescription drug costs, continued historical year over year increases in enrollees and variability in prescription data, historical rebate information may not be predictive for management to estimate the rebate accrual and thus, management supplements its historical data analysis with qualitative adjustments based upon current utilization.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We tested the Company's controls addressing the identified risks of material misstatement related to the valuation of the sales rebate and discount liabilities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This included testing controls over management's review of the significant assumptions used to calculate the Medicaid, Managed Care, and Medicare rebate liabilities, including the significant assumptions discussed above.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This testing also included management's control to compare actual activity to forecasted activity and controls to ensure the data used to evaluate the significant assumptions was complete and accurate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures included, among others, evaluating for reasonableness the significant assumptions in light of economic trends, product profiles, and other regulatory factors. Our testing involved assessing the historical accuracy of management's estimates by comparing actual activity to previous estimates and performing analytical procedures, based on internal and external data sources, to evaluate the completeness of the reserves. Additionally, our procedures included reviewing a sample of contracts, testing a sample of rebate payments and testing the underlying data used in management's evaluation. For Medicaid, we involved our professionals with an understanding of the statutory reimbursement requirements to assess the consistency of the Company's calculation methodologies with the applicable government regulations and policy.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Medicare we evaluated the reasonableness of assumptions made by management in estimating the Medicare coverage gap liability.</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"></td><td style="width:16.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Retirement Benefits - Valuation of Alternative Investments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 15 to the consolidated financial statements under the caption "Benefit Plan Investments," the Company's benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. At December 31, 2022 the Company had $15,688.3 million in plan assets related to the defined benefit pension plans and retiree health benefit plans. Approximately 50 percent of the total pension and retiree health assets are in hedge funds and private equity-like investment funds ("alternative investments"). These alternative investments are valued using significant unobservable inputs or are valued at net asset value (NAV) reported by the counterparty, adjusted as necessary.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the fair value of these alternative investments is challenging because of the higher estimation uncertainty of the inputs to the fair value calculations, including the underlying net asset values ("NAVs"), discounted cash flow valuations, comparable market valuations, and adjustments for currency, credit, liquidity and other risks. Additionally, certain information regarding the fair value of these alternative investments is based on unaudited information available to management at the time of valuation. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We tested the Company's controls addressing the risks of material misstatement relating to valuation of alternative investments. This included testing management's review controls over alternative investment valuation, which included a comparison of returns to benchmarks and monitoring of investment firms' valuation policies and procedures, as well as portfolio performance. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures included, among others, comparing fund returns to selected relevant benchmarks and understanding variations, obtaining the latest audited financial statements and comparing to the Company's estimated fair values. We also inquired of management about changes to the investment portfolio and/or related investment strategies and considerations. We assessed the historical accuracy of management's estimates by comparing actual activity to previous estimates. We evaluated for contrary evidence by confirming the fair value of the investments and ownership interest directly with the trustees and a sample of managers at year end. </span></div><div><span><br/></span></div></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNTEvZnJhZzo5YzA2ZDg0NTEwMWY0OGU0YmFkZWQ1ZDk0MzE3ZDA5Yy90ZXh0cmVnaW9uOjljMDZkODQ1MTAxZjQ4ZTRiYWRlZDVkOTQzMTdkMDljXzM1NzI_a58897d7-b537-436f-87d5-0acebc7f09b5">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 1940. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNTEvZnJhZzo5YzA2ZDg0NTEwMWY0OGU0YmFkZWQ1ZDk0MzE3ZDA5Yy90ZXh0cmVnaW9uOjljMDZkODQ1MTAxZjQ4ZTRiYWRlZDVkOTQzMTdkMDljXzM1NzM_d22bef63-634f-4ba5-81e6-c07b96351d64">Indianapolis, Indiana</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;22, 2023 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_154"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Shareholders of Eli Lilly and Company</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited Eli Lilly and Company and subsidiaries' internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control &#8212; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Eli Lilly and Company and subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on the COSO criteria.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive income (loss), shareholders' equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes and our report dated February 22, 2023 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.549%"><tr><td style="width:1.0%"></td><td style="width:75.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Ernst &amp; Young LLP</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indianapolis, Indiana</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;22, 2023 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_157"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 9.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_160"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 9A.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:2pt">Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under applicable Securities and Exchange Commission (SEC) regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company's "disclosure controls and procedures," which are defined generally as controls and other procedures designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Form&#160;10-K) is recorded, processed, summarized, and reported on a timely basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of David Ricks, president and chief executive officer, and Anat Ashkenazi, executive vice president and chief financial officer, evaluated our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of December&#160;31, 2022, and concluded that they were effective.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Ricks and Ms.&#160;Ashkenazi provided a report on behalf of management on our internal control over financial reporting, in which management concluded that the company's internal control over financial reporting is effective at December&#160;31, 2022 based on the framework in "Internal Control&#8212;Integrated Framework" (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States. Due to the inherent limitations, no evaluation over internal control can provide absolute assurance that no material misstatements or fraud exist. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Ernst&#160;&amp; Young LLP, the company's independent registered public accounting firm, issued an attestation report on the company's internal control over financial reporting as of December&#160;31, 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You can find the full text of management's report and Ernst&#160;&amp; Young's attestation report in Item&#160;8.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_163"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 9B.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:2pt">Other Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_166"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:12pt;margin-top:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_169"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Part&#160;III</span></div><div id="i909b702f7db044078a8e3e150503788d_172"></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 10.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Directors, Executive Officers, and Corporate Governance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Directors and Executive Officers</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to our board of directors is found in our Definitive Proxy Statement, to be dated on or about March&#160;17, 2023 (Proxy Statement), under "Governance - How We Build an Effective Board" and is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to our executive officers is found at Item 1, "Business - Executive Officers of the Company" and is incorporated by reference herein. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Ethics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to our code of ethics is found in our Proxy Statement under "Governance - How We Operate an Effective Board - Governance Practices - Board Oversight - Key Areas of Oversight by the Board and Its Committees - Governance - Code of Ethics" and is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Governance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the procedures by which shareholders can recommend nominees to our board of directors is found in our Proxy Statement under "Governance - How We Build an Effective Board - Director Nominations - Shareholder Director Candidates" and is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The board of directors has appointed an audit committee consisting entirely of independent directors in accordance with applicable Securities and Exchange Commission and New York Stock Exchange requirements for audit committees. Information about our audit committee is found in our Proxy Statement under "Governance - How We Operate an Effective Board - Board Structure - Meetings of the Board and Its Committees - Committees of the Board - Audit Committee" and is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 16(a) Reporting Compliance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about our compliance with Section 16(a) is found in our Proxy Statement under "Ownership of Common Stock - Delinquent Section 16(a) Reports" and is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_175"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 11.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Executive Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on director compensation, executive compensation, and talent and compensation committee matters can be found in the Proxy Statement under "Governance - How We Operate an Effective Board - Board Alignment - Director Compensation," "- How We Operate an Effective Board - Board Structure - Meetings of the Board and Its Committees - Committees of the Board - Talent and Compensation Committee," "Compensation - Compensation Discussion and Analysis," "- Talent and Compensation Committee Matters," and "- Executive Compensation." Such information is incorporated in this Annual Report on Form 10-K by reference. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_178"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 12.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security Ownership of Certain Beneficial Owners and Management</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to ownership of the company's common stock by management and by persons known by the company to be the beneficial owners of more than five percent of the outstanding shares of common stock is found in the Proxy Statement under "Ownership of Company Stock" and incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information as of December&#160;31, 2022 regarding the company's compensation plans under which shares of the company's common stock have been authorized for issuance.</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan category</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a) Number of securities to be issued upon exercise of outstanding options, warrants, and rights </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b) Weighted-average exercise price of outstanding options, warrants, and rights</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 19pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,953,648&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plan not approved by security holders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="2" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,953,648&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 4,175,980 shares are underlying outstanding equity awards other than options.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_181"></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 13.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Related Person Transactions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to the policies and procedures for approval of related person transactions by our board of directors can be found in the Proxy Statement under "Governance - How We Operate an Effective Board - Board Alignment - Conflicts of Interest and Transactions with Related Persons." Such information is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Independence</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to director independence can be found in the Proxy Statement under "Governance - How We Build an Effective Board - Director Qualifications - Independence" and is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_184"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 14.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Principal Accountant Fees and Services</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the fees and services of our principal independent accountants, Ernst &amp; Young LLP, can be found in the Proxy Statement under "Audit Matters - Item 4. Ratification of the Appointment of the Independent Auditor - Services Performed by the Independent Auditor" and "- Independent Auditor Fees." Such information is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_187"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 15.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Exhibits and Financial Statement Schedules</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following consolidated financial statements of the company and its subsidiaries are found at Item&#160;8:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated Statements of Operations&#8212;Years Ended December&#160;31, 2022, 2021, and 2020 </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated Statements of Comprehensive Income (Loss)&#8212;Years Ended December&#160;31, 2022, 2021, and 2020</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated Balance Sheets&#8212;December&#160;31, 2022 and 2021</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated Statements of Shareholders' Equity&#8212;Years Ended December&#160;31, 2022, 2021, and 2020</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated Statements of Cash Flows&#8212;Years Ended December&#160;31, 2022, 2021, and 2020</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Notes to Consolidated Financial Statements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)2.&#160;&#160;&#160;&#160;Financial Statement Schedules</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statement schedules of the company and its subsidiaries have been omitted because they are not required, are inapplicable, or are adequately explained in the financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial statements of interests of 50&#160;percent or less, which are accounted for by the equity method, have been omitted because they do not, considered in the aggregate as a single subsidiary, constitute a significant subsidiary.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)3.&#160;&#160;&#160;&#160;Exhibits</span></div><div id="i909b702f7db044078a8e3e150503788d_190"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as part of this report:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.463%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947822000138/articlesofincorporationlly.htm">Amended Articles of Incorporation, incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on May 4, 2022</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947822000138/bylaws.htm">Bylaws, as amended, incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed on May 4, 2022</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947813000010/exhibit41-indenturedatedfe.htm">Indenture, dated February 1, 1991, between the Company and Deutsche Bank Trust Company Americas, as successor trustee to Citibank, N.A., as Trustee, incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-3, Registration No. 333-186979</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000095015209001897/c49534exv4w2.htm">Tripartite Agreement, dated September 13, 2007, appointing Deutsche Bank Trust Company Americas as Successor Trustee under the Indenture listed in Exhibit 4.1, incorporated by reference to Exhibit 4.2 to the Company's Annual Report on Form 10-K for the year ended December 31, 2008</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit43.htm">Description of the Company's Common Stock, incorporated by reference to Exhibit 4.3 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit44.htm">Description of the Company's 1.625% Notes due 2026</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit44.htm"> and 2.125% Notes due 2030, incorporated by reference to Exhibit 4.4 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit45.htm">Description of the Company's 6.77% Notes due 2036, incorporated by reference to Exhibit 4.5 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit46.htm">Description of the Company's 7 1/8% Notes due 2025, incorporated by reference to Exhibit 4.6 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit47.htm">Description of the Company's 0.625% Notes due 2031 and 1.700% Notes due 2049, incorporated by reference to Exhibit 4.7 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.463%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947822000068/lly-20211231x10kexhibit48.htm">Description of the Company's 0.500% Notes due 2033, 1.125% Notes due 2051, and 1.375% Notes due 2061, incorporated by reference to Exhibit 4.8 to the Company's Annual Report on Form 10-K for the year ended December 31, 2021</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947822000068/lly-20211231x10kexhibit49.htm">Description of the Company's 1.625% Notes due 2043, incorporated by reference to Exhibit 4.9 to the Company's Annual Report on Form 10-K for the year ended December 31, 2021</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947818000188/lly-6302018x10qxexhibit101.htm">Amended and Restated 2002 Lilly Stock Plan</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947818000188/lly-6302018x10qxexhibit101.htm">(1)</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947818000188/lly-6302018x10qxexhibit101.htm">, incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2018</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20221231x10kexhibit102.htm">Form of Performance Award under the 2002 Lilly Stock Plan</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline" href="lly-20221231x10kexhibit102.htm">(1)</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20221231x10kexhibit102.htm">*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20221231x10kexhibit103.htm">Form of Shareholder Value Award under the 2002 Lilly Stock Plan</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline" href="lly-20221231x10kexhibit103.htm">(1)</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20221231x10kexhibit103.htm">*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20221231x10kexhibit104.htm">Form of Relative Value Award under the 2002 Lilly Stock Plan</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline" href="lly-20221231x10kexhibit104.htm">(1)</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20221231x10kexhibit104.htm">*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="lly-20221231x10kexhibit105.htm">Form of Non-Compete Payment Agreement</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline" href="lly-20221231x10kexhibit105.htm">(1)</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="lly-20221231x10kexhibit105.htm">*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit105.htm">The Lilly Deferred Compensation Plan, as amended</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit105.htm">(1)</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit105.htm">, incorporated by reference to Exhibit 10.5 to the Company's annual report on Form 10-K for the year ended December 31, 2013</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947817000183/lly-6302017x10qxexhibit10.htm">The Lilly Directors' Deferral Plan, as amended</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947817000183/lly-6302017x10qxexhibit10.htm">(1)</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947817000183/lly-6302017x10qxexhibit10.htm">, incorporated by reference to Exhibit 10 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231x10kexhibit1014.htm">The Eli Lilly and Company Bonus Plan, as amended</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231x10kexhibit1014.htm">(1)</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231x10kexhibit1014.htm">, incorporated by reference to Exhibit 10.14 to the Company's Annual Report on Form 10-K for the year ended December 31, 2020</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947822000068/lly-20211231x10kexhibit1017.htm">The Loxo Oncology, Inc. Bonus Plan</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947822000068/lly-20211231x10kexhibit1017.htm">(1)</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947822000068/lly-20211231x10kexhibit1017.htm">, incorporated by reference to Exhibit 10.17 to the Company's Annual Report on Form 10-K for the year ended December 31, 2021</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231x10kexhibit1015.htm">2007 Change in Control Severance Pay Plan for Select Employees, as amended</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:1.41pt;vertical-align:baseline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231x10kexhibit1015.htm">(1)</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231x10kexhibit1015.htm">, incorporated by reference to Exhibit 10.15 to the Company's Annual Report on Form 10-K for the year ended December 31, 2020</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20221231x10kexhibit21.htm">List of Subsidiaries*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20221231x10kexhibit23.htm">Consent of Independent Registered Public Accounting Firm*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20221231x10kexhibit311.htm">Rule 13a-14(a) Certification of David Ricks, Chair, President, and Chief Executive Officer*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20221231x10kexhibit312.htm">Rule 13a-14(a) Certification of Anat Ashkenazi, Executive Vice President and Chief Financial Officer*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20221231x10kexhibit32.htm">Section 1350 Certification*</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data File*</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)*</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Indicates management contract or compensatory plan.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* Filed herewith.</span></div><div style="margin-bottom:12pt"><span><br/></span></div><div id="i909b702f7db044078a8e3e150503788d_196"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 16.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Form 10-K Summary</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><div id="i909b702f7db044078a8e3e150503788d_199"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Eli Lilly and Company</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.185%"><tr><td style="width:1.0%"></td><td style="width:5.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;David Ricks</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">David Ricks</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair, President,&#160;and&#160;Chief&#160;Executive&#160;Officer</span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;22, 2023 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on February&#160;22, 2023 by the following persons on behalf of the Registrant and in the capacities indicated.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"></td><td style="width:50.608%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.484%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;David Ricks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair, President, and Chief Executive Officer (principal executive officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DAVID RICKS</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Anat Ashkenazi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer (principal financial officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANAT ASHKENAZI</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Donald Zakrowski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Finance, and Chief Accounting Officer (principal accounting officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DONALD ZAKROWSKI</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Ralph Alvarez</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RALPH ALVAREZ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Katherine Baicker, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KATHERINE BAICKER, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Erik Fyrwald</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ERIK FYRWALD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Mary Lynne Hedley, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MARY LYNNE HEDLEY, Ph. D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Jamere Jackson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JAMERE JACKSON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Kimberly Johnson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIMBERLY JOHNSON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;William Kaelin, Jr., M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WILLIAM KAELIN, JR., M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Juan Luciano</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JUAN LUCIANO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Marschall Runge, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MARSCHALL RUNGE, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160; Gabrielle Sulzberger</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GABRIELLE SULZBERGER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Jackson Tai</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JACKSON TAI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Karen Walker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KAREN WALKER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks Used In This Report</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks or service marks owned by Eli Lilly and Company or its affiliates, when first used in each item of this report, appear with an initial capital and are followed by the symbol </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as applicable. In subsequent uses of the marks in the item, the symbols may be omitted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Byetta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a trademark of Amylin Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are trademarks of Boehringer Ingelheim International GmbH.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a trademark of Innovent Biologics (Suzhou) Co., Ltd. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>lly-20221231x10kexhibit102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iefcd8f859ee64c94a37067e1a39557b1_97"></div><div style="min-height:64.08pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.2 Form of Performance Award under the 2002 Lilly Stock Plan</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Performance Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:400;line-height:100%">(for Executive Officers)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Performance Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Performance Award Agreement (the &#8220;Grantee&#8221;).</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Levels&#58; &#91;&#8226;&#93;</font></div><div style="text-indent:13.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Period&#58;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:16pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:14pt;font-weight:400;line-height:100%">&#91;&#8226;&#93; &#8211; &#91;&#8226;&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Service Vesting Date&#58;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:16pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:14pt;font-weight:400;line-height:100%">&#91;&#8226;&#93;</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Table of Contents</font></div><div style="padding-right:1.8pt;text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant of Performance Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grantee&#8217;s Acknowledgments</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 12.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 13.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 14.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 15.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 16.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></td></tr></table></div><div style="padding-left:76.5pt;text-indent:-64.5pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:12pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 1.&#160;&#160;&#160;&#160;Grant of Performance Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Performance Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Performance Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#34;Target Number of Shares&#34;).   </font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Performance Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern except with respect to the provisions described in Section 12 below (in which case, the terms of the Award Agreement shall govern). </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of units eligible to vest (&#8220;Performance Units&#8221;) based on the actual cumulative Earnings Per Share (&#34;EPS&#34;) for the Performance Period and using the Non-GAAP EPS (as adjusted to the extent determined by the Committee) for the year immediately prior to the commencement of the Performance Period as a reference point (as shown on page 1 of this document) (&#8220;EPS Growth&#8221;), the corresponding payout multiple and the Target Number of Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;The actual cumulative EPS for the Performance Period shall be computed using the following procedures&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;A determination of adjusted consolidated net income ascertained from the Company's audited consolidated financial statements shall be made for each fiscal year in the Performance Period in accordance with accounting principles currently applicable in the United States (&#34;US GAAP&#34;), adjusted to the extent deemed appropriate by the Committee for any unusual items deemed significant by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;The number of shares of outstanding Lilly Common Stock used to compute consolidated EPS shall be determined as of the end of each fiscal year in the Performance Period on a diluted basis or its equivalent in accordance with US GAAP.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;To calculate consolidated EPS for each fiscal year in the Performance Period, the adjusted consolidated net income shall be divided by the number of shares of outstanding Lilly Common Stock as computed in accordance with subsection (ii) above and the quotient rounded to the nearest cent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv.&#160;&#160;&#160;&#160;To determine the cumulative EPS for the Performance Period, the EPS amounts for each fiscal year as determined above shall be added.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;The payout multiple corresponding to the EPS Growth (as shown on page 1 of this document) shall then be applied to the Target Number of Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;The number of Performance Units under this Performance Award will be the number resulting from the calculation described in subsection (b) above. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;In the event the Grantee&#8217;s Service is terminated prior to the Service Vesting Date for any reason or in any circumstance other than as described in Section 3 below, the Award, including any accrued Dividend Equivalent Rights, shall be forfeited.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 3.&#160;&#160;&#160;&#160;Impact of Certain Employment Status Changes </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retirement&#59; Death</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided below (including Section 12), in the event the Grantee&#8217;s Service is terminated (i) on or following the Retirement Vesting Date (A) due to the Grantee&#8217;s Retirement or (B) due to the Grantee&#8217;s Qualifying Termination (as defined below) on a date that the Grantee is eligible for Retirement, or (ii) due to the Grantee&#8217;s death, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.  For the avoidance of any doubt, the Award shall be forfeited in the event the Grantee&#8217;s Service is terminated prior to the Retirement Vesting Date due to the Grantee&#8217;s Retirement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement&#8221; means retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under The Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements or (E) otherwise determined to be a retired employee in the sole discretion of the Company.  A Grantee who has not received a year-end individual performance rating and (i) is on final written warning (or equivalent as determined by the Committee) for unsatisfactory performance and elects to retire in lieu of a termination of employment&#59; or (ii) elects to retire in lieu of termination of employment because of an immediately terminable offense (e.g., absence of three days without notice, insubordination, violation of substance abuse policy, possession of firearms, misconduct) will not be considered to have terminated due to Retirement as described herein.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement Vesting Date&#8221; means the date that is on or following December 31 immediately following the commencement of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided in section 3(b), in the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the Performance Units shall vest, provided that if the Qualifying Termination occurs prior to the last day of the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation, including reallocation due to the Grantee&#8217;s inability to continue to work due to medical reasons, in the United States (or equivalent as determined by the Committee).</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, cancel this Performance Award or reduce the number of Performance Units, prorated according to time or other measure as determined appropriate by the Company, if during any period prior to the Service Vesting Date the Grantee has been (i) subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Retirement, (3) the Grantee is eligible for Retirement, (4) the Grantee&#8217;s Service has been terminated as a direct result of either a plant closing or a reduction in force, and (5) the Grantee's service has been terminated as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 4.&#160;&#160;&#160;&#160;Change in Control</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;In the event of a Transaction that occurs prior to the end of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Performance Units, to be calculated in a manner consistent with Section 2, but the cumulative EPS shall equal the Company&#8217;s cumulative EPS expected results (as determined by the Company&#8217;s last approved forecast prior to the consummation of the Transaction, not considering the impact of the Transaction) (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.  </font></div><div style="padding-left:108pt;text-indent:-18.01pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the last day of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (as amended from time to time) or any successor plan or arrangement thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;The following shall apply in the event of a Transaction that occurs subsequent to the last day of the Performance Period but prior to the Service Vesting Date&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;In the event that the Performance Units are not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Performance Units shall vest automatically in full.</font></div><div style="padding-left:108pt;text-indent:-18.01pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;In the event that the Performance Units are converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination prior to the Service Vesting Date, then immediately as of the date of the Covered Termination, the Performance Units shall vest automatically in full.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 5.&#160;&#160;&#160;&#160;Settlement  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Except as provided below, a vested Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days following the Service Vesting Date, including if the Award vests pursuant to Sections 3(b) or 3(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;If the Award vests pursuant to Section 3(b)(ii), the Award shall be paid to the Grantee no later than sixty (60) days following (i) the date the Committee determines the number of units eligible to vest in accordance with Section 2, if the vesting event occurs on or prior to the last day of the Performance Period or (ii) the date of the vesting event, if the vesting event occurs after the last day of the Performance Period, provided that if the Award is considered an item of nonqualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;), the Award shall be paid in the calendar year containing the Service Vesting Date.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;If the Award vests pursuant to Section 4(b)(i) or Section 4(c)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered NQ Deferred Compensation and the Transaction does not constitute a &#8220;change in control event&#8221; under Section 409A of the Code (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the Service Vesting Date.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;If the Award vests pursuant to Section 4(b)(ii) or Section 4(c)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation (and provided that the Transaction constitutes a 409A CIC), (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a Section 409A Separation, and (ii) if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the date of the Section 409A Separation, the Award shall instead be paid on the earliest of (1) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;At the time of settlement provided in this Section 5, Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(f) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;At any time prior to the Service Vesting Date or until the Performance Units are paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Performance Units in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Restriction Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(d).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;Dividend Equivalent Rights, if any, that accrue hereunder shall be settled in cash.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.&#160;&#160;&#160;&#160;In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 6.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Performance Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Performance Award is settled and Shares are issued or transferred to the Grantee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dividend Equivalent Rights</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On each date that the Company pays a cash dividend to holders of Shares during the period commencing on the date the number of Performance Units are determined continuing through the date the Performance Units are settled, the Grantee shall be credited with Dividend Equivalent Rights in an amount equal to the total number of Performance Units, multiplied by the dollar amount of the cash dividend paid per Share by the Company on such date.  Dividend Equivalent Rights shall accrue in an account denominated in U.S. dollars and shall not accrue interest or other credits prior to being paid.  The Dividend Equivalent Rights shall be subject to the same vesting conditions and restrictions as the Performance Units to which the Dividend Equivalent Rights relate, and the Dividend Equivalent Rights shall be forfeited in the event that the Performance Units with respect to which such Dividend Equivalent Rights were credited are forfeited.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 7.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 8.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Regardless of any action Lilly and&#47;or the Grantee&#8217;s Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i) make no representations or </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Performance Award, the vesting of the Performance Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the accrual and payment of Dividend Equivalent Rights, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:99pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;If the Performance Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:99pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;If the Performance Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C) withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:99pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;If the Performance Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, for Tax-Related Items other than U.S. Federal Insurance Contribution Act taxes or other Tax-Related Items that become payable in a year prior to the year in which Shares are issued upon settlement of the Performance Award, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 9.&#160;&#160;&#160;&#160;Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 10.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgments</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.&#160;&#160;&#160;&#160;the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">j.&#160;&#160;&#160;&#160;for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award and any Dividend Equivalent Rights after such termination of employment or services (regardless of the reason for such termination and whether or not such </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any) will be measured by the date the Grantee ceases to actively provide services and will not be extended by any notice period (e.g., active service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively providing services for purposes of the Award (including whether the Grantee may still be considered to be actively providing services while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">k.&#160;&#160;&#160;&#160;unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l.&#160;&#160;&#160;&#160;the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m.&#160;&#160;&#160;&#160;the Company has communicated share ownership guidelines that apply to the Grantee, and the Grantee understands and agrees that those guidelines may impact any shares of Lilly Stock that may be issued pursuant to this Award.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 11.&#160;&#160;&#160;&#160;Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Performance Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on Applicable Laws and that, depending on where the Grantee is based and subject to the conditions set out in such Applicable Laws, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 12.&#160;&#160;&#160;&#160;Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In consideration of the Grantee&#8217;s receipt of the Award from Lilly, the Grantee agrees that during the Grantee&#8217;s employment with Lilly or an Affiliate that the Grantee provided services to or had access to confidential information concerning (&#8220;Covered Affiliate&#8221;) and for twelve (12) months immediately following the end of the Grantee&#8217;s employment (regardless of reason), the Grantee will not directly or indirectly, on a worldwide basis, engage in any of the following activities&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;Work for, advise, manage, act as an agent, employee or consultant for, or otherwise provide any services, in a Competitively-Sensitive Capacity, to&#58; (a) any person or entity engaged in research, development, production, sale, or distribution of a product or service competitive with or substantially similar to any product or service in research, development or design, or manufactured, produced, sold, or distributed by Lilly or a Covered Affiliate&#59; </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or (b) any person or entity that otherwise competes or intends to compete with Lilly or a Covered Affiliate.    </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;Directly or indirectly solicit, urge, divert, induce, or seek to induce any of Lilly&#8217;s (or Covered Affiliate&#8217;s) independent contractors, subcontractors, business partners, distributors, brokers, consultants, sales representatives, customers, vendors, suppliers or any other person with whom Lilly or Covered Affiliate has a business relationship and with whom the Grantee interacted during the Grantee&#8217;s employment with Lilly or Covered Affiliate to terminate their relationship with, or representation of, Lilly or Covered Affiliate or to cancel, withdraw, reduce, limit or in any manner modify any such person's business with, or representation of, Lilly or a Covered Affiliate. </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges and agrees that any Lilly Affiliate is an intended third-party beneficiary of this Award Agreement, which may be enforced by Lilly or any such Affiliate, either singularly or jointly.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Competitively-Sensitive Capacity&#8221; means&#58; (A) the same or similar capacity or function in which the Grantee worked for Lilly or a Covered Affiliate at any time during the two (2) years immediately preceding the end of the Grantee&#8217;s employment&#59; (B) any officer, director, executive or senior management capacity or function&#59; (C) any research and development capacity or function&#59; (D) any sales management or business development management capacity or function&#59; (E) any ownership capacity (except the Grantee may own as a passive investment up to 2% of any publicly traded securities)&#59; and&#47;or (F) any other capacity or function in which there is a material risk that the Grantee likely would inevitably use or disclose trade secrets and&#47;or confidential information Lilly or a Covered Affiliate.  For purposes of clarity, if a competing business has multiple divisions, lines or segments, some of which are not competitive with the business of Lilly, including its Covered Affiliates, nothing in this Award Agreement will prohibit the Grantee from being employed by, working for or assisting only that division, line or segment of such competing business that is not competitive with the business of Lilly or a Covered Affiliate, provided the Grantee is not involved in a Competitively-Sensitive Capacity in the research, development, manufacture, provision or sale of any products that compete with any products of Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee and Lilly acknowledge and agree that the worldwide geographic scope of the foregoing covenants is reasonable and necessary given, among other things, that&#58; (a) absent the restrictions, the Grantee could utilize Lilly&#8217;s (or its Affiliates) trade secrets and&#47;or confidential information and compete with Lilly or Affiliate from virtually anywhere&#59; and (b) such scope is the only way for Lilly and its Affiliates to protect their trade secrets and confidential information.  In the event the Grantee violates any of the restrictive covenants contained herein, their duration will automatically be extended by the length of time during which the Grantee was in violation of any of the restrictive covenants.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges and agrees that during the course of the Grantee&#8217;s employment with Lilly or a Covered Affiliate, the Grantee will become intimately familiar with confidential information and trade secrets key to its unique competitive advantage.  The Grantee also acknowledges and agrees that Lilly&#8217;s (and Covered Affiliate&#8217;s) confidential information and trade secrets will retain continuing vitality throughout and beyond the one-year restricted period.  And the Grantee acknowledges and agrees that, should the Grantee leave Lilly or Covered Affiliate and, near the Grantee&#8217;s departure from Lilly or Covered Affiliate, work with another person or entity that engages in business activities similar to those of Lilly and&#47;or Covered Affiliate, it would be highly likely, if not inevitable, that the Grantee would rely on confidential information of Lilly and&#47;or Covered Affiliate in the course of the Grantee&#8217;s work, either consciously or subconsciously, harming Lilly and any </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Covered Affiliates.  For these and other reasons, the Grantee agrees that the restrictions above are reasonably necessary to protect Lilly&#8217;s and its Covered Affiliate&#8217;s legitimate business interests, and do so by creating a specific amount of time after the Grantee&#8217;s employment ends during which the Grantee will not be able to engage or prepare to engage in the activities above.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee and Lilly further acknowledge and agree that if any particular covenant or provision is determined to be unreasonable or unenforceable for any reason, including, without limitation, the time period, geographic area, and&#47;or scope of activity covered by any restrictive covenant, such covenant or provision will automatically be deemed reformed so that the contested covenant or provision will have the closest effect permitted by applicable law to the original form and will be given effect and enforced as so reformed to whatever extent would be reasonable and enforceable under applicable law.  Any court interpreting any restrictive covenant provision of this Award Agreement will, if necessary, reform any such provision to make it enforceable under applicable law.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Award Agreement is intended, among other things, to supplement (and not supersede) all applicable statutes protecting trade secrets and the duties the Grantee owes to Lilly and&#47;or Covered Affiliates under the common law, as well as any other non-competition, non-solicitation, or confidentiality provisions that the Grantee agreed to in the past, including those in the Grantee&#8217;s Employee Confidentiality and Invention Agreement and any other Non-Compete Payment Agreement entered into between Grantee and Lilly, each of which remains in full force and effect, or that the Grantee agrees to in the future.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges that a breach by the Grantee of this Award Agreement will give rise to irreparable injury to Lilly and Covered Affiliates and money damages will not be adequate relief for such injury.  As a result, the Grantee agrees that Lilly (including any third-party beneficiary) will be entitled to obtain equitable or injunctive relief without having to post any bond or other security to restrain or prohibit any such breach or threatened breach, in addition to any other remedies which may be available, including the recovery of monetary damages from the Grantee.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Company determines that the Grantee has violated any applicable provisions of this Section 12, in addition to injunctive relief and damages, the Grantee agrees and covenants that&#58; (i) the Award shall be immediately rescinded&#59; (ii) the Grantee shall automatically forfeit any rights the Grantee may have with respect to the Award as of the date of such determination, including the rights to continue to be eligible to vest or receive a payment under the Award&#59; and (iii) the foregoing remedies set forth in this Section 12 shall not be Lilly&#8217;s exclusive remedies.  Lilly reserves all other rights and remedies available to it at law or in equity.</font><font style="color:#c00000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Insider Trading &#47; Market Abuse Laws</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Grantee may be subject to insider trading restrictions and&#47;or market abuse laws in applicable jurisdictions, including but not limited to the United States and the Grantee&#8217;s country of residence, which may affect the Grantee&#8217;s ability to directly or indirectly, for the Grantee or for a third party, acquire or sell, or attempt to sell, or otherwise dispose of Shares, rights to acquire Shares (e.g., the Performance Award) under the Plan during such times as the Grantee is considered to have &#8220;inside information&#8221; regarding the Company (as determined under the laws or regulations in the applicable jurisdictions).  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  The Grantee acknowledges that it is his or her responsibility to comply with any applicable restrictions, and the Grantee should consult with his or her personal legal advisor on this matter.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Performance Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 13.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the application of substantive law of any jurisdiction other than Indiana.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in Marion</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 14.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Grantee acknowledges that he or she is proficient in the English language or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different from the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 15.&#160;&#160;&#160;&#160;Compensation Recovery</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At any time during the three years following the date on which the number of Performance Units subject to the Award has been determined under Section 2 above, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any Shares that have been issued or cash that has been paid pursuant to this Award if&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;(i) the number of Shares or the amount of the cash payment was calculated based, directly or indirectly, upon the achievement of financial results that were subsequently the subject of a restatement of all or a portion of the Company&#8217;s financial statements&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) the number of Shares or the amount of cash payment that would have been issued or paid to the Grantee had the financial results been properly reported would have been lower than the number of Shares actually issued or the amount of cash actually paid&#59; or </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such misconduct causes significant harm to the company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Furthermore, in the event the number of Shares issued or cash paid pursuant to this Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will (A) seek restitution of the Shares or cash paid pursuant to this Award to the extent that the number of Shares issued or the amount paid exceeded the number of Shares that would have been issued or the amount that would have been paid had the inaccuracy or error not occurred, or (B) issue additional Shares or make additional payment to the extent that the number of Shares issued or the amount paid was less than the correct amount.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Section 15 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 16.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:270pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ELI LILLY AND COMPANY</font></div><div style="padding-left:270pt;text-align:justify"><font><br></font></div><div style="padding-left:270pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:270pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _________________________</font></div><div style="padding-left:270pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 16</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>lly-20221231x10kexhibit103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3f4c42309c954804baf16c7a42215948_111"></div><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="padding-left:15.3pt;padding-right:15.3pt;text-align:center"><font><br></font></div><div style="padding-left:19.8pt;padding-right:19.8pt;text-align:center"><font><br></font></div><div style="padding-right:39.6pt"><font><br></font></div><div style="padding-right:39.6pt"><font><br></font></div><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.3 Form of Shareholder Value Award under the 2002 Lilly Stock Plan</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Shareholder Value Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:24pt;font-weight:400;line-height:100%">(for Executive Officers)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Shareholder Value Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Shareholder Value Award Agreement (the &#8220;Grantee&#8221;).</font></div><div style="padding-right:39.6pt"><font><br></font></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Lilly Stock Price Performance Levels&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">&#91;&#8226;&#93;</font></div><div style="padding-right:39.6pt"><font><br></font></div><div style="padding-left:19.8pt;padding-right:19.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Period&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:14pt;font-weight:400;line-height:100%">&#91;&#8226;&#93; &#8211; &#91;&#8226;&#93;</font></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Table of Contents</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant of Shareholder Value Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grantee&#8217;s Acknowledgment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 11.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 12.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 13.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 14.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 15.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 16.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></td></tr></table></div><div style="padding-left:23.75pt"><font><br></font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 2</font></div></div></div><div id="i3f4c42309c954804baf16c7a42215948_114"></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer) </font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 1.&#160;&#160;&#160;&#160;Grant of Shareholder Value Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Shareholder Value Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Shareholder Value Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#34;Target Number of Shares&#34;).</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Shareholder Value Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern except with respect to the provisions described in Section 12 below (in which case, the terms of the Award Agreement shall govern). </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of Shares that are eligible to vest which shall be equal to the product of (i) the Target Number of Shares, multiplied by (ii) the Percent of Target, where&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Percent of Target</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the percentage set forth in the Lilly Stock Price Performance Levels table set forth on the first page of this document representing the attainment level of the Final Lilly Stock Price measured against the performance goal attainment levels set forth in the table.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Lilly Stock Price</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the average of the closing price of a share of Lilly Common Stock on the New York Stock Exchange for each trading day in the last two months of the Performance Period, rounded to the nearest cent. </font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event the Grantee&#8217;s Service is terminated prior to the end of the Performance Period for any reason or in any circumstance other than as described in Section 3 below, the Award shall be forfeited.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 3.&#160;&#160;&#160;&#160;Impact of Certain Employment Status Changes</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retirement&#59; Death</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided below (including Section 12), in the event the Grantee&#8217;s Service is terminated (i) on or following the Retirement Vesting Date (A) due to the Grantee&#8217;s Retirement or (B) due to the Grantee&#8217;s Qualifying Termination (as defined below) on a date that the Grantee is eligible for Retirement, or (ii) due to the Grantee&#8217;s death, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.  For the avoidance of any doubt, the Award shall be forfeited in the event the Grantee&#8217;s Service is terminated prior to the Retirement Vesting Date due to the Grantee&#8217;s Retirement.</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement&#8221; means retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under The Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements or (E) otherwise determined to be a retired employee in the sole discretion of the Company. A Grantee who has not received a year-end individual performance rating and (i) is on final written warning (or equivalent as determined by the Committee) for unsatisfactory performance and elects to retire in lieu of a termination of employment&#59; or (ii) elects to retire in lieu of termination of employment because of an immediately terminable offense (e.g., absence of three days without notice, insubordination, violation of substance abuse policy, possession of firearms, misconduct) will not be considered to have terminated due to Retirement as described herein.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement Vesting Date&#8221; means the date that is on or following December 31 immediately following the commencement of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided in section 3(b), in the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation, including reallocation due to the Grantee&#8217;s inability to continue to work due to medical reasons, in the United States (or equivalent as determined by the Committee).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee may, in its sole discretion, cancel this Shareholder Value Award or reduce the number of Shares eligible to vest, prorated according to time or other measure as determined appropriate by the Committee, if during any portion of the Performance Period the Grantee has been (i) subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Retirement, (3) the Grantee is eligible for Retirement, (4) the Grantee&#8217;s Service has been terminated as a direct result of either a plant closing or a reduction in force, and (5) the Grantee's service has been terminated as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 4.&#160;&#160;&#160;&#160;Change in Control</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;In the event of a Transaction that occurs prior to the end of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Shares eligible to vest, calculated in a manner consistent with Section 2, but the Final Lilly Stock Price shall be equal to the value of Shares established for the consideration to be paid to holders of Shares in the Transaction (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the end of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (as amended from time to time) or any successor plan or arrangement thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 4, then references to Shares in this Award Agreement shall be read to mean stock of the successor or surviving corporation, or a parent or subsidiary thereof, as and when applicable.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 5.&#160;&#160;&#160;&#160;Settlement  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Except as provided below, the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the last day of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;If the Award vests pursuant to Section 4(b)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered an item of non-qualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;) and the Transaction does not constitute a &#8220;change in control event,&#8221; within the meaning of the U.S. Treasury Regulations (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the earliest of (i) the date that the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;Section 409A Separation&#8221;), provided that if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date, the Award shall instead be paid on the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation, (ii) the date of the Grantee&#8217;s death and (iii) the date set forth in Section 5(a) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;If the Award vests pursuant to Section 4(b)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation (and provided that the Transaction constitutes a 409A CIC), (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a Section 409A Separation, and (ii) if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the date of the Section 409A Separation, the Award shall instead be paid on the earliest of (1) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation, and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;At the time of settlement provided in this Section 5,</font><font style="color:#0000ff;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(e) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;At any time prior to the end of the Performance Period or until the Award is paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Award in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Performance Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 6.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Shareholder Value Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Shareholder Value Award is settled and Shares are issued or transferred to the Grantee.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 7.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 8.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i) make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Shareholder Value Award, the vesting of the Shareholder Value Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;If the Shareholder Value Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;If the Shareholder Value Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C) withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;If the Shareholder Value Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for Tax-Related Items other than U.S. Federal Insurance Contribution Act taxes or other Tax-Related Items that become payable in a year prior to the year in which Shares are issued upon settlement of the </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Shareholder Value Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 10.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgment</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.&#160;&#160;&#160;&#160;the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">j.&#160;&#160;&#160;&#160;for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award after such </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">termination of employment or services (regardless of the reason for such termination and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any) will be measured by the date the Grantee ceases to actively provide services and will not be extended by any notice period (e.g., active service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively providing services for purposes of the Award (including whether the Grantee may still be considered to be actively providing services while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">k.&#160;&#160;&#160;&#160;unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l.&#160;&#160;&#160;&#160;the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m.&#160;&#160;&#160;&#160;the Company has communicated share ownership guidelines that apply to the Grantee, and the Grantee understands and agrees that those guidelines may impact any Shares subject to, or issued pursuant to the Award.   </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Shareholder Value Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on Applicable Laws and that, depending on where the Grantee is based and subject to the conditions set out in such Applicable Laws, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 12.&#160;&#160;&#160;&#160;Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In consideration of the Grantee&#8217;s receipt of the Award from Lilly, the Grantee agrees that during the Grantee&#8217;s employment with Lilly or an Affiliate that the Grantee provided services to or had access to confidential information concerning (&#8220;Covered Affiliate&#8221;) and for twelve (12) months immediately following the end of the Grantee&#8217;s employment (regardless of reason), the Grantee will not directly or indirectly, on a worldwide basis, engage in any of the following activities&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;Work for, advise, manage, act as an agent, employee or consultant for, or otherwise provide any services, in a Competitively-Sensitive Capacity, to&#58; (a) any person or </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">entity engaged in research, development, production, sale, or distribution of a product or service competitive with or substantially similar to any product or service in research, development or design, or manufactured, produced, sold, or distributed by Lilly or a Covered Affiliate&#59; or (b) any person or entity that otherwise competes or intends to compete with Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;Directly or indirectly solicit, urge, divert, induce, or seek to induce any of Lilly&#8217;s (or Covered Affiliate&#8217;s) independent contractors, subcontractors, business partners, distributors, brokers, consultants, sales representatives, customers, vendors, suppliers or any other person with whom Lilly or Covered Affiliate has a business relationship and with whom the Grantee interacted during the Grantee&#8217;s employment with Lilly or Covered Affiliate to terminate their relationship with, or representation of, Lilly or Covered Affiliate or to cancel, withdraw, reduce, limit or in any manner modify any such person's business with, or representation of, Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges and agrees that any Lilly Affiliate is an intended third-party beneficiary of this Award Agreement, which may be enforced by Lilly or any such Affiliate, either singularly or jointly.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Competitively-Sensitive Capacity&#8221; means&#58; (A) the same or similar capacity or function in which the Grantee worked for Lilly or a Covered Affiliate at any time during the two (2) years immediately preceding the end of the Grantee&#8217;s employment&#59; (B) any officer, director, executive or senior management capacity or function&#59; (C) any research and development capacity or function&#59; (D) any sales management or business development management capacity or function&#59; (E) any ownership capacity (except the Grantee may own as a passive investment up to 2% of any publicly traded securities)&#59; and&#47;or (F) any other capacity or function in which there is a material risk that the Grantee likely would inevitably use or disclose trade secrets and&#47;or confidential information Lilly or a Covered Affiliate.  For purposes of clarity, if a competing business has multiple divisions, lines or segments, some of which are not competitive with the business of Lilly, including its Covered Affiliates, nothing in this Award Agreement will prohibit the Grantee from being employed by, working for or assisting only that division, line or segment of such competing business that is not competitive with the business of Lilly or a Covered Affiliate, provided the Grantee is not involved in a Competitively-Sensitive Capacity in the research, development, manufacture, provision or sale of any products that compete with any products of Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee and Lilly acknowledge and agree that the worldwide geographic scope of the foregoing covenants is reasonable and necessary given, among other things, that&#58; (a) absent the restrictions, the Grantee could utilize Lilly&#8217;s (or its Affiliates) trade secrets and&#47;or confidential information and compete with Lilly or Affiliate from virtually anywhere&#59; and (b) such scope is the only way for Lilly and its Affiliates to protect their trade secrets and confidential information.  In the event the Grantee violates any of the restrictive covenants contained herein, their duration will automatically be extended by the length of time during which the Grantee was in violation of any of the restrictive covenants.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges and agrees that during the course of Grantee&#8217;s employment with Lilly or a Covered Affiliate, the Grantee will become intimately familiar with confidential information and trade secrets key to its unique competitive advantage.  The Grantee also acknowledges and agrees that Lilly&#8217;s (and Covered Affiliate&#8217;s) confidential information and trade secrets will retain continuing vitality throughout and beyond the one-year restricted period.  And the Grantee acknowledges and agrees that, should the Grantee leave Lilly or Covered Affiliate and, near the Grantee&#8217;s departure from Lilly or </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Covered Affiliate, work with another person or entity that engages in business activities similar to those of Lilly and&#47;or Covered Affiliate, it would be highly likely, if not inevitable, that the Grantee would rely on confidential information of Lilly and&#47;or Covered Affiliate in the course of the Grantee&#8217;s work, either consciously or subconsciously, harming Lilly and any Covered Affiliates.  For these and other reasons, the Grantee agrees that the restrictions above are reasonably necessary to protect Lilly&#8217;s and its Covered Affiliate&#8217;s legitimate business interests, and do so by creating a specific amount of time after the Grantee&#8217;s employment ends during which the Grantee will not be able to engage or prepare to engage in the activities above.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee and Lilly further acknowledge and agree that if any particular covenant or provision is determined to be unreasonable or unenforceable for any reason, including, without limitation, the time period, geographic area, and&#47;or scope of activity covered by any restrictive covenant, such covenant or provision will automatically be deemed reformed so that the contested covenant or provision will have the closest effect permitted by applicable law to the original form and will be given effect and enforced as so reformed to whatever extent would be reasonable and enforceable under applicable law.  Any court interpreting any restrictive covenant provision of this Award Agreement will, if necessary, reform any such provision to make it enforceable under applicable law.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Award Agreement is intended, among other things, to supplement (and not supersede) all applicable statutes protecting trade secrets and the duties the Grantee owes to Lilly and&#47;or Covered Affiliates under the common law, as well as any other non-competition, non-solicitation, or confidentiality provisions that the Grantee agreed to in the past, including those in the Grantee&#8217;s Employee Confidentiality and Invention Agreement and any other Non-Compete Payment Agreement entered into between Grantee and Lilly, each of which remains in full force and effect, or that the Grantee agrees to in the future.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges that a breach by the Grantee of this Award Agreement will give rise to irreparable injury to Lilly and Covered Affiliates and money damages will not be adequate relief for such injury.  As a result, the Grantee agrees that Lilly (including any third party beneficiary) will be entitled to obtain equitable or injunctive relief without having to post any bond or other security to restrain or prohibit any such breach or threatened breach, in addition to any other remedies which may be available, including the recovery of monetary damages from the Grantee.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Company determines that the Grantee has violated any applicable provisions of this Section 12, in addition to injunctive relief and damages, the Grantee agrees and covenants that&#58; (i) the Award shall be immediately rescinded&#59; (ii) the Grantee shall automatically forfeit any rights the Grantee may have with respect to the Award as of the date of such determination, including the rights to continue to be eligible to vest or receive a payment under the Award&#59; and (iii) the foregoing remedies set forth in this Section 12 shall not be Lilly&#8217;s exclusive remedies.  Lilly reserves all other rights and remedies available to it at law or in equity. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Insider Trading &#47; Market Abuse Laws</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Grantee may be subject to insider trading restrictions and&#47;or market abuse laws in applicable jurisdictions, including but not limited to the United States and the Grantee&#8217;s country of residence, which may affect the Grantee&#8217;s ability to directly or indirectly, for the Grantee or for a third party, acquire or sell, or attempt to sell, or otherwise dispose of Shares, rights to acquire Shares (e.g., the Shareholder Value Award) under the Plan during such times as the Grantee is considered to have &#8220;inside information&#8221; regarding the Company (as determined under the laws or regulations in the applicable jurisdictions).  Any restrictions under these laws or </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  The Grantee acknowledges that it is his or her responsibility to comply with any applicable restrictions, and the Grantee should consult with his or her personal legal advisor on this matter.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Shareholder Value Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 13.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the application of substantive law of any jurisdiction other than Indiana.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in Marion</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 14.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Grantee acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 15.&#160;&#160;&#160;&#160;Compensation Recovery</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At any time during the three years following the date on which the number of Shares eligible to vest under this Award has been determined under Section 2 above, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any Shares that have been issued or cash that has been paid pursuant to this Award if&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;(i) the number of Shares or the amount of the cash payment was calculated based, directly or indirectly, upon the achievement of financial results that were subsequently the subject of a restatement of all or a portion of the Company&#8217;s financial statements, (ii) the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and (iii) the number of Shares or the amount of cash payment that would have been issued or paid to the Grantee had the financial results been properly reported would have been lower than the number of Shares actually issued or the amount of cash actually paid&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such misconduct causes significant harm to the company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Furthermore, in the event the number of Shares issued or cash paid pursuant to this Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will (A) seek restitution of the Shares or cash paid pursuant to this Award to the extent that the number of Shares issued or the amount paid exceeded the number of Shares that would have been issued or the amount that would have been paid had the inaccuracy or error not occurred, or (B) issue additional Shares or make additional payment to the extent that the number of Shares issued or the amount paid was less than the correct amount.</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Section 15 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 16.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:274.5pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _________________________</font></div><div style="padding-left:288pt"><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 14</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>4
<FILENAME>lly-20221231x10kexhibit104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="idd2a7c3d2df24900b4dfecc7dedd2441_183"></div><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="padding-left:15.3pt;padding-right:15.3pt;text-align:center"><font><br></font></div><div style="padding-left:19.8pt;padding-right:19.8pt;text-align:center"><font><br></font></div><div style="padding-right:39.6pt"><font><br></font></div><div style="padding-right:39.6pt"><font><br></font></div><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.4 Form of Relative Value Award under the 2002 Lilly Stock Plan</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Relative Value Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:24pt;font-weight:400;line-height:100%">(for Executive Officers)</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:18pt;padding-right:9pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Relative Value Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Relative Value Award Agreement (the &#8220;Grantee&#8221;).</font></div><div style="padding-left:18pt;padding-right:39.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:39.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:39.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Lilly Relative Total Shareholder Return Performance Levels&#58; &#91;&#8226;&#93;</font></div><div style="padding-left:18pt;padding-right:39.6pt"><font><br></font></div><div style="padding-left:13.5pt;padding-right:39.6pt"><font><br></font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Period&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:14pt;font-weight:400;line-height:100%">&#91;&#8226;&#93; &#8211; &#91;&#8226;&#93;</font></div><div style="padding-left:128.25pt;padding-right:128.25pt;text-align:center;text-indent:-198pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Table of Contents</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant of Relative Value Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grantee&#8217;s Acknowledgment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 11.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 12.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 13.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 14.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 15.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 16.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></td></tr></table></div><div style="padding-left:23.75pt"><font><br></font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 2</font></div></div></div><div id="idd2a7c3d2df24900b4dfecc7dedd2441_186"></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Relative Value Award</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 1.&#160;&#160;&#160;&#160;Grant of Relative Value Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Relative Value Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Relative Value Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#34;Target Number of Shares&#34;).</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Relative Value Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern except with respect to the provisions described in Section 12 below (in which case, the terms of the Award Agreement shall govern). </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of Shares that are eligible to vest which shall be equal to the product of (i) the Target Number of Shares, multiplied by (ii) the Payout Multiple, where&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payout Multiple</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the payout multiple set forth in the Lilly Relative Total Shareholder Return Performance Levels table set forth on the first page of this document, representing the attainment level of Lilly&#8217;s rTSR, measured against the performance goal attainment levels set forth in the table.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Lilly Stock Price</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the average of the closing price of a share of Lilly Common Stock on the New York Stock Exchange for each trading day in the last two months of the Performance Period, rounded to the nearest cent. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Total Shareholder Return</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">TSR</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the quotient of (i) the Final Lilly Stock Price or Final Peer Stock Price, as applicable, minus the corresponding Beginning Stock Price, including the impact of Dividend reinvestment on each ex-dividend date, if any, paid by the applicable issuer during the Performance Period, divided by (ii) the corresponding Beginning Stock Price.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The stock prices and cash dividend payments reflected in the calculation of TSR shall be adjusted to reflect stock splits during the Performance Period and dividends shall be assumed to be reinvested in the relevant issuer&#8217;s shares for purposes of the calculation of TSR.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Relative Total Shareholder Return</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">rTSR</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the comparison between Lilly&#8217;s TSR and the TSR of the Peer Group over the Performance Period, measured as the absolute percentage point difference in the performance of the Company&#8217;s TSR compared to the Peer Group&#8217;s median TSR.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Beginning Stock Price</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the average closing price of a share of Lilly Common Stock on the New York Stock Exchange or a share of each Peer Group company&#8217;s stock, as applicable, for each trading day in the two month period immediately preceding the Performance Period, rounded to the nearest cent.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Peer Stock Price</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the average of the closing price of a share of each Peer Group company&#8217;s stock, on Nasdaq, the New York Stock Exchange, or other market where an independent share price can be </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determined, for each trading day in the last two months of the Performance Period, rounded to the nearest cent.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dividend</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean ordinary or extraordinary cash dividends paid by Lilly or a Peer Group company to its shareholders of record at any time during the Performance Period.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Peer Group</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all companies identified and most recently approved by the Committee as a member of the Company&#8217;s Peer Group in effect as of the Grant Date.  Companies that are members of the Peer Group at the beginning of the Performance Period that subsequently cease to be traded on a market where an independent share price can be determined shall be excluded from the Peer Group.   </font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event the Grantee&#8217;s Service is terminated prior to the end of the Performance Period for any reason or in any circumstance other than as described in Section 3 below, the Award shall be forfeited.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 3.&#160;&#160;&#160;&#160;Impact of Certain Employment Status Changes</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retirement&#59; Death</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided below (including Section 12), in the event the Grantee&#8217;s Service is terminated (i) on or following the Retirement Vesting Date (A) due to the Grantee&#8217;s Retirement or (B) due to the Grantee&#8217;s Qualifying Termination (as defined below) on a date that the Grantee is eligible for Retirement, or (ii) due to the Grantee&#8217;s death, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.  For the avoidance of any doubt, the Award shall be forfeited in the event the Grantee&#8217;s Service is terminated prior to the Retirement Vesting Date due to the Grantee&#8217;s Retirement. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement&#8221; means retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under The Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements or (E) otherwise determined to be a retired employee in the sole discretion of the Company. A Grantee who has not received a year-end individual performance rating and (i) is on final written warning (or equivalent as determined by the Committee) for unsatisfactory performance and elects to retire in lieu of a termination of employment&#59; or (ii) elects to retire in lieu of termination of employment because of an immediately terminable offense (e.g., absence of three days without notice, insubordination, violation of substance abuse policy, possession of firearms, misconduct) will not be considered to have terminated due to Retirement as described herein.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement Vesting Date&#8221; means the date that is on or following December 31 immediately following the commencement of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided in section 3(b), in the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the number of Shares eligible to vest shall be the number determined in accordance with </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation, including reallocation due to the Grantee&#8217;s inability to continue to work due to medical reasons, in the United States (or equivalent as determined by the Committee).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee may, in its sole discretion, cancel this Relative Value Award or reduce the number of Shares eligible to vest, prorated according to time or other measure as determined appropriate by the Committee, if during any portion of the Performance Period the Grantee has been (i) subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Retirement, (3) the Grantee is eligible for Retirement, (4) the Grantee&#8217;s Service has been terminated as a direct result of either a plant closing or a reduction in force and (5) the Grantee&#8217;s Service has been terminated of as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 4.&#160;&#160;&#160;&#160;Change in Control</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;In the event of a Transaction that occurs prior to the end of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Shares eligible to vest, calculated in a manner consistent with Section 2, but the Final Lilly Stock Price shall be equal to the value of Shares established for the consideration to be paid to holders of Shares in the Transaction and the Final Peer Stock Price shall be equal to the closing price of a share of each Peer Group company&#8217;s stock, on Nasdaq, the New York Stock Exchange, or other market where an independent share price can be determined, on the date the Transaction closes (or if such day is not a trading date, the first trading date immediately preceding such date) (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the end of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (as amended from time to time) or any successor plan or arrangement thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 4, then references to Shares in this Award Agreement shall be read to mean stock of the successor or surviving corporation, or a parent or subsidiary thereof, as and when applicable.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 5.&#160;&#160;&#160;&#160;Settlement  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Except as provided below, the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the last day of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;If the Award vests pursuant to Section 4(b)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered an item of non-qualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;) and the Transaction does not constitute a &#8220;change in control event,&#8221; within the meaning of the U.S. Treasury Regulations (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the earliest of (i) the date that the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;Section 409A Separation&#8221;), provided that if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation, (ii) the date of the Grantee&#8217;s death and (iii) the date set forth in Section 5(a) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;If the Award vests pursuant to Section 4(b)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation (and provided that the Transaction constitutes a 409A CIC), (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a Section 409A Separation, and (ii) if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the date of the Section 409A Separation, the Award shall instead be paid on the earliest of (1) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;At the time of settlement provided in this Section 5,</font><font style="color:#0000ff;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(e) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;At any time prior to the end of the Performance Period or until the Award is paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Award in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Performance Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 6.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Relative Value Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Relative Value Award is settled and Shares are issued or transferred to the Grantee.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 7.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 8.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i) make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Relative Value Award, the vesting of the Relative Value Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;If the Relative Value Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;If the Relative Value Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C) withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;If the Relative Value Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for Tax-Related Items other than U.S. Federal Insurance Contribution Act taxes or other Tax-Related Items that become payable in a year prior to the year in which Shares are issued upon settlement of the </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Relative Value Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 10.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgment</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;unless otherwise agreed with Lilly, the Award and any Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, the service the Grantee may provide as a director of an Affiliate&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.&#160;&#160;&#160;&#160;neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">j.&#160;&#160;&#160;&#160;no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">k.&#160;&#160;&#160;&#160;for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award after such termination of employment or services (regardless of the reason for such termination and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any) will be measured by the date the Grantee ceases to actively provide services and will not be extended by any notice period (e.g., active service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively providing services for purposes of the Award (including whether the Grantee may still be considered to be actively providing services while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l.&#160;&#160;&#160;&#160;unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m.&#160;&#160;&#160;&#160;the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n.&#160;&#160;&#160;&#160;neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between the Grantee&#8217;s local currency and the United States Dollar that may affect the value of the Award or any amounts due to the Grantee pursuant to the settlement of the Award or the subsequent sale of any Shares acquired upon settlement.   </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Relative Value Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on Applicable Laws and that, depending on where the Grantee is based and subject to the conditions set out in such Applicable Laws, the Grantee </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 12.&#160;&#160;&#160;&#160;Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In consideration of the Grantee&#8217;s receipt of the Award from Lilly, the Grantee agrees that during the Grantee&#8217;s employment with Lilly or an Affiliate that the Grantee provided services to or had access to confidential information concerning (&#8220;Covered Affiliate&#8221;) and for twelve (12) months immediately following the end of the Grantee&#8217;s employment (regardless of reason), the Grantee will not directly or indirectly, on a worldwide basis, engage in any of the following activities&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;Work for, advise, manage, act as an agent, employee or consultant for, or otherwise provide any services, in a Competitively-Sensitive Capacity, to&#58; (a) any person or entity engaged in research, development, production, sale, or distribution of a product or service competitive with or substantially similar to any product or service in research, development or design, or manufactured, produced, sold, or distributed by Lilly or a Covered Affiliate&#59; or (b) any person or entity that otherwise competes or intends to compete with Lilly or a Covered Affiliate.    </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;Directly or indirectly solicit, urge, divert, induce, or seek to induce any of Lilly&#8217;s (or Covered Affiliate&#8217;s) independent contractors, subcontractors, business partners, distributors, brokers, consultants, sales representatives, customers, vendors, suppliers or any other person with whom Lilly or Covered Affiliate has a business relationship and with whom the Grantee interacted during the Grantee&#8217;s employment with Lilly or Covered Affiliate to terminate their relationship with, or representation of, Lilly or Covered Affiliate or to cancel, withdraw, reduce, limit or in any manner modify any such person's business with, or representation of, Lilly or a Covered Affiliate. </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges and agrees that any Lilly Affiliate is an intended third-party beneficiary of this Award Agreement, which may be enforced by Lilly or any such Affiliate, either singularly or jointly.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Competively-Sensitive Capacity&#8221; means&#58; (A) the same or similar capacity or function in which the Grantee worked for Lilly or a Covered </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Affiliate at any time during the two (2) years immediately preceding the end of the Grantee&#8217;s employment&#59; (B) any officer, director, executive or senior management capacity or function&#59; (C) any research and development capacity or function&#59; (D) any sales management or business development management capacity or function&#59; (E) any ownership capacity (except the Grantee may own as a passive investment up to 2% of any publicly traded securities)&#59; and&#47;or (F) any other capacity or function in which there is a material risk that the Grantee likely would inevitably use or disclose trade secrets and&#47;or confidential information Lilly or a Covered Affiliate.  For purposes of clarity, if a competing business has multiple divisions, lines or segments, some of which are not competitive with the business of Lilly, including its Covered Affiliates, nothing in this Award Agreement will prohibit the Grantee from being employed by, working for or assisting only that division, line or segment of such competing business that is not competitive with the business of Lilly or a Covered Affiliate, provided the Grantee is not involved in a Competitively-Sensitive Capacity in the research, development, manufacture, provision or sale of any products that compete with any products of Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee and Lilly acknowledge and agree that the worldwide geographic scope of the foregoing covenants is reasonable and necessary given, among other things, that&#58; (a) absent the restrictions, the Grantee could utilize Lilly&#8217;s (or its Affiliates) trade secrets and&#47;or confidential information and compete with Lilly or Affiliate from virtually anywhere&#59; and (b) such scope is the only way for Lilly and its Affiliates to protect their trade secrets and confidential information.  In the event the Grantee violates any of the restrictive covenants contained herein, their duration will automatically be extended by the length of time during which the Grantee was in violation of any of the restrictive covenants.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges and agrees that during the course of the Grantee&#8217;s employment with Lilly or a Covered Affiliate, the Grantee will become intimately familiar with confidential information and trade secrets key to its unique competitive advantage.  The Grantee also acknowledges and agrees that Lilly&#8217;s (and Covered Affiliate&#8217;s) confidential information and trade secrets will retain continuing vitality throughout and beyond the one-year restricted period.  And the Grantee acknowledges and agrees that, should the Grantee leave Lilly or Covered Affiliate and, near the Grantee&#8217;s departure from Lilly or Covered Affiliate, work with another person or entity that engages in business activities similar to those of Lilly and&#47;or Covered Affiliate, it would be highly likely, if not inevitable, that the Grantee would rely on confidential information of Lilly and&#47;or Covered Affiliate in the course of the Grantee&#8217;s work, either consciously or subconsciously, harming Lilly and any Covered Affiliates.  For these and other reasons, the Grantee agrees that the restrictions above are reasonably necessary to protect Lilly&#8217;s and its Covered Affiliate&#8217;s legitimate business interests, and do so by creating a specific amount of time after the Grantee&#8217;s employment ends during which the Grantee will not be able to engage or prepare to engage in the activities above.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee and Lilly further acknowledge and agree that if any particular covenant or provision is determined to be unreasonable or unenforceable for any reason, including, without limitation, the time period, geographic area, and&#47;or scope of activity covered by any restrictive covenant, such covenant or provision will automatically be deemed reformed so that the contested covenant or provision will have the closest effect permitted by applicable law to the original form and will be given effect and enforced as so reformed to whatever extent would be reasonable and enforceable under applicable law.  Any court interpreting any restrictive covenant provision of this Award Agreement will, if necessary, reform any such provision to make it enforceable under applicable law.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Award Agreement is intended, among other things, to supplement (and not supersede) all applicable statutes protecting trade secrets and the duties the Grantee owes to Lilly and&#47;or Covered Affiliates under the common law, as well as any other non-</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">competition, non-solicitation, or confidentiality provisions that the Grantee agreed to in the past, including those in the Grantee&#8217;s Employee Confidentiality and Invention Agreement and any other Non-Compete Payment Agreement entered into between Grantee and Lilly, each of which remains in full force and effect, or that the Grantee agrees to in the future.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges that a breach by the Grantee of this Award Agreement will give rise to irreparable injury to Lilly and Covered Affiliates and money damages will not be adequate relief for such injury.  As a result, the Grantee agrees that Lilly (including any third party beneficiary) will be entitled to obtain equitable or injunctive relief without having to post any bond or other security to restrain or prohibit any such breach or threatened breach, in addition to any other remedies which may be available, including the recovery of monetary damages from the Grantee.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Company determines that the Grantee has violated any applicable provisions of this Section 12, in addition to injunctive relief and damages, the Grantee agrees and covenants that&#58; (i) the Award shall be immediately rescinded&#59; (ii) the Grantee shall automatically forfeit any rights the Grantee may have with respect to the Award as of the date of such determination, including the rights to continue to be eligible to vest or receive a payment under the Award&#59; and (iii) the foregoing remedies set forth in this Section 12 shall not be Lilly&#8217;s exclusive remedies.  Lilly reserves all other rights and remedies available to it at law or in equity.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Insider Trading &#47; Market Abuse Laws</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Grantee may be subject to insider trading restrictions and&#47;or market abuse laws in applicable jurisdictions, including but not limited to the United States and the Grantee&#8217;s country of residence, which may affect the Grantee&#8217;s ability to directly or indirectly, for the Grantee or for a third party, acquire or sell, or attempt to sell, or otherwise dispose of Shares, rights to acquire Shares (e.g., the Relative Value Award) under the Plan during such times as the Grantee is considered to have &#8220;inside information&#8221; regarding the Company (as determined under the laws or regulations in the applicable jurisdictions).  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  The Grantee acknowledges that it is his or her responsibility to comply with any applicable restrictions, and the Grantee should consult with his or her personal legal advisor on this matter.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Relative Value Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 13.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the application of substantive law of any jurisdiction other than Indiana.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in Marion</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">County, Indiana, or the federal courts for the </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 14.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Grantee acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:13pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 15.&#160;&#160;&#160;&#160;Compensation Recovery</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At any time during the three years following the date on which the number of Shares eligible to vest under this Award has been determined under Section 2 above, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any Shares that have been issued or cash that has been paid pursuant to this Award if&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;(i) the number of Shares or the amount of the cash payment was calculated based, directly or indirectly, upon the achievement of financial results that were subsequently the subject </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of a restatement of all or a portion of the Company&#8217;s financial statements, (ii) the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and (iii) the number of Shares or the amount of cash payment that would have been issued or paid to the Grantee had the financial results been properly reported would have been lower than the number of Shares actually issued or the amount of cash actually paid&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such misconduct causes significant harm to the company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Furthermore, in the event the number of Shares issued or cash paid pursuant to this Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will (A) seek restitution of the Shares or cash paid pursuant to this Award to the extent that the number of Shares issued or the amount paid exceeded the number of Shares that would have been issued or the amount that would have been paid had the inaccuracy or error not occurred, or (B) issue additional Shares or make additional payment to the extent that the number of Shares issued or the amount paid was less than the correct amount.</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Section 15 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 16.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:274.5pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _________________________</font></div><div><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 15</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>5
<FILENAME>lly-20221231x10kexhibit105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="idef66b84c4054144a9a48f7724a0ca16_77"></div><div style="min-height:84.96pt;width:100%"><div style="padding-left:360pt;text-indent:36pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.5 Form of Non-Compete Payment Agreement</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.320%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. +1.317.276.2000 www.lilly.com</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;&#8226;&#93;, &#91;&#8226;&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Name&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Address&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Address&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Non-Compete Payment Agreement</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dear &#91;Name&#93;&#58;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This sets forth the terms of the Non-Compete Payment Agreement (the &#8220;Agreement&#8221;) between &#91;name&#93; (&#8220;Executive&#8221;) and Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), regarding Executive&#8217;s post-employment restrictive covenants.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Notification of Subsequent Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. At least fourteen (14) calendar days before commencing employment or engaging in any other business activities during the Restricted Period (defined below), Executive agrees to provide the Chief Executive Officer and the Executive Vice President, Human Resources and Diversity (or equivalent) of the Company with written notification of the name and address of any subsequent employer or person or entity with whom or which Executive intends to engage in business activities and the nature of Executive&#8217;s job duties and other business activities. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Restrictive Covenants, Remedies, and Additional Terms and Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;As consideration for the Company&#8217;s obligations set forth in Section 3 below, Executive agrees that during Executive&#8217;s employment with Lilly or an affiliate that Executive provided services to or had access to confidential information concerning (&#8220;Covered Affiliate&#8221;) and for twelve (12) months immediately following the end of Executive&#8217;s employment (regardless of reason)(the &#8220;Restricted Period&#8221;), Executive will not directly or indirectly, on a worldwide basis, engage in any of the following activities&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;Work for, advise, manage, act as an agent, employee or consultant for, or otherwise provide any services, in a Competitively-Sensitive Capacity, to&#58; (a) any person or entity engaged in research, development, production, sale, or distribution of a product or service competitive with or substantially similar to any product or service in research, development or design, or manufactured, produced, sold, or distributed by Lilly or a Covered Affiliate&#59; or (b) any person or entity that otherwise competes or intends to compete with Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;Directly or indirectly solicit, urge, divert, induce, or seek to induce any of Lilly&#8217;s (or Covered Affiliate&#8217;s) independent contractors, subcontractors, business </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Employee Name&#93;</font></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Date&#93;</font></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 2 of 5</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">partners, distributors, brokers, consultants, sales representatives, customers, vendors, suppliers or any other person with whom Lilly or Covered Affiliate has a business relationship and with whom Executive interacted during Executive&#8217;s employment with Lilly or Covered Affiliate to terminate their relationship with, or representation of, Lilly or Covered Affiliate or to cancel, withdraw, reduce, limit or in any manner modify any such person's business with, or representation of, Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive acknowledges and agrees that any Lilly Affiliate is an intended third-party beneficiary of this Agreement, which may be enforced by Lilly or any such Affiliate, either singularly or jointly.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of this Agreement, &#8220;Competitively-Sensitive Capacity&#8221; means&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(A) the same or similar capacity or function in which Executive worked for Lilly or a Covered Affiliate at any time during the two (2) years immediately preceding the end of Executive&#8217;s employment&#59; (B) any officer, director, executive or senior management capacity or function&#59; (C) any research and development capacity or function&#59; (D) any sales management or business development management capacity or function&#59; (E) any ownership capacity (except Executive may own as a passive investment up to 2% of any publicly traded securities)&#59; and&#47;or (F) any other capacity or function in which there is a material risk that Executive likely would inevitably use or disclose trade secrets and&#47;or confidential information Lilly or a Covered Affiliate. For purposes of clarity, if a competing business has multiple divisions, lines or segments, some of which are not competitive with the business of Lilly, including its Covered Affiliates, nothing in this Agreement will prohibit Executive from being employed by, working for or assisting only that division, line or segment of such competing business that is not competitive with the business of Lilly or a Covered Affiliate, provided Executive is not involved in a Competitively-Sensitive Capacity in the research, development, manufacture, provision or sale of any products that compete with any products of Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive and Lilly acknowledge and agree that the worldwide geographic scope of the foregoing covenants is reasonable and necessary given, among other things, that&#58; (a) absent the restrictions, Executive could utilize Lilly&#8217;s (or its Affiliates) trade secrets and&#47;or confidential information and compete with Lilly or Affiliate from virtually anywhere&#59; and (b) such scope is the only way for Lilly and its Affiliates to protect their trade secrets and confidential information. In the event Executive violates any of the restrictive covenants contained herein, their duration will automatically be extended by the length of time during which Executive was in violation of any of the restrictive covenants.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive acknowledges and agrees that during the course of Executive&#8217;s employment with Lilly or a Covered Affiliate, Executive will become intimately familiar with confidential information and trade secrets key to its unique competitive advantage. Executive also acknowledges and agrees that Lilly&#8217;s (and Covered Affiliate&#8217;s) confidential information and trade secrets will retain continuing vitality throughout and beyond the one-year restricted period. And Executive acknowledges and agrees that, should Executive leave Lilly or Covered Affiliate and, near Executive&#8217;s departure from Lilly or Covered Affiliate, work with another person or entity that engages in business activities similar to those of Lilly and&#47;or Covered Affiliate, it would be highly likely, if not inevitable, that Executive would rely on confidential information of Lilly and&#47;or Covered Affiliate in the course of Executive&#8217;s work, either consciously or subconsciously, harming Lilly and any Covered Affiliates. For these and other reasons, Executive agrees that the restrictions above are reasonably necessary to protect Lilly&#8217;s and its Covered Affiliate&#8217;s legitimate business interests, and do so by creating a specific amount of time after Executive&#8217;s employment ends during which Executive will not be able to engage or prepare to engage in the activities above.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Employee Name&#93;</font></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Date&#93;</font></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 3 of 5</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive and Lilly further acknowledge and agree that if any particular covenant or provision is determined to be unreasonable or unenforceable for any reason, including, without limitation, the time period, geographic area, and&#47;or scope of activity covered by any restrictive covenant, such covenant or provision will automatically be deemed reformed so that the contested covenant or provision will have the closest effect permitted by applicable law to the original form and will be given effect and enforced as so reformed to whatever extent would be reasonable and enforceable under applicable law. Any court interpreting any restrictive covenant provision of this Agreement will, if necessary, reform any such provision to make it enforceable under applicable law.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement is intended, among other things, to supplement (and not supersede) all applicable statutes protecting trade secrets and the duties Executive owes to Lilly and&#47;or Covered Affiliates under the common law, as well as any other non-competition, non-solicitation, or confidentiality provisions that Executive agreed to in the past, including those in Executive&#8217;s Employee Confidentiality and Invention Agreement (the &#8220;ECIA), each of which remains in full force and effect, or that Executive agrees to in the future&#59; provided, however, the restrictive covenants contained herein shall supersede and replace the restrictive covenant provisions contained in any Performance Award Agreement (for Executive Officers), Relative Value Award Agreement (for Executive Officers), or Shareholder Value Award Agreement (for Executive Officers) entered into between Lilly and Executive (collectively, &#8220;Equity Grant Agreement&#8221; or &#8220;Equity Grant Agreements&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive acknowledges that a breach by Executive of this Agreement will give rise to irreparable injury to Lilly and Covered Affiliates and money damages will not be adequate relief for such injury. As a result, Executive agrees that Lilly (including any third-party beneficiary) will be entitled to obtain equitable or injunctive relief without having to post any bond or other security to restrain or prohibit any such breach or threatened breach, in addition to any other remedies which may be available, including the recovery of monetary damages from Executive.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Remedies. If the Company determines that Executive has violated any applicable provisions of this Section 2, in addition to injunctive relief and damages, Executive agrees and covenants that&#58; (i) the Non-Compete Payment shall immediately cease&#59; and (ii) the foregoing remedies set forth in this Section 2 shall not be Lilly&#8217;s exclusive remedies. Lilly reserves all other rights and remedies available to it at law or in equity.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non-Compete Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Subject to 3(b) and (c) below, upon Executive&#8217;s termination of employment, regardless of reason, the Company agrees to compensate Executive during any remaining  Restricted Period with a payment in the amount of &#91;amount&#93; (the &#8220;Non-Compete Payment&#8221;), less applicable deductions required by law for the payment of wages&#59; provided, however, that Company&#8217;s obligation to make the Non-Compete  Payment shall immediately cease if Executive violates Executive&#8217;s ECIA obligations owed to Company, or the restrictive covenants set forth herein. The Non-Compete Payment will be paid in equal amounts on a monthly basis and will be subject to applicable withholdings. The payment of the Non-Compete Payment shall be the sole obligation of Company hereunder, and all other benefits of employment shall terminate as of the date of termination, except as provided by law. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;In the event that Executive&#8217;s employment is terminated due to Executive&#8217;s Retirement, any performance-based award, relative value award, or shareholder value award received by Executive pursuant to any Equity Award Grant Agreement shall vest according to the terms of the applicable Equity Award Agreement.  Provided, however, Executive shall not be entitled to any Non-Compete Pay in the event that Executive&#8217;s employment terminates due to Executive&#8217;s Retirement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Employee Name&#93;</font></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Date&#93;</font></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 4 of 5</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Retirement&#8221; means retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired person under The Lilly Retirement Plan&#59; (B) a retired person under the retirement plan or program of an affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements&#59; or (E) otherwise determined to be a retired employee in the sole discretion of the Company.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As further inducement and consideration for this Section 3(b), Executive has received &#91;&#8226;&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;The Company may at any time, in its sole and absolute discretion, reduce the length of the Restricted Period. Executive shall not be entitled to receive any Non-Compete Payment from Company for any period of time for which the Restricted Period has been reduced or otherwise waived by Company.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">No Guarantee of Continued Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Nothing in this Agreement guarantees Executive&#8217;s employment for any period of time.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tolling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event of any violation of this Agreement, Executive agrees that the post-termination restrictions contained in Section 2 shall be extended by a period of time equal to the period of such violation, it being the intention of the Parties hereto that the running of the applicable post-termination Restricted Period shall be tolled during any period of such violation.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Attorneys&#8217; Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event of any breach or threatened breach by Executive of any provision of this Agreement, the Company shall be entitled to seek recovery of all reasonable attorneys&#8217; fees, costs, and expenses incurred by the Company in obtaining such relief.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The parties agree that should any provision of this Agreement be declared or determined by any court to be illegal, invalid or unenforceable, the remainder of the Agreement shall nonetheless remain binding and enforceable, and the illegal, invalid or unenforceable provision(s) shall be modified only so much as necessary to comply with applicable law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by and construed in accordance with the laws of the State of Indiana, without regard to conflicts of laws principles.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page Follows&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Employee Name&#93;</font></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Date&#93;</font></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 5 of 5</font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Please indicate your agreement to the foregoing by signing a copy of this Agreement where indicated below and returning this Agreement to &#91;&#8226;&#93;.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ELI LILLY AND COMPANY</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;____________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AGREED AND ACKNOWLEDGED</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Name&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;&#160;&#160;&#160;&#160;______________________________</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>6
<FILENAME>lly-20221231x10kexhibit21.htm
<DESCRIPTION>EX-21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3acb3a983ffb42308d5c7aa806b9c639_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21 &#8212; List of Subsidiaries&#160;&#38; Affiliates</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The following are subsidiaries and affiliated corporations of the company at December 31, 2022.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain subsidiaries have been omitted as they are not significant in the aggregate.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State or Jurisdiction<br>of Incorporation<br>or Organization</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Akouos, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alnara Pharmaceuticals, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andean Technical Operations Center</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peru</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARMO Biosciences, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avid Radiopharmaceuticals, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CoLucid Pharmaceuticals, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compania Farmaceutica Eli Lilly de Centro America SA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Guatemala</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dermira, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disarm Therapeutics Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dista Ilac Ticaret Limited Sirketi</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dista, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dista-Produtos Quimicos &#38; Farmaceuticos, LDA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elanco Animal Health Ireland Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELCO Dominicana SRL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dominican Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELCO for Trade and Marketing, S.A.E.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELCO Insurance Company Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELCO Management, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELGO Insurance Company Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly (Malaysia) Sdn. Bhd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly (Philippines), Incorporated</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly (S.A.) (Proprietary) Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly (Singapore) Pte. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly (Suisse) S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company (India) Pvt. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company (Ireland) Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company (N.Z.) Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company (Taiwan), Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Asia Pacific SSC Sdn Bhd</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Asia, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Australia Pty. Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Benelux S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly B-H d.o.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bosnia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Bienes y Servicios S de RL de CV</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Canada Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Clinical Diagnostics Laboratory LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Cork Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly CR s.r.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Danmark A&#47;S</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State or Jurisdiction<br>of Incorporation<br>or Organization</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly de Costa Rica, S.R.L.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly do Brasil Limitada</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Egypt, for Trading</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly European Clinical Trial Services SA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Export S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly farmacevtska druzba, d.o.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovenia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Finance, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Ges.m.b.H.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Group Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Hrvatska d.o.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Croatia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Interamerica Inc., y Compania Limitada</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chile</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Interamerica, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly International Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Ireland Holdings Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Israel Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Italia S.p.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Japan K.K.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Kinsale Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Nederland B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Nigeria Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nigeria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Norge A.S.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Pakistan (Pvt.) Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pakistan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Polska Sp. z.o.o. (Ltd.)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Regional Operations GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Romania SRL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Romania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Saudi Arabia Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saudi Arabia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Services India Private Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Slovakia s.r.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovakia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Sweden AB</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Vostok S.A., Geneva</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly y Compania de Mexico, S.A. de C.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly y Compania de Venezuela, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venezuela</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glycostasis, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greenfield-Produtos Farmaceuticos, Lda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICOS Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Washington</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImClone LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImClone Systems Holdings, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImClone Systems LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Irisfarma S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LDH I Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LDH II Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LDH III Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly (Shanghai) Management Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State or Jurisdiction<br>of Incorporation<br>or Organization</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Asia Ventures Fund I, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Asia Ventures Fund II, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Asian Ventures Fund III, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Cayman Holdings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Centre for Clinical Pharmacology PTE. LTD.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly China Research and Development Co., Ltd</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly del Caribe, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Deutschland GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly France S.A.S.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Global Nederland Holdings BV</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Global Services, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Holding GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Holdings B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Hungaria KFT</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Ilac Ticaret Limited Sirketi</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Japan Financing G.K.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Korea Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Nederland Finance B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Nederland Holding B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Pharma Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Portugal - Produtos Farmaceuticos, Lda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Suzhou Pharmaceutical Co. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Trading Co. LTD</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly USA, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Ventures Fund I LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loxo Oncology, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OY Eli Lilly Finland AB</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Petra Pharma Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaserve-Lilly S.A.C.I.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prevail Therapeutics Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protomer Technologies, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PT. Eli Lilly Indonesia</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indonesia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGX Pharmaceuticals, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spaly Bioquimica, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UAB Eli Lilly Lietuva</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lithuania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valquifarma, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vitalfarma - Produtos Farmaceuticos, Lda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>7
<FILENAME>lly-20221231x10kexhibit23.htm
<DESCRIPTION>EX-23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i23af6fbf64484ec98bee23b158f8d947_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Exhibit 23</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">We consent to the incorporation by reference in the Registration Statements (Form S-3 ASR No. 333-262943&#59; and Form S-8 Nos. 333-104057, 333-172422, 333-258801, and 333-258803) of Eli Lilly and Company and in the related Prospectus of our reports dated February&#160;22, 2023, with respect to the consolidated financial statements of Eli Lilly and Company and subsidiaries, and the effectiveness of internal control over financial reporting of Eli Lilly and Company and subsidiaries, included in this Annual Report (10-K) for the year ended December&#160;31, 2022.</font></div><div style="margin-top:6pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Indianapolis, Indiana</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">February&#160;22, 2023 </font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>lly-20221231x10kexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iecff799218834d6f9d8da22b5eb91b54_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1 Rule 13a-14(a) Certification of David Ricks, Chair, President, and Chief Executive Officer </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS </font></div><div style="margin-top:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David Ricks, Chair, President, and Chief Executive Officer, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I have reviewed this report on Form 10-K of Eli Lilly and Company&#59;</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;22, 2023 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.777%"><tr><td style="width:1.0%"></td><td style="width:6.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair, President, and Chief&#160;Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>lly-20221231x10kexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if66d31039ff24fcaa31a44eb9a572f41_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2 Rule 13a-14(a) Certification of Anat Ashkenazi, Executive Vice President and Chief Financial Officer</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS </font></div><div style="margin-top:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Anat Ashkenazi, Executive Vice President and Chief Financial Officer, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I have reviewed this report on Form 10-K of Eli Lilly and Company&#59;</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:13.5pt"><font><br></font></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;22, 2023 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.637%"><tr><td style="width:1.0%"></td><td style="width:7.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>10
<FILENAME>lly-20221231x10kexhibit32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1c77cf7bafc74f42be1321797908c105_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32 Section&#160;1350 Certification </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Eli Lilly and Company, an Indiana corporation (the &#8220;Company&#8221;), does hereby certify that, to the best of their knowledge&#58; </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the &#8220;Form 10-K&#8221;) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair, President, and Chief Executive Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and<br>Chief Financial Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>lly-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:ccabaa9f-f08b-4cef-8cc5-6b16fc2f1828,g:814ba434-7768-4150-bd97-753155d7ed58-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lly="http://www.lilly.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lilly.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.lilly.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.lilly.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.lilly.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>0000004 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.lilly.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000005 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000006 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquity" roleURI="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity">
        <link:definition>0000007 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquityParenthetical" roleURI="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical">
        <link:definition>0000008 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.lilly.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards" roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards">
        <link:definition>0000010 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.lilly.com/role/Revenue">
        <link:definition>0000011 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.lilly.com/role/Acquisitions">
        <link:definition>0000012 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangements" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangements">
        <link:definition>0000013 - Disclosure - Collaborations and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialCharges" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges">
        <link:definition>0000014 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.lilly.com/role/Inventories">
        <link:definition>0000015 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.lilly.com/role/FinancialInstruments">
        <link:definition>0000016 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibles" roleURI="http://www.lilly.com/role/GoodwillandOtherIntangibles">
        <link:definition>0000017 - Disclosure - Goodwill and Other Intangibles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.lilly.com/role/PropertyandEquipment">
        <link:definition>0000018 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.lilly.com/role/Leases">
        <link:definition>0000019 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://www.lilly.com/role/Borrowings">
        <link:definition>0000020 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.lilly.com/role/StockBasedCompensation">
        <link:definition>0000021 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.lilly.com/role/ShareholdersEquity">
        <link:definition>0000022 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.lilly.com/role/IncomeTaxes">
        <link:definition>0000023 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefits" roleURI="http://www.lilly.com/role/RetirementBenefits">
        <link:definition>0000024 - Disclosure - Retirement Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.lilly.com/role/Contingencies">
        <link:definition>0000025 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLoss" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLoss">
        <link:definition>0000026 - Disclosure - Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpense" roleURI="http://www.lilly.com/role/OtherNetIncomeExpense">
        <link:definition>0000027 - Disclosure - Other-Net, (Income) Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies" roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies">
        <link:definition>0000028 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.lilly.com/role/RevenueTables">
        <link:definition>0000029 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.lilly.com/role/AcquisitionsTables">
        <link:definition>0000030 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsTables" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables">
        <link:definition>0000031 - Disclosure - Collaborations and Other Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialChargesTables" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables">
        <link:definition>0000032 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.lilly.com/role/InventoriesTables">
        <link:definition>0000033 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.lilly.com/role/FinancialInstrumentsTables">
        <link:definition>0000034 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesTables" roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesTables">
        <link:definition>0000035 - Disclosure - Goodwill and Other Intangibles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.lilly.com/role/PropertyandEquipmentTables">
        <link:definition>0000036 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.lilly.com/role/LeasesTables">
        <link:definition>0000037 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://www.lilly.com/role/BorrowingsTables">
        <link:definition>0000038 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.lilly.com/role/StockBasedCompensationTables">
        <link:definition>0000039 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.lilly.com/role/IncomeTaxesTables">
        <link:definition>0000040 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsTables" roleURI="http://www.lilly.com/role/RetirementBenefitsTables">
        <link:definition>0000041 - Disclosure - Retirement Benefits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossTables" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables">
        <link:definition>0000042 - Disclosure - Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpenseTables" roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseTables">
        <link:definition>0000043 - Disclosure - Other - Net, (Income) Expense (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsDetails" roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsDetails">
        <link:definition>0000044 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueSummaryofRevenueRecognizedDetails" roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails">
        <link:definition>0000045 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails" roleURI="http://www.lilly.com/role/RevenueNarrativeDetails">
        <link:definition>0000046 - Disclosure - Revenue (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueContractLiabilitiesDetails" roleURI="http://www.lilly.com/role/RevenueContractLiabilitiesDetails">
        <link:definition>0000047 - Disclosure - Revenue (Contract Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofRevenuebyProductDetails" roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails">
        <link:definition>0000048 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofRevenuebyGeographicalAreaDetails" roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails">
        <link:definition>0000049 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.lilly.com/role/AcquisitionsNarrativeDetails">
        <link:definition>0000050 - Disclosure - Acquisitions (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>0000051 - Disclosure - Acquisitions (Assets Acquired and Liabilities Assumed) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAssetAcquisitionsDetails" roleURI="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails">
        <link:definition>0000052 - Disclosure - Acquisitions (Asset Acquisitions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails">
        <link:definition>0000053 - Disclosure - Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsNetProductRevenueDetails" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails">
        <link:definition>0000054 - Disclosure - Collaborations and Other Arrangements (Net Product Revenue) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsNarrativeDetails" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails">
        <link:definition>0000055 - Disclosure - Collaborations and Other Arrangements (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails">
        <link:definition>0000056 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges - Schedule of Other Operating Cost and Expense, by Component (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails">
        <link:definition>0000057 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.lilly.com/role/InventoriesDetails">
        <link:definition>0000058 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>0000059 - Disclosure - Financial Instruments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofContractualMaturitiesDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails">
        <link:definition>0000060 - Disclosure - Financial Instruments (Schedule of Contractual Maturities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsUnrealizedGainsandLossesDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails">
        <link:definition>0000061 - Disclosure - Financial Instruments (Unrealized Gains and Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsRealizedGainsandLossesDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails">
        <link:definition>0000062 - Disclosure - Financial Instruments (Realized Gains and Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofFairValueMeasurementDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails">
        <link:definition>0000063 - Disclosure - Financial Instruments (Schedule of Fair Value Measurement) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails">
        <link:definition>0000064 - Disclosure - Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails">
        <link:definition>0000065 - Disclosure - Financial Instruments (Schedule of Foreign Currency Forward Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofEffectofRiskManagementDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails">
        <link:definition>0000066 - Disclosure - Financial Instruments (Schedule of Effect of Risk Management) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails">
        <link:definition>0000067 - Disclosure - Financial Instruments (Schedule of Risk Management Instruments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesNarrativeDetails" roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails">
        <link:definition>0000068 - Disclosure - Goodwill and Other Intangibles (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails">
        <link:definition>0000069 - Disclosure - Goodwill and Other Intangibles (Schedule of Finite-lived and Indefinite-lived Intangible Assets other than Goodwill) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails" roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails">
        <link:definition>0000070 - Disclosure - Goodwill and Other Intangibles (Schedule of Amortization Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails" roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails">
        <link:definition>0000071 - Disclosure - Goodwill and Other Intangibles (Schedule of Estimated Amortization Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNarrativeDetails" roleURI="http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails">
        <link:definition>0000072 - Disclosure - Property and Equipment (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofPropertyandEquipmentDetails" roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
        <link:definition>0000073 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofDepreciationExpenseDetails" roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails">
        <link:definition>0000074 - Disclosure - Property and Equipment (Schedule of Depreciation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofGeographicInformationDetails" roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails">
        <link:definition>0000075 - Disclosure - Property and Equipment (Schedule of Geographic Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.lilly.com/role/LeasesNarrativeDetails">
        <link:definition>0000076 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails" roleURI="http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails">
        <link:definition>0000077 - Disclosure - Leases (Impact of Leases to Consolidated Condensed Financial Statements) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>0000078 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>0000078 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofDebtDetails" roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails">
        <link:definition>0000079 - Disclosure - Borrowings (Schedule of Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofDebtDetails_1" roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1">
        <link:definition>0000079 - Disclosure - Borrowings (Schedule of Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://www.lilly.com/role/BorrowingsNarrativeDetails">
        <link:definition>0000080 - Disclosure - Borrowings (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsSummaryofLongtermNotesDetails" roleURI="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails">
        <link:definition>0000081 - Disclosure - Borrowings (Summary of Long-term Notes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofDebtMaturitiesDetails" roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails">
        <link:definition>0000082 - Disclosure - Borrowings (Schedule of Debt Maturities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails" roleURI="http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails">
        <link:definition>0000083 - Disclosure - Borrowings (Schedule of Cash Payments for Interest on Borrowings) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails" roleURI="http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>0000084 - Disclosure - Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.lilly.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>0000085 - Disclosure - Stock-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofAssumptionsUsedDetails" roleURI="http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails">
        <link:definition>0000086 - Disclosure - Stock-Based Compensation (Schedule of Assumptions Used) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDetails" roleURI="http://www.lilly.com/role/ShareholdersEquityDetails">
        <link:definition>0000087 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails">
        <link:definition>0000088 - Disclosure - Income Taxes (Schedule of Composition of Income Tax Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails">
        <link:definition>0000089 - Disclosure - Income Taxes (Schedule of Deferred Tax Asset and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.lilly.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000090 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails">
        <link:definition>0000091 - Disclosure - Income Taxes (Schedule of Cash Payments of Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails">
        <link:definition>0000092 - Disclosure - Income Taxes (Schedule of Future Cash Payments Relating to the Toll Tax) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails">
        <link:definition>0000093 - Disclosure - Income Taxes (Schedule of Reconciliation of Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails">
        <link:definition>0000094 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails">
        <link:definition>0000095 - Disclosure - Retirement Benefits (Schedule of Benefit Obligations and Plan Assets and Funded Status) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails">
        <link:definition>0000096 - Disclosure - Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsNarrativeDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails">
        <link:definition>0000097 - Disclosure - Retirement Benefits (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails">
        <link:definition>0000098 - Disclosure - Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails">
        <link:definition>0000099 - Disclosure - Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsScheduleofFairValueDisclosuresDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails">
        <link:definition>0000100 - Disclosure - Retirement Benefits (Schedule of Fair Value Disclosures) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.lilly.com/role/ContingenciesDetails">
        <link:definition>0000101 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails">
        <link:definition>0000102 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Component of Other Comprehensive Income (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails">
        <link:definition>0000103 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Tax Effects) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails">
        <link:definition>0000104 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpenseDetails" roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails">
        <link:definition>0000105 - Disclosure - Other - Net, (Income) Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lly_BuyUsdSellEuroMember" abstract="true" name="BuyUsdSellEuroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" abstract="false" name="BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lly_DiabetesMember" abstract="true" name="DiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A7125NotesDue2025Member" abstract="true" name="A7125NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CyramzaMember" abstract="true" name="CyramzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A235NotesDue2022Member" abstract="true" name="A235NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_VerzenioMember" abstract="true" name="VerzenioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EmployeeLitigationMember" abstract="true" name="EmployeeLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" abstract="false" name="TaxCutAndJobsActTollTaxToBePaidWithinOneYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_LossContingencyNumberOfPatents" abstract="false" name="LossContingencyNumberOfPatents" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" abstract="false" name="ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lly_ZyprexaMember" abstract="true" name="ZyprexaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" abstract="true" name="AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A10EuroDenominatedNotesDue2022Member" abstract="true" name="A10EuroDenominatedNotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" abstract="false" name="AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_AkouosAcquisitionMember" abstract="true" name="AkouosAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AddDeductAbstract" abstract="true" name="AddDeductAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_JardianceMember" abstract="true" name="JardianceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A395NotesDue2049Member" abstract="true" name="A395NotesDue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_NoExpirationMember" abstract="true" name="NoExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AlimtaMember" abstract="true" name="AlimtaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_PrecisionBiosciencesIncMember" abstract="true" name="PrecisionBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A37NotesDue2045Member" abstract="true" name="A37NotesDue2045Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RelativeValueAwardsMember" abstract="true" name="RelativeValueAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherNeuroscienceMember" abstract="true" name="OtherNeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" abstract="false" name="DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" abstract="false" name="AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_A395NotesDue2047Member" abstract="true" name="A395NotesDue2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_PetraPharmaCorporationMember" abstract="true" name="PetraPharmaCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_FixedIncomeFundsEmergingMarketsMember" abstract="true" name="FixedIncomeFundsEmergingMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuyUSdollarSellJapaneseYenMember" abstract="true" name="BuyUSdollarSellJapaneseYenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A2.125NotesDueJune32030Member" abstract="true" name="A2.125NotesDueJune32030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_FairValueHedgeAbstract" abstract="true" name="FairValueHedgeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_A17EuroDenominatedNotesDue2049Member" abstract="true" name="A17EuroDenominatedNotesDue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ExpirationBy2026Member" abstract="true" name="ExpirationBy2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A25NotesDue2060Member" abstract="true" name="A25NotesDue2060Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EmgalityPatentLitigationMember" abstract="true" name="EmgalityPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" abstract="false" name="DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_LebrikizumabMember" abstract="true" name="LebrikizumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DeferredTaxAssetsCorrectiveTaxAdjustments" abstract="false" name="DeferredTaxAssetsCorrectiveTaxAdjustments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_OlumiantMember" abstract="true" name="OlumiantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A225NotesDue2050Member" abstract="true" name="A225NotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ForteoMember" abstract="true" name="ForteoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A3375NotesDue2029Member" abstract="true" name="A3375NotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1.700Notesdue2049Member" abstract="true" name="A1.700Notesdue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_PaymentsForAssetAcquisitions" abstract="false" name="PaymentsForAssetAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_OtherOncologyMember" abstract="true" name="OtherOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CialisMember" abstract="true" name="CialisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RocheMember" abstract="true" name="RocheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" abstract="false" name="CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_CollaborationandOtherRevenueMember" abstract="true" name="CollaborationandOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DisarmTherapeuticsIncMember" abstract="true" name="DisarmTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherProductTotalMember" abstract="true" name="OtherProductTotalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A30NotesDue2022Member" abstract="true" name="A30NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ByettaMember" abstract="true" name="ByettaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" abstract="false" name="AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_CashFlowHedgeAbstract" abstract="true" name="CashFlowHedgeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" abstract="false" name="SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lly_SellChineseYuanMember" abstract="true" name="SellChineseYuanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BasaglarMember" abstract="true" name="BasaglarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" abstract="false" name="BusinessAcquisitionContingentValueRightAdditionalPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lly_A6.77NotesDueJanuary12036Member" abstract="true" name="A6.77NotesDueJanuary12036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DeferredTaxAssetsSalesRebatesAndDiscounts" abstract="false" name="DeferredTaxAssetsSalesRebatesAndDiscounts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_A1625BritishPoundDenominatedNotesDue2043Member" abstract="true" name="A1625BritishPoundDenominatedNotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_FoghornTherapeuticsIncMember" abstract="true" name="FoghornTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ErbituxMember" abstract="true" name="ErbituxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" abstract="false" name="RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="lly_HedgedFixedRateDebtMember" abstract="true" name="HedgedFixedRateDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CollaborativeArrangementRightsAndObligationsRightsObligations" abstract="false" name="CollaborativeArrangementRightsAndObligationsRightsObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_DeferredTaxAssetsForeignTaxRedeterminations" abstract="false" name="DeferredTaxAssetsForeignTaxRedeterminations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_SwapSwissFrancsToU.S.DollarsMember" abstract="true" name="SwapSwissFrancsToU.S.DollarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A2125EuroDenominatedNotesDue2030Member" abstract="true" name="A2125EuroDenominatedNotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherImmunologyMember" abstract="true" name="OtherImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" abstract="false" name="RevenuePerformanceObligationSalesRebatePaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" abstract="false" name="LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_A5000NotesDue2033Member" abstract="true" name="A5000NotesDue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CymbaltaMember" abstract="true" name="CymbaltaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherProductMember" abstract="true" name="OtherProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" abstract="false" name="AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" abstract="false" name="ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lly_SeniorNotesDueMay2050AndSeptember2060Member" abstract="true" name="SeniorNotesDueMay2050AndSeptember2060Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A55NotesDue2027Member" abstract="true" name="A55NotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TrulicityMemberMember" abstract="true" name="TrulicityMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" abstract="false" name="TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" abstract="false" name="RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_BuyGBPSellUSDMember" abstract="true" name="BuyGBPSellUSDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A97YenDenominatedNotesDue2049Member" abstract="true" name="A97YenDenominatedNotesDue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsDevelopmentAndRegulatoryMember" abstract="true" name="MilestonePaymentsDevelopmentAndRegulatoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A415NotesDue2059Member" abstract="true" name="A415NotesDue2059Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuySwissFrancSellUSDollarMember" abstract="true" name="BuySwissFrancSellUSDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_COVID19AntibodiesMember" abstract="true" name="COVID19AntibodiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" abstract="false" name="ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lly_FixedIncomeFundsRepurchasedAgreementsMember" abstract="true" name="FixedIncomeFundsRepurchasedAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RevenuefromContractPaymentTermMaximum" abstract="false" name="RevenuefromContractPaymentTermMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_MilestonePaymentsSalesBasedMember" abstract="true" name="MilestonePaymentsSalesBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RigelPharmaceuticalsIncMember" abstract="true" name="RigelPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SalesRebatesAndDiscounts" abstract="false" name="SalesRebatesAndDiscounts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" abstract="true" name="TaxCutAndJobsActTollTaxPaymentDueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_EquityMethodAndOtherInvestmentsMember" abstract="true" name="EquityMethodAndOtherInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ImmunologyMember" abstract="true" name="ImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EmgalityMember" abstract="true" name="EmgalityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A677NotesDue2036Member" abstract="true" name="A677NotesDue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" abstract="false" name="RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TrajentaBIMember" abstract="true" name="TrajentaBIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" abstract="true" name="MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A595NotesDue2037Member" abstract="true" name="A595NotesDue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BioMarinPharmaceuticalIncMember" abstract="true" name="BioMarinPharmaceuticalIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A42YenDenominatedNotesDue2029Member" abstract="true" name="A42YenDenominatedNotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SellEuroMember" abstract="true" name="SellEuroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DermiraInc.Member" abstract="true" name="DermiraInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DerivativeInstrumentsGainLossRecognized" abstract="false" name="DerivativeInstrumentsGainLossRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_LesseeLeaseRemainingLeaseTerm" abstract="false" name="LesseeLeaseRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_PurchasedInProcessResearchAndDevelopment" abstract="false" name="PurchasedInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_DescriptionOfDerivativeActivityVolumePercent" abstract="false" name="DescriptionOfDerivativeActivityVolumePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_AdvertisingExpensePercentageOfRevenue" abstract="false" name="AdvertisingExpensePercentageOfRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" abstract="false" name="BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_BuyUSDollarSellChineseYuanMember" abstract="true" name="BuyUSDollarSellChineseYuanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TaxCutAndJobsActTollTaxToBePaid" abstract="false" name="TaxCutAndJobsActTollTaxToBePaid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_May2021ShareRepurchaseProgramMember" abstract="true" name="May2021ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A718NotesDueJune12025Member" abstract="true" name="A718NotesDueJune12025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CarryforwardMember" abstract="true" name="CarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1125NotesDue2051Member" abstract="true" name="A1125NotesDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" abstract="false" name="RevenuePerformanceObligationSalesReturnsProductExpirationDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_A045SwissFrancDenominatedNotesDue2028Member" abstract="true" name="A045SwissFrancDenominatedNotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ShareholderValueAwardsMember" abstract="true" name="ShareholderValueAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A625EuroDenominatedNotesDue2031Member" abstract="true" name="A625EuroDenominatedNotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CollaborativeArrangementRightsAndObligationsPercent" abstract="false" name="CollaborativeArrangementRightsAndObligationsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_HumalogMember" abstract="true" name="HumalogMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MaturityDate2023Member" abstract="true" name="MaturityDate2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CostOfSalesOperatingExpensesAndOtherNet" abstract="false" name="CostOfSalesOperatingExpensesAndOtherNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_PrevailTherapeuticsIncMember" abstract="true" name="PrevailTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AcquiredInProcessResearchAndDevelopment" abstract="false" name="AcquiredInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_A56YenDenominatedNotesDue2034Member" abstract="true" name="A56YenDenominatedNotesDue2034Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1625EuroDenominatedNotesDue2026Member" abstract="true" name="A1625EuroDenominatedNotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_UNITEDSTATESAndPUERTORICOMember" abstract="true" name="UNITEDSTATESAndPUERTORICOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A3875NotesDue2039Member" abstract="true" name="A3875NotesDue2039Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MarketableSecuritiesMember" abstract="true" name="MarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1.625NotesDueJune22026Member" abstract="true" name="A1.625NotesDueJune22026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ProductLiabilityMember" abstract="true" name="ProductLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_InnoventBiologicsIncMember" abstract="true" name="InnoventBiologicsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A555NotesDue2037Member" abstract="true" name="A555NotesDue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" abstract="false" name="ProceedsfromSaleofEquityandAvailableforSaleSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_MounjaroMember" abstract="true" name="MounjaroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MaturityDate2026Member" abstract="true" name="MaturityDate2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" abstract="false" name="RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_RevenuefromContractPaymentTermMinimum" abstract="false" name="RevenuefromContractPaymentTermMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" abstract="false" name="AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_OtherEquitySecuritiesMember" abstract="true" name="OtherEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_HumalogHumulinAndForteoMember" abstract="true" name="HumalogHumulinAndForteoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherForeignCountriesMember" abstract="true" name="OtherForeignCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" abstract="false" name="DebtSecuritiesAvailableforsaleUnrealizedGainPosition" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_TYVYTMember" abstract="true" name="TYVYTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A625Notesdue2031Member" abstract="true" name="A625Notesdue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ExpirationBy2027Member" abstract="true" name="ExpirationBy2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1375NotesDue2061Member" abstract="true" name="A1375NotesDue2061Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuyJapaneseYenSellUSDollarMember" abstract="true" name="BuyJapaneseYenSellUSDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherDiabetesMember" abstract="true" name="OtherDiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuyEuroSellUsDollarMember" abstract="true" name="BuyEuroSellUsDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A31NotesDue2027Member" abstract="true" name="A31NotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ExpirationBetween2028And2042Member" abstract="true" name="ExpirationBetween2028And2042Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A465NotesDue2044Member" abstract="true" name="A465NotesDue2044Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A015SwissFrancDenominatedNotesDue2024Member" abstract="true" name="A015SwissFrancDenominatedNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DesignatedUnusableMember" abstract="true" name="DesignatedUnusableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TaltzMember" abstract="true" name="TaltzMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" abstract="false" name="FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_LongTermDebtFairValueAdjustment" abstract="false" name="LongTermDebtFairValueAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_A275NotesDue2025Member" abstract="true" name="A275NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_HumulinMember" abstract="true" name="HumulinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SwapUSDollarsToEuroMember" abstract="true" name="SwapUSDollarsToEuroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_ForeignCurrencyDenominatedDebtMember" abstract="true" name="ForeignCurrencyDenominatedDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ThreeLargestWholesalesMember" abstract="true" name="ThreeLargestWholesalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lly_DefineBenefitPlanOtherMember" abstract="true" name="DefineBenefitPlanOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>lly-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:ccabaa9f-f08b-4cef-8cc5-6b16fc2f1828,g:814ba434-7768-4150-bd97-753155d7ed58-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="lly-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_82ce8bcd-e574-476a-9a50-aabbe69a91a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a406da55-45d0-40ab-a060-ba2c8f977a96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_82ce8bcd-e574-476a-9a50-aabbe69a91a9" xlink:to="loc_us-gaap_Revenues_a406da55-45d0-40ab-a060-ba2c8f977a96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_7273d92e-572f-4e8b-9027-ed5f5c81c6aa" xlink:href="lly-20221231.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_82ce8bcd-e574-476a-9a50-aabbe69a91a9" xlink:to="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_7273d92e-572f-4e8b-9027-ed5f5c81c6aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_38e658d9-120f-460a-8885-18d92db35978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c13f28e3-5544-4b4a-b044-a3d1cfb46520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_38e658d9-120f-460a-8885-18d92db35978" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c13f28e3-5544-4b4a-b044-a3d1cfb46520" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4e22b494-07ac-40fd-8732-3659dc037973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_38e658d9-120f-460a-8885-18d92db35978" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4e22b494-07ac-40fd-8732-3659dc037973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_e6928c89-ca06-4e34-b039-92801b731885" xlink:href="lly-20221231.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e970a4d5-28ec-4da2-8ab1-caab480730b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_e6928c89-ca06-4e34-b039-92801b731885" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e970a4d5-28ec-4da2-8ab1-caab480730b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b7fad6f5-35b0-4cf5-a1f0-04f42b0dac0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_e6928c89-ca06-4e34-b039-92801b731885" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b7fad6f5-35b0-4cf5-a1f0-04f42b0dac0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b73e42c9-ef9e-42f4-b11b-71d40e4eb5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_e6928c89-ca06-4e34-b039-92801b731885" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b73e42c9-ef9e-42f4-b11b-71d40e4eb5d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_a8aefffd-6299-4550-aed8-16c0440c0c76" xlink:href="lly-20221231.xsd#lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_e6928c89-ca06-4e34-b039-92801b731885" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_a8aefffd-6299-4550-aed8-16c0440c0c76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_721f8173-d25c-4766-abb6-bf356bdb726f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_e6928c89-ca06-4e34-b039-92801b731885" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_721f8173-d25c-4766-abb6-bf356bdb726f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ccc68d16-2ce3-4cfb-ae1c-e344e967d6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_e6928c89-ca06-4e34-b039-92801b731885" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ccc68d16-2ce3-4cfb-ae1c-e344e967d6a1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20221231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_f6d2fb7b-220d-4f5a-abc8-f81189f0388c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_a9e75e15-6e3c-4615-8f2e-b4e26fd8e933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_f6d2fb7b-220d-4f5a-abc8-f81189f0388c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_a9e75e15-6e3c-4615-8f2e-b4e26fd8e933" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_6c5074a8-ee4d-44fe-87ef-249ac01473ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_f6d2fb7b-220d-4f5a-abc8-f81189f0388c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_6c5074a8-ee4d-44fe-87ef-249ac01473ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_02b4cc6a-f524-4645-ac5c-dbe52833159b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_f6d2fb7b-220d-4f5a-abc8-f81189f0388c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_02b4cc6a-f524-4645-ac5c-dbe52833159b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_5c1ba6a4-d6c2-4d81-9048-66931ea65f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_f6d2fb7b-220d-4f5a-abc8-f81189f0388c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_5c1ba6a4-d6c2-4d81-9048-66931ea65f1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ffed54eb-55b8-4ba4-8e8f-d45605e52222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_c549ebce-a62b-4ee9-8cf3-38f3ae4bb587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ffed54eb-55b8-4ba4-8e8f-d45605e52222" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_c549ebce-a62b-4ee9-8cf3-38f3ae4bb587" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_eac1bb42-7dd2-4d85-968c-f76443ee65e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ffed54eb-55b8-4ba4-8e8f-d45605e52222" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_eac1bb42-7dd2-4d85-968c-f76443ee65e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_351e8f50-897c-4865-9930-3d32b9a7bb61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_22cb3de7-b379-423b-9548-71871a08ceed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_351e8f50-897c-4865-9930-3d32b9a7bb61" xlink:to="loc_us-gaap_NetIncomeLoss_22cb3de7-b379-423b-9548-71871a08ceed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4a3f6154-9a9c-41df-ac3e-739c39c04894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_351e8f50-897c-4865-9930-3d32b9a7bb61" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4a3f6154-9a9c-41df-ac3e-739c39c04894" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lly-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3e0c766f-a591-45d7-b9bd-12207d9a05ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_76b829ae-22c1-437c-a7d9-a433d8b841e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3e0c766f-a591-45d7-b9bd-12207d9a05ee" xlink:to="loc_us-gaap_ShortTermInvestments_76b829ae-22c1-437c-a7d9-a433d8b841e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9f832428-72bf-4b84-bd42-cc51ef790126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3e0c766f-a591-45d7-b9bd-12207d9a05ee" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9f832428-72bf-4b84-bd42-cc51ef790126" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bb178d10-a687-4778-9b25-02ce1e5c8f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3e0c766f-a591-45d7-b9bd-12207d9a05ee" xlink:to="loc_us-gaap_InventoryNet_bb178d10-a687-4778-9b25-02ce1e5c8f07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3f90ba4b-c9ff-47b7-a165-45e26be5af37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3e0c766f-a591-45d7-b9bd-12207d9a05ee" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3f90ba4b-c9ff-47b7-a165-45e26be5af37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_74e53950-4f88-4aa1-92d1-14d12dfb2e02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3e0c766f-a591-45d7-b9bd-12207d9a05ee" xlink:to="loc_us-gaap_OtherReceivables_74e53950-4f88-4aa1-92d1-14d12dfb2e02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5e181652-2176-47be-9f94-4ebe24286334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3e0c766f-a591-45d7-b9bd-12207d9a05ee" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5e181652-2176-47be-9f94-4ebe24286334" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_132df7ea-8ebf-4e62-9cb7-a4b0fad6f6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_12873dc7-0de2-4ab2-bedf-895baa546497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_132df7ea-8ebf-4e62-9cb7-a4b0fad6f6c1" xlink:to="loc_us-gaap_CommonStockValue_12873dc7-0de2-4ab2-bedf-895baa546497" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3ba895a4-03d9-4db4-b90d-7224ca00c273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_132df7ea-8ebf-4e62-9cb7-a4b0fad6f6c1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3ba895a4-03d9-4db4-b90d-7224ca00c273" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1679f0b0-3f3d-4549-9c60-f223579c9760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_132df7ea-8ebf-4e62-9cb7-a4b0fad6f6c1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1679f0b0-3f3d-4549-9c60-f223579c9760" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_254bba22-36bd-4767-927d-20627210d4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_132df7ea-8ebf-4e62-9cb7-a4b0fad6f6c1" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_254bba22-36bd-4767-927d-20627210d4dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d07966a8-3e14-4a1f-a54a-0f68d9379041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_132df7ea-8ebf-4e62-9cb7-a4b0fad6f6c1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d07966a8-3e14-4a1f-a54a-0f68d9379041" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_fc484c44-ede7-4089-8673-c53dd3e198e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_132df7ea-8ebf-4e62-9cb7-a4b0fad6f6c1" xlink:to="loc_us-gaap_TreasuryStockCommonValue_fc484c44-ede7-4089-8673-c53dd3e198e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_25057e76-ba0a-4a43-870a-91d76475eea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5df44d6f-3b2a-42a6-ad14-9e81aaa445b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_25057e76-ba0a-4a43-870a-91d76475eea3" xlink:to="loc_us-gaap_LiabilitiesCurrent_5df44d6f-3b2a-42a6-ad14-9e81aaa445b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_c128eb9c-87ca-4fe8-821c-1b8108427aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_25057e76-ba0a-4a43-870a-91d76475eea3" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_c128eb9c-87ca-4fe8-821c-1b8108427aef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6868beeb-5565-4b79-90d8-44740976c7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_25057e76-ba0a-4a43-870a-91d76475eea3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6868beeb-5565-4b79-90d8-44740976c7f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0cbf1b60-9206-4893-9462-42119fca831f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_25057e76-ba0a-4a43-870a-91d76475eea3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0cbf1b60-9206-4893-9462-42119fca831f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_ae505f62-c9ca-4fca-ba30-b4e75f133b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_eb9d1393-a08d-4245-9aef-f657e7c6f009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_ae505f62-c9ca-4fca-ba30-b4e75f133b29" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_eb9d1393-a08d-4245-9aef-f657e7c6f009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_780e4ea4-8a83-4485-ab23-6fa1f1b0b9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_ae505f62-c9ca-4fca-ba30-b4e75f133b29" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_780e4ea4-8a83-4485-ab23-6fa1f1b0b9ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_fcbdf0c0-661d-4e77-8f12-ddb1b40d5e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_ae505f62-c9ca-4fca-ba30-b4e75f133b29" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_fcbdf0c0-661d-4e77-8f12-ddb1b40d5e87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9e08e2c5-e867-487b-8ac3-0f6ac67e7c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_ae505f62-c9ca-4fca-ba30-b4e75f133b29" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9e08e2c5-e867-487b-8ac3-0f6ac67e7c33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_fd7cc421-56de-4ca8-a3de-b0e280c785df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_ae505f62-c9ca-4fca-ba30-b4e75f133b29" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_fd7cc421-56de-4ca8-a3de-b0e280c785df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a1a687dd-888c-4c68-b128-99c5d240de00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_930cc314-af92-4ae7-bb4e-eb7ed11cde39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a1a687dd-888c-4c68-b128-99c5d240de00" xlink:to="loc_us-gaap_AssetsCurrent_930cc314-af92-4ae7-bb4e-eb7ed11cde39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_c77776c2-60e1-4a17-9c07-926675759e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a1a687dd-888c-4c68-b128-99c5d240de00" xlink:to="loc_us-gaap_LongTermInvestments_c77776c2-60e1-4a17-9c07-926675759e17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_68acfc37-0d7f-420d-a923-908f085f677e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a1a687dd-888c-4c68-b128-99c5d240de00" xlink:to="loc_us-gaap_Goodwill_68acfc37-0d7f-420d-a923-908f085f677e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3a6e2483-6767-4801-b8a5-4c23ad853825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a1a687dd-888c-4c68-b128-99c5d240de00" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3a6e2483-6767-4801-b8a5-4c23ad853825" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_39794c08-a5e6-495b-a648-0b37f53ff286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a1a687dd-888c-4c68-b128-99c5d240de00" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_39794c08-a5e6-495b-a648-0b37f53ff286" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7c05d04b-2d2b-4364-9f6c-dc6cb1bd2f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a1a687dd-888c-4c68-b128-99c5d240de00" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7c05d04b-2d2b-4364-9f6c-dc6cb1bd2f29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_46152e8b-8723-4ec0-97ee-46ced9d545d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a1a687dd-888c-4c68-b128-99c5d240de00" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_46152e8b-8723-4ec0-97ee-46ced9d545d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_38cbbf36-c245-4069-955b-a3b7d2054054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_244479f5-8478-4145-93ba-9c4bb29f6c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_38cbbf36-c245-4069-955b-a3b7d2054054" xlink:to="loc_us-gaap_DebtCurrent_244479f5-8478-4145-93ba-9c4bb29f6c63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d3c86af0-02df-4c60-8848-389aa4e4af90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_38cbbf36-c245-4069-955b-a3b7d2054054" xlink:to="loc_us-gaap_AccountsPayableCurrent_d3c86af0-02df-4c60-8848-389aa4e4af90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_62cd1592-cde7-401e-b601-953da8cd4d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_38cbbf36-c245-4069-955b-a3b7d2054054" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_62cd1592-cde7-401e-b601-953da8cd4d1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts_4d2afa29-223e-40f4-87c5-b18c681fd729" xlink:href="lly-20221231.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_38cbbf36-c245-4069-955b-a3b7d2054054" xlink:to="loc_lly_SalesRebatesAndDiscounts_4d2afa29-223e-40f4-87c5-b18c681fd729" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_cff13570-98e8-4ed0-8e78-168afa5e6190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_38cbbf36-c245-4069-955b-a3b7d2054054" xlink:to="loc_us-gaap_DividendsPayableCurrent_cff13570-98e8-4ed0-8e78-168afa5e6190" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_1c586d92-db85-4c14-951b-0b4a6d257402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_38cbbf36-c245-4069-955b-a3b7d2054054" xlink:to="loc_us-gaap_TaxesPayableCurrent_1c586d92-db85-4c14-951b-0b4a6d257402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b293cab5-9bdb-45a2-9ea3-2418bef21408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_38cbbf36-c245-4069-955b-a3b7d2054054" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b293cab5-9bdb-45a2-9ea3-2418bef21408" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ee238228-0229-471e-90ae-1c7c629b522b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5a9d7e05-34be-450d-b293-9dbd7e1b2e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ee238228-0229-471e-90ae-1c7c629b522b" xlink:to="loc_us-gaap_CommonStockValue_5a9d7e05-34be-450d-b293-9dbd7e1b2e78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_727ba9e5-00a4-4c12-8846-0d55a1708d85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ee238228-0229-471e-90ae-1c7c629b522b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_727ba9e5-00a4-4c12-8846-0d55a1708d85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d41e4e72-9d05-4641-8a89-858756854b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ee238228-0229-471e-90ae-1c7c629b522b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d41e4e72-9d05-4641-8a89-858756854b43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_70d75333-8826-4ab6-905d-608b1fa712eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ee238228-0229-471e-90ae-1c7c629b522b" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_70d75333-8826-4ab6-905d-608b1fa712eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d55054a7-a049-4c54-a1c5-277588232d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ee238228-0229-471e-90ae-1c7c629b522b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d55054a7-a049-4c54-a1c5-277588232d0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_8a982703-311d-4a5b-bb0f-43ab2ab327fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ee238228-0229-471e-90ae-1c7c629b522b" xlink:to="loc_us-gaap_TreasuryStockCommonValue_8a982703-311d-4a5b-bb0f-43ab2ab327fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_137bc6f0-ebad-4fc3-ae86-d012b1036304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ee238228-0229-471e-90ae-1c7c629b522b" xlink:to="loc_us-gaap_MinorityInterest_137bc6f0-ebad-4fc3-ae86-d012b1036304" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lly-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ad9ee00c-a71e-46c4-ac48-e87f07500942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_e532a11b-c6d8-4735-a72b-3df51b0b134c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ad9ee00c-a71e-46c4-ac48-e87f07500942" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_e532a11b-c6d8-4735-a72b-3df51b0b134c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f25299d9-edc1-45b1-a275-c581f8a3f868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ad9ee00c-a71e-46c4-ac48-e87f07500942" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f25299d9-edc1-45b1-a275-c581f8a3f868" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ac8611a5-9ccc-4454-807f-78a6d10400b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ad9ee00c-a71e-46c4-ac48-e87f07500942" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ac8611a5-9ccc-4454-807f-78a6d10400b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a9a51a7a-4b66-4396-9a87-288c2434277d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ad9ee00c-a71e-46c4-ac48-e87f07500942" xlink:to="loc_us-gaap_ShareBasedCompensation_a9a51a7a-4b66-4396-9a87-288c2434277d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_8f39fa29-a32e-4346-9ebe-6781bdd6e37b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ad9ee00c-a71e-46c4-ac48-e87f07500942" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_8f39fa29-a32e-4346-9ebe-6781bdd6e37b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_adae8189-5a68-4527-94c3-cd81ab42d5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ad9ee00c-a71e-46c4-ac48-e87f07500942" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_adae8189-5a68-4527-94c3-cd81ab42d5b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_de1e9259-05d0-47eb-8a30-ece0d5c660f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ad9ee00c-a71e-46c4-ac48-e87f07500942" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_de1e9259-05d0-47eb-8a30-ece0d5c660f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_a3fc8ed5-e8ac-427c-8418-c6ea1f81901d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ad9ee00c-a71e-46c4-ac48-e87f07500942" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_a3fc8ed5-e8ac-427c-8418-c6ea1f81901d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_1a691744-775e-41d2-9531-922fa2f7df1b" xlink:href="lly-20221231.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ad9ee00c-a71e-46c4-ac48-e87f07500942" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_1a691744-775e-41d2-9531-922fa2f7df1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_559212ee-aea7-45bc-a958-d20d10ba3127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ad9ee00c-a71e-46c4-ac48-e87f07500942" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_559212ee-aea7-45bc-a958-d20d10ba3127" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_f2faba65-8d89-47b4-b1b7-221554c59a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ad9ee00c-a71e-46c4-ac48-e87f07500942" xlink:to="loc_us-gaap_GainLossOnInvestments_f2faba65-8d89-47b4-b1b7-221554c59a4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_90eaa219-cff3-4058-8bb6-a5d51cd36067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ad9ee00c-a71e-46c4-ac48-e87f07500942" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_90eaa219-cff3-4058-8bb6-a5d51cd36067" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cb398f2d-a391-441b-839e-caaa115dd6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ad9ee00c-a71e-46c4-ac48-e87f07500942" xlink:to="loc_us-gaap_NetIncomeLoss_cb398f2d-a391-441b-839e-caaa115dd6b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a710ae2b-4b91-447f-8bf8-fd79905a1351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_871ffc11-3ef8-4115-a62a-e36e9bbe77d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a710ae2b-4b91-447f-8bf8-fd79905a1351" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_871ffc11-3ef8-4115-a62a-e36e9bbe77d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_ed6b00c5-fc05-48ba-87bd-2c03a571c569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a710ae2b-4b91-447f-8bf8-fd79905a1351" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_ed6b00c5-fc05-48ba-87bd-2c03a571c569" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_b261f155-55e9-4c21-96c2-414ceff17876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a710ae2b-4b91-447f-8bf8-fd79905a1351" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_b261f155-55e9-4c21-96c2-414ceff17876" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_f1885b44-fe83-4008-be78-50d1f98749f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a710ae2b-4b91-447f-8bf8-fd79905a1351" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_f1885b44-fe83-4008-be78-50d1f98749f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_0bf5a423-6af8-49f1-a2a4-b977d44bb58a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a710ae2b-4b91-447f-8bf8-fd79905a1351" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_0bf5a423-6af8-49f1-a2a4-b977d44bb58a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasedInProcessResearchAndDevelopment_baf6a8d4-a7ff-4561-a1f0-15ca30b98bc8" xlink:href="lly-20221231.xsd#lly_PurchasedInProcessResearchAndDevelopment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a710ae2b-4b91-447f-8bf8-fd79905a1351" xlink:to="loc_lly_PurchasedInProcessResearchAndDevelopment_baf6a8d4-a7ff-4561-a1f0-15ca30b98bc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9263a928-f4e5-4496-8e97-16b873136ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a710ae2b-4b91-447f-8bf8-fd79905a1351" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9263a928-f4e5-4496-8e97-16b873136ad9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_bb6279e7-e371-4d47-b921-7476b0a6c2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a710ae2b-4b91-447f-8bf8-fd79905a1351" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_bb6279e7-e371-4d47-b921-7476b0a6c2ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7bd87755-2468-485b-945f-e37d249819d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_647a728f-dbbf-43f4-a280-44fb3e8ff65e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7bd87755-2468-485b-945f-e37d249819d5" xlink:to="loc_us-gaap_PaymentsOfDividends_647a728f-dbbf-43f4-a280-44fb3e8ff65e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_304382d1-b886-4dcd-b382-fea477cfaf88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7bd87755-2468-485b-945f-e37d249819d5" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_304382d1-b886-4dcd-b382-fea477cfaf88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_84a9aa9e-c5fb-4931-a395-89fe9dc068ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7bd87755-2468-485b-945f-e37d249819d5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_84a9aa9e-c5fb-4931-a395-89fe9dc068ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_cea69af4-14c6-472c-a0a7-62feb7e2b364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7bd87755-2468-485b-945f-e37d249819d5" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_cea69af4-14c6-472c-a0a7-62feb7e2b364" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_bc6c555b-45fc-4bab-85ba-6712b9835d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7bd87755-2468-485b-945f-e37d249819d5" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_bc6c555b-45fc-4bab-85ba-6712b9835d3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_27793c64-555f-4660-92d2-82282a8a30da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7bd87755-2468-485b-945f-e37d249819d5" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_27793c64-555f-4660-92d2-82282a8a30da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7f8fbeeb-fdbf-4c90-aae9-ef3c66705df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ced68f3a-4c41-47a2-b477-610482a2668b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7f8fbeeb-fdbf-4c90-aae9-ef3c66705df0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ced68f3a-4c41-47a2-b477-610482a2668b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a308c6eb-9df5-4607-9de8-3118b3f5847e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7f8fbeeb-fdbf-4c90-aae9-ef3c66705df0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a308c6eb-9df5-4607-9de8-3118b3f5847e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0daa2f1-6a77-4d27-a762-6e26706ce2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7f8fbeeb-fdbf-4c90-aae9-ef3c66705df0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0daa2f1-6a77-4d27-a762-6e26706ce2f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56ebd9e4-c1d3-40e0-afbe-2a186fa6ad35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7f8fbeeb-fdbf-4c90-aae9-ef3c66705df0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56ebd9e4-c1d3-40e0-afbe-2a186fa6ad35" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_fa740a37-68c6-4780-81fb-d4b22f91b95d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_76c24e2d-445f-474b-8174-f3730eaa5298" xlink:href="lly-20221231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_fa740a37-68c6-4780-81fb-d4b22f91b95d" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_76c24e2d-445f-474b-8174-f3730eaa5298" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_309d2564-3d4f-40f9-9faf-f94858db7528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_fa740a37-68c6-4780-81fb-d4b22f91b95d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_309d2564-3d4f-40f9-9faf-f94858db7528" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_473b22fc-23e8-4d47-8254-2a53e20445a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_fa740a37-68c6-4780-81fb-d4b22f91b95d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_473b22fc-23e8-4d47-8254-2a53e20445a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1cbf8214-4112-4bad-85a9-f2f00f475f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_fa740a37-68c6-4780-81fb-d4b22f91b95d" xlink:to="loc_us-gaap_Goodwill_1cbf8214-4112-4bad-85a9-f2f00f475f3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_adced46f-f758-4ee4-aa1e-7ff142e494b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_fa740a37-68c6-4780-81fb-d4b22f91b95d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_adced46f-f758-4ee4-aa1e-7ff142e494b1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_1bc8450b-48c2-41dc-a46d-58ccf346d4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_f3924a25-1dda-4c12-a393-1c7bbc07bd57" xlink:href="lly-20221231.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_1bc8450b-48c2-41dc-a46d-58ccf346d4c9" xlink:to="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_f3924a25-1dda-4c12-a393-1c7bbc07bd57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_e229c650-f20c-409f-a95d-dfdd84736958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_1bc8450b-48c2-41dc-a46d-58ccf346d4c9" xlink:to="loc_us-gaap_SeveranceCosts1_e229c650-f20c-409f-a95d-dfdd84736958" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/InventoriesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ab7c6e7f-5c12-4a34-9149-ee4b375cc19e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_c7100c17-19b7-43f9-a4f6-e6b2fc8fc38c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_ab7c6e7f-5c12-4a34-9149-ee4b375cc19e" xlink:to="loc_us-gaap_InventoryGross_c7100c17-19b7-43f9-a4f6-e6b2fc8fc38c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve_7f2ddb70-28ec-43d6-b441-3b1ea07a17f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_ab7c6e7f-5c12-4a34-9149-ee4b375cc19e" xlink:to="loc_us-gaap_InventoryLIFOReserve_7f2ddb70-28ec-43d6-b441-3b1ea07a17f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_562ddc09-8b01-47e1-947c-4aee895f73b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_b68e3c60-fff6-4af9-995b-2ab5751ac3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_562ddc09-8b01-47e1-947c-4aee895f73b2" xlink:to="loc_us-gaap_InventoryFinishedGoods_b68e3c60-fff6-4af9-995b-2ab5751ac3c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_b27be203-fc4f-47f5-874a-b35b1ffe9b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_562ddc09-8b01-47e1-947c-4aee895f73b2" xlink:to="loc_us-gaap_InventoryWorkInProcess_b27be203-fc4f-47f5-874a-b35b1ffe9b52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_c461cabc-1057-41ab-9bf5-8196697e7671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_562ddc09-8b01-47e1-947c-4aee895f73b2" xlink:to="loc_us-gaap_InventoryRawMaterials_c461cabc-1057-41ab-9bf5-8196697e7671" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstrumentsScheduleofContractualMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_43bc4d5e-f34a-434b-8971-4c0f96a0a50f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c339063e-7df2-4aeb-93d5-2215f839ef97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_43bc4d5e-f34a-434b-8971-4c0f96a0a50f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c339063e-7df2-4aeb-93d5-2215f839ef97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ce6aa942-6870-4816-bb8c-6bbdc0e1318e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_43bc4d5e-f34a-434b-8971-4c0f96a0a50f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ce6aa942-6870-4816-bb8c-6bbdc0e1318e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_cb9e9609-bb1f-4f59-9fed-ad6023daf788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_43bc4d5e-f34a-434b-8971-4c0f96a0a50f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_cb9e9609-bb1f-4f59-9fed-ad6023daf788" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_0f8934b7-9427-4353-a048-c2ebab743e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_43bc4d5e-f34a-434b-8971-4c0f96a0a50f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_0f8934b7-9427-4353-a048-c2ebab743e03" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstrumentsScheduleofFairValueMeasurementDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_cfa3d34f-189b-46ac-9f58-58ff8b70f5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e4133046-559e-4049-bbbc-82f3759484a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_cfa3d34f-189b-46ac-9f58-58ff8b70f5d4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e4133046-559e-4049-bbbc-82f3759484a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_37b5ca17-7125-488a-a590-458362b7e42f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_cfa3d34f-189b-46ac-9f58-58ff8b70f5d4" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_37b5ca17-7125-488a-a590-458362b7e42f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_22b070c6-e0fc-4972-861c-393d89345927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_cfa3d34f-189b-46ac-9f58-58ff8b70f5d4" xlink:to="loc_us-gaap_OtherLongTermInvestments_22b070c6-e0fc-4972-861c-393d89345927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_3dea336c-960f-4d08-a226-6c6af22943d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_cfa3d34f-189b-46ac-9f58-58ff8b70f5d4" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_3dea336c-960f-4d08-a226-6c6af22943d3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstrumentsScheduleofEffectofRiskManagementDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_a0b06c41-3ed1-426b-bf58-bf16f92c27af" xlink:href="lly-20221231.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_a3fc2f23-a020-4749-8991-87babb934697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_a0b06c41-3ed1-426b-bf58-bf16f92c27af" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_a3fc2f23-a020-4749-8991-87babb934697" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_3cd967fd-efa4-4c39-a5ec-2d3035aa5cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_a0b06c41-3ed1-426b-bf58-bf16f92c27af" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_3cd967fd-efa4-4c39-a5ec-2d3035aa5cff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_81b97f20-4d74-4c86-835c-0385bcfacac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_a0b06c41-3ed1-426b-bf58-bf16f92c27af" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_81b97f20-4d74-4c86-835c-0385bcfacac5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d1a078ab-34e3-42c6-9fc8-eb764f32dfe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_a0b06c41-3ed1-426b-bf58-bf16f92c27af" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d1a078ab-34e3-42c6-9fc8-eb764f32dfe8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_dd8f06e6-32bf-49be-9438-4c870adf259f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_fc47d557-7192-4dad-95fc-70eb97bd8a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_dd8f06e6-32bf-49be-9438-4c870adf259f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_fc47d557-7192-4dad-95fc-70eb97bd8a5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c2f7fc36-52e8-43db-aa36-cca8267a3d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_dd8f06e6-32bf-49be-9438-4c870adf259f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c2f7fc36-52e8-43db-aa36-cca8267a3d5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c4141c32-7e31-4424-bc6a-db9d7351645b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3aad3bf2-0f08-4f0f-99b5-376dfdc85510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c4141c32-7e31-4424-bc6a-db9d7351645b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3aad3bf2-0f08-4f0f-99b5-376dfdc85510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_215acdca-5f30-4d80-baf6-e3d7668855b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c4141c32-7e31-4424-bc6a-db9d7351645b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_215acdca-5f30-4d80-baf6-e3d7668855b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_54c590bb-51b7-49ea-858c-097ea4e6af8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9fd5f7e9-fd31-49b9-a5a7-a6c0bbf54671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_54c590bb-51b7-49ea-858c-097ea4e6af8d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9fd5f7e9-fd31-49b9-a5a7-a6c0bbf54671" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e1f23c91-2de8-420a-b882-c1d804d0ccad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_54c590bb-51b7-49ea-858c-097ea4e6af8d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e1f23c91-2de8-420a-b882-c1d804d0ccad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4561ef49-c8d3-476a-9ae0-7b8c541b46d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_387d1ee1-3687-440b-82c4-c9ffc42d7bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4561ef49-c8d3-476a-9ae0-7b8c541b46d1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_387d1ee1-3687-440b-82c4-c9ffc42d7bb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ee7654e3-9d42-4ce1-95b5-182bff92cb41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4561ef49-c8d3-476a-9ae0-7b8c541b46d1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ee7654e3-9d42-4ce1-95b5-182bff92cb41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_457e8f89-1b34-4a40-8764-3a50cdd229c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_405271d6-711d-42eb-876b-cf5bc91a7602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_457e8f89-1b34-4a40-8764-3a50cdd229c2" xlink:to="loc_us-gaap_Land_405271d6-711d-42eb-876b-cf5bc91a7602" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_531e6f09-c2af-4585-b4e3-0da794cbc31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_457e8f89-1b34-4a40-8764-3a50cdd229c2" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_531e6f09-c2af-4585-b4e3-0da794cbc31f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_972e3bb0-3429-4bcf-8eb1-be11544203ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_457e8f89-1b34-4a40-8764-3a50cdd229c2" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_972e3bb0-3429-4bcf-8eb1-be11544203ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_02f31529-8fca-4388-aba2-726f78bbdab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_457e8f89-1b34-4a40-8764-3a50cdd229c2" xlink:to="loc_us-gaap_ConstructionInProgressGross_02f31529-8fca-4388-aba2-726f78bbdab5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84566c1e-6c67-4151-8804-04baeb8e4397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_09808502-67d9-4312-8b80-c66e99c9fabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84566c1e-6c67-4151-8804-04baeb8e4397" xlink:to="loc_us-gaap_OperatingLeaseLiability_09808502-67d9-4312-8b80-c66e99c9fabf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d572dc09-21ac-4591-b1e9-fe356a37bf7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84566c1e-6c67-4151-8804-04baeb8e4397" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d572dc09-21ac-4591-b1e9-fe356a37bf7d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="lly-20221231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1edc4f21-3c4e-40c5-bcf9-7eafaa938044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_40bbdeeb-d0fa-447f-9033-f18ff80034ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1edc4f21-3c4e-40c5-bcf9-7eafaa938044" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_40bbdeeb-d0fa-447f-9033-f18ff80034ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f04afebd-99a4-415e-b24e-101b4eda8a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1edc4f21-3c4e-40c5-bcf9-7eafaa938044" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f04afebd-99a4-415e-b24e-101b4eda8a3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a5b7c777-a78d-426e-9430-b58381882fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1edc4f21-3c4e-40c5-bcf9-7eafaa938044" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a5b7c777-a78d-426e-9430-b58381882fd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1274d9d4-44af-443d-a9da-2d08fd45d22b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1edc4f21-3c4e-40c5-bcf9-7eafaa938044" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1274d9d4-44af-443d-a9da-2d08fd45d22b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_02803915-b59c-4db8-b618-bf3b39bc356c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1edc4f21-3c4e-40c5-bcf9-7eafaa938044" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_02803915-b59c-4db8-b618-bf3b39bc356c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ec12bb6e-1439-4711-83eb-ce278d9240e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1edc4f21-3c4e-40c5-bcf9-7eafaa938044" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ec12bb6e-1439-4711-83eb-ce278d9240e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#BorrowingsScheduleofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_d3a7b048-d37f-4965-bb1e-585b35123a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_d4dcf3bc-919b-463e-8076-cbe9819d6247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_d3a7b048-d37f-4965-bb1e-585b35123a2a" xlink:to="loc_us-gaap_DebtCurrent_d4dcf3bc-919b-463e-8076-cbe9819d6247" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_be143b3c-d20c-4531-9672-89b76cef798d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_d3a7b048-d37f-4965-bb1e-585b35123a2a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_be143b3c-d20c-4531-9672-89b76cef798d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1" xlink:type="simple" xlink:href="lly-20221231.xsd#BorrowingsScheduleofDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_d661f244-b2a7-4bc7-984d-ffd86ac2a1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_5251eb8f-eaf3-427f-a220-79abda44a9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_d661f244-b2a7-4bc7-984d-ffd86ac2a1d6" xlink:to="loc_us-gaap_NotesPayable_5251eb8f-eaf3-427f-a220-79abda44a9c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNotesPayable_33e11ec7-54e5-420f-afa1-653e5775cc83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_d661f244-b2a7-4bc7-984d-ffd86ac2a1d6" xlink:to="loc_us-gaap_OtherNotesPayable_33e11ec7-54e5-420f-afa1-653e5775cc83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_259e80fe-bbb8-4dcb-8608-42d68cc1370d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_d661f244-b2a7-4bc7-984d-ffd86ac2a1d6" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_259e80fe-bbb8-4dcb-8608-42d68cc1370d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LongTermDebtFairValueAdjustment_644de1dc-e47a-4e0f-a9f6-6fe0de6a8eac" xlink:href="lly-20221231.xsd#lly_LongTermDebtFairValueAdjustment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_d661f244-b2a7-4bc7-984d-ffd86ac2a1d6" xlink:to="loc_lly_LongTermDebtFairValueAdjustment_644de1dc-e47a-4e0f-a9f6-6fe0de6a8eac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_daf97204-413d-4baf-9e2a-6149c7373df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_d661f244-b2a7-4bc7-984d-ffd86ac2a1d6" xlink:to="loc_us-gaap_CommercialPaper_daf97204-413d-4baf-9e2a-6149c7373df5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#BorrowingsSummaryofLongtermNotesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2cea1584-65fe-46d8-987f-eae62fda5f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_dc115b6c-c4da-4023-8069-422728ac9a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2cea1584-65fe-46d8-987f-eae62fda5f38" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_dc115b6c-c4da-4023-8069-422728ac9a99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_db3c331b-70c6-4260-b132-f1b9a8098087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2cea1584-65fe-46d8-987f-eae62fda5f38" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_db3c331b-70c6-4260-b132-f1b9a8098087" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_20b34417-ee25-4eb2-b633-6af51c493f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a3df5d79-f191-4a48-bec0-7874e56a1beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_20b34417-ee25-4eb2-b633-6af51c493f25" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a3df5d79-f191-4a48-bec0-7874e56a1beb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_31c87067-287e-4949-8c46-a51fa93eebef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_20b34417-ee25-4eb2-b633-6af51c493f25" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_31c87067-287e-4949-8c46-a51fa93eebef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_eabbfe7c-e16e-448f-8e97-380f5bac8442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_9bb7ea41-5195-49c0-ae7c-6d353afcc265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_eabbfe7c-e16e-448f-8e97-380f5bac8442" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_9bb7ea41-5195-49c0-ae7c-6d353afcc265" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5c9bbc0a-3483-4735-adb3-57e8da2997a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_eabbfe7c-e16e-448f-8e97-380f5bac8442" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5c9bbc0a-3483-4735-adb3-57e8da2997a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_493f6780-e33f-42d5-88f8-f4683a7c04ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_eabbfe7c-e16e-448f-8e97-380f5bac8442" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_493f6780-e33f-42d5-88f8-f4683a7c04ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c5d8cdb8-7e5f-4e51-8696-099716b3163c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d3668241-b4a3-48b6-a628-0052c97beb24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c5d8cdb8-7e5f-4e51-8696-099716b3163c" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d3668241-b4a3-48b6-a628-0052c97beb24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_65e3588b-8a80-4b58-9dd7-c8617fe38277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c5d8cdb8-7e5f-4e51-8696-099716b3163c" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_65e3588b-8a80-4b58-9dd7-c8617fe38277" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_f0738421-d252-476d-852a-b41d9665a991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c5d8cdb8-7e5f-4e51-8696-099716b3163c" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_f0738421-d252-476d-852a-b41d9665a991" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2a92ae3a-1ba6-4993-8671-b00f655d665b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2aeed732-bc85-42a8-b720-9dcd755f5202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_2a92ae3a-1ba6-4993-8671-b00f655d665b" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_2aeed732-bc85-42a8-b720-9dcd755f5202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_87470915-d9f8-42e1-b2b9-fb6b7173c70c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_2a92ae3a-1ba6-4993-8671-b00f655d665b" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_87470915-d9f8-42e1-b2b9-fb6b7173c70c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_91b97d10-5d38-4145-9b91-9cef03352755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_83382767-fa49-49c0-a72b-2cafaa02f7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_91b97d10-5d38-4145-9b91-9cef03352755" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_83382767-fa49-49c0-a72b-2cafaa02f7e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_de7488b2-f4c5-4534-bc15-a416f6a9125f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_91b97d10-5d38-4145-9b91-9cef03352755" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_de7488b2-f4c5-4534-bc15-a416f6a9125f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_03a17e97-9207-48e0-8d8c-05ade0eeda48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_91b97d10-5d38-4145-9b91-9cef03352755" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_03a17e97-9207-48e0-8d8c-05ade0eeda48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_283f20c9-b134-4ddd-9093-7fc72fc68251" xlink:href="lly-20221231.xsd#lly_DeferredTaxAssetsCorrectiveTaxAdjustments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_91b97d10-5d38-4145-9b91-9cef03352755" xlink:to="loc_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_283f20c9-b134-4ddd-9093-7fc72fc68251" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_d9b89935-7dfc-4993-89cd-a5525775a2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_91b97d10-5d38-4145-9b91-9cef03352755" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_d9b89935-7dfc-4993-89cd-a5525775a2ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_c67ced3d-e09e-4adb-85af-a07c30e76db8" xlink:href="lly-20221231.xsd#lly_DeferredTaxAssetsSalesRebatesAndDiscounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_91b97d10-5d38-4145-9b91-9cef03352755" xlink:to="loc_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_c67ced3d-e09e-4adb-85af-a07c30e76db8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_7f1262a2-6f8f-4553-b1ad-e9089d8305f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_91b97d10-5d38-4145-9b91-9cef03352755" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_7f1262a2-6f8f-4553-b1ad-e9089d8305f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsOperatingLeaseLiability_99436bb6-c6e6-4c19-9e17-cebfb29103cc" xlink:href="lly-20221231.xsd#lly_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_91b97d10-5d38-4145-9b91-9cef03352755" xlink:to="loc_lly_DeferredTaxAssetsOperatingLeaseLiability_99436bb6-c6e6-4c19-9e17-cebfb29103cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsForeignTaxRedeterminations_512fbfb2-81b6-40d9-812e-b20b4c9c76c1" xlink:href="lly-20221231.xsd#lly_DeferredTaxAssetsForeignTaxRedeterminations"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_91b97d10-5d38-4145-9b91-9cef03352755" xlink:to="loc_lly_DeferredTaxAssetsForeignTaxRedeterminations_512fbfb2-81b6-40d9-812e-b20b4c9c76c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_0d771759-7563-4ed3-ac9a-cea724035b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_91b97d10-5d38-4145-9b91-9cef03352755" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_0d771759-7563-4ed3-ac9a-cea724035b0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d7ddab88-b8d8-49bd-8832-a110fb0407c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_8d617dfa-c40b-46de-804b-2352c6767d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d7ddab88-b8d8-49bd-8832-a110fb0407c3" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_8d617dfa-c40b-46de-804b-2352c6767d32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_7c75f0b8-adfd-49ef-b6f5-738c7c643155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d7ddab88-b8d8-49bd-8832-a110fb0407c3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_7c75f0b8-adfd-49ef-b6f5-738c7c643155" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_c55bc28a-2ab3-41c4-9304-9663c0d0fafe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_379cd768-e608-4547-b6ee-d773df2a0970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c55bc28a-2ab3-41c4-9304-9663c0d0fafe" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_379cd768-e608-4547-b6ee-d773df2a0970" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_f470e2ca-b2bf-454f-a2a0-817ead6f6052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c55bc28a-2ab3-41c4-9304-9663c0d0fafe" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_f470e2ca-b2bf-454f-a2a0-817ead6f6052" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_f09f61d7-e6c6-45ce-a099-1b98450c11e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c55bc28a-2ab3-41c4-9304-9663c0d0fafe" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_f09f61d7-e6c6-45ce-a099-1b98450c11e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_66410b4e-866f-4f6d-9fd2-18747ed1bdba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c55bc28a-2ab3-41c4-9304-9663c0d0fafe" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_66410b4e-866f-4f6d-9fd2-18747ed1bdba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_ab94eb39-5e2a-4d7e-893f-290222fbd904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c55bc28a-2ab3-41c4-9304-9663c0d0fafe" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_ab94eb39-5e2a-4d7e-893f-290222fbd904" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_a85ca976-57cf-42d8-a134-ddc5520e372e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c55bc28a-2ab3-41c4-9304-9663c0d0fafe" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_a85ca976-57cf-42d8-a134-ddc5520e372e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_fb365053-c646-4d34-8384-45e11f2d6217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c55bc28a-2ab3-41c4-9304-9663c0d0fafe" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_fb365053-c646-4d34-8384-45e11f2d6217" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaid_b03309de-1814-4e3a-bca0-54b73fddba20" xlink:href="lly-20221231.xsd#lly_TaxCutAndJobsActTollTaxToBePaid"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_3e30f35c-0e09-43b8-84f1-2ba6bebb16c2" xlink:href="lly-20221231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_TaxCutAndJobsActTollTaxToBePaid_b03309de-1814-4e3a-bca0-54b73fddba20" xlink:to="loc_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_3e30f35c-0e09-43b8-84f1-2ba6bebb16c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_5b279d31-cf99-4e9c-9c86-fecb60e33395" xlink:href="lly-20221231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_TaxCutAndJobsActTollTaxToBePaid_b03309de-1814-4e3a-bca0-54b73fddba20" xlink:to="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_5b279d31-cf99-4e9c-9c86-fecb60e33395" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ab5c809f-01f2-482c-be39-77cfdb5223a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_9a95f40e-b874-4e76-bb20-fdb3db0d5f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ab5c809f-01f2-482c-be39-77cfdb5223a4" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_9a95f40e-b874-4e76-bb20-fdb3db0d5f0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_242e4a82-269d-4603-ad50-3a2e4aedca9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ab5c809f-01f2-482c-be39-77cfdb5223a4" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_242e4a82-269d-4603-ad50-3a2e4aedca9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_9203faa9-b330-4e51-80db-7823726b7b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ab5c809f-01f2-482c-be39-77cfdb5223a4" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_9203faa9-b330-4e51-80db-7823726b7b9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_45f63cbe-cbab-4526-a03e-87bcf7f4a61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ab5c809f-01f2-482c-be39-77cfdb5223a4" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_45f63cbe-cbab-4526-a03e-87bcf7f4a61b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_f59a6d76-1939-429a-8dae-ba0dcfc150e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ab5c809f-01f2-482c-be39-77cfdb5223a4" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_f59a6d76-1939-429a-8dae-ba0dcfc150e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_43e148c9-6123-4db0-8cab-97bb1ecd9718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ab5c809f-01f2-482c-be39-77cfdb5223a4" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_43e148c9-6123-4db0-8cab-97bb1ecd9718" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_6cc44925-a503-41c7-8f46-db4ce541d708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_db99734c-5cf6-45a0-967d-285b35e3770f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_6cc44925-a503-41c7-8f46-db4ce541d708" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_db99734c-5cf6-45a0-967d-285b35e3770f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_7199da2f-fd77-4f89-8f66-f4ca62a7aabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_6cc44925-a503-41c7-8f46-db4ce541d708" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_7199da2f-fd77-4f89-8f66-f4ca62a7aabc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_5817baae-ee3a-429e-a6af-bb9ae9a03568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_6cc44925-a503-41c7-8f46-db4ce541d708" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_5817baae-ee3a-429e-a6af-bb9ae9a03568" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_d9268273-9502-4ab2-a317-4fc61cf13b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_0d12b617-df34-462a-b803-a86f356a1375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_d9268273-9502-4ab2-a317-4fc61cf13b5f" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_0d12b617-df34-462a-b803-a86f356a1375" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_ad282f1d-4b68-4d4b-9971-842ac6c8a786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_d9268273-9502-4ab2-a317-4fc61cf13b5f" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_ad282f1d-4b68-4d4b-9971-842ac6c8a786" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_642cafc8-e22e-4c9c-ae62-8344cf66208d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_d9268273-9502-4ab2-a317-4fc61cf13b5f" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_642cafc8-e22e-4c9c-ae62-8344cf66208d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_d8785320-5f8e-492f-9d45-93489d7a780e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_d9268273-9502-4ab2-a317-4fc61cf13b5f" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_d8785320-5f8e-492f-9d45-93489d7a780e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_db3fa353-a49b-47f2-b788-ceebfc8a9457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_fa3f63ae-2d9f-4e2c-aaeb-7d7c66d0e05a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_db3fa353-a49b-47f2-b788-ceebfc8a9457" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_fa3f63ae-2d9f-4e2c-aaeb-7d7c66d0e05a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_647f91fb-bad2-45e3-ad26-e3c5bba7d02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_db3fa353-a49b-47f2-b788-ceebfc8a9457" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_647f91fb-bad2-45e3-ad26-e3c5bba7d02d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_2b8917ea-0c31-46fb-8380-2ab103216b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_db3fa353-a49b-47f2-b788-ceebfc8a9457" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_2b8917ea-0c31-46fb-8380-2ab103216b2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_ef16e688-429b-44c8-93df-aa5397ef0fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_db3fa353-a49b-47f2-b788-ceebfc8a9457" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_ef16e688-429b-44c8-93df-aa5397ef0fe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_ac23dfa8-7031-454a-82e6-9097e11cdc40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_db3fa353-a49b-47f2-b788-ceebfc8a9457" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_ac23dfa8-7031-454a-82e6-9097e11cdc40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_2160e779-6659-452b-ae79-b4ecb1407286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_88231a99-f3dd-41bd-ad36-62fac03db769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_2160e779-6659-452b-ae79-b4ecb1407286" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_88231a99-f3dd-41bd-ad36-62fac03db769" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_ba8285c4-6b2d-4f8e-858b-c2584c1d611b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_2160e779-6659-452b-ae79-b4ecb1407286" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_ba8285c4-6b2d-4f8e-858b-c2584c1d611b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_8a39bc72-834c-4b5b-8add-6628907caaff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_2160e779-6659-452b-ae79-b4ecb1407286" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_8a39bc72-834c-4b5b-8add-6628907caaff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_cec99247-ac12-4d77-8842-cff59936ddb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_2160e779-6659-452b-ae79-b4ecb1407286" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_cec99247-ac12-4d77-8842-cff59936ddb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_288df0a8-eab9-4a7d-b151-0da849c2ada4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_2160e779-6659-452b-ae79-b4ecb1407286" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_288df0a8-eab9-4a7d-b151-0da849c2ada4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3b405668-4047-44db-8855-aed32e2ae9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_169a6306-d313-470e-bfbe-3571473eee22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3b405668-4047-44db-8855-aed32e2ae9ee" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_169a6306-d313-470e-bfbe-3571473eee22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_816c3ff2-c605-41ca-912b-551615214137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3b405668-4047-44db-8855-aed32e2ae9ee" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_816c3ff2-c605-41ca-912b-551615214137" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#OtherNetIncomeExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b1bf2f36-aa91-4e55-b417-e6b4228c8e05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fe033d02-bc1f-4f5c-a7da-243284e112de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b1bf2f36-aa91-4e55-b417-e6b4228c8e05" xlink:to="loc_us-gaap_InterestExpense_fe033d02-bc1f-4f5c-a7da-243284e112de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_57192e0c-220a-49e2-956d-d755e4c2cf68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b1bf2f36-aa91-4e55-b417-e6b4228c8e05" xlink:to="loc_us-gaap_InvestmentIncomeInterest_57192e0c-220a-49e2-956d-d755e4c2cf68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_619c2ff1-ba19-402d-b640-f0e75655c2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b1bf2f36-aa91-4e55-b417-e6b4228c8e05" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_619c2ff1-ba19-402d-b640-f0e75655c2e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_10c609a3-f049-482a-bda9-10a09601541d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b1bf2f36-aa91-4e55-b417-e6b4228c8e05" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_10c609a3-f049-482a-bda9-10a09601541d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_858b9054-92a0-443b-be95-643c480b3b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b1bf2f36-aa91-4e55-b417-e6b4228c8e05" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_858b9054-92a0-443b-be95-643c480b3b93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_2923162c-2347-43e2-978a-8361a37eb53d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b1bf2f36-aa91-4e55-b417-e6b4228c8e05" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_2923162c-2347-43e2-978a-8361a37eb53d" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>lly-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:ccabaa9f-f08b-4cef-8cc5-6b16fc2f1828,g:814ba434-7768-4150-bd97-753155d7ed58-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20221231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended" id="if04a5eeac77b4b06a3f3f7bc08e27ea3_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b524d60b-5219-408d-bd84-56a75aff36e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_DocumentType_b524d60b-5219-408d-bd84-56a75aff36e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_01b0f7f5-17d4-42f2-afb5-927a9fbfde0c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_DocumentPeriodEndDate_01b0f7f5-17d4-42f2-afb5-927a9fbfde0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_94253958-a078-4f12-a043-bd4ac3db6546" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_CurrentFiscalYearEndDate_94253958-a078-4f12-a043-bd4ac3db6546" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ad1d7730-0773-468f-8767-0d239bd235a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityFileNumber_ad1d7730-0773-468f-8767-0d239bd235a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ef1e2010-0c59-4057-bf2a-9c22cae92a32" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityRegistrantName_ef1e2010-0c59-4057-bf2a-9c22cae92a32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a4c49160-7031-4054-8eab-c8dd7754eab8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a4c49160-7031-4054-8eab-c8dd7754eab8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_94728fce-d743-4bbd-ae20-9deb342649b6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityTaxIdentificationNumber_94728fce-d743-4bbd-ae20-9deb342649b6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_75f070d8-0b6f-437b-a4f9-f48e6ff9116b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityAddressAddressLine1_75f070d8-0b6f-437b-a4f9-f48e6ff9116b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ccb47e8f-dff8-42d1-a4df-9ba051271bc3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityAddressCityOrTown_ccb47e8f-dff8-42d1-a4df-9ba051271bc3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a28e75b6-3a79-410a-b682-0aa193cbfa23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityAddressStateOrProvince_a28e75b6-3a79-410a-b682-0aa193cbfa23" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_826cbac4-8950-415d-a1d0-2deec15fa2a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityAddressPostalZipCode_826cbac4-8950-415d-a1d0-2deec15fa2a6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_34b037bc-6489-4c5d-9886-643e15354f63" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_CityAreaCode_34b037bc-6489-4c5d-9886-643e15354f63" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_24e1bed5-8d9f-43e6-a7cb-4ea30289c6e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_LocalPhoneNumber_24e1bed5-8d9f-43e6-a7cb-4ea30289c6e0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4757b4c9-52b4-4ed7-9205-d188f8d224bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_Security12bTitle_4757b4c9-52b4-4ed7-9205-d188f8d224bf" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_dfa3cd2f-e480-40a6-9bb3-c900325e0ab1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_TradingSymbol_dfa3cd2f-e480-40a6-9bb3-c900325e0ab1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8268a7c8-148b-413e-962d-17c78ebf054d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_SecurityExchangeName_8268a7c8-148b-413e-962d-17c78ebf054d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_348fa6da-cb86-4155-94e6-2e3cafdd5795" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_348fa6da-cb86-4155-94e6-2e3cafdd5795" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_1120a355-5b91-47f9-840d-46b62f0bd70c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityVoluntaryFilers_1120a355-5b91-47f9-840d-46b62f0bd70c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_b7d8faa7-53d6-4de6-9512-6ffd5d4cbae6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityCurrentReportingStatus_b7d8faa7-53d6-4de6-9512-6ffd5d4cbae6" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_00958e17-0c47-4034-b55c-1e29c6ffe567" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityInteractiveDataCurrent_00958e17-0c47-4034-b55c-1e29c6ffe567" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_06acaaee-e55b-4702-b86e-df1918de8b6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityFilerCategory_06acaaee-e55b-4702-b86e-df1918de8b6f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e325d7ce-d874-42b5-b4be-bfee3ebf3e67" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntitySmallBusiness_e325d7ce-d874-42b5-b4be-bfee3ebf3e67" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_04de8375-a31f-4c4f-a8ad-016991c39914" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityEmergingGrowthCompany_04de8375-a31f-4c4f-a8ad-016991c39914" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_742fba89-bd73-46df-82f5-c8053a7a7a65" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_IcfrAuditorAttestationFlag_742fba89-bd73-46df-82f5-c8053a7a7a65" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2def7334-b468-496c-8225-a09f556e3048" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityShellCompany_2def7334-b468-496c-8225-a09f556e3048" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_0d753fec-199f-44b2-bf0d-51349470df34" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityPublicFloat_0d753fec-199f-44b2-bf0d-51349470df34" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9aca2ab9-9a7b-48bd-b585-bbde65048d74" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9aca2ab9-9a7b-48bd-b585-bbde65048d74" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_337d98cd-d370-4978-89dc-01693ec45b3c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_337d98cd-d370-4978-89dc-01693ec45b3c" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_d4873c87-96b4-4e7c-af41-cb0f4d0f6e34" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_DocumentAnnualReport_d4873c87-96b4-4e7c-af41-cb0f4d0f6e34" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_008e1731-91c6-493c-8b39-6a57e166b607" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_DocumentTransitionReport_008e1731-91c6-493c-8b39-6a57e166b607" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_6e0311bb-d0d1-47cc-bcdb-1bf42ade1ddd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_AmendmentFlag_6e0311bb-d0d1-47cc-bcdb-1bf42ade1ddd" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0c9aeec6-da65-49eb-a739-44d60e53172e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_DocumentFiscalYearFocus_0c9aeec6-da65-49eb-a739-44d60e53172e" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9dd8daff-244b-4089-9a85-17f2a4690568" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9dd8daff-244b-4089-9a85-17f2a4690568" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_98f9f843-c978-4655-8d77-3a03d8893010" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityCentralIndexKey_98f9f843-c978-4655-8d77-3a03d8893010" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_301da636-c7a8-4bf1-b42a-b886687a1924" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_DocumentInformationTable_301da636-c7a8-4bf1-b42a-b886687a1924" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_227f8878-06b1-4a16-a19c-b6c118025fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_301da636-c7a8-4bf1-b42a-b886687a1924" xlink:to="loc_us-gaap_StatementClassOfStockAxis_227f8878-06b1-4a16-a19c-b6c118025fd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_227f8878-06b1-4a16-a19c-b6c118025fd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_227f8878-06b1-4a16-a19c-b6c118025fd3" xlink:to="loc_us-gaap_ClassOfStockDomain_227f8878-06b1-4a16-a19c-b6c118025fd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_227f8878-06b1-4a16-a19c-b6c118025fd3" xlink:to="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_a22349c1-59d0-4d90-a47d-e451a3b8ac79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_us-gaap_CommonClassAMember_a22349c1-59d0-4d90-a47d-e451a3b8ac79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_fe557603-f56a-447d-a156-050f17991221" xlink:href="lly-20221231.xsd#lly_A718NotesDueJune12025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A718NotesDueJune12025Member_fe557603-f56a-447d-a156-050f17991221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_a3abdc4b-6067-4199-ad4b-ce3a28b91403" xlink:href="lly-20221231.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A1.625NotesDueJune22026Member_a3abdc4b-6067-4199-ad4b-ce3a28b91403" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_655d46f1-47bd-4a59-a0bf-c80d77457094" xlink:href="lly-20221231.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A2.125NotesDueJune32030Member_655d46f1-47bd-4a59-a0bf-c80d77457094" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_e04998c9-a635-4ebe-a9ba-1c22a20e6b6a" xlink:href="lly-20221231.xsd#lly_A625Notesdue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A625Notesdue2031Member_e04998c9-a635-4ebe-a9ba-1c22a20e6b6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A5000NotesDue2033Member_5f655309-9e59-4a42-8e54-43e67d792030" xlink:href="lly-20221231.xsd#lly_A5000NotesDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A5000NotesDue2033Member_5f655309-9e59-4a42-8e54-43e67d792030" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_f65ee495-50fe-47dc-83c6-9cbb0393dfd4" xlink:href="lly-20221231.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_f65ee495-50fe-47dc-83c6-9cbb0393dfd4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625BritishPoundDenominatedNotesDue2043Member_5e0997a0-a1eb-4733-82d3-a669e2e40060" xlink:href="lly-20221231.xsd#lly_A1625BritishPoundDenominatedNotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A1625BritishPoundDenominatedNotesDue2043Member_5e0997a0-a1eb-4733-82d3-a669e2e40060" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_6f1b0577-5940-4178-89be-4ea14904127e" xlink:href="lly-20221231.xsd#lly_A1.700Notesdue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A1.700Notesdue2049Member_6f1b0577-5940-4178-89be-4ea14904127e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_1f3bdf83-6f37-43e5-b647-e9d712c9cbc5" xlink:href="lly-20221231.xsd#lly_A1125NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A1125NotesDue2051Member_1f3bdf83-6f37-43e5-b647-e9d712c9cbc5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_3a19a144-9a23-4c76-954a-59c851296548" xlink:href="lly-20221231.xsd#lly_A1375NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A1375NotesDue2061Member_3a19a144-9a23-4c76-954a-59c851296548" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="lly-20221231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="i60700a87521b4827854a1b34e67632c3_ConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a4e0a991-3026-4962-a58a-81b41ce93c26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4e0a991-3026-4962-a58a-81b41ce93c26" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b41de3e4-8b83-4636-9da7-7e2dfd2ecd53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_CommonStockSharesIssued_b41de3e4-8b83-4636-9da7-7e2dfd2ecd53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_5fc349f5-5a26-481b-b67e-6823161e5f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_TreasuryStockCommonShares_5fc349f5-5a26-481b-b67e-6823161e5f8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3f730845-7a94-4a30-b9a7-edb66b747816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3f730845-7a94-4a30-b9a7-edb66b747816" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d0b4a32a-2234-422d-8669-6673b880a468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_ProfitLoss_d0b4a32a-2234-422d-8669-6673b880a468" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_19b5c0e2-6724-4e20-86d3-c411e1fefde5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_19b5c0e2-6724-4e20-86d3-c411e1fefde5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_76dfe2cf-6eed-48d1-bb1e-3d7b2a538a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_Dividends_76dfe2cf-6eed-48d1-bb1e-3d7b2a538a71" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_e0990b60-c967-4c68-844b-684f2de927f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_e0990b60-c967-4c68-844b-684f2de927f3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_016f2a82-d47b-4c9d-a069-8bb283475532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_016f2a82-d47b-4c9d-a069-8bb283475532" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_4b9c6077-c18e-41b0-adf4-0025e0b23ede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_4b9c6077-c18e-41b0-adf4-0025e0b23ede" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_9f0d7ed9-6952-4476-adf9-ad065d870ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_9f0d7ed9-6952-4476-adf9-ad065d870ddd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6d840127-268b-4a57-a2b6-ee50ae8e0dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6d840127-268b-4a57-a2b6-ee50ae8e0dd2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_836d89e1-6574-4388-93aa-04137f1bf4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_836d89e1-6574-4388-93aa-04137f1bf4b3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2bc08248-4f11-48c2-a206-732403bffcd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2bc08248-4f11-48c2-a206-732403bffcd9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_e09e28e5-e182-4fab-b5f3-fe48aea1ec12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_StockholdersEquityOther_e09e28e5-e182-4fab-b5f3-fe48aea1ec12" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_89da0baa-e377-49cd-8df8-141fecfa7ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_0422c41f-6e1f-45f7-a144-892a512af272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f3098832-4a02-43d9-aca7-cfac5cf27115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_19727e29-7fb8-4a35-a16a-af73b4d05f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a4e0a991-3026-4962-a58a-81b41ce93c26" xlink:to="loc_us-gaap_StatementTable_19727e29-7fb8-4a35-a16a-af73b4d05f9b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_70a76fa2-240e-4ca4-b824-25688a51caf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_19727e29-7fb8-4a35-a16a-af73b4d05f9b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_70a76fa2-240e-4ca4-b824-25688a51caf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_70a76fa2-240e-4ca4-b824-25688a51caf5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_70a76fa2-240e-4ca4-b824-25688a51caf5" xlink:to="loc_us-gaap_EquityComponentDomain_70a76fa2-240e-4ca4-b824-25688a51caf5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_56c04e12-d8a4-4fb6-bc82-048643e66e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_70a76fa2-240e-4ca4-b824-25688a51caf5" xlink:to="loc_us-gaap_EquityComponentDomain_56c04e12-d8a4-4fb6-bc82-048643e66e8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fabfae70-b0a7-4262-8f93-72c5d324021f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56c04e12-d8a4-4fb6-bc82-048643e66e8e" xlink:to="loc_us-gaap_CommonStockMember_fabfae70-b0a7-4262-8f93-72c5d324021f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_948203c7-c1d9-49af-8534-7c1de86a6704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56c04e12-d8a4-4fb6-bc82-048643e66e8e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_948203c7-c1d9-49af-8534-7c1de86a6704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6fda78d9-26b9-4d92-8f96-d6be77c131f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56c04e12-d8a4-4fb6-bc82-048643e66e8e" xlink:to="loc_us-gaap_RetainedEarningsMember_6fda78d9-26b9-4d92-8f96-d6be77c131f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember_ee7876f9-b493-4466-aa45-f6d0e1de43d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56c04e12-d8a4-4fb6-bc82-048643e66e8e" xlink:to="loc_us-gaap_TrustForBenefitOfEmployeesMember_ee7876f9-b493-4466-aa45-f6d0e1de43d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fc72f471-f85e-44b8-81eb-53d3bc4c6947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56c04e12-d8a4-4fb6-bc82-048643e66e8e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fc72f471-f85e-44b8-81eb-53d3bc4c6947" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_454195ae-d49a-45b2-8aa2-698c896411e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56c04e12-d8a4-4fb6-bc82-048643e66e8e" xlink:to="loc_us-gaap_TreasuryStockCommonMember_454195ae-d49a-45b2-8aa2-698c896411e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_b606e5a8-df81-4e88-8549-e496da242eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56c04e12-d8a4-4fb6-bc82-048643e66e8e" xlink:to="loc_us-gaap_NoncontrollingInterestMember_b606e5a8-df81-4e88-8549-e496da242eea" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RevenueSummaryofRevenueRecognizedDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="extended" id="i1acdce1b37714c96a5282c62fe90179f_RevenueSummaryofRevenueRecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_349751b8-1021-4a7f-b038-4f5ac6ef7ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ae68c0e2-98bb-4fce-b82d-8de254c87c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_349751b8-1021-4a7f-b038-4f5ac6ef7ed3" xlink:to="loc_us-gaap_Revenues_ae68c0e2-98bb-4fce-b82d-8de254c87c24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6b2c36f4-2a57-44db-bb44-c6f72662b2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_349751b8-1021-4a7f-b038-4f5ac6ef7ed3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6b2c36f4-2a57-44db-bb44-c6f72662b2a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_87a47fe4-7b7b-431c-9b8f-5c0d354fd4f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6b2c36f4-2a57-44db-bb44-c6f72662b2a4" xlink:to="loc_srt_ProductOrServiceAxis_87a47fe4-7b7b-431c-9b8f-5c0d354fd4f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_87a47fe4-7b7b-431c-9b8f-5c0d354fd4f9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_87a47fe4-7b7b-431c-9b8f-5c0d354fd4f9" xlink:to="loc_srt_ProductsAndServicesDomain_87a47fe4-7b7b-431c-9b8f-5c0d354fd4f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9964ccde-0813-451e-8428-61fc71c7c34f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_87a47fe4-7b7b-431c-9b8f-5c0d354fd4f9" xlink:to="loc_srt_ProductsAndServicesDomain_9964ccde-0813-451e-8428-61fc71c7c34f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_07cd240d-f217-4fa2-a259-ec4c93e0c2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9964ccde-0813-451e-8428-61fc71c7c34f" xlink:to="loc_us-gaap_ProductMember_07cd240d-f217-4fa2-a259-ec4c93e0c2d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember_1ee9238f-bacc-4e7a-86c1-31cc73f8aa8e" xlink:href="lly-20221231.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9964ccde-0813-451e-8428-61fc71c7c34f" xlink:to="loc_lly_CollaborationandOtherRevenueMember_1ee9238f-bacc-4e7a-86c1-31cc73f8aa8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_5af78a32-3ca0-4f4c-9659-2fac56c44344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9964ccde-0813-451e-8428-61fc71c7c34f" xlink:to="loc_us-gaap_RoyaltyMember_5af78a32-3ca0-4f4c-9659-2fac56c44344" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RevenueNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueNarrativeDetails" xlink:type="extended" id="iac7867228b334c3da8022467f5a0abc7_RevenueNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuefromContractPaymentTermMinimum_a2c9b08b-4bb5-4f9e-9359-ec2d7e5c5d1d" xlink:href="lly-20221231.xsd#lly_RevenuefromContractPaymentTermMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:to="loc_lly_RevenuefromContractPaymentTermMinimum_a2c9b08b-4bb5-4f9e-9359-ec2d7e5c5d1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuefromContractPaymentTermMaximum_d0835779-24ec-4f4b-9cd1-11559b2cb213" xlink:href="lly-20221231.xsd#lly_RevenuefromContractPaymentTermMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:to="loc_lly_RevenuefromContractPaymentTermMaximum_d0835779-24ec-4f4b-9cd1-11559b2cb213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_cb49ab71-51be-43ba-a426-0aea47eed0c4" xlink:href="lly-20221231.xsd#lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:to="loc_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_cb49ab71-51be-43ba-a426-0aea47eed0c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_54d53709-8b63-4ea3-9a67-6f3d88b47cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_54d53709-8b63-4ea3-9a67-6f3d88b47cfc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_31195653-3fdf-4e52-a33e-268bb597fb16" xlink:href="lly-20221231.xsd#lly_RevenuePerformanceObligationSalesRebatePaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:to="loc_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_31195653-3fdf-4e52-a33e-268bb597fb16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_3d645deb-3917-41f5-9772-7060b6559546" xlink:href="lly-20221231.xsd#lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:to="loc_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_3d645deb-3917-41f5-9772-7060b6559546" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_b0e4c19b-c164-42cf-a973-a291c5c634ba" xlink:href="lly-20221231.xsd#lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:to="loc_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_b0e4c19b-c164-42cf-a973-a291c5c634ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_b4ed179b-5926-40ad-a96b-4330a6436ecf" xlink:href="lly-20221231.xsd#lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:to="loc_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_b4ed179b-5926-40ad-a96b-4330a6436ecf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_215190ca-03fb-4542-8fa2-a4798cac5718" xlink:href="lly-20221231.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:to="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_215190ca-03fb-4542-8fa2-a4798cac5718" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_607fd334-ceb1-4f3f-a4e1-c70232ca99fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_607fd334-ceb1-4f3f-a4e1-c70232ca99fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9cfd6856-4aa6-4d3a-b3ca-6513f740e4a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_607fd334-ceb1-4f3f-a4e1-c70232ca99fe" xlink:to="loc_srt_MajorCustomersAxis_9cfd6856-4aa6-4d3a-b3ca-6513f740e4a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9cfd6856-4aa6-4d3a-b3ca-6513f740e4a5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_9cfd6856-4aa6-4d3a-b3ca-6513f740e4a5" xlink:to="loc_srt_NameOfMajorCustomerDomain_9cfd6856-4aa6-4d3a-b3ca-6513f740e4a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ae81d9b8-a273-43b3-a868-b69302df112b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_9cfd6856-4aa6-4d3a-b3ca-6513f740e4a5" xlink:to="loc_srt_NameOfMajorCustomerDomain_ae81d9b8-a273-43b3-a868-b69302df112b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ThreeLargestWholesalesMember_3d607b84-2459-4285-8573-9f7a1926c005" xlink:href="lly-20221231.xsd#lly_ThreeLargestWholesalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ae81d9b8-a273-43b3-a868-b69302df112b" xlink:to="loc_lly_ThreeLargestWholesalesMember_3d607b84-2459-4285-8573-9f7a1926c005" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b08b020c-7d15-4a6a-b00e-2edfed463736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_607fd334-ceb1-4f3f-a4e1-c70232ca99fe" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b08b020c-7d15-4a6a-b00e-2edfed463736" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b08b020c-7d15-4a6a-b00e-2edfed463736_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b08b020c-7d15-4a6a-b00e-2edfed463736" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b08b020c-7d15-4a6a-b00e-2edfed463736_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a4897bf8-d41e-4798-b5d9-d934d30674d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b08b020c-7d15-4a6a-b00e-2edfed463736" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a4897bf8-d41e-4798-b5d9-d934d30674d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_353383dd-3f0d-4d28-a701-be8ec5880580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a4897bf8-d41e-4798-b5d9-d934d30674d7" xlink:to="loc_us-gaap_SalesRevenueNetMember_353383dd-3f0d-4d28-a701-be8ec5880580" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_7d9d200f-2310-4ec2-8cfd-fa0adb9de48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a4897bf8-d41e-4798-b5d9-d934d30674d7" xlink:to="loc_us-gaap_AccountsReceivableMember_7d9d200f-2310-4ec2-8cfd-fa0adb9de48c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9b9223f2-cddb-4671-8fd5-62668c4f6dce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_607fd334-ceb1-4f3f-a4e1-c70232ca99fe" xlink:to="loc_srt_RangeAxis_9b9223f2-cddb-4671-8fd5-62668c4f6dce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b9223f2-cddb-4671-8fd5-62668c4f6dce_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9b9223f2-cddb-4671-8fd5-62668c4f6dce" xlink:to="loc_srt_RangeMember_9b9223f2-cddb-4671-8fd5-62668c4f6dce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_65088812-6b60-4cad-be88-2d137607365a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9b9223f2-cddb-4671-8fd5-62668c4f6dce" xlink:to="loc_srt_RangeMember_65088812-6b60-4cad-be88-2d137607365a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ddd49963-36e1-4282-a524-47718d78a11c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_65088812-6b60-4cad-be88-2d137607365a" xlink:to="loc_srt_MinimumMember_ddd49963-36e1-4282-a524-47718d78a11c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_288b3009-99e2-45c4-8ac8-acb51d35fd4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_65088812-6b60-4cad-be88-2d137607365a" xlink:to="loc_srt_MaximumMember_288b3009-99e2-45c4-8ac8-acb51d35fd4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3c8d0c44-feb2-47bf-a9ef-13212f51ab3e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_607fd334-ceb1-4f3f-a4e1-c70232ca99fe" xlink:to="loc_srt_StatementGeographicalAxis_3c8d0c44-feb2-47bf-a9ef-13212f51ab3e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3c8d0c44-feb2-47bf-a9ef-13212f51ab3e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_3c8d0c44-feb2-47bf-a9ef-13212f51ab3e" xlink:to="loc_srt_SegmentGeographicalDomain_3c8d0c44-feb2-47bf-a9ef-13212f51ab3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9077d401-8183-42f5-a030-12fb0bd11777" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_3c8d0c44-feb2-47bf-a9ef-13212f51ab3e" xlink:to="loc_srt_SegmentGeographicalDomain_9077d401-8183-42f5-a030-12fb0bd11777" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3370f47f-f2b6-425f-9de2-6d2fc0f521a2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9077d401-8183-42f5-a030-12fb0bd11777" xlink:to="loc_country_US_3370f47f-f2b6-425f-9de2-6d2fc0f521a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_b58070d9-7fb4-4c57-9652-5abae04561fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_607fd334-ceb1-4f3f-a4e1-c70232ca99fe" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_b58070d9-7fb4-4c57-9652-5abae04561fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_b58070d9-7fb4-4c57-9652-5abae04561fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_b58070d9-7fb4-4c57-9652-5abae04561fb" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_b58070d9-7fb4-4c57-9652-5abae04561fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_fd8210be-209a-4a02-a82b-cc1dfdd3b0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_b58070d9-7fb4-4c57-9652-5abae04561fb" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_fd8210be-209a-4a02-a82b-cc1dfdd3b0c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_e59787cb-48f6-45b3-bcd6-0d3255fd6bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_fd8210be-209a-4a02-a82b-cc1dfdd3b0c9" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_e59787cb-48f6-45b3-bcd6-0d3255fd6bf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_be272b93-d928-4561-8d01-180efc455ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_607fd334-ceb1-4f3f-a4e1-c70232ca99fe" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_be272b93-d928-4561-8d01-180efc455ee7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_be272b93-d928-4561-8d01-180efc455ee7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_be272b93-d928-4561-8d01-180efc455ee7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_be272b93-d928-4561-8d01-180efc455ee7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_54b0dcf0-e1a6-45a1-b94f-9f86ae8596b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_be272b93-d928-4561-8d01-180efc455ee7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_54b0dcf0-e1a6-45a1-b94f-9f86ae8596b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_b549e87a-c69c-4ea5-8f88-b89c46563ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_54b0dcf0-e1a6-45a1-b94f-9f86ae8596b3" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_b549e87a-c69c-4ea5-8f88-b89c46563ba4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RevenueDisaggregationofRevenuebyProductDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="extended" id="ib4ac23fd1e654586abf7d39e1c0a8197_RevenueDisaggregationofRevenuebyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7da71d4e-9b2d-47d6-bfc1-a513b2fc6697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cac1cf2b-e50e-44ee-b171-6895df0e2680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7da71d4e-9b2d-47d6-bfc1-a513b2fc6697" xlink:to="loc_us-gaap_Revenues_cac1cf2b-e50e-44ee-b171-6895df0e2680" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_152ef89d-d055-4ca3-8cc0-a9a669e2a297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7da71d4e-9b2d-47d6-bfc1-a513b2fc6697" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_152ef89d-d055-4ca3-8cc0-a9a669e2a297" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c0e9c6fb-a412-4b9f-be3f-6eed2d0a8f76" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_152ef89d-d055-4ca3-8cc0-a9a669e2a297" xlink:to="loc_srt_ProductOrServiceAxis_c0e9c6fb-a412-4b9f-be3f-6eed2d0a8f76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c0e9c6fb-a412-4b9f-be3f-6eed2d0a8f76_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c0e9c6fb-a412-4b9f-be3f-6eed2d0a8f76" xlink:to="loc_srt_ProductsAndServicesDomain_c0e9c6fb-a412-4b9f-be3f-6eed2d0a8f76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_61010694-c82a-44c4-b5e4-402d962180b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c0e9c6fb-a412-4b9f-be3f-6eed2d0a8f76" xlink:to="loc_srt_ProductsAndServicesDomain_61010694-c82a-44c4-b5e4-402d962180b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember_7d223998-bff0-4100-93d9-8c694d08a9e7" xlink:href="lly-20221231.xsd#lly_DiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_61010694-c82a-44c4-b5e4-402d962180b1" xlink:to="loc_lly_DiabetesMember_7d223998-bff0-4100-93d9-8c694d08a9e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMemberMember_5ddf082f-5368-421d-97ce-4a78d02b9537" xlink:href="lly-20221231.xsd#lly_TrulicityMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_7d223998-bff0-4100-93d9-8c694d08a9e7" xlink:to="loc_lly_TrulicityMemberMember_5ddf082f-5368-421d-97ce-4a78d02b9537" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_93f6edf1-71fd-40d7-b46f-210fd02689e8" xlink:href="lly-20221231.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_7d223998-bff0-4100-93d9-8c694d08a9e7" xlink:to="loc_lly_JardianceMember_93f6edf1-71fd-40d7-b46f-210fd02689e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember_913ef67d-dcaf-4c5d-a92a-01de11aaf656" xlink:href="lly-20221231.xsd#lly_HumalogMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_7d223998-bff0-4100-93d9-8c694d08a9e7" xlink:to="loc_lly_HumalogMember_913ef67d-dcaf-4c5d-a92a-01de11aaf656" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember_58e331d9-f436-42a1-9c09-9c8042bc09fb" xlink:href="lly-20221231.xsd#lly_HumulinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_7d223998-bff0-4100-93d9-8c694d08a9e7" xlink:to="loc_lly_HumulinMember_58e331d9-f436-42a1-9c09-9c8042bc09fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_3ae3e568-5d2b-4d60-9988-e531e4f108c8" xlink:href="lly-20221231.xsd#lly_BasaglarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_7d223998-bff0-4100-93d9-8c694d08a9e7" xlink:to="loc_lly_BasaglarMember_3ae3e568-5d2b-4d60-9988-e531e4f108c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MounjaroMember_c0f4884e-8a0a-41af-8e90-e2773f7e2301" xlink:href="lly-20221231.xsd#lly_MounjaroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_7d223998-bff0-4100-93d9-8c694d08a9e7" xlink:to="loc_lly_MounjaroMember_c0f4884e-8a0a-41af-8e90-e2773f7e2301" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember_84c68d51-d952-4a56-9879-2d68c1f0e9c5" xlink:href="lly-20221231.xsd#lly_OtherDiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_7d223998-bff0-4100-93d9-8c694d08a9e7" xlink:to="loc_lly_OtherDiabetesMember_84c68d51-d952-4a56-9879-2d68c1f0e9c5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember_7f611d38-94ca-4c00-a640-b534a9aa3753" xlink:href="lly-20221231.xsd#lly_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_61010694-c82a-44c4-b5e4-402d962180b1" xlink:to="loc_lly_OncologyMember_7f611d38-94ca-4c00-a640-b534a9aa3753" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember_5574ab93-0ab1-44bc-afec-6ffeafc1b996" xlink:href="lly-20221231.xsd#lly_VerzenioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_7f611d38-94ca-4c00-a640-b534a9aa3753" xlink:to="loc_lly_VerzenioMember_5574ab93-0ab1-44bc-afec-6ffeafc1b996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember_8c7c8798-68fb-429a-8c0b-7b4bfd7da353" xlink:href="lly-20221231.xsd#lly_CyramzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_7f611d38-94ca-4c00-a640-b534a9aa3753" xlink:to="loc_lly_CyramzaMember_8c7c8798-68fb-429a-8c0b-7b4bfd7da353" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember_2ec3065f-cb7d-4135-9146-f4faf5a56df7" xlink:href="lly-20221231.xsd#lly_AlimtaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_7f611d38-94ca-4c00-a640-b534a9aa3753" xlink:to="loc_lly_AlimtaMember_2ec3065f-cb7d-4135-9146-f4faf5a56df7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember_0e32d0dc-079f-433d-aa4b-69bdf7066659" xlink:href="lly-20221231.xsd#lly_ErbituxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_7f611d38-94ca-4c00-a640-b534a9aa3753" xlink:to="loc_lly_ErbituxMember_0e32d0dc-079f-433d-aa4b-69bdf7066659" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_8ebfec99-13a5-4106-a952-bf56c5005b3a" xlink:href="lly-20221231.xsd#lly_TYVYTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_7f611d38-94ca-4c00-a640-b534a9aa3753" xlink:to="loc_lly_TYVYTMember_8ebfec99-13a5-4106-a952-bf56c5005b3a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember_7e3d5562-7fc9-4789-a7cc-abe9a8b55440" xlink:href="lly-20221231.xsd#lly_OtherOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_7f611d38-94ca-4c00-a640-b534a9aa3753" xlink:to="loc_lly_OtherOncologyMember_7e3d5562-7fc9-4789-a7cc-abe9a8b55440" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember_410e8aaa-afd0-4aff-aafa-3a759c04e315" xlink:href="lly-20221231.xsd#lly_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_61010694-c82a-44c4-b5e4-402d962180b1" xlink:to="loc_lly_ImmunologyMember_410e8aaa-afd0-4aff-aafa-3a759c04e315" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember_9672cea9-e5b2-4af3-837c-e15addb0bcd8" xlink:href="lly-20221231.xsd#lly_TaltzMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_410e8aaa-afd0-4aff-aafa-3a759c04e315" xlink:to="loc_lly_TaltzMember_9672cea9-e5b2-4af3-837c-e15addb0bcd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_6389f2bf-9e2a-4a89-b099-576f8ee57f8b" xlink:href="lly-20221231.xsd#lly_OlumiantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_410e8aaa-afd0-4aff-aafa-3a759c04e315" xlink:to="loc_lly_OlumiantMember_6389f2bf-9e2a-4a89-b099-576f8ee57f8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember_a2ead966-7cc3-4e1d-94d9-d1de38d27c48" xlink:href="lly-20221231.xsd#lly_OtherImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_410e8aaa-afd0-4aff-aafa-3a759c04e315" xlink:to="loc_lly_OtherImmunologyMember_a2ead966-7cc3-4e1d-94d9-d1de38d27c48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember_a8c2afa9-3be1-4791-960a-9ffd2be8a699" xlink:href="lly-20221231.xsd#lly_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_61010694-c82a-44c4-b5e4-402d962180b1" xlink:to="loc_lly_NeuroscienceMember_a8c2afa9-3be1-4791-960a-9ffd2be8a699" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember_849cf32e-0988-4faf-bfd0-171d0186fb40" xlink:href="lly-20221231.xsd#lly_EmgalityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_a8c2afa9-3be1-4791-960a-9ffd2be8a699" xlink:to="loc_lly_EmgalityMember_849cf32e-0988-4faf-bfd0-171d0186fb40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ZyprexaMember_81a25d7a-cc4f-48a5-9b87-19f68c607480" xlink:href="lly-20221231.xsd#lly_ZyprexaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_a8c2afa9-3be1-4791-960a-9ffd2be8a699" xlink:to="loc_lly_ZyprexaMember_81a25d7a-cc4f-48a5-9b87-19f68c607480" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CymbaltaMember_5cfb3277-7e19-4cb6-9a77-fe1b1677d747" xlink:href="lly-20221231.xsd#lly_CymbaltaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_a8c2afa9-3be1-4791-960a-9ffd2be8a699" xlink:to="loc_lly_CymbaltaMember_5cfb3277-7e19-4cb6-9a77-fe1b1677d747" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember_a7185862-66d2-4ead-ae6a-d2fb4bd1b21d" xlink:href="lly-20221231.xsd#lly_OtherNeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_a8c2afa9-3be1-4791-960a-9ffd2be8a699" xlink:to="loc_lly_OtherNeuroscienceMember_a7185862-66d2-4ead-ae6a-d2fb4bd1b21d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember_b66165ef-cd95-4011-b595-ad865d735cb0" xlink:href="lly-20221231.xsd#lly_OtherProductTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_61010694-c82a-44c4-b5e4-402d962180b1" xlink:to="loc_lly_OtherProductTotalMember_b66165ef-cd95-4011-b595-ad865d735cb0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_97368d6b-39ba-4c19-829e-426e801302e7" xlink:href="lly-20221231.xsd#lly_COVID19AntibodiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_b66165ef-cd95-4011-b595-ad865d735cb0" xlink:to="loc_lly_COVID19AntibodiesMember_97368d6b-39ba-4c19-829e-426e801302e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember_19e56d73-3e8b-4d7a-8d42-137309037a28" xlink:href="lly-20221231.xsd#lly_ForteoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_b66165ef-cd95-4011-b595-ad865d735cb0" xlink:to="loc_lly_ForteoMember_19e56d73-3e8b-4d7a-8d42-137309037a28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_2920daa8-2cc1-40e7-b78f-307a3cf2051b" xlink:href="lly-20221231.xsd#lly_CialisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_b66165ef-cd95-4011-b595-ad865d735cb0" xlink:to="loc_lly_CialisMember_2920daa8-2cc1-40e7-b78f-307a3cf2051b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember_112eda1a-0cef-49c5-96ee-014364b2a91f" xlink:href="lly-20221231.xsd#lly_OtherProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_b66165ef-cd95-4011-b595-ad865d735cb0" xlink:to="loc_lly_OtherProductMember_112eda1a-0cef-49c5-96ee-014364b2a91f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6d98cc07-97ac-45c4-9a37-ff0d0e55d6c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_152ef89d-d055-4ca3-8cc0-a9a669e2a297" xlink:to="loc_srt_StatementGeographicalAxis_6d98cc07-97ac-45c4-9a37-ff0d0e55d6c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6d98cc07-97ac-45c4-9a37-ff0d0e55d6c7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6d98cc07-97ac-45c4-9a37-ff0d0e55d6c7" xlink:to="loc_srt_SegmentGeographicalDomain_6d98cc07-97ac-45c4-9a37-ff0d0e55d6c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f889d9e6-5297-464a-8de4-0a8ac6c6ba30" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6d98cc07-97ac-45c4-9a37-ff0d0e55d6c7" xlink:to="loc_srt_SegmentGeographicalDomain_f889d9e6-5297-464a-8de4-0a8ac6c6ba30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9b763866-9fa2-47b3-b4d0-59c50e9bcf3f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f889d9e6-5297-464a-8de4-0a8ac6c6ba30" xlink:to="loc_country_US_9b763866-9fa2-47b3-b4d0-59c50e9bcf3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_bbee29f2-5199-4e42-98a3-4a9f2dc05ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f889d9e6-5297-464a-8de4-0a8ac6c6ba30" xlink:to="loc_us-gaap_NonUsMember_bbee29f2-5199-4e42-98a3-4a9f2dc05ec3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RevenueDisaggregationofRevenuebyGeographicalAreaDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="extended" id="i5fe1ef30d7884d7db18b54c02baf34ee_RevenueDisaggregationofRevenuebyGeographicalAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_07aa12dd-e222-4788-80b0-e0cbe7f8d761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_88549904-c2fd-4e96-adde-de7d45f9aadf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_07aa12dd-e222-4788-80b0-e0cbe7f8d761" xlink:to="loc_us-gaap_Revenues_88549904-c2fd-4e96-adde-de7d45f9aadf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b5a326bf-54db-4906-9342-5c9546d3e1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_07aa12dd-e222-4788-80b0-e0cbe7f8d761" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b5a326bf-54db-4906-9342-5c9546d3e1d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a9e5950f-2459-4849-9795-1e5c5d38c2a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5a326bf-54db-4906-9342-5c9546d3e1d5" xlink:to="loc_srt_StatementGeographicalAxis_a9e5950f-2459-4849-9795-1e5c5d38c2a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a9e5950f-2459-4849-9795-1e5c5d38c2a8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a9e5950f-2459-4849-9795-1e5c5d38c2a8" xlink:to="loc_srt_SegmentGeographicalDomain_a9e5950f-2459-4849-9795-1e5c5d38c2a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ec9965ed-8989-4db5-9236-c206a26ebef3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a9e5950f-2459-4849-9795-1e5c5d38c2a8" xlink:to="loc_srt_SegmentGeographicalDomain_ec9965ed-8989-4db5-9236-c206a26ebef3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a2c052c6-73a5-4311-912e-3bffef9b898f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ec9965ed-8989-4db5-9236-c206a26ebef3" xlink:to="loc_country_US_a2c052c6-73a5-4311-912e-3bffef9b898f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_d733e048-b3d0-4ad7-a7f5-abf563f8ae36" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ec9965ed-8989-4db5-9236-c206a26ebef3" xlink:to="loc_srt_EuropeMember_d733e048-b3d0-4ad7-a7f5-abf563f8ae36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_1c36adee-5d5e-4aa1-99d3-16f39930e66a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ec9965ed-8989-4db5-9236-c206a26ebef3" xlink:to="loc_country_JP_1c36adee-5d5e-4aa1-99d3-16f39930e66a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_81f27611-8280-4110-ae5d-d62628ffc788" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ec9965ed-8989-4db5-9236-c206a26ebef3" xlink:to="loc_country_CN_81f27611-8280-4110-ae5d-d62628ffc788" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_f61a0b37-f8a3-47af-bf5f-308de51b8dfd" xlink:href="lly-20221231.xsd#lly_OtherForeignCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ec9965ed-8989-4db5-9236-c206a26ebef3" xlink:to="loc_lly_OtherForeignCountriesMember_f61a0b37-f8a3-47af-bf5f-308de51b8dfd" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" id="i2cdc0e8cc5d443f0969460b0db49e4d4_AcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_1abdce91-355e-4c43-92fe-72f06da835f3" xlink:href="lly-20221231.xsd#lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_1abdce91-355e-4c43-92fe-72f06da835f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_9da553cc-00fd-4a54-b069-d83f87d1199c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_9da553cc-00fd-4a54-b069-d83f87d1199c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bc4ac2b1-2ce0-4ec4-a00b-6a151e19c61f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bc4ac2b1-2ce0-4ec4-a00b-6a151e19c61f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_e76495e6-23b6-4e7f-8306-b2a148505e75" xlink:href="lly-20221231.xsd#lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_e76495e6-23b6-4e7f-8306-b2a148505e75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_f2654c65-a493-429e-bfae-3c4137e1d4d6" xlink:href="lly-20221231.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_f2654c65-a493-429e-bfae-3c4137e1d4d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_d5686157-d722-4a1e-a2d7-97003ebb1c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_d5686157-d722-4a1e-a2d7-97003ebb1c18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_05212bf3-92d3-49c0-a80d-c48f03579242" xlink:href="lly-20221231.xsd#lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_05212bf3-92d3-49c0-a80d-c48f03579242" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_4cc8a7d1-930d-442c-92fa-6075550ec288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_4cc8a7d1-930d-442c-92fa-6075550ec288" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_17d3bfbe-3873-4244-a4db-8d4b5a4a8552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_us-gaap_Goodwill_17d3bfbe-3873-4244-a4db-8d4b5a4a8552" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ed998c03-3f27-4aa4-90ab-5ea1f898751b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ed998c03-3f27-4aa4-90ab-5ea1f898751b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c95de0fd-5311-4f81-bc65-745761ab3f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c95de0fd-5311-4f81-bc65-745761ab3f8a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_af63d8bb-91d4-4a6f-b31c-b18eb27b0ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_af63d8bb-91d4-4a6f-b31c-b18eb27b0ed6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f1771f71-01cf-4141-a321-c6d7e6a7d496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f1771f71-01cf-4141-a321-c6d7e6a7d496" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForAssetAcquisitions_8339f687-b35a-4425-9d07-57ceec0e9da5" xlink:href="lly-20221231.xsd#lly_PaymentsForAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_lly_PaymentsForAssetAcquisitions_8339f687-b35a-4425-9d07-57ceec0e9da5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3edf25f9-4b74-4442-af5c-c448ab301d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3edf25f9-4b74-4442-af5c-c448ab301d8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_daf49d9a-b690-44f3-85b7-8468864a35fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3edf25f9-4b74-4442-af5c-c448ab301d8e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_daf49d9a-b690-44f3-85b7-8468864a35fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_daf49d9a-b690-44f3-85b7-8468864a35fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_daf49d9a-b690-44f3-85b7-8468864a35fe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_daf49d9a-b690-44f3-85b7-8468864a35fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dae62549-6bc6-4c6c-9807-6a7188d97064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_daf49d9a-b690-44f3-85b7-8468864a35fe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dae62549-6bc6-4c6c-9807-6a7188d97064" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AkouosAcquisitionMember_3c9695f0-0c3e-4c23-8682-3b8990a7b612" xlink:href="lly-20221231.xsd#lly_AkouosAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dae62549-6bc6-4c6c-9807-6a7188d97064" xlink:to="loc_lly_AkouosAcquisitionMember_3c9695f0-0c3e-4c23-8682-3b8990a7b612" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_58f854d2-91a8-4a6b-a6ac-5e6c2a7f7154" xlink:href="lly-20221231.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dae62549-6bc6-4c6c-9807-6a7188d97064" xlink:to="loc_lly_PrevailTherapeuticsIncMember_58f854d2-91a8-4a6b-a6ac-5e6c2a7f7154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DermiraInc.Member_d92e96fb-25dd-468c-b159-27d430310416" xlink:href="lly-20221231.xsd#lly_DermiraInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dae62549-6bc6-4c6c-9807-6a7188d97064" xlink:to="loc_lly_DermiraInc.Member_d92e96fb-25dd-468c-b159-27d430310416" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i094d3ec3d8e649d88235679de38901ec_AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a3e3172d-466b-4432-8ef0-47ca69635899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a3e3172d-466b-4432-8ef0-47ca69635899" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_97c16dab-6579-4743-99e4-9d0cddcfa415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_97c16dab-6579-4743-99e4-9d0cddcfa415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8161504c-39e2-4cdd-bc31-b26a63ed25e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:to="loc_us-gaap_Goodwill_8161504c-39e2-4cdd-bc31-b26a63ed25e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3506d52c-9452-44f3-baf3-7a3f01e93504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3506d52c-9452-44f3-baf3-7a3f01e93504" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_3d28e0da-ebaa-42b5-94eb-978ebadf0506" xlink:href="lly-20221231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_3d28e0da-ebaa-42b5-94eb-978ebadf0506" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_cab32884-d466-4af6-b66f-108c7c19bfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_cab32884-d466-4af6-b66f-108c7c19bfb0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_8e3b1ae4-bb66-43aa-a975-b36aef7d8341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_8e3b1ae4-bb66-43aa-a975-b36aef7d8341" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_d2b0ac0b-b8fd-42d9-81d6-82b1459441d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_d2b0ac0b-b8fd-42d9-81d6-82b1459441d9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bb33b18b-01da-4fef-b1f4-9488f11a5715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bb33b18b-01da-4fef-b1f4-9488f11a5715" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b261f04c-79a6-4f05-bde6-17d9e86063d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b261f04c-79a6-4f05-bde6-17d9e86063d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_30f51f80-ab0f-4598-ab40-103882f31f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b261f04c-79a6-4f05-bde6-17d9e86063d6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_30f51f80-ab0f-4598-ab40-103882f31f1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_30f51f80-ab0f-4598-ab40-103882f31f1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_30f51f80-ab0f-4598-ab40-103882f31f1f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_30f51f80-ab0f-4598-ab40-103882f31f1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aba75ba3-e8e1-45a6-8c85-3fbe296a6834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_30f51f80-ab0f-4598-ab40-103882f31f1f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aba75ba3-e8e1-45a6-8c85-3fbe296a6834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AkouosAcquisitionMember_beb98d87-9dea-4794-b95e-7400513e663c" xlink:href="lly-20221231.xsd#lly_AkouosAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aba75ba3-e8e1-45a6-8c85-3fbe296a6834" xlink:to="loc_lly_AkouosAcquisitionMember_beb98d87-9dea-4794-b95e-7400513e663c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_39d1f5ae-7858-438a-a4b2-13bcfdc6ab16" xlink:href="lly-20221231.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aba75ba3-e8e1-45a6-8c85-3fbe296a6834" xlink:to="loc_lly_PrevailTherapeuticsIncMember_39d1f5ae-7858-438a-a4b2-13bcfdc6ab16" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#AcquisitionsAssetAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails" xlink:type="extended" id="i7ed4abb528b84c62a0d2c661fb680e1b_AcquisitionsAssetAcquisitionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_cf0d2e51-4e69-4035-a449-8026e71b4eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForAssetAcquisitions_bd81e3af-2ead-4e8d-afab-2ea518e9a886" xlink:href="lly-20221231.xsd#lly_PaymentsForAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cf0d2e51-4e69-4035-a449-8026e71b4eba" xlink:to="loc_lly_PaymentsForAssetAcquisitions_bd81e3af-2ead-4e8d-afab-2ea518e9a886" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a3a21c4d-2c62-48c6-9717-299b9a326944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cf0d2e51-4e69-4035-a449-8026e71b4eba" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a3a21c4d-2c62-48c6-9717-299b9a326944" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_646c4c85-1fee-4572-94af-53b82c95a83e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a3a21c4d-2c62-48c6-9717-299b9a326944" xlink:to="loc_us-gaap_AssetAcquisitionAxis_646c4c85-1fee-4572-94af-53b82c95a83e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_646c4c85-1fee-4572-94af-53b82c95a83e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_646c4c85-1fee-4572-94af-53b82c95a83e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_646c4c85-1fee-4572-94af-53b82c95a83e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_c15a4a2d-98ec-4bbc-95b0-3fd96cf7d27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_646c4c85-1fee-4572-94af-53b82c95a83e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_c15a4a2d-98ec-4bbc-95b0-3fd96cf7d27f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BioMarinPharmaceuticalIncMember_bfdcdada-2777-4fb8-a6c5-35d5748b1def" xlink:href="lly-20221231.xsd#lly_BioMarinPharmaceuticalIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c15a4a2d-98ec-4bbc-95b0-3fd96cf7d27f" xlink:to="loc_lly_BioMarinPharmaceuticalIncMember_bfdcdada-2777-4fb8-a6c5-35d5748b1def" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FoghornTherapeuticsIncMember_8fd805d1-54c3-4b76-ae5c-c1be568ee6aa" xlink:href="lly-20221231.xsd#lly_FoghornTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c15a4a2d-98ec-4bbc-95b0-3fd96cf7d27f" xlink:to="loc_lly_FoghornTherapeuticsIncMember_8fd805d1-54c3-4b76-ae5c-c1be568ee6aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RigelPharmaceuticalsIncMember_26b9d00f-2e2f-415d-bed8-9e86625e2cdf" xlink:href="lly-20221231.xsd#lly_RigelPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c15a4a2d-98ec-4bbc-95b0-3fd96cf7d27f" xlink:to="loc_lly_RigelPharmaceuticalsIncMember_26b9d00f-2e2f-415d-bed8-9e86625e2cdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBiosciencesIncMember_ad8dcb2f-506d-47bb-96e7-bfc8bb786fe3" xlink:href="lly-20221231.xsd#lly_PrecisionBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c15a4a2d-98ec-4bbc-95b0-3fd96cf7d27f" xlink:to="loc_lly_PrecisionBiosciencesIncMember_ad8dcb2f-506d-47bb-96e7-bfc8bb786fe3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember_a0bd8849-74a3-4a1e-9c44-a9d47925ecc1" xlink:href="lly-20221231.xsd#lly_InnoventBiologicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c15a4a2d-98ec-4bbc-95b0-3fd96cf7d27f" xlink:to="loc_lly_InnoventBiologicsIncMember_a0bd8849-74a3-4a1e-9c44-a9d47925ecc1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PetraPharmaCorporationMember_9d8158cb-11e2-42c0-953f-e011f6f474d0" xlink:href="lly-20221231.xsd#lly_PetraPharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c15a4a2d-98ec-4bbc-95b0-3fd96cf7d27f" xlink:to="loc_lly_PetraPharmaCorporationMember_9d8158cb-11e2-42c0-953f-e011f6f474d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisarmTherapeuticsIncMember_677f0414-b2ae-493f-9abe-21d63ff71cc2" xlink:href="lly-20221231.xsd#lly_DisarmTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c15a4a2d-98ec-4bbc-95b0-3fd96cf7d27f" xlink:to="loc_lly_DisarmTherapeuticsIncMember_677f0414-b2ae-493f-9abe-21d63ff71cc2" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" xlink:type="extended" id="i66b33cee4714448c9d4dd531a0c0d987_CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8da8f3c0-8a69-48d1-aeeb-c7f51700c0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_e36b9ade-1145-411c-baea-8dade2342099" xlink:href="lly-20221231.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8da8f3c0-8a69-48d1-aeeb-c7f51700c0bc" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_e36b9ade-1145-411c-baea-8dade2342099" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_545a33d7-f8e3-4619-a31b-6bb266d78a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8da8f3c0-8a69-48d1-aeeb-c7f51700c0bc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_545a33d7-f8e3-4619-a31b-6bb266d78a19" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f6828dc9-640b-4d07-bfc9-52d2bb692cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_545a33d7-f8e3-4619-a31b-6bb266d78a19" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f6828dc9-640b-4d07-bfc9-52d2bb692cdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6828dc9-640b-4d07-bfc9-52d2bb692cdf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f6828dc9-640b-4d07-bfc9-52d2bb692cdf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6828dc9-640b-4d07-bfc9-52d2bb692cdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c69f249-ebf5-45d6-8739-aab8d0454137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f6828dc9-640b-4d07-bfc9-52d2bb692cdf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c69f249-ebf5-45d6-8739-aab8d0454137" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_19d3f14c-748a-45dc-ab0e-ce288d307dcb" xlink:href="lly-20221231.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c69f249-ebf5-45d6-8739-aab8d0454137" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_19d3f14c-748a-45dc-ab0e-ce288d307dcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4f95c1ca-a89b-4620-a3fb-6693265535d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_545a33d7-f8e3-4619-a31b-6bb266d78a19" xlink:to="loc_srt_ProductOrServiceAxis_4f95c1ca-a89b-4620-a3fb-6693265535d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4f95c1ca-a89b-4620-a3fb-6693265535d0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4f95c1ca-a89b-4620-a3fb-6693265535d0" xlink:to="loc_srt_ProductsAndServicesDomain_4f95c1ca-a89b-4620-a3fb-6693265535d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_34e6e460-d63e-44fd-8975-0e43b5307d2a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4f95c1ca-a89b-4620-a3fb-6693265535d0" xlink:to="loc_srt_ProductsAndServicesDomain_34e6e460-d63e-44fd-8975-0e43b5307d2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_2f02c7ac-2c37-43ec-a4c6-2e77ada10cd9" xlink:href="lly-20221231.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_34e6e460-d63e-44fd-8975-0e43b5307d2a" xlink:to="loc_lly_JardianceMember_2f02c7ac-2c37-43ec-a4c6-2e77ada10cd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_c38a4e10-4291-4d80-b58e-4717b06fcea3" xlink:href="lly-20221231.xsd#lly_TrajentaBIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_34e6e460-d63e-44fd-8975-0e43b5307d2a" xlink:to="loc_lly_TrajentaBIMember_c38a4e10-4291-4d80-b58e-4717b06fcea3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_faa301c8-6eb3-4fed-aec5-0cb1d4928785" xlink:href="lly-20221231.xsd#lly_BasaglarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_34e6e460-d63e-44fd-8975-0e43b5307d2a" xlink:to="loc_lly_BasaglarMember_faa301c8-6eb3-4fed-aec5-0cb1d4928785" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#CollaborationsandOtherArrangementsNetProductRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails" xlink:type="extended" id="i35b4ffc7e3df47b0a57c3786d582ef81_CollaborationsandOtherArrangementsNetProductRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2d2cebd-909a-4947-985d-2eee2f6f846b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a90de216-5a81-4e0a-98bc-24c9fc612532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2d2cebd-909a-4947-985d-2eee2f6f846b" xlink:to="loc_us-gaap_Revenues_a90de216-5a81-4e0a-98bc-24c9fc612532" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d4221c4-3f29-493f-998d-97411ea0d4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2d2cebd-909a-4947-985d-2eee2f6f846b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d4221c4-3f29-493f-998d-97411ea0d4b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2bb5559f-f3c8-4901-9894-2c0c20fe573c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d4221c4-3f29-493f-998d-97411ea0d4b3" xlink:to="loc_srt_ProductOrServiceAxis_2bb5559f-f3c8-4901-9894-2c0c20fe573c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2bb5559f-f3c8-4901-9894-2c0c20fe573c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2bb5559f-f3c8-4901-9894-2c0c20fe573c" xlink:to="loc_srt_ProductsAndServicesDomain_2bb5559f-f3c8-4901-9894-2c0c20fe573c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d57b7a92-e181-4f9a-906a-bd8c94746671" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2bb5559f-f3c8-4901-9894-2c0c20fe573c" xlink:to="loc_srt_ProductsAndServicesDomain_d57b7a92-e181-4f9a-906a-bd8c94746671" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_eb1be344-6ae2-4b3d-89f5-422053624c24" xlink:href="lly-20221231.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d57b7a92-e181-4f9a-906a-bd8c94746671" xlink:to="loc_lly_JardianceMember_eb1be344-6ae2-4b3d-89f5-422053624c24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_ed65267b-0abf-4b4d-9f99-096e5b12ca7d" xlink:href="lly-20221231.xsd#lly_BasaglarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d57b7a92-e181-4f9a-906a-bd8c94746671" xlink:to="loc_lly_BasaglarMember_ed65267b-0abf-4b4d-9f99-096e5b12ca7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_7a9f9658-3ec9-4dda-a46f-b8813f3ca545" xlink:href="lly-20221231.xsd#lly_TrajentaBIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d57b7a92-e181-4f9a-906a-bd8c94746671" xlink:to="loc_lly_TrajentaBIMember_7a9f9658-3ec9-4dda-a46f-b8813f3ca545" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_b50eabce-4202-4dbf-a6a4-7f42b92917a3" xlink:href="lly-20221231.xsd#lly_OlumiantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d57b7a92-e181-4f9a-906a-bd8c94746671" xlink:to="loc_lly_OlumiantMember_b50eabce-4202-4dbf-a6a4-7f42b92917a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_959ff808-85c2-42fc-aa0a-220a711b08c4" xlink:href="lly-20221231.xsd#lly_TYVYTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d57b7a92-e181-4f9a-906a-bd8c94746671" xlink:to="loc_lly_TYVYTMember_959ff808-85c2-42fc-aa0a-220a711b08c4" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#CollaborationsandOtherArrangementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails" xlink:type="extended" id="i76a0d44a7384452c8d619d814e03995e_CollaborationsandOtherArrangementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dee99b3d-9703-4a48-b97e-c0b333b8f057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_d4dd8ffb-e1ad-49c0-836f-a7357a31c7cf" xlink:href="lly-20221231.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dee99b3d-9703-4a48-b97e-c0b333b8f057" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_d4dd8ffb-e1ad-49c0-836f-a7357a31c7cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_90bd473a-f62a-413c-a69d-02510ba9e934" xlink:href="lly-20221231.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dee99b3d-9703-4a48-b97e-c0b333b8f057" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_90bd473a-f62a-413c-a69d-02510ba9e934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c081d5cc-faca-4a89-ba3a-d463524665f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dee99b3d-9703-4a48-b97e-c0b333b8f057" xlink:to="loc_us-gaap_Revenues_c081d5cc-faca-4a89-ba3a-d463524665f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f098bd77-851e-4846-bf2e-cc88ed1a32be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dee99b3d-9703-4a48-b97e-c0b333b8f057" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f098bd77-851e-4846-bf2e-cc88ed1a32be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e579297c-ab6f-40ed-bc12-7433a6977307" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f098bd77-851e-4846-bf2e-cc88ed1a32be" xlink:to="loc_srt_ProductOrServiceAxis_e579297c-ab6f-40ed-bc12-7433a6977307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e579297c-ab6f-40ed-bc12-7433a6977307_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e579297c-ab6f-40ed-bc12-7433a6977307" xlink:to="loc_srt_ProductsAndServicesDomain_e579297c-ab6f-40ed-bc12-7433a6977307_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_52e90d1d-b9ef-4102-a865-c07106775c5f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e579297c-ab6f-40ed-bc12-7433a6977307" xlink:to="loc_srt_ProductsAndServicesDomain_52e90d1d-b9ef-4102-a865-c07106775c5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_586fb0ef-239e-4ada-87f4-db5ceee4414d" xlink:href="lly-20221231.xsd#lly_OlumiantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_52e90d1d-b9ef-4102-a865-c07106775c5f" xlink:to="loc_lly_OlumiantMember_586fb0ef-239e-4ada-87f4-db5ceee4414d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_c72ad686-23ef-4a44-9da2-28b45bb4b807" xlink:href="lly-20221231.xsd#lly_COVID19AntibodiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_52e90d1d-b9ef-4102-a865-c07106775c5f" xlink:to="loc_lly_COVID19AntibodiesMember_c72ad686-23ef-4a44-9da2-28b45bb4b807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember_0571d8e1-3389-4b01-a7cf-8199f29ddeeb" xlink:href="lly-20221231.xsd#lly_LebrikizumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_52e90d1d-b9ef-4102-a865-c07106775c5f" xlink:to="loc_lly_LebrikizumabMember_0571d8e1-3389-4b01-a7cf-8199f29ddeeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e7739781-d5ef-45fa-a886-21980237865c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f098bd77-851e-4846-bf2e-cc88ed1a32be" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e7739781-d5ef-45fa-a886-21980237865c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7739781-d5ef-45fa-a886-21980237865c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e7739781-d5ef-45fa-a886-21980237865c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e7739781-d5ef-45fa-a886-21980237865c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17a1c0af-c019-45b7-950c-41199940d70e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e7739781-d5ef-45fa-a886-21980237865c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17a1c0af-c019-45b7-950c-41199940d70e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_0a32aa02-f18d-4dc6-9206-8cbb9535aff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17a1c0af-c019-45b7-950c-41199940d70e" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_0a32aa02-f18d-4dc6-9206-8cbb9535aff8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_4dd628c2-b4ca-41cf-a825-b6402b1be0b7" xlink:href="lly-20221231.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17a1c0af-c019-45b7-950c-41199940d70e" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_4dd628c2-b4ca-41cf-a825-b6402b1be0b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_95f3b475-bb06-47b0-8bab-2f0974c13301" xlink:href="lly-20221231.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17a1c0af-c019-45b7-950c-41199940d70e" xlink:to="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_95f3b475-bb06-47b0-8bab-2f0974c13301" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember_ae5722b7-35cb-4bb0-99b4-8d783821f143" xlink:href="lly-20221231.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17a1c0af-c019-45b7-950c-41199940d70e" xlink:to="loc_lly_MilestonePaymentsSalesBasedMember_ae5722b7-35cb-4bb0-99b4-8d783821f143" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c4d5d80c-a336-4aaa-87ec-f5ef4ab236b4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f098bd77-851e-4846-bf2e-cc88ed1a32be" xlink:to="loc_dei_LegalEntityAxis_c4d5d80c-a336-4aaa-87ec-f5ef4ab236b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c4d5d80c-a336-4aaa-87ec-f5ef4ab236b4_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_c4d5d80c-a336-4aaa-87ec-f5ef4ab236b4" xlink:to="loc_dei_EntityDomain_c4d5d80c-a336-4aaa-87ec-f5ef4ab236b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8142062f-055e-40f4-b222-8faf64966f42" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_c4d5d80c-a336-4aaa-87ec-f5ef4ab236b4" xlink:to="loc_dei_EntityDomain_8142062f-055e-40f4-b222-8faf64966f42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember_fd0710e0-2ba0-4bfc-88dd-722900b37d96" xlink:href="lly-20221231.xsd#lly_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_8142062f-055e-40f4-b222-8faf64966f42" xlink:to="loc_lly_RocheMember_fd0710e0-2ba0-4bfc-88dd-722900b37d96" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i14b744b955504767bac992edac9f94f3_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_e13841d4-a89f-4318-b725-ffeea6a9b146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_e13841d4-a89f-4318-b725-ffeea6a9b146" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_c83d42c8-3a76-4db4-8949-5af514251b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_c83d42c8-3a76-4db4-8949-5af514251b38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_205546da-3ad4-46d0-a586-ef11fd622f87" xlink:href="lly-20221231.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_205546da-3ad4-46d0-a586-ef11fd622f87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_20895cd5-edf9-4264-930a-88b4783677aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_20895cd5-edf9-4264-930a-88b4783677aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_9170fccd-96ff-4639-8abb-442d7440369f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_9170fccd-96ff-4639-8abb-442d7440369f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_595a53b3-bd74-4456-a1aa-27f63ae3f1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_595a53b3-bd74-4456-a1aa-27f63ae3f1f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_53efc510-97ab-46cf-aab1-13d2d53ec5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_53efc510-97ab-46cf-aab1-13d2d53ec5f4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_004298b6-da58-4a1a-98fa-9e33969e00e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_LongTermDebt_004298b6-da58-4a1a-98fa-9e33969e00e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_8c0082da-0c11-4fa4-bff1-49658bbf730e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_8c0082da-0c11-4fa4-bff1-49658bbf730e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_cbfd3c3f-0bac-4aab-b9d1-e3a33980e75b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_cbfd3c3f-0bac-4aab-b9d1-e3a33980e75b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_d6b9bb4f-3803-42a2-862c-7fa2afae5993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_d6b9bb4f-3803-42a2-862c-7fa2afae5993" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_e9610af9-34dd-46f8-a4a5-60378a1ba0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_e9610af9-34dd-46f8-a4a5-60378a1ba0f9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_01c87509-78ce-40a1-bad8-605b44fea326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_DerivativeNotionalAmount_01c87509-78ce-40a1-bad8-605b44fea326" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_0be13842-9570-41a5-a3a0-d1100125d089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_0be13842-9570-41a5-a3a0-d1100125d089" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_981c8d73-6329-4144-ab9f-e53103371165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_DerivativeTable_981c8d73-6329-4144-ab9f-e53103371165" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ef8b26ca-a226-4e82-b734-1e11dfa4bdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_981c8d73-6329-4144-ab9f-e53103371165" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ef8b26ca-a226-4e82-b734-1e11dfa4bdc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ef8b26ca-a226-4e82-b734-1e11dfa4bdc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ef8b26ca-a226-4e82-b734-1e11dfa4bdc5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ef8b26ca-a226-4e82-b734-1e11dfa4bdc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0a72f89c-8751-4e0c-bc8b-f678d120a18d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ef8b26ca-a226-4e82-b734-1e11dfa4bdc5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0a72f89c-8751-4e0c-bc8b-f678d120a18d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember_ec85e9fe-6c27-4aad-944a-6c09f506719c" xlink:href="lly-20221231.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0a72f89c-8751-4e0c-bc8b-f678d120a18d" xlink:to="loc_lly_ForeignCurrencyDenominatedDebtMember_ec85e9fe-6c27-4aad-944a-6c09f506719c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c157480a-5ade-4ab5-a3e7-4242b140eed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_981c8d73-6329-4144-ab9f-e53103371165" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c157480a-5ade-4ab5-a3e7-4242b140eed8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c157480a-5ade-4ab5-a3e7-4242b140eed8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c157480a-5ade-4ab5-a3e7-4242b140eed8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c157480a-5ade-4ab5-a3e7-4242b140eed8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9cd23c8c-07b1-4600-a1fc-84547eb09551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c157480a-5ade-4ab5-a3e7-4242b140eed8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9cd23c8c-07b1-4600-a1fc-84547eb09551" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapUSDollarsToEuroMember_768bf746-18fc-4b56-a4c7-d457cac9b849" xlink:href="lly-20221231.xsd#lly_SwapUSDollarsToEuroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9cd23c8c-07b1-4600-a1fc-84547eb09551" xlink:to="loc_lly_SwapUSDollarsToEuroMember_768bf746-18fc-4b56-a4c7-d457cac9b849" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember_ebec46f8-6268-4549-b154-41dc423b0682" xlink:href="lly-20221231.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9cd23c8c-07b1-4600-a1fc-84547eb09551" xlink:to="loc_lly_SwapSwissFrancsToU.S.DollarsMember_ebec46f8-6268-4549-b154-41dc423b0682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SellEuroMember_4c68a85f-ada3-4f19-ad82-c92477e1906d" xlink:href="lly-20221231.xsd#lly_SellEuroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9cd23c8c-07b1-4600-a1fc-84547eb09551" xlink:to="loc_lly_SellEuroMember_4c68a85f-ada3-4f19-ad82-c92477e1906d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SellChineseYuanMember_ceaa67b0-9450-4ebc-8ed4-190a498958df" xlink:href="lly-20221231.xsd#lly_SellChineseYuanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9cd23c8c-07b1-4600-a1fc-84547eb09551" xlink:to="loc_lly_SellChineseYuanMember_ceaa67b0-9450-4ebc-8ed4-190a498958df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_89849e10-5f74-4c83-9865-1b4bcdb125b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9cd23c8c-07b1-4600-a1fc-84547eb09551" xlink:to="loc_us-gaap_InterestRateSwapMember_89849e10-5f74-4c83-9865-1b4bcdb125b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_12a6ef63-a8d9-42df-b74c-5da053f6348e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_981c8d73-6329-4144-ab9f-e53103371165" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_12a6ef63-a8d9-42df-b74c-5da053f6348e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_12a6ef63-a8d9-42df-b74c-5da053f6348e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_12a6ef63-a8d9-42df-b74c-5da053f6348e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_12a6ef63-a8d9-42df-b74c-5da053f6348e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_edba6e87-f8ba-42e1-9634-b1df4f880558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_12a6ef63-a8d9-42df-b74c-5da053f6348e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_edba6e87-f8ba-42e1-9634-b1df4f880558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_0102d8e5-2b03-4d42-92cb-ad70f1177245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_edba6e87-f8ba-42e1-9634-b1df4f880558" xlink:to="loc_us-gaap_CashFlowHedgingMember_0102d8e5-2b03-4d42-92cb-ad70f1177245" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_464d38ed-1cc3-45e3-9136-48bcf61582d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_981c8d73-6329-4144-ab9f-e53103371165" xlink:to="loc_us-gaap_HedgingDesignationAxis_464d38ed-1cc3-45e3-9136-48bcf61582d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_464d38ed-1cc3-45e3-9136-48bcf61582d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_464d38ed-1cc3-45e3-9136-48bcf61582d7" xlink:to="loc_us-gaap_HedgingDesignationDomain_464d38ed-1cc3-45e3-9136-48bcf61582d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_15edf46e-2e2b-4546-b9d6-7b414f3987f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_464d38ed-1cc3-45e3-9136-48bcf61582d7" xlink:to="loc_us-gaap_HedgingDesignationDomain_15edf46e-2e2b-4546-b9d6-7b414f3987f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d7274371-ac4f-4731-8ca7-9772b2ab699b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_15edf46e-2e2b-4546-b9d6-7b414f3987f7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d7274371-ac4f-4731-8ca7-9772b2ab699b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstrumentsScheduleofFairValueMeasurementDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="extended" id="i3deb604518c04ad4bae532e3d16ab3d5_FinancialInstrumentsScheduleofFairValueMeasurementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e3bc15b3-0b07-48e3-bfde-4211bb6babbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_89e72a58-167e-4fcb-9377-12a4e0cab6df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e3bc15b3-0b07-48e3-bfde-4211bb6babbe" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_89e72a58-167e-4fcb-9377-12a4e0cab6df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5ec144f8-c285-49b3-a72a-85eddcd9fdab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e3bc15b3-0b07-48e3-bfde-4211bb6babbe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5ec144f8-c285-49b3-a72a-85eddcd9fdab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e38ed1d2-e874-413c-8150-19417cfbad63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e3bc15b3-0b07-48e3-bfde-4211bb6babbe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e38ed1d2-e874-413c-8150-19417cfbad63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_ba6b69d7-4ab8-43e2-a91b-fb48bcc13fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e3bc15b3-0b07-48e3-bfde-4211bb6babbe" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_ba6b69d7-4ab8-43e2-a91b-fb48bcc13fbb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e644b3b6-ac5c-4f2a-972e-3fcdc5c0e7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e3bc15b3-0b07-48e3-bfde-4211bb6babbe" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e644b3b6-ac5c-4f2a-972e-3fcdc5c0e7e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_13fdd7fe-c2e2-4425-a647-037237719be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e3bc15b3-0b07-48e3-bfde-4211bb6babbe" xlink:to="loc_us-gaap_OtherLongTermInvestments_13fdd7fe-c2e2-4425-a647-037237719be3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_a3750a88-45b7-4076-883a-6f3e2ec492b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e3bc15b3-0b07-48e3-bfde-4211bb6babbe" xlink:to="loc_us-gaap_LongTermInvestments_a3750a88-45b7-4076-883a-6f3e2ec492b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4f3aa845-d94e-4c84-b205-018ff380f6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e3bc15b3-0b07-48e3-bfde-4211bb6babbe" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4f3aa845-d94e-4c84-b205-018ff380f6b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_ce9ccb8b-911a-4582-825b-2d2f16920cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4f3aa845-d94e-4c84-b205-018ff380f6b5" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_ce9ccb8b-911a-4582-825b-2d2f16920cf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ce9ccb8b-911a-4582-825b-2d2f16920cf2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ce9ccb8b-911a-4582-825b-2d2f16920cf2" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ce9ccb8b-911a-4582-825b-2d2f16920cf2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1d595146-ea71-4e53-afde-5b8472063371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ce9ccb8b-911a-4582-825b-2d2f16920cf2" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1d595146-ea71-4e53-afde-5b8472063371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_78e8c85b-0f28-491e-9933-ca2bb882a87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1d595146-ea71-4e53-afde-5b8472063371" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_78e8c85b-0f28-491e-9933-ca2bb882a87f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_7276ab2e-d4e2-4474-991d-309f03567ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1d595146-ea71-4e53-afde-5b8472063371" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_7276ab2e-d4e2-4474-991d-309f03567ef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_70ce4199-2ae7-4eaa-8c4c-188f270de822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1d595146-ea71-4e53-afde-5b8472063371" xlink:to="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_70ce4199-2ae7-4eaa-8c4c-188f270de822" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d55a765a-5948-4d33-b222-a9d3abadad95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1d595146-ea71-4e53-afde-5b8472063371" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d55a765a-5948-4d33-b222-a9d3abadad95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17b1dd2c-e845-4793-9cc6-570881267fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4f3aa845-d94e-4c84-b205-018ff380f6b5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17b1dd2c-e845-4793-9cc6-570881267fcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17b1dd2c-e845-4793-9cc6-570881267fcb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17b1dd2c-e845-4793-9cc6-570881267fcb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17b1dd2c-e845-4793-9cc6-570881267fcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7907df26-fa9f-40af-8d0c-83925c759856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17b1dd2c-e845-4793-9cc6-570881267fcb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7907df26-fa9f-40af-8d0c-83925c759856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_de82dfcd-8b1b-47e8-98c3-f8f5d3727ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7907df26-fa9f-40af-8d0c-83925c759856" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_de82dfcd-8b1b-47e8-98c3-f8f5d3727ba1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0815a7a4-6f47-4c83-a040-3e7aebc4ca8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7907df26-fa9f-40af-8d0c-83925c759856" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0815a7a4-6f47-4c83-a040-3e7aebc4ca8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_aaa6a82c-dae6-4ad3-bc64-b8db76fe1bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7907df26-fa9f-40af-8d0c-83925c759856" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_aaa6a82c-dae6-4ad3-bc64-b8db76fe1bec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7bb1019e-6fde-40ce-8e58-16d71e1dbac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4f3aa845-d94e-4c84-b205-018ff380f6b5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7bb1019e-6fde-40ce-8e58-16d71e1dbac7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7bb1019e-6fde-40ce-8e58-16d71e1dbac7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7bb1019e-6fde-40ce-8e58-16d71e1dbac7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7bb1019e-6fde-40ce-8e58-16d71e1dbac7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7bb1019e-6fde-40ce-8e58-16d71e1dbac7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c174c3ab-31fb-43d0-9143-ec2cc2a5f110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c174c3ab-31fb-43d0-9143-ec2cc2a5f110" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_897fd3f6-6317-4f00-aacd-85ae8d085720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_897fd3f6-6317-4f00-aacd-85ae8d085720" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_4c8e95a9-6cd9-4b58-86ea-de5b8d8595a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_4c8e95a9-6cd9-4b58-86ea-de5b8d8595a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_99a46b11-ecff-41ac-b0f2-2f048019d819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_99a46b11-ecff-41ac-b0f2-2f048019d819" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_1cb3cbf3-c3c3-441c-9faa-cf6cd1ecb858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_1cb3cbf3-c3c3-441c-9faa-cf6cd1ecb858" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember_8aed6976-e13a-47b8-aac9-56d6be9342ba" xlink:href="lly-20221231.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:to="loc_lly_OtherEquitySecuritiesMember_8aed6976-e13a-47b8-aac9-56d6be9342ba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember_698f80c3-1aa4-45f5-95b6-b13c9d118bff" xlink:href="lly-20221231.xsd#lly_MarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:to="loc_lly_MarketableSecuritiesMember_698f80c3-1aa4-45f5-95b6-b13c9d118bff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EquityMethodAndOtherInvestmentsMember_858c29f2-8eb0-4ef7-a5b2-f1c22eff0fce" xlink:href="lly-20221231.xsd#lly_EquityMethodAndOtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:to="loc_lly_EquityMethodAndOtherInvestmentsMember_858c29f2-8eb0-4ef7-a5b2-f1c22eff0fce" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" xlink:type="extended" id="ic9f22380836c448fbbfbc546fe1ca937_FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e43eb964-8968-4471-9569-970b133d43f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_307a574a-a2df-414d-ad5d-2f94d1a138df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e43eb964-8968-4471-9569-970b133d43f7" xlink:to="loc_us-gaap_CommercialPaper_307a574a-a2df-414d-ad5d-2f94d1a138df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4a6b8c50-24c4-42e7-b24f-4a5ac0532db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e43eb964-8968-4471-9569-970b133d43f7" xlink:to="loc_us-gaap_LongTermDebt_4a6b8c50-24c4-42e7-b24f-4a5ac0532db9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9b8f0e0a-6b8d-44e8-9f4f-3095ab64028f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e43eb964-8968-4471-9569-970b133d43f7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9b8f0e0a-6b8d-44e8-9f4f-3095ab64028f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d181111b-6bbf-4aab-bc09-1d018d44ef17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9b8f0e0a-6b8d-44e8-9f4f-3095ab64028f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d181111b-6bbf-4aab-bc09-1d018d44ef17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d181111b-6bbf-4aab-bc09-1d018d44ef17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d181111b-6bbf-4aab-bc09-1d018d44ef17" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d181111b-6bbf-4aab-bc09-1d018d44ef17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_723c522c-e00f-41d7-be23-7138f9a559d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d181111b-6bbf-4aab-bc09-1d018d44ef17" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_723c522c-e00f-41d7-be23-7138f9a559d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ba6ae2d0-faff-46c1-911c-12ed43a915c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_723c522c-e00f-41d7-be23-7138f9a559d5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ba6ae2d0-faff-46c1-911c-12ed43a915c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_bc846272-1570-4720-a8f3-d83bbb301450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_723c522c-e00f-41d7-be23-7138f9a559d5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_bc846272-1570-4720-a8f3-d83bbb301450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c452524f-b477-40ce-91f2-f543d60a3376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_723c522c-e00f-41d7-be23-7138f9a559d5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c452524f-b477-40ce-91f2-f543d60a3376" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_a2b26032-fba4-4347-a378-22e1c2525b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9b8f0e0a-6b8d-44e8-9f4f-3095ab64028f" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_a2b26032-fba4-4347-a378-22e1c2525b7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a2b26032-fba4-4347-a378-22e1c2525b7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a2b26032-fba4-4347-a378-22e1c2525b7e" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a2b26032-fba4-4347-a378-22e1c2525b7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e55b300f-e9ef-4d1f-8cfd-4bc7ae7c7bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a2b26032-fba4-4347-a378-22e1c2525b7e" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e55b300f-e9ef-4d1f-8cfd-4bc7ae7c7bee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_49f8ebd4-0bb7-4183-88f3-107c54a9761c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e55b300f-e9ef-4d1f-8cfd-4bc7ae7c7bee" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_49f8ebd4-0bb7-4183-88f3-107c54a9761c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3fdb8777-daa3-4490-99ae-68e14a003e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e55b300f-e9ef-4d1f-8cfd-4bc7ae7c7bee" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3fdb8777-daa3-4490-99ae-68e14a003e6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2bb0b272-8128-458a-a3ef-347e7c7456c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e55b300f-e9ef-4d1f-8cfd-4bc7ae7c7bee" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2bb0b272-8128-458a-a3ef-347e7c7456c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_e3e7414e-02be-45fc-8f98-e7927f650a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9b8f0e0a-6b8d-44e8-9f4f-3095ab64028f" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_e3e7414e-02be-45fc-8f98-e7927f650a4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_e3e7414e-02be-45fc-8f98-e7927f650a4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_e3e7414e-02be-45fc-8f98-e7927f650a4e" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_e3e7414e-02be-45fc-8f98-e7927f650a4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_2ffaf090-6bf3-40a1-b214-b7d40ec294a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_e3e7414e-02be-45fc-8f98-e7927f650a4e" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_2ffaf090-6bf3-40a1-b214-b7d40ec294a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_27266812-2a39-4660-ab16-f45b6eba17eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_2ffaf090-6bf3-40a1-b214-b7d40ec294a8" xlink:to="loc_us-gaap_CommercialPaperMember_27266812-2a39-4660-ab16-f45b6eba17eb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails" xlink:type="extended" id="iab3cfeb7871345e9ad057a3d4adef3a9_FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsLineItems_8b3e6451-b433-4189-ac1a-edd6c9c0f0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_8b77660d-7a08-4701-8850-7620798ceb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_8b3e6451-b433-4189-ac1a-edd6c9c0f0f7" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_8b77660d-7a08-4701-8850-7620798ceb9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_c6c20545-87dd-42b1-90d6-b3c2b8ba84e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_8b3e6451-b433-4189-ac1a-edd6c9c0f0f7" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_c6c20545-87dd-42b1-90d6-b3c2b8ba84e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsTable_5cd5c2d3-0381-4c58-978b-f1071c31a3db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_8b3e6451-b433-4189-ac1a-edd6c9c0f0f7" xlink:to="loc_us-gaap_OffsettingAssetsTable_5cd5c2d3-0381-4c58-978b-f1071c31a3db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4595d535-0d9c-43bc-a03a-32bd8c826527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OffsettingAssetsTable_5cd5c2d3-0381-4c58-978b-f1071c31a3db" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4595d535-0d9c-43bc-a03a-32bd8c826527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4595d535-0d9c-43bc-a03a-32bd8c826527_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4595d535-0d9c-43bc-a03a-32bd8c826527" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4595d535-0d9c-43bc-a03a-32bd8c826527_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bf51c353-9d35-43fe-92f7-e390358a2176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4595d535-0d9c-43bc-a03a-32bd8c826527" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bf51c353-9d35-43fe-92f7-e390358a2176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsdSellEuroMember_e4f5fafc-eeaf-4b9b-9e6e-7f63da7eab06" xlink:href="lly-20221231.xsd#lly_BuyUsdSellEuroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf51c353-9d35-43fe-92f7-e390358a2176" xlink:to="loc_lly_BuyUsdSellEuroMember_e4f5fafc-eeaf-4b9b-9e6e-7f63da7eab06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember_cadc9923-3e96-4888-964a-44b627cce94c" xlink:href="lly-20221231.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf51c353-9d35-43fe-92f7-e390358a2176" xlink:to="loc_lly_BuyEuroSellUsDollarMember_cadc9923-3e96-4888-964a-44b627cce94c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSDollarSellChineseYuanMember_34cb6455-23ef-4506-a037-d37ce0bc45f8" xlink:href="lly-20221231.xsd#lly_BuyUSDollarSellChineseYuanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf51c353-9d35-43fe-92f7-e390358a2176" xlink:to="loc_lly_BuyUSDollarSellChineseYuanMember_34cb6455-23ef-4506-a037-d37ce0bc45f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyJapaneseYenSellUSDollarMember_c1332780-37ac-4474-ba30-ac40d1d7f004" xlink:href="lly-20221231.xsd#lly_BuyJapaneseYenSellUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf51c353-9d35-43fe-92f7-e390358a2176" xlink:to="loc_lly_BuyJapaneseYenSellUSDollarMember_c1332780-37ac-4474-ba30-ac40d1d7f004" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSdollarSellJapaneseYenMember_e99c7df8-7d1f-4e88-8984-cf560f37da7a" xlink:href="lly-20221231.xsd#lly_BuyUSdollarSellJapaneseYenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf51c353-9d35-43fe-92f7-e390358a2176" xlink:to="loc_lly_BuyUSdollarSellJapaneseYenMember_e99c7df8-7d1f-4e88-8984-cf560f37da7a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyGBPSellUSDMember_1c647ac4-3702-4771-b03b-63cb909ae721" xlink:href="lly-20221231.xsd#lly_BuyGBPSellUSDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf51c353-9d35-43fe-92f7-e390358a2176" xlink:to="loc_lly_BuyGBPSellUSDMember_1c647ac4-3702-4771-b03b-63cb909ae721" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuySwissFrancSellUSDollarMember_72cd1eae-dbcb-4766-885a-88265d43cd5f" xlink:href="lly-20221231.xsd#lly_BuySwissFrancSellUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf51c353-9d35-43fe-92f7-e390358a2176" xlink:to="loc_lly_BuySwissFrancSellUSDollarMember_72cd1eae-dbcb-4766-885a-88265d43cd5f" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstrumentsScheduleofEffectofRiskManagementDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="extended" id="i59b238b216d54812a4c2532723b3dda9_FinancialInstrumentsScheduleofEffectofRiskManagementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_3cb648cd-2672-4c66-8cc3-50bdc3ebf956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract_6c94fbac-8a25-45ba-ad0f-c4ca96c36ca6" xlink:href="lly-20221231.xsd#lly_FairValueHedgeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_3cb648cd-2672-4c66-8cc3-50bdc3ebf956" xlink:to="loc_lly_FairValueHedgeAbstract_6c94fbac-8a25-45ba-ad0f-c4ca96c36ca6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_8f5075d8-03aa-47f8-8f80-44274c8ac4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_FairValueHedgeAbstract_6c94fbac-8a25-45ba-ad0f-c4ca96c36ca6" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_8f5075d8-03aa-47f8-8f80-44274c8ac4d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_8c7a5859-032f-497d-9366-5d5e6f0f1913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_FairValueHedgeAbstract_6c94fbac-8a25-45ba-ad0f-c4ca96c36ca6" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_8c7a5859-032f-497d-9366-5d5e6f0f1913" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract_b7571ef9-6d2e-40bb-b376-6d626607013a" xlink:href="lly-20221231.xsd#lly_CashFlowHedgeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_3cb648cd-2672-4c66-8cc3-50bdc3ebf956" xlink:to="loc_lly_CashFlowHedgeAbstract_b7571ef9-6d2e-40bb-b376-6d626607013a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_b703ecef-3188-45d2-b477-03b608c55e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_CashFlowHedgeAbstract_b7571ef9-6d2e-40bb-b376-6d626607013a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_b703ecef-3188-45d2-b477-03b608c55e9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_0151022d-5cd6-4a8c-8c98-10a4a8207be9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_3cb648cd-2672-4c66-8cc3-50bdc3ebf956" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_0151022d-5cd6-4a8c-8c98-10a4a8207be9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_334f0d0d-c90e-4c15-9056-06486c458295" xlink:href="lly-20221231.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_3cb648cd-2672-4c66-8cc3-50bdc3ebf956" xlink:to="loc_lly_DerivativeInstrumentsGainLossRecognized_334f0d0d-c90e-4c15-9056-06486c458295" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4fd94510-714f-426b-bd8d-525ab8dbe244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_3cb648cd-2672-4c66-8cc3-50bdc3ebf956" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4fd94510-714f-426b-bd8d-525ab8dbe244" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_bb25aed8-b482-4cca-8911-61ac2b0e3610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_3cb648cd-2672-4c66-8cc3-50bdc3ebf956" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_bb25aed8-b482-4cca-8911-61ac2b0e3610" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_8f7acf36-f9c2-4d6e-a7a3-b2b3dabd6e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_3cb648cd-2672-4c66-8cc3-50bdc3ebf956" xlink:to="loc_us-gaap_DerivativeTable_8f7acf36-f9c2-4d6e-a7a3-b2b3dabd6e33" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_df9bc55f-b95b-4e63-a768-bbf9438bfa64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_8f7acf36-f9c2-4d6e-a7a3-b2b3dabd6e33" xlink:to="loc_us-gaap_HedgingDesignationAxis_df9bc55f-b95b-4e63-a768-bbf9438bfa64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_df9bc55f-b95b-4e63-a768-bbf9438bfa64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_df9bc55f-b95b-4e63-a768-bbf9438bfa64" xlink:to="loc_us-gaap_HedgingDesignationDomain_df9bc55f-b95b-4e63-a768-bbf9438bfa64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8fcf011a-8502-41c6-a15b-8099a531d625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_df9bc55f-b95b-4e63-a768-bbf9438bfa64" xlink:to="loc_us-gaap_HedgingDesignationDomain_8fcf011a-8502-41c6-a15b-8099a531d625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1e3e1b20-c41f-472a-baed-5e82f2ee9183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_8fcf011a-8502-41c6-a15b-8099a531d625" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1e3e1b20-c41f-472a-baed-5e82f2ee9183" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_45833642-9881-4e0c-8e92-82ddea2c4024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_8fcf011a-8502-41c6-a15b-8099a531d625" xlink:to="loc_us-gaap_NondesignatedMember_45833642-9881-4e0c-8e92-82ddea2c4024" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1d33d30d-e038-4d43-aad4-9508e6079123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_8f7acf36-f9c2-4d6e-a7a3-b2b3dabd6e33" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1d33d30d-e038-4d43-aad4-9508e6079123" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1d33d30d-e038-4d43-aad4-9508e6079123_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1d33d30d-e038-4d43-aad4-9508e6079123" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1d33d30d-e038-4d43-aad4-9508e6079123_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_057d2833-1244-4080-84c2-5aa57859dade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1d33d30d-e038-4d43-aad4-9508e6079123" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_057d2833-1244-4080-84c2-5aa57859dade" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember_9c6d715d-d0b5-4026-a86c-6b7a76b7cdc8" xlink:href="lly-20221231.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_057d2833-1244-4080-84c2-5aa57859dade" xlink:to="loc_lly_HedgedFixedRateDebtMember_9c6d715d-d0b5-4026-a86c-6b7a76b7cdc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_7e2fca79-2b06-405b-8d3f-62c59dba05f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_057d2833-1244-4080-84c2-5aa57859dade" xlink:to="loc_us-gaap_InterestRateContractMember_7e2fca79-2b06-405b-8d3f-62c59dba05f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_3ac91bd1-0783-4d42-ad0e-5db16ad998e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_057d2833-1244-4080-84c2-5aa57859dade" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_3ac91bd1-0783-4d42-ad0e-5db16ad998e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d087e640-d96b-4f99-a1b5-1dae629678bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_057d2833-1244-4080-84c2-5aa57859dade" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d087e640-d96b-4f99-a1b5-1dae629678bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_35aabad4-3d41-4b2c-921a-2a9e9ace26ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_057d2833-1244-4080-84c2-5aa57859dade" xlink:to="loc_us-gaap_InterestRateSwapMember_35aabad4-3d41-4b2c-921a-2a9e9ace26ad" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" xlink:type="extended" id="ie27aed28b91449b09d3a517f6d39918d_FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_680d0c5a-f936-4ada-bac5-5853ae22f8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_1c77f2b9-7e77-485c-99be-cc4ad0a304f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_680d0c5a-f936-4ada-bac5-5853ae22f8cb" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_1c77f2b9-7e77-485c-99be-cc4ad0a304f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_e8e31239-d3eb-4423-8a22-b18ef9ff2123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_680d0c5a-f936-4ada-bac5-5853ae22f8cb" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_e8e31239-d3eb-4423-8a22-b18ef9ff2123" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_88ee5ec5-a232-4486-a2d0-71521b41bc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_680d0c5a-f936-4ada-bac5-5853ae22f8cb" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_88ee5ec5-a232-4486-a2d0-71521b41bc0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_2fab3b44-5278-48b3-8f9e-250a14f3d3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_680d0c5a-f936-4ada-bac5-5853ae22f8cb" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_2fab3b44-5278-48b3-8f9e-250a14f3d3e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_678aa8ec-7765-4e86-b757-7c7b0b12da85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_680d0c5a-f936-4ada-bac5-5853ae22f8cb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_678aa8ec-7765-4e86-b757-7c7b0b12da85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7f3b1ac0-4063-4050-990a-23e96ddf3847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_680d0c5a-f936-4ada-bac5-5853ae22f8cb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7f3b1ac0-4063-4050-990a-23e96ddf3847" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6ec7d5e-e5aa-48cd-be2c-ee9511998019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_680d0c5a-f936-4ada-bac5-5853ae22f8cb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6ec7d5e-e5aa-48cd-be2c-ee9511998019" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1e3dd0eb-3670-4f9d-b172-541b029d9f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6ec7d5e-e5aa-48cd-be2c-ee9511998019" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1e3dd0eb-3670-4f9d-b172-541b029d9f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1e3dd0eb-3670-4f9d-b172-541b029d9f39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1e3dd0eb-3670-4f9d-b172-541b029d9f39" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1e3dd0eb-3670-4f9d-b172-541b029d9f39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b61b7eff-a59d-4bc5-a13d-f00264628f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1e3dd0eb-3670-4f9d-b172-541b029d9f39" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b61b7eff-a59d-4bc5-a13d-f00264628f74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_e2b51fab-4c5f-459a-8d7d-9336b2375455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b61b7eff-a59d-4bc5-a13d-f00264628f74" xlink:to="loc_us-gaap_FairValueHedgingMember_e2b51fab-4c5f-459a-8d7d-9336b2375455" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_cdf6fdb0-8926-40ba-a029-9044fd1bd526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b61b7eff-a59d-4bc5-a13d-f00264628f74" xlink:to="loc_us-gaap_CashFlowHedgingMember_cdf6fdb0-8926-40ba-a029-9044fd1bd526" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_9dfbd021-5d3d-44e4-baa6-dcfcb877ef13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b61b7eff-a59d-4bc5-a13d-f00264628f74" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_9dfbd021-5d3d-44e4-baa6-dcfcb877ef13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_a5aa565f-e5e6-48fb-ac36-b0fb393474cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6ec7d5e-e5aa-48cd-be2c-ee9511998019" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_a5aa565f-e5e6-48fb-ac36-b0fb393474cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a5aa565f-e5e6-48fb-ac36-b0fb393474cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a5aa565f-e5e6-48fb-ac36-b0fb393474cd" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a5aa565f-e5e6-48fb-ac36-b0fb393474cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f5d89934-a57c-4a4a-a858-a18a56b677fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a5aa565f-e5e6-48fb-ac36-b0fb393474cd" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f5d89934-a57c-4a4a-a858-a18a56b677fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_50386d38-866c-4043-a328-e1bae59d0d17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f5d89934-a57c-4a4a-a858-a18a56b677fc" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_50386d38-866c-4043-a328-e1bae59d0d17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_24732649-39de-4a65-8c37-a5caf0765928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f5d89934-a57c-4a4a-a858-a18a56b677fc" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_24732649-39de-4a65-8c37-a5caf0765928" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_7a6e1eb4-d062-4e6a-a18e-5ecfd8313186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f5d89934-a57c-4a4a-a858-a18a56b677fc" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_7a6e1eb4-d062-4e6a-a18e-5ecfd8313186" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f4c33df4-999e-470d-9ee4-918291238d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6ec7d5e-e5aa-48cd-be2c-ee9511998019" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f4c33df4-999e-470d-9ee4-918291238d6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f4c33df4-999e-470d-9ee4-918291238d6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f4c33df4-999e-470d-9ee4-918291238d6a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f4c33df4-999e-470d-9ee4-918291238d6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4e0f73aa-2777-40ef-93de-c5a44d68ea5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f4c33df4-999e-470d-9ee4-918291238d6a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4e0f73aa-2777-40ef-93de-c5a44d68ea5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_6184b1a0-fc15-4bea-ba15-f5ed9e9d305b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4e0f73aa-2777-40ef-93de-c5a44d68ea5d" xlink:to="loc_us-gaap_InterestRateContractMember_6184b1a0-fc15-4bea-ba15-f5ed9e9d305b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_1ca737ca-fd63-4dde-a63d-734da5288ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4e0f73aa-2777-40ef-93de-c5a44d68ea5d" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_1ca737ca-fd63-4dde-a63d-734da5288ebf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_7ee179db-75f7-4195-be9c-8f404034c2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4e0f73aa-2777-40ef-93de-c5a44d68ea5d" xlink:to="loc_us-gaap_ForeignExchangeContractMember_7ee179db-75f7-4195-be9c-8f404034c2c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_68e4a099-7686-48cd-9974-e62b41f42f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6ec7d5e-e5aa-48cd-be2c-ee9511998019" xlink:to="loc_us-gaap_HedgingDesignationAxis_68e4a099-7686-48cd-9974-e62b41f42f2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_68e4a099-7686-48cd-9974-e62b41f42f2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_68e4a099-7686-48cd-9974-e62b41f42f2f" xlink:to="loc_us-gaap_HedgingDesignationDomain_68e4a099-7686-48cd-9974-e62b41f42f2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_32a63cd2-43a5-4ddc-ba10-6632b437b53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_68e4a099-7686-48cd-9974-e62b41f42f2f" xlink:to="loc_us-gaap_HedgingDesignationDomain_32a63cd2-43a5-4ddc-ba10-6632b437b53f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_120695c1-da01-4b9d-b88c-ea1c69b42686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_32a63cd2-43a5-4ddc-ba10-6632b437b53f" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_120695c1-da01-4b9d-b88c-ea1c69b42686" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_b92a656b-d6c8-44f1-81f6-2b67055a7432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_32a63cd2-43a5-4ddc-ba10-6632b437b53f" xlink:to="loc_us-gaap_NondesignatedMember_b92a656b-d6c8-44f1-81f6-2b67055a7432" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8400ae06-c8ef-4855-827e-b7cceb9c3d57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6ec7d5e-e5aa-48cd-be2c-ee9511998019" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8400ae06-c8ef-4855-827e-b7cceb9c3d57" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8400ae06-c8ef-4855-827e-b7cceb9c3d57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8400ae06-c8ef-4855-827e-b7cceb9c3d57" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8400ae06-c8ef-4855-827e-b7cceb9c3d57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ce435e6-5f03-42ab-bb18-7e61110d0d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8400ae06-c8ef-4855-827e-b7cceb9c3d57" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ce435e6-5f03-42ab-bb18-7e61110d0d84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6b10190e-3f39-48da-ab27-741468dae118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ce435e6-5f03-42ab-bb18-7e61110d0d84" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6b10190e-3f39-48da-ab27-741468dae118" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_97ead35f-cc9d-4f03-8c19-11b8ab47f587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ce435e6-5f03-42ab-bb18-7e61110d0d84" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_97ead35f-cc9d-4f03-8c19-11b8ab47f587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cf36db0d-14cc-48df-8967-994cf8335c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ce435e6-5f03-42ab-bb18-7e61110d0d84" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cf36db0d-14cc-48df-8967-994cf8335c8f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#GoodwillandOtherIntangiblesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="extended" id="i7569ba7986754fc489e4967f3160e048_GoodwillandOtherIntangiblesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b28e3ab0-7d23-4279-8bab-142de0769909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_1c16ab11-922e-449a-bf78-eb9f23221a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b28e3ab0-7d23-4279-8bab-142de0769909" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_1c16ab11-922e-449a-bf78-eb9f23221a76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6ce90a0e-1a2c-40a6-b711-de742c6d6446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b28e3ab0-7d23-4279-8bab-142de0769909" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6ce90a0e-1a2c-40a6-b711-de742c6d6446" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_4d03f512-cd92-4893-bb18-cae1f22b9e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b28e3ab0-7d23-4279-8bab-142de0769909" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_4d03f512-cd92-4893-bb18-cae1f22b9e72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5a8f21ec-c0df-4055-ae2f-0b29a98ce441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b28e3ab0-7d23-4279-8bab-142de0769909" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5a8f21ec-c0df-4055-ae2f-0b29a98ce441" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ec817cce-0c4d-4a35-96c6-5edc839c63df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5a8f21ec-c0df-4055-ae2f-0b29a98ce441" xlink:to="loc_srt_RangeAxis_ec817cce-0c4d-4a35-96c6-5edc839c63df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ec817cce-0c4d-4a35-96c6-5edc839c63df_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ec817cce-0c4d-4a35-96c6-5edc839c63df" xlink:to="loc_srt_RangeMember_ec817cce-0c4d-4a35-96c6-5edc839c63df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_21a5389b-25a2-4043-bc08-82d5d3923afc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ec817cce-0c4d-4a35-96c6-5edc839c63df" xlink:to="loc_srt_RangeMember_21a5389b-25a2-4043-bc08-82d5d3923afc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3ca9ec9f-8ac7-4195-be5e-2d8c188bc451" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_21a5389b-25a2-4043-bc08-82d5d3923afc" xlink:to="loc_srt_MinimumMember_3ca9ec9f-8ac7-4195-be5e-2d8c188bc451" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ac521931-7457-478e-91d2-7bcbe6a90ad0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_21a5389b-25a2-4043-bc08-82d5d3923afc" xlink:to="loc_srt_MaximumMember_ac521931-7457-478e-91d2-7bcbe6a90ad0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" xlink:type="extended" id="idba4c0b739484511bed828bf70e58ad5_GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a868e811-c6b4-4822-be9a-c1012f784bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e842d1ba-cbca-4279-8548-d7d281cbfe4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a868e811-c6b4-4822-be9a-c1012f784bcc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e842d1ba-cbca-4279-8548-d7d281cbfe4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a80b569e-86c8-499f-adf0-28838ce25bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a868e811-c6b4-4822-be9a-c1012f784bcc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a80b569e-86c8-499f-adf0-28838ce25bfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_47fec359-e8fa-412d-abee-e5d58d17b887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a868e811-c6b4-4822-be9a-c1012f784bcc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_47fec359-e8fa-412d-abee-e5d58d17b887" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9174bea-edcd-4b51-bfae-cbc5a00d511a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a868e811-c6b4-4822-be9a-c1012f784bcc" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9174bea-edcd-4b51-bfae-cbc5a00d511a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_46fad51b-e34b-4f93-916b-ec1fe116e0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9174bea-edcd-4b51-bfae-cbc5a00d511a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_46fad51b-e34b-4f93-916b-ec1fe116e0ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_46fad51b-e34b-4f93-916b-ec1fe116e0ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_46fad51b-e34b-4f93-916b-ec1fe116e0ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_46fad51b-e34b-4f93-916b-ec1fe116e0ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db6cf384-1b9d-478f-8070-f7c4f81bfa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_46fad51b-e34b-4f93-916b-ec1fe116e0ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db6cf384-1b9d-478f-8070-f7c4f81bfa3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_31f94a6d-8993-44fc-9981-3822fe5ba382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db6cf384-1b9d-478f-8070-f7c4f81bfa3f" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_31f94a6d-8993-44fc-9981-3822fe5ba382" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_b24da9e7-62c7-47d4-b615-ae208b0d5423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db6cf384-1b9d-478f-8070-f7c4f81bfa3f" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_b24da9e7-62c7-47d4-b615-ae208b0d5423" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_74defa27-b737-4b30-b671-523f00bfcdd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_78f8728b-f39b-4072-bef5-800f8d393276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_74defa27-b737-4b30-b671-523f00bfcdd5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_78f8728b-f39b-4072-bef5-800f8d393276" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_71e089cc-cf97-4b83-b8fa-06c8f7dffca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_74defa27-b737-4b30-b671-523f00bfcdd5" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_71e089cc-cf97-4b83-b8fa-06c8f7dffca8" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_221ef768-320f-42c5-8051-d973f0f964df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_71e089cc-cf97-4b83-b8fa-06c8f7dffca8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_221ef768-320f-42c5-8051-d973f0f964df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_221ef768-320f-42c5-8051-d973f0f964df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_221ef768-320f-42c5-8051-d973f0f964df" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_221ef768-320f-42c5-8051-d973f0f964df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_84d617de-2df1-4757-8b13-5c10ea8e609a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_221ef768-320f-42c5-8051-d973f0f964df" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_84d617de-2df1-4757-8b13-5c10ea8e609a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_b69f19e5-669b-4263-899d-878c14baf7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_84d617de-2df1-4757-8b13-5c10ea8e609a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_b69f19e5-669b-4263-899d-878c14baf7b8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended" id="if7d694903da04919b89bb3904f1bf10f_PropertyandEquipmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fd3ef04-4ff9-4cfe-a1c9-a8028ec3047e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_53a29e29-b7fe-4269-8e89-5e72f868e939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fd3ef04-4ff9-4cfe-a1c9-a8028ec3047e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_53a29e29-b7fe-4269-8e89-5e72f868e939" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_abe3f7e2-8abd-47e6-a706-a95832ed4ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fd3ef04-4ff9-4cfe-a1c9-a8028ec3047e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_abe3f7e2-8abd-47e6-a706-a95832ed4ca8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7f90d32-c8bd-4355-88c3-8fa54d0073d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_abe3f7e2-8abd-47e6-a706-a95832ed4ca8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7f90d32-c8bd-4355-88c3-8fa54d0073d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f7f90d32-c8bd-4355-88c3-8fa54d0073d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7f90d32-c8bd-4355-88c3-8fa54d0073d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f7f90d32-c8bd-4355-88c3-8fa54d0073d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2dff3047-378e-455d-87f9-880332913a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7f90d32-c8bd-4355-88c3-8fa54d0073d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2dff3047-378e-455d-87f9-880332913a72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_e2860a0f-22b9-4cc6-b184-32f500229594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2dff3047-378e-455d-87f9-880332913a72" xlink:to="loc_us-gaap_BuildingMember_e2860a0f-22b9-4cc6-b184-32f500229594" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_0c8e76a2-8898-4392-94c4-bd34765bbc97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2dff3047-378e-455d-87f9-880332913a72" xlink:to="loc_us-gaap_EquipmentMember_0c8e76a2-8898-4392-94c4-bd34765bbc97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_31a242d0-bc89-4460-a23f-ea7d9e8ca3cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_abe3f7e2-8abd-47e6-a706-a95832ed4ca8" xlink:to="loc_srt_RangeAxis_31a242d0-bc89-4460-a23f-ea7d9e8ca3cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_31a242d0-bc89-4460-a23f-ea7d9e8ca3cb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_31a242d0-bc89-4460-a23f-ea7d9e8ca3cb" xlink:to="loc_srt_RangeMember_31a242d0-bc89-4460-a23f-ea7d9e8ca3cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fc15cb34-8cc7-4c6d-a67a-f8664d60d0c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_31a242d0-bc89-4460-a23f-ea7d9e8ca3cb" xlink:to="loc_srt_RangeMember_fc15cb34-8cc7-4c6d-a67a-f8664d60d0c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7eea7fb2-bc3a-43ef-b9b8-2469ba32e7ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fc15cb34-8cc7-4c6d-a67a-f8664d60d0c5" xlink:to="loc_srt_MinimumMember_7eea7fb2-bc3a-43ef-b9b8-2469ba32e7ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_66145302-9290-4cd3-92e7-b7705c475c51" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fc15cb34-8cc7-4c6d-a67a-f8664d60d0c5" xlink:to="loc_srt_MaximumMember_66145302-9290-4cd3-92e7-b7705c475c51" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#PropertyandEquipmentScheduleofGeographicInformationDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails" xlink:type="extended" id="i9b7307b008e447b8ab74500445ba76c0_PropertyandEquipmentScheduleofGeographicInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_74a94f84-5f8c-4007-a340-8f27c49e5314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_fb9eaf3a-cab7-4aa1-836f-115ff2504ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_74a94f84-5f8c-4007-a340-8f27c49e5314" xlink:to="loc_us-gaap_NoncurrentAssets_fb9eaf3a-cab7-4aa1-836f-115ff2504ab5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f521ae89-af24-480e-9d88-07412d3741ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_74a94f84-5f8c-4007-a340-8f27c49e5314" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f521ae89-af24-480e-9d88-07412d3741ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_48e0264b-41cf-4928-826f-21dd19845aee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f521ae89-af24-480e-9d88-07412d3741ec" xlink:to="loc_srt_StatementGeographicalAxis_48e0264b-41cf-4928-826f-21dd19845aee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_48e0264b-41cf-4928-826f-21dd19845aee_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_48e0264b-41cf-4928-826f-21dd19845aee" xlink:to="loc_srt_SegmentGeographicalDomain_48e0264b-41cf-4928-826f-21dd19845aee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_54e30d30-2221-4c50-ae2a-f660f5c6a22a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_48e0264b-41cf-4928-826f-21dd19845aee" xlink:to="loc_srt_SegmentGeographicalDomain_54e30d30-2221-4c50-ae2a-f660f5c6a22a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_UNITEDSTATESAndPUERTORICOMember_79938ad1-a159-4310-bf37-0fda2352c3b6" xlink:href="lly-20221231.xsd#lly_UNITEDSTATESAndPUERTORICOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_54e30d30-2221-4c50-ae2a-f660f5c6a22a" xlink:to="loc_lly_UNITEDSTATESAndPUERTORICOMember_79938ad1-a159-4310-bf37-0fda2352c3b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_5ca32533-1b76-43e3-8683-8edf1823f4b5" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_54e30d30-2221-4c50-ae2a-f660f5c6a22a" xlink:to="loc_country_IE_5ca32533-1b76-43e3-8683-8edf1823f4b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_2659db7d-715e-4324-b1b8-3c127dc234ba" xlink:href="lly-20221231.xsd#lly_OtherForeignCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_54e30d30-2221-4c50-ae2a-f660f5c6a22a" xlink:to="loc_lly_OtherForeignCountriesMember_2659db7d-715e-4324-b1b8-3c127dc234ba" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/BorrowingsNarrativeDetails" xlink:type="extended" id="ib2cba05153464bc581776efcab626b2b_BorrowingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_b2635db7-05ec-4f03-96ce-848353946301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_b2635db7-05ec-4f03-96ce-848353946301" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_3afcb09b-7345-4e50-870e-6053692242f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_3afcb09b-7345-4e50-870e-6053692242f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f4a22627-808e-40d3-b544-d31217d1dbba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f4a22627-808e-40d3-b544-d31217d1dbba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_9005d5df-450f-431d-b0e4-e270d1795f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_DebtInstrumentTerm_9005d5df-450f-431d-b0e4-e270d1795f6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fc61ad50-fd62-4859-a36f-984b5357f886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fc61ad50-fd62-4859-a36f-984b5357f886" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b4562efa-4c0c-4fa9-89b0-e87399147b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b4562efa-4c0c-4fa9-89b0-e87399147b75" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_6dd45d62-961c-4e85-89c8-bf2b91bb35d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_6dd45d62-961c-4e85-89c8-bf2b91bb35d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_b21737c1-590c-4a98-8cd5-7e26cf499d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_b21737c1-590c-4a98-8cd5-7e26cf499d16" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_beb21afe-13b1-4a1e-a26b-e1a2f43daf57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_beb21afe-13b1-4a1e-a26b-e1a2f43daf57" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_13e057ca-7634-434f-bf07-d6aeb86abdb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_13e057ca-7634-434f-bf07-d6aeb86abdb1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DescriptionOfDerivativeActivityVolumePercent_2c93dded-871a-41f1-9e32-3a9a95222e0a" xlink:href="lly-20221231.xsd#lly_DescriptionOfDerivativeActivityVolumePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_lly_DescriptionOfDerivativeActivityVolumePercent_2c93dded-871a-41f1-9e32-3a9a95222e0a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2926e217-89d4-4a62-9c0e-e4e438cf6026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2926e217-89d4-4a62-9c0e-e4e438cf6026" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_37497c7b-94b4-4c63-b9c4-1d3d7cf27fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_DebtInstrumentTable_37497c7b-94b4-4c63-b9c4-1d3d7cf27fe4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_648b0acf-ab7d-436f-a435-d50a05851af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_37497c7b-94b4-4c63-b9c4-1d3d7cf27fe4" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_648b0acf-ab7d-436f-a435-d50a05851af6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_648b0acf-ab7d-436f-a435-d50a05851af6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_648b0acf-ab7d-436f-a435-d50a05851af6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_648b0acf-ab7d-436f-a435-d50a05851af6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4b1c92cc-7360-46e2-8dcd-8f750220539f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_648b0acf-ab7d-436f-a435-d50a05851af6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4b1c92cc-7360-46e2-8dcd-8f750220539f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2026Member_95d340c5-d289-481b-8aa1-bd76735f6995" xlink:href="lly-20221231.xsd#lly_MaturityDate2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4b1c92cc-7360-46e2-8dcd-8f750220539f" xlink:to="loc_lly_MaturityDate2026Member_95d340c5-d289-481b-8aa1-bd76735f6995" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2023Member_b3d71cee-bc50-4a6e-80bc-b40b75df5f95" xlink:href="lly-20221231.xsd#lly_MaturityDate2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4b1c92cc-7360-46e2-8dcd-8f750220539f" xlink:to="loc_lly_MaturityDate2023Member_b3d71cee-bc50-4a6e-80bc-b40b75df5f95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_629d247a-f879-474c-bd5d-40c012054370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_37497c7b-94b4-4c63-b9c4-1d3d7cf27fe4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_629d247a-f879-474c-bd5d-40c012054370" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_629d247a-f879-474c-bd5d-40c012054370_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_629d247a-f879-474c-bd5d-40c012054370" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_629d247a-f879-474c-bd5d-40c012054370_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cc9c2e16-529d-4ab3-89a8-ef5a3060d323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_629d247a-f879-474c-bd5d-40c012054370" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cc9c2e16-529d-4ab3-89a8-ef5a3060d323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember_f311232d-1a21-4ff3-bd08-a614329077c9" xlink:href="lly-20221231.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc9c2e16-529d-4ab3-89a8-ef5a3060d323" xlink:to="loc_lly_ForeignCurrencyDenominatedDebtMember_f311232d-1a21-4ff3-bd08-a614329077c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ea4d2d91-5695-4515-9845-ddfb12c30463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc9c2e16-529d-4ab3-89a8-ef5a3060d323" xlink:to="loc_us-gaap_SeniorNotesMember_ea4d2d91-5695-4515-9845-ddfb12c30463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2987da37-5837-4bbf-a621-b47753f242ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_37497c7b-94b4-4c63-b9c4-1d3d7cf27fe4" xlink:to="loc_us-gaap_DebtInstrumentAxis_2987da37-5837-4bbf-a621-b47753f242ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2987da37-5837-4bbf-a621-b47753f242ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2987da37-5837-4bbf-a621-b47753f242ac" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2987da37-5837-4bbf-a621-b47753f242ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2987da37-5837-4bbf-a621-b47753f242ac" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A5000NotesDue2033Member_bbac3aad-1a1e-4314-88b9-02999efca734" xlink:href="lly-20221231.xsd#lly_A5000NotesDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_A5000NotesDue2033Member_bbac3aad-1a1e-4314-88b9-02999efca734" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_55411efa-ee71-4245-a609-041b6435b5cc" xlink:href="lly-20221231.xsd#lly_A1125NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_A1125NotesDue2051Member_55411efa-ee71-4245-a609-041b6435b5cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_9351f4df-b4f6-4b47-8b88-187e0a96902b" xlink:href="lly-20221231.xsd#lly_A1375NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_A1375NotesDue2061Member_9351f4df-b4f6-4b47-8b88-187e0a96902b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625BritishPoundDenominatedNotesDue2043Member_00f55e45-6c56-415e-acfe-bd4adeebc2e1" xlink:href="lly-20221231.xsd#lly_A1625BritishPoundDenominatedNotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_A1625BritishPoundDenominatedNotesDue2043Member_00f55e45-6c56-415e-acfe-bd4adeebc2e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member_1e559fa6-cc81-43c3-8b8b-24ed65aec5a7" xlink:href="lly-20221231.xsd#lly_A395NotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_A395NotesDue2049Member_1e559fa6-cc81-43c3-8b8b-24ed65aec5a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member_77aa503c-b83a-4525-ac47-936306d69786" xlink:href="lly-20221231.xsd#lly_A415NotesDue2059Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_A415NotesDue2059Member_77aa503c-b83a-4525-ac47-936306d69786" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member_10e2b76f-24a6-4421-846b-7972501427cd" xlink:href="lly-20221231.xsd#lly_A3375NotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_A3375NotesDue2029Member_10e2b76f-24a6-4421-846b-7972501427cd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A225NotesDue2050Member_d71804e4-5eff-4f53-9aae-5870baf892eb" xlink:href="lly-20221231.xsd#lly_A225NotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_A225NotesDue2050Member_d71804e4-5eff-4f53-9aae-5870baf892eb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A25NotesDue2060Member_566e4dd6-7022-4ed4-9b6b-3acdddf2ccd6" xlink:href="lly-20221231.xsd#lly_A25NotesDue2060Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_A25NotesDue2060Member_566e4dd6-7022-4ed4-9b6b-3acdddf2ccd6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_cab0ac44-86ff-4e51-9688-813f222442c2" xlink:href="lly-20221231.xsd#lly_SeniorNotesDueMay2050AndSeptember2060Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_cab0ac44-86ff-4e51-9688-813f222442c2" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#BorrowingsSummaryofLongtermNotesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails" xlink:type="extended" id="id0c5641eac7c43cba339603273ad1dda_BorrowingsSummaryofLongtermNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_40d623c2-572b-49fe-85a6-cc8f39b1e37e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9a6167ee-ad04-450a-b169-cb3890094033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40d623c2-572b-49fe-85a6-cc8f39b1e37e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9a6167ee-ad04-450a-b169-cb3890094033" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3aed92fb-2a21-4d08-835e-60519a9bd8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40d623c2-572b-49fe-85a6-cc8f39b1e37e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3aed92fb-2a21-4d08-835e-60519a9bd8dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1309e9d5-3079-4806-974d-cdb9af04435d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40d623c2-572b-49fe-85a6-cc8f39b1e37e" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1309e9d5-3079-4806-974d-cdb9af04435d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_27eccdc4-8619-44f5-8911-9ac548808805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40d623c2-572b-49fe-85a6-cc8f39b1e37e" xlink:to="loc_us-gaap_LongTermDebt_27eccdc4-8619-44f5-8911-9ac548808805" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_50f7756c-672f-4627-9401-0857e838dfc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40d623c2-572b-49fe-85a6-cc8f39b1e37e" xlink:to="loc_us-gaap_DebtInstrumentTable_50f7756c-672f-4627-9401-0857e838dfc2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f173ea8a-eb4e-44fe-9a13-6c41b0107793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_50f7756c-672f-4627-9401-0857e838dfc2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f173ea8a-eb4e-44fe-9a13-6c41b0107793" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f173ea8a-eb4e-44fe-9a13-6c41b0107793_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f173ea8a-eb4e-44fe-9a13-6c41b0107793" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f173ea8a-eb4e-44fe-9a13-6c41b0107793_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_08bcc859-284e-479e-b7cd-749c431e5d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f173ea8a-eb4e-44fe-9a13-6c41b0107793" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_08bcc859-284e-479e-b7cd-749c431e5d54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e5d20d0d-5506-4109-8177-e0eb4ca9f623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_08bcc859-284e-479e-b7cd-749c431e5d54" xlink:to="loc_us-gaap_SeniorNotesMember_e5d20d0d-5506-4109-8177-e0eb4ca9f623" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2aa63c25-ca83-4b69-b0f6-2cd8ecbd306d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_50f7756c-672f-4627-9401-0857e838dfc2" xlink:to="loc_us-gaap_DebtInstrumentAxis_2aa63c25-ca83-4b69-b0f6-2cd8ecbd306d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2aa63c25-ca83-4b69-b0f6-2cd8ecbd306d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2aa63c25-ca83-4b69-b0f6-2cd8ecbd306d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2aa63c25-ca83-4b69-b0f6-2cd8ecbd306d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2aa63c25-ca83-4b69-b0f6-2cd8ecbd306d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A235NotesDue2022Member_aa1c56b6-70ad-407b-8dda-4b8c0e93b70b" xlink:href="lly-20221231.xsd#lly_A235NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A235NotesDue2022Member_aa1c56b6-70ad-407b-8dda-4b8c0e93b70b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A30NotesDue2022Member_76a8f438-8e0c-452e-a965-f4f081b4e33b" xlink:href="lly-20221231.xsd#lly_A30NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A30NotesDue2022Member_76a8f438-8e0c-452e-a965-f4f081b4e33b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A10EuroDenominatedNotesDue2022Member_8a3b0827-1573-409f-a3da-c242ffc99327" xlink:href="lly-20221231.xsd#lly_A10EuroDenominatedNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A10EuroDenominatedNotesDue2022Member_8a3b0827-1573-409f-a3da-c242ffc99327" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A015SwissFrancDenominatedNotesDue2024Member_705066ad-515c-40e2-8ea6-725d8cabb534" xlink:href="lly-20221231.xsd#lly_A015SwissFrancDenominatedNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A015SwissFrancDenominatedNotesDue2024Member_705066ad-515c-40e2-8ea6-725d8cabb534" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A7125NotesDue2025Member_70287d04-f8c6-4ed7-a8df-bc5c097722ad" xlink:href="lly-20221231.xsd#lly_A7125NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A7125NotesDue2025Member_70287d04-f8c6-4ed7-a8df-bc5c097722ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A275NotesDue2025Member_07c7dd51-4b2a-43fc-9b5d-74d7f4dc719d" xlink:href="lly-20221231.xsd#lly_A275NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A275NotesDue2025Member_07c7dd51-4b2a-43fc-9b5d-74d7f4dc719d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625EuroDenominatedNotesDue2026Member_8c3004bb-b7be-4644-a11c-2b9283a10614" xlink:href="lly-20221231.xsd#lly_A1625EuroDenominatedNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A1625EuroDenominatedNotesDue2026Member_8c3004bb-b7be-4644-a11c-2b9283a10614" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A55NotesDue2027Member_fc5c3c99-8938-44b5-a7d5-06e9c9289a39" xlink:href="lly-20221231.xsd#lly_A55NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A55NotesDue2027Member_fc5c3c99-8938-44b5-a7d5-06e9c9289a39" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A31NotesDue2027Member_b77b1e5c-daeb-4b2e-ac8d-5bfd59ba7912" xlink:href="lly-20221231.xsd#lly_A31NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A31NotesDue2027Member_b77b1e5c-daeb-4b2e-ac8d-5bfd59ba7912" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A045SwissFrancDenominatedNotesDue2028Member_ae4cb062-59b7-4197-b4ab-a68a7ca67b07" xlink:href="lly-20221231.xsd#lly_A045SwissFrancDenominatedNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A045SwissFrancDenominatedNotesDue2028Member_ae4cb062-59b7-4197-b4ab-a68a7ca67b07" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member_f4809ca0-6409-40d9-9123-f1a5c81fb55d" xlink:href="lly-20221231.xsd#lly_A3375NotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A3375NotesDue2029Member_f4809ca0-6409-40d9-9123-f1a5c81fb55d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A42YenDenominatedNotesDue2029Member_4fa77e33-bf4e-41d5-a3d7-a40bfb7caac0" xlink:href="lly-20221231.xsd#lly_A42YenDenominatedNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A42YenDenominatedNotesDue2029Member_4fa77e33-bf4e-41d5-a3d7-a40bfb7caac0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2125EuroDenominatedNotesDue2030Member_ba5ee84f-6992-458f-a23c-fe535c907c6c" xlink:href="lly-20221231.xsd#lly_A2125EuroDenominatedNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A2125EuroDenominatedNotesDue2030Member_ba5ee84f-6992-458f-a23c-fe535c907c6c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625EuroDenominatedNotesDue2031Member_0abf6964-b10e-48fd-9587-40f87dc3220f" xlink:href="lly-20221231.xsd#lly_A625EuroDenominatedNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A625EuroDenominatedNotesDue2031Member_0abf6964-b10e-48fd-9587-40f87dc3220f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A5000NotesDue2033Member_6092d9b5-0a64-4850-9f53-53d9b22cee0e" xlink:href="lly-20221231.xsd#lly_A5000NotesDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A5000NotesDue2033Member_6092d9b5-0a64-4850-9f53-53d9b22cee0e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A56YenDenominatedNotesDue2034Member_a7f76a2e-cf47-427a-93fb-29f0a71837c8" xlink:href="lly-20221231.xsd#lly_A56YenDenominatedNotesDue2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A56YenDenominatedNotesDue2034Member_a7f76a2e-cf47-427a-93fb-29f0a71837c8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A677NotesDue2036Member_a15c9b07-cd01-47b3-9449-074362addd91" xlink:href="lly-20221231.xsd#lly_A677NotesDue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A677NotesDue2036Member_a15c9b07-cd01-47b3-9449-074362addd91" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A555NotesDue2037Member_c4d49de0-f2ad-4c8d-a521-cbf1a73e7397" xlink:href="lly-20221231.xsd#lly_A555NotesDue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A555NotesDue2037Member_c4d49de0-f2ad-4c8d-a521-cbf1a73e7397" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A595NotesDue2037Member_8e5f93c5-be15-4156-835a-bd14b1939f02" xlink:href="lly-20221231.xsd#lly_A595NotesDue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A595NotesDue2037Member_8e5f93c5-be15-4156-835a-bd14b1939f02" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3875NotesDue2039Member_2758a26d-5b28-4050-9262-99f287bb1102" xlink:href="lly-20221231.xsd#lly_A3875NotesDue2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A3875NotesDue2039Member_2758a26d-5b28-4050-9262-99f287bb1102" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625BritishPoundDenominatedNotesDue2043Member_2ab3b952-5f92-485b-aa8d-fe4bf7ba6a0e" xlink:href="lly-20221231.xsd#lly_A1625BritishPoundDenominatedNotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A1625BritishPoundDenominatedNotesDue2043Member_2ab3b952-5f92-485b-aa8d-fe4bf7ba6a0e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A465NotesDue2044Member_c4e1e97e-fb66-4bb7-a1c5-9ef7a6298bc5" xlink:href="lly-20221231.xsd#lly_A465NotesDue2044Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A465NotesDue2044Member_c4e1e97e-fb66-4bb7-a1c5-9ef7a6298bc5" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A37NotesDue2045Member_5763241c-57c3-4127-b212-3470ff944fbf" xlink:href="lly-20221231.xsd#lly_A37NotesDue2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A37NotesDue2045Member_5763241c-57c3-4127-b212-3470ff944fbf" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2047Member_a618002e-6408-4fc4-851e-8409b640912a" xlink:href="lly-20221231.xsd#lly_A395NotesDue2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A395NotesDue2047Member_a618002e-6408-4fc4-851e-8409b640912a" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member_d1afeea4-f639-4e04-98d2-ef59341f6f45" xlink:href="lly-20221231.xsd#lly_A395NotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A395NotesDue2049Member_d1afeea4-f639-4e04-98d2-ef59341f6f45" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A17EuroDenominatedNotesDue2049Member_32edac8d-b01f-4f37-b256-a4a436d35d3a" xlink:href="lly-20221231.xsd#lly_A17EuroDenominatedNotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A17EuroDenominatedNotesDue2049Member_32edac8d-b01f-4f37-b256-a4a436d35d3a" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A97YenDenominatedNotesDue2049Member_e68c7731-7541-42cc-848e-9ff9ca775a38" xlink:href="lly-20221231.xsd#lly_A97YenDenominatedNotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A97YenDenominatedNotesDue2049Member_e68c7731-7541-42cc-848e-9ff9ca775a38" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A225NotesDue2050Member_ad90dcf4-2a99-453c-a218-b0f23647a278" xlink:href="lly-20221231.xsd#lly_A225NotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A225NotesDue2050Member_ad90dcf4-2a99-453c-a218-b0f23647a278" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_6d6220b8-f263-4d57-a90b-93156afe2d4d" xlink:href="lly-20221231.xsd#lly_A1125NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A1125NotesDue2051Member_6d6220b8-f263-4d57-a90b-93156afe2d4d" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member_9c452546-ee04-45fd-94c7-08d07041ef2f" xlink:href="lly-20221231.xsd#lly_A415NotesDue2059Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A415NotesDue2059Member_9c452546-ee04-45fd-94c7-08d07041ef2f" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A25NotesDue2060Member_b448581e-3816-4e97-b202-f087ef20d5b2" xlink:href="lly-20221231.xsd#lly_A25NotesDue2060Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A25NotesDue2060Member_b448581e-3816-4e97-b202-f087ef20d5b2" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_440917cf-0e45-479e-80cc-a68f831490b8" xlink:href="lly-20221231.xsd#lly_A1375NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A1375NotesDue2061Member_440917cf-0e45-479e-80cc-a68f831490b8" xlink:type="arc" order="31"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i16cffd646a5245aebe52d794f89a0224_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_11714833-b0e3-47a1-b069-1a685f2644f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_11714833-b0e3-47a1-b069-1a685f2644f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bc34378a-433d-41b1-b5ca-6e9dd81b58c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bc34378a-433d-41b1-b5ca-6e9dd81b58c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_603fa948-2f47-4ac6-ad6a-21a0afa2e6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_603fa948-2f47-4ac6-ad6a-21a0afa2e6c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_bd8dd692-5f69-4926-9bf5-f47722851fea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_bd8dd692-5f69-4926-9bf5-f47722851fea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_b5ca08d0-1398-44f4-9ad3-392ffb14a7ff" xlink:href="lly-20221231.xsd#lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:to="loc_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_b5ca08d0-1398-44f4-9ad3-392ffb14a7ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_de41e3c2-3bac-4a39-8332-6b80e4420428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_de41e3c2-3bac-4a39-8332-6b80e4420428" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0fd12fbf-c4c6-441f-a832-4d0cd5cfacc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0fd12fbf-c4c6-441f-a832-4d0cd5cfacc4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9e5ea690-f0fd-46c1-9fe5-9e06701134a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9e5ea690-f0fd-46c1-9fe5-9e06701134a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89e73efb-e7c9-42a4-a951-d9763800d371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89e73efb-e7c9-42a4-a951-d9763800d371" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cb655c95-3175-493d-8afa-05b4d76d810c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89e73efb-e7c9-42a4-a951-d9763800d371" xlink:to="loc_us-gaap_AwardTypeAxis_cb655c95-3175-493d-8afa-05b4d76d810c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb655c95-3175-493d-8afa-05b4d76d810c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cb655c95-3175-493d-8afa-05b4d76d810c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb655c95-3175-493d-8afa-05b4d76d810c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ee2d640-22b1-4978-ab49-76d293e371c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cb655c95-3175-493d-8afa-05b4d76d810c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ee2d640-22b1-4978-ab49-76d293e371c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_a9cfc44c-ef98-4f95-a050-0da5e00cedb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ee2d640-22b1-4978-ab49-76d293e371c9" xlink:to="loc_us-gaap_PerformanceSharesMember_a9cfc44c-ef98-4f95-a050-0da5e00cedb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareholderValueAwardsMember_3e5c9d43-9e8a-4364-afb4-9668fa5c7c71" xlink:href="lly-20221231.xsd#lly_ShareholderValueAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ee2d640-22b1-4978-ab49-76d293e371c9" xlink:to="loc_lly_ShareholderValueAwardsMember_3e5c9d43-9e8a-4364-afb4-9668fa5c7c71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RelativeValueAwardsMember_93aacf79-7557-49ff-a536-9831e4b8da53" xlink:href="lly-20221231.xsd#lly_RelativeValueAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ee2d640-22b1-4978-ab49-76d293e371c9" xlink:to="loc_lly_RelativeValueAwardsMember_93aacf79-7557-49ff-a536-9831e4b8da53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b3fdd13b-17f1-4887-81a0-ec519fc11283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ee2d640-22b1-4978-ab49-76d293e371c9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b3fdd13b-17f1-4887-81a0-ec519fc11283" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#StockBasedCompensationScheduleofAssumptionsUsedDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails" xlink:type="extended" id="i79f475f1248e4675b636473f328192c3_StockBasedCompensationScheduleofAssumptionsUsedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36344cbf-49f9-4233-b7fb-40524e2d8116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6b2cf841-6223-48d5-9a16-8d95dee6465a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36344cbf-49f9-4233-b7fb-40524e2d8116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6b2cf841-6223-48d5-9a16-8d95dee6465a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_93fe8dc2-5b2f-4fdb-b74a-c1b77c985f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36344cbf-49f9-4233-b7fb-40524e2d8116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_93fe8dc2-5b2f-4fdb-b74a-c1b77c985f5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9f1b2a04-29e0-40a7-8291-de14f88b1a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36344cbf-49f9-4233-b7fb-40524e2d8116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9f1b2a04-29e0-40a7-8291-de14f88b1a41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_058632bd-33b3-4ec3-a095-8b762a48c056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36344cbf-49f9-4233-b7fb-40524e2d8116" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_058632bd-33b3-4ec3-a095-8b762a48c056" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5ba963e1-fba3-4ca4-a9bc-b72788a7b18b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_058632bd-33b3-4ec3-a095-8b762a48c056" xlink:to="loc_us-gaap_AwardTypeAxis_5ba963e1-fba3-4ca4-a9bc-b72788a7b18b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ba963e1-fba3-4ca4-a9bc-b72788a7b18b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5ba963e1-fba3-4ca4-a9bc-b72788a7b18b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ba963e1-fba3-4ca4-a9bc-b72788a7b18b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87927264-b7f3-426b-95af-0af3e9ec391e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5ba963e1-fba3-4ca4-a9bc-b72788a7b18b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87927264-b7f3-426b-95af-0af3e9ec391e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareholderValueAwardsMember_57e0ccad-f324-4191-b8c4-1bc87dee15b8" xlink:href="lly-20221231.xsd#lly_ShareholderValueAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87927264-b7f3-426b-95af-0af3e9ec391e" xlink:to="loc_lly_ShareholderValueAwardsMember_57e0ccad-f324-4191-b8c4-1bc87dee15b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RelativeValueAwardsMember_ef2c91de-58cf-420c-9f2d-08d595672f84" xlink:href="lly-20221231.xsd#lly_RelativeValueAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87927264-b7f3-426b-95af-0af3e9ec391e" xlink:to="loc_lly_RelativeValueAwardsMember_ef2c91de-58cf-420c-9f2d-08d595672f84" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#ShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ShareholdersEquityDetails" xlink:type="extended" id="ia6f7ddc05a6a4bb19473e3600f42c186_ShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_6ac50d06-caf0-4e1a-8b5d-2dad4553ed41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f767d35e-fa1a-4d95-8f13-b566302fd12b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_6ac50d06-caf0-4e1a-8b5d-2dad4553ed41" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f767d35e-fa1a-4d95-8f13-b566302fd12b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_805e0fda-2722-4ffd-a7c6-54d9cb616582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_6ac50d06-caf0-4e1a-8b5d-2dad4553ed41" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_805e0fda-2722-4ffd-a7c6-54d9cb616582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d70b2032-eba9-403b-b8f3-3ef41dc7e76a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_6ac50d06-caf0-4e1a-8b5d-2dad4553ed41" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d70b2032-eba9-403b-b8f3-3ef41dc7e76a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_73471126-8973-4eba-9376-4325fbd71f75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_6ac50d06-caf0-4e1a-8b5d-2dad4553ed41" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_73471126-8973-4eba-9376-4325fbd71f75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_dabd857a-cc75-4ce3-89ff-c7f91dcdb691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_6ac50d06-caf0-4e1a-8b5d-2dad4553ed41" xlink:to="loc_us-gaap_PreferredStockSharesIssued_dabd857a-cc75-4ce3-89ff-c7f91dcdb691" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrustShares_99381411-ce3c-4ade-a8b3-9bc8aef616bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrustShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_6ac50d06-caf0-4e1a-8b5d-2dad4553ed41" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrustShares_99381411-ce3c-4ade-a8b3-9bc8aef616bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_7dcbf36f-574e-47ca-a141-29cf1cc305ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_6ac50d06-caf0-4e1a-8b5d-2dad4553ed41" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_7dcbf36f-574e-47ca-a141-29cf1cc305ad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_f8f8adbd-705a-4bfb-be8c-fb1331d647f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_6ac50d06-caf0-4e1a-8b5d-2dad4553ed41" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_f8f8adbd-705a-4bfb-be8c-fb1331d647f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_9d1a8e3e-462c-4e08-99ec-3783e4fb4019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_f8f8adbd-705a-4bfb-be8c-fb1331d647f7" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_9d1a8e3e-462c-4e08-99ec-3783e4fb4019" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_9d1a8e3e-462c-4e08-99ec-3783e4fb4019_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_9d1a8e3e-462c-4e08-99ec-3783e4fb4019" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_9d1a8e3e-462c-4e08-99ec-3783e4fb4019_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_173e9f25-07a1-454c-9cf0-18a92c49b568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_9d1a8e3e-462c-4e08-99ec-3783e4fb4019" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_173e9f25-07a1-454c-9cf0-18a92c49b568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_May2021ShareRepurchaseProgramMember_879e1a51-f956-4174-8add-16ba0a62cefa" xlink:href="lly-20221231.xsd#lly_May2021ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_173e9f25-07a1-454c-9cf0-18a92c49b568" xlink:to="loc_lly_May2021ShareRepurchaseProgramMember_879e1a51-f956-4174-8add-16ba0a62cefa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i15d88f2588f841b595f3bddfe6c008ee_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_25a2de8a-5d06-4d7f-8364-a61267227dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_25a2de8a-5d06-4d7f-8364-a61267227dd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_770b7912-46d0-4b24-8857-42240ba1ec16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:to="loc_us-gaap_OperatingLossCarryforwards_770b7912-46d0-4b24-8857-42240ba1ec16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_c2ec93f0-b3f4-4451-b3f4-fa547b72461f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_c2ec93f0-b3f4-4451-b3f4-fa547b72461f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_cb36497a-108c-41d3-91ae-65c4736b9ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:to="loc_us-gaap_PrepaidTaxes_cb36497a-108c-41d3-91ae-65c4736b9ae1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_304199d5-04a7-4d5c-a620-0817bc1d7fae" xlink:href="lly-20221231.xsd#lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:to="loc_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_304199d5-04a7-4d5c-a620-0817bc1d7fae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_2ac2b96f-8bda-4c91-891a-5634b7342388" xlink:href="lly-20221231.xsd#lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:to="loc_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_2ac2b96f-8bda-4c91-891a-5634b7342388" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c8b8f41c-2f30-40e2-ac4b-325b895d36e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c8b8f41c-2f30-40e2-ac4b-325b895d36e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4b007740-76e1-4b3b-9ef2-9fbc84da8192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4b007740-76e1-4b3b-9ef2-9fbc84da8192" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_7965028b-de1b-4b12-b33b-f507f478280f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_7965028b-de1b-4b12-b33b-f507f478280f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_f654df09-a58c-4aae-a802-5897f5e9d718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7965028b-de1b-4b12-b33b-f507f478280f" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_f654df09-a58c-4aae-a802-5897f5e9d718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f654df09-a58c-4aae-a802-5897f5e9d718_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_f654df09-a58c-4aae-a802-5897f5e9d718" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f654df09-a58c-4aae-a802-5897f5e9d718_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_21d6bd6f-9b07-44a7-b157-439186e2a187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_f654df09-a58c-4aae-a802-5897f5e9d718" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_21d6bd6f-9b07-44a7-b157-439186e2a187" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CarryforwardMember_c2f31221-0b8a-4fb3-80bb-9c467f2c0b3e" xlink:href="lly-20221231.xsd#lly_CarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_21d6bd6f-9b07-44a7-b157-439186e2a187" xlink:to="loc_lly_CarryforwardMember_c2f31221-0b8a-4fb3-80bb-9c467f2c0b3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ExpirationBy2026Member_99d05ca1-772d-48fb-a1fb-1fb41274ff74" xlink:href="lly-20221231.xsd#lly_ExpirationBy2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_21d6bd6f-9b07-44a7-b157-439186e2a187" xlink:to="loc_lly_ExpirationBy2026Member_99d05ca1-772d-48fb-a1fb-1fb41274ff74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ExpirationBetween2028And2042Member_accdc78f-6819-4893-ae80-cbd1d2d0bc76" xlink:href="lly-20221231.xsd#lly_ExpirationBetween2028And2042Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_21d6bd6f-9b07-44a7-b157-439186e2a187" xlink:to="loc_lly_ExpirationBetween2028And2042Member_accdc78f-6819-4893-ae80-cbd1d2d0bc76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DesignatedUnusableMember_b9491c22-aac3-4a92-a52f-144e0b8fe4fa" xlink:href="lly-20221231.xsd#lly_DesignatedUnusableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_21d6bd6f-9b07-44a7-b157-439186e2a187" xlink:to="loc_lly_DesignatedUnusableMember_b9491c22-aac3-4a92-a52f-144e0b8fe4fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ExpirationBy2027Member_a8f5e6d6-8de0-42e5-a572-1bd8a3a55404" xlink:href="lly-20221231.xsd#lly_ExpirationBy2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_21d6bd6f-9b07-44a7-b157-439186e2a187" xlink:to="loc_lly_ExpirationBy2027Member_a8f5e6d6-8de0-42e5-a572-1bd8a3a55404" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NoExpirationMember_5fce7dd8-7a78-4543-b04a-b52326c07b11" xlink:href="lly-20221231.xsd#lly_NoExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_21d6bd6f-9b07-44a7-b157-439186e2a187" xlink:to="loc_lly_NoExpirationMember_5fce7dd8-7a78-4543-b04a-b52326c07b11" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_7d4fff57-224a-4607-ba60-a61acafa2037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7965028b-de1b-4b12-b33b-f507f478280f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_7d4fff57-224a-4607-ba60-a61acafa2037" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7d4fff57-224a-4607-ba60-a61acafa2037_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_7d4fff57-224a-4607-ba60-a61acafa2037" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7d4fff57-224a-4607-ba60-a61acafa2037_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8ecb04aa-38ef-4269-af86-aab7f1e8785f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_7d4fff57-224a-4607-ba60-a61acafa2037" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8ecb04aa-38ef-4269-af86-aab7f1e8785f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_b12d5edd-e72a-499a-8f48-60e2bd0a5f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8ecb04aa-38ef-4269-af86-aab7f1e8785f" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_b12d5edd-e72a-499a-8f48-60e2bd0a5f91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_2df076bc-3d2a-4b13-9a8f-571b0be80b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8ecb04aa-38ef-4269-af86-aab7f1e8785f" xlink:to="loc_us-gaap_ForeignCountryMember_2df076bc-3d2a-4b13-9a8f-571b0be80b1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_7d19809e-e713-45aa-9e2b-fa919846dd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8ecb04aa-38ef-4269-af86-aab7f1e8785f" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_7d19809e-e713-45aa-9e2b-fa919846dd5f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" xlink:type="extended" id="i7b057b552bfa4ac08a94ce4f71c4aff3_RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c716a757-455f-41db-b085-2edb091b5c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e15f615f-0140-45b2-ac54-f8918e11d75f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c716a757-455f-41db-b085-2edb091b5c6e" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e15f615f-0140-45b2-ac54-f8918e11d75f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_09476610-c95c-4abf-bda5-546f35e775dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e15f615f-0140-45b2-ac54-f8918e11d75f" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_09476610-c95c-4abf-bda5-546f35e775dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_44ff74d0-4621-4c17-8b24-f4793c14765d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e15f615f-0140-45b2-ac54-f8918e11d75f" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_44ff74d0-4621-4c17-8b24-f4793c14765d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_1e961b30-9435-422d-ad19-ba4ef9670f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e15f615f-0140-45b2-ac54-f8918e11d75f" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_1e961b30-9435-422d-ad19-ba4ef9670f1d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_1d8382a2-9c7e-4144-89a5-a1aa775a1dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e15f615f-0140-45b2-ac54-f8918e11d75f" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_1d8382a2-9c7e-4144-89a5-a1aa775a1dac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_8187f9be-4079-488d-8618-90f3250c69ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e15f615f-0140-45b2-ac54-f8918e11d75f" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_8187f9be-4079-488d-8618-90f3250c69ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_c09abddd-9107-47a8-8361-6e2787245b05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e15f615f-0140-45b2-ac54-f8918e11d75f" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_c09abddd-9107-47a8-8361-6e2787245b05" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_1b7404ca-0e16-4197-9024-496b175668fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_9fff5ae5-7b82-4e82-af5b-c70bd28bb9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c716a757-455f-41db-b085-2edb091b5c6e" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_9fff5ae5-7b82-4e82-af5b-c70bd28bb9f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f0dbecb6-4987-44e2-ba40-0b1ca8d42765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_9fff5ae5-7b82-4e82-af5b-c70bd28bb9f3" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f0dbecb6-4987-44e2-ba40-0b1ca8d42765" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_733fbc9b-696a-4ac4-8c48-336ca2059754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_9fff5ae5-7b82-4e82-af5b-c70bd28bb9f3" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_733fbc9b-696a-4ac4-8c48-336ca2059754" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_c8a5b299-183d-40ac-ba2d-6d7238bd4d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_9fff5ae5-7b82-4e82-af5b-c70bd28bb9f3" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_c8a5b299-183d-40ac-ba2d-6d7238bd4d7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_09ceb3c0-d0f7-4d71-9c39-a92523aca7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_9fff5ae5-7b82-4e82-af5b-c70bd28bb9f3" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_09ceb3c0-d0f7-4d71-9c39-a92523aca7b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_4bac18ad-f844-454a-99a7-9eeebd3c7da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_9fff5ae5-7b82-4e82-af5b-c70bd28bb9f3" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_4bac18ad-f844-454a-99a7-9eeebd3c7da7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_0ce101c0-d6f0-4275-bd0b-98d2e73518f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_c2c159bd-e64e-40c3-b184-e940e78341e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c716a757-455f-41db-b085-2edb091b5c6e" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_c2c159bd-e64e-40c3-b184-e940e78341e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_460a6369-73cb-42c8-a380-261da4b7365f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c716a757-455f-41db-b085-2edb091b5c6e" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_460a6369-73cb-42c8-a380-261da4b7365f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_c8b24180-1722-4797-a88b-acf6c3eabe41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c716a757-455f-41db-b085-2edb091b5c6e" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_c8b24180-1722-4797-a88b-acf6c3eabe41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_3edca30d-1681-44ca-9691-58d4d5c07e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c716a757-455f-41db-b085-2edb091b5c6e" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_3edca30d-1681-44ca-9691-58d4d5c07e31" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ab6418bf-a2f0-4545-88ef-b597268749ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c716a757-455f-41db-b085-2edb091b5c6e" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ab6418bf-a2f0-4545-88ef-b597268749ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_38bf88a4-13b5-41d1-88ec-854e511b6124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ab6418bf-a2f0-4545-88ef-b597268749ae" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_38bf88a4-13b5-41d1-88ec-854e511b6124" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_38bf88a4-13b5-41d1-88ec-854e511b6124_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_38bf88a4-13b5-41d1-88ec-854e511b6124" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_38bf88a4-13b5-41d1-88ec-854e511b6124_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_35f72e3b-f540-4b24-9db6-b1f2ddbcfcca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_38bf88a4-13b5-41d1-88ec-854e511b6124" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_35f72e3b-f540-4b24-9db6-b1f2ddbcfcca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_f7388692-a094-45fc-82e0-ab8aff58f344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_35f72e3b-f540-4b24-9db6-b1f2ddbcfcca" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_f7388692-a094-45fc-82e0-ab8aff58f344" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_323d26c4-db87-413c-a117-f7f12ddc3271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_35f72e3b-f540-4b24-9db6-b1f2ddbcfcca" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_323d26c4-db87-413c-a117-f7f12ddc3271" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" xlink:type="extended" id="i4912d01a3d3e467c9ac342268677b9f7_RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4a96393a-045c-4b9a-bbaa-77e0611308ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c9d9f7d3-9932-40e4-8f1c-ebfe925be986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4a96393a-045c-4b9a-bbaa-77e0611308ec" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c9d9f7d3-9932-40e4-8f1c-ebfe925be986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_6d434f09-eb85-46e6-af97-bbe26f52ce83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c9d9f7d3-9932-40e4-8f1c-ebfe925be986" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_6d434f09-eb85-46e6-af97-bbe26f52ce83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_9fd69a23-0c84-4a92-81a1-91514240a35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c9d9f7d3-9932-40e4-8f1c-ebfe925be986" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_9fd69a23-0c84-4a92-81a1-91514240a35b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_21e0ea8a-5615-412a-9a18-8d5bafc1268a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c9d9f7d3-9932-40e4-8f1c-ebfe925be986" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_21e0ea8a-5615-412a-9a18-8d5bafc1268a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_e60826aa-8c74-42ad-80a2-4275e629eea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c9d9f7d3-9932-40e4-8f1c-ebfe925be986" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_e60826aa-8c74-42ad-80a2-4275e629eea3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_57b066bf-4a8f-467c-907e-f84ab95c8df2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c9d9f7d3-9932-40e4-8f1c-ebfe925be986" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_57b066bf-4a8f-467c-907e-f84ab95c8df2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_5117c2ce-a9aa-4bee-8309-5acc3be872e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4a96393a-045c-4b9a-bbaa-77e0611308ec" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_5117c2ce-a9aa-4bee-8309-5acc3be872e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8206f1ab-bb2b-483b-8f05-28c6ef5a4667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_5117c2ce-a9aa-4bee-8309-5acc3be872e7" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8206f1ab-bb2b-483b-8f05-28c6ef5a4667" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8206f1ab-bb2b-483b-8f05-28c6ef5a4667_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8206f1ab-bb2b-483b-8f05-28c6ef5a4667" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8206f1ab-bb2b-483b-8f05-28c6ef5a4667_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7eef5ecf-a008-48d7-8045-73910e62fb82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8206f1ab-bb2b-483b-8f05-28c6ef5a4667" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7eef5ecf-a008-48d7-8045-73910e62fb82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_80577a20-305e-493b-b2b1-d12a147a4ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_7eef5ecf-a008-48d7-8045-73910e62fb82" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_80577a20-305e-493b-b2b1-d12a147a4ebe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_9c8e728c-1dde-443d-b953-2efdd62e0638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_7eef5ecf-a008-48d7-8045-73910e62fb82" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_9c8e728c-1dde-443d-b953-2efdd62e0638" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RetirementBenefitsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="extended" id="i74fcf0fc4f6c4128b1197b09fb3a53e5_RetirementBenefitsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_231180eb-0878-46ef-9bd1-9b6a06e5b761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_debcbb40-789f-4e6a-96ba-3a452e9c75bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_231180eb-0878-46ef-9bd1-9b6a06e5b761" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_debcbb40-789f-4e6a-96ba-3a452e9c75bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_8c1eded9-298f-4ab9-9749-f2318f3c27c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_231180eb-0878-46ef-9bd1-9b6a06e5b761" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_8c1eded9-298f-4ab9-9749-f2318f3c27c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_7d1cdd18-3341-450f-9555-0a6615716acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_231180eb-0878-46ef-9bd1-9b6a06e5b761" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_7d1cdd18-3341-450f-9555-0a6615716acd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_d3529071-2d70-467f-8d81-87356faf5fe8" xlink:href="lly-20221231.xsd#lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_231180eb-0878-46ef-9bd1-9b6a06e5b761" xlink:to="loc_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_d3529071-2d70-467f-8d81-87356faf5fe8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_bf64dd20-10f4-401b-bac7-f818367c327c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_231180eb-0878-46ef-9bd1-9b6a06e5b761" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_bf64dd20-10f4-401b-bac7-f818367c327c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_bb39a84c-b808-4d01-b210-ced4b73531f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_231180eb-0878-46ef-9bd1-9b6a06e5b761" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_bb39a84c-b808-4d01-b210-ced4b73531f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_165b04f1-02aa-49b9-bab4-84294b272211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_231180eb-0878-46ef-9bd1-9b6a06e5b761" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_165b04f1-02aa-49b9-bab4-84294b272211" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b171b179-b6a7-4659-8418-daad8afad161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_165b04f1-02aa-49b9-bab4-84294b272211" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b171b179-b6a7-4659-8418-daad8afad161" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_b171b179-b6a7-4659-8418-daad8afad161_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b171b179-b6a7-4659-8418-daad8afad161" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_b171b179-b6a7-4659-8418-daad8afad161_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_bc4b52f0-fe4f-41af-bd4a-228fca18832e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b171b179-b6a7-4659-8418-daad8afad161" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_bc4b52f0-fe4f-41af-bd4a-228fca18832e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_989b5d11-c8e2-423e-a560-17b417eae512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_bc4b52f0-fe4f-41af-bd4a-228fca18832e" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_989b5d11-c8e2-423e-a560-17b417eae512" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember_0a01df66-02ed-4b0d-8d2d-420f6a0f752b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_bc4b52f0-fe4f-41af-bd4a-228fca18832e" xlink:to="loc_us-gaap_FixedIncomeFundsMember_0a01df66-02ed-4b0d-8d2d-420f6a0f752b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a2161ebc-2c08-4d1a-9d81-3cf690cff68b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_165b04f1-02aa-49b9-bab4-84294b272211" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a2161ebc-2c08-4d1a-9d81-3cf690cff68b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a2161ebc-2c08-4d1a-9d81-3cf690cff68b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a2161ebc-2c08-4d1a-9d81-3cf690cff68b" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a2161ebc-2c08-4d1a-9d81-3cf690cff68b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_772985c3-5ea5-4990-9adf-5f881ca07dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a2161ebc-2c08-4d1a-9d81-3cf690cff68b" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_772985c3-5ea5-4990-9adf-5f881ca07dcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_09541794-0b65-4d45-9f28-19e39752d682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_772985c3-5ea5-4990-9adf-5f881ca07dcf" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_09541794-0b65-4d45-9f28-19e39752d682" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails" xlink:type="extended" id="id1acfafc6a3e48599bb7c9d1150dd74a_RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_cd18e348-b420-4036-b084-30ece2562d63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_596503de-5bee-4267-8816-8ea24b44247d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_cd18e348-b420-4036-b084-30ece2562d63" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_596503de-5bee-4267-8816-8ea24b44247d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_5f6de1f4-7821-40ef-bd1f-5f80cde2700e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_cd18e348-b420-4036-b084-30ece2562d63" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_5f6de1f4-7821-40ef-bd1f-5f80cde2700e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_86e79083-8b94-414d-b40e-2beb6d33b842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_cd18e348-b420-4036-b084-30ece2562d63" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_86e79083-8b94-414d-b40e-2beb6d33b842" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_797f608d-4afc-4bc9-b538-e9b9c749fc39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_cd18e348-b420-4036-b084-30ece2562d63" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_797f608d-4afc-4bc9-b538-e9b9c749fc39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_62c3c725-5729-49a7-8d7f-6421d5063d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_cd18e348-b420-4036-b084-30ece2562d63" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_62c3c725-5729-49a7-8d7f-6421d5063d6f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_55f272aa-aa5c-4cc4-88ac-3065685d8894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_cd18e348-b420-4036-b084-30ece2562d63" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_55f272aa-aa5c-4cc4-88ac-3065685d8894" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2d0ee974-8113-41cf-8950-01b370033dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_55f272aa-aa5c-4cc4-88ac-3065685d8894" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2d0ee974-8113-41cf-8950-01b370033dd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2d0ee974-8113-41cf-8950-01b370033dd7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2d0ee974-8113-41cf-8950-01b370033dd7" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2d0ee974-8113-41cf-8950-01b370033dd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_b2aba7e1-6357-40eb-9d14-50449f005637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2d0ee974-8113-41cf-8950-01b370033dd7" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_b2aba7e1-6357-40eb-9d14-50449f005637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_de4e4858-e7f2-4a34-954d-c53003e7fa62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_b2aba7e1-6357-40eb-9d14-50449f005637" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_de4e4858-e7f2-4a34-954d-c53003e7fa62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_eb78c9a2-90c6-44ed-8414-37dea3ed6f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_b2aba7e1-6357-40eb-9d14-50449f005637" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_eb78c9a2-90c6-44ed-8414-37dea3ed6f95" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" xlink:type="extended" id="i87db0b6cb08b44148fd5cff6100c60bd_RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4648beb3-15a8-4110-85a4-da678b58d58b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_22e94caf-5947-41c8-92f3-3afa3bcd9fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4648beb3-15a8-4110-85a4-da678b58d58b" xlink:to="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_22e94caf-5947-41c8-92f3-3afa3bcd9fbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_3fa3ee18-56b7-4acd-afcf-30090dcd83a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_22e94caf-5947-41c8-92f3-3afa3bcd9fbe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_3fa3ee18-56b7-4acd-afcf-30090dcd83a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_fd4ec60c-a57b-49f5-b4ac-54a18fe0ad6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_22e94caf-5947-41c8-92f3-3afa3bcd9fbe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_fd4ec60c-a57b-49f5-b4ac-54a18fe0ad6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_43eabc9b-a97d-4905-83c0-25c230a8f6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_22e94caf-5947-41c8-92f3-3afa3bcd9fbe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_43eabc9b-a97d-4905-83c0-25c230a8f6fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_0aa6e818-e642-4a20-9457-02f04a2d1266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_22e94caf-5947-41c8-92f3-3afa3bcd9fbe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_0aa6e818-e642-4a20-9457-02f04a2d1266" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_85186c3d-4a26-4fa0-968f-fad6132f2e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_22e94caf-5947-41c8-92f3-3afa3bcd9fbe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_85186c3d-4a26-4fa0-968f-fad6132f2e71" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_3b368688-b1ba-4352-b32d-6c55091c111a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_22e94caf-5947-41c8-92f3-3afa3bcd9fbe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_3b368688-b1ba-4352-b32d-6c55091c111a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_255f728b-ad5c-4ce4-bb36-6e128592ab41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4648beb3-15a8-4110-85a4-da678b58d58b" xlink:to="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_255f728b-ad5c-4ce4-bb36-6e128592ab41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_b0428fcc-9ad0-4f86-a1c7-0a1bdf6ecd67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_255f728b-ad5c-4ce4-bb36-6e128592ab41" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_b0428fcc-9ad0-4f86-a1c7-0a1bdf6ecd67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_2961a65c-f247-4283-b4d1-b4ea7ae15fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_255f728b-ad5c-4ce4-bb36-6e128592ab41" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_2961a65c-f247-4283-b4d1-b4ea7ae15fa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_e36e65b6-6de9-40dc-b39c-57d8bf7c7822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4648beb3-15a8-4110-85a4-da678b58d58b" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_e36e65b6-6de9-40dc-b39c-57d8bf7c7822" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_bf1e044a-dc5a-4232-aaea-1fcecd524dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_e36e65b6-6de9-40dc-b39c-57d8bf7c7822" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_bf1e044a-dc5a-4232-aaea-1fcecd524dd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_ea190e3d-d757-417c-aaf2-d066537b7bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_4ecfabc6-32aa-45cb-9e2f-4d758609f12d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4648beb3-15a8-4110-85a4-da678b58d58b" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_4ecfabc6-32aa-45cb-9e2f-4d758609f12d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_462a7148-897f-4f29-9742-0c2934a81ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_4ecfabc6-32aa-45cb-9e2f-4d758609f12d" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_462a7148-897f-4f29-9742-0c2934a81ba3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_0750b1eb-9636-401c-976a-7d9b17a93349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_4ecfabc6-32aa-45cb-9e2f-4d758609f12d" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_0750b1eb-9636-401c-976a-7d9b17a93349" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_c305f641-d5e3-4a67-9173-07df8f8ac3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_4ecfabc6-32aa-45cb-9e2f-4d758609f12d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_c305f641-d5e3-4a67-9173-07df8f8ac3d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_cf53e8c3-dc1c-441a-88dc-44479be3ab50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_4ecfabc6-32aa-45cb-9e2f-4d758609f12d" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_cf53e8c3-dc1c-441a-88dc-44479be3ab50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_8737ff59-cd88-4a0d-a292-0dc0c8180325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_4ecfabc6-32aa-45cb-9e2f-4d758609f12d" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_8737ff59-cd88-4a0d-a292-0dc0c8180325" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_b108a228-27c6-4de7-b5fe-70a3d49bdd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_4ecfabc6-32aa-45cb-9e2f-4d758609f12d" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_b108a228-27c6-4de7-b5fe-70a3d49bdd3a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_166055a5-b822-484c-a550-20a6c00523f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4648beb3-15a8-4110-85a4-da678b58d58b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_166055a5-b822-484c-a550-20a6c00523f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_3eb6bce2-ea12-4c6f-b859-0d95076ff7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_166055a5-b822-484c-a550-20a6c00523f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_3eb6bce2-ea12-4c6f-b859-0d95076ff7c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_cf1b7777-2080-48eb-ba9b-5b05d8ed1337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_166055a5-b822-484c-a550-20a6c00523f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_cf1b7777-2080-48eb-ba9b-5b05d8ed1337" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_9492afc1-df2a-428c-ad8d-05cf35778a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_166055a5-b822-484c-a550-20a6c00523f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_9492afc1-df2a-428c-ad8d-05cf35778a2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_725a3e60-a2cd-43ca-866b-2be784bbdda8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_166055a5-b822-484c-a550-20a6c00523f1" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_725a3e60-a2cd-43ca-866b-2be784bbdda8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_2143a526-b1e8-4744-ae6d-006d7d2fd128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_166055a5-b822-484c-a550-20a6c00523f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_2143a526-b1e8-4744-ae6d-006d7d2fd128" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_1c4d9fdd-8263-4c2e-a252-cf519c82112c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_166055a5-b822-484c-a550-20a6c00523f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_1c4d9fdd-8263-4c2e-a252-cf519c82112c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ef0a40a4-e12d-40b8-b795-f32c5739cd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4648beb3-15a8-4110-85a4-da678b58d58b" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ef0a40a4-e12d-40b8-b795-f32c5739cd4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2ecd58d8-e583-447b-941b-367bdf424e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ef0a40a4-e12d-40b8-b795-f32c5739cd4f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2ecd58d8-e583-447b-941b-367bdf424e14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2ecd58d8-e583-447b-941b-367bdf424e14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2ecd58d8-e583-447b-941b-367bdf424e14" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2ecd58d8-e583-447b-941b-367bdf424e14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8afa2b52-1dec-47a1-9084-d4227c6b2354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2ecd58d8-e583-447b-941b-367bdf424e14" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8afa2b52-1dec-47a1-9084-d4227c6b2354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_cb40ec18-cce6-40ee-a8a8-65a585a9ce3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8afa2b52-1dec-47a1-9084-d4227c6b2354" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_cb40ec18-cce6-40ee-a8a8-65a585a9ce3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_57174b3b-44b5-445d-acc8-19d44aa02503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8afa2b52-1dec-47a1-9084-d4227c6b2354" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_57174b3b-44b5-445d-acc8-19d44aa02503" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RetirementBenefitsScheduleofFairValueDisclosuresDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails" xlink:type="extended" id="id68658ffadab4c13a750687d4e332723_RetirementBenefitsScheduleofFairValueDisclosuresDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff928df9-5e11-479d-837a-559df631e83e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2ad128e4-8baf-4e8f-b93b-74cea4d2ec1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff928df9-5e11-479d-837a-559df631e83e" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2ad128e4-8baf-4e8f-b93b-74cea4d2ec1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d75d9bc4-d848-490c-ac4b-58e43b8075f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff928df9-5e11-479d-837a-559df631e83e" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d75d9bc4-d848-490c-ac4b-58e43b8075f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_278fa2b6-f159-49f9-8e4b-8eb6ea97618c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d75d9bc4-d848-490c-ac4b-58e43b8075f3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_278fa2b6-f159-49f9-8e4b-8eb6ea97618c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_278fa2b6-f159-49f9-8e4b-8eb6ea97618c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_278fa2b6-f159-49f9-8e4b-8eb6ea97618c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_278fa2b6-f159-49f9-8e4b-8eb6ea97618c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0aa8fb7-8001-4c8e-bb71-058be446c3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_278fa2b6-f159-49f9-8e4b-8eb6ea97618c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0aa8fb7-8001-4c8e-bb71-058be446c3ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_167e007d-bf8e-49b5-bcc9-69b595a94f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0aa8fb7-8001-4c8e-bb71-058be446c3ca" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_167e007d-bf8e-49b5-bcc9-69b595a94f7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_696a40e2-093e-4ed7-851a-c0de4638dad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0aa8fb7-8001-4c8e-bb71-058be446c3ca" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_696a40e2-093e-4ed7-851a-c0de4638dad5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d4997057-eb95-457a-8a1d-fe645b9f5992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0aa8fb7-8001-4c8e-bb71-058be446c3ca" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d4997057-eb95-457a-8a1d-fe645b9f5992" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_348074cf-ebcd-4e60-8d27-5cddc609483d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0aa8fb7-8001-4c8e-bb71-058be446c3ca" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_348074cf-ebcd-4e60-8d27-5cddc609483d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_34d869e2-6c37-4365-a20f-e274e1cfe8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d75d9bc4-d848-490c-ac4b-58e43b8075f3" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_34d869e2-6c37-4365-a20f-e274e1cfe8a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_34d869e2-6c37-4365-a20f-e274e1cfe8a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_34d869e2-6c37-4365-a20f-e274e1cfe8a7" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_34d869e2-6c37-4365-a20f-e274e1cfe8a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_34d869e2-6c37-4365-a20f-e274e1cfe8a7" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_855bcafb-bb56-4b2d-aaf6-b97963ca3f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_855bcafb-bb56-4b2d-aaf6-b97963ca3f69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_449943e0-49b3-4763-9e51-438497f2c9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_449943e0-49b3-4763-9e51-438497f2c9e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember_ca011641-882d-4882-aa68-2237b8ed1f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_us-gaap_FixedIncomeFundsMember_ca011641-882d-4882-aa68-2237b8ed1f2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FixedIncomeFundsRepurchasedAgreementsMember_f2230741-c120-4886-876d-f2032df02764" xlink:href="lly-20221231.xsd#lly_FixedIncomeFundsRepurchasedAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_lly_FixedIncomeFundsRepurchasedAgreementsMember_f2230741-c120-4886-876d-f2032df02764" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FixedIncomeFundsEmergingMarketsMember_71166f04-426f-43ad-8efd-56b0636d6431" xlink:href="lly-20221231.xsd#lly_FixedIncomeFundsEmergingMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_lly_FixedIncomeFundsEmergingMarketsMember_71166f04-426f-43ad-8efd-56b0636d6431" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember_9212d960-0a14-4411-af62-6179d8928add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgeFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_us-gaap_HedgeFundsMember_9212d960-0a14-4411-af62-6179d8928add" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember_d93da01d-9425-40f8-81d4-14eec3ae2ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_us-gaap_EquityFundsMember_d93da01d-9425-40f8-81d4-14eec3ae2ac7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember_58f435a5-4c25-434e-98fe-57e4861ef985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_us-gaap_OtherContractMember_58f435a5-4c25-434e-98fe-57e4861ef985" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember_f74adeee-72ca-4e4a-ac0a-9d53368ec360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_us-gaap_DefinedBenefitPlanRealEstateMember_f74adeee-72ca-4e4a-ac0a-9d53368ec360" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefineBenefitPlanOtherMember_ed29a6c7-a01d-4e9c-bf1d-e657e60f9e4b" xlink:href="lly-20221231.xsd#lly_DefineBenefitPlanOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_lly_DefineBenefitPlanOtherMember_ed29a6c7-a01d-4e9c-bf1d-e657e60f9e4b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_503b44c5-f8da-48e8-9f18-cf5ef161bec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d75d9bc4-d848-490c-ac4b-58e43b8075f3" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_503b44c5-f8da-48e8-9f18-cf5ef161bec0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_503b44c5-f8da-48e8-9f18-cf5ef161bec0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_503b44c5-f8da-48e8-9f18-cf5ef161bec0" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_503b44c5-f8da-48e8-9f18-cf5ef161bec0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8eefb2ef-427a-49f8-938b-0e87c1274fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_503b44c5-f8da-48e8-9f18-cf5ef161bec0" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8eefb2ef-427a-49f8-938b-0e87c1274fb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_5dd4b5cf-9ac2-4d64-9b0a-6ff96701ca70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8eefb2ef-427a-49f8-938b-0e87c1274fb2" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_5dd4b5cf-9ac2-4d64-9b0a-6ff96701ca70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_bbd7eebe-f68e-476a-8f22-ac81632cc98d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8eefb2ef-427a-49f8-938b-0e87c1274fb2" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_bbd7eebe-f68e-476a-8f22-ac81632cc98d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#ContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ContingenciesDetails" xlink:type="extended" id="ia57562140a41457cbc993902e4addb14_ContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_75ac0c90-f967-4074-a0b3-556adecd394b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents_0b962f83-189a-409a-b609-5be481ec6ace" xlink:href="lly-20221231.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_75ac0c90-f967-4074-a0b3-556adecd394b" xlink:to="loc_lly_LossContingencyNumberOfPatents_0b962f83-189a-409a-b609-5be481ec6ace" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_b6b5d836-f3d2-4fac-bcce-e8af561eb673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_75ac0c90-f967-4074-a0b3-556adecd394b" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_b6b5d836-f3d2-4fac-bcce-e8af561eb673" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_28531c69-f2f5-42da-ba04-5753bebc4c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_75ac0c90-f967-4074-a0b3-556adecd394b" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_28531c69-f2f5-42da-ba04-5753bebc4c07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_c560943e-776a-4f20-9768-24b56362300e" xlink:href="lly-20221231.xsd#lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_75ac0c90-f967-4074-a0b3-556adecd394b" xlink:to="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_c560943e-776a-4f20-9768-24b56362300e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_fca1d7d5-0345-4e91-9503-a1ed96313ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_75ac0c90-f967-4074-a0b3-556adecd394b" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_fca1d7d5-0345-4e91-9503-a1ed96313ac8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_66aa5f2c-558b-484a-acd5-d1778bebfa28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_75ac0c90-f967-4074-a0b3-556adecd394b" xlink:to="loc_us-gaap_LossContingenciesTable_66aa5f2c-558b-484a-acd5-d1778bebfa28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_35008708-f5d1-4977-a213-68de6d85a904" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_66aa5f2c-558b-484a-acd5-d1778bebfa28" xlink:to="loc_srt_LitigationCaseAxis_35008708-f5d1-4977-a213-68de6d85a904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_35008708-f5d1-4977-a213-68de6d85a904_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_35008708-f5d1-4977-a213-68de6d85a904" xlink:to="loc_srt_LitigationCaseTypeDomain_35008708-f5d1-4977-a213-68de6d85a904_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2f25ce9a-519b-450b-a9a0-3dad153e2a24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_35008708-f5d1-4977-a213-68de6d85a904" xlink:to="loc_srt_LitigationCaseTypeDomain_2f25ce9a-519b-450b-a9a0-3dad153e2a24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember_e2edce11-411e-4524-9e0b-8d79e901fa48" xlink:href="lly-20221231.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2f25ce9a-519b-450b-a9a0-3dad153e2a24" xlink:to="loc_lly_EmgalityPatentLitigationMember_e2edce11-411e-4524-9e0b-8d79e901fa48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationMember_d81409a3-9a41-44aa-bbcd-4bdee1ef444b" xlink:href="lly-20221231.xsd#lly_EmployeeLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2f25ce9a-519b-450b-a9a0-3dad153e2a24" xlink:to="loc_lly_EmployeeLitigationMember_d81409a3-9a41-44aa-bbcd-4bdee1ef444b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b163f7f6-3511-4fcb-a743-743d1a64ef9a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_66aa5f2c-558b-484a-acd5-d1778bebfa28" xlink:to="loc_srt_ProductOrServiceAxis_b163f7f6-3511-4fcb-a743-743d1a64ef9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b163f7f6-3511-4fcb-a743-743d1a64ef9a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b163f7f6-3511-4fcb-a743-743d1a64ef9a" xlink:to="loc_srt_ProductsAndServicesDomain_b163f7f6-3511-4fcb-a743-743d1a64ef9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_43362188-03fd-4429-8887-22e086341e0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b163f7f6-3511-4fcb-a743-743d1a64ef9a" xlink:to="loc_srt_ProductsAndServicesDomain_43362188-03fd-4429-8887-22e086341e0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ByettaMember_75e73cba-97b4-4d0d-bfed-8ed12b4cd106" xlink:href="lly-20221231.xsd#lly_ByettaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_43362188-03fd-4429-8887-22e086341e0f" xlink:to="loc_lly_ByettaMember_75e73cba-97b4-4d0d-bfed-8ed12b4cd106" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember_cfcf65e7-4186-4ae4-bfb6-678eaad11660" xlink:href="lly-20221231.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_43362188-03fd-4429-8887-22e086341e0f" xlink:to="loc_lly_HumalogHumulinAndForteoMember_cfcf65e7-4186-4ae4-bfb6-678eaad11660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8dd50567-d9eb-4858-bdc0-97ed0d04f623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_66aa5f2c-558b-484a-acd5-d1778bebfa28" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8dd50567-d9eb-4858-bdc0-97ed0d04f623" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_8dd50567-d9eb-4858-bdc0-97ed0d04f623_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8dd50567-d9eb-4858-bdc0-97ed0d04f623" xlink:to="loc_us-gaap_LossContingencyNatureDomain_8dd50567-d9eb-4858-bdc0-97ed0d04f623_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_7bbebca3-d3dc-418e-84a7-4e539b54ea3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8dd50567-d9eb-4858-bdc0-97ed0d04f623" xlink:to="loc_us-gaap_LossContingencyNatureDomain_7bbebca3-d3dc-418e-84a7-4e539b54ea3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProductLiabilityMember_704a857f-02d3-40e0-8509-e87981399846" xlink:href="lly-20221231.xsd#lly_ProductLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7bbebca3-d3dc-418e-84a7-4e539b54ea3b" xlink:to="loc_lly_ProductLiabilityMember_704a857f-02d3-40e0-8509-e87981399846" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_c98c871f-5687-4c72-aeb8-24d30e3247f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7bbebca3-d3dc-418e-84a7-4e539b54ea3b" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_c98c871f-5687-4c72-aeb8-24d30e3247f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_355b081c-aaa8-4e7b-8d8c-e253bf7f083d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_66aa5f2c-558b-484a-acd5-d1778bebfa28" xlink:to="loc_srt_StatementGeographicalAxis_355b081c-aaa8-4e7b-8d8c-e253bf7f083d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_355b081c-aaa8-4e7b-8d8c-e253bf7f083d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_355b081c-aaa8-4e7b-8d8c-e253bf7f083d" xlink:to="loc_srt_SegmentGeographicalDomain_355b081c-aaa8-4e7b-8d8c-e253bf7f083d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1ad9e89d-79c0-4ed6-8225-752f14cfe012" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_355b081c-aaa8-4e7b-8d8c-e253bf7f083d" xlink:to="loc_srt_SegmentGeographicalDomain_1ad9e89d-79c0-4ed6-8225-752f14cfe012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR_5a38b2f3-ed83-484b-8cfc-2a3e44d31c64" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1ad9e89d-79c0-4ed6-8225-752f14cfe012" xlink:to="loc_country_BR_5a38b2f3-ed83-484b-8cfc-2a3e44d31c64" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i70b90fbf78e74287ad91427571d0436a_OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6871ae2e-9328-443b-963d-062e84da3895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc7b4e79-acce-41cf-bf9a-f97363810467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6871ae2e-9328-443b-963d-062e84da3895" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc7b4e79-acce-41cf-bf9a-f97363810467" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_56452f16-1dfb-4d0d-85e9-9f8d22172386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc7b4e79-acce-41cf-bf9a-f97363810467" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_56452f16-1dfb-4d0d-85e9-9f8d22172386" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_aabb3b39-798d-44cb-bf57-fff4ebd98ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc7b4e79-acce-41cf-bf9a-f97363810467" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_aabb3b39-798d-44cb-bf57-fff4ebd98ac2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_d84018ac-2417-4eb4-85da-e3014e3821eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc7b4e79-acce-41cf-bf9a-f97363810467" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_d84018ac-2417-4eb4-85da-e3014e3821eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c0f0ae7a-7e96-42da-acba-8c1ece0a2b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc7b4e79-acce-41cf-bf9a-f97363810467" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c0f0ae7a-7e96-42da-acba-8c1ece0a2b34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7541c120-9bbe-4ab6-bc31-603e99287648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_241254bb-f6d3-4d67-bbf1-7740c16241c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6871ae2e-9328-443b-963d-062e84da3895" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_241254bb-f6d3-4d67-bbf1-7740c16241c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fa10e7f5-380b-4a5e-a288-ea320c1223a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_241254bb-f6d3-4d67-bbf1-7740c16241c5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fa10e7f5-380b-4a5e-a288-ea320c1223a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fa10e7f5-380b-4a5e-a288-ea320c1223a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fa10e7f5-380b-4a5e-a288-ea320c1223a8" xlink:to="loc_us-gaap_EquityComponentDomain_fa10e7f5-380b-4a5e-a288-ea320c1223a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_83095ba6-17c1-418f-8f9d-02ad7b34d7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fa10e7f5-380b-4a5e-a288-ea320c1223a8" xlink:to="loc_us-gaap_EquityComponentDomain_83095ba6-17c1-418f-8f9d-02ad7b34d7c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_fbd5f666-a3db-4b64-9332-541beefb3b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_83095ba6-17c1-418f-8f9d-02ad7b34d7c8" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_fbd5f666-a3db-4b64-9332-541beefb3b8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_37e7bf5d-889b-4c19-84fc-6d7fafaf0783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_fbd5f666-a3db-4b64-9332-541beefb3b8d" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_37e7bf5d-889b-4c19-84fc-6d7fafaf0783" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_c2578b59-3315-486d-9f1d-e137ba474d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_fbd5f666-a3db-4b64-9332-541beefb3b8d" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_c2578b59-3315-486d-9f1d-e137ba474d94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_6c8b0cea-8d67-467b-aa02-ed58b28d396b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_fbd5f666-a3db-4b64-9332-541beefb3b8d" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_6c8b0cea-8d67-467b-aa02-ed58b28d396b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_f9fa8e82-53b6-43cb-b05c-ed374b9a36d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_fbd5f666-a3db-4b64-9332-541beefb3b8d" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_f9fa8e82-53b6-43cb-b05c-ed374b9a36d7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails" xlink:type="extended" id="i7882b3650ddb4d408745482f034d8704_OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_47cb73c2-cfff-4c80-9eed-8def762c96f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_bfacb48f-8302-4402-ab79-f3f0e1f29d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_47cb73c2-cfff-4c80-9eed-8def762c96f3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_bfacb48f-8302-4402-ab79-f3f0e1f29d3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_44b7c36d-6237-4273-bf4e-078990d89d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_47cb73c2-cfff-4c80-9eed-8def762c96f3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_44b7c36d-6237-4273-bf4e-078990d89d73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2d373270-5654-430f-be8b-b68a8dc23d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_44b7c36d-6237-4273-bf4e-078990d89d73" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2d373270-5654-430f-be8b-b68a8dc23d89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2d373270-5654-430f-be8b-b68a8dc23d89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2d373270-5654-430f-be8b-b68a8dc23d89" xlink:to="loc_us-gaap_EquityComponentDomain_2d373270-5654-430f-be8b-b68a8dc23d89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0308499f-1bd9-4f71-9456-0ac655f48210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2d373270-5654-430f-be8b-b68a8dc23d89" xlink:to="loc_us-gaap_EquityComponentDomain_0308499f-1bd9-4f71-9456-0ac655f48210" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_e6dc21b9-3378-4284-b10d-bf0f828f5e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0308499f-1bd9-4f71-9456-0ac655f48210" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_e6dc21b9-3378-4284-b10d-bf0f828f5e94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_5ac53309-2579-4cac-a537-7a6bbda28816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0308499f-1bd9-4f71-9456-0ac655f48210" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_5ac53309-2579-4cac-a537-7a6bbda28816" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_344d5e8c-1b8b-466c-8c80-b7dabe34a089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0308499f-1bd9-4f71-9456-0ac655f48210" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_344d5e8c-1b8b-466c-8c80-b7dabe34a089" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_a74f081f-0db8-4b34-9c3e-22941ab7b0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0308499f-1bd9-4f71-9456-0ac655f48210" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_a74f081f-0db8-4b34-9c3e-22941ab7b0a4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="i6ed50f406ca544cd9a7cd4bfd95b8c70_OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_4526d642-3d11-4ca4-abf0-5b4124c457af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_15b591a3-1f6e-40d5-8510-67591a00283f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_4526d642-3d11-4ca4-abf0-5b4124c457af" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_15b591a3-1f6e-40d5-8510-67591a00283f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c32ff456-93d5-436d-adc4-6ccf76e4f751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_4526d642-3d11-4ca4-abf0-5b4124c457af" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c32ff456-93d5-436d-adc4-6ccf76e4f751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_057e81ab-209a-4204-8652-79081e13f1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_4526d642-3d11-4ca4-abf0-5b4124c457af" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_057e81ab-209a-4204-8652-79081e13f1a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_685d5d73-db9d-40a8-a29f-fbb4654156fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_4526d642-3d11-4ca4-abf0-5b4124c457af" xlink:to="loc_us-gaap_ProfitLoss_685d5d73-db9d-40a8-a29f-fbb4654156fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_83d2b639-6053-4499-bf29-745b5c67a9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_4526d642-3d11-4ca4-abf0-5b4124c457af" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_83d2b639-6053-4499-bf29-745b5c67a9a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c8bafb9a-93e3-44d3-b3a3-b9b56a72fc73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_83d2b639-6053-4499-bf29-745b5c67a9a3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c8bafb9a-93e3-44d3-b3a3-b9b56a72fc73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c8bafb9a-93e3-44d3-b3a3-b9b56a72fc73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c8bafb9a-93e3-44d3-b3a3-b9b56a72fc73" xlink:to="loc_us-gaap_EquityComponentDomain_c8bafb9a-93e3-44d3-b3a3-b9b56a72fc73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_053e5dd0-43ac-4109-b1f9-3c0940dfc82d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c8bafb9a-93e3-44d3-b3a3-b9b56a72fc73" xlink:to="loc_us-gaap_EquityComponentDomain_053e5dd0-43ac-4109-b1f9-3c0940dfc82d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_bb4eb1bb-365c-4422-b365-8379c4d1522f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_053e5dd0-43ac-4109-b1f9-3c0940dfc82d" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_bb4eb1bb-365c-4422-b365-8379c4d1522f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_2f5b9168-b8d9-468c-829e-d388ed1a4a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_bb4eb1bb-365c-4422-b365-8379c4d1522f" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_2f5b9168-b8d9-468c-829e-d388ed1a4a3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_72fa3c91-2a7e-4473-8e43-96b4ec9de956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_bb4eb1bb-365c-4422-b365-8379c4d1522f" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_72fa3c91-2a7e-4473-8e43-96b4ec9de956" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_d97a4be7-d52d-4931-88d2-56ffee5fddf9" xlink:href="lly-20221231.xsd#lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_053e5dd0-43ac-4109-b1f9-3c0940dfc82d" xlink:to="loc_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_d97a4be7-d52d-4931-88d2-56ffee5fddf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d95659b8-aea7-4907-93e7-00dcc46fe169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_83d2b639-6053-4499-bf29-745b5c67a9a3" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d95659b8-aea7-4907-93e7-00dcc46fe169" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d95659b8-aea7-4907-93e7-00dcc46fe169_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d95659b8-aea7-4907-93e7-00dcc46fe169" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d95659b8-aea7-4907-93e7-00dcc46fe169_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d5006e86-b437-4120-9215-e31cf88adeef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d95659b8-aea7-4907-93e7-00dcc46fe169" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d5006e86-b437-4120-9215-e31cf88adeef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_d3a00930-441c-4eee-b8a6-36a5a55a3320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d5006e86-b437-4120-9215-e31cf88adeef" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_d3a00930-441c-4eee-b8a6-36a5a55a3320" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>lly-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:ccabaa9f-f08b-4cef-8cc5-6b16fc2f1828,g:814ba434-7768-4150-bd97-753155d7ed58-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_72e89eda-dab3-4425-ad24-b4673034263c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OlumiantMember_b1518428-281a-4e5a-95c3-39757793b4f3_terseLabel_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant&#174;</link:label>
    <link:label id="lab_lly_OlumiantMember_label_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant [Member]</link:label>
    <link:label id="lab_lly_OlumiantMember_documentation_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember" xlink:href="lly-20221231.xsd#lly_OlumiantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OlumiantMember" xlink:to="lab_lly_OlumiantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRealEstateMember_bfd7d82e-de5f-4a52-91be-1344ae2fd038_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRealEstateMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Real Estate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:to="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_668cdff3-4939-44ef-a13e-5bded7a8cf8c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ddd1ff48-f7aa-4a7a-a506-508e1f636690_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_f5afbd4a-4198-4406-baf8-03b8407cdae0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of pending lawsuits</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_2718d2c6-2f5e-406f-b8f1-09951e7d0d13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Assets Acquired Other than Through Business Combination</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_64880979-d777-4f02-87a0-daba60cfc469_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets (Note 14)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_ef7aec7a-fab5-4fec-bad4-bb8ac67b7660_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term notes, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LebrikizumabMember_9a1e38bd-a6ee-4e46-870a-c1d939ae5230_terseLabel_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab</link:label>
    <link:label id="lab_lly_LebrikizumabMember_label_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab [Member]</link:label>
    <link:label id="lab_lly_LebrikizumabMember_documentation_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember" xlink:href="lly-20221231.xsd#lly_LebrikizumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LebrikizumabMember" xlink:to="lab_lly_LebrikizumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_NeuroscienceMember_59514f52-7757-414b-b3b6-bc92b9f98305_terseLabel_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_lly_NeuroscienceMember_label_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_lly_NeuroscienceMember_documentation_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue to unaffiliated customers, Neuroscience</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember" xlink:href="lly-20221231.xsd#lly_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_NeuroscienceMember" xlink:to="lab_lly_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A7125NotesDue2025Member_a6254df8-53f2-433c-aac4-d0aa0a28edef_terseLabel_en-US" xlink:label="lab_lly_A7125NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.125% notes due 2025</link:label>
    <link:label id="lab_lly_A7125NotesDue2025Member_label_en-US" xlink:label="lab_lly_A7125NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.125% Notes Due 2025 [Member]</link:label>
    <link:label id="lab_lly_A7125NotesDue2025Member_documentation_en-US" xlink:label="lab_lly_A7125NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.125% Notes Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A7125NotesDue2025Member" xlink:href="lly-20221231.xsd#lly_A7125NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A7125NotesDue2025Member" xlink:to="lab_lly_A7125NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_22f57de4-1bc3-4cbd-b080-4d531ef19bf4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_ad1f160b-712a-4884-a84e-b1f0270105fe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment (gains) losses</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_4b2c5a7f-338b-4f67-8228-ddf1eda55ed7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherDiabetesMember_5f872747-5c1a-4d89-a6f6-c3d63ceb7964_terseLabel_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other diabetes</link:label>
    <link:label id="lab_lly_OtherDiabetesMember_label_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Diabetes [Member]</link:label>
    <link:label id="lab_lly_OtherDiabetesMember_documentation_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Diabetes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember" xlink:href="lly-20221231.xsd#lly_OtherDiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherDiabetesMember" xlink:to="lab_lly_OtherDiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_76b344ee-8ed9-4ab9-ad51-6afd9e2b46d1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DermiraInc.Member_cb7a0c98-4824-41c4-8b88-a6c44db758fe_terseLabel_en-US" xlink:label="lab_lly_DermiraInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermira</link:label>
    <link:label id="lab_lly_DermiraInc.Member_label_en-US" xlink:label="lab_lly_DermiraInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermira, Inc. [Member]</link:label>
    <link:label id="lab_lly_DermiraInc.Member_documentation_en-US" xlink:label="lab_lly_DermiraInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermira, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DermiraInc.Member" xlink:href="lly-20221231.xsd#lly_DermiraInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DermiraInc.Member" xlink:to="lab_lly_DermiraInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_022f1884-40eb-4343-8cb3-3b85e8681604_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-lived Intangible Assets other than Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_a76efe3e-e26b-4add-b7ee-45338072ff85_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_63966a0b-2c78-42c5-8e76-05a0c0650a8b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect from interest rate contracts</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_c8d5b113-eae8-47cf-b38f-89d2468539e9_terseLabel_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, information used to determine revenue recognized, change in accounting estimate, percent (or less)</link:label>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_label_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</link:label>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_documentation_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:href="lly-20221231.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:to="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_07199183-0160-4c9b-8138-297548c0afef_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_42d719f0-a77a-45ed-b0e1-242410c0c47a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_323ccd2f-f416-48b6-9202-2dd08b6c3ad7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6-10 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce840fe3-7aed-46a9-a8b8-671d34e0fb66_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_6e96b031-3bba-42cf-938a-e2e34782a6b1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_89fdce57-1957-4863-a000-2898292663ba_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RigelPharmaceuticalsIncMember_b2eb30a0-6a88-4dfc-a9c6-e2acd68ff03c_terseLabel_en-US" xlink:label="lab_lly_RigelPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rigel Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_lly_RigelPharmaceuticalsIncMember_label_en-US" xlink:label="lab_lly_RigelPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rigel Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_lly_RigelPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_lly_RigelPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rigel Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RigelPharmaceuticalsIncMember" xlink:href="lly-20221231.xsd#lly_RigelPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RigelPharmaceuticalsIncMember" xlink:to="lab_lly_RigelPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_1528124e-98f9-4215-8cf2-098d65a4ae37_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_66757bce-6de1-401d-ae15-090ff26291b4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MarketableSecuritiesMember_cde40045-fd8e-47a8-805d-862db0020541_terseLabel_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_lly_MarketableSecuritiesMember_label_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:label id="lab_lly_MarketableSecuritiesMember_documentation_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember" xlink:href="lly-20221231.xsd#lly_MarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MarketableSecuritiesMember" xlink:to="lab_lly_MarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_b9246e4c-2bf2-4ca7-8ac1-079a67769246_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_14998777-f24b-4bf4-ba48-39a90f86a90c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b39f3fc8-0265-4eea-93a6-0b2875af3663_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_a55c7ba7-01dc-4b6b-a6f6-2d5486c66b16_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in foreign currency translation gains (losses)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_53928f40-4b38-45f1-a3bd-20a5d4b22fcb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_b164b546-dcdd-4a06-826f-4e2d3aab429d_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_14efbe04-2bad-4697-a2a6-1124cbeaf5c1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments of income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_9b024a68-52be-4318-ac56-b0d2afdc85c7_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_8a8cb37b-7e62-487f-8ecc-20d7a709f797_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_bdba1ec8-f6ce-4090-8c06-2a3af86b0320_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_6b0ab131-8f1b-4ad3-8bb2-2e71d940b1f5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_94ac9a74-2d01-4a71-9c60-de79ea0d8923_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_42af0a96-8c5b-4a53-8cf3-d31c5e20f2ef_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After 2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_31736c51-ef56-4964-997d-9b70bc392cdb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b58e06fb-8c06-465c-9e5d-8ec0cd9fd94a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_9e93b3d0-1c29-4b33-87b2-3c9301264039_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c1e21566-836c-47d0-85f7-f831999ebc1f_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_1e02ad8c-2ea3-4947-a3c3-0ca55c23b0d4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_a8601c6b-63f4-4102-bb1f-f0fa846d8a35_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_e528e20e-fd26-4a6f-b8fd-24335708c1f4_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1230836c-708d-4323-b96f-227562daf760_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets at beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_55121b6d-42b9-4c38-bba0-66c599163a02_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets at end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_8d880034-7bb9-421e-9265-3696cb55ae12_netLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DesignatedUnusableMember_43f980b1-1e33-41d2-a22e-43d0f7b85f2b_terseLabel_en-US" xlink:label="lab_lly_DesignatedUnusableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated Unusable</link:label>
    <link:label id="lab_lly_DesignatedUnusableMember_label_en-US" xlink:label="lab_lly_DesignatedUnusableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated Unusable [Member]</link:label>
    <link:label id="lab_lly_DesignatedUnusableMember_documentation_en-US" xlink:label="lab_lly_DesignatedUnusableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Those operating loss/tax credit carryforwards/carrybacks included that have been designated to be unusable and therefore, is fully reserved.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DesignatedUnusableMember" xlink:href="lly-20221231.xsd#lly_DesignatedUnusableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DesignatedUnusableMember" xlink:to="lab_lly_DesignatedUnusableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_cae6dc63-001a-4292-a161-840972701bca_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LongTermDebtFairValueAdjustment_5e940d62-ee8a-498e-8acd-cefb2cdc3a76_terseLabel_en-US" xlink:label="lab_lly_LongTermDebtFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustment on hedged long-term notes</link:label>
    <link:label id="lab_lly_LongTermDebtFairValueAdjustment_label_en-US" xlink:label="lab_lly_LongTermDebtFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value Adjustment</link:label>
    <link:label id="lab_lly_LongTermDebtFairValueAdjustment_documentation_en-US" xlink:label="lab_lly_LongTermDebtFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustment to carrying value of long term debt to arrive at total fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LongTermDebtFairValueAdjustment" xlink:href="lly-20221231.xsd#lly_LongTermDebtFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LongTermDebtFairValueAdjustment" xlink:to="lab_lly_LongTermDebtFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmployeeLitigationMember_4f5a2ba9-5b21-44d6-8afe-47451a0dc169_terseLabel_en-US" xlink:label="lab_lly_EmployeeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation</link:label>
    <link:label id="lab_lly_EmployeeLitigationMember_label_en-US" xlink:label="lab_lly_EmployeeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation [Member]</link:label>
    <link:label id="lab_lly_EmployeeLitigationMember_documentation_en-US" xlink:label="lab_lly_EmployeeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationMember" xlink:href="lly-20221231.xsd#lly_EmployeeLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmployeeLitigationMember" xlink:to="lab_lly_EmployeeLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_96403005-1ec2-43e6-b073-9f2a26acb217_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_39f74543-9115-4adb-b253-0e8c389d46c8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_51584413-d496-4191-bcd0-2a7570532642_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_e9c8bd92-5de3-494e-878c-b477f12f0369_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings of foreign subsidiaries</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_2f189bd0-ade0-4d14-86bd-40d158ddf123_terseLabel_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded commitments to invest in venture capital funds, anticipated payment period</link:label>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_label_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</link:label>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_documentation_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:href="lly-20221231.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:to="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_5c2c2079-201c-47d5-8530-eae3e2f9abde_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_d4960386-40c2-4211-8ca4-c75d00477c51_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of retirement benefit items</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_ad53340c-bdf3-48e1-a053-d5a16c33e299_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_5e2dd653-3df9-42b8-9cd9-e8244316705e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gain) loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_ee6f66ce-2f0c-48d3-9acb-9d96be025c03_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_6a008290-47d4-4310-a315-9c8d2e9d512d_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_07a92168-567e-4c59-8cc9-13183d45f113_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_c04de4bd-3d4c-458e-be9b-f581b75d91f2_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in defined benefit pension and retiree health benefit plans (Note 15)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_1e00f4d1-a38d-432e-aa27-c8181f969c3e_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss) during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_InnoventBiologicsIncMember_bf15ddca-9083-4d6e-b54b-e10e5baf2935_terseLabel_en-US" xlink:label="lab_lly_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics, Inc. (Innovent)</link:label>
    <link:label id="lab_lly_InnoventBiologicsIncMember_label_en-US" xlink:label="lab_lly_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics, Inc. [Member]</link:label>
    <link:label id="lab_lly_InnoventBiologicsIncMember_documentation_en-US" xlink:label="lab_lly_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember" xlink:href="lly-20221231.xsd#lly_InnoventBiologicsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_InnoventBiologicsIncMember" xlink:to="lab_lly_InnoventBiologicsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_37f63e9f-2de5-4c6a-8ea1-f524ac6f3be2_terseLabel_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, sales returns, percentage of net revenue (less than)</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_label_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_documentation_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" xlink:href="lly-20221231.xsd#lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" xlink:to="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_d98f6c5e-2ef7-41e7-a2e8-4c1178eaa179_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, expenses, and other:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_NoExpirationMember_df9c3a18-4271-4821-b091-774d85ec4082_terseLabel_en-US" xlink:label="lab_lly_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No Expiration</link:label>
    <link:label id="lab_lly_NoExpirationMember_label_en-US" xlink:label="lab_lly_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No Expiration [Member]</link:label>
    <link:label id="lab_lly_NoExpirationMember_documentation_en-US" xlink:label="lab_lly_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Those operating loss/tax credit carryforwards/carrybacks included that have no expiration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NoExpirationMember" xlink:href="lly-20221231.xsd#lly_NoExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_NoExpirationMember" xlink:to="lab_lly_NoExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_d52bfc51-cb01-4e31-a52a-b3e4a6575f94_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt (Note 11)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_4e7e158c-8bd3-4849-9488-1f739ef5e044_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ByettaMember_3aa16e9b-359a-4bfe-9c32-eb122e84ab58_terseLabel_en-US" xlink:label="lab_lly_ByettaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Byetta</link:label>
    <link:label id="lab_lly_ByettaMember_label_en-US" xlink:label="lab_lly_ByettaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Byetta [Member]</link:label>
    <link:label id="lab_lly_ByettaMember_documentation_en-US" xlink:label="lab_lly_ByettaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Byetta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ByettaMember" xlink:href="lly-20221231.xsd#lly_ByettaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ByettaMember" xlink:to="lab_lly_ByettaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a7e19c21-c7e0-48f0-b4ad-ea38e788c223_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5cbabab-e5d8-4263-a4b7-0181e9ed8a65_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2be8394f-4f2b-4d56-8436-4472e07ee769_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherForeignCountriesMember_63300606-ae77-47a2-b332-62b78795751e_terseLabel_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other foreign countries</link:label>
    <link:label id="lab_lly_OtherForeignCountriesMember_4732e468-332d-453f-ad50-ac4ae9455897_verboseLabel_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other foreign countries</link:label>
    <link:label id="lab_lly_OtherForeignCountriesMember_label_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Foreign Countries [Member]</link:label>
    <link:label id="lab_lly_OtherForeignCountriesMember_documentation_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Foreign Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember" xlink:href="lly-20221231.xsd#lly_OtherForeignCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherForeignCountriesMember" xlink:to="lab_lly_OtherForeignCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_62ada3b1-d435-48e1-9604-68e9f38deb45_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_5da862e7-77c3-4b3a-ae48-671f25f6e77b_terseLabel_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential achievements</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_label_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Rights (Obligations)</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_documentation_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Rights (Obligations)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:href="lly-20221231.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:to="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_b132f17d-9f7b-4551-8452-cea480aa1c95_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_a7e6f251-f3fc-4138-aef1-b467e7b1fc9d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan amendments during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_c0806c8b-eb5d-4e33-ba67-fa837fce8c65_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a89cc861-af24-41b6-a6eb-b97cd886b624_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_09d9e565-3938-41ec-ad15-72d763bfd585_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BasaglarMember_31256352-18a1-4c20-8f58-e7ebb37c68b6_verboseLabel_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar&#174;</link:label>
    <link:label id="lab_lly_BasaglarMember_label_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar [Member]</link:label>
    <link:label id="lab_lly_BasaglarMember_documentation_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember" xlink:href="lly-20221231.xsd#lly_BasaglarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BasaglarMember" xlink:to="lab_lly_BasaglarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_aefb222f-210d-4347-a22e-fab568d328fd_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_ba32a66a-05f7-42fc-978e-435a2f1b939a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_40014580-357c-4f24-802a-7620dcff1860_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net periodic (benefit) cost:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_9045e37c-ac7b-4643-8b67-96881e18eaaa_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of noncurrent investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3e8799e0-b501-477e-aa58-94b5ffdb90c2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_905e92b9-93a2-45e2-9064-1fc7be9924a6_terseLabel_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, monthly reduction</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_label_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Regulatory Approval Delay, Monthly Reduction</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_documentation_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:href="lly-20221231.xsd#lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:to="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_69ce5930-48b7-4a57-bc1b-feadedd88a50_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_3192d678-d9fd-43ab-a9bd-d8b247427f77_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_568a1c16-4dea-4652-8b59-ad13cc2c43ae_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Portion of Cash&#160;Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_f03ac564-e5dd-472c-856c-6a7d142dd7d4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_d37d92e7-1fa2-440b-bedd-fc0b3c859f17_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_99071c3a-b7bb-408f-987d-4aff8b4e597f_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketed products</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_86c70811-8ce7-418a-a88d-eebf15b0b786_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_0566e890-d54f-4ee4-af89-4c5201927956_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recorded for Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PrecisionBiosciencesIncMember_7860dc9c-4ea8-422b-92ca-dac2bfc7c8de_terseLabel_en-US" xlink:label="lab_lly_PrecisionBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Biosciences, Inc.</link:label>
    <link:label id="lab_lly_PrecisionBiosciencesIncMember_label_en-US" xlink:label="lab_lly_PrecisionBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_lly_PrecisionBiosciencesIncMember_documentation_en-US" xlink:label="lab_lly_PrecisionBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Biosciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBiosciencesIncMember" xlink:href="lly-20221231.xsd#lly_PrecisionBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PrecisionBiosciencesIncMember" xlink:to="lab_lly_PrecisionBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_61503678-ad30-4b78-80bf-c466c2710b0e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International operations, including Puerto Rico</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_e8d25a7c-e753-472e-83c7-0b8487469453_terseLabel_en-US" xlink:label="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, payment terms, financing component, period between transfer of control and payment receipt (or less)</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_label_en-US" xlink:label="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_documentation_en-US" xlink:label="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" xlink:href="lly-20221231.xsd#lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" xlink:to="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_e33a736c-a1b4-447a-ade0-67f104ba0d4e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_39e67b7b-cb5c-41a2-b25e-dfe213ea7d6f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment, restructuring, and other special charges (Note 5)</link:label>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_e591be01-5045-4d29-83ec-917249b85597_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total asset impairment, restructuring, and other special charges</link:label>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_label_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Settlement and Impairment Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:to="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_b4b04d39-c816-4449-b8ed-a04abbf43c24_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of nonperforming assets</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_b39d8f49-7e9f-4ec2-87e6-90ad2cba4c81_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_b7d5d0e7-9eb4-4522-a06e-61b6190cfcba_negatedNetLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit (provision) for income taxes related to other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaltzMember_94d8bc33-88e6-4732-9d2f-159fa97ba2b7_terseLabel_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz&#174;</link:label>
    <link:label id="lab_lly_TaltzMember_label_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz [Member]</link:label>
    <link:label id="lab_lly_TaltzMember_documentation_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember" xlink:href="lly-20221231.xsd#lly_TaltzMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaltzMember" xlink:to="lab_lly_TaltzMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_45f82564-d0a9-4719-b8ba-2721bc0f724a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used for Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_ba2fe9bc-72dd-4f5b-a698-0018d0c15360_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit obligation, period decrease</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_e8a45d40-b0ce-4065-b531-44fd7d714895_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A30NotesDue2022Member_4c75ac7b-9630-4fa3-97b8-9c6b1d51430c_terseLabel_en-US" xlink:label="lab_lly_A30NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.00% notes due 2022</link:label>
    <link:label id="lab_lly_A30NotesDue2022Member_label_en-US" xlink:label="lab_lly_A30NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.0% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_lly_A30NotesDue2022Member_documentation_en-US" xlink:label="lab_lly_A30NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.0% Notes Due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A30NotesDue2022Member" xlink:href="lly-20221231.xsd#lly_A30NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A30NotesDue2022Member" xlink:to="lab_lly_A30NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_2fe79eff-f30d-43af-b2c2-b6587e368c16_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_eedb5eb3-2e2d-4290-949c-fb667c4e59dd_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ffbda914-de85-439d-8e8b-5e16156a1b2d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_75717641-14c7-471b-a89f-18907f58b3d9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A395NotesDue2049Member_2e76cb34-a514-4966-90c3-12346784ed59_terseLabel_en-US" xlink:label="lab_lly_A395NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% notes due 2049</link:label>
    <link:label id="lab_lly_A395NotesDue2049Member_label_en-US" xlink:label="lab_lly_A395NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due 2049 [Member]</link:label>
    <link:label id="lab_lly_A395NotesDue2049Member_documentation_en-US" xlink:label="lab_lly_A395NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member" xlink:href="lly-20221231.xsd#lly_A395NotesDue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A395NotesDue2049Member" xlink:to="lab_lly_A395NotesDue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_VerzenioMember_ca6edce3-78bd-4899-b6b1-e19dbd3d8adc_terseLabel_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio&#174;</link:label>
    <link:label id="lab_lly_VerzenioMember_label_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio [Member]</link:label>
    <link:label id="lab_lly_VerzenioMember_documentation_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember" xlink:href="lly-20221231.xsd#lly_VerzenioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_VerzenioMember" xlink:to="lab_lly_VerzenioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_1284b855-a34b-4919-ade9-210c2ef0c42b_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_c637869f-bf18-45a4-95ec-c57a52e23251_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Gains&#160;(Losses)</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_254d26d5-9465-43b4-b66d-ca06cecefdd8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A415NotesDue2059Member_89aede99-ea81-47c2-811a-2d3df5c938bc_terseLabel_en-US" xlink:label="lab_lly_A415NotesDue2059Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% notes due 2059</link:label>
    <link:label id="lab_lly_A415NotesDue2059Member_label_en-US" xlink:label="lab_lly_A415NotesDue2059Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Notes Due 2059 [Member]</link:label>
    <link:label id="lab_lly_A415NotesDue2059Member_documentation_en-US" xlink:label="lab_lly_A415NotesDue2059Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Notes Due 2059 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member" xlink:href="lly-20221231.xsd#lly_A415NotesDue2059Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A415NotesDue2059Member" xlink:to="lab_lly_A415NotesDue2059Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_55309b99-3113-488f-80de-7fc331bcbebe_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_06b2e4b4-5379-4d08-81e4-bc4f1dc29025_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_cb648517-9dac-4365-b3cb-d51c5b4fc93f_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8b4c31e1-32ab-4d8d-b2a5-c8989360f3ff_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for recognition of the compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_da06eca7-a7ec-48ac-a9a0-dff21a8b0688_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-lived Intangible Assets other than Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_7772540f-ea29-4527-ab71-02c13d22e168_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_d34771aa-b56b-43fe-ba67-a3ec93e4a9f1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, by Balance Sheet Grouping</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_01defba2-8504-4dd6-bb9e-e2ade58048d9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of noncurrent investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_a5c936cb-53f9-4f15-a124-63ef9b059605_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4101906b-aa98-48fa-813b-6cd6840e5868_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_7f671f10-23ad-47fd-9991-1110018346aa_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A595NotesDue2037Member_b442737a-95ab-4ddf-b8df-b65ada533824_terseLabel_en-US" xlink:label="lab_lly_A595NotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% notes due 2037</link:label>
    <link:label id="lab_lly_A595NotesDue2037Member_label_en-US" xlink:label="lab_lly_A595NotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes Due 2037 [Member]</link:label>
    <link:label id="lab_lly_A595NotesDue2037Member_documentation_en-US" xlink:label="lab_lly_A595NotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes Due 2037</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A595NotesDue2037Member" xlink:href="lly-20221231.xsd#lly_A595NotesDue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A595NotesDue2037Member" xlink:to="lab_lly_A595NotesDue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_0c99b988-f707-4861-8859-36e89c50f9f9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_946992bf-d1f3-4891-a964-b6fe680d9072_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffsettingAssetsLineItems_92fe5769-2068-4d22-9911-ccf2d8c88982_terseLabel_en-US" xlink:label="lab_us-gaap_OffsettingAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OffsettingAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OffsettingAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffsettingAssetsLineItems" xlink:to="lab_us-gaap_OffsettingAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_d7e8b776-b599-4176-be34-9b45e6ca071e_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_b2fef5b0-c113-4aac-81bd-4b5e1c7b117a_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_75fde097-82ae-4b53-a0e1-074a6234c0db_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cc8e5c2d-5088-4d09-b9a3-dcdb9a84d736_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_13a25555-fbe9-4954-8310-746c8686d862_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0dc0f46b-4baf-461c-8b25-064f89a72642_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_46bf8c91-f64c-4c9b-a542-8329c1f615ba_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax loss and other tax carryforwards and carrybacks</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_620f0ef3-2972-4c9c-858b-93d7c8c53603_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherOncologyMember_4b3be9b2-eb83-465c-9389-ff87d5bc4adf_terseLabel_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other oncology</link:label>
    <link:label id="lab_lly_OtherOncologyMember_label_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:label id="lab_lly_OtherOncologyMember_documentation_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember" xlink:href="lly-20221231.xsd#lly_OtherOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherOncologyMember" xlink:to="lab_lly_OtherOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_257638d7-55b4-4666-8ecf-50e9e7f273a6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_95d3b66f-96cb-4c24-83a0-eea0742ad975_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b31b2b44-1ce4-4f69-9c60-16645c2379d3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4acd510f-dd73-4e28-b416-ab0d04b02a0f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_fed5a3b7-7bb8-4ab3-8393-ba7b09d26604_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_289e0dd7-aa3d-41ed-9dd0-ae449f1b50b2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c95f7b73-9cb8-4b6d-9f81-3511d712ec92_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_3d8c7114-1bb9-4bb9-9233-daddf74e3ec0_terseLabel_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Fixed Rate Debt</link:label>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_label_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Fixed Rate Debt [Member]</link:label>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_documentation_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Fixed-Rate Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember" xlink:href="lly-20221231.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HedgedFixedRateDebtMember" xlink:to="lab_lly_HedgedFixedRateDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CarryforwardMember_dc73c1af-056a-472b-8c79-b27b1811d523_terseLabel_en-US" xlink:label="lab_lly_CarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carryforward</link:label>
    <link:label id="lab_lly_CarryforwardMember_label_en-US" xlink:label="lab_lly_CarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carryforward [Member]</link:label>
    <link:label id="lab_lly_CarryforwardMember_documentation_en-US" xlink:label="lab_lly_CarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CarryforwardMember" xlink:href="lly-20221231.xsd#lly_CarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CarryforwardMember" xlink:to="lab_lly_CarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8059e586-6e09-4f4d-b66f-10e5c6ba7541_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d94e830b-dc6e-4fd7-b3ef-b699dda545ef_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_667086ac-9b63-4f79-b0a3-7bc5695d76c5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_7ebc7bb8-09fb-4c14-a23f-e8d0e0f89ca5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6836cfec-3e4e-4bf5-b8b5-b57954e0da3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FoghornTherapeuticsIncMember_c760e817-bbe4-4a59-927f-30e0f6ba8813_terseLabel_en-US" xlink:label="lab_lly_FoghornTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foghorn Therapeutics Inc.</link:label>
    <link:label id="lab_lly_FoghornTherapeuticsIncMember_label_en-US" xlink:label="lab_lly_FoghornTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foghorn Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_lly_FoghornTherapeuticsIncMember_documentation_en-US" xlink:label="lab_lly_FoghornTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foghorn Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FoghornTherapeuticsIncMember" xlink:href="lly-20221231.xsd#lly_FoghornTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FoghornTherapeuticsIncMember" xlink:to="lab_lly_FoghornTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_31864bb7-7b70-4f98-bf24-2fe3b66d06f2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_f168d3e8-3582-4a09-9cbc-a4c82e00135d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future employer contributions, next fiscal year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_5237d2b5-2865-4ea8-837b-cfe37c2c96f2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_3e7f4ff7-4538-471a-994c-d5edd8e738f2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6f7cd0e2-dd38-45f8-ae03-7f47898bfaa6_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition date fair value of consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FairValueHedgeAbstract_4686f56d-a2a1-43fe-8566-358f4e37870e_terseLabel_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value hedges:</link:label>
    <link:label id="lab_lly_FairValueHedgeAbstract_label_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedge [Abstract]</link:label>
    <link:label id="lab_lly_FairValueHedgeAbstract_documentation_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedge [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract" xlink:href="lly-20221231.xsd#lly_FairValueHedgeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FairValueHedgeAbstract" xlink:to="lab_lly_FairValueHedgeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_88292996-64f8-4bfd-934e-d0178d6f31a2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6970151e-e178-412b-b761-91e7fb4c3189_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities&#8212;increase (decrease)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_975c82f7-670c-4cfd-b1af-a904752284dc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AlimtaMember_26df4798-4864-43e0-aeb7-fd011d4637fd_terseLabel_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta&#174;</link:label>
    <link:label id="lab_lly_AlimtaMember_label_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta [Member]</link:label>
    <link:label id="lab_lly_AlimtaMember_documentation_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember" xlink:href="lly-20221231.xsd#lly_AlimtaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AlimtaMember" xlink:to="lab_lly_AlimtaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock_c6edefff-ea1f-43e2-bca9-dda0eeb5b403_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Accumulated Postemployment Benefit Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Accumulated Postemployment Benefit Obligations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9d43fecb-baab-4c25-806c-8be64870c3cf_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount, Gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0a75c558-d2ab-430d-ae3d-5e8c181394e0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_39536024-227a-4540-8338-87baec827c41_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_427c389c-c59a-481f-b09a-c7e06bc5880b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in effective portion of cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_2ca35c93-f336-4b31-9198-7ff829a4c0ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Subsidiary or Equity Method Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4a4f2d73-78f1-4343-9d73-2e7cd434cbc3_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SwapUSDollarsToEuroMember_408c261b-4db2-48ca-9613-6205a74707b0_terseLabel_en-US" xlink:label="lab_lly_SwapUSDollarsToEuroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap U.S Dollars To Euro</link:label>
    <link:label id="lab_lly_SwapUSDollarsToEuroMember_label_en-US" xlink:label="lab_lly_SwapUSDollarsToEuroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap U.S. Dollars To Euro [Member]</link:label>
    <link:label id="lab_lly_SwapUSDollarsToEuroMember_documentation_en-US" xlink:label="lab_lly_SwapUSDollarsToEuroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap U.S. Dollars To Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapUSDollarsToEuroMember" xlink:href="lly-20221231.xsd#lly_SwapUSDollarsToEuroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SwapUSDollarsToEuroMember" xlink:to="lab_lly_SwapUSDollarsToEuroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_e107c7e9-bfda-4de5-9977-c93ec722872f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4787e121-276a-43fc-855b-02089cefdc67_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A718NotesDueJune12025Member_5ab69301-5586-4981-9241-b46a87755c42_terseLabel_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes due 2025</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_label_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_documentation_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member" xlink:href="lly-20221231.xsd#lly_A718NotesDueJune12025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A718NotesDueJune12025Member" xlink:to="lab_lly_A718NotesDueJune12025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_5784b50e-02a8-4aa0-9f79-4be86721d12e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3f78a979-8c9a-4237-b0ad-d9d027d179e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89f79b17-bf28-49da-820b-80496cb3d3b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in operating assets and liabilities, net of acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_0c757aeb-ed4f-4aa0-a20c-7f7138e47470_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_69fa3152-cea9-47fe-ba12-c1c2badea0cc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock_a51b621d-2ead-43f1-8fec-33e37dd7d831_terseLabel_en-US" xlink:label="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Borrowings Disclosures</link:label>
    <link:label id="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock_label_en-US" xlink:label="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Borrowings Disclosures [Table Text Block]</link:label>
    <link:label id="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock_documentation_en-US" xlink:label="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Borrowings Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" xlink:href="lly-20221231.xsd#lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" xlink:to="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0435f02d-7b02-4136-95e8-550c1d2b660d_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax (Note 17)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59c15730-36e7-431b-9121-79fd9f315d07_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_61afcaf7-fb32-40ec-8f76-b3820afa4f25_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_43a7b1d6-9719-4930-b747-d8d9d8e85a2d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaper_fb533629-4bab-4f76-8427-04c513dea4d4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term commercial paper borrowings</link:label>
    <link:label id="lab_us-gaap_CommercialPaper_705bd0a2-1193-4a60-a0ae-39d11d763c71_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term commercial paper borrowings</link:label>
    <link:label id="lab_us-gaap_CommercialPaper_label_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaper" xlink:to="lab_us-gaap_CommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_1ca5aabf-757c-435b-89fd-a5d56d0db390_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_262edadf-74aa-4366-9efc-ca57c2a5fd22_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyUSDollarSellChineseYuanMember_e37fe619-a07c-4947-b059-70c0ff5f00b9_terseLabel_en-US" xlink:label="lab_lly_BuyUSDollarSellChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US Dollar Sell Chinese Yuan</link:label>
    <link:label id="lab_lly_BuyUSDollarSellChineseYuanMember_label_en-US" xlink:label="lab_lly_BuyUSDollarSellChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US Dollar Sell Chinese Yuan [Member]</link:label>
    <link:label id="lab_lly_BuyUSDollarSellChineseYuanMember_documentation_en-US" xlink:label="lab_lly_BuyUSDollarSellChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US Dollar Sell Chinese Yuan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSDollarSellChineseYuanMember" xlink:href="lly-20221231.xsd#lly_BuyUSDollarSellChineseYuanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyUSDollarSellChineseYuanMember" xlink:to="lab_lly_BuyUSDollarSellChineseYuanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_097f41b0-2e11-44fd-be2d-79aa351ce9d7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ImmunologyMember_22f902ac-830c-4820-94b9-9540047958c8_terseLabel_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology</link:label>
    <link:label id="lab_lly_ImmunologyMember_label_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:label id="lab_lly_ImmunologyMember_documentation_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember" xlink:href="lly-20221231.xsd#lly_ImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ImmunologyMember" xlink:to="lab_lly_ImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_a8b8b364-4585-429c-8f83-854e8f657685_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ProductLiabilityMember_4e923069-219b-492c-877f-bb6df706e407_terseLabel_en-US" xlink:label="lab_lly_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:label id="lab_lly_ProductLiabilityMember_label_en-US" xlink:label="lab_lly_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability [Member]</link:label>
    <link:label id="lab_lly_ProductLiabilityMember_documentation_en-US" xlink:label="lab_lly_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProductLiabilityMember" xlink:href="lly-20221231.xsd#lly_ProductLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ProductLiabilityMember" xlink:to="lab_lly_ProductLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ExpirationBy2027Member_c0975cc6-7df2-4589-8851-2b688a6f03e0_terseLabel_en-US" xlink:label="lab_lly_ExpirationBy2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration By 2027</link:label>
    <link:label id="lab_lly_ExpirationBy2027Member_label_en-US" xlink:label="lab_lly_ExpirationBy2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration By 2027 [Member]</link:label>
    <link:label id="lab_lly_ExpirationBy2027Member_documentation_en-US" xlink:label="lab_lly_ExpirationBy2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration By 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ExpirationBy2027Member" xlink:href="lly-20221231.xsd#lly_ExpirationBy2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ExpirationBy2027Member" xlink:to="lab_lly_ExpirationBy2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SellChineseYuanMember_4da0b565-8213-4bb7-9ce7-da16adf6782d_terseLabel_en-US" xlink:label="lab_lly_SellChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sell Chinese Yuan</link:label>
    <link:label id="lab_lly_SellChineseYuanMember_label_en-US" xlink:label="lab_lly_SellChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sell Chinese Yuan [Member]</link:label>
    <link:label id="lab_lly_SellChineseYuanMember_documentation_en-US" xlink:label="lab_lly_SellChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sell Chinese Yuan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SellChineseYuanMember" xlink:href="lly-20221231.xsd#lly_SellChineseYuanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SellChineseYuanMember" xlink:to="lab_lly_SellChineseYuanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_b6c474c1-e9ee-4eef-8b6c-378d62300f48_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_d26d0ad1-1803-493f-8e30-9e1a5260bf33_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c1c7bb5a-1433-4fd0-b275-b2708f2ff1bf_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_a7da3212-2896-4f80-a11b-e61332670831_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_12fec36f-476c-4cfd-b3b1-6fc4b9e79c01_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1625EuroDenominatedNotesDue2026Member_75ed0aaa-95f6-4c6f-9633-6635a7033e3a_terseLabel_en-US" xlink:label="lab_lly_A1625EuroDenominatedNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% euro denominated notes due 2026</link:label>
    <link:label id="lab_lly_A1625EuroDenominatedNotesDue2026Member_label_en-US" xlink:label="lab_lly_A1625EuroDenominatedNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Euro-denominated Notes Due 2026 [Member]</link:label>
    <link:label id="lab_lly_A1625EuroDenominatedNotesDue2026Member_documentation_en-US" xlink:label="lab_lly_A1625EuroDenominatedNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Euro-denominated Notes Due 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625EuroDenominatedNotesDue2026Member" xlink:href="lly-20221231.xsd#lly_A1625EuroDenominatedNotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1625EuroDenominatedNotesDue2026Member" xlink:to="lab_lly_A1625EuroDenominatedNotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c27ff75b-07e1-46d7-a1f3-e7f8cd519742_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_e8ca5e44-6976-451d-8374-901705f3afb7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_f7995f7f-ce55-4b6a-930e-81e20217807a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b489d555-5f86-4a61-bcc0-d2262424139d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_bdf5d5ea-4f82-4e92-90c0-47e35d789bfd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_9a5d5561-5a85-4448-85ea-89afafe91d29_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_c9aabf5a-3e38-4365-9aa1-486c7a5b601d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_54e550a2-d956-4ff6-8561-17357e523eaa_terseLabel_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gross gains on sales</link:label>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_label_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</link:label>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_documentation_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:href="lly-20221231.xsd#lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:to="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A015SwissFrancDenominatedNotesDue2024Member_1324e1ec-7c7b-4854-afc1-1d54daf2da0e_terseLabel_en-US" xlink:label="lab_lly_A015SwissFrancDenominatedNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% Swiss franc denominated notes due 2024</link:label>
    <link:label id="lab_lly_A015SwissFrancDenominatedNotesDue2024Member_label_en-US" xlink:label="lab_lly_A015SwissFrancDenominatedNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% Swiss Franc-denominated Notes Due 2024 [Member]</link:label>
    <link:label id="lab_lly_A015SwissFrancDenominatedNotesDue2024Member_documentation_en-US" xlink:label="lab_lly_A015SwissFrancDenominatedNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% Swiss Franc-denominated Notes Due 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A015SwissFrancDenominatedNotesDue2024Member" xlink:href="lly-20221231.xsd#lly_A015SwissFrancDenominatedNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A015SwissFrancDenominatedNotesDue2024Member" xlink:to="lab_lly_A015SwissFrancDenominatedNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f3b26657-2b1a-468c-9125-458772e90e8f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_6dcf3bbf-7609-426c-927a-40055ff00511_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_51c91b84-8a5d-43a1-8130-bbb3f0b3c395_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_f0e03a36-cf57-4f08-bc66-bd8af78e1901_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A2125EuroDenominatedNotesDue2030Member_0e559c2d-db3e-46f1-86e0-dcb82e22011e_terseLabel_en-US" xlink:label="lab_lly_A2125EuroDenominatedNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% euro denominated notes due 2030</link:label>
    <link:label id="lab_lly_A2125EuroDenominatedNotesDue2030Member_label_en-US" xlink:label="lab_lly_A2125EuroDenominatedNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Euro-denominated Notes Due 2030 [Member]</link:label>
    <link:label id="lab_lly_A2125EuroDenominatedNotesDue2030Member_documentation_en-US" xlink:label="lab_lly_A2125EuroDenominatedNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Euro-denominated Notes Due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2125EuroDenominatedNotesDue2030Member" xlink:href="lly-20221231.xsd#lly_A2125EuroDenominatedNotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2125EuroDenominatedNotesDue2030Member" xlink:to="lab_lly_A2125EuroDenominatedNotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_32ad9bc7-629d-4a77-a1bb-079039a355b2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories&#8212;(increase) decrease</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A235NotesDue2022Member_72565a48-cdbd-4c7f-b2ba-5d657f32ab38_terseLabel_en-US" xlink:label="lab_lly_A235NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% notes due 2022</link:label>
    <link:label id="lab_lly_A235NotesDue2022Member_label_en-US" xlink:label="lab_lly_A235NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_lly_A235NotesDue2022Member_documentation_en-US" xlink:label="lab_lly_A235NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A235NotesDue2022Member" xlink:href="lly-20221231.xsd#lly_A235NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A235NotesDue2022Member" xlink:to="lab_lly_A235NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_8cbe85c4-ee1b-4ebf-8bf1-02d05834015e_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_88fef81c-3b2b-40a2-a1bc-aef71fe6bfd9_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_9c2fe410-9b43-4f5c-8058-84ab2ce04674_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (approximates replacement cost)</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_aa862716-ea41-4626-ad08-7bfda405a737_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill (Note 8)</link:label>
    <link:label id="lab_us-gaap_Goodwill_95a983c5-eb25-48da-b563-592870cdd7ca_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_b36358b2-e3e8-434e-9982-bbfce15d8d1b_netLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_2769b8e6-3d67-4ddf-b255-34cf45633b2b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_a84648d7-f2fb-4a0b-b6c9-56b03038e5ae_terseLabel_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales</link:label>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_label_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity and Available for Sale Securities</link:label>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_documentation_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity and Available for Sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:href="lly-20221231.xsd#lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:to="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60942231-0d71-40fa-b10f-f1aaf9df8356_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_2119c1a9-bba4-4eeb-bb0d-19c69e039522_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_5fb58d71-7ebc-486b-bc3f-9fef6f3011db_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term notes</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_1884d0fa-e0e3-4195-b5f9-d7d76a4f14af_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Net Gains (Losses) on&#160;Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityFundsMember_261c3ade-427d-41d3-bbb9-149835234cf2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-like funds</link:label>
    <link:label id="lab_us-gaap_EquityFundsMember_label_en-US" xlink:label="lab_us-gaap_EquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFundsMember" xlink:to="lab_us-gaap_EquityFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A42YenDenominatedNotesDue2029Member_cb6a3567-5e5a-40c3-9291-47d115d2e920_terseLabel_en-US" xlink:label="lab_lly_A42YenDenominatedNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.42% Japanese yen denominated notes due 2029</link:label>
    <link:label id="lab_lly_A42YenDenominatedNotesDue2029Member_label_en-US" xlink:label="lab_lly_A42YenDenominatedNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.42% Yen-denominated Notes Due 2029 [Member]</link:label>
    <link:label id="lab_lly_A42YenDenominatedNotesDue2029Member_documentation_en-US" xlink:label="lab_lly_A42YenDenominatedNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.42% Yen-denominated Notes Due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A42YenDenominatedNotesDue2029Member" xlink:href="lly-20221231.xsd#lly_A42YenDenominatedNotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A42YenDenominatedNotesDue2029Member" xlink:to="lab_lly_A42YenDenominatedNotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_17125044-9526-45cf-a751-c543b5ef882b_terseLabel_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and obligations percent (up to)</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_label_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations Percent</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_documentation_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:href="lly-20221231.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:to="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_03b9f353-2b28-483a-a04a-7db53d82ace1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5c6f4f88-cb3c-49cf-ad71-38e9b7f834e7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes (Note 14)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_470e4858-9098-4355-a7cc-4fe329826f20_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e0dcfd21-11a0-428a-89d6-6e73d433812f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_e0f4610f-2228-4877-b2b4-5f499281e1ef_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_f04ecabc-dc06-45f6-86e7-12f06dd7a3ef_terseLabel_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1-3 Years</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_label_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_documentation_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" xlink:href="lly-20221231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" xlink:to="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_a5d01528-1e6e-466a-8f5b-e884e4af47ee_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowances</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_6886ed53-c88f-4d96-bff8-32c674bae9f8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities (Note 14)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TrulicityMemberMember_b147316d-02a9-48b6-a792-b6e678fd407a_terseLabel_en-US" xlink:label="lab_lly_TrulicityMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity&#174;</link:label>
    <link:label id="lab_lly_TrulicityMemberMember_label_en-US" xlink:label="lab_lly_TrulicityMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity [Member] [Member]</link:label>
    <link:label id="lab_lly_TrulicityMemberMember_documentation_en-US" xlink:label="lab_lly_TrulicityMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMemberMember" xlink:href="lly-20221231.xsd#lly_TrulicityMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TrulicityMemberMember" xlink:to="lab_lly_TrulicityMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b2a7b3d4-5082-4232-9906-e9e4fcbf6438_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_58820f60-5cea-4cac-97bb-9d5c7c11522d_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_a4ba3002-fd46-4f00-8068-466b074444e1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PurchasedInProcessResearchAndDevelopment_3e8e1d44-3aac-45c9-89ea-f1067709b458_negatedTerseLabel_en-US" xlink:label="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of in-process research and development</link:label>
    <link:label id="lab_lly_PurchasedInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased in-process research and development</link:label>
    <link:label id="lab_lly_PurchasedInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasedInProcessResearchAndDevelopment" xlink:href="lly-20221231.xsd#lly_PurchasedInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PurchasedInProcessResearchAndDevelopment" xlink:to="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d75104db-f209-443d-9c77-db9ee3eb35ba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DiabetesMember_4a97b7bf-5b3d-4b37-9022-615634abcfab_terseLabel_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes</link:label>
    <link:label id="lab_lly_DiabetesMember_label_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes [Member]</link:label>
    <link:label id="lab_lly_DiabetesMember_documentation_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember" xlink:href="lly-20221231.xsd#lly_DiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DiabetesMember" xlink:to="lab_lly_DiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_2fbf12d6-644f-4859-aa41-92a25664f09e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_51745bb3-a5b2-4f88-9d2c-73e3da06c77e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35aa85e2-888e-4688-8b97-cd1ea3a0d07c_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_64c10998-67df-40e8-baf8-b520a3e6a285_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_412ac3d4-5008-464e-8b58-dd0def774905_terseLabel_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gross losses on sales</link:label>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_label_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale Securities and Equity Securities, FV-NI, Realized Loss</link:label>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_documentation_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale Securities and Equity Securities, FV-NI, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:href="lly-20221231.xsd#lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:to="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_29be7b3c-616f-43be-993a-1800edf622f5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;no par value Authorized shares: 3,200,000 Issued shares: 950,632 (2022)&#160;and 954,116 (2021)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_96fc4d53-7b71-48b8-a0ce-9d3145384487_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_168dcd4a-6215-4c36-a54a-f20e7966725f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_2cf021cf-18fb-4f72-83ba-c5250e819001_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_beeb0cf8-8357-4d07-8cc4-d4b50f7fbfb2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_d68c9974-3dc4-47ab-a1f0-784a2556271e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Portion of Risk-Management Instruments that was Recognized in Other Comprehensive Income (Loss), Cash Flow Hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_328bcb8d-7a3c-4004-8508-14d1c055dd97_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_7776d801-c075-4c49-9a08-3e81fdba1800_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_62d10286-907c-4641-aa6b-5de3f3b3d0e1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_ea9600b4-f50e-4a16-ae8a-54a089ae8733_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_887fe12a-e4bf-4856-975d-4750db347b18_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the Fair Value of Available-for-Sale Securities in an Unrealized Gain or Loss Position</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_ba9d9afa-462b-4d88-93ea-d43fc7e14df6_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_00e5c787-3439-40fa-9731-e8f200697b1f_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_37ab5bfb-525e-427a-895b-07d968058b64_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of securities in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_37ee2dc3-5cf4-40eb-b6b6-a552fc5b4817_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_a318b5b5-f1ea-4e95-97ef-19d67fa3537e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A97YenDenominatedNotesDue2049Member_5c7fef98-b71e-46a6-bf9e-9737a001c0cf_terseLabel_en-US" xlink:label="lab_lly_A97YenDenominatedNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.97% Japanese yen denominated notes due 2049</link:label>
    <link:label id="lab_lly_A97YenDenominatedNotesDue2049Member_label_en-US" xlink:label="lab_lly_A97YenDenominatedNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.97% Yen-denominated Notes Due 2049 [Member]</link:label>
    <link:label id="lab_lly_A97YenDenominatedNotesDue2049Member_documentation_en-US" xlink:label="lab_lly_A97YenDenominatedNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.97% Yen-denominated Notes Due 2049</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A97YenDenominatedNotesDue2049Member" xlink:href="lly-20221231.xsd#lly_A97YenDenominatedNotesDue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A97YenDenominatedNotesDue2049Member" xlink:to="lab_lly_A97YenDenominatedNotesDue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_7504d903-67f4-4c39-a546-157c75af6f43_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_f0215969-7df0-43ba-ad59-23a44506282c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value hedges</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_02aac6db-271a-44ac-95f8-27bea76d8e3c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amortization period</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_22f0458e-c9fa-4886-809f-205292ed108e_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax (Note 17)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PaymentsForAssetAcquisitions_673b40c3-369f-4408-abdd-91a7be3ab38f_terseLabel_en-US" xlink:label="lab_lly_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D Expense</link:label>
    <link:label id="lab_lly_PaymentsForAssetAcquisitions_label_en-US" xlink:label="lab_lly_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions</link:label>
    <link:label id="lab_lly_PaymentsForAssetAcquisitions_documentation_en-US" xlink:label="lab_lly_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForAssetAcquisitions" xlink:href="lly-20221231.xsd#lly_PaymentsForAssetAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PaymentsForAssetAcquisitions" xlink:to="lab_lly_PaymentsForAssetAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_f9e2c0e9-62a8-4638-8198-e8aa25f806b8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value Information, Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuefromContractPaymentTermMaximum_1b555594-49e5-4053-97b3-a41f2a5391c2_terseLabel_en-US" xlink:label="lab_lly_RevenuefromContractPaymentTermMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, payment terms, days from date of shipment, maximum</link:label>
    <link:label id="lab_lly_RevenuefromContractPaymentTermMaximum_label_en-US" xlink:label="lab_lly_RevenuefromContractPaymentTermMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract, Payment Term, Maximum</link:label>
    <link:label id="lab_lly_RevenuefromContractPaymentTermMaximum_documentation_en-US" xlink:label="lab_lly_RevenuefromContractPaymentTermMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract, Payment Term, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuefromContractPaymentTermMaximum" xlink:href="lly-20221231.xsd#lly_RevenuefromContractPaymentTermMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuefromContractPaymentTermMaximum" xlink:to="lab_lly_RevenuefromContractPaymentTermMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A3875NotesDue2039Member_e71d8558-68f0-4c83-9827-5fa5b3d4e90e_terseLabel_en-US" xlink:label="lab_lly_A3875NotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% notes due 2039</link:label>
    <link:label id="lab_lly_A3875NotesDue2039Member_label_en-US" xlink:label="lab_lly_A3875NotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Notes Due 2039 [Member]</link:label>
    <link:label id="lab_lly_A3875NotesDue2039Member_documentation_en-US" xlink:label="lab_lly_A3875NotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2039 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3875NotesDue2039Member" xlink:href="lly-20221231.xsd#lly_A3875NotesDue2039Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A3875NotesDue2039Member" xlink:to="lab_lly_A3875NotesDue2039Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f9654925-d4dc-4cc7-b892-dfdfa183d82f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gross gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_844a8a15-8d75-4b75-9b08-725c9246be19_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e589b799-c8b7-486b-a27a-6040c2aa973b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_3cf57ce1-249f-40d5-b759-183bc1354f33_terseLabel_en-US" xlink:label="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic and Puerto Rican companies contribution</link:label>
    <link:label id="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_label_en-US" xlink:label="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic and Puerto Rican Contribution to Income before Income Taxes</link:label>
    <link:label id="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_documentation_en-US" xlink:label="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent contribution of most significant (domestic, including Puerto Rico) areas that contributed to the consolidated income (loss) before income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" xlink:href="lly-20221231.xsd#lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" xlink:to="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_2cab16fe-db47-4366-a655-f6fcaa4bd3a7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_eb5d0b2a-9f97-4b21-9d90-ee72916da378_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_d185fd7c-8d5d-4142-b905-49fd76c733cb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_f5e20846-5c13-4a92-b01f-bb817fa1c989_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A625Notesdue2031Member_f62bca54-f951-4733-838d-716021aca005_terseLabel_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.625% Notes due 2031</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_label_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_documentation_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member" xlink:href="lly-20221231.xsd#lly_A625Notesdue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A625Notesdue2031Member" xlink:to="lab_lly_A625Notesdue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuefromContractPaymentTermMinimum_66f1f6f6-f489-460b-b207-996742a35a6e_terseLabel_en-US" xlink:label="lab_lly_RevenuefromContractPaymentTermMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, payment terms, days from date of shipment, minimum</link:label>
    <link:label id="lab_lly_RevenuefromContractPaymentTermMinimum_label_en-US" xlink:label="lab_lly_RevenuefromContractPaymentTermMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract, Payment Term, Minimum</link:label>
    <link:label id="lab_lly_RevenuefromContractPaymentTermMinimum_documentation_en-US" xlink:label="lab_lly_RevenuefromContractPaymentTermMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuefromContractPaymentTermMinimum" xlink:href="lly-20221231.xsd#lly_RevenuefromContractPaymentTermMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuefromContractPaymentTermMinimum" xlink:to="lab_lly_RevenuefromContractPaymentTermMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a9512ebc-3946-484f-b17f-a585add0c2cb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ee00fb58-e079-4e27-b98b-f16ed7108d95_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7c1f9342-8266-4e98-976e-4f64e2e91ed3_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation_36ee73d4-8cc6-4c95-a7fd-3960d075da86_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes related to the impact of foreign currency translation</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_2a471d54-020f-4676-b08f-749b9e3cf221_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_d74eab66-0d35-483c-a517-df3f48b68d5a_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_67820915-abf7-4682-9f76-7fcb0bc3477b_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_d61b096a-7d05-4322-aa10-33735f93789a_terseLabel_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, sales returns, product expiration date</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_label_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Returns, Product Expiration Date</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_documentation_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Returns, Product Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" xlink:href="lly-20221231.xsd#lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" xlink:to="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f3da2715-7c79-4487-b1ad-0a6cb4547d91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_92bf3d15-f517-4e67-af56-e05d9d7d0eda_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-Net, (Income) Expense</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_a39da163-fdd5-4612-ae42-2fd7e61b6ad6_terseLabel_en-US" xlink:label="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average remaining maturity of foreign currency derivatives</link:label>
    <link:label id="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_label_en-US" xlink:label="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Remaining Maturity of Foreign Currency Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:to="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_429c1bd9-4938-4f76-9ec9-50ef57b315ed_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowances</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c8f272fc-2262-4544-8790-db917473b5a0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_11f4d480-c82a-495b-8f9e-6ac3fb291e6a_verboseLabel_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development and development milestones (Note 3)</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_f20a7690-6c3e-4643-8ee1-225ed5cb32fa_terseLabel_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development and development milestones</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_label_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In-Process Research And Development And Development Milestones</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_documentation_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In-Process Research And Development And Development Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" xlink:href="lly-20221231.xsd#lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" xlink:to="lab_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_937ded71-d1be-427c-a754-958d68df394a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b9abcbd7-6cdb-4d08-abf8-5376165772f3_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MaturityDate2023Member_4224dfcb-31f7-4b0c-88d9-ef2ec7a7d910_terseLabel_en-US" xlink:label="lab_lly_MaturityDate2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date, 2019</link:label>
    <link:label id="lab_lly_MaturityDate2023Member_label_en-US" xlink:label="lab_lly_MaturityDate2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date, 2023 [Member]</link:label>
    <link:label id="lab_lly_MaturityDate2023Member_documentation_en-US" xlink:label="lab_lly_MaturityDate2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date, 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2023Member" xlink:href="lly-20221231.xsd#lly_MaturityDate2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MaturityDate2023Member" xlink:to="lab_lly_MaturityDate2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cfe3cf92-74eb-42cd-ba62-f507f2b414a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2f03a64e-df51-453c-bc81-30079c1ca1fc_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents (Note 7)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_9f3dbc5f-119f-47ca-b1f7-267708506845_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_5d1eb71e-7e41-439e-98e9-a401b6848bce_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment gains on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_f98bd655-932e-4746-9053-84cfc1741a84_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment (gains) losses on equity securities (Note 7)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_b4d39670-7492-4864-8dda-4d59016bdf1b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_d1619d3b-2147-4d81-b3e7-c1f5caed5942_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_7d6318b0-ec3b-4825-9cfa-7d403abeb8b6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cc5587db-703f-4219-a3e3-ef96b47570c7_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_bc5edb39-67fb-4c8b-a830-dcb03655e329_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_450bc4de-9326-473d-9a1c-0ce80beb4275_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_e2cb99d9-e4bd-433d-a70d-95cf9adc1dfb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_917c4a77-b833-4a6f-a2af-d90fb2ad91a1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A37NotesDue2045Member_e8aa2225-48cf-4d87-b245-2fb743a4f3f6_terseLabel_en-US" xlink:label="lab_lly_A37NotesDue2045Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.7% notes due 2045</link:label>
    <link:label id="lab_lly_A37NotesDue2045Member_label_en-US" xlink:label="lab_lly_A37NotesDue2045Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.7% Notes Due 2045 [Member]</link:label>
    <link:label id="lab_lly_A37NotesDue2045Member_documentation_en-US" xlink:label="lab_lly_A37NotesDue2045Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.7% Notes Due 2045</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A37NotesDue2045Member" xlink:href="lly-20221231.xsd#lly_A37NotesDue2045Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A37NotesDue2045Member" xlink:to="lab_lly_A37NotesDue2045Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_a4bf73bd-8696-4ba2-bbc3-6f427f0b5468_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_c0c39bb8-ce21-4d3d-b091-8cc2c30f1d0e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrustShares_434e33ca-e122-493c-ada0-d7fb57a31e71_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrustShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares held in employee trust (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrustShares_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrustShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Held in Employee Trust, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrustShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrustShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesHeldInEmployeeTrustShares" xlink:to="lab_us-gaap_CommonStockSharesHeldInEmployeeTrustShares" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_COVID19AntibodiesMember_beff3dd1-1d2e-4ea0-a2ff-18fcec57ce2a_verboseLabel_en-US" xlink:label="lab_lly_COVID19AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 antibodies</link:label>
    <link:label id="lab_lly_COVID19AntibodiesMember_c40965cd-c948-4f35-b278-869040531232_terseLabel_en-US" xlink:label="lab_lly_COVID19AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Antibodies</link:label>
    <link:label id="lab_lly_COVID19AntibodiesMember_label_en-US" xlink:label="lab_lly_COVID19AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Antibodies [Member]</link:label>
    <link:label id="lab_lly_COVID19AntibodiesMember_documentation_en-US" xlink:label="lab_lly_COVID19AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Antibodies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember" xlink:href="lly-20221231.xsd#lly_COVID19AntibodiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_COVID19AntibodiesMember" xlink:to="lab_lly_COVID19AntibodiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BioMarinPharmaceuticalIncMember_3c48f62a-6b47-42e5-80c5-efc155596bc4_terseLabel_en-US" xlink:label="lab_lly_BioMarinPharmaceuticalIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioMarin Pharmaceutical Inc.</link:label>
    <link:label id="lab_lly_BioMarinPharmaceuticalIncMember_label_en-US" xlink:label="lab_lly_BioMarinPharmaceuticalIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioMarin Pharmaceutical Inc [Member]</link:label>
    <link:label id="lab_lly_BioMarinPharmaceuticalIncMember_documentation_en-US" xlink:label="lab_lly_BioMarinPharmaceuticalIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioMarin Pharmaceutical Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BioMarinPharmaceuticalIncMember" xlink:href="lly-20221231.xsd#lly_BioMarinPharmaceuticalIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BioMarinPharmaceuticalIncMember" xlink:to="lab_lly_BioMarinPharmaceuticalIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_10337180-ef90-4de4-82c3-a3c784225cc5_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c3bcf4e2-deb3-4b09-8d00-aa5ba7386761_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_21247bcf-d10b-41b1-af3a-516c11cf65a4_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaid_a024e43d-68f3-4900-b520-efcf7c16db6a_totalLabel_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaid" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaid_label_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaid_documentation_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaid" xlink:href="lly-20221231.xsd#lly_TaxCutAndJobsActTollTaxToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaxCutAndJobsActTollTaxToBePaid" xlink:to="lab_lly_TaxCutAndJobsActTollTaxToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_54f98945-9d2b-4b3d-a5b0-fcd8bc2838a8_terseLabel_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of securities in an unrealized gain position</link:label>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_label_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain Position</link:label>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_documentation_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:href="lly-20221231.xsd#lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:to="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock_d807ce1d-8e6d-4d71-b45b-7cc30e4eb486_terseLabel_en-US" xlink:label="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Stock-Based Compensation Disclosures</link:label>
    <link:label id="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock_label_en-US" xlink:label="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]</link:label>
    <link:label id="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock_documentation_en-US" xlink:label="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" xlink:href="lly-20221231.xsd#lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" xlink:to="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyGBPSellUSDMember_a1f0abfa-2bfa-429c-b383-dfa72558bb3c_terseLabel_en-US" xlink:label="lab_lly_BuyGBPSellUSDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy GBP Sell USD</link:label>
    <link:label id="lab_lly_BuyGBPSellUSDMember_label_en-US" xlink:label="lab_lly_BuyGBPSellUSDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy GBP Sell USD [Member]</link:label>
    <link:label id="lab_lly_BuyGBPSellUSDMember_documentation_en-US" xlink:label="lab_lly_BuyGBPSellUSDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy GBP Sell USD</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyGBPSellUSDMember" xlink:href="lly-20221231.xsd#lly_BuyGBPSellUSDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyGBPSellUSDMember" xlink:to="lab_lly_BuyGBPSellUSDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AuditInformationAbstract_label_en-US" xlink:label="lab_lly_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_lly_AuditInformationAbstract_documentation_en-US" xlink:label="lab_lly_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AuditInformationAbstract" xlink:href="lly-20221231.xsd#lly_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AuditInformationAbstract" xlink:to="lab_lly_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_04285064-86bb-48ee-a862-a883cdcb235a_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments (Note 7)</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_3d6febb9-0bcc-4863-8a19-a9026f117bf3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_7ba4d25d-7da1-483a-ba77-55a2f1165702_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_6fdc820c-a0eb-4196-8c02-ac680a937963_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivables_1ab42ff7-964d-4907-83fb-2c7dcf1b3f6a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivables_label_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivables" xlink:to="lab_us-gaap_OtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A5000NotesDue2033Member_48465bd1-b764-4a81-a7e7-a7a5d6cd73eb_terseLabel_en-US" xlink:label="lab_lly_A5000NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2033</link:label>
    <link:label id="lab_lly_A5000NotesDue2033Member_faabf4a4-db29-4965-ad31-54392b85b33b_verboseLabel_en-US" xlink:label="lab_lly_A5000NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.50% euro denominated notes due 2033</link:label>
    <link:label id="lab_lly_A5000NotesDue2033Member_label_en-US" xlink:label="lab_lly_A5000NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.5000% Notes Due 2033 [Member]</link:label>
    <link:label id="lab_lly_A5000NotesDue2033Member_documentation_en-US" xlink:label="lab_lly_A5000NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.5000% Notes Due 2033</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A5000NotesDue2033Member" xlink:href="lly-20221231.xsd#lly_A5000NotesDue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A5000NotesDue2033Member" xlink:to="lab_lly_A5000NotesDue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_UNITEDSTATESAndPUERTORICOMember_80db3165-897a-4b56-85c6-e2ab0a40ea19_verboseLabel_en-US" xlink:label="lab_lly_UNITEDSTATESAndPUERTORICOMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. and Puerto Rico</link:label>
    <link:label id="lab_lly_UNITEDSTATESAndPUERTORICOMember_label_en-US" xlink:label="lab_lly_UNITEDSTATESAndPUERTORICOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES And PUERTO RICO [Member]</link:label>
    <link:label id="lab_lly_UNITEDSTATESAndPUERTORICOMember_documentation_en-US" xlink:label="lab_lly_UNITEDSTATESAndPUERTORICOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES And PUERTO RICO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_UNITEDSTATESAndPUERTORICOMember" xlink:href="lly-20221231.xsd#lly_UNITEDSTATESAndPUERTORICOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_UNITEDSTATESAndPUERTORICOMember" xlink:to="lab_lly_UNITEDSTATESAndPUERTORICOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cf75d582-82fb-4a80-9126-723fc6a892cc_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5c677462-f0a6-4770-81ad-7c255b0474c7_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_427ef9b4-2d1a-498a-bea2-875556a3a063_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_996cb27b-7bd0-46c0-a89a-b667591a8bbf_terseLabel_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation</link:label>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_label_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation [Member]</link:label>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_documentation_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember" xlink:href="lly-20221231.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmgalityPatentLitigationMember" xlink:to="lab_lly_EmgalityPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4cb2d32d-65f3-445d-baca-958771b48bed_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in calculation of earnings per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_3f9c95a4-932f-40a9-a0fe-3927b6378cb7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories (Note 6)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_8a199e15-3b28-4e60-8190-a9b2c2f53750_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AkouosAcquisitionMember_6abcb1b9-c5aa-49bf-af7f-70e23de9a5b5_terseLabel_en-US" xlink:label="lab_lly_AkouosAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akouos Acquisition</link:label>
    <link:label id="lab_lly_AkouosAcquisitionMember_label_en-US" xlink:label="lab_lly_AkouosAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akouos Acquisition [Member]</link:label>
    <link:label id="lab_lly_AkouosAcquisitionMember_documentation_en-US" xlink:label="lab_lly_AkouosAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akouos Acquisition [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AkouosAcquisitionMember" xlink:href="lly-20221231.xsd#lly_AkouosAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AkouosAcquisitionMember" xlink:to="lab_lly_AkouosAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b49b7487-be87-4c48-8e0d-eaf6b31b5953_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_609a8def-69bf-49a1-b48a-fb2605169407_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_ce36a99e-3537-4c17-905f-9a7243af4930_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized note discounts</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SellEuroMember_e20ed415-2ea5-4fbc-8436-381c97f8da07_terseLabel_en-US" xlink:label="lab_lly_SellEuroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sell Euro</link:label>
    <link:label id="lab_lly_SellEuroMember_label_en-US" xlink:label="lab_lly_SellEuroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sell Euro [Member]</link:label>
    <link:label id="lab_lly_SellEuroMember_documentation_en-US" xlink:label="lab_lly_SellEuroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sell Euro [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SellEuroMember" xlink:href="lly-20221231.xsd#lly_SellEuroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SellEuroMember" xlink:to="lab_lly_SellEuroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1125NotesDue2051Member_841ff18f-6121-4a00-b27f-461f8931841a_terseLabel_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_a392f1be-c1bd-469d-ba61-e2e3dc04c926_verboseLabel_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% euro denominated notes due 2051</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_label_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes Due 2051 [Member]</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_documentation_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes Due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member" xlink:href="lly-20221231.xsd#lly_A1125NotesDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1125NotesDue2051Member" xlink:to="lab_lly_A1125NotesDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_212a452d-d61a-42c8-85e5-318752f63982_terseLabel_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes due 2026</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_label_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_documentation_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member" xlink:href="lly-20221231.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.625NotesDueJune22026Member" xlink:to="lab_lly_A1.625NotesDueJune22026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7e1713bc-eb15-43a2-b519-d977499229bc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_689d7b0f-cce8-47d8-b302-824cb9b30d25_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in plan assets:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_772e0eab-6477-442e-adb6-6fdfba7ce2f2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets, target allocation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrustForBenefitOfEmployeesMember_50c70c81-4523-4ec8-8d8e-10bf45abb194_terseLabel_en-US" xlink:label="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Trust</link:label>
    <link:label id="lab_us-gaap_TrustForBenefitOfEmployeesMember_label_en-US" xlink:label="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trust for Benefit of Employees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrustForBenefitOfEmployeesMember" xlink:to="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_14cdaa03-3976-4bdc-a695-8f4ae069c957_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e1f3cdcd-d310-410b-b969-34088d20e215_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_25896d8b-fe1c-4096-9e2f-3d00ef0691dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_26963709-6060-4cac-bb57-cc484d50346a_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_392edede-43e6-4bc0-b34d-d350c42d3225_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_a31a4143-b0a2-4f72-abcb-1f28bb7cdf71_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable&#8212;increase (decrease)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A10EuroDenominatedNotesDue2022Member_b49eeef1-cb83-42b9-98f2-8114b46bbc9b_terseLabel_en-US" xlink:label="lab_lly_A10EuroDenominatedNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.00% euro denominated notes due 2022</link:label>
    <link:label id="lab_lly_A10EuroDenominatedNotesDue2022Member_label_en-US" xlink:label="lab_lly_A10EuroDenominatedNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.0% Euro-denominated Notes Due 2022 [Member]</link:label>
    <link:label id="lab_lly_A10EuroDenominatedNotesDue2022Member_documentation_en-US" xlink:label="lab_lly_A10EuroDenominatedNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.0% Euro-denominated Notes Due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A10EuroDenominatedNotesDue2022Member" xlink:href="lly-20221231.xsd#lly_A10EuroDenominatedNotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A10EuroDenominatedNotesDue2022Member" xlink:to="lab_lly_A10EuroDenominatedNotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_e34e9683-4714-48ea-abb0-3a83400f8dd1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings and current maturities of long-term debt (Note 11)</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_b1bda1aa-1f78-45f8-aaa5-626c8213ead6_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_d5aa7576-09f5-4030-b3ae-c508ec8beffd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_6bc7c61b-0f1e-412f-999c-09a1e59c7a78_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_2649127d-6bcf-4d78-9290-f564b963b51e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a71b163d-420e-4af0-9aa7-0ee403e7969b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1ea1adda-37d8-4d94-973e-1c138cd86c61_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_96fd38f8-33df-4e62-8eab-dd69bd6d8c85_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_c2a96ac6-7b6d-40d8-8798-24142c400eb1_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of sites jointly and severally liable for cleanup (fewer than)</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:href="lly-20221231.xsd#lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:to="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_aeaae4f3-0b20-47cd-934a-161163013a3b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange rate changes and other adjustments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2689eeac-48d7-4d7d-9e69-cae9e11bc6d6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_78448fa2-e18d-4791-a6f2-a9fe16fcab9b_terseLabel_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, sales returns, average inventory level (or less)</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_label_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Returns, Average Inventory Level</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_documentation_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Returns, Average Inventory Level</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" xlink:href="lly-20221231.xsd#lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" xlink:to="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_f3bcd21c-e0c0-4919-8666-1f966383b527_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmgalityMember_25cadd52-bc14-4039-a61f-98fcb48b5e95_terseLabel_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality&#174;</link:label>
    <link:label id="lab_lly_EmgalityMember_label_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality [Member]</link:label>
    <link:label id="lab_lly_EmgalityMember_documentation_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember" xlink:href="lly-20221231.xsd#lly_EmgalityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmgalityMember" xlink:to="lab_lly_EmgalityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_b49c1e7b-a4f2-4cf3-b4d8-3c59aa2bd893_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:href="lly-20221231.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:to="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.700Notesdue2049Member_87a8767d-8694-4a03-84d7-e6acfb36bcf0_terseLabel_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_label_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_documentation_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member" xlink:href="lly-20221231.xsd#lly_A1.700Notesdue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.700Notesdue2049Member" xlink:to="lab_lly_A1.700Notesdue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_8c6b4873-666b-43cf-b03b-617d22acb9c7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f412fddd-c5e0-486a-9d66-25e2e59ce6ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_cd70f529-5f36-49e3-9572-9421d06edfba_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_a5bad85f-8ed9-4a1e-9d96-ba141ab19adc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect from hedged fixed-rate debt</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_4515e874-615c-4d76-b2d9-bd4c311a20b4_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of debt, amount</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_af3b366f-1a82-4145-b6f2-6f0859056715_terseLabel_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_label_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_documentation_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts" xlink:href="lly-20221231.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SalesRebatesAndDiscounts" xlink:to="lab_lly_SalesRebatesAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c688995c-be6a-4c35-a1bb-7dee11d83424_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a9fd101f-9a7c-4c9c-8cc3-c7fe741c46ac_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisitions, net of cash acquired (Note 3)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d0690a40-11e5-4ae1-8e98-8d7fb9a5851a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_e9b7b8cf-9dbc-41e6-bcd0-f526002d4e7b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6ff18fbe-59bb-432e-9e8e-ec72af5b84f6_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_dfafcb8d-7754-44f6-9133-91c6afe0e32c_negatedTotalLabel_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_label_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized</link:label>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_documentation_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized" xlink:href="lly-20221231.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized" xlink:to="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CialisMember_a7672e77-ad57-4d1e-820d-1120cea776b4_terseLabel_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis&#174;</link:label>
    <link:label id="lab_lly_CialisMember_label_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis [Member]</link:label>
    <link:label id="lab_lly_CialisMember_documentation_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember" xlink:href="lly-20221231.xsd#lly_CialisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CialisMember" xlink:to="lab_lly_CialisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_3422ed48-6c5c-499a-82fb-10e69ac7099b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_cac1e956-f1ca-4672-a441-317660c0677b_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangibles, net (Note 8)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_2605c12e-b279-40b5-b644-ba7aafbe2f99_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_83f587a6-b48a-418b-ba93-3369c85f83b6_terseLabel_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other securities, noncurrent investments</link:label>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_label_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equity Securities [Member]</link:label>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_documentation_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember" xlink:href="lly-20221231.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherEquitySecuritiesMember" xlink:to="lab_lly_OtherEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDerivatives_820eb272-ba14-43ba-803f-06bad77054c5_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDerivatives_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_66fe5542-beb9-42a9-938f-ab67ce588e8e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_57365105-c802-496b-b1e7-7d1a3f94badd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_b0d2e664-aeb1-48f2-8163-5823b6901704_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_282532a0-d5bd-4731-b6ca-2635fb3a74c2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term income taxes payable (Note 14)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b642bcfc-b6fb-404a-91d7-0873e3420196_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_61cc9e84-5495-41c5-854a-2986bb4e143f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_d1e9b69d-3d3c-4312-8fa8-f02332967dc1_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_1bda1906-73c7-4399-aad4-1f01aafa88b5_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payments Received</link:label>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:to="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_eaf3c9d0-aead-478e-b771-9b0d672dd8a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9bca3512-81a4-4a84-bfc5-3bfabeae044c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financing activities, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_b6ced3bc-2ba8-43be-b02d-71ffb9dfc233_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets, indefinite-lived</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1375NotesDue2061Member_08342a63-710a-4882-a9a3-295005739ee8_terseLabel_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_012bed94-828a-4fdc-a1fe-b8a29862290c_verboseLabel_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% euro denominated notes due 2061</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_label_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes Due 2061 [Member]</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_documentation_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes Due 2061</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member" xlink:href="lly-20221231.xsd#lly_A1375NotesDue2061Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1375NotesDue2061Member" xlink:to="lab_lly_A1375NotesDue2061Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_57313711-f6e4-4de1-bb21-b89d7793b52a_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_cd350b43-2cee-4856-945d-8ebe0997fbed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_31728b35-42ad-494c-b933-dc3ab35b1ca7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4f1eb321-5e07-40f3-b303-9ee99b7c11ee_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A3375NotesDue2029Member_c52e738a-841a-42a4-a621-6fb4dbfde269_terseLabel_en-US" xlink:label="lab_lly_A3375NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% notes due 2029</link:label>
    <link:label id="lab_lly_A3375NotesDue2029Member_label_en-US" xlink:label="lab_lly_A3375NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes Due 2029 [Member]</link:label>
    <link:label id="lab_lly_A3375NotesDue2029Member_documentation_en-US" xlink:label="lab_lly_A3375NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes Due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member" xlink:href="lly-20221231.xsd#lly_A3375NotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A3375NotesDue2029Member" xlink:to="lab_lly_A3375NotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherContractMember_83cf3214-3eea-4bdf-ad70-49d20a236f82_terseLabel_en-US" xlink:label="lab_us-gaap_OtherContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash value of trust owned insurance contract</link:label>
    <link:label id="lab_us-gaap_OtherContractMember_label_en-US" xlink:label="lab_us-gaap_OtherContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherContractMember" xlink:to="lab_us-gaap_OtherContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AdvertisingExpensePercentageOfRevenue_60b254be-1e46-48bc-8d0f-909e905c49dd_terseLabel_en-US" xlink:label="lab_lly_AdvertisingExpensePercentageOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense, percentage of revenue</link:label>
    <link:label id="lab_lly_AdvertisingExpensePercentageOfRevenue_label_en-US" xlink:label="lab_lly_AdvertisingExpensePercentageOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense, Percentage Of Revenue</link:label>
    <link:label id="lab_lly_AdvertisingExpensePercentageOfRevenue_documentation_en-US" xlink:label="lab_lly_AdvertisingExpensePercentageOfRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense, Percentage Of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AdvertisingExpensePercentageOfRevenue" xlink:href="lly-20221231.xsd#lly_AdvertisingExpensePercentageOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AdvertisingExpensePercentageOfRevenue" xlink:to="lab_lly_AdvertisingExpensePercentageOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_db5671c0-79d6-47e4-8bf6-a752d2dafa8f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e8388bfa-083f-472d-931b-840dca709763_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_a7fb94ed-d892-47b3-9e7d-37bab3a3a35f_terseLabel_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action</link:label>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_label_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:to="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_f2db5083-c07f-465c-bf44-8125b1a086c7_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ForteoMember_c954bdf1-54b5-49c5-a418-7aee0a002cee_terseLabel_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo&#174;</link:label>
    <link:label id="lab_lly_ForteoMember_label_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo [Member]</link:label>
    <link:label id="lab_lly_ForteoMember_documentation_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember" xlink:href="lly-20221231.xsd#lly_ForteoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ForteoMember" xlink:to="lab_lly_ForteoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_e22629dc-2f84-4815-842d-04ab3beac18c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and benefits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_56be563d-adae-45b4-810e-b416e5664a4e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized net actuarial (gain) loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_28623b2c-4c2e-47d2-a007-d801fea3bb6e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5e0780aa-2189-4df9-bcf6-c022f37d6618_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MaturityDate2026Member_5bf563ea-4d76-4907-a306-630533e0b10a_terseLabel_en-US" xlink:label="lab_lly_MaturityDate2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date, 2023</link:label>
    <link:label id="lab_lly_MaturityDate2026Member_label_en-US" xlink:label="lab_lly_MaturityDate2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date, 2026 [Member]</link:label>
    <link:label id="lab_lly_MaturityDate2026Member_documentation_en-US" xlink:label="lab_lly_MaturityDate2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2026Member" xlink:href="lly-20221231.xsd#lly_MaturityDate2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MaturityDate2026Member" xlink:to="lab_lly_MaturityDate2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RocheMember_9f5d157b-1e7f-49f8-89bb-48f4fa300286_terseLabel_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_lly_RocheMember_label_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_lly_RocheMember_documentation_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember" xlink:href="lly-20221231.xsd#lly_RocheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RocheMember" xlink:to="lab_lly_RocheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_d491e517-a405-4830-8e1a-4b676c59305c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Operating Cost and Expense, by Component</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e1a83a5b-da33-4583-87a2-c54981dd5f0b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_3d8f97a2-07d9-470b-8b65-120a7eb25be9_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_571de7ec-4833-4178-ba11-72742ca8deb3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_110f4576-d41c-40af-ac4c-66253a370917_terseLabel_en-US" xlink:label="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares expected to be issued (in shares)</link:label>
    <link:label id="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_label_en-US" xlink:label="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued</link:label>
    <link:label id="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_documentation_en-US" xlink:label="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares expected to be issued in the next twelve months under the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" xlink:href="lly-20221231.xsd#lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" xlink:to="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_46eedd33-4ffb-4683-9103-801e12d7ff78_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b0352cd7-9bf4-4986-a52b-eb1e43055a44_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_c1aca69b-8d00-4d95-b56e-412cfdd2cf20_terseLabel_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Euro Sell USD</link:label>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_label_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Euro Sell Us Dollar [Member]</link:label>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_documentation_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Forward Commitment to Buy euro Sell US dollar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember" xlink:href="lly-20221231.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyEuroSellUsDollarMember" xlink:to="lab_lly_BuyEuroSellUsDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc723a4b-ad6c-47d2-971d-e3dff0451a05_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_7bf446d0-fc3d-41a6-8cd2-3885297bfc05_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations and Other Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_b91e779a-025e-48b0-b850-7fa3a7c74d66_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_ab62a782-a6bd-4213-b63b-be590f19c401_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_2d23b015-8393-43e8-bd76-e738ea51fa64_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b5072594-61c4-4a6e-a47d-e66d497cc57f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_35892c3e-fd6b-4c86-8224-1ed46f0d75f5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b983a380-43d1-48a2-8d78-8f188508d0e2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_3d9ed815-e455-4078-bbff-74f13ad90276_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_e9ae001d-ec27-4a5b-8b1a-e888450527cc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded commitments to invest in venture capital funds</link:label>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_label_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:to="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_9ef1cae4-d19e-406a-aa1b-cf0fd19e8309_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount recognized</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_45614ed3-39ab-4e48-81ad-a3b7ac6f5159_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateralized Mortgage-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_5db356e4-0d66-4eb2-b4e1-13ddd40cdc59_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange rate changes and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_a95e52b8-5809-4390-b54e-981325e66fb0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share (EPS)</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_80defa36-fff6-4f10-ac8e-870c3b987eab_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_2eb24197-b975-442c-bced-230b11178bb9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8ceefa25-99e4-47ee-bf08-678422e5be72_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_a6186c31-2c5c-42ed-9a6b-a40cb50cff1a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MounjaroMember_53bdb421-0e81-46ec-811d-b6fe3de00daa_terseLabel_en-US" xlink:label="lab_lly_MounjaroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mounjaro&#174;</link:label>
    <link:label id="lab_lly_MounjaroMember_label_en-US" xlink:label="lab_lly_MounjaroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mounjaro [Member]</link:label>
    <link:label id="lab_lly_MounjaroMember_documentation_en-US" xlink:label="lab_lly_MounjaroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mounjaro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MounjaroMember" xlink:href="lly-20221231.xsd#lly_MounjaroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MounjaroMember" xlink:to="lab_lly_MounjaroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_b055708d-401b-4bd4-ae34-be428b8999ef_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DescriptionOfDerivativeActivityVolumePercent_509440ed-76fd-4411-a479-9531ec210d4a_terseLabel_en-US" xlink:label="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of derivative activity volume percent</link:label>
    <link:label id="lab_lly_DescriptionOfDerivativeActivityVolumePercent_label_en-US" xlink:label="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Derivative Activity Volume Percent</link:label>
    <link:label id="lab_lly_DescriptionOfDerivativeActivityVolumePercent_documentation_en-US" xlink:label="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Derivative Activity Volume Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:href="lly-20221231.xsd#lly_DescriptionOfDerivativeActivityVolumePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:to="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_59125a54-f7d5-4381-989a-af417efafc10_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_d07ca6bb-74d1-4565-96ae-8fa0c399134b_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation at beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_fb59bb7e-2ed5-4c60-820c-6b4e24e1fa69_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation at end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b870976c-b333-4ea8-b4d7-8c442bac42ed_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ZyprexaMember_8489fb20-8d4a-4603-9430-2cc3617fcfc5_terseLabel_en-US" xlink:label="lab_lly_ZyprexaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyprexa&#174;</link:label>
    <link:label id="lab_lly_ZyprexaMember_label_en-US" xlink:label="lab_lly_ZyprexaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyprexa [Member]</link:label>
    <link:label id="lab_lly_ZyprexaMember_documentation_en-US" xlink:label="lab_lly_ZyprexaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyprexa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ZyprexaMember" xlink:href="lly-20221231.xsd#lly_ZyprexaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ZyprexaMember" xlink:to="lab_lly_ZyprexaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_7909a8e1-92d4-4f51-ae46-712a5317b636_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_983a6a9b-24cd-4dda-b648-64a4db0f1e20_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 1 Year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_47e7e295-5622-4b03-be8d-f1c72c6dadec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d440b92-249f-4a42-be41-0de7fb2abb1a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_5ae8521c-f400-4cc8-a241-dfd98ba7954b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of compensation increase for net benefit costs</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9447423e-5214-4d30-a6cc-faf397079eb9_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_6722aa7a-7ac3-4150-9843-e58dd9c5ce77_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_9b5e501e-95c5-473e-966c-b08259039639_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reclassifications for the period, net of tax</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_16ab86ba-88e7-476b-9865-5cb04d63f103_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ebebc6f6-216b-4322-a32f-4d111e081a2f_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d1998450-77fa-4fe1-8530-026458434e1f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A045SwissFrancDenominatedNotesDue2028Member_7dc74be2-422d-4dc0-aad3-6a1d6dbf16a5_terseLabel_en-US" xlink:label="lab_lly_A045SwissFrancDenominatedNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.45% Swiss franc denominated notes due 2028</link:label>
    <link:label id="lab_lly_A045SwissFrancDenominatedNotesDue2028Member_label_en-US" xlink:label="lab_lly_A045SwissFrancDenominatedNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.45% Swiss Franc Denominated Notes Due 2028 [Member]</link:label>
    <link:label id="lab_lly_A045SwissFrancDenominatedNotesDue2028Member_documentation_en-US" xlink:label="lab_lly_A045SwissFrancDenominatedNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.45% Swiss Franc Denominated Notes Due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A045SwissFrancDenominatedNotesDue2028Member" xlink:href="lly-20221231.xsd#lly_A045SwissFrancDenominatedNotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A045SwissFrancDenominatedNotesDue2028Member" xlink:to="lab_lly_A045SwissFrancDenominatedNotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_366a876a-aa9f-4822-8e8c-b4ce3bf76799_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f6c0f676-6006-411d-8b26-720edc1196a5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_f025b24d-d5e6-4590-af1f-5e7c25b960f9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A555NotesDue2037Member_aefdd3dc-9715-45e4-b7b8-e7240fb83b3d_terseLabel_en-US" xlink:label="lab_lly_A555NotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.55% notes due 2037</link:label>
    <link:label id="lab_lly_A555NotesDue2037Member_label_en-US" xlink:label="lab_lly_A555NotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.55% Notes Due 2037 [Member]</link:label>
    <link:label id="lab_lly_A555NotesDue2037Member_documentation_en-US" xlink:label="lab_lly_A555NotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.55% Notes Due 2037</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A555NotesDue2037Member" xlink:href="lly-20221231.xsd#lly_A555NotesDue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A555NotesDue2037Member" xlink:to="lab_lly_A555NotesDue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_3b8a499e-3dac-47b2-b1d4-372d7e1574b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired" xlink:to="lab_us-gaap_TreasuryStockSharesRetired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_6e545770-d944-4395-b66b-6e7a3346a670_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_3435f5ba-70dc-4d7e-80fd-fc4f8cff6cca_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded, value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_3063b912-091a-428c-8c61-36fdfa7f3a37_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_3e44b052-4f27-47bf-bf3e-edb1503fbf40_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CashFlowHedgeAbstract_5f76ab75-45bc-487d-86e7-494fb100becb_terseLabel_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_lly_CashFlowHedgeAbstract_label_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge [Abstract]</link:label>
    <link:label id="lab_lly_CashFlowHedgeAbstract_documentation_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract" xlink:href="lly-20221231.xsd#lly_CashFlowHedgeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CashFlowHedgeAbstract" xlink:to="lab_lly_CashFlowHedgeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0fac3c0f-e87f-4c9f-b597-1c39e10b09d8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing activities, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_6ffbbb5a-894b-4a02-89f4-b9de346db22c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_70c98f97-79ea-4216-b692-00aa8ef1e5fb_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_ff2996b8-0ac2-4efa-9bb7-57f4c39aef2d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_3c3b69a7-3a05-4da8-9854-08a9cd46c5ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8f9fc6d7-9a38-4d33-9f42-0312ef8a5aa0_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_63a24533-3c98-4232-a60a-b0796bd90bfd_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapses of statutes of limitation</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_7727d27e-bfc0-4ac6-a1fb-1071a3d5cd68_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f1b6040e-cbdb-4fc4-82a9-057c2a651f4e_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic (benefit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_3e2f68bc-7802-4dae-9751-cc0de49dd00a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_edc82c75-47e7-4efb-8e90-516290d9abfe_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase for treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_3bd8c5bd-2613-438e-a212-fe2648978960_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a6aeb80a-d701-46be-8df8-a4b7cfa571c1_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d97052b5-2c7b-4a92-9d0c-afd6d7e84a96_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1-5 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_1a0eede4-8077-42bd-80e3-023196098966_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_129ddc20-565a-46f6-9b4a-d45e41ab9b20_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_940f4045-0800-457c-b7ef-140d78c0dc5b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_15fe7d7c-27aa-407b-b661-4946cc5e3828_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service (benefit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_5efd23aa-e759-44b7-9fd9-ea8fb173d1f7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of compensation increase for benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A677NotesDue2036Member_f03ed024-e7c0-4a39-b1fd-08cc1542cecd_terseLabel_en-US" xlink:label="lab_lly_A677NotesDue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77% notes due 2036</link:label>
    <link:label id="lab_lly_A677NotesDue2036Member_label_en-US" xlink:label="lab_lly_A677NotesDue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77% Notes Due 2036 [Member]</link:label>
    <link:label id="lab_lly_A677NotesDue2036Member_documentation_en-US" xlink:label="lab_lly_A677NotesDue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77% Notes Due 2036</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A677NotesDue2036Member" xlink:href="lly-20221231.xsd#lly_A677NotesDue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A677NotesDue2036Member" xlink:to="lab_lly_A677NotesDue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A17EuroDenominatedNotesDue2049Member_9d7547b1-05ed-4695-a496-0d73a759fc93_terseLabel_en-US" xlink:label="lab_lly_A17EuroDenominatedNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.70% euro denominated notes due 2049</link:label>
    <link:label id="lab_lly_A17EuroDenominatedNotesDue2049Member_label_en-US" xlink:label="lab_lly_A17EuroDenominatedNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.7% Euro-denominated Notes Due 2049 [Member]</link:label>
    <link:label id="lab_lly_A17EuroDenominatedNotesDue2049Member_documentation_en-US" xlink:label="lab_lly_A17EuroDenominatedNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.7% Euro-deonominated Notes Due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A17EuroDenominatedNotesDue2049Member" xlink:href="lly-20221231.xsd#lly_A17EuroDenominatedNotesDue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A17EuroDenominatedNotesDue2049Member" xlink:to="lab_lly_A17EuroDenominatedNotesDue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_8f69f9af-92d6-48e8-b00e-51d2821fee8f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance release</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_23b6d68f-e05f-4831-8e6e-e573e058106f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_096a96a3-9008-4b44-a402-a49da7665115_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of common stock in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyUsdSellEuroMember_1856f5af-1981-450b-a397-7ffcd77d691c_terseLabel_en-US" xlink:label="lab_lly_BuyUsdSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy USD Sell Euro</link:label>
    <link:label id="lab_lly_BuyUsdSellEuroMember_label_en-US" xlink:label="lab_lly_BuyUsdSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy USD Sell Euro [Member]</link:label>
    <link:label id="lab_lly_BuyUsdSellEuroMember_documentation_en-US" xlink:label="lab_lly_BuyUsdSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy USD Sell Euro [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsdSellEuroMember" xlink:href="lly-20221231.xsd#lly_BuyUsdSellEuroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyUsdSellEuroMember" xlink:to="lab_lly_BuyUsdSellEuroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_ae7f08b6-7879-4542-8de9-59be2098cc88_terseLabel_en-US" xlink:label="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment (gain) and other special charges</link:label>
    <link:label id="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_label_en-US" xlink:label="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges (Recoveries) And Other Special Charges</link:label>
    <link:label id="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_documentation_en-US" xlink:label="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges (Recoveries) And Other Special Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:href="lly-20221231.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:to="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_2afa786d-20cb-4272-a999-6556c2564c49_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_d9609a25-1259-4862-8f39-78a222b70fbc_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_247b0d69-7a04-4014-9cc6-3b0bd52a23f5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets related to state net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_d83bfa1a-cda4-4d66-8e7b-d4597690707c_terseLabel_en-US" xlink:label="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_label_en-US" xlink:label="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Sales Rebates And Discounts</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_documentation_en-US" xlink:label="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Sales Rebates And Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsSalesRebatesAndDiscounts" xlink:href="lly-20221231.xsd#lly_DeferredTaxAssetsSalesRebatesAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DeferredTaxAssetsSalesRebatesAndDiscounts" xlink:to="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_26f8d569-1138-4a14-bba9-e7505470d653_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LesseeLeaseRemainingLeaseTerm_a8209f6f-0adf-4e5e-86e9-703a38dcd3ba_terseLabel_en-US" xlink:label="lab_lly_LesseeLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, lease, remaining lease term (up to)</link:label>
    <link:label id="lab_lly_LesseeLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_lly_LesseeLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Remaining Lease Term</link:label>
    <link:label id="lab_lly_LesseeLeaseRemainingLeaseTerm_documentation_en-US" xlink:label="lab_lly_LesseeLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LesseeLeaseRemainingLeaseTerm" xlink:href="lly-20221231.xsd#lly_LesseeLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LesseeLeaseRemainingLeaseTerm" xlink:to="lab_lly_LesseeLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5c489e17-3c83-4db6-ab1f-d54a2ea6eef1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A625EuroDenominatedNotesDue2031Member_eb8b7e4d-0f93-4fe4-955b-55df0fa52b57_terseLabel_en-US" xlink:label="lab_lly_A625EuroDenominatedNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.625% euro denominated notes due 2031</link:label>
    <link:label id="lab_lly_A625EuroDenominatedNotesDue2031Member_label_en-US" xlink:label="lab_lly_A625EuroDenominatedNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Euro-denominated Notes Due 2031 [Member]</link:label>
    <link:label id="lab_lly_A625EuroDenominatedNotesDue2031Member_documentation_en-US" xlink:label="lab_lly_A625EuroDenominatedNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Euro-deonominated Notes Due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625EuroDenominatedNotesDue2031Member" xlink:href="lly-20221231.xsd#lly_A625EuroDenominatedNotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A625EuroDenominatedNotesDue2031Member" xlink:to="lab_lly_A625EuroDenominatedNotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_6ce09b13-5e99-40db-9fbd-3748a651578f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_1715925a-824e-4f5e-a80e-3e3956a178e9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized prior service (benefit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_3ccd9c32-f2d9-4e76-9ed2-5639f8a0107e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables&#8212;(increase) decrease</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_734be133-d46b-432e-afb8-899065d640bb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A31NotesDue2027Member_589bd0b9-926c-4e60-84cf-20da13744e15_terseLabel_en-US" xlink:label="lab_lly_A31NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.1% notes due 2027</link:label>
    <link:label id="lab_lly_A31NotesDue2027Member_label_en-US" xlink:label="lab_lly_A31NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.1% Notes Due 2027 [Member]</link:label>
    <link:label id="lab_lly_A31NotesDue2027Member_documentation_en-US" xlink:label="lab_lly_A31NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.1% Notes Due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A31NotesDue2027Member" xlink:href="lly-20221231.xsd#lly_A31NotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A31NotesDue2027Member" xlink:to="lab_lly_A31NotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_0aaf1d36-8181-4ac0-ac89-a2c36f98ed6e_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherNeuroscienceMember_eb086425-942b-4121-b304-282d896fe304_terseLabel_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other neuroscience</link:label>
    <link:label id="lab_lly_OtherNeuroscienceMember_label_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience [Member]</link:label>
    <link:label id="lab_lly_OtherNeuroscienceMember_documentation_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember" xlink:href="lly-20221231.xsd#lly_OtherNeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherNeuroscienceMember" xlink:to="lab_lly_OtherNeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_73fcf941-dff8-4be0-8f61-7e3738feba14_terseLabel_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement benefit plans</link:label>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_label_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:to="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_5747908f-3495-4e22-94af-08f36d90c041_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses expected to be reclassified in the next 12 months</link:label>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_label_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:to="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_576dcafe-2830-4367-b3ec-5a243e764fb4_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_d81187f6-d634-499a-8aa3-2fc780ac2b1f_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_60343ebe-7fe7-484d-90f5-aeb71efacb22_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_604ea869-4ca1-4d24-bb88-c4a3bd6b5b1e_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_ff0422e5-199d-4424-bb17-210948711114_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_a355e2a8-dec6-4d93-afc3-7af278d3078a_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_94aa948f-4074-47f6-b899-4629070120ab_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued retirement benefits (Note 15)</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_bcd3172b-41df-4190-a69c-c4411dc060df_negatedNetLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued retirement benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_5ba495e9-4a7f-40ad-8dd0-1d1fff5f3b6a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A25NotesDue2060Member_21d585a0-7eb2-4a11-9c66-a48d7de56f4e_terseLabel_en-US" xlink:label="lab_lly_A25NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% notes due 2060</link:label>
    <link:label id="lab_lly_A25NotesDue2060Member_label_en-US" xlink:label="lab_lly_A25NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.5% Notes Due 2060 [Member]</link:label>
    <link:label id="lab_lly_A25NotesDue2060Member_documentation_en-US" xlink:label="lab_lly_A25NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.5% Notes Due 2060</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A25NotesDue2060Member" xlink:href="lly-20221231.xsd#lly_A25NotesDue2060Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A25NotesDue2060Member" xlink:to="lab_lly_A25NotesDue2060Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_54bcd4ba-a135-4711-9a8a-6d54a64f61a5_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5bda7085-2cc3-4299-8d7e-695e5dda7457_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_adc470ae-42fe-49ef-bc27-fe3a3b8983fb_terseLabel_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, sales rebate payment period (up to)</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_label_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Rebate Payment Period</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_documentation_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Rebate Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" xlink:href="lly-20221231.xsd#lly_RevenuePerformanceObligationSalesRebatePaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" xlink:to="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_30d20b36-02b2-430f-a334-2c96ac6b65c0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_6c201b4f-fafc-4f6d-a531-30fe6d0b1147_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPostretirementHealthCoverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retiree Health Benefit Plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPostretirementHealthCoverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement Health Coverage [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember" xlink:to="lab_us-gaap_DefinedBenefitPostretirementHealthCoverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_03b1a676-0538-4c37-a45b-0af746177fd3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b37cbe69-6dd8-4a4f-8021-2746af976c5d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_2dfaa974-fb2e-499f-a707-0584be6f6f67_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_3bb43b55-9b90-4ebc-a3c6-f4350772dc0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_8be193da-9ce2-450e-86ba-dc692cea1753_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_3eed2348-c220-4ba4-a87f-39e27c7e516d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_ba427297-54dc-4232-bb77-449d512ef89e_terseLabel_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_label_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net</link:label>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_documentation_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:href="lly-20221231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:to="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_21b36f4c-a699-4c6b-a346-8d59d4a9b4f7_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2e79d3ae-bc71-4a2c-882d-45637e00edb1_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_e11ec632-b19b-4887-9d56-9cd9b486106b_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_a2c53ae2-dea8-4247-a09b-5bf86f1f91ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_860de88d-7631-46ba-9179-02e03c3c4161_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5a8a0407-fc22-4262-ae29-9f3df9cc6b02_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_99c90e7f-ba69-403f-b0e3-f277a1eed7f1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_35979566-0233-42e8-98c9-73ea327a9852_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_afc16c91-365c-4671-acf8-150ddc95fea8_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents" xlink:href="lly-20221231.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfPatents" xlink:to="lab_lly_LossContingencyNumberOfPatents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_703dbf94-23bc-46c9-8b2a-f3e153a02634_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_bc06a57d-d1b1-4867-83ef-8e3138a2ea8f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_1908900f-41aa-468c-b0ff-97e202c23dec_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment, Restructuring, And Other Special Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment, and Other Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_7bd9d15e-bc76-445f-95e0-e609914b5fcd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service (benefit) cost included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_90d19081-bd0b-4231-8fd8-7869cdbee895_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_6e22bb2c-fe4e-43a2-94c4-9fac3bb01ba8_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_996d7080-dac5-4475-be82-61a6634522fe_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock_87191e65-8880-45de-9d66-1656ccdf4d8a_terseLabel_en-US" xlink:label="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Awards, Fair Value Assumptions Used</link:label>
    <link:label id="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]</link:label>
    <link:label id="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock_documentation_en-US" xlink:label="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" xlink:href="lly-20221231.xsd#lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" xlink:to="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_7fd9db75-4b32-4ab6-bf09-8a4ca0ee064b_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_183c97d0-e852-4a52-995f-bbe76d3d2436_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward-starting interest rate swaps</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_62452712-c092-49c7-b84f-696b9c333522_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_bceda237-031b-48a7-9ca2-1f0f534cf7d4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments (Note 7)</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_322fbc76-027c-471e-8b4e-41ae972412fc_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_278cba53-5b9d-43c8-8249-9b66532ad3f1_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_41bec00b-5a8e-4f37-b9ec-3552065b7465_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_ac3c001f-4e8a-45b9-bb9d-a75d3ce29976_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_75a9f191-5db7-4f5e-a60f-a6fffd6cdf16_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ThreeLargestWholesalesMember_eba775d2-fcf1-4f09-80fc-d121750d46cf_terseLabel_en-US" xlink:label="lab_lly_ThreeLargestWholesalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest Wholesales</link:label>
    <link:label id="lab_lly_ThreeLargestWholesalesMember_label_en-US" xlink:label="lab_lly_ThreeLargestWholesalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest Wholesales [Member]</link:label>
    <link:label id="lab_lly_ThreeLargestWholesalesMember_documentation_en-US" xlink:label="lab_lly_ThreeLargestWholesalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest Wholesales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ThreeLargestWholesalesMember" xlink:href="lly-20221231.xsd#lly_ThreeLargestWholesalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ThreeLargestWholesalesMember" xlink:to="lab_lly_ThreeLargestWholesalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f513e816-d699-4f40-9fdf-aaacc0082772_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7d643b2b-d9a8-462d-b29c-1f569058ac82_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total before tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec93dd8e-38bd-4ac6-9a6f-e8cf43d5246b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNotesPayable_a8105cb1-7b20-44ca-89df-a597f443baec_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term debt</link:label>
    <link:label id="lab_us-gaap_OtherNotesPayable_label_en-US" xlink:label="lab_us-gaap_OtherNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNotesPayable" xlink:to="lab_us-gaap_OtherNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_f3f1916d-2325-4c70-a7a2-e47e5547c293_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt extinguishment loss (Note 11)</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_b91e6452-2a39-454f-a4fa-74a9de36ae39_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt extinguishment loss (Note 11)</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_1d1e0450-820d-419b-b2dc-c370ab529a66_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effects of Risk-Management Instruments Were Recognized in Other&#8211;Net, (Income) Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_39d88829-b302-4d1f-864a-2c8989362b09_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts recognized in the consolidated balance sheet consisted&#160;of:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ExpirationBy2026Member_8db0b92d-b4bf-4531-a252-bf5996913208_terseLabel_en-US" xlink:label="lab_lly_ExpirationBy2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration By 2026</link:label>
    <link:label id="lab_lly_ExpirationBy2026Member_label_en-US" xlink:label="lab_lly_ExpirationBy2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration By 2026 [Member]</link:label>
    <link:label id="lab_lly_ExpirationBy2026Member_documentation_en-US" xlink:label="lab_lly_ExpirationBy2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration By 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ExpirationBy2026Member" xlink:href="lly-20221231.xsd#lly_ExpirationBy2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ExpirationBy2026Member" xlink:to="lab_lly_ExpirationBy2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_bc2285b2-57db-432e-999b-885f29f4adfb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished products</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_May2021ShareRepurchaseProgramMember_78ba13f0-1e3a-41b5-8f0a-7aab657d29e7_terseLabel_en-US" xlink:label="lab_lly_May2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2021 Share Repurchase Program</link:label>
    <link:label id="lab_lly_May2021ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_lly_May2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2021 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_lly_May2021ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_lly_May2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2021 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_May2021ShareRepurchaseProgramMember" xlink:href="lly-20221231.xsd#lly_May2021ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_May2021ShareRepurchaseProgramMember" xlink:to="lab_lly_May2021ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_b8aa3660-f9a3-4625-afa7-e7b556b5d90d_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment hedges</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_4ed350c5-2a4f-4f13-b049-3fd1aad645bb_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EquityMethodAndOtherInvestmentsMember_c3b35fab-651d-49ec-86ca-736e9ad7759b_terseLabel_en-US" xlink:label="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_lly_EquityMethodAndOtherInvestmentsMember_label_en-US" xlink:label="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method And Other Investments [Member]</link:label>
    <link:label id="lab_lly_EquityMethodAndOtherInvestmentsMember_documentation_en-US" xlink:label="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method and Other Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EquityMethodAndOtherInvestmentsMember" xlink:href="lly-20221231.xsd#lly_EquityMethodAndOtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EquityMethodAndOtherInvestmentsMember" xlink:to="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_644d5ecd-46a0-47a8-9331-aa7e7f36f6ae_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_a9fb3d13-41e4-43cd-9d08-692e61bd909d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange rate changes and other adjustments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_338ef276-a83f-4007-b11a-273d5fb3586a_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028-2032</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_7f3845b6-479b-4836-acc7-cf958d995623_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_8f78d0f9-2181-4c8d-92f7-277708a63511_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_985a347e-76db-4486-bb8e-0543b13484b8_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and other revenue associated with prior period transfers of intellectual property</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_BR_29d5c096-3218-4ad3-8230-a3565c6e56b8_terseLabel_en-US" xlink:label="lab_country_BR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brazil</link:label>
    <link:label id="lab_country_BR_label_en-US" xlink:label="lab_country_BR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRAZIL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR" xlink:to="lab_country_BR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_20d0574b-17ef-4a74-bbc4-a7f625b4ec47_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock in Treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_8fec2ada-7357-4af8-8d30-21a02990fb7d_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_f12a5c54-decf-44b1-af04-36c8e1858f0e_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_5c8aaffc-c626-487e-89d8-6e4ee9ec3127_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_481c8354-3d5f-44d9-90e6-e9976d55b390_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_76b6a7aa-23dd-4612-a5aa-525a77514950_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_186be807-44fa-4841-b467-7e5d7f9817e7_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_f66fe6da-0465-4c98-8ad8-dee7b4563064_verboseLabel_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development and development milestones (Note 3)</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of expense related to research and development that are acquired directly in a transaction other than a business combination, that do not have an alternative future use and are therefore written off in the period of acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment" xlink:href="lly-20221231.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AcquiredInProcessResearchAndDevelopment" xlink:to="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_6ce4f460-6dc3-44a3-9c31-6653209ba8e5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_05be741a-b17c-4427-b197-cd4e3bbc4efa_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_bcb735e3-8d58-4d75-b82e-a4f4e7568382_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_610d2892-d433-4d50-bed4-49d57eff586a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Valued at Net Asset Value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:to="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_1c5081d5-b1b1-466b-9eec-df6899e0c63a_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_179929c9-91c2-410d-bbe7-c395a82e1371_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_eeeab674-53ec-408e-8c3f-492ce63a2b81_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_d33effc5-29b4-4ee0-b73d-1d5c957203b3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_2142f19d-1491-4504-be85-42352561f5f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Fair Value of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Fair Value of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_7c078acd-109c-4095-9f34-094d133fe253_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue (Note 2)</link:label>
    <link:label id="lab_us-gaap_Revenues_32f791c7-336c-4a7d-9ee8-4fa8ffa3b6bc_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock_e5486abc-11cb-4c3e-b5dc-5acde9f9c82d_terseLabel_en-US" xlink:label="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Payments Relating to Income Taxes and Tax Act Toll Tax</link:label>
    <link:label id="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock_label_en-US" xlink:label="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Income Tax Disclosures [Table Text Block]</link:label>
    <link:label id="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock_documentation_en-US" xlink:label="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Income Tax Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" xlink:href="lly-20221231.xsd#lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" xlink:to="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A275NotesDue2025Member_69f8874c-c5d7-46ea-8da1-46ee8b37830b_terseLabel_en-US" xlink:label="lab_lly_A275NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% notes due 2025</link:label>
    <link:label id="lab_lly_A275NotesDue2025Member_label_en-US" xlink:label="lab_lly_A275NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% Notes Due 2025 [Member]</link:label>
    <link:label id="lab_lly_A275NotesDue2025Member_documentation_en-US" xlink:label="lab_lly_A275NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% Notes Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A275NotesDue2025Member" xlink:href="lly-20221231.xsd#lly_A275NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A275NotesDue2025Member" xlink:to="lab_lly_A275NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_e242d86e-b4e5-4681-abce-a882d270498f_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:href="lly-20221231.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:to="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_d8327839-81ee-49c3-a2ed-a7302c266ea0_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for debt extinguishment</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_599c8b71-7cd4-4b61-a990-38d443374114_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_f09243ea-27c3-40bb-9019-573cb39c8244_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_7a9124a9-59f2-43e8-aca2-7ec5dd103e01_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments for interest on borrowings</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_3cee173f-92ad-4b63-b606-3cb489c40622_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AddDeductAbstract_ebbe8df7-d2d4-4cdd-9e5c-ea92362ab970_terseLabel_en-US" xlink:label="lab_lly_AddDeductAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add (deduct):</link:label>
    <link:label id="lab_lly_AddDeductAbstract_label_en-US" xlink:label="lab_lly_AddDeductAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add (Deduct) [Abstract]</link:label>
    <link:label id="lab_lly_AddDeductAbstract_documentation_en-US" xlink:label="lab_lly_AddDeductAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add (Deduct) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AddDeductAbstract" xlink:href="lly-20221231.xsd#lly_AddDeductAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AddDeductAbstract" xlink:to="lab_lly_AddDeductAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dd4a45dc-ab27-4279-8f18-54331d90eb5c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_fcb318a3-bf09-4dd5-b588-0eb239ef2c0d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_7834016d-7aaa-472d-8366-afdb8bad7de8_totalLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-Term and Short-Term, Combined Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_a12ffba1-3a63-4090-b124-623224179d06_terseLabel_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs to USD</link:label>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_label_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs To U.S. Dollars [Member]</link:label>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_documentation_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs To U.S. Dollars [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:href="lly-20221231.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:to="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_cad91a31-dd1b-472e-9246-baed81c907aa_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_047924ca-1639-464b-8d60-323bcb770a95_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_5bfa424f-83e8-4f62-bf41-e0ee0170ba6b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Eli Lilly and Company shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_979e8f36-e518-4bbf-ab36-c6a081cd0d5f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0de95a72-8804-4610-a711-6526e0655eae_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents at End of Year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_6858cfeb-e344-4c80-ad22-1a31df9b4427_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ErbituxMember_ccbeebb1-5406-4f2e-9d68-191493a7c324_terseLabel_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux&#174;</link:label>
    <link:label id="lab_lly_ErbituxMember_label_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux [Member]</link:label>
    <link:label id="lab_lly_ErbituxMember_documentation_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember" xlink:href="lly-20221231.xsd#lly_ErbituxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ErbituxMember" xlink:to="lab_lly_ErbituxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IE_94ce59e2-7c39-469a-ac54-376e548ef9ed_terseLabel_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ireland</link:label>
    <link:label id="lab_country_IE_label_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IRELAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IE" xlink:to="lab_country_IE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a1f0ed4f-a466-4429-ab9e-161a5dfd20cb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_4200becc-8438-4972-9ee0-a0ebdddc94fa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_feddd5da-b8ac-4ddd-8cd5-a4a2a7f064a7_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_efa9daa6-8e29-4961-ba94-ddf265d669da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_b5b8fccf-d851-432d-abdb-ea2ad881c107_terseLabel_en-US" xlink:label="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable derecognized</link:label>
    <link:label id="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_label_en-US" xlink:label="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of Financial Assets Accounted for as Sales, Amount Derecognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:to="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_843c7bf0-5aaf-4d5f-a124-03ad25dab314_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_88a8f47f-a240-4c27-864f-8d8dfa33bf76_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Miscellaneous, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_f11a0ad0-e530-4b4f-ac8a-9c9401bc938b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_2fe29108-bae6-442b-b26e-098e61f9522f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_11e2739c-0407-48f7-91f8-fd42c9bf476e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_cf048739-2b34-440a-860b-82a990e4dd99_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_c17b8c45-d8e8-43b0-8304-132668ed953e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Impact of Leases to Consolidated Condensed Financial Statements</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d9ef84e4-94d4-4586-aad7-950a93b847d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_8aac1d1e-b05f-4ad4-ade0-f4ba270812e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_9aa87a3d-4eb0-4606-9e77-ef44e4734d42_totalLabel_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, expenses, and other</link:label>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_label_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales, operating expenses, and other-net</link:label>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_documentation_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales, operating expenses, and other-net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:href="lly-20221231.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:to="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_75a2c6ab-65b2-4b8e-bd8b-3642af4227bb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_4edbf010-ce13-42d5-869c-f885671263da_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ExpirationBetween2028And2042Member_99fbad36-92e6-4ea1-b5c2-241ea8e49236_terseLabel_en-US" xlink:label="lab_lly_ExpirationBetween2028And2042Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Between 2028 and 2042</link:label>
    <link:label id="lab_lly_ExpirationBetween2028And2042Member_label_en-US" xlink:label="lab_lly_ExpirationBetween2028And2042Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Between 2028 and 2042 [Member]</link:label>
    <link:label id="lab_lly_ExpirationBetween2028And2042Member_documentation_en-US" xlink:label="lab_lly_ExpirationBetween2028And2042Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Between 2028 and 2042 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ExpirationBetween2028And2042Member" xlink:href="lly-20221231.xsd#lly_ExpirationBetween2028And2042Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ExpirationBetween2028And2042Member" xlink:to="lab_lly_ExpirationBetween2028And2042Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_d08636b0-a358-43f3-b5cd-131ff1d846ab_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense under the plans</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0920b49b-f0e6-4939-9804-a796f75a3902_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_f624d496-a6fc-4a55-89ad-61198ceac874_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_eabb1f16-fdc4-4b4e-9f93-038d9d3af884_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b3607f3a-c87a-4d4e-9f61-537c417c5b57_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_a111b582-6697-460b-b17f-974e84700084_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales returns, rebates, and discounts</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_d9efc0a8-22d8-4425-973a-a15543a5212b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash operating activities, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_09fe71e2-5f8a-4ed7-a0a5-e4063c04e5bf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances of $16.0 (2022)&#160;and $22.5 (2021)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_278c875c-71f7-4974-8e42-125fc1467a67_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_782dbda8-87f8-47f4-9727-bf40d74fa51c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Balance Sheet</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Balance Sheet [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1625BritishPoundDenominatedNotesDue2043Member_4c4d085d-77ef-440c-91c6-b6c1ca32cbf0_terseLabel_en-US" xlink:label="lab_lly_A1625BritishPoundDenominatedNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes due 2043</link:label>
    <link:label id="lab_lly_A1625BritishPoundDenominatedNotesDue2043Member_label_en-US" xlink:label="lab_lly_A1625BritishPoundDenominatedNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% British Pound Denominated Notes Due 2043 [Member]</link:label>
    <link:label id="lab_lly_A1625BritishPoundDenominatedNotesDue2043Member_documentation_en-US" xlink:label="lab_lly_A1625BritishPoundDenominatedNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% British Pound Denominated Notes Due 2043</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625BritishPoundDenominatedNotesDue2043Member" xlink:href="lly-20221231.xsd#lly_A1625BritishPoundDenominatedNotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1625BritishPoundDenominatedNotesDue2043Member" xlink:to="lab_lly_A1625BritishPoundDenominatedNotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_a8cdc8bb-ea91-481e-9353-5e1f3643e05f_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_924b9cc8-a3c2-419c-a722-c280349346d7_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_dfd46333-b424-4b5f-bbac-ad18dacf5da0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_5871fa48-bfd2-4ffe-ac51-0582ed824aaf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_9860c6bf-9fcd-4702-ab64-48f2db09b49f_negatedLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8212;net, (income) expense (Note 18)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_a65f5e7e-c50e-4ca2-8425-73e6e58cdc90_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8211;net, (income) expense</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_c8bdf88e-bbb3-4cb8-b3b7-54063e4abb31_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_273623f9-bcbe-4109-8452-8313c2020f9b_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing, selling, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_248ccc12-35db-46b3-8f01-a34dc9314cb1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6d1a67b5-f76d-49f9-ad3f-0f495f44b230_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gross losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e663dfa5-bad2-4bb9-a7c1-be538d741be7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_bfa06654-d9d0-4944-88ef-ed630f6661de_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_bbabfa5e-9769-494f-aa85-2697f97f349f_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherProductTotalMember_74c0b832-9736-456a-a7f5-ee7a3a8a6c0a_terseLabel_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lly_OtherProductTotalMember_label_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product, Total [Member]</link:label>
    <link:label id="lab_lly_OtherProductTotalMember_documentation_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product, Total [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember" xlink:href="lly-20221231.xsd#lly_OtherProductTotalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherProductTotalMember" xlink:to="lab_lly_OtherProductTotalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_620aa15b-e1f0-4d51-8faa-db62d532553a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_fa538399-b133-4678-a8f5-0c88786a64d9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_0859dccc-d42f-433d-9a68-534f5c0aaeac_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A465NotesDue2044Member_8bd617d4-5f64-40e9-b5f7-a938b8f2690c_terseLabel_en-US" xlink:label="lab_lly_A465NotesDue2044Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.65% notes due 2044</link:label>
    <link:label id="lab_lly_A465NotesDue2044Member_label_en-US" xlink:label="lab_lly_A465NotesDue2044Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.65% Notes Due 2044 [Member]</link:label>
    <link:label id="lab_lly_A465NotesDue2044Member_documentation_en-US" xlink:label="lab_lly_A465NotesDue2044Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.65% Notes Due 2044</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A465NotesDue2044Member" xlink:href="lly-20221231.xsd#lly_A465NotesDue2044Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A465NotesDue2044Member" xlink:to="lab_lly_A465NotesDue2044Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_ada0d875-2c82-447c-9982-47cbd285b8c2_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_913226c5-fba9-4d26-9691-b9b48d219b90_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4628e4eb-8927-4354-a3d3-0c7923d2b244_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implementation of New Financial Accounting Standard</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A225NotesDue2050Member_068ac4a0-3147-4f20-9b5d-8b1e63da99f0_terseLabel_en-US" xlink:label="lab_lly_A225NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% notes due 2050</link:label>
    <link:label id="lab_lly_A225NotesDue2050Member_label_en-US" xlink:label="lab_lly_A225NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes Due 2050 [Member]</link:label>
    <link:label id="lab_lly_A225NotesDue2050Member_documentation_en-US" xlink:label="lab_lly_A225NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes Due 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A225NotesDue2050Member" xlink:href="lly-20221231.xsd#lly_A225NotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A225NotesDue2050Member" xlink:to="lab_lly_A225NotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_5421a41d-2c28-42b2-a53c-ba1b0544325f_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_5ecaefc4-a529-44c4-995d-4df12c8d2760_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign-derived intangible income deduction</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f36c9b52-5000-4407-83b1-e8b615ff02ee_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d6710fce-7737-436b-91eb-951ee609bdae_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangibles</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0f8fa96f-5f13-4f01-887a-d1933930a8a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2e0a8ee3-8763-4c15-bc20-5f7af322e4e0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e05b585a-d1fb-47ce-be4e-7bbdff920748_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5d00830d-1dfc-472d-82ea-566a648b6cf9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_022d3c94-f23b-4ff9-9df3-772e09b41617_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_a3119a7c-353e-40dd-9d49-7f6b2773625b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_726e5045-2007-4923-a7a9-434c028907a4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_8b93037d-e5dd-43d1-aac2-6e6cf534dc07_terseLabel_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin and Forteo</link:label>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_label_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin, And Forteo [Member]</link:label>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_documentation_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin, And Forteo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember" xlink:href="lly-20221231.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumalogHumulinAndForteoMember" xlink:to="lab_lly_HumalogHumulinAndForteoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_6930fbd2-d699-42e6-9210-a98268d0cc27_terseLabel_en-US" xlink:label="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of global investments in plan assets</link:label>
    <link:label id="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_label_en-US" xlink:label="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Percentage of Global Investments in Plan Assets</link:label>
    <link:label id="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_documentation_en-US" xlink:label="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage description of US defined benefit and other postretirement plan assets as compared to the total global investment balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" xlink:href="lly-20221231.xsd#lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" xlink:to="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_5a1ca6ca-817c-4bea-a478-32e022c40fcc_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid employee benefits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_1faec229-5df4-4240-8a7f-62d195db2de7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CyramzaMember_b0752542-5780-45d3-9b66-97bc439e4407_terseLabel_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza&#174;</link:label>
    <link:label id="lab_lly_CyramzaMember_label_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza [Member]</link:label>
    <link:label id="lab_lly_CyramzaMember_documentation_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember" xlink:href="lly-20221231.xsd#lly_CyramzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CyramzaMember" xlink:to="lab_lly_CyramzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_99e01edd-c8f4-43e0-9a23-9e959cadfeda_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_68529bbd-1762-4b8d-aa54-6a6cb22feeb9_terseLabel_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes due 2030</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_label_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_documentation_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member" xlink:href="lly-20221231.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2.125NotesDueJune32030Member" xlink:to="lab_lly_A2.125NotesDueJune32030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_dc5123a6-3e35-4768-9014-21600b6666b8_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based</link:label>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember" xlink:href="lly-20221231.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsSalesBasedMember" xlink:to="lab_lly_MilestonePaymentsSalesBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_ae06483a-a03b-475d-b767-10b8e77be687_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_1905fa4d-3550-442a-88d6-d00bee3a58aa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in net unrealized gains (losses) on securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_eb8cacc0-4a73-48e1-a1dc-18a8743b67c5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_fd139fc3-3a9c-4c5c-8e95-219bfe1014ea_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherProductMember_f4648dcd-c0cd-43df-9413-218df91d8116_terseLabel_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lly_OtherProductMember_label_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product [Member]</link:label>
    <link:label id="lab_lly_OtherProductMember_documentation_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember" xlink:href="lly-20221231.xsd#lly_OtherProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherProductMember" xlink:to="lab_lly_OtherProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_e251a2a4-7984-492a-b481-f3b4273696a5_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DeferredTaxAssetsOperatingLeaseLiability_b5f45a97-c27b-453b-9355-07b8131b9715_terseLabel_en-US" xlink:label="lab_lly_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_lly_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_lly_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="lly-20221231.xsd#lly_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_lly_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6551b40e-6b76-4033-8c31-56e48ece80f1_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_8a4babc2-c2d3-4887-a23a-4b4b8936c6e8_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency-denominated notes, designated as hedge</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8ad57fed-3af3-4447-8b4c-c8190cadf0c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PetraPharmaCorporationMember_9202444a-63c8-48ec-b03a-c970c0f49384_terseLabel_en-US" xlink:label="lab_lly_PetraPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Petra Pharma Corporation (Petra)</link:label>
    <link:label id="lab_lly_PetraPharmaCorporationMember_label_en-US" xlink:label="lab_lly_PetraPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Petra Pharma Corporation [Member]</link:label>
    <link:label id="lab_lly_PetraPharmaCorporationMember_documentation_en-US" xlink:label="lab_lly_PetraPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Petra Pharma Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PetraPharmaCorporationMember" xlink:href="lly-20221231.xsd#lly_PetraPharmaCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PetraPharmaCorporationMember" xlink:to="lab_lly_PetraPharmaCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_c6195fc2-668e-4112-889f-16d35f258427_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial losses</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a10a4a8e-b26a-4edd-846a-80a88780f8de_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_88648d37-b5f6-44bd-9cab-246a337b5f69_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_41565f04-d56f-44f5-b807-8dc69a5de2a8_terseLabel_en-US" xlink:label="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term income taxes payable, estimated timing of future cash outflows not possible</link:label>
    <link:label id="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_label_en-US" xlink:label="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible</link:label>
    <link:label id="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_documentation_en-US" xlink:label="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" xlink:href="lly-20221231.xsd#lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" xlink:to="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuySwissFrancSellUSDollarMember_e64e685a-d885-469b-a621-dd16a2bde6ee_terseLabel_en-US" xlink:label="lab_lly_BuySwissFrancSellUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Swiss Franc Sell US Dollar</link:label>
    <link:label id="lab_lly_BuySwissFrancSellUSDollarMember_label_en-US" xlink:label="lab_lly_BuySwissFrancSellUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Swiss Franc Sell US Dollar [Member]</link:label>
    <link:label id="lab_lly_BuySwissFrancSellUSDollarMember_documentation_en-US" xlink:label="lab_lly_BuySwissFrancSellUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Swiss Franc Sell US Dollar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuySwissFrancSellUSDollarMember" xlink:href="lly-20221231.xsd#lly_BuySwissFrancSellUSDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuySwissFrancSellUSDollarMember" xlink:to="lab_lly_BuySwissFrancSellUSDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_189db884-aa1e-4e85-8d99-baefd641e965_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets, finite-lived</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f37e37bf-bacc-44f1-87fc-f54c86729b42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Portion of Risk-Management Instruments that was Recognized in Other Comprehensive Income (Loss), Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b80d7c13-9c2f-46ae-9a97-668193bb822d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_49d4f377-60c3-4c6d-8c26-4c08c4c38a27_terseLabel_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, additional price per share (in dollars per share)</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_label_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Additional Price Per Share</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_documentation_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Additional Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:href="lly-20221231.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:to="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_dc683336-b49e-4a6f-82e3-f30e819cf5f8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_39951842-7632-4784-ac3b-feb0f89d96e2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2a8efb3e-790a-4a95-8c22-ed36864a6ad1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_91a38987-26e5-4a14-90bb-c25cc1ec6872_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A395NotesDue2047Member_dabda5c5-94c3-41dc-b1e7-6ccde440c164_terseLabel_en-US" xlink:label="lab_lly_A395NotesDue2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% notes due 2047</link:label>
    <link:label id="lab_lly_A395NotesDue2047Member_label_en-US" xlink:label="lab_lly_A395NotesDue2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due 2047 [Member]</link:label>
    <link:label id="lab_lly_A395NotesDue2047Member_documentation_en-US" xlink:label="lab_lly_A395NotesDue2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due 2047</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2047Member" xlink:href="lly-20221231.xsd#lly_A395NotesDue2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A395NotesDue2047Member" xlink:to="lab_lly_A395NotesDue2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_924f89c6-a5a4-47e4-98cc-eed15ac9df19_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_bebd4c1e-695a-41d7-8cb4-136f8f19f408_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_bf19c676-35d6-475f-a184-0bef9e011b7f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4a7c2b20-3e28-4e4b-9a88-f9265f13e0df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_db96a5b4-ed33-4677-98b6-82ce44df186d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used for Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_76b88b46-6aeb-420b-9c5c-221d3e6340d6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of net actuarial (gain) loss included in net income</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_3e191c77-86a8-483f-aae9-a04dc9ca43de_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_176b6962-2e85-40f4-86de-3a22a63a4bb8_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS)</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_7aa5bb24-792a-4fa6-9dc6-2af3148b0bc3_netLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under employee stock plans, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_bbd735e0-751f-4384-b8f2-0e780e71a407_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_c99f4ed9-aa5c-4ccf-9141-c8d5b7e027a3_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CymbaltaMember_b73827ee-72b0-4e5f-add9-866410582e1a_terseLabel_en-US" xlink:label="lab_lly_CymbaltaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cymbalta&#174;</link:label>
    <link:label id="lab_lly_CymbaltaMember_label_en-US" xlink:label="lab_lly_CymbaltaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cymbalta [Member]</link:label>
    <link:label id="lab_lly_CymbaltaMember_documentation_en-US" xlink:label="lab_lly_CymbaltaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cymbalta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CymbaltaMember" xlink:href="lly-20221231.xsd#lly_CymbaltaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CymbaltaMember" xlink:to="lab_lly_CymbaltaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_426ec207-351f-4904-91b9-1604c04ffc31_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FixedIncomeFundsEmergingMarketsMember_d4e7d3cf-e0e9-4ac3-8da6-e703574c3da4_terseLabel_en-US" xlink:label="lab_lly_FixedIncomeFundsEmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging markets</link:label>
    <link:label id="lab_lly_FixedIncomeFundsEmergingMarketsMember_label_en-US" xlink:label="lab_lly_FixedIncomeFundsEmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Funds Emerging Markets [Member]</link:label>
    <link:label id="lab_lly_FixedIncomeFundsEmergingMarketsMember_documentation_en-US" xlink:label="lab_lly_FixedIncomeFundsEmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An investment that pools funds from many investors to invest in a combination of underlying investments, primarily fixed income investments in EMERGING MARKETS.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FixedIncomeFundsEmergingMarketsMember" xlink:href="lly-20221231.xsd#lly_FixedIncomeFundsEmergingMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FixedIncomeFundsEmergingMarketsMember" xlink:to="lab_lly_FixedIncomeFundsEmergingMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_9b15d0c9-bef3-4a94-9065-3ed7ca8537da_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_21c12476-ebc3-456c-a344-bc38b14571c2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities on long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_fe4f44ff-2087-4506-ae26-03ccf8be9b3e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Funded Status</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Funded Status [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetFundedStatusTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_ea9a5b38-d354-4072-8363-0d6eef7fabbf_terseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency interest rate swaps</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_da063243-d7a3-46f0-8216-18a4b305e02c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_e3bc83c2-52c2-4701-9d9d-45dba496f196_verboseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_91a16984-289f-46b6-878c-1d371e24a622_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under employee stock plans, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_bb9186ac-c836-4970-b161-a98b2918463c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_dd32090e-6426-4953-bb87-3f31590ecfc6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_5c63f44e-67e9-4a69-91bb-9a5279405367_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd3ae09d-baf2-4d92-b917-162408eeedca_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_0356f532-c9c4-4560-b544-a48bbabb405d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of CVR liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6a68ef90-cea6-43a9-9b1d-2a85f47bc313_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e45cb0fc-2206-4a6a-9103-56f3bae41501_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net (Note 9)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2d3900d7-fa10-40b5-881e-c06e76cfd07e_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LIFOInventoryAmount_a4bbfd31-1dbf-4e3e-966f-c584600077a3_terseLabel_en-US" xlink:label="lab_us-gaap_LIFOInventoryAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIFO inventory amount</link:label>
    <link:label id="lab_us-gaap_LIFOInventoryAmount_label_en-US" xlink:label="lab_us-gaap_LIFOInventoryAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIFO Inventory Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LIFOInventoryAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LIFOInventoryAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LIFOInventoryAmount" xlink:to="lab_us-gaap_LIFOInventoryAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_9e654ca0-a819-4135-ae40-edfb99a12875_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_1fa02b15-1e08-4361-8bed-e9d6bca988ff_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, additional price per share, aggregate amount</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_216bc490-8801-4f3e-91c2-60bd23b28d4d_negatedLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_c1d40e7d-b143-4617-ae48-ae8c465e6122_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b9f87dc4-252b-4029-8d38-64b6bd5da5c6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_10af70de-c2bf-4b18-8831-78d49a18f2ff_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_fa0c507e-d3cb-4690-93f0-1019b8b55e7c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_000e5090-ae67-459e-adef-e7450448ba0e_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_c96f2536-9f10-4d40-a3e9-dd4bfbacb553_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term notes</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cb504352-ef03-4c49-8693-8b89792e7aba_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss (Note 17)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_c9a0b01f-eff3-448a-9250-3833e0672446_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock (no par value)</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_79928121-7f04-40a9-a710-be6fdab34ee9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets for net benefit costs</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_85c7d74d-92b7-4adf-adb1-2a753d8cb0c0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_09ca02ec-b6ba-4694-8b27-0ed73b58512d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable (Note 14)</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherImmunologyMember_505ea5b5-e98b-489c-b99c-7fae5e9a4eb0_terseLabel_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other immunology</link:label>
    <link:label id="lab_lly_OtherImmunologyMember_label_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:label id="lab_lly_OtherImmunologyMember_documentation_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember" xlink:href="lly-20221231.xsd#lly_OtherImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherImmunologyMember" xlink:to="lab_lly_OtherImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a943710e-0d12-49f5-8d45-b03381af2b52_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_9225d89c-ae33-47e8-a4fe-0d3609244973_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_59eeb5c2-55d4-437b-b6a6-94042559b367_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_15d6e6f4-335b-4478-b2b2-559be3d64038_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividend declared per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_67efa830-32bf-40d4-a6b9-cdf10268190d_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount, Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member_1d068c00-c640-45d4-8f4c-fb4207098874_terseLabel_en-US" xlink:label="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due May 2050 and September 2060</link:label>
    <link:label id="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member_label_en-US" xlink:label="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due May 2050 And September 2060 [Member]</link:label>
    <link:label id="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member_documentation_en-US" xlink:label="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due May 2050 And September 2060</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member" xlink:href="lly-20221231.xsd#lly_SeniorNotesDueMay2050AndSeptember2060Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member" xlink:to="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_f2ddce53-42f1-4f36-b1d8-1b576e4aca66_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Information, Assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1be1d906-b164-4969-89e7-447e6a70bed2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_460dcb23-ff7c-464a-a50f-e44b453c1d70_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:to="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_950414a6-e30a-483e-a806-e776fe9b61d5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_a64fc6d7-91dc-47e5-8673-ff77ee89b797_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A55NotesDue2027Member_83b96cbc-5213-4805-b7f6-79f81202cd62_terseLabel_en-US" xlink:label="lab_lly_A55NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.5% notes due 2027</link:label>
    <link:label id="lab_lly_A55NotesDue2027Member_label_en-US" xlink:label="lab_lly_A55NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.5% Notes Due 2027 [Member]</link:label>
    <link:label id="lab_lly_A55NotesDue2027Member_documentation_en-US" xlink:label="lab_lly_A55NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.5% Notes Due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A55NotesDue2027Member" xlink:href="lly-20221231.xsd#lly_A55NotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A55NotesDue2027Member" xlink:to="lab_lly_A55NotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_889d4130-f376-4fd1-85a1-704967d90e98_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_90fd7a67-189e-4a33-b464-7610662f1b0c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c0fab0ca-7dd4-43cb-8278-f7692a7edbf1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_f452f314-7afa-44db-a4d3-d2427c7b0887_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_b451be2c-ee7d-4d62-8932-ee6b5687f8f8_terseLabel_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt</link:label>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_label_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt [Member]</link:label>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_documentation_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember" xlink:href="lly-20221231.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ForeignCurrencyDenominatedDebtMember" xlink:to="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_36311b1b-a72a-433b-b533-272b1e1c32ac_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6fdf2102-130c-4eba-ade8-ec113fe16b16_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FixedIncomeFundsMember_3f6ee013-fc1a-42ba-87a5-cf7c1a302ff9_terseLabel_en-US" xlink:label="lab_us-gaap_FixedIncomeFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed markets</link:label>
    <link:label id="lab_us-gaap_FixedIncomeFundsMember_label_en-US" xlink:label="lab_us-gaap_FixedIncomeFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FixedIncomeFundsMember" xlink:to="lab_us-gaap_FixedIncomeFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f2bd3ae0-6e40-4411-b450-2f9ae626d824_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_c00648d3-91b1-422e-a09a-7c0efbbe2a61_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_37584381-c37d-4e38-9715-af164a0cd463_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_3a69b27a-724e-40e2-affb-fda162f5d570_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_c74c0476-45b0-4bea-9fa7-716f12b4a640_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service benefits, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b7b3b50a-b9d5-4f75-8920-691617495bc2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets&#8212;(increase) decrease</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_b18fc92a-186b-46f1-aa4b-4739af939812_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_a6e2939e-ab76-40eb-85df-ed7a2aab662f_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_7bd4b566-7ee7-4c72-836c-40c97d5fb27a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the Contractual Maturities of Our Investments in Debt Securities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_7834e0fe-0e86-41c4-ae1b-5f53fb4ce557_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_6cd2e4b5-ae06-45c1-ac84-f2bc205f24c4_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffsettingAssetsTable_5607967f-9e6b-4d62-94c6-9ae754eb59a7_terseLabel_en-US" xlink:label="lab_us-gaap_OffsettingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offsetting Assets [Table]</link:label>
    <link:label id="lab_us-gaap_OffsettingAssetsTable_label_en-US" xlink:label="lab_us-gaap_OffsettingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offsetting Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffsettingAssetsTable" xlink:to="lab_us-gaap_OffsettingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations_7fddc588-e4d3-43db-a2a1-2c8cefb459e6_terseLabel_en-US" xlink:label="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax redeterminations</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations_label_en-US" xlink:label="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Foreign Tax Redeterminations</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations_documentation_en-US" xlink:label="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Foreign Tax Redeterminations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsForeignTaxRedeterminations" xlink:href="lly-20221231.xsd#lly_DeferredTaxAssetsForeignTaxRedeterminations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DeferredTaxAssetsForeignTaxRedeterminations" xlink:to="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d987dbb1-cab1-40ac-9ddb-0a83bdf342f0_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_ce397cde-5b8b-457d-be8f-7cede8ffa32b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company Shareholders' Equity (Notes 12 and 13)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_780c67fd-da27-412d-8c79-b862e10d2ddd_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_20b8f6f6-c93b-43c0-bc37-b6775e1ddde1_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_d64a793f-5074-4408-8ae2-41b7b58f53c7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust_3706fd2e-9f6e-43aa-9324-1700afecadd0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit trust</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust_e0ab1048-a82f-4a08-bf7a-0b05d68d1dc7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit trust</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Held in Employee Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:to="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e6b9caf4-db67-45c1-a4c1-3843fa942328_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_2d3d11ee-8c68-4de3-9898-3a82448d9ad7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 16)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_bc248fc3-7e1c-4794-aced-86366fc499d4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c0596182-a2f8-47df-8b07-6d450aedd2ba_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TYVYTMember_614494ad-ce97-496d-b0fb-2ac2034fc052_terseLabel_en-US" xlink:label="lab_lly_TYVYTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tyvyt&#174;</link:label>
    <link:label id="lab_lly_TYVYTMember_label_en-US" xlink:label="lab_lly_TYVYTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYVYT [Member]</link:label>
    <link:label id="lab_lly_TYVYTMember_documentation_en-US" xlink:label="lab_lly_TYVYTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYVYT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember" xlink:href="lly-20221231.xsd#lly_TYVYTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TYVYTMember" xlink:to="lab_lly_TYVYTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_0378aa75-a1f7-4152-b313-c6be7f647c78_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_789a47cb-3795-477c-ab2f-6bac169a41ce_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward_f14cb888-22ae-490b-b6f9-d0d55903aa09_terseLabel_en-US" xlink:label="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current federal tax expense, utilization of net operating loss carryforward</link:label>
    <link:label id="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward_label_en-US" xlink:label="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward</link:label>
    <link:label id="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward_documentation_en-US" xlink:label="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" xlink:href="lly-20221231.xsd#lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" xlink:to="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_0a665156-26f9-4494-97be-c6d0b0a6bfdb_terseLabel_en-US" xlink:label="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Correlative tax adjustments</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_label_en-US" xlink:label="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Corrective Tax Adjustments</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_documentation_en-US" xlink:label="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Corrective Tax Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsCorrectiveTaxAdjustments" xlink:href="lly-20221231.xsd#lly_DeferredTaxAssetsCorrectiveTaxAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DeferredTaxAssetsCorrectiveTaxAdjustments" xlink:to="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_fee05279-424e-41f3-8189-c4f872d56d3f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_5e5e7c58-7706-4c10-a53f-593956a8e547_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_e63494f6-4c1c-4054-8aa9-dce2f10507a1_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_47c866db-7786-4b37-bff0-5845ec7b0e02_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5f4bf7ab-6807-4dbe-9864-563e81e8956a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_d89553c6-05ca-4887-ba71-5ce476aa6cc0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash acquired</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OncologyMember_5ce31f3a-5b78-4d79-bd86-5d1ad000c436_terseLabel_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology</link:label>
    <link:label id="lab_lly_OncologyMember_label_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_lly_OncologyMember_documentation_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue to unaffiliated customers, Oncology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember" xlink:href="lly-20221231.xsd#lly_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OncologyMember" xlink:to="lab_lly_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a62496fa-e31d-4105-bcf0-90cad8ef4534_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in benefit obligation:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_3b2dc2e6-56ac-4aea-a9c3-f98c0af5a842_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5fd04844-780a-40d3-9ab3-1d7761569f43_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bb89db6b-fbe3-42ff-ae68-07f18d78d8f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ShareholderValueAwardsMember_475eca45-53f1-4a32-9bf1-d9a57449ce33_terseLabel_en-US" xlink:label="lab_lly_ShareholderValueAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Value Awards</link:label>
    <link:label id="lab_lly_ShareholderValueAwardsMember_label_en-US" xlink:label="lab_lly_ShareholderValueAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Value Awards [Member]</link:label>
    <link:label id="lab_lly_ShareholderValueAwardsMember_documentation_en-US" xlink:label="lab_lly_ShareholderValueAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Value Awards are granted to officers and management and are payable in shares of common stock at the end of a 3 yr period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareholderValueAwardsMember" xlink:href="lly-20221231.xsd#lly_ShareholderValueAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ShareholderValueAwardsMember" xlink:to="lab_lly_ShareholderValueAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_9f281986-8870-42a2-bbdb-ff952acc8f24_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_cefdf5e7-a423-4283-8298-ad199c3989a7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized actuarial (gain) loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_4ec1bc27-d8a0-4a08-b70d-b67662aced7b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate for benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_23d53e8e-cafa-4f61-b7c8-da02e13a49f0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_ac995537-7c50-4bb0-ac57-aed9556dfd27_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Other than Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_09e76df5-4573-4c2b-9be0-d13128351425_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General business credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_76efdd9a-a6fd-4ecf-ac02-0a70242f50a0_terseLabel_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Tax Act Toll Tax</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_label_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, Payment, Due [Abstract]</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_documentation_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" xlink:href="lly-20221231.xsd#lly_TaxCutAndJobsActTollTaxPaymentDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" xlink:to="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_fab8e4c5-dd05-4d7a-a447-ae4ee911bca0_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_a32e87b4-15dd-4d98-80bb-76f9ad1502fb_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_706687ea-2581-4ade-8693-4e3187de18f6_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_6ee78f84-a78e-46f6-a752-b156734d68fa_terseLabel_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes due 2036</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_label_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_documentation_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member" xlink:href="lly-20221231.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A6.77NotesDueJanuary12036Member" xlink:to="lab_lly_A6.77NotesDueJanuary12036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_2527c1cb-602e-4267-b44f-6304f2a398d3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_0e84c7ed-b40d-4d6c-976d-7402a82799ee_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside U.S.</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_3de8f934-4f1d-40df-9513-4b3da345634c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_16c1bb9e-a1e9-4e12-9d91-3b82d74240db_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_cc2d7379-d806-4563-8e92-2e71c3e4e8a4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals for the payment of interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a7ea56d9-880f-466e-a083-0ed29785788e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f166e303-d87d-4d7f-adf4-431c90721ca8_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_8ba284e0-cc79-4ff8-a9c9-27592683207c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accumulated benefit obligation for our defined benefit pension plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_15008739-8426-4795-9c6c-1b1ccbbb02f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_19dc9031-0ee4-4977-bec3-71e008c0a676_terseLabel_en-US" xlink:label="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net of tax</link:label>
    <link:label id="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_label_en-US" xlink:label="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:label id="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_documentation_en-US" xlink:label="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" xlink:href="lly-20221231.xsd#lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" xlink:to="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5a3ac7e7-62e8-4287-be86-4825808b99eb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_d1c5add7-f6fc-4239-925f-6bdaa8a31ef1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More Than 10 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation_529465d7-b6c3-44be-9443-20deeded4fe0_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes related to the impact of foreign currency translation</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_cfcabd5c-d79a-4c0d-b20e-74b433241de5_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_bc58e049-14a2-4849-a582-0a1bd90d612e_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_af10a8ea-8909-496d-a488-6c7d653b2eb4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RelativeValueAwardsMember_677b2dd7-8fca-41d4-9bff-4fbc87d28fbf_terseLabel_en-US" xlink:label="lab_lly_RelativeValueAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relative Value Awards</link:label>
    <link:label id="lab_lly_RelativeValueAwardsMember_label_en-US" xlink:label="lab_lly_RelativeValueAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relative Value Awards [Member]</link:label>
    <link:label id="lab_lly_RelativeValueAwardsMember_documentation_en-US" xlink:label="lab_lly_RelativeValueAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relative Value Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RelativeValueAwardsMember" xlink:href="lly-20221231.xsd#lly_RelativeValueAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RelativeValueAwardsMember" xlink:to="lab_lly_RelativeValueAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_0d65642f-914c-4417-8786-9e447c2c202c_verboseLabel_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and other revenue</link:label>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_label_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Revenue [Member]</link:label>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_documentation_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember" xlink:href="lly-20221231.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborationandOtherRevenueMember" xlink:to="lab_lly_CollaborationandOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_d5bd0d22-d314-4c7c-835e-2e0517e9a92b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_818064b5-0903-4a9b-9a12-3064947f8f5e_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_189e930a-7c44-4857-b4a4-dd7db96c8d39_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate for net benefit costs</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7bd46b4e-14b2-442b-bed9-dcb68338266f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0989bc9d-f11c-49e3-994f-c5f6ac456b81_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_9d4b947a-3bb7-4465-9e38-5ddf76e84c41_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_b35a6983-5c4c-4946-b82b-7a87a91f7de0_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_7a110f7a-a364-43b7-9276-f9224c090294_terseLabel_en-US" xlink:label="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, number of contingent value rights</link:label>
    <link:label id="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_label_en-US" xlink:label="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Number Of Contingent Value Rights</link:label>
    <link:label id="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_documentation_en-US" xlink:label="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Number Of Contingent Value Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:href="lly-20221231.xsd#lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:to="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_ed9c29aa-1f2c-4402-8672-09d991615038_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgeFundsMember_13810039-34fb-462a-b53d-baa8e57ab375_terseLabel_en-US" xlink:label="lab_us-gaap_HedgeFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge funds</link:label>
    <link:label id="lab_us-gaap_HedgeFundsMember_label_en-US" xlink:label="lab_us-gaap_HedgeFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgeFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgeFundsMember" xlink:to="lab_us-gaap_HedgeFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_91297d77-3e6d-4f7b-a4b4-bbf812284c0e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_8487ee9c-bd84-44c1-ac0c-9c215764e675_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_bc94f128-49f8-482c-a47d-e01c45884599_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_11cd43b0-0094-4d3f-b4b5-c2d97f795aa1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_88505925-9389-4327-bfe6-6499a71155a2_terseLabel_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 1 Year</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_label_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_documentation_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" xlink:href="lly-20221231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" xlink:to="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_d55b21b4-1837-4a86-8ce8-025882fd8fbe_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PrevailTherapeuticsIncMember_4f02c8e4-338a-4c44-a58d-ec0a7dd5acfe_terseLabel_en-US" xlink:label="lab_lly_PrevailTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevail Therapeutics Inc.</link:label>
    <link:label id="lab_lly_PrevailTherapeuticsIncMember_label_en-US" xlink:label="lab_lly_PrevailTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevail Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_lly_PrevailTherapeuticsIncMember_documentation_en-US" xlink:label="lab_lly_PrevailTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevail Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember" xlink:href="lly-20221231.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PrevailTherapeuticsIncMember" xlink:to="lab_lly_PrevailTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumulinMember_56da43d6-f36d-4ec8-8f11-a84ebeb21a18_terseLabel_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin&#174;</link:label>
    <link:label id="lab_lly_HumulinMember_label_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin [Member]</link:label>
    <link:label id="lab_lly_HumulinMember_documentation_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember" xlink:href="lly-20221231.xsd#lly_HumulinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumulinMember" xlink:to="lab_lly_HumulinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_9271d7c9-68d2-4e82-95e4-3580b83ff279_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumalogMember_19ee30d1-40d4-44f1-bb4c-47c750db4fc8_terseLabel_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog&#174;</link:label>
    <link:label id="lab_lly_HumalogMember_label_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog [Member]</link:label>
    <link:label id="lab_lly_HumalogMember_documentation_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember" xlink:href="lly-20221231.xsd#lly_HumalogMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumalogMember" xlink:to="lab_lly_HumalogMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_JardianceMember_d47edf27-f37d-4baa-97e6-b55fa9ca71c5_verboseLabel_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance&#174;</link:label>
    <link:label id="lab_lly_JardianceMember_label_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance [Member]</link:label>
    <link:label id="lab_lly_JardianceMember_documentation_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember" xlink:href="lly-20221231.xsd#lly_JardianceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_JardianceMember" xlink:to="lab_lly_JardianceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_c843a0a6-aaca-4390-ae9e-65c6d187cfd8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Long-term Notes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_72646dc8-a3e7-4a1d-b526-9434223e8937_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_b31bd969-0e0b-475c-881d-de85150a7ce5_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_35538bab-d64d-4784-b9a5-bc8932e26038_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_30a73546-47fb-49e5-8470-68e9b436456e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded status</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_b7f535a7-3c92-4c0b-9be9-4b81d162e734_negatedLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLIFOReserve_6e7d5b51-ecf8-445f-9c6b-86b7cce68aae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InventoryLIFOReserve" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to LIFO cost</link:label>
    <link:label id="lab_us-gaap_InventoryLIFOReserve_label_en-US" xlink:label="lab_us-gaap_InventoryLIFOReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, LIFO Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLIFOReserve" xlink:to="lab_us-gaap_InventoryLIFOReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DisarmTherapeuticsIncMember_7921ccb9-3354-475e-99e4-3555a454fc78_terseLabel_en-US" xlink:label="lab_lly_DisarmTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disarm Therapeutics, Inc.</link:label>
    <link:label id="lab_lly_DisarmTherapeuticsIncMember_label_en-US" xlink:label="lab_lly_DisarmTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disarm Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_lly_DisarmTherapeuticsIncMember_documentation_en-US" xlink:label="lab_lly_DisarmTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disarm Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisarmTherapeuticsIncMember" xlink:href="lly-20221231.xsd#lly_DisarmTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DisarmTherapeuticsIncMember" xlink:to="lab_lly_DisarmTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_a434fb5d-d226-4ed9-9fbb-2bc61ed80085_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum remaining maturity of foreign currency derivatives</link:label>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_label_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Remaining Maturity of Foreign Currency Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:to="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_62ae2d36-797c-4456-b520-b4218820db72_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_4bb78c3b-af99-4b24-ba18-d6f4e9ceaf6e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_cb895503-b20b-4e17-9623-f59241e5160f_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_54247907-e26c-44a8-9f64-c846e6760232_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TrajentaBIMember_1dd5b0d0-3a87-4173-a36a-5a0a3b98ed85_verboseLabel_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta&#174;</link:label>
    <link:label id="lab_lly_TrajentaBIMember_label_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta (BI) [Member]</link:label>
    <link:label id="lab_lly_TrajentaBIMember_documentation_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta (BI) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember" xlink:href="lly-20221231.xsd#lly_TrajentaBIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TrajentaBIMember" xlink:to="lab_lly_TrajentaBIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyJapaneseYenSellUSDollarMember_3e51b594-9371-41a0-ba27-f8d0f0469771_terseLabel_en-US" xlink:label="lab_lly_BuyJapaneseYenSellUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Japanese Yen Sell US Dollar</link:label>
    <link:label id="lab_lly_BuyJapaneseYenSellUSDollarMember_label_en-US" xlink:label="lab_lly_BuyJapaneseYenSellUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Japanese Yen Sell US Dollar [Member]</link:label>
    <link:label id="lab_lly_BuyJapaneseYenSellUSDollarMember_documentation_en-US" xlink:label="lab_lly_BuyJapaneseYenSellUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Japanese Yen Sell US Dollar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyJapaneseYenSellUSDollarMember" xlink:href="lly-20221231.xsd#lly_BuyJapaneseYenSellUSDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyJapaneseYenSellUSDollarMember" xlink:to="lab_lly_BuyJapaneseYenSellUSDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_d06532d3-a46b-438d-b2b0-3dc84e3820f8_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_9f0423b5-bcb2-45db-9640-086aeaed8a30_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_004a691b-10cb-4e7f-8078-c66549372937_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_2a82a32d-9fe7-4f6d-b247-6e75e434e730_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1202e11e-3796-4fb1-9c65-70284ddc3056_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense and Acquired In-Process Research and Development (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyUSdollarSellJapaneseYenMember_fb40ca7e-9d9c-4d66-b736-9e16507c9ddf_terseLabel_en-US" xlink:label="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy USD Sell Japanese Yen</link:label>
    <link:label id="lab_lly_BuyUSdollarSellJapaneseYenMember_label_en-US" xlink:label="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US dollar Sell Japanese Yen [Member]</link:label>
    <link:label id="lab_lly_BuyUSdollarSellJapaneseYenMember_documentation_en-US" xlink:label="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US dollar Sell Japanese Yen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSdollarSellJapaneseYenMember" xlink:href="lly-20221231.xsd#lly_BuyUSdollarSellJapaneseYenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyUSdollarSellJapaneseYenMember" xlink:to="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DefineBenefitPlanOtherMember_6ed0f15d-9aad-4e04-858a-dd3d6d446591_terseLabel_en-US" xlink:label="lab_lly_DefineBenefitPlanOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lly_DefineBenefitPlanOtherMember_label_en-US" xlink:label="lab_lly_DefineBenefitPlanOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Define Benefit Plan, Other [Member]</link:label>
    <link:label id="lab_lly_DefineBenefitPlanOtherMember_documentation_en-US" xlink:label="lab_lly_DefineBenefitPlanOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Define Benefit Plan, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefineBenefitPlanOtherMember" xlink:href="lly-20221231.xsd#lly_DefineBenefitPlanOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DefineBenefitPlanOtherMember" xlink:to="lab_lly_DefineBenefitPlanOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_0826d48b-6aae-4bc9-be71-48b84dace652_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_bf726731-c446-4d4f-bb57-9731a3d00533_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (income) loss before income taxes</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_92534186-659b-45d5-bb42-727d36166f4d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_565f69d1-dcc5-49c1-b565-16d3b130cfa2_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_7a8a9b13-3fbe-4142-99c8-0fb0b1f8d462_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other securities</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_1d2ba23c-5853-4be5-90fa-b22f184ce879_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5b863408-47e6-4ac2-add6-a8fe0b62d84c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax at the U.S. federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_f5fd2d02-7aca-4326-b90d-571e193730ed_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expenses</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember_5c14b244-f22c-4c1d-8c72-ae3dea8c3e27_terseLabel_en-US" xlink:label="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed markets - repurchase agreements</link:label>
    <link:label id="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember_label_en-US" xlink:label="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Funds - Repurchased Agreements [Member]</link:label>
    <link:label id="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember_documentation_en-US" xlink:label="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Funds - Repurchased Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FixedIncomeFundsRepurchasedAgreementsMember" xlink:href="lly-20221231.xsd#lly_FixedIncomeFundsRepurchasedAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FixedIncomeFundsRepurchasedAgreementsMember" xlink:to="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_14e40c93-55ad-4851-afe9-519b5b48875b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_4d205428-aad3-4015-8503-348ef3806393_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity Related to Our Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A56YenDenominatedNotesDue2034Member_33abb258-3306-4454-867c-c6c1a02ed17e_terseLabel_en-US" xlink:label="lab_lly_A56YenDenominatedNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.56% Japanese yen denominated notes due 2034</link:label>
    <link:label id="lab_lly_A56YenDenominatedNotesDue2034Member_label_en-US" xlink:label="lab_lly_A56YenDenominatedNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.56% Yen-denominated Notes Due 2034 [Member]</link:label>
    <link:label id="lab_lly_A56YenDenominatedNotesDue2034Member_documentation_en-US" xlink:label="lab_lly_A56YenDenominatedNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.56% Yen-denominated Notes Due 2034 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A56YenDenominatedNotesDue2034Member" xlink:href="lly-20221231.xsd#lly_A56YenDenominatedNotesDue2034Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A56YenDenominatedNotesDue2034Member" xlink:to="lab_lly_A56YenDenominatedNotesDue2034Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_c232924e-09ef-4836-a6b9-0e5348d407c0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_d89e7fbb-723c-47ff-88c6-3cdeaf753629_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_61be761a-9ecb-41af-92d4-f0f345deab50_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>lly-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:ccabaa9f-f08b-4cef-8cc5-6b16fc2f1828,g:814ba434-7768-4150-bd97-753155d7ed58-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e4bd9a79-8621-43fb-ac5d-c64bfb0b4706" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_301da636-c7a8-4bf1-b42a-b886687a1924" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e4bd9a79-8621-43fb-ac5d-c64bfb0b4706" xlink:to="loc_dei_DocumentInformationTable_301da636-c7a8-4bf1-b42a-b886687a1924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_227f8878-06b1-4a16-a19c-b6c118025fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_301da636-c7a8-4bf1-b42a-b886687a1924" xlink:to="loc_us-gaap_StatementClassOfStockAxis_227f8878-06b1-4a16-a19c-b6c118025fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_227f8878-06b1-4a16-a19c-b6c118025fd3" xlink:to="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_a22349c1-59d0-4d90-a47d-e451a3b8ac79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_us-gaap_CommonClassAMember_a22349c1-59d0-4d90-a47d-e451a3b8ac79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_fe557603-f56a-447d-a156-050f17991221" xlink:href="lly-20221231.xsd#lly_A718NotesDueJune12025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A718NotesDueJune12025Member_fe557603-f56a-447d-a156-050f17991221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_a3abdc4b-6067-4199-ad4b-ce3a28b91403" xlink:href="lly-20221231.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A1.625NotesDueJune22026Member_a3abdc4b-6067-4199-ad4b-ce3a28b91403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_655d46f1-47bd-4a59-a0bf-c80d77457094" xlink:href="lly-20221231.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A2.125NotesDueJune32030Member_655d46f1-47bd-4a59-a0bf-c80d77457094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_e04998c9-a635-4ebe-a9ba-1c22a20e6b6a" xlink:href="lly-20221231.xsd#lly_A625Notesdue2031Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A625Notesdue2031Member_e04998c9-a635-4ebe-a9ba-1c22a20e6b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A5000NotesDue2033Member_5f655309-9e59-4a42-8e54-43e67d792030" xlink:href="lly-20221231.xsd#lly_A5000NotesDue2033Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A5000NotesDue2033Member_5f655309-9e59-4a42-8e54-43e67d792030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_f65ee495-50fe-47dc-83c6-9cbb0393dfd4" xlink:href="lly-20221231.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_f65ee495-50fe-47dc-83c6-9cbb0393dfd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625BritishPoundDenominatedNotesDue2043Member_5e0997a0-a1eb-4733-82d3-a669e2e40060" xlink:href="lly-20221231.xsd#lly_A1625BritishPoundDenominatedNotesDue2043Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A1625BritishPoundDenominatedNotesDue2043Member_5e0997a0-a1eb-4733-82d3-a669e2e40060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_6f1b0577-5940-4178-89be-4ea14904127e" xlink:href="lly-20221231.xsd#lly_A1.700Notesdue2049Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A1.700Notesdue2049Member_6f1b0577-5940-4178-89be-4ea14904127e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_1f3bdf83-6f37-43e5-b647-e9d712c9cbc5" xlink:href="lly-20221231.xsd#lly_A1125NotesDue2051Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A1125NotesDue2051Member_1f3bdf83-6f37-43e5-b647-e9d712c9cbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_3a19a144-9a23-4c76-954a-59c851296548" xlink:href="lly-20221231.xsd#lly_A1375NotesDue2061Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ae8ded56-c212-4865-b4df-397462daa012" xlink:to="loc_lly_A1375NotesDue2061Member_3a19a144-9a23-4c76-954a-59c851296548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_301da636-c7a8-4bf1-b42a-b886687a1924" xlink:to="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b524d60b-5219-408d-bd84-56a75aff36e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_DocumentType_b524d60b-5219-408d-bd84-56a75aff36e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_01b0f7f5-17d4-42f2-afb5-927a9fbfde0c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_DocumentPeriodEndDate_01b0f7f5-17d4-42f2-afb5-927a9fbfde0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_94253958-a078-4f12-a043-bd4ac3db6546" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_CurrentFiscalYearEndDate_94253958-a078-4f12-a043-bd4ac3db6546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ad1d7730-0773-468f-8767-0d239bd235a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityFileNumber_ad1d7730-0773-468f-8767-0d239bd235a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ef1e2010-0c59-4057-bf2a-9c22cae92a32" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityRegistrantName_ef1e2010-0c59-4057-bf2a-9c22cae92a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a4c49160-7031-4054-8eab-c8dd7754eab8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a4c49160-7031-4054-8eab-c8dd7754eab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_94728fce-d743-4bbd-ae20-9deb342649b6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityTaxIdentificationNumber_94728fce-d743-4bbd-ae20-9deb342649b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_75f070d8-0b6f-437b-a4f9-f48e6ff9116b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityAddressAddressLine1_75f070d8-0b6f-437b-a4f9-f48e6ff9116b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ccb47e8f-dff8-42d1-a4df-9ba051271bc3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityAddressCityOrTown_ccb47e8f-dff8-42d1-a4df-9ba051271bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a28e75b6-3a79-410a-b682-0aa193cbfa23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityAddressStateOrProvince_a28e75b6-3a79-410a-b682-0aa193cbfa23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_826cbac4-8950-415d-a1d0-2deec15fa2a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityAddressPostalZipCode_826cbac4-8950-415d-a1d0-2deec15fa2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_34b037bc-6489-4c5d-9886-643e15354f63" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_CityAreaCode_34b037bc-6489-4c5d-9886-643e15354f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_24e1bed5-8d9f-43e6-a7cb-4ea30289c6e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_LocalPhoneNumber_24e1bed5-8d9f-43e6-a7cb-4ea30289c6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4757b4c9-52b4-4ed7-9205-d188f8d224bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_Security12bTitle_4757b4c9-52b4-4ed7-9205-d188f8d224bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_dfa3cd2f-e480-40a6-9bb3-c900325e0ab1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_TradingSymbol_dfa3cd2f-e480-40a6-9bb3-c900325e0ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8268a7c8-148b-413e-962d-17c78ebf054d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_SecurityExchangeName_8268a7c8-148b-413e-962d-17c78ebf054d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_348fa6da-cb86-4155-94e6-2e3cafdd5795" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_348fa6da-cb86-4155-94e6-2e3cafdd5795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_1120a355-5b91-47f9-840d-46b62f0bd70c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityVoluntaryFilers_1120a355-5b91-47f9-840d-46b62f0bd70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_b7d8faa7-53d6-4de6-9512-6ffd5d4cbae6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityCurrentReportingStatus_b7d8faa7-53d6-4de6-9512-6ffd5d4cbae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_00958e17-0c47-4034-b55c-1e29c6ffe567" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityInteractiveDataCurrent_00958e17-0c47-4034-b55c-1e29c6ffe567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_06acaaee-e55b-4702-b86e-df1918de8b6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityFilerCategory_06acaaee-e55b-4702-b86e-df1918de8b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e325d7ce-d874-42b5-b4be-bfee3ebf3e67" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntitySmallBusiness_e325d7ce-d874-42b5-b4be-bfee3ebf3e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_04de8375-a31f-4c4f-a8ad-016991c39914" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityEmergingGrowthCompany_04de8375-a31f-4c4f-a8ad-016991c39914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_742fba89-bd73-46df-82f5-c8053a7a7a65" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_IcfrAuditorAttestationFlag_742fba89-bd73-46df-82f5-c8053a7a7a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2def7334-b468-496c-8225-a09f556e3048" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityShellCompany_2def7334-b468-496c-8225-a09f556e3048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_0d753fec-199f-44b2-bf0d-51349470df34" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityPublicFloat_0d753fec-199f-44b2-bf0d-51349470df34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9aca2ab9-9a7b-48bd-b585-bbde65048d74" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9aca2ab9-9a7b-48bd-b585-bbde65048d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_337d98cd-d370-4978-89dc-01693ec45b3c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_337d98cd-d370-4978-89dc-01693ec45b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_d4873c87-96b4-4e7c-af41-cb0f4d0f6e34" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_DocumentAnnualReport_d4873c87-96b4-4e7c-af41-cb0f4d0f6e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_008e1731-91c6-493c-8b39-6a57e166b607" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_DocumentTransitionReport_008e1731-91c6-493c-8b39-6a57e166b607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_6e0311bb-d0d1-47cc-bcdb-1bf42ade1ddd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_AmendmentFlag_6e0311bb-d0d1-47cc-bcdb-1bf42ade1ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0c9aeec6-da65-49eb-a739-44d60e53172e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_DocumentFiscalYearFocus_0c9aeec6-da65-49eb-a739-44d60e53172e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9dd8daff-244b-4089-9a85-17f2a4690568" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9dd8daff-244b-4089-9a85-17f2a4690568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_98f9f843-c978-4655-8d77-3a03d8893010" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3be80ec5-64dd-427b-bdba-1a47c7b432d3" xlink:to="loc_dei_EntityCentralIndexKey_98f9f843-c978-4655-8d77-3a03d8893010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AuditInformation" xlink:type="simple" xlink:href="lly-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lly_AuditInformationAbstract_8c809f32-722e-4eb6-90e7-1c3582123d6d" xlink:href="lly-20221231.xsd#lly_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_485adc62-4ce3-42d7-b7fa-183d2ae655f1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AuditInformationAbstract_8c809f32-722e-4eb6-90e7-1c3582123d6d" xlink:to="loc_dei_AuditorName_485adc62-4ce3-42d7-b7fa-183d2ae655f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_d6fb10a7-6b0d-475d-82e4-c3a75a1a32ac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AuditInformationAbstract_8c809f32-722e-4eb6-90e7-1c3582123d6d" xlink:to="loc_dei_AuditorFirmId_d6fb10a7-6b0d-475d-82e4-c3a75a1a32ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_9ac1d715-2b7a-4204-bfa0-9fe76c6fdaea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AuditInformationAbstract_8c809f32-722e-4eb6-90e7-1c3582123d6d" xlink:to="loc_dei_AuditorLocation_9ac1d715-2b7a-4204-bfa0-9fe76c6fdaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="lly-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_f46ef877-44bc-4d9b-be15-286ff7f10323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bfc4eb8b-a4db-45fe-ba3d-af2fb29310f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f46ef877-44bc-4d9b-be15-286ff7f10323" xlink:to="loc_us-gaap_Revenues_bfc4eb8b-a4db-45fe-ba3d-af2fb29310f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_ef79af26-ef23-4791-8ff3-e99033b8a2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f46ef877-44bc-4d9b-be15-286ff7f10323" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_ef79af26-ef23-4791-8ff3-e99033b8a2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_80dee720-11e8-4156-a47c-eaf8b3eebecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ef79af26-ef23-4791-8ff3-e99033b8a2f4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_80dee720-11e8-4156-a47c-eaf8b3eebecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1b1d6a3b-a345-4dde-aa07-189fbf5511a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ef79af26-ef23-4791-8ff3-e99033b8a2f4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1b1d6a3b-a345-4dde-aa07-189fbf5511a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0f1c79c5-9bb2-4b39-be31-10122b625838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ef79af26-ef23-4791-8ff3-e99033b8a2f4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0f1c79c5-9bb2-4b39-be31-10122b625838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_7fd78b92-1b29-4d1e-80db-38360b62276b" xlink:href="lly-20221231.xsd#lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ef79af26-ef23-4791-8ff3-e99033b8a2f4" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_7fd78b92-1b29-4d1e-80db-38360b62276b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_4630b520-aee6-473b-a3e7-1698378c1bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ef79af26-ef23-4791-8ff3-e99033b8a2f4" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_4630b520-aee6-473b-a3e7-1698378c1bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_678780a4-2e8e-4725-bd0b-eb4475241c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ef79af26-ef23-4791-8ff3-e99033b8a2f4" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_678780a4-2e8e-4725-bd0b-eb4475241c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_da31cb1b-c724-49f8-adc9-2abad5ae75bd" xlink:href="lly-20221231.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ef79af26-ef23-4791-8ff3-e99033b8a2f4" xlink:to="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_da31cb1b-c724-49f8-adc9-2abad5ae75bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cf96ebd0-35d5-4535-aaed-81e323d5a881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f46ef877-44bc-4d9b-be15-286ff7f10323" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cf96ebd0-35d5-4535-aaed-81e323d5a881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_803b9035-8560-404c-8229-0c724eaac02f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f46ef877-44bc-4d9b-be15-286ff7f10323" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_803b9035-8560-404c-8229-0c724eaac02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_93f226d7-7055-4b4c-bede-921454d67e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f46ef877-44bc-4d9b-be15-286ff7f10323" xlink:to="loc_us-gaap_NetIncomeLoss_93f226d7-7055-4b4c-bede-921454d67e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_82cf3f94-0cb7-4f3e-88c8-5e57d1a79523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f46ef877-44bc-4d9b-be15-286ff7f10323" xlink:to="loc_us-gaap_EarningsPerShareAbstract_82cf3f94-0cb7-4f3e-88c8-5e57d1a79523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_55496543-f6a5-4455-8e26-db25ec28fb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_82cf3f94-0cb7-4f3e-88c8-5e57d1a79523" xlink:to="loc_us-gaap_EarningsPerShareBasic_55496543-f6a5-4455-8e26-db25ec28fb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7c12d44d-fdc9-4186-b0c4-47c7ff50488b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_82cf3f94-0cb7-4f3e-88c8-5e57d1a79523" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7c12d44d-fdc9-4186-b0c4-47c7ff50488b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ae892bec-0654-4dc4-89e2-2e6dfdfb93f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f46ef877-44bc-4d9b-be15-286ff7f10323" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ae892bec-0654-4dc4-89e2-2e6dfdfb93f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4cc22195-3e3d-4d0d-97bd-1bd217f59595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ae892bec-0654-4dc4-89e2-2e6dfdfb93f9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4cc22195-3e3d-4d0d-97bd-1bd217f59595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9f31940a-1db0-402f-be6e-09a2ddc0d77d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ae892bec-0654-4dc4-89e2-2e6dfdfb93f9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9f31940a-1db0-402f-be6e-09a2ddc0d77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20221231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f45c338-3be7-402f-9c74-32eb8500db61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_289bafc0-a060-4c5a-a602-3bd45022e04d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f45c338-3be7-402f-9c74-32eb8500db61" xlink:to="loc_us-gaap_NetIncomeLoss_289bafc0-a060-4c5a-a602-3bd45022e04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_ea67a287-b4da-4da0-b669-6ed3fbd0c2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f45c338-3be7-402f-9c74-32eb8500db61" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_ea67a287-b4da-4da0-b669-6ed3fbd0c2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_336be2a1-b4dc-4b7d-bbee-e862cafd5d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_ea67a287-b4da-4da0-b669-6ed3fbd0c2e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_336be2a1-b4dc-4b7d-bbee-e862cafd5d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_8d1fda4c-0048-424b-b40e-028557a6dabd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_ea67a287-b4da-4da0-b669-6ed3fbd0c2e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_8d1fda4c-0048-424b-b40e-028557a6dabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_1dd41517-5232-422f-a310-275e60e831e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_ea67a287-b4da-4da0-b669-6ed3fbd0c2e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_1dd41517-5232-422f-a310-275e60e831e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_3d9546bd-9b49-4151-bd01-67db15c6c6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_ea67a287-b4da-4da0-b669-6ed3fbd0c2e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_3d9546bd-9b49-4151-bd01-67db15c6c6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_83479d8a-e09f-450c-84db-125ceae9f366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_ea67a287-b4da-4da0-b669-6ed3fbd0c2e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_83479d8a-e09f-450c-84db-125ceae9f366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_8ece38e8-3ae6-4f02-ae7e-4a0ebf53efc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f45c338-3be7-402f-9c74-32eb8500db61" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_8ece38e8-3ae6-4f02-ae7e-4a0ebf53efc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8ce443d2-cd2d-4edf-9b23-662130a98376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f45c338-3be7-402f-9c74-32eb8500db61" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8ce443d2-cd2d-4edf-9b23-662130a98376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_33d434b4-32d8-49e6-b4f7-ce426d331ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7f45c338-3be7-402f-9c74-32eb8500db61" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_33d434b4-32d8-49e6-b4f7-ce426d331ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lly-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_48402245-bceb-4802-a1f9-5e70960d7145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8e62debd-b12c-49e6-b650-75febfd7b59e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_48402245-bceb-4802-a1f9-5e70960d7145" xlink:to="loc_us-gaap_AssetsAbstract_8e62debd-b12c-49e6-b650-75febfd7b59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4af77132-26f4-4c60-8277-6c7f3d17e5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e62debd-b12c-49e6-b650-75febfd7b59e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4af77132-26f4-4c60-8277-6c7f3d17e5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ab0a94c4-3070-4d6b-afb9-3cd32cd2cbf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4af77132-26f4-4c60-8277-6c7f3d17e5cb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ab0a94c4-3070-4d6b-afb9-3cd32cd2cbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_cd41f61b-156b-4ce2-8eca-311645ed9e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4af77132-26f4-4c60-8277-6c7f3d17e5cb" xlink:to="loc_us-gaap_ShortTermInvestments_cd41f61b-156b-4ce2-8eca-311645ed9e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2846ec3f-f4c0-4582-b6db-84996be228c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4af77132-26f4-4c60-8277-6c7f3d17e5cb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2846ec3f-f4c0-4582-b6db-84996be228c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_c4dccda2-d8b0-4930-a64f-0f459affd189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4af77132-26f4-4c60-8277-6c7f3d17e5cb" xlink:to="loc_us-gaap_OtherReceivables_c4dccda2-d8b0-4930-a64f-0f459affd189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_24f0c62a-c340-45c3-874b-2c36ddce7dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4af77132-26f4-4c60-8277-6c7f3d17e5cb" xlink:to="loc_us-gaap_InventoryNet_24f0c62a-c340-45c3-874b-2c36ddce7dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cdbdb343-e367-4b4f-bfed-6de39db6dde1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4af77132-26f4-4c60-8277-6c7f3d17e5cb" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cdbdb343-e367-4b4f-bfed-6de39db6dde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_261f6db8-0a5d-496e-80cf-2b231931dd18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4af77132-26f4-4c60-8277-6c7f3d17e5cb" xlink:to="loc_us-gaap_AssetsCurrent_261f6db8-0a5d-496e-80cf-2b231931dd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_d89b2ef8-edf7-4dce-8de2-a978966241e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e62debd-b12c-49e6-b650-75febfd7b59e" xlink:to="loc_us-gaap_LongTermInvestments_d89b2ef8-edf7-4dce-8de2-a978966241e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_348013fd-ec5d-4bc4-8586-bf084b2d5515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e62debd-b12c-49e6-b650-75febfd7b59e" xlink:to="loc_us-gaap_Goodwill_348013fd-ec5d-4bc4-8586-bf084b2d5515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_63fffd64-b0f3-4087-b757-4ea9c061c5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e62debd-b12c-49e6-b650-75febfd7b59e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_63fffd64-b0f3-4087-b757-4ea9c061c5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_ae4b64df-3d93-4305-9a41-e06255ab42f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e62debd-b12c-49e6-b650-75febfd7b59e" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_ae4b64df-3d93-4305-9a41-e06255ab42f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3e4c0962-0d76-402c-918e-d0d4c17fe77c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e62debd-b12c-49e6-b650-75febfd7b59e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3e4c0962-0d76-402c-918e-d0d4c17fe77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_11286e6b-9fe1-4807-8aa6-c03cba589df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e62debd-b12c-49e6-b650-75febfd7b59e" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_11286e6b-9fe1-4807-8aa6-c03cba589df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_02f4661f-ad52-47c9-94c1-c6f422107a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e62debd-b12c-49e6-b650-75febfd7b59e" xlink:to="loc_us-gaap_Assets_02f4661f-ad52-47c9-94c1-c6f422107a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_648989b1-86b1-450b-bb63-2b02cf78ab29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_48402245-bceb-4802-a1f9-5e70960d7145" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_648989b1-86b1-450b-bb63-2b02cf78ab29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7ef33925-a252-480a-81e3-988c0a5a2c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_648989b1-86b1-450b-bb63-2b02cf78ab29" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7ef33925-a252-480a-81e3-988c0a5a2c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_c2f57255-8b16-483d-a7cc-572d19266bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7ef33925-a252-480a-81e3-988c0a5a2c41" xlink:to="loc_us-gaap_DebtCurrent_c2f57255-8b16-483d-a7cc-572d19266bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0a3fbee3-8b7c-417c-a148-231cdf20082b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7ef33925-a252-480a-81e3-988c0a5a2c41" xlink:to="loc_us-gaap_AccountsPayableCurrent_0a3fbee3-8b7c-417c-a148-231cdf20082b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e0e7242c-451d-4636-aca6-0c75345945b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7ef33925-a252-480a-81e3-988c0a5a2c41" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e0e7242c-451d-4636-aca6-0c75345945b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts_261580b3-b478-4774-b561-27bce8890212" xlink:href="lly-20221231.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7ef33925-a252-480a-81e3-988c0a5a2c41" xlink:to="loc_lly_SalesRebatesAndDiscounts_261580b3-b478-4774-b561-27bce8890212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_59f2cb68-bce4-4fe0-b7f8-ece86afd649f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7ef33925-a252-480a-81e3-988c0a5a2c41" xlink:to="loc_us-gaap_DividendsPayableCurrent_59f2cb68-bce4-4fe0-b7f8-ece86afd649f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_2ab5c796-5c59-4894-8682-9df9bd331890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7ef33925-a252-480a-81e3-988c0a5a2c41" xlink:to="loc_us-gaap_TaxesPayableCurrent_2ab5c796-5c59-4894-8682-9df9bd331890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_59ef91aa-ab96-4ec3-8027-35c917df530a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7ef33925-a252-480a-81e3-988c0a5a2c41" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_59ef91aa-ab96-4ec3-8027-35c917df530a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e4e5c0b5-ef53-4f35-b220-13bc613db230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7ef33925-a252-480a-81e3-988c0a5a2c41" xlink:to="loc_us-gaap_LiabilitiesCurrent_e4e5c0b5-ef53-4f35-b220-13bc613db230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_684e27bb-00bf-4b2a-af2e-004024961190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_648989b1-86b1-450b-bb63-2b02cf78ab29" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_684e27bb-00bf-4b2a-af2e-004024961190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8725141b-35be-4e3f-a4c1-167b745fe702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_684e27bb-00bf-4b2a-af2e-004024961190" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8725141b-35be-4e3f-a4c1-167b745fe702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_1a1f66da-1e95-42fb-b2b3-b7b230bf5bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_684e27bb-00bf-4b2a-af2e-004024961190" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_1a1f66da-1e95-42fb-b2b3-b7b230bf5bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_8ac4bcf0-4f08-4f32-b60a-63041df9d8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_684e27bb-00bf-4b2a-af2e-004024961190" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_8ac4bcf0-4f08-4f32-b60a-63041df9d8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0124d5ac-a845-4647-93fb-6c4862e48b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_684e27bb-00bf-4b2a-af2e-004024961190" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0124d5ac-a845-4647-93fb-6c4862e48b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3d9bf0d3-3a7c-43c4-a2e1-ed8ec2673aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_684e27bb-00bf-4b2a-af2e-004024961190" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3d9bf0d3-3a7c-43c4-a2e1-ed8ec2673aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_81b71c19-ed12-4713-a902-a0a5df3c5388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_684e27bb-00bf-4b2a-af2e-004024961190" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_81b71c19-ed12-4713-a902-a0a5df3c5388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f02accea-8035-4ad3-a4f5-21141d2a87a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_648989b1-86b1-450b-bb63-2b02cf78ab29" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f02accea-8035-4ad3-a4f5-21141d2a87a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_272b965b-3135-4091-926a-ea43420a2580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_648989b1-86b1-450b-bb63-2b02cf78ab29" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_272b965b-3135-4091-926a-ea43420a2580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e0faf050-98a0-4957-97f4-dc3a2deb0f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_272b965b-3135-4091-926a-ea43420a2580" xlink:to="loc_us-gaap_CommonStockValue_e0faf050-98a0-4957-97f4-dc3a2deb0f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_90e68d09-756f-400f-8602-d7912cadf279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_272b965b-3135-4091-926a-ea43420a2580" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_90e68d09-756f-400f-8602-d7912cadf279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_79a8f803-fd24-48cc-bd38-c1964eb914e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_272b965b-3135-4091-926a-ea43420a2580" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_79a8f803-fd24-48cc-bd38-c1964eb914e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_e14054bc-0945-4541-800c-5e87a8055cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_272b965b-3135-4091-926a-ea43420a2580" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_e14054bc-0945-4541-800c-5e87a8055cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d3987bc0-a6c4-464e-a879-971af0b8ff67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_272b965b-3135-4091-926a-ea43420a2580" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d3987bc0-a6c4-464e-a879-971af0b8ff67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_52b16c53-f32b-451f-b7a7-467b59d5f223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_272b965b-3135-4091-926a-ea43420a2580" xlink:to="loc_us-gaap_TreasuryStockCommonValue_52b16c53-f32b-451f-b7a7-467b59d5f223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2099ea1c-855a-495f-87c7-32942e0d56a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_272b965b-3135-4091-926a-ea43420a2580" xlink:to="loc_us-gaap_StockholdersEquity_2099ea1c-855a-495f-87c7-32942e0d56a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_0baae946-5383-4502-9d84-f7452abe29c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_272b965b-3135-4091-926a-ea43420a2580" xlink:to="loc_us-gaap_MinorityInterest_0baae946-5383-4502-9d84-f7452abe29c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_33d18096-344a-4346-9624-92f5206013d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_272b965b-3135-4091-926a-ea43420a2580" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_33d18096-344a-4346-9624-92f5206013d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_dde062a2-4d4a-416b-bbbd-95038b3f14c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_648989b1-86b1-450b-bb63-2b02cf78ab29" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_dde062a2-4d4a-416b-bbbd-95038b3f14c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="lly-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0f208d68-d304-40cf-bd6a-5bf14a872aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_805792bf-31cd-4b70-a8c8-c77ca3122168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0f208d68-d304-40cf-bd6a-5bf14a872aa9" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_805792bf-31cd-4b70-a8c8-c77ca3122168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b642b88b-7815-452f-8f56-6ddf872f64dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0f208d68-d304-40cf-bd6a-5bf14a872aa9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b642b88b-7815-452f-8f56-6ddf872f64dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e78e5980-e08c-4136-8b8f-40804a32cda6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0f208d68-d304-40cf-bd6a-5bf14a872aa9" xlink:to="loc_us-gaap_CommonStockSharesIssued_e78e5980-e08c-4136-8b8f-40804a32cda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="lly-20221231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d7bcace2-932d-4d8e-9aa7-ee7ab0c6c07e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_19727e29-7fb8-4a35-a16a-af73b4d05f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d7bcace2-932d-4d8e-9aa7-ee7ab0c6c07e" xlink:to="loc_us-gaap_StatementTable_19727e29-7fb8-4a35-a16a-af73b4d05f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_70a76fa2-240e-4ca4-b824-25688a51caf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_19727e29-7fb8-4a35-a16a-af73b4d05f9b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_70a76fa2-240e-4ca4-b824-25688a51caf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_56c04e12-d8a4-4fb6-bc82-048643e66e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_70a76fa2-240e-4ca4-b824-25688a51caf5" xlink:to="loc_us-gaap_EquityComponentDomain_56c04e12-d8a4-4fb6-bc82-048643e66e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fabfae70-b0a7-4262-8f93-72c5d324021f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56c04e12-d8a4-4fb6-bc82-048643e66e8e" xlink:to="loc_us-gaap_CommonStockMember_fabfae70-b0a7-4262-8f93-72c5d324021f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_948203c7-c1d9-49af-8534-7c1de86a6704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56c04e12-d8a4-4fb6-bc82-048643e66e8e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_948203c7-c1d9-49af-8534-7c1de86a6704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6fda78d9-26b9-4d92-8f96-d6be77c131f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56c04e12-d8a4-4fb6-bc82-048643e66e8e" xlink:to="loc_us-gaap_RetainedEarningsMember_6fda78d9-26b9-4d92-8f96-d6be77c131f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember_ee7876f9-b493-4466-aa45-f6d0e1de43d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56c04e12-d8a4-4fb6-bc82-048643e66e8e" xlink:to="loc_us-gaap_TrustForBenefitOfEmployeesMember_ee7876f9-b493-4466-aa45-f6d0e1de43d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fc72f471-f85e-44b8-81eb-53d3bc4c6947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56c04e12-d8a4-4fb6-bc82-048643e66e8e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fc72f471-f85e-44b8-81eb-53d3bc4c6947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_454195ae-d49a-45b2-8aa2-698c896411e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56c04e12-d8a4-4fb6-bc82-048643e66e8e" xlink:to="loc_us-gaap_TreasuryStockCommonMember_454195ae-d49a-45b2-8aa2-698c896411e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_b606e5a8-df81-4e88-8549-e496da242eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56c04e12-d8a4-4fb6-bc82-048643e66e8e" xlink:to="loc_us-gaap_NoncontrollingInterestMember_b606e5a8-df81-4e88-8549-e496da242eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a4e0a991-3026-4962-a58a-81b41ce93c26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_19727e29-7fb8-4a35-a16a-af73b4d05f9b" xlink:to="loc_us-gaap_StatementLineItems_a4e0a991-3026-4962-a58a-81b41ce93c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4e0a991-3026-4962-a58a-81b41ce93c26" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b41de3e4-8b83-4636-9da7-7e2dfd2ecd53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_CommonStockSharesIssued_b41de3e4-8b83-4636-9da7-7e2dfd2ecd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_5fc349f5-5a26-481b-b67e-6823161e5f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_TreasuryStockCommonShares_5fc349f5-5a26-481b-b67e-6823161e5f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3f730845-7a94-4a30-b9a7-edb66b747816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3f730845-7a94-4a30-b9a7-edb66b747816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d0b4a32a-2234-422d-8669-6673b880a468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_ProfitLoss_d0b4a32a-2234-422d-8669-6673b880a468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_19b5c0e2-6724-4e20-86d3-c411e1fefde5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_19b5c0e2-6724-4e20-86d3-c411e1fefde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_76dfe2cf-6eed-48d1-bb1e-3d7b2a538a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_Dividends_76dfe2cf-6eed-48d1-bb1e-3d7b2a538a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_e0990b60-c967-4c68-844b-684f2de927f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_e0990b60-c967-4c68-844b-684f2de927f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_016f2a82-d47b-4c9d-a069-8bb283475532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_016f2a82-d47b-4c9d-a069-8bb283475532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_4b9c6077-c18e-41b0-adf4-0025e0b23ede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_4b9c6077-c18e-41b0-adf4-0025e0b23ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_9f0d7ed9-6952-4476-adf9-ad065d870ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_9f0d7ed9-6952-4476-adf9-ad065d870ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6d840127-268b-4a57-a2b6-ee50ae8e0dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6d840127-268b-4a57-a2b6-ee50ae8e0dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_836d89e1-6574-4388-93aa-04137f1bf4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_836d89e1-6574-4388-93aa-04137f1bf4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2bc08248-4f11-48c2-a206-732403bffcd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2bc08248-4f11-48c2-a206-732403bffcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_e09e28e5-e182-4fab-b5f3-fe48aea1ec12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_StockholdersEquityOther_e09e28e5-e182-4fab-b5f3-fe48aea1ec12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_89da0baa-e377-49cd-8df8-141fecfa7ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_CommonStockSharesIssued_89da0baa-e377-49cd-8df8-141fecfa7ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_0422c41f-6e1f-45f7-a144-892a512af272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_TreasuryStockCommonShares_0422c41f-6e1f-45f7-a144-892a512af272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f3098832-4a02-43d9-aca7-cfac5cf27115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_383dda8e-a000-4d27-9270-11aa4e27dd39" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f3098832-4a02-43d9-aca7-cfac5cf27115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="simple" xlink:href="lly-20221231.xsd#ConsolidatedStatementsofShareholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_acb4921b-2ec2-4101-8b84-93ddc0c111b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_063ecdda-b68b-4769-9316-47f63df5fec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_acb4921b-2ec2-4101-8b84-93ddc0c111b9" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_063ecdda-b68b-4769-9316-47f63df5fec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lly-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6102a2ac-d4e2-4eb4-949d-af643604d329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a287666-ff5b-48a2-8b15-8d86f620aedf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6102a2ac-d4e2-4eb4-949d-af643604d329" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a287666-ff5b-48a2-8b15-8d86f620aedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3a700b19-a834-4102-adff-918d5ba5fbd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a287666-ff5b-48a2-8b15-8d86f620aedf" xlink:to="loc_us-gaap_NetIncomeLoss_3a700b19-a834-4102-adff-918d5ba5fbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c7ac98c6-81a7-4b44-86dd-863781a649b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a287666-ff5b-48a2-8b15-8d86f620aedf" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c7ac98c6-81a7-4b44-86dd-863781a649b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_91f1a047-4e64-4ed6-bc2f-a83bf23cef94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c7ac98c6-81a7-4b44-86dd-863781a649b1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_91f1a047-4e64-4ed6-bc2f-a83bf23cef94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4c25a90e-0f08-4ca2-a420-ce423449f531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c7ac98c6-81a7-4b44-86dd-863781a649b1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4c25a90e-0f08-4ca2-a420-ce423449f531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_a3683c73-6d04-4ae6-a49a-f9cb5335da30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c7ac98c6-81a7-4b44-86dd-863781a649b1" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_a3683c73-6d04-4ae6-a49a-f9cb5335da30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5fff6672-c0a3-4e1b-aa1c-04f520e02591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c7ac98c6-81a7-4b44-86dd-863781a649b1" xlink:to="loc_us-gaap_ShareBasedCompensation_5fff6672-c0a3-4e1b-aa1c-04f520e02591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_d1d53b1c-b080-435c-99a0-c893a2cf0b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c7ac98c6-81a7-4b44-86dd-863781a649b1" xlink:to="loc_us-gaap_GainLossOnInvestments_d1d53b1c-b080-435c-99a0-c893a2cf0b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_6b95fa14-a47d-467d-aec8-56f3e37221b7" xlink:href="lly-20221231.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c7ac98c6-81a7-4b44-86dd-863781a649b1" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_6b95fa14-a47d-467d-aec8-56f3e37221b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_aab24cc8-d73f-4a57-9ad8-b4400ed7b03b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c7ac98c6-81a7-4b44-86dd-863781a649b1" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_aab24cc8-d73f-4a57-9ad8-b4400ed7b03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_34f9b3ac-95e4-4412-8e89-66f1d755c15d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c7ac98c6-81a7-4b44-86dd-863781a649b1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_34f9b3ac-95e4-4412-8e89-66f1d755c15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_f99946b9-0ec8-43e0-952e-a699170da5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_34f9b3ac-95e4-4412-8e89-66f1d755c15d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_f99946b9-0ec8-43e0-952e-a699170da5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3780bd6c-0063-4359-95ac-b66b2b9ddea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_34f9b3ac-95e4-4412-8e89-66f1d755c15d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3780bd6c-0063-4359-95ac-b66b2b9ddea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_728084a4-6ba6-4387-b21d-2060c902df02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_34f9b3ac-95e4-4412-8e89-66f1d755c15d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_728084a4-6ba6-4387-b21d-2060c902df02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_39b22390-ada1-4e0a-b471-f2a9e214b82c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_34f9b3ac-95e4-4412-8e89-66f1d755c15d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_39b22390-ada1-4e0a-b471-f2a9e214b82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2cd7a2ea-40f9-4068-838e-dd0eb65d7b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_34f9b3ac-95e4-4412-8e89-66f1d755c15d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2cd7a2ea-40f9-4068-838e-dd0eb65d7b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3195bf02-55f1-49d1-af13-33c0606ca6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a287666-ff5b-48a2-8b15-8d86f620aedf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3195bf02-55f1-49d1-af13-33c0606ca6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_50568a24-0782-4fed-a2f7-e9907e81c5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6102a2ac-d4e2-4eb4-949d-af643604d329" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_50568a24-0782-4fed-a2f7-e9907e81c5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_20237d19-38c0-4868-9c46-019c35d8ad31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_50568a24-0782-4fed-a2f7-e9907e81c5ae" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_20237d19-38c0-4868-9c46-019c35d8ad31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_042a50ee-756f-4976-bed0-11413bedd81c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_50568a24-0782-4fed-a2f7-e9907e81c5ae" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_042a50ee-756f-4976-bed0-11413bedd81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_d29c8e29-25e8-4b89-8fe4-ed74c22222a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_50568a24-0782-4fed-a2f7-e9907e81c5ae" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_d29c8e29-25e8-4b89-8fe4-ed74c22222a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_32bf39ea-6a01-46c3-b033-0f388e1ff619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_50568a24-0782-4fed-a2f7-e9907e81c5ae" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_32bf39ea-6a01-46c3-b033-0f388e1ff619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_69078143-3a9d-47ac-95a1-c59f89f7fbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_50568a24-0782-4fed-a2f7-e9907e81c5ae" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_69078143-3a9d-47ac-95a1-c59f89f7fbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasedInProcessResearchAndDevelopment_917ed63d-8dca-42c5-9fe5-992c84d8c107" xlink:href="lly-20221231.xsd#lly_PurchasedInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_50568a24-0782-4fed-a2f7-e9907e81c5ae" xlink:to="loc_lly_PurchasedInProcessResearchAndDevelopment_917ed63d-8dca-42c5-9fe5-992c84d8c107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_86d90a7b-cdac-4e76-bf28-b9e0d7b95fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_50568a24-0782-4fed-a2f7-e9907e81c5ae" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_86d90a7b-cdac-4e76-bf28-b9e0d7b95fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_aeeeef83-0d1f-4267-b5aa-a9c24315fe38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_50568a24-0782-4fed-a2f7-e9907e81c5ae" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_aeeeef83-0d1f-4267-b5aa-a9c24315fe38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2345c5bb-6967-4794-b52d-2b30b4624461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_50568a24-0782-4fed-a2f7-e9907e81c5ae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2345c5bb-6967-4794-b52d-2b30b4624461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2f78144-adbc-4a60-9a37-b495597a42c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6102a2ac-d4e2-4eb4-949d-af643604d329" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2f78144-adbc-4a60-9a37-b495597a42c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_b3b22f97-78ee-46ad-9286-6a22a219c64d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2f78144-adbc-4a60-9a37-b495597a42c9" xlink:to="loc_us-gaap_PaymentsOfDividends_b3b22f97-78ee-46ad-9286-6a22a219c64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_2a2f02cf-4bc8-4716-acf0-85fb7df5d3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2f78144-adbc-4a60-9a37-b495597a42c9" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_2a2f02cf-4bc8-4716-acf0-85fb7df5d3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2471e571-6024-4aff-bda4-80a1ee3e9496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2f78144-adbc-4a60-9a37-b495597a42c9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2471e571-6024-4aff-bda4-80a1ee3e9496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_9ad164e7-18d2-43d9-a022-2f105477dbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2f78144-adbc-4a60-9a37-b495597a42c9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_9ad164e7-18d2-43d9-a022-2f105477dbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_13e6904a-dbec-4164-b1ac-93984550f135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2f78144-adbc-4a60-9a37-b495597a42c9" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_13e6904a-dbec-4164-b1ac-93984550f135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f4c80ea5-0800-4a56-a078-917f0987c15d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2f78144-adbc-4a60-9a37-b495597a42c9" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f4c80ea5-0800-4a56-a078-917f0987c15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dff0ce1a-8edf-43e8-bb39-ec4efc8e93e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2f78144-adbc-4a60-9a37-b495597a42c9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dff0ce1a-8edf-43e8-bb39-ec4efc8e93e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65509186-a9c7-4d91-92c9-af481968c026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6102a2ac-d4e2-4eb4-949d-af643604d329" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65509186-a9c7-4d91-92c9-af481968c026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5add2162-01df-470c-9151-424a62ab7bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6102a2ac-d4e2-4eb4-949d-af643604d329" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5add2162-01df-470c-9151-424a62ab7bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_a63cf4fc-123d-46a5-a6d5-43515ab9ed37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6102a2ac-d4e2-4eb4-949d-af643604d329" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_a63cf4fc-123d-46a5-a6d5-43515ab9ed37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_97c1b16f-35af-4936-bde3-7797824dc9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6102a2ac-d4e2-4eb4-949d-af643604d329" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_97c1b16f-35af-4936-bde3-7797824dc9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards" xlink:type="simple" xlink:href="lly-20221231.xsd#SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f1f6514d-724f-4e36-aaa7-5f0789ff5539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_41291b0a-7763-4eee-a09b-80dbef574d06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f1f6514d-724f-4e36-aaa7-5f0789ff5539" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_41291b0a-7763-4eee-a09b-80dbef574d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Revenue" xlink:type="simple" xlink:href="lly-20221231.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b9988222-507b-40dd-83d2-02ca413df578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_03646682-128f-4f4c-943e-b9c79b206da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b9988222-507b-40dd-83d2-02ca413df578" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_03646682-128f-4f4c-943e-b9c79b206da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Acquisitions" xlink:type="simple" xlink:href="lly-20221231.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_082bcca0-04c6-40c2-bc6d-da3d489b58e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock_3f53834d-013a-4b80-b7bd-dda692da5a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_082bcca0-04c6-40c2-bc6d-da3d489b58e9" xlink:to="loc_us-gaap_AssetAcquisitionTextBlock_3f53834d-013a-4b80-b7bd-dda692da5a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_ffa8240d-b5e6-492f-8a4e-ef69e489f43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_082bcca0-04c6-40c2-bc6d-da3d489b58e9" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_ffa8240d-b5e6-492f-8a4e-ef69e489f43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="simple" xlink:href="lly-20221231.xsd#CollaborationsandOtherArrangements"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ddd35c3b-363a-446a-9318-30d14b8dfedc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ac32a2e2-0e97-46cf-a2e8-30a93d7202db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ddd35c3b-363a-446a-9318-30d14b8dfedc" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ac32a2e2-0e97-46cf-a2e8-30a93d7202db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="simple" xlink:href="lly-20221231.xsd#AssetImpairmentRestructuringandOtherSpecialCharges"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e380d654-0dcd-4339-8bb4-48f0722f29a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_ccdd06c3-d32c-48c4-ad63-c6837cafe13c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e380d654-0dcd-4339-8bb4-48f0722f29a0" xlink:to="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_ccdd06c3-d32c-48c4-ad63-c6837cafe13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Inventories" xlink:type="simple" xlink:href="lly-20221231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6a39de21-fc5a-443c-9699-866f1029e9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_7f054e23-2f5c-44d2-927c-9bdab61ea8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6a39de21-fc5a-443c-9699-866f1029e9b6" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_7f054e23-2f5c-44d2-927c-9bdab61ea8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstruments" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_da09d1d0-4b51-4ef2-8de1-aff97bdbc749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_88e2aef5-9a16-494d-bd7c-146da23a8d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_da09d1d0-4b51-4ef2-8de1-aff97bdbc749" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_88e2aef5-9a16-494d-bd7c-146da23a8d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangibles" xlink:type="simple" xlink:href="lly-20221231.xsd#GoodwillandOtherIntangibles"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangibles" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e7490c98-1439-4c19-98cb-23af929aec3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1dba61d4-326f-4a21-bdea-34373f2c925b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e7490c98-1439-4c19-98cb-23af929aec3c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1dba61d4-326f-4a21-bdea-34373f2c925b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="lly-20221231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0d315d81-ca05-43aa-b17a-4029cc22df8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7c74aef0-b740-48cf-be98-abddf661d9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0d315d81-ca05-43aa-b17a-4029cc22df8a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7c74aef0-b740-48cf-be98-abddf661d9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Leases" xlink:type="simple" xlink:href="lly-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9f35062c-a50f-46da-b9ca-2642bdd5bac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_0f6d8e45-6776-4d12-a6ad-333024bc3886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9f35062c-a50f-46da-b9ca-2642bdd5bac6" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_0f6d8e45-6776-4d12-a6ad-333024bc3886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_1c8f4477-ad69-47fd-aa9c-1f98bb2c87c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9f35062c-a50f-46da-b9ca-2642bdd5bac6" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_1c8f4477-ad69-47fd-aa9c-1f98bb2c87c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Borrowings" xlink:type="simple" xlink:href="lly-20221231.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2fb56deb-e4e6-4ef0-a81b-89e0302ca0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_e6caf09c-78be-4a82-9ab2-e7cb40dac3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2fb56deb-e4e6-4ef0-a81b-89e0302ca0ad" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_e6caf09c-78be-4a82-9ab2-e7cb40dac3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="lly-20221231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df579601-a672-4691-9d5c-5d1392fa5d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_61cd2af2-4d91-4ce9-8f00-c84b7bb78596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df579601-a672-4691-9d5c-5d1392fa5d42" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_61cd2af2-4d91-4ce9-8f00-c84b7bb78596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="lly-20221231.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0dc328c4-0c7b-4270-84e9-a8aa9fd5acf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_90900625-c137-42f0-8347-5fce6729931a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0dc328c4-0c7b-4270-84e9-a8aa9fd5acf9" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_90900625-c137-42f0-8347-5fce6729931a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lly-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4f2b624b-1cce-4e80-993d-bfe70caa628d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_12bf92af-4bc1-4335-b0a1-a4e20435926e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4f2b624b-1cce-4e80-993d-bfe70caa628d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_12bf92af-4bc1-4335-b0a1-a4e20435926e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefits" xlink:type="simple" xlink:href="lly-20221231.xsd#RetirementBenefits"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_76ee212a-f359-4c55-9a1e-40f5b42734d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_c493c723-b625-446e-b1e9-6f6e66617b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_76ee212a-f359-4c55-9a1e-40f5b42734d5" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_c493c723-b625-446e-b1e9-6f6e66617b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Contingencies" xlink:type="simple" xlink:href="lly-20221231.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_acadb5d1-4cb2-463c-a10f-c12cfc372c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d8ef5652-b1ca-4dd9-8b5e-bdc353ec98dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_acadb5d1-4cb2-463c-a10f-c12cfc372c3b" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d8ef5652-b1ca-4dd9-8b5e-bdc353ec98dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20221231.xsd#OtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b04e3d52-9aed-4e61-819f-3e30be0c345d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_5906d3fc-fac0-4c22-9e0b-8773e2db881b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b04e3d52-9aed-4e61-819f-3e30be0c345d" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_5906d3fc-fac0-4c22-9e0b-8773e2db881b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="simple" xlink:href="lly-20221231.xsd#OtherNetIncomeExpense"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c102ae7b-7ebe-484e-9ad9-dc72f18e1219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_14af548a-be8b-4e2a-8152-67fc12bc21cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c102ae7b-7ebe-484e-9ad9-dc72f18e1219" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_14af548a-be8b-4e2a-8152-67fc12bc21cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies" xlink:type="simple" xlink:href="lly-20221231.xsd#SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d511abb3-7803-46a5-96b7-4bbcba67dbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5a812cdc-3829-4c75-bc90-764b56f188a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d511abb3-7803-46a5-96b7-4bbcba67dbd7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5a812cdc-3829-4c75-bc90-764b56f188a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_73632056-88bf-4e63-814e-9db8d8b81a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d511abb3-7803-46a5-96b7-4bbcba67dbd7" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_73632056-88bf-4e63-814e-9db8d8b81a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_36d6716e-d3b7-458d-8b56-5cec4d34514e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d511abb3-7803-46a5-96b7-4bbcba67dbd7" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_36d6716e-d3b7-458d-8b56-5cec4d34514e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_4656bec7-17a9-4078-b5bd-51eb88ba1cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d511abb3-7803-46a5-96b7-4bbcba67dbd7" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_4656bec7-17a9-4078-b5bd-51eb88ba1cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4ccc0a0c-75be-4d40-a71e-cb39078ec9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d511abb3-7803-46a5-96b7-4bbcba67dbd7" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4ccc0a0c-75be-4d40-a71e-cb39078ec9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_5e59f630-2b81-49d4-ab82-6dbd094bb2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d511abb3-7803-46a5-96b7-4bbcba67dbd7" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_5e59f630-2b81-49d4-ab82-6dbd094bb2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_fe450d5d-dfaa-44f7-9c38-e37ba137efc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d511abb3-7803-46a5-96b7-4bbcba67dbd7" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_fe450d5d-dfaa-44f7-9c38-e37ba137efc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9ca45da7-5f1e-4c72-98ba-700cfcb9a0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d511abb3-7803-46a5-96b7-4bbcba67dbd7" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9ca45da7-5f1e-4c72-98ba-700cfcb9a0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_b16d1b42-630b-4b94-94b8-1a6bff2c6126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d511abb3-7803-46a5-96b7-4bbcba67dbd7" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_b16d1b42-630b-4b94-94b8-1a6bff2c6126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_847f48db-0b2d-41f9-a3f3-29c5e4c104cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d511abb3-7803-46a5-96b7-4bbcba67dbd7" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_847f48db-0b2d-41f9-a3f3-29c5e4c104cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_cba24982-a60a-441c-83d1-d13e53e588c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d511abb3-7803-46a5-96b7-4bbcba67dbd7" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_cba24982-a60a-441c-83d1-d13e53e588c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4034d4e2-4b7b-4ef5-9513-fc0b5eae1793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d511abb3-7803-46a5-96b7-4bbcba67dbd7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4034d4e2-4b7b-4ef5-9513-fc0b5eae1793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f426dabf-f4c2-4bbd-a406-85d516491982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d511abb3-7803-46a5-96b7-4bbcba67dbd7" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f426dabf-f4c2-4bbd-a406-85d516491982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_623f19b7-b7b1-4537-92e5-3809355010df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d511abb3-7803-46a5-96b7-4bbcba67dbd7" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_623f19b7-b7b1-4537-92e5-3809355010df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_9fc4c0ee-cf58-4344-beaf-2c8cb5237f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d511abb3-7803-46a5-96b7-4bbcba67dbd7" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_9fc4c0ee-cf58-4344-beaf-2c8cb5237f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueTables" xlink:type="simple" xlink:href="lly-20221231.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ecc80e96-7573-453d-8266-896feb47a2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_495c269b-fed7-4f32-9858-0808e42ccb65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ecc80e96-7573-453d-8266-896feb47a2d2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_495c269b-fed7-4f32-9858-0808e42ccb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_d6596833-9894-4df6-9031-316f06470385" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ecc80e96-7573-453d-8266-896feb47a2d2" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_d6596833-9894-4df6-9031-316f06470385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="lly-20221231.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_723039b4-627f-41bd-aad9-3ecdd2a4832d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_dee9bced-9dce-4ef7-af0a-6c0dd3aa719a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_723039b4-627f-41bd-aad9-3ecdd2a4832d" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_dee9bced-9dce-4ef7-af0a-6c0dd3aa719a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_c098ba9c-8c38-4d6c-9c2c-f46c054296be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_723039b4-627f-41bd-aad9-3ecdd2a4832d" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_c098ba9c-8c38-4d6c-9c2c-f46c054296be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="simple" xlink:href="lly-20221231.xsd#CollaborationsandOtherArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ee54009e-33cc-4ce2-ade4-d935cc955b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_a11c94f6-a97a-4b22-b695-e44bade59a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ee54009e-33cc-4ce2-ade4-d935cc955b8f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_a11c94f6-a97a-4b22-b695-e44bade59a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="simple" xlink:href="lly-20221231.xsd#AssetImpairmentRestructuringandOtherSpecialChargesTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_29ad365b-0620-4217-bd7f-d1563b019016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_e4805b43-cd98-49e9-81d7-a08a26a33a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_29ad365b-0620-4217-bd7f-d1563b019016" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_e4805b43-cd98-49e9-81d7-a08a26a33a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/InventoriesTables" xlink:type="simple" xlink:href="lly-20221231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8112ff5f-2a65-43f2-a675-d2314cd83519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4bf75f09-0c54-4e72-adfd-6e223bc62c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8112ff5f-2a65-43f2-a675-d2314cd83519" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4bf75f09-0c54-4e72-adfd-6e223bc62c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0a4d95f9-3768-4932-a811-4e3e138b3522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_7184c331-7088-45ad-aa94-d82da487ecfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0a4d95f9-3768-4932-a811-4e3e138b3522" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_7184c331-7088-45ad-aa94-d82da487ecfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_b6a52698-8525-4fcd-82bd-dc1a160100cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0a4d95f9-3768-4932-a811-4e3e138b3522" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_b6a52698-8525-4fcd-82bd-dc1a160100cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_82a7f573-19d6-45e1-8a4e-987f3dae8b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0a4d95f9-3768-4932-a811-4e3e138b3522" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_82a7f573-19d6-45e1-8a4e-987f3dae8b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_3a76ab24-a6e4-45e0-9f90-12b38cb76eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0a4d95f9-3768-4932-a811-4e3e138b3522" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_3a76ab24-a6e4-45e0-9f90-12b38cb76eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_682ce617-69c2-48f8-8841-1e65f4dcb412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0a4d95f9-3768-4932-a811-4e3e138b3522" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_682ce617-69c2-48f8-8841-1e65f4dcb412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_5dc7ec6c-3bf9-4f2b-a0a4-3e1cf2586c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0a4d95f9-3768-4932-a811-4e3e138b3522" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_5dc7ec6c-3bf9-4f2b-a0a4-3e1cf2586c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_0d8ccd39-1155-447e-99a7-d4f1303be191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0a4d95f9-3768-4932-a811-4e3e138b3522" xlink:to="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_0d8ccd39-1155-447e-99a7-d4f1303be191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_bc133788-ab9c-4df6-b3f2-5539d1029d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0a4d95f9-3768-4932-a811-4e3e138b3522" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_bc133788-ab9c-4df6-b3f2-5539d1029d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1534949a-b91c-4b53-9e91-cc02bb2d1b73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0a4d95f9-3768-4932-a811-4e3e138b3522" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1534949a-b91c-4b53-9e91-cc02bb2d1b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_5529a03b-f99c-4772-b7b4-6664f868a443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0a4d95f9-3768-4932-a811-4e3e138b3522" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_5529a03b-f99c-4772-b7b4-6664f868a443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesTables" xlink:type="simple" xlink:href="lly-20221231.xsd#GoodwillandOtherIntangiblesTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d69fedf0-41af-444f-b717-84f951df915a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f1801b5b-6ca6-47f1-ab36-f564d7fd9dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d69fedf0-41af-444f-b717-84f951df915a" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f1801b5b-6ca6-47f1-ab36-f564d7fd9dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_00ff6e54-c50f-4b06-804d-580a87aa687b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d69fedf0-41af-444f-b717-84f951df915a" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_00ff6e54-c50f-4b06-804d-580a87aa687b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_85688e0e-1df6-4642-bc49-4838a127f6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d69fedf0-41af-444f-b717-84f951df915a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_85688e0e-1df6-4642-bc49-4838a127f6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_0e306f90-9580-476b-a0aa-d4d54d754cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d69fedf0-41af-444f-b717-84f951df915a" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_0e306f90-9580-476b-a0aa-d4d54d754cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="lly-20221231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_40ee61e7-594a-4082-9fb2-0b5a7c7ac01b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0fd5dc6b-13b0-4ec8-a91a-b3abec0c9957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_40ee61e7-594a-4082-9fb2-0b5a7c7ac01b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0fd5dc6b-13b0-4ec8-a91a-b3abec0c9957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_78e8f1c1-2133-4882-a1a7-2555e6faf8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_40ee61e7-594a-4082-9fb2-0b5a7c7ac01b" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_78e8f1c1-2133-4882-a1a7-2555e6faf8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesTables" xlink:type="simple" xlink:href="lly-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_edb7364a-4767-427e-99e2-00172a1a5a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_2935307f-b75c-4346-be76-44612d2543b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_edb7364a-4767-427e-99e2-00172a1a5a8f" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_2935307f-b75c-4346-be76-44612d2543b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f0c53b3e-eda7-4161-9c98-4c087cb40610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_edb7364a-4767-427e-99e2-00172a1a5a8f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f0c53b3e-eda7-4161-9c98-4c087cb40610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsTables" xlink:type="simple" xlink:href="lly-20221231.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_744c0a9a-da70-4158-9900-b6fb6d10087f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_f11c9af2-a5b8-4c35-8c1b-5840ad8d1494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_744c0a9a-da70-4158-9900-b6fb6d10087f" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_f11c9af2-a5b8-4c35-8c1b-5840ad8d1494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_7b05d845-7c5c-462f-9d76-820d221e428d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_744c0a9a-da70-4158-9900-b6fb6d10087f" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_7b05d845-7c5c-462f-9d76-820d221e428d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_19b0db26-62a7-4228-869c-cc612e0364cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_744c0a9a-da70-4158-9900-b6fb6d10087f" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_19b0db26-62a7-4228-869c-cc612e0364cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock_be1a7a92-5019-4e03-bbaf-33280274e330" xlink:href="lly-20221231.xsd#lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_744c0a9a-da70-4158-9900-b6fb6d10087f" xlink:to="loc_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock_be1a7a92-5019-4e03-bbaf-33280274e330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="lly-20221231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_033b3c8a-7873-4d02-9edf-a2f0aff7dc14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock_0df3143e-d90d-43f1-9bac-5688adaa41dd" xlink:href="lly-20221231.xsd#lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_033b3c8a-7873-4d02-9edf-a2f0aff7dc14" xlink:to="loc_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock_0df3143e-d90d-43f1-9bac-5688adaa41dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock_d5935a73-97be-40d2-9bd7-3e6edeb12123" xlink:href="lly-20221231.xsd#lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_033b3c8a-7873-4d02-9edf-a2f0aff7dc14" xlink:to="loc_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock_d5935a73-97be-40d2-9bd7-3e6edeb12123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lly-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_79e39bf6-d5eb-48a2-b71f-a2e378125e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_f3d87b0f-fac7-40ef-9a75-a614d905a943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_79e39bf6-d5eb-48a2-b71f-a2e378125e58" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_f3d87b0f-fac7-40ef-9a75-a614d905a943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2306e9d0-89ac-4f2f-9e15-0442171fafea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_79e39bf6-d5eb-48a2-b71f-a2e378125e58" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2306e9d0-89ac-4f2f-9e15-0442171fafea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock_bec2de9a-509e-4933-997b-2f03234d34dd" xlink:href="lly-20221231.xsd#lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_79e39bf6-d5eb-48a2-b71f-a2e378125e58" xlink:to="loc_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock_bec2de9a-509e-4933-997b-2f03234d34dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e079c652-000d-458d-9e4b-986e8db5c6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_79e39bf6-d5eb-48a2-b71f-a2e378125e58" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e079c652-000d-458d-9e4b-986e8db5c6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_69a213f0-c3dc-4234-8c02-cdd304601442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_79e39bf6-d5eb-48a2-b71f-a2e378125e58" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_69a213f0-c3dc-4234-8c02-cdd304601442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="simple" xlink:href="lly-20221231.xsd#RetirementBenefitsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_96025b32-53c8-46a1-ac86-0f78016f0c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock_89437c88-1e0e-493e-92d6-7a6828131fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_96025b32-53c8-46a1-ac86-0f78016f0c75" xlink:to="loc_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock_89437c88-1e0e-493e-92d6-7a6828131fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_a772cf54-ac1e-4a98-bd87-cb324afdcea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_96025b32-53c8-46a1-ac86-0f78016f0c75" xlink:to="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_a772cf54-ac1e-4a98-bd87-cb324afdcea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_450e20e1-b4ed-4508-86b2-237e70960172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetFundedStatusTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_96025b32-53c8-46a1-ac86-0f78016f0c75" xlink:to="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_450e20e1-b4ed-4508-86b2-237e70960172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_a62e60c4-fc9e-4daf-9e32-eaf9f820b22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_96025b32-53c8-46a1-ac86-0f78016f0c75" xlink:to="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_a62e60c4-fc9e-4daf-9e32-eaf9f820b22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_74b99015-1574-47b0-904a-b1fb6e63d81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_96025b32-53c8-46a1-ac86-0f78016f0c75" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_74b99015-1574-47b0-904a-b1fb6e63d81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_cf26dfbe-ee2c-4450-a8e6-1bbc01527ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_96025b32-53c8-46a1-ac86-0f78016f0c75" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_cf26dfbe-ee2c-4450-a8e6-1bbc01527ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_216f474d-879a-464a-8e31-355ea71e5fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_96025b32-53c8-46a1-ac86-0f78016f0c75" xlink:to="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_216f474d-879a-464a-8e31-355ea71e5fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_1d67d719-b327-439c-99c3-f8b78bf9fc05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_96025b32-53c8-46a1-ac86-0f78016f0c75" xlink:to="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_1d67d719-b327-439c-99c3-f8b78bf9fc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_8836cdf9-062e-4e86-b919-5a04a6c76148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_96025b32-53c8-46a1-ac86-0f78016f0c75" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_8836cdf9-062e-4e86-b919-5a04a6c76148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_72a88483-8bd1-42c2-9fc1-6ead98ad57e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_96025b32-53c8-46a1-ac86-0f78016f0c75" xlink:to="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_72a88483-8bd1-42c2-9fc1-6ead98ad57e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_2404ec18-29f1-493a-9c64-7812f507499a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_96025b32-53c8-46a1-ac86-0f78016f0c75" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_2404ec18-29f1-493a-9c64-7812f507499a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="lly-20221231.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e8e8364b-eaa1-443d-b1a7-03c6b3c279c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b07a195a-e6c2-4f37-aa89-666afbd19cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e8e8364b-eaa1-443d-b1a7-03c6b3c279c6" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b07a195a-e6c2-4f37-aa89-666afbd19cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_350e3c0c-debe-4768-b584-75ea1bc44dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e8e8364b-eaa1-443d-b1a7-03c6b3c279c6" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_350e3c0c-debe-4768-b584-75ea1bc44dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="simple" xlink:href="lly-20221231.xsd#OtherNetIncomeExpenseTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5a0d2ad3-2520-4d57-b105-44b74d305753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_a4aa53d6-ba98-489b-991e-d0ad7c986422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5a0d2ad3-2520-4d57-b105-44b74d305753" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_a4aa53d6-ba98-489b-991e-d0ad7c986422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ca8b16f9-87f1-4602-a113-35bbbc1c59bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_a8b2957c-550f-4084-abae-c51c937c7654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca8b16f9-87f1-4602-a113-35bbbc1c59bd" xlink:to="loc_us-gaap_AdvertisingExpense_a8b2957c-550f-4084-abae-c51c937c7654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AdvertisingExpensePercentageOfRevenue_5cdb281b-7fe8-408d-a9fb-a13567317ee9" xlink:href="lly-20221231.xsd#lly_AdvertisingExpensePercentageOfRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca8b16f9-87f1-4602-a113-35bbbc1c59bd" xlink:to="loc_lly_AdvertisingExpensePercentageOfRevenue_5cdb281b-7fe8-408d-a9fb-a13567317ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RevenueSummaryofRevenueRecognizedDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e15ad1ec-d3a6-4322-88b9-b4fdb384347c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6b2c36f4-2a57-44db-bb44-c6f72662b2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e15ad1ec-d3a6-4322-88b9-b4fdb384347c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6b2c36f4-2a57-44db-bb44-c6f72662b2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_87a47fe4-7b7b-431c-9b8f-5c0d354fd4f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6b2c36f4-2a57-44db-bb44-c6f72662b2a4" xlink:to="loc_srt_ProductOrServiceAxis_87a47fe4-7b7b-431c-9b8f-5c0d354fd4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9964ccde-0813-451e-8428-61fc71c7c34f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_87a47fe4-7b7b-431c-9b8f-5c0d354fd4f9" xlink:to="loc_srt_ProductsAndServicesDomain_9964ccde-0813-451e-8428-61fc71c7c34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_07cd240d-f217-4fa2-a259-ec4c93e0c2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9964ccde-0813-451e-8428-61fc71c7c34f" xlink:to="loc_us-gaap_ProductMember_07cd240d-f217-4fa2-a259-ec4c93e0c2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember_1ee9238f-bacc-4e7a-86c1-31cc73f8aa8e" xlink:href="lly-20221231.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9964ccde-0813-451e-8428-61fc71c7c34f" xlink:to="loc_lly_CollaborationandOtherRevenueMember_1ee9238f-bacc-4e7a-86c1-31cc73f8aa8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_5af78a32-3ca0-4f4c-9659-2fac56c44344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9964ccde-0813-451e-8428-61fc71c7c34f" xlink:to="loc_us-gaap_RoyaltyMember_5af78a32-3ca0-4f4c-9659-2fac56c44344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_349751b8-1021-4a7f-b038-4f5ac6ef7ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6b2c36f4-2a57-44db-bb44-c6f72662b2a4" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_349751b8-1021-4a7f-b038-4f5ac6ef7ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ae68c0e2-98bb-4fce-b82d-8de254c87c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_349751b8-1021-4a7f-b038-4f5ac6ef7ed3" xlink:to="loc_us-gaap_Revenues_ae68c0e2-98bb-4fce-b82d-8de254c87c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1de8b7cd-6013-4c93-a069-cff4ba2e73d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_607fd334-ceb1-4f3f-a4e1-c70232ca99fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1de8b7cd-6013-4c93-a069-cff4ba2e73d1" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_607fd334-ceb1-4f3f-a4e1-c70232ca99fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9cfd6856-4aa6-4d3a-b3ca-6513f740e4a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_607fd334-ceb1-4f3f-a4e1-c70232ca99fe" xlink:to="loc_srt_MajorCustomersAxis_9cfd6856-4aa6-4d3a-b3ca-6513f740e4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ae81d9b8-a273-43b3-a868-b69302df112b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_9cfd6856-4aa6-4d3a-b3ca-6513f740e4a5" xlink:to="loc_srt_NameOfMajorCustomerDomain_ae81d9b8-a273-43b3-a868-b69302df112b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ThreeLargestWholesalesMember_3d607b84-2459-4285-8573-9f7a1926c005" xlink:href="lly-20221231.xsd#lly_ThreeLargestWholesalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ae81d9b8-a273-43b3-a868-b69302df112b" xlink:to="loc_lly_ThreeLargestWholesalesMember_3d607b84-2459-4285-8573-9f7a1926c005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b08b020c-7d15-4a6a-b00e-2edfed463736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_607fd334-ceb1-4f3f-a4e1-c70232ca99fe" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b08b020c-7d15-4a6a-b00e-2edfed463736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a4897bf8-d41e-4798-b5d9-d934d30674d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b08b020c-7d15-4a6a-b00e-2edfed463736" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a4897bf8-d41e-4798-b5d9-d934d30674d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_353383dd-3f0d-4d28-a701-be8ec5880580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a4897bf8-d41e-4798-b5d9-d934d30674d7" xlink:to="loc_us-gaap_SalesRevenueNetMember_353383dd-3f0d-4d28-a701-be8ec5880580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_7d9d200f-2310-4ec2-8cfd-fa0adb9de48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a4897bf8-d41e-4798-b5d9-d934d30674d7" xlink:to="loc_us-gaap_AccountsReceivableMember_7d9d200f-2310-4ec2-8cfd-fa0adb9de48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9b9223f2-cddb-4671-8fd5-62668c4f6dce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_607fd334-ceb1-4f3f-a4e1-c70232ca99fe" xlink:to="loc_srt_RangeAxis_9b9223f2-cddb-4671-8fd5-62668c4f6dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_65088812-6b60-4cad-be88-2d137607365a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9b9223f2-cddb-4671-8fd5-62668c4f6dce" xlink:to="loc_srt_RangeMember_65088812-6b60-4cad-be88-2d137607365a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ddd49963-36e1-4282-a524-47718d78a11c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_65088812-6b60-4cad-be88-2d137607365a" xlink:to="loc_srt_MinimumMember_ddd49963-36e1-4282-a524-47718d78a11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_288b3009-99e2-45c4-8ac8-acb51d35fd4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_65088812-6b60-4cad-be88-2d137607365a" xlink:to="loc_srt_MaximumMember_288b3009-99e2-45c4-8ac8-acb51d35fd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3c8d0c44-feb2-47bf-a9ef-13212f51ab3e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_607fd334-ceb1-4f3f-a4e1-c70232ca99fe" xlink:to="loc_srt_StatementGeographicalAxis_3c8d0c44-feb2-47bf-a9ef-13212f51ab3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9077d401-8183-42f5-a030-12fb0bd11777" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_3c8d0c44-feb2-47bf-a9ef-13212f51ab3e" xlink:to="loc_srt_SegmentGeographicalDomain_9077d401-8183-42f5-a030-12fb0bd11777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3370f47f-f2b6-425f-9de2-6d2fc0f521a2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9077d401-8183-42f5-a030-12fb0bd11777" xlink:to="loc_country_US_3370f47f-f2b6-425f-9de2-6d2fc0f521a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_b58070d9-7fb4-4c57-9652-5abae04561fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_607fd334-ceb1-4f3f-a4e1-c70232ca99fe" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_b58070d9-7fb4-4c57-9652-5abae04561fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_fd8210be-209a-4a02-a82b-cc1dfdd3b0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_b58070d9-7fb4-4c57-9652-5abae04561fb" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_fd8210be-209a-4a02-a82b-cc1dfdd3b0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_e59787cb-48f6-45b3-bcd6-0d3255fd6bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_fd8210be-209a-4a02-a82b-cc1dfdd3b0c9" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_e59787cb-48f6-45b3-bcd6-0d3255fd6bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_be272b93-d928-4561-8d01-180efc455ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_607fd334-ceb1-4f3f-a4e1-c70232ca99fe" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_be272b93-d928-4561-8d01-180efc455ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_54b0dcf0-e1a6-45a1-b94f-9f86ae8596b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_be272b93-d928-4561-8d01-180efc455ee7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_54b0dcf0-e1a6-45a1-b94f-9f86ae8596b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_b549e87a-c69c-4ea5-8f88-b89c46563ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_54b0dcf0-e1a6-45a1-b94f-9f86ae8596b3" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_b549e87a-c69c-4ea5-8f88-b89c46563ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_607fd334-ceb1-4f3f-a4e1-c70232ca99fe" xlink:to="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuefromContractPaymentTermMinimum_a2c9b08b-4bb5-4f9e-9359-ec2d7e5c5d1d" xlink:href="lly-20221231.xsd#lly_RevenuefromContractPaymentTermMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:to="loc_lly_RevenuefromContractPaymentTermMinimum_a2c9b08b-4bb5-4f9e-9359-ec2d7e5c5d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuefromContractPaymentTermMaximum_d0835779-24ec-4f4b-9cd1-11559b2cb213" xlink:href="lly-20221231.xsd#lly_RevenuefromContractPaymentTermMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:to="loc_lly_RevenuefromContractPaymentTermMaximum_d0835779-24ec-4f4b-9cd1-11559b2cb213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_cb49ab71-51be-43ba-a426-0aea47eed0c4" xlink:href="lly-20221231.xsd#lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:to="loc_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_cb49ab71-51be-43ba-a426-0aea47eed0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_54d53709-8b63-4ea3-9a67-6f3d88b47cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_54d53709-8b63-4ea3-9a67-6f3d88b47cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_31195653-3fdf-4e52-a33e-268bb597fb16" xlink:href="lly-20221231.xsd#lly_RevenuePerformanceObligationSalesRebatePaymentPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:to="loc_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_31195653-3fdf-4e52-a33e-268bb597fb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_3d645deb-3917-41f5-9772-7060b6559546" xlink:href="lly-20221231.xsd#lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:to="loc_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_3d645deb-3917-41f5-9772-7060b6559546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_b0e4c19b-c164-42cf-a973-a291c5c634ba" xlink:href="lly-20221231.xsd#lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:to="loc_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_b0e4c19b-c164-42cf-a973-a291c5c634ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_b4ed179b-5926-40ad-a96b-4330a6436ecf" xlink:href="lly-20221231.xsd#lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:to="loc_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_b4ed179b-5926-40ad-a96b-4330a6436ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_215190ca-03fb-4542-8fa2-a4798cac5718" xlink:href="lly-20221231.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_9f044fdd-8e0a-460d-a6c8-4c31fb6085dd" xlink:to="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_215190ca-03fb-4542-8fa2-a4798cac5718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RevenueContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e072d5bd-f046-4158-b8f9-5a8d1d357637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ed1c1fa2-5f63-4d60-adbb-d66fb7641d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e072d5bd-f046-4158-b8f9-5a8d1d357637" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ed1c1fa2-5f63-4d60-adbb-d66fb7641d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RevenueDisaggregationofRevenuebyProductDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1fd36e5e-a448-47b9-9e36-e6ac9defeaaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_152ef89d-d055-4ca3-8cc0-a9a669e2a297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1fd36e5e-a448-47b9-9e36-e6ac9defeaaf" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_152ef89d-d055-4ca3-8cc0-a9a669e2a297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c0e9c6fb-a412-4b9f-be3f-6eed2d0a8f76" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_152ef89d-d055-4ca3-8cc0-a9a669e2a297" xlink:to="loc_srt_ProductOrServiceAxis_c0e9c6fb-a412-4b9f-be3f-6eed2d0a8f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_61010694-c82a-44c4-b5e4-402d962180b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c0e9c6fb-a412-4b9f-be3f-6eed2d0a8f76" xlink:to="loc_srt_ProductsAndServicesDomain_61010694-c82a-44c4-b5e4-402d962180b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember_7d223998-bff0-4100-93d9-8c694d08a9e7" xlink:href="lly-20221231.xsd#lly_DiabetesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_61010694-c82a-44c4-b5e4-402d962180b1" xlink:to="loc_lly_DiabetesMember_7d223998-bff0-4100-93d9-8c694d08a9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMemberMember_5ddf082f-5368-421d-97ce-4a78d02b9537" xlink:href="lly-20221231.xsd#lly_TrulicityMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_7d223998-bff0-4100-93d9-8c694d08a9e7" xlink:to="loc_lly_TrulicityMemberMember_5ddf082f-5368-421d-97ce-4a78d02b9537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_93f6edf1-71fd-40d7-b46f-210fd02689e8" xlink:href="lly-20221231.xsd#lly_JardianceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_7d223998-bff0-4100-93d9-8c694d08a9e7" xlink:to="loc_lly_JardianceMember_93f6edf1-71fd-40d7-b46f-210fd02689e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember_913ef67d-dcaf-4c5d-a92a-01de11aaf656" xlink:href="lly-20221231.xsd#lly_HumalogMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_7d223998-bff0-4100-93d9-8c694d08a9e7" xlink:to="loc_lly_HumalogMember_913ef67d-dcaf-4c5d-a92a-01de11aaf656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember_58e331d9-f436-42a1-9c09-9c8042bc09fb" xlink:href="lly-20221231.xsd#lly_HumulinMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_7d223998-bff0-4100-93d9-8c694d08a9e7" xlink:to="loc_lly_HumulinMember_58e331d9-f436-42a1-9c09-9c8042bc09fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_3ae3e568-5d2b-4d60-9988-e531e4f108c8" xlink:href="lly-20221231.xsd#lly_BasaglarMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_7d223998-bff0-4100-93d9-8c694d08a9e7" xlink:to="loc_lly_BasaglarMember_3ae3e568-5d2b-4d60-9988-e531e4f108c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MounjaroMember_c0f4884e-8a0a-41af-8e90-e2773f7e2301" xlink:href="lly-20221231.xsd#lly_MounjaroMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_7d223998-bff0-4100-93d9-8c694d08a9e7" xlink:to="loc_lly_MounjaroMember_c0f4884e-8a0a-41af-8e90-e2773f7e2301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember_84c68d51-d952-4a56-9879-2d68c1f0e9c5" xlink:href="lly-20221231.xsd#lly_OtherDiabetesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_7d223998-bff0-4100-93d9-8c694d08a9e7" xlink:to="loc_lly_OtherDiabetesMember_84c68d51-d952-4a56-9879-2d68c1f0e9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember_7f611d38-94ca-4c00-a640-b534a9aa3753" xlink:href="lly-20221231.xsd#lly_OncologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_61010694-c82a-44c4-b5e4-402d962180b1" xlink:to="loc_lly_OncologyMember_7f611d38-94ca-4c00-a640-b534a9aa3753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember_5574ab93-0ab1-44bc-afec-6ffeafc1b996" xlink:href="lly-20221231.xsd#lly_VerzenioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_7f611d38-94ca-4c00-a640-b534a9aa3753" xlink:to="loc_lly_VerzenioMember_5574ab93-0ab1-44bc-afec-6ffeafc1b996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember_8c7c8798-68fb-429a-8c0b-7b4bfd7da353" xlink:href="lly-20221231.xsd#lly_CyramzaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_7f611d38-94ca-4c00-a640-b534a9aa3753" xlink:to="loc_lly_CyramzaMember_8c7c8798-68fb-429a-8c0b-7b4bfd7da353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember_2ec3065f-cb7d-4135-9146-f4faf5a56df7" xlink:href="lly-20221231.xsd#lly_AlimtaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_7f611d38-94ca-4c00-a640-b534a9aa3753" xlink:to="loc_lly_AlimtaMember_2ec3065f-cb7d-4135-9146-f4faf5a56df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember_0e32d0dc-079f-433d-aa4b-69bdf7066659" xlink:href="lly-20221231.xsd#lly_ErbituxMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_7f611d38-94ca-4c00-a640-b534a9aa3753" xlink:to="loc_lly_ErbituxMember_0e32d0dc-079f-433d-aa4b-69bdf7066659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_8ebfec99-13a5-4106-a952-bf56c5005b3a" xlink:href="lly-20221231.xsd#lly_TYVYTMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_7f611d38-94ca-4c00-a640-b534a9aa3753" xlink:to="loc_lly_TYVYTMember_8ebfec99-13a5-4106-a952-bf56c5005b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember_7e3d5562-7fc9-4789-a7cc-abe9a8b55440" xlink:href="lly-20221231.xsd#lly_OtherOncologyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_7f611d38-94ca-4c00-a640-b534a9aa3753" xlink:to="loc_lly_OtherOncologyMember_7e3d5562-7fc9-4789-a7cc-abe9a8b55440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember_410e8aaa-afd0-4aff-aafa-3a759c04e315" xlink:href="lly-20221231.xsd#lly_ImmunologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_61010694-c82a-44c4-b5e4-402d962180b1" xlink:to="loc_lly_ImmunologyMember_410e8aaa-afd0-4aff-aafa-3a759c04e315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember_9672cea9-e5b2-4af3-837c-e15addb0bcd8" xlink:href="lly-20221231.xsd#lly_TaltzMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_410e8aaa-afd0-4aff-aafa-3a759c04e315" xlink:to="loc_lly_TaltzMember_9672cea9-e5b2-4af3-837c-e15addb0bcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_6389f2bf-9e2a-4a89-b099-576f8ee57f8b" xlink:href="lly-20221231.xsd#lly_OlumiantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_410e8aaa-afd0-4aff-aafa-3a759c04e315" xlink:to="loc_lly_OlumiantMember_6389f2bf-9e2a-4a89-b099-576f8ee57f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember_a2ead966-7cc3-4e1d-94d9-d1de38d27c48" xlink:href="lly-20221231.xsd#lly_OtherImmunologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_410e8aaa-afd0-4aff-aafa-3a759c04e315" xlink:to="loc_lly_OtherImmunologyMember_a2ead966-7cc3-4e1d-94d9-d1de38d27c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember_a8c2afa9-3be1-4791-960a-9ffd2be8a699" xlink:href="lly-20221231.xsd#lly_NeuroscienceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_61010694-c82a-44c4-b5e4-402d962180b1" xlink:to="loc_lly_NeuroscienceMember_a8c2afa9-3be1-4791-960a-9ffd2be8a699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember_849cf32e-0988-4faf-bfd0-171d0186fb40" xlink:href="lly-20221231.xsd#lly_EmgalityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_a8c2afa9-3be1-4791-960a-9ffd2be8a699" xlink:to="loc_lly_EmgalityMember_849cf32e-0988-4faf-bfd0-171d0186fb40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ZyprexaMember_81a25d7a-cc4f-48a5-9b87-19f68c607480" xlink:href="lly-20221231.xsd#lly_ZyprexaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_a8c2afa9-3be1-4791-960a-9ffd2be8a699" xlink:to="loc_lly_ZyprexaMember_81a25d7a-cc4f-48a5-9b87-19f68c607480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CymbaltaMember_5cfb3277-7e19-4cb6-9a77-fe1b1677d747" xlink:href="lly-20221231.xsd#lly_CymbaltaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_a8c2afa9-3be1-4791-960a-9ffd2be8a699" xlink:to="loc_lly_CymbaltaMember_5cfb3277-7e19-4cb6-9a77-fe1b1677d747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember_a7185862-66d2-4ead-ae6a-d2fb4bd1b21d" xlink:href="lly-20221231.xsd#lly_OtherNeuroscienceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_a8c2afa9-3be1-4791-960a-9ffd2be8a699" xlink:to="loc_lly_OtherNeuroscienceMember_a7185862-66d2-4ead-ae6a-d2fb4bd1b21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember_b66165ef-cd95-4011-b595-ad865d735cb0" xlink:href="lly-20221231.xsd#lly_OtherProductTotalMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_61010694-c82a-44c4-b5e4-402d962180b1" xlink:to="loc_lly_OtherProductTotalMember_b66165ef-cd95-4011-b595-ad865d735cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_97368d6b-39ba-4c19-829e-426e801302e7" xlink:href="lly-20221231.xsd#lly_COVID19AntibodiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_b66165ef-cd95-4011-b595-ad865d735cb0" xlink:to="loc_lly_COVID19AntibodiesMember_97368d6b-39ba-4c19-829e-426e801302e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember_19e56d73-3e8b-4d7a-8d42-137309037a28" xlink:href="lly-20221231.xsd#lly_ForteoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_b66165ef-cd95-4011-b595-ad865d735cb0" xlink:to="loc_lly_ForteoMember_19e56d73-3e8b-4d7a-8d42-137309037a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_2920daa8-2cc1-40e7-b78f-307a3cf2051b" xlink:href="lly-20221231.xsd#lly_CialisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_b66165ef-cd95-4011-b595-ad865d735cb0" xlink:to="loc_lly_CialisMember_2920daa8-2cc1-40e7-b78f-307a3cf2051b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember_112eda1a-0cef-49c5-96ee-014364b2a91f" xlink:href="lly-20221231.xsd#lly_OtherProductMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_b66165ef-cd95-4011-b595-ad865d735cb0" xlink:to="loc_lly_OtherProductMember_112eda1a-0cef-49c5-96ee-014364b2a91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6d98cc07-97ac-45c4-9a37-ff0d0e55d6c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_152ef89d-d055-4ca3-8cc0-a9a669e2a297" xlink:to="loc_srt_StatementGeographicalAxis_6d98cc07-97ac-45c4-9a37-ff0d0e55d6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f889d9e6-5297-464a-8de4-0a8ac6c6ba30" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6d98cc07-97ac-45c4-9a37-ff0d0e55d6c7" xlink:to="loc_srt_SegmentGeographicalDomain_f889d9e6-5297-464a-8de4-0a8ac6c6ba30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9b763866-9fa2-47b3-b4d0-59c50e9bcf3f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f889d9e6-5297-464a-8de4-0a8ac6c6ba30" xlink:to="loc_country_US_9b763866-9fa2-47b3-b4d0-59c50e9bcf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_bbee29f2-5199-4e42-98a3-4a9f2dc05ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f889d9e6-5297-464a-8de4-0a8ac6c6ba30" xlink:to="loc_us-gaap_NonUsMember_bbee29f2-5199-4e42-98a3-4a9f2dc05ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7da71d4e-9b2d-47d6-bfc1-a513b2fc6697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_152ef89d-d055-4ca3-8cc0-a9a669e2a297" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_7da71d4e-9b2d-47d6-bfc1-a513b2fc6697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cac1cf2b-e50e-44ee-b171-6895df0e2680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7da71d4e-9b2d-47d6-bfc1-a513b2fc6697" xlink:to="loc_us-gaap_Revenues_cac1cf2b-e50e-44ee-b171-6895df0e2680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RevenueDisaggregationofRevenuebyGeographicalAreaDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_01a1743d-6645-4a4a-82a6-f878c79815e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b5a326bf-54db-4906-9342-5c9546d3e1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_01a1743d-6645-4a4a-82a6-f878c79815e8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b5a326bf-54db-4906-9342-5c9546d3e1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a9e5950f-2459-4849-9795-1e5c5d38c2a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5a326bf-54db-4906-9342-5c9546d3e1d5" xlink:to="loc_srt_StatementGeographicalAxis_a9e5950f-2459-4849-9795-1e5c5d38c2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ec9965ed-8989-4db5-9236-c206a26ebef3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a9e5950f-2459-4849-9795-1e5c5d38c2a8" xlink:to="loc_srt_SegmentGeographicalDomain_ec9965ed-8989-4db5-9236-c206a26ebef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a2c052c6-73a5-4311-912e-3bffef9b898f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ec9965ed-8989-4db5-9236-c206a26ebef3" xlink:to="loc_country_US_a2c052c6-73a5-4311-912e-3bffef9b898f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_d733e048-b3d0-4ad7-a7f5-abf563f8ae36" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ec9965ed-8989-4db5-9236-c206a26ebef3" xlink:to="loc_srt_EuropeMember_d733e048-b3d0-4ad7-a7f5-abf563f8ae36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_1c36adee-5d5e-4aa1-99d3-16f39930e66a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ec9965ed-8989-4db5-9236-c206a26ebef3" xlink:to="loc_country_JP_1c36adee-5d5e-4aa1-99d3-16f39930e66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_81f27611-8280-4110-ae5d-d62628ffc788" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ec9965ed-8989-4db5-9236-c206a26ebef3" xlink:to="loc_country_CN_81f27611-8280-4110-ae5d-d62628ffc788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_f61a0b37-f8a3-47af-bf5f-308de51b8dfd" xlink:href="lly-20221231.xsd#lly_OtherForeignCountriesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ec9965ed-8989-4db5-9236-c206a26ebef3" xlink:to="loc_lly_OtherForeignCountriesMember_f61a0b37-f8a3-47af-bf5f-308de51b8dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_07aa12dd-e222-4788-80b0-e0cbe7f8d761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5a326bf-54db-4906-9342-5c9546d3e1d5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_07aa12dd-e222-4788-80b0-e0cbe7f8d761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_88549904-c2fd-4e96-adde-de7d45f9aadf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_07aa12dd-e222-4788-80b0-e0cbe7f8d761" xlink:to="loc_us-gaap_Revenues_88549904-c2fd-4e96-adde-de7d45f9aadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_687b9544-7084-4878-8583-c8ca39acfb33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3edf25f9-4b74-4442-af5c-c448ab301d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_687b9544-7084-4878-8583-c8ca39acfb33" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3edf25f9-4b74-4442-af5c-c448ab301d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_daf49d9a-b690-44f3-85b7-8468864a35fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3edf25f9-4b74-4442-af5c-c448ab301d8e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_daf49d9a-b690-44f3-85b7-8468864a35fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dae62549-6bc6-4c6c-9807-6a7188d97064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_daf49d9a-b690-44f3-85b7-8468864a35fe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dae62549-6bc6-4c6c-9807-6a7188d97064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AkouosAcquisitionMember_3c9695f0-0c3e-4c23-8682-3b8990a7b612" xlink:href="lly-20221231.xsd#lly_AkouosAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dae62549-6bc6-4c6c-9807-6a7188d97064" xlink:to="loc_lly_AkouosAcquisitionMember_3c9695f0-0c3e-4c23-8682-3b8990a7b612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_58f854d2-91a8-4a6b-a6ac-5e6c2a7f7154" xlink:href="lly-20221231.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dae62549-6bc6-4c6c-9807-6a7188d97064" xlink:to="loc_lly_PrevailTherapeuticsIncMember_58f854d2-91a8-4a6b-a6ac-5e6c2a7f7154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DermiraInc.Member_d92e96fb-25dd-468c-b159-27d430310416" xlink:href="lly-20221231.xsd#lly_DermiraInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dae62549-6bc6-4c6c-9807-6a7188d97064" xlink:to="loc_lly_DermiraInc.Member_d92e96fb-25dd-468c-b159-27d430310416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3edf25f9-4b74-4442-af5c-c448ab301d8e" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_1abdce91-355e-4c43-92fe-72f06da835f3" xlink:href="lly-20221231.xsd#lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones_1abdce91-355e-4c43-92fe-72f06da835f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_9da553cc-00fd-4a54-b069-d83f87d1199c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_9da553cc-00fd-4a54-b069-d83f87d1199c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bc4ac2b1-2ce0-4ec4-a00b-6a151e19c61f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bc4ac2b1-2ce0-4ec4-a00b-6a151e19c61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_e76495e6-23b6-4e7f-8306-b2a148505e75" xlink:href="lly-20221231.xsd#lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_e76495e6-23b6-4e7f-8306-b2a148505e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_f2654c65-a493-429e-bfae-3c4137e1d4d6" xlink:href="lly-20221231.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_f2654c65-a493-429e-bfae-3c4137e1d4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_d5686157-d722-4a1e-a2d7-97003ebb1c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_d5686157-d722-4a1e-a2d7-97003ebb1c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_05212bf3-92d3-49c0-a80d-c48f03579242" xlink:href="lly-20221231.xsd#lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_05212bf3-92d3-49c0-a80d-c48f03579242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_4cc8a7d1-930d-442c-92fa-6075550ec288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_4cc8a7d1-930d-442c-92fa-6075550ec288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_17d3bfbe-3873-4244-a4db-8d4b5a4a8552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_us-gaap_Goodwill_17d3bfbe-3873-4244-a4db-8d4b5a4a8552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ed998c03-3f27-4aa4-90ab-5ea1f898751b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ed998c03-3f27-4aa4-90ab-5ea1f898751b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c95de0fd-5311-4f81-bc65-745761ab3f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c95de0fd-5311-4f81-bc65-745761ab3f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_af63d8bb-91d4-4a6f-b31c-b18eb27b0ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_af63d8bb-91d4-4a6f-b31c-b18eb27b0ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f1771f71-01cf-4141-a321-c6d7e6a7d496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f1771f71-01cf-4141-a321-c6d7e6a7d496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForAssetAcquisitions_8339f687-b35a-4425-9d07-57ceec0e9da5" xlink:href="lly-20221231.xsd#lly_PaymentsForAssetAcquisitions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_93135d2e-8ca0-449b-9e40-f5fbc73388d2" xlink:to="loc_lly_PaymentsForAssetAcquisitions_8339f687-b35a-4425-9d07-57ceec0e9da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a1ae1875-2c24-4273-ac41-bc1fa867251e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b261f04c-79a6-4f05-bde6-17d9e86063d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a1ae1875-2c24-4273-ac41-bc1fa867251e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b261f04c-79a6-4f05-bde6-17d9e86063d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_30f51f80-ab0f-4598-ab40-103882f31f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b261f04c-79a6-4f05-bde6-17d9e86063d6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_30f51f80-ab0f-4598-ab40-103882f31f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aba75ba3-e8e1-45a6-8c85-3fbe296a6834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_30f51f80-ab0f-4598-ab40-103882f31f1f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aba75ba3-e8e1-45a6-8c85-3fbe296a6834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AkouosAcquisitionMember_beb98d87-9dea-4794-b95e-7400513e663c" xlink:href="lly-20221231.xsd#lly_AkouosAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aba75ba3-e8e1-45a6-8c85-3fbe296a6834" xlink:to="loc_lly_AkouosAcquisitionMember_beb98d87-9dea-4794-b95e-7400513e663c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_39d1f5ae-7858-438a-a4b2-13bcfdc6ab16" xlink:href="lly-20221231.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aba75ba3-e8e1-45a6-8c85-3fbe296a6834" xlink:to="loc_lly_PrevailTherapeuticsIncMember_39d1f5ae-7858-438a-a4b2-13bcfdc6ab16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b261f04c-79a6-4f05-bde6-17d9e86063d6" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a3e3172d-466b-4432-8ef0-47ca69635899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a3e3172d-466b-4432-8ef0-47ca69635899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_97c16dab-6579-4743-99e4-9d0cddcfa415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_97c16dab-6579-4743-99e4-9d0cddcfa415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8161504c-39e2-4cdd-bc31-b26a63ed25e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:to="loc_us-gaap_Goodwill_8161504c-39e2-4cdd-bc31-b26a63ed25e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3506d52c-9452-44f3-baf3-7a3f01e93504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3506d52c-9452-44f3-baf3-7a3f01e93504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_3d28e0da-ebaa-42b5-94eb-978ebadf0506" xlink:href="lly-20221231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_3d28e0da-ebaa-42b5-94eb-978ebadf0506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_cab32884-d466-4af6-b66f-108c7c19bfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_cab32884-d466-4af6-b66f-108c7c19bfb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_8e3b1ae4-bb66-43aa-a975-b36aef7d8341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_8e3b1ae4-bb66-43aa-a975-b36aef7d8341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_d2b0ac0b-b8fd-42d9-81d6-82b1459441d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_d2b0ac0b-b8fd-42d9-81d6-82b1459441d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bb33b18b-01da-4fef-b1f4-9488f11a5715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b0f79584-6188-4bbb-bfa3-acdb78ef8413" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bb33b18b-01da-4fef-b1f4-9488f11a5715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#AcquisitionsAssetAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c3c2436f-9184-42bf-8169-44c991b70595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a3a21c4d-2c62-48c6-9717-299b9a326944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c3c2436f-9184-42bf-8169-44c991b70595" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a3a21c4d-2c62-48c6-9717-299b9a326944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_646c4c85-1fee-4572-94af-53b82c95a83e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a3a21c4d-2c62-48c6-9717-299b9a326944" xlink:to="loc_us-gaap_AssetAcquisitionAxis_646c4c85-1fee-4572-94af-53b82c95a83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_c15a4a2d-98ec-4bbc-95b0-3fd96cf7d27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_646c4c85-1fee-4572-94af-53b82c95a83e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_c15a4a2d-98ec-4bbc-95b0-3fd96cf7d27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BioMarinPharmaceuticalIncMember_bfdcdada-2777-4fb8-a6c5-35d5748b1def" xlink:href="lly-20221231.xsd#lly_BioMarinPharmaceuticalIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c15a4a2d-98ec-4bbc-95b0-3fd96cf7d27f" xlink:to="loc_lly_BioMarinPharmaceuticalIncMember_bfdcdada-2777-4fb8-a6c5-35d5748b1def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FoghornTherapeuticsIncMember_8fd805d1-54c3-4b76-ae5c-c1be568ee6aa" xlink:href="lly-20221231.xsd#lly_FoghornTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c15a4a2d-98ec-4bbc-95b0-3fd96cf7d27f" xlink:to="loc_lly_FoghornTherapeuticsIncMember_8fd805d1-54c3-4b76-ae5c-c1be568ee6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RigelPharmaceuticalsIncMember_26b9d00f-2e2f-415d-bed8-9e86625e2cdf" xlink:href="lly-20221231.xsd#lly_RigelPharmaceuticalsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c15a4a2d-98ec-4bbc-95b0-3fd96cf7d27f" xlink:to="loc_lly_RigelPharmaceuticalsIncMember_26b9d00f-2e2f-415d-bed8-9e86625e2cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBiosciencesIncMember_ad8dcb2f-506d-47bb-96e7-bfc8bb786fe3" xlink:href="lly-20221231.xsd#lly_PrecisionBiosciencesIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c15a4a2d-98ec-4bbc-95b0-3fd96cf7d27f" xlink:to="loc_lly_PrecisionBiosciencesIncMember_ad8dcb2f-506d-47bb-96e7-bfc8bb786fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember_a0bd8849-74a3-4a1e-9c44-a9d47925ecc1" xlink:href="lly-20221231.xsd#lly_InnoventBiologicsIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c15a4a2d-98ec-4bbc-95b0-3fd96cf7d27f" xlink:to="loc_lly_InnoventBiologicsIncMember_a0bd8849-74a3-4a1e-9c44-a9d47925ecc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PetraPharmaCorporationMember_9d8158cb-11e2-42c0-953f-e011f6f474d0" xlink:href="lly-20221231.xsd#lly_PetraPharmaCorporationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c15a4a2d-98ec-4bbc-95b0-3fd96cf7d27f" xlink:to="loc_lly_PetraPharmaCorporationMember_9d8158cb-11e2-42c0-953f-e011f6f474d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisarmTherapeuticsIncMember_677f0414-b2ae-493f-9abe-21d63ff71cc2" xlink:href="lly-20221231.xsd#lly_DisarmTherapeuticsIncMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c15a4a2d-98ec-4bbc-95b0-3fd96cf7d27f" xlink:to="loc_lly_DisarmTherapeuticsIncMember_677f0414-b2ae-493f-9abe-21d63ff71cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_cf0d2e51-4e69-4035-a449-8026e71b4eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a3a21c4d-2c62-48c6-9717-299b9a326944" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_cf0d2e51-4e69-4035-a449-8026e71b4eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForAssetAcquisitions_bd81e3af-2ead-4e8d-afab-2ea518e9a886" xlink:href="lly-20221231.xsd#lly_PaymentsForAssetAcquisitions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cf0d2e51-4e69-4035-a449-8026e71b4eba" xlink:to="loc_lly_PaymentsForAssetAcquisitions_bd81e3af-2ead-4e8d-afab-2ea518e9a886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2e0a8b51-dc88-4bf3-818a-439ed53c8a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_545a33d7-f8e3-4619-a31b-6bb266d78a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2e0a8b51-dc88-4bf3-818a-439ed53c8a4c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_545a33d7-f8e3-4619-a31b-6bb266d78a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f6828dc9-640b-4d07-bfc9-52d2bb692cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_545a33d7-f8e3-4619-a31b-6bb266d78a19" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f6828dc9-640b-4d07-bfc9-52d2bb692cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c69f249-ebf5-45d6-8739-aab8d0454137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f6828dc9-640b-4d07-bfc9-52d2bb692cdf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c69f249-ebf5-45d6-8739-aab8d0454137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_19d3f14c-748a-45dc-ab0e-ce288d307dcb" xlink:href="lly-20221231.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c69f249-ebf5-45d6-8739-aab8d0454137" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_19d3f14c-748a-45dc-ab0e-ce288d307dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4f95c1ca-a89b-4620-a3fb-6693265535d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_545a33d7-f8e3-4619-a31b-6bb266d78a19" xlink:to="loc_srt_ProductOrServiceAxis_4f95c1ca-a89b-4620-a3fb-6693265535d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_34e6e460-d63e-44fd-8975-0e43b5307d2a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4f95c1ca-a89b-4620-a3fb-6693265535d0" xlink:to="loc_srt_ProductsAndServicesDomain_34e6e460-d63e-44fd-8975-0e43b5307d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_2f02c7ac-2c37-43ec-a4c6-2e77ada10cd9" xlink:href="lly-20221231.xsd#lly_JardianceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_34e6e460-d63e-44fd-8975-0e43b5307d2a" xlink:to="loc_lly_JardianceMember_2f02c7ac-2c37-43ec-a4c6-2e77ada10cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_c38a4e10-4291-4d80-b58e-4717b06fcea3" xlink:href="lly-20221231.xsd#lly_TrajentaBIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_34e6e460-d63e-44fd-8975-0e43b5307d2a" xlink:to="loc_lly_TrajentaBIMember_c38a4e10-4291-4d80-b58e-4717b06fcea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_faa301c8-6eb3-4fed-aec5-0cb1d4928785" xlink:href="lly-20221231.xsd#lly_BasaglarMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_34e6e460-d63e-44fd-8975-0e43b5307d2a" xlink:to="loc_lly_BasaglarMember_faa301c8-6eb3-4fed-aec5-0cb1d4928785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8da8f3c0-8a69-48d1-aeeb-c7f51700c0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_545a33d7-f8e3-4619-a31b-6bb266d78a19" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8da8f3c0-8a69-48d1-aeeb-c7f51700c0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_e36b9ade-1145-411c-baea-8dade2342099" xlink:href="lly-20221231.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8da8f3c0-8a69-48d1-aeeb-c7f51700c0bc" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_e36b9ade-1145-411c-baea-8dade2342099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#CollaborationsandOtherArrangementsNetProductRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_da06e1b5-fa67-4615-bf0a-fcefa3ae6288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d4221c4-3f29-493f-998d-97411ea0d4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_da06e1b5-fa67-4615-bf0a-fcefa3ae6288" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d4221c4-3f29-493f-998d-97411ea0d4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2bb5559f-f3c8-4901-9894-2c0c20fe573c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d4221c4-3f29-493f-998d-97411ea0d4b3" xlink:to="loc_srt_ProductOrServiceAxis_2bb5559f-f3c8-4901-9894-2c0c20fe573c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d57b7a92-e181-4f9a-906a-bd8c94746671" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2bb5559f-f3c8-4901-9894-2c0c20fe573c" xlink:to="loc_srt_ProductsAndServicesDomain_d57b7a92-e181-4f9a-906a-bd8c94746671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_eb1be344-6ae2-4b3d-89f5-422053624c24" xlink:href="lly-20221231.xsd#lly_JardianceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d57b7a92-e181-4f9a-906a-bd8c94746671" xlink:to="loc_lly_JardianceMember_eb1be344-6ae2-4b3d-89f5-422053624c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_ed65267b-0abf-4b4d-9f99-096e5b12ca7d" xlink:href="lly-20221231.xsd#lly_BasaglarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d57b7a92-e181-4f9a-906a-bd8c94746671" xlink:to="loc_lly_BasaglarMember_ed65267b-0abf-4b4d-9f99-096e5b12ca7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_7a9f9658-3ec9-4dda-a46f-b8813f3ca545" xlink:href="lly-20221231.xsd#lly_TrajentaBIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d57b7a92-e181-4f9a-906a-bd8c94746671" xlink:to="loc_lly_TrajentaBIMember_7a9f9658-3ec9-4dda-a46f-b8813f3ca545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_b50eabce-4202-4dbf-a6a4-7f42b92917a3" xlink:href="lly-20221231.xsd#lly_OlumiantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d57b7a92-e181-4f9a-906a-bd8c94746671" xlink:to="loc_lly_OlumiantMember_b50eabce-4202-4dbf-a6a4-7f42b92917a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_959ff808-85c2-42fc-aa0a-220a711b08c4" xlink:href="lly-20221231.xsd#lly_TYVYTMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d57b7a92-e181-4f9a-906a-bd8c94746671" xlink:to="loc_lly_TYVYTMember_959ff808-85c2-42fc-aa0a-220a711b08c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2d2cebd-909a-4947-985d-2eee2f6f846b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d4221c4-3f29-493f-998d-97411ea0d4b3" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2d2cebd-909a-4947-985d-2eee2f6f846b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a90de216-5a81-4e0a-98bc-24c9fc612532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2d2cebd-909a-4947-985d-2eee2f6f846b" xlink:to="loc_us-gaap_Revenues_a90de216-5a81-4e0a-98bc-24c9fc612532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#CollaborationsandOtherArrangementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_99170bfc-b1f1-4745-b05b-52ff9535324c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f098bd77-851e-4846-bf2e-cc88ed1a32be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_99170bfc-b1f1-4745-b05b-52ff9535324c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f098bd77-851e-4846-bf2e-cc88ed1a32be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e579297c-ab6f-40ed-bc12-7433a6977307" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f098bd77-851e-4846-bf2e-cc88ed1a32be" xlink:to="loc_srt_ProductOrServiceAxis_e579297c-ab6f-40ed-bc12-7433a6977307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_52e90d1d-b9ef-4102-a865-c07106775c5f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e579297c-ab6f-40ed-bc12-7433a6977307" xlink:to="loc_srt_ProductsAndServicesDomain_52e90d1d-b9ef-4102-a865-c07106775c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_586fb0ef-239e-4ada-87f4-db5ceee4414d" xlink:href="lly-20221231.xsd#lly_OlumiantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_52e90d1d-b9ef-4102-a865-c07106775c5f" xlink:to="loc_lly_OlumiantMember_586fb0ef-239e-4ada-87f4-db5ceee4414d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_c72ad686-23ef-4a44-9da2-28b45bb4b807" xlink:href="lly-20221231.xsd#lly_COVID19AntibodiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_52e90d1d-b9ef-4102-a865-c07106775c5f" xlink:to="loc_lly_COVID19AntibodiesMember_c72ad686-23ef-4a44-9da2-28b45bb4b807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember_0571d8e1-3389-4b01-a7cf-8199f29ddeeb" xlink:href="lly-20221231.xsd#lly_LebrikizumabMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_52e90d1d-b9ef-4102-a865-c07106775c5f" xlink:to="loc_lly_LebrikizumabMember_0571d8e1-3389-4b01-a7cf-8199f29ddeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e7739781-d5ef-45fa-a886-21980237865c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f098bd77-851e-4846-bf2e-cc88ed1a32be" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e7739781-d5ef-45fa-a886-21980237865c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17a1c0af-c019-45b7-950c-41199940d70e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e7739781-d5ef-45fa-a886-21980237865c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17a1c0af-c019-45b7-950c-41199940d70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_0a32aa02-f18d-4dc6-9206-8cbb9535aff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17a1c0af-c019-45b7-950c-41199940d70e" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_0a32aa02-f18d-4dc6-9206-8cbb9535aff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_4dd628c2-b4ca-41cf-a825-b6402b1be0b7" xlink:href="lly-20221231.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17a1c0af-c019-45b7-950c-41199940d70e" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_4dd628c2-b4ca-41cf-a825-b6402b1be0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_95f3b475-bb06-47b0-8bab-2f0974c13301" xlink:href="lly-20221231.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17a1c0af-c019-45b7-950c-41199940d70e" xlink:to="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_95f3b475-bb06-47b0-8bab-2f0974c13301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember_ae5722b7-35cb-4bb0-99b4-8d783821f143" xlink:href="lly-20221231.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17a1c0af-c019-45b7-950c-41199940d70e" xlink:to="loc_lly_MilestonePaymentsSalesBasedMember_ae5722b7-35cb-4bb0-99b4-8d783821f143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c4d5d80c-a336-4aaa-87ec-f5ef4ab236b4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f098bd77-851e-4846-bf2e-cc88ed1a32be" xlink:to="loc_dei_LegalEntityAxis_c4d5d80c-a336-4aaa-87ec-f5ef4ab236b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8142062f-055e-40f4-b222-8faf64966f42" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_c4d5d80c-a336-4aaa-87ec-f5ef4ab236b4" xlink:to="loc_dei_EntityDomain_8142062f-055e-40f4-b222-8faf64966f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember_fd0710e0-2ba0-4bfc-88dd-722900b37d96" xlink:href="lly-20221231.xsd#lly_RocheMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_8142062f-055e-40f4-b222-8faf64966f42" xlink:to="loc_lly_RocheMember_fd0710e0-2ba0-4bfc-88dd-722900b37d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dee99b3d-9703-4a48-b97e-c0b333b8f057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f098bd77-851e-4846-bf2e-cc88ed1a32be" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dee99b3d-9703-4a48-b97e-c0b333b8f057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_d4dd8ffb-e1ad-49c0-836f-a7357a31c7cf" xlink:href="lly-20221231.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dee99b3d-9703-4a48-b97e-c0b333b8f057" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_d4dd8ffb-e1ad-49c0-836f-a7357a31c7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_90bd473a-f62a-413c-a69d-02510ba9e934" xlink:href="lly-20221231.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dee99b3d-9703-4a48-b97e-c0b333b8f057" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_90bd473a-f62a-413c-a69d-02510ba9e934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c081d5cc-faca-4a89-ba3a-d463524665f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dee99b3d-9703-4a48-b97e-c0b333b8f057" xlink:to="loc_us-gaap_Revenues_c081d5cc-faca-4a89-ba3a-d463524665f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_11d0db5e-4182-4fef-b1e5-d9c4c697e342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_4d8f81aa-fbce-4fc5-946c-648f3537f617" xlink:href="lly-20221231.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_11d0db5e-4182-4fef-b1e5-d9c4c697e342" xlink:to="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_4d8f81aa-fbce-4fc5-946c-648f3537f617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_e5ef3f60-0e91-4531-98e4-6a1ed9608c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_11d0db5e-4182-4fef-b1e5-d9c4c697e342" xlink:to="loc_us-gaap_SeveranceCosts1_e5ef3f60-0e91-4531-98e4-6a1ed9608c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_416d3def-d34a-43c4-bf4d-bf405832073a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_11d0db5e-4182-4fef-b1e5-d9c4c697e342" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_416d3def-d34a-43c4-bf4d-bf405832073a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c0465d8f-e642-4720-8758-9623ad1d2803" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_96542c0f-f6aa-498f-aa5c-f08c45dd5312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c0465d8f-e642-4720-8758-9623ad1d2803" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_96542c0f-f6aa-498f-aa5c-f08c45dd5312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_53a4dba1-192a-46f7-8c6b-1f2234d758d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c0465d8f-e642-4720-8758-9623ad1d2803" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_53a4dba1-192a-46f7-8c6b-1f2234d758d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_ec25c65e-55f4-4a98-b3be-2d2785d30c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c0465d8f-e642-4720-8758-9623ad1d2803" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_ec25c65e-55f4-4a98-b3be-2d2785d30c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7fd9dc89-3f54-44ba-9b81-1b6717bd8fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c0465d8f-e642-4720-8758-9623ad1d2803" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7fd9dc89-3f54-44ba-9b81-1b6717bd8fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/InventoriesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_98be8ce1-75d2-4f1d-9181-34eaf20f3af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_5599b7ca-ea19-4594-8992-9e3426f18664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_98be8ce1-75d2-4f1d-9181-34eaf20f3af1" xlink:to="loc_us-gaap_InventoryFinishedGoods_5599b7ca-ea19-4594-8992-9e3426f18664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_9d22c507-75a1-445b-8749-f60e027028df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_98be8ce1-75d2-4f1d-9181-34eaf20f3af1" xlink:to="loc_us-gaap_InventoryWorkInProcess_9d22c507-75a1-445b-8749-f60e027028df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_985d5bd0-de45-4d64-a7d3-ad57e78bde63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_98be8ce1-75d2-4f1d-9181-34eaf20f3af1" xlink:to="loc_us-gaap_InventoryRawMaterials_985d5bd0-de45-4d64-a7d3-ad57e78bde63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_610e1002-b6ef-4aa3-89ce-c2d493472aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_98be8ce1-75d2-4f1d-9181-34eaf20f3af1" xlink:to="loc_us-gaap_InventoryGross_610e1002-b6ef-4aa3-89ce-c2d493472aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve_9bc1b3f9-1b38-40b6-aded-a0c0d15ce6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_98be8ce1-75d2-4f1d-9181-34eaf20f3af1" xlink:to="loc_us-gaap_InventoryLIFOReserve_9bc1b3f9-1b38-40b6-aded-a0c0d15ce6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_359e2ef9-e9e8-4738-a81e-d851b9b9fa6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_98be8ce1-75d2-4f1d-9181-34eaf20f3af1" xlink:to="loc_us-gaap_InventoryNet_359e2ef9-e9e8-4738-a81e-d851b9b9fa6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LIFOInventoryAmount_f509f3d8-39c2-4a2d-a41e-dd8ae5b46ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LIFOInventoryAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_98be8ce1-75d2-4f1d-9181-34eaf20f3af1" xlink:to="loc_us-gaap_LIFOInventoryAmount_f509f3d8-39c2-4a2d-a41e-dd8ae5b46ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_e30bf694-9069-400c-91ef-2125c9789455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_98be8ce1-75d2-4f1d-9181-34eaf20f3af1" xlink:to="loc_us-gaap_InventoryWriteDown_e30bf694-9069-400c-91ef-2125c9789455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c7b9eb9a-516e-442b-bcca-35d2e8e87a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_981c8d73-6329-4144-ab9f-e53103371165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c7b9eb9a-516e-442b-bcca-35d2e8e87a89" xlink:to="loc_us-gaap_DerivativeTable_981c8d73-6329-4144-ab9f-e53103371165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ef8b26ca-a226-4e82-b734-1e11dfa4bdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_981c8d73-6329-4144-ab9f-e53103371165" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ef8b26ca-a226-4e82-b734-1e11dfa4bdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0a72f89c-8751-4e0c-bc8b-f678d120a18d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ef8b26ca-a226-4e82-b734-1e11dfa4bdc5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0a72f89c-8751-4e0c-bc8b-f678d120a18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember_ec85e9fe-6c27-4aad-944a-6c09f506719c" xlink:href="lly-20221231.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0a72f89c-8751-4e0c-bc8b-f678d120a18d" xlink:to="loc_lly_ForeignCurrencyDenominatedDebtMember_ec85e9fe-6c27-4aad-944a-6c09f506719c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c157480a-5ade-4ab5-a3e7-4242b140eed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_981c8d73-6329-4144-ab9f-e53103371165" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c157480a-5ade-4ab5-a3e7-4242b140eed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9cd23c8c-07b1-4600-a1fc-84547eb09551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c157480a-5ade-4ab5-a3e7-4242b140eed8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9cd23c8c-07b1-4600-a1fc-84547eb09551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapUSDollarsToEuroMember_768bf746-18fc-4b56-a4c7-d457cac9b849" xlink:href="lly-20221231.xsd#lly_SwapUSDollarsToEuroMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9cd23c8c-07b1-4600-a1fc-84547eb09551" xlink:to="loc_lly_SwapUSDollarsToEuroMember_768bf746-18fc-4b56-a4c7-d457cac9b849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember_ebec46f8-6268-4549-b154-41dc423b0682" xlink:href="lly-20221231.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9cd23c8c-07b1-4600-a1fc-84547eb09551" xlink:to="loc_lly_SwapSwissFrancsToU.S.DollarsMember_ebec46f8-6268-4549-b154-41dc423b0682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SellEuroMember_4c68a85f-ada3-4f19-ad82-c92477e1906d" xlink:href="lly-20221231.xsd#lly_SellEuroMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9cd23c8c-07b1-4600-a1fc-84547eb09551" xlink:to="loc_lly_SellEuroMember_4c68a85f-ada3-4f19-ad82-c92477e1906d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SellChineseYuanMember_ceaa67b0-9450-4ebc-8ed4-190a498958df" xlink:href="lly-20221231.xsd#lly_SellChineseYuanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9cd23c8c-07b1-4600-a1fc-84547eb09551" xlink:to="loc_lly_SellChineseYuanMember_ceaa67b0-9450-4ebc-8ed4-190a498958df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_89849e10-5f74-4c83-9865-1b4bcdb125b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9cd23c8c-07b1-4600-a1fc-84547eb09551" xlink:to="loc_us-gaap_InterestRateSwapMember_89849e10-5f74-4c83-9865-1b4bcdb125b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_12a6ef63-a8d9-42df-b74c-5da053f6348e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_981c8d73-6329-4144-ab9f-e53103371165" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_12a6ef63-a8d9-42df-b74c-5da053f6348e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_edba6e87-f8ba-42e1-9634-b1df4f880558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_12a6ef63-a8d9-42df-b74c-5da053f6348e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_edba6e87-f8ba-42e1-9634-b1df4f880558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_0102d8e5-2b03-4d42-92cb-ad70f1177245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_edba6e87-f8ba-42e1-9634-b1df4f880558" xlink:to="loc_us-gaap_CashFlowHedgingMember_0102d8e5-2b03-4d42-92cb-ad70f1177245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_464d38ed-1cc3-45e3-9136-48bcf61582d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_981c8d73-6329-4144-ab9f-e53103371165" xlink:to="loc_us-gaap_HedgingDesignationAxis_464d38ed-1cc3-45e3-9136-48bcf61582d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_15edf46e-2e2b-4546-b9d6-7b414f3987f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_464d38ed-1cc3-45e3-9136-48bcf61582d7" xlink:to="loc_us-gaap_HedgingDesignationDomain_15edf46e-2e2b-4546-b9d6-7b414f3987f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d7274371-ac4f-4731-8ca7-9772b2ab699b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_15edf46e-2e2b-4546-b9d6-7b414f3987f7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d7274371-ac4f-4731-8ca7-9772b2ab699b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_981c8d73-6329-4144-ab9f-e53103371165" xlink:to="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_e13841d4-a89f-4318-b725-ffeea6a9b146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_e13841d4-a89f-4318-b725-ffeea6a9b146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_c83d42c8-3a76-4db4-8949-5af514251b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_c83d42c8-3a76-4db4-8949-5af514251b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_205546da-3ad4-46d0-a586-ef11fd622f87" xlink:href="lly-20221231.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_205546da-3ad4-46d0-a586-ef11fd622f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_20895cd5-edf9-4264-930a-88b4783677aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_20895cd5-edf9-4264-930a-88b4783677aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_9170fccd-96ff-4639-8abb-442d7440369f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_9170fccd-96ff-4639-8abb-442d7440369f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_595a53b3-bd74-4456-a1aa-27f63ae3f1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_595a53b3-bd74-4456-a1aa-27f63ae3f1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_53efc510-97ab-46cf-aab1-13d2d53ec5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_53efc510-97ab-46cf-aab1-13d2d53ec5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_004298b6-da58-4a1a-98fa-9e33969e00e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_LongTermDebt_004298b6-da58-4a1a-98fa-9e33969e00e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_8c0082da-0c11-4fa4-bff1-49658bbf730e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_8c0082da-0c11-4fa4-bff1-49658bbf730e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_cbfd3c3f-0bac-4aab-b9d1-e3a33980e75b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_cbfd3c3f-0bac-4aab-b9d1-e3a33980e75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_d6b9bb4f-3803-42a2-862c-7fa2afae5993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_d6b9bb4f-3803-42a2-862c-7fa2afae5993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_e9610af9-34dd-46f8-a4a5-60378a1ba0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_e9610af9-34dd-46f8-a4a5-60378a1ba0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_01c87509-78ce-40a1-bad8-605b44fea326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_DerivativeNotionalAmount_01c87509-78ce-40a1-bad8-605b44fea326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_0be13842-9570-41a5-a3a0-d1100125d089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b0e27c8e-dec2-4df1-929c-118cd3135afa" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_0be13842-9570-41a5-a3a0-d1100125d089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstrumentsScheduleofContractualMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9dc56896-049f-44f7-abca-b71f7a3e9c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d18ea5b8-cc74-4e1f-a55d-0e1d634c5204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9dc56896-049f-44f7-abca-b71f7a3e9c07" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d18ea5b8-cc74-4e1f-a55d-0e1d634c5204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d2b091a6-4c47-4156-8f27-d8e5158ec0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9dc56896-049f-44f7-abca-b71f7a3e9c07" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d2b091a6-4c47-4156-8f27-d8e5158ec0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_84844ee6-d216-4470-b179-d13bb4f62ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9dc56896-049f-44f7-abca-b71f7a3e9c07" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_84844ee6-d216-4470-b179-d13bb4f62ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_f0450a6b-6222-4ced-a64f-e031a788173f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9dc56896-049f-44f7-abca-b71f7a3e9c07" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_f0450a6b-6222-4ced-a64f-e031a788173f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_d0ecee3a-7e74-4e90-9fa3-d95a62d3842b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9dc56896-049f-44f7-abca-b71f7a3e9c07" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_d0ecee3a-7e74-4e90-9fa3-d95a62d3842b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstrumentsUnrealizedGainsandLossesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7da2fa54-0dfc-4923-b4c9-186af61b198c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3f3b90a9-836a-4942-926e-10d49b11da83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7da2fa54-0dfc-4923-b4c9-186af61b198c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3f3b90a9-836a-4942-926e-10d49b11da83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_71d214c8-3d73-4783-9c93-dc95ffbcab5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7da2fa54-0dfc-4923-b4c9-186af61b198c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_71d214c8-3d73-4783-9c93-dc95ffbcab5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_95dae074-ac44-4075-b576-1be043b86650" xlink:href="lly-20221231.xsd#lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7da2fa54-0dfc-4923-b4c9-186af61b198c" xlink:to="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_95dae074-ac44-4075-b576-1be043b86650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_7ca97db5-31eb-4e78-8c29-4ec7b1574168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7da2fa54-0dfc-4923-b4c9-186af61b198c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_7ca97db5-31eb-4e78-8c29-4ec7b1574168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstrumentsRealizedGainsandLossesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c9fffc71-31e1-4719-81cd-dee50b788a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_4a439425-747b-4aa1-9b0b-748bfdcdf30e" xlink:href="lly-20221231.xsd#lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c9fffc71-31e1-4719-81cd-dee50b788a49" xlink:to="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_4a439425-747b-4aa1-9b0b-748bfdcdf30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_d2c51b34-ca7a-4739-9d5a-a27853b07eaf" xlink:href="lly-20221231.xsd#lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c9fffc71-31e1-4719-81cd-dee50b788a49" xlink:to="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_d2c51b34-ca7a-4739-9d5a-a27853b07eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_175c4cd2-01da-470e-b172-e0781824d8bc" xlink:href="lly-20221231.xsd#lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c9fffc71-31e1-4719-81cd-dee50b788a49" xlink:to="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_175c4cd2-01da-470e-b172-e0781824d8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstrumentsScheduleofFairValueMeasurementDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ba5c15d5-c715-40d4-95d8-a5b0cf10bf13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4f3aa845-d94e-4c84-b205-018ff380f6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ba5c15d5-c715-40d4-95d8-a5b0cf10bf13" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4f3aa845-d94e-4c84-b205-018ff380f6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_ce9ccb8b-911a-4582-825b-2d2f16920cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4f3aa845-d94e-4c84-b205-018ff380f6b5" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_ce9ccb8b-911a-4582-825b-2d2f16920cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1d595146-ea71-4e53-afde-5b8472063371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ce9ccb8b-911a-4582-825b-2d2f16920cf2" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1d595146-ea71-4e53-afde-5b8472063371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_78e8c85b-0f28-491e-9933-ca2bb882a87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1d595146-ea71-4e53-afde-5b8472063371" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_78e8c85b-0f28-491e-9933-ca2bb882a87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_7276ab2e-d4e2-4474-991d-309f03567ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1d595146-ea71-4e53-afde-5b8472063371" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_7276ab2e-d4e2-4474-991d-309f03567ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_70ce4199-2ae7-4eaa-8c4c-188f270de822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1d595146-ea71-4e53-afde-5b8472063371" xlink:to="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_70ce4199-2ae7-4eaa-8c4c-188f270de822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d55a765a-5948-4d33-b222-a9d3abadad95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1d595146-ea71-4e53-afde-5b8472063371" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d55a765a-5948-4d33-b222-a9d3abadad95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17b1dd2c-e845-4793-9cc6-570881267fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4f3aa845-d94e-4c84-b205-018ff380f6b5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17b1dd2c-e845-4793-9cc6-570881267fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7907df26-fa9f-40af-8d0c-83925c759856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17b1dd2c-e845-4793-9cc6-570881267fcb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7907df26-fa9f-40af-8d0c-83925c759856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_de82dfcd-8b1b-47e8-98c3-f8f5d3727ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7907df26-fa9f-40af-8d0c-83925c759856" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_de82dfcd-8b1b-47e8-98c3-f8f5d3727ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0815a7a4-6f47-4c83-a040-3e7aebc4ca8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7907df26-fa9f-40af-8d0c-83925c759856" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0815a7a4-6f47-4c83-a040-3e7aebc4ca8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_aaa6a82c-dae6-4ad3-bc64-b8db76fe1bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7907df26-fa9f-40af-8d0c-83925c759856" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_aaa6a82c-dae6-4ad3-bc64-b8db76fe1bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7bb1019e-6fde-40ce-8e58-16d71e1dbac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4f3aa845-d94e-4c84-b205-018ff380f6b5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7bb1019e-6fde-40ce-8e58-16d71e1dbac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7bb1019e-6fde-40ce-8e58-16d71e1dbac7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c174c3ab-31fb-43d0-9143-ec2cc2a5f110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c174c3ab-31fb-43d0-9143-ec2cc2a5f110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_897fd3f6-6317-4f00-aacd-85ae8d085720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_897fd3f6-6317-4f00-aacd-85ae8d085720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_4c8e95a9-6cd9-4b58-86ea-de5b8d8595a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_4c8e95a9-6cd9-4b58-86ea-de5b8d8595a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_99a46b11-ecff-41ac-b0f2-2f048019d819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_99a46b11-ecff-41ac-b0f2-2f048019d819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_1cb3cbf3-c3c3-441c-9faa-cf6cd1ecb858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_1cb3cbf3-c3c3-441c-9faa-cf6cd1ecb858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember_8aed6976-e13a-47b8-aac9-56d6be9342ba" xlink:href="lly-20221231.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:to="loc_lly_OtherEquitySecuritiesMember_8aed6976-e13a-47b8-aac9-56d6be9342ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember_698f80c3-1aa4-45f5-95b6-b13c9d118bff" xlink:href="lly-20221231.xsd#lly_MarketableSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:to="loc_lly_MarketableSecuritiesMember_698f80c3-1aa4-45f5-95b6-b13c9d118bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EquityMethodAndOtherInvestmentsMember_858c29f2-8eb0-4ef7-a5b2-f1c22eff0fce" xlink:href="lly-20221231.xsd#lly_EquityMethodAndOtherInvestmentsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0d7493b-ee76-4ec0-9eb4-51ddb12a9096" xlink:to="loc_lly_EquityMethodAndOtherInvestmentsMember_858c29f2-8eb0-4ef7-a5b2-f1c22eff0fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e3bc15b3-0b07-48e3-bfde-4211bb6babbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4f3aa845-d94e-4c84-b205-018ff380f6b5" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e3bc15b3-0b07-48e3-bfde-4211bb6babbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_89e72a58-167e-4fcb-9377-12a4e0cab6df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e3bc15b3-0b07-48e3-bfde-4211bb6babbe" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_89e72a58-167e-4fcb-9377-12a4e0cab6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5ec144f8-c285-49b3-a72a-85eddcd9fdab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e3bc15b3-0b07-48e3-bfde-4211bb6babbe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5ec144f8-c285-49b3-a72a-85eddcd9fdab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e38ed1d2-e874-413c-8150-19417cfbad63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e3bc15b3-0b07-48e3-bfde-4211bb6babbe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e38ed1d2-e874-413c-8150-19417cfbad63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_ba6b69d7-4ab8-43e2-a91b-fb48bcc13fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e3bc15b3-0b07-48e3-bfde-4211bb6babbe" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_ba6b69d7-4ab8-43e2-a91b-fb48bcc13fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e644b3b6-ac5c-4f2a-972e-3fcdc5c0e7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e3bc15b3-0b07-48e3-bfde-4211bb6babbe" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e644b3b6-ac5c-4f2a-972e-3fcdc5c0e7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_13fdd7fe-c2e2-4425-a647-037237719be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e3bc15b3-0b07-48e3-bfde-4211bb6babbe" xlink:to="loc_us-gaap_OtherLongTermInvestments_13fdd7fe-c2e2-4425-a647-037237719be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_a3750a88-45b7-4076-883a-6f3e2ec492b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e3bc15b3-0b07-48e3-bfde-4211bb6babbe" xlink:to="loc_us-gaap_LongTermInvestments_a3750a88-45b7-4076-883a-6f3e2ec492b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e6e06466-79e3-4647-8520-73c51d7bec00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9b8f0e0a-6b8d-44e8-9f4f-3095ab64028f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e6e06466-79e3-4647-8520-73c51d7bec00" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9b8f0e0a-6b8d-44e8-9f4f-3095ab64028f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d181111b-6bbf-4aab-bc09-1d018d44ef17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9b8f0e0a-6b8d-44e8-9f4f-3095ab64028f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d181111b-6bbf-4aab-bc09-1d018d44ef17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_723c522c-e00f-41d7-be23-7138f9a559d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d181111b-6bbf-4aab-bc09-1d018d44ef17" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_723c522c-e00f-41d7-be23-7138f9a559d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ba6ae2d0-faff-46c1-911c-12ed43a915c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_723c522c-e00f-41d7-be23-7138f9a559d5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ba6ae2d0-faff-46c1-911c-12ed43a915c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_bc846272-1570-4720-a8f3-d83bbb301450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_723c522c-e00f-41d7-be23-7138f9a559d5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_bc846272-1570-4720-a8f3-d83bbb301450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c452524f-b477-40ce-91f2-f543d60a3376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_723c522c-e00f-41d7-be23-7138f9a559d5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c452524f-b477-40ce-91f2-f543d60a3376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_a2b26032-fba4-4347-a378-22e1c2525b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9b8f0e0a-6b8d-44e8-9f4f-3095ab64028f" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_a2b26032-fba4-4347-a378-22e1c2525b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e55b300f-e9ef-4d1f-8cfd-4bc7ae7c7bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a2b26032-fba4-4347-a378-22e1c2525b7e" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e55b300f-e9ef-4d1f-8cfd-4bc7ae7c7bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_49f8ebd4-0bb7-4183-88f3-107c54a9761c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e55b300f-e9ef-4d1f-8cfd-4bc7ae7c7bee" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_49f8ebd4-0bb7-4183-88f3-107c54a9761c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3fdb8777-daa3-4490-99ae-68e14a003e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e55b300f-e9ef-4d1f-8cfd-4bc7ae7c7bee" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3fdb8777-daa3-4490-99ae-68e14a003e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2bb0b272-8128-458a-a3ef-347e7c7456c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e55b300f-e9ef-4d1f-8cfd-4bc7ae7c7bee" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2bb0b272-8128-458a-a3ef-347e7c7456c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_e3e7414e-02be-45fc-8f98-e7927f650a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9b8f0e0a-6b8d-44e8-9f4f-3095ab64028f" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_e3e7414e-02be-45fc-8f98-e7927f650a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_2ffaf090-6bf3-40a1-b214-b7d40ec294a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_e3e7414e-02be-45fc-8f98-e7927f650a4e" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_2ffaf090-6bf3-40a1-b214-b7d40ec294a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_27266812-2a39-4660-ab16-f45b6eba17eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_2ffaf090-6bf3-40a1-b214-b7d40ec294a8" xlink:to="loc_us-gaap_CommercialPaperMember_27266812-2a39-4660-ab16-f45b6eba17eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e43eb964-8968-4471-9569-970b133d43f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9b8f0e0a-6b8d-44e8-9f4f-3095ab64028f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e43eb964-8968-4471-9569-970b133d43f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_307a574a-a2df-414d-ad5d-2f94d1a138df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e43eb964-8968-4471-9569-970b133d43f7" xlink:to="loc_us-gaap_CommercialPaper_307a574a-a2df-414d-ad5d-2f94d1a138df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4a6b8c50-24c4-42e7-b24f-4a5ac0532db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e43eb964-8968-4471-9569-970b133d43f7" xlink:to="loc_us-gaap_LongTermDebt_4a6b8c50-24c4-42e7-b24f-4a5ac0532db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d8db1862-c528-48c4-a7f7-634df624e73f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsTable_5cd5c2d3-0381-4c58-978b-f1071c31a3db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d8db1862-c528-48c4-a7f7-634df624e73f" xlink:to="loc_us-gaap_OffsettingAssetsTable_5cd5c2d3-0381-4c58-978b-f1071c31a3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4595d535-0d9c-43bc-a03a-32bd8c826527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsTable_5cd5c2d3-0381-4c58-978b-f1071c31a3db" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4595d535-0d9c-43bc-a03a-32bd8c826527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bf51c353-9d35-43fe-92f7-e390358a2176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4595d535-0d9c-43bc-a03a-32bd8c826527" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bf51c353-9d35-43fe-92f7-e390358a2176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsdSellEuroMember_e4f5fafc-eeaf-4b9b-9e6e-7f63da7eab06" xlink:href="lly-20221231.xsd#lly_BuyUsdSellEuroMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf51c353-9d35-43fe-92f7-e390358a2176" xlink:to="loc_lly_BuyUsdSellEuroMember_e4f5fafc-eeaf-4b9b-9e6e-7f63da7eab06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember_cadc9923-3e96-4888-964a-44b627cce94c" xlink:href="lly-20221231.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf51c353-9d35-43fe-92f7-e390358a2176" xlink:to="loc_lly_BuyEuroSellUsDollarMember_cadc9923-3e96-4888-964a-44b627cce94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSDollarSellChineseYuanMember_34cb6455-23ef-4506-a037-d37ce0bc45f8" xlink:href="lly-20221231.xsd#lly_BuyUSDollarSellChineseYuanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf51c353-9d35-43fe-92f7-e390358a2176" xlink:to="loc_lly_BuyUSDollarSellChineseYuanMember_34cb6455-23ef-4506-a037-d37ce0bc45f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyJapaneseYenSellUSDollarMember_c1332780-37ac-4474-ba30-ac40d1d7f004" xlink:href="lly-20221231.xsd#lly_BuyJapaneseYenSellUSDollarMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf51c353-9d35-43fe-92f7-e390358a2176" xlink:to="loc_lly_BuyJapaneseYenSellUSDollarMember_c1332780-37ac-4474-ba30-ac40d1d7f004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSdollarSellJapaneseYenMember_e99c7df8-7d1f-4e88-8984-cf560f37da7a" xlink:href="lly-20221231.xsd#lly_BuyUSdollarSellJapaneseYenMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf51c353-9d35-43fe-92f7-e390358a2176" xlink:to="loc_lly_BuyUSdollarSellJapaneseYenMember_e99c7df8-7d1f-4e88-8984-cf560f37da7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyGBPSellUSDMember_1c647ac4-3702-4771-b03b-63cb909ae721" xlink:href="lly-20221231.xsd#lly_BuyGBPSellUSDMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf51c353-9d35-43fe-92f7-e390358a2176" xlink:to="loc_lly_BuyGBPSellUSDMember_1c647ac4-3702-4771-b03b-63cb909ae721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuySwissFrancSellUSDollarMember_72cd1eae-dbcb-4766-885a-88265d43cd5f" xlink:href="lly-20221231.xsd#lly_BuySwissFrancSellUSDollarMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf51c353-9d35-43fe-92f7-e390358a2176" xlink:to="loc_lly_BuySwissFrancSellUSDollarMember_72cd1eae-dbcb-4766-885a-88265d43cd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsLineItems_8b3e6451-b433-4189-ac1a-edd6c9c0f0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsTable_5cd5c2d3-0381-4c58-978b-f1071c31a3db" xlink:to="loc_us-gaap_OffsettingAssetsLineItems_8b3e6451-b433-4189-ac1a-edd6c9c0f0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_8b77660d-7a08-4701-8850-7620798ceb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_8b3e6451-b433-4189-ac1a-edd6c9c0f0f7" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_8b77660d-7a08-4701-8850-7620798ceb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_c6c20545-87dd-42b1-90d6-b3c2b8ba84e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_8b3e6451-b433-4189-ac1a-edd6c9c0f0f7" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_c6c20545-87dd-42b1-90d6-b3c2b8ba84e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstrumentsScheduleofEffectofRiskManagementDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a208f0c8-70e4-4f85-a356-0008a35d3743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_8f7acf36-f9c2-4d6e-a7a3-b2b3dabd6e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a208f0c8-70e4-4f85-a356-0008a35d3743" xlink:to="loc_us-gaap_DerivativeTable_8f7acf36-f9c2-4d6e-a7a3-b2b3dabd6e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_df9bc55f-b95b-4e63-a768-bbf9438bfa64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_8f7acf36-f9c2-4d6e-a7a3-b2b3dabd6e33" xlink:to="loc_us-gaap_HedgingDesignationAxis_df9bc55f-b95b-4e63-a768-bbf9438bfa64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8fcf011a-8502-41c6-a15b-8099a531d625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_df9bc55f-b95b-4e63-a768-bbf9438bfa64" xlink:to="loc_us-gaap_HedgingDesignationDomain_8fcf011a-8502-41c6-a15b-8099a531d625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1e3e1b20-c41f-472a-baed-5e82f2ee9183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_8fcf011a-8502-41c6-a15b-8099a531d625" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1e3e1b20-c41f-472a-baed-5e82f2ee9183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_45833642-9881-4e0c-8e92-82ddea2c4024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_8fcf011a-8502-41c6-a15b-8099a531d625" xlink:to="loc_us-gaap_NondesignatedMember_45833642-9881-4e0c-8e92-82ddea2c4024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1d33d30d-e038-4d43-aad4-9508e6079123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_8f7acf36-f9c2-4d6e-a7a3-b2b3dabd6e33" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1d33d30d-e038-4d43-aad4-9508e6079123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_057d2833-1244-4080-84c2-5aa57859dade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1d33d30d-e038-4d43-aad4-9508e6079123" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_057d2833-1244-4080-84c2-5aa57859dade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember_9c6d715d-d0b5-4026-a86c-6b7a76b7cdc8" xlink:href="lly-20221231.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_057d2833-1244-4080-84c2-5aa57859dade" xlink:to="loc_lly_HedgedFixedRateDebtMember_9c6d715d-d0b5-4026-a86c-6b7a76b7cdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_7e2fca79-2b06-405b-8d3f-62c59dba05f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_057d2833-1244-4080-84c2-5aa57859dade" xlink:to="loc_us-gaap_InterestRateContractMember_7e2fca79-2b06-405b-8d3f-62c59dba05f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_3ac91bd1-0783-4d42-ad0e-5db16ad998e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_057d2833-1244-4080-84c2-5aa57859dade" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_3ac91bd1-0783-4d42-ad0e-5db16ad998e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d087e640-d96b-4f99-a1b5-1dae629678bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_057d2833-1244-4080-84c2-5aa57859dade" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d087e640-d96b-4f99-a1b5-1dae629678bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_35aabad4-3d41-4b2c-921a-2a9e9ace26ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_057d2833-1244-4080-84c2-5aa57859dade" xlink:to="loc_us-gaap_InterestRateSwapMember_35aabad4-3d41-4b2c-921a-2a9e9ace26ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_3cb648cd-2672-4c66-8cc3-50bdc3ebf956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_8f7acf36-f9c2-4d6e-a7a3-b2b3dabd6e33" xlink:to="loc_us-gaap_DerivativeLineItems_3cb648cd-2672-4c66-8cc3-50bdc3ebf956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract_6c94fbac-8a25-45ba-ad0f-c4ca96c36ca6" xlink:href="lly-20221231.xsd#lly_FairValueHedgeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_3cb648cd-2672-4c66-8cc3-50bdc3ebf956" xlink:to="loc_lly_FairValueHedgeAbstract_6c94fbac-8a25-45ba-ad0f-c4ca96c36ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_8f5075d8-03aa-47f8-8f80-44274c8ac4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_FairValueHedgeAbstract_6c94fbac-8a25-45ba-ad0f-c4ca96c36ca6" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_8f5075d8-03aa-47f8-8f80-44274c8ac4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_8c7a5859-032f-497d-9366-5d5e6f0f1913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_FairValueHedgeAbstract_6c94fbac-8a25-45ba-ad0f-c4ca96c36ca6" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_8c7a5859-032f-497d-9366-5d5e6f0f1913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract_b7571ef9-6d2e-40bb-b376-6d626607013a" xlink:href="lly-20221231.xsd#lly_CashFlowHedgeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_3cb648cd-2672-4c66-8cc3-50bdc3ebf956" xlink:to="loc_lly_CashFlowHedgeAbstract_b7571ef9-6d2e-40bb-b376-6d626607013a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_b703ecef-3188-45d2-b477-03b608c55e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_CashFlowHedgeAbstract_b7571ef9-6d2e-40bb-b376-6d626607013a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_b703ecef-3188-45d2-b477-03b608c55e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_0151022d-5cd6-4a8c-8c98-10a4a8207be9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_3cb648cd-2672-4c66-8cc3-50bdc3ebf956" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_0151022d-5cd6-4a8c-8c98-10a4a8207be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_334f0d0d-c90e-4c15-9056-06486c458295" xlink:href="lly-20221231.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_3cb648cd-2672-4c66-8cc3-50bdc3ebf956" xlink:to="loc_lly_DerivativeInstrumentsGainLossRecognized_334f0d0d-c90e-4c15-9056-06486c458295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4fd94510-714f-426b-bd8d-525ab8dbe244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_3cb648cd-2672-4c66-8cc3-50bdc3ebf956" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4fd94510-714f-426b-bd8d-525ab8dbe244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_bb25aed8-b482-4cca-8911-61ac2b0e3610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_3cb648cd-2672-4c66-8cc3-50bdc3ebf956" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_bb25aed8-b482-4cca-8911-61ac2b0e3610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ea22521d-2e8b-4e74-8897-daf5f9c7bf41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6ec7d5e-e5aa-48cd-be2c-ee9511998019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ea22521d-2e8b-4e74-8897-daf5f9c7bf41" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6ec7d5e-e5aa-48cd-be2c-ee9511998019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1e3dd0eb-3670-4f9d-b172-541b029d9f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6ec7d5e-e5aa-48cd-be2c-ee9511998019" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1e3dd0eb-3670-4f9d-b172-541b029d9f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b61b7eff-a59d-4bc5-a13d-f00264628f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1e3dd0eb-3670-4f9d-b172-541b029d9f39" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b61b7eff-a59d-4bc5-a13d-f00264628f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_e2b51fab-4c5f-459a-8d7d-9336b2375455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b61b7eff-a59d-4bc5-a13d-f00264628f74" xlink:to="loc_us-gaap_FairValueHedgingMember_e2b51fab-4c5f-459a-8d7d-9336b2375455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_cdf6fdb0-8926-40ba-a029-9044fd1bd526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b61b7eff-a59d-4bc5-a13d-f00264628f74" xlink:to="loc_us-gaap_CashFlowHedgingMember_cdf6fdb0-8926-40ba-a029-9044fd1bd526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_9dfbd021-5d3d-44e4-baa6-dcfcb877ef13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b61b7eff-a59d-4bc5-a13d-f00264628f74" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_9dfbd021-5d3d-44e4-baa6-dcfcb877ef13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_a5aa565f-e5e6-48fb-ac36-b0fb393474cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6ec7d5e-e5aa-48cd-be2c-ee9511998019" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_a5aa565f-e5e6-48fb-ac36-b0fb393474cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f5d89934-a57c-4a4a-a858-a18a56b677fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a5aa565f-e5e6-48fb-ac36-b0fb393474cd" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f5d89934-a57c-4a4a-a858-a18a56b677fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_50386d38-866c-4043-a328-e1bae59d0d17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f5d89934-a57c-4a4a-a858-a18a56b677fc" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_50386d38-866c-4043-a328-e1bae59d0d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_24732649-39de-4a65-8c37-a5caf0765928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f5d89934-a57c-4a4a-a858-a18a56b677fc" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_24732649-39de-4a65-8c37-a5caf0765928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_7a6e1eb4-d062-4e6a-a18e-5ecfd8313186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f5d89934-a57c-4a4a-a858-a18a56b677fc" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_7a6e1eb4-d062-4e6a-a18e-5ecfd8313186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f4c33df4-999e-470d-9ee4-918291238d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6ec7d5e-e5aa-48cd-be2c-ee9511998019" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f4c33df4-999e-470d-9ee4-918291238d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4e0f73aa-2777-40ef-93de-c5a44d68ea5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f4c33df4-999e-470d-9ee4-918291238d6a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4e0f73aa-2777-40ef-93de-c5a44d68ea5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_6184b1a0-fc15-4bea-ba15-f5ed9e9d305b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4e0f73aa-2777-40ef-93de-c5a44d68ea5d" xlink:to="loc_us-gaap_InterestRateContractMember_6184b1a0-fc15-4bea-ba15-f5ed9e9d305b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_1ca737ca-fd63-4dde-a63d-734da5288ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4e0f73aa-2777-40ef-93de-c5a44d68ea5d" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_1ca737ca-fd63-4dde-a63d-734da5288ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_7ee179db-75f7-4195-be9c-8f404034c2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4e0f73aa-2777-40ef-93de-c5a44d68ea5d" xlink:to="loc_us-gaap_ForeignExchangeContractMember_7ee179db-75f7-4195-be9c-8f404034c2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_68e4a099-7686-48cd-9974-e62b41f42f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6ec7d5e-e5aa-48cd-be2c-ee9511998019" xlink:to="loc_us-gaap_HedgingDesignationAxis_68e4a099-7686-48cd-9974-e62b41f42f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_32a63cd2-43a5-4ddc-ba10-6632b437b53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_68e4a099-7686-48cd-9974-e62b41f42f2f" xlink:to="loc_us-gaap_HedgingDesignationDomain_32a63cd2-43a5-4ddc-ba10-6632b437b53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_120695c1-da01-4b9d-b88c-ea1c69b42686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_32a63cd2-43a5-4ddc-ba10-6632b437b53f" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_120695c1-da01-4b9d-b88c-ea1c69b42686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_b92a656b-d6c8-44f1-81f6-2b67055a7432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_32a63cd2-43a5-4ddc-ba10-6632b437b53f" xlink:to="loc_us-gaap_NondesignatedMember_b92a656b-d6c8-44f1-81f6-2b67055a7432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8400ae06-c8ef-4855-827e-b7cceb9c3d57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6ec7d5e-e5aa-48cd-be2c-ee9511998019" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8400ae06-c8ef-4855-827e-b7cceb9c3d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ce435e6-5f03-42ab-bb18-7e61110d0d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8400ae06-c8ef-4855-827e-b7cceb9c3d57" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ce435e6-5f03-42ab-bb18-7e61110d0d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6b10190e-3f39-48da-ab27-741468dae118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ce435e6-5f03-42ab-bb18-7e61110d0d84" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6b10190e-3f39-48da-ab27-741468dae118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_97ead35f-cc9d-4f03-8c19-11b8ab47f587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ce435e6-5f03-42ab-bb18-7e61110d0d84" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_97ead35f-cc9d-4f03-8c19-11b8ab47f587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cf36db0d-14cc-48df-8967-994cf8335c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ce435e6-5f03-42ab-bb18-7e61110d0d84" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cf36db0d-14cc-48df-8967-994cf8335c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_680d0c5a-f936-4ada-bac5-5853ae22f8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6ec7d5e-e5aa-48cd-be2c-ee9511998019" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_680d0c5a-f936-4ada-bac5-5853ae22f8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_1c77f2b9-7e77-485c-99be-cc4ad0a304f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_680d0c5a-f936-4ada-bac5-5853ae22f8cb" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_1c77f2b9-7e77-485c-99be-cc4ad0a304f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_e8e31239-d3eb-4423-8a22-b18ef9ff2123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_680d0c5a-f936-4ada-bac5-5853ae22f8cb" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_e8e31239-d3eb-4423-8a22-b18ef9ff2123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_88ee5ec5-a232-4486-a2d0-71521b41bc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_680d0c5a-f936-4ada-bac5-5853ae22f8cb" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_88ee5ec5-a232-4486-a2d0-71521b41bc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_2fab3b44-5278-48b3-8f9e-250a14f3d3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_680d0c5a-f936-4ada-bac5-5853ae22f8cb" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_2fab3b44-5278-48b3-8f9e-250a14f3d3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_678aa8ec-7765-4e86-b757-7c7b0b12da85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_680d0c5a-f936-4ada-bac5-5853ae22f8cb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_678aa8ec-7765-4e86-b757-7c7b0b12da85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7f3b1ac0-4063-4050-990a-23e96ddf3847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_680d0c5a-f936-4ada-bac5-5853ae22f8cb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7f3b1ac0-4063-4050-990a-23e96ddf3847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#GoodwillandOtherIntangiblesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9e1b8d37-d145-46ca-bed7-7f0e5c1a632d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5a8f21ec-c0df-4055-ae2f-0b29a98ce441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9e1b8d37-d145-46ca-bed7-7f0e5c1a632d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5a8f21ec-c0df-4055-ae2f-0b29a98ce441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ec817cce-0c4d-4a35-96c6-5edc839c63df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5a8f21ec-c0df-4055-ae2f-0b29a98ce441" xlink:to="loc_srt_RangeAxis_ec817cce-0c4d-4a35-96c6-5edc839c63df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_21a5389b-25a2-4043-bc08-82d5d3923afc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ec817cce-0c4d-4a35-96c6-5edc839c63df" xlink:to="loc_srt_RangeMember_21a5389b-25a2-4043-bc08-82d5d3923afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3ca9ec9f-8ac7-4195-be5e-2d8c188bc451" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_21a5389b-25a2-4043-bc08-82d5d3923afc" xlink:to="loc_srt_MinimumMember_3ca9ec9f-8ac7-4195-be5e-2d8c188bc451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ac521931-7457-478e-91d2-7bcbe6a90ad0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_21a5389b-25a2-4043-bc08-82d5d3923afc" xlink:to="loc_srt_MaximumMember_ac521931-7457-478e-91d2-7bcbe6a90ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b28e3ab0-7d23-4279-8bab-142de0769909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5a8f21ec-c0df-4055-ae2f-0b29a98ce441" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b28e3ab0-7d23-4279-8bab-142de0769909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_1c16ab11-922e-449a-bf78-eb9f23221a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b28e3ab0-7d23-4279-8bab-142de0769909" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_1c16ab11-922e-449a-bf78-eb9f23221a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6ce90a0e-1a2c-40a6-b711-de742c6d6446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b28e3ab0-7d23-4279-8bab-142de0769909" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6ce90a0e-1a2c-40a6-b711-de742c6d6446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_4d03f512-cd92-4893-bb18-cae1f22b9e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b28e3ab0-7d23-4279-8bab-142de0769909" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_4d03f512-cd92-4893-bb18-cae1f22b9e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d55287fe-2010-4791-87eb-f928f7c34776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9174bea-edcd-4b51-bfae-cbc5a00d511a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d55287fe-2010-4791-87eb-f928f7c34776" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9174bea-edcd-4b51-bfae-cbc5a00d511a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_46fad51b-e34b-4f93-916b-ec1fe116e0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9174bea-edcd-4b51-bfae-cbc5a00d511a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_46fad51b-e34b-4f93-916b-ec1fe116e0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db6cf384-1b9d-478f-8070-f7c4f81bfa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_46fad51b-e34b-4f93-916b-ec1fe116e0ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db6cf384-1b9d-478f-8070-f7c4f81bfa3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_31f94a6d-8993-44fc-9981-3822fe5ba382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db6cf384-1b9d-478f-8070-f7c4f81bfa3f" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_31f94a6d-8993-44fc-9981-3822fe5ba382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_b24da9e7-62c7-47d4-b615-ae208b0d5423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db6cf384-1b9d-478f-8070-f7c4f81bfa3f" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_b24da9e7-62c7-47d4-b615-ae208b0d5423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a868e811-c6b4-4822-be9a-c1012f784bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9174bea-edcd-4b51-bfae-cbc5a00d511a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a868e811-c6b4-4822-be9a-c1012f784bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e842d1ba-cbca-4279-8548-d7d281cbfe4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a868e811-c6b4-4822-be9a-c1012f784bcc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e842d1ba-cbca-4279-8548-d7d281cbfe4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a80b569e-86c8-499f-adf0-28838ce25bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a868e811-c6b4-4822-be9a-c1012f784bcc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a80b569e-86c8-499f-adf0-28838ce25bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_47fec359-e8fa-412d-abee-e5d58d17b887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a868e811-c6b4-4822-be9a-c1012f784bcc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_47fec359-e8fa-412d-abee-e5d58d17b887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_71e089cc-cf97-4b83-b8fa-06c8f7dffca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d55287fe-2010-4791-87eb-f928f7c34776" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_71e089cc-cf97-4b83-b8fa-06c8f7dffca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_221ef768-320f-42c5-8051-d973f0f964df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_71e089cc-cf97-4b83-b8fa-06c8f7dffca8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_221ef768-320f-42c5-8051-d973f0f964df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_84d617de-2df1-4757-8b13-5c10ea8e609a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_221ef768-320f-42c5-8051-d973f0f964df" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_84d617de-2df1-4757-8b13-5c10ea8e609a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_b69f19e5-669b-4263-899d-878c14baf7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_84d617de-2df1-4757-8b13-5c10ea8e609a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_b69f19e5-669b-4263-899d-878c14baf7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_74defa27-b737-4b30-b671-523f00bfcdd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_71e089cc-cf97-4b83-b8fa-06c8f7dffca8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_74defa27-b737-4b30-b671-523f00bfcdd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_78f8728b-f39b-4072-bef5-800f8d393276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_74defa27-b737-4b30-b671-523f00bfcdd5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_78f8728b-f39b-4072-bef5-800f8d393276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_da1ce3c9-c91a-4c04-8e78-3e0c0283506a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d55287fe-2010-4791-87eb-f928f7c34776" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_da1ce3c9-c91a-4c04-8e78-3e0c0283506a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7d1be0f5-0b48-4e41-bf68-111969584a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_da1ce3c9-c91a-4c04-8e78-3e0c0283506a" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7d1be0f5-0b48-4e41-bf68-111969584a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_de8865ee-f362-4e15-90cd-9b07d9098c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_da1ce3c9-c91a-4c04-8e78-3e0c0283506a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_de8865ee-f362-4e15-90cd-9b07d9098c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6d39f155-6f33-4aef-802f-2eb95d52b42b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_da1ce3c9-c91a-4c04-8e78-3e0c0283506a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6d39f155-6f33-4aef-802f-2eb95d52b42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05e15cfb-c7e0-4f8d-b6e4-68554aff99f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_699e39f9-5a53-451b-b63f-76c5c1c6fdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05e15cfb-c7e0-4f8d-b6e4-68554aff99f9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_699e39f9-5a53-451b-b63f-76c5c1c6fdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d0d29f32-85dc-4671-9d94-aab6ae6ee547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_19c1ffae-acbe-4e8f-a6ef-4fc8199df100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d0d29f32-85dc-4671-9d94-aab6ae6ee547" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_19c1ffae-acbe-4e8f-a6ef-4fc8199df100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4697c519-845d-42c0-a870-bc48cdc8f8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_19c1ffae-acbe-4e8f-a6ef-4fc8199df100" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4697c519-845d-42c0-a870-bc48cdc8f8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6dd3780b-307f-450a-9bc6-97d60c90be58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_19c1ffae-acbe-4e8f-a6ef-4fc8199df100" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6dd3780b-307f-450a-9bc6-97d60c90be58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4392e90f-73af-4668-a06f-323fe9138445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_19c1ffae-acbe-4e8f-a6ef-4fc8199df100" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4392e90f-73af-4668-a06f-323fe9138445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_085c4529-d373-4a94-9847-2fcb72058a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_19c1ffae-acbe-4e8f-a6ef-4fc8199df100" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_085c4529-d373-4a94-9847-2fcb72058a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_65539a8f-dbe5-4ae5-8fcf-11284ff869a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_19c1ffae-acbe-4e8f-a6ef-4fc8199df100" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_65539a8f-dbe5-4ae5-8fcf-11284ff869a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2d15f1ce-ad76-4a65-9189-d8fd7f8b1987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_abe3f7e2-8abd-47e6-a706-a95832ed4ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2d15f1ce-ad76-4a65-9189-d8fd7f8b1987" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_abe3f7e2-8abd-47e6-a706-a95832ed4ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7f90d32-c8bd-4355-88c3-8fa54d0073d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_abe3f7e2-8abd-47e6-a706-a95832ed4ca8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7f90d32-c8bd-4355-88c3-8fa54d0073d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2dff3047-378e-455d-87f9-880332913a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7f90d32-c8bd-4355-88c3-8fa54d0073d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2dff3047-378e-455d-87f9-880332913a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_e2860a0f-22b9-4cc6-b184-32f500229594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2dff3047-378e-455d-87f9-880332913a72" xlink:to="loc_us-gaap_BuildingMember_e2860a0f-22b9-4cc6-b184-32f500229594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_0c8e76a2-8898-4392-94c4-bd34765bbc97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2dff3047-378e-455d-87f9-880332913a72" xlink:to="loc_us-gaap_EquipmentMember_0c8e76a2-8898-4392-94c4-bd34765bbc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_31a242d0-bc89-4460-a23f-ea7d9e8ca3cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_abe3f7e2-8abd-47e6-a706-a95832ed4ca8" xlink:to="loc_srt_RangeAxis_31a242d0-bc89-4460-a23f-ea7d9e8ca3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fc15cb34-8cc7-4c6d-a67a-f8664d60d0c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_31a242d0-bc89-4460-a23f-ea7d9e8ca3cb" xlink:to="loc_srt_RangeMember_fc15cb34-8cc7-4c6d-a67a-f8664d60d0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7eea7fb2-bc3a-43ef-b9b8-2469ba32e7ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fc15cb34-8cc7-4c6d-a67a-f8664d60d0c5" xlink:to="loc_srt_MinimumMember_7eea7fb2-bc3a-43ef-b9b8-2469ba32e7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_66145302-9290-4cd3-92e7-b7705c475c51" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fc15cb34-8cc7-4c6d-a67a-f8664d60d0c5" xlink:to="loc_srt_MaximumMember_66145302-9290-4cd3-92e7-b7705c475c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fd3ef04-4ff9-4cfe-a1c9-a8028ec3047e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_abe3f7e2-8abd-47e6-a706-a95832ed4ca8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fd3ef04-4ff9-4cfe-a1c9-a8028ec3047e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_53a29e29-b7fe-4269-8e89-5e72f868e939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fd3ef04-4ff9-4cfe-a1c9-a8028ec3047e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_53a29e29-b7fe-4269-8e89-5e72f868e939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_75cb822e-f785-4764-8432-84228ac184c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_965e1c07-006e-4789-ad72-d17ec8461ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_75cb822e-f785-4764-8432-84228ac184c0" xlink:to="loc_us-gaap_Land_965e1c07-006e-4789-ad72-d17ec8461ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_495ab343-4103-4164-a125-8fb5050b21f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_75cb822e-f785-4764-8432-84228ac184c0" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_495ab343-4103-4164-a125-8fb5050b21f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_f44f8f80-bac0-4bff-9116-f1cce73e3e22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_75cb822e-f785-4764-8432-84228ac184c0" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_f44f8f80-bac0-4bff-9116-f1cce73e3e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_0c92fbec-6685-4114-90d8-07d5713bf0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_75cb822e-f785-4764-8432-84228ac184c0" xlink:to="loc_us-gaap_ConstructionInProgressGross_0c92fbec-6685-4114-90d8-07d5713bf0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3906736b-0229-4f5a-97b8-17706dd8c2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_75cb822e-f785-4764-8432-84228ac184c0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3906736b-0229-4f5a-97b8-17706dd8c2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f0864443-401b-4fae-9887-b27db1ccebc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_75cb822e-f785-4764-8432-84228ac184c0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f0864443-401b-4fae-9887-b27db1ccebc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5d476574-31da-4a79-bf9d-3f96ffe55059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_75cb822e-f785-4764-8432-84228ac184c0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5d476574-31da-4a79-bf9d-3f96ffe55059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#PropertyandEquipmentScheduleofDepreciationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0f79d418-a744-437e-9fdc-b371d18205c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_742989d5-8802-4fab-b2c6-e0b3e91b81e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0f79d418-a744-437e-9fdc-b371d18205c5" xlink:to="loc_us-gaap_Depreciation_742989d5-8802-4fab-b2c6-e0b3e91b81e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#PropertyandEquipmentScheduleofGeographicInformationDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_49925764-ddbb-4efe-80cf-08df4be3f8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f521ae89-af24-480e-9d88-07412d3741ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_49925764-ddbb-4efe-80cf-08df4be3f8c7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f521ae89-af24-480e-9d88-07412d3741ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_48e0264b-41cf-4928-826f-21dd19845aee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f521ae89-af24-480e-9d88-07412d3741ec" xlink:to="loc_srt_StatementGeographicalAxis_48e0264b-41cf-4928-826f-21dd19845aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_54e30d30-2221-4c50-ae2a-f660f5c6a22a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_48e0264b-41cf-4928-826f-21dd19845aee" xlink:to="loc_srt_SegmentGeographicalDomain_54e30d30-2221-4c50-ae2a-f660f5c6a22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_UNITEDSTATESAndPUERTORICOMember_79938ad1-a159-4310-bf37-0fda2352c3b6" xlink:href="lly-20221231.xsd#lly_UNITEDSTATESAndPUERTORICOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_54e30d30-2221-4c50-ae2a-f660f5c6a22a" xlink:to="loc_lly_UNITEDSTATESAndPUERTORICOMember_79938ad1-a159-4310-bf37-0fda2352c3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_5ca32533-1b76-43e3-8683-8edf1823f4b5" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_54e30d30-2221-4c50-ae2a-f660f5c6a22a" xlink:to="loc_country_IE_5ca32533-1b76-43e3-8683-8edf1823f4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_2659db7d-715e-4324-b1b8-3c127dc234ba" xlink:href="lly-20221231.xsd#lly_OtherForeignCountriesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_54e30d30-2221-4c50-ae2a-f660f5c6a22a" xlink:to="loc_lly_OtherForeignCountriesMember_2659db7d-715e-4324-b1b8-3c127dc234ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_74a94f84-5f8c-4007-a340-8f27c49e5314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f521ae89-af24-480e-9d88-07412d3741ec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_74a94f84-5f8c-4007-a340-8f27c49e5314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_fb9eaf3a-cab7-4aa1-836f-115ff2504ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_74a94f84-5f8c-4007-a340-8f27c49e5314" xlink:to="loc_us-gaap_NoncurrentAssets_fb9eaf3a-cab7-4aa1-836f-115ff2504ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_69911768-56ff-4665-8acd-e3c94a10e6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LesseeLeaseRemainingLeaseTerm_ad5c90f1-2f48-4b39-8ddd-4050380c0c49" xlink:href="lly-20221231.xsd#lly_LesseeLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_69911768-56ff-4665-8acd-e3c94a10e6c0" xlink:to="loc_lly_LesseeLeaseRemainingLeaseTerm_ad5c90f1-2f48-4b39-8ddd-4050380c0c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_9deb4f2b-1dc8-4ec4-9eb1-dd3c86cdb6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_69911768-56ff-4665-8acd-e3c94a10e6c0" xlink:to="loc_us-gaap_OperatingLeaseCost_9deb4f2b-1dc8-4ec4-9eb1-dd3c86cdb6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_aac2765e-9e59-4246-b739-58236b8d31f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_caadc209-0a50-4a19-a71f-13db303c1494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aac2765e-9e59-4246-b739-58236b8d31f4" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_caadc209-0a50-4a19-a71f-13db303c1494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_144144e7-f74b-4812-98be-09b1efb713ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aac2765e-9e59-4246-b739-58236b8d31f4" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_144144e7-f74b-4812-98be-09b1efb713ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_759dd6f1-bae9-4a8a-9a23-f98d82ecaee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aac2765e-9e59-4246-b739-58236b8d31f4" xlink:to="loc_us-gaap_OperatingLeasePayments_759dd6f1-bae9-4a8a-9a23-f98d82ecaee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_86a7674a-7ea7-474a-ae24-b7cede338ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aac2765e-9e59-4246-b739-58236b8d31f4" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_86a7674a-7ea7-474a-ae24-b7cede338ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c717394e-b51a-4f95-a3b5-a36625d8fd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_87c0047f-a5b1-45d8-b2af-6a589118c2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c717394e-b51a-4f95-a3b5-a36625d8fd2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_87c0047f-a5b1-45d8-b2af-6a589118c2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4d1a6ad6-ae50-4e7f-a5f0-6076c5d30945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c717394e-b51a-4f95-a3b5-a36625d8fd2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4d1a6ad6-ae50-4e7f-a5f0-6076c5d30945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_92d50078-605f-493e-b855-10ce54b6417b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c717394e-b51a-4f95-a3b5-a36625d8fd2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_92d50078-605f-493e-b855-10ce54b6417b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2fb03da8-5306-4b5b-ad60-449f482bb039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c717394e-b51a-4f95-a3b5-a36625d8fd2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2fb03da8-5306-4b5b-ad60-449f482bb039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_101be59c-23b2-412d-8b79-40b4b5802f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c717394e-b51a-4f95-a3b5-a36625d8fd2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_101be59c-23b2-412d-8b79-40b4b5802f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_bb09f8b8-1451-442d-9695-9d4a11949ede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c717394e-b51a-4f95-a3b5-a36625d8fd2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_bb09f8b8-1451-442d-9695-9d4a11949ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7a74f6c6-1d3b-445e-ae2d-b3ddd93797f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c717394e-b51a-4f95-a3b5-a36625d8fd2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7a74f6c6-1d3b-445e-ae2d-b3ddd93797f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_78d5cb44-e503-4647-ae69-12e4bbaa573f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c717394e-b51a-4f95-a3b5-a36625d8fd2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_78d5cb44-e503-4647-ae69-12e4bbaa573f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4dba16c4-c0ef-457d-bfa9-7766f850dad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c717394e-b51a-4f95-a3b5-a36625d8fd2b" xlink:to="loc_us-gaap_OperatingLeaseLiability_4dba16c4-c0ef-457d-bfa9-7766f850dad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_8bf9a538-3c92-4917-a6d8-18ae3caa5877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c717394e-b51a-4f95-a3b5-a36625d8fd2b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_8bf9a538-3c92-4917-a6d8-18ae3caa5877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="lly-20221231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#BorrowingsScheduleofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0be36081-5ee4-4e7c-bbd7-eb6db734b64d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_c4fbd741-0081-4dcb-a90c-668bd872efba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0be36081-5ee4-4e7c-bbd7-eb6db734b64d" xlink:to="loc_us-gaap_CommercialPaper_c4fbd741-0081-4dcb-a90c-668bd872efba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_b68a4d49-dc63-45e1-8090-b1073d604b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0be36081-5ee4-4e7c-bbd7-eb6db734b64d" xlink:to="loc_us-gaap_NotesPayable_b68a4d49-dc63-45e1-8090-b1073d604b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNotesPayable_313e64ac-e3ec-4f8e-81b7-6ae4d1ba2a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0be36081-5ee4-4e7c-bbd7-eb6db734b64d" xlink:to="loc_us-gaap_OtherNotesPayable_313e64ac-e3ec-4f8e-81b7-6ae4d1ba2a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_a3ae29f9-68ee-49fa-9e91-3ab49e5933d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0be36081-5ee4-4e7c-bbd7-eb6db734b64d" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_a3ae29f9-68ee-49fa-9e91-3ab49e5933d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LongTermDebtFairValueAdjustment_bde515b1-974b-4ac0-9a06-3c298cc2d83a" xlink:href="lly-20221231.xsd#lly_LongTermDebtFairValueAdjustment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0be36081-5ee4-4e7c-bbd7-eb6db734b64d" xlink:to="loc_lly_LongTermDebtFairValueAdjustment_bde515b1-974b-4ac0-9a06-3c298cc2d83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_c89b42ea-b23b-48ec-bf74-ca21840d93c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0be36081-5ee4-4e7c-bbd7-eb6db734b64d" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_c89b42ea-b23b-48ec-bf74-ca21840d93c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_8e61d0d7-725a-4151-8113-b193469c4261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0be36081-5ee4-4e7c-bbd7-eb6db734b64d" xlink:to="loc_us-gaap_DebtCurrent_8e61d0d7-725a-4151-8113-b193469c4261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0d95dcb2-9ccc-42e9-9221-344d5b5b48d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0be36081-5ee4-4e7c-bbd7-eb6db734b64d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0d95dcb2-9ccc-42e9-9221-344d5b5b48d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1" xlink:type="simple" xlink:href="lly-20221231.xsd#BorrowingsScheduleofDebtDetails_1"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_18c2af71-5359-4e63-8096-e1abf460b178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_37497c7b-94b4-4c63-b9c4-1d3d7cf27fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_18c2af71-5359-4e63-8096-e1abf460b178" xlink:to="loc_us-gaap_DebtInstrumentTable_37497c7b-94b4-4c63-b9c4-1d3d7cf27fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_648b0acf-ab7d-436f-a435-d50a05851af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_37497c7b-94b4-4c63-b9c4-1d3d7cf27fe4" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_648b0acf-ab7d-436f-a435-d50a05851af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4b1c92cc-7360-46e2-8dcd-8f750220539f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_648b0acf-ab7d-436f-a435-d50a05851af6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4b1c92cc-7360-46e2-8dcd-8f750220539f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2026Member_95d340c5-d289-481b-8aa1-bd76735f6995" xlink:href="lly-20221231.xsd#lly_MaturityDate2026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4b1c92cc-7360-46e2-8dcd-8f750220539f" xlink:to="loc_lly_MaturityDate2026Member_95d340c5-d289-481b-8aa1-bd76735f6995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2023Member_b3d71cee-bc50-4a6e-80bc-b40b75df5f95" xlink:href="lly-20221231.xsd#lly_MaturityDate2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4b1c92cc-7360-46e2-8dcd-8f750220539f" xlink:to="loc_lly_MaturityDate2023Member_b3d71cee-bc50-4a6e-80bc-b40b75df5f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_629d247a-f879-474c-bd5d-40c012054370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_37497c7b-94b4-4c63-b9c4-1d3d7cf27fe4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_629d247a-f879-474c-bd5d-40c012054370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cc9c2e16-529d-4ab3-89a8-ef5a3060d323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_629d247a-f879-474c-bd5d-40c012054370" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cc9c2e16-529d-4ab3-89a8-ef5a3060d323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember_f311232d-1a21-4ff3-bd08-a614329077c9" xlink:href="lly-20221231.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc9c2e16-529d-4ab3-89a8-ef5a3060d323" xlink:to="loc_lly_ForeignCurrencyDenominatedDebtMember_f311232d-1a21-4ff3-bd08-a614329077c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ea4d2d91-5695-4515-9845-ddfb12c30463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc9c2e16-529d-4ab3-89a8-ef5a3060d323" xlink:to="loc_us-gaap_SeniorNotesMember_ea4d2d91-5695-4515-9845-ddfb12c30463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2987da37-5837-4bbf-a621-b47753f242ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_37497c7b-94b4-4c63-b9c4-1d3d7cf27fe4" xlink:to="loc_us-gaap_DebtInstrumentAxis_2987da37-5837-4bbf-a621-b47753f242ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2987da37-5837-4bbf-a621-b47753f242ac" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A5000NotesDue2033Member_bbac3aad-1a1e-4314-88b9-02999efca734" xlink:href="lly-20221231.xsd#lly_A5000NotesDue2033Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_A5000NotesDue2033Member_bbac3aad-1a1e-4314-88b9-02999efca734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_55411efa-ee71-4245-a609-041b6435b5cc" xlink:href="lly-20221231.xsd#lly_A1125NotesDue2051Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_A1125NotesDue2051Member_55411efa-ee71-4245-a609-041b6435b5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_9351f4df-b4f6-4b47-8b88-187e0a96902b" xlink:href="lly-20221231.xsd#lly_A1375NotesDue2061Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_A1375NotesDue2061Member_9351f4df-b4f6-4b47-8b88-187e0a96902b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625BritishPoundDenominatedNotesDue2043Member_00f55e45-6c56-415e-acfe-bd4adeebc2e1" xlink:href="lly-20221231.xsd#lly_A1625BritishPoundDenominatedNotesDue2043Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_A1625BritishPoundDenominatedNotesDue2043Member_00f55e45-6c56-415e-acfe-bd4adeebc2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member_1e559fa6-cc81-43c3-8b8b-24ed65aec5a7" xlink:href="lly-20221231.xsd#lly_A395NotesDue2049Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_A395NotesDue2049Member_1e559fa6-cc81-43c3-8b8b-24ed65aec5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member_77aa503c-b83a-4525-ac47-936306d69786" xlink:href="lly-20221231.xsd#lly_A415NotesDue2059Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_A415NotesDue2059Member_77aa503c-b83a-4525-ac47-936306d69786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member_10e2b76f-24a6-4421-846b-7972501427cd" xlink:href="lly-20221231.xsd#lly_A3375NotesDue2029Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_A3375NotesDue2029Member_10e2b76f-24a6-4421-846b-7972501427cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A225NotesDue2050Member_d71804e4-5eff-4f53-9aae-5870baf892eb" xlink:href="lly-20221231.xsd#lly_A225NotesDue2050Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_A225NotesDue2050Member_d71804e4-5eff-4f53-9aae-5870baf892eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A25NotesDue2060Member_566e4dd6-7022-4ed4-9b6b-3acdddf2ccd6" xlink:href="lly-20221231.xsd#lly_A25NotesDue2060Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_A25NotesDue2060Member_566e4dd6-7022-4ed4-9b6b-3acdddf2ccd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_cab0ac44-86ff-4e51-9688-813f222442c2" xlink:href="lly-20221231.xsd#lly_SeniorNotesDueMay2050AndSeptember2060Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_432762db-b30b-4f8f-bcc2-8c3e4e32f916" xlink:to="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_cab0ac44-86ff-4e51-9688-813f222442c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_37497c7b-94b4-4c63-b9c4-1d3d7cf27fe4" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_b2635db7-05ec-4f03-96ce-848353946301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_b2635db7-05ec-4f03-96ce-848353946301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_3afcb09b-7345-4e50-870e-6053692242f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_3afcb09b-7345-4e50-870e-6053692242f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f4a22627-808e-40d3-b544-d31217d1dbba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f4a22627-808e-40d3-b544-d31217d1dbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_9005d5df-450f-431d-b0e4-e270d1795f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_DebtInstrumentTerm_9005d5df-450f-431d-b0e4-e270d1795f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fc61ad50-fd62-4859-a36f-984b5357f886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fc61ad50-fd62-4859-a36f-984b5357f886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b4562efa-4c0c-4fa9-89b0-e87399147b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b4562efa-4c0c-4fa9-89b0-e87399147b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_6dd45d62-961c-4e85-89c8-bf2b91bb35d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_6dd45d62-961c-4e85-89c8-bf2b91bb35d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_b21737c1-590c-4a98-8cd5-7e26cf499d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_b21737c1-590c-4a98-8cd5-7e26cf499d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_beb21afe-13b1-4a1e-a26b-e1a2f43daf57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_beb21afe-13b1-4a1e-a26b-e1a2f43daf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_13e057ca-7634-434f-bf07-d6aeb86abdb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_13e057ca-7634-434f-bf07-d6aeb86abdb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DescriptionOfDerivativeActivityVolumePercent_2c93dded-871a-41f1-9e32-3a9a95222e0a" xlink:href="lly-20221231.xsd#lly_DescriptionOfDerivativeActivityVolumePercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_lly_DescriptionOfDerivativeActivityVolumePercent_2c93dded-871a-41f1-9e32-3a9a95222e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2926e217-89d4-4a62-9c0e-e4e438cf6026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ac188809-2fb1-4f2c-a3de-59ae20f4f623" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2926e217-89d4-4a62-9c0e-e4e438cf6026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#BorrowingsSummaryofLongtermNotesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0c9f2b5b-ddc0-4285-86a0-31e3e1151f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_50f7756c-672f-4627-9401-0857e838dfc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0c9f2b5b-ddc0-4285-86a0-31e3e1151f12" xlink:to="loc_us-gaap_DebtInstrumentTable_50f7756c-672f-4627-9401-0857e838dfc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f173ea8a-eb4e-44fe-9a13-6c41b0107793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_50f7756c-672f-4627-9401-0857e838dfc2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f173ea8a-eb4e-44fe-9a13-6c41b0107793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_08bcc859-284e-479e-b7cd-749c431e5d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f173ea8a-eb4e-44fe-9a13-6c41b0107793" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_08bcc859-284e-479e-b7cd-749c431e5d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e5d20d0d-5506-4109-8177-e0eb4ca9f623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_08bcc859-284e-479e-b7cd-749c431e5d54" xlink:to="loc_us-gaap_SeniorNotesMember_e5d20d0d-5506-4109-8177-e0eb4ca9f623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2aa63c25-ca83-4b69-b0f6-2cd8ecbd306d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_50f7756c-672f-4627-9401-0857e838dfc2" xlink:to="loc_us-gaap_DebtInstrumentAxis_2aa63c25-ca83-4b69-b0f6-2cd8ecbd306d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2aa63c25-ca83-4b69-b0f6-2cd8ecbd306d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A235NotesDue2022Member_aa1c56b6-70ad-407b-8dda-4b8c0e93b70b" xlink:href="lly-20221231.xsd#lly_A235NotesDue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A235NotesDue2022Member_aa1c56b6-70ad-407b-8dda-4b8c0e93b70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A30NotesDue2022Member_76a8f438-8e0c-452e-a965-f4f081b4e33b" xlink:href="lly-20221231.xsd#lly_A30NotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A30NotesDue2022Member_76a8f438-8e0c-452e-a965-f4f081b4e33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A10EuroDenominatedNotesDue2022Member_8a3b0827-1573-409f-a3da-c242ffc99327" xlink:href="lly-20221231.xsd#lly_A10EuroDenominatedNotesDue2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A10EuroDenominatedNotesDue2022Member_8a3b0827-1573-409f-a3da-c242ffc99327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A015SwissFrancDenominatedNotesDue2024Member_705066ad-515c-40e2-8ea6-725d8cabb534" xlink:href="lly-20221231.xsd#lly_A015SwissFrancDenominatedNotesDue2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A015SwissFrancDenominatedNotesDue2024Member_705066ad-515c-40e2-8ea6-725d8cabb534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A7125NotesDue2025Member_70287d04-f8c6-4ed7-a8df-bc5c097722ad" xlink:href="lly-20221231.xsd#lly_A7125NotesDue2025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A7125NotesDue2025Member_70287d04-f8c6-4ed7-a8df-bc5c097722ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A275NotesDue2025Member_07c7dd51-4b2a-43fc-9b5d-74d7f4dc719d" xlink:href="lly-20221231.xsd#lly_A275NotesDue2025Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A275NotesDue2025Member_07c7dd51-4b2a-43fc-9b5d-74d7f4dc719d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625EuroDenominatedNotesDue2026Member_8c3004bb-b7be-4644-a11c-2b9283a10614" xlink:href="lly-20221231.xsd#lly_A1625EuroDenominatedNotesDue2026Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A1625EuroDenominatedNotesDue2026Member_8c3004bb-b7be-4644-a11c-2b9283a10614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A55NotesDue2027Member_fc5c3c99-8938-44b5-a7d5-06e9c9289a39" xlink:href="lly-20221231.xsd#lly_A55NotesDue2027Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A55NotesDue2027Member_fc5c3c99-8938-44b5-a7d5-06e9c9289a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A31NotesDue2027Member_b77b1e5c-daeb-4b2e-ac8d-5bfd59ba7912" xlink:href="lly-20221231.xsd#lly_A31NotesDue2027Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A31NotesDue2027Member_b77b1e5c-daeb-4b2e-ac8d-5bfd59ba7912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A045SwissFrancDenominatedNotesDue2028Member_ae4cb062-59b7-4197-b4ab-a68a7ca67b07" xlink:href="lly-20221231.xsd#lly_A045SwissFrancDenominatedNotesDue2028Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A045SwissFrancDenominatedNotesDue2028Member_ae4cb062-59b7-4197-b4ab-a68a7ca67b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member_f4809ca0-6409-40d9-9123-f1a5c81fb55d" xlink:href="lly-20221231.xsd#lly_A3375NotesDue2029Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A3375NotesDue2029Member_f4809ca0-6409-40d9-9123-f1a5c81fb55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A42YenDenominatedNotesDue2029Member_4fa77e33-bf4e-41d5-a3d7-a40bfb7caac0" xlink:href="lly-20221231.xsd#lly_A42YenDenominatedNotesDue2029Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A42YenDenominatedNotesDue2029Member_4fa77e33-bf4e-41d5-a3d7-a40bfb7caac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2125EuroDenominatedNotesDue2030Member_ba5ee84f-6992-458f-a23c-fe535c907c6c" xlink:href="lly-20221231.xsd#lly_A2125EuroDenominatedNotesDue2030Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A2125EuroDenominatedNotesDue2030Member_ba5ee84f-6992-458f-a23c-fe535c907c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625EuroDenominatedNotesDue2031Member_0abf6964-b10e-48fd-9587-40f87dc3220f" xlink:href="lly-20221231.xsd#lly_A625EuroDenominatedNotesDue2031Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A625EuroDenominatedNotesDue2031Member_0abf6964-b10e-48fd-9587-40f87dc3220f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A5000NotesDue2033Member_6092d9b5-0a64-4850-9f53-53d9b22cee0e" xlink:href="lly-20221231.xsd#lly_A5000NotesDue2033Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A5000NotesDue2033Member_6092d9b5-0a64-4850-9f53-53d9b22cee0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A56YenDenominatedNotesDue2034Member_a7f76a2e-cf47-427a-93fb-29f0a71837c8" xlink:href="lly-20221231.xsd#lly_A56YenDenominatedNotesDue2034Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A56YenDenominatedNotesDue2034Member_a7f76a2e-cf47-427a-93fb-29f0a71837c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A677NotesDue2036Member_a15c9b07-cd01-47b3-9449-074362addd91" xlink:href="lly-20221231.xsd#lly_A677NotesDue2036Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A677NotesDue2036Member_a15c9b07-cd01-47b3-9449-074362addd91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A555NotesDue2037Member_c4d49de0-f2ad-4c8d-a521-cbf1a73e7397" xlink:href="lly-20221231.xsd#lly_A555NotesDue2037Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A555NotesDue2037Member_c4d49de0-f2ad-4c8d-a521-cbf1a73e7397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A595NotesDue2037Member_8e5f93c5-be15-4156-835a-bd14b1939f02" xlink:href="lly-20221231.xsd#lly_A595NotesDue2037Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A595NotesDue2037Member_8e5f93c5-be15-4156-835a-bd14b1939f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3875NotesDue2039Member_2758a26d-5b28-4050-9262-99f287bb1102" xlink:href="lly-20221231.xsd#lly_A3875NotesDue2039Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A3875NotesDue2039Member_2758a26d-5b28-4050-9262-99f287bb1102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625BritishPoundDenominatedNotesDue2043Member_2ab3b952-5f92-485b-aa8d-fe4bf7ba6a0e" xlink:href="lly-20221231.xsd#lly_A1625BritishPoundDenominatedNotesDue2043Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A1625BritishPoundDenominatedNotesDue2043Member_2ab3b952-5f92-485b-aa8d-fe4bf7ba6a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A465NotesDue2044Member_c4e1e97e-fb66-4bb7-a1c5-9ef7a6298bc5" xlink:href="lly-20221231.xsd#lly_A465NotesDue2044Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A465NotesDue2044Member_c4e1e97e-fb66-4bb7-a1c5-9ef7a6298bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A37NotesDue2045Member_5763241c-57c3-4127-b212-3470ff944fbf" xlink:href="lly-20221231.xsd#lly_A37NotesDue2045Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A37NotesDue2045Member_5763241c-57c3-4127-b212-3470ff944fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2047Member_a618002e-6408-4fc4-851e-8409b640912a" xlink:href="lly-20221231.xsd#lly_A395NotesDue2047Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A395NotesDue2047Member_a618002e-6408-4fc4-851e-8409b640912a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member_d1afeea4-f639-4e04-98d2-ef59341f6f45" xlink:href="lly-20221231.xsd#lly_A395NotesDue2049Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A395NotesDue2049Member_d1afeea4-f639-4e04-98d2-ef59341f6f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A17EuroDenominatedNotesDue2049Member_32edac8d-b01f-4f37-b256-a4a436d35d3a" xlink:href="lly-20221231.xsd#lly_A17EuroDenominatedNotesDue2049Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A17EuroDenominatedNotesDue2049Member_32edac8d-b01f-4f37-b256-a4a436d35d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A97YenDenominatedNotesDue2049Member_e68c7731-7541-42cc-848e-9ff9ca775a38" xlink:href="lly-20221231.xsd#lly_A97YenDenominatedNotesDue2049Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A97YenDenominatedNotesDue2049Member_e68c7731-7541-42cc-848e-9ff9ca775a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A225NotesDue2050Member_ad90dcf4-2a99-453c-a218-b0f23647a278" xlink:href="lly-20221231.xsd#lly_A225NotesDue2050Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A225NotesDue2050Member_ad90dcf4-2a99-453c-a218-b0f23647a278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_6d6220b8-f263-4d57-a90b-93156afe2d4d" xlink:href="lly-20221231.xsd#lly_A1125NotesDue2051Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A1125NotesDue2051Member_6d6220b8-f263-4d57-a90b-93156afe2d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member_9c452546-ee04-45fd-94c7-08d07041ef2f" xlink:href="lly-20221231.xsd#lly_A415NotesDue2059Member"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A415NotesDue2059Member_9c452546-ee04-45fd-94c7-08d07041ef2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A25NotesDue2060Member_b448581e-3816-4e97-b202-f087ef20d5b2" xlink:href="lly-20221231.xsd#lly_A25NotesDue2060Member"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A25NotesDue2060Member_b448581e-3816-4e97-b202-f087ef20d5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_440917cf-0e45-479e-80cc-a68f831490b8" xlink:href="lly-20221231.xsd#lly_A1375NotesDue2061Member"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8301d3ab-e3cf-499c-b77b-a9748ef72a64" xlink:to="loc_lly_A1375NotesDue2061Member_440917cf-0e45-479e-80cc-a68f831490b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_40d623c2-572b-49fe-85a6-cc8f39b1e37e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_50f7756c-672f-4627-9401-0857e838dfc2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_40d623c2-572b-49fe-85a6-cc8f39b1e37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9a6167ee-ad04-450a-b169-cb3890094033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40d623c2-572b-49fe-85a6-cc8f39b1e37e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9a6167ee-ad04-450a-b169-cb3890094033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3aed92fb-2a21-4d08-835e-60519a9bd8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40d623c2-572b-49fe-85a6-cc8f39b1e37e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3aed92fb-2a21-4d08-835e-60519a9bd8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1309e9d5-3079-4806-974d-cdb9af04435d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40d623c2-572b-49fe-85a6-cc8f39b1e37e" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1309e9d5-3079-4806-974d-cdb9af04435d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_27eccdc4-8619-44f5-8911-9ac548808805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40d623c2-572b-49fe-85a6-cc8f39b1e37e" xlink:to="loc_us-gaap_LongTermDebt_27eccdc4-8619-44f5-8911-9ac548808805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#BorrowingsScheduleofDebtMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f6446683-78f5-420d-af9a-b48f695c7b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_a9cad15d-09a8-4798-8f95-fe61ae119fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f6446683-78f5-420d-af9a-b48f695c7b3a" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_a9cad15d-09a8-4798-8f95-fe61ae119fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6dc851f4-a6ce-4b02-a1ea-656c7cefc727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_a9cad15d-09a8-4798-8f95-fe61ae119fc8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6dc851f4-a6ce-4b02-a1ea-656c7cefc727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ddf64978-5c2a-4012-afba-be9d23fda8af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_a9cad15d-09a8-4798-8f95-fe61ae119fc8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ddf64978-5c2a-4012-afba-be9d23fda8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f8576f04-e86b-4a6b-8738-9dbec70af602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_a9cad15d-09a8-4798-8f95-fe61ae119fc8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f8576f04-e86b-4a6b-8738-9dbec70af602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_70e788a1-4ba6-4e3b-b1f4-7617fd525fef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_a9cad15d-09a8-4798-8f95-fe61ae119fc8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_70e788a1-4ba6-4e3b-b1f4-7617fd525fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_71243bf3-618e-476a-9ec7-74d682120eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_a9cad15d-09a8-4798-8f95-fe61ae119fc8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_71243bf3-618e-476a-9ec7-74d682120eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_55bf8ca3-9b77-436a-88f5-994b77fa6cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_2dcbad4b-f679-48eb-9c83-91c4d251f142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_55bf8ca3-9b77-436a-88f5-994b77fa6cb6" xlink:to="loc_us-gaap_InterestPaidNet_2dcbad4b-f679-48eb-9c83-91c4d251f142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_46a12956-c43f-4649-a8c7-0204f83fbd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3073d43a-c442-45b7-aea1-86a05313c3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_46a12956-c43f-4649-a8c7-0204f83fbd2e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3073d43a-c442-45b7-aea1-86a05313c3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_2897c48a-5880-424b-af36-be5228cb07a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_46a12956-c43f-4649-a8c7-0204f83fbd2e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_2897c48a-5880-424b-af36-be5228cb07a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73fd23a9-b982-4b47-ad9e-33e8570a68eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89e73efb-e7c9-42a4-a951-d9763800d371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73fd23a9-b982-4b47-ad9e-33e8570a68eb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89e73efb-e7c9-42a4-a951-d9763800d371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cb655c95-3175-493d-8afa-05b4d76d810c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89e73efb-e7c9-42a4-a951-d9763800d371" xlink:to="loc_us-gaap_AwardTypeAxis_cb655c95-3175-493d-8afa-05b4d76d810c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ee2d640-22b1-4978-ab49-76d293e371c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cb655c95-3175-493d-8afa-05b4d76d810c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ee2d640-22b1-4978-ab49-76d293e371c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_a9cfc44c-ef98-4f95-a050-0da5e00cedb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ee2d640-22b1-4978-ab49-76d293e371c9" xlink:to="loc_us-gaap_PerformanceSharesMember_a9cfc44c-ef98-4f95-a050-0da5e00cedb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareholderValueAwardsMember_3e5c9d43-9e8a-4364-afb4-9668fa5c7c71" xlink:href="lly-20221231.xsd#lly_ShareholderValueAwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ee2d640-22b1-4978-ab49-76d293e371c9" xlink:to="loc_lly_ShareholderValueAwardsMember_3e5c9d43-9e8a-4364-afb4-9668fa5c7c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RelativeValueAwardsMember_93aacf79-7557-49ff-a536-9831e4b8da53" xlink:href="lly-20221231.xsd#lly_RelativeValueAwardsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ee2d640-22b1-4978-ab49-76d293e371c9" xlink:to="loc_lly_RelativeValueAwardsMember_93aacf79-7557-49ff-a536-9831e4b8da53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b3fdd13b-17f1-4887-81a0-ec519fc11283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ee2d640-22b1-4978-ab49-76d293e371c9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b3fdd13b-17f1-4887-81a0-ec519fc11283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89e73efb-e7c9-42a4-a951-d9763800d371" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_11714833-b0e3-47a1-b069-1a685f2644f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_11714833-b0e3-47a1-b069-1a685f2644f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bc34378a-433d-41b1-b5ca-6e9dd81b58c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bc34378a-433d-41b1-b5ca-6e9dd81b58c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_603fa948-2f47-4ac6-ad6a-21a0afa2e6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_603fa948-2f47-4ac6-ad6a-21a0afa2e6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_bd8dd692-5f69-4926-9bf5-f47722851fea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_bd8dd692-5f69-4926-9bf5-f47722851fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_b5ca08d0-1398-44f4-9ad3-392ffb14a7ff" xlink:href="lly-20221231.xsd#lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:to="loc_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_b5ca08d0-1398-44f4-9ad3-392ffb14a7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_de41e3c2-3bac-4a39-8332-6b80e4420428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_de41e3c2-3bac-4a39-8332-6b80e4420428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0fd12fbf-c4c6-441f-a832-4d0cd5cfacc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0fd12fbf-c4c6-441f-a832-4d0cd5cfacc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9e5ea690-f0fd-46c1-9fe5-9e06701134a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e3bb4a5-6d5a-4f45-a65d-a8d89e4d334e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9e5ea690-f0fd-46c1-9fe5-9e06701134a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#StockBasedCompensationScheduleofAssumptionsUsedDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2978292a-76d2-424f-90d9-b6c112423fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_058632bd-33b3-4ec3-a095-8b762a48c056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2978292a-76d2-424f-90d9-b6c112423fb4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_058632bd-33b3-4ec3-a095-8b762a48c056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5ba963e1-fba3-4ca4-a9bc-b72788a7b18b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_058632bd-33b3-4ec3-a095-8b762a48c056" xlink:to="loc_us-gaap_AwardTypeAxis_5ba963e1-fba3-4ca4-a9bc-b72788a7b18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87927264-b7f3-426b-95af-0af3e9ec391e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5ba963e1-fba3-4ca4-a9bc-b72788a7b18b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87927264-b7f3-426b-95af-0af3e9ec391e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareholderValueAwardsMember_57e0ccad-f324-4191-b8c4-1bc87dee15b8" xlink:href="lly-20221231.xsd#lly_ShareholderValueAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87927264-b7f3-426b-95af-0af3e9ec391e" xlink:to="loc_lly_ShareholderValueAwardsMember_57e0ccad-f324-4191-b8c4-1bc87dee15b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RelativeValueAwardsMember_ef2c91de-58cf-420c-9f2d-08d595672f84" xlink:href="lly-20221231.xsd#lly_RelativeValueAwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87927264-b7f3-426b-95af-0af3e9ec391e" xlink:to="loc_lly_RelativeValueAwardsMember_ef2c91de-58cf-420c-9f2d-08d595672f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36344cbf-49f9-4233-b7fb-40524e2d8116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_058632bd-33b3-4ec3-a095-8b762a48c056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36344cbf-49f9-4233-b7fb-40524e2d8116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6b2cf841-6223-48d5-9a16-8d95dee6465a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36344cbf-49f9-4233-b7fb-40524e2d8116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6b2cf841-6223-48d5-9a16-8d95dee6465a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_93fe8dc2-5b2f-4fdb-b74a-c1b77c985f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36344cbf-49f9-4233-b7fb-40524e2d8116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_93fe8dc2-5b2f-4fdb-b74a-c1b77c985f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9f1b2a04-29e0-40a7-8291-de14f88b1a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36344cbf-49f9-4233-b7fb-40524e2d8116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9f1b2a04-29e0-40a7-8291-de14f88b1a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#ShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1dbeab50-e2d8-46f8-bfeb-e3f2f1c6720e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_f8f8adbd-705a-4bfb-be8c-fb1331d647f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1dbeab50-e2d8-46f8-bfeb-e3f2f1c6720e" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_f8f8adbd-705a-4bfb-be8c-fb1331d647f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_9d1a8e3e-462c-4e08-99ec-3783e4fb4019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_f8f8adbd-705a-4bfb-be8c-fb1331d647f7" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_9d1a8e3e-462c-4e08-99ec-3783e4fb4019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_173e9f25-07a1-454c-9cf0-18a92c49b568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_9d1a8e3e-462c-4e08-99ec-3783e4fb4019" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_173e9f25-07a1-454c-9cf0-18a92c49b568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_May2021ShareRepurchaseProgramMember_879e1a51-f956-4174-8add-16ba0a62cefa" xlink:href="lly-20221231.xsd#lly_May2021ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_173e9f25-07a1-454c-9cf0-18a92c49b568" xlink:to="loc_lly_May2021ShareRepurchaseProgramMember_879e1a51-f956-4174-8add-16ba0a62cefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_6ac50d06-caf0-4e1a-8b5d-2dad4553ed41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_f8f8adbd-705a-4bfb-be8c-fb1331d647f7" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_6ac50d06-caf0-4e1a-8b5d-2dad4553ed41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f767d35e-fa1a-4d95-8f13-b566302fd12b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_6ac50d06-caf0-4e1a-8b5d-2dad4553ed41" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f767d35e-fa1a-4d95-8f13-b566302fd12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_805e0fda-2722-4ffd-a7c6-54d9cb616582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_6ac50d06-caf0-4e1a-8b5d-2dad4553ed41" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_805e0fda-2722-4ffd-a7c6-54d9cb616582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d70b2032-eba9-403b-b8f3-3ef41dc7e76a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_6ac50d06-caf0-4e1a-8b5d-2dad4553ed41" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d70b2032-eba9-403b-b8f3-3ef41dc7e76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_73471126-8973-4eba-9376-4325fbd71f75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_6ac50d06-caf0-4e1a-8b5d-2dad4553ed41" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_73471126-8973-4eba-9376-4325fbd71f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_dabd857a-cc75-4ce3-89ff-c7f91dcdb691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_6ac50d06-caf0-4e1a-8b5d-2dad4553ed41" xlink:to="loc_us-gaap_PreferredStockSharesIssued_dabd857a-cc75-4ce3-89ff-c7f91dcdb691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrustShares_99381411-ce3c-4ade-a8b3-9bc8aef616bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrustShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_6ac50d06-caf0-4e1a-8b5d-2dad4553ed41" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrustShares_99381411-ce3c-4ade-a8b3-9bc8aef616bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_7dcbf36f-574e-47ca-a141-29cf1cc305ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_6ac50d06-caf0-4e1a-8b5d-2dad4553ed41" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_7dcbf36f-574e-47ca-a141-29cf1cc305ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9187ef04-3a94-4c90-8359-e5322c6b41b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_d1a5006b-6f81-4bee-b920-5a1502e57998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9187ef04-3a94-4c90-8359-e5322c6b41b2" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_d1a5006b-6f81-4bee-b920-5a1502e57998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_e1fd7d76-090a-4e3b-a895-45719be50624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_d1a5006b-6f81-4bee-b920-5a1502e57998" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_e1fd7d76-090a-4e3b-a895-45719be50624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_97acd2b0-0631-4a6d-aacc-78929167a791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_d1a5006b-6f81-4bee-b920-5a1502e57998" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_97acd2b0-0631-4a6d-aacc-78929167a791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_85350ff6-31d3-4420-9703-b1ee1d2bb2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_d1a5006b-6f81-4bee-b920-5a1502e57998" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_85350ff6-31d3-4420-9703-b1ee1d2bb2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1694aa8b-543f-4660-bb48-7e4a7e90f83d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_d1a5006b-6f81-4bee-b920-5a1502e57998" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1694aa8b-543f-4660-bb48-7e4a7e90f83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_4e4c90f9-d648-49c3-916e-8b09de4827fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9187ef04-3a94-4c90-8359-e5322c6b41b2" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_4e4c90f9-d648-49c3-916e-8b09de4827fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0e98d2a0-c6d0-4d7d-b7ec-91e281e2616b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_4e4c90f9-d648-49c3-916e-8b09de4827fc" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0e98d2a0-c6d0-4d7d-b7ec-91e281e2616b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_53410291-3554-474d-ac57-fd6aa6869972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_4e4c90f9-d648-49c3-916e-8b09de4827fc" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_53410291-3554-474d-ac57-fd6aa6869972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_75b26f24-9db4-4a07-99e6-f3641dde7803" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_4e4c90f9-d648-49c3-916e-8b09de4827fc" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_75b26f24-9db4-4a07-99e6-f3641dde7803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_680e9955-72f2-4700-95b4-8963f060881a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_4e4c90f9-d648-49c3-916e-8b09de4827fc" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_680e9955-72f2-4700-95b4-8963f060881a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2ed9d6a6-192f-47f8-8141-e2dc757007d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9187ef04-3a94-4c90-8359-e5322c6b41b2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2ed9d6a6-192f-47f8-8141-e2dc757007d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward_53a38532-8485-4651-9e09-acb7dad7367a" xlink:href="lly-20221231.xsd#lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9187ef04-3a94-4c90-8359-e5322c6b41b2" xlink:to="loc_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward_53a38532-8485-4651-9e09-acb7dad7367a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_16221f39-fbd1-44ab-9c18-cf52ef5672bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_226b842b-0b11-4ba3-abc8-2ccf661d8561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_16221f39-fbd1-44ab-9c18-cf52ef5672bd" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_226b842b-0b11-4ba3-abc8-2ccf661d8561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_7af503b1-051e-4cda-bd24-14d90d0c83b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_226b842b-0b11-4ba3-abc8-2ccf661d8561" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_7af503b1-051e-4cda-bd24-14d90d0c83b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_18fb5596-aee8-4e82-b75a-1404be487442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_226b842b-0b11-4ba3-abc8-2ccf661d8561" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_18fb5596-aee8-4e82-b75a-1404be487442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_7afc2001-e813-47fe-9e58-8e9522aa9b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_226b842b-0b11-4ba3-abc8-2ccf661d8561" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_7afc2001-e813-47fe-9e58-8e9522aa9b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7b23e7f6-f425-419d-888b-fc48cee07d57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_226b842b-0b11-4ba3-abc8-2ccf661d8561" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7b23e7f6-f425-419d-888b-fc48cee07d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_cda8d613-a030-4df7-8db5-4a524c9c2315" xlink:href="lly-20221231.xsd#lly_DeferredTaxAssetsSalesRebatesAndDiscounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_226b842b-0b11-4ba3-abc8-2ccf661d8561" xlink:to="loc_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_cda8d613-a030-4df7-8db5-4a524c9c2315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_154019f3-1fb3-41ba-bbf5-ffb871696cc2" xlink:href="lly-20221231.xsd#lly_DeferredTaxAssetsCorrectiveTaxAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_226b842b-0b11-4ba3-abc8-2ccf661d8561" xlink:to="loc_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_154019f3-1fb3-41ba-bbf5-ffb871696cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsForeignTaxRedeterminations_645415ef-a429-4a8e-bcaa-5d53ad73634b" xlink:href="lly-20221231.xsd#lly_DeferredTaxAssetsForeignTaxRedeterminations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_226b842b-0b11-4ba3-abc8-2ccf661d8561" xlink:to="loc_lly_DeferredTaxAssetsForeignTaxRedeterminations_645415ef-a429-4a8e-bcaa-5d53ad73634b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsOperatingLeaseLiability_0835332f-e93e-4e6d-8348-ecd70dc91916" xlink:href="lly-20221231.xsd#lly_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_226b842b-0b11-4ba3-abc8-2ccf661d8561" xlink:to="loc_lly_DeferredTaxAssetsOperatingLeaseLiability_0835332f-e93e-4e6d-8348-ecd70dc91916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_c0c51050-03a2-40f6-8db3-aff20c1fda67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_226b842b-0b11-4ba3-abc8-2ccf661d8561" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_c0c51050-03a2-40f6-8db3-aff20c1fda67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_a96ab2c0-bad5-44c9-8250-22c959a93b41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_226b842b-0b11-4ba3-abc8-2ccf661d8561" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_a96ab2c0-bad5-44c9-8250-22c959a93b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_704db212-1bd9-4c8e-8bd7-abebc7f1bd87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_226b842b-0b11-4ba3-abc8-2ccf661d8561" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_704db212-1bd9-4c8e-8bd7-abebc7f1bd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_54830626-4ede-4fa4-ba30-3790e928169f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_226b842b-0b11-4ba3-abc8-2ccf661d8561" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_54830626-4ede-4fa4-ba30-3790e928169f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_512edc55-2da6-4b2e-8125-77a384b058e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_226b842b-0b11-4ba3-abc8-2ccf661d8561" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_512edc55-2da6-4b2e-8125-77a384b058e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_6d8b76fa-085f-4dd5-9b87-079ce619393c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_16221f39-fbd1-44ab-9c18-cf52ef5672bd" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_6d8b76fa-085f-4dd5-9b87-079ce619393c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_bd3f1cd0-7bc4-458a-a35e-7e0e0e91ee90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_6d8b76fa-085f-4dd5-9b87-079ce619393c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_bd3f1cd0-7bc4-458a-a35e-7e0e0e91ee90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_fadaf7e2-0d44-4e7d-be32-7aafae1a8e10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_6d8b76fa-085f-4dd5-9b87-079ce619393c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_fadaf7e2-0d44-4e7d-be32-7aafae1a8e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_219ab973-a5b1-49f0-8b9d-b5c259498388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_6d8b76fa-085f-4dd5-9b87-079ce619393c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_219ab973-a5b1-49f0-8b9d-b5c259498388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_c0673f85-6b75-4596-b9d3-7b1e7dbba345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_6d8b76fa-085f-4dd5-9b87-079ce619393c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_c0673f85-6b75-4596-b9d3-7b1e7dbba345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cb480de2-30e5-4787-b062-7d2d0d3953e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_6d8b76fa-085f-4dd5-9b87-079ce619393c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cb480de2-30e5-4787-b062-7d2d0d3953e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_3b630e5d-78ec-4fe0-8bdd-b914b0ad2062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_6d8b76fa-085f-4dd5-9b87-079ce619393c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_3b630e5d-78ec-4fe0-8bdd-b914b0ad2062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_96877aaf-7a55-4688-b03f-ea1def086b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_6d8b76fa-085f-4dd5-9b87-079ce619393c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_96877aaf-7a55-4688-b03f-ea1def086b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1f587784-4461-4d7a-a931-e9d71ae68ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_6d8b76fa-085f-4dd5-9b87-079ce619393c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_1f587784-4461-4d7a-a931-e9d71ae68ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9c8694cb-02ec-413c-90db-e080ab5f54ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_16221f39-fbd1-44ab-9c18-cf52ef5672bd" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9c8694cb-02ec-413c-90db-e080ab5f54ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_750ac107-1c05-458f-8f65-d212e2d9e920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_7965028b-de1b-4b12-b33b-f507f478280f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_750ac107-1c05-458f-8f65-d212e2d9e920" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_7965028b-de1b-4b12-b33b-f507f478280f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_f654df09-a58c-4aae-a802-5897f5e9d718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7965028b-de1b-4b12-b33b-f507f478280f" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_f654df09-a58c-4aae-a802-5897f5e9d718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_21d6bd6f-9b07-44a7-b157-439186e2a187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_f654df09-a58c-4aae-a802-5897f5e9d718" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_21d6bd6f-9b07-44a7-b157-439186e2a187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CarryforwardMember_c2f31221-0b8a-4fb3-80bb-9c467f2c0b3e" xlink:href="lly-20221231.xsd#lly_CarryforwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_21d6bd6f-9b07-44a7-b157-439186e2a187" xlink:to="loc_lly_CarryforwardMember_c2f31221-0b8a-4fb3-80bb-9c467f2c0b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ExpirationBy2026Member_99d05ca1-772d-48fb-a1fb-1fb41274ff74" xlink:href="lly-20221231.xsd#lly_ExpirationBy2026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_21d6bd6f-9b07-44a7-b157-439186e2a187" xlink:to="loc_lly_ExpirationBy2026Member_99d05ca1-772d-48fb-a1fb-1fb41274ff74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ExpirationBetween2028And2042Member_accdc78f-6819-4893-ae80-cbd1d2d0bc76" xlink:href="lly-20221231.xsd#lly_ExpirationBetween2028And2042Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_21d6bd6f-9b07-44a7-b157-439186e2a187" xlink:to="loc_lly_ExpirationBetween2028And2042Member_accdc78f-6819-4893-ae80-cbd1d2d0bc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DesignatedUnusableMember_b9491c22-aac3-4a92-a52f-144e0b8fe4fa" xlink:href="lly-20221231.xsd#lly_DesignatedUnusableMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_21d6bd6f-9b07-44a7-b157-439186e2a187" xlink:to="loc_lly_DesignatedUnusableMember_b9491c22-aac3-4a92-a52f-144e0b8fe4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ExpirationBy2027Member_a8f5e6d6-8de0-42e5-a572-1bd8a3a55404" xlink:href="lly-20221231.xsd#lly_ExpirationBy2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_21d6bd6f-9b07-44a7-b157-439186e2a187" xlink:to="loc_lly_ExpirationBy2027Member_a8f5e6d6-8de0-42e5-a572-1bd8a3a55404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NoExpirationMember_5fce7dd8-7a78-4543-b04a-b52326c07b11" xlink:href="lly-20221231.xsd#lly_NoExpirationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_21d6bd6f-9b07-44a7-b157-439186e2a187" xlink:to="loc_lly_NoExpirationMember_5fce7dd8-7a78-4543-b04a-b52326c07b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_7d4fff57-224a-4607-ba60-a61acafa2037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7965028b-de1b-4b12-b33b-f507f478280f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_7d4fff57-224a-4607-ba60-a61acafa2037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8ecb04aa-38ef-4269-af86-aab7f1e8785f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_7d4fff57-224a-4607-ba60-a61acafa2037" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8ecb04aa-38ef-4269-af86-aab7f1e8785f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_b12d5edd-e72a-499a-8f48-60e2bd0a5f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8ecb04aa-38ef-4269-af86-aab7f1e8785f" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_b12d5edd-e72a-499a-8f48-60e2bd0a5f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_2df076bc-3d2a-4b13-9a8f-571b0be80b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8ecb04aa-38ef-4269-af86-aab7f1e8785f" xlink:to="loc_us-gaap_ForeignCountryMember_2df076bc-3d2a-4b13-9a8f-571b0be80b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_7d19809e-e713-45aa-9e2b-fa919846dd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8ecb04aa-38ef-4269-af86-aab7f1e8785f" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_7d19809e-e713-45aa-9e2b-fa919846dd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7965028b-de1b-4b12-b33b-f507f478280f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_25a2de8a-5d06-4d7f-8364-a61267227dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_25a2de8a-5d06-4d7f-8364-a61267227dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_770b7912-46d0-4b24-8857-42240ba1ec16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:to="loc_us-gaap_OperatingLossCarryforwards_770b7912-46d0-4b24-8857-42240ba1ec16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_c2ec93f0-b3f4-4451-b3f4-fa547b72461f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_c2ec93f0-b3f4-4451-b3f4-fa547b72461f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_cb36497a-108c-41d3-91ae-65c4736b9ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:to="loc_us-gaap_PrepaidTaxes_cb36497a-108c-41d3-91ae-65c4736b9ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_304199d5-04a7-4d5c-a620-0817bc1d7fae" xlink:href="lly-20221231.xsd#lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:to="loc_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_304199d5-04a7-4d5c-a620-0817bc1d7fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_2ac2b96f-8bda-4c91-891a-5634b7342388" xlink:href="lly-20221231.xsd#lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:to="loc_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_2ac2b96f-8bda-4c91-891a-5634b7342388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c8b8f41c-2f30-40e2-ac4b-325b895d36e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c8b8f41c-2f30-40e2-ac4b-325b895d36e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4b007740-76e1-4b3b-9ef2-9fbc84da8192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63ccabb8-2e3c-46b9-b756-696feb73f0d5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4b007740-76e1-4b3b-9ef2-9fbc84da8192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9b6e417a-0567-4e30-bb6e-c922e6d91993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_f02d682c-f465-4713-963c-8dbb7d073eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9b6e417a-0567-4e30-bb6e-c922e6d91993" xlink:to="loc_us-gaap_IncomeTaxesPaid_f02d682c-f465-4713-963c-8dbb7d073eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_84a145e0-e3da-4e4f-b4b0-26a51d815de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_4e0309d2-46a3-45a7-ac6a-45374e2a1436" xlink:href="lly-20221231.xsd#lly_TaxCutAndJobsActTollTaxPaymentDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84a145e0-e3da-4e4f-b4b0-26a51d815de5" xlink:to="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_4e0309d2-46a3-45a7-ac6a-45374e2a1436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaid_65ec77e4-b37f-4c5d-9594-364921041f10" xlink:href="lly-20221231.xsd#lly_TaxCutAndJobsActTollTaxToBePaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_4e0309d2-46a3-45a7-ac6a-45374e2a1436" xlink:to="loc_lly_TaxCutAndJobsActTollTaxToBePaid_65ec77e4-b37f-4c5d-9594-364921041f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_59544716-703d-4b35-98cd-8b323bb544ec" xlink:href="lly-20221231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_4e0309d2-46a3-45a7-ac6a-45374e2a1436" xlink:to="loc_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_59544716-703d-4b35-98cd-8b323bb544ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_0410dcc2-06fb-4670-ba2d-3d228a2666f3" xlink:href="lly-20221231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_4e0309d2-46a3-45a7-ac6a-45374e2a1436" xlink:to="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_0410dcc2-06fb-4670-ba2d-3d228a2666f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c598f76e-5ac0-4c6c-bf45-fb487127c465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_e8d23e96-c9cc-472d-9f72-724a32109fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c598f76e-5ac0-4c6c-bf45-fb487127c465" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_e8d23e96-c9cc-472d-9f72-724a32109fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AddDeductAbstract_5e47f4d4-2448-484b-95ed-0bbe0fc0f455" xlink:href="lly-20221231.xsd#lly_AddDeductAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c598f76e-5ac0-4c6c-bf45-fb487127c465" xlink:to="loc_lly_AddDeductAbstract_5e47f4d4-2448-484b-95ed-0bbe0fc0f455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_cac3cc73-d705-426d-a5e0-25d47519d201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AddDeductAbstract_5e47f4d4-2448-484b-95ed-0bbe0fc0f455" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_cac3cc73-d705-426d-a5e0-25d47519d201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_ba52a2f3-059f-471f-b907-90a650c01ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AddDeductAbstract_5e47f4d4-2448-484b-95ed-0bbe0fc0f455" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_ba52a2f3-059f-471f-b907-90a650c01ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_f0638888-3310-4ecc-b211-ffafb7c90946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AddDeductAbstract_5e47f4d4-2448-484b-95ed-0bbe0fc0f455" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_f0638888-3310-4ecc-b211-ffafb7c90946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_6ddf4c1f-275c-4ed1-9d68-d81d080917da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AddDeductAbstract_5e47f4d4-2448-484b-95ed-0bbe0fc0f455" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_6ddf4c1f-275c-4ed1-9d68-d81d080917da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_44be29b7-c44d-494a-a597-7d3b726eb271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AddDeductAbstract_5e47f4d4-2448-484b-95ed-0bbe0fc0f455" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_44be29b7-c44d-494a-a597-7d3b726eb271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_acc50d2f-fab9-4e4f-bf4b-e9dde0540e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c598f76e-5ac0-4c6c-bf45-fb487127c465" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_acc50d2f-fab9-4e4f-bf4b-e9dde0540e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0a37fad2-3126-4d0f-aa80-a03ed3bb9439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6cb015d2-774a-4c88-8b81-270d93c6d66b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0a37fad2-3126-4d0f-aa80-a03ed3bb9439" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6cb015d2-774a-4c88-8b81-270d93c6d66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1ae88e14-6bce-44d4-9d98-f0accfbf76e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6cb015d2-774a-4c88-8b81-270d93c6d66b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1ae88e14-6bce-44d4-9d98-f0accfbf76e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f5f0755c-9585-42c1-8cc4-d1bb77befb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6cb015d2-774a-4c88-8b81-270d93c6d66b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f5f0755c-9585-42c1-8cc4-d1bb77befb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_18b911d5-2508-4441-94e4-ce81595769af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6cb015d2-774a-4c88-8b81-270d93c6d66b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_18b911d5-2508-4441-94e4-ce81595769af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_a6f921c6-d519-43aa-a5c7-4f639aa53281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6cb015d2-774a-4c88-8b81-270d93c6d66b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_a6f921c6-d519-43aa-a5c7-4f639aa53281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_ce0bac03-1fb8-4b29-8dfd-21c0ded7112d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6cb015d2-774a-4c88-8b81-270d93c6d66b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_ce0bac03-1fb8-4b29-8dfd-21c0ded7112d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_5199fbd7-0698-4afe-92c7-e4b3ffec2fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6cb015d2-774a-4c88-8b81-270d93c6d66b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_5199fbd7-0698-4afe-92c7-e4b3ffec2fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation_f9321ee5-0ff2-4ed4-83b6-32df089f3544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6cb015d2-774a-4c88-8b81-270d93c6d66b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation_f9321ee5-0ff2-4ed4-83b6-32df089f3544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation_08d30625-7315-4934-b578-b77f02616339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6cb015d2-774a-4c88-8b81-270d93c6d66b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation_08d30625-7315-4934-b578-b77f02616339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7e964ba6-f1d1-44b8-99d6-077b57ed804b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6cb015d2-774a-4c88-8b81-270d93c6d66b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_7e964ba6-f1d1-44b8-99d6-077b57ed804b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_95c6a850-51c7-4e56-9461-acaea801a53d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ab6418bf-a2f0-4545-88ef-b597268749ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_95c6a850-51c7-4e56-9461-acaea801a53d" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ab6418bf-a2f0-4545-88ef-b597268749ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_38bf88a4-13b5-41d1-88ec-854e511b6124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ab6418bf-a2f0-4545-88ef-b597268749ae" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_38bf88a4-13b5-41d1-88ec-854e511b6124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_35f72e3b-f540-4b24-9db6-b1f2ddbcfcca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_38bf88a4-13b5-41d1-88ec-854e511b6124" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_35f72e3b-f540-4b24-9db6-b1f2ddbcfcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_f7388692-a094-45fc-82e0-ab8aff58f344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_35f72e3b-f540-4b24-9db6-b1f2ddbcfcca" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_f7388692-a094-45fc-82e0-ab8aff58f344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_323d26c4-db87-413c-a117-f7f12ddc3271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_35f72e3b-f540-4b24-9db6-b1f2ddbcfcca" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_323d26c4-db87-413c-a117-f7f12ddc3271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c716a757-455f-41db-b085-2edb091b5c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ab6418bf-a2f0-4545-88ef-b597268749ae" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c716a757-455f-41db-b085-2edb091b5c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e15f615f-0140-45b2-ac54-f8918e11d75f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c716a757-455f-41db-b085-2edb091b5c6e" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e15f615f-0140-45b2-ac54-f8918e11d75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_09476610-c95c-4abf-bda5-546f35e775dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e15f615f-0140-45b2-ac54-f8918e11d75f" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_09476610-c95c-4abf-bda5-546f35e775dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_44ff74d0-4621-4c17-8b24-f4793c14765d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e15f615f-0140-45b2-ac54-f8918e11d75f" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_44ff74d0-4621-4c17-8b24-f4793c14765d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_1e961b30-9435-422d-ad19-ba4ef9670f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e15f615f-0140-45b2-ac54-f8918e11d75f" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_1e961b30-9435-422d-ad19-ba4ef9670f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_1d8382a2-9c7e-4144-89a5-a1aa775a1dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e15f615f-0140-45b2-ac54-f8918e11d75f" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_1d8382a2-9c7e-4144-89a5-a1aa775a1dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_8187f9be-4079-488d-8618-90f3250c69ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e15f615f-0140-45b2-ac54-f8918e11d75f" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_8187f9be-4079-488d-8618-90f3250c69ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_c09abddd-9107-47a8-8361-6e2787245b05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e15f615f-0140-45b2-ac54-f8918e11d75f" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_c09abddd-9107-47a8-8361-6e2787245b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_1b7404ca-0e16-4197-9024-496b175668fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e15f615f-0140-45b2-ac54-f8918e11d75f" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_1b7404ca-0e16-4197-9024-496b175668fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_9fff5ae5-7b82-4e82-af5b-c70bd28bb9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c716a757-455f-41db-b085-2edb091b5c6e" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_9fff5ae5-7b82-4e82-af5b-c70bd28bb9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f0dbecb6-4987-44e2-ba40-0b1ca8d42765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_9fff5ae5-7b82-4e82-af5b-c70bd28bb9f3" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f0dbecb6-4987-44e2-ba40-0b1ca8d42765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_733fbc9b-696a-4ac4-8c48-336ca2059754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_9fff5ae5-7b82-4e82-af5b-c70bd28bb9f3" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_733fbc9b-696a-4ac4-8c48-336ca2059754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_c8a5b299-183d-40ac-ba2d-6d7238bd4d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_9fff5ae5-7b82-4e82-af5b-c70bd28bb9f3" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_c8a5b299-183d-40ac-ba2d-6d7238bd4d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_09ceb3c0-d0f7-4d71-9c39-a92523aca7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_9fff5ae5-7b82-4e82-af5b-c70bd28bb9f3" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_09ceb3c0-d0f7-4d71-9c39-a92523aca7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_4bac18ad-f844-454a-99a7-9eeebd3c7da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_9fff5ae5-7b82-4e82-af5b-c70bd28bb9f3" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_4bac18ad-f844-454a-99a7-9eeebd3c7da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_0ce101c0-d6f0-4275-bd0b-98d2e73518f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_9fff5ae5-7b82-4e82-af5b-c70bd28bb9f3" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_0ce101c0-d6f0-4275-bd0b-98d2e73518f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_c2c159bd-e64e-40c3-b184-e940e78341e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c716a757-455f-41db-b085-2edb091b5c6e" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_c2c159bd-e64e-40c3-b184-e940e78341e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_460a6369-73cb-42c8-a380-261da4b7365f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c716a757-455f-41db-b085-2edb091b5c6e" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_460a6369-73cb-42c8-a380-261da4b7365f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_c8b24180-1722-4797-a88b-acf6c3eabe41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c716a757-455f-41db-b085-2edb091b5c6e" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_c8b24180-1722-4797-a88b-acf6c3eabe41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_3edca30d-1681-44ca-9691-58d4d5c07e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_c716a757-455f-41db-b085-2edb091b5c6e" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_3edca30d-1681-44ca-9691-58d4d5c07e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ffd76982-bcb3-4dd6-99cd-1426d7504d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_5117c2ce-a9aa-4bee-8309-5acc3be872e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ffd76982-bcb3-4dd6-99cd-1426d7504d00" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_5117c2ce-a9aa-4bee-8309-5acc3be872e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8206f1ab-bb2b-483b-8f05-28c6ef5a4667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_5117c2ce-a9aa-4bee-8309-5acc3be872e7" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8206f1ab-bb2b-483b-8f05-28c6ef5a4667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7eef5ecf-a008-48d7-8045-73910e62fb82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8206f1ab-bb2b-483b-8f05-28c6ef5a4667" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7eef5ecf-a008-48d7-8045-73910e62fb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_80577a20-305e-493b-b2b1-d12a147a4ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_7eef5ecf-a008-48d7-8045-73910e62fb82" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_80577a20-305e-493b-b2b1-d12a147a4ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_9c8e728c-1dde-443d-b953-2efdd62e0638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_7eef5ecf-a008-48d7-8045-73910e62fb82" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_9c8e728c-1dde-443d-b953-2efdd62e0638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4a96393a-045c-4b9a-bbaa-77e0611308ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_5117c2ce-a9aa-4bee-8309-5acc3be872e7" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4a96393a-045c-4b9a-bbaa-77e0611308ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c9d9f7d3-9932-40e4-8f1c-ebfe925be986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4a96393a-045c-4b9a-bbaa-77e0611308ec" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c9d9f7d3-9932-40e4-8f1c-ebfe925be986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_6d434f09-eb85-46e6-af97-bbe26f52ce83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c9d9f7d3-9932-40e4-8f1c-ebfe925be986" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_6d434f09-eb85-46e6-af97-bbe26f52ce83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_9fd69a23-0c84-4a92-81a1-91514240a35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c9d9f7d3-9932-40e4-8f1c-ebfe925be986" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_9fd69a23-0c84-4a92-81a1-91514240a35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_21e0ea8a-5615-412a-9a18-8d5bafc1268a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c9d9f7d3-9932-40e4-8f1c-ebfe925be986" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_21e0ea8a-5615-412a-9a18-8d5bafc1268a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_e60826aa-8c74-42ad-80a2-4275e629eea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c9d9f7d3-9932-40e4-8f1c-ebfe925be986" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_e60826aa-8c74-42ad-80a2-4275e629eea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_57b066bf-4a8f-467c-907e-f84ab95c8df2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c9d9f7d3-9932-40e4-8f1c-ebfe925be986" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_57b066bf-4a8f-467c-907e-f84ab95c8df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RetirementBenefitsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e7115ae8-0662-4168-bbeb-527ba1d9248e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_165b04f1-02aa-49b9-bab4-84294b272211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e7115ae8-0662-4168-bbeb-527ba1d9248e" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_165b04f1-02aa-49b9-bab4-84294b272211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b171b179-b6a7-4659-8418-daad8afad161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_165b04f1-02aa-49b9-bab4-84294b272211" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b171b179-b6a7-4659-8418-daad8afad161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_bc4b52f0-fe4f-41af-bd4a-228fca18832e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b171b179-b6a7-4659-8418-daad8afad161" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_bc4b52f0-fe4f-41af-bd4a-228fca18832e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_989b5d11-c8e2-423e-a560-17b417eae512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_bc4b52f0-fe4f-41af-bd4a-228fca18832e" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_989b5d11-c8e2-423e-a560-17b417eae512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember_0a01df66-02ed-4b0d-8d2d-420f6a0f752b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_bc4b52f0-fe4f-41af-bd4a-228fca18832e" xlink:to="loc_us-gaap_FixedIncomeFundsMember_0a01df66-02ed-4b0d-8d2d-420f6a0f752b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a2161ebc-2c08-4d1a-9d81-3cf690cff68b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_165b04f1-02aa-49b9-bab4-84294b272211" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a2161ebc-2c08-4d1a-9d81-3cf690cff68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_772985c3-5ea5-4990-9adf-5f881ca07dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a2161ebc-2c08-4d1a-9d81-3cf690cff68b" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_772985c3-5ea5-4990-9adf-5f881ca07dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_09541794-0b65-4d45-9f28-19e39752d682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_772985c3-5ea5-4990-9adf-5f881ca07dcf" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_09541794-0b65-4d45-9f28-19e39752d682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_231180eb-0878-46ef-9bd1-9b6a06e5b761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_165b04f1-02aa-49b9-bab4-84294b272211" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_231180eb-0878-46ef-9bd1-9b6a06e5b761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_debcbb40-789f-4e6a-96ba-3a452e9c75bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_231180eb-0878-46ef-9bd1-9b6a06e5b761" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_debcbb40-789f-4e6a-96ba-3a452e9c75bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_8c1eded9-298f-4ab9-9749-f2318f3c27c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_231180eb-0878-46ef-9bd1-9b6a06e5b761" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_8c1eded9-298f-4ab9-9749-f2318f3c27c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_7d1cdd18-3341-450f-9555-0a6615716acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_231180eb-0878-46ef-9bd1-9b6a06e5b761" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_7d1cdd18-3341-450f-9555-0a6615716acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_d3529071-2d70-467f-8d81-87356faf5fe8" xlink:href="lly-20221231.xsd#lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_231180eb-0878-46ef-9bd1-9b6a06e5b761" xlink:to="loc_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_d3529071-2d70-467f-8d81-87356faf5fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_bf64dd20-10f4-401b-bac7-f818367c327c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_231180eb-0878-46ef-9bd1-9b6a06e5b761" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_bf64dd20-10f4-401b-bac7-f818367c327c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_bb39a84c-b808-4d01-b210-ced4b73531f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_231180eb-0878-46ef-9bd1-9b6a06e5b761" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_bb39a84c-b808-4d01-b210-ced4b73531f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_449ae7f4-3890-45d7-af85-5fc18efdc3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_55f272aa-aa5c-4cc4-88ac-3065685d8894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_449ae7f4-3890-45d7-af85-5fc18efdc3e7" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_55f272aa-aa5c-4cc4-88ac-3065685d8894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2d0ee974-8113-41cf-8950-01b370033dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_55f272aa-aa5c-4cc4-88ac-3065685d8894" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2d0ee974-8113-41cf-8950-01b370033dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_b2aba7e1-6357-40eb-9d14-50449f005637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2d0ee974-8113-41cf-8950-01b370033dd7" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_b2aba7e1-6357-40eb-9d14-50449f005637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_de4e4858-e7f2-4a34-954d-c53003e7fa62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_b2aba7e1-6357-40eb-9d14-50449f005637" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_de4e4858-e7f2-4a34-954d-c53003e7fa62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_eb78c9a2-90c6-44ed-8414-37dea3ed6f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_b2aba7e1-6357-40eb-9d14-50449f005637" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_eb78c9a2-90c6-44ed-8414-37dea3ed6f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_cd18e348-b420-4036-b084-30ece2562d63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_55f272aa-aa5c-4cc4-88ac-3065685d8894" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_cd18e348-b420-4036-b084-30ece2562d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_596503de-5bee-4267-8816-8ea24b44247d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_cd18e348-b420-4036-b084-30ece2562d63" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_596503de-5bee-4267-8816-8ea24b44247d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_5f6de1f4-7821-40ef-bd1f-5f80cde2700e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_cd18e348-b420-4036-b084-30ece2562d63" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_5f6de1f4-7821-40ef-bd1f-5f80cde2700e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_86e79083-8b94-414d-b40e-2beb6d33b842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_cd18e348-b420-4036-b084-30ece2562d63" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_86e79083-8b94-414d-b40e-2beb6d33b842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_797f608d-4afc-4bc9-b538-e9b9c749fc39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_cd18e348-b420-4036-b084-30ece2562d63" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_797f608d-4afc-4bc9-b538-e9b9c749fc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_62c3c725-5729-49a7-8d7f-6421d5063d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_cd18e348-b420-4036-b084-30ece2562d63" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_62c3c725-5729-49a7-8d7f-6421d5063d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f7390942-c7b0-4d83-893a-c93a6f98c765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ef0a40a4-e12d-40b8-b795-f32c5739cd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f7390942-c7b0-4d83-893a-c93a6f98c765" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ef0a40a4-e12d-40b8-b795-f32c5739cd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2ecd58d8-e583-447b-941b-367bdf424e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ef0a40a4-e12d-40b8-b795-f32c5739cd4f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2ecd58d8-e583-447b-941b-367bdf424e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8afa2b52-1dec-47a1-9084-d4227c6b2354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2ecd58d8-e583-447b-941b-367bdf424e14" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8afa2b52-1dec-47a1-9084-d4227c6b2354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_cb40ec18-cce6-40ee-a8a8-65a585a9ce3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8afa2b52-1dec-47a1-9084-d4227c6b2354" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_cb40ec18-cce6-40ee-a8a8-65a585a9ce3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_57174b3b-44b5-445d-acc8-19d44aa02503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8afa2b52-1dec-47a1-9084-d4227c6b2354" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_57174b3b-44b5-445d-acc8-19d44aa02503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4648beb3-15a8-4110-85a4-da678b58d58b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ef0a40a4-e12d-40b8-b795-f32c5739cd4f" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4648beb3-15a8-4110-85a4-da678b58d58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_22e94caf-5947-41c8-92f3-3afa3bcd9fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4648beb3-15a8-4110-85a4-da678b58d58b" xlink:to="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_22e94caf-5947-41c8-92f3-3afa3bcd9fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_3fa3ee18-56b7-4acd-afcf-30090dcd83a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_22e94caf-5947-41c8-92f3-3afa3bcd9fbe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_3fa3ee18-56b7-4acd-afcf-30090dcd83a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_fd4ec60c-a57b-49f5-b4ac-54a18fe0ad6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_22e94caf-5947-41c8-92f3-3afa3bcd9fbe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_fd4ec60c-a57b-49f5-b4ac-54a18fe0ad6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_43eabc9b-a97d-4905-83c0-25c230a8f6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_22e94caf-5947-41c8-92f3-3afa3bcd9fbe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_43eabc9b-a97d-4905-83c0-25c230a8f6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_0aa6e818-e642-4a20-9457-02f04a2d1266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_22e94caf-5947-41c8-92f3-3afa3bcd9fbe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_0aa6e818-e642-4a20-9457-02f04a2d1266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_85186c3d-4a26-4fa0-968f-fad6132f2e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_22e94caf-5947-41c8-92f3-3afa3bcd9fbe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_85186c3d-4a26-4fa0-968f-fad6132f2e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_3b368688-b1ba-4352-b32d-6c55091c111a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_22e94caf-5947-41c8-92f3-3afa3bcd9fbe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_3b368688-b1ba-4352-b32d-6c55091c111a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_255f728b-ad5c-4ce4-bb36-6e128592ab41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4648beb3-15a8-4110-85a4-da678b58d58b" xlink:to="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_255f728b-ad5c-4ce4-bb36-6e128592ab41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_b0428fcc-9ad0-4f86-a1c7-0a1bdf6ecd67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_255f728b-ad5c-4ce4-bb36-6e128592ab41" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_b0428fcc-9ad0-4f86-a1c7-0a1bdf6ecd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_2961a65c-f247-4283-b4d1-b4ea7ae15fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_255f728b-ad5c-4ce4-bb36-6e128592ab41" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_2961a65c-f247-4283-b4d1-b4ea7ae15fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_e36e65b6-6de9-40dc-b39c-57d8bf7c7822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4648beb3-15a8-4110-85a4-da678b58d58b" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_e36e65b6-6de9-40dc-b39c-57d8bf7c7822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_bf1e044a-dc5a-4232-aaea-1fcecd524dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_e36e65b6-6de9-40dc-b39c-57d8bf7c7822" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_bf1e044a-dc5a-4232-aaea-1fcecd524dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_ea190e3d-d757-417c-aaf2-d066537b7bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_e36e65b6-6de9-40dc-b39c-57d8bf7c7822" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_ea190e3d-d757-417c-aaf2-d066537b7bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_4ecfabc6-32aa-45cb-9e2f-4d758609f12d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4648beb3-15a8-4110-85a4-da678b58d58b" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_4ecfabc6-32aa-45cb-9e2f-4d758609f12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_462a7148-897f-4f29-9742-0c2934a81ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_4ecfabc6-32aa-45cb-9e2f-4d758609f12d" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_462a7148-897f-4f29-9742-0c2934a81ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_0750b1eb-9636-401c-976a-7d9b17a93349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_4ecfabc6-32aa-45cb-9e2f-4d758609f12d" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_0750b1eb-9636-401c-976a-7d9b17a93349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_c305f641-d5e3-4a67-9173-07df8f8ac3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_4ecfabc6-32aa-45cb-9e2f-4d758609f12d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_c305f641-d5e3-4a67-9173-07df8f8ac3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_cf53e8c3-dc1c-441a-88dc-44479be3ab50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_4ecfabc6-32aa-45cb-9e2f-4d758609f12d" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_cf53e8c3-dc1c-441a-88dc-44479be3ab50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_8737ff59-cd88-4a0d-a292-0dc0c8180325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_4ecfabc6-32aa-45cb-9e2f-4d758609f12d" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_8737ff59-cd88-4a0d-a292-0dc0c8180325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_b108a228-27c6-4de7-b5fe-70a3d49bdd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_4ecfabc6-32aa-45cb-9e2f-4d758609f12d" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_b108a228-27c6-4de7-b5fe-70a3d49bdd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_166055a5-b822-484c-a550-20a6c00523f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4648beb3-15a8-4110-85a4-da678b58d58b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_166055a5-b822-484c-a550-20a6c00523f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_3eb6bce2-ea12-4c6f-b859-0d95076ff7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_166055a5-b822-484c-a550-20a6c00523f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_3eb6bce2-ea12-4c6f-b859-0d95076ff7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_cf1b7777-2080-48eb-ba9b-5b05d8ed1337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_166055a5-b822-484c-a550-20a6c00523f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_cf1b7777-2080-48eb-ba9b-5b05d8ed1337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_9492afc1-df2a-428c-ad8d-05cf35778a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_166055a5-b822-484c-a550-20a6c00523f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_9492afc1-df2a-428c-ad8d-05cf35778a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_725a3e60-a2cd-43ca-866b-2be784bbdda8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_166055a5-b822-484c-a550-20a6c00523f1" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_725a3e60-a2cd-43ca-866b-2be784bbdda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_2143a526-b1e8-4744-ae6d-006d7d2fd128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_166055a5-b822-484c-a550-20a6c00523f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_2143a526-b1e8-4744-ae6d-006d7d2fd128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_1c4d9fdd-8263-4c2e-a252-cf519c82112c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_166055a5-b822-484c-a550-20a6c00523f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_1c4d9fdd-8263-4c2e-a252-cf519c82112c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#RetirementBenefitsScheduleofFairValueDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2a1f609c-270a-4f1f-86bc-eb002ae921e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d75d9bc4-d848-490c-ac4b-58e43b8075f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2a1f609c-270a-4f1f-86bc-eb002ae921e7" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d75d9bc4-d848-490c-ac4b-58e43b8075f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_278fa2b6-f159-49f9-8e4b-8eb6ea97618c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d75d9bc4-d848-490c-ac4b-58e43b8075f3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_278fa2b6-f159-49f9-8e4b-8eb6ea97618c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0aa8fb7-8001-4c8e-bb71-058be446c3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_278fa2b6-f159-49f9-8e4b-8eb6ea97618c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0aa8fb7-8001-4c8e-bb71-058be446c3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_167e007d-bf8e-49b5-bcc9-69b595a94f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0aa8fb7-8001-4c8e-bb71-058be446c3ca" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_167e007d-bf8e-49b5-bcc9-69b595a94f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_696a40e2-093e-4ed7-851a-c0de4638dad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0aa8fb7-8001-4c8e-bb71-058be446c3ca" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_696a40e2-093e-4ed7-851a-c0de4638dad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d4997057-eb95-457a-8a1d-fe645b9f5992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0aa8fb7-8001-4c8e-bb71-058be446c3ca" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d4997057-eb95-457a-8a1d-fe645b9f5992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_348074cf-ebcd-4e60-8d27-5cddc609483d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0aa8fb7-8001-4c8e-bb71-058be446c3ca" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_348074cf-ebcd-4e60-8d27-5cddc609483d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_34d869e2-6c37-4365-a20f-e274e1cfe8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d75d9bc4-d848-490c-ac4b-58e43b8075f3" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_34d869e2-6c37-4365-a20f-e274e1cfe8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_34d869e2-6c37-4365-a20f-e274e1cfe8a7" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_855bcafb-bb56-4b2d-aaf6-b97963ca3f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_855bcafb-bb56-4b2d-aaf6-b97963ca3f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_449943e0-49b3-4763-9e51-438497f2c9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_449943e0-49b3-4763-9e51-438497f2c9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember_ca011641-882d-4882-aa68-2237b8ed1f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_us-gaap_FixedIncomeFundsMember_ca011641-882d-4882-aa68-2237b8ed1f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FixedIncomeFundsRepurchasedAgreementsMember_f2230741-c120-4886-876d-f2032df02764" xlink:href="lly-20221231.xsd#lly_FixedIncomeFundsRepurchasedAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_lly_FixedIncomeFundsRepurchasedAgreementsMember_f2230741-c120-4886-876d-f2032df02764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FixedIncomeFundsEmergingMarketsMember_71166f04-426f-43ad-8efd-56b0636d6431" xlink:href="lly-20221231.xsd#lly_FixedIncomeFundsEmergingMarketsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_lly_FixedIncomeFundsEmergingMarketsMember_71166f04-426f-43ad-8efd-56b0636d6431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember_9212d960-0a14-4411-af62-6179d8928add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgeFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_us-gaap_HedgeFundsMember_9212d960-0a14-4411-af62-6179d8928add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember_d93da01d-9425-40f8-81d4-14eec3ae2ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFundsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_us-gaap_EquityFundsMember_d93da01d-9425-40f8-81d4-14eec3ae2ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember_58f435a5-4c25-434e-98fe-57e4861ef985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherContractMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_us-gaap_OtherContractMember_58f435a5-4c25-434e-98fe-57e4861ef985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember_f74adeee-72ca-4e4a-ac0a-9d53368ec360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_us-gaap_DefinedBenefitPlanRealEstateMember_f74adeee-72ca-4e4a-ac0a-9d53368ec360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefineBenefitPlanOtherMember_ed29a6c7-a01d-4e9c-bf1d-e657e60f9e4b" xlink:href="lly-20221231.xsd#lly_DefineBenefitPlanOtherMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_40623235-3895-4464-83bc-f4034c198004" xlink:to="loc_lly_DefineBenefitPlanOtherMember_ed29a6c7-a01d-4e9c-bf1d-e657e60f9e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_503b44c5-f8da-48e8-9f18-cf5ef161bec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d75d9bc4-d848-490c-ac4b-58e43b8075f3" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_503b44c5-f8da-48e8-9f18-cf5ef161bec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8eefb2ef-427a-49f8-938b-0e87c1274fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_503b44c5-f8da-48e8-9f18-cf5ef161bec0" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8eefb2ef-427a-49f8-938b-0e87c1274fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_5dd4b5cf-9ac2-4d64-9b0a-6ff96701ca70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8eefb2ef-427a-49f8-938b-0e87c1274fb2" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_5dd4b5cf-9ac2-4d64-9b0a-6ff96701ca70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_bbd7eebe-f68e-476a-8f22-ac81632cc98d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8eefb2ef-427a-49f8-938b-0e87c1274fb2" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_bbd7eebe-f68e-476a-8f22-ac81632cc98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff928df9-5e11-479d-837a-559df631e83e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d75d9bc4-d848-490c-ac4b-58e43b8075f3" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff928df9-5e11-479d-837a-559df631e83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2ad128e4-8baf-4e8f-b93b-74cea4d2ec1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff928df9-5e11-479d-837a-559df631e83e" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2ad128e4-8baf-4e8f-b93b-74cea4d2ec1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#ContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a3e3d1ac-5e83-462f-afd7-56dff30f35ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_66aa5f2c-558b-484a-acd5-d1778bebfa28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a3e3d1ac-5e83-462f-afd7-56dff30f35ba" xlink:to="loc_us-gaap_LossContingenciesTable_66aa5f2c-558b-484a-acd5-d1778bebfa28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_35008708-f5d1-4977-a213-68de6d85a904" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_66aa5f2c-558b-484a-acd5-d1778bebfa28" xlink:to="loc_srt_LitigationCaseAxis_35008708-f5d1-4977-a213-68de6d85a904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2f25ce9a-519b-450b-a9a0-3dad153e2a24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_35008708-f5d1-4977-a213-68de6d85a904" xlink:to="loc_srt_LitigationCaseTypeDomain_2f25ce9a-519b-450b-a9a0-3dad153e2a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember_e2edce11-411e-4524-9e0b-8d79e901fa48" xlink:href="lly-20221231.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2f25ce9a-519b-450b-a9a0-3dad153e2a24" xlink:to="loc_lly_EmgalityPatentLitigationMember_e2edce11-411e-4524-9e0b-8d79e901fa48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationMember_d81409a3-9a41-44aa-bbcd-4bdee1ef444b" xlink:href="lly-20221231.xsd#lly_EmployeeLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2f25ce9a-519b-450b-a9a0-3dad153e2a24" xlink:to="loc_lly_EmployeeLitigationMember_d81409a3-9a41-44aa-bbcd-4bdee1ef444b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b163f7f6-3511-4fcb-a743-743d1a64ef9a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_66aa5f2c-558b-484a-acd5-d1778bebfa28" xlink:to="loc_srt_ProductOrServiceAxis_b163f7f6-3511-4fcb-a743-743d1a64ef9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_43362188-03fd-4429-8887-22e086341e0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b163f7f6-3511-4fcb-a743-743d1a64ef9a" xlink:to="loc_srt_ProductsAndServicesDomain_43362188-03fd-4429-8887-22e086341e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ByettaMember_75e73cba-97b4-4d0d-bfed-8ed12b4cd106" xlink:href="lly-20221231.xsd#lly_ByettaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_43362188-03fd-4429-8887-22e086341e0f" xlink:to="loc_lly_ByettaMember_75e73cba-97b4-4d0d-bfed-8ed12b4cd106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember_cfcf65e7-4186-4ae4-bfb6-678eaad11660" xlink:href="lly-20221231.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_43362188-03fd-4429-8887-22e086341e0f" xlink:to="loc_lly_HumalogHumulinAndForteoMember_cfcf65e7-4186-4ae4-bfb6-678eaad11660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8dd50567-d9eb-4858-bdc0-97ed0d04f623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_66aa5f2c-558b-484a-acd5-d1778bebfa28" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8dd50567-d9eb-4858-bdc0-97ed0d04f623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_7bbebca3-d3dc-418e-84a7-4e539b54ea3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8dd50567-d9eb-4858-bdc0-97ed0d04f623" xlink:to="loc_us-gaap_LossContingencyNatureDomain_7bbebca3-d3dc-418e-84a7-4e539b54ea3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProductLiabilityMember_704a857f-02d3-40e0-8509-e87981399846" xlink:href="lly-20221231.xsd#lly_ProductLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7bbebca3-d3dc-418e-84a7-4e539b54ea3b" xlink:to="loc_lly_ProductLiabilityMember_704a857f-02d3-40e0-8509-e87981399846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_c98c871f-5687-4c72-aeb8-24d30e3247f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7bbebca3-d3dc-418e-84a7-4e539b54ea3b" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_c98c871f-5687-4c72-aeb8-24d30e3247f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_355b081c-aaa8-4e7b-8d8c-e253bf7f083d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_66aa5f2c-558b-484a-acd5-d1778bebfa28" xlink:to="loc_srt_StatementGeographicalAxis_355b081c-aaa8-4e7b-8d8c-e253bf7f083d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1ad9e89d-79c0-4ed6-8225-752f14cfe012" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_355b081c-aaa8-4e7b-8d8c-e253bf7f083d" xlink:to="loc_srt_SegmentGeographicalDomain_1ad9e89d-79c0-4ed6-8225-752f14cfe012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR_5a38b2f3-ed83-484b-8cfc-2a3e44d31c64" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1ad9e89d-79c0-4ed6-8225-752f14cfe012" xlink:to="loc_country_BR_5a38b2f3-ed83-484b-8cfc-2a3e44d31c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_75ac0c90-f967-4074-a0b3-556adecd394b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_66aa5f2c-558b-484a-acd5-d1778bebfa28" xlink:to="loc_us-gaap_LossContingenciesLineItems_75ac0c90-f967-4074-a0b3-556adecd394b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents_0b962f83-189a-409a-b609-5be481ec6ace" xlink:href="lly-20221231.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_75ac0c90-f967-4074-a0b3-556adecd394b" xlink:to="loc_lly_LossContingencyNumberOfPatents_0b962f83-189a-409a-b609-5be481ec6ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_b6b5d836-f3d2-4fac-bcce-e8af561eb673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_75ac0c90-f967-4074-a0b3-556adecd394b" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_b6b5d836-f3d2-4fac-bcce-e8af561eb673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_28531c69-f2f5-42da-ba04-5753bebc4c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_75ac0c90-f967-4074-a0b3-556adecd394b" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_28531c69-f2f5-42da-ba04-5753bebc4c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_c560943e-776a-4f20-9768-24b56362300e" xlink:href="lly-20221231.xsd#lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_75ac0c90-f967-4074-a0b3-556adecd394b" xlink:to="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_c560943e-776a-4f20-9768-24b56362300e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_fca1d7d5-0345-4e91-9503-a1ed96313ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_75ac0c90-f967-4074-a0b3-556adecd394b" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_fca1d7d5-0345-4e91-9503-a1ed96313ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c485b8e2-f2d7-48ee-9e27-aea33a994a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_241254bb-f6d3-4d67-bbf1-7740c16241c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c485b8e2-f2d7-48ee-9e27-aea33a994a30" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_241254bb-f6d3-4d67-bbf1-7740c16241c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fa10e7f5-380b-4a5e-a288-ea320c1223a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_241254bb-f6d3-4d67-bbf1-7740c16241c5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fa10e7f5-380b-4a5e-a288-ea320c1223a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_83095ba6-17c1-418f-8f9d-02ad7b34d7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fa10e7f5-380b-4a5e-a288-ea320c1223a8" xlink:to="loc_us-gaap_EquityComponentDomain_83095ba6-17c1-418f-8f9d-02ad7b34d7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_fbd5f666-a3db-4b64-9332-541beefb3b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_83095ba6-17c1-418f-8f9d-02ad7b34d7c8" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_fbd5f666-a3db-4b64-9332-541beefb3b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_37e7bf5d-889b-4c19-84fc-6d7fafaf0783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_fbd5f666-a3db-4b64-9332-541beefb3b8d" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_37e7bf5d-889b-4c19-84fc-6d7fafaf0783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_c2578b59-3315-486d-9f1d-e137ba474d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_fbd5f666-a3db-4b64-9332-541beefb3b8d" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_c2578b59-3315-486d-9f1d-e137ba474d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_6c8b0cea-8d67-467b-aa02-ed58b28d396b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_fbd5f666-a3db-4b64-9332-541beefb3b8d" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_6c8b0cea-8d67-467b-aa02-ed58b28d396b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_f9fa8e82-53b6-43cb-b05c-ed374b9a36d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_fbd5f666-a3db-4b64-9332-541beefb3b8d" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_f9fa8e82-53b6-43cb-b05c-ed374b9a36d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6871ae2e-9328-443b-963d-062e84da3895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_241254bb-f6d3-4d67-bbf1-7740c16241c5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6871ae2e-9328-443b-963d-062e84da3895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc7b4e79-acce-41cf-bf9a-f97363810467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6871ae2e-9328-443b-963d-062e84da3895" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc7b4e79-acce-41cf-bf9a-f97363810467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_56452f16-1dfb-4d0d-85e9-9f8d22172386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc7b4e79-acce-41cf-bf9a-f97363810467" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_56452f16-1dfb-4d0d-85e9-9f8d22172386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_aabb3b39-798d-44cb-bf57-fff4ebd98ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc7b4e79-acce-41cf-bf9a-f97363810467" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_aabb3b39-798d-44cb-bf57-fff4ebd98ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_d84018ac-2417-4eb4-85da-e3014e3821eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc7b4e79-acce-41cf-bf9a-f97363810467" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_d84018ac-2417-4eb4-85da-e3014e3821eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c0f0ae7a-7e96-42da-acba-8c1ece0a2b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc7b4e79-acce-41cf-bf9a-f97363810467" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c0f0ae7a-7e96-42da-acba-8c1ece0a2b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7541c120-9bbe-4ab6-bc31-603e99287648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dc7b4e79-acce-41cf-bf9a-f97363810467" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7541c120-9bbe-4ab6-bc31-603e99287648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c3865f49-709b-4d25-b970-3b32b5aa03b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_44b7c36d-6237-4273-bf4e-078990d89d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c3865f49-709b-4d25-b970-3b32b5aa03b4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_44b7c36d-6237-4273-bf4e-078990d89d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2d373270-5654-430f-be8b-b68a8dc23d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_44b7c36d-6237-4273-bf4e-078990d89d73" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2d373270-5654-430f-be8b-b68a8dc23d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0308499f-1bd9-4f71-9456-0ac655f48210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2d373270-5654-430f-be8b-b68a8dc23d89" xlink:to="loc_us-gaap_EquityComponentDomain_0308499f-1bd9-4f71-9456-0ac655f48210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_e6dc21b9-3378-4284-b10d-bf0f828f5e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0308499f-1bd9-4f71-9456-0ac655f48210" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_e6dc21b9-3378-4284-b10d-bf0f828f5e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_5ac53309-2579-4cac-a537-7a6bbda28816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0308499f-1bd9-4f71-9456-0ac655f48210" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_5ac53309-2579-4cac-a537-7a6bbda28816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_344d5e8c-1b8b-466c-8c80-b7dabe34a089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0308499f-1bd9-4f71-9456-0ac655f48210" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_344d5e8c-1b8b-466c-8c80-b7dabe34a089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_a74f081f-0db8-4b34-9c3e-22941ab7b0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0308499f-1bd9-4f71-9456-0ac655f48210" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_a74f081f-0db8-4b34-9c3e-22941ab7b0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_47cb73c2-cfff-4c80-9eed-8def762c96f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_44b7c36d-6237-4273-bf4e-078990d89d73" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_47cb73c2-cfff-4c80-9eed-8def762c96f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_bfacb48f-8302-4402-ab79-f3f0e1f29d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_47cb73c2-cfff-4c80-9eed-8def762c96f3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_bfacb48f-8302-4402-ab79-f3f0e1f29d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_883d7e40-944e-4599-a67f-9313759c80f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_83d2b639-6053-4499-bf29-745b5c67a9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_883d7e40-944e-4599-a67f-9313759c80f0" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_83d2b639-6053-4499-bf29-745b5c67a9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c8bafb9a-93e3-44d3-b3a3-b9b56a72fc73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_83d2b639-6053-4499-bf29-745b5c67a9a3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c8bafb9a-93e3-44d3-b3a3-b9b56a72fc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_053e5dd0-43ac-4109-b1f9-3c0940dfc82d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c8bafb9a-93e3-44d3-b3a3-b9b56a72fc73" xlink:to="loc_us-gaap_EquityComponentDomain_053e5dd0-43ac-4109-b1f9-3c0940dfc82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_bb4eb1bb-365c-4422-b365-8379c4d1522f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_053e5dd0-43ac-4109-b1f9-3c0940dfc82d" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_bb4eb1bb-365c-4422-b365-8379c4d1522f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_2f5b9168-b8d9-468c-829e-d388ed1a4a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_bb4eb1bb-365c-4422-b365-8379c4d1522f" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_2f5b9168-b8d9-468c-829e-d388ed1a4a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_72fa3c91-2a7e-4473-8e43-96b4ec9de956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_bb4eb1bb-365c-4422-b365-8379c4d1522f" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_72fa3c91-2a7e-4473-8e43-96b4ec9de956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_d97a4be7-d52d-4931-88d2-56ffee5fddf9" xlink:href="lly-20221231.xsd#lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_053e5dd0-43ac-4109-b1f9-3c0940dfc82d" xlink:to="loc_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_d97a4be7-d52d-4931-88d2-56ffee5fddf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d95659b8-aea7-4907-93e7-00dcc46fe169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_83d2b639-6053-4499-bf29-745b5c67a9a3" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d95659b8-aea7-4907-93e7-00dcc46fe169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d5006e86-b437-4120-9215-e31cf88adeef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d95659b8-aea7-4907-93e7-00dcc46fe169" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d5006e86-b437-4120-9215-e31cf88adeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_d3a00930-441c-4eee-b8a6-36a5a55a3320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d5006e86-b437-4120-9215-e31cf88adeef" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_d3a00930-441c-4eee-b8a6-36a5a55a3320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_4526d642-3d11-4ca4-abf0-5b4124c457af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_83d2b639-6053-4499-bf29-745b5c67a9a3" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_4526d642-3d11-4ca4-abf0-5b4124c457af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_15b591a3-1f6e-40d5-8510-67591a00283f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_4526d642-3d11-4ca4-abf0-5b4124c457af" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_15b591a3-1f6e-40d5-8510-67591a00283f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c32ff456-93d5-436d-adc4-6ccf76e4f751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_4526d642-3d11-4ca4-abf0-5b4124c457af" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c32ff456-93d5-436d-adc4-6ccf76e4f751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_057e81ab-209a-4204-8652-79081e13f1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_4526d642-3d11-4ca4-abf0-5b4124c457af" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_057e81ab-209a-4204-8652-79081e13f1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_685d5d73-db9d-40a8-a29f-fbb4654156fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_4526d642-3d11-4ca4-abf0-5b4124c457af" xlink:to="loc_us-gaap_ProfitLoss_685d5d73-db9d-40a8-a29f-fbb4654156fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="simple" xlink:href="lly-20221231.xsd#OtherNetIncomeExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2afa69d2-3cb3-4824-b847-e4795cdc36a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c27365f8-bbb5-4662-9949-d9999173acab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2afa69d2-3cb3-4824-b847-e4795cdc36a8" xlink:to="loc_us-gaap_InterestExpense_c27365f8-bbb5-4662-9949-d9999173acab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d7138e7b-9404-4ae5-af9e-c42e25e8fccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2afa69d2-3cb3-4824-b847-e4795cdc36a8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d7138e7b-9404-4ae5-af9e-c42e25e8fccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_d7855755-1720-4a8e-85a3-35a8dac41214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2afa69d2-3cb3-4824-b847-e4795cdc36a8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_d7855755-1720-4a8e-85a3-35a8dac41214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_df9155ad-64b6-4285-9985-b734f1af5503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2afa69d2-3cb3-4824-b847-e4795cdc36a8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_df9155ad-64b6-4285-9985-b734f1af5503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_2536978b-b29d-4274-abf8-ffe10fcb48ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2afa69d2-3cb3-4824-b847-e4795cdc36a8" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_2536978b-b29d-4274-abf8-ffe10fcb48ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ddff7ff7-07b6-42de-88a8-7112462b5c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2afa69d2-3cb3-4824-b847-e4795cdc36a8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ddff7ff7-07b6-42de-88a8-7112462b5c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_bc24a47e-485a-4a39-99b7-25f6284d8c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2afa69d2-3cb3-4824-b847-e4795cdc36a8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_bc24a47e-485a-4a39-99b7-25f6284d8c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>lly-20221231_g1.jpg
<TEXT>
begin 644 lly-20221231_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR/\ !7XA>/I_^#:G]M7Q3/XXUA]3L/C7XHBL=1?4Y3/;HMYI05(Y-VY% )P
M0!D^M?I9^RK^WA\"/AKX1_9:_8X^)_BC5+;X@?%7X*:5J7A%[O3I7M=4-MI,
M<MRANSE!.%0L48[CO3J7 /Y>?!#_ )5C/VX/^RX^*O\ TLTFOI#_ (*?_!WQ
MDG_!%K]F?]O[X,Z=YOC_ /9=T/P9X\T<QYWW&FI8V2:C;$]HFC$4TGJEJ1SG
M! /T1_:L_;4^ O[&=KX*D^-NN7T-S\1/'%EX1\'Z;I6F27EUJ.JW6[R8ECC!
M(7Y<%SA5+*"1N&?6*_+KP=\2/"O_  5L_P""YGP\\?\ @2[.J?";]F/X.6/C
M&UF.&BN/$_B>TCGL0X'!*6#13+R2DMNP[FOU%H **** "BBB@ HKYPUOXF?\
M%/X-9NX-!_9C^&\]BEU(ME//XTE5Y(@QV,R[>"5P2.QJM_PM'_@JI_T:S\,O
M_"XE_P#B: /IBOS-_P"#BO\ YH]_W,/_ +C:^FO^%H_\%5/^C6?AE_X7$O\
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M*(0%4XP<\T ?5]%? /\ PT/_ ,'''_2.K]G_ /\ #NW'_P ;H_X:'_X../\
MI'5^S_\ ^'=N/_C= 'W]6?XL\5^&_ GA74_''C'6K?3=(T;3YK[5=1NY D5K
M;0H9)978_=545F)[ &OA'_AH?_@XX_Z1U?L__P#AW;C_ .-U^<__  <0?\%:
MO^"J_P */V<9/V&OVJ?@5\*_AW=?%O2V:YG\">-KC5-1.D13H)D92JK#%.P,
M.XYWHLZ ?>( .H_X(W_\'#7B3]I7_@MY\2_ _P 6O$=Q:_#GXZZ@MC\+].OY
M2$T2YL%:/38@I.(VN[<.LH'W[EXL=:_>ZOX$_"?BOQ)X$\5:9XX\':U<:;J^
MC:A#?:5J-I(4EM;F%Q)%*C#[K*ZJP/8@5_4-^P%_P5A_X+A?\% OV9=%_:)_
M9[_8K^ GB31[B233[Z^N?B3<V-PM];D).LML4)@8G$@3)&R5""00: /UFHKX
M!_X:'_X../\ I'5^S_\ ^'=N/_C='_#0_P#P<<?](ZOV?_\ P[MQ_P#&Z /O
MZBO@'_AH?_@XX_Z1U?L__P#AW;C_ .-U]7?LA^*OVLO&7P;@UO\ ;2^%'A?P
M9XX;4)TGT3PAKKZC9+; CRG$S@$LPSD8XH ^%O\ @XO^/GCWPKXJ_9H_9-O?
MVB=9^#OPI^,_Q$O--^+GQ/T+4/L,]A8VZ6IBLOMA^6U6X\^;=(V% @R^Z-9%
M;!^*G_!M7^R#H'P,U3XV_P#!+;XL_$/P3\8K/1Y-3\!>._#WQ3N9TUJ_C0O#
M#<R/*8FAF91&SH4"[]QRH*'ZE_;L^.?_  3_ /B=^T-X#_X).?MN?!^3Q/+\
M9]+NM2\,+K>DQ-H[S6BRDQBZ,RRP7@",(S$N_,J ."X!^6/B_P#\&S_PN_9T
MT+7?C/\ \$M/VV_BU^SUXJTRSFU"QL+?QI+<^'I7B0R"*Z20B8Q-MVL\DLJJ
MO+1O@J0#[G^ >M_MNW/_  3[TK5?CQX.TNP^/UO\/KA-4TR&[MYK2?7XH)$A
MD+0,8=DTB1RE4.U?-*\;<#^>W2]4_9A\8_\ !/+2/VD? 7QI^)UY_P %.+SX
MN?V3# OBK4G\33:TNL 2VCZ=YGE)8+8'AC$ )E\HMP\0^X?B/_P7&_;'\3_\
M&\?PK_:RT"[T[P[\7/BO\18OAK<^.Y+)(K/393/?1R:TJ%?+C9HK(@X79'+(
M[*N$5:H_M:?\$J?B%_P0UUCPC_P6(_8=\:>)/B7XA\!6LP_:5L_'6K&ZO/&V
MF74FZ_U599-Q@F#-E@I;:J12'>8IO. /UK^+%QXQM_V2/$MWXQ>&'Q GPYO7
MU5K!R(TO!8.93&>H42;MI],5^.7_  0Z_P""(W[,'_!0'_@F9\/OVKOC_P#&
MKXUMXK\2W.LIJ1T7XG7-M;8MM6N[6+9&5;;^[A3/)R<GO7V1_P $R/V[_P!H
M_P#X*3?\$X/C?^UM\:M(T33/"^MZOXKMOA3I>GV@2\M]!@@E6,7K+*ZO,'+1
M9 0GR2_(=37Q7_P0:_X)@_M@?M'?\$MOAS\8?A3_ ,%@?B]\*="U6YUI;/P)
MX5L87L=.,6KWD+F,M*I/F/&TK<?>D:@#V/X!^#?B?_P2'_X+L_"K_@GM\'_V
MF_'WC[X-?'7P#JFHS>"OB#XA;5;CPM>6=O>3K<V[D#RXV:SV9 7<LDH?>T2,
M/U\KXR_8#_X(M?"/]BWX\ZQ^U_\ $CX_?$+XV_&36M*.F2_$/XFZL+J:QLR1
MNAM(\'R0P 4DLY"@HA16=6^N_&.O:'X5\(ZKXG\3:HUCINFZ;/=:A>H&)MX(
MXV>20;06RJ@G@$\< T ?@M^SWX6_8F_;M\?_ !O_ &M?^"@'_!7WQ]\'5\2_
MM">)--^%WA;2/C[;>'H)/#]M+&L$ZV]RKG9N9H]Z[8P83W-?HG>Z7\*O^"*/
M_!)CXM?'SX#?'?QK\6--L-)N_%GAS7OB/XS37VNKZXMK:TLHHKF)(U-FTR0-
MM7/^LD8-\PQE?\$Z?^"2W_!"CQ%^RG'XN_9:_9X\"?%;P5XSN+V2/QMXTT9-
M9OKS9/);R1I<7L(EMUC>-T"H(\%-_+'>?SAL/A]XI\.?\$N_^"H_[ _P=UC4
M=6^%?P:^(EM-\-X9[I[D:9;QZFUYJ5C'(Q)*01V*%AG[S2.?FD8D ^J_@7_P
M0V\0_M'_ +".A?MB_$C]L+XR_P##5GCGP5#XOT_XDVGQ#O+=='U2ZMQ>6NGQ
M6D;K"EI'OBA>,*. _EM&NQ5S_&W_  6U_:&\:?\ !N;X)_:T^'^H16GQR^(V
MOVGPQM-42!$%OXA>ZFMI;Y4QM61[:VDN% &U))5^7";3^BW[%'Q6\#ZE_P $
M\?A3\:!KEO%X>/P=T759KXR#RX+9=+AD=F/;8H;<#T*D'I7X+^%O"6N^$/\
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M4F",#T8"0 CL1B@#Z8HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (<[_P#!.3_HW7_R[M7_ /DNC_ASO_P3D_Z-U_\ +NU?_P"2Z /S-_X([_\
M*1OX=?\ <7_]-%[7[EUX9\'?^";/[%?P!^(^G?%OX2?!C^R?$.D^=_9^H?\
M"1ZE/Y7FPO#)^[FN'1LQR.O*G&<C! (]SH **** "OG?X1_\$ZOA[\(?^"BO
MQ8_X*-Z3X_UF[\1?%KP[I>D:KX?N8HA96,=C;VT"/$RKO+,+52=Q(RQQVKZ(
MHH *^9O^"A__  2Z^#7_  4'?PAXZU7Q[XI^'OQ*^'5\]Y\/OBCX"OQ:ZMH[
MOCS(LL"LT#[5W1M@\':R[GW?3-% 'PM\&O\ @BC<G]I?PA^U?^WC^W)\0?VB
M/$WPXG>X^'.G>*K"TTW1]"NB01>+96J[9+E2L9$I(^:-6*DI&4ZS]MK_ ()$
M^"?VH/VA=(_;0^!O[0_C7X'?&K1])_LEOB!X">%QJVGYR+74+293'=HIQMR5
M. H;>(XPGU[10!\=?L8_\$@O#/[.W[2M[^V_^T9^TSXU^._QHN-%.CZ;XV\<
M)!!#H>GG.^#3[* >7:[]SAB">'<+M\R3?Z/^QA_P3]\!?L6?$[XV?$_P;XZU
M?6+GXW?$FY\9:U;:G'$L>G7,S.3!!L4$QC><%LGCK7OU% !7S!_P43_X))_L
MJ?\ !25="\4?%4>(?"WC[PB=W@WXH> =6.G:[HQW%PB3A6#QAR6".IVDL4*,
MS,?I^B@#\S=:_P"#>[XZ?%ZP_P"%>?M4?\%M/VD/'?P_<>7>^$(=52P.HP?\
M\;JXWR_:5/.[?&2>V" :^A/B?_P1U_9$\2_\$U?$/_!+?X.:#-\-_A]XABMO
MM-SX= FO?.BO+:Z:YDDN-YGFD:V16DD+';@# 50/JZB@#D;'X)^!'^ \'[.?
MB[28=?\ #/\ PB2>'-3L=5A5TU&Q^RBVDCF7H1)'D,.GS&O@W3_^#?OQ[\._
M!5_^SA^SQ_P5E^.O@/X&:E)<+)\+[%[.ZEL;2=BTUG9:E*GGVL)W.-H5N')8
MN68M^D%% 'SA+_P2D_8M'_!.V[_X)>:9\.IK'X4WFB&PFL[2\(O3+YXN?MQG
M8'=="Y5;CS&!7>H^78-E?,<O_!NQJOQ$^"US^S'^U!_P5#^-WQ(^&5CH,NG>
M#O!.HS6UI;:6X@:*SN+EXP7U%K0E)84D*QK)#&2A5=M?I710!^/7_!>']CSX
M<^%OV;?^"?O[ 6K:OJFI^$M/^/G@KP!=7YG%O>W>G):+IS2;XP/+E:($[E V
ML<CH*^@]._X(0WOQ'\?>%+G]N3_@HE\6_CSX \ :Q#J?@[X:>,Q:06+7,(Q!
M)J<D"!]49!GYI I;+!LJ[HWW-XR^&/PV^(UQI-Y\0?A[H>NRZ!JD>I:%+K.D
MPW3:=>QG,=S 958PS*>5D3##L:W* "BBB@ HHHH **** "BBB@#/\6>*_#?@
M3PKJ?CCQCK5OIND:-I\U]JNHW<@2*UMH4,DLKL?NJJ*S$]@#7\47_!6?]OCQ
M)_P4I_;S\=?M3ZI+<1Z1J.H?8?!NG7!(-AHEN3':1;?X69,RR <>;-(>]?V>
M_'[X#?"W]I_X->(?V?\ XV^'[C5O"7BO3S8Z_I=MJ]U8-=VS$%HC/:2Q3(K8
MPP5QN4LK95B#\8?\0N/_  0H_P"C&?\ S)OB?_Y9T ?R!5^OW_!H1_P4B_X9
ML_;)U#]B'XC:]Y/A'XR[?[!^T2XCL_$D"'R,9X7[3$&@/=I$ME[5^O\ _P 0
MN/\ P0H_Z,9_\R;XG_\ EG6AX3_X-G/^")?@3Q5IGCCP=^QG<:;J^C:A#?:5
MJ-I\4?%"2VMS"XDBE1AJ?RLKJK ]B!0!]WT444 %%%% 'SO_ ,%&O^"8O[,G
M_!3OX7:9\/?V@;+5[#4O#>HG4?!OC3PO?BTUCP]>';F6VF*L &V)N1E96*(V
M R(R_*.I?\&]W[0/Q+T5OA-^T=_P6]_:-\;?#.X00ZEX-;4%MIM2M> ;>YO&
MEE,\; 88/&0?0'FOTVHH ^??BM_P2^_8L^+W["*?\$X->^$D-E\*[32(;'1]
M)TN<QSZ6T+;XKN"=MS"Y63,AE?<9&9_,WB1PWRS%_P &\.O_ !%TG1?@Y^UW
M_P %3OCG\5_@[X>F@-C\*]5OHK*"]B@(,%O?W4),MY&NU>R,, JR$ U^E%%
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M&"&-8X88D"I&@& J@<  #  J2B@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5I?ALQ,F$W$LS/P.G0&O??L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
MZ#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QJK%<>,9M6ETA=7M0\,2R,QMN"
M#^- '145C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0
M;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\
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M16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
M8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45SM_<>,=/N
M;6UEU>U8W4OEH5MN <9YYJU]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\
MP&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_
M ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_
M /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&
M_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q
M16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\
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MC_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\
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MP4W_ ."9?AKP=XVF^(_A6TT3XP_"7QCK;:5_:TMFJI9ZC9WFTQQS)$B1$28
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M_B7_ )"^C_\ 7Z?_ $$UL4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1110 4444 %%%% !1110 4444 %9OC'_ )%B]_ZX&M*LWQC_ ,BQ>_\ 7 T
M7-._Y!\'_7%?Y"IJAT[_ )!\'_7%?Y"IJ "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** ,?Q+_R%]'_ .OT_P#H)K8K
M'\2_\A?1_P#K]/\ Z":V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1110 5F^,?\ D6+W_K@:TJS?&/\ R+%[_P!<#0!<T[_D'P?]<5_D*FJ'3O\
MD'P?]<5_D*FH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH Q_$O_(7T?\ Z_3_ .@FMBL?Q+_R%]'_ .OT_P#H)K8H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *Q_ _\ R")?^OV;_P!"K8K'\#_\@B7_ *_9O_0J -BBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\X\<?%S7-:\0
M2_"_X)VL5_K:?+J6JR#-II*G@L[='DZX09Y'.<%: /%OV[?#>DV?Q#L?$=AJ
M4#75[IX6_LD;,D?EG"2L.P92%&?[E>%U]Y> /@GX5\&:7>1ZJO\ ;>I:LA&M
MZKJ:"22]SU4@YVIZ)TX&<GFO/O&?["7P^UR^>^\)>([S11(V3;-$+B)/]T,5
M8#ZL: /DZOH;]A?X6:C-KEU\5]4M6CM(('M=,9UQYLK'#NOLJ@KGH2Y_NFM_
MX7_L4?#]&_MCQ?KEYJPAN&06BH((GVG'S8)8_0,/QKWG3]/L-)L8M,TNSBM[
M>",)#!"@5(U'0 #@"@":BBB@ HHHH **** "BBB@ HHKX?\ ^"R7[;7[3OP%
MU_X'?L=?L5ZIHNA?%#]H?QQ/H>C>-?$5@MW:^&[*U2&2[NQ X*33 3Q;$<,I
M <;22N #[@HK\7/V3]4_X+8_LI?%'Q!\4? G[0FM_M-^![+]J75? _Q6\ :A
MX.MH=12!$@,OB&RFC8FU4!CFU#"&-A&-KB1FC_8SQ_X]\&?"OP-K'Q,^(WB6
MTT;0/#^F3ZCK6K7\H2"SM84,DLSL>BJBDD^U &O17YE_\$=_^"PG[0W_  4I
M_P""AOQR\"^*_"'_  C/PLT'PGI6M?"[0;_2%@U%]/NG7[/?W$A^=C=0%+A4
M^ZJS*%W !VZ+_@H7^V3_ ,%*]9_X*>>#_P#@FY_P3-\3?#'2=7F^#]QXZ\7Z
MK\2=*N;FVMX!J#6D2[K8,Z$LH&-ASYJDD#% 'Z)45\B?L-^"?^"W'A[XS3W_
M /P4-^,WP"U_P&=#G2WL?AGI6I0ZB-1,D7E.S7,*)Y003!AG.2F!UKP^W_:Z
M_P""GG_!3?\ :G^+OP]_X)M_&/P'\(_A1\$/%3^$K[Q[XG\(?V[?>*_$, S=
MP0Q,PBAM8CA=X^<AXW!82;8@#]*Z*^-O^"4/[?OQT_:3\1_%C]D#]M7PCH&B
M?'3X#>(;;3?&7_"+M(-,URQNHFEL=5M4E.]%FC4ED/3,;83S!&GV30 4444
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MWR@$'[)08_\ !T1^U<=)_P"/8?!+PJ-6V=/M7DZ=Y6[_ &O*SCVK],J^-/\
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MX275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\
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M^$EU?_H4+W_OI:/^$EU?_H4+W_OI:V** ,?_ (275_\ H4+W_OI:/^$EU?\
MZ%"]_P"^EK8HH Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI:V** ,?_ (275_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3_Z":V*Q_$O_ "%]'_Z_3_Z":V* "BBB@ HHHH **** "BBB@ HHHH ****
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M47\S0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5F^,?^18O?^N!K2K-\8_\BQ>_]<#0!<T[_D'P?]<5_D*FJ'3O
M^0?!_P!<5_D*FH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH Q_$O_ "%]'_Z_3_Z":V*Q_$O_ "%]'_Z_3_Z":V*
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MB@ HHHH **** "BBB@ HHHH Q_ __((E_P"OV;_T*MBL?P/_ ,@B7_K]F_\
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M%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\
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MZ6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: #P/_ ,@B7_K]F_\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-\8_\
M(L7O_7 UI5F^,?\ D6+W_K@: +FG?\@^#_KBO\A4U0Z=_P @^#_KBO\ (5-0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!C^)?^0OH_\ U^G_ -!-;%8_B7_D+Z/_ -?I_P#036Q0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C^!_\
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M;_T*MBL?P/\ \@B7_K]F_P#0JV* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#P7]KG_ )+A\#/^Q[E_]$5[U7@O[7/_ "7#X&?]
MCW+_ .B*]ZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY+A\#/\ L>Y?_1%>]5X+^US_ ,EP^!G_ &/<O_HBO>J "BBB@ HHHH ****
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M8O/#WB33]>TYRL]E>Q3PE>NY7##^5?HM0 4444 %%%% !1110 4444 %%%%
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ML"2#5M)GA6%F8<IASG([UZA10!\>_&3XV?$+X@?';X.1^)_V=O$GA86?C0O
M^JS0L+HM'M*IL/51\QSVKZJ_X275_P#H4+W_ +Z6O'?VN?\ DN'P,_['N7_T
M17O5 &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]"A>_
M]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
MWTM;%% &/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[
M_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]"A>_]]+1_P )+J__ $*%[_WT
MM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]"A>_
M]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
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M^$EU?_H4+W_OI:/^$EU?_H4+W_OI:V** ,?_ (275_\ H4+W_OI:/^$EU?\
MZ%"]_P"^EK8HH Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI:V** ,?_ (275_\
MH4+W_OI:H^)=>U.YT&Z@F\,74*M$0979<+[FNFK-\8_\BQ>_]<#0!4LO$>JI
M9Q(OA*\8")0&#+@\=:E_X275_P#H4+W_ +Z6M+3O^0?!_P!<5_D*FH Q_P#A
M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\
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M^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH
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MB^3(?5HCQG_=*Y[YKAO!7["OAO42;_7_ !]>S0)<.A@M;)(F8*<?>9G_ )4
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M* "BBB@ HHHH **** "L>R_Y'>]_Z\HOYFMBL>R_Y'>]_P"O*+^9H V****
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MO_0J -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/_U^G_T$UL4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%8_CKQUX:^'/AR?Q3XJOQ!;0C"@<O*YZ1HO\3'L/Q. ":C^(7Q#\,_#/PY)X
MD\3W92-3L@@C&Z6XD/W8XU_B8_IU. ,UQW@;X>>)?'_B2#XN?&:T$<\)W>'O
M#1.8M,0\B1Q_%,>#D_=]B $ (O!_@7Q-\6/$-O\ %3XPZ>;>VMV\SPWX5DY2
MT':><?Q2D<X/W?T'J5%% !1110 5C^!_^01+_P!?LW_H5;%8_@?_ )!$O_7[
M-_Z%0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'_Y!$O\ U^S?^A4 ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\
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MC\*M8@UM_BG\5KJ._P#%-W'MB1.8-*B/2"$= <'!;OD\G)+>@5C_ /"2ZO\
M]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[
M_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\
M0H7O_?2T?\)+J_\ T*%[_P!]+0!L5C^!_P#D$2_]?LW_ *%1_P )+J__ $*%
M[_WTM9GA77-1M=.DCA\-W,X-S(Q=&7 );I^% '5T5C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L4
M5C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L4
M5C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
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M ,EP^!G_ &/<O_HBO>J\%_:Y_P"2X? S_L>Y?_1%>]4 %%%% !1110 4444
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M10 4444 %%%% !1110 4444 %%%% !1110!C^!_^01+_ -?LW_H5;%8_@?\
MY!$O_7[-_P"A5L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '@O[7/_ "7#X&?]CW+_ .B*]ZKP7]KG_DN'P,_['N7_ -$5[U0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5CV7_([WO_7E%_,UL5CV7_([WO\ UY1?S- &Q1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6;XQ_Y%B]_ZX&M*
MLWQC_P BQ>_]<#0!<T[_ )!\'_7%?Y"IJAT[_D'P?]<5_D*FH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_$O\
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M 5CV7_([WO\ UY1?S-;%8]E_R.][_P!>47\S0!L4444 %%%% !1110 4444
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MX@_M)?L;_L]>"8=-TWX*:;X*\)_$OXR75TGA^WMGEAU"Z-O#99N+BX^T/-$
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M'_OT*/[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5<_L[3_\
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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M_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[]"@"G_P )CX8_Z#4'_?5'_"8^&/\
MH-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\ H-0?]]4?\)CX
M8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC_H-0?]]4?\)C
MX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]
M4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U
M!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"G_PF/AC_
M *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0H I_\)CX
M8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\
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M_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4C6.FHI=[.  #))C& * *?_"8^&/\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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M/<O_ *(KWJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K'LO^1WO?^O*+^9K8K'LO^1WO?\ KRB_F: -BBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LWQ
MC_R+%[_UP-:59OC'_D6+W_K@: +FG?\ (/@_ZXK_ "%35#IW_(/@_P"N*_R%
M34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 8_B7_ )"^C_\ 7Z?_ $$UL5C^)?\ D+Z/_P!?I_\ 036Q0 445'=W
M=K86LE[>W"0PPH7EEE<*J*!DL2>  .] #IIHK>)KBXE5(T4L[NV H')))Z"O
M)=4UC7OVE-4F\+^$+R>P\$6TICU;6HLK)JS _-! >T?9G[_3@MN;O7?VG=3?
M3-*FN-/\ 6LVV[O%S'-KCJ>8T[K"".3W^OW?5M)TG3-"TV#1]&L8K:UMHQ'!
M;PH%5%'0 "@!F@Z#H_AC1[?0/#^G16EG:QA(+>%<*BC^9[DGDDY-6Z** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?P/\ \@B7_K]F
M_P#0JV*Q_ __ "")?^OV;_T*@#8HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_ __((E_P"OV;_T*MBL?P/_
M ,@B7_K]F_\ 0JV* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#P7]KG_DN'P,_['N7_ -$5[U7@O[7/_)</@9_V/<O_ *(KWJ@
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M4*J*!@  <  =J &V%A9:791:;IMI'!;P1B.&&% JHH& H X  J6BB@ HHHH
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S?&/_(L7O_7
MUI5F^,?^18O?^N!H N:=_P @^#_KBO\ (5-4.G?\@^#_ *XK_(5-0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%!( R30!B_$
M3QA;^ / VJ^,KF,.-.LGE2,G D?&$7/;+$#\:^ O$?B+6?%NNW7B3Q!?/<WE
MY,9+B9SR2?Y #  Z   5]9_M4?%/X<WOPLUGP%9>,+6XU:[CC\FSLF,SY25)
M&#; 0G"G[Q%?'] !4EK<-:74=VD<;F*0.$E0,K$'."#P1Z@]:CHH _0GX;>+
M++QSX"TCQ;86Z0QWUC')Y$?W8FQAD'LK K^%;=<)^S-H]YH7P)\-V%^A61K)
MI\-U"RR/*O\ XZXKNZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *Q_ __ "")?^OV;_T*MBL?P/\ \@B7_K]F_P#0J -B
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#'\#_P#((E_Z_9O_ $*MBL?P/_R")?\ K]F_]"K8H **** "BBB@
M HHHH **** "OFK_ (*7?\%)?"?_  3L\ >%9;7X4:U\1OB%\1O$T?A[X9_#
M;P[.L-UKVHM@D&9U800H&3?+M?:9$&TY)'TK7Q#_ ,%D_P!A7]I_]H[5?@K^
MUQ^Q%>Z!<?%G]GKQE<:[X;\,>*IS#8>(;6YCB2[LFER!%(XMX@K,R+@N-Z$A
M@ ?/G[.?_!?K]K+X>?%]O"?_  4Z_8@C\">"/$'QNO?A[IGQ&\+^*[?4;+PQ
MK:K$8](OTC7,@7?DWH95==Y5&$;E?L#_ (*"?\%2OAM^PMXO\%_ W0_A%XN^
M*GQ;^([S?\(3\+O =JDE]=PQ F6[GDD8);6RX;,C9^XY"E8Y&3\^?^">_P#P
M5Q^"OPW^)OC[]G;_ (*F_L8>(/AM??$']IO6[^Q\0>)-(M]:\):3XCE6VC;3
M&U$#8MS"P_UR(55)@[-&A+']7=0_9&_9RO\ ]JBS_;?U/X<0R?$_3/![^&++
MQ7+J-SNM]):9IVMU@\WR!^\=VW^7O^=ANP2* /FS]G+_ (+,S>+/VI?#W[%O
M[;G[%GCO]GGXA>-K2:?P#%XKO[74=)\1&(;I+>WO[4A/M 7!\LKCD+N#O&K]
M+^W!_P %8=&_9@^/VA_L;? #]FGQ?\<_C3KNAOK9\!>"YX+=-*TM6V"[O[R<
M^7:HS_*F0<G&[;OCW_*OQN^)UE_P6C_X+!?!;X?_ +)$(U;X4?LD^-7\5_$K
MXMVJ[K"\UQ3$UOH]A,/EG^>!1(RDJRO(PRL2F7L?^"2^/B%_P6W_ ."A?Q9\
M3+Y^KZ3XC\(>'-,FDY:VL(K.[0QKZ*_V6W8@<$QYZT ?1W_!/_\ X*C^!OVW
M/'7C3]G[QE\%?%GPD^,'PZ$,GC'X7^.(X_M<-K-CRKVVFB)2ZMFW*/-4#!=#
MC;)&S\)^T-_P64U7PU^T[XG_ &1/V(?V'O'O[0WB_P"'T$$GQ)G\)ZC::?I?
MAUY@6CM7O+DE9;HJ"?)4#[K*&+)(J>6?M.R-X"_X.D/V9]=\-?Z//X\^ _B7
M0_$9A^7[5:VBWU["),?>Q,B$9_N+Z"D_X-=L>*_V4_C=\<M;7SO$7CO]IWQ7
MJ6O7TG,LLF+7",W4@%I& [&1O6@#ZT_X)Y_\%$_@S_P48^%6K>._AKH&O^&=
M>\*:]-H7CWP%XOL1:ZOX:U2+[]M<Q9/7DJX.&PP.UT=%]^K\SOV*I&\!?\',
M?[8'P]\-?Z/I/BOX6>$_$>J6</$;7\-O:0+(5'&XBXF8GJ3(Q[U^F- !117!
M_$']I[X ?"KQ&WA+XB?%32](U)(4E:SNY&#A&Y5N >#0!P/[7/\ R7#X&?\
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M&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\
MOJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_
MX3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*L>R_P"1WO?^O*+^9J;_ (3'PQ_T
M&H/^^JR[3Q+H*>+;N]?5(A$]K&J29X)!.10!TU%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
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M $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J
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M?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/
M^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK
M-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?
M]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_
M +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJQ_
M _\ R")?^OV;_P!"J;_A,?#'_0:@_P"^J^=O^">__!2W]F+]NK3OB1!\%O%L
M<K?#GXBWWAS4Q+*#]J$9S%?18ZVT^)/+;^+RG]* /INBLW_A,?#'_0:@_P"^
MJ/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A
M,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H
M/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJ
MC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^
M$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:
M@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^
MJ/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A
M,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH A\#_\ ((E_Z_9O_0JV*QO S!M'D93D
M&\E(/_ JV: "BBB@ HHHH **** "BBB@ KXA_P""O/QO_P""@/[)?CKX,?M9
M?LP>'O$7C7X2^%/$=W#\?/AGX1T&WO=3U'3)XT2&_@!C,["VS.Y2-T7<8B_R
M!W3[>HH _GA^*G[1%O\ \%9?V=OC!_P38_8C^!OC/Q7XI^,O[6=]XID\4ZGX
M0N;/2_!6A>?92_VA>W$R@03?N7C,7WMK2+G<T:2?1G_!P)^VA\>HOC1X+_X)
MG^%/!'QQM?@W)HEM<_'3X@?";P//J6LZU:.C!-'LY3LA02(BF>0OS]H"E66.
M2*;]8_A)\"OAC\#6\4-\,_#[Z>?&7B^\\3^(=]Y+-]IU2Z$8GF'F,WEAA&GR
M)A!C@#)KKZ /S(_X)^_\%<?V#?A/;?#S]A?]E7_@F?\ M+_#[P_?ZW9:'H\F
MJ?!T6NGVD]U.D)O+ZY-V[D;G$DUP^]R S'.*QOB3XX\0?\$8/^"OOQA_:X^*
MGP@\8ZQ\ /VE] T6ZU3QEX,\/3ZJ/"OB+3(7@\J]A@5I$BF62>42 '+3J%#;
M)-GZH44 ?F%^QC-XZ_X*C?\ !8]O^"IVG_!_Q5X2^"WPG^%\O@[X6:AXST63
M3KOQ5J=W-*UUJ,-O* ZVRQ331;CUQ%T;S4CX7]E;]I&Q_P"" GQU^._[*O[8
M?PA\>Q?"SQO\5=0\??!KXC^%?!]UJ^GW<&HK$)-)E-LK-#<0F*)0K#YF\QCM
M5HF?]=Z* /SH_P""-GPK^,_QT_;!_:)_X*^?&_X/:[X MOC1=:5HOPN\)>*K
M,VVJ0>'--MUA6\N8#DPFY,<#A">L<C#<CQNWZ+T44 %9>K>"/!>O7AU#7/"&
MEWMP5"F>[T^.1R!T&YE)Q6I10!\Y_M2>#O".A?'+X(-H?A73;(S>.9!*;2QC
MCW@0Y .T#/-?0W]G:?\ \^,/_?H5X7^US_R7#X&?]CW+_P"B*]ZH A_L[3_^
M?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH
M A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&
M'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^
MSM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#G
MQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A
M_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\
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M #XP_P#?H5G>+K&RC\-7CQV<2L(3@K& 16O6;XQ_Y%B]_P"N!H FT_3[!K"
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MK8H A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\
M^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]
M"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_
M /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FH
MH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?
M&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C
M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*\&_:G_X*H_\
M!.S]BI;B#]IC]L#P3X;U"U!,V@_VL+S5!C_IQM1)<GTXCKYU_P"'VOQ\_:0_
MT'_@F;_P2A^,7Q/@G^6T\<>/H8O!GAN0'I-%=7V7N% Y*!$8]!R10!)_P<B?
M\%$K#_@G=_P3CUX^"=1AM/B%\3?,\+^"/)PLUMYL9^V7ZXY'D6Y;:X^[-+!Z
MU^ G_!M__P %&X/^">W_  4<T >/-82W^'OQ,\OPOXV^T,!#:^;(/L=^V>%\
MBX*[G/W899_6O/\ _@L__P %*OVG_P#@H_\ M7W&K?M(:CX10?#\W/A[0M)\
M 2SR:-;*EPWGS023,S7#2.HW3\+(L4>T!0M?(= ']^W]G:?_ ,^,/_?H4?V=
MI_\ SXP_]^A7X:?\$0/^"@G_  7:_:\_9)/C?X ?%GX&?%Y/A_>1^'_$7@7X
MG6EWI/B&UBCA4VDD5[9 0W EB&!/<#<SQ3!MS*7;[+'_  69_:]^!'[C]O3_
M ((L?''PC##Q=>(_A3+:>.-+C4?\MY)+-HV@C/7D,PR <F@#] /[.T__ )\8
M?^_0H_L[3_\ GQA_[]"OD3X$_P#!?#_@D?\ M :@- \.?MJ>&/#VL"3RI]#^
M((F\.W,,W_/(C4DA1GSQA&;)X&:^L_#GB;PWXQT6#Q)X1\06.JZ==)OMK_3;
MM)X9E]5="58>X- %C^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&
M'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^
MSM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_
M0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T_
M_GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\
MOT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM
M/_Y\8?\ OT*/[.T__GQA_P"_0J:B@#&\#@#2)0!_R^2_^A5LUC^!_P#D$2_]
M?LW_ *%6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 >"_M<_\ )</@9_V/<O\ Z(KWJO!?VN?^2X? S_L>Y?\ T17O5 !1110
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MP!KB/^$-_:(\>_-XQ^(=GX6LGZZ?X9A+W!'HT\GW&]TR*UO"O[._PI\+7?\
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MYS2?\*J_X.)?VN/F^)/[1GP?_9:\.7/72_AWX?;Q7XC6,_>CFN;TBT1R.!+
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MBBB@ HHHH **** "BBB@ HHHH **** ,?Q+_ ,A?1_\ K]/_ *":V*Q_$O\
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M>HVFGZ7X=>8%H[5[RY)66Z*@GR5 ^ZRABR2*@!]O45X#_P $\_\ @HG\&?\
M@HQ\*M6\=_#70-?\,Z]X4UZ;0O'O@+Q?8BUU?PUJD7W[:YBR>O)5P<-A@=KH
MZ+[]0 4444 >"_M<_P#)</@9_P!CW+_Z(KWJO!?VN?\ DN'P,_['N7_T17O5
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !6/9?\ ([WO_7E%_,UL5CV7_([WO_7E%_,T ;%%%% !1110 4444 %%
M%% !1110 4444 %%%% !15;4M:T?18O/UC5K:T3^_<SK&/S8BN4UK]HGX(:!
MG[?\3-+8KU%I,;@_E$&H [2BO-?^&H/!^H<>#_!?BO7L_<;2]!D*GWR^W ]Z
M/^%J_''6>/#/[/%Q"C=+C6M;A@V_6, M^M 'I5%>:_9?VKM<_P!=JG@W0XVZ
M?9X)[F9?KO\ D-'_  IGXJ:QSXM_:-UMPWWDT6PAL<>P9<G\: /26944N[
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M  <3?M<?+\.?V>?@]^RSX<N>FI_$'7V\6>(TC/W9(K>S"VB.1R8YQD="<CD
M_0>22.&-III%1$4EF8X  ZDFOE7]IC_@MW_P2V_91U!_#?Q*_:_\,ZCX@$OD
MQ^%?!4CZ]J;SDX$)M]/65HG)X EV#D<C->1Q_P#! VS^/<BZI_P4W_X*%?&S
M]H-Y&W7GA:;Q ?#7A>4]3C2]-9=GI\LPXP,5]5_LS_L#?L5?L;Z>EC^R]^R[
MX)\$NL?EOJ&B:!"E[,N,?O;H@SS<<9=V- 'RG_P]8_X*2?M1?Z+_ ,$]/^"/
M7C:#3+C_ (]_'_[1&K0^%+"->TRV&Y[JZB;J#&P)'./0_P"'=O\ P6*_:K_?
M_MR?\%:Y/A]HUQ_Q]>!/V7O#8T@1@]1'K5X&O.G&&0CO7Z$T4 ?''P _X('?
M\$LO@%K_ /PGDO[-%I\0/%LD@EO/&'Q9OYO$M_<S#I,WVYGA20==T<:'/-?7
M^EZ5I>AZ;!H^B:;;V=I;1".VM;6%8XXD P%55 "@#L.*L44 %%%% !1110 4
M444 %%%% !1110 4444 %?,W_!17_@HK_P ,"?\ "'?\6>_X2S_A+/[0_P"9
MA^P?9?LOV;_IWFW[OM'^SC9WSQ],U^9O_!Q7_P T>_[F'_W&T '_ !$5_P#5
MGG_F0?\ [WU3T/\ X.%/[&M&M?\ AD3S-TSR;O\ A/\ &-QSC_CP-?FS10!^
MF7_$17_U9Y_YD'_[WU^F5?S-U_0-XB_;\_8G\+;O[5_:G\#,5X9;+Q%!=,#Z
M8A9S0!Z]17S;J7_!6_\ 8(M;DZ?I'QGN-9NQTM=%\+ZC<,WT(M]I_P"^JK_\
M/0/ 6K<> /V6OCGXH#?<DT7X;RF,_5I)$P/?% 'TU17S+_PV]^U'K_\ R('_
M  33^(-R3]S_ (2+6[+2?S\PMBC_ (73_P %1O$O_($_8I\$>&MWW?\ A(OB
M.E[L^OV1!G\* /IJBOF;^R/^"NWB7F^\7_ CPS$W3^S=/U6\F0>_G$(3].*3
M_AFG_@HUXB^;Q/\ \%&[32HS]^U\._"RQ.?I+*^\?E0!]-45\S?\.^OBCKW_
M "/_ /P43^-=T&Y== UN#2@?PCC; ]J3_AU)^SEJO_)0/'?Q-\69_P!9_P )
M'\0;N3S/][RRE 'T)XA\?>!?"0)\5^--)TP 9)U#48H<#_@;"N#\1?MO_L<>
M%<C7/VH_ 4;K]Z*+Q5:RR#ZI&[-^E<=X>_X)5_\ !/[PR0UA^S9I4[ Y+:EJ
M%Y=Y/OY\SYKN_#O['7[)GA+#>'/V9? 5HXZ31^$K/S/^^S'N/YT >>:W_P %
M9/\ @G]HDWV0_M!V][.3A(-*T._NBY] 8H&7]:H?\/3_ (,:K_R3_P"!_P 8
MO%F[_5_\([\.+B3S/]WS&2OHS1/"_AKPU#]G\.>';'3X\8V65HD0QZ84"KU
M'S-_PWG\>-?&? '_  3?^+-SG[G_  D2VND_GYCMBD/[0'_!3'Q'QH'[ 'A_
MP^I^Y+XB^*5K<<>I6V0$?2OIJB@#YFS_ ,%>O$O1?@)X9@;U.K7ERG\HS1_P
MH'_@IGXDYU[]OSP[X>#??B\._"ZVN>/0-<N"/KVKZ9HH ^9?^&#OCYKP_P"*
M_P#^"D/Q6N<_>_X1T6ND_EY:-BL#QY_P1:_9*^,]JMC^T9XM^(OQ.@48\GQ_
MXO:_4YZ\&-<?ABOKFB@#\[?B!_P:U_\ !(/Q19%_AW\*?%_PWU8@@^(/ 'Q
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MP]XB\:_"7PIXCNX?CY\,_".@V][J>HZ9/&B0W\ ,9G86V9W*1NB[C$7^0.Z
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M+J[N'W2S2GDGT'8 =@. .!5.@#]$$\:>%9$$D>NV[*PRK!L@CUIW_"8^&/\
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MX_"HC\7/CUK9_P")5X$\,:*#T.LZZUQCW(@ KU;^SM/_ .?&'_OT*/[.T_\
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M8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\
M?59_BCQ1X?O/#]W:VNJQ/(\1"(IY)K<_L[3_ /GQA_[]"L[Q=8V4?AJ\>.SB
M5A"<%8P"* "Q\7>&H[*&-]9A#+$H()Z'%2_\)CX8_P"@U!_WU4VGZ?8-80$V
M4))A7),8]!4W]G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^
M^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J
M#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'P
MQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\
MOJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T
M&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\
M,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%
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M\!_A$D@_>Q?";X-OKNP'JJ-K3J?8$\]Z /O;_A,?#'_0:@_[ZKYR_P""K?\
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M_P!!J#_OJC_A,?#'_0:@_P"^JQ?'/Q:^!GPP1G^)/Q*\*>'PHR?[:UBVM?\
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M!;?RL+[9X% 'JWC7]L/]E;X=!QXW_:$\(Z;)']ZWN==A$WX1AMY_ 5Y?J_\
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M_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[]"@"G_P )CX8_Z#4'_?5'_"8^&/\
MH-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\ H-0?]]4?\)CX
M8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC_H-0?]]4?\)C
MX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]
M4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U
M!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"G_PF/AC_
M *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0H I_\)CX
M8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\
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M&UO_  23M-5C\3?%'X*>)?B7K,8XUCXD?$75]2E;U+)]H2)LD<YCKZ&^$O\
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MY/FN/^"A/[0A9OOF/QTB GO@"#BC_AVC _RW/[>O[2LT9^]%+\5"58>AQ;T
M>+?\.]/^"V'Q:_>?'?\ X+A?\(S9RG]]H/PE^"VFV>SUV7]PYG'XK1_Q#R_
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M*]BM_A)\*;,%;3X9>'H@Q^81Z+ N?R2K<'@/P-;1B&V\&:3&@Z*FG1 #\ M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#'\#_\ ((E_Z_9O_0JV*Q_ _P#R")?^OV;_ -"K8H **** "BBB@ HH
MHH **** "OFK_@I=_P %)?"?_!.SP!X5EM?A1K7Q&^(7Q&\31^'OAG\-O#LZ
MPW6O:BV"09G5A!"@9-\NU]ID0;3DD?2M?$/_  63_85_:?\ VCM5^"O[7'[$
M5[H%Q\6?V>O&5QKOAOPQXJG,-AXAM;F.)+NR:7($4CBWB"LS(N"XWH2& !\^
M?LY_\%^OVLOAY\7V\)_\%.OV((_ G@CQ!\;KWX>Z9\1O"_BNWU&R\,:VJQ&/
M2+](US(%WY-Z&577>51A&Y7]3_&'C'PE\/?"NH^.O'OB?3]%T72+.2[U75]5
MO$M[:S@12SRRRR$*B* 268@ "OQJ_P"">_\ P5Q^"OPW^)OC[]G;_@J;^QAX
M@^&U]\0?VF];O['Q!XDTBWUKPEI/B.5;:-M,;40-BW,+#_7(A54F#LT:$L?T
MM_;G_P""<W[/G_!16Q\(>%/VG;GQ)J/A3PGK3ZI/X,TS7I++3M>GVJL:Z@L6
M'GCC(+*H9/F8Y)!((!R?_!,S_@JU\%_^"IDWQ3UKX ^&KZ+PQ\.O&BZ#IOB*
M\GX\0(81)]LCA**T$;'.U7)8KM8A22HS?VX/^"L.C?LP?'[0_P!C;X ?LT^+
M_CG\:==T-];/@+P7/!;II6EJVP7=_>3GR[5&?Y4R#DXW;=\>_P"?/^#>#PEX
M6\ _'_\ ;L\#>!_#ECH^BZ-^U/JMEI.DZ9:I!;65M$TJ1PQ1H L:*BA54
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MQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\
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M_LJ_LZ6:V'P!_9K\!>"8E39CPKX1L[ L,8^8P1J6)[DDD]Z[W^SM/_Y\8?\
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M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\
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ME9;"Y@\U@F54R;M@=]N-[9]PHH ^ /\ B%Q_X(4?]&,_^9-\3_\ RSK-M?\
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M **** "BBB@ HHHH **** "BBB@#'\2_\A?1_P#K]/\ Z":V*Q_$O_(7T?\
MZ_3_ .@FMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K'\#_P#((E_Z_9O_ $*MBL?P/_R")?\ K]F_]"H V***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** ,?P/\ \@B7_K]F_P#0JV*Q_ __ "")?^OV;_T*MB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \%_:Y_Y+A\#/^Q[E_\
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MHOYF@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K-\8_\BQ>_P#7 UI5F^,?^18O?^N!H N:=_R#X/\ KBO\A4U0
MZ=_R#X/^N*_R%34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 8_B7_D+Z/_U^G_T$UL5C^)?^0OH__7Z?_036Q0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5C^!_^01+_P!?LW_H5;%8_@?_ )!$O_7[-_Z%0!L4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8_@?_D$2
M_P#7[-_Z%6Q6/X'_ .01+_U^S?\ H5;% !1110 4444 %%%% !1110 4444
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M_P"(H X7_AN[]D/_ *+QHG_?4G_Q%'_#=W[(?_1>-$_[ZD_^(KNO^%3?"O\
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MKX>> -9^#>JW6L>!M'NY5\;ZO&LESID4C!%N2%4%E)P!T':@#LO^&[OV0_\
MHO&B?]]2?_$4?\-W?LA_]%XT3_OJ3_XBNZ_X5-\*_P#HFGA__P $T'_Q%'_"
MIOA7_P!$T\/_ /@F@_\ B* .%_X;N_9#_P"B\:)_WU)_\11_PW=^R'_T7C1/
M^^I/_B*[K_A4WPK_ .B:>'__  30?_$4?\*F^%?_ $33P_\ ^":#_P"(H X7
M_AN[]D/_ *+QHG_?4G_Q%'_#=W[(?_1>-$_[ZD_^(KNO^%3?"O\ Z)IX?_\
M!-!_\11_PJ;X5_\ 1-/#_P#X)H/_ (B@#A?^&[OV0_\ HO&B?]]2?_$4?\-W
M?LA_]%XT3_OJ3_XBNZ_X5-\*_P#HFGA__P $T'_Q%'_"IOA7_P!$T\/_ /@F
M@_\ B* .%_X;N_9#_P"B\:)_WU)_\11_PW=^R'_T7C1/^^I/_B*[K_A4WPK_
M .B:>'__  30?_$4?\*F^%?_ $33P_\ ^":#_P"(H X7_AN[]D/_ *+QHG_?
M4G_Q%'_#=W[(?_1>-$_[ZD_^(KNO^%3?"O\ Z)IX?_\ !-!_\11_PJ;X5_\
M1-/#_P#X)H/_ (B@#A?^&[OV0_\ HO&B?]]2?_$4?\-W?LA_]%XT3_OJ3_XB
MNZ_X5-\*_P#HFGA__P $T'_Q%'_"IOA7_P!$T\/_ /@F@_\ B* .%_X;N_9#
M_P"B\:)_WU)_\11_PW=^R'_T7C1/^^I/_B*[K_A4WPK_ .B:>'__  30?_$4
M?\*F^%?_ $33P_\ ^":#_P"(H X7_AN[]D/_ *+QHG_?4G_Q%'_#=W[(?_1>
M-$_[ZD_^(KNO^%3?"O\ Z)IX?_\ !-!_\11_PJ;X5_\ 1-/#_P#X)H/_ (B@
M#A?^&[OV0_\ HO&B?]]2?_$4?\-W?LA_]%XT3_OJ3_XBNZ_X5-\*_P#HFGA_
M_P $T'_Q%'_"IOA7_P!$T\/_ /@F@_\ B* .%_X;N_9#_P"B\:)_WU)_\11_
MPW=^R'_T7C1/^^I/_B*[K_A4WPK_ .B:>'__  30?_$4?\*F^%?_ $33P_\
M^":#_P"(H X7_AN[]D/_ *+QHG_?4G_Q%'_#=W[(?_1>-$_[ZD_^(KNO^%3?
M"O\ Z)IX?_\ !-!_\11_PJ;X5_\ 1-/#_P#X)H/_ (B@#A?^&[OV0_\ HO&B
M?]]2?_$4?\-W?LA_]%XT3_OJ3_XBNZ_X5-\*_P#HFGA__P $T'_Q%'_"IOA7
M_P!$T\/_ /@F@_\ B* *7P8\:^%/'WA"3Q!X-UR#4+(ZC<1BXMR2N]7^9>>X
MKK:\)_X)Z(D?P0U6.- JKXYUD*JC  ^TGBO=J "BBB@ HHHH **** "BBB@
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M_P 7_$*[0:;#XRT6&T:WLMS"74'B9A(;:(1R,\@& (VYX- 'Z/T444 %%%%
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M-7PR_P""C_PR_P""8OA)E\6^/_'5W=Q^(CI.I)Y/A)(K26XC%UA6W3RB)@(
M5=5P[[0R!_3?V_?V^_V?O^";O[/%Y^T;^T3J=\-.2^BT_1M&T:U$^H:WJ,H8
MQ65K$64/*P1VY95549F( - 'M=%? /@O_@N5XF\'>,/"-I^WW_P3F^*7[/?A
M#X@:M!I?A'X@^*[JUO=,6\G&8(-2\DK)I;R<@"53@ABVU5=E^_J "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHK\]/VF/^"Z7Q'^$7[>?C_P#8&^ 7
M_!-/XB_&3Q#\/--TV_UF_P#!NL0 "WO+.VN4D,31,R*#<K'DDY(SWH _0NBO
MS=TK_@XFTGX3^/\ 0/"W_!1/_@G;\:/V==#\3ZDFGZ1X]\8Z8MSH:7+=$N+E
M%3R>A)(5]H&Y@J!F'Z/6MU;7UM'>V5Q'-#-&'AFB<,KJ1D,"."".010!)111
M0!S?C?X4^$?B#XB\.>*/$<,[7?A;4FOM),,Y15F*%"6'\0P>E=)110 45\<?
MMA?\%>]+^!/[3:_L/?LO?LJ>-_CW\8K?1$UC7O"?@N:WM+3P_8N%,<E_?7!\
MNV:0/&RJ5.1(A)7?&'O_ +"G_!6GP?\ M:_'3Q'^Q]\8_P!GKQE\$_C5X6TE
M=6OOAWXY$4AOM.9E7[98W4)\N[B5F4,0%^]E=P5BH!]<45\0?M"?\%EM5\._
MM.>*/V1_V(/V'/'O[0WBWX>PPO\ $JX\)ZC::?I?AV24%DM'N[DE9;K:&/DJ
M!RK*&+)(J>Q?\$]/^"B7P8_X*,_"?5/'_P ,]!U[PUKGA;7IM"\>> _%]B+7
M5_#6JQ?ZRVN8LG'JK@X;!!VNCHH![[1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%?E9\!_^#C[]HC]J7P3)\3?V;O^"*'QE\;>&X]2GL!KF@:[
M;36[7$1 DCW"#[PW+D>XKW7]BC_@N)\'OVG/VC1^Q;\>_P!GCXB? /XQW%BU
MYH_@CXHZ4+<:W JLS-97 P)R%1VP43<J,4+[6V@'V]1110 5S?PM^%/A'X/>
M'9_"_@N&=+2XU*XOI!<3F1O.F?>YR>V>@[5TE% !117Y[7/_  79\:?&3Q?X
MIA_X)W_\$U/BC\?O!?@K69M*U[XC:%J=EIFEW5W#S-'IQN"7U#;D?<"D[E(!
M5D9@#]":*\)_X)[_ /!0OX#_ /!2/X'2_&GX(Q:QILNE:Q/HWBSPGXGL?LNJ
M^'M4AQYMG=0[F"N RD$$@@]0P95\]_;P_P""Q?[-7[#?[1'PD_9*U%E\5?$C
MXK^/M(T"+PMI6I(DVAV=]<QVXU.[.UO+0-*FR(@--\VTA59@ ?7%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 45XC_P4<_;7T'_ ()U_L7^-?VR
MO$_@.\\36/@N*Q>?0["\2WENOM-_;68"R.K!=IN YR#D*1WKX_T#_@NY^VYX
ME\,6/CG1/^"!7[0%]HNHV,5]9WVG7L-Q]HM9$$B2Q*L&9-R,&4#KD4 ?I=17
MS7_P3A_X*H?LT?\ !37P=KVI?!N+7O#_ (I\'7XL?'/P\\::<++6O#]R2RA9
MX=S HS)( ZDC*,K!75E'TI0 4444 <W\+?A3X1^#WAV?POX+AG2TN-2N+Z07
M$YD;SIGWN<GMGH.U=)17#_M)_M%_"']DCX%>)_VD/CSXKCT3PEX1TQK[6=1>
M,N50$*J(B\R2.[)&B#EG=5')H [BBOS9OO\ @X#^+?AGX:0?M5^/_P#@CY\=
M=%^ T\$=[_PLJ6XT^2\@TV0C9?S:4K^;' 5*OYADV["&#$$$_37[4'_!4S]D
M3]EC]B_1_P!NKQ-XQNO$'@WQ7#8?\();^%K,W-]XGN;V,R6MK9PL4W3.@9MK
ME-@1]VTJ10!]&45^=M]_P7G\=_ O5O#OB+_@H+_P3!^+/P*^''BK58-.T_XE
M:UJ%GJ5EITTW^J.I16Y$E@IYSN#,"#\IVMC]$(9H;B%+BWE62.10R.C9# \@
M@CJ* '4444 %%%% !1110 4444 %%%% !7Y>_P#!;_\ Y2T?\$W?^RL>(?Y:
M/7ZA5^4G_!Q#XD\4_"/]M_\ 8:_::LO@KX[\:>'_ (;^._$6K>)[;P#X8EU.
M[A@ TC: B84,VUMH=E!VMSP: /U8N;:WO+>2SO+=)8I4*2Q2(&5U(P5(/!!'
M&*_%K_@E1^TUX7_X)B>!_P#@I7IVFZ,US\/?V?\ XOZAK'@OPU#+LB22X:]@
MBT^-N?+4M9V<)(!VYW8)SGWCQ9_P<<OXQT&Y\-_LF?\ !)[]JSQAX[NH630=
M)U[X6G3=/\XC"O=7*3S-%$"068(> <E>HP/V9_\ @B7\=V_X(X?'[X$?M$>(
M=.'Q\_::O-4\7>-+L3J]M8ZW,ZW-G9/+'E61)T#2.FX*]Q,$+JJE@#R#X'_$
M#XS_ +5/[/NF?M=?&K_@YM\*?"[XO>+=(37-#^''A_QEX<MO#/A;SD$MMIM[
MI\TIDN&12BR^8?,1BRMYK(6?T+3O^#@KXM7_ /P0CN_VW+'P?H-]\;[7QU_P
MJ^*RL2)=*NO%!D0)>1A6P\36KK=! VTO\@.PAJ\0_9P^.?\ P25_9Z_9CT/X
M%?M\?\$.9[']HGP7H$6BZQX0A_9OBU&?Q?J%M&(5O+2\CMVAF%T560R,X&Z1
MBID7:[>L_&3_ ()S_M<_M0?\$&8M+\-_L2_##X+?&+3_ (C6OQ/\-_![X:>'
M1I-K)-:$110W432L/[1DLPQ.67YE@B81LK;0#T?Q_P#\$Y?^"VGP7^#,'[2'
MP._X*P>-OB5\=]/^RW^J_#?Q-9:;#X-UYS(OVG3X('6)+1 K.%FW(6\L8$)8
M-']V0?M9?!;P=HVE:7^T)\7? G@+QE+HUI<^(/".L^.+!)]+N984D> EI1O"
MLQ42 ;7 ##((KX.^+7_!P1X@^+GP#E^$G[$7[('QC;]J+7K.'3].^'7B'X97
M<,7AC4I&"2W%_<7"+;BV@Q(P<MAMJ[Q&I<I]$^+O^".'[$7[5::)\8_V_OV8
M_!OC_P"+UUX7TRU\<^*X1=6\-]?P6D<4K0QI,H2+>K!%QD+C.3S0!Z'^V!^R
M+^S_ /\ !3W]GK3/A3\0?B+K5Y\/K_6[;5[X> _%/V>#Q';1+*HLI[B#/FVC
MLX9U1E):)"&4KFOB/_@D-\&_A9^SY_P72_;E^"_P3\!Z;X8\*^'?#OP\M=%T
M+2+816]K$-&5B%4=26+,S'+,S,S$LQ)_2KX,_!KX8_L]?"[1/@K\&/!]MH'A
M;PY9"ST31K-G,5I "2$4N6;&2>I/6OA+_@G]\/O'N@_\%]OVZ_'>N^"-7LM#
MUS2_ 2Z+K-WILL=IJ!BT=%D$$S*$EV-\K;2=IX.* /NSXV?%_P "_L^_![Q3
M\=?B=JOV'P[X.\/WFLZW=8R8[6VA::0J/XFVH<+U)( ZU\!?\$!?@SX]^/5I
MXY_X+2_M2Z46^)7[0FHRGPC:W!WCPSX-@EV6-A;Y^XDGEB0D?ZQ([=S\S.6Z
M'_@YF/QI\2?\$M]5^!OP)\)ZWJVL?$_QSH7A>Y70M,FNI;:TDN?M,TKK$I*Q
M$6HC=CA=LI!/S5]Q_"?X:>%?@Q\+?#?P>\"6"VNB>%- L]'T>U0 "*UMH4AB
M0 >B(H_"@#H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\O?^#1
M7_E$O+_V5CQ!_.WK,_X.K])T[X<?L_\ P%_;-\)6J6WQ ^&7[0NAMX8UB%<3
MB&:.XFEM@PY*O):6[E>A\KIR:^:O^"%/_!5/0?\ @F/^Q!/^S+^T%^P?^TUJ
M/B!?'>K:M]I\)_"*2YM#!<&+8 \TT+;OD.1MQTY->W_$"7]JO_@X/_:Q^#VF
MZC^QG\0O@[^R[\(?&D/C3Q#J?Q;TD:;JGC+4K<$6MK!9[F_=8:6,NCNH2>9B
MZN(XV .W_P""G7_!0GXD^.?^"DVC?\$L?A=^W/X9_9J\*Z/X&7Q7\6?BYK6H
MV%MJ$PED5;;1]->^=8HYF5XI6=3OVNS#Y8627B/A+^W;XG_8"_X*#_!G]GC0
M_P#@K#I'[5_P?^.>M/X9GCU7Q3I6K>(_!FN-Y:V<YN;!MTUM<2R)'MD 5<.1
M\P!>+_@J)^RSX(_9H_X*]V__  4E_:;_ &$Q\>_@%\0_AU!X;\=QVW@:+Q%<
M^"=7MFC$&IFS=&/DM##'&95Q@23 _,(DED_9P\2_L:_M5_M\_"_1_P#@E;_P
M1O\ AK:_#SPOJ7]M_$OXY^./@,=$71I('26TBT:1E@?[>)4R&*/M9HW"[8W<
M '=ZG\1?VU_^"NW_  46^-W[-'P0_;%\2_ KX(?L]7]IX?UC4OA[:P+K_BK7
MY4D,P%W*K&VA@>*5,)P0(R58R$Q>W?L-:!_P4/\ V-?BS\3OA5^WA\>K3X@_
M K1M/M-2^&GQR\9ZGIUAJ<32,B3Z9J*HZE]K/\MQ(H!*'YOWBQQ_-WA+XJ:Q
M_P $-O\ @I=^T?XQ_:8^#OC?4?@;^T/XCMO&GA7XF^#O"UQJUMH^J[9C>V%_
M';*SPLTDS[#@Y6)2 0[^7[%^S1\8?C%_P6-^+GQ8L/C%^SI?Z?\ L8WGA6TT
M;PKHGQ$\+2Z9JGC/5EN(YYM00%EF2R3RRH!P&/E$$,LR* ?9?@3]I?\ 9P^*
M6OKX4^&7[0'@CQ'JCQ-*FFZ%XKL[RX9%^\PCBD9B!W.,"ORA_P"#B[_@ES^R
MG\$/^"='[2_[=,>BZMXI^*_C/7M%N&\8>,=4:_GT2UF\1V'_ !+]-5@$L[9$
M8Q*$&_RR4+E3MK]!_P!F7_@D9_P3?_8W^*,7QJ_9D_9/\/>#_%,-E-9Q:SIL
M]TTJP2@"1,22LN& &>.U>,?\'-7@7QO\2?\ @BQ\7/!OPZ\':KK^L7=UX=-K
MI6BZ?+=7,P37]/=]D42LS;55F.!P%)/ H ^B/CSHWPC\2?\ !.?Q=X7^/OCE
M?#'@?5O@S>V'B[Q$\FW^S=-GTIX;BX!P?F2-V8  DD  $\5^0'[+?[>__!5G
MX3?\$:-2^"/[/?\ P32U+XD_#?0/#&J:%X&_:!6X.GQWOA]C*B:H?#LJ->7/
MEQ.S QML?8"=VUM_ZE?\%"/V3_'O[:/_  2<\<?LI?#Z\2Q\3>*?AK;V^C+=
MR>2CWL*PSQ6\C'_5K))"(F8_=#DD<8KY+_9;_P""\GPQ_9C_ &/?!W[,?QZ_
M8R^-VB_'/X?>"[+PRWPCTOX87TTFL7MC;1VL;6,\<9A^SS%$96)^57.T2 *7
M /I[_@A)X+_9_P#AU_P2=^#?@?\ 9D^-*?$'PG8:%<M%XI6T>V-S>SWMQ<WJ
M-!)\\!CNIIX_*?YD" $GJ?KBOA__ (-\/V-/C;^Q1_P3LL?!W[1'AZ/0?%OC
M#QAJGB[4O"D3 KH"WSIY5CP2%98XD9D'W&D93RI-?<% !1110 4444 %%%%
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M]GO]D#3/#6O>&/#&H3RW_AI+NYOI+18&DFAAB:5_,=UCP% RQP!UK\A_V?\
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<H **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206523329472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-06351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELI LILLY AND COMPANY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">IN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">35-0470950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lilly Corporate Center<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Indianapolis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">276-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,296,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the Registrant's Proxy Statement for the 2023 Annual Meeting of Shareholders have been incorporated by reference into Part III of this report.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000059478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock (no par value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock (no par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member', window );">7 1/8% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">7 1/8% Notes due 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member', window );">1.625% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member', window );">2.125% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Notes due 2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member', window );">0.625% Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Notes due 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A5000NotesDue2033Member', window );">0.500% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.500% Notes due 2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member', window );">6.77%&#160;Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">6.77%&#160;Notes due 2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1625BritishPoundDenominatedNotesDue2043Member', window );">1.625% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member', window );">1.700% Notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.700% Notes due 2049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY49A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member', window );">1.125% Notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.125% Notes due 2051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member', window );">1.375% Notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Notes due 2061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A5000NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A5000NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1625BritishPoundDenominatedNotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1625BritishPoundDenominatedNotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206524955872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Indianapolis, Indiana<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206526418608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue (Note 2)</a></td>
<td class="nump">$ 28,541.4<span></span>
</td>
<td class="nump">$ 28,318.4<span></span>
</td>
<td class="nump">$ 24,539.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs, expenses, and other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">6,629.8<span></span>
</td>
<td class="nump">7,312.8<span></span>
</td>
<td class="nump">5,483.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,190.8<span></span>
</td>
<td class="nump">6,930.7<span></span>
</td>
<td class="nump">5,976.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Marketing, selling, and administrative</a></td>
<td class="nump">6,440.4<span></span>
</td>
<td class="nump">6,431.6<span></span>
</td>
<td class="nump">6,121.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones', window );">Acquired in-process research and development and development milestones (Note 3)</a></td>
<td class="nump">908.5<span></span>
</td>
<td class="nump">970.1<span></span>
</td>
<td class="nump">769.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Asset impairment, restructuring, and other special charges (Note 5)</a></td>
<td class="nump">244.6<span></span>
</td>
<td class="nump">316.1<span></span>
</td>
<td class="nump">131.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other&#8212;net, (income) expense (Note 18)</a></td>
<td class="nump">320.9<span></span>
</td>
<td class="nump">201.6<span></span>
</td>
<td class="num">(1,171.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CostOfSalesOperatingExpensesAndOtherNet', window );">Costs, expenses, and other</a></td>
<td class="nump">21,735.0<span></span>
</td>
<td class="nump">22,162.9<span></span>
</td>
<td class="nump">17,309.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">6,806.4<span></span>
</td>
<td class="nump">6,155.5<span></span>
</td>
<td class="nump">7,229.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes (Note 14)</a></td>
<td class="nump">561.6<span></span>
</td>
<td class="nump">573.8<span></span>
</td>
<td class="nump">1,036.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 6,244.8<span></span>
</td>
<td class="nump">$ 5,581.7<span></span>
</td>
<td class="nump">$ 6,193.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 6.93<span></span>
</td>
<td class="nump">$ 6.15<span></span>
</td>
<td class="nump">$ 6.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="nump">$ 6.12<span></span>
</td>
<td class="nump">$ 6.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in calculation of earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">901,736<span></span>
</td>
<td class="nump">906,963<span></span>
</td>
<td class="nump">907,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">904,619<span></span>
</td>
<td class="nump">911,681<span></span>
</td>
<td class="nump">912,505<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired In-Process Research And Development And Development Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CostOfSalesOperatingExpensesAndOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of sales, operating expenses, and other-net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CostOfSalesOperatingExpensesAndOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringSettlementAndImpairmentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of restructuring charges, remediation cost, and asset impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringSettlementAndImpairmentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206526378608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 6,244.8<span></span>
</td>
<td class="nump">$ 5,581.7<span></span>
</td>
<td class="nump">$ 6,193.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Change in foreign currency translation gains (losses)</a></td>
<td class="num">(248.1)<span></span>
</td>
<td class="nump">13.5<span></span>
</td>
<td class="nump">122.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax', window );">Change in net unrealized gains (losses) on securities</a></td>
<td class="num">(53.2)<span></span>
</td>
<td class="num">(15.9)<span></span>
</td>
<td class="nump">14.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Change in defined benefit pension and retiree health benefit plans (Note 15)</a></td>
<td class="nump">616.9<span></span>
</td>
<td class="nump">2,699.4<span></span>
</td>
<td class="num">(157.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax', window );">Change in effective portion of cash flow hedges</a></td>
<td class="nump">432.9<span></span>
</td>
<td class="nump">151.6<span></span>
</td>
<td class="num">(152.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Other comprehensive income (loss) before income taxes</a></td>
<td class="nump">748.5<span></span>
</td>
<td class="nump">2,848.6<span></span>
</td>
<td class="num">(173.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Benefit (provision) for income taxes related to other comprehensive income (loss)</a></td>
<td class="num">(250.0)<span></span>
</td>
<td class="num">(695.3)<span></span>
</td>
<td class="nump">200.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax (Note 17)</a></td>
<td class="nump">498.5<span></span>
</td>
<td class="nump">2,153.3<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 6,743.3<span></span>
</td>
<td class="nump">$ 7,735.0<span></span>
</td>
<td class="nump">$ 6,220.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206526237120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents (Note 7)</a></td>
<td class="nump">$ 2,067.0<span></span>
</td>
<td class="nump">$ 3,818.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments (Note 7)</a></td>
<td class="nump">144.8<span></span>
</td>
<td class="nump">90.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $16.0 (2022)&#160;and $22.5 (2021)</a></td>
<td class="nump">6,896.0<span></span>
</td>
<td class="nump">6,672.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">1,662.9<span></span>
</td>
<td class="nump">1,454.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (Note 6)</a></td>
<td class="nump">4,309.7<span></span>
</td>
<td class="nump">3,886.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,954.1<span></span>
</td>
<td class="nump">2,530.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">18,034.5<span></span>
</td>
<td class="nump">18,452.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments (Note 7)</a></td>
<td class="nump">2,901.8<span></span>
</td>
<td class="nump">3,212.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Note 8)</a></td>
<td class="nump">4,073.0<span></span>
</td>
<td class="nump">3,892.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net (Note 8)</a></td>
<td class="nump">7,206.6<span></span>
</td>
<td class="nump">7,691.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets (Note 14)</a></td>
<td class="nump">2,792.9<span></span>
</td>
<td class="nump">2,489.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net (Note 9)</a></td>
<td class="nump">10,144.0<span></span>
</td>
<td class="nump">8,985.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">4,337.0<span></span>
</td>
<td class="nump">4,082.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">49,489.8<span></span>
</td>
<td class="nump">48,806.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings and current maturities of long-term debt (Note 11)</a></td>
<td class="nump">1,501.1<span></span>
</td>
<td class="nump">1,538.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,930.6<span></span>
</td>
<td class="nump">1,670.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation</a></td>
<td class="nump">1,059.8<span></span>
</td>
<td class="nump">958.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_SalesRebatesAndDiscounts', window );">Sales rebates and discounts</a></td>
<td class="nump">8,784.1<span></span>
</td>
<td class="nump">6,845.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="nump">1,017.2<span></span>
</td>
<td class="nump">885.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable (Note 14)</a></td>
<td class="nump">475.1<span></span>
</td>
<td class="nump">126.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">2,370.3<span></span>
</td>
<td class="nump">3,027.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">17,138.2<span></span>
</td>
<td class="nump">15,052.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Other Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt (Note 11)</a></td>
<td class="nump">14,737.5<span></span>
</td>
<td class="nump">15,346.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Accrued retirement benefits (Note 15)</a></td>
<td class="nump">1,305.1<span></span>
</td>
<td class="nump">1,954.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term income taxes payable (Note 14)</a></td>
<td class="nump">3,709.6<span></span>
</td>
<td class="nump">3,920.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities (Note 14)</a></td>
<td class="nump">87.3<span></span>
</td>
<td class="nump">1,733.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">1,736.7<span></span>
</td>
<td class="nump">1,644.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total other liabilities</a></td>
<td class="nump">21,576.2<span></span>
</td>
<td class="nump">24,598.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Eli Lilly and Company Shareholders' Equity (Notes 12 and 13)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;no par value Authorized shares: 3,200,000 Issued shares: 950,632 (2022)&#160;and 954,116 (2021)</a></td>
<td class="nump">594.1<span></span>
</td>
<td class="nump">596.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">6,921.4<span></span>
</td>
<td class="nump">6,833.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">10,042.6<span></span>
</td>
<td class="nump">8,958.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesHeldInEmployeeTrust', window );">Employee benefit trust</a></td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss (Note 17)</a></td>
<td class="num">(3,844.6)<span></span>
</td>
<td class="num">(4,343.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Cost of common stock in treasury</a></td>
<td class="num">(50.5)<span></span>
</td>
<td class="num">(52.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Eli Lilly and Company shareholders' equity</a></td>
<td class="nump">10,649.8<span></span>
</td>
<td class="nump">8,979.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">125.6<span></span>
</td>
<td class="nump">175.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">10,775.4<span></span>
</td>
<td class="nump">9,154.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 49,489.8<span></span>
</td>
<td class="nump">$ 48,806.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_SalesRebatesAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales rebates and discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_SalesRebatesAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesHeldInEmployeeTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesHeldInEmployeeTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206526417360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowances</a></td>
<td class="nump">$ 16.0<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">3,200,000,000<span></span>
</td>
<td class="nump">3,200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">950,632,000<span></span>
</td>
<td class="nump">954,116,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206523417584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Employee Benefit Trust</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Common Stock in Treasury</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598.8<span></span>
</td>
<td class="nump">$ 6,685.3<span></span>
</td>
<td class="nump">$ 4,920.4<span></span>
</td>
<td class="num">$ (3,013.2)<span></span>
</td>
<td class="num">$ (6,523.6)<span></span>
</td>
<td class="num">$ (60.8)<span></span>
</td>
<td class="nump">$ 92.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,193.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">$ 27.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Cash dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,786.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(497.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury shares</a></td>
<td class="num">(500.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="num">(212.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35.2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598.2<span></span>
</td>
<td class="nump">6,778.5<span></span>
</td>
<td class="nump">7,830.2<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(6,496.4)<span></span>
</td>
<td class="num">$ (55.7)<span></span>
</td>
<td class="nump">183.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,581.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">2,153.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,153.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Cash dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,201.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,246.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury shares</a></td>
<td class="num">$ (1,250.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,250.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="num">(287.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.4)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">954,116<span></span>
</td>
<td class="nump">954,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 9,154.8<span></span>
</td>
<td class="nump">$ 596.3<span></span>
</td>
<td class="nump">6,833.4<span></span>
</td>
<td class="nump">8,958.5<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(4,343.1)<span></span>
</td>
<td class="num">$ (52.7)<span></span>
</td>
<td class="nump">175.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,244.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">498.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Cash dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,667.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,607)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,607)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,496.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury shares</a></td>
<td class="num">$ (1,500.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,500.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="num">(283.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29.1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">950,632<span></span>
</td>
<td class="nump">950,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 10,775.4<span></span>
</td>
<td class="nump">$ 594.1<span></span>
</td>
<td class="nump">$ 6,921.4<span></span>
</td>
<td class="nump">$ 10,042.6<span></span>
</td>
<td class="num">$ (3,013.2)<span></span>
</td>
<td class="num">$ (3,844.6)<span></span>
</td>
<td class="num">$ (50.5)<span></span>
</td>
<td class="nump">$ 125.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206530878256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividend declared per share (in usd per share)</a></td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="nump">$ 3.53<span></span>
</td>
<td class="nump">$ 3.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206526280048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 6,244.8<span></span>
</td>
<td class="nump">$ 5,581.7<span></span>
</td>
<td class="nump">$ 6,193.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,522.5<span></span>
</td>
<td class="nump">1,547.6<span></span>
</td>
<td class="nump">1,323.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment loss (Note 11)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">405.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Change in deferred income taxes</a></td>
<td class="num">(2,185.2)<span></span>
</td>
<td class="num">(802.3)<span></span>
</td>
<td class="num">(134.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">371.1<span></span>
</td>
<td class="nump">342.8<span></span>
</td>
<td class="nump">308.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Net investment (gains) losses</a></td>
<td class="nump">420.0<span></span>
</td>
<td class="num">(178.0)<span></span>
</td>
<td class="num">(1,438.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development and development milestones (Note 3)</a></td>
<td class="nump">420.9<span></span>
</td>
<td class="nump">874.9<span></span>
</td>
<td class="nump">660.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other non-cash operating activities, net</a></td>
<td class="nump">304.8<span></span>
</td>
<td class="nump">511.4<span></span>
</td>
<td class="nump">333.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Other changes in operating assets and liabilities, net of acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Receivables&#8212;(increase) decrease</a></td>
<td class="num">(299.6)<span></span>
</td>
<td class="num">(1,278.3)<span></span>
</td>
<td class="num">(1,350.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories&#8212;(increase) decrease</a></td>
<td class="num">(599.7)<span></span>
</td>
<td class="num">(235.9)<span></span>
</td>
<td class="num">(533.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets&#8212;(increase) decrease</a></td>
<td class="num">(793.5)<span></span>
</td>
<td class="nump">1,515.4<span></span>
</td>
<td class="num">(457.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable&#8212;increase (decrease)</a></td>
<td class="nump">346.6<span></span>
</td>
<td class="num">(359.7)<span></span>
</td>
<td class="nump">322.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other liabilities&#8212;increase (decrease)</a></td>
<td class="nump">1,331.7<span></span>
</td>
<td class="num">(664.1)<span></span>
</td>
<td class="nump">1,271.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by Operating Activities</a></td>
<td class="nump">7,084.4<span></span>
</td>
<td class="nump">7,260.7<span></span>
</td>
<td class="nump">6,499.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,854.3)<span></span>
</td>
<td class="num">(1,309.8)<span></span>
</td>
<td class="num">(1,387.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sales and maturities of short-term investments</a></td>
<td class="nump">121.4<span></span>
</td>
<td class="nump">47.4<span></span>
</td>
<td class="nump">129.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(107.4)<span></span>
</td>
<td class="num">(83.5)<span></span>
</td>
<td class="num">(11.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from sales of noncurrent investments</a></td>
<td class="nump">342.2<span></span>
</td>
<td class="nump">800.0<span></span>
</td>
<td class="nump">757.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Purchases of noncurrent investments</a></td>
<td class="num">(600.2)<span></span>
</td>
<td class="num">(929.9)<span></span>
</td>
<td class="num">(358.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_PurchasedInProcessResearchAndDevelopment', window );">Purchases of in-process research and development</a></td>
<td class="num">(629.7)<span></span>
</td>
<td class="num">(563.4)<span></span>
</td>
<td class="num">(641.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisitions, net of cash acquired (Note 3)</a></td>
<td class="num">(327.2)<span></span>
</td>
<td class="num">(747.4)<span></span>
</td>
<td class="num">(849.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities, net</a></td>
<td class="num">(206.4)<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
<td class="nump">102.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used for Investing Activities</a></td>
<td class="num">(3,261.6)<span></span>
</td>
<td class="num">(2,762.3)<span></span>
</td>
<td class="num">(2,258.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(3,535.8)<span></span>
</td>
<td class="num">(3,086.8)<span></span>
</td>
<td class="num">(2,687.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt', window );">Net change in short-term borrowings</a></td>
<td class="nump">1,498.0<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(1,494.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2,410.8<span></span>
</td>
<td class="nump">2,062.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="num">(1,560.0)<span></span>
</td>
<td class="num">(1,905.4)<span></span>
</td>
<td class="num">(276.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of common stock</a></td>
<td class="num">(1,500.0)<span></span>
</td>
<td class="num">(1,250.0)<span></span>
</td>
<td class="num">(500.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities, net</a></td>
<td class="num">(308.9)<span></span>
</td>
<td class="num">(295.9)<span></span>
</td>
<td class="num">(241.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Used for Financing Activities</a></td>
<td class="num">(5,406.7)<span></span>
</td>
<td class="num">(4,131.3)<span></span>
</td>
<td class="num">(3,137.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(167.6)<span></span>
</td>
<td class="num">(205.7)<span></span>
</td>
<td class="nump">216.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(1,751.5)<span></span>
</td>
<td class="nump">161.4<span></span>
</td>
<td class="nump">1,319.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">3,818.5<span></span>
</td>
<td class="nump">3,657.1<span></span>
</td>
<td class="nump">2,337.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents at End of Year</a></td>
<td class="nump">$ 2,067.0<span></span>
</td>
<td class="nump">$ 3,818.5<span></span>
</td>
<td class="nump">$ 3,657.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense related to research and development that are acquired directly in a transaction other than a business combination, that do not have an alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PurchasedInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PurchasedInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206620048048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards</a></td>
<td class="text">Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include Eli Lilly and Company and all subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). We consider majority voting interests, as well as effective economic or other control over an entity when deciding whether or not to consolidate an entity. We generally do not have control by means other than voting interests. Where our ownership of consolidated subsidiaries is less than 100 percent, the noncontrolling shareholders' interests are reflected as a separate component of equity. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing of this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D) and Development Milestones</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including but not limited to, compensation and benefits, facilities and overhead expense, clinical trial expense and fees paid to contract research organizations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D and development milestones include the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use. Additionally, milestone payment obligations related to these transactions that are incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings Per Share (EPS)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis. We calculate basic EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising are expensed as incurred and are included in marketing, selling, and administrative expenses. Advertising expenses, comprised primarily of television, radio, print media, and internet advertising, totaled approximately $1.0 billion, $1.2 billion, and $1.1 billion in 2022, 2021, and 2020, respectively, which was less than 5 percent of revenue each year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Significant Accounting Policies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other significant accounting policies are described in the remaining appropriate notes to the consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Implementation of New Financial Accounting Standards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update (ASU) 2021-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes annual disclosure requirements for companies that analogize to a grant or contribution accounting model for government assistance transactions. We adopted the standard as of January 1, 2022. The adoption did not impact our financial statement disclosures. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as further modified by ASU 2021-01 and ASU 2022-06, provides for temporary optional expedients and exceptions in applying current GAAP to contracts, hedging relationships, and other transactions affected by the transition from the use of the London Interbank Offered Rate (LIBOR) to an alternative reference rate. The standard is currently applicable to contracts entered into before January 1, 2025. We adopted the standard in the first quarter of 2022. The adoption did not have a material impact on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206611402000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated statements of operations:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.669%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,462.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,957.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,694.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,078.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,360.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,845.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,541.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,318.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,539.8&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $163.4 million, $175.0 million, and $135.6 million during the years ended December 31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaborations, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 70 days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates, discounts, and returns are established in the same period the related product sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our products are sold to wholesalers that serve pharmacies, physicians and other healthcare professionals, and hospitals. For the years ended December&#160;31, 2022, 2021, and 2020, our three largest wholesalers each accounted for between 16 percent and 21 percent of consolidated revenue. Further, they each accounted for between 18 percent and 29 percent of accounts receivable as of December&#160;31, 2022 and 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates, discounts, and returns. The following describe the most significant of these judgments:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sales Rebates and Discounts - Background and Uncertainties</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We initially invoice our customers at contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medicaid, chargebacks, long-term care, hospital, patient assistance programs, and various other programs. We estimate these accruals using an expected value approach.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The largest of our sales rebate and discount amounts include rebates associated with sales covered by managed care, Medicare, Medicaid, and chargeback programs, as well as reductions in revenue related to our patient assistance programs, in the U.S. In determining the appropriate accrual amount, we consider our historical rebate payments for these programs, as well as patient assistance program costs, by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing. Although we accrue a liability for revenue reductions related to these programs at the time we record the sale, the reduction related to that sale is typically paid up to six months later. Because of this time lag, in any particular period our net product revenue may incorporate revisions of accruals for several periods.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. An estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sales Returns - Background and Uncertainties</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">When product sales occur, to determine the appropriate transaction price for our sales, we estimate a reserve for future product returns related to those sales using an expected value approach. This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately 24 months after the initial sale of a product to our customer), and estimated levels of inventory in the wholesale and retail channels, as well as any other specifically identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and discontinuations, or a changing competitive environment. We maintain a returns policy that allows most U.S. customers to return most of our products for dating issues within a specified period prior to and subsequent to the product's expiration date. Following the loss of exclusivity for a patent-dependent product, we expect to experience an elevated level of product returns as product inventory remaining in the wholesale and retail channels expires. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions. We record the return amounts as a deduction to arrive at our net product revenue. Once the product is returned, it is destroyed; we do not record a right of return asset. Our returns policies outside the U.S. are generally more restrictive than in the U.S. as returns are not allowed for reasons other than failure to meet product specifications in many countries. Our reserve for future product returns for product sales outside the U.S. is not material.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As a part of our process to estimate a reserve for product returns, we regularly review the supply levels of our significant products at the major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain U.S. wholesaler inventory levels at an average of approximately one month or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements provides us with data on inventory levels at our wholesalers; however, our data on inventory levels in the retail channel is more limited. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Actual U.S. product returns have been less than 2 percent of our U.S. revenue during each of the past three years and have not fluctuated significantly as a percentage of revenue, although fluctuations are more likely in periods following loss of patent exclusivity for major products in the U.S. market. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Adjustments to Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to increase revenue, recognized as a result of changes in estimates for our most significant U.S. sales returns, rebates, and discounts liability balances for products shipped in previous periods, were less than 1 percent of U.S. revenue during each of the years ended December 31, 2022, 2021, and 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration and Other Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize several types of revenue from our collaborations and other arrangements, which we discuss in general terms immediately below and more specifically in Note 4 for each of our material collaborations and other arrangements. Our collaborations and other arrangements are not contracts with customers but are evaluated to determine whether any aspects of the arrangements are contracts with customers. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue related to products we sell pursuant to these arrangements is included in net product revenue, while other sources of revenue (e.g., royalties and profit sharing from our partner) are included in collaboration and other revenue.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty revenue from licensees and certain of our collaboration partners, which is based on sales to third-parties of licensed products and technology, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This royalty revenue is included in collaboration and other revenue.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For arrangements involving multiple goods or services (e.g., research and development, marketing and selling, manufacturing, and distribution), each required good or service is evaluated to determine whether it is distinct. If a good or service does not qualify as distinct, it is combined with the other non-distinct goods or services within the arrangement and these combined goods or services are treated as a single performance obligation for accounting purposes. The arrangement's transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation. For arrangements that involve variable consideration where we have sold intellectual property, we recognize revenue based on estimates of the amount of consideration we believe we will be entitled to receive from the other party, subject to a constraint. These estimates are adjusted to reflect the actual amounts to be collected when those facts and circumstances become known.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development will not receive regulatory approval, we generally do not recognize any contingent payments that would be due to us upon or after regulatory approval. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contract Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.6&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract liabilities balances disclosed above as of December&#160;31, 2022 and 2021 were primarily related to the remaining license period of symbolic intellectual property and obligations to perform research and development activities or supply product for a defined period of time.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021, and 2020, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.537%"><tr><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.202%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="12" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,688.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,914.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,835.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,750.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,194.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">871.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (2)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,191.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">868.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">730.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">289.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">470.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">289.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Mounjaro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">366.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">115.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other diabetes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">268.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">367.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total diabetes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,911.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,719.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,909.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,553.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,468.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,925.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,653.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">830.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">351.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">620.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">543.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">384.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">500.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">293.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other oncology</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">169.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">254.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,218.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,028.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,448.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,724.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">757.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (3)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">148.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">682.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other immunology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total immunology</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,892.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,451.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">462.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">188.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">306.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">249.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">189.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total neuroscience</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">612.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">933.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,008.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">367.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">245.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">552.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">144.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">151.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,555.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,566.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">964.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,190.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,811.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,229.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,351.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,507.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,310.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Humalog revenue includes insulin lispro.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:38.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,190.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,811.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,229.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,299.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,776.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,187.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,747.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,583.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,452.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,852.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,702.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,541.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,318.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,539.8&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206528989056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage in various forms of business development activities to enhance our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements. In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, January 2021, and February 2020, we completed the acquisitions of Akouos, Inc. (Akouos), Prevail Therapeutics Inc. (Prevail), and Dermira, Inc. (Dermira), respectively. These transactions, as further discussed below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development in 2022, 2021, and 2020, which are further discussed below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs. We recognized acquired IPR&amp;D and development milestone charges of $908.5 million, $970.1 million, and $769.8&#160;million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions of Businesses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Akouos Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we acquired all shares of Akouos for a purchase price that included $12.50 per share in cash (or an aggregate of $327.2&#160;million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles the Akouos shareholders up to an additional $3.00 per share in cash (or an aggregate of approximately $122&#160;million) payable, subject to certain terms and conditions, upon the achievement of certain specified milestones. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired potential gene therapy treatments for hearing loss and other inner ear conditions. The lead gene therapies in clinical development that we acquired included GJB2 (which encodes connexin 26) for a common form of monogenic deafness and hearing loss; AK-OTOF for hearing loss due to mutations in the otoferlin gene; AK-CLRN1 for Usher Type 3A, an autosomal recessive disorder characterized by progressive loss of both hearing and vision; and AK-antiVEGF for vestibular schwannoma.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our access to Akouos information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.888%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at December 1, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.0</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.2</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to GJB2.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Akouos and is not deductible for tax purposes. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 7 for a discussion on the estimation of the CVR liability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations attributable to Akouos for the year ended December&#160;31, 2022 were immaterial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2022 and 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Prevail Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4&#160;million, net of cash acquired) plus one non-tradable CVR per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition established a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.888%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903.8</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001. In the third quarter of 2022, we impaired the intangible asset related to PR001. See Note 5 for additional information.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 7 for a discussion on the estimation of the CVR liability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations attributable to Prevail for the years ended December&#160;31, 2022 and 2021 were immaterial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Dermira Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we acquired all shares of Dermira for a purchase price of approximately $849.3 million, net of cash acquired. Under terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. We also acquired Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the year ended December 31, 2021, we sold the rights to Qbrexza. See Note 5 for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $86.8 million, other intangibles of $1.20 billion primarily related to lebrikizumab, deferred income tax liabilities of $49.5 million, and long-term debt of $375.5 million. After the acquisition, we repaid $276.2&#160;million of long-term debt assumed as part of our acquisition of Dermira.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue attributable to assets acquired in the Dermira acquisition did not have a material impact on our consolidated statement of operations for the years ended December&#160;31, 2022, 2021, and 2020. We are unable to provide the results of operations for the years ended December&#160;31, 2022, 2021, and 2020 attributable to Dermira as those operations were substantially integrated into our legacy business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included because this acquisition did not have a material impact on our consolidated statements of operations for the year ended December 31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant asset acquisitions during 2022, 2021, and 2020.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.718%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s),Therapy, or Asset</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority Review Voucher</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foghorn Therapeutics Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new oncology medicines</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Innovent Biologics, Inc. (Innovent)</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine, for geographies outside of China</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Petra Pharma Corporation (Petra)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutant-selective PI3K</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#945;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> inhibitor that could lead to potential new medicine</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disarm Therapeutics, Inc. </span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disease-modifying therapeutics program for patients with axonal degeneration</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.3&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In 2022, we terminated our license for sintilimab injection for geographies outside of China and reverted rights to Innovent.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Petra, we were required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3K</span><span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#945;</span> inhibitor. In 2022, we entered into agreements with substantially all Petra shareholders to acquire their rights to receive any future milestone payments in exchange for a one-time payment. As a result of these agreements, we recognized a charge of $333.8&#160;million as a development milestone in 2022. Any remaining contingent milestones payments linked to the success of the mutant-selective PI3K&#945; are not expected to be material. We did not recognize other significant development milestones during the years ended December&#160;31, 2022, 2021, and 2020.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage in various forms of business development activities to enhance our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements. In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, January 2021, and February 2020, we completed the acquisitions of Akouos, Inc. (Akouos), Prevail Therapeutics Inc. (Prevail), and Dermira, Inc. (Dermira), respectively. These transactions, as further discussed below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development in 2022, 2021, and 2020, which are further discussed below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs. We recognized acquired IPR&amp;D and development milestone charges of $908.5 million, $970.1 million, and $769.8&#160;million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions of Businesses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Akouos Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we acquired all shares of Akouos for a purchase price that included $12.50 per share in cash (or an aggregate of $327.2&#160;million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles the Akouos shareholders up to an additional $3.00 per share in cash (or an aggregate of approximately $122&#160;million) payable, subject to certain terms and conditions, upon the achievement of certain specified milestones. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired potential gene therapy treatments for hearing loss and other inner ear conditions. The lead gene therapies in clinical development that we acquired included GJB2 (which encodes connexin 26) for a common form of monogenic deafness and hearing loss; AK-OTOF for hearing loss due to mutations in the otoferlin gene; AK-CLRN1 for Usher Type 3A, an autosomal recessive disorder characterized by progressive loss of both hearing and vision; and AK-antiVEGF for vestibular schwannoma.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our access to Akouos information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.888%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at December 1, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.0</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.2</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to GJB2.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Akouos and is not deductible for tax purposes. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 7 for a discussion on the estimation of the CVR liability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations attributable to Akouos for the year ended December&#160;31, 2022 were immaterial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2022 and 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Prevail Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4&#160;million, net of cash acquired) plus one non-tradable CVR per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition established a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.888%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903.8</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001. In the third quarter of 2022, we impaired the intangible asset related to PR001. See Note 5 for additional information.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 7 for a discussion on the estimation of the CVR liability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations attributable to Prevail for the years ended December&#160;31, 2022 and 2021 were immaterial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Dermira Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we acquired all shares of Dermira for a purchase price of approximately $849.3 million, net of cash acquired. Under terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. We also acquired Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the year ended December 31, 2021, we sold the rights to Qbrexza. See Note 5 for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $86.8 million, other intangibles of $1.20 billion primarily related to lebrikizumab, deferred income tax liabilities of $49.5 million, and long-term debt of $375.5 million. After the acquisition, we repaid $276.2&#160;million of long-term debt assumed as part of our acquisition of Dermira.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue attributable to assets acquired in the Dermira acquisition did not have a material impact on our consolidated statement of operations for the years ended December&#160;31, 2022, 2021, and 2020. We are unable to provide the results of operations for the years ended December&#160;31, 2022, 2021, and 2020 attributable to Dermira as those operations were substantially integrated into our legacy business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included because this acquisition did not have a material impact on our consolidated statements of operations for the year ended December 31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant asset acquisitions during 2022, 2021, and 2020.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.718%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s),Therapy, or Asset</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority Review Voucher</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foghorn Therapeutics Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new oncology medicines</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Innovent Biologics, Inc. (Innovent)</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine, for geographies outside of China</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Petra Pharma Corporation (Petra)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutant-selective PI3K</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#945;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> inhibitor that could lead to potential new medicine</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disarm Therapeutics, Inc. </span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disease-modifying therapeutics program for patients with axonal degeneration</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.3&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In 2022, we terminated our license for sintilimab injection for geographies outside of China and reverted rights to Innovent.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Petra, we were required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3K</span><span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#945;</span> inhibitor. In 2022, we entered into agreements with substantially all Petra shareholders to acquire their rights to receive any future milestone payments in exchange for a one-time payment. As a result of these agreements, we recognized a charge of $333.8&#160;million as a development milestone in 2022. Any remaining contingent milestones payments linked to the success of the mutant-selective PI3K&#945; are not expected to be material. We did not recognize other significant development milestones during the years ended December&#160;31, 2022, 2021, and 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525759472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations and Other Arrangements</a></td>
<td class="text">Collaborations and Other Arrangements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Boehringer Ingelheim Diabetes Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim's oral diabetes products: Jardiance, Glyxambi, Synjardy, Trijardy XR, Trajenta, and Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as our basal insulin, Basaglar. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Jardiance, Trajenta, and Basaglar in the U.S., Europe, and Japan, milestone payments made for Jardiance and Trajenta were capitalized as intangible assets and are being amortized to cost of sales, and milestone payments received for Basaglar were recorded as contract liabilities and are being amortized to collaboration and other revenue. The milestones pertaining to Jardiance and Trajenta are being amortized through their respective term under the collaboration, which, depending on country or region, is determined based on the latest to occur of (a) a defined number of years following launch date, (b) the expiration of the compound patent, or (c) the expiration of marketing authorization exclusivity. The milestones pertaining to Basaglar are being amortized through 2029. The table below summarizes the net milestones capitalized with respect to the Jardiance and Trajenta families of products and the net milestones deferred with respect to Basaglar as of December 31: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones Capitalized (Deferred)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">116.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(130.6)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149.3)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Jardiance product family, we and Boehringer Ingelheim share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. The royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to Basaglar:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,066.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,490.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">760.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">383.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Olumiant</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to baricitinib, which is branded and trademarked as Olumiant, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases and COVID-19. Incyte has the right to receive tiered, double digit royalty payments on worldwide net sales with rates ranging up to 20 percent. Incyte has the right to receive an additional royalty ranging up to the low teens on worldwide net sales for the treatment of COVID-19 that exceed a specified aggregate worldwide net sales threshold. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, as well as achievement of a sales-based milestone, milestone payments of $330.0 million and $260.0 million were capitalized as intangible assets as of December&#160;31, 2022 and 2021, respectively, and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, Incyte is eligible to receive up to $100.0&#160;million of additional payments from us in potential sales-based milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Olumiant, including sales of baricitinib that were made pursuant to EUA or similar regulatory authorizations, to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. The following table summarizes our net product revenue recognized with respect to Olumiant:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">830.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Antibodies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with AbCellera Biologics Inc. (AbCellera) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab and bebtelovimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on worldwide net sales of bamlanivimab and bebtelovimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a license and collaboration agreement with Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of mainland China and the Special Administrative Regions of Hong Kong and Macau. Junshi Biosciences received royalty payments in the mid-teens on our net sales of etesevimab. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to EUAs or similar regulatory authorizations, we recognized $2.02&#160;billion, $2.24&#160;billion, and $871.2&#160;million of net product revenue associated with our sales of our COVID-19 antibodies during the years ended December&#160;31, 2022, 2021, and 2020, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tyvyt</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Innovent to jointly develop and commercialize sintilimab injection in China, where it is branded and trademarked as Tyvyt. We record our sales of Tyvyt to third parties as net product revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We report as collaboration and other revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. The following table summarizes our revenue recognized in China with respect to Tyvyt: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">293.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418.1&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.7&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lebrikizumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively, Roche), which provides us the worldwide development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future worldwide net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of December&#160;31, 2022, Roche is eligible to receive up to $165.0 million of additional payments from us contingent upon the achievement of success-based regulatory milestones and up to $1.03 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab. During the year ended December&#160;31, 2022, milestone payments to Roche were not material.</span></div>We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of December&#160;31, 2022, we are eligible to receive additional payments of $65.0 million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $1.25&#160;billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab. There were no remaining contract liabilities as of December&#160;31, 2022. As of December 31, 2021 and 2020, contract liabilities were not material. During the years ended December&#160;31, 2022, 2021, and 2020, collaboration and other revenue recognized was not material.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206528907952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock', window );">Asset Impairment, Restructuring, And Other Special Charges</a></td>
<td class="text">Asset Impairment, Restructuring, and Other Special Charges<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2XzIxOTkwMjMyNTgzMTA_a65ace08-5ec6-44b7-98e1-20a4af3312ff"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2XzIxOTkwMjMyNTgzMTA_b860e1a5-db44-4847-b689-049eb53e6544">asset impairment, restructuring, and other special charges</span></span> in our consolidated statements of operations are described below: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment (gain) and other special charges</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">221.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">244.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.1&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.2&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairment, restructuring, and other special charges recognized during the year ended December&#160;31, 2022 were primarily related to an intangible asset impairment for GBA1 Gene Therapy (PR001), acquired in the Prevail acquisition, as a result of changes in key assumptions used in the valuation due to delays in estimated launch timing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we recognized $128.0 million of intangible asset impairment as a result of the decision by Bayer AG to discontinue the development of a Phase I molecule related to a contract-based intangible asset from our acquisition of Loxo Oncology, Inc. Additionally, we recognized $108.1 million of intangible asset impairment from the sale of the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. </span></div>Severance costs recognized during the year ended December 31, 2020 were incurred as a result of actions taken worldwide to reduce our cost structure.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525671072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost. Inventories measured using LIFO must be valued at the lower of cost or market. Inventories measured using FIFO must be valued at the lower of cost or net realizable value. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories at December&#160;31 consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">901.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,597.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">801.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates replacement cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,300.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,851.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase to LIFO cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,309.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,886.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories valued under the LIFO method comprised $1.23 billion and $1.36 billion of total inventories at December&#160;31, 2022 and 2021, respectively.</span></div>We recognized a net inventory impairment charge related to our COVID-19 antibodies of $339.7 million during the year ended December 31, 2021 in cost of sales in our consolidated statements of operations. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic evolved during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to demand from U.S. and international governments, including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525679360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments in Equity and Debt Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded for the years ended December&#160;31, 2022, 2021, and 2020 were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net gains (losses) recognized in our consolidated statements of operations for equity securities were $(410.7)&#160;million, $176.9&#160;million, and $1.44&#160;billion for the years ended December&#160;31, 2022, 2021, and 2020, respectively. The net gains (losses) recognized for the years ended December&#160;31, 2022, 2021, and 2020 on equity securities sold during the respective periods were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had approximately $957&#160;million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to 10 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our available-for-sale debt securities at fair value, with changes in fair value reported as a component of accumulated other comprehensive income (loss). We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the years ended December&#160;31, 2022, 2021, and 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December&#160;31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.552%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More Than 10 Years</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">568.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 99 percent of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of December&#160;31, 2022, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of a material default on interest or principal payments for our debt securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">132.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value of Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain fair value information at December&#160;31, 2022 and 2021 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">657.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">657.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">650.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">657.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">31.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">53.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">53.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">53.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">53.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">58.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">58.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">39.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">58.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">144.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="36" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">146.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">163.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">146.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">146.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">213.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">235.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">213.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">213.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">149.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">161.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">149.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">149.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">52.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">398.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">34.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">311.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">398.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">683.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">484.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">683.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">683.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">478.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">781.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,901.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,379.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,379.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,361.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,379.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.1&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,279.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">487.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,279.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,279.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,212.6&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. Fair values are not readily available for certain equity investments measured under the measurement alternative.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Debt</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain fair value information at December&#160;31, 2022 and 2021 for our short-term and long-term debt:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:37.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term commercial paper borrowings</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,498.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,492.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,492.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(14,740.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,329.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,329.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,884.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,157.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,157.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Management and Related Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions.&#160;We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their investment grade credit ratings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $422.1 million and $550.5 million&#160;of accounts receivable as of December&#160;31, 2022 and 2021, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated results of operations for the years ended December&#160;31, 2022, 2021, and 2020 were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive income (loss) (see Note 17) and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive income (loss) (see Note 17). Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, Chinese yuan, Japanese yen, and Swiss franc). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At December&#160;31, 2022, we had outstanding foreign currency forward commitments as follows, all of which have settlement dates within 180 days:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.487%"><tr><td style="width:1.0%"/><td style="width:23.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.440%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchase</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sell</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,516.2</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,575.3</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.8</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chinese yuan</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,139.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.3</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.9</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,212.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British pounds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.7</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.4</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.3</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange risk is also managed through the use of foreign currency debt, cross-currency interest rate swaps, and foreign currency forward contracts. Our foreign currency-denominated notes had carrying amounts of $6.83 billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.90&#160;billion as of December&#160;31, 2022 and 2021, respectively, of which $5.45&#160;billion and $5.79&#160;billion have been designated as, and are effective as, economic hedges of net investments in certain of our foreign operations as of December&#160;31, 2022 and 2021, respectively. At December&#160;31, 2022, we had outstanding cross currency swaps with notional amounts of $1.02 billion swapping U.S. dollars to euro and $1.00&#160;billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed-rate debt to foreign-denominated fixed rate debt, have also been designated as, and are effective as, economic hedges of net investments. At December&#160;31, 2022, we had outstanding foreign currency forward contracts to sell 325.0 million euro and to sell 1.82 billion Chinese yuan, with settlement dates ranging through 2023, which have been designated as, and are effective as, economic hedges of net investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows. At December&#160;31, 2022, substantially all of our total long-term debt is at a fixed rate. We have converted approximately 10 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss) (see Note 17) and, upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of December&#160;31, 2022, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $1.85&#160;billion, which have settlement dates ranging between 2023 and 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">The Effect of Risk Management Instruments on the Consolidated Statements of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(209.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">191.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">216.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209.7)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021, and 2020, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">324.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(404.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">391.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the next 12 months, we expect to reclassify $16.8 million of pretax net losses on cash flow hedges from accumulated other comprehensive income (loss) to other&#8211;net, (income) expense. During the years ended December&#160;31, 2022, 2021, and 2020, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value of Risk-Management Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain fair value information at December&#160;31, 2022 and 2021 for risk-management assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:40.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.898%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:40.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.898%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.</span></div>Contingent consideration liabilities relate to our liabilities arising in connection with the CVRs issued as a result of both the Akouos and Prevail acquisitions. The fair values of the CVR liabilities were estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payments associated with the agreed upon regulatory milestones based on probabilities of technical success, timing of the potential milestone events for the compounds, and estimated discount rates. See Note 3 for additional information related to the CVR arrangements for both Akouos and Prevail.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525600304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangibles</a></td>
<td class="text">Goodwill and Other Intangibles<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value to its carrying value is performed to determine the amount of any impairment. The change in goodwill during 2022 was primarily related to our acquisition of Akouos. See Note 3 for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No impairments occurred with respect to the carrying value of goodwill for the years ended December&#160;31, 2022, 2021, and 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Intangibles</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of intangible assets other than goodwill at December&#160;31 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:26.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,922.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,589.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,332.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,987.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,229.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,758.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(32.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,957.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,622.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,334.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,056.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,289.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,766.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,871.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,871.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,829.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,622.7)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,206.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,981.6&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,289.7)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,691.9&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction (U.S., Europe, and Japan) and capitalized milestone payments. For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other finite-lived intangible assets consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies, and customer relationships from business combinations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D consists of the fair values of acquired IPR&amp;D projects acquired in business combination, adjusted for subsequent impairments, if any. The costs of acquired IPR&amp;D projects acquired directly in a transaction other than a business combination are capitalized as other intangible assets if the projects have an alternative future use; otherwise, they are expensed immediately. See Note 3 for significant acquired IPR&amp;D projects that had no alternative future use. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the "income method," which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, analyst expectations, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&amp;D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in acquired IPR&amp;D intangibles in 2022 is due to the impairment of an intangible asset for GBA1 Gene Therapy (PR001). See Note 5 for additional information. This decrease was partially offset by acquired IPR&amp;D assets recognized from the acquisition of Akouos. See Note 3 for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&amp;D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives are capitalized and are amortized primarily to cost of sales over their estimated useful lives, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzQ4OTk_d5717d76-4a43-4c49-bf30-1707e388a603">one</span> to 20 years. As of December&#160;31, 2022, the remaining weighted-average amortization period for finite-lived intangible assets was approximately 13 years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to finite-lived intangible assets was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">579.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December&#160;31, 2022 is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.517%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated amortization expense</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447.7&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525573120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzI3Mg_0bc998e4-b996-4544-9f0f-ef94e39f535f">three</span> to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value, and the cost basis is adjusted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, property and equipment consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">256.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,915.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,588.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,406.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,937.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,798.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,177.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,377.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,961.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,233.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,976.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,144.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,985.1&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">816.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized interest costs were not material for the years ended December&#160;31, 2022, 2021, and 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-lived assets by geographical area:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.248%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,709.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,620.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,898.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,702.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,625.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,691.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,234.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,013.3&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment, net, operating lease assets, and certain other noncurrent assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525651712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. We have leases with terms up to 14 years primarily for corporate offices, research and development facilities, vehicles, and equipment, including some of which have options to extend and/or early-terminate the leases. We determine the lease term by assuming the exercise of any renewal and/or early-termination options that are reasonably assured.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets are presented as other noncurrent assets in our consolidated balance sheets, and the current and long-term portions of operating lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, in our consolidated balance sheets. Short-term leases, which are deemed at inception to have a lease term of 12 months or less, are not recorded on the consolidated balance sheets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets represent our right to use an underlying asset for the lease term, and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for operating lease assets, which is recognized on a straight-line basis over the lease term, was $148.8 million, $159.4 million, and $154.6 million during the years ended December&#160;31, 2022, 2021, and 2020, respectively. Variable lease payments, which represent non-lease components such as maintenance, insurance and taxes, and which vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the payment obligation is incurred and were not material during the years ended December&#160;31, 2022, 2021, and 2020. Short-term lease expense was not material during the years ended December&#160;31, 2022, 2021, and 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases as of December&#160;31, 2022 and 2021 was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.801%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.950%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2022, 2021, and 2020 was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">155.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.7</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2022 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.740%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzktMC0xLTEtMTk3MTgy_8ddc8d02-9a67-4865-bc1c-83f42fdd1643">Total</span></span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728.2&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases are included in property and equipment, short-term borrowings and current maturities of long-term debt, and long-term debt in our consolidated balance sheets. Finance leases are not material to our consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. We have leases with terms up to 14 years primarily for corporate offices, research and development facilities, vehicles, and equipment, including some of which have options to extend and/or early-terminate the leases. We determine the lease term by assuming the exercise of any renewal and/or early-termination options that are reasonably assured.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets are presented as other noncurrent assets in our consolidated balance sheets, and the current and long-term portions of operating lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, in our consolidated balance sheets. Short-term leases, which are deemed at inception to have a lease term of 12 months or less, are not recorded on the consolidated balance sheets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets represent our right to use an underlying asset for the lease term, and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for operating lease assets, which is recognized on a straight-line basis over the lease term, was $148.8 million, $159.4 million, and $154.6 million during the years ended December&#160;31, 2022, 2021, and 2020, respectively. Variable lease payments, which represent non-lease components such as maintenance, insurance and taxes, and which vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the payment obligation is incurred and were not material during the years ended December&#160;31, 2022, 2021, and 2020. Short-term lease expense was not material during the years ended December&#160;31, 2022, 2021, and 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases as of December&#160;31, 2022 and 2021 was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.801%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.950%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2022, 2021, and 2020 was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">155.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.7</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2022 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.740%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzktMC0xLTEtMTk3MTgy_8ddc8d02-9a67-4865-bc1c-83f42fdd1643">Total</span></span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728.2&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases are included in property and equipment, short-term borrowings and current maturities of long-term debt, and long-term debt in our consolidated balance sheets. Finance leases are not material to our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525659984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt at December&#160;31 consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term commercial paper borrowings</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,498.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term notes </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,815.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,741.2</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(77.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment on hedged long-term notes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,238.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,884.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,501.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,538.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,737.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,346.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average effective borrowing rate on short-term commercial paper borrowings at December 31, 2022 was 4.20 percent.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-term notes at December 31:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.640%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.179%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.35% notes due 2022</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.00% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.00% euro denominated notes due 2022</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">678.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.15% Swiss franc denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">649.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">654.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.125% notes due 2025</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">217.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">217.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.75% notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">560.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">560.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.625% euro denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">799.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">847.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.5% notes due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">364.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">364.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.1% notes due 2027</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">401.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">401.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.45% Swiss franc denominated notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">433.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">436.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.375% notes due 2029</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">930.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">930.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.42% Japanese yen denominated notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">172.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">199.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.125% euro denominated notes due 2030</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">799.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">847.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.625% euro denominated notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">639.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">678.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.50% euro denominated notes due 2033</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">639.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">678.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.56% Japanese yen denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">69.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">80.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.77% notes due 2036</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">158.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">158.6&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.55% notes due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">444.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">444.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.95% notes due 2037</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">266.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">266.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.875% notes due 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">240.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">240.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.625% British pound denominated notes due 2043</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">301.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">337.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.65% notes due 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">38.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.7% notes due 2045</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">386.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">386.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.95% notes due 2047</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">347.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">347.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.95% notes due 2049</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">958.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">958.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.70% euro denominated notes due 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,065.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,130.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.97% Japanese yen denominated notes due 2049</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">57.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.25% notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,250.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.125% euro denominated notes due 2051</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">532.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">565.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.15% notes due 2059</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">591.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">591.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.50% notes due 2060</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">850.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.375% euro denominated notes due 2061</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">746.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">791.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unamortized note discounts</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(96.1)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(105.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total long-term notes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">14,815.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16,741.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average effective borrowing rate for each issuance of the long term-notes approximates the stated interest rate. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had a total of $7.33 billion of unused committed bank credit facilities, which consisted primarily of a $3.00 billion credit facility that expires in December 2026 and a $4.00&#160;billion 364-day facility that expires in September 2023, both of which are available to support our commercial paper program. We have not drawn against the $3.00 billion and $4.00 billion facilities as of December&#160;31, 2022. Of the remaining committed bank credit facilities, the outstanding balances as of December&#160;31, 2022 and 2021 were not material. Compensating balances and commitment fees are not material, and there are no conditions that are probable of occurring under which the lines may be withdrawn. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we issued euro-denominated notes consisting of &#8364;600.0&#160;million of 0.50 percent fixed-rate notes due in September 2033, with interest to be paid annually. The net proceeds from the offering have been, and will continue to be, used to fund, in whole or in part, eligible projects designed to advance one or more of our environmental, social, and governance objectives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we issued euro-denominated notes consisting of &#8364;500.0&#160;million of 1.125 percent fixed-rate notes due in September 2051 and &#8364;700.0&#160;million of 1.375 percent fixed-rate notes due in September 2061, with interest to be paid annually, and British pound-denominated notes consisting of &#163;250.0&#160;million of 1.625 percent fixed-rate notes due in September 2043, with interest to be paid annually. We paid $1.91&#160;billion of the net cash proceeds from the offering to purchase and redeem certain higher interest rate U.S. dollar-denominated notes with an aggregate principal amount of $1.50&#160;billion, resulting in a debt extinguishment loss of $405.2&#160;million. This loss was included in other-net, (income) expense in our consolidated statement of operations for the year ended December 31, 2021. The $1.50&#160;billion principal amount of higher interest rate U.S. dollar-denominated notes that were redeemed primarily included $541.8&#160;million of 3.95 percent notes due 2049, $408.7&#160;million of 4.15 percent notes due 2059, and $219.4&#160;million of 3.375 percent notes due 2029. We used the remaining net proceeds from the offering to prefund certain 2022 debt maturities and for general corporate purposes. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we issued $1.00&#160;billion of 2.25 percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $988.6 million for general corporate purposes, including the repayment of outstanding commercial paper. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we issued $850.0 million of 2.50 percent fixed-rate notes due in September 2060 and an additional $250.0 million of our 2.25 percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $1.07 billion for general corporate purposes, including the repayment of outstanding commercial paper. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amounts of maturities on long-term debt for the next five years are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:49.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.180%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities on long-term debt</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have converted approximately 10 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. The weighted-average effective borrowing rates based on long-term debt obligations and interest rates at December&#160;31, 2022 and 2021, including the effects of interest rate swaps for hedged debt obligations, were 2.87 percent and 2.27 percent, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments for interest on borrowings</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">323.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the requirements of derivatives and hedging guidance, the portion of our fixed-rate debt obligations that is hedged as a fair value hedge is reflected in the consolidated balance sheets as an amount equal to the sum of the debt's carrying value plus the fair value adjustment representing changes in fair value of the hedged debt attributable to movements in market interest rates subsequent to the inception of the hedge.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206528972944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock-based compensation expense consists of performance awards (PAs), shareholder value awards (SVAs), relative value awards (RVAs), and restricted stock units (RSUs). We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, RVA, and RSU shares.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense and the related tax benefits were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">371.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, stock-based compensation awards may be granted under the 2002 Lilly Stock Plan for not more than 50.0 million additional shares. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Award Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain pre-established earnings-per-share targets over a two-year period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period. The fair values of PAs granted for the years ended December&#160;31, 2022, 2021, and 2020 were $234.93, $198.57, and $137.33, respectively. The number of shares ultimately issued for the PA program is dependent upon the EPS achieved during the vesting period. Pursuant to this program, approximately 0.7 million shares, 0.7 million shares, and 1.1&#160;million shares were issued during the years ended December&#160;31, 2022, 2021, and 2020, respectively. Approximately 0.5 million shares are expected to be issued in 2023. As of December&#160;31, 2022, the total remaining unrecognized compensation cost related to nonvested PAs was $38.4 million, which will be amortized over the weighted-average remaining requisite service period of 12 months.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Value Award Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SVAs are granted to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on our stock price at the end of the three-year vesting period compared to pre-established target stock prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair values of the SVA units granted during the years ended December&#160;31, 2022, 2021, and 2020 were $203.88, $230.19, and $139.14, respectively, determined using the following assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32.99</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.42&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.90&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this program, approximately 0.5 million shares, 1.0 million shares, and 0.8 million shares were issued during the years ended December&#160;31, 2022, 2021, and 2020, respectively. Approximately 0.3&#160;million shares are expected to be issued in 2023. As of December&#160;31, 2022, the total remaining unrecognized compensation cost related to nonvested SVAs was $43.3 million, which will be amortized over the weighted-average remaining requisite service period of 21 months.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Relative Value Award Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RVAs are granted to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on the growth of our stock price at the end of the three-year vesting period compared to our peers. We measure the fair value of the RVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price and our peers' stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair value of the RVA units granted during the years ended December&#160;31, 2022, 2021 and 2020 were $230.00, $286.71, and $179.90, respectively, determined using the following assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32.86</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.95&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.89&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 0.1 million shares are expected to be issued in 2023. As of December&#160;31, 2022, the total remaining unrecognized compensation cost related to nonvested RVAs was $17.5 million, which will be amortized over the weighted-average remaining requisite service period of 22 months.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically three years. The weighted-average fair values of RSU awards granted during the years ended December&#160;31, 2022, 2021, and 2020 were $239.88, $196.30, and $135.42, respectively. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures. Pursuant to this program, 1.0 million, 0.7 million, and 1.1 million shares were granted and approximately 0.8 million, 0.6 million, and 0.6 million shares were issued during the years ended December&#160;31, 2022, 2021, and 2020, respectively. Approximately 0.6 million shares are expected to be issued in 2023. As of December&#160;31, 2022, the total remaining unrecognized compensation cost related to nonvested RSUs was $221.6 million, which will be amortized over the weighted-average remaining requisite service period of 25 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525649792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders' Equity<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, 2021, and 2020, we repurchased $1.50 billion, $1.25 billion, and $500.0 million, respectively, of shares associated with our share repurchase programs. As of December&#160;31, 2022, we had $3.25 billion remaining under our $5.00 billion share repurchase program that our board authorized in May 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have 5.0 million authorized shares of preferred stock. As of December&#160;31, 2022 and 2021, no preferred stock was issued.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an employee benefit trust that held 50.0 million shares of our common stock at both December&#160;31, 2022 and 2021, to provide a source of funds to assist us in meeting our obligations under various employee benefit plans. The cost basis of the shares held in the trust was $3.01&#160;billion at both December&#160;31, 2022 and 2021, and is shown as a reduction of shareholders' equity. Any dividend transactions between us and the trust are eliminated. Stock held by the trust is not considered outstanding in the computation of EPS. The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended December&#160;31, 2022, 2021, and 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525759472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Deferred taxes related to global intangible low-taxed income (GILTI) are also recognized for the future tax effects of temporary differences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position, based on its technical merits, will be sustained upon examination by the taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is the composition of income tax expense:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,153.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">547.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,746.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,992.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(977.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(78.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(114.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,185.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(802.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">561.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573.8&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036.2&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The 2022, 2021, and 2020 current tax expense includes $189.5 million, $64.7 million, and $144.4 million of tax benefit, respectively, from utilization of net operating loss and other tax carryforwards. </span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities as of December&#160;31 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,071.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,347.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">427.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">477.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss and other tax carryforwards and carrybacks</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">626.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,312.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Correlative tax adjustments</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">752.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax redeterminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">267.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">147.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,615.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">361.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,059.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,662.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowances</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(775.1)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(875.6)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,284.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,786.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings of foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,226.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,583.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,387.9)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,516.1)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(639.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(596.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid employee benefits</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(546.5)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(560.6)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(433.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial instruments</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(215.0)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303.0)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(130.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,579.1)</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,030.7)</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets - net</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,705.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred tax asset and related valuation allowance amounts for U.S. federal, international, and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, based on filed tax returns we have tax credit carryforwards and carrybacks of $873.6&#160;million available to reduce future income taxes; $148.8 million, if unused, will expire by 2026, and $27.1&#160;million, if unused, will expire between 2028 and 2042. The remaining portion of the tax credit carryforwards is related to federal tax credits of $68.6 million, international tax credits of $118.6&#160;million, and state tax credits of $510.5 million, all of which are fully reserved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, based on filed tax returns we had net operating losses and other carryforwards for international and U.S. federal income tax purposes of $2.52 billion: $319.1 million will expire by 2027; $1.44&#160;billion will expire between 2028 and 2042; and $762.0 million of the carryforwards will never expire. Net operating losses and other carryforwards for international and U.S. federal income tax purposes are partially reserved. Deferred tax assets related to state net operating losses and other carryforwards of $246.2&#160;million are fully reserved as of December&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, prepaid expenses and other current assets included prepaid taxes of $2.37&#160;billion and $1.98 billion, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic and Puerto Rican companies contributed approximately 33 percent, 28 percent, and 39 percent for the years ended December&#160;31, 2022, 2021, and 2020, respectively, to consolidated income before income taxes. We have a subsidiary operating in Puerto Rico under a tax incentive grant effective through the end of 2031, which was amended in 2022 to apply the alternate tax regime established by recently enacted Puerto Rico legislation starting in 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Substantially all of the unremitted earnings of our foreign subsidiaries are considered not to be indefinitely reinvested for continued use in our foreign operations. At December&#160;31, 2022 and 2021, we accrued an immaterial amount of foreign withholding taxes and state income taxes that would be owed upon future distributions of unremitted earnings of our foreign subsidiaries that are not indefinitely reinvested. For the amount considered to be indefinitely reinvested, it is not practicable to determine the amount of the related deferred income tax liability due to the complexities in the tax laws and assumptions we would have to make.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments of U.S. federal, state, and foreign income taxes, net of refunds, were as follows: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments of income taxes</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,672.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Tax Cuts and Job Act (2017 Tax Act) was signed into law. The 2017 Tax Act included significant changes to the U.S. corporate income tax system, including a one-time repatriation transition tax (also known as the 'Toll Tax') on unremitted foreign earnings. The 2017 Tax Act provided an election to taxpayers subject to the Toll Tax to make payments over an eight-year period beginning in 2018 through 2025. Having made this election, our future cash payments relating to the Toll Tax as of December&#160;31, 2022 are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.764%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.253%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 1 Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-3 Years</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Tax Act Toll Tax</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we have additional noncurrent income tax payables of $2.28&#160;billion unrelated to the Toll Tax; we cannot reasonably estimate the timing of future cash outflows associated with these liabilities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a reconciliation of the consolidated income tax expense applying the U.S. federal statutory rate to income before income taxes to reported consolidated income tax expense: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at the U.S. federal statutory tax rate</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,429.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add (deduct):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations, including Puerto Rico</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(299.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(447.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(155.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(287.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance release</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(116.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">561.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes the impact of Puerto Rico Excise Tax, GILTI tax, and other U.S. taxation of foreign income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January&#160;1</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,798.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,551.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">274.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(44.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapses of statutes of limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes related to the impact of foreign currency translation</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(52.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,987.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,798.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,551.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was $1.70&#160;billion at both December&#160;31, 2022 and 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file U.S. federal, foreign, and various state and local income tax returns. We are no longer subject to U.S. federal income tax examination for years before 2016. In most major foreign and state jurisdictions, we are no longer subject to income tax examination for years before 2012.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. examination of tax years 2016-2018 began in 2019 and remains ongoing. While it is reasonably possible that the Internal Revenue Service examination of these tax years could conclude within the next 12 months, final resolution of certain matters is dependent upon several factors, including the potential for formal administrative proceedings. As a result, an estimate of the range of reasonably possible changes in unrecognized tax benefits cannot be made. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to unrecognized tax benefits are recognized in income tax expense and were not material for the years ended December&#160;31, 2022, 2021, and 2020. Our accrued interest and penalties related to unrecognized tax benefits were $271.5&#160;million and $220.1&#160;million at December&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525673504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Benefits</a></td>
<td class="text">Retirement Benefits<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a measurement date of December&#160;31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December&#160;31 for our defined benefit pension and retiree health benefit plans, which were as follows: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,565.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,225.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,663.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,753.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">351.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">398.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,158.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(395.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(608.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(86.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other adjustments</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(325.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at end of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,222.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,565.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,258.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,663.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,416.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,579.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,361.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,227.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,388.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,458.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(796.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(608.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(86.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(341.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,195.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,416.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,492.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,361.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(26.2)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,149.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,233.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,687.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,908.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(497.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized prior service (benefit) cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(62.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,669.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,770.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,226.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in the consolidated balance sheet consisted&#160;of:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,208.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,383.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,910.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(70.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,163.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,749.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(141.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (income) loss before income taxes</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,695.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(614.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,669.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,770.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,226.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized net actuarial (gain) loss and unrecognized prior service (benefit) cost have not yet been recognized in net periodic pension costs and were included in accumulated other comprehensive loss at December&#160;31, 2022 and 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $4.75&#160;billion and $750.4&#160;million declines in benefit obligation in 2022 and 2021, respectively, were both driven primarily by increases in the discount rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents our weighted-average assumptions as of December&#160;31:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate for benefit obligation</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate for net benefit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase for benefit obligation</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase for net benefit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets for net benefit costs</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We annually evaluate the expected return on plan assets in our defined benefit pension and retiree health benefit plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the design of our retiree health benefit plans, healthcare-cost trend rates do not have a material impact on our financial condition or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028-2032</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension plans</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,079.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retiree health benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,211.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,360.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">977.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.758%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health <br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,721.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,532.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">652.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total accumulated benefit obligation for our defined benefit pension plans was $12.01 billion and $16.44&#160;billion at December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit expense included the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:38.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.375%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic (benefit) cost:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">351.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">398.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(947.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(949.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(901.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(152.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (benefit) cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(54.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">342.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">147.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.6&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.6&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(121.6)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120.9)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136.1)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents the amounts recognized in other comprehensive income (loss) for the years ended December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, and 2020:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.320%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined&#160;Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree&#160;Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss) arising during period</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">823.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,072.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(663.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(552.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (benefit) cost included in net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(54.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial (gain) loss included in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">342.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">55.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss) during period</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,223.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335.9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(607.0)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have defined contribution savings plans that cover our eligible employees worldwide. The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plans are based on employee contributions and the level of our match. Expenses under the plans totaled $170.6 million, $167.3 million, and $164.3 million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide certain other postemployment benefits primarily related to disability benefits and accrue for the related cost over the service lives of employees. Expenses associated with these benefit plans for the years ended December&#160;31, 2022, 2021, and 2020 were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Benefit Plan Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. U.S. and Puerto Rico plans represent approximately 85 percent of our global investments. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control, and limit concentrations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our portfolio to minimize concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global benefit plans may enter into contractual arrangements (derivatives) to implement the local investment policy or manage particular portfolio risks. Derivatives are principally used to increase or decrease exposure to a particular public equity, fixed income, commodity, or currency market more rapidly or less expensively than could be accomplished through the use of the cash markets. The plans utilize both exchange-traded and over-the-counter instruments. The maximum exposure to either a market or counterparty credit loss is limited to the carrying value of the receivable, and is managed within contractual limits. We expect all of our counterparties to meet their obligations. The gross values of these derivative receivables and payables are not material to the global asset portfolio, and their values are reflected within the tables below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The defined benefit pension and retiree health benefit plan allocation for the U.S. and Puerto Rico currently comprises approximately 75 percent growth investments and 25 percent fixed-income investments. The growth investment allocation encompasses U.S. and international public equity securities, hedge funds, private equity-like investments, and real estate. These portfolio allocations are intended to reduce overall risk by providing diversification, while seeking moderate to high returns over the long term.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public equity securities are well diversified and invested in U.S. and international small-to-large companies across various asset managers and styles. The remaining portion of the growth portfolio is invested in private alternative investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed-income investments primarily consist of fixed-income securities in U.S. treasuries and agencies, emerging market debt obligations, corporate bonds, bank loans, mortgage-backed securities, commercial mortgage-backed obligations, and any related repurchase agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hedge funds are privately owned institutional investment funds that generally have moderate liquidity. Hedge funds seek specified levels of absolute return regardless of overall market conditions, and generally have low correlations to public equity and debt markets. Hedge funds often invest substantially in financial market instruments (stocks, bonds, commodities, currencies, derivatives, etc.) using a very broad range of trading activities to manage portfolio risks. Hedge fund strategies focus primarily on security selection and seek to be neutral with respect to market moves. Common groupings of hedge fund strategies include relative value, tactical, and event driven. Relative value strategies include arbitrage, when the same asset can simultaneously be bought and sold at different prices, achieving an immediate profit. Tactical strategies often take long and short positions to reduce or eliminate overall market risks while seeking a particular investment opportunity. Event strategy opportunities can evolve from specific company announcements such as mergers and acquisitions, and typically have little correlation to overall market directional movements. Our hedge fund investments are made through limited partnership interests in fund-of-funds structures and directly into hedge funds. Plan holdings in hedge funds are valued based on net asset values (NAVs) calculated by each fund or general partner, as applicable, and we have the ability to redeem these investments at NAV.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private equity-like investment funds typically have low liquidity and are made through long-term partnerships or joint ventures that invest in pools of capital invested in primarily non-publicly traded entities. Underlying investments include venture capital (early stage investing), buyout, special situations, private debt, and private real estate investments. Private equity management firms typically acquire and then reorganize private companies to create increased long term value. Private equity-like funds usually have a limited life of approximately 10-15 years, and require a minimum investment commitment from their limited partners. Our private equity-like investments are made both directly into funds and through fund-of-funds structures to ensure broad diversification of management styles and assets across the portfolio. Plan holdings in private equity-like investments are valued using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual audited financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Real estate is composed of public holdings. Real estate investments in registered investment companies that trade on an exchange are classified as Level 1 on the fair value hierarchy. Real estate investments in funds measured at fair value on the basis of NAV provided by the fund manager are classified as such. These NAVs are developed with inputs including discounted cash flow, independent appraisal, and market comparable analyses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets include cash and cash equivalents and mark-to-market value of derivatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash value of the trust-owned insurance contract is primarily invested in investment-grade publicly traded equity and fixed-income securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than hedge funds, private equity-like investments, and a portion of the real estate holdings, which are discussed above, we determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2022 by asset category were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:30.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices in Active Markets&#160;for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Observable&#160;<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investments Valued at Net Asset Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,445.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,058.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets - repurchase agreements</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(706.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(713.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,014.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,988.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,261.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,195.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,335.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash value of trust owned insurance contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,492.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December&#160;31, 2022. The activity in the Level 3 investments during the year ended December&#160;31, 2022 was not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2021 by asset category were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:30.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices in Active Markets&#160;for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investments Valued at Net Asset Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,722.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,907.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,496.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,356.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets - repurchase agreements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,816.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,808.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,416.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,170.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash value of trust owned insurance contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,166.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,166.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,361.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,290.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December&#160;31, 2021. The activity in the Level 3 investments during the year ended December&#160;31, 2021 was not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we expect to contribute approximately $30 million to our defined benefit pension plans to satisfy minimum funding requirements for the year. We do not currently expect to make material discretionary contributions in 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525614752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the final outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Alimta European Patent Litigation</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Alimta (pemetrexed)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was protected by a patent through June 2021. A number of legal proceedings that were initiated prior to patent expiration are ongoing</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Emgality Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a named defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts seeking a ruling that various claims in three different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following a trial, in November 2022, a jury returned a verdict in favor of Teva. The parties have filed post-trial motions on which the court will rule and then enter final judgment in the case. We intend to appeal the jury verdict if necessary. Pursuant to agreement by the parties, the award, if any, will not become due until completion of the appeal process. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we were named as a defendant in a second litigation filed by Teva in the U.S. District Court for the District of Massachusetts seeking a ruling that two of Teva's patents, which are directed toward use of the active ingredient in Emgality to treat migraine, would be infringed by our continued sales of Emgality. We challenged these two patents by filing requests for Inter Partes Review with the Patent Trial and Appeal Board (PTAB) and in October 2022, the PTAB granted our requests.The corresponding district court litigation is stayed while this PTAB proceeding is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Boehringer Ingelheim, our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court for the District of Delaware alleging infringement arising from submissions of Abbreviated New Drug Applications (ANDA) by a number of generic companies seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, the generic companies' ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. This litigation has been stayed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Taltz Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in May 2020, Lilly and Novartis Pharma AG (Novartis) had been litigating the validity and alleged infringement by Taltz of certain patents Novartis acquired from Genentech, Inc. (Genentech). As of October 2022, we had pending cases in Ireland, Italy, Switzerland, and the Netherlands where Novartis sought injunctions to stop Taltz commercialization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we entered into a cashless (no-payment) settlement and mutual release agreement with Novartis, which resolved such disputes. Without any admission of liability or wrongdoing, we and Novartis have agreed to mutual releases for past claims and mutual covenants not to sue the other in relation to Taltz and the patents Novartis purchased from Genentech. This matter is closed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Zyprexa Canada Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the mid-2000s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trademark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgment, thereby dismissing Apotex's case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021. In August 2022, the Court dismissed the appeal and in October 2022, Apotex appealed the decision. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Byetta&#174; Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in over 500 Byetta product liability lawsuits in the U.S. that were first initiated in March 2009 and involved over 800 plaintiffs. These lawsuits have been filed in various state and federal jurisdictions, including California state court (coordinated in Los Angeles County Superior Court), and various federal courts, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. The majority of these suits contained allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer). All of the MDL and state court lawsuits have been dismissed as of January 2023 and we consider these matters closed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Proceedings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than 10 sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">340B Litigation and Investigations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies and HHS's Administrative Dispute Resolution regulations. We seek a declaratory judgment that the defendants violated the Administrative Procedure Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government's enforcement of the administrative dispute resolution process against us. In May 2021, HRSA notified us that it determined that our policy was contrary to the 340B statute. In response, in May 2021, we amended our complaint to bring claims related to HRSA's determination and filed a motion for preliminary injunction and temporary restraining order requesting that the U.S. District Court for the Southern District of Indiana enjoin defendants from taking any action against us relating to the 340B drug pricing program until after the court issues a final judgment on the aforementioned litigation. In May 2021, the court denied our motion for a temporary restraining order but deferred resolution of our motion for preliminary injunction. In June 2021, the defendants withdrew the HHS December 30, 2020 advisory opinion. In July 2021, the court held oral argument on the parties' cross motions for summary judgment, the defendants' motion to dismiss, and our motion for preliminary injunction related to HRSA's May 2021 enforcement letter. In October 2021, the court denied the defendants' motion to dismiss, and granted in part and denied in part the parties' cross motions for summary judgment. Both parties filed notices of appeal related to the court's summary judgment order. In October 2022, the U.S. Court of Appeals for the Seventh Circuit held oral argument. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administrative Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government's enforcement of this administrative dispute resolution process against us. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we, along with Sanofi-Aventis U.S., LLC (Sanofi), Novo Nordisk Inc. (Novo Nordisk), and AstraZeneca Pharmaceuticals LP, were named as a defendant in a purported class action lawsuit filed in the U.S. District Court for the Western District of New York by Mosaic Health, Inc. alleging antitrust and unjust enrichment claims related to the defendants' 340B distribution programs. We, with Sanofi and Novo Nordisk, filed a motion to dismiss the lawsuit, which was granted in September 2022. In October 2022, the plaintiffs filed a motion for leave to amend their complaint. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a civil investigative subpoena in February 2021 from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Branchburg Manufacturing Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received a subpoena from the U.S. Department of Justice requesting the production of certain documents relating to our manufacturing site in Branchburg, New Jersey. We are cooperating with the subpoena.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Brazil Litigation &#8211; Cosmopolis Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Labor Attorney Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a Public Civil Action brought by the Labor Public Attorney (LPA) for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, (the Labor Court) alleging possible harm to employees and former employees caused by alleged exposure to soil and groundwater contaminants at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the Labor Court judge ruled against Lilly Brasil, ordering it to undertake several remedial and compensatory actions including health coverage for a class of individuals and certain of their children. In July 2018, the appeals court (TRT) generally affirmed our appeal of the Labor Court's ruling, which included a liquidated award of 300 million Brazilian reais, which, when adjusted for inflation and the addition of pre and post judgment interest using the current Central Bank of Brazil's special system of clearance and custody rate, is approximately one billion Brazilian reais (approximately $184&#160;million as of December&#160;31, 2022). In August 2019, Lilly Brasil filed an appeal to the superior labor court (TST) and in June 2021, the TRT published its decision on the admissibility of Lilly Brasil's appeal, allowing the majority of the elements, which were allowed to proceed in June 2021; elements not proceeding are subject to an interlocutory appeal to the TST that was filed in June 2021. In September 2019, the TRT stayed a number of elements of its trial court decision pending the determination of Lilly Brasil's appeal to the TST.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019 and September 2020, the LPA filed applications in the Labor Court for enforcement of certain remedies granted by the TRT in its July 2018 decision, requested restrictions on Lilly Brasil&#8217;s assets in Brazil, and required Lilly Brasil and Antibi&#243;ticos do Brasil Ltda. (ABL) to submit a list of potential beneficiaries of the Public Civil Action. In July 2019, the Labor Court issued a ruling requiring a freeze of Lilly Brasil&#8217;s immovable property or, alternatively, a security deposit or lien of 500 million Brazilian reais, which ruling was subsequently limited in scope and the security was reduced to 100 million Brazilian reais. ABL and LPA appealed the June 2021 Labor Court ruling to the TST, which appeal is under review. The Labor Court is currently assessing the status of Lilly Brasil&#8217;s and ABL&#8217;s compliance with such portion of the July 2018 TRT decision and an inspection in the industrial plant is expected. These matters are ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Individual Former Employee Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly Brasil is also named in various pending lawsuits filed in the Labor Court by individual former employees making related claims. These individual lawsuits are at various stages in the litigation process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Puerto Rico Tax Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2013, the Municipality of Carolina in Puerto Rico (Municipality) filed a lawsuit against us alleging noncompliance with respect to a contract with the Municipality and seeking a declaratory judgment. In December 2020, the Puerto Rico Appellate Court (AP) reversed the summary judgment previously granted by the Court of First Instance (CFI) in our favor, dismissing the Municipality's complaint in its entirety. The AP remanded the case to the CFI for trial on the merits. The trial began in May 2022; however, the Municipality filed a new motion requesting the CFI to award damages. The request was denied by the CFI in our favor and the Municipality filed for revision at the AP, which we opposed, staying the case. In February 2023, the AP denied the Municipality's motion for revision. This matter is ongoing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Average Manufacturer Price Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, we, along with another pharmaceutical manufacturer, were named as co-defendants in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Following a trial in August 2022, the jury returned a verdict in favor of the plaintiff. The case is proceeding with post-trial motions after which the court will enter final judgment in the case. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Health Choice Alliance </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in two lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively, for certain patient support programs related to our products Humalog, Humulin, and Forteo. The Texas state court action has been stayed. The New Jersey state court action was dismissed with prejudice pending an ongoing appeal before the Appellate Division of the New Jersey Superior Court. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pricing Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, along with Sanofi, Novo Nordisk, and in some matters certain pharmacy benefit managers, have been named in lawsuits related to insulin pricing that assert various theories, including consumer protection, fraud, false advertising, unjust enrichment, civil conspiracy, federal and state RICO statutes, deceptive trade practices, and unfair competition claims. These lawsuits include In re. Insulin Pricing Litigation, a putative consumer class action (U.S. District Court for the District of New Jersey, 2017); </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (U.S. District Court for the District of New Jersey, 2018); </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a putative class action brought by direct purchasers of insulin (U.S. District Court for the District of New Jersey, 2020), and suits brought by the State of Minnesota (U.S. District Court for the District of New Jersey, 2018), State of Kentucky (Franklin County Circuit Court, 2019), State of Mississippi (U.S. District Court for the Southern District of Mississippi, 2021), State of Arkansas (U.S. District Court for the Eastern District of Arkansas, 2022), County of Albany, New York (U.S. District Court for the Northern District of New York, 2022), State of Montana (U.S. District Court for the District of Montana, 2022), State of Kansas (U.S. District Court for the District of Kansas, 2022), State of Illinois (U.S. District Court for the Northern District of Illinois, 2022), State of California (Los Angeles County Superior Court, 2023), Jackson County, Missouri in a putative class action on behalf of Missouri counties and municipalities (Jackson County Circuit Court, 2023), and the Government of Puerto Rico (Court of First Instance Superior Court, San Juan, 2023). These lawsuits are at various stages in the litigation process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investigations, Subpoenas, and Inquiries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the pricing and sale of our insulin and other products, we have been subject to various investigations and received subpoenas, civil investigative demand requests, information requests, interrogatories, and other inquiries from various governmental entities. These include subpoenas from the New York and Vermont Attorney General Offices, civil investigative demands from the Washington, New Mexico, Colorado, Louisiana, Texas and Ohio Attorney General Offices, the U.S. Department of Justice and the U.S. Federal Trade Commission, as well as information requests from the Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada Attorney General Offices. In January 2022, the Michigan Attorney General filed a petition in Michigan state court seeking authorization to investigate Lilly for potential violations of the Michigan Consumer Protection Act (MCPA), and a complaint seeking a declaratory judgment that the Attorney General has authority to investigate Lilly's sale of insulin under the MCPA. The court authorized the proposed investigation and the issuance of civil investigative subpoenas. In April 2022, the parties entered into a stipulation providing that the State of Michigan will not issue any civil investigative subpoena to us under the MCPA until the declaratory judgment action is resolved. In July 2022, the court dismissed the case in its entirety. The Michigan Attorney General filed a notice of appeal to the Michigan Court of Appeals, which remains pending. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a request in January 2019 from the House of Representatives' Committee on Oversight and Reform seeking commercial information and business records related to the pricing of insulin products, among other issues. We also received similar requests from the Senate Finance Committee and the Senate Committee on Health, Education, Labor, and Pensions, and separate requests from the House Committee on Energy and Commerce majority and minority members. In January 2021, the Senate Finance Committee released a report summarizing the findings of its investigation. In December 2021 the House of Representatives' Committee on Oversight and Reform majority and minority staffs released separate reports with findings from their investigations into drug pricing, including of insulin products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are cooperating with all of the aforementioned investigations, subpoenas, and inquiries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Research Corporation Technologies, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. In October 2021, the court issued a summary judgment decision finding in favor of RCT on certain issues, including with respect to a disputed royalty. Both parties filed motions for reconsideration, which were denied. We filed supplemental summary judgment motions. In November 2022, the court stayed proceedings so the parties can pursue mediation. A trial date has not been set. Potential damages payable under the litigation, if finally awarded after an appeal, could be material but are not currently reasonably estimable. This matter is ongoing.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525754688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text">Other Comprehensive Income (Loss)<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to each component of other comprehensive income (loss):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.405%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2020</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,678.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,638.6)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211.9)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,523.6)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(379.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,427.5)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,751.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332.7)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,496.4)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,823.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,795.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,167.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,153.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,550.2)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,583.6)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,343.1)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(324.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(52.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">291.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">332.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">247.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(324.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(40.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">521.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">342.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">498.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance at December 31, 2022</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,874.2)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(37.1)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,062.3)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,844.6)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(75.9)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136.2)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(95.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(532.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(90.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(250.0)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(695.3)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.9&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 7), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated statements of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.230%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other <br/>Comprehensive Loss Components</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Statements of Operations</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(52.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">343.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.3&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">290.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(61.1)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91.5)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.0)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.9&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.4&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206528907952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other-Net, (Income) Expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other-Net, (Income) Expense</a></td>
<td class="text">Other&#8211;Net, (Income) Expense<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">331.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(62.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment (gains) losses on equity securities (Note 7)</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">410.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,442.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment loss (Note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(372.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(289.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">320.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,171.9)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI https://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI https://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206526172608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense and Acquired In-Process Research and Development (IPR&amp;D)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D) and Development Milestones</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including but not limited to, compensation and benefits, facilities and overhead expense, clinical trial expense and fees paid to contract research organizations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D and development milestones include the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use. Additionally, milestone payment obligations related to these transactions that are incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share (EPS)</a></td>
<td class="text">Earnings Per Share (EPS)All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis. We calculate basic EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Expenses</a></td>
<td class="text">Advertising ExpensesCosts associated with advertising are expensed as incurred and are included in marketing, selling, and administrative expenses.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Implementation of New Financial Accounting Standard</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Implementation of New Financial Accounting Standards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update (ASU) 2021-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes annual disclosure requirements for companies that analogize to a grant or contribution accounting model for government assistance transactions. We adopted the standard as of January 1, 2022. The adoption did not impact our financial statement disclosures. </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform</span>, as further modified by ASU 2021-01 and ASU 2022-06, provides for temporary optional expedients and exceptions in applying current GAAP to contracts, hedging relationships, and other transactions affected by the transition from the use of the London Interbank Offered Rate (LIBOR) to an alternative reference rate. The standard is currently applicable to contracts entered into before January 1, 2025. We adopted the standard in the first quarter of 2022. The adoption did not have a material impact on our consolidated financial statements<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed if the compound has no alternative future use.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text">We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Investment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div>We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors.We record our available-for-sale debt securities at fair value, with changes in fair value reported as a component of accumulated other comprehensive income (loss). We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk</a></td>
<td class="text">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions.&#160;We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their investment grade credit ratings.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive income (loss) (see Note 17) and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive income (loss) (see Note 17). Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div>We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, Chinese yuan, Japanese yen, and Swiss franc). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments.In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows.We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss) (see Note 17) and, upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value to its carrying value is performed to determine the amount of any impairment.For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.The costs of acquired IPR&amp;D projects acquired directly in a transaction other than a business combination are capitalized as other intangible assets if the projects have an alternative future use; otherwise, they are expensed immediately. See Note 3 for significant acquired IPR&amp;D projects that had no alternative future use. Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the "income method," which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, analyst expectations, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&amp;D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate.ndefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&amp;D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzI3Mg_0bc998e4-b996-4544-9f0f-ef94e39f535f">three</span> to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value, and the cost basis is adjusted.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans</a></td>
<td class="text">We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, RVA, and RSU shares.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Deferred taxes related to global intangible low-taxed income (GILTI) are also recognized for the future tax effects of temporary differences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position, based on its technical merits, will be sustained upon examination by the taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525662208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated statements of operations:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.669%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,462.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,957.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,694.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,078.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,360.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,845.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,541.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,318.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,539.8&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $163.4 million, $175.0 million, and $135.6 million during the years ended December 31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.537%"><tr><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.202%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="12" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,688.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,914.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,835.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,750.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,194.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">871.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (2)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,191.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">868.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">730.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">289.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">470.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">289.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Mounjaro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">366.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">115.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other diabetes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">268.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">367.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total diabetes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,911.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,719.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,909.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,553.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,468.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,925.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,653.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">830.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">351.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">620.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">543.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">384.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">500.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">293.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other oncology</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">169.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">254.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,218.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,028.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,448.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,724.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">757.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (3)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">148.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">682.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other immunology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total immunology</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,892.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,451.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">462.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">188.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">306.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">249.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">189.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total neuroscience</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">612.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">933.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,008.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">367.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">245.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">552.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">144.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">151.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,555.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,566.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">964.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,190.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,811.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,229.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,351.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,507.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,310.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Humalog revenue includes insulin lispro.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:38.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,190.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,811.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,229.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,299.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,776.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,187.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,747.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,583.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,452.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,852.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,702.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,541.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,318.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,539.8&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div>(1) Revenue is attributed to the countries based on the location of the customer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Amounts Recorded for Contract Liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.6&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525651840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.888%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at December 1, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.0</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.2</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to GJB2.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Akouos and is not deductible for tax purposes. </span></div>(3) See Note 7 for a discussion on the estimation of the CVR liability.<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.888%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903.8</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001. In the third quarter of 2022, we impaired the intangible asset related to PR001. See Note 5 for additional information.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div>(3) See Note 7 for a discussion on the estimation of the CVR liability.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock', window );">Schedule of Research and Development Assets Acquired Other than Through Business Combination</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant asset acquisitions during 2022, 2021, and 2020.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.718%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s),Therapy, or Asset</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority Review Voucher</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foghorn Therapeutics Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new oncology medicines</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Innovent Biologics, Inc. (Innovent)</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine, for geographies outside of China</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Petra Pharma Corporation (Petra)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutant-selective PI3K</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#945;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> inhibitor that could lead to potential new medicine</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disarm Therapeutics, Inc. </span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disease-modifying therapeutics program for patients with axonal degeneration</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.3&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In 2022, we terminated our license for sintilimab injection for geographies outside of China and reverted rights to Innovent.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525759472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Arrangements</a></td>
<td class="text">The table below summarizes the net milestones capitalized with respect to the Jardiance and Trajenta families of products and the net milestones deferred with respect to Basaglar as of December 31: <div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones Capitalized (Deferred)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">116.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(130.6)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149.3)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to Basaglar:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,066.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,490.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">760.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">383.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The following table summarizes our net product revenue recognized with respect to Olumiant:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">830.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The following table summarizes our revenue recognized in China with respect to Tyvyt: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">293.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418.1&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.7&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206523217312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Other Operating Cost and Expense, by Component</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2XzIxOTkwMjMyNTgzMTA_a65ace08-5ec6-44b7-98e1-20a4af3312ff"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2XzIxOTkwMjMyNTgzMTA_b860e1a5-db44-4847-b689-049eb53e6544">asset impairment, restructuring, and other special charges</span></span> in our consolidated statements of operations are described below: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment (gain) and other special charges</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">221.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">244.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.1&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.2&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206523217312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories at December&#160;31 consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">901.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,597.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">801.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates replacement cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,300.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,851.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase to LIFO cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,309.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,886.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206526216304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of the Contractual Maturities of Our Investments in Debt Securities Measured at Fair Value</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December&#160;31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.552%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More Than 10 Years</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Summary of the Fair Value of Available-for-Sale Securities in an Unrealized Gain or Loss Position</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">568.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Schedule of Activity Related to Our Available-for-Sale Securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">132.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Information, Assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain fair value information at December&#160;31, 2022 and 2021 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">657.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">657.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">650.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">657.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">31.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">53.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">53.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">53.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">53.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">58.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">58.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">39.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">58.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">144.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="36" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">146.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">163.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">146.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">146.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">213.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">235.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">213.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">213.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">149.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">161.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">149.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">149.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">52.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">398.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">34.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">311.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">398.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">683.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">484.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">683.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">683.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">478.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">781.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,901.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,379.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,379.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,361.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,379.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.1&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,279.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">487.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,279.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,279.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,212.6&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Summary of Fair Value Information, Liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain fair value information at December&#160;31, 2022 and 2021 for our short-term and long-term debt:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:37.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term commercial paper borrowings</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,498.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,492.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,492.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(14,740.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,329.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,329.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,884.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,157.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,157.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of Derivative Instruments</a></td>
<td class="text">At December&#160;31, 2022, we had outstanding foreign currency forward commitments as follows, all of which have settlement dates within 180 days:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.487%"><tr><td style="width:1.0%"/><td style="width:23.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.440%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchase</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sell</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,516.2</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,575.3</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.8</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chinese yuan</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,139.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.3</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.9</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,212.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British pounds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.7</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.4</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.3</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Effects of Risk-Management Instruments Were Recognized in Other&#8211;Net, (Income) Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(209.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">191.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">216.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209.7)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Effective Portion of Risk-Management Instruments that was Recognized in Other Comprehensive Income (Loss), Net Investment Hedges</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">324.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(404.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">391.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Effective Portion of Risk-Management Instruments that was Recognized in Other Comprehensive Income (Loss), Cash Flow Hedges</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">324.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(404.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">391.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of Fair Value, by Balance Sheet Grouping</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain fair value information at December&#160;31, 2022 and 2021 for risk-management assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:40.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.898%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:40.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.898%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206527438432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-lived Intangible Assets other than Goodwill</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of intangible assets other than goodwill at December&#160;31 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:26.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,922.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,589.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,332.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,987.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,229.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,758.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(32.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,957.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,622.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,334.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,056.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,289.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,766.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,871.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,871.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,829.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,622.7)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,206.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,981.6&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,289.7)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,691.9&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite-lived Intangible Assets other than Goodwill</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of intangible assets other than goodwill at December&#160;31 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:26.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,922.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,589.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,332.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,987.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,229.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,758.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(32.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,957.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,622.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,334.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,056.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,289.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,766.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,871.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,871.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,829.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,622.7)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,206.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,981.6&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,289.7)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,691.9&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Finite-lived Intangible Assets Amortization Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to finite-lived intangible assets was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">579.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December&#160;31, 2022 is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.517%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated amortization expense</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447.7&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206523180064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, property and equipment consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">256.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,915.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,588.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,406.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,937.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,798.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,177.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,377.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,961.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,233.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,976.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,144.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,985.1&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">816.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Long-lived Assets by Geographic Areas</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-lived assets by geographical area:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.248%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,709.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,620.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,898.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,702.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,625.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,691.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,234.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,013.3&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment, net, operating lease assets, and certain other noncurrent assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206527260944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Impact of Leases to Consolidated Condensed Financial Statements</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases as of December&#160;31, 2022 and 2021 was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.801%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.950%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2022, 2021, and 2020 was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">155.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.7</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2022 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.740%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzktMC0xLTEtMTk3MTgy_8ddc8d02-9a67-4865-bc1c-83f42fdd1643">Total</span></span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728.2&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206523181184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt at December&#160;31 consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term commercial paper borrowings</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,498.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term notes </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,815.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,741.2</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(77.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment on hedged long-term notes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,238.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,884.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,501.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,538.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,737.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,346.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Long-term Notes</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-term notes at December 31:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.640%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.179%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.35% notes due 2022</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.00% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.00% euro denominated notes due 2022</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">678.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.15% Swiss franc denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">649.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">654.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.125% notes due 2025</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">217.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">217.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.75% notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">560.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">560.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.625% euro denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">799.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">847.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.5% notes due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">364.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">364.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.1% notes due 2027</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">401.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">401.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.45% Swiss franc denominated notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">433.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">436.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.375% notes due 2029</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">930.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">930.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.42% Japanese yen denominated notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">172.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">199.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.125% euro denominated notes due 2030</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">799.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">847.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.625% euro denominated notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">639.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">678.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.50% euro denominated notes due 2033</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">639.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">678.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.56% Japanese yen denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">69.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">80.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.77% notes due 2036</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">158.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">158.6&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.55% notes due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">444.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">444.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.95% notes due 2037</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">266.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">266.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.875% notes due 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">240.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">240.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.625% British pound denominated notes due 2043</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">301.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">337.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.65% notes due 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">38.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.7% notes due 2045</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">386.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">386.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.95% notes due 2047</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">347.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">347.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.95% notes due 2049</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">958.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">958.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.70% euro denominated notes due 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,065.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,130.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.97% Japanese yen denominated notes due 2049</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">57.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.25% notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,250.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.125% euro denominated notes due 2051</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">532.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">565.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.15% notes due 2059</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">591.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">591.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.50% notes due 2060</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">850.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.375% euro denominated notes due 2061</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">746.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">791.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unamortized note discounts</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(96.1)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(105.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total long-term notes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">14,815.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16,741.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amounts of maturities on long-term debt for the next five years are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:49.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.180%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities on long-term debt</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock', window );">Schedule of Additional Borrowings Disclosures</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments for interest on borrowings</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">323.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Additional Borrowings Disclosures [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206523252320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock', window );">Schedule of Additional Stock-Based Compensation Disclosures</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense and the related tax benefits were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">371.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock', window );">Share-based Compensation Awards, Fair Value Assumptions Used</a></td>
<td class="text">The weighted-average fair values of the SVA units granted during the years ended December&#160;31, 2022, 2021, and 2020 were $203.88, $230.19, and $139.14, respectively, determined using the following assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32.99</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.42&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.90&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The weighted-average fair value of the RVA units granted during the years ended December&#160;31, 2022, 2021 and 2020 were $230.00, $286.71, and $179.90, respectively, determined using the following assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32.86</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.95&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.89&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206530776688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is the composition of income tax expense:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,153.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">547.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,746.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,992.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(977.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(78.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(114.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,185.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(802.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">561.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573.8&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036.2&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) The 2022, 2021, and 2020 current tax expense includes $189.5 million, $64.7 million, and $144.4 million of tax benefit, respectively, from utilization of net operating loss and other tax carryforwards.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities as of December&#160;31 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,071.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,347.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">427.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">477.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss and other tax carryforwards and carrybacks</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">626.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,312.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Correlative tax adjustments</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">752.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax redeterminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">267.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">147.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,615.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">361.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,059.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,662.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowances</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(775.1)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(875.6)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,284.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,786.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings of foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,226.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,583.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,387.9)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,516.1)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(639.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(596.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid employee benefits</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(546.5)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(560.6)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(433.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial instruments</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(215.0)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303.0)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(130.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,579.1)</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,030.7)</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets - net</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,705.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock', window );">Schedule of Cash Payments Relating to Income Taxes and Tax Act Toll Tax</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments of U.S. federal, state, and foreign income taxes, net of refunds, were as follows: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments of income taxes</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,672.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Having made this election, our future cash payments relating to the Toll Tax as of December&#160;31, 2022 are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.764%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.253%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 1 Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-3 Years</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Tax Act Toll Tax</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a reconciliation of the consolidated income tax expense applying the U.S. federal statutory rate to income before income taxes to reported consolidated income tax expense: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at the U.S. federal statutory tax rate</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,429.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add (deduct):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations, including Puerto Rico</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(299.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(447.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(155.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(287.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance release</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(116.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">561.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes the impact of Puerto Rico Excise Tax, GILTI tax, and other U.S. taxation of foreign income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Income Tax Contingencies</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January&#160;1</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,798.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,551.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">274.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(44.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapses of statutes of limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes related to the impact of foreign currency translation</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(52.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,987.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,798.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,551.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Additional Income Tax Disclosures [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525774288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock', window );">Schedule of Changes in Accumulated Postemployment Benefit Obligations</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a measurement date of December&#160;31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December&#160;31 for our defined benefit pension and retiree health benefit plans, which were as follows: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,565.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,225.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,663.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,753.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">351.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">398.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,158.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(395.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(608.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(86.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other adjustments</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(325.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at end of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,222.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,565.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,258.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,663.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Changes in Fair Value of Plan Assets</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,416.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,579.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,361.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,227.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,388.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,458.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(796.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(608.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(86.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(341.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,195.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,416.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,492.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,361.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetFundedStatusTableTextBlock', window );">Schedule of Net Funded Status</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(26.2)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,149.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,233.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,687.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,908.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(497.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized prior service (benefit) cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(62.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,669.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,770.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,226.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock', window );">Schedule of Amounts Recognized in Balance Sheet</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in the consolidated balance sheet consisted&#160;of:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,208.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,383.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,910.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(70.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,163.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,749.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(141.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (income) loss before income taxes</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,695.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(614.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,669.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,770.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,226.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of Assumptions Used</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents our weighted-average assumptions as of December&#160;31:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate for benefit obligation</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate for net benefit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase for benefit obligation</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase for net benefit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets for net benefit costs</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Schedule of Expected Benefit Payments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028-2032</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension plans</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,079.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retiree health benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,211.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,360.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">977.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.758%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health <br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,721.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,532.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">652.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of Net Benefit Costs</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit expense included the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:38.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.375%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic (benefit) cost:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">351.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">398.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(947.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(949.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(901.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(152.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (benefit) cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(54.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">342.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">147.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.6&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.6&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(121.6)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120.9)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136.1)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Amounts Recognized in Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents the amounts recognized in other comprehensive income (loss) for the years ended December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, and 2020:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.320%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined&#160;Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree&#160;Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss) arising during period</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">823.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,072.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(663.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(552.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (benefit) cost included in net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(54.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial (gain) loss included in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">342.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">55.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss) during period</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,223.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335.9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(607.0)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Schedule of Allocation of Plan Assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2022 by asset category were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:30.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices in Active Markets&#160;for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Observable&#160;<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investments Valued at Net Asset Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,445.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,058.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets - repurchase agreements</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(706.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(713.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,014.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,988.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,261.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,195.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,335.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash value of trust owned insurance contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,492.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2021 by asset category were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:30.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices in Active Markets&#160;for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investments Valued at Net Asset Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,722.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,907.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,496.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,356.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets - repurchase agreements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,816.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,808.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,416.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,170.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash value of trust owned insurance contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,166.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,166.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,361.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,290.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in the accumulated postemployment benefit obligation from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetFundedStatusTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of net funded status of pension plans and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetFundedStatusTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206529002752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to each component of other comprehensive income (loss):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.405%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2020</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,678.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,638.6)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211.9)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,523.6)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(379.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,427.5)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,751.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332.7)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,496.4)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,823.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,795.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,167.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,153.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,550.2)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,583.6)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,343.1)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(324.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(52.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">291.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">332.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">247.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(324.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(40.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">521.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">342.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">498.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance at December 31, 2022</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,874.2)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(37.1)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,062.3)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,844.6)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(75.9)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136.2)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(95.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(532.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(90.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(250.0)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(695.3)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.9&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Schedule of Amounts Recognized in Other Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.230%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other <br/>Comprehensive Loss Components</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Statements of Operations</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(52.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">343.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.3&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">290.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(61.1)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91.5)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.0)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.9&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.4&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206519564400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other - Net, (Income) Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Nonoperating Income (Expense)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">331.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(62.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment (gains) losses on equity securities (Note 7)</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">410.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,442.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment loss (Note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(372.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(289.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">320.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,171.9)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206530776528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AdvertisingExpensePercentageOfRevenue', window );">Advertising expense, percentage of revenue</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AdvertisingExpensePercentageOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advertising Expense, Percentage Of Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AdvertisingExpensePercentageOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206526132784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Summary of Revenue Recognized) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 28,541.4<span></span>
</td>
<td class="nump">$ 28,318.4<span></span>
</td>
<td class="nump">$ 24,539.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">25,462.8<span></span>
</td>
<td class="nump">25,957.9<span></span>
</td>
<td class="nump">22,694.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember', window );">Collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,078.6<span></span>
</td>
<td class="nump">2,360.5<span></span>
</td>
<td class="nump">1,845.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Collaboration and other revenue associated with prior period transfers of intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 163.4<span></span>
</td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="nump">$ 135.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206523336240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_RevenuefromContractPaymentTermMinimum', window );">Revenue, performance obligation, payment terms, days from date of shipment, minimum</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_RevenuefromContractPaymentTermMaximum', window );">Revenue, performance obligation, payment terms, days from date of shipment, maximum</a></td>
<td class="text">70 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt', window );">Revenue, performance obligation, payment terms, financing component, period between transfer of control and payment receipt (or less)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod', window );">Revenue, performance obligation, sales rebate payment period (up to)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate', window );">Revenue, performance obligation, sales returns, product expiration date</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel', window );">Revenue, performance obligation, sales returns, average inventory level (or less)</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue', window );">Revenue, performance obligation, sales returns, percentage of net revenue (less than)</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Sales returns, rebates, and discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent', window );">Revenue, information used to determine revenue recognized, change in accounting estimate, percent (or less)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=lly_ThreeLargestWholesalesMember', window );">Three Largest Wholesales | Revenue Benchmark | Minimum | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=lly_ThreeLargestWholesalesMember', window );">Three Largest Wholesales | Revenue Benchmark | Maximum | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=lly_ThreeLargestWholesalesMember', window );">Three Largest Wholesales | Accounts Receivable | Minimum | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=lly_ThreeLargestWholesalesMember', window );">Three Largest Wholesales | Accounts Receivable | Maximum | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Sales Rebate Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuePerformanceObligationSalesRebatePaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Sales Returns, Average Inventory Level</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Sales Returns, Product Expiration Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuefromContractPaymentTermMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from Contract, Payment Term, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuefromContractPaymentTermMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuefromContractPaymentTermMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from Contract, Payment Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuefromContractPaymentTermMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lly_ThreeLargestWholesalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lly_ThreeLargestWholesalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206526024816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue (Contract Liabilities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">$ 219.2<span></span>
</td>
<td class="nump">$ 262.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206517068592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Disaggregation of Revenue by Product) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 28,541.4<span></span>
</td>
<td class="nump">$ 28,318.4<span></span>
</td>
<td class="nump">$ 24,539.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">18,190.0<span></span>
</td>
<td class="nump">16,811.0<span></span>
</td>
<td class="nump">14,229.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">10,351.3<span></span>
</td>
<td class="nump">11,507.4<span></span>
</td>
<td class="nump">10,310.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_DiabetesMember', window );">Diabetes | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">9,911.1<span></span>
</td>
<td class="nump">8,719.3<span></span>
</td>
<td class="nump">7,909.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_DiabetesMember', window );">Diabetes | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">4,553.7<span></span>
</td>
<td class="nump">4,468.8<span></span>
</td>
<td class="nump">3,925.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrulicityMemberMember', window );">Trulicity&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">5,688.8<span></span>
</td>
<td class="nump">4,914.4<span></span>
</td>
<td class="nump">3,835.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrulicityMemberMember', window );">Trulicity&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,750.9<span></span>
</td>
<td class="nump">1,557.6<span></span>
</td>
<td class="nump">1,232.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,066.0<span></span>
</td>
<td class="nump">1,490.8<span></span>
</td>
<td class="nump">1,153.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,194.5<span></span>
</td>
<td class="nump">807.3<span></span>
</td>
<td class="nump">620.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">871.5<span></span>
</td>
<td class="nump">683.5<span></span>
</td>
<td class="nump">533.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogMember', window );">Humalog&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,191.9<span></span>
</td>
<td class="nump">1,320.7<span></span>
</td>
<td class="nump">1,485.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogMember', window );">Humalog&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">868.7<span></span>
</td>
<td class="nump">1,132.3<span></span>
</td>
<td class="nump">1,140.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumulinMember', window );">Humulin&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">730.2<span></span>
</td>
<td class="nump">832.9<span></span>
</td>
<td class="nump">866.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumulinMember', window );">Humulin&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">289.2<span></span>
</td>
<td class="nump">389.6<span></span>
</td>
<td class="nump">393.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">760.4<span></span>
</td>
<td class="nump">892.5<span></span>
</td>
<td class="nump">1,124.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">470.7<span></span>
</td>
<td class="nump">588.3<span></span>
</td>
<td class="nump">842.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">289.7<span></span>
</td>
<td class="nump">304.2<span></span>
</td>
<td class="nump">282.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_MounjaroMember', window );">Mounjaro&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">366.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_MounjaroMember', window );">Mounjaro&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">115.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember', window );">Other diabetes | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">268.4<span></span>
</td>
<td class="nump">255.7<span></span>
</td>
<td class="nump">258.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember', window );">Other diabetes | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">367.8<span></span>
</td>
<td class="nump">401.6<span></span>
</td>
<td class="nump">344.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OncologyMember', window );">Oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,218.1<span></span>
</td>
<td class="nump">3,028.8<span></span>
</td>
<td class="nump">2,792.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OncologyMember', window );">Oncology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,448.1<span></span>
</td>
<td class="nump">2,712.5<span></span>
</td>
<td class="nump">2,527.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_VerzenioMember', window );">Verzenio&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,653.2<span></span>
</td>
<td class="nump">834.9<span></span>
</td>
<td class="nump">618.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_VerzenioMember', window );">Verzenio&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">830.3<span></span>
</td>
<td class="nump">515.0<span></span>
</td>
<td class="nump">294.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CyramzaMember', window );">Cyramza&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">351.4<span></span>
</td>
<td class="nump">358.1<span></span>
</td>
<td class="nump">381.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CyramzaMember', window );">Cyramza&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">620.0<span></span>
</td>
<td class="nump">674.8<span></span>
</td>
<td class="nump">650.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_AlimtaMember', window );">Alimta&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">543.7<span></span>
</td>
<td class="nump">1,233.9<span></span>
</td>
<td class="nump">1,265.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_AlimtaMember', window );">Alimta&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">384.0<span></span>
</td>
<td class="nump">827.5<span></span>
</td>
<td class="nump">1,064.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ErbituxMember', window );">Erbitux&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">500.1<span></span>
</td>
<td class="nump">481.8<span></span>
</td>
<td class="nump">480.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ErbituxMember', window );">Erbitux&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">66.4<span></span>
</td>
<td class="nump">66.4<span></span>
</td>
<td class="nump">56.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">293.3<span></span>
</td>
<td class="nump">418.1<span></span>
</td>
<td class="nump">308.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">293.3<span></span>
</td>
<td class="nump">418.1<span></span>
</td>
<td class="nump">308.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember', window );">Other oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">169.7<span></span>
</td>
<td class="nump">120.1<span></span>
</td>
<td class="nump">46.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember', window );">Other oncology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">254.1<span></span>
</td>
<td class="nump">210.7<span></span>
</td>
<td class="nump">152.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ImmunologyMember', window );">Immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,892.8<span></span>
</td>
<td class="nump">1,881.8<span></span>
</td>
<td class="nump">1,372.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ImmunologyMember', window );">Immunology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,451.8<span></span>
</td>
<td class="nump">1,479.0<span></span>
</td>
<td class="nump">1,089.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TaltzMember', window );">Taltz&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,724.6<span></span>
</td>
<td class="nump">1,542.4<span></span>
</td>
<td class="nump">1,288.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TaltzMember', window );">Taltz&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">757.4<span></span>
</td>
<td class="nump">670.4<span></span>
</td>
<td class="nump">500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">830.5<span></span>
</td>
<td class="nump">1,115.1<span></span>
</td>
<td class="nump">638.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">148.2<span></span>
</td>
<td class="nump">324.1<span></span>
</td>
<td class="nump">63.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">682.3<span></span>
</td>
<td class="nump">791.0<span></span>
</td>
<td class="nump">575.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember', window );">Other immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">15.3<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember', window );">Other immunology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">12.1<span></span>
</td>
<td class="nump">17.6<span></span>
</td>
<td class="nump">14.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember', window );">Neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">612.4<span></span>
</td>
<td class="nump">614.8<span></span>
</td>
<td class="nump">487.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember', window );">Neuroscience | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">933.8<span></span>
</td>
<td class="nump">1,283.7<span></span>
</td>
<td class="nump">1,344.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_EmgalityMember', window );">Emgality&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">462.8<span></span>
</td>
<td class="nump">434.5<span></span>
</td>
<td class="nump">325.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_EmgalityMember', window );">Emgality&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">188.1<span></span>
</td>
<td class="nump">142.7<span></span>
</td>
<td class="nump">37.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ZyprexaMember', window );">Zyprexa&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">30.4<span></span>
</td>
<td class="nump">39.6<span></span>
</td>
<td class="nump">46.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ZyprexaMember', window );">Zyprexa&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">306.5<span></span>
</td>
<td class="nump">390.7<span></span>
</td>
<td class="nump">360.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CymbaltaMember', window );">Cymbalta&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">33.7<span></span>
</td>
<td class="nump">38.7<span></span>
</td>
<td class="nump">42.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CymbaltaMember', window );">Cymbalta&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">249.6<span></span>
</td>
<td class="nump">542.8<span></span>
</td>
<td class="nump">725.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember', window );">Other neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">85.5<span></span>
</td>
<td class="nump">102.0<span></span>
</td>
<td class="nump">73.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember', window );">Other neuroscience | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">189.6<span></span>
</td>
<td class="nump">207.5<span></span>
</td>
<td class="nump">220.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,555.7<span></span>
</td>
<td class="nump">2,566.4<span></span>
</td>
<td class="nump">1,668.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember', window );">Other | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">964.0<span></span>
</td>
<td class="nump">1,563.5<span></span>
</td>
<td class="nump">1,424.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,020.0<span></span>
</td>
<td class="nump">2,240.0<span></span>
</td>
<td class="nump">871.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 antibodies | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,008.9<span></span>
</td>
<td class="nump">1,978.0<span></span>
</td>
<td class="nump">850.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 antibodies | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">14.7<span></span>
</td>
<td class="nump">261.4<span></span>
</td>
<td class="nump">21.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ForteoMember', window );">Forteo&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">367.3<span></span>
</td>
<td class="nump">441.6<span></span>
</td>
<td class="nump">510.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ForteoMember', window );">Forteo&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">245.8<span></span>
</td>
<td class="nump">360.3<span></span>
</td>
<td class="nump">536.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">35.2<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">61.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">552.1<span></span>
</td>
<td class="nump">707.9<span></span>
</td>
<td class="nump">545.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">144.2<span></span>
</td>
<td class="nump">136.1<span></span>
</td>
<td class="nump">246.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductMember', window );">Other | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 151.3<span></span>
</td>
<td class="nump">$ 233.9<span></span>
</td>
<td class="nump">$ 321.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_DiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_DiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrulicityMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrulicityMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumalogMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumalogMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumulinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumulinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BasaglarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BasaglarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_MounjaroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_MounjaroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherDiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_VerzenioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_VerzenioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CyramzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CyramzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_AlimtaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_AlimtaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ErbituxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ErbituxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TYVYTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TYVYTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TaltzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TaltzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OlumiantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OlumiantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_EmgalityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_EmgalityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ZyprexaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ZyprexaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CymbaltaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CymbaltaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherProductTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ForteoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ForteoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CialisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CialisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525802672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Disaggregation of Revenue by Geographical Area) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 28,541.4<span></span>
</td>
<td class="nump">$ 28,318.4<span></span>
</td>
<td class="nump">$ 24,539.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">18,190.0<span></span>
</td>
<td class="nump">16,811.0<span></span>
</td>
<td class="nump">14,229.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">4,299.2<span></span>
</td>
<td class="nump">4,776.8<span></span>
</td>
<td class="nump">4,187.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,747.3<span></span>
</td>
<td class="nump">2,367.0<span></span>
</td>
<td class="nump">2,583.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,452.8<span></span>
</td>
<td class="nump">1,661.4<span></span>
</td>
<td class="nump">1,116.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember', window );">Other foreign countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 2,852.0<span></span>
</td>
<td class="nump">$ 2,702.2<span></span>
</td>
<td class="nump">$ 2,422.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206519098304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Narrative) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 22, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>right </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>right </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones', window );">Acquired in-process research and development and development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 908.5<span></span>
</td>
<td class="nump">$ 970.1<span></span>
</td>
<td class="nump">$ 769.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327.2<span></span>
</td>
<td class="nump">747.4<span></span>
</td>
<td class="nump">849.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,073.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,073.0<span></span>
</td>
<td class="nump">3,892.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,560.0<span></span>
</td>
<td class="nump">$ 1,905.4<span></span>
</td>
<td class="nump">$ 276.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_PaymentsForAssetAcquisitions', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 333.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_AkouosAcquisitionMember', window );">Akouos Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 327.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights', window );">Consideration transferred, number of contingent value rights | right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare', window );">Contingent value right, additional price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent value right, additional price per share, aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 184.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember', window );">Prevail Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="nump">$ 747.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 747.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights', window );">Consideration transferred, number of contingent value rights | right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare', window );">Contingent value right, additional price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent value right, additional price per share, aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction', window );">Contingent value right, monthly reduction | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">126.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="nump">824.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">$ 106.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_DermiraInc.Member', window );">Dermira</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 849.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt', window );">Long-term debt assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired In-Process Research And Development And Development Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Contingent Value Right, Additional Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Number Of Contingent Value Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PaymentsForAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PaymentsForAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_AkouosAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_AkouosAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_DermiraInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_DermiraInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206518798688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Assets Acquired and Liabilities Assumed) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 01, 2022</div></th>
<th class="th"><div>Jan. 22, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,073.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,073.0<span></span>
</td>
<td class="nump">$ 3,892.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 327.2<span></span>
</td>
<td class="nump">$ 747.4<span></span>
</td>
<td class="nump">$ 849.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_AkouosAcquisitionMember', window );">Akouos Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">$ 153.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="nump">184.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">181.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="nump">28.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Acquisition date fair value of consideration transferred</a></td>
<td class="nump">547.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="num">(153.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability', window );">Fair value of CVR liability</a></td>
<td class="num">$ (66.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 327.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember', window );">Prevail Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">824.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Acquisition date fair value of consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">903.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability', window );">Fair value of CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 747.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 747.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_AkouosAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_AkouosAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525877488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Asset Acquisitions) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_PaymentsForAssetAcquisitions', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 333.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_BioMarinPharmaceuticalIncMember', window );">BioMarin Pharmaceutical Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_PaymentsForAssetAcquisitions', window );">Acquired IPR&amp;D Expense</a></td>
<td class="nump">$ 110.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_FoghornTherapeuticsIncMember', window );">Foghorn Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_PaymentsForAssetAcquisitions', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 316.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_RigelPharmaceuticalsIncMember', window );">Rigel Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_PaymentsForAssetAcquisitions', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_PrecisionBiosciencesIncMember', window );">Precision Biosciences, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_PaymentsForAssetAcquisitions', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_InnoventBiologicsIncMember', window );">Innovent Biologics, Inc. (Innovent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_PaymentsForAssetAcquisitions', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_PetraPharmaCorporationMember', window );">Petra Pharma Corporation (Petra)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_PaymentsForAssetAcquisitions', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_DisarmTherapeuticsIncMember', window );">Disarm Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_PaymentsForAssetAcquisitions', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PaymentsForAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PaymentsForAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_BioMarinPharmaceuticalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_BioMarinPharmaceuticalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_FoghornTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_FoghornTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_RigelPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_RigelPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_PrecisionBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_PrecisionBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_InnoventBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_InnoventBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_PetraPharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_PetraPharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_DisarmTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_DisarmTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206518723952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details) - Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember', window );">Jardiance&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">$ 116.2<span></span>
</td>
<td class="nump">$ 136.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember', window );">Trajenta&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">63.5<span></span>
</td>
<td class="nump">88.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember', window );">Basaglar&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="num">$ (130.6)<span></span>
</td>
<td class="num">$ (149.3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Rights (Obligations)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsRightsObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrajentaBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BasaglarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BasaglarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206527272576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Net Product Revenue) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 28,541.4<span></span>
</td>
<td class="nump">$ 28,318.4<span></span>
</td>
<td class="nump">$ 24,539.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,066.0<span></span>
</td>
<td class="nump">1,490.8<span></span>
</td>
<td class="nump">1,153.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">760.4<span></span>
</td>
<td class="nump">892.5<span></span>
</td>
<td class="nump">1,124.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember', window );">Trajenta&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">383.7<span></span>
</td>
<td class="nump">372.5<span></span>
</td>
<td class="nump">358.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">830.5<span></span>
</td>
<td class="nump">1,115.1<span></span>
</td>
<td class="nump">638.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 293.3<span></span>
</td>
<td class="nump">$ 418.1<span></span>
</td>
<td class="nump">$ 308.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BasaglarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BasaglarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrajentaBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OlumiantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OlumiantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TYVYTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TYVYTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206527312512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 28,541.4<span></span>
</td>
<td class="nump">$ 28,318.4<span></span>
</td>
<td class="nump">$ 24,539.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 830.5<span></span>
</td>
<td class="nump">1,115.1<span></span>
</td>
<td class="nump">638.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | Royalty Payments Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsPercent', window );">Collaborative arrangement, rights and obligations percent (up to)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">$ 330.0<span></span>
</td>
<td class="nump">260.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | Milestone Payments, Development and Regulatory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 Antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,020.0<span></span>
</td>
<td class="nump">$ 2,240.0<span></span>
</td>
<td class="nump">$ 871.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember', window );">Lebrikizumab | Milestone Payments, Development and Regulatory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember', window );">Lebrikizumab | Milestone Payments, Development and Regulatory | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">165.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember', window );">Lebrikizumab | Milestone Payments, Sales-based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">1,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember', window );">Lebrikizumab | Milestone Payments, Sales-based | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">$ 1,030.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Rights (Obligations)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsRightsObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OlumiantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OlumiantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_LebrikizumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lly_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lly_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206526313920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges - Schedule of Other Operating Cost and Expense, by Component (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges', window );">Asset impairment (gain) and other special charges</a></td>
<td class="nump">$ 221.6<span></span>
</td>
<td class="nump">$ 303.1<span></span>
</td>
<td class="num">$ (20.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance</a></td>
<td class="nump">23.0<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="nump">151.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Total asset impairment, restructuring, and other special charges</a></td>
<td class="nump">$ 244.6<span></span>
</td>
<td class="nump">$ 316.1<span></span>
</td>
<td class="nump">$ 131.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Impairment Charges (Recoveries) And Other Special Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringSettlementAndImpairmentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of restructuring charges, remediation cost, and asset impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringSettlementAndImpairmentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206519604896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Asset impairment, restructuring, and other special charges (Note 5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Asset impairment, restructuring, and other special charges (Note 5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets, finite-lived</a></td>
<td class="nump">$ 128.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets, indefinite-lived</a></td>
<td class="nump">$ 108.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of indefinite-lived intangible asset excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525993072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished products</a></td>
<td class="nump">$ 761.9<span></span>
</td>
<td class="nump">$ 901.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">2,372.7<span></span>
</td>
<td class="nump">2,597.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials and supplies</a></td>
<td class="nump">717.2<span></span>
</td>
<td class="nump">801.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total (approximates replacement cost)</a></td>
<td class="nump">3,851.8<span></span>
</td>
<td class="nump">4,300.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLIFOReserve', window );">Increase to LIFO cost</a></td>
<td class="nump">34.2<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">3,886.0<span></span>
</td>
<td class="nump">4,309.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LIFOInventoryAmount', window );">LIFO inventory amount</a></td>
<td class="nump">1,360.0<span></span>
</td>
<td class="nump">$ 1,230.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">$ 339.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LIFOInventoryAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of LIFO (last in first out) inventory present at the reporting date when inventory is also valued using different valuation methods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LIFOInventoryAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206523344320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Narrative) (Details)<br> &#8364; in Millions, &#165; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net investment gains on equity securities</a></td>
<td class="num">$ (410.7)<span></span>
</td>
<td class="nump">$ 176.9<span></span>
</td>
<td class="nump">$ 1,442.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments', window );">Unfunded commitments to invest in venture capital funds</a></td>
<td class="nump">$ 957.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod', window );">Unfunded commitments to invest in venture capital funds, anticipated payment period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets', window );">Percentage of nonperforming assets</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized', window );">Accounts receivable derecognized</a></td>
<td class="nump">$ 422.1<span></span>
</td>
<td class="nump">550.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1', window );">Average remaining maturity of foreign currency derivatives</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1', window );">Maximum remaining maturity of foreign currency derivatives</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 14,815.3<span></span>
</td>
<td class="nump">16,741.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax', window );">Foreign currency-denominated notes, designated as hedge</a></td>
<td class="nump">$ 5,450.0<span></span>
</td>
<td class="nump">5,790.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Variable rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet', window );">Losses expected to be reclassified in the next 12 months</a></td>
<td class="nump">$ 16.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapUSDollarsToEuroMember', window );">Swap U.S Dollars To Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">1,020.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember', window );">Swap Swiss Francs to USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SellEuroMember', window );">Sell Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 325.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SellChineseYuanMember', window );">Sell Chinese Yuan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 1,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Forward-starting interest rate swaps | Cash flow hedges | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">1,850.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 6,830.0<span></span>
</td>
<td class="nump">$ 7,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the percentage of nonperforming assets that the underlying assets in the security represent and which were considered as one of the potential factors in reaching a conclusion that the available-for-sale investments are not other-than-temporarily impaired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average period remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL6742756-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of cumulative translation adjustment attributable to gain (loss) on foreign currency derivatives that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapUSDollarsToEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_SwapUSDollarsToEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SellEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_SellEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SellChineseYuanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_SellChineseYuanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206519167104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Contractual Maturities) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 646.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less Than 1 Year</a></td>
<td class="nump">86.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">1-5 Years</a></td>
<td class="nump">242.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">6-10 Years</a></td>
<td class="nump">104.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">More Than 10 Years</a></td>
<td class="nump">$ 214.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206526149600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Unrealized Gains and Losses) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gross gains</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized gross losses</a></td>
<td class="nump">49.2<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition', window );">Fair value of securities in an unrealized gain position</a></td>
<td class="nump">46.8<span></span>
</td>
<td class="nump">250.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair value of securities in an unrealized loss position</a></td>
<td class="nump">$ 568.7<span></span>
</td>
<td class="nump">$ 290.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Unrealized Gain Position</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206527451056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Realized Gains and Losses) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities', window );">Proceeds from sales</a></td>
<td class="nump">$ 132.9<span></span>
</td>
<td class="nump">$ 174.7<span></span>
</td>
<td class="nump">$ 264.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain', window );">Realized gross gains on sales</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss', window );">Realized gross losses on sales</a></td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 8.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale Securities and Equity Securities, FV-NI, Realized Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Equity and Available for Sale Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206523791312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Fair Value Measurement) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Noncurrent investments</a></td>
<td class="nump">$ 2,901.8<span></span>
</td>
<td class="nump">$ 3,212.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">657.4<span></span>
</td>
<td class="nump">2,379.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">144.8<span></span>
</td>
<td class="nump">90.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments without readily determinable fair values</a></td>
<td class="nump">478.4<span></span>
</td>
<td class="nump">548.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Noncurrent investments</a></td>
<td class="nump">2,901.8<span></span>
</td>
<td class="nump">3,212.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">30.8<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">146.4<span></span>
</td>
<td class="nump">137.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">53.4<span></span>
</td>
<td class="nump">43.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">213.9<span></span>
</td>
<td class="nump">235.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">149.2<span></span>
</td>
<td class="nump">109.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">50.6<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Other securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">58.6<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">398.6<span></span>
</td>
<td class="nump">108.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">683.6<span></span>
</td>
<td class="nump">1,279.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Equity method investments</a></td>
<td class="nump">781.1<span></span>
</td>
<td class="nump">771.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">657.4<span></span>
</td>
<td class="nump">2,379.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">31.1<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">163.2<span></span>
</td>
<td class="nump">136.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">53.5<span></span>
</td>
<td class="nump">43.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">235.8<span></span>
</td>
<td class="nump">232.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">161.5<span></span>
</td>
<td class="nump">108.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">52.5<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Other securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">58.6<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">34.5<span></span>
</td>
<td class="nump">22.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">484.7<span></span>
</td>
<td class="nump">487.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">657.4<span></span>
</td>
<td class="nump">2,379.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">30.8<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">146.4<span></span>
</td>
<td class="nump">137.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">53.4<span></span>
</td>
<td class="nump">43.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">213.9<span></span>
</td>
<td class="nump">235.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">149.2<span></span>
</td>
<td class="nump">109.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">50.6<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">58.6<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">398.6<span></span>
</td>
<td class="nump">108.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">683.6<span></span>
</td>
<td class="nump">1,279.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">650.4<span></span>
</td>
<td class="nump">2,361.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">30.8<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">146.4<span></span>
</td>
<td class="nump">137.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">683.6<span></span>
</td>
<td class="nump">1,279.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">18.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">53.4<span></span>
</td>
<td class="nump">43.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">213.9<span></span>
</td>
<td class="nump">235.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">149.2<span></span>
</td>
<td class="nump">109.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">50.6<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Other securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">39.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">311.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Other securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">19.5<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">87.6<span></span>
</td>
<td class="nump">108.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_EquityMethodAndOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_EquityMethodAndOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206526091312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Short-term and Long-term Classification) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="num">$ (1,498.0)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(14,815.3)<span></span>
</td>
<td class="num">(16,741.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(14,740.6)<span></span>
</td>
<td class="num">(16,884.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="num">(1,498.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(12,329.3)<span></span>
</td>
<td class="num">(18,157.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="num">(1,492.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Estimate of Fair Value Measurement | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(12,329.3)<span></span>
</td>
<td class="num">(18,157.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Estimate of Fair Value Measurement | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="num">(1,492.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Estimate of Fair Value Measurement | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206523774688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Foreign Currency Forward Commitments) (Details) - Dec. 31, 2022<br> &#8364; in Millions, &#165; in Millions, &#165; in Millions, &#163; in Millions, SFr in Millions, $ in Millions</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>EUR (&#8364;)</div></th>
<th class="th"><div>CNY (&#165;)</div></th>
<th class="th"><div>JPY (&#165;)</div></th>
<th class="th"><div>GBP (&#163;)</div></th>
<th class="th"><div>CHF (SFr)</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsdSellEuroMember', window );">Buy USD Sell Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">$ 2,516.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,369.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember', window );">Buy Euro Sell USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,371.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">3,575.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSDollarSellChineseYuanMember', window );">Buy US Dollar Sell Chinese Yuan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">199.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 1,396.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyJapaneseYenSellUSDollarMember', window );">Buy Japanese Yen Sell US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 14,139.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">105.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellJapaneseYenMember', window );">Buy USD Sell Japanese Yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">90.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 12,212.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyGBPSellUSDMember', window );">Buy GBP Sell USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 207.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">254.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuySwissFrancSellUSDollarMember', window );">Buy Swiss Franc Sell US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 101.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">$ 109.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsdSellEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsdSellEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSDollarSellChineseYuanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSDollarSellChineseYuanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyJapaneseYenSellUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyJapaneseYenSellUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellJapaneseYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellJapaneseYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyGBPSellUSDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyGBPSellUSDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuySwissFrancSellUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuySwissFrancSellUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206519135216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Effect of Risk Management) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_DerivativeInstrumentsGainLossRecognized', window );">Total</a></td>
<td class="nump">$ 216.4<span></span>
</td>
<td class="nump">$ 263.0<span></span>
</td>
<td class="num">$ (209.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember', window );">Hedged Fixed Rate Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="nump">324.9<span></span>
</td>
<td class="nump">435.0<span></span>
</td>
<td class="num">(404.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="nump">52.0<span></span>
</td>
<td class="nump">213.7<span></span>
</td>
<td class="num">(207.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="nump">29.8<span></span>
</td>
<td class="nump">42.3<span></span>
</td>
<td class="num">(53.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="num">(15.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Forward-starting interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="nump">391.5<span></span>
</td>
<td class="nump">97.6<span></span>
</td>
<td class="num">(110.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Hedged Fixed Rate Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_FairValueHedgeAbstract', window );"><strong>Fair value hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Effect from hedged fixed-rate debt</a></td>
<td class="num">(209.8)<span></span>
</td>
<td class="num">(78.5)<span></span>
</td>
<td class="nump">86.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_FairValueHedgeAbstract', window );"><strong>Fair value hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Effect from interest rate contracts</a></td>
<td class="nump">209.8<span></span>
</td>
<td class="nump">78.5<span></span>
</td>
<td class="num">(86.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">16.5<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
<td class="nump">16.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">8.6<span></span>
</td>
<td class="nump">41.8<span></span>
</td>
<td class="num">(102.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Foreign Exchange Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</a></td>
<td class="nump">$ 191.3<span></span>
</td>
<td class="nump">$ 204.6<span></span>
</td>
<td class="num">$ (123.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CashFlowHedgeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow Hedge [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CashFlowHedgeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DerivativeInstrumentsGainLossRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments, Gain (Loss) Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DerivativeInstrumentsGainLossRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_FairValueHedgeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Hedge [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_FairValueHedgeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206516375744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Risk Management Instruments) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Other current liabilities</a></td>
<td class="num">$ (39.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Other noncurrent liabilities</a></td>
<td class="num">(70.6)<span></span>
</td>
<td class="num">$ (70.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Foreign Exchange Contract | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(38.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Foreign Exchange Contract | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">26.6<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(21.5)<span></span>
</td>
<td class="num">(35.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Other current liabilities</a></td>
<td class="num">(39.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Other noncurrent liabilities</a></td>
<td class="num">(70.6)<span></span>
</td>
<td class="num">(70.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Other current liabilities</a></td>
<td class="num">(39.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Other noncurrent liabilities</a></td>
<td class="num">(70.6)<span></span>
</td>
<td class="num">(70.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign Exchange Contract | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(38.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign Exchange Contract | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign Exchange Contract | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(38.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign Exchange Contract | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign Exchange Contract | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">26.6<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(21.5)<span></span>
</td>
<td class="num">(35.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign Exchange Contract | Not Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign Exchange Contract | Not Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">26.6<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(21.5)<span></span>
</td>
<td class="num">(35.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign Exchange Contract | Not Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair value hedges | Carrying Amount | Interest Rate Contract | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(134.3)<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair value hedges | Estimate of Fair Value Measurement | Interest Rate Contract | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(134.3)<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair value hedges | Estimate of Fair Value Measurement | Interest Rate Contract | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair value hedges | Estimate of Fair Value Measurement | Interest Rate Contract | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(134.3)<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair value hedges | Estimate of Fair Value Measurement | Interest Rate Contract | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Carrying Amount | Interest Rate Contract | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">162.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">246.0<span></span>
</td>
<td class="nump">49.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Carrying Amount | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">53.1<span></span>
</td>
<td class="nump">33.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Estimate of Fair Value Measurement | Interest Rate Contract | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">162.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">246.0<span></span>
</td>
<td class="nump">49.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Estimate of Fair Value Measurement | Interest Rate Contract | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Estimate of Fair Value Measurement | Interest Rate Contract | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">162.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">246.0<span></span>
</td>
<td class="nump">49.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Estimate of Fair Value Measurement | Interest Rate Contract | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">53.1<span></span>
</td>
<td class="nump">33.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">53.1<span></span>
</td>
<td class="nump">33.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Carrying Amount | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">67.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">67.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">67.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206530464992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, impairment loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Remaining amortization period</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206519624144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangibles (Schedule of Finite-lived and Indefinite-lived Intangible Assets other than Goodwill) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Carrying Amount, Gross</a></td>
<td class="nump">$ 7,957.5<span></span>
</td>
<td class="nump">$ 8,056.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,622.7)<span></span>
</td>
<td class="num">(2,289.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Carrying Amount, Net</a></td>
<td class="nump">5,334.8<span></span>
</td>
<td class="nump">5,766.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Carrying Amount, Gross</a></td>
<td class="nump">9,829.3<span></span>
</td>
<td class="nump">9,981.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,622.7)<span></span>
</td>
<td class="num">(2,289.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Carrying Amount, Net</a></td>
<td class="nump">7,206.6<span></span>
</td>
<td class="nump">7,691.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="nump">1,871.8<span></span>
</td>
<td class="nump">1,925.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Carrying Amount, Gross</a></td>
<td class="nump">7,922.1<span></span>
</td>
<td class="nump">7,987.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,589.9)<span></span>
</td>
<td class="num">(2,229.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Carrying Amount, Net</a></td>
<td class="nump">5,332.2<span></span>
</td>
<td class="nump">5,758.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,589.9)<span></span>
</td>
<td class="num">(2,229.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Carrying Amount, Gross</a></td>
<td class="nump">35.4<span></span>
</td>
<td class="nump">69.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(32.8)<span></span>
</td>
<td class="num">(60.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Carrying Amount, Net</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (32.8)<span></span>
</td>
<td class="num">$ (60.5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206530326944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles (Schedule of Amortization Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 579.7<span></span>
</td>
<td class="nump">$ 628.8<span></span>
</td>
<td class="nump">$ 428.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206530909552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangibles (Schedule of Estimated Amortization Expense) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Estimated amortization expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 497.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">447.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">435.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">424.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">$ 422.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206530282896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">50 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206531070624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Property and Equipment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">$ 256.6<span></span>
</td>
<td class="nump">$ 258.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings</a></td>
<td class="nump">7,915.9<span></span>
</td>
<td class="nump">7,588.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Equipment</a></td>
<td class="nump">9,406.3<span></span>
</td>
<td class="nump">8,937.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">2,798.6<span></span>
</td>
<td class="nump">2,177.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">20,377.4<span></span>
</td>
<td class="nump">18,961.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(10,233.4)<span></span>
</td>
<td class="num">(9,976.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 10,144.0<span></span>
</td>
<td class="nump">$ 8,985.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206526100896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Depreciation Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 816.6<span></span>
</td>
<td class="nump">$ 787.0<span></span>
</td>
<td class="nump">$ 765.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525922000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Geographic Information) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 11,234.1<span></span>
</td>
<td class="nump">$ 10,013.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=lly_UNITEDSTATESAndPUERTORICOMember', window );">U.S. and Puerto Rico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">7,709.7<span></span>
</td>
<td class="nump">6,620.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">1,898.5<span></span>
</td>
<td class="nump">1,702.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember', window );">Other foreign countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 1,625.9<span></span>
</td>
<td class="nump">$ 1,691.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lly_UNITEDSTATESAndPUERTORICOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lly_UNITEDSTATESAndPUERTORICOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206526142368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_LesseeLeaseRemainingLeaseTerm', window );">Lessee, lease, remaining lease term (up to)</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Lease expense</a></td>
<td class="nump">$ 148.8<span></span>
</td>
<td class="nump">$ 159.4<span></span>
</td>
<td class="nump">$ 154.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LesseeLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Lease, Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LesseeLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206518719824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Impact of Leases to Consolidated Condensed Financial Statements) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 149.7<span></span>
</td>
<td class="nump">$ 156.7<span></span>
</td>
<td class="nump">$ 160.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 155.4<span></span>
</td>
<td class="nump">$ 163.5<span></span>
</td>
<td class="nump">$ 136.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525764208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Maturities of Operating Lease Liabilities) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 154.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">131.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">115.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">96.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">76.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">After 2027</a></td>
<td class="nump">250.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">823.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="nump">95.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 728.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other noncurrent liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206516929376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings (Schedule of Debt) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="nump">$ 1,498.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Long-term notes</a></td>
<td class="nump">14,815.3<span></span>
</td>
<td class="nump">16,741.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Other long-term debt</a></td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="num">(77.2)<span></span>
</td>
<td class="num">(84.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_LongTermDebtFairValueAdjustment', window );">Fair value adjustment on hedged long-term notes</a></td>
<td class="num">(4.4)<span></span>
</td>
<td class="nump">216.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Total debt</a></td>
<td class="nump">16,238.6<span></span>
</td>
<td class="nump">16,884.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Less current portion</a></td>
<td class="num">(1,501.1)<span></span>
</td>
<td class="num">(1,538.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 14,737.5<span></span>
</td>
<td class="nump">$ 15,346.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LongTermDebtFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustment to carrying value of long term debt to arrive at total fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LongTermDebtFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206522325536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit facility, remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,330,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment loss (Note 11)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 405,200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_DescriptionOfDerivativeActivityVolumePercent', window );">Description of derivative activity volume percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.87%<span></span>
</td>
<td class="nump">2.27%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payment for debt extinguishment</a></td>
<td class="nump">$ 1,910,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment loss (Note 11)</a></td>
<td class="nump">405,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 0.500% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 1.125% Notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.50%<span></span>
</td>
<td class="nump">112.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 1.375% Notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137.50%<span></span>
</td>
<td class="nump">137.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 1.625% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162.50%<span></span>
</td>
<td class="nump">162.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 3.95% notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395.00%<span></span>
</td>
<td class="nump">395.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="nump">541,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 4.15% notes due 2059</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415.00%<span></span>
</td>
<td class="nump">415.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="nump">408,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 3.375% notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337.50%<span></span>
</td>
<td class="nump">337.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="nump">$ 219,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.500% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.125% Notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.375% Notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.625% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.95% notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.15% notes due 2059</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.375% notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.25% notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 988,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.50% notes due 2060</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Senior Notes Due May 2050 and September 2060</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,070,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2026Member', window );">Maturity Date, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2023Member', window );">Maturity Date, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DescriptionOfDerivativeActivityVolumePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of Derivative Activity Volume Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DescriptionOfDerivativeActivityVolumePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of short-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A5000NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A5000NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1125NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1125NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1375NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1375NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1625BritishPoundDenominatedNotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1625BritishPoundDenominatedNotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A395NotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A395NotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A415NotesDue2059Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A415NotesDue2059Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A3375NotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A3375NotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A225NotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A225NotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A25NotesDue2060Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A25NotesDue2060Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_SeniorNotesDueMay2050AndSeptember2060Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_SeniorNotesDueMay2050AndSeptember2060Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206516547328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings (Summary of Long-term Notes) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized note discounts</a></td>
<td class="num">$ (96.1)<span></span>
</td>
<td class="num">$ (105.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term notes</a></td>
<td class="nump">$ 14,815.3<span></span>
</td>
<td class="nump">16,741.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.35% notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.00% notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">99.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.00% euro denominated notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">678.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.15% Swiss franc denominated notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 649.5<span></span>
</td>
<td class="nump">654.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 7.125% notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">7.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 217.5<span></span>
</td>
<td class="nump">217.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.75% notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 560.6<span></span>
</td>
<td class="nump">560.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.625% euro denominated notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 799.3<span></span>
</td>
<td class="nump">847.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.5% notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 364.3<span></span>
</td>
<td class="nump">364.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.1% notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 401.5<span></span>
</td>
<td class="nump">401.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.45% Swiss franc denominated notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 433.0<span></span>
</td>
<td class="nump">436.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.375% notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 930.6<span></span>
</td>
<td class="nump">930.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.42% Japanese yen denominated notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 172.1<span></span>
</td>
<td class="nump">199.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.125% euro denominated notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 799.3<span></span>
</td>
<td class="nump">847.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.625% euro denominated notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 639.4<span></span>
</td>
<td class="nump">678.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.50% euro denominated notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 639.4<span></span>
</td>
<td class="nump">678.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.56% Japanese yen denominated notes due 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 69.7<span></span>
</td>
<td class="nump">80.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.77% notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 158.6<span></span>
</td>
<td class="nump">158.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.55% notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">5.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 444.7<span></span>
</td>
<td class="nump">444.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.95% notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 266.8<span></span>
</td>
<td class="nump">266.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% notes due 2039</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 240.3<span></span>
</td>
<td class="nump">240.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.625% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 301.2<span></span>
</td>
<td class="nump">337.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.65% notes due 2044</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 38.3<span></span>
</td>
<td class="nump">38.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.7% notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 386.8<span></span>
</td>
<td class="nump">386.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.95% notes due 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 347.0<span></span>
</td>
<td class="nump">347.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.95% notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 958.2<span></span>
</td>
<td class="nump">958.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.70% euro denominated notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 1,065.7<span></span>
</td>
<td class="nump">1,130.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.97% Japanese yen denominated notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 57.4<span></span>
</td>
<td class="nump">66.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.25% notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 1,250.0<span></span>
</td>
<td class="nump">1,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.125% euro denominated notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 532.9<span></span>
</td>
<td class="nump">565.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.15% notes due 2059</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 591.3<span></span>
</td>
<td class="nump">591.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.50% notes due 2060</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 850.0<span></span>
</td>
<td class="nump">850.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.375% euro denominated notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 746.0<span></span>
</td>
<td class="nump">$ 791.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A235NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A235NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A30NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A30NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A10EuroDenominatedNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A10EuroDenominatedNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A015SwissFrancDenominatedNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A015SwissFrancDenominatedNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A7125NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A7125NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A275NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A275NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1625EuroDenominatedNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1625EuroDenominatedNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A55NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A55NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A31NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A31NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A045SwissFrancDenominatedNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A045SwissFrancDenominatedNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A3375NotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A3375NotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A42YenDenominatedNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A42YenDenominatedNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A2125EuroDenominatedNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A2125EuroDenominatedNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A625EuroDenominatedNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A625EuroDenominatedNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A5000NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A5000NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A56YenDenominatedNotesDue2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A56YenDenominatedNotesDue2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A677NotesDue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A677NotesDue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A555NotesDue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A555NotesDue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A595NotesDue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A595NotesDue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A3875NotesDue2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A3875NotesDue2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1625BritishPoundDenominatedNotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1625BritishPoundDenominatedNotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A465NotesDue2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A465NotesDue2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A37NotesDue2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A37NotesDue2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A395NotesDue2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A395NotesDue2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A395NotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A395NotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A17EuroDenominatedNotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A17EuroDenominatedNotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A97YenDenominatedNotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A97YenDenominatedNotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A225NotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A225NotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1125NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1125NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A415NotesDue2059Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A415NotesDue2059Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A25NotesDue2060Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A25NotesDue2060Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1375NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1375NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206526345280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings (Schedule of Debt Maturities) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Maturities on long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">649.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">778.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">799.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">$ 765.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206523180064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Schedule of Cash Payments for Interest on Borrowings) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash payments for interest on borrowings</a></td>
<td class="nump">$ 323.7<span></span>
</td>
<td class="nump">$ 338.0<span></span>
</td>
<td class="nump">$ 345.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206523194608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 371.1<span></span>
</td>
<td class="nump">$ 342.8<span></span>
</td>
<td class="nump">$ 308.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit</a></td>
<td class="nump">$ 77.9<span></span>
</td>
<td class="nump">$ 72.0<span></span>
</td>
<td class="nump">$ 64.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206516945952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Narrative) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 234.93<span></span>
</td>
<td class="nump">$ 198.57<span></span>
</td>
<td class="nump">$ 137.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period (in shares)</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued', window );">Shares expected to be issued (in shares)</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost not yet recognized</a></td>
<td class="nump">$ 38.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of the compensation cost not yet recognized</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lly_ShareholderValueAwardsMember', window );">Shareholder Value Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 203.88<span></span>
</td>
<td class="nump">$ 230.19<span></span>
</td>
<td class="nump">$ 139.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period (in shares)</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued', window );">Shares expected to be issued (in shares)</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost not yet recognized</a></td>
<td class="nump">$ 43.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of the compensation cost not yet recognized</a></td>
<td class="text">21 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lly_RelativeValueAwardsMember', window );">Relative Value Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 230.00<span></span>
</td>
<td class="nump">$ 286.71<span></span>
</td>
<td class="nump">$ 179.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued', window );">Shares expected to be issued (in shares)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost not yet recognized</a></td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of the compensation cost not yet recognized</a></td>
<td class="text">22 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 239.88<span></span>
</td>
<td class="nump">$ 196.30<span></span>
</td>
<td class="nump">$ 135.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period (in shares)</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued', window );">Shares expected to be issued (in shares)</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost not yet recognized</a></td>
<td class="nump">$ 221.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of the compensation cost not yet recognized</a></td>
<td class="text">25 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants in period (in shares)</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares expected to be issued in the next twelve months under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lly_ShareholderValueAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lly_ShareholderValueAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lly_RelativeValueAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lly_RelativeValueAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206518683936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Schedule of Assumptions Used) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lly_ShareholderValueAwardsMember', window );">Shareholder Value Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.57%<span></span>
</td>
<td class="nump">0.19%<span></span>
</td>
<td class="nump">1.38%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">32.99%<span></span>
</td>
<td class="nump">31.42%<span></span>
</td>
<td class="nump">20.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lly_RelativeValueAwardsMember', window );">Relative Value Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.57%<span></span>
</td>
<td class="nump">0.19%<span></span>
</td>
<td class="nump">1.38%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">32.86%<span></span>
</td>
<td class="nump">30.95%<span></span>
</td>
<td class="nump">19.89%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lly_ShareholderValueAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lly_ShareholderValueAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lly_RelativeValueAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lly_RelativeValueAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206523290080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Schedule of Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase for treasury</a></td>
<td class="nump">$ 1,500.0<span></span>
</td>
<td class="nump">$ 1,250.0<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesHeldInEmployeeTrustShares', window );">Shares held in employee trust (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesHeldInEmployeeTrust', window );">Employee benefit trust</a></td>
<td class="nump">$ 3,013.2<span></span>
</td>
<td class="nump">$ 3,013.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=lly_May2021ShareRepurchaseProgramMember', window );">May 2021 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Schedule of Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized repurchase amount</a></td>
<td class="nump">$ 3,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesHeldInEmployeeTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesHeldInEmployeeTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesHeldInEmployeeTrustShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock held in a trust that has been set up specifically to accumulate stock for the sole purpose of distribution to participating employees but not yet earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16701-113920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesHeldInEmployeeTrustShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=lly_May2021ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=lly_May2021ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206518688528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Composition of Income Tax Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 2,153.6<span></span>
</td>
<td class="nump">$ 938.5<span></span>
</td>
<td class="nump">$ 567.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">547.7<span></span>
</td>
<td class="nump">466.0<span></span>
</td>
<td class="nump">650.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">45.5<span></span>
</td>
<td class="num">(28.4)<span></span>
</td>
<td class="num">(47.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">2,746.8<span></span>
</td>
<td class="nump">1,376.1<span></span>
</td>
<td class="nump">1,170.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(1,992.4)<span></span>
</td>
<td class="num">(977.5)<span></span>
</td>
<td class="num">(97.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(78.2)<span></span>
</td>
<td class="nump">174.6<span></span>
</td>
<td class="num">(16.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(114.6)<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(20.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax benefit</a></td>
<td class="num">(2,185.2)<span></span>
</td>
<td class="num">(802.3)<span></span>
</td>
<td class="num">(134.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="nump">561.6<span></span>
</td>
<td class="nump">573.8<span></span>
</td>
<td class="nump">1,036.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward', window );">Current federal tax expense, utilization of net operating loss carryforward</a></td>
<td class="nump">$ 189.5<span></span>
</td>
<td class="nump">$ 64.7<span></span>
</td>
<td class="nump">$ 144.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206525825952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Deferred Tax Asset and Liabilities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Purchases of intangible assets</a></td>
<td class="nump">$ 2,071.3<span></span>
</td>
<td class="nump">$ 2,347.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Compensation and benefits</a></td>
<td class="nump">427.9<span></span>
</td>
<td class="nump">634.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">477.6<span></span>
</td>
<td class="nump">463.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Tax loss and other tax carryforwards and carrybacks</a></td>
<td class="nump">626.0<span></span>
</td>
<td class="nump">645.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_DeferredTaxAssetsSalesRebatesAndDiscounts', window );">Sales rebates and discounts</a></td>
<td class="nump">1,312.9<span></span>
</td>
<td class="nump">832.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_DeferredTaxAssetsCorrectiveTaxAdjustments', window );">Correlative tax adjustments</a></td>
<td class="nump">752.5<span></span>
</td>
<td class="nump">560.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_DeferredTaxAssetsForeignTaxRedeterminations', window );">Foreign tax redeterminations</a></td>
<td class="nump">267.8<span></span>
</td>
<td class="nump">274.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">147.5<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">1,615.4<span></span>
</td>
<td class="nump">275.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">361.0<span></span>
</td>
<td class="nump">477.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">8,059.9<span></span>
</td>
<td class="nump">6,662.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowances</a></td>
<td class="num">(775.1)<span></span>
</td>
<td class="num">(875.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">7,284.8<span></span>
</td>
<td class="nump">5,786.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Earnings of foreign subsidiaries</a></td>
<td class="num">(1,226.0)<span></span>
</td>
<td class="num">(1,583.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="num">(1,387.9)<span></span>
</td>
<td class="num">(1,516.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts', window );">Inventories</a></td>
<td class="num">(639.5)<span></span>
</td>
<td class="num">(596.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid employee benefits</a></td>
<td class="num">(546.5)<span></span>
</td>
<td class="num">(560.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(433.5)<span></span>
</td>
<td class="num">(338.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDerivatives', window );">Financial instruments</a></td>
<td class="num">(215.0)<span></span>
</td>
<td class="num">(303.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease assets</a></td>
<td class="num">(130.7)<span></span>
</td>
<td class="num">(132.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(4,579.1)<span></span>
</td>
<td class="num">(5,030.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">$ 2,705.7<span></span>
</td>
<td class="nump">$ 755.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DeferredTaxAssetsCorrectiveTaxAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Corrective Tax Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DeferredTaxAssetsCorrectiveTaxAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DeferredTaxAssetsForeignTaxRedeterminations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Foreign Tax Redeterminations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DeferredTaxAssetsForeignTaxRedeterminations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DeferredTaxAssetsSalesRebatesAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Sales Rebates And Discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DeferredTaxAssetsSalesRebatesAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206519591376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">$ 2,370.0<span></span>
</td>
<td class="nump">$ 1,980.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes', window );">Domestic and Puerto Rican companies contribution</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible', window );">Long-term income taxes payable, estimated timing of future cash outflows not possible</a></td>
<td class="nump">$ 2,280.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">1,700.0<span></span>
</td>
<td class="nump">$ 1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accruals for the payment of interest and penalties</a></td>
<td class="nump">271.5<span></span>
</td>
<td class="nump">$ 220.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_CarryforwardMember', window );">Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">873.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">2,520.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_ExpirationBy2026Member', window );">Expiration By 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">148.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_ExpirationBetween2028And2042Member', window );">Expiration Between 2028 and 2042</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">27.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">1,440.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_DesignatedUnusableMember', window );">Designated Unusable | Internal Revenue Service (IRS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">68.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_DesignatedUnusableMember', window );">Designated Unusable | Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">118.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_DesignatedUnusableMember', window );">Designated Unusable | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">510.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred tax assets related to state net operating losses</a></td>
<td class="nump">246.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_ExpirationBy2027Member', window );">Expiration By 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">319.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_NoExpirationMember', window );">No Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 762.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent contribution of most significant (domestic, including Puerto Rico) areas that contributed to the consolidated income (loss) before income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_CarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_CarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_ExpirationBy2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_ExpirationBy2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_ExpirationBetween2028And2042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_ExpirationBetween2028And2042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_DesignatedUnusableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_DesignatedUnusableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_ExpirationBy2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_ExpirationBy2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_NoExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_NoExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206528944768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Cash Payments of Income Taxes) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash payments of income taxes</a></td>
<td class="nump">$ 2,672.9<span></span>
</td>
<td class="nump">$ 1,598.8<span></span>
</td>
<td class="nump">$ 954.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206519114144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Future Cash Payments Relating to the Toll Tax) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract', window );"><strong>2017 Tax Act Toll Tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_TaxCutAndJobsActTollTaxToBePaid', window );">Total</a></td>
<td class="nump">$ 1,895.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear', window );">Less than 1 Year</a></td>
<td class="nump">475.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears', window );">1-3 Years</a></td>
<td class="nump">$ 1,420.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cut And Jobs Act, Toll Tax, Payment, Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_TaxCutAndJobsActTollTaxPaymentDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_TaxCutAndJobsActTollTaxToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cut And Jobs Act, Toll Tax, To Be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_TaxCutAndJobsActTollTaxToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206519059136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Reconciliation of Income Taxes) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax at the U.S. federal statutory tax rate</a></td>
<td class="nump">$ 1,429.3<span></span>
</td>
<td class="nump">$ 1,292.6<span></span>
</td>
<td class="nump">$ 1,518.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AddDeductAbstract', window );"><strong>Add (deduct):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign', window );">International operations, including Puerto Rico</a></td>
<td class="num">(299.5)<span></span>
</td>
<td class="num">(447.5)<span></span>
</td>
<td class="num">(297.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">General business credits</a></td>
<td class="num">(155.0)<span></span>
</td>
<td class="num">(100.5)<span></span>
</td>
<td class="num">(97.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign-derived intangible income deduction</a></td>
<td class="num">(287.5)<span></span>
</td>
<td class="num">(86.7)<span></span>
</td>
<td class="num">(71.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance release</a></td>
<td class="num">(116.4)<span></span>
</td>
<td class="num">(19.0)<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(9.3)<span></span>
</td>
<td class="num">(65.1)<span></span>
</td>
<td class="num">(5.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="nump">$ 561.6<span></span>
</td>
<td class="nump">$ 573.8<span></span>
</td>
<td class="nump">$ 1,036.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AddDeductAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Add (Deduct) [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AddDeductAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206529495360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Unrecognized Tax Benefits) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 2,798.3<span></span>
</td>
<td class="nump">$ 2,551.9<span></span>
</td>
<td class="nump">$ 2,108.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">274.2<span></span>
</td>
<td class="nump">310.3<span></span>
</td>
<td class="nump">225.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="nump">34.6<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
<td class="nump">310.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(10.9)<span></span>
</td>
<td class="num">(8.1)<span></span>
</td>
<td class="num">(52.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(44.8)<span></span>
</td>
<td class="num">(38.5)<span></span>
</td>
<td class="num">(72.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapses of statutes of limitation</a></td>
<td class="num">(11.8)<span></span>
</td>
<td class="num">(49.7)<span></span>
</td>
<td class="num">(41.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation', window );">Changes related to the impact of foreign currency translation</a></td>
<td class="num">(52.6)<span></span>
</td>
<td class="num">(66.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation', window );">Changes related to the impact of foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 2,987.0<span></span>
</td>
<td class="nump">$ 2,798.3<span></span>
</td>
<td class="nump">$ 2,551.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206518894048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Schedule of Benefit Obligations and Plan Assets and Funded Status) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation at beginning of year</a></td>
<td class="nump">$ 17,565.0<span></span>
</td>
<td class="nump">$ 18,225.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">351.7<span></span>
</td>
<td class="nump">369.2<span></span>
</td>
<td class="nump">$ 325.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">398.1<span></span>
</td>
<td class="nump">337.8<span></span>
</td>
<td class="nump">425.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gain) loss</a></td>
<td class="num">(4,158.9)<span></span>
</td>
<td class="num">(564.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(608.9)<span></span>
</td>
<td class="num">(630.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Foreign currency exchange rate changes and other adjustments</a></td>
<td class="num">(325.0)<span></span>
</td>
<td class="num">(173.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation at end of year</a></td>
<td class="nump">13,222.0<span></span>
</td>
<td class="nump">17,565.0<span></span>
</td>
<td class="nump">18,225.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at beginning of year</a></td>
<td class="nump">16,416.0<span></span>
</td>
<td class="nump">14,579.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="num">(2,388.1)<span></span>
</td>
<td class="nump">2,458.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contribution</a></td>
<td class="nump">118.1<span></span>
</td>
<td class="nump">131.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(608.9)<span></span>
</td>
<td class="num">(630.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Foreign currency exchange rate changes and other adjustments</a></td>
<td class="num">(341.3)<span></span>
</td>
<td class="num">(122.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at end of year</a></td>
<td class="nump">13,195.8<span></span>
</td>
<td class="nump">16,416.0<span></span>
</td>
<td class="nump">14,579.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status</a></td>
<td class="num">(26.2)<span></span>
</td>
<td class="num">(1,149.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Unrecognized net actuarial (gain) loss</a></td>
<td class="nump">2,687.2<span></span>
</td>
<td class="nump">3,908.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Unrecognized prior service (benefit) cost</a></td>
<td class="nump">8.4<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Net amount recognized</a></td>
<td class="nump">2,669.4<span></span>
</td>
<td class="nump">2,770.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember', window );">Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation at beginning of year</a></td>
<td class="nump">1,663.8<span></span>
</td>
<td class="nump">1,753.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">46.6<span></span>
</td>
<td class="nump">49.2<span></span>
</td>
<td class="nump">40.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">37.8<span></span>
</td>
<td class="nump">32.5<span></span>
</td>
<td class="nump">43.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gain) loss</a></td>
<td class="num">(395.9)<span></span>
</td>
<td class="num">(86.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(86.8)<span></span>
</td>
<td class="num">(79.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Foreign currency exchange rate changes and other adjustments</a></td>
<td class="num">(6.7)<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation at end of year</a></td>
<td class="nump">1,258.8<span></span>
</td>
<td class="nump">1,663.8<span></span>
</td>
<td class="nump">1,753.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at beginning of year</a></td>
<td class="nump">3,361.4<span></span>
</td>
<td class="nump">3,227.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="num">(796.0)<span></span>
</td>
<td class="nump">202.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contribution</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">11.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(86.8)<span></span>
</td>
<td class="num">(79.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Foreign currency exchange rate changes and other adjustments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at end of year</a></td>
<td class="nump">2,492.5<span></span>
</td>
<td class="nump">3,361.4<span></span>
</td>
<td class="nump">$ 3,227.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status</a></td>
<td class="nump">1,233.7<span></span>
</td>
<td class="nump">1,697.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Unrecognized net actuarial (gain) loss</a></td>
<td class="nump">54.5<span></span>
</td>
<td class="num">(497.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Unrecognized prior service (benefit) cost</a></td>
<td class="num">(62.2)<span></span>
</td>
<td class="num">(117.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Net amount recognized</a></td>
<td class="nump">$ 1,226.0<span></span>
</td>
<td class="nump">$ 1,082.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206518851872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recognized in the consolidated balance sheet consisted&#160;of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Accrued retirement benefits</a></td>
<td class="num">$ (1,305.1)<span></span>
</td>
<td class="num">$ (1,954.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recognized in the consolidated balance sheet consisted&#160;of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">1,208.0<span></span>
</td>
<td class="nump">668.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="num">(70.4)<span></span>
</td>
<td class="num">(68.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Accrued retirement benefits</a></td>
<td class="num">(1,163.8)<span></span>
</td>
<td class="num">(1,749.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Accumulated other comprehensive (income) loss before income taxes</a></td>
<td class="nump">2,695.6<span></span>
</td>
<td class="nump">3,919.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Net amount recognized</a></td>
<td class="nump">2,669.4<span></span>
</td>
<td class="nump">2,770.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember', window );">Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recognized in the consolidated balance sheet consisted&#160;of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">1,383.4<span></span>
</td>
<td class="nump">1,910.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="num">(8.4)<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Accrued retirement benefits</a></td>
<td class="num">(141.3)<span></span>
</td>
<td class="num">(204.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Accumulated other comprehensive (income) loss before income taxes</a></td>
<td class="num">(7.7)<span></span>
</td>
<td class="num">(614.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Net amount recognized</a></td>
<td class="nump">$ 1,226.0<span></span>
</td>
<td class="nump">$ 1,082.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206523378560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease', window );">Defined benefit obligation, period decrease</a></td>
<td class="nump">$ 4,750.0<span></span>
</td>
<td class="nump">$ 750.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expense under the plans</a></td>
<td class="nump">$ 170.6<span></span>
</td>
<td class="nump">167.3<span></span>
</td>
<td class="nump">$ 164.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets', window );">Percentage of global investments in plan assets</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Total accumulated benefit obligation for our defined benefit pension plans</a></td>
<td class="nump">$ 12,010.0<span></span>
</td>
<td class="nump">$ 16,440.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected future employer contributions, next fiscal year</a></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Plan assets, target allocation</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember', window );">Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Plan assets, target allocation</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage description of US defined benefit and other postretirement plan assets as compared to the total global investment balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206529431184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate for benefit obligation</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate for net benefit costs</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase for benefit obligation</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase for net benefit costs</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected return on plan assets for net benefit costs</a></td>
<td class="nump">8.10%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember', window );">Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate for benefit obligation</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate for net benefit costs</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected return on plan assets for net benefit costs</a></td>
<td class="nump">7.30%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206522756240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Projected benefit obligation</a></td>
<td class="nump">$ 2,211.2<span></span>
</td>
<td class="nump">$ 3,360.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">977.1<span></span>
</td>
<td class="nump">1,542.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">977.1<span></span>
</td>
<td class="nump">1,542.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract', window );"><strong>Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total other comprehensive income (loss) during period</a></td>
<td class="nump">616.9<span></span>
</td>
<td class="nump">2,699.4<span></span>
</td>
<td class="num">$ (157.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract', window );"><strong>Defined Benefit Plan, Expected Future Benefit Payment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2023</a></td>
<td class="nump">648.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2024</a></td>
<td class="nump">664.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2025</a></td>
<td class="nump">682.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2026</a></td>
<td class="nump">705.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2027</a></td>
<td class="nump">732.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2028-2032</a></td>
<td class="nump">4,079.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">652.7<span></span>
</td>
<td class="nump">973.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="nump">1,721.7<span></span>
</td>
<td class="nump">2,532.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">652.7<span></span>
</td>
<td class="nump">973.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Components of net periodic (benefit) cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">351.7<span></span>
</td>
<td class="nump">369.2<span></span>
</td>
<td class="nump">325.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">398.1<span></span>
</td>
<td class="nump">337.8<span></span>
</td>
<td class="nump">425.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(947.6)<span></span>
</td>
<td class="num">(949.3)<span></span>
</td>
<td class="num">(901.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service (benefit) cost</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial (gain) loss</a></td>
<td class="nump">342.4<span></span>
</td>
<td class="nump">487.7<span></span>
</td>
<td class="nump">396.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="nump">147.0<span></span>
</td>
<td class="nump">249.6<span></span>
</td>
<td class="nump">250.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract', window );"><strong>Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Actuarial gain (loss) arising during period</a></td>
<td class="nump">823.6<span></span>
</td>
<td class="nump">2,072.4<span></span>
</td>
<td class="num">(663.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Plan amendments during period</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Amortization of prior service (benefit) cost included in net income</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax', window );">Amortization of net actuarial (gain) loss included in net income</a></td>
<td class="nump">342.4<span></span>
</td>
<td class="nump">487.7<span></span>
</td>
<td class="nump">396.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Foreign currency exchange rate changes and other</a></td>
<td class="nump">55.5<span></span>
</td>
<td class="nump">47.2<span></span>
</td>
<td class="num">(71.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total other comprehensive income (loss) during period</a></td>
<td class="nump">1,223.9<span></span>
</td>
<td class="nump">2,611.5<span></span>
</td>
<td class="num">(335.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember', window );">Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract', window );"><strong>Defined Benefit Plan, Expected Future Benefit Payment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2023</a></td>
<td class="nump">89.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2024</a></td>
<td class="nump">91.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2025</a></td>
<td class="nump">92.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2026</a></td>
<td class="nump">92.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2027</a></td>
<td class="nump">93.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2028-2032</a></td>
<td class="nump">468.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="nump">149.8<span></span>
</td>
<td class="nump">212.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Components of net periodic (benefit) cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">46.6<span></span>
</td>
<td class="nump">49.2<span></span>
</td>
<td class="nump">40.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">37.8<span></span>
</td>
<td class="nump">32.5<span></span>
</td>
<td class="nump">43.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(152.1)<span></span>
</td>
<td class="num">(146.2)<span></span>
</td>
<td class="num">(158.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service (benefit) cost</a></td>
<td class="num">(54.8)<span></span>
</td>
<td class="num">(59.6)<span></span>
</td>
<td class="num">(59.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial (gain) loss</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="num">(121.6)<span></span>
</td>
<td class="num">(120.9)<span></span>
</td>
<td class="num">(136.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract', window );"><strong>Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Actuarial gain (loss) arising during period</a></td>
<td class="num">(552.2)<span></span>
</td>
<td class="nump">142.5<span></span>
</td>
<td class="nump">238.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Plan amendments during period</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Amortization of prior service (benefit) cost included in net income</a></td>
<td class="num">(54.8)<span></span>
</td>
<td class="num">(59.6)<span></span>
</td>
<td class="num">(59.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax', window );">Amortization of net actuarial (gain) loss included in net income</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Foreign currency exchange rate changes and other</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total other comprehensive income (loss) during period</a></td>
<td class="num">$ (607.0)<span></span>
</td>
<td class="nump">$ 88.0<span></span>
</td>
<td class="nump">$ 178.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206514013584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Retirement Benefits (Schedule of Fair Value Disclosures) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 13,195.8<span></span>
</td>
<td class="nump">$ 16,416.0<span></span>
</td>
<td class="nump">$ 14,579.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember', window );">Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,492.5<span></span>
</td>
<td class="nump">3,361.4<span></span>
</td>
<td class="nump">$ 3,227.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember', window );">U.S. | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,132.4<span></span>
</td>
<td class="nump">1,325.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember', window );">U.S. | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">104.2<span></span>
</td>
<td class="nump">124.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember', window );">International | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,177.1<span></span>
</td>
<td class="nump">2,722.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember', window );">International | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">72.0<span></span>
</td>
<td class="nump">180.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember', window );">Developed markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,445.5<span></span>
</td>
<td class="nump">4,496.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember', window );">Developed markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">63.1<span></span>
</td>
<td class="nump">102.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsRepurchasedAgreementsMember', window );">Developed markets - repurchase agreements | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="num">(706.6)<span></span>
</td>
<td class="num">(1,376.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsEmergingMarketsMember', window );">Emerging markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">273.5<span></span>
</td>
<td class="nump">611.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsEmergingMarketsMember', window );">Emerging markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">21.0<span></span>
</td>
<td class="nump">51.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_HedgeFundsMember', window );">Hedge funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,249.0<span></span>
</td>
<td class="nump">3,046.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_HedgeFundsMember', window );">Hedge funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">294.9<span></span>
</td>
<td class="nump">275.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquityFundsMember', window );">Equity-like funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4,014.1<span></span>
</td>
<td class="nump">3,816.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquityFundsMember', window );">Equity-like funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">332.8<span></span>
</td>
<td class="nump">317.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherContractMember', window );">Cash value of trust owned insurance contract | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,470.8<span></span>
</td>
<td class="nump">2,166.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember', window );">Real estate | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">349.1<span></span>
</td>
<td class="nump">630.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember', window );">Real estate | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">36.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_DefineBenefitPlanOtherMember', window );">Other | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,261.7<span></span>
</td>
<td class="nump">1,143.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_DefineBenefitPlanOtherMember', window );">Other | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">112.1<span></span>
</td>
<td class="nump">106.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,288.7<span></span>
</td>
<td class="nump">1,728.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">113.4<span></span>
</td>
<td class="nump">147.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">396.6<span></span>
</td>
<td class="nump">430.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">35.7<span></span>
</td>
<td class="nump">40.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | International | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">369.4<span></span>
</td>
<td class="nump">815.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | International | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">31.9<span></span>
</td>
<td class="nump">47.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Developed markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">19.8<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Developed markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Developed markets - repurchase agreements | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">6.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Emerging markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">11.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Emerging markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Hedge funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Hedge funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Equity-like funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Equity-like funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash value of trust owned insurance contract | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Real estate | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">234.9<span></span>
</td>
<td class="nump">363.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Real estate | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">34.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Other | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">251.0<span></span>
</td>
<td class="nump">103.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Other | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">24.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,546.4<span></span>
</td>
<td class="nump">2,501.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,514.0<span></span>
</td>
<td class="nump">2,290.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | U.S. | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | U.S. | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | International | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">300.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | International | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Developed markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,058.2<span></span>
</td>
<td class="nump">3,356.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Developed markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">63.1<span></span>
</td>
<td class="nump">80.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Developed markets - repurchase agreements | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="num">(713.0)<span></span>
</td>
<td class="num">(1,376.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Emerging markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">32.0<span></span>
</td>
<td class="nump">250.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Emerging markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">23.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Hedge funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Hedge funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Equity-like funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Equity-like funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Cash value of trust owned insurance contract | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,470.8<span></span>
</td>
<td class="nump">2,166.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Real estate | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Real estate | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Other | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="num">(131.8)<span></span>
</td>
<td class="nump">263.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Other | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="num">(19.9)<span></span>
</td>
<td class="nump">18.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">25.5<span></span>
</td>
<td class="nump">15.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | U.S. | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | U.S. | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | International | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | International | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Developed markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Developed markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Developed markets - repurchase agreements | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Emerging markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Emerging markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Hedge funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Hedge funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Equity-like funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">25.4<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Equity-like funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Cash value of trust owned insurance contract | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Real estate | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Real estate | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Other | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Other | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">10,335.2<span></span>
</td>
<td class="nump">12,170.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">862.7<span></span>
</td>
<td class="nump">922.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | U.S. | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">735.7<span></span>
</td>
<td class="nump">893.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | U.S. | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">68.5<span></span>
</td>
<td class="nump">83.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | International | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">506.8<span></span>
</td>
<td class="nump">1,907.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | International | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">40.1<span></span>
</td>
<td class="nump">132.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Developed markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">367.4<span></span>
</td>
<td class="nump">1,136.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Developed markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">21.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Developed markets - repurchase agreements | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Emerging markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">230.9<span></span>
</td>
<td class="nump">349.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Emerging markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">21.0<span></span>
</td>
<td class="nump">27.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Hedge funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,249.0<span></span>
</td>
<td class="nump">3,046.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Hedge funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">294.9<span></span>
</td>
<td class="nump">275.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Equity-like funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,988.7<span></span>
</td>
<td class="nump">3,808.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Equity-like funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">330.4<span></span>
</td>
<td class="nump">317.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Cash value of trust owned insurance contract | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Real estate | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">114.2<span></span>
</td>
<td class="nump">248.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Real estate | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Other | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,142.5<span></span>
</td>
<td class="nump">779.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Other | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 107.8<span></span>
</td>
<td class="nump">$ 63.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsRepurchasedAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsRepurchasedAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsEmergingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsEmergingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_HedgeFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_HedgeFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquityFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquityFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_DefineBenefitPlanOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_DefineBenefitPlanOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206519160688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Details)<br> R$ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">166 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>BRL (R$) </div>
<div>patent</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>BRL (R$)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>BRL (R$)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>BRL (R$) </div>
<div>site </div>
<div>lawsuit </div>
<div>patent</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>site </div>
<div>lawsuit </div>
<div>patent</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>lawsuit </div>
<div>plaintiff </div>
<div>patent </div>
<div>site</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>patent</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember', window );">Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup', window );">Number of sites jointly and severally liable for cleanup (fewer than) | site</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember', window );">Humalog, Humulin and Forteo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember', window );">Emgality Patent Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_LossContingencyNumberOfPatents', window );">Number of patents | patent</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_EmployeeLitigationMember', window );">Employee Litigation | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded, value</a></td>
<td class="nump">R$ 100<span></span>
</td>
<td class="nump">R$ 500<span></span>
</td>
<td class="nump">R$ 300<span></span>
</td>
<td class="nump">R$ 1,000<span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Patents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ByettaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ByettaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=lly_ProductLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=lly_ProductLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_EmployeeLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_EmployeeLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206512659008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Schedule of Component of Other Comprehensive Income (Loss)) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 9,154.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">247.7<span></span>
</td>
<td class="nump">$ 1,795.4<span></span>
</td>
<td class="num">$ (256.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">250.8<span></span>
</td>
<td class="nump">357.9<span></span>
</td>
<td class="nump">283.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax (Note 17)</a></td>
<td class="nump">498.5<span></span>
</td>
<td class="nump">2,153.3<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">10,775.4<span></span>
</td>
<td class="nump">9,154.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(4,343.1)<span></span>
</td>
<td class="num">(6,496.4)<span></span>
</td>
<td class="num">(6,523.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(3,844.6)<span></span>
</td>
<td class="num">(4,343.1)<span></span>
</td>
<td class="num">(6,496.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Gains&#160;(Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(1,550.2)<span></span>
</td>
<td class="num">(1,427.5)<span></span>
</td>
<td class="num">(1,678.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(324.4)<span></span>
</td>
<td class="num">(122.7)<span></span>
</td>
<td class="nump">250.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax (Note 17)</a></td>
<td class="num">(324.0)<span></span>
</td>
<td class="num">(122.7)<span></span>
</td>
<td class="nump">250.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(1,874.2)<span></span>
</td>
<td class="num">(1,550.2)<span></span>
</td>
<td class="num">(1,427.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized Net Gains (Losses) on&#160;Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(52.2)<span></span>
</td>
<td class="num">(11.9)<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">11.4<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax (Note 17)</a></td>
<td class="num">(40.8)<span></span>
</td>
<td class="num">(11.1)<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(37.1)<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(2,583.6)<span></span>
</td>
<td class="num">(4,751.0)<span></span>
</td>
<td class="num">(4,638.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">291.5<span></span>
</td>
<td class="nump">1,823.4<span></span>
</td>
<td class="num">(379.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">229.8<span></span>
</td>
<td class="nump">344.0<span></span>
</td>
<td class="nump">267.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax (Note 17)</a></td>
<td class="nump">521.3<span></span>
</td>
<td class="nump">2,167.4<span></span>
</td>
<td class="num">(112.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(2,062.3)<span></span>
</td>
<td class="num">(2,583.6)<span></span>
</td>
<td class="num">(4,751.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember', window );">Effective Portion of Cash&#160;Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(213.0)<span></span>
</td>
<td class="num">(332.7)<span></span>
</td>
<td class="num">(211.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">332.8<span></span>
</td>
<td class="nump">106.6<span></span>
</td>
<td class="num">(133.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">9.2<span></span>
</td>
<td class="nump">13.1<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax (Note 17)</a></td>
<td class="nump">342.0<span></span>
</td>
<td class="nump">119.7<span></span>
</td>
<td class="num">(120.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">$ 129.0<span></span>
</td>
<td class="num">$ (213.0)<span></span>
</td>
<td class="num">$ (332.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206512657696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Schedule of Tax Effects) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">$ (250.0)<span></span>
</td>
<td class="num">$ (695.3)<span></span>
</td>
<td class="nump">$ 200.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Gains&#160;(Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">(75.9)<span></span>
</td>
<td class="num">(136.2)<span></span>
</td>
<td class="nump">128.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized Net Gains (Losses) on&#160;Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="nump">12.4<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="num">(4.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">(95.6)<span></span>
</td>
<td class="num">(532.0)<span></span>
</td>
<td class="nump">44.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember', window );">Effective Portion of Cash&#160;Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">$ (90.9)<span></span>
</td>
<td class="num">$ (31.8)<span></span>
</td>
<td class="nump">$ 32.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206530769712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net (income) expense</a></td>
<td class="num">$ (14.3)<span></span>
</td>
<td class="nump">$ 51.4<span></span>
</td>
<td class="num">$ (195.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total before tax</a></td>
<td class="nump">6,806.4<span></span>
</td>
<td class="nump">6,155.5<span></span>
</td>
<td class="nump">7,229.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="num">(561.6)<span></span>
</td>
<td class="num">(573.8)<span></span>
</td>
<td class="num">(1,036.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total reclassifications for the period, net of tax</a></td>
<td class="nump">250.8<span></span>
</td>
<td class="nump">357.9<span></span>
</td>
<td class="nump">283.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Amortization of retirement benefit items | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total before tax</a></td>
<td class="nump">290.9<span></span>
</td>
<td class="nump">435.5<span></span>
</td>
<td class="nump">338.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="num">(61.1)<span></span>
</td>
<td class="num">(91.5)<span></span>
</td>
<td class="num">(71.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total reclassifications for the period, net of tax</a></td>
<td class="nump">229.8<span></span>
</td>
<td class="nump">344.0<span></span>
</td>
<td class="nump">267.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember', window );">Prior service benefits, net | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net (income) expense</a></td>
<td class="num">(52.4)<span></span>
</td>
<td class="num">(55.4)<span></span>
</td>
<td class="num">(55.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Actuarial losses | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net (income) expense</a></td>
<td class="nump">343.3<span></span>
</td>
<td class="nump">490.9<span></span>
</td>
<td class="nump">393.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember', window );">Other, net of tax | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net (income) expense</a></td>
<td class="nump">$ 21.0<span></span>
</td>
<td class="nump">$ 13.9<span></span>
</td>
<td class="nump">$ 16.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140206529479312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other - Net, (Income) Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 331.6<span></span>
</td>
<td class="nump">$ 339.8<span></span>
</td>
<td class="nump">$ 359.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(62.8)<span></span>
</td>
<td class="num">(25.4)<span></span>
</td>
<td class="num">(33.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net investment (gains) losses on equity securities (Note 7)</a></td>
<td class="nump">410.7<span></span>
</td>
<td class="num">(176.9)<span></span>
</td>
<td class="num">(1,442.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment loss (Note 11)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">405.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Retirement benefit plans</a></td>
<td class="num">(372.9)<span></span>
</td>
<td class="num">(289.7)<span></span>
</td>
<td class="num">(251.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense</a></td>
<td class="nump">14.3<span></span>
</td>
<td class="num">(51.4)<span></span>
</td>
<td class="nump">195.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="nump">$ 320.9<span></span>
</td>
<td class="nump">$ 201.6<span></span>
</td>
<td class="num">$ (1,171.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>lly-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lly="http://www.lilly.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lly-20221231.xsd" xlink:type="simple"/>
    <context id="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0123f42da8014c4e80a496f4ec156d49_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia6faa5dfbefd43faba61396886103e54_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7506ecec16a548918d36c633b7d2886f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i74727aae65ec420f8d2a7d3f2fc82caa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8b6679d8bf73400fb57c1d771b743b9f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idd78f7ed1d134dcf8be4669929f8630d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1ec7aad2a8d0401f82a878dda7a7a03e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icee8de005b2e49f9879377e478c0b2db_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625BritishPoundDenominatedNotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifbdd41c0af48472b8577f5e8157441c2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i62b9486903fe42cd82d7869cb7d772c4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0bfa6ff0f0fa4248813d3e66ff3abdab_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if754bc01888f45ac8d951c81d205bc32_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i57c62c4ea2844c0e9a340732ae328cbc_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ife049f03c96e47288db50605b1356b32_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id1b649fc71124f56ae26b2e43abf1d5d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i356b319ab866417988ad019b9794d8cb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9021134b4fbc4e258ea850eb3c4c4c7b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5a2f5f0abb434012bb2af32c10ddc89c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6870f7c27b5d40b09b8227c732a66406_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i89c86fcc6d9848e19d2dcbf04813b652_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0cfd19befed844bdbd1e65f027b7a2ec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4b11cb527104470694b7931c221de577_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6964671a05464b22a4eb74dbbd4d79e7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i774298166b774d40bff6c0588b2f3c56_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5b0c0c02225844c6b4ea5018b890387d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i375d8504588144e3bb7b25036361f87c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i19f9560e8da24c70a901e8c074917400_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i16cfc9ba4c614087a5a71a8d2a07e024_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia61f75ab6b7546e7a580ad9a5b93f8d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a274dc2077148a0b820a07f6dfed9f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7559b91ac864734b64c8cb3e513830a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibf02933ba36a42cfbfedca3bc4a05dea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idfab23ce152040e39f298e6d61067c78_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ae7226bbaa54a2bbab2e5672eb2325b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4862d64d1a0c4143be7faa33eecd5fae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if05c4645dada4161887047e966e0cacc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ief070a1731ef4d1cbff5877950a5d572_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i641baa148fc94939a4e053beaf2b5f97_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i44b2a1ce17cf4dcf80f4b720f9b9853c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1a1511cc032b4cc28578302f22e2c378_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i18e2767e0827495582d56de8c7445b9d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id08bbbd0c60b41d489ec1b27da14ee41_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5849b31083f849e0a1279866ce821c8d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d74411eaba3495eb1fb5b40272b8e0b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f874e14a4254206a744a4d998b3e21e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9397c716ecc8492dbfa355270ffb58b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8898e7952db94e61a40bdb19eaf218e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id4292c3a6efd4496b3c10175cfb14871_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64797ebd6cf24a2b83d33c497b3a79cc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i03cb5dfdc26c46d3b41f02d740b93582_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iadf0599f6d15415f8e902c9d74e9a82f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i25b818086dc044f0bd310156d54327e0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib71f55d1f6214dbc90efad0d6e0c1bb4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i611da2eb6b9c4c8bb17a1786b533ae67_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i178450cc0eef447cab2a5bd78e323b88_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i37f9e6a906424b848ddbd2a24ab91d95_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i71b32db201354064b5cb0802d4c538dd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i42001d8086bb49dda45b041109c50d00_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a6bea1aa20b446397b350ac2671efab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i54accb4bb2b648519e8a5ddd0145dcb3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i79b34353006b49229fc2d875ac767766_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i68cf5a8007734a98a36e143a7305b0b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib66e8131e7a64596bd768a5869bc86ab_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie555d2f92f6542cc95e629676af2b0dc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i99575cf533c942e98caf27205363dccd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i78dd629925fb4ae4a5093b5fc180b030_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i08fdadf5ca3249bb9c4fb62f22fd5774_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i09ca7f6b539b42c9bf6134ac1b709820_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c9c826fd2b347378c7aa9dfe51568b7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iadec1e1743a24bc4aa16803f33246e23_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6618dd5b6c274f07b8f2d7da01455ae9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i46e71ff65ed94973b8d1406f4b8985bd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia3cb0bc9a28341368653294b04baaed1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3c4252adafce48d88948c0f7b97ac340_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9fd0e5a16356409e8036bedd277f4b6c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i85cc049a60e14b52a4c0ca5ac603af8d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i688f1fee1d614afdae131948a26e41be_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99ecb99c796447d88385d69144bcd82c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic3df9d79b482447198c448522c1b720b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0918ef1c05fb4f68ab4e15f2a8283a12_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibbf827440e1c44ed9d4fa7f91748f0b5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie4e5c7fafd8141999915cd2f615aaeb8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i91192a23f0104c96a6b1188f603bb21a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1a5b41d1ce604fd1b7157e4bb21a41c7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i79ee633bf3254f18873fa97220a9dff2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibed6c41cdbc8431bac939f81410f22c9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i908ec847fcf64bb7913cbcb485ad4d96_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie8129ef6df6f431e977d79c1b651ea70_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3d1a32c39d7543c5bda93421375a60d8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id4677e27f1be4111b8e4c3d118b419a1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ac4e905749940e0acc95a2b2b4d06c1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1429058ec4bd4a89b6ef2f638439c0e5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i90ebccca38314b2b893a86d4df3e24ed_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i940a532a79364120a9f3635e0d2abcec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4ee509ded6c2446891ec496e86228071_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i353b4ca1ec8545e29d12179593b5f304_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2c31d4c6617549a6926ef9edc6b8d19d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic0a89f71ff7840b2aee585821fdc79bb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic6129a4ae188436e997eb164885bd944_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iba2beed36c49496f8c05407dbded623c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icf3a669814bf4e739636b5862a5a79d3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i42a13a96ce9d4498957d2c9c70ac693b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie734d147b3a94c178e55911be7120159_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i83a6a8aae9224f21a121e9d9db314173_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5838c7dc2be042b2a3ab858cf9b880e6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icbedbb47344e4f2cb3b8765fa2aff470_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9ed9fab22d754adeb11fb4fe998cb3a6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i63f062d00a9b498abb19bb45e988b8a2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7c28332273c24b679e3f1bb73cf7cc58_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7c493cb7f8944bb2b545e0e6d00775bc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i625ee4d76d334362b8de4352af1b773d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia873c39e36f34f9880aa324b4f3c6b89_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5019cb5a09214868a6ffd5c421748740_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idf887a499d9b4c1f9b06d18769bf3a1d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idf2974bb2f68427da48e46d951d464e4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i64eacb976de14569ac6ff1899c6605de_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6306f16596f249559125fb3a670c3326_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id7b5bde978fc4056b0f67115cb95bdc1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a2a0156508b46d6a429156a9e507b0a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9e04de56005e49cf9693a8f1a4d921b6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2a158eedd1b1481995dd35bc68fea4dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie94ce0194f2a42f986e5b3f0d5e00c05_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic9763e7d353848e4a659a5f54585d4a3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i87c4deaeae714216a5ee408c78d2cf02_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie572e122731f4d66b7d209d9d838c85f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ieb2c52e8eea34a75a5e2f2b51206fa4b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icb4fc43fe5434bd9b22e62377d8e4f20_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5b43b7a7eb4a42ea96b75af06d3894fc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia8fe6893994d4f3da2aed48164588249_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i08d12e8f58234c72a009dbbd89e1ef87_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2045052682ee483d9ecaaf59cf44fdb5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i725c992052d041e192d4ee9a85e23fe8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia6b37c5bfb894eb683d061c2663d2135_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id0093b813b28435d89b38aaa707cb59a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i815000e020f14a53a097e53a2b56cf06_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2d08de0a5b1a48e693777db50fe7ee4e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iebb55033007f414c8fa01ecddd9bf258_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i436f39f0114a4a5b9a126d5a84fad158_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icf01e8c322a64b3cb59c38b35cf69a28_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic463dd1900c549c09de91b07ab6ca276_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6bc3a2798eef4b98bf1cda7f51dbb961_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i34b6a251be9e4777827eee958db02629_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibfa9bb0a325b4912942a0407bfd24c96_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if7e2990f5e8845a191e0fb00304c2103_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2cc3f43284394154b2281bd30b634ec5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i96f6b8a0775b4507983b982add0eaa15_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i475b2a44ffaa4b3ab01390955fe7fb4e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4e84d0c1a5604dc399d2032784a2c381_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie1d59b98a2b84f41bcf716a679809aef_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i47bf0038a1cf485685beffa18825039e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibbe5cf54b9584a46ba3abe1a6a45520b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i77bb27eccc6e416b96871a23917489a6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i99feddef0f9d4b61ae8c11159fdbbed6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3881ed56ede64167839562a909065542_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4da626bf5e3e4942861f067702818432_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9d4ae7d53fa74012826220f9d9aefec0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7e5fa2fc32ec4622803f8565f86727be_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icc6ab3bc43384429a45007709c2c734c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3d903025752047dc8b7cdd55eb19a7ed_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifb7822de8b36448bbb44fa84bf3d26b2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic1dfa84e409446888abbc37fbcf675ba_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7ec671c462234f09b93b6aebd0b48663_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2ea2a5bdd3934abbababa751cef82703_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia800ee3300054be0a311fc0ded6756a4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i050aca7ad92848f7bce2d263075706f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iedf81083b171427593695e6bf008b9ca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i38d43d13cc4649cdb4b312a0c6e19672_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4403e2fd87d64f338b43367544717790_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie5e9ce589b3341e59b661221502733d3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if37fae77f3fd48b39b0930752704bc6a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3eceda29c176407a87bd531353a1c6e8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia87e1143e93f432785a964577b99cef5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i20f5d0530c744df690ab8c031e4207b2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i760024cf4c2b4368ae467fa2e123ad6a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5d7597d5af254ee68dee4515242f8889_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8399f74b1bdf46aeb1528d1b339e6322_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia0ea5b089cf44e24b8e07841f4632655_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idf3ddbf27f6d4e1f91bb0bb812805861_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib32eab706ca94218a617e1064dbc8ab2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4223c4a3b6f241dfb2bdcc2730d74722_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id1e350402b214cd6a481e96fcc09dc2d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia6e79e5873c04265ae9f72597e7f8655_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i657624079cc0470f8c99a900c86bb61e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic8d7a484c7774a6fafe5d1a16b52d73c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4bd0bb01de3b4defa7e5a43ea90f78fa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i89ca17c8c8fa4a3c97af54a9338d556b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie11d2b1d901b4c59b9940a3eec5fac7e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7bbf7ffff8d940379635573118d0f46d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ieb60edeed6364e088d8dbb6b15046831_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iae608dbd9c8b41bba6dbf7a3b438fbf1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id3072b728afd41dda5c1bc25d9a2f756_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic4a1e442fced4165a82ae4740cb22603_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i68b90bf218ec4f59bc626928cee0157a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if0f6cf7efc0d4c7fa84a45bd8424a737_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i17d469e38c5249c1b559efdd08d0b75f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8250de8fcc304ad3ba9fd98d5ffe1067_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaab72e5a9431446392b87064073da439_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaefaac168c674bd8bbaf0ba59c09b345_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie8f82cf734df4f228c6ca91846be4abc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic8b87668f0c34cfe8c41218fb3f7c47d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i140a6b9bf6b14209800b8ed52032d8f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic9daf68a25164d62b1bb8bf1e3e52307_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id1cc6ca8f8f148fbbce02f358ee33e7b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6cbe097595924436a04ba8cc2a5d2e99_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib156c3b2d1414c94bf4093abcc3dafc8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i33fca98fda4a48f79d860f14183ce7e3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie34501579b964c8abb3704d789d36cdb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i77f2f9e5632a4e7c9163699499944509_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i60c850a7c7894db69b4a040b6d233af0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0d17a977fd83415c9e00512147086a44_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iad01c8f917b44cacad101857ae82b796_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i027e5de11b114136913aecf0144ddbc2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib0fafe92cc1347b5bc9f75c189771831_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8037b2d8309d4fb482c5ec2dedc8a023_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i05b4f558633e4ea782159ade55b154e9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic41b44053bbf475aa1692687a86d75c8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7a7fe42f8eac44919bbccc5a618cf3f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i785953ac34004786aaaaf3b2c864ba77_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i32f96b235c0b43198bae6d8ec75f0a44_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ife00cbd3aa774f1faba1231e784a9643_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib74ddbdf3df74b23b09907d3377b3d56_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6bfddc1069524fcd8b6e480aa1ef27c3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6538ec30c43840a99b5e15dc4bcc8131_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7b4a05b525764d80b2afbc012254fe88_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i75c9e82d787c47c0bdb7e1e3d16ce5f4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if30607cf1ea84cf498de520dba0098c7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i698cd7cf5e334be397e08d1f53f737ab_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i09c32552bbc74587b3fe07cd98986a93_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i83ddfe09bcd8407bab751faee3cfa0bf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i322d3171da864966aedc55c9b681518f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5621221cf9f34eef9b9959e16714579c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0247f0ebdb344b409d4ad90e21eedad1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib15d3cae66954118a6d0296e4d23df93_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if841f2a4ceaf4fe58f4697466e041316_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8429e0edc9214436aaddaab1bcaeb6b9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6e963233c54e48a888c15bcf4c23ffde_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8cfffcec45ae40fb8465dac10b22a976_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic7501982382a4a88bbc9f7e3e3e85161_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6dd637301dfb459db236d29c1bcf0177_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i77b859afefa6475bbb5c098a0f192a8d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i061bb5f86557438ea2fcf07c86b17b69_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i45698e97012941fdb7ec2890f67c1c66_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i24ef4fbd510845ce85f4028d457ed43c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2762e4d8c5664efd8b887ca758f9b9c4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i74331b3977d84386b77d2682b2d47eb2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia8f45af4cef54b1ca2871b3cd9a01e27_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b7a565db26f4dbaaefe0953a8a80479_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia31a0ff6d06240dda20f93d85ba7a1b0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if85eef2cfec74cb1a86907d6bcafb6ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i958d4fe65ef3466d9c1b806dc825fd05_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i71acdff4e8334d96837f9b23f9643937_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iff78a5e546e044469bcb8ddfffc41863_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i02714f6a0b344ffaabb940f97f9422bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1a75711b53cf4bd4854c933fc91f0554_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0deffb51001949c4bd36158c98e3df90_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i12173600f90244fa8c910b03b4b7685b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6a9c8e37f3254306908fbf67a57a962f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6c655ff0b6734b1b895917ead0f1d0bc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib57a805732c14379adc9748655cc8c8a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic5231cf59d554630ab8ee2ab6a543866_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i06358e5e2c9543f9b4d8af95e8fbee1a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie66a1354c46c40fd8326cd7ee4fa99c1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1e3a4aa6df1d471499e619affd59a81c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia2d92d62baf647fba64657e6da2c5cc7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia0743faca88f49c9a9a69941934ee01a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icb29b5e537384747850aedf57eea8ac5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if04be40612da46cd8c72bcf49f6acda6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if6d44e44e5ef4e85b17fd98791ed3f74_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3a19b43d72264c28838a978d205164c4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i864722d9b52d4c70b0ca7b1f3f30b98b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id79c2882668a445497ebd9d63d0e6b0f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5c2193c6723347899232bf1d50d961c5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie596f23aada14611bc47697f70b8e788_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idb22934230f849698cd861bdcfad137e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1be2a9f3e7684d60a8f1c56366cb8f4f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i26f622dfdd764d8da1a4d607b1b94085_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idd3aa04d3e924b2ebf2ea8e693f3b76c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2bfc2608a4d84b308f03c62f86081700_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i24ac34b561704aaf9cdc8cf15d9421c4_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iceb5a7f2472e4bb0a0f8c4fe22cd2d24_I20221201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-01</instant>
        </period>
    </context>
    <context id="ic28ae7a6137047c1a086087e77b37fc7_D20221201-20221201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-01</endDate>
        </period>
    </context>
    <context id="i9bbccb3f78b34d48a0c51e4a8de0644e_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="ibeb47b42169c4a378f20a2bb7a0d88f6_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i79e8bd3a88dd451697bfede1f38f914c_I20210122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-22</instant>
        </period>
    </context>
    <context id="i592f678cd37f48ac8b0d09a457ed8878_D20210122-20210122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-22</startDate>
            <endDate>2021-01-22</endDate>
        </period>
    </context>
    <context id="i911ffcfb85b543048b73c602e046f88a_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i57500d6d00fa48b2a37e2a728d955386_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i22bda1e261ac4b2488c77f767678e525_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:BioMarinPharmaceuticalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="icb08a5c1f49e4f2990ebe8463033cbeb_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:FoghornTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie0973cb0fd694b219690663eb984716f_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:RigelPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i81d67d91f47b4d55acc7e70b5b593208_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PrecisionBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i4554cea5b47540518c88b975dda8a988_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i76b78baacb0a4d53bbd37d9f5f91b297_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PetraPharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ifdaaf6c7f8004c49b4ff53eb161a0b68_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:DisarmTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="ib72f8530223f4b8b9206e3912e939d05_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3307f82bfdc14dd5a7869a1f5a407fe3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie6382df2fed0453f9d14c9ca82bc5c85_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5b54345933e846e39cc3f792be5b88ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i191cd21724a847a1ab7b4f35246862d4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i485f72de6db64da1bfe2334d8014678b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93deb0a502fc4527a3920971ba7c2c0f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i95a63cfe221f41ebba6cd651af9ddf9b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ea327d1c37d4bfca7f2723b4565f151_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icb1a49e986754a4593a59e0e5166de8d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iac449f4acefe4dc984d41cb41455bae6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib09d7cfc9f57482cacbac86586144b4f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i540e1253ab844a0bbc43a8cfb3ee0920_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iadfe8a33be5c4ba7afa22a73eed9d5ef_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c91f4e2d9c840879cf9a65000a09847_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i81b687c200704d14b8cd74e649ddccdc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id1f7f5218520412cb6fd499f49c829c4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69ac6765ad604943bedfef80dbb59046_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0b97a2e15744cdfa799e948994a62f0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieb5d7e7fe6df47d69da986515824156b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i39d7234845174224b663942a5c72f5c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i36f40f8db5514b028a508fdf20bcd89f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6f3dc4d892d343b49ec303ecaf36d9bd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icc949a713d77433c984ccf27f4feda59_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7cb32af28a4d439d8eae4393101c3901_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5000c09e5ee64486a770c6f98d826b1f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i841f858d8d814afcbb33413461967380_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic1b1742cf89b4c1fb470b6fea7034191_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i11abecbd539d44bca9891ae6f43a6b9d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i340330379c1b4d17a5d1893688ec0953_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7796b711e49341dab27420fbab5beae5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i88b5d5e3acab4840b3a4b0c187d24ff5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib2046b6b3eed4ac6b751298dc54b230f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i85739ca7c6b04f86b9f0f4e04dac3933_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4c6d39fa7dff407a9bb5b5c2e98c8f37_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if819ebce2b824e4f956b1fc03a244870_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6d41b93e38c04495a8c9e35a8f93a51b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7a6cadf85ae74e19b0b4b3d94566c950_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib29cb4f6b7524096a38ea003c862f821_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9e73f160e8f04f4eaddf6e0c2226046d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4cc4f4f8668840918ffb5f33a50164aa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i83db6edf74c94f7dbe7af9c3b57e71cd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i96a991509ebf43809a439058ce22fa7e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icf3de48b5cde4b74bd86492c49a3cfff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iab0fa37d1d26458698fec203c6de3170_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7b78ecf596654f379406da98609085ad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e65c1e9f8314c05bb18488e182dcdc8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5c6b6db44fad4227b0e7923dd144dad5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i267eeb3d4c4544ed98a8e040d42e3659_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie08ea2826b404bb1b32d7612d132d1fc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4360dfda4bcd4ae8aacb3842d8b38544_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iecdb9bef83534c1ca768e9eb267d15fb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icd68026d385248dc99ec6cebbbcf4fe0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8623252cacd94e8eacc974d3c5bb281a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia3b93d9016f347f7a42304dbc2662cbf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie7745ed8eaec4896a79398bf44e3ee0c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib2c6931fe5d44a29a69a4915f25c3aa3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e449ba54e0f4910991f72fc6586c372_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i202f70807f944a99b3c4a8546c4c57b6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i96434fbfa57540c3bf2a773a2c2ff46e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifc245c7e9eab4641886b085a802fcb71_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic744f4b830ac467eb5deba8b1de59644_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i09eaf08a82294887bec59eec2190dd1e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic0b4fd6680c24327b70dbadbcdab8d00_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6c609093db884ac09f9b0f30051477e4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3257f473d8d344f2a056bb2771c42f6e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i43ea231ef1224a80971a531780a87b35_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i31f61c2016124d9faff9cfc9175c8e0b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaa948220bcab4ce3b0bd4520c7b48b28_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ica209a2bd9434d09b84c0795cb110ef9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iecb3faf84ac344d18fad6aa15881f6ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i87a3049207dd433897dc2049c4a35614_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i97d710d13dea404c9c76ca03cfd32cae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9fb8d947138d48f4ba4234d90a755569_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id93e165c23a14eb4848c3cfac9842a39_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ide566100c19446ef9e02ffe6729e317a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i206922eb76584eceb418d0469c699ef1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a592b428bb4466ca49b8ab98ac79c2f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie77fee34bd8143b9865e1a7ce56ae13b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7cb09673cd4d4a51aeae0a4b4fad802f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idec2713ca1764f9984742765f2a3f5f6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3ef264a2971a4d6d9632968955a88874_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67745cb3a266420caea7e92585afd798_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic1d701e8a7d846deb5dfed51dc19420e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e3bd9c97de44684a6f54ff2b763dce6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6543e2dc57fc4942a80a5c4b47c6a4d6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icbf3bc2cf6f14b3e986aed5486e859be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c7e6db0a0f342f38f0da6050795d81e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70d18d4fe82d4e3799255211fdb7c961_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e527334606a4f5cb5eb429d7720b579_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21be69bc53c046e5bc04d738798632b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i00463fe56920430aa066d2ecd7dce5ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc6345dbf99e4b10a664854739c10ab7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i09d53a5267d54e38ab69be8d99e1a128_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i791959b335d9411682c43bc9a3d30863_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1424fba935ab49b1bca8d99d589337e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i995cc780a15a4e11a297abb46a4670e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if923bd42b75741279230d2a8db22bf73_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie18586de026d4b76ac4be48157ae8d1d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i630ee0edbef7428faf2976f9c169689f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66776fea49f94b9a845efebd8dc9043a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1dd7f0aa7ba940b4871022bad3341f93_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iefd7992238674ff3901e725d12b4b20f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i40df2b9b5ee34ab0aa3950d2139dfd76_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea1803ebd97a4e4f87e68572966755b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0d644ad67b64ed896bb8c35759604a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i065e0d87c04c401fae0f22c40bf7957c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id97791b6d6d4420180779511ef340d85_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9a5c2ba711e441db5517f030cff4003_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i114748072ce44e029035eb08efa37d1f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i825718d9a8af4d88a0b8aa9db37556e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83265c7960c34844bb2725361d24deba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i869fd0d7109b41d4815c68ea3a46ebac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8bae18362b342449e21722305a0c0ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67b95f772703429a8a0357ffd550d665_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id72a1c59b3e84bdabceb3740c94a39b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia286896d0b5e4e60be5600fdf1b2b12e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5351b4419e648ebbac325c9a8f25776_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97a76897f7614783bbc3b95171430289_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08786343c67b4a868c5253051cd773cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0f4d070f3f34eacab1aaebe39cae662_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4762367938c14cfca0c24d191f73550c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e291e2320cd48a3aa360f816a7fed28_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib49d1436b4674f92b884ce9b352c35d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68ab827622544f9ea9120e5ce5dd8bab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7a8b848d1d8427c890edfad8cc5f8cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc8331fd4f1147f4992919b2c03cbd9c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7cfbaeb1387403689ac26389c2117c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6613a24a2ca74795845a7f065003a508_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i86203110a3b4409f801853ea6da76a28_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05a9e0f210644523adfae49f8876648c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib1ea8deb8e384d8cb4e5f60294c5ed92_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i19b69bc057c7444085abf4374f69f116_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iedff9c53d09a4160b981746e70812997_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7b78813a7f544e37b44ae5f03d274d1e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7159491c93374658b5b5847e6ac5edf6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9001871d7424666bd9d0957d8242b6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab54aa3b8b47409280b75c28d3043c2f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1028e48517574b909d8fcf57e1818f87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39ef4f84d9484b978fdf61e96ab0edaa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie250a0992fc5431f969a7964f8245fdc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUsdSellEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7e9395f4903c4d1e8256befb608125af_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyEuroSellUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3ea07b15fab64564acb30e6db85e870e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSDollarSellChineseYuanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i94c6020cd3ae44f998a4fa76cd815d56_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyJapaneseYenSellUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iceee439d84744b8d804526bc0f2adeab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSdollarSellJapaneseYenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e20eef33fbc4dec93f944ed6836a620_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyGBPSellUSDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i61a09d5cb8a14ccea8468a476ea53884_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuySwissFrancSellUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibf02b938757d412587be87a02a84f028_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifd3cce905838492e986c48f76166193c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4778e0d847b8442d93aeec9ae0fcc5af_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapUSDollarsToEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5cef174a144b4c2b89d92be601c8cc4f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapSwissFrancsToU.S.DollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if6c65f3c28a542199950c644aa1cf261_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SellEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f3aff17db1c4acb85c8851f9450065d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SellChineseYuanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia85b3dcb7d4541c7aad67c44e3261dea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i21e6e625c3cb4498ba3bf6924f8d2408_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic7662cc39cfe4433b0594d699b335670_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6798f46f87f74360b20909f04395afc3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idbbe46ca06b34c009dcda97ccf3beb64_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if399b1d939d243708da92494b6325f95_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4cdf044d78494e7694b33040bfab47e7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7e9fe4a4a4094271b4b30ac4a4625c89_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i912fb880c8bf46f58edb6cd6fdf00e0d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i971ee4b6404c4ed885962afd497cc6c4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7af19dae3f054b648cdca7471fa01367_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7fa81b5097b2466db639a8a9b4205905_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9a1804ba514d421fa041c53b09e064df_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i544fc2f9696049b4b7cbe0345f8fde19_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i526dbe18caa14f808c563a07c118fdec_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5ad852d92b9f48d787f3e17319eca10c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idb73f5b531de4d949faf24baf79a438d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i813ae3ce219c4fb99714b7ffced341ac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2a07487d016f4962ae2b2023e270baed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie637e63779d34f95ab0e1211537d3d90_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3222ddf3a8ac4302b584f8b59946a14b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic146904e7a5d4de8860196733919670c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4ace96eae50846258f2aa585eca6aab7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie36116f601d041c795e77b729ac2bd12_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ecf981515d64142ae2c545ec8473910_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5197ef213a4645978df5f719742ae403_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i50e4a751923845029648d84b7970c686_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ife02be8abfd44063a559e3b91d3451e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i96ba97b94ac14d2785bd7fa84c035ba6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4f476c609f70478db4f2ecd35dc8eb68_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i22c86b90cca74ee28587fd7b463de73e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8155874edc7f4d55bd1452edf423993c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i36992cb2187547dfa9f7e206d125f62d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2840be8f4a94f848fa12213edee040f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if8790eb3b0704b11bbbdffca311b63b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i36c4a0d2b7e245eabd1f07bf17e8efea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4c71c6fa987a4120a284c9b9145e27e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b33940746b24ac0b52755c11e6154f0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia5b2741087f34d8badb76a8ebcb2b3fd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7b1936dd4cad4f59a9112c82012622aa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic11c3f50a6ad41aaaa6ec682a1a2bf69_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i32517cdb203a46dbb43f88560fafdc6e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i233ef483a0f64f039b86216aee108bfa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a806ed2d9564a57a182b6ed0c5fe28f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2ea6da8b55e34d8189b756c1edd72ca2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i52cdc2ce968e46748102e49a49b2747c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5626e89be6054126b0e88da30ec22edb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i76ad9553f0574ea0869f164b30ead95a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie253e8109f6b4b66b779831838983108_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4eb0b46018c54f5c946184e340c3804d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5172caf5b4c745e49a779865e4df8b6d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6e87bdf692d44f63b49e30cb351f8be1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2277951e04244daea0a2517c6b972ce4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i177a13f9ceb04b04ac9f5de0f3c10743_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1960642f8dbc465babdbb93b28ddece6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia14954f687c6405ab00a4364d579fd9a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i588da95a877d48e8954f17fe68f586a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96d7fb6d960d43a18ef69089fff51e0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0180c6864ed746a8b3d870461649834a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia760ea075df24dcfa76244f5eb52e815_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id945978cb9e34780a08b5b17c28c3dae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i377eee7df67949f38f58d5844a15b18c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4ba21050cbf4b33a8dce7b1f2a8fba8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15f875e3e2144b5391ee55f902226825_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b5c16eeb8a64c579a2fa0a33daa5b36_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i314c0f6b364b4833a2bf7dc6a7d484ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64c6a536ce224bd0a7d1bacbad4b9f82_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85bddc6b22b045908bcc27ca039aa3f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i233603743e32403cba2427b98f94cd71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb4bb153c0824966869a2e351056f2e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9cd010e314334386addf3e1c41d3fba9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc2482a53a724280953dce9975c1774d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie2d3bf8b263f4308af9996212c4ea414_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia46188499bcd4b979e789d0ac42002c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i863c16ddfefc491d81ad6914ccd53e60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80d6f9b361384095856711315cacf141_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iefe9492781434d5eb9e61902a0768540_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7aabc6919dd54de293fd5ab586ac3010_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19ce6f75fe844b619eed1f83ac0c0e45_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i039334735ea6463da706b51515b478f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i024cb51bbd8f473892a3c8c4eb2d1047_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1ffb9e56119443489f2dea0c32378917_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc9330205fa247e0a9d3b8796fe79d3e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i10d20920da5045eaa6a64364e50740b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i78739e5e4dd447ee99f90605c73e27ac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie1a89a2666b74590bf74ff22f798d881_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b274ca23e0b42b29ed5c9770e8e2696_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibb1db2575cf945c4b53c0b1c6bcbffc0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i84043b4b737545c9b8356075843761af_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibc25faf9338644178cb1e8c7d5454052_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic6e3f53705dc4d19ba4af718a25d24c1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3c90a1dfddcc4a0b8f2e9d9ade98f0f7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibdc99a357f5645e68fea63babcf6e1a1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:UNITEDSTATESAndPUERTORICOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i23db86fa8b8e464f9ab3b7f022c25c05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:UNITEDSTATESAndPUERTORICOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4eff6ba2e6fb4744acc735827cfe6e99_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idef4bb393b97493c912842acdbb55c84_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf3c5f0215ae42afafbd93e42ab13afc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1cd853d454b54902b5326960dc6dae46_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7296a85c804344a4b823ccbd1579e425_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A235NotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i74a66519f1704bd5891f02b44669f2ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A235NotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iafbbc254a62f477095aad8da1c3c29cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A30NotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49ed564e316641a190e2ea5bc0d13358_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A30NotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5cb67bf176ed48d699fda531feb23c5c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A10EuroDenominatedNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieee67ef519a14645b909c395101668dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A10EuroDenominatedNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic91bf59cc87d4b018a72edb84c344f75_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A015SwissFrancDenominatedNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5c45ef9bd50d43fd98a3d77dab23bf12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A015SwissFrancDenominatedNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61abf79406074265841d9e59afd0b927_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A7125NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iab38c12183ba4ea08deb88ed706456ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A7125NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b3c6352b0e54655905b05316d9d6f6e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A275NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7460ec1a2ce645628f9b4950c383a2e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A275NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if91ad0b4d0f445169909fc587ad4be66_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625EuroDenominatedNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia43db658a17f4423b0dfd76ce053a30a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625EuroDenominatedNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26c8536d6b204e03856812446168bceb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A55NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i674e9d0712e3435bb2d0ecdf73d1e2f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A55NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f1a3b951bfe4ef2a9d50583c4bbd77c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A31NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e1618d7d24c48259896e1e2026a0aed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A31NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87bad62899d149bdaac599617b653af1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A045SwissFrancDenominatedNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i933751a82f6445a3b8dcbd93c8fc716a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A045SwissFrancDenominatedNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08a6834348314addb7e7dc8a7a6dfac1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia61b26c361d64e2b848451ac3c78f961_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie374eb8422b44d6781dd2c7369a9bbe9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A42YenDenominatedNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i53bdc5a3a83441b19c9683bb0db20458_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A42YenDenominatedNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19faddcfa3a6449f9e5d54d4c7cc0a5d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A2125EuroDenominatedNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i20625f40121146dbbad262af55cd252c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A2125EuroDenominatedNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0aa8cf85cde34e54833cd650ef5410b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A625EuroDenominatedNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie7f6d19c2b7d422585182914ccfc57a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A625EuroDenominatedNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8db52983c5fb45929449da08901ec208_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4811598343304ab1a6ac92a4d4384082_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i525c05f6af404e8e88124f226b94e2ce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A56YenDenominatedNotesDue2034Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i58706ae52cd04d5787f689decd555c79_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A56YenDenominatedNotesDue2034Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i62868cd48e734ea186f9dbc3ddc52276_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A677NotesDue2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i039f506220b44e9b92088ddadae4d438_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A677NotesDue2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia861290fae084d9dad2fa74b54a93f61_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A555NotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if0f1ac1cc9084ecbb7ec146e7a0ecf59_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A555NotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08e38bce3a2645658e249867cecec63c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A595NotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic1a7b88a64384880b61cf8aa84d05774_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A595NotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0343f767507d45eeae7ccb730acb9974_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3875NotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id9ce6e78973845499d30563930a6453b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3875NotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieed40c2fbef84f74b11d5910f62ad4eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625BritishPoundDenominatedNotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0f3c74be38f245b8b6ed35611a69d273_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625BritishPoundDenominatedNotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54e0e0101a7841daae4f2106284daf1d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A465NotesDue2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1d2c94e9725b44148fcdb6193e2870fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A465NotesDue2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieeb8b7e9ed7a49e49e94f6af00648190_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A37NotesDue2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea58f3bd452e4a36842dd6ec45db98a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A37NotesDue2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea465f0f6ff843b3ae0b1c8b37cd87ef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i59316aeff65f444fa246fc62593bfeef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41a65a471c734c42a6d546c096e16d1b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icd3a46888e13415cb278b164998a5c33_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibfc0c52db55940be9c4b62d052da668e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A17EuroDenominatedNotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibeb85aea19744a2ab1f156a41e098a53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A17EuroDenominatedNotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdba7d3f60f347eca7dbb1d8296ddcdc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A97YenDenominatedNotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4c07500c2b6f4b61a48ebb178947c8db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A97YenDenominatedNotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06e56a449d7e46f5a50fe0e1d8d8f32b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i867cfd6e85ca49dc8bc5f47a7e85af14_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e986ddd3ce54fd1b852b00b58b6aa8c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0fbb357599024d59874aed080c948903_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i60c6d92c70bb4827b8d11ed6c2927a17_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7ed86b00b5854fb5ad549409205591d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iedd1c12277a041ab81c0a54878416b3c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A25NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id73e022a19034845867e9f0ce636e37e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A25NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58f74fa5874e4bab94a1ead5e6fd1e49_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9fffe809d4dc437bbf367bdf220199fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icbbad28b34b342babe4bf7cc2a5134cb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieb7eeafef488487ca857290e624770bd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c779efd9f6c4ddea6602f310141dc09_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0b321af1dafc43ccbaeaa9699581dab7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i57ce917b0f0c422ca61e881f3f692344_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4a5e0b9bc64e491cb66aa141907b7e5c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i451dcfd995634628a4d966f35c25b82c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625BritishPoundDenominatedNotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0b24bd1f49ea4586a8301239a10ac27e_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7c474d66fd4941be8ee1af7f8bc945a2_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i341d1442ad9c4796ad0ad6233bebae92_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ied580748898946bdaf1108b103303bdd_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3b7e5b5013ea482e858c341d9431d76f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie9ac3bd2cc2c4fb7844518c2ea52b6ed_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8e29d24af5de402499fe4ebe60451143_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifdbadac98c4141e0b7b6c55a77240061_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i6441fa6a78ef4e12b30986772baa1b26_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i06c599f0bde9445fa16d1cc4feb31a6f_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A25NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i8a93a3c5ae824553bbd8a41bbef49dbb_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ic0163626092d4db6b26a6af6487a4108_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:SeniorNotesDueMay2050AndSeptember2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i34e736a6ca514f689eb35288b8ec7b70_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id89b274231544b368ef56d599d8e67f0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9e110f0e24e249d59282a44ccaa3721e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie786c6b1fada4a3dbc69ad548931dec2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i03b05f63c9574af38cc3b218f3d7f04c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i171e2f5cc14f445bbc2e02aa39c75b98_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ide30b7bea6124a16bed5fd85591c653f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i34c6e2fee53c4d53a400e54ee5da855d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:RelativeValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie9f12c5407404719932a1a7e44769cdb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:RelativeValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie4ee98787c674df09daac84147aa1690_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:RelativeValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if5945a2c316d46c8a331422ade10498d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:RelativeValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia611d9892499421694f697dc5c368ddb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4c55e65384854a888970465b0818f479_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i27e6f36ed2b84f35a058e35522e9b351_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifbf91d3e9e6846ab8570536827522ece_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icf5b57373be441b6bfebc18bd3f1612c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">lly:May2021ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i15d3684123a54cc4bc7e71a64f370060_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">lly:May2021ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i89d3a6dd2c454e45a2881b0daf36f171_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:CarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibac57721c29548ee93eb53c76de5151c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:ExpirationBy2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e25213daac34fafad0267f51e54ab7e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:ExpirationBetween2028And2042Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i652bcd633d9e4b988a731c9c680da3b1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6b497353dce84fff8af5126132c7d5aa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8aaea1c0c5f449f78c245961a000b0ae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8e1fc18a41da4a52b4f290bd30b05e25_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:ExpirationBy2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i38c21f98a7ad430e92e87e091c5eebdb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i29379dfc9c24409c9bb7a52d0165f08f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i057f9a4808af4123bcdfdc6c3301e04b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d98baaa405f4230aa08556aee4f87ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i125b075ff711498b8733b378408d98e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if520336c52c54904ba5808790e7ec324_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c073455f233450ea6806f68e460a7bc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i97e3f341714546fea22d7415bf7423fc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iad4ae6cfb47049b5bd782e22f164d8b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a0874db15724bfb8216d84461801c57_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia316b6b7c534488da162855e12856aee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if80d17ed3d7341139c95e570648359b1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3a731db9bce5491f98e9d3db25b05e57_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i01910d1722ed432eac20033caa81d3e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib43d57949131458885d98c8a93ecc8ff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9058615b4dac4d84a46d1a194938b1d0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1210e6088eb043d5b57234e2c04d5495_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i304ba8d5a46e4918b1388a3aa5a0d641_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d88291b946e4fada2d92e7be0e6c4ca_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i08f9dd15c5264811a0adf0cd5ddbcd70_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaf36ffdc2a634608b0576bc6c10d74a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie67f316541574a54a1c5e224c4068a84_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic8597a970d914e7eac33966ec50e2e45_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8aa3bc29c31c46e9841c05765cc07cbb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0f741744892048f79ba678614ab460e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id53867d3f4f742a7a401891b83a35ccf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if8d9e90e67b644c1b7eb36d3e839d86c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i63893449a2d84076a10449b426a8a463_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibcb0e523afe1433d98caca75025ecee4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i09007bccf7314e778accdfc89455e47b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if606ee97c9704abab603056e8b0edf59_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iabe7285b3fc24407971675b7ceb932de_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3749025b65a24fee9b938b61605247bd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i646d525b330b4affbcc9bcbad3171961_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5111829abe1472899906644ebdadd1d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7453fa11715a4896b1ff0f0ff5f09c00_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i512f904a58b2427780f61c85d1dd6a60_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6e8af31081da45808fbffb31cff06d39_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i97fa38adcb92459287110b63f86477a0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia76c0aca32f2426babb3ee042aaa4e38_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i60107ebc9335412ca6f1bd84bb68da84_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3068b14ed0e644b6a479187e62d04177_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0de112ae15004511bf9407f3cf72d975_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i09a2d55b1e1c44d2871d456003ef7230_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic04e46f294ce4c0fb14fa8b921ae66cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9c1c27297ae64abdb64c978fa594cbaa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba64a2ba2ee54c4d8ce53c70040e9ff0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib078fa49932d485e98c330eba8129f3c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9b15966785264fd6be87c35ad8b78710_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if24ea8f19b4a4e008be14e1cb7ea857b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea985983bda74c2b82efe6e81f782028_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if6bce240b92c4b78a32086372012e86c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9076ad0d4db44a508631c37b130697de_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idfe24bf9e81d43ec9e96c7d669380b3c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i686e8ff5c4a8496da94e3e68008b4845_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i343ea5fd96b643009c59bf6456fe7731_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic6e300f5e5754a95992494e35bb4fad2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i580abbf76b7b4f58b638cef09a78edb0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifbf22e6860aa4abdaf439b706e4a6866_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idc86bd5686bc4e3badb3c7e166fac6f4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id0ff8e7d4cbb47789b98e55ac9b9b579_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i57b56107f1e043c1a3ad9569212ecacb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iebe855aa68c84719bddaf01cf7d20e04_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b0a212192da4a3395f2bbeacd3c312f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2f2751d7d37f4b76ad3b2e86c47f4de3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6b541896dac543b49b5eb351edb80e69_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia5150947e1ab4960a30b20610ac83cff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8c5b75e2b27940d7bb2d6260640d34c3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id5a9db5d280b4dc4bfdd26c9e650a29c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2bcf9c01534f47bea99586f19a3f1740_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i00e53324a4a84c8dae1e489c5b3ca7f8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7dd2dddf24274ba4b7eaca5d40b7c7db_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id68a32c29c1344a8a0b3ed2942d12fcb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8aecc4a27cff4b94aaf8df6b2ede03a1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i86e7e8e7c42c482380a28afa9ecf2c76_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b8f63f573404294a870cfa838208b7e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibe30650bfb8d48aca6dbadae71597e65_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7950f077c83c4b968114ecde2e2b0bd4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i66c5b68aaa0a4c93bc23b9644ce7ffac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i17d44c14ec1b4c2eac9a8389f7430791_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie0ee3659217840abbe55a716b6c7657a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i27a0f7402b7543f39f6f976686d8a1b5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i91fb865ecf4145fdb3d535b6bf576475_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i27650537dca947bd9b29fafaf84048a2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id9cc9944568941598d1e56273115b999_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icea19db21d1f4850ad503d0164f02ee0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i01671d18379a4457892b23355b0f63c3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i76954bb677604e0f941a30448e281a31_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id11b13c420a14cce9b018741905d1215_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3e95f60a2ff14f7a97e13a88c47f23f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i214c74f186244036ad65d031acecd8f4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i61594b0a985e418eb0de58c665ee7a9b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb8608c8404a41bc91d4b199b497742a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i482b293366b34226b38b20258e4f2ad2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic00e07bcbece4f109e90289df0b99c67_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i943b1859aecd4fa38530943834fb212b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icfe4715993be47369f1c27e1cf4db3cb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7b1abf4ee53847788edba9a69ea4a81f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i538c50f08a0144988c39feeb3a4731aa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib62a4aeb2d014482b292e1b7aa806e54_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b7b4fe31ce54233aefaaf027ce7e8ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie2a5ae8949b04000ac5560edc4d7e9f2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icfdcf6378ed942a7996ee1a9da26e09d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ied4d313aab9b4f8e8034b9f72db4c6fc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic2c2d4e821d048eeaf50b62f405c3e71_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0ff6377b237b439999bb2d77c5a32fec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iee337558500947b7a15e1c6d6b59308a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7c54b0e2a7354d1ebf52c04c3b53f6d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib132a0af29334d8a89770179f4a4c6e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20851fdc53e743b38af1e76d003c6b3a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52ee54330e824cfdbed0febda5250fe6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d7d1ea05ba24b2f993e48849a306d14_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48bf8cce218249108f768811cdf3855e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c05e60f32ed4c1ca1330ed0411bd74e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1829f3c584ad46e09fa69d3bdf4dc092_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic042d55e713d42e19343e9d8183251f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0c88f62a561a44a69856cba4e6223aaf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iebf3bab110174c6a97b925581b28f022_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c0f80e4c70a4dd7a7f479eb93de4798_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8694353f6b5944bcbe80d4ab90db02f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6900b09ea625493ca6b4be8dd33fd73a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6bce15f7824346e9b1c4801a21ba7d71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib3a21ae3393e41d2ba9480eaa0b21d70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if383bbdeabc347c3a143b1392643d685_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia372a081047f4dbf909c87201c2dd657_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6cccb32003004700acd3e2d5c3acc3ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b6be538722f49cd8981ecd65c3e7940_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i436b8c7264ce4c04bb05b44bfd87ca82_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f1e4df3ea5b421eb52a4e93ecf681d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic6ac3978756e4b5fb17fbea6da4f990d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9c29a065a0846b9ac55a37fa94c8241_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92b5f5e714014f79bfda8cdf1d9b2a7c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6c67444f0284e208beac9c4be9a2f0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3dee72abed824f43841304219403a584_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a95086891b14aaf917d8c2716ac3e3d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i42734379ac9542d89b7f72f1422d85f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0cef80ce2abe42448dfd3c31b2730530_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i082bf7a8d7da4db2b649a2e7f798417f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i295f7348ee104256b1ad8f7695918565_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ide75442ca7484565b7ece117ea2f7059_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b695768bf7d42a3bcd05424e7e3f801_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieda949f586eb474d94003b25eeb0028d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied3619ec524f4266a7e63df4bffc201d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5cc405af174407082725f9ad493bde7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54dba7ed180b415fabfb7905a989ee6f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0af2032243144ef284ce6407829b4dee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i901ab2be4c854280b4098c1694160fde_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie3f5f72c269e4e2f8f39b493b30dee70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6e5fa70dfa147419df6887b95a1c72a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb10e0158e6e4678aba453d3e46e07c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30a6b7ac42614433b9f0fa273ce3a0bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9017de5b93e24421b9baf62ead566064_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0cfc4ac7e4a54ac497e9a40c408806fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibad8ae81108d443a8d7b7c73c118e1b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3788338e5f754c888353b212dd5956a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0015f68641264909839363808c4359b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i348b81fae8ab42de8c1879ac0c79e30c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia56272ad45124bdc80feb1442c60a30d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i757f940abbe04ca0bc0b713ee02d015c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i345e2321a45e415d986e9e3fbe0a8b1e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i402b1f58d5d94b2e89c8d64936db028d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f6287de46e54474b2e7b025101c06f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifda53d5c5113486194c825c985c42f46_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i227d6a2f64bb432583256bb6d486f599_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie71f4ed1e3434f8687ea6d6c4e0184d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41aac4ca412c41fabad0761de653d3e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibacb732d9a3e42ecb1b0d3672103ab48_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd0e7a73c5654d22b1fb7d1f44eec75b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i143d17ad6d23439bbe5839cb7f2fa3d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i82b433b6c64f411cbf07c20ec03e6cc0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ecc36ab470d4e41be47e03d24ef4065_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id86c9caf6218488d8edebac267e948ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifbf66898d55a4866946d2c1b7d0808c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0d702f1019341bc888bc0e964569748_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa4a4b71cd744411915501b9954c7190_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i689b0515d1e94c50807ae2688713eb9a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7475b438e64f45c889b5836a9b35767c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1fba731405fa40f08f44c49bbce45751_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad19a6d6a32c4de3b7b3d6e7f1edf524_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie71ccfe9ea594f9b9006353fffcd6bd2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58114e11cdf547b081755beebbfc89d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i55c8b439a98248178a88acf2e2f0d064_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib8d28a152a83416bace6b87dcae9c074_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6bb519b30c624115a193843ede27be5e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if209ba23a08741c5a788dd9694d2de32_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i29dcd560ceb84008813877608a70d4fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i043b55ba16e04186b3221ade43979e4b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3a21e55d8164183ac65c36e858f86e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i905bdea6d6d74e49ba3fae3f028d50c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25b644c98bfd4c39b72d7a1615c8880e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib73e985ef58a4760a5c29be61384bb88_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib8bcd2b4b6ca476fadb8cce5fd37f874_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5e89110b5ca48398995bbf99899d921_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b9ad2ac337a4df9a8bc5ff2950a967b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5967fb68324426389a6dc239fcdd98d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i463ba1a48ccc4e9c9cb4282e58cd05a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i299c48115d8542b08f12325d39cefe4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27dc976858f044bdbd3ba64895aeb4cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6462a3f459994819a179b58529f573e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic623b25c46754468b1e9528796093989_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a1d3b46d2544213bc3eb41e5d6e128c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5ef3078b94645859a7ca03beed57c99_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf76714ef18e4ce6b454dfc623ac6be7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0dae23a26dd4790bdef9addc65290ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i560967994b3c4feaa52141c4dad6145c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i00b75991e2e34b09b2420ae55e962bf3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied91fc6d6fdd4a9db5f172426ce099f6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaead771b48fe47589b2c796815693940_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i63382dd666fe46d0b3e154a58b6cfe75_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i31efe8055d7c4c549c6b4e3589629dce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i62bc7ea2d50e4f44a034b2205030f1c9_D20090301-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idb638f2256714679a5c385f7893d6fbf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69662148bb09444d89587f00392b3075_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="ie6e063495e83471dbc258b40a141debf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iad23c8f46fec4d02b0a1bcb29a2373cb_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i63ea09a048414de7b321b1ada8f7b0a4_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie5a9f8356a0c4d9ca2c89e981a149cb5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogHumulinAndForteoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idc973a7f9e3144daaacecbbb0e56d8b2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i782d346d63cd4661b107c0a82f9e4b82_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7be554abe40648b39a94f657bb20d919_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icc3cb8d5258a4da9a5d7c9e511159aa3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i06509abf85c548088ad01601353119b6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if9a8c569328a4f30be03a86aa6c30d95_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i551c81f2cb044ba38f8c330455e4e04c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i17390e21b41d40f786eda486ba1ce2c7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i05873b0c5a3d432cb9d95359fb5df095_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifce42ff1cd2e4bbd9d84d0fa5ad5830e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f5a08b9d5ec477b89e3e3d1f861d631_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5108cbcfc4b74ce7b92ac3b0def03d6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa5d7c8469594718ad1fc73143d3d064_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3316d423843f422793957a50410a8a36_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7653b13d4d7a4b1ea53ccf1f2894f8e0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d8b6b1d95db4e629430b1a90c83d5ed_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i57369029d5994ec1a83968149ccf0c57_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i223571c60a5b423f8ffc9ccfbe85991b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i556ef38e7ad6431685ad87cfb8474525_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66b44aaa3e8a45e08cb1bf413d8b0659_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i17c04e1ff996458393a87969564ad1fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i972702fe45444acb9e6640afa709e559_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i555a212b77e94fec899486cbaa76fc01_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2aa5e5ddf4514d70abb39fde1aef3c0c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9c2f066479d04e8a991d5d71e2aa8bac_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i66b74eb9d22141c790775d44d424fc2f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib6f1b84d8e0044fba3da52e09503d7ef_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie3ab662330354f1d9f630d917b2b9226_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie36998435f274cd5b1ef204d97105cbd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia343b309a27649efbcdc14994affb7a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i463002f84e9c4e7ba72e5b39ba3391e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib916975408c44e2c89551e919105a31d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6fb8bb210d8244f89d422fb23165a4e3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i023d933f184447ddac5d72ebf87e0336_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i472a66eae4d2427ba823727867f6c0f9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i84dd851668914a6db57dd7071efd43cf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i514b258fa8244695bafee3af86f5baa4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic9961583d4b548ebbcb37171c99e617d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i344999926eb8490985eec925cad19570_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4d7c5f720a834207b54353c4bd105eba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i18678afeadcd4e3d83ea294339141d26_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9b856402e0234773bcad0e3fc79b8715_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia960d127a0284a50a7e9041cfc5cc3ff_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib01471a2ae8e487caadc07f6eb55dd21_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if3a0343f9166479e970860fc345fb4c5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1a4ec401a8f24eeda71c72518a06d67d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iefbc11fe7e2b4373988b6e83dcf18945_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="right">
        <measure>lly:right</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="cny">
        <measure>iso4217:CNY</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="chf">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="patent">
        <measure>lly:patent</measure>
    </unit>
    <unit id="lawsuit">
        <measure>lly:lawsuit</measure>
    </unit>
    <unit id="plaintiff">
        <measure>lly:plaintiff</measure>
    </unit>
    <unit id="site">
        <measure>lly:site</measure>
    </unit>
    <unit id="brl">
        <measure>iso4217:BRL</measure>
    </unit>
    <dei:DocumentAnnualReport
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF80L2ZyYWc6MzZmZjcyNGU3NzkzNDAxYzljM2Y3NjAwZmE3ZTE0N2EvdGFibGU6N2Q0MWE4NDJlNzdlNGQ0ZWIzOGMxMzVmYjY0OTMxOWUvdGFibGVyYW5nZTo3ZDQxYTg0MmU3N2U0ZDRlYjM4YzEzNWZiNjQ5MzE5ZV8yLTEtMS0xLTE5NzE4Mg_94f5edce-4a9e-42e5-9535-c905ae220709">true</dei:DocumentAnnualReport>
    <dei:DocumentTransitionReport
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF80L2ZyYWc6MzZmZjcyNGU3NzkzNDAxYzljM2Y3NjAwZmE3ZTE0N2EvdGFibGU6N2Q0MWE4NDJlNzdlNGQ0ZWIzOGMxMzVmYjY0OTMxOWUvdGFibGVyYW5nZTo3ZDQxYTg0MmU3N2U0ZDRlYjM4YzEzNWZiNjQ5MzE5ZV8zLTEtMS0xLTE5NzE4Mg_5e0da8b0-fc23-40bc-ad47-1179c84d6439">false</dei:DocumentTransitionReport>
    <dei:AmendmentFlag
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF80L2ZyYWc6MzZmZjcyNGU3NzkzNDAxYzljM2Y3NjAwZmE3ZTE0N2EvdGFibGU6N2Q0MWE4NDJlNzdlNGQ0ZWIzOGMxMzVmYjY0OTMxOWUvdGFibGVyYW5nZTo3ZDQxYTg0MmU3N2U0ZDRlYjM4YzEzNWZiNjQ5MzE5ZV80LTEtMS0xLTE5NzE4Mg_b65041eb-e118-45a7-980b-7293f10dc0cd">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF80L2ZyYWc6MzZmZjcyNGU3NzkzNDAxYzljM2Y3NjAwZmE3ZTE0N2EvdGFibGU6N2Q0MWE4NDJlNzdlNGQ0ZWIzOGMxMzVmYjY0OTMxOWUvdGFibGVyYW5nZTo3ZDQxYTg0MmU3N2U0ZDRlYjM4YzEzNWZiNjQ5MzE5ZV81LTEtMS0xLTE5NzE4Mg_8508add8-21af-4214-a234-82fb7a576251">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF80L2ZyYWc6MzZmZjcyNGU3NzkzNDAxYzljM2Y3NjAwZmE3ZTE0N2EvdGFibGU6N2Q0MWE4NDJlNzdlNGQ0ZWIzOGMxMzVmYjY0OTMxOWUvdGFibGVyYW5nZTo3ZDQxYTg0MmU3N2U0ZDRlYjM4YzEzNWZiNjQ5MzE5ZV82LTEtMS0xLTE5NzE4Mg_5d103170-3e9a-40cf-a7d2-1f22e6311b16">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF80L2ZyYWc6MzZmZjcyNGU3NzkzNDAxYzljM2Y3NjAwZmE3ZTE0N2EvdGFibGU6N2Q0MWE4NDJlNzdlNGQ0ZWIzOGMxMzVmYjY0OTMxOWUvdGFibGVyYW5nZTo3ZDQxYTg0MmU3N2U0ZDRlYjM4YzEzNWZiNjQ5MzE5ZV83LTEtMS0xLTE5NzE4Mg_5921cbcd-8fb8-4ea5-a83b-349fe25e0d20">0000059478</dei:EntityCentralIndexKey>
    <us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2XzIxOTkwMjMyNTgzMTA_a65ace08-5ec6-44b7-98e1-20a4af3312ff">http://fasb.org/us-gaap/2022#RestructuringSettlementAndImpairmentProvisions</us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2XzIxOTkwMjMyNTgzMTA_b860e1a5-db44-4847-b689-049eb53e6544">http://fasb.org/us-gaap/2022#RestructuringSettlementAndImpairmentProvisions</us-gaap:ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6b274ca23e0b42b29ed5c9770e8e2696_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzQ4OTk_d5717d76-4a43-4c49-bf30-1707e388a603">P1Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic6e3f53705dc4d19ba4af718a25d24c1_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzI3Mg_0bc998e4-b996-4544-9f0f-ef94e39f535f">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzktMC0xLTEtMTk3MTgy_8ddc8d02-9a67-4865-bc1c-83f42fdd1643">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDg2_7c4e1473-b1dc-4385-b35a-0cc0990d5f51">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8yMDE_eb823fe3-d2af-4acf-b240-5d7f447b8c15">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8yMDE_4ddb4333-b91e-49b5-98ec-1d85e5c7e51b">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFileNumber
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDky_7fbb660b-d6b3-4b21-8996-b28bb2285669">001-06351</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8yMzc_742da120-e287-476f-bb22-4faafced49bd">ELI LILLY AND COMPANY</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6Y2I5ZTY4NjM0ZWVlNGM4NmEwMTViMTJmM2I5MTVjY2MvdGFibGVyYW5nZTpjYjllNjg2MzRlZWU0Yzg2YTAxNWIxMmYzYjkxNWNjY18wLTItMS0xLTE5NzE4Mg_139530b5-20f0-4e1a-9e48-ea56c5259be1">IN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6Y2I5ZTY4NjM0ZWVlNGM4NmEwMTViMTJmM2I5MTVjY2MvdGFibGVyYW5nZTpjYjllNjg2MzRlZWU0Yzg2YTAxNWIxMmYzYjkxNWNjY18wLTUtMS0xLTE5NzE4Mg_0ac9597b-5e55-4a13-bfa2-b7f2663037cc">35-0470950</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDgy_f1c7c32a-1953-4549-9ac7-ba5c1b28c4da">Lilly Corporate Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDg3_01e3a314-b046-4361-9920-a4fb8be01a03">Indianapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDgz_55d80609-766f-4d53-997d-8048de520e34">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDg0_7dbbc5d2-ef2d-452f-b7a2-10c74d61802d">46285</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl80NTY_13a1bb1a-269d-4066-880f-82c460c32f7f">317</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDgw_54f69473-524c-4960-8915-df79852421da">276-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i0123f42da8014c4e80a496f4ec156d49_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18xLTAtMS0xLTE5NzE4Mg_efb0814b-fb2b-42ae-85e8-dd1fac7cfdf9">Common Stock (no par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0123f42da8014c4e80a496f4ec156d49_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18xLTEtMS0xLTE5NzE4Mg_1a0cc0e7-3343-4557-b5b6-b78e856353a5">LLY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0123f42da8014c4e80a496f4ec156d49_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18xLTItMS0xLTE5NzE4Mg_75fc2004-f0ea-4512-ad4c-0e7c0b7665d6">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ia6faa5dfbefd43faba61396886103e54_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18yLTAtMS0xLTE5NzE4Mg_5ed422b2-eacb-4260-822b-7cc9f79d6946">7 1/8% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia6faa5dfbefd43faba61396886103e54_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18yLTEtMS0xLTE5NzE4Mg_9be41701-6dd0-4b7d-b516-5a67adc3b4b6">LLY25</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia6faa5dfbefd43faba61396886103e54_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18yLTItMS0xLTE5NzE4Mg_008aa05f-2712-476b-8a31-affbe9360c10">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i7506ecec16a548918d36c633b7d2886f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18zLTAtMS0xLTE5NzE4Mg_9d81ceb6-b630-47e5-a669-9a761e4c995d">1.625% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7506ecec16a548918d36c633b7d2886f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18zLTEtMS0xLTE5NzE4Mg_d0048868-0af1-4e56-b0be-7b6c1576cee5">LLY26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7506ecec16a548918d36c633b7d2886f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18zLTItMS0xLTE5NzE4Mg_575de243-02b9-4d34-89fc-ea97cdec2784">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i74727aae65ec420f8d2a7d3f2fc82caa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM180LTAtMS0xLTE5NzE4Mg_62872ec8-0f63-4ca7-8ff3-d3e154fd1b0b">2.125% Notes due 2030</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i74727aae65ec420f8d2a7d3f2fc82caa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM180LTEtMS0xLTE5NzE4Mg_531186ef-3044-481d-81f4-4ae9511c785c">LLY30</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i74727aae65ec420f8d2a7d3f2fc82caa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM180LTItMS0xLTE5NzE4Mg_55ab3908-810c-46f4-94ec-4e25f8dd6944">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i8b6679d8bf73400fb57c1d771b743b9f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM181LTAtMS0xLTE5NzE4Mg_6f1c0955-4657-41d6-bf97-6ae1abf1eaad">0.625% Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i8b6679d8bf73400fb57c1d771b743b9f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM181LTEtMS0xLTE5NzE4Mg_c61bb1be-3b13-48b2-968a-e0a43714c94c">LLY31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i8b6679d8bf73400fb57c1d771b743b9f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM181LTItMS0xLTE5NzE4Mg_92e3c32b-242a-4e54-be00-8273b7251340">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="idd78f7ed1d134dcf8be4669929f8630d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM182LTAtMS0xLTE5NzE4Mg_b79e3a2c-08f3-4bfe-ae51-8248ffed3853">0.500% Notes due 2033</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="idd78f7ed1d134dcf8be4669929f8630d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM182LTEtMS0xLTE5NzE4Mg_7dbd0608-37de-4287-8a76-ee0daa236be4">LLY33</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="idd78f7ed1d134dcf8be4669929f8630d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM182LTItMS0xLTE5NzE4Mg_9939fd7a-8e28-44d2-b76a-3c1fe5d3552f">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i1ec7aad2a8d0401f82a878dda7a7a03e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM183LTAtMS0xLTE5NzE4Mg_5541671a-b4c3-4ede-b288-3ee67ac4bca2">6.77%&#160;Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i1ec7aad2a8d0401f82a878dda7a7a03e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM183LTEtMS0xLTE5NzE4Mg_daac9a7b-0a64-41a1-afa2-f1afaca08723">LLY36</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i1ec7aad2a8d0401f82a878dda7a7a03e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM183LTItMS0xLTE5NzE4Mg_a0c75165-318d-4b02-baf9-815e52e6efa2">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="icee8de005b2e49f9879377e478c0b2db_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM184LTAtMS0xLTE5NzE4Mg_815d01d5-6b0c-4f45-b5da-6ddf5fb83ee4">1.625% Notes due 2043</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icee8de005b2e49f9879377e478c0b2db_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM184LTEtMS0xLTE5NzE4Mg_b77057b6-de5d-4c5a-ad6a-7cf6b28532e1">LLY43</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icee8de005b2e49f9879377e478c0b2db_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM184LTItMS0xLTE5NzE4Mg_6d8130cf-a6a3-4af7-b4ac-a49736743585">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ifbdd41c0af48472b8577f5e8157441c2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM185LTAtMS0xLTE5NzE4Mg_bf7aaed3-0286-496d-8687-63b8dcc39a27">1.700% Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ifbdd41c0af48472b8577f5e8157441c2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM185LTEtMS0xLTE5NzE4Mg_9b321e6c-a71b-4a87-ae63-6983aed649a5">LLY49A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ifbdd41c0af48472b8577f5e8157441c2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM185LTItMS0xLTE5NzE4Mg_6219bbe6-0ed5-452b-8d9c-e6269aeda1fa">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i62b9486903fe42cd82d7869cb7d772c4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18xMC0wLTEtMS0xOTcxODI_daf5536a-cbe5-40ca-9efe-f3c406ff49ff">1.125% Notes due 2051</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i62b9486903fe42cd82d7869cb7d772c4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18xMC0xLTEtMS0xOTcxODI_75bdfb34-fe0a-4b93-93fd-424a48942f9d">LLY51</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i62b9486903fe42cd82d7869cb7d772c4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18xMC0yLTEtMS0xOTcxODI_0e321fb6-edbf-4b6c-b59d-292f5b04cbf1">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i0bfa6ff0f0fa4248813d3e66ff3abdab_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18xMS0wLTEtMS0xOTcxODI_6d1d824a-c9a1-444f-bab6-92121f632bfc">1.375% Notes due 2061</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0bfa6ff0f0fa4248813d3e66ff3abdab_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18xMS0xLTEtMS0xOTcxODI_aa42d788-aa4c-4eed-9e27-9ebc286cb169">LLY61</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0bfa6ff0f0fa4248813d3e66ff3abdab_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6NjNmNzk1MGM1YmMyNDFmOTgxM2FmYzg1MWI3NTZlMDMvdGFibGVyYW5nZTo2M2Y3OTUwYzViYzI0MWY5ODEzYWZjODUxYjc1NmUwM18xMS0yLTEtMS0xOTcxODI_efc5f1bb-e2c1-4018-82f5-d3202adec84a">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDgx_b3ca633c-bb9a-4777-b432-07ca701bf0ad">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDkw_84ff9eec-a147-444e-a745-e7bab3ff9952">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDkx_92898ba8-2c8e-49ab-8234-d22d077fd3c1">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDg4_cc2ccda4-d26e-4423-8530-b2a87151ee7d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6Y2NiZmRiNzRhZDczNGM1ZjgzNTY0ZGFiMDEwYTNjODgvdGFibGVyYW5nZTpjY2JmZGI3NGFkNzM0YzVmODM1NjRkYWIwMTBhM2M4OF8wLTAtMS0xLTE5NzE4Mg_8d82d2ef-0148-4aff-b10b-6f6431cfacec">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6Y2NiZmRiNzRhZDczNGM1ZjgzNTY0ZGFiMDEwYTNjODgvdGFibGVyYW5nZTpjY2JmZGI3NGFkNzM0YzVmODM1NjRkYWIwMTBhM2M4OF8xLTctMS0xLTE5NzE4Mg_0d08907b-107e-4e5f-9abe-1e0cc460b465">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGFibGU6Y2NiZmRiNzRhZDczNGM1ZjgzNTY0ZGFiMDEwYTNjODgvdGFibGVyYW5nZTpjY2JmZGI3NGFkNzM0YzVmODM1NjRkYWIwMTBhM2M4OF8yLTctMS0xLTE5NzE4Mg_ae936fb4-f956-4e99-9a33-dbf5dc34a94c">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDg1_185f1884-740e-42bb-8e18-22e44a7a327c">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDkz_e4243202-fdda-49e5-a49d-906f32d18655">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="if754bc01888f45ac8d951c81d205bc32_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8yODYz_3a783d28-be6e-44b0-b8dd-cd492941fbcf"
      unitRef="usd">274342000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i57c62c4ea2844c0e9a340732ae328cbc_I20230217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8yOTIy_923cc5f5-b8aa-4c9f-a793-7b5a495876dd"
      unitRef="shares">950296118</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xL2ZyYWc6NWZjN2FhMDYzNGFmNDNjMzg1ZjhkNGUxYzNkMmMzM2YvdGV4dHJlZ2lvbjo1ZmM3YWEwNjM0YWY0M2MzODVmOGQ0ZTFjM2QyYzMzZl8zMDg5_192fcec3-2fce-4f4a-8490-ffdff269e715">Portions of the Registrant's Proxy Statement for the 2023 Annual Meeting of Shareholders have been incorporated by reference into Part III of this report.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:Revenues
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMS00LTEtMS0xOTcxODI_2a3d8417-cd94-4487-b5d9-1d4a254620bf"
      unitRef="usd">28541400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMS02LTEtMS0xOTcxODI_a1db985c-6b79-4b2a-b6ac-10fdcd4cb895"
      unitRef="usd">28318400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMS04LTEtMS0xOTcxODI_9d4a671c-7a6f-48fa-809b-0cf0f41fc94c"
      unitRef="usd">24539800000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMy00LTEtMS0xOTcxODI_e5ee7537-0002-4cf0-9b2e-d015aff381f0"
      unitRef="usd">6629800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMy02LTEtMS0xOTcxODI_dbec22c9-4bbb-4f02-8bfb-62b5e2e0a5d0"
      unitRef="usd">7312800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMy04LTEtMS0xOTcxODI_d22fba28-c936-4adb-b0e7-946af6261f95"
      unitRef="usd">5483300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNC00LTEtMS0xOTcxODI_b0de80ef-3cd0-4d59-9381-15cffaee2379"
      unitRef="usd">7190800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNC02LTEtMS0xOTcxODI_845edef5-3208-46a7-928e-9b40fc851b55"
      unitRef="usd">6930700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNC04LTEtMS0xOTcxODI_4e54d8e8-bbba-47da-ab26-658f59ff0805"
      unitRef="usd">5976300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNS00LTEtMS0xOTcxODI_0ca1d9a4-ae67-4364-a8c8-24fd48ffffa0"
      unitRef="usd">6440400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNS02LTEtMS0xOTcxODI_2a3d0d6f-9e17-4ada-934a-1c7996e0ec9c"
      unitRef="usd">6431600000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNS04LTEtMS0xOTcxODI_a55f4050-5f92-4322-9a3b-c21acb09e5fc"
      unitRef="usd">6121200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNi00LTEtMS0xOTcxODI_baff4a8b-830f-4c11-904c-efb0462138b4"
      unitRef="usd">908500000</lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones>
    <lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNi02LTEtMS0xOTcxODI_ebd203ce-4a32-42a7-9b6f-96612aa2e9ae"
      unitRef="usd">970100000</lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones>
    <lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNi04LTEtMS0xOTcxODI_a24ad2dc-1d0d-4d4e-bf67-0bf3b4988841"
      unitRef="usd">769800000</lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNy00LTEtMS0xOTcxODI_aeddbb38-4085-4fe3-a128-b3cb38bcd829"
      unitRef="usd">244600000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNy02LTEtMS0xOTcxODI_eebd5d7b-7f9e-48dd-807e-e830680bf8c5"
      unitRef="usd">316100000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfNy04LTEtMS0xOTcxODI_737c3c0a-7eb4-49dd-9427-594000d6db21"
      unitRef="usd">131200000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfOC00LTEtMS0xOTcxODI_bd070b80-bc64-4053-94af-852a7763058b"
      unitRef="usd">-320900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfOC02LTEtMS0xOTcxODI_6f33b035-3620-47b0-bdc0-69c1a89d0a3c"
      unitRef="usd">-201600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfOC04LTEtMS0xOTcxODI_b229d220-ea87-4324-a48f-1abcfb80dfd1"
      unitRef="usd">1171900000</us-gaap:NonoperatingIncomeExpense>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfOS00LTEtMS0xOTcxODI_a8dd7d06-2c2b-4c36-8e5d-4d69ead65bf8"
      unitRef="usd">21735000000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfOS02LTEtMS0xOTcxODI_8945d183-94ce-4cde-9cd5-d01eba369617"
      unitRef="usd">22162900000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfOS04LTEtMS0xOTcxODI_7557c30b-dc4b-410e-9987-629c86cc5eb5"
      unitRef="usd">17309900000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTAtNC0xLTEtMTk3MTgy_a1467945-7b09-4830-b35b-4b09ce08af65"
      unitRef="usd">6806400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTAtNi0xLTEtMTk3MTgy_68b9d782-4280-40bf-b5b1-e83088676b41"
      unitRef="usd">6155500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTAtOC0xLTEtMTk3MTgy_ff6b94fb-3111-4150-96cf-ced45afdf375"
      unitRef="usd">7229900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTEtNC0xLTEtMTk3MTgy_a15aa45f-a185-4381-8024-4d87f0fff1b4"
      unitRef="usd">561600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTEtNi0xLTEtMTk3MTgy_a5945d4e-a638-482e-b692-bb66192f5c92"
      unitRef="usd">573800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTEtOC0xLTEtMTk3MTgy_eb3380e3-3ad9-412c-923e-31d1f69abccf"
      unitRef="usd">1036200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTQtNC0xLTEtMTk3MTgy_21a4af03-c8dd-4245-87b5-eae635fb6d2f"
      unitRef="usd">6244800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTQtNi0xLTEtMTk3MTgy_1fa38700-fa84-4919-b383-0f1500d0250e"
      unitRef="usd">5581700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTQtOC0xLTEtMTk3MTgy_8cc89653-1e63-4c06-a0cf-ad668a87cee6"
      unitRef="usd">6193700000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTktNC0xLTEtMTk3MTgy_57b2ab7d-397e-4875-bc6e-bb056af5b963"
      unitRef="usdPerShare">6.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTktNi0xLTEtMTk3MTgy_6a7e0b59-a5fa-45b8-9241-142c93580deb"
      unitRef="usdPerShare">6.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMTktOC0xLTEtMTk3MTgy_d9b6a1c3-18f7-4a47-96dd-eefc73be459e"
      unitRef="usdPerShare">6.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMjMtNC0xLTEtMTk3MTgy_11c9bcd5-ea8c-4607-8fde-30413a136dfb"
      unitRef="usdPerShare">6.90</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMjMtNi0xLTEtMTk3MTgy_878b97d0-34a6-4f32-836a-98eef08bc822"
      unitRef="usdPerShare">6.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMjMtOC0xLTEtMTk3MTgy_0cb71c06-51ee-4354-a108-23213fa1eb45"
      unitRef="usdPerShare">6.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMjYtNC0xLTEtMTk3MTgy_82b9cec2-7b44-4d33-8e9e-3bebdf8854f8"
      unitRef="shares">901736000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMjYtNi0xLTEtMTk3MTgy_874e2854-3124-47d4-bfcd-e2fed9d682eb"
      unitRef="shares">906963000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMjYtOC0xLTEtMTk3MTgy_17a1eb1a-7259-43d0-9830-9d919865152b"
      unitRef="shares">907634000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMjctNC0xLTEtMTk3MTgy_d137c619-e224-40a8-91fc-05af250251e9"
      unitRef="shares">904619000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMjctNi0xLTEtMTk3MTgy_ef08873d-b8c3-4abd-9cd7-9fbe6c6b0ceb"
      unitRef="shares">911681000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83Ni9mcmFnOmIxZTliMmUzZTA5NzQwOWU5Yjc1ZWJmN2U4ZmQ4NmNmL3RhYmxlOmYwYmNlNWRmNjlkMTQ0NDI5MDkwYTFiNTEzNDc2MTViL3RhYmxlcmFuZ2U6ZjBiY2U1ZGY2OWQxNDQ0MjkwOTBhMWI1MTM0NzYxNWJfMjctOC0xLTEtMTk3MTgy_3fb076a1-86e6-42d8-8497-0a466b140f38"
      unitRef="shares">912505000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfMS00LTEtMS0xOTcxODI_4ce7a97b-84bf-4f6b-8266-4c29830194f8"
      unitRef="usd">6244800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfMS02LTEtMS0xOTcxODI_5c1e4cdf-1e6a-444a-a376-5f5a7ab744c8"
      unitRef="usd">5581700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfMS04LTEtMS0xOTcxODI_40f2856f-b3be-45ce-9a3b-902348d7a2c7"
      unitRef="usd">6193700000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfMy00LTEtMS0xOTcxODI_3b83e774-b9a0-4909-8378-69db592c432f"
      unitRef="usd">-248100000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfMy02LTEtMS0xOTcxODI_7214dca8-3327-44de-9e7e-8b36700e5184"
      unitRef="usd">13500000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfMy04LTEtMS0xOTcxODI_c8720a99-3463-4cf7-8393-772b519eb5dd"
      unitRef="usd">122100000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNC00LTEtMS0xOTcxODI_d702b24e-826a-476b-bad6-027d6ed079f8"
      unitRef="usd">-53200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNC02LTEtMS0xOTcxODI_a1f49844-f71c-476d-92cf-b7ddeff478fe"
      unitRef="usd">-15900000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNC04LTEtMS0xOTcxODI_b193e578-bfa7-4662-8453-ecf7a636f39a"
      unitRef="usd">14200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNS00LTEtMS0xOTcxODI_25267950-7ba3-4e30-97f5-bbdd4da45c3d"
      unitRef="usd">-616900000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNS02LTEtMS0xOTcxODI_d807d762-62bd-44ec-9182-6f7f5d322bbe"
      unitRef="usd">-2699400000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNS04LTEtMS0xOTcxODI_c1385818-3867-4adc-9da7-ed465d5e4306"
      unitRef="usd">157100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNi00LTEtMS0xOTcxODI_526b3ba2-e337-48e7-b521-a9e33fbe669d"
      unitRef="usd">432900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNi02LTEtMS0xOTcxODI_234f269f-f7c4-435a-883d-03f977e00ed3"
      unitRef="usd">151600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNi04LTEtMS0xOTcxODI_71b1cc80-87bf-4034-8f48-79e136a2c9a0"
      unitRef="usd">-152900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNy00LTEtMS0xOTcxODI_275c9a42-9615-4bdb-ab73-e20d438b6e82"
      unitRef="usd">748500000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNy02LTEtMS0xOTcxODI_2eb81990-42cf-45c6-8a28-56a44f146430"
      unitRef="usd">2848600000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfNy04LTEtMS0xOTcxODI_c8e19113-2495-41d8-aec8-f5d86fa26f31"
      unitRef="usd">-173700000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfOC00LTEtMS0xOTcxODI_33a1ea6d-d39f-4123-b8db-e7548b4e0d83"
      unitRef="usd">250000000.0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfOC02LTEtMS0xOTcxODI_2877e434-a0e4-46f5-8759-6982d8d8cd33"
      unitRef="usd">695300000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfOC04LTEtMS0xOTcxODI_7c9e988e-584b-40ed-9b53-c7f831c0b683"
      unitRef="usd">-200900000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfOS00LTEtMS0xOTcxODI_edf8fead-674e-4378-95ba-6368fe31ec3c"
      unitRef="usd">498500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfOS02LTEtMS0xOTcxODI_bbf9c8e4-da5f-49dd-b720-07fffbb116ec"
      unitRef="usd">2153300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfOS04LTEtMS0xOTcxODI_20cd51a5-ed17-48c2-a73c-54379c492736"
      unitRef="usd">27200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfMTItNC0xLTEtMTk3MTgy_e03ebbcd-102f-47dd-b562-1753bcfe79c6"
      unitRef="usd">6743300000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfMTItNi0xLTEtMTk3MTgy_893e1c1e-dc68-4312-8b63-480dad561de9"
      unitRef="usd">7735000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF83OS9mcmFnOmZlMjYwYzA4ZDE0NjQzNjM4NzBkNjkxYmNmYTQ0NjNlL3RhYmxlOmYxZTFhNDg3NTljMzQxNTU4NjVjMjA5MzNmOTgxMmIwL3RhYmxlcmFuZ2U6ZjFlMWE0ODc1OWMzNDE1NTg2NWMyMDkzM2Y5ODEyYjBfMTItOC0xLTEtMTk3MTgy_d869620e-f909-4f13-a5b4-6e0e0cf48e88"
      unitRef="usd">6220900000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMy00LTEtMS0xOTcxODI_ee847f79-31d3-43d6-bf83-f421d1047787"
      unitRef="usd">2067000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMy02LTEtMS0xOTcxODI_83acf139-c535-4792-a654-2876d49b2982"
      unitRef="usd">3818500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNC00LTEtMS0xOTcxODI_b70fecba-f024-44a9-ae90-f994ca8f78ed"
      unitRef="usd">144800000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNC02LTEtMS0xOTcxODI_c607d822-3282-4426-8728-61c2cfaf9a4a"
      unitRef="usd">90100000</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNS0wLTEtMS0xOTcxODIvdGV4dHJlZ2lvbjpjMjFjOTZhYTdiOWM0YjgxOGYzZTdhODYwMmVjYmYwYl80Nw_e3b0069d-a448-4bd1-ab5e-142f9320d857"
      unitRef="usd">16000000.0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNS0wLTEtMS0xOTcxODIvdGV4dHJlZ2lvbjpjMjFjOTZhYTdiOWM0YjgxOGYzZTdhODYwMmVjYmYwYl81OQ_70c63f9e-9abe-492c-9664-7e4f6ee1a9e0"
      unitRef="usd">22500000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNS00LTEtMS0xOTcxODI_4d23613d-0f59-4daa-a33b-655e886be397"
      unitRef="usd">6896000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNS02LTEtMS0xOTcxODI_6a9f0bb3-2a26-4f5c-8b4a-914235a0de9c"
      unitRef="usd">6672800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivables
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNi00LTEtMS0xOTcxODI_c72a8ed4-d20a-4953-8f1c-7b2f459b8032"
      unitRef="usd">1662900000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNi02LTEtMS0xOTcxODI_3a5c317a-a772-47bd-88a8-a1b8c4b83e17"
      unitRef="usd">1454400000</us-gaap:OtherReceivables>
    <us-gaap:InventoryNet
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNy00LTEtMS0xOTcxODI_2c5eaa6b-6fb8-49a2-a416-342dfc4fca86"
      unitRef="usd">4309700000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNy02LTEtMS0xOTcxODI_d4d778d8-07aa-4ae9-a85c-4cd1af0cb55b"
      unitRef="usd">3886000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfOC00LTEtMS0xOTcxODI_98617a57-3b2c-4801-be6a-a30fbae4c9a3"
      unitRef="usd">2954100000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfOC02LTEtMS0xOTcxODI_9ec25993-c6f5-492f-9291-b8ebcf064cc9"
      unitRef="usd">2530600000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTAtNC0xLTEtMTk3MTgy_b41d6e72-8dd6-4b2e-b8c3-08f82b3670a0"
      unitRef="usd">18034500000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTAtNi0xLTEtMTk3MTgy_260815c2-af1d-4e25-85db-3ab660d3e5f6"
      unitRef="usd">18452400000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTEtNC0xLTEtMTk3MTgy_9d5a2328-c54b-44ac-9e20-95d8bf64403a"
      unitRef="usd">2901800000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTEtNi0xLTEtMTk3MTgy_d0a79f9f-1bba-4e5e-9461-677e6767c7c8"
      unitRef="usd">3212600000</us-gaap:LongTermInvestments>
    <us-gaap:Goodwill
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTItNC0xLTEtMTk3MTgy_3babf8b4-e566-4fe9-8a6e-17fbe9c913bd"
      unitRef="usd">4073000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTItNi0xLTEtMTk3MTgy_a91cb7bc-d99c-49fe-b4ae-9438c28e2024"
      unitRef="usd">3892000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTMtNC0xLTEtMTk3MTgy_7a24eeac-9cd7-49dd-8a10-f0abc9ae4582"
      unitRef="usd">7206600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTMtNi0xLTEtMTk3MTgy_53b82931-cda6-4c7e-97c1-fa86817d5fe9"
      unitRef="usd">7691900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTQtNC0xLTEtMTk3MTgy_fa9e0455-96ab-4ec0-aac4-470108d18d26"
      unitRef="usd">2792900000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTQtNi0xLTEtMTk3MTgy_78f1766b-85a7-4d8c-82f9-cf08cd22d2db"
      unitRef="usd">2489300000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTUtNC0xLTEtMTk3MTgy_5a4c1e38-2103-4563-bcdb-fef6b28f60da"
      unitRef="usd">10144000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTUtNi0xLTEtMTk3MTgy_707a1920-48a9-4342-87d1-65cebdf79881"
      unitRef="usd">8985100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTctNC0xLTEtMTk3MTgy_dd4a4903-1092-410a-b9a0-410f2210c1f8"
      unitRef="usd">4337000000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTctNi0xLTEtMTk3MTgy_36ae6317-47ff-4d27-91c5-e04ae03efd8a"
      unitRef="usd">4082700000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:Assets
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTktNC0xLTEtMTk3MTgy_7d556992-bba1-4d4f-936c-de44ee1e4f7b"
      unitRef="usd">49489800000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMTktNi0xLTEtMTk3MTgy_2148a1c4-6272-42b1-9d6c-4d9c6a8e0f03"
      unitRef="usd">48806000000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjItNC0xLTEtMTk3MTgy_7b26f788-7115-445a-97df-8ae1061a99c6"
      unitRef="usd">1501100000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjItNi0xLTEtMTk3MTgy_d7cd3c52-f90a-44dc-aeb7-16117ea7fe59"
      unitRef="usd">1538300000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjMtNC0xLTEtMTk3MTgy_490c8b87-5efc-4249-8d9e-a72415556c6d"
      unitRef="usd">1930600000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjMtNi0xLTEtMTk3MTgy_98d2baf6-97d0-45cf-8c44-e17e25561348"
      unitRef="usd">1670600000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjQtNC0xLTEtMTk3MTgy_6c03b281-3652-4928-8a38-87391e82c4bc"
      unitRef="usd">1059800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjQtNi0xLTEtMTk3MTgy_91da9fa5-967d-4f98-bba9-61965ab7febb"
      unitRef="usd">958100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <lly:SalesRebatesAndDiscounts
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjUtNC0xLTEtMTk3MTgy_107ea4cc-42b5-48a0-8d33-fcbdfd2237f0"
      unitRef="usd">8784100000</lly:SalesRebatesAndDiscounts>
    <lly:SalesRebatesAndDiscounts
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjUtNi0xLTEtMTk3MTgy_72c3c5f5-2c82-4a28-8b39-e8b1ae7ca62c"
      unitRef="usd">6845800000</lly:SalesRebatesAndDiscounts>
    <us-gaap:DividendsPayableCurrent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjYtNC0xLTEtMTk3MTgy_c8fbe7a5-6527-4887-8e3a-c2f05b7d05d1"
      unitRef="usd">1017200000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjYtNi0xLTEtMTk3MTgy_9cd3d134-8be0-4d76-9554-b45d8d2f85d1"
      unitRef="usd">885500000</us-gaap:DividendsPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjctNC0xLTEtMTk3MTgy_dd010223-1acf-42a0-9eb6-5c7c329ac1e3"
      unitRef="usd">475100000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjctNi0xLTEtMTk3MTgy_c0c73f5e-4606-4e30-b743-7b52b16e27a7"
      unitRef="usd">126900000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjgtNC0xLTEtMTk3MTgy_d4aff757-d574-40ee-886f-682253b1143c"
      unitRef="usd">2370300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMjgtNi0xLTEtMTk3MTgy_266ea945-4e1f-419e-81df-1c059b49e8d6"
      unitRef="usd">3027500000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzAtNC0xLTEtMTk3MTgy_52db124b-0be2-44df-8648-dcbe5d93468c"
      unitRef="usd">17138200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzAtNi0xLTEtMTk3MTgy_e193368e-5107-449e-8d8a-b83d9cc719df"
      unitRef="usd">15052700000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzItNC0xLTEtMTk3MTgy_44ec558b-da5e-4954-bbe9-a310f62c9380"
      unitRef="usd">14737500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzItNi0xLTEtMTk3MTgy_c915af09-ecdc-428c-a5f0-3baf9af75c59"
      unitRef="usd">15346400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzMtNC0xLTEtMTk3MTgy_324eb94a-0df5-401a-8a7c-f8fa8e433402"
      unitRef="usd">1305100000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzMtNi0xLTEtMTk3MTgy_eac11c3c-6370-4157-a704-7a088295bd86"
      unitRef="usd">1954100000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzQtNC0xLTEtMTk3MTgy_17078785-3f1d-4111-9ff6-b6def04ff9fc"
      unitRef="usd">3709600000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzQtNi0xLTEtMTk3MTgy_c5fa92be-5181-423d-b63d-1af5f82a28b6"
      unitRef="usd">3920000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzUtNC0xLTEtMTk3MTgy_d37b3ced-a4c7-4ca0-887f-5217d80db6bc"
      unitRef="usd">87300000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzUtNi0xLTEtMTk3MTgy_b1218330-23db-45e2-a52d-866e93067c17"
      unitRef="usd">1733700000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzYtNC0xLTEtMTk3MTgy_b66051ff-ce11-4c9f-bd93-38ec4f049a4f"
      unitRef="usd">1736700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzYtNi0xLTEtMTk3MTgy_5e6f6b3a-c47a-407c-95fc-3b0b31fe577c"
      unitRef="usd">1644300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzgtNC0xLTEtMTk3MTgy_500b6a9f-f993-434a-a591-923e3f04925b"
      unitRef="usd">21576200000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzgtNi0xLTEtMTk3MTgy_a641fd98-0f93-4ab9-837c-f9299de9a758"
      unitRef="usd">24598500000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzktNC0xLTEtMTk3MTgy_ad39234a-3e85-4b24-886d-41da88e1611d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfMzktNi0xLTEtMTk3MTgy_3e84cc2e-f539-4761-a6c5-637dfb9fa44c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDEtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246YzBhOGZlYzBhYzY0NGM1Zjg2M2VhN2M0YzJhZDJjZTRfNDk_89455235-6bfa-4eec-803c-b933365c37d5"
      unitRef="shares">3200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDEtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246YzBhOGZlYzBhYzY0NGM1Zjg2M2VhN2M0YzJhZDJjZTRfNDk_ba9d0f51-c507-44f5-9ef3-366735c064e9"
      unitRef="shares">3200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDEtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246YzBhOGZlYzBhYzY0NGM1Zjg2M2VhN2M0YzJhZDJjZTRfNjc_c91326ce-0ae8-4684-ae15-dfcb126e39ba"
      unitRef="shares">950632000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDEtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246YzBhOGZlYzBhYzY0NGM1Zjg2M2VhN2M0YzJhZDJjZTRfODE_be250d77-9c8f-449e-aa82-d79b4c7c2ec2"
      unitRef="shares">954116000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDEtNC0xLTEtMTk3MTgy_31fabd41-34a2-439f-a0a7-15821feb647c"
      unitRef="usd">594100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDEtNi0xLTEtMTk3MTgy_ff4d5030-62a7-49df-98c9-1c81e82f99fa"
      unitRef="usd">596300000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDItNC0xLTEtMTk3MTgy_9e47888a-01c3-418a-9398-f9244c78d1ff"
      unitRef="usd">6921400000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDItNi0xLTEtMTk3MTgy_2c347ab7-aef9-40ac-ae18-e14c761094dc"
      unitRef="usd">6833400000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDMtNC0xLTEtMTk3MTgy_f7f24e58-d7d0-49da-beba-bf386d8549d8"
      unitRef="usd">10042600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDMtNi0xLTEtMTk3MTgy_48ba4f6b-f4b9-4cc5-88a9-76d073c5de9d"
      unitRef="usd">8958500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDQtNC0xLTEtMTk3MTgy_eeb48956-8f75-44a2-9da1-654defaf8220"
      unitRef="usd">3013200000</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDQtNi0xLTEtMTk3MTgy_b2243ca5-161c-4977-8f1c-bbcc1c4907c0"
      unitRef="usd">3013200000</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDUtNC0xLTEtMTk3MTgy_e170d053-369d-4580-8525-231e1057736b"
      unitRef="usd">-3844600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDUtNi0xLTEtMTk3MTgy_dc9162f0-1b72-4970-ae9c-dcff3363a44e"
      unitRef="usd">-4343100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockCommonValue
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDYtNC0xLTEtMTk3MTgy_f722b83c-4b3d-4dcc-b51c-485f0a898e37"
      unitRef="usd">50500000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDYtNi0xLTEtMTk3MTgy_f0c8cf0a-909e-4c8d-85ab-79d5595b053c"
      unitRef="usd">52700000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDctNC0xLTEtMTk3MTgy_fdc76c7d-c5e8-4b08-aeb3-49d93deb8901"
      unitRef="usd">10649800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDctNi0xLTEtMTk3MTgy_2f1123d2-6fd4-49a6-9a39-c4e42ce2448b"
      unitRef="usd">8979200000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDgtNC0xLTEtMTk3MTgy_179f42b9-b98c-471b-a6ef-d4ecf00eff21"
      unitRef="usd">125600000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDgtNi0xLTEtMTk3MTgy_01997221-cec2-4bb3-bd11-aed4da0bb6cf"
      unitRef="usd">175600000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDktNC0xLTEtMTk3MTgy_66ab7bc1-8fbb-4f1d-8d3c-85ec33501507"
      unitRef="usd">10775400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNDktNi0xLTEtMTk3MTgy_7433fec5-97bd-4d0e-8d39-ecb96aae2bff"
      unitRef="usd">9154800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNTAtNC0xLTEtMTk3MTgy_a255c79e-c9ee-4ded-974d-879992cc88f9"
      unitRef="usd">49489800000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84Mi9mcmFnOmYyM2U3YjdlYzQ2YjRjNzA5NzRhZGM3ZGYxODZjZWVlL3RhYmxlOjNjNmFlOWI1NjJhOTRlZTdiM2Y3MDY2ODgyZmUzNzIyL3RhYmxlcmFuZ2U6M2M2YWU5YjU2MmE5NGVlN2IzZjcwNjY4ODJmZTM3MjJfNTAtNi0xLTEtMTk3MTgy_4d6228fa-69f6-44e8-a54b-fb1ee23c7cbf"
      unitRef="usd">48806000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i356b319ab866417988ad019b9794d8cb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMy0xLTEtMS0xOTcxODI_c0300d13-6917-45a2-8965-34c492012a90"
      unitRef="shares">958056000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i356b319ab866417988ad019b9794d8cb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMy0zLTEtMS0xOTcxODI_0e2141cc-ad35-4ff1-affe-5de8b01e1570"
      unitRef="usd">598800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9021134b4fbc4e258ea850eb3c4c4c7b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMy01LTEtMS0xOTcxODI_5e9f3623-c4b5-454b-bac2-0261b08c59e0"
      unitRef="usd">6685300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a2f5f0abb434012bb2af32c10ddc89c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMy03LTEtMS0xOTcxODI_30f170ad-ac60-42ab-8770-a350c38b3a68"
      unitRef="usd">4920400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6870f7c27b5d40b09b8227c732a66406_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMy05LTEtMS0xOTcxODI_531bb3fd-6080-451d-a4f8-04e84d876974"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89c86fcc6d9848e19d2dcbf04813b652_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMy0xMS0xLTEtMTk3MTgy_51311629-38ab-4595-8ca4-092f94375bad"
      unitRef="usd">-6523600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i0cfd19befed844bdbd1e65f027b7a2ec_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMy0xMy0xLTEtMTk3MTgy_b597b73c-7827-4a41-99f1-e5b7af4c4ecb"
      unitRef="shares">530000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0cfd19befed844bdbd1e65f027b7a2ec_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMy0xNS0xLTEtMTk3MTgy_3b8c3dfb-14ea-4233-989c-b5f898c9515f"
      unitRef="usd">-60800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b11cb527104470694b7931c221de577_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMy0xNy0xLTEtMTk3MTgy_214c116d-a4d2-4004-a6f1-8cfaf8a029a7"
      unitRef="usd">92200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i6964671a05464b22a4eb74dbbd4d79e7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNC03LTEtMS0xOTcxODI_bf4c1f6d-ff7c-47d2-901d-1a480a38d73b"
      unitRef="usd">6193700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i774298166b774d40bff6c0588b2f3c56_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNC0xNy0xLTEtMTk3MTgy_aa095316-3967-40ad-acdf-13bebb60aa1b"
      unitRef="usd">126600000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5b0c0c02225844c6b4ea5018b890387d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNS0xMS0xLTEtMTk3MTgy_1c27b239-d860-4975-a021-76519f9b5be6"
      unitRef="usd">27200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNi0wLTEtMS0xOTcxODIvdGV4dHJlZ2lvbjo4M2Q4YTI1YmEwMWQ0OTVjOWUzODBhYjFiZjRkMGJiMF8zOQ_6e32d87b-40ce-4404-9b95-98f068ae2478"
      unitRef="usdPerShare">3.07</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="i6964671a05464b22a4eb74dbbd4d79e7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNi03LTEtMS0xOTcxODI_8e8dfa9e-a6b4-497e-a768-b8fb410598a7"
      unitRef="usd">2786200000</us-gaap:Dividends>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i375d8504588144e3bb7b25036361f87c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNy0xLTEtMS0xOTcxODI_4b4a6cad-59db-40a6-825b-bbe8c887994f"
      unitRef="shares">3627000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i375d8504588144e3bb7b25036361f87c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNy0zLTEtMS0xOTcxODI_71f538e3-fcd4-4c5c-bea9-0c2501f48d9e"
      unitRef="usd">2300000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i6964671a05464b22a4eb74dbbd4d79e7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNy03LTEtMS0xOTcxODI_f9ea041d-652d-487f-8bd0-aa0743d23521"
      unitRef="usd">497700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i19f9560e8da24c70a901e8c074917400_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNy0xMy0xLTEtMTk3MTgy_310c2cfa-b007-46ef-a49b-0c383127c31a"
      unitRef="shares">3627000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i19f9560e8da24c70a901e8c074917400_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfNy0xNS0xLTEtMTk3MTgy_8aef3499-bfcb-4870-8fa2-ab00bc2a6b48"
      unitRef="usd">-500000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i19f9560e8da24c70a901e8c074917400_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfOC0xMy0xLTEtMTk3MTgy_5a2daed6-4261-40e0-993b-2c5862a77bee"
      unitRef="shares">3627000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i19f9560e8da24c70a901e8c074917400_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfOC0xNS0xLTEtMTk3MTgy_e4a75118-d4cc-4dd3-894f-b63001afffb7"
      unitRef="usd">500000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i375d8504588144e3bb7b25036361f87c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfOS0xLTEtMS0xOTcxODI_5b709857-c603-4421-8212-7eda383abdca"
      unitRef="shares">2648000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i375d8504588144e3bb7b25036361f87c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfOS0zLTEtMS0xOTcxODI_ef0047c2-dc5b-4638-9302-8df3a047b5c0"
      unitRef="usd">1700000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i16cfc9ba4c614087a5a71a8d2a07e024_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfOS01LTEtMS0xOTcxODI_f5b5f78c-ddb0-494a-b3fc-e3d083e127a0"
      unitRef="usd">-212700000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i19f9560e8da24c70a901e8c074917400_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfOS0xMy0xLTEtMTk3MTgy_450d1c96-c87d-452a-870d-12c423fe3778"
      unitRef="shares">-43000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i19f9560e8da24c70a901e8c074917400_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfOS0xNS0xLTEtMTk3MTgy_d032176a-4d4d-49ae-903f-321ffb691f77"
      unitRef="usd">5100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i16cfc9ba4c614087a5a71a8d2a07e024_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTAtNS0xLTEtMTk3MTgy_a9e25c2e-c92c-42a7-8271-c4ed5d64d2ce"
      unitRef="usd">308100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="i16cfc9ba4c614087a5a71a8d2a07e024_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTMtNS0xLTEtMTk3MTgy_367ac503-5e55-4f63-a65f-77acc63228c1"
      unitRef="usd">2200000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i774298166b774d40bff6c0588b2f3c56_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTMtMTctMS0xLTE5NzE4Mg_6c72293d-3c06-44da-8795-7c1831e38ef5"
      unitRef="usd">35200000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia61f75ab6b7546e7a580ad9a5b93f8d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTQtMS0xLTEtMTk3MTgy_22151b19-599b-441b-8301-7f83026e47f3"
      unitRef="shares">957077000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia61f75ab6b7546e7a580ad9a5b93f8d2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTQtMy0xLTEtMTk3MTgy_abc0005c-0577-4069-a83c-00f3dc7f5ba3"
      unitRef="usd">598200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a274dc2077148a0b820a07f6dfed9f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTQtNS0xLTEtMTk3MTgy_96470cc3-a851-45e2-a494-55166e0e438f"
      unitRef="usd">6778500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic7559b91ac864734b64c8cb3e513830a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTQtNy0xLTEtMTk3MTgy_3581a59b-4989-407f-8fd1-8b65b8eee524"
      unitRef="usd">7830200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf02933ba36a42cfbfedca3bc4a05dea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTQtOS0xLTEtMTk3MTgy_d06fdb25-acb3-4958-a11e-715692873d8d"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idfab23ce152040e39f298e6d61067c78_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTQtMTEtMS0xLTE5NzE4Mg_c9f20d58-19b0-4a2c-83c4-9ed976faac88"
      unitRef="usd">-6496400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i8ae7226bbaa54a2bbab2e5672eb2325b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTQtMTMtMS0xLTE5NzE4Mg_e56330f3-2431-4e85-b1d9-f41353e2b691"
      unitRef="shares">487000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ae7226bbaa54a2bbab2e5672eb2325b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTQtMTUtMS0xLTE5NzE4Mg_549e06c3-1f4c-4617-b6a3-48173a774c45"
      unitRef="usd">-55700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4862d64d1a0c4143be7faa33eecd5fae_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTQtMTctMS0xLTE5NzE4Mg_4b32b67e-1e34-4f89-b4b7-3d5c99895796"
      unitRef="usd">183600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="if05c4645dada4161887047e966e0cacc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTUtNy0xLTEtMTk3MTgy_17de5c0a-bcca-4b48-bccd-21ac9939ad9f"
      unitRef="usd">5581700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ief070a1731ef4d1cbff5877950a5d572_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTUtMTctMS0xLTE5NzE4Mg_abc9733f-d059-46ed-b614-d85b14c49b33"
      unitRef="usd">3400000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i641baa148fc94939a4e053beaf2b5f97_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTYtMTEtMS0xLTE5NzE4Mg_2f99c01c-1d9a-453b-8f0f-74ecaf7f6381"
      unitRef="usd">2153300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTctMC0xLTEtMTk3MTgyL3RleHRyZWdpb246MGJmNzY4YmFmZWE4NDkzMjlkMmIyYmVlYTEwNjZiNzFfMzk_8ed24ef9-1058-4a81-b421-7a3ebf942bbd"
      unitRef="usdPerShare">3.53</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="if05c4645dada4161887047e966e0cacc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTctNy0xLTEtMTk3MTgy_855e14bf-9db7-4031-84a7-c5af67bd5f36"
      unitRef="usd">3201700000</us-gaap:Dividends>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i44b2a1ce17cf4dcf80f4b720f9b9853c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTgtMS0xLTEtMTk3MTgy_d63190d1-67ee-4768-8485-9c0fc33ebf81"
      unitRef="shares">5412000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i44b2a1ce17cf4dcf80f4b720f9b9853c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTgtMy0xLTEtMTk3MTgy_f52978b2-4299-4293-b5d0-bbc05320e7a5"
      unitRef="usd">3400000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="if05c4645dada4161887047e966e0cacc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTgtNy0xLTEtMTk3MTgy_16996918-fc51-44dd-baeb-b67e6b835779"
      unitRef="usd">1246600000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i1a1511cc032b4cc28578302f22e2c378_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTgtMTMtMS0xLTE5NzE4Mg_8522d1de-b019-4395-b634-42366bf22e15"
      unitRef="shares">5412000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i1a1511cc032b4cc28578302f22e2c378_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTgtMTUtMS0xLTE5NzE4Mg_1ce90fcf-870d-4010-bd4f-18a3af31f6bc"
      unitRef="usd">-1250000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i1a1511cc032b4cc28578302f22e2c378_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTktMTMtMS0xLTE5NzE4Mg_faf15ea2-b07f-459a-9f8d-03168c59ee63"
      unitRef="shares">5412000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i1a1511cc032b4cc28578302f22e2c378_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMTktMTUtMS0xLTE5NzE4Mg_5d18817e-f102-45e5-975d-8b2d7e6b0983"
      unitRef="usd">1250000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i44b2a1ce17cf4dcf80f4b720f9b9853c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjAtMS0xLTEtMTk3MTgy_bba0662f-fadc-4bb9-aa29-b25944a58f0a"
      unitRef="shares">2451000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i44b2a1ce17cf4dcf80f4b720f9b9853c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjAtMy0xLTEtMTk3MTgy_f806a4cf-d63a-4773-8fe7-3151f38097eb"
      unitRef="usd">1500000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i18e2767e0827495582d56de8c7445b9d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjAtNS0xLTEtMTk3MTgy_1fc41105-6817-438f-96da-05565b215657"
      unitRef="usd">-287900000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i1a1511cc032b4cc28578302f22e2c378_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjAtMTMtMS0xLTE5NzE4Mg_a893c4c3-2f8c-405d-a683-15ae67e01354"
      unitRef="shares">-24000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i1a1511cc032b4cc28578302f22e2c378_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjAtMTUtMS0xLTE5NzE4Mg_6cb72473-4807-4953-b106-0316bb6dca13"
      unitRef="usd">3000000.0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i18e2767e0827495582d56de8c7445b9d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjEtNS0xLTEtMTk3MTgy_d0c74c53-36b4-4d1a-9e82-f51260274b85"
      unitRef="usd">342800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="i18e2767e0827495582d56de8c7445b9d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjQtNS0xLTEtMTk3MTgy_9ce124dc-6179-4367-a3d2-8de924e689bc"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="if05c4645dada4161887047e966e0cacc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjQtNy0xLTEtMTk3MTgy_1b4630dc-608e-4db8-9ad4-afb26cf1e715"
      unitRef="usd">5100000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ief070a1731ef4d1cbff5877950a5d572_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjQtMTctMS0xLTE5NzE4Mg_de8c7a87-576d-4a6d-b883-83413866e007"
      unitRef="usd">11400000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="id08bbbd0c60b41d489ec1b27da14ee41_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjUtMS0xLTEtMTk3MTgy_2826aeef-55d3-4bdb-ba69-787aec22432b"
      unitRef="shares">954116000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id08bbbd0c60b41d489ec1b27da14ee41_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjUtMy0xLTEtMTk3MTgy_cda4327e-ecc6-4776-8e13-ac2af321a701"
      unitRef="usd">596300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5849b31083f849e0a1279866ce821c8d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjUtNS0xLTEtMTk3MTgy_514510a4-e022-4bde-b734-ec139ee1c952"
      unitRef="usd">6833400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d74411eaba3495eb1fb5b40272b8e0b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjUtNy0xLTEtMTk3MTgy_e180a134-1eef-406e-b815-e03884d7894e"
      unitRef="usd">8958500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9f874e14a4254206a744a4d998b3e21e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjUtOS0xLTEtMTk3MTgy_f5844005-a1af-4e87-82ba-da5c3d2e15a9"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9397c716ecc8492dbfa355270ffb58b6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjUtMTEtMS0xLTE5NzE4Mg_db3def59-ab7c-4131-80a5-472242a9bb66"
      unitRef="usd">-4343100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i8898e7952db94e61a40bdb19eaf218e7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjUtMTMtMS0xLTE5NzE4Mg_74087450-5530-44d4-8e02-40ea367dbcb9"
      unitRef="shares">463000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8898e7952db94e61a40bdb19eaf218e7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjUtMTUtMS0xLTE5NzE4Mg_52c4af6b-02b3-49d1-a9be-a8c5ff312dec"
      unitRef="usd">-52700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id4292c3a6efd4496b3c10175cfb14871_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjUtMTctMS0xLTE5NzE4Mg_2f9914b9-a1b5-4391-b5ca-63086ea7082e"
      unitRef="usd">175600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i64797ebd6cf24a2b83d33c497b3a79cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjYtNy0xLTEtMTk3MTgy_19b483c9-2c23-4cc7-af45-d3c7fa2c7233"
      unitRef="usd">6244800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i03cb5dfdc26c46d3b41f02d740b93582_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjYtMTctMS0xLTE5NzE4Mg_b758d3e4-f45b-462b-a2a6-1aaffa1d6ede"
      unitRef="usd">-20900000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iadf0599f6d15415f8e902c9d74e9a82f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjctMTEtMS0xLTE5NzE4Mg_4d34163e-5192-4a27-895c-f61683192557"
      unitRef="usd">498500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjgtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246ZWYxZTgxYjljOGE1NDcwZDhhOTJjZGJiMmY1ZmJkZDZfMzk_3df4b3a4-a7fd-4a11-8857-a1ed3c3018fb"
      unitRef="usdPerShare">4.07</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="i64797ebd6cf24a2b83d33c497b3a79cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjgtNy0xLTEtMTk3MTgy_4fc7efd8-bdbf-4981-b85e-b5eb24a1cc3e"
      unitRef="usd">3667500000</us-gaap:Dividends>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i25b818086dc044f0bd310156d54327e0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjktMS0xLTEtMTk3MTgy_6ea23331-0387-4774-8f6e-3a2e2c3df64e"
      unitRef="shares">5607000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i25b818086dc044f0bd310156d54327e0_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjktMy0xLTEtMTk3MTgy_a3b9111d-4546-4902-a533-8c3030b1aaf4"
      unitRef="usd">3500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i64797ebd6cf24a2b83d33c497b3a79cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjktNy0xLTEtMTk3MTgy_d4c9a130-f684-4d48-a505-504c21e5754a"
      unitRef="usd">1496500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="ib71f55d1f6214dbc90efad0d6e0c1bb4_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjktMTMtMS0xLTE5NzE4Mg_ce521660-80bf-4cb3-a843-80c6dfc3069b"
      unitRef="shares">5607000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ib71f55d1f6214dbc90efad0d6e0c1bb4_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMjktMTUtMS0xLTE5NzE4Mg_1f21c611-cac5-41b6-86b8-5af54ab92548"
      unitRef="usd">-1500000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ib71f55d1f6214dbc90efad0d6e0c1bb4_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzAtMTMtMS0xLTE5NzE4Mg_1d413793-88f4-4c9f-9595-c60968c70ef9"
      unitRef="shares">5607000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib71f55d1f6214dbc90efad0d6e0c1bb4_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzAtMTUtMS0xLTE5NzE4Mg_8dbc8553-71fc-46dd-abdb-d966a2ef57c5"
      unitRef="usd">1500000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i25b818086dc044f0bd310156d54327e0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzEtMS0xLTEtMTk3MTgy_1eab3179-2761-44c8-8ea1-27c7218ed240"
      unitRef="shares">2123000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i25b818086dc044f0bd310156d54327e0_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzEtMy0xLTEtMTk3MTgy_8cedbd68-7185-4db6-a2da-6591d05b7598"
      unitRef="usd">1300000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i611da2eb6b9c4c8bb17a1786b533ae67_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzEtNS0xLTEtMTk3MTgy_26eb1967-6641-46d5-941e-aeb8a9068d7b"
      unitRef="usd">-283100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ib71f55d1f6214dbc90efad0d6e0c1bb4_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzEtMTMtMS0xLTE5NzE4Mg_ed4b8196-eb5a-4881-b824-c767ad9468d9"
      unitRef="shares">-13000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ib71f55d1f6214dbc90efad0d6e0c1bb4_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzEtMTUtMS0xLTE5NzE4Mg_863188cb-7bc4-4955-97a6-c2aed9ad499d"
      unitRef="usd">2200000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i611da2eb6b9c4c8bb17a1786b533ae67_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzItNS0xLTEtMTk3MTgy_3d7682bd-925c-48d5-acb2-73c521c23a6d"
      unitRef="usd">371100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="i64797ebd6cf24a2b83d33c497b3a79cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzUtNy0xLTEtMTk3MTgy_b21543fc-5089-4c08-9025-6780289f2d52"
      unitRef="usd">-3300000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i03cb5dfdc26c46d3b41f02d740b93582_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzUtMTctMS0xLTE5NzE4Mg_bff138f0-222f-4adb-a114-a9b2c2f55ae4"
      unitRef="usd">29100000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i178450cc0eef447cab2a5bd78e323b88_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzYtMS0xLTEtMTk3MTgy_1cd96021-a1a4-4cd1-9fd4-e5b0b0e8530b"
      unitRef="shares">950632000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i178450cc0eef447cab2a5bd78e323b88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzYtMy0xLTEtMTk3MTgy_dd57e38d-051c-45c5-999d-b169e600e0cd"
      unitRef="usd">594100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i37f9e6a906424b848ddbd2a24ab91d95_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzYtNS0xLTEtMTk3MTgy_2f433e3c-e5a5-4436-a669-be12c6dbf63e"
      unitRef="usd">6921400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i71b32db201354064b5cb0802d4c538dd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzYtNy0xLTEtMTk3MTgy_a6409c07-45b8-4118-aa67-6575094c5c84"
      unitRef="usd">10042600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i42001d8086bb49dda45b041109c50d00_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzYtOS0xLTEtMTk3MTgy_94725afc-df06-49ea-b88e-52dd144aac6a"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a6bea1aa20b446397b350ac2671efab_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzYtMTEtMS0xLTE5NzE4Mg_4a914708-8fa4-47cb-ad9b-d96d156cb1e5"
      unitRef="usd">-3844600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i54accb4bb2b648519e8a5ddd0145dcb3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzYtMTMtMS0xLTE5NzE4Mg_f70837ee-660e-4715-9cd9-b5d0b0825ef5"
      unitRef="shares">450000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i54accb4bb2b648519e8a5ddd0145dcb3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzYtMTUtMS0xLTE5NzE4Mg_6dfc8e3e-efbd-48aa-bb0e-0a6153eb2f8f"
      unitRef="usd">-50500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79b34353006b49229fc2d875ac767766_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84NS9mcmFnOjkzODA4YTU0MmI3YTQ3NTlhZmQ2ZGY0ZjYwODdiNWRmL3RhYmxlOjJiMmI5MDg2NDZhYjQ3NTM4ZmQxMGJiMWYwNGQ4M2MxL3RhYmxlcmFuZ2U6MmIyYjkwODY0NmFiNDc1MzhmZDEwYmIxZjA0ZDgzYzFfMzYtMTctMS0xLTE5NzE4Mg_72184bf3-e972-4b4d-bb10-40a6cf6f7d41"
      unitRef="usd">125600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMi00LTEtMS0xOTcxODI_4ce7a97b-84bf-4f6b-8266-4c29830194f8"
      unitRef="usd">6244800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMi02LTEtMS0xOTcxODI_5c1e4cdf-1e6a-444a-a376-5f5a7ab744c8"
      unitRef="usd">5581700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMi04LTEtMS0xOTcxODI_40f2856f-b3be-45ce-9a3b-902348d7a2c7"
      unitRef="usd">6193700000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNi00LTEtMS0xOTcxODI_b634928a-15b2-45c5-bcb9-18a7a3c3507a"
      unitRef="usd">1522500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNi02LTEtMS0xOTcxODI_49622885-f497-4b0e-9b9b-050f9ddd54f5"
      unitRef="usd">1547600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNi04LTEtMS0xOTcxODI_7a7654a7-66e5-4b04-a3cc-288e0278f2a8"
      unitRef="usd">1323900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNy00LTEtMS0xOTcxODI_133c9294-82a2-4acb-9bff-0bc2d3766187"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNy02LTEtMS0xOTcxODI_3581fbc7-34df-468e-8f47-2e2f13259e19"
      unitRef="usd">-405200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNy04LTEtMS0xOTcxODI_60d20df6-d36d-4aba-a24e-3953e3b41e0a"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfOC00LTEtMS0xOTcxODI_55a01b8f-f210-43ed-8425-a1c22c408888"
      unitRef="usd">2185200000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfOC02LTEtMS0xOTcxODI_b91e7a07-e85e-45c8-b5d1-61787df241a3"
      unitRef="usd">802300000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfOC04LTEtMS0xOTcxODI_d6afe109-c718-43cf-a80d-d6f74bc46fe2"
      unitRef="usd">134500000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:ShareBasedCompensation
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfOS00LTEtMS0xOTcxODI_6a967c18-76cb-4dcc-ac11-b9a2ed20fbae"
      unitRef="usd">371100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfOS02LTEtMS0xOTcxODI_c2224ec1-4417-4030-b371-2b19f077e912"
      unitRef="usd">342800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfOS04LTEtMS0xOTcxODI_e19997f6-6ae0-49f4-aeb3-3fcceac4f268"
      unitRef="usd">308100000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnInvestments
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTAtNC0xLTEtMTk3MTgy_57fbecaf-98b0-4142-ad83-c111c811d2a3"
      unitRef="usd">-420000000.0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTAtNi0xLTEtMTk3MTgy_c7ac88db-bf4d-4000-874e-a852e2cd3221"
      unitRef="usd">178000000.0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTAtOC0xLTEtMTk3MTgy_b4cd1694-68d3-4c96-9feb-47e39aba361d"
      unitRef="usd">1438500000</us-gaap:GainLossOnInvestments>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTEtNC0xLTEtMTk3MTgy_411f469e-e259-48db-a79f-a955f3716447"
      unitRef="usd">420900000</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTEtNi0xLTEtMTk3MTgy_3f378f71-9551-4499-9591-4dd7e7a1c1f1"
      unitRef="usd">874900000</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTEtOC0xLTEtMTk3MTgy_76248d0a-670f-4b43-99d0-990df28a2368"
      unitRef="usd">660400000</lly:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTItNC0xLTEtMTk3MTgy_71a45564-5542-4df7-8fb8-83b62ea20baf"
      unitRef="usd">304800000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTItNi0xLTEtMTk3MTgy_f0696134-3d53-4adb-9a45-af3edbe8ee34"
      unitRef="usd">511400000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTItOC0xLTEtMTk3MTgy_a8676b8e-445e-4f31-85a0-0f7eaf13519b"
      unitRef="usd">333900000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTQtNC0xLTEtMTk3MTgy_27ed8481-1074-4b5d-a600-a488a87e732b"
      unitRef="usd">299600000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTQtNi0xLTEtMTk3MTgy_c9d742bf-3a5d-458a-9c02-ea0e58091fbe"
      unitRef="usd">1278300000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTQtOC0xLTEtMTk3MTgy_74214f29-257e-4a52-8822-272440b64bac"
      unitRef="usd">1350200000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTUtNC0xLTEtMTk3MTgy_f8bf0200-73a8-4615-938d-14b3de9f836c"
      unitRef="usd">599700000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTUtNi0xLTEtMTk3MTgy_cf2457c0-7ca1-4edd-9911-981b4f70c545"
      unitRef="usd">235900000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTUtOC0xLTEtMTk3MTgy_997f0726-4af5-499b-b3b9-4f340f9475ad"
      unitRef="usd">533400000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTYtNC0xLTEtMTk3MTgy_33f490e1-aacc-4b9b-8583-4bcbd472cd03"
      unitRef="usd">793500000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTYtNi0xLTEtMTk3MTgy_7afe1e70-5ca0-44f7-b8ff-dbe9e4130479"
      unitRef="usd">-1515400000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTYtOC0xLTEtMTk3MTgy_600ed8e5-ac04-4a39-8985-a4b91dc4c346"
      unitRef="usd">457100000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTctNC0xLTEtMTk3MTgy_b5b354be-2c92-4ff3-a311-f569841006c2"
      unitRef="usd">346600000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTctNi0xLTEtMTk3MTgy_4e87e763-8796-43a3-8aa0-4fce591ec83f"
      unitRef="usd">-359700000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTctOC0xLTEtMTk3MTgy_380cdc5c-9991-4aa2-b8eb-a09b7db804f7"
      unitRef="usd">322000000.0</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTgtNC0xLTEtMTk3MTgy_6be0c96a-2d73-4132-b808-921cbbc14e46"
      unitRef="usd">1331700000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTgtNi0xLTEtMTk3MTgy_043a7497-3b08-4b49-a105-783d876a217b"
      unitRef="usd">-664100000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTgtOC0xLTEtMTk3MTgy_3b213220-7a42-4167-a518-ceebb860a599"
      unitRef="usd">1271300000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTktNC0xLTEtMTk3MTgy_3ab28726-3aa0-49cc-85ff-bd10cc236677"
      unitRef="usd">7084400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTktNi0xLTEtMTk3MTgy_6df45312-9559-4dd3-9c49-71d81c296c19"
      unitRef="usd">7260700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMTktOC0xLTEtMTk3MTgy_35d88e97-7b35-4307-ae85-d3ad7c079eff"
      unitRef="usd">6499600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjEtNC0xLTEtMTk3MTgy_467e7fa3-e75e-4d2b-aaa0-0b1762e553bc"
      unitRef="usd">1854300000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjEtNi0xLTEtMTk3MTgy_f397cddf-9a25-4860-a8da-9c6cd1c5b4a9"
      unitRef="usd">1309800000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjEtOC0xLTEtMTk3MTgy_1515322e-b8f6-489f-a41f-bad7cefebb6d"
      unitRef="usd">1387900000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjItNC0xLTEtMTk3MTgy_631bf1eb-65f8-4de8-8b40-78b03bd73b12"
      unitRef="usd">121400000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjItNi0xLTEtMTk3MTgy_6e166bf8-fe24-4c17-85bf-071997b3dd28"
      unitRef="usd">47400000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjItOC0xLTEtMTk3MTgy_4838f6a6-cc6c-46e4-b009-100758e81f91"
      unitRef="usd">129700000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjMtNC0xLTEtMTk3MTgy_a2f8b1cf-5efe-400a-87a9-6f51d58d6a9e"
      unitRef="usd">107400000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjMtNi0xLTEtMTk3MTgy_4b299cdf-e7e2-456a-b7d4-01f5094f7b4c"
      unitRef="usd">83500000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjMtOC0xLTEtMTk3MTgy_c7e5c567-367c-427b-a1c3-f0983a77fcf2"
      unitRef="usd">11400000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjQtNC0xLTEtMTk3MTgy_d0cd0b51-b8d6-40bb-8125-31cb3ff926eb"
      unitRef="usd">342200000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjQtNi0xLTEtMTk3MTgy_dc109c14-d82e-4dbb-b4c6-e625abeba269"
      unitRef="usd">800000000.0</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjQtOC0xLTEtMTk3MTgy_7b4a82a7-cd3a-46d2-9498-812466091314"
      unitRef="usd">757100000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjUtNC0xLTEtMTk3MTgy_42fd1a6c-1db7-4afe-91ae-e53ae69a28bf"
      unitRef="usd">600200000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjUtNi0xLTEtMTk3MTgy_a32c465e-009f-4d60-b7ea-600c259d2ea0"
      unitRef="usd">929900000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjUtOC0xLTEtMTk3MTgy_c283b0f7-6a46-48b0-bc8b-2ae6f391f728"
      unitRef="usd">358700000</us-gaap:PaymentsToAcquireOtherInvestments>
    <lly:PurchasedInProcessResearchAndDevelopment
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjYtNC0xLTEtMTk3MTgy_bd8b5b68-f332-47a7-9b8e-77521e5ab58c"
      unitRef="usd">629700000</lly:PurchasedInProcessResearchAndDevelopment>
    <lly:PurchasedInProcessResearchAndDevelopment
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjYtNi0xLTEtMTk3MTgy_766c712c-e832-402a-9df9-76231612889b"
      unitRef="usd">563400000</lly:PurchasedInProcessResearchAndDevelopment>
    <lly:PurchasedInProcessResearchAndDevelopment
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjYtOC0xLTEtMTk3MTgy_1607dca7-0329-4779-8e39-7c0bda81cd76"
      unitRef="usd">641200000</lly:PurchasedInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjctNC0xLTEtMTk3MTgy_30125d49-1d11-448a-9990-3e6fd617304f"
      unitRef="usd">327200000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjctNi0xLTEtMTk3MTgy_49cd8754-5326-4b39-b7b9-a2699351ba6b"
      unitRef="usd">747400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMjctOC0xLTEtMTk3MTgy_ead3da49-4038-4428-b634-b3a61688bc87"
      unitRef="usd">849300000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzAtNC0xLTEtMTk3MTgy_e338f6fc-041c-4f40-9448-0787c8733d62"
      unitRef="usd">206400000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzAtNi0xLTEtMTk3MTgy_e2306603-d481-4018-a698-37d58dd53bdb"
      unitRef="usd">-24300000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzAtOC0xLTEtMTk3MTgy_ec2d8e50-c41d-4cbf-a92b-2ff7fd83325d"
      unitRef="usd">-102800000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzEtNC0xLTEtMTk3MTgy_d262cc75-d341-406d-b659-5039ab78d49a"
      unitRef="usd">-3261600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzEtNi0xLTEtMTk3MTgy_3b3548ae-33db-46de-9c82-1afa23c0422a"
      unitRef="usd">-2762300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzEtOC0xLTEtMTk3MTgy_e78e43a5-d065-4c66-9cad-e12aa91e1636"
      unitRef="usd">-2258900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfDividends
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzMtNC0xLTEtMTk3MTgy_d123b66f-b5de-4670-b222-494150e5dada"
      unitRef="usd">3535800000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzMtNi0xLTEtMTk3MTgy_ce23fb8a-2f8c-4a09-9078-40aadbbae8d3"
      unitRef="usd">3086800000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzMtOC0xLTEtMTk3MTgy_a5b0860f-b791-4a93-ab51-1026514dd0b9"
      unitRef="usd">2687100000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzQtNC0xLTEtMTk3MTgy_3c4a8e42-a118-46f9-a280-ff08998faeaf"
      unitRef="usd">1498000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzQtNi0xLTEtMTk3MTgy_19adaba4-84e3-4cb2-b58c-5b8c434c21fc"
      unitRef="usd">-4000000.0</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzQtOC0xLTEtMTk3MTgy_c561c68d-504f-476f-8869-47aff226183b"
      unitRef="usd">-1494200000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzUtNC0xLTEtMTk3MTgy_8b17d5f5-f94d-4ac5-b3aa-c635b4449ff5"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzUtNi0xLTEtMTk3MTgy_b6ab0654-450d-423b-abcc-72abcfeadc46"
      unitRef="usd">2410800000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzUtOC0xLTEtMTk3MTgy_4f82ec99-6b0d-47a8-b0e3-be6629b26f46"
      unitRef="usd">2062300000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzYtNC0xLTEtMTk3MTgy_3547da0b-f5c1-4541-9ff9-b35c2857cd2c"
      unitRef="usd">1560000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzYtNi0xLTEtMTk3MTgy_a88ad3ed-2a71-442f-933b-103659052d1b"
      unitRef="usd">1905400000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzYtOC0xLTEtMTk3MTgy_c20bec0f-17ea-428e-9343-71b4bd589e96"
      unitRef="usd">276500000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzctNC0xLTEtMTk3MTgy_e4b16ec3-8b9d-4bca-97da-86cd65509149"
      unitRef="usd">1500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzctNi0xLTEtMTk3MTgy_86985f03-bb99-45aa-841d-a06152ba1033"
      unitRef="usd">1250000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzctOC0xLTEtMTk3MTgy_c610d8a9-f75d-4fe9-8be7-285e45874ba3"
      unitRef="usd">500000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzktNC0xLTEtMTk3MTgy_03a22323-c032-4986-b95c-1d1adc6936b2"
      unitRef="usd">-308900000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzktNi0xLTEtMTk3MTgy_c25fc339-d319-454a-aa68-428136b85f57"
      unitRef="usd">-295900000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfMzktOC0xLTEtMTk3MTgy_5bd8a726-958d-47e4-904d-3ab4dc33058f"
      unitRef="usd">-241600000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDAtNC0xLTEtMTk3MTgy_3d736c61-c2a6-410b-93fa-45bfc95849c4"
      unitRef="usd">-5406700000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDAtNi0xLTEtMTk3MTgy_4c9242f0-7a93-4939-ab20-97559b41f74a"
      unitRef="usd">-4131300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDAtOC0xLTEtMTk3MTgy_1615661d-8a58-4e3c-a6b1-7a9a14e63252"
      unitRef="usd">-3137100000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDEtNC0xLTEtMTk3MTgy_10301f87-0079-4cfe-a2ae-f95314d436c7"
      unitRef="usd">-167600000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDEtNi0xLTEtMTk3MTgy_d958eae0-2964-49c5-a0ba-0d24c3526bd1"
      unitRef="usd">-205700000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDEtOC0xLTEtMTk3MTgy_4ac5deed-9095-453a-9d1b-04bec83fa145"
      unitRef="usd">216000000.0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDItNC0xLTEtMTk3MTgy_a57a0298-4b7f-49aa-8177-50fc3503c59c"
      unitRef="usd">-1751500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDItNi0xLTEtMTk3MTgy_9c4f98cb-2f02-48b8-8734-bd374b104c3f"
      unitRef="usd">161400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDItOC0xLTEtMTk3MTgy_c7254469-b2fa-4da0-8880-1d26fd911456"
      unitRef="usd">1319600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDMtNC0xLTEtMTk3MTgy_9c10fa64-9b7b-410d-a32a-6368217f82b8"
      unitRef="usd">3818500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i68cf5a8007734a98a36e143a7305b0b7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDMtNi0xLTEtMTk3MTgy_69df54ca-6c7c-4762-8490-219ac6f2ac2c"
      unitRef="usd">3657100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ib66e8131e7a64596bd768a5869bc86ab_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDMtOC0xLTEtMTk3MTgy_9f0a4e8d-1c1b-4786-a87a-28d6ac596e5c"
      unitRef="usd">2337500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDQtNC0xLTEtMTk3MTgy_2af6b2c1-b996-46f6-8266-4c240f4dc281"
      unitRef="usd">2067000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDQtNi0xLTEtMTk3MTgy_2d11fa94-87fe-42aa-aebb-a9fd4d007c71"
      unitRef="usd">3818500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i68cf5a8007734a98a36e143a7305b0b7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF84OC9mcmFnOjNkYWI1ODRkNjA5ZjQ2YWY4M2JiYWY5MjA3MTkyMzRmL3RhYmxlOmZlZmMxM2IwNGMyMjRiODdhOWYwMzFmNTk4ODE3MWY0L3RhYmxlcmFuZ2U6ZmVmYzEzYjA0YzIyNGI4N2E5ZjAzMWY1OTg4MTcxZjRfNDQtOC0xLTEtMTk3MTgy_b78845d9-8a67-4e99-b96c-bbde2d5cc173"
      unitRef="usd">3657100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNTQ0MA_45eab13d-16c3-4ae8-92b5-44fd00e59202">Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include Eli Lilly and Company and all subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). We consider majority voting interests, as well as effective economic or other control over an entity when deciding whether or not to consolidate an entity. We generally do not have control by means other than voting interests. Where our ownership of consolidated subsidiaries is less than 100 percent, the noncontrolling shareholders' interests are reflected as a separate component of equity. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;amp;D) and Development Milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including but not limited to, compensation and benefits, facilities and overhead expense, clinical trial expense and fees paid to contract research organizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D and development milestones include the initial costs of externally developed IPR&amp;amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use. Additionally, milestone payment obligations related to these transactions that are incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Earnings Per Share (EPS)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis. We calculate basic EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with advertising are expensed as incurred and are included in marketing, selling, and administrative expenses. Advertising expenses, comprised primarily of television, radio, print media, and internet advertising, totaled approximately $1.0 billion, $1.2 billion, and $1.1 billion in 2022, 2021, and 2020, respectively, which was less than 5 percent of revenue each year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our other significant accounting policies are described in the remaining appropriate notes to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Implementation of New Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Update (ASU) 2021-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, establishes annual disclosure requirements for companies that analogize to a grant or contribution accounting model for government assistance transactions. We adopted the standard as of January 1, 2022. The adoption did not impact our financial statement disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as further modified by ASU 2021-01 and ASU 2022-06, provides for temporary optional expedients and exceptions in applying current GAAP to contracts, hedging relationships, and other transactions affected by the transition from the use of the London Interbank Offered Rate (LIBOR) to an alternative reference rate. The standard is currently applicable to contracts entered into before January 1, 2025. We adopted the standard in the first quarter of 2022. The adoption did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNTQ2OQ_ede03294-8a2e-4368-aa1d-8aa8565eb789">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;amp;D) and Development Milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including but not limited to, compensation and benefits, facilities and overhead expense, clinical trial expense and fees paid to contract research organizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D and development milestones include the initial costs of externally developed IPR&amp;amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use. Additionally, milestone payment obligations related to these transactions that are incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNTQ3MA_c199fd87-f9a0-4493-8cbe-00d3cbbaded3">Earnings Per Share (EPS)All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis. We calculate basic EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNTQ2MQ_9cc01501-830e-4806-a0a8-92993f9ac52e">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNTQ3Mg_1075e5fd-bfc9-46b1-97e0-0dd3e7385cd8">Advertising ExpensesCosts associated with advertising are expensed as incurred and are included in marketing, selling, and administrative expenses.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNDU3NA_09bd9a04-eeff-4579-ad84-dd8a7b181cf2"
      unitRef="usd">1000000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNDU3OA_06e9c0b9-dc42-4ccc-a54a-efaa22c85090"
      unitRef="usd">1200000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNDU4Ng_069f52df-2e53-4c03-a0fc-84d9ac6e41e7"
      unitRef="usd">1100000000</us-gaap:AdvertisingExpense>
    <lly:AdvertisingExpensePercentageOfRevenue
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNDY0Mg_1696a1bc-c285-4c4d-9393-599338472e87"
      unitRef="number">0.05</lly:AdvertisingExpensePercentageOfRevenue>
    <lly:AdvertisingExpensePercentageOfRevenue
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNDY0Mg_45dc5ab0-054a-4f9c-b7b2-bdda65dfe740"
      unitRef="number">0.05</lly:AdvertisingExpensePercentageOfRevenue>
    <lly:AdvertisingExpensePercentageOfRevenue
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNDY0Mg_58dd2fb0-244b-4bc0-b2be-98e522cc544c"
      unitRef="number">0.05</lly:AdvertisingExpensePercentageOfRevenue>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85NC9mcmFnOmZlYWIzNWRhNDc5NDQ5MDdiOTE4OTA2MDQwNTQ3YTUwL3RleHRyZWdpb246ZmVhYjM1ZGE0Nzk0NDkwN2I5MTg5MDYwNDA1NDdhNTBfNTQ1Mg_8e2564ee-5ef3-4df7-9c73-99593b62af8a">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Implementation of New Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Update (ASU) 2021-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, establishes annual disclosure requirements for companies that analogize to a grant or contribution accounting model for government assistance transactions. We adopted the standard as of January 1, 2022. The adoption did not impact our financial statement disclosures. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform&lt;/span&gt;, as further modified by ASU 2021-01 and ASU 2022-06, provides for temporary optional expedients and exceptions in applying current GAAP to contracts, hedging relationships, and other transactions affected by the transition from the use of the London Interbank Offered Rate (LIBOR) to an alternative reference rate. The standard is currently applicable to contracts entered into before January 1, 2025. We adopted the standard in the first quarter of 2022. The adoption did not have a material impact on our consolidated financial statements</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMTM0OTM_ae7ac4ca-3a13-4aa5-817f-e68c1cc10ff4">Revenue&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our revenue recognized in our consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,462.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,957.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,694.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration and other revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,078.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,360.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,845.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;28,541.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,318.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,539.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Collaboration and other revenue associated with prior period transfers of intellectual property was $163.4 million, $175.0 million, and $135.6 million during the years ended December 31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaborations, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trajenta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 70 days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates, discounts, and returns are established in the same period the related product sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most of our products are sold to wholesalers that serve pharmacies, physicians and other healthcare professionals, and hospitals. For the years ended December&#160;31, 2022, 2021, and 2020, our three largest wholesalers each accounted for between 16 percent and 21 percent of consolidated revenue. Further, they each accounted for between 18 percent and 29 percent of accounts receivable as of December&#160;31, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates, discounts, and returns. The following describe the most significant of these judgments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Sales Rebates and Discounts - Background and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We initially invoice our customers at contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medicaid, chargebacks, long-term care, hospital, patient assistance programs, and various other programs. We estimate these accruals using an expected value approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The largest of our sales rebate and discount amounts include rebates associated with sales covered by managed care, Medicare, Medicaid, and chargeback programs, as well as reductions in revenue related to our patient assistance programs, in the U.S. In determining the appropriate accrual amount, we consider our historical rebate payments for these programs, as well as patient assistance program costs, by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing. Although we accrue a liability for revenue reductions related to these programs at the time we record the sale, the reduction related to that sale is typically paid up to six months later. Because of this time lag, in any particular period our net product revenue may incorporate revisions of accruals for several periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. An estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Sales Returns - Background and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;When product sales occur, to determine the appropriate transaction price for our sales, we estimate a reserve for future product returns related to those sales using an expected value approach. This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately 24 months after the initial sale of a product to our customer), and estimated levels of inventory in the wholesale and retail channels, as well as any other specifically identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and discontinuations, or a changing competitive environment. We maintain a returns policy that allows most U.S. customers to return most of our products for dating issues within a specified period prior to and subsequent to the product's expiration date. Following the loss of exclusivity for a patent-dependent product, we expect to experience an elevated level of product returns as product inventory remaining in the wholesale and retail channels expires. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions. We record the return amounts as a deduction to arrive at our net product revenue. Once the product is returned, it is destroyed; we do not record a right of return asset. Our returns policies outside the U.S. are generally more restrictive than in the U.S. as returns are not allowed for reasons other than failure to meet product specifications in many countries. Our reserve for future product returns for product sales outside the U.S. is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;As a part of our process to estimate a reserve for product returns, we regularly review the supply levels of our significant products at the major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain U.S. wholesaler inventory levels at an average of approximately one month or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements provides us with data on inventory levels at our wholesalers; however, our data on inventory levels in the retail channel is more limited. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Actual U.S. product returns have been less than 2 percent of our U.S. revenue during each of the past three years and have not fluctuated significantly as a percentage of revenue, although fluctuations are more likely in periods following loss of patent exclusivity for major products in the U.S. market. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Adjustments to Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjustments to increase revenue, recognized as a result of changes in estimates for our most significant U.S. sales returns, rebates, and discounts liability balances for products shipped in previous periods, were less than 1 percent of U.S. revenue during each of the years ended December 31, 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration and Other Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize several types of revenue from our collaborations and other arrangements, which we discuss in general terms immediately below and more specifically in Note 4 for each of our material collaborations and other arrangements. Our collaborations and other arrangements are not contracts with customers but are evaluated to determine whether any aspects of the arrangements are contracts with customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Revenue related to products we sell pursuant to these arrangements is included in net product revenue, while other sources of revenue (e.g., royalties and profit sharing from our partner) are included in collaboration and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Royalty revenue from licensees and certain of our collaboration partners, which is based on sales to third-parties of licensed products and technology, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This royalty revenue is included in collaboration and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For arrangements involving multiple goods or services (e.g., research and development, marketing and selling, manufacturing, and distribution), each required good or service is evaluated to determine whether it is distinct. If a good or service does not qualify as distinct, it is combined with the other non-distinct goods or services within the arrangement and these combined goods or services are treated as a single performance obligation for accounting purposes. The arrangement's transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation. For arrangements that involve variable consideration where we have sold intellectual property, we recognize revenue based on estimates of the amount of consideration we believe we will be entitled to receive from the other party, subject to a constraint. These estimates are adjusted to reflect the actual amounts to be collected when those facts and circumstances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development will not receive regulatory approval, we generally do not recognize any contingent payments that would be due to us upon or after regulatory approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;219.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contract liabilities balances disclosed above as of December&#160;31, 2022 and 2021 were primarily related to the remaining license period of symbolic intellectual property and obligations to perform research and development activities or supply product for a defined period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, 2021, and 2020, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by product:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.537%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trulicity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,688.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,914.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,835.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,750.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,557.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,194.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;871.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humalog&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,191.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,320.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,485.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;868.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;730.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;289.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;470.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;289.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Mounjaro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;366.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;115.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;268.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;367.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,911.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,719.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,909.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,553.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,468.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,925.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Verzenio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,653.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;830.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cyramza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;351.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;620.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Alimta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;543.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,233.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;384.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;500.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;66.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;293.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;169.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;254.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,218.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,028.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,792.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,448.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,712.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,527.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Taltz&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,724.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,542.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;757.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;148.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;682.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,892.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,881.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,451.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emgality&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;462.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;188.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zyprexa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;306.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cymbalta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;33.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;249.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;85.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;189.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;612.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;933.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,283.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,344.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;COVID-19 antibodies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,008.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,978.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Forteo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;367.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;245.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cialis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;552.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;144.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;151.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,555.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,566.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;964.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,563.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,190.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,811.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,229.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,351.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,507.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,310.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Jardiance revenue includes Glyxambi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, Synjardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, and Trijardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; XR.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Humalog revenue includes insulin lispro.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,190.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,811.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,229.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,299.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,776.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,187.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,747.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,367.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,583.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,452.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,852.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,702.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;28,541.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,318.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,539.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Revenue is attributed to the countries based on the location of the customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMTM0OTg_d25c79ae-cd38-4a3c-a201-6138c648eb18">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our revenue recognized in our consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,462.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,957.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,694.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration and other revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,078.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,360.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,845.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;28,541.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,318.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,539.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Collaboration and other revenue associated with prior period transfers of intellectual property was $163.4 million, $175.0 million, and $135.6 million during the years ended December 31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by product:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.537%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trulicity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,688.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,914.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,835.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,750.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,557.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,194.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;871.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humalog&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,191.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,320.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,485.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;868.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;730.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;289.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;470.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;289.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Mounjaro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;366.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;115.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;268.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;367.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,911.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,719.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,909.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,553.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,468.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,925.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Verzenio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,653.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;830.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cyramza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;351.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;620.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Alimta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;543.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,233.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;384.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;500.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;66.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;293.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;169.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;254.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,218.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,028.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,792.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,448.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,712.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,527.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Taltz&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,724.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,542.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;757.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;148.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;682.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,892.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,881.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,451.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emgality&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;462.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;188.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zyprexa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;306.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cymbalta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;33.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;249.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;85.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;189.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;612.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;933.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,283.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,344.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;COVID-19 antibodies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,008.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,978.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Forteo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;367.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;245.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cialis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;552.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;144.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;151.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,555.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,566.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;964.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,563.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,190.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,811.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,229.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,351.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,507.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,310.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Jardiance revenue includes Glyxambi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, Synjardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, and Trijardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; XR.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Humalog revenue includes insulin lispro.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,190.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,811.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,229.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,299.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,776.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,187.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,747.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,367.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,583.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,452.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,852.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,702.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;28,541.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,318.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,539.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;(1) Revenue is attributed to the countries based on the location of the customer</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="ie555d2f92f6542cc95e629676af2b0dc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjJiMDE5MDNmMDk5YjRkYWNiYzcxMGQ1Yzg5Njg3ZTdiL3RhYmxlcmFuZ2U6MmIwMTkwM2YwOTliNGRhY2JjNzEwZDVjODk2ODdlN2JfMS0xLTEtMS0xOTcxODI_df666909-8fe9-4d7d-aa18-1fbf19533674"
      unitRef="usd">25462800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99575cf533c942e98caf27205363dccd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjJiMDE5MDNmMDk5YjRkYWNiYzcxMGQ1Yzg5Njg3ZTdiL3RhYmxlcmFuZ2U6MmIwMTkwM2YwOTliNGRhY2JjNzEwZDVjODk2ODdlN2JfMS0zLTEtMS0xOTcxODI_891d7356-acdf-4340-bd7f-f3b0af7b1b10"
      unitRef="usd">25957900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i78dd629925fb4ae4a5093b5fc180b030_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjJiMDE5MDNmMDk5YjRkYWNiYzcxMGQ1Yzg5Njg3ZTdiL3RhYmxlcmFuZ2U6MmIwMTkwM2YwOTliNGRhY2JjNzEwZDVjODk2ODdlN2JfMS01LTEtMS0xOTcxODI_1a33ed50-ba5b-469b-9265-91d598b6aea9"
      unitRef="usd">22694800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i08fdadf5ca3249bb9c4fb62f22fd5774_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjJiMDE5MDNmMDk5YjRkYWNiYzcxMGQ1Yzg5Njg3ZTdiL3RhYmxlcmFuZ2U6MmIwMTkwM2YwOTliNGRhY2JjNzEwZDVjODk2ODdlN2JfMi0xLTEtMS0xOTcxODI_74dba910-bba1-4b0c-ad45-1b09b5cd1f26"
      unitRef="usd">3078600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i09ca7f6b539b42c9bf6134ac1b709820_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjJiMDE5MDNmMDk5YjRkYWNiYzcxMGQ1Yzg5Njg3ZTdiL3RhYmxlcmFuZ2U6MmIwMTkwM2YwOTliNGRhY2JjNzEwZDVjODk2ODdlN2JfMi0zLTEtMS0xOTcxODI_a5ad2c23-106f-469c-8733-7c13d4936ec8"
      unitRef="usd">2360500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c9c826fd2b347378c7aa9dfe51568b7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjJiMDE5MDNmMDk5YjRkYWNiYzcxMGQ1Yzg5Njg3ZTdiL3RhYmxlcmFuZ2U6MmIwMTkwM2YwOTliNGRhY2JjNzEwZDVjODk2ODdlN2JfMi01LTEtMS0xOTcxODI_7d96a95f-b0db-49b6-9ed9-5aca8f487011"
      unitRef="usd">1845000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjJiMDE5MDNmMDk5YjRkYWNiYzcxMGQ1Yzg5Njg3ZTdiL3RhYmxlcmFuZ2U6MmIwMTkwM2YwOTliNGRhY2JjNzEwZDVjODk2ODdlN2JfMy0xLTEtMS0xOTcxODI_0905ad92-23b4-42b2-81e4-d48fb2dc405d"
      unitRef="usd">28541400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjJiMDE5MDNmMDk5YjRkYWNiYzcxMGQ1Yzg5Njg3ZTdiL3RhYmxlcmFuZ2U6MmIwMTkwM2YwOTliNGRhY2JjNzEwZDVjODk2ODdlN2JfMy0zLTEtMS0xOTcxODI_72f13fd6-b8fa-4b8e-b239-21ada5f47e5b"
      unitRef="usd">28318400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjJiMDE5MDNmMDk5YjRkYWNiYzcxMGQ1Yzg5Njg3ZTdiL3RhYmxlcmFuZ2U6MmIwMTkwM2YwOTliNGRhY2JjNzEwZDVjODk2ODdlN2JfMy01LTEtMS0xOTcxODI_19604575-ee79-44db-9df8-ef603490b718"
      unitRef="usd">24539800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iadec1e1743a24bc4aa16803f33246e23_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjI3_b5c017c8-0bbd-4919-8fcd-ea88b946f916"
      unitRef="usd">163400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6618dd5b6c274f07b8f2d7da01455ae9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjMx_bd8d8f9f-8c5d-488d-96cf-68d41eb36719"
      unitRef="usd">175000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i46e71ff65ed94973b8d1406f4b8985bd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjM5_42b48b39-cd41-46fd-a093-70e8d71735e2"
      unitRef="usd">135600000</us-gaap:Revenues>
    <lly:RevenuefromContractPaymentTermMinimum
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMTQ3Nw_2c64cac3-16eb-4807-b2d5-0b9b99668200">P30D</lly:RevenuefromContractPaymentTermMinimum>
    <lly:RevenuefromContractPaymentTermMaximum
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMTM0ODA_2f0c8a45-91d4-4865-8d49-aac22d21e114">P70D</lly:RevenuefromContractPaymentTermMaximum>
    <lly:RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMTc0NA_dc8a115d-d1a3-47ee-9dba-ab80fdb34ecd">P1Y</lly:RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia3cb0bc9a28341368653294b04baaed1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjY5NA_43db9614-1a89-4e69-b7a1-25453d295d40"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3c4252adafce48d88948c0f7b97ac340_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjY5NA_8193be13-fa1e-44e8-9571-5e700e6703bd"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9fd0e5a16356409e8036bedd277f4b6c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjY5NA_c4010d9e-87dc-4135-aaf6-67cd2c20ddde"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i85cc049a60e14b52a4c0ca5ac603af8d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjcwMQ_3545db78-8925-43cc-9b9e-b8279331b0cb"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i688f1fee1d614afdae131948a26e41be_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjcwMQ_52541d19-581c-4d9b-af6f-7b1fba1ca965"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i99ecb99c796447d88385d69144bcd82c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjcwMQ_8b3fb7eb-2fa8-42a8-b99f-84981b4181fe"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic3df9d79b482447198c448522c1b720b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjc3MA_c07baf1a-f138-46ae-b490-4838c1cd422c"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0918ef1c05fb4f68ab4e15f2a8283a12_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjc3MA_f16e19a6-21d3-41a1-9ebd-baeb25b0dcd9"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibbf827440e1c44ed9d4fa7f91748f0b5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjc3Nw_1f37b45d-9c72-42d5-8c3b-d73670e228ee"
      unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie4e5c7fafd8141999915cd2f615aaeb8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMjc3Nw_2537637b-072d-463c-8e83-1272140ac78d"
      unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
    <lly:RevenuePerformanceObligationSalesRebatePaymentPeriod
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfNDgwNw_e17cc6f2-7209-4257-a263-67d78c125ed2">P6M</lly:RevenuePerformanceObligationSalesRebatePaymentPeriod>
    <lly:RevenuePerformanceObligationSalesReturnsProductExpirationDate
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfNTc1NQ_93075510-e2e4-41af-8afc-277a32bdade6">P24M</lly:RevenuePerformanceObligationSalesReturnsProductExpirationDate>
    <lly:RevenuePerformanceObligationSalesReturnsAverageInventoryLevel
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfNzUyNQ_7bcb11b7-5862-4974-883c-0e98588715cc">P1M</lly:RevenuePerformanceObligationSalesReturnsAverageInventoryLevel>
    <lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfODIwNA_3e1ea2b2-e284-431e-8111-49924abd40ab"
      unitRef="number">0.02</lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue>
    <lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfODIwNA_7fbd4ef0-69d9-499c-95c0-acaa780e79f8"
      unitRef="number">0.02</lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue>
    <lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfODIwNA_9403c054-0e5b-4723-868f-e1a2e332776c"
      unitRef="number">0.02</lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="i91192a23f0104c96a6b1188f603bb21a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfOTM0NTg0ODg1MDIxMw_4d32b876-513b-4162-b387-3dcc85c63b94"
      unitRef="number">0.01</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="i1a5b41d1ce604fd1b7157e4bb21a41c7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfOTM0NTg0ODg1MDIxMw_5ec7076b-c863-4a9a-bc53-60d784e42800"
      unitRef="number">0.01</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="i79ee633bf3254f18873fa97220a9dff2_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfOTM0NTg0ODg1MDIxMw_88862a80-8382-4145-94f9-6532b790c6e9"
      unitRef="number">0.01</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RleHRyZWdpb246YTczNDhjY2MwYTliNDA3ZmJmNDRjODU1ZGY5YTZjZTlfMTM0ODE_58a1ee1c-f3ea-4330-940a-8321b088ea06">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;219.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjg3ZWE5MGEwODAwMzQ1MjNiNzMwNGM1YWNmY2VjNTcyL3RhYmxlcmFuZ2U6ODdlYTkwYTA4MDAzNDUyM2I3MzA0YzVhY2ZjZWM1NzJfMS0xLTEtMS0xOTcxODI_241101dc-b65b-48d0-bcd9-01271b85863c"
      unitRef="usd">219200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjg3ZWE5MGEwODAwMzQ1MjNiNzMwNGM1YWNmY2VjNTcyL3RhYmxlcmFuZ2U6ODdlYTkwYTA4MDAzNDUyM2I3MzA0YzVhY2ZjZWM1NzJfMS0zLTEtMS0xOTcxODI_9ddeee92-dd67-419d-b126-8d073ef9f4ac"
      unitRef="usd">262600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues
      contextRef="ibed6c41cdbc8431bac939f81410f22c9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNi0zLTEtMS0xOTcxODI_94312414-5196-489d-b3e0-99624f210c1c"
      unitRef="usd">5688800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i908ec847fcf64bb7913cbcb485ad4d96_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNi01LTEtMS0xOTcxODI_cfe6cb50-6a2e-4856-a11f-a158b3905336"
      unitRef="usd">4914400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie8129ef6df6f431e977d79c1b651ea70_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNi03LTEtMS0xOTcxODI_99c12c94-4932-4a6a-ab6f-28f767a8836c"
      unitRef="usd">3835900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d1a32c39d7543c5bda93421375a60d8_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNi05LTEtMS0xOTcxODI_239cdf73-1621-4fac-84b8-e3ac863100ec"
      unitRef="usd">1750900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id4677e27f1be4111b8e4c3d118b419a1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNi0xMS0xLTEtMTk3MTgy_a5491261-6a30-439e-b010-2a38993e34ba"
      unitRef="usd">1557600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ac4e905749940e0acc95a2b2b4d06c1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNi0xMy0xLTEtMTk3MTgy_5a9e11b6-37d6-4454-afe3-20b90e174ffd"
      unitRef="usd">1232200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1429058ec4bd4a89b6ef2f638439c0e5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy0zLTEtMS0yMjY3NzQ_7096107c-b07c-4001-aab4-d1436b403cdf"
      unitRef="usd">1194500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i90ebccca38314b2b893a86d4df3e24ed_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy01LTEtMS0yMjY3NzQ_fd57aff2-1be3-470d-b91f-b9ce4d8e098c"
      unitRef="usd">807300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i940a532a79364120a9f3635e0d2abcec_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy03LTEtMS0yMjY3NzQ_b35a41a4-3a29-44ef-89d3-aeb3d2ff0ded"
      unitRef="usd">620800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ee509ded6c2446891ec496e86228071_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy05LTEtMS0yMjY3NzQ_5e78d97c-4576-477b-a9aa-ab33a3d10122"
      unitRef="usd">871500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i353b4ca1ec8545e29d12179593b5f304_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy0xMS0xLTEtMjI2Nzc0_6a1dbee3-21ca-487e-8b1c-0a076cb818b7"
      unitRef="usd">683500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c31d4c6617549a6926ef9edc6b8d19d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy0xMy0xLTEtMjI2Nzc0_9a1a89a8-426a-4048-ae61-fed01c48395a"
      unitRef="usd">533000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic0a89f71ff7840b2aee585821fdc79bb_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy0zLTEtMS0xOTcxODI_ad33dc25-5a8b-4a8e-93b2-64f5a5b700df"
      unitRef="usd">1191900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic6129a4ae188436e997eb164885bd944_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy01LTEtMS0xOTcxODI_b6db9d85-df7f-47e0-9195-978b2dda0033"
      unitRef="usd">1320700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba2beed36c49496f8c05407dbded623c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy03LTEtMS0xOTcxODI_59470cb5-f139-49da-ab05-ac70b7efbb6c"
      unitRef="usd">1485600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf3a669814bf4e739636b5862a5a79d3_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy05LTEtMS0xOTcxODI_501dec96-74ae-4b74-9b98-a822df38cd3f"
      unitRef="usd">868700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i42a13a96ce9d4498957d2c9c70ac693b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy0xMS0xLTEtMTk3MTgy_557c769e-9503-46c3-80b6-01b736576619"
      unitRef="usd">1132300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie734d147b3a94c178e55911be7120159_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNy0xMy0xLTEtMTk3MTgy_7183b1e0-fe34-43cf-9522-bdf1bc29e43b"
      unitRef="usd">1140300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i83a6a8aae9224f21a121e9d9db314173_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfOS0zLTEtMS0xOTcxODI_0c98da31-dcf0-47d8-8f3e-70ca97c453bc"
      unitRef="usd">730200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5838c7dc2be042b2a3ab858cf9b880e6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfOS01LTEtMS0xOTcxODI_9374c8ff-6505-4fd7-b78a-e2b231bfee18"
      unitRef="usd">832900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icbedbb47344e4f2cb3b8765fa2aff470_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfOS03LTEtMS0xOTcxODI_3b066e48-2f72-48ea-8ff3-8b6449a6b474"
      unitRef="usd">866400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ed9fab22d754adeb11fb4fe998cb3a6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfOS05LTEtMS0xOTcxODI_aca050da-082a-4a61-96d6-c8b5a0ff5bff"
      unitRef="usd">289200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i63f062d00a9b498abb19bb45e988b8a2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfOS0xMS0xLTEtMTk3MTgy_54a46399-e307-4c61-9318-0d10e907a2f7"
      unitRef="usd">389600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7c28332273c24b679e3f1bb73cf7cc58_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfOS0xMy0xLTEtMTk3MTgy_fc9fe3c2-a568-4342-bac6-4b085a10a416"
      unitRef="usd">393200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7c493cb7f8944bb2b545e0e6d00775bc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTAtMy0xLTEtMTk3MTgy_dd61e482-8184-433a-9322-3d2fba72da00"
      unitRef="usd">470700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i625ee4d76d334362b8de4352af1b773d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTAtNS0xLTEtMTk3MTgy_e1852d96-03ef-4bfd-b844-96ec25c8b65b"
      unitRef="usd">588300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia873c39e36f34f9880aa324b4f3c6b89_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTAtNy0xLTEtMTk3MTgy_2b6c5d93-c5f8-44b4-a8db-e2a4877ac8fb"
      unitRef="usd">842300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5019cb5a09214868a6ffd5c421748740_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTAtOS0xLTEtMTk3MTgy_ea7d6f44-7fd1-4972-bda8-ca894ba641e4"
      unitRef="usd">289700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf887a499d9b4c1f9b06d18769bf3a1d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTAtMTEtMS0xLTE5NzE4Mg_684db544-232e-403c-97f2-2acd0ad9f434"
      unitRef="usd">304200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf2974bb2f68427da48e46d951d464e4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTAtMTMtMS0xLTE5NzE4Mg_2db3e10b-1d37-420c-aaf6-220dcfc89c9f"
      unitRef="usd">282100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i64eacb976de14569ac6ff1899c6605de_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTEtMy0xLTEtMTk5ODY4_854f3a37-80cc-4536-9491-b3b06aef3d60"
      unitRef="usd">366600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6306f16596f249559125fb3a670c3326_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTEtNS0xLTEtMTk5ODg2_46598a54-419a-4938-9529-3cce70fcc81f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id7b5bde978fc4056b0f67115cb95bdc1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTEtNy0xLTEtMTk5ODkz_2a928dad-ab2a-4f1e-9482-6a48fe58f27c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9a2a0156508b46d6a429156a9e507b0a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTEtOS0xLTEtMTk5ODgz_58482d00-a02d-4a19-85e1-504453430be3"
      unitRef="usd">115900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9e04de56005e49cf9693a8f1a4d921b6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTEtMTEtMS0xLTE5OTkwMA_d1a5a942-7aeb-48a6-9ac7-c7805c5c39a6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a158eedd1b1481995dd35bc68fea4dc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTEtMTMtMS0xLTE5OTkwNw_8540bf16-4ba4-4005-a6d6-1931b9a641bf"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie94ce0194f2a42f986e5b3f0d5e00c05_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTItMy0xLTEtMTk3MTgy_0d6d9603-909f-4dc2-851c-4d2e97b4e92e"
      unitRef="usd">268400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic9763e7d353848e4a659a5f54585d4a3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTItNS0xLTEtMTk3MTgy_8f4e432d-30e3-40d3-8830-0e6a155a7340"
      unitRef="usd">255700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i87c4deaeae714216a5ee408c78d2cf02_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTItNy0xLTEtMTk3MTgy_be8267ac-0551-41ee-ba0a-34d0289f6ab6"
      unitRef="usd">258100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie572e122731f4d66b7d209d9d838c85f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTItOS0xLTEtMTk3MTgy_61829540-4ae7-4988-8aae-a23709ad5452"
      unitRef="usd">367800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieb2c52e8eea34a75a5e2f2b51206fa4b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTItMTEtMS0xLTE5NzE4Mg_4b5bb6f3-d8fc-4c68-adf3-341ac72bed9a"
      unitRef="usd">401600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb4fc43fe5434bd9b22e62377d8e4f20_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTItMTMtMS0xLTE5NzE4Mg_1695099e-07e7-4caf-8e46-e08291751618"
      unitRef="usd">344500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b43b7a7eb4a42ea96b75af06d3894fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTMtMy0xLTEtMTk3MTgy_83cf771f-9e3f-4a14-a08b-f814c0b89ede"
      unitRef="usd">9911100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8fe6893994d4f3da2aed48164588249_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTMtNS0xLTEtMTk3MTgy_afcb6b07-cdee-444b-9a69-571a9b7b8db7"
      unitRef="usd">8719300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i08d12e8f58234c72a009dbbd89e1ef87_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTMtNy0xLTEtMTk3MTgy_4b5bcfca-43eb-476d-9cfd-11edff7561f2"
      unitRef="usd">7909100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2045052682ee483d9ecaaf59cf44fdb5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTMtOS0xLTEtMTk3MTgy_b79ac0f9-b894-48b4-b103-de5cd6964b26"
      unitRef="usd">4553700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i725c992052d041e192d4ee9a85e23fe8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTMtMTEtMS0xLTE5NzE4Mg_d6645576-2350-4c73-a793-3199ae103050"
      unitRef="usd">4468800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia6b37c5bfb894eb683d061c2663d2135_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTMtMTMtMS0xLTE5NzE4Mg_02b5aa4a-238c-405d-8666-abe09fcf9bdc"
      unitRef="usd">3925300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id0093b813b28435d89b38aaa707cb59a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctMy0xLTEtMjI2Nzgz_1f83c8e6-59e6-4666-9954-ae58c01faf24"
      unitRef="usd">1653200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i815000e020f14a53a097e53a2b56cf06_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctNS0xLTEtMjI2Nzgz_84ad6e4d-6bed-41a1-9b16-c48bbc4b7115"
      unitRef="usd">834900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2d08de0a5b1a48e693777db50fe7ee4e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctNy0xLTEtMjI2Nzgz_0c4937e5-9b79-44d8-8d98-0a5e87352154"
      unitRef="usd">618200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iebb55033007f414c8fa01ecddd9bf258_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctOS0xLTEtMjI2Nzgz_3297a357-6b33-4623-897f-d2818b641b96"
      unitRef="usd">830300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i436f39f0114a4a5b9a126d5a84fad158_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctMTEtMS0xLTIyNjc4Mw_1fe95ee0-05fe-4643-97fb-0788e95cc5ff"
      unitRef="usd">515000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf01e8c322a64b3cb59c38b35cf69a28_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctMTMtMS0xLTIyNjc4Mw_fb3bb46b-f45c-44da-a916-bf007db577e8"
      unitRef="usd">294400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic463dd1900c549c09de91b07ab6ca276_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTgtMy0xLTEtMjI2ODU3_6980f285-4f8c-496d-b8b0-4eebc03be1ad"
      unitRef="usd">351400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6bc3a2798eef4b98bf1cda7f51dbb961_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTgtNS0xLTEtMjI2ODU3_ac35ad60-a664-488e-8799-7bece6d2792d"
      unitRef="usd">358100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i34b6a251be9e4777827eee958db02629_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTgtNy0xLTEtMjI2ODU3_b40190b7-92ad-4163-b440-f18ebb109a59"
      unitRef="usd">381900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibfa9bb0a325b4912942a0407bfd24c96_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTgtOS0xLTEtMjI2ODU3_d1a1124b-5c2c-4b63-a1c8-fb081942b042"
      unitRef="usd">620000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7e2990f5e8845a191e0fb00304c2103_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTgtMTEtMS0xLTIyNjg1Nw_2df13f49-b4ba-449d-bed2-c84f06f4d6b2"
      unitRef="usd">674800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2cc3f43284394154b2281bd30b634ec5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTgtMTMtMS0xLTIyNjg1Nw_dda791d8-99dd-47ec-8100-1569e6e3b543"
      unitRef="usd">650800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i96f6b8a0775b4507983b982add0eaa15_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTYtMy0xLTEtMTk3MTgy_fcac69ef-50f5-427a-92f7-c9549cb2e827"
      unitRef="usd">543700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i475b2a44ffaa4b3ab01390955fe7fb4e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTYtNS0xLTEtMTk3MTgy_5752c991-61ab-4138-b65a-8c2458130030"
      unitRef="usd">1233900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e84d0c1a5604dc399d2032784a2c381_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTYtNy0xLTEtMTk3MTgy_34822df9-fcf3-4eeb-b7d0-16cea4547094"
      unitRef="usd">1265300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie1d59b98a2b84f41bcf716a679809aef_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTYtOS0xLTEtMTk3MTgy_ae481d61-fd78-4733-a968-0f1a4ad249fb"
      unitRef="usd">384000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i47bf0038a1cf485685beffa18825039e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTYtMTEtMS0xLTE5NzE4Mg_69217c74-e500-434e-b4ca-8db6a1620c6b"
      unitRef="usd">827500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibbe5cf54b9584a46ba3abe1a6a45520b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTYtMTMtMS0xLTE5NzE4Mg_99ec412f-1835-4805-a228-f7e53e842993"
      unitRef="usd">1064700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i77bb27eccc6e416b96871a23917489a6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctMy0xLTEtMTk3MTgy_ce371e18-ca05-40a9-b0c9-7b2768f23bb6"
      unitRef="usd">500100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99feddef0f9d4b61ae8c11159fdbbed6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctNS0xLTEtMTk3MTgy_e405843e-a1fa-4584-ba1d-b4991257f99a"
      unitRef="usd">481800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3881ed56ede64167839562a909065542_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctNy0xLTEtMTk3MTgy_8ea6e459-e253-4d29-993e-e8c4468994ee"
      unitRef="usd">480100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4da626bf5e3e4942861f067702818432_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctOS0xLTEtMTk3MTgy_5912613d-907f-4e34-a12d-17e167b3b550"
      unitRef="usd">66400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9d4ae7d53fa74012826220f9d9aefec0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctMTEtMS0xLTE5NzE4Mg_8189764f-3796-41a9-98c8-78baa48fae5f"
      unitRef="usd">66400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7e5fa2fc32ec4622803f8565f86727be_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMTctMTMtMS0xLTE5NzE4Mg_6a0ab5c0-212c-4e97-ad8c-9e1eb0485ca6"
      unitRef="usd">56300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc6ab3bc43384429a45007709c2c734c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjAtMy0xLTEtMTk3MTgy_a6a7ddb1-2160-4e52-8168-59519ba99554"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d903025752047dc8b7cdd55eb19a7ed_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjAtNS0xLTEtMTk3MTgy_baaa318e-dcde-493a-9f00-e2505f2aa804"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifb7822de8b36448bbb44fa84bf3d26b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjAtNy0xLTEtMTk3MTgy_405dc2a5-0025-4036-9f16-cc86ebfb3b7a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic1dfa84e409446888abbc37fbcf675ba_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjAtOS0xLTEtMTk3MTgy_b3fca4f8-b69c-4853-9093-6e02df82f504"
      unitRef="usd">293300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ec671c462234f09b93b6aebd0b48663_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjAtMTEtMS0xLTE5NzE4Mg_bd75c9f1-430a-49ee-85cb-75dc83d8647f"
      unitRef="usd">418100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ea2a5bdd3934abbababa751cef82703_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjAtMTMtMS0xLTE5NzE4Mg_4c0ee359-04f3-4885-9ce2-60f6b1eb883f"
      unitRef="usd">308700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia800ee3300054be0a311fc0ded6756a4_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjEtMy0xLTEtMTk3MTgy_900ca234-18d5-4111-9c87-a76b1911aa49"
      unitRef="usd">169700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i050aca7ad92848f7bce2d263075706f3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjEtNS0xLTEtMTk3MTgy_68843427-fa53-422a-8edd-12c8bd937563"
      unitRef="usd">120100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iedf81083b171427593695e6bf008b9ca_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjEtNy0xLTEtMTk3MTgy_a56a533a-4fc5-49dd-869c-ea1a375d1d4e"
      unitRef="usd">46600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i38d43d13cc4649cdb4b312a0c6e19672_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjEtOS0xLTEtMTk3MTgy_c8ba3591-dbea-4fd7-913e-06db78cee4f3"
      unitRef="usd">254100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4403e2fd87d64f338b43367544717790_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjEtMTEtMS0xLTE5NzE4Mg_badb9849-6413-4e0f-80c1-e10a0e5307c6"
      unitRef="usd">210700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie5e9ce589b3341e59b661221502733d3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjEtMTMtMS0xLTE5NzE4Mg_e892dabd-bd7a-4234-aa3a-617fdb529aeb"
      unitRef="usd">152300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if37fae77f3fd48b39b0930752704bc6a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjItMy0xLTEtMTk3MTgy_8b393641-6497-434e-81af-50f88facfc05"
      unitRef="usd">3218100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3eceda29c176407a87bd531353a1c6e8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjItNS0xLTEtMTk3MTgy_f53655cc-f0a8-4aac-8cf1-802dc6c000da"
      unitRef="usd">3028800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia87e1143e93f432785a964577b99cef5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjItNy0xLTEtMTk3MTgy_1c3158a3-4bcc-4736-bcdc-d0568dc5828a"
      unitRef="usd">2792100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i20f5d0530c744df690ab8c031e4207b2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjItOS0xLTEtMTk3MTgy_91b5dfff-730a-488a-9dbb-b0b53224a63b"
      unitRef="usd">2448100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i760024cf4c2b4368ae467fa2e123ad6a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjItMTEtMS0xLTE5NzE4Mg_2604e57f-8403-4cde-91f8-6a5d49f9b3f7"
      unitRef="usd">2712500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d7597d5af254ee68dee4515242f8889_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjItMTMtMS0xLTE5NzE4Mg_e7e4dfec-c4cc-4367-8bbd-8c930892fd82"
      unitRef="usd">2527200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8399f74b1bdf46aeb1528d1b339e6322_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjUtMy0xLTEtMTk3MTgy_021e4026-3346-442e-be20-4fe6754804e1"
      unitRef="usd">1724600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia0ea5b089cf44e24b8e07841f4632655_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjUtNS0xLTEtMTk3MTgy_8ec1c3e6-c51f-4b01-aa1b-9debdd97489f"
      unitRef="usd">1542400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf3ddbf27f6d4e1f91bb0bb812805861_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjUtNy0xLTEtMTk3MTgy_edceff95-626f-4d9c-85c9-1e461a63c533"
      unitRef="usd">1288500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib32eab706ca94218a617e1064dbc8ab2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjUtOS0xLTEtMTk3MTgy_67aa3f19-edb4-414f-99db-9cc6570d4f40"
      unitRef="usd">757400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4223c4a3b6f241dfb2bdcc2730d74722_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjUtMTEtMS0xLTE5NzE4Mg_9156164f-5285-48ba-9fa1-5413fecdc435"
      unitRef="usd">670400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1e350402b214cd6a481e96fcc09dc2d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjUtMTMtMS0xLTE5NzE4Mg_c29dc61c-955c-4326-a87a-1fc32dc68e66"
      unitRef="usd">500000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia6e79e5873c04265ae9f72597e7f8655_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjYtMy0xLTEtMTk3MTgy_d4c54ddf-0832-4676-8611-719c688f43a9"
      unitRef="usd">148200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i657624079cc0470f8c99a900c86bb61e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjYtNS0xLTEtMTk3MTgy_4863bb6a-f989-41b4-9fb9-d66856967dc9"
      unitRef="usd">324100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic8d7a484c7774a6fafe5d1a16b52d73c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjYtNy0xLTEtMTk3MTgy_eb648e0d-1bf3-4e54-8140-9ec9c3760c6b"
      unitRef="usd">63800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4bd0bb01de3b4defa7e5a43ea90f78fa_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjYtOS0xLTEtMTk3MTgy_97395605-b966-4216-9aea-e5d946f44d6d"
      unitRef="usd">682300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i89ca17c8c8fa4a3c97af54a9338d556b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjYtMTEtMS0xLTE5NzE4Mg_9e7d4539-6521-4d93-a42c-02f5471b2431"
      unitRef="usd">791000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie11d2b1d901b4c59b9940a3eec5fac7e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjYtMTMtMS0xLTE5NzE4Mg_6fa18873-a236-4cce-a821-c6fc80af5991"
      unitRef="usd">575000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7bbf7ffff8d940379635573118d0f46d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjctMy0xLTEtMTk3MTgy_b31f94e4-591b-4036-9ed9-db36ad823264"
      unitRef="usd">20000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieb60edeed6364e088d8dbb6b15046831_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjctNS0xLTEtMTk3MTgy_69ab9ed0-9038-4c51-97fe-73593e7fd0a6"
      unitRef="usd">15300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iae608dbd9c8b41bba6dbf7a3b438fbf1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjctNy0xLTEtMTk3MTgy_dc40747b-e075-4e0d-8990-8a8a355a0585"
      unitRef="usd">20000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id3072b728afd41dda5c1bc25d9a2f756_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjctOS0xLTEtMTk3MTgy_4afbf275-6bb2-4b7c-9666-90f6d8fd2910"
      unitRef="usd">12100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic4a1e442fced4165a82ae4740cb22603_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjctMTEtMS0xLTE5NzE4Mg_ef7a4e3f-58db-46de-bc1c-5959b3a2542d"
      unitRef="usd">17600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i68b90bf218ec4f59bc626928cee0157a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjctMTMtMS0xLTE5NzE4Mg_28fc5d5a-87fc-41a4-abbe-6af1a46a9f19"
      unitRef="usd">14600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0f6cf7efc0d4c7fa84a45bd8424a737_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjgtMy0xLTEtMTk3MTgy_b437ca48-20ec-46f5-ae98-1f77c5c2d9fc"
      unitRef="usd">1892800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i17d469e38c5249c1b559efdd08d0b75f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjgtNS0xLTEtMTk3MTgy_20e7f68d-9d69-4a64-9a36-39b49f4fab8f"
      unitRef="usd">1881800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8250de8fcc304ad3ba9fd98d5ffe1067_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjgtNy0xLTEtMTk3MTgy_3e6433c4-71ad-494d-b573-da77e44cc67e"
      unitRef="usd">1372300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaab72e5a9431446392b87064073da439_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjgtOS0xLTEtMTk3MTgy_7e4ed3f4-8a8a-43b1-b02b-37314daf6403"
      unitRef="usd">1451800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaefaac168c674bd8bbaf0ba59c09b345_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjgtMTEtMS0xLTE5NzE4Mg_1cb78c09-03fa-4dca-9351-96f2ad3ab611"
      unitRef="usd">1479000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie8f82cf734df4f228c6ca91846be4abc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMjgtMTMtMS0xLTE5NzE4Mg_0559da85-2bf2-4ce2-bb27-6ecec7c11b09"
      unitRef="usd">1089600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic8b87668f0c34cfe8c41218fb3f7c47d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzItMy0xLTEtMjI2ODA0_38558c06-831d-4973-85e6-f87fe832f08e"
      unitRef="usd">462800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i140a6b9bf6b14209800b8ed52032d8f3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzItNS0xLTEtMjI2ODA0_0f402bf1-e7dc-4ec0-9d9e-bec7eccba4c8"
      unitRef="usd">434500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic9daf68a25164d62b1bb8bf1e3e52307_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzItNy0xLTEtMjI2ODA0_d178d34b-60eb-4ac2-ab35-f45d51ee88a0"
      unitRef="usd">325900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1cc6ca8f8f148fbbce02f358ee33e7b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzItOS0xLTEtMjI2ODA0_b6024a06-4d5f-4a4d-8fc6-1fdb293f3a69"
      unitRef="usd">188100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6cbe097595924436a04ba8cc2a5d2e99_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzItMTEtMS0xLTIyNjgwNA_489e887c-c7c7-451c-ab97-4e5febd50ef2"
      unitRef="usd">142700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib156c3b2d1414c94bf4093abcc3dafc8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzItMTMtMS0xLTIyNjgwNA_d983c3c3-a7e9-4f1c-9db6-440107b01e10"
      unitRef="usd">37000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i33fca98fda4a48f79d860f14183ce7e3_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzMtMy0xLTEtMjI2ODY5_ad20474a-e4ee-482c-8cf6-0f83b96c5e13"
      unitRef="usd">30400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie34501579b964c8abb3704d789d36cdb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzMtNS0xLTEtMjI2ODY5_ed56d070-8f63-42be-baec-9ae8b2f12e2b"
      unitRef="usd">39600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i77f2f9e5632a4e7c9163699499944509_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzMtNy0xLTEtMjI2ODY5_fc71ac6f-6867-4547-a719-8aa9b2f9d9dc"
      unitRef="usd">46100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i60c850a7c7894db69b4a040b6d233af0_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzMtOS0xLTEtMjI2ODY5_3c73512a-0eff-4b1a-97b3-0c70b49e2423"
      unitRef="usd">306500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d17a977fd83415c9e00512147086a44_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzMtMTEtMS0xLTIyNjg2OQ_64d66fbd-274b-4978-9f2f-22a8d68e9c08"
      unitRef="usd">390700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iad01c8f917b44cacad101857ae82b796_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzMtMTMtMS0xLTIyNjg2OQ_aa942874-f11f-41d8-93be-d7b18f282da6"
      unitRef="usd">360500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i027e5de11b114136913aecf0144ddbc2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzEtMy0xLTEtMTk3MTgy_5ba2b260-a7ba-449f-9bda-70d44f2cf143"
      unitRef="usd">33700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib0fafe92cc1347b5bc9f75c189771831_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzEtNS0xLTEtMTk3MTgy_86e2a4dd-0d18-4483-a353-c110783fea26"
      unitRef="usd">38700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8037b2d8309d4fb482c5ec2dedc8a023_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzEtNy0xLTEtMTk3MTgy_a43966b7-c1ed-403f-8b4a-d4548d8b98d5"
      unitRef="usd">42100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i05b4f558633e4ea782159ade55b154e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzEtOS0xLTEtMTk3MTgy_d4606c5a-b8a7-4e0a-9b83-077a8bb91d80"
      unitRef="usd">249600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic41b44053bbf475aa1692687a86d75c8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzEtMTEtMS0xLTE5NzE4Mg_88586230-96bd-44f3-94cc-3e431b31400b"
      unitRef="usd">542800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7a7fe42f8eac44919bbccc5a618cf3f4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzEtMTMtMS0xLTE5NzE4Mg_e6c8e308-b0ae-45f8-9fe9-3b0ef37ee9a6"
      unitRef="usd">725600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i785953ac34004786aaaaf3b2c864ba77_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzUtMy0xLTEtMTk3MTgy_f7e8411e-5961-4d1d-ab3f-5dd363baf7df"
      unitRef="usd">85500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i32f96b235c0b43198bae6d8ec75f0a44_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzUtNS0xLTEtMTk3MTgy_317d1e49-ba68-42b2-a274-a89e319e25f1"
      unitRef="usd">102000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ife00cbd3aa774f1faba1231e784a9643_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzUtNy0xLTEtMTk3MTgy_6267d01f-280b-48e3-bb5f-b2af70fe3082"
      unitRef="usd">73200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib74ddbdf3df74b23b09907d3377b3d56_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzUtOS0xLTEtMTk3MTgy_b6aad4cf-9b7e-4fe1-9553-305973b5a4a5"
      unitRef="usd">189600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6bfddc1069524fcd8b6e480aa1ef27c3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzUtMTEtMS0xLTE5NzE4Mg_ce23bbe0-9a0d-4b92-aa78-1410e6ae566e"
      unitRef="usd">207500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6538ec30c43840a99b5e15dc4bcc8131_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzUtMTMtMS0xLTE5NzE4Mg_b144a51a-599d-4547-b1e5-7a5081da5f80"
      unitRef="usd">220900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b4a05b525764d80b2afbc012254fe88_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzYtMy0xLTEtMTk3MTgy_e7a03a22-2fea-4754-89d7-fa0b2901d17b"
      unitRef="usd">612400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i75c9e82d787c47c0bdb7e1e3d16ce5f4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzYtNS0xLTEtMTk3MTgy_0c14698d-4849-4268-bdc2-0720a8a0b953"
      unitRef="usd">614800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if30607cf1ea84cf498de520dba0098c7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzYtNy0xLTEtMTk3MTgy_a35699fe-7194-4ae0-8e85-e038641e7367"
      unitRef="usd">487300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i698cd7cf5e334be397e08d1f53f737ab_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzYtOS0xLTEtMTk3MTgy_cc5b84a9-4df0-4461-a65a-ae2d4ccd1df0"
      unitRef="usd">933800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i09c32552bbc74587b3fe07cd98986a93_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzYtMTEtMS0xLTE5NzE4Mg_836d0f24-9a92-4086-a786-65fc40c0b0d6"
      unitRef="usd">1283700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i83ddfe09bcd8407bab751faee3cfa0bf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzYtMTMtMS0xLTE5NzE4Mg_cddc5605-2c4d-4b1d-9f6e-1f65d2a78ad6"
      unitRef="usd">1344000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i322d3171da864966aedc55c9b681518f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzktMy0xLTEtMTk3MTgy_50483c8e-2563-4b9e-8e69-cd75d114644e"
      unitRef="usd">2008900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5621221cf9f34eef9b9959e16714579c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzktNS0xLTEtMTk3MTgy_ea76f048-e653-4bf7-b6c2-3dbfb732cc25"
      unitRef="usd">1978000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0247f0ebdb344b409d4ad90e21eedad1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzktNy0xLTEtMTk3MTgy_09727e58-8c97-4abd-916d-97560a2f1877"
      unitRef="usd">850000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib15d3cae66954118a6d0296e4d23df93_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzktOS0xLTEtMTk3MTgy_dfe8ea67-ab36-4596-840d-ce161bc42110"
      unitRef="usd">14700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if841f2a4ceaf4fe58f4697466e041316_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzktMTEtMS0xLTE5NzE4Mg_6f5a9cc9-1a86-40c1-bc4d-2dea19f04e73"
      unitRef="usd">261400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8429e0edc9214436aaddaab1bcaeb6b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfMzktMTMtMS0xLTE5NzE4Mg_354b1880-b7d2-4c2b-991f-8b6752a94909"
      unitRef="usd">21200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e963233c54e48a888c15bcf4c23ffde_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDAtMy0xLTEtMTk3MTgy_6c70a4e4-d3ef-4621-b60a-5c74928127cb"
      unitRef="usd">367300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8cfffcec45ae40fb8465dac10b22a976_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDAtNS0xLTEtMTk3MTgy_eb25351e-8835-40b0-828a-612a16e3169d"
      unitRef="usd">441600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic7501982382a4a88bbc9f7e3e3e85161_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDAtNy0xLTEtMTk3MTgy_4bdf4e06-4328-44f8-acb6-986cf7efec36"
      unitRef="usd">510300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6dd637301dfb459db236d29c1bcf0177_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDAtOS0xLTEtMTk3MTgy_1376dd9b-ac8a-47c9-a68e-a9e1af214d8f"
      unitRef="usd">245800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i77b859afefa6475bbb5c098a0f192a8d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDAtMTEtMS0xLTE5NzE4Mg_f3a71b53-6b20-4ea7-8eec-ee39af9dc573"
      unitRef="usd">360300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i061bb5f86557438ea2fcf07c86b17b69_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDAtMTMtMS0xLTE5NzE4Mg_96be0d57-d537-4c3e-a32f-a6d14adff813"
      unitRef="usd">536000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i45698e97012941fdb7ec2890f67c1c66_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDEtMy0xLTEtMTk3MTgy_a913a711-4955-465f-9849-b171e1502d8d"
      unitRef="usd">35200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i24ef4fbd510845ce85f4028d457ed43c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDEtNS0xLTEtMTk3MTgy_a468fa4a-7b4d-40f8-b779-64c0e59cfa76"
      unitRef="usd">10600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2762e4d8c5664efd8b887ca758f9b9c4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDEtNy0xLTEtMTk3MTgy_9d83a7fe-ad61-43f0-a578-cc78be3cf06a"
      unitRef="usd">61800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74331b3977d84386b77d2682b2d47eb2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDEtOS0xLTEtMTk3MTgy_03fd1776-ad3a-4c58-81d5-6f06b93bb5cc"
      unitRef="usd">552100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8f45af4cef54b1ca2871b3cd9a01e27_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDEtMTEtMS0xLTE5NzE4Mg_9bc177bf-6204-4407-9a37-f45fddeb918c"
      unitRef="usd">707900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8b7a565db26f4dbaaefe0953a8a80479_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDEtMTMtMS0xLTE5NzE4Mg_0a1ba50f-6ccf-4065-9dac-88aeb27abe4c"
      unitRef="usd">545400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia31a0ff6d06240dda20f93d85ba7a1b0_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDItMy0xLTEtMTk3MTgy_5c55aeeb-bd0b-473a-a778-474363f44c47"
      unitRef="usd">144200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if85eef2cfec74cb1a86907d6bcafb6ee_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDItNS0xLTEtMTk3MTgy_7a019406-e447-4a0a-a1d9-702354cf0f22"
      unitRef="usd">136100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i958d4fe65ef3466d9c1b806dc825fd05_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDItNy0xLTEtMTk3MTgy_723d955f-979e-439e-b8f2-bc2a17ae24e8"
      unitRef="usd">246400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i71acdff4e8334d96837f9b23f9643937_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDItOS0xLTEtMTk3MTgy_7660c17c-ba0d-4abd-b768-269bd25db63e"
      unitRef="usd">151300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iff78a5e546e044469bcb8ddfffc41863_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDItMTEtMS0xLTE5NzE4Mg_9f594548-26dc-430f-9960-3852b1bd3f1b"
      unitRef="usd">233900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i02714f6a0b344ffaabb940f97f9422bb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDItMTMtMS0xLTE5NzE4Mg_b5da919c-b859-41da-b98b-9d3f1cacfed2"
      unitRef="usd">321800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a75711b53cf4bd4854c933fc91f0554_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDMtMy0xLTEtMTk3MTgy_acbef196-a51b-4e16-9678-88491961903b"
      unitRef="usd">2555700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0deffb51001949c4bd36158c98e3df90_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDMtNS0xLTEtMTk3MTgy_c056888d-b7d8-44ac-8238-a54853e16707"
      unitRef="usd">2566400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i12173600f90244fa8c910b03b4b7685b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDMtNy0xLTEtMTk3MTgy_160313a9-895a-4469-a05f-8d53755987b9"
      unitRef="usd">1668400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6a9c8e37f3254306908fbf67a57a962f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDMtOS0xLTEtMTk3MTgy_644c5838-d3d3-4026-8788-26c5eeadc767"
      unitRef="usd">964000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c655ff0b6734b1b895917ead0f1d0bc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDMtMTEtMS0xLTE5NzE4Mg_aef00de7-5a83-4e51-92d4-a5f2d863ee22"
      unitRef="usd">1563500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib57a805732c14379adc9748655cc8c8a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDMtMTMtMS0xLTE5NzE4Mg_94fb0266-5ce8-4832-baca-747340d04f0d"
      unitRef="usd">1424400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic5231cf59d554630ab8ee2ab6a543866_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDUtMy0xLTEtMTk3MTgy_93a09734-a6ca-4945-82d2-d662569f6fb8"
      unitRef="usd">18190000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i06358e5e2c9543f9b4d8af95e8fbee1a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDUtNS0xLTEtMTk3MTgy_6c3eaf64-f90a-4581-ad5d-02e5290b55c9"
      unitRef="usd">16811000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie66a1354c46c40fd8326cd7ee4fa99c1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDUtNy0xLTEtMTk3MTgy_803b7228-2959-4276-a179-199752c1e15d"
      unitRef="usd">14229300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1e3a4aa6df1d471499e619affd59a81c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDUtOS0xLTEtMTk3MTgy_0287b396-4867-46cd-8420-3f333adc6800"
      unitRef="usd">10351300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia2d92d62baf647fba64657e6da2c5cc7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDUtMTEtMS0xLTE5NzE4Mg_0c781e11-4bd1-44ec-942f-8e67bf71ec26"
      unitRef="usd">11507400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia0743faca88f49c9a9a69941934ee01a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOmU5MTM2YWM3ZDZlNjQ2ZmU4NmEzN2RiNzg4YTliNDEzL3RhYmxlcmFuZ2U6ZTkxMzZhYzdkNmU2NDZmZTg2YTM3ZGI3ODhhOWI0MTNfNDUtMTMtMS0xLTE5NzE4Mg_fa42fe24-821e-4fac-a7ad-4573b7d9bc92"
      unitRef="usd">10310500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic5231cf59d554630ab8ee2ab6a543866_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfMy00LTEtMS0xOTcxODI_6b2d9420-e3a6-4f91-8940-0b4897cfec31"
      unitRef="usd">18190000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i06358e5e2c9543f9b4d8af95e8fbee1a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfMy02LTEtMS0xOTcxODI_484d8235-27dd-445d-ba24-2d18b9c48dd1"
      unitRef="usd">16811000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie66a1354c46c40fd8326cd7ee4fa99c1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfMy04LTEtMS0xOTcxODI_7364a0ee-3de7-4f12-ad20-7e1c9e59b6ff"
      unitRef="usd">14229300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb29b5e537384747850aedf57eea8ac5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNC00LTEtMS0xOTcxODI_120f7b65-c959-43f6-837c-96931e036d5a"
      unitRef="usd">4299200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if04be40612da46cd8c72bcf49f6acda6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNC02LTEtMS0xOTcxODI_007a0ff8-b550-4ab2-96bf-dde658f6a45c"
      unitRef="usd">4776800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if6d44e44e5ef4e85b17fd98791ed3f74_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNC04LTEtMS0xOTcxODI_701a9a8d-a94d-45dd-ba85-606800831aa1"
      unitRef="usd">4187700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a19b43d72264c28838a978d205164c4_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNS00LTEtMS0xOTcxODI_d30da061-3ad6-435b-a2b0-0695d162f532"
      unitRef="usd">1747300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i864722d9b52d4c70b0ca7b1f3f30b98b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNS02LTEtMS0xOTcxODI_d0b7acb2-d932-4d03-812c-ac1e5d66db1e"
      unitRef="usd">2367000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id79c2882668a445497ebd9d63d0e6b0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNS04LTEtMS0xOTcxODI_7cef5753-3fd0-4018-947c-32259bb29594"
      unitRef="usd">2583100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5c2193c6723347899232bf1d50d961c5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNi00LTEtMS0xOTcxODI_95edcf13-d44f-4b31-a06b-9cf2865b7dca"
      unitRef="usd">1452800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie596f23aada14611bc47697f70b8e788_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNi02LTEtMS0xOTcxODI_3dae45c8-6d74-48be-a41f-0ae778e89ffe"
      unitRef="usd">1661400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idb22934230f849698cd861bdcfad137e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNi04LTEtMS0xOTcxODI_e1111e59-069c-4ab9-8894-71c6b2fec5df"
      unitRef="usd">1116900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1be2a9f3e7684d60a8f1c56366cb8f4f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNy00LTEtMS0xOTcxODI_a2052cfe-3655-4006-ba6b-339a51d8b975"
      unitRef="usd">2852000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26f622dfdd764d8da1a4d607b1b94085_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNy02LTEtMS0xOTcxODI_537fbe91-27cf-477b-b875-b5c86bf40472"
      unitRef="usd">2702200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd3aa04d3e924b2ebf2ea8e693f3b76c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfNy04LTEtMS0xOTcxODI_79df88f6-ea97-4df3-8d0c-5b75c1ff87e1"
      unitRef="usd">2422700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfOC00LTEtMS0xOTcxODI_e046e779-4760-49bf-a3f7-07494a5551cc"
      unitRef="usd">28541400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfOC02LTEtMS0xOTcxODI_0f06ecb0-6861-48de-be26-1deeee3829b5"
      unitRef="usd">28318400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF85Ny9mcmFnOmE3MzQ4Y2NjMGE5YjQwN2ZiZjQ0Yzg1NWRmOWE2Y2U5L3RhYmxlOjU1Y2RhY2NmNGZjNDRmYTJiNGFkMDg4Yzk3YWZmNWZhL3RhYmxlcmFuZ2U6NTVjZGFjY2Y0ZmM0NGZhMmI0YWQwODhjOTdhZmY1ZmFfOC04LTEtMS0xOTcxODI_01c2231f-bc2d-4044-b3b7-b4ed1cb4a56a"
      unitRef="usd">24539800000</us-gaap:Revenues>
    <us-gaap:AssetAcquisitionTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzcwNTg_4398cc7b-f107-4d6d-b98e-9c3383274053">Acquisitions&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We engage in various forms of business development activities to enhance our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements. In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, January 2021, and February 2020, we completed the acquisitions of Akouos, Inc. (Akouos), Prevail Therapeutics Inc. (Prevail), and Dermira, Inc. (Dermira), respectively. These transactions, as further discussed below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired assets in development in 2022, 2021, and 2020, which are further discussed below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;amp;D was immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs. We recognized acquired IPR&amp;amp;D and development milestone charges of $908.5 million, $970.1 million, and $769.8&#160;million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions of Businesses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Akouos Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, we acquired all shares of Akouos for a purchase price that included $12.50 per share in cash (or an aggregate of $327.2&#160;million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles the Akouos shareholders up to an additional $3.00 per share in cash (or an aggregate of approximately $122&#160;million) payable, subject to certain terms and conditions, upon the achievement of certain specified milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we acquired potential gene therapy treatments for hearing loss and other inner ear conditions. The lead gene therapies in clinical development that we acquired included GJB2 (which encodes connexin 26) for a common form of monogenic deafness and hearing loss; AK-OTOF for hearing loss due to mutations in the otoferlin gene; AK-CLRN1 for Usher Type 3A, an autosomal recessive disorder characterized by progressive loss of both hearing and vision; and AK-antiVEGF for vestibular schwannoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our access to Akouos information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at December 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to GJB2.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Akouos and is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See Note 7 for a discussion on the estimation of the CVR liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations attributable to Akouos for the year ended December&#160;31, 2022 were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Prevail Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4&#160;million, net of cash acquired) plus one non-tradable CVR per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition established a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at January 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to PR001. In the third quarter of 2022, we impaired the intangible asset related to PR001. See Note 5 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; The goodwill recognized from this acquisition is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See Note 7 for a discussion on the estimation of the CVR liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations attributable to Prevail for the years ended December&#160;31, 2022 and 2021 were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Dermira Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, we acquired all shares of Dermira for a purchase price of approximately $849.3 million, net of cash acquired. Under terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. We also acquired Qbrexza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the year ended December 31, 2021, we sold the rights to Qbrexza. See Note 5 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $86.8 million, other intangibles of $1.20 billion primarily related to lebrikizumab, deferred income tax liabilities of $49.5 million, and long-term debt of $375.5 million. After the acquisition, we repaid $276.2&#160;million of long-term debt assumed as part of our acquisition of Dermira.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue attributable to assets acquired in the Dermira acquisition did not have a material impact on our consolidated statement of operations for the years ended December&#160;31, 2022, 2021, and 2020. We are unable to provide the results of operations for the years ended December&#160;31, 2022, 2021, and 2020 attributable to Dermira as those operations were substantially integrated into our legacy business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma information has not been included because this acquisition did not have a material impact on our consolidated statements of operations for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our significant asset acquisitions during 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s),Therapy, or Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BioMarin Pharmaceutical Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Priority Review Voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not applicable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foghorn Therapeutics Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new oncology medicines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rigel Pharmaceuticals, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Precision Biosciences, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential in vivo therapies for genetic disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Innovent Biologics, Inc. (Innovent)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine, for geographies outside of China&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Petra Pharma Corporation (Petra)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutant-selective PI3K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x3b1;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; inhibitor that could lead to potential new medicine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disarm Therapeutics, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disease-modifying therapeutics program for patients with axonal degeneration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; In 2022, we terminated our license for sintilimab injection for geographies outside of China and reverted rights to Innovent.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Petra, we were required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x3b1;&lt;/span&gt; inhibitor. In 2022, we entered into agreements with substantially all Petra shareholders to acquire their rights to receive any future milestone payments in exchange for a one-time payment. As a result of these agreements, we recognized a charge of $333.8&#160;million as a development milestone in 2022. Any remaining contingent milestones payments linked to the success of the mutant-selective PI3K&#x3b1; are not expected to be material. We did not recognize other significant development milestones during the years ended December&#160;31, 2022, 2021, and 2020.</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzcwNTg_ca790005-364d-4504-850e-2109a462180c">Acquisitions&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We engage in various forms of business development activities to enhance our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements. In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, January 2021, and February 2020, we completed the acquisitions of Akouos, Inc. (Akouos), Prevail Therapeutics Inc. (Prevail), and Dermira, Inc. (Dermira), respectively. These transactions, as further discussed below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired assets in development in 2022, 2021, and 2020, which are further discussed below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;amp;D was immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs. We recognized acquired IPR&amp;amp;D and development milestone charges of $908.5 million, $970.1 million, and $769.8&#160;million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions of Businesses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Akouos Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, we acquired all shares of Akouos for a purchase price that included $12.50 per share in cash (or an aggregate of $327.2&#160;million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles the Akouos shareholders up to an additional $3.00 per share in cash (or an aggregate of approximately $122&#160;million) payable, subject to certain terms and conditions, upon the achievement of certain specified milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we acquired potential gene therapy treatments for hearing loss and other inner ear conditions. The lead gene therapies in clinical development that we acquired included GJB2 (which encodes connexin 26) for a common form of monogenic deafness and hearing loss; AK-OTOF for hearing loss due to mutations in the otoferlin gene; AK-CLRN1 for Usher Type 3A, an autosomal recessive disorder characterized by progressive loss of both hearing and vision; and AK-antiVEGF for vestibular schwannoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our access to Akouos information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at December 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to GJB2.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Akouos and is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See Note 7 for a discussion on the estimation of the CVR liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations attributable to Akouos for the year ended December&#160;31, 2022 were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Prevail Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4&#160;million, net of cash acquired) plus one non-tradable CVR per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition established a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at January 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to PR001. In the third quarter of 2022, we impaired the intangible asset related to PR001. See Note 5 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; The goodwill recognized from this acquisition is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See Note 7 for a discussion on the estimation of the CVR liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations attributable to Prevail for the years ended December&#160;31, 2022 and 2021 were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Dermira Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, we acquired all shares of Dermira for a purchase price of approximately $849.3 million, net of cash acquired. Under terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. We also acquired Qbrexza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the year ended December 31, 2021, we sold the rights to Qbrexza. See Note 5 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $86.8 million, other intangibles of $1.20 billion primarily related to lebrikizumab, deferred income tax liabilities of $49.5 million, and long-term debt of $375.5 million. After the acquisition, we repaid $276.2&#160;million of long-term debt assumed as part of our acquisition of Dermira.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue attributable to assets acquired in the Dermira acquisition did not have a material impact on our consolidated statement of operations for the years ended December&#160;31, 2022, 2021, and 2020. We are unable to provide the results of operations for the years ended December&#160;31, 2022, 2021, and 2020 attributable to Dermira as those operations were substantially integrated into our legacy business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma information has not been included because this acquisition did not have a material impact on our consolidated statements of operations for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our significant asset acquisitions during 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s),Therapy, or Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BioMarin Pharmaceutical Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Priority Review Voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not applicable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foghorn Therapeutics Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new oncology medicines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rigel Pharmaceuticals, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Precision Biosciences, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential in vivo therapies for genetic disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Innovent Biologics, Inc. (Innovent)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine, for geographies outside of China&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Petra Pharma Corporation (Petra)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutant-selective PI3K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x3b1;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; inhibitor that could lead to potential new medicine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disarm Therapeutics, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disease-modifying therapeutics program for patients with axonal degeneration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; In 2022, we terminated our license for sintilimab injection for geographies outside of China and reverted rights to Innovent.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Petra, we were required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x3b1;&lt;/span&gt; inhibitor. In 2022, we entered into agreements with substantially all Petra shareholders to acquire their rights to receive any future milestone payments in exchange for a one-time payment. As a result of these agreements, we recognized a charge of $333.8&#160;million as a development milestone in 2022. Any remaining contingent milestones payments linked to the success of the mutant-selective PI3K&#x3b1; are not expected to be material. We did not recognize other significant development milestones during the years ended December&#160;31, 2022, 2021, and 2020.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzcwNTA_7cfe8fcd-1105-497a-824b-1257a99da86a">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.Upon each acquisition, the cost allocated to acquired IPR&amp;amp;D was immediately expensed if the compound has no alternative future use.</us-gaap:BusinessCombinationsPolicy>
    <lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzE4Mjg_ec16c415-6a2e-43bf-a821-e1e07ab64ccc"
      unitRef="usd">908500000</lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones>
    <lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzE4MzI_0793e8ec-3df7-4d4b-b9a4-001e835251a6"
      unitRef="usd">970100000</lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones>
    <lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzE4NDA_18df601b-28f8-41be-ab32-7c7dfa9de9a6"
      unitRef="usd">769800000</lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i2bfc2608a4d84b308f03c62f86081700_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzU0OTc1NTgyNDQxNg_e1600f39-d36a-4be7-b922-e3ce9382d40c"
      unitRef="usdPerShare">12.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i24ac34b561704aaf9cdc8cf15d9421c4_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzU0OTc1NTgzMDM2OA_979dadb4-ef43-4e98-8216-57e3ccb4d0bc"
      unitRef="usd">327200000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights
      contextRef="i24ac34b561704aaf9cdc8cf15d9421c4_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzU0OTc1NTgyNDUwMA_0a3ea3e0-99ea-4e7b-987a-c9a8e3b27494"
      unitRef="right">1</lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights>
    <lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare
      contextRef="i2bfc2608a4d84b308f03c62f86081700_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzU0OTc1NTgyNDU5MQ_bc1b0d10-91db-42f1-a61f-67d47a41c37f"
      unitRef="usdPerShare">3.00</lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i2bfc2608a4d84b308f03c62f86081700_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzU0OTc1NTgzMzM3NQ_10b86a93-e68e-4922-b105-9bab3056ad5b"
      unitRef="usd">122000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzI3NDg3NzkwODM0ODY_0255a792-35ae-4b0b-b504-338e2ea2cc6b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at December 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to GJB2.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Akouos and is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;(3) See Note 7 for a discussion on the estimation of the CVR liability.&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at January 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to PR001. In the third quarter of 2022, we impaired the intangible asset related to PR001. See Note 5 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; The goodwill recognized from this acquisition is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;(3) See Note 7 for a discussion on the estimation of the CVR liability.</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="iceb5a7f2472e4bb0a0f8c4fe22cd2d24_I20221201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTo4ZmJjZmI2NjFmZjM0YzFkOWUzYWEzZThhZjMwNjlkMi90YWJsZXJhbmdlOjhmYmNmYjY2MWZmMzRjMWQ5ZTNhYTNlOGFmMzA2OWQyXzEtMS0xLTEtMjE5ODIx_31e8e7a5-49f8-402f-8a61-68bb260a37d2"
      unitRef="usd">153200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="iceb5a7f2472e4bb0a0f8c4fe22cd2d24_I20221201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTo4ZmJjZmI2NjFmZjM0YzFkOWUzYWEzZThhZjMwNjlkMi90YWJsZXJhbmdlOjhmYmNmYjY2MWZmMzRjMWQ5ZTNhYTNlOGFmMzA2OWQyXzItMS0xLTEtMjE5ODIx_a12c8988-b5c7-442f-a1d5-0dc200111b0b"
      unitRef="usd">184000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="iceb5a7f2472e4bb0a0f8c4fe22cd2d24_I20221201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTo4ZmJjZmI2NjFmZjM0YzFkOWUzYWEzZThhZjMwNjlkMi90YWJsZXJhbmdlOjhmYmNmYjY2MWZmMzRjMWQ5ZTNhYTNlOGFmMzA2OWQyXzMtMS0xLTEtMjE5ODIx_4b4a14ef-9dfb-4097-9c3f-671e9c6e12d0"
      unitRef="usd">181200000</us-gaap:Goodwill>
    <lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet
      contextRef="iceb5a7f2472e4bb0a0f8c4fe22cd2d24_I20221201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTo4ZmJjZmI2NjFmZjM0YzFkOWUzYWEzZThhZjMwNjlkMi90YWJsZXJhbmdlOjhmYmNmYjY2MWZmMzRjMWQ5ZTNhYTNlOGFmMzA2OWQyXzUtMS0xLTEtMjE5ODIx_8ad8b21b-cfc9-4da9-ba89-9ba9f3c5e5d5"
      unitRef="usd">28900000</lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="iceb5a7f2472e4bb0a0f8c4fe22cd2d24_I20221201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTo4ZmJjZmI2NjFmZjM0YzFkOWUzYWEzZThhZjMwNjlkMi90YWJsZXJhbmdlOjhmYmNmYjY2MWZmMzRjMWQ5ZTNhYTNlOGFmMzA2OWQyXzYtMS0xLTEtMjE5ODIx_e79774be-8378-4aba-a5bd-389c2b8d6320"
      unitRef="usd">547300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="ic28ae7a6137047c1a086087e77b37fc7_D20221201-20221201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTo4ZmJjZmI2NjFmZjM0YzFkOWUzYWEzZThhZjMwNjlkMi90YWJsZXJhbmdlOjhmYmNmYjY2MWZmMzRjMWQ5ZTNhYTNlOGFmMzA2OWQyXzgtMS0xLTEtMjIwMTIy_1bb1ebff-4f38-4db7-86c9-0b87ce2a2673"
      unitRef="usd">153200000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
      contextRef="iceb5a7f2472e4bb0a0f8c4fe22cd2d24_I20221201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTo4ZmJjZmI2NjFmZjM0YzFkOWUzYWEzZThhZjMwNjlkMi90YWJsZXJhbmdlOjhmYmNmYjY2MWZmMzRjMWQ5ZTNhYTNlOGFmMzA2OWQyXzktMS0xLTEtMjIwMTIy_c20c04b7-ab5d-4f22-bd6a-a3f9ea505e69"
      unitRef="usd">66900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i24ac34b561704aaf9cdc8cf15d9421c4_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTo4ZmJjZmI2NjFmZjM0YzFkOWUzYWEzZThhZjMwNjlkMi90YWJsZXJhbmdlOjhmYmNmYjY2MWZmMzRjMWQ5ZTNhYTNlOGFmMzA2OWQyXzEwLTEtMS0xLTIyMDEyMg_979dadb4-ef43-4e98-8216-57e3ccb4d0bc"
      unitRef="usd">327200000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i9bbccb3f78b34d48a0c51e4a8de0644e_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzMyOTg1MzQ4OTI1ODU_f4692da5-d274-4266-beec-6be360ca9d2d"
      unitRef="usdPerShare">22.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ibeb47b42169c4a378f20a2bb7a0d88f6_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzMyOTg1MzQ4OTI1Njk_b8d5f3e8-0ef4-40f5-b1c9-7fd13fef94d8"
      unitRef="usd">747400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights
      contextRef="ibeb47b42169c4a378f20a2bb7a0d88f6_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzU0OTc1NTgxNDgxODA_50c37e7d-5b08-4f67-8c3f-3485d04436d1"
      unitRef="right">1</lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights>
    <lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare
      contextRef="i9bbccb3f78b34d48a0c51e4a8de0644e_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzMyOTg1MzQ4OTI1OTU_18209a9e-70b9-4892-9596-d8351bfdca4d"
      unitRef="usdPerShare">4.00</lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i9bbccb3f78b34d48a0c51e4a8de0644e_I20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzMyOTg1MzQ4OTI2MTQ_fc0f5f45-4586-4f43-9772-e5876852a196"
      unitRef="usd">160000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction
      contextRef="i9bbccb3f78b34d48a0c51e4a8de0644e_I20210131"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzU0OTc1NTgxNDgxODk_c7d041a4-5936-4ed0-892b-586d6d9baa43"
      unitRef="usdPerShare">0.083</lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i79e8bd3a88dd451697bfede1f38f914c_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTphMzZhYjkwYzg3Yzg0ZWMwYWVkZWUyYTI1YWMwYWMzMy90YWJsZXJhbmdlOmEzNmFiOTBjODdjODRlYzBhZWRlZTJhMjVhYzBhYzMzXzEtMS0xLTEtMTk3MTgy_495cd62d-0830-4cb4-8255-89db4941e53b"
      unitRef="usd">90500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i79e8bd3a88dd451697bfede1f38f914c_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTphMzZhYjkwYzg3Yzg0ZWMwYWVkZWUyYTI1YWMwYWMzMy90YWJsZXJhbmdlOmEzNmFiOTBjODdjODRlYzBhZWRlZTJhMjVhYzBhYzMzXzItMS0xLTEtMTk3MTgy_744289e9-55e5-4a11-ae8e-1c9db6cbc8f3"
      unitRef="usd">824000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="i79e8bd3a88dd451697bfede1f38f914c_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTphMzZhYjkwYzg3Yzg0ZWMwYWVkZWUyYTI1YWMwYWMzMy90YWJsZXJhbmdlOmEzNmFiOTBjODdjODRlYzBhZWRlZTJhMjVhYzBhYzMzXzMtMS0xLTEtMTk3MTgy_15a64fa9-6a27-426e-8c3f-9b7ef93f0e9d"
      unitRef="usd">126800000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i79e8bd3a88dd451697bfede1f38f914c_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTphMzZhYjkwYzg3Yzg0ZWMwYWVkZWUyYTI1YWMwYWMzMy90YWJsZXJhbmdlOmEzNmFiOTBjODdjODRlYzBhZWRlZTJhMjVhYzBhYzMzXzQtMS0xLTEtMTk3MTgy_5a7552e9-966d-45a0-ba3c-0e38352b15be"
      unitRef="usd">106000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet
      contextRef="i79e8bd3a88dd451697bfede1f38f914c_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTphMzZhYjkwYzg3Yzg0ZWMwYWVkZWUyYTI1YWMwYWMzMy90YWJsZXJhbmdlOmEzNmFiOTBjODdjODRlYzBhZWRlZTJhMjVhYzBhYzMzXzUtMS0xLTEtMTk3MTgy_e314d002-1e7a-4fc1-a3c5-3e8712496980"
      unitRef="usd">-31500000</lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i79e8bd3a88dd451697bfede1f38f914c_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTphMzZhYjkwYzg3Yzg0ZWMwYWVkZWUyYTI1YWMwYWMzMy90YWJsZXJhbmdlOmEzNmFiOTBjODdjODRlYzBhZWRlZTJhMjVhYzBhYzMzXzYtMS0xLTEtMTk3MTgy_68e7e61a-5120-40cd-a9c6-40cc34e319d9"
      unitRef="usd">903800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="i592f678cd37f48ac8b0d09a457ed8878_D20210122-20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTphMzZhYjkwYzg3Yzg0ZWMwYWVkZWUyYTI1YWMwYWMzMy90YWJsZXJhbmdlOmEzNmFiOTBjODdjODRlYzBhZWRlZTJhMjVhYzBhYzMzXzgtMS0xLTEtMTk3MTgy_c44c2918-6383-447d-9bd3-3bac74dc786f"
      unitRef="usd">90500000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
      contextRef="i79e8bd3a88dd451697bfede1f38f914c_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTphMzZhYjkwYzg3Yzg0ZWMwYWVkZWUyYTI1YWMwYWMzMy90YWJsZXJhbmdlOmEzNmFiOTBjODdjODRlYzBhZWRlZTJhMjVhYzBhYzMzXzktMS0xLTEtMTk3MTgy_adfbcf02-4e06-4ac1-8565-c2b7b205406e"
      unitRef="usd">65900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i592f678cd37f48ac8b0d09a457ed8878_D20210122-20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTphMzZhYjkwYzg3Yzg0ZWMwYWVkZWUyYTI1YWMwYWMzMy90YWJsZXJhbmdlOmEzNmFiOTBjODdjODRlYzBhZWRlZTJhMjVhYzBhYzMzXzEwLTEtMS0xLTE5NzE4Mg_854590e6-cf1c-4772-8e0d-f09c4f535a79"
      unitRef="usd">747400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i911ffcfb85b543048b73c602e046f88a_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzQ0NjM_05652d90-75ea-4428-b2c7-32ad14fb6a38"
      unitRef="usd">849300000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:Goodwill
      contextRef="i57500d6d00fa48b2a37e2a728d955386_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzUxOTQ_e27a538d-b9c5-4ad7-9b7b-5569e3771e53"
      unitRef="usd">86800000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i57500d6d00fa48b2a37e2a728d955386_I20200229"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzUyMTk_a06c11b7-f100-4a14-945e-4812f8d08de9"
      unitRef="usd">1200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i57500d6d00fa48b2a37e2a728d955386_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzUyOTI_4e5824ec-72d8-4d1b-a466-9c4be4a85759"
      unitRef="usd">49500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
      contextRef="i57500d6d00fa48b2a37e2a728d955386_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzUzMTg_adbfabb4-f088-4a28-86ef-b3cd1cfa93d3"
      unitRef="usd">375500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i911ffcfb85b543048b73c602e046f88a_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzUzNTU_cd679f3a-b3bf-47b1-9726-65afe747c115"
      unitRef="usd">276200000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzcwMzk_332fa35c-e980-4722-acb8-60910c07911e">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our significant asset acquisitions during 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s),Therapy, or Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BioMarin Pharmaceutical Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Priority Review Voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not applicable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foghorn Therapeutics Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new oncology medicines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rigel Pharmaceuticals, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Precision Biosciences, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential in vivo therapies for genetic disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Innovent Biologics, Inc. (Innovent)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine, for geographies outside of China&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Petra Pharma Corporation (Petra)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutant-selective PI3K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x3b1;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; inhibitor that could lead to potential new medicine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disarm Therapeutics, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disease-modifying therapeutics program for patients with axonal degeneration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; In 2022, we terminated our license for sintilimab injection for geographies outside of China and reverted rights to Innovent.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock>
    <lly:PaymentsForAssetAcquisitions
      contextRef="i22bda1e261ac4b2488c77f767678e525_D20220201-20220228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTpmNzNmNDBlNjdkMTM0NzE4OGQ4N2YxMTVlNTBhNDUwOC90YWJsZXJhbmdlOmY3M2Y0MGU2N2QxMzQ3MTg4ZDg3ZjExNWU1MGE0NTA4XzEtNi0xLTEtMjA3MDEx_72e24e57-96f1-4102-9f89-2b9ee994dded"
      unitRef="usd">110000000.0</lly:PaymentsForAssetAcquisitions>
    <lly:PaymentsForAssetAcquisitions
      contextRef="icb08a5c1f49e4f2990ebe8463033cbeb_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTpmNzNmNDBlNjdkMTM0NzE4OGQ4N2YxMTVlNTBhNDUwOC90YWJsZXJhbmdlOmY3M2Y0MGU2N2QxMzQ3MTg4ZDg3ZjExNWU1MGE0NTA4XzMtNi0xLTEtMTk3MTgy_4080adc9-71ec-46df-a6de-c3b09f7c6f4c"
      unitRef="usd">316600000</lly:PaymentsForAssetAcquisitions>
    <lly:PaymentsForAssetAcquisitions
      contextRef="ie0973cb0fd694b219690663eb984716f_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTpmNzNmNDBlNjdkMTM0NzE4OGQ4N2YxMTVlNTBhNDUwOC90YWJsZXJhbmdlOmY3M2Y0MGU2N2QxMzQ3MTg4ZDg3ZjExNWU1MGE0NTA4XzQtNi0xLTEtMTk3MTgy_13c4194b-6a64-4455-b62b-86a45b72139f"
      unitRef="usd">125000000.0</lly:PaymentsForAssetAcquisitions>
    <lly:PaymentsForAssetAcquisitions
      contextRef="i81d67d91f47b4d55acc7e70b5b593208_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTpmNzNmNDBlNjdkMTM0NzE4OGQ4N2YxMTVlNTBhNDUwOC90YWJsZXJhbmdlOmY3M2Y0MGU2N2QxMzQ3MTg4ZDg3ZjExNWU1MGE0NTA4XzUtNi0xLTEtMTk3MTgy_dfae80eb-39f4-4e88-8f82-62f682c35ca2"
      unitRef="usd">107800000</lly:PaymentsForAssetAcquisitions>
    <lly:PaymentsForAssetAcquisitions
      contextRef="i4554cea5b47540518c88b975dda8a988_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTpmNzNmNDBlNjdkMTM0NzE4OGQ4N2YxMTVlNTBhNDUwOC90YWJsZXJhbmdlOmY3M2Y0MGU2N2QxMzQ3MTg4ZDg3ZjExNWU1MGE0NTA4XzctNi0xLTEtMTk3MTgy_5f16e5cd-530c-4d19-9604-b462732b19fa"
      unitRef="usd">200000000.0</lly:PaymentsForAssetAcquisitions>
    <lly:PaymentsForAssetAcquisitions
      contextRef="i76b78baacb0a4d53bbd37d9f5f91b297_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTpmNzNmNDBlNjdkMTM0NzE4OGQ4N2YxMTVlNTBhNDUwOC90YWJsZXJhbmdlOmY3M2Y0MGU2N2QxMzQ3MTg4ZDg3ZjExNWU1MGE0NTA4XzgtNi0xLTEtMTk3MTgy_50b23889-6397-4a0d-b615-a2b779bd8a90"
      unitRef="usd">174800000</lly:PaymentsForAssetAcquisitions>
    <lly:PaymentsForAssetAcquisitions
      contextRef="ifdaaf6c7f8004c49b4ff53eb161a0b68_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90YWJsZTpmNzNmNDBlNjdkMTM0NzE4OGQ4N2YxMTVlNTBhNDUwOC90YWJsZXJhbmdlOmY3M2Y0MGU2N2QxMzQ3MTg4ZDg3ZjExNWU1MGE0NTA4XzktNi0xLTEtMTk3MTgy_8f803053-7919-459d-aa6c-3b02acf49140"
      unitRef="usd">126300000</lly:PaymentsForAssetAcquisitions>
    <lly:PaymentsForAssetAcquisitions
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDAvZnJhZzoxNDczNDI2M2U4ZDY0Mjk1YTFhMGJiMDU3MDk3NDQ2Mi90ZXh0cmVnaW9uOjE0NzM0MjYzZThkNjQyOTVhMWEwYmIwNTcwOTc0NDYyXzY3NDM_43c625ab-b34e-4462-a294-c8596d62c02a"
      unitRef="usd">333800000</lly:PaymentsForAssetAcquisitions>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzExMzQ5_99af30bf-dd25-4c40-a0aa-f72f21b834e4">Collaborations and Other Arrangements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Boehringer Ingelheim Diabetes Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim's oral diabetes products: Jardiance, Glyxambi, Synjardy, Trijardy XR, Trajenta, and Jentadueto&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as well as our basal insulin, Basaglar. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the regulatory approvals of Jardiance, Trajenta, and Basaglar in the U.S., Europe, and Japan, milestone payments made for Jardiance and Trajenta were capitalized as intangible assets and are being amortized to cost of sales, and milestone payments received for Basaglar were recorded as contract liabilities and are being amortized to collaboration and other revenue. The milestones pertaining to Jardiance and Trajenta are being amortized through their respective term under the collaboration, which, depending on country or region, is determined based on the latest to occur of (a) a defined number of years following launch date, (b) the expiration of the compound patent, or (c) the expiration of marketing authorization exclusivity. The milestones pertaining to Basaglar are being amortized through 2029. The table below summarizes the net milestones capitalized with respect to the Jardiance and Trajenta families of products and the net milestones deferred with respect to Basaglar as of December 31: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Milestones Capitalized (Deferred)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;116.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(130.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the Jardiance product family, we and Boehringer Ingelheim share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. The royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to Basaglar:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,066.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,490.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;760.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;892.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;383.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Olumiant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to baricitinib, which is branded and trademarked as Olumiant, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases and COVID-19. Incyte has the right to receive tiered, double digit royalty payments on worldwide net sales with rates ranging up to 20 percent. Incyte has the right to receive an additional royalty ranging up to the low teens on worldwide net sales for the treatment of COVID-19 that exceed a specified aggregate worldwide net sales threshold. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, as well as achievement of a sales-based milestone, milestone payments of $330.0 million and $260.0 million were capitalized as intangible assets as of December&#160;31, 2022 and 2021, respectively, and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, Incyte is eligible to receive up to $100.0&#160;million of additional payments from us in potential sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record our sales of Olumiant, including sales of baricitinib that were made pursuant to EUA or similar regulatory authorizations, to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. The following table summarizes our net product revenue recognized with respect to Olumiant:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;830.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID-19 Antibodies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a worldwide license and collaboration agreement with AbCellera Biologics Inc. (AbCellera) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab and bebtelovimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on worldwide net sales of bamlanivimab and bebtelovimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a license and collaboration agreement with Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of mainland China and the Special Administrative Regions of Hong Kong and Macau. Junshi Biosciences received royalty payments in the mid-teens on our net sales of etesevimab. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to EUAs or similar regulatory authorizations, we recognized $2.02&#160;billion, $2.24&#160;billion, and $871.2&#160;million of net product revenue associated with our sales of our COVID-19 antibodies during the years ended December&#160;31, 2022, 2021, and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tyvyt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Innovent to jointly develop and commercialize sintilimab injection in China, where it is branded and trademarked as Tyvyt. We record our sales of Tyvyt to third parties as net product revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We report as collaboration and other revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. The following table summarizes our revenue recognized in China with respect to Tyvyt: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;293.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lebrikizumab&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a worldwide license agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively, Roche), which provides us the worldwide development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future worldwide net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of December&#160;31, 2022, Roche is eligible to receive up to $165.0 million of additional payments from us contingent upon the achievement of success-based regulatory milestones and up to $1.03 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab. During the year ended December&#160;31, 2022, milestone payments to Roche were not material.&lt;/span&gt;&lt;/div&gt;We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of December&#160;31, 2022, we are eligible to receive additional payments of $65.0 million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $1.25&#160;billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab. There were no remaining contract liabilities as of December&#160;31, 2022. As of December 31, 2021 and 2020, contract liabilities were not material. During the years ended December&#160;31, 2022, 2021, and 2020, collaboration and other revenue recognized was not material.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzExMzUx_5c08aabb-ea05-4a02-b04d-568c8597604d">The table below summarizes the net milestones capitalized with respect to the Jardiance and Trajenta families of products and the net milestones deferred with respect to Basaglar as of December 31: &lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Milestones Capitalized (Deferred)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;116.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(130.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to Basaglar:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,066.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,490.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;760.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;892.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;383.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table summarizes our net product revenue recognized with respect to Olumiant:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;830.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;The following table summarizes our revenue recognized in China with respect to Tyvyt: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;293.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ib72f8530223f4b8b9206e3912e939d05_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTpjZGIwOTU4YThlYTk0NzY5YmExYTk2NGU2OTVjODRlOS90YWJsZXJhbmdlOmNkYjA5NThhOGVhOTQ3NjliYTFhOTY0ZTY5NWM4NGU5XzItMS0xLTEtMTk3MTgy_2d634a23-cff3-47fa-95cd-e380b2448060"
      unitRef="usd">116200000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i3307f82bfdc14dd5a7869a1f5a407fe3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTpjZGIwOTU4YThlYTk0NzY5YmExYTk2NGU2OTVjODRlOS90YWJsZXJhbmdlOmNkYjA5NThhOGVhOTQ3NjliYTFhOTY0ZTY5NWM4NGU5XzItMi0xLTEtMTk3MTgy_8b891805-515e-4b3b-9e9d-d091fdc2c628"
      unitRef="usd">136100000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ie6382df2fed0453f9d14c9ca82bc5c85_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTpjZGIwOTU4YThlYTk0NzY5YmExYTk2NGU2OTVjODRlOS90YWJsZXJhbmdlOmNkYjA5NThhOGVhOTQ3NjliYTFhOTY0ZTY5NWM4NGU5XzMtMS0xLTEtMTk3MTgy_0cd6a12e-0ee0-4eab-91ba-8222fd4a1ad1"
      unitRef="usd">63500000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i5b54345933e846e39cc3f792be5b88ff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTpjZGIwOTU4YThlYTk0NzY5YmExYTk2NGU2OTVjODRlOS90YWJsZXJhbmdlOmNkYjA5NThhOGVhOTQ3NjliYTFhOTY0ZTY5NWM4NGU5XzMtMi0xLTEtMTk3MTgy_854c6456-6478-4f0a-a5ff-13d99796e388"
      unitRef="usd">88500000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i191cd21724a847a1ab7b4f35246862d4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTpjZGIwOTU4YThlYTk0NzY5YmExYTk2NGU2OTVjODRlOS90YWJsZXJhbmdlOmNkYjA5NThhOGVhOTQ3NjliYTFhOTY0ZTY5NWM4NGU5XzQtMS0xLTEtMTk3MTgy_cab1f512-a2b0-4185-8430-e9969b5b289c"
      unitRef="usd">-130600000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i485f72de6db64da1bfe2334d8014678b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTpjZGIwOTU4YThlYTk0NzY5YmExYTk2NGU2OTVjODRlOS90YWJsZXJhbmdlOmNkYjA5NThhOGVhOTQ3NjliYTFhOTY0ZTY5NWM4NGU5XzQtMi0xLTEtMTk3MTgy_3b17fee3-b123-4bc5-b5fd-bc9b79b520d7"
      unitRef="usd">-149300000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:Revenues
      contextRef="i93deb0a502fc4527a3920971ba7c2c0f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo3NWE0YjdlYjAxNGQ0MGRmYWEwNzFjNzE3MDBhZDFhMS90YWJsZXJhbmdlOjc1YTRiN2ViMDE0ZDQwZGZhYTA3MWM3MTcwMGFkMWExXzEtMS0xLTEtMTk3MTgy_4b5e2bfb-9398-4d4a-a49f-4829230692e5"
      unitRef="usd">2066000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i95a63cfe221f41ebba6cd651af9ddf9b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo3NWE0YjdlYjAxNGQ0MGRmYWEwNzFjNzE3MDBhZDFhMS90YWJsZXJhbmdlOjc1YTRiN2ViMDE0ZDQwZGZhYTA3MWM3MTcwMGFkMWExXzEtMy0xLTEtMTk3MTgy_c528d5e4-eae6-45e4-990a-b7d7035bf139"
      unitRef="usd">1490800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ea327d1c37d4bfca7f2723b4565f151_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo3NWE0YjdlYjAxNGQ0MGRmYWEwNzFjNzE3MDBhZDFhMS90YWJsZXJhbmdlOjc1YTRiN2ViMDE0ZDQwZGZhYTA3MWM3MTcwMGFkMWExXzEtNS0xLTEtMTk3MTgy_471235b2-9f02-476f-ac60-200412d8465b"
      unitRef="usd">1153800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb1a49e986754a4593a59e0e5166de8d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo3NWE0YjdlYjAxNGQ0MGRmYWEwNzFjNzE3MDBhZDFhMS90YWJsZXJhbmdlOjc1YTRiN2ViMDE0ZDQwZGZhYTA3MWM3MTcwMGFkMWExXzItMS0xLTEtMTk3MTgy_92fd2a6c-ecd7-4551-80fc-4a3875123a09"
      unitRef="usd">760400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iac449f4acefe4dc984d41cb41455bae6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo3NWE0YjdlYjAxNGQ0MGRmYWEwNzFjNzE3MDBhZDFhMS90YWJsZXJhbmdlOjc1YTRiN2ViMDE0ZDQwZGZhYTA3MWM3MTcwMGFkMWExXzItMy0xLTEtMTk3MTgy_b6355e75-d24a-492b-bbb4-2e197495f70d"
      unitRef="usd">892500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib09d7cfc9f57482cacbac86586144b4f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo3NWE0YjdlYjAxNGQ0MGRmYWEwNzFjNzE3MDBhZDFhMS90YWJsZXJhbmdlOjc1YTRiN2ViMDE0ZDQwZGZhYTA3MWM3MTcwMGFkMWExXzItNS0xLTEtMTk3MTgy_bb36314d-2638-41fe-a258-3bd8740e2f6b"
      unitRef="usd">1124400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i540e1253ab844a0bbc43a8cfb3ee0920_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo3NWE0YjdlYjAxNGQ0MGRmYWEwNzFjNzE3MDBhZDFhMS90YWJsZXJhbmdlOjc1YTRiN2ViMDE0ZDQwZGZhYTA3MWM3MTcwMGFkMWExXzMtMS0xLTEtMTk3MTgy_bd09b64c-d8f3-41a1-97da-0ab32087aa08"
      unitRef="usd">383700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iadfe8a33be5c4ba7afa22a73eed9d5ef_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo3NWE0YjdlYjAxNGQ0MGRmYWEwNzFjNzE3MDBhZDFhMS90YWJsZXJhbmdlOjc1YTRiN2ViMDE0ZDQwZGZhYTA3MWM3MTcwMGFkMWExXzMtMy0xLTEtMTk3MTgy_a5354597-140f-4de0-8894-40d7b69e2ee7"
      unitRef="usd">372500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c91f4e2d9c840879cf9a65000a09847_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo3NWE0YjdlYjAxNGQ0MGRmYWEwNzFjNzE3MDBhZDFhMS90YWJsZXJhbmdlOjc1YTRiN2ViMDE0ZDQwZGZhYTA3MWM3MTcwMGFkMWExXzMtNS0xLTEtMTk3MTgy_11291c4e-c78f-46b8-8f6e-c50454536c5c"
      unitRef="usd">358500000</us-gaap:Revenues>
    <lly:CollaborativeArrangementRightsAndObligationsPercent
      contextRef="i81b687c200704d14b8cd74e649ddccdc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzQ3MTA_837d4d2c-9488-4380-92ad-d4712c5d7d60"
      unitRef="number">0.20</lly:CollaborativeArrangementRightsAndObligationsPercent>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="id1f7f5218520412cb6fd499f49c829c4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzUyMTY_248195d1-fc75-4b8e-be7b-78ac0eea0d86"
      unitRef="usd">330000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i69ac6765ad604943bedfef80dbb59046_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzUyMjM_cd17625b-9b4d-4b0c-a20f-3432136058c5"
      unitRef="usd">260000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ib0b97a2e15744cdfa799e948994a62f0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzU1NjY_e440443b-f2f5-4270-9da5-ddc942b4f3b6"
      unitRef="usd">100000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:Revenues
      contextRef="ieb5d7e7fe6df47d69da986515824156b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTplZjEwZmZmYWYzYWI0ZmNiYjc5YmI4ZjQzMzhkYjRiNy90YWJsZXJhbmdlOmVmMTBmZmZhZjNhYjRmY2JiNzliYjhmNDMzOGRiNGI3XzEtMS0xLTEtMTk3MTgy_952ee925-ad92-44f4-b590-f426a6e7ce4e"
      unitRef="usd">830500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i39d7234845174224b663942a5c72f5c7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTplZjEwZmZmYWYzYWI0ZmNiYjc5YmI4ZjQzMzhkYjRiNy90YWJsZXJhbmdlOmVmMTBmZmZhZjNhYjRmY2JiNzliYjhmNDMzOGRiNGI3XzEtMy0xLTEtMTk3MTgy_41409a0c-de71-4742-8756-cbf4e27bce72"
      unitRef="usd">1115100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i36f40f8db5514b028a508fdf20bcd89f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTplZjEwZmZmYWYzYWI0ZmNiYjc5YmI4ZjQzMzhkYjRiNy90YWJsZXJhbmdlOmVmMTBmZmZhZjNhYjRmY2JiNzliYjhmNDMzOGRiNGI3XzEtNS0xLTEtMTk3MTgy_9a7c2f73-3762-4824-97dc-88eaee054f54"
      unitRef="usd">638900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6f3dc4d892d343b49ec303ecaf36d9bd_D20220101-20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzk4OTU2MDQ2NzA1NTQ_c0f92bb4-f7c6-44f6-9cad-366bb68f7bde"
      unitRef="usd">2020000000.00</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc949a713d77433c984ccf27f4feda59_D20210101-20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzk4OTU2MDQ2NzA1NTk_66c5bcae-af40-4a60-9b43-33478076e541"
      unitRef="usd">2240000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7cb32af28a4d439d8eae4393101c3901_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzk4OTU2MDQ2NzA1Njg_38e2a9d8-c8ba-48cf-b70e-cba76770c264"
      unitRef="usd">871200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5000c09e5ee64486a770c6f98d826b1f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo4N2JmYjlhY2ZhNzU0YTg4YTVhM2U3NzNhNmJhYThkYS90YWJsZXJhbmdlOjg3YmZiOWFjZmE3NTRhODhhNWEzZTc3M2E2YmFhOGRhXzEtMS0xLTEtMTk3MTgy_fad8a89c-4c72-476c-b6f6-21b986aa9a64"
      unitRef="usd">293300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i841f858d8d814afcbb33413461967380_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo4N2JmYjlhY2ZhNzU0YTg4YTVhM2U3NzNhNmJhYThkYS90YWJsZXJhbmdlOjg3YmZiOWFjZmE3NTRhODhhNWEzZTc3M2E2YmFhOGRhXzEtMi0xLTEtMTk3MTgy_90d0f724-8acb-4144-975a-ea1501d9d4bf"
      unitRef="usd">418100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic1b1742cf89b4c1fb470b6fea7034191_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90YWJsZTo4N2JmYjlhY2ZhNzU0YTg4YTVhM2U3NzNhNmJhYThkYS90YWJsZXJhbmdlOjg3YmZiOWFjZmE3NTRhODhhNWEzZTc3M2E2YmFhOGRhXzEtMy0xLTEtMTk3MTgy_bde4d42c-1350-4a9e-88b5-945bd5bb8303"
      unitRef="usd">308700000</us-gaap:Revenues>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i11abecbd539d44bca9891ae6f43a6b9d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzEwMjAz_8d76170d-79ae-42b6-beb2-ff2d3f747dc1"
      unitRef="usd">165000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i340330379c1b4d17a5d1893688ec0953_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzEwMzA3_ac1cbdcc-976a-4bc2-9c7a-73d5a7afb1d0"
      unitRef="usd">1030000000.00</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i7796b711e49341dab27420fbab5beae5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzEwOTYz_9781c61e-bdea-45ee-a2dd-071254ff149a"
      unitRef="usd">65000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i88b5d5e3acab4840b3a4b0c187d24ff5_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDMvZnJhZzo5YTQ5ZGJhZTA1M2M0YzlkYjg1ZGFjMzg1YWU2NzljYi90ZXh0cmVnaW9uOjlhNDlkYmFlMDUzYzRjOWRiODVkYWMzODVhZTY3OWNiXzExMDYx_3f6856b5-4ae9-4d1d-933f-95eaa004fd1e"
      unitRef="usd">1250000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2Xzk1OA_96d514fd-e38d-4b5a-b886-6dcf05049cb8">Asset Impairment, Restructuring, and Other Special Charges&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the charges included in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2XzIxOTkwMjMyNTgzMTA_a65ace08-5ec6-44b7-98e1-20a4af3312ff"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2XzIxOTkwMjMyNTgzMTA_b860e1a5-db44-4847-b689-049eb53e6544"&gt;asset impairment, restructuring, and other special charges&lt;/span&gt;&lt;/span&gt; in our consolidated statements of operations are described below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment (gain) and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;221.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total asset impairment, restructuring, and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;244.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairment, restructuring, and other special charges recognized during the year ended December&#160;31, 2022 were primarily related to an intangible asset impairment for GBA1 Gene Therapy (PR001), acquired in the Prevail acquisition, as a result of changes in key assumptions used in the valuation due to delays in estimated launch timing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, we recognized $128.0 million of intangible asset impairment as a result of the decision by Bayer AG to discontinue the development of a Phase I molecule related to a contract-based intangible asset from our acquisition of Loxo Oncology, Inc. Additionally, we recognized $108.1 million of intangible asset impairment from the sale of the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. &lt;/span&gt;&lt;/div&gt;Severance costs recognized during the year ended December 31, 2020 were incurred as a result of actions taken worldwide to reduce our cost structure.</us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2Xzk2MA_159221ca-1853-46de-8630-f188884bb1d7">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the charges included in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2XzIxOTkwMjMyNTgzMTA_a65ace08-5ec6-44b7-98e1-20a4af3312ff"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2XzIxOTkwMjMyNTgzMTA_b860e1a5-db44-4847-b689-049eb53e6544"&gt;asset impairment, restructuring, and other special charges&lt;/span&gt;&lt;/span&gt; in our consolidated statements of operations are described below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment (gain) and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;221.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total asset impairment, restructuring, and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;244.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90YWJsZTo2MmE0MDU4ZmU4ZjE0MmZmYjdlOGMxYWQ1ZWQ5MTljOC90YWJsZXJhbmdlOjYyYTQwNThmZThmMTQyZmZiN2U4YzFhZDVlZDkxOWM4XzEtMS0xLTEtMjAwMDM0_a0a05dc3-3954-44c6-ad71-d76d97f01990"
      unitRef="usd">221600000</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90YWJsZTo2MmE0MDU4ZmU4ZjE0MmZmYjdlOGMxYWQ1ZWQ5MTljOC90YWJsZXJhbmdlOjYyYTQwNThmZThmMTQyZmZiN2U4YzFhZDVlZDkxOWM4XzEtMy0xLTEtMjAwMDM0_62b39e3b-d4f6-4327-93d3-0f13e9542152"
      unitRef="usd">303100000</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90YWJsZTo2MmE0MDU4ZmU4ZjE0MmZmYjdlOGMxYWQ1ZWQ5MTljOC90YWJsZXJhbmdlOjYyYTQwNThmZThmMTQyZmZiN2U4YzFhZDVlZDkxOWM4XzEtNS0xLTEtMjAwMDM0_e84f0738-b638-4e0d-9a48-7bd42236743b"
      unitRef="usd">-20000000.0</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <us-gaap:SeveranceCosts1
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90YWJsZTo2MmE0MDU4ZmU4ZjE0MmZmYjdlOGMxYWQ1ZWQ5MTljOC90YWJsZXJhbmdlOjYyYTQwNThmZThmMTQyZmZiN2U4YzFhZDVlZDkxOWM4XzEtMS0xLTEtMTk3MTgy_ac3e556e-f0f9-4062-9242-2405929c765f"
      unitRef="usd">23000000.0</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90YWJsZTo2MmE0MDU4ZmU4ZjE0MmZmYjdlOGMxYWQ1ZWQ5MTljOC90YWJsZXJhbmdlOjYyYTQwNThmZThmMTQyZmZiN2U4YzFhZDVlZDkxOWM4XzEtMy0xLTEtMTk3MTgy_97620614-692c-44e9-b85b-0b664304cf3d"
      unitRef="usd">13000000.0</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90YWJsZTo2MmE0MDU4ZmU4ZjE0MmZmYjdlOGMxYWQ1ZWQ5MTljOC90YWJsZXJhbmdlOjYyYTQwNThmZThmMTQyZmZiN2U4YzFhZDVlZDkxOWM4XzEtNS0xLTEtMTk3MTgy_fd9ca0dd-7090-4d35-a5d6-dce0df8ac16a"
      unitRef="usd">151200000</us-gaap:SeveranceCosts1>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90YWJsZTo2MmE0MDU4ZmU4ZjE0MmZmYjdlOGMxYWQ1ZWQ5MTljOC90YWJsZXJhbmdlOjYyYTQwNThmZThmMTQyZmZiN2U4YzFhZDVlZDkxOWM4XzQtMS0xLTEtMTk3MTgy_e63f92ab-a72b-44d4-8e45-5682dc26b5b1"
      unitRef="usd">244600000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90YWJsZTo2MmE0MDU4ZmU4ZjE0MmZmYjdlOGMxYWQ1ZWQ5MTljOC90YWJsZXJhbmdlOjYyYTQwNThmZThmMTQyZmZiN2U4YzFhZDVlZDkxOWM4XzQtMy0xLTEtMTk3MTgy_14603f0a-0ad8-4dfb-9823-d0d61aae7216"
      unitRef="usd">316100000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90YWJsZTo2MmE0MDU4ZmU4ZjE0MmZmYjdlOGMxYWQ1ZWQ5MTljOC90YWJsZXJhbmdlOjYyYTQwNThmZThmMTQyZmZiN2U4YzFhZDVlZDkxOWM4XzQtNS0xLTEtMTk3MTgy_b233c668-0420-4e59-915d-1eab2e7894f3"
      unitRef="usd">131200000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2XzU0OTc1NTgxNTg3NQ_2e6454b9-b438-4774-8e73-3a501259a57f"
      unitRef="usd">128000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDYvZnJhZzo5OGQ5MGEyMDFjZGY0YTI0ODQ3NTBjNzkzMThlMjRkNi90ZXh0cmVnaW9uOjk4ZDkwYTIwMWNkZjRhMjQ4NDc1MGM3OTMxOGUyNGQ2XzU0OTc1NTgxNjEwNg_bf9c30ba-2fdb-403d-a500-58e2ff95e003"
      unitRef="usd">108100000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90ZXh0cmVnaW9uOjFkNGMwMTFmNzc3YjQxMDg4MzM0NmIzYTE2MjI4ZmVjXzEzNzY_f37ecf10-5303-4dfa-9a2b-5b6aca519459">Inventories&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost. Inventories measured using LIFO must be valued at the lower of cost or market. Inventories measured using FIFO must be valued at the lower of cost or net realizable value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories at December&#160;31 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;901.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,597.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;801.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total (approximates replacement cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,300.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,851.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase to LIFO cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,309.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,886.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories valued under the LIFO method comprised $1.23 billion and $1.36 billion of total inventories at December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;We recognized a net inventory impairment charge related to our COVID-19 antibodies of $339.7 million during the year ended December 31, 2021 in cost of sales in our consolidated statements of operations. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic evolved during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to demand from U.S. and international governments, including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90ZXh0cmVnaW9uOjFkNGMwMTFmNzc3YjQxMDg4MzM0NmIzYTE2MjI4ZmVjXzEzNjI_7a2bb54f-bcb3-472d-903d-ffea09ea3a9a">We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90ZXh0cmVnaW9uOjFkNGMwMTFmNzc3YjQxMDg4MzM0NmIzYTE2MjI4ZmVjXzEzNjQ_7f4e6c85-4d58-4f45-9116-22822a7e9328">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories at December&#160;31 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;901.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,597.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;801.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total (approximates replacement cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,300.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,851.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase to LIFO cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,309.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,886.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzEtMS0xLTEtMTk3MTgy_6b501efb-2902-4765-b2c6-688413cb9c90"
      unitRef="usd">901200000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzEtMy0xLTEtMTk3MTgy_cb768152-1a34-4a0d-b1a1-54f5af271f52"
      unitRef="usd">761900000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcess
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzItMS0xLTEtMTk3MTgy_cb8f65d4-0d3b-43db-87f8-0407fed3b9e8"
      unitRef="usd">2597700000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzItMy0xLTEtMTk3MTgy_0b4cd1a2-e969-4788-a064-18e85ef6d1c2"
      unitRef="usd">2372700000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterials
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzMtMS0xLTEtMTk3MTgy_09d7c756-e91c-4785-b31b-44590d390bd3"
      unitRef="usd">801900000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzMtMy0xLTEtMTk3MTgy_dd501953-7853-42b4-a46a-cdd3bfe77684"
      unitRef="usd">717200000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryGross
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzQtMS0xLTEtMTk3MTgy_7baa7cf8-2c3e-4f4a-bb23-cc2519525206"
      unitRef="usd">4300800000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzQtMy0xLTEtMTk3MTgy_38bf78cb-b750-4f60-9098-14d2a8912ce3"
      unitRef="usd">3851800000</us-gaap:InventoryGross>
    <us-gaap:InventoryLIFOReserve
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzUtMS0xLTEtMTk3MTgy_46311f4b-ee62-4ce5-91fe-ff4337683045"
      unitRef="usd">-8900000</us-gaap:InventoryLIFOReserve>
    <us-gaap:InventoryLIFOReserve
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzUtMy0xLTEtMTk3MTgy_1967d702-976a-4234-bcb7-459b031b0906"
      unitRef="usd">-34200000</us-gaap:InventoryLIFOReserve>
    <us-gaap:InventoryNet
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzYtMS0xLTEtMTk3MTgy_1c5b249f-0931-4a6f-89ca-9526e1da7566"
      unitRef="usd">4309700000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90YWJsZTphNmNiY2Q1NGE0OGY0NGM3YjQzZjYzMGZmM2QxNjFmOS90YWJsZXJhbmdlOmE2Y2JjZDU0YTQ4ZjQ0YzdiNDNmNjMwZmYzZDE2MWY5XzYtMy0xLTEtMTk3MTgy_88d6b486-b3a2-4c5b-bf20-3d1f2ac92bde"
      unitRef="usd">3886000000</us-gaap:InventoryNet>
    <us-gaap:LIFOInventoryAmount
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90ZXh0cmVnaW9uOjFkNGMwMTFmNzc3YjQxMDg4MzM0NmIzYTE2MjI4ZmVjXzUzOA_63bb7967-2269-4801-945a-7f62600878a0"
      unitRef="usd">1230000000</us-gaap:LIFOInventoryAmount>
    <us-gaap:LIFOInventoryAmount
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90ZXh0cmVnaW9uOjFkNGMwMTFmNzc3YjQxMDg4MzM0NmIzYTE2MjI4ZmVjXzU0NQ_177c6b53-380d-4d3a-a6c6-097671656959"
      unitRef="usd">1360000000</us-gaap:LIFOInventoryAmount>
    <us-gaap:InventoryWriteDown
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMDkvZnJhZzoxZDRjMDExZjc3N2I0MTA4ODMzNDZiM2ExNjIyOGZlYy90ZXh0cmVnaW9uOjFkNGMwMTFmNzc3YjQxMDg4MzM0NmIzYTE2MjI4ZmVjXzY4Mw_bdccb9ef-d514-4f85-b066-fc7be96d7733"
      unitRef="usd">339700000</us-gaap:InventoryWriteDown>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE0ODk0_217ee481-4ebd-4af2-a681-59094e472e43">Financial Instruments&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments in Equity and Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our equity investments are accounted for using three different methods depending on the type of equity investment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded for the years ended December&#160;31, 2022, 2021, and 2020 were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net gains (losses) recognized in our consolidated statements of operations for equity securities were $(410.7)&#160;million, $176.9&#160;million, and $1.44&#160;billion for the years ended December&#160;31, 2022, 2021, and 2020, respectively. The net gains (losses) recognized for the years ended December&#160;31, 2022, 2021, and 2020 on equity securities sold during the respective periods were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we had approximately $957&#160;million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record our available-for-sale debt securities at fair value, with changes in fair value reported as a component of accumulated other comprehensive income (loss). We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the years ended December&#160;31, 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.552%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturities by Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than&lt;br/&gt;1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-5&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6-10&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More Than 10 Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross gains&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized gain position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized loss position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;568.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 99 percent of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of December&#160;31, 2022, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of a material default on interest or principal payments for our debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity related to our available-for-sale securities was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;132.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross gains on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross losses on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Fair Value of Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes certain fair value information at December&#160;31, 2022 and 2021 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;657.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;657.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;650.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;657.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;30.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;31.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;30.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;30.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;53.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;53.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;53.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;53.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;58.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;58.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;39.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;58.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;144.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;146.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;163.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;146.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;146.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;213.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;235.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;213.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;213.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;149.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;161.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;149.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;149.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;50.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;52.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;50.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;50.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;398.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;34.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;311.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;87.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;398.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;683.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;484.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;683.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;683.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;478.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;781.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,901.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,379.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,379.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,361.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,379.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;232.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,279.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;487.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,279.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,279.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;548.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,212.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. Fair values are not readily available for certain equity investments measured under the measurement alternative.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes certain fair value information at December&#160;31, 2022 and 2021 for our short-term and long-term debt:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term commercial paper borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,498.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,492.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,492.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, including current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(14,740.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12,329.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12,329.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,884.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,157.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,157.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Risk Management and Related Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions.&#160;We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their investment grade credit ratings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $422.1 million and $550.5 million&#160;of accounts receivable as of December&#160;31, 2022 and 2021, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated results of operations for the years ended December&#160;31, 2022, 2021, and 2020 were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive income (loss) (see Note 17) and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive income (loss) (see Note 17). Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, Chinese yuan, Japanese yen, and Swiss franc). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#x2013;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At December&#160;31, 2022, we had outstanding foreign currency forward commitments as follows, all of which have settlement dates within 180 days:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.487%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sell&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,516.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,369.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,371.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,575.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chinese yuan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,139.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,212.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;British pounds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency exchange risk is also managed through the use of foreign currency debt, cross-currency interest rate swaps, and foreign currency forward contracts. Our foreign currency-denominated notes had carrying amounts of $6.83 billion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$7.90&#160;billion as of December&#160;31, 2022 and 2021, respectively, of which $5.45&#160;billion and $5.79&#160;billion have been designated as, and are effective as, economic hedges of net investments in certain of our foreign operations as of December&#160;31, 2022 and 2021, respectively. At December&#160;31, 2022, we had outstanding cross currency swaps with notional amounts of $1.02 billion swapping U.S. dollars to euro and $1.00&#160;billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed-rate debt to foreign-denominated fixed rate debt, have also been designated as, and are effective as, economic hedges of net investments. At December&#160;31, 2022, we had outstanding foreign currency forward contracts to sell 325.0 million euro and to sell 1.82 billion Chinese yuan, with settlement dates ranging through 2023, which have been designated as, and are effective as, economic hedges of net investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows. At December&#160;31, 2022, substantially all of our total long-term debt is at a fixed rate. We have converted approximately 10 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss) (see Note 17) and, upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of December&#160;31, 2022, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $1.85&#160;billion, which have settlement dates ranging between 2023 and 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;The Effect of Risk Management Instruments on the Consolidated Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following effects of risk-management instruments were recognized in other&#x2013;net, (income) expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from hedged fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(209.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;209.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;191.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;216.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, 2021, and 2020, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;324.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(404.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;52.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(15.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;391.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the next 12 months, we expect to reclassify $16.8 million of pretax net losses on cash flow hedges from accumulated other comprehensive income (loss) to other&#x2013;net, (income) expense. During the years ended December&#160;31, 2022, 2021, and 2020, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Fair Value of Risk-Management Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes certain fair value information at December&#160;31, 2022 and 2021 for risk-management assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.&lt;/span&gt;&lt;/div&gt;Contingent consideration liabilities relate to our liabilities arising in connection with the CVRs issued as a result of both the Akouos and Prevail acquisitions. The fair values of the CVR liabilities were estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payments associated with the agreed upon regulatory milestones based on probabilities of technical success, timing of the potential milestone events for the compounds, and estimated discount rates. See Note 3 for additional information related to the CVR arrangements for both Akouos and Prevail.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzI3NDg3NzkxMDIxNTM_c5ae80f8-6bbb-45c4-968e-059b17a5ee9c">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our equity investments are accounted for using three different methods depending on the type of equity investment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors.We record our available-for-sale debt securities at fair value, with changes in fair value reported as a component of accumulated other comprehensive income (loss). We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzEwNDQ1MzYwNDg0Nzk0_4d26cfa4-3112-4d7d-bf28-b77fc80b7526"
      unitRef="usd">-410700000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzEwNDQ1MzYwNDg0Nzk5_a54cbcef-9999-4eff-aab0-ef2c42dc8416"
      unitRef="usd">176900000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzEwNDQ1MzYwNDg0ODA4_7e2d904c-41a9-4bea-87d9-8b264f4c4064"
      unitRef="usd">1440000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzEwNDQ1MzYwNDg1MTk2_a8e233b2-541a-4f11-95e8-7c32b22c8dfc"
      unitRef="usd">957000000</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments>
    <lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzEwNDQ1MzYwNDg1MzE2_fcbd0ed2-ecef-4c7b-af0f-9a64e4cb7cf4">P10Y</lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzI3NDg3NzkxMDIxNTE_1cab454c-f496-4e7c-b41c-237722c00285">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.552%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturities by Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than&lt;br/&gt;1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-5&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6-10&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More Than 10 Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpjMWIzYjNjZDY4NTM0NWEyODE5ZTVmODU2MWIxZGEyMC90YWJsZXJhbmdlOmMxYjNiM2NkNjg1MzQ1YTI4MTllNWY4NTYxYjFkYTIwXzItMS0xLTEtMjM4OTAy_4d3e8cab-dabd-441d-88dc-bfcb3eddd1a4"
      unitRef="usd">646300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpjMWIzYjNjZDY4NTM0NWEyODE5ZTVmODU2MWIxZGEyMC90YWJsZXJhbmdlOmMxYjNiM2NkNjg1MzQ1YTI4MTllNWY4NTYxYjFkYTIwXzItMy0xLTEtMjM4OTAy_60604cd7-5a74-4fd8-a2a7-321a52be0a5a"
      unitRef="usd">86200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpjMWIzYjNjZDY4NTM0NWEyODE5ZTVmODU2MWIxZGEyMC90YWJsZXJhbmdlOmMxYjNiM2NkNjg1MzQ1YTI4MTllNWY4NTYxYjFkYTIwXzItNS0xLTEtMjM4OTAy_e73e008a-ffe9-44d6-986c-bb488c12e680"
      unitRef="usd">242000000.0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpjMWIzYjNjZDY4NTM0NWEyODE5ZTVmODU2MWIxZGEyMC90YWJsZXJhbmdlOmMxYjNiM2NkNjg1MzQ1YTI4MTllNWY4NTYxYjFkYTIwXzItNy0xLTEtMjM4OTAy_bcf4bf14-27cb-4408-a4f6-5493397c615b"
      unitRef="usd">104000000.0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpjMWIzYjNjZDY4NTM0NWEyODE5ZTVmODU2MWIxZGEyMC90YWJsZXJhbmdlOmMxYjNiM2NkNjg1MzQ1YTI4MTllNWY4NTYxYjFkYTIwXzItOS0xLTEtMjM4OTAy_f1d79d72-fe3c-46d9-9ff7-2d1d44c26106"
      unitRef="usd">214100000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzI3NDg3NzkxMDIxNDY_4c9ee139-aab5-49f0-a0e4-9f10b7260fba">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross gains&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized gain position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized loss position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;568.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpiYWNjYWZkZmU0M2U0OGE0OGU3NzdlMzk3YmEwMjA3My90YWJsZXJhbmdlOmJhY2NhZmRmZTQzZTQ4YTQ4ZTc3N2UzOTdiYTAyMDczXzEtMS0xLTEtMjM4OTI4_b286ab98-73ea-4d4a-96bf-fcdb98d324d0"
      unitRef="usd">600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpiYWNjYWZkZmU0M2U0OGE0OGU3NzdlMzk3YmEwMjA3My90YWJsZXJhbmdlOmJhY2NhZmRmZTQzZTQ4YTQ4ZTc3N2UzOTdiYTAyMDczXzEtMy0xLTEtMjM4OTI4_8cabdfc7-82b3-4b9b-abb2-052183494658"
      unitRef="usd">9700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpiYWNjYWZkZmU0M2U0OGE0OGU3NzdlMzk3YmEwMjA3My90YWJsZXJhbmdlOmJhY2NhZmRmZTQzZTQ4YTQ4ZTc3N2UzOTdiYTAyMDczXzItMS0xLTEtMjM4OTI4_5d23ec36-7444-41d1-9a63-84fd058be4a2"
      unitRef="usd">49200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpiYWNjYWZkZmU0M2U0OGE0OGU3NzdlMzk3YmEwMjA3My90YWJsZXJhbmdlOmJhY2NhZmRmZTQzZTQ4YTQ4ZTc3N2UzOTdiYTAyMDczXzItMy0xLTEtMjM4OTI4_9bc7a656-7691-4917-b3b1-373bde48e92b"
      unitRef="usd">5200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpiYWNjYWZkZmU0M2U0OGE0OGU3NzdlMzk3YmEwMjA3My90YWJsZXJhbmdlOmJhY2NhZmRmZTQzZTQ4YTQ4ZTc3N2UzOTdiYTAyMDczXzMtMS0xLTEtMjM4OTI4_54926f19-04b7-4578-9c5e-082f21143dac"
      unitRef="usd">46800000</lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition>
    <lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpiYWNjYWZkZmU0M2U0OGE0OGU3NzdlMzk3YmEwMjA3My90YWJsZXJhbmdlOmJhY2NhZmRmZTQzZTQ4YTQ4ZTc3N2UzOTdiYTAyMDczXzMtMy0xLTEtMjM4OTI4_7af09b3a-43c8-41ee-82a6-c4fae66093a5"
      unitRef="usd">250700000</lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpiYWNjYWZkZmU0M2U0OGE0OGU3NzdlMzk3YmEwMjA3My90YWJsZXJhbmdlOmJhY2NhZmRmZTQzZTQ4YTQ4ZTc3N2UzOTdiYTAyMDczXzQtMS0xLTEtMjM4OTI4_ee849c50-5cca-485b-bda5-4d9f64881aaa"
      unitRef="usd">568700000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpiYWNjYWZkZmU0M2U0OGE0OGU3NzdlMzk3YmEwMjA3My90YWJsZXJhbmdlOmJhY2NhZmRmZTQzZTQ4YTQ4ZTc3N2UzOTdiYTAyMDczXzQtMy0xLTEtMjM4OTI4_eccce1f0-7adc-4bba-aa07-fcbd940cdec0"
      unitRef="usd">290200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzEwNDQ1MzYwNDg4Mjkw_9226ad24-646f-4ca6-abeb-a3f1e9aafa9c"
      unitRef="number">0.99</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzI3NDg3NzkxMDIxNDc_45ada370-5cc7-4db1-a3a1-beecb80aa980">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity related to our available-for-sale securities was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;132.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross gains on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross losses on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo3MDYyMmI3NWE3YzQ0NzBjYjI4ZWRhYjllZjg4YTFlZi90YWJsZXJhbmdlOjcwNjIyYjc1YTdjNDQ3MGNiMjhlZGFiOWVmODhhMWVmXzEtMS0xLTEtMjM4OTY4_add78c4e-7c4c-4b49-bd17-8bb2f3a08756"
      unitRef="usd">132900000</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo3MDYyMmI3NWE3YzQ0NzBjYjI4ZWRhYjllZjg4YTFlZi90YWJsZXJhbmdlOjcwNjIyYjc1YTdjNDQ3MGNiMjhlZGFiOWVmODhhMWVmXzEtMy0xLTEtMjM4OTY4_7ac6cc21-a664-4ae8-a20a-ca73d3dc0a36"
      unitRef="usd">174700000</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo3MDYyMmI3NWE3YzQ0NzBjYjI4ZWRhYjllZjg4YTFlZi90YWJsZXJhbmdlOjcwNjIyYjc1YTdjNDQ3MGNiMjhlZGFiOWVmODhhMWVmXzEtNS0xLTEtMjM4OTY4_bab3918c-531a-4633-8176-89f9160ffcf0"
      unitRef="usd">264800000</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo3MDYyMmI3NWE3YzQ0NzBjYjI4ZWRhYjllZjg4YTFlZi90YWJsZXJhbmdlOjcwNjIyYjc1YTdjNDQ3MGNiMjhlZGFiOWVmODhhMWVmXzItMS0xLTEtMjM4OTY4_4fa8c3e7-8e9e-4240-8ffc-d5f63aed0467"
      unitRef="usd">400000</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo3MDYyMmI3NWE3YzQ0NzBjYjI4ZWRhYjllZjg4YTFlZi90YWJsZXJhbmdlOjcwNjIyYjc1YTdjNDQ3MGNiMjhlZGFiOWVmODhhMWVmXzItMy0xLTEtMjM4OTY4_543e1dd2-3c05-4809-b4d4-250d5b492643"
      unitRef="usd">2800000</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo3MDYyMmI3NWE3YzQ0NzBjYjI4ZWRhYjllZjg4YTFlZi90YWJsZXJhbmdlOjcwNjIyYjc1YTdjNDQ3MGNiMjhlZGFiOWVmODhhMWVmXzItNS0xLTEtMjM4OTY4_6a76d4e5-e209-4a2a-9bab-a5923700110e"
      unitRef="usd">4500000</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo3MDYyMmI3NWE3YzQ0NzBjYjI4ZWRhYjllZjg4YTFlZi90YWJsZXJhbmdlOjcwNjIyYjc1YTdjNDQ3MGNiMjhlZGFiOWVmODhhMWVmXzMtMS0xLTEtMjM4OTY4_0a487e58-9768-4ec8-8b26-805c085480d3"
      unitRef="usd">9700000</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo3MDYyMmI3NWE3YzQ0NzBjYjI4ZWRhYjllZjg4YTFlZi90YWJsZXJhbmdlOjcwNjIyYjc1YTdjNDQ3MGNiMjhlZGFiOWVmODhhMWVmXzMtMy0xLTEtMjM4OTY4_d4a04d86-8793-4419-9ad2-80c73591ddf7"
      unitRef="usd">1700000</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo3MDYyMmI3NWE3YzQ0NzBjYjI4ZWRhYjllZjg4YTFlZi90YWJsZXJhbmdlOjcwNjIyYjc1YTdjNDQ3MGNiMjhlZGFiOWVmODhhMWVmXzMtNS0xLTEtMjM4OTY4_ac97b495-0a7d-46af-9e58-baef8ec02402"
      unitRef="usd">8200000</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzI3NDg3NzkxMDIxNDk_02aaedbe-4618-4701-a0a2-faa3a07060af">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes certain fair value information at December&#160;31, 2022 and 2021 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;657.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;657.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;650.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;657.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;30.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;31.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;30.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;30.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;53.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;53.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;53.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;53.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;58.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;58.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;39.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;58.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;144.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;146.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;163.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;146.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;146.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;213.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;235.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;213.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;213.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;149.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;161.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;149.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;149.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;50.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;52.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;50.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;50.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;398.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;34.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;311.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;87.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;398.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;683.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;484.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;683.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;683.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;478.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;781.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,901.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,379.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,379.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,361.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,379.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;232.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,279.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;487.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,279.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,279.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;548.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,212.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib2046b6b3eed4ac6b751298dc54b230f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMtMS0xLTEtMjM5MDA5_038dfb46-de2d-4de8-9470-bc4f701390a9"
      unitRef="usd">657400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i85739ca7c6b04f86b9f0f4e04dac3933_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMtMy0xLTEtMjM5MDA5_eedfadb4-b476-4ab0-b782-3a5fd2a9d00e"
      unitRef="usd">657400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4c6d39fa7dff407a9bb5b5c2e98c8f37_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMtNS0xLTEtMjM5MDA5_c83c4800-5a91-4c4a-9bcf-6f596cc6ff27"
      unitRef="usd">650400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if819ebce2b824e4f956b1fc03a244870_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMtNy0xLTEtMjM5MDA5_3732709c-171b-42ed-8176-29600b839caf"
      unitRef="usd">7000000.0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6d41b93e38c04495a8c9e35a8f93a51b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMtOS0xLTEtMjM5MDA5_06c9d063-1651-40a6-9132-4a57fba10b0f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7a6cadf85ae74e19b0b4b3d94566c950_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMtMTEtMS0xLTI0MDExNw_a6c4f31c-5d56-4ec7-aa5d-3f5739fff86d"
      unitRef="usd">657400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib29cb4f6b7524096a38ea003c862f821_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzUtMS0xLTEtMjM5MDA5_247f38f8-440f-41b8-adaf-da46a4f3bf32"
      unitRef="usd">30800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9e73f160e8f04f4eaddf6e0c2226046d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzUtMy0xLTEtMjM5MDA5_0b6fdf83-3a75-405d-933d-33809d85b0e3"
      unitRef="usd">31100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4cc4f4f8668840918ffb5f33a50164aa_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzUtNS0xLTEtMjM5MDA5_55326e24-3a4b-47a4-baa5-f6d5f187ab7c"
      unitRef="usd">30800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i83db6edf74c94f7dbe7af9c3b57e71cd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzUtNy0xLTEtMjM5MDA5_2db2839c-d3c7-4c0f-9222-b56cf138ff2e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i96a991509ebf43809a439058ce22fa7e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzUtOS0xLTEtMjM5MDA5_bd2fdb07-62d9-4e06-8186-bb129ea2afa1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icf3de48b5cde4b74bd86492c49a3cfff_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzUtMTEtMS0xLTI0MDA4Nw_7108f670-79e8-41b2-94a9-1473fed0706b"
      unitRef="usd">30800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iab0fa37d1d26458698fec203c6de3170_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzYtMS0xLTEtMjM5MDA5_a460b6c9-7784-4acc-96cc-086ea2382cfc"
      unitRef="usd">53400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7b78ecf596654f379406da98609085ad_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzYtMy0xLTEtMjM5MDA5_90e608cd-81db-4889-95e8-6d2fce26db08"
      unitRef="usd">53500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0e65c1e9f8314c05bb18488e182dcdc8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzYtNS0xLTEtMjM5MDA5_92cbd92e-248b-437b-bd45-a954d60cbf45"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5c6b6db44fad4227b0e7923dd144dad5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzYtNy0xLTEtMjM5MDA5_ff15922a-3d3e-41b1-908c-c05f4698df2b"
      unitRef="usd">53400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i267eeb3d4c4544ed98a8e040d42e3659_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzYtOS0xLTEtMjM5MDA5_b3de3371-23bf-4140-8544-67d950797cb1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie08ea2826b404bb1b32d7612d132d1fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzYtMTEtMS0xLTI0MDA4Nw_bdf2b07f-d849-4f17-949c-0e4e510ca995"
      unitRef="usd">53400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4360dfda4bcd4ae8aacb3842d8b38544_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzgtMS0xLTEtMjM5MDA5_6cde02f3-f889-4e55-8117-bfd10e148961"
      unitRef="usd">2000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iecdb9bef83534c1ca768e9eb267d15fb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzgtMy0xLTEtMjM5MDA5_dbc4be71-37b8-4cd9-aade-2326c263415b"
      unitRef="usd">2000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icd68026d385248dc99ec6cebbbcf4fe0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzgtNS0xLTEtMjM5MDA5_ce7e7de8-bdef-4b01-be95-f795c1494830"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8623252cacd94e8eacc974d3c5bb281a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzgtNy0xLTEtMjM5MDA5_31f544c4-72aa-4770-adac-1113c787b706"
      unitRef="usd">2000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia3b93d9016f347f7a42304dbc2662cbf_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzgtOS0xLTEtMjM5MDA5_65b3ac40-d45d-4bc3-af93-9d98d6a33608"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie7745ed8eaec4896a79398bf44e3ee0c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzgtMTEtMS0xLTI0MDA4Nw_48882939-9050-4c8a-b127-368031666322"
      unitRef="usd">2000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib2c6931fe5d44a29a69a4915f25c3aa3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzktMS0xLTEtMjM5MDA5_3d9d44cd-8204-4a59-b1cc-3343a43d1dae"
      unitRef="usd">58600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0e449ba54e0f4910991f72fc6586c372_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzktMy0xLTEtMjM5MDA5_2fa21e01-3bdf-4360-a355-6e3e486e3e09"
      unitRef="usd">58600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i202f70807f944a99b3c4a8546c4c57b6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzktNS0xLTEtMjM5MDA5_12e40e64-0596-46ea-beb8-9a386615b0cf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i96434fbfa57540c3bf2a773a2c2ff46e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzktNy0xLTEtMjM5MDA5_3ba808c7-cfae-403d-9a46-6d5b5359c814"
      unitRef="usd">39100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ifc245c7e9eab4641886b085a802fcb71_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzktOS0xLTEtMjM5MDA5_0e560cf8-fa4f-4033-88f6-1abd008cd7fa"
      unitRef="usd">19500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic744f4b830ac467eb5deba8b1de59644_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzktMTEtMS0xLTI0MDA4Nw_344d708a-fc66-4731-bac8-54f5761e37b5"
      unitRef="usd">58600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib2046b6b3eed4ac6b751298dc54b230f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzExLTEtMS0xLTI0MDA5OQ_9142e6d9-941b-4920-8cfe-874a4881809b"
      unitRef="usd">144800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib29cb4f6b7524096a38ea003c862f821_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzEzLTEtMS0xLTIzOTAwOQ_91b3656c-2784-4693-9f65-c37916d236e1"
      unitRef="usd">146400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9e73f160e8f04f4eaddf6e0c2226046d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzEzLTMtMS0xLTIzOTAwOQ_89c8609f-75b5-4f6b-be1a-93d2f0239cf7"
      unitRef="usd">163200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i4cc4f4f8668840918ffb5f33a50164aa_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzEzLTUtMS0xLTIzOTAwOQ_040771c2-e4a7-4f0f-898c-ad1ebcf865d7"
      unitRef="usd">146400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i83db6edf74c94f7dbe7af9c3b57e71cd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzEzLTctMS0xLTIzOTAwOQ_e187c918-ab64-4a16-b3e3-0e70c4a2a5fe"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i96a991509ebf43809a439058ce22fa7e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzEzLTktMS0xLTIzOTAwOQ_f7f1f87d-96d7-4c7a-affe-30083870f1ca"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="icf3de48b5cde4b74bd86492c49a3cfff_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzEzLTExLTEtMS0yNDAwODk_a9b6f765-47d4-42ac-9e6b-38e91e675281"
      unitRef="usd">146400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iab0fa37d1d26458698fec203c6de3170_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE0LTEtMS0xLTI0MDA5Nw_ab239393-4206-41ae-bd08-c6367e3f547d"
      unitRef="usd">213900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i7b78ecf596654f379406da98609085ad_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE0LTMtMS0xLTIzOTAwOQ_e772789b-491f-4c9a-887a-2250bd287e85"
      unitRef="usd">235800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0e65c1e9f8314c05bb18488e182dcdc8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE0LTUtMS0xLTIzOTAwOQ_e285f747-314e-4368-9f52-43171b268d24"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5c6b6db44fad4227b0e7923dd144dad5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE0LTctMS0xLTIzOTAwOQ_248b5824-43b5-45a0-a823-dcc5c72731fd"
      unitRef="usd">213900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i267eeb3d4c4544ed98a8e040d42e3659_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE0LTktMS0xLTIzOTAwOQ_101dae74-9859-4e5c-ad88-4a1d74007116"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ie08ea2826b404bb1b32d7612d132d1fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE0LTExLTEtMS0yNDAwODk_0c4c0b47-9a36-4bb2-a8f0-4a3df4652da0"
      unitRef="usd">213900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i09eaf08a82294887bec59eec2190dd1e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE1LTEtMS0xLTI0MDA5Nw_b2bea4fc-d436-4148-83b0-cbff436763f8"
      unitRef="usd">149200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ic0b4fd6680c24327b70dbadbcdab8d00_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE1LTMtMS0xLTIzOTAwOQ_f57407fe-0e9f-470b-8d38-87682e09ea10"
      unitRef="usd">161500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6c609093db884ac09f9b0f30051477e4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE1LTUtMS0xLTIzOTAwOQ_66fd1757-87a1-4aad-986c-d32d3e563364"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i3257f473d8d344f2a056bb2771c42f6e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE1LTctMS0xLTIzOTAwOQ_8a1568f2-e30b-4a82-8fe0-3fad5f09c541"
      unitRef="usd">149200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i43ea231ef1224a80971a531780a87b35_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE1LTktMS0xLTIzOTAwOQ_73518ae5-cc09-4514-8cb6-572fdd4ba2b9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i31f61c2016124d9faff9cfc9175c8e0b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE1LTExLTEtMS0yNDAwODk_04806c82-0de5-442a-bedd-bd9d7744d2d1"
      unitRef="usd">149200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i4360dfda4bcd4ae8aacb3842d8b38544_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE2LTEtMS0xLTI0MDA5Nw_59fe0337-18bb-4a3d-9e06-44b5370a8e1f"
      unitRef="usd">50600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iecdb9bef83534c1ca768e9eb267d15fb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE2LTMtMS0xLTIzOTAwOQ_476def96-66bd-4e5c-a360-187b9138bc3c"
      unitRef="usd">52500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="icd68026d385248dc99ec6cebbbcf4fe0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE2LTUtMS0xLTIzOTAwOQ_31bd7a28-4781-4862-9d5d-740a84ef7c13"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i8623252cacd94e8eacc974d3c5bb281a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE2LTctMS0xLTIzOTAwOQ_2a2425ae-b81b-4472-bf2d-18dbfa92afea"
      unitRef="usd">50600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia3b93d9016f347f7a42304dbc2662cbf_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE2LTktMS0xLTIzOTAwOQ_b2f64e30-edf5-4438-8e0d-a5f343c7babc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ie7745ed8eaec4896a79398bf44e3ee0c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE2LTExLTEtMS0yNDAwODk_78856eb6-45d3-410a-9de7-5cd4e15105b4"
      unitRef="usd">50600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="iaa948220bcab4ce3b0bd4520c7b48b28_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE3LTEtMS0xLTI0MDA5Nw_10724dd6-adfa-4dba-b478-97241182296f"
      unitRef="usd">398600000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="ica209a2bd9434d09b84c0795cb110ef9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE3LTMtMS0xLTIzOTAwOQ_25f10434-f9f6-42e5-abb6-abc8b7ef71d3"
      unitRef="usd">34500000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="iecb3faf84ac344d18fad6aa15881f6ed_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE3LTUtMS0xLTIzOTAwOQ_a8ffaa65-643d-4293-bf77-756ba274df3e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i87a3049207dd433897dc2049c4a35614_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE3LTctMS0xLTIzOTAwOQ_efc40c3f-577f-4d85-b29c-88c72f631982"
      unitRef="usd">311000000.0</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i97d710d13dea404c9c76ca03cfd32cae_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE3LTktMS0xLTIzOTAwOQ_aa178eec-6f19-4cf6-843b-8cc0e9c1afb6"
      unitRef="usd">87600000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i9fb8d947138d48f4ba4234d90a755569_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE3LTExLTEtMS0yNDAwODk_69334b73-38df-4a8e-9e72-7dd62b19a228"
      unitRef="usd">398600000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="id93e165c23a14eb4848c3cfac9842a39_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE4LTEtMS0xLTI0MDA5Nw_282c59b7-eff8-41d9-9b0a-7268dec07556"
      unitRef="usd">683600000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="ide566100c19446ef9e02ffe6729e317a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE4LTMtMS0xLTIzOTAwOQ_d0915346-999f-4321-bc40-4f5a15ed847e"
      unitRef="usd">484700000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i206922eb76584eceb418d0469c699ef1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE4LTUtMS0xLTIzOTAwOQ_1cbc5394-c177-4952-bf55-1f1685a110cf"
      unitRef="usd">683600000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i2a592b428bb4466ca49b8ab98ac79c2f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE4LTctMS0xLTIzOTAwOQ_49aca476-2fe5-4788-87a4-2edcb079737f"
      unitRef="usd">0</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="ie77fee34bd8143b9865e1a7ce56ae13b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE4LTktMS0xLTIzOTAwOQ_43c90ccb-2233-4c35-888d-9ea47062a017"
      unitRef="usd">0</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i7cb09673cd4d4a51aeae0a4b4fad802f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE4LTExLTEtMS0yNDAwODk_b19e51f7-3f21-449f-8ddf-5c51514e9ec4"
      unitRef="usd">683600000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ib2046b6b3eed4ac6b751298dc54b230f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzE5LTEtMS0xLTIzOTAwOQ_0fe80eb9-efb2-40ec-8788-4bf558d8c6fb"
      unitRef="usd">478400000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherLongTermInvestments
      contextRef="idec2713ca1764f9984742765f2a3f5f6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzIwLTEtMS0xLTIzOTAwOQ_739aa598-7920-4af7-98e3-31892858ad5f"
      unitRef="usd">781100000</us-gaap:OtherLongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ib2046b6b3eed4ac6b751298dc54b230f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzIxLTEtMS0xLTI0MDEwMQ_29a07017-5111-4128-b1df-c3c2f2f01650"
      unitRef="usd">2901800000</us-gaap:LongTermInvestments>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3ef264a2971a4d6d9632968955a88874_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI0LTEtMS0xLTIzOTAwOQ_abf6ffb9-5f71-4065-a9aa-9bdfdda884cc"
      unitRef="usd">2379500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i67745cb3a266420caea7e92585afd798_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI0LTMtMS0xLTIzOTAwOQ_71cdd9a4-04be-406b-9e11-219e4d6a5b0d"
      unitRef="usd">2379500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic1d701e8a7d846deb5dfed51dc19420e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI0LTUtMS0xLTIzOTAwOQ_bd582689-a88b-47cc-9ae9-bb4f2224202e"
      unitRef="usd">2361000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6e3bd9c97de44684a6f54ff2b763dce6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI0LTctMS0xLTIzOTAwOQ_37fce205-cc4b-4c50-a04d-b41693bbfe94"
      unitRef="usd">18500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6543e2dc57fc4942a80a5c4b47c6a4d6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI0LTktMS0xLTIzOTAwOQ_7c569454-c10d-4dff-9536-744d58e9a7d8"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icbf3bc2cf6f14b3e986aed5486e859be_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI0LTExLTEtMS0yNDAwOTE_f4720f54-e7d9-4656-917d-067410a463f8"
      unitRef="usd">2379500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6c7e6db0a0f342f38f0da6050795d81e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI2LTEtMS0xLTI0MDEwMw_23d0775f-0041-4c4f-9894-c32bbb95497b"
      unitRef="usd">25700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i70d18d4fe82d4e3799255211fdb7c961_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI2LTMtMS0xLTIzOTAwOQ_058a9c48-90a5-4d7d-9593-71112736784a"
      unitRef="usd">25600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6e527334606a4f5cb5eb429d7720b579_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI2LTUtMS0xLTIzOTAwOQ_aff2e97a-0968-4eda-a478-895bdbe1287e"
      unitRef="usd">25700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i21be69bc53c046e5bc04d738798632b0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI2LTctMS0xLTIzOTAwOQ_4ed4014f-9710-40fc-a4c0-2a0dfd4627bc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i00463fe56920430aa066d2ecd7dce5ec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI2LTktMS0xLTIzOTAwOQ_aec61647-cbd4-43fe-8f0e-3fb4fba7ae7e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibc6345dbf99e4b10a664854739c10ab7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI2LTExLTEtMS0yNDAwOTM_bda8ac20-de01-4864-ac99-ad34448ff8f2"
      unitRef="usd">25700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i09d53a5267d54e38ab69be8d99e1a128_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI3LTEtMS0xLTIzOTAwOQ_bc48954c-512f-4e82-a074-ca8573e19b3a"
      unitRef="usd">43700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i791959b335d9411682c43bc9a3d30863_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI3LTMtMS0xLTIzOTAwOQ_50b8110c-172c-4df6-83d5-d2089dff730e"
      unitRef="usd">43700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i1424fba935ab49b1bca8d99d589337e3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI3LTUtMS0xLTIzOTAwOQ_b89c7c74-01eb-489b-8e7d-19022794fdc3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i995cc780a15a4e11a297abb46a4670e5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI3LTctMS0xLTIzOTAwOQ_e0c1f280-72e8-4c82-8f62-2ad52729f27d"
      unitRef="usd">43700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if923bd42b75741279230d2a8db22bf73_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI3LTktMS0xLTIzOTAwOQ_fe431c13-264a-4364-a4b4-2507cd7bc537"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie18586de026d4b76ac4be48157ae8d1d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI3LTExLTEtMS0yNDAwOTM_26cd8cc7-fc9f-46bb-84c7-59db9458608f"
      unitRef="usd">43700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i630ee0edbef7428faf2976f9c169689f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI4LTEtMS0xLTIzOTAwOQ_25d367f7-b8b8-4ca7-b3ac-b8b6a82c8355"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i66776fea49f94b9a845efebd8dc9043a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI4LTMtMS0xLTIzOTAwOQ_6208fb3a-964c-4249-b806-b5641cba298d"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i1dd7f0aa7ba940b4871022bad3341f93_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI4LTUtMS0xLTIzOTAwOQ_ebf454ca-de53-4c8f-9b08-d7c4fbbfe5c6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iefd7992238674ff3901e725d12b4b20f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI4LTctMS0xLTIzOTAwOQ_87c32c50-abb2-491a-8f1c-065feacb9593"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i40df2b9b5ee34ab0aa3950d2139dfd76_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI4LTktMS0xLTIzOTAwOQ_667a253b-2478-4dc7-adb7-8cbc897d5d60"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iea1803ebd97a4e4f87e68572966755b4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI4LTExLTEtMS0yNDAwOTM_283feab5-644f-4b56-b735-a6ef07046aff"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib0d644ad67b64ed896bb8c35759604a5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI5LTEtMS0xLTIzOTAwOQ_d01c0d70-2b18-4af3-8963-1637d0a969ae"
      unitRef="usd">6200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i065e0d87c04c401fae0f22c40bf7957c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI5LTMtMS0xLTIzOTAwOQ_2a081c01-45a9-4b1d-ad0c-447cf6974863"
      unitRef="usd">6200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id97791b6d6d4420180779511ef340d85_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI5LTUtMS0xLTIzOTAwOQ_e5c274bf-b436-4f84-965b-d8ee41f3ee6f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id9a5c2ba711e441db5517f030cff4003_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI5LTctMS0xLTIzOTAwOQ_84f5fe0e-4068-446e-a45b-27055757dc79"
      unitRef="usd">6200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i114748072ce44e029035eb08efa37d1f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI5LTktMS0xLTIzOTAwOQ_134eea15-e525-4af8-b634-7f49b7e1ef4f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i825718d9a8af4d88a0b8aa9db37556e2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzI5LTExLTEtMS0yNDAwOTM_3a23d765-f618-4364-b3d1-0ee59357adeb"
      unitRef="usd">6200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i83265c7960c34844bb2725361d24deba_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMwLTEtMS0xLTIzOTAwOQ_68165e13-8030-44a5-b381-99d62ed83f5e"
      unitRef="usd">14300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i869fd0d7109b41d4815c68ea3a46ebac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMwLTMtMS0xLTIzOTAwOQ_a9e8f73a-f414-4f38-8723-7b491d8dd5a1"
      unitRef="usd">14300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if8bae18362b342449e21722305a0c0ea_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMwLTUtMS0xLTIzOTAwOQ_b68e994c-5569-434f-a4b3-2045cba7baa1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i67b95f772703429a8a0357ffd550d665_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMwLTctMS0xLTIzOTAwOQ_5a905724-9553-435b-8aed-5f6573104bd2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id72a1c59b3e84bdabceb3740c94a39b2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMwLTktMS0xLTIzOTAwOQ_ad8e1120-8b47-4e99-a1ec-24acdb36b016"
      unitRef="usd">14300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia286896d0b5e4e60be5600fdf1b2b12e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMwLTExLTEtMS0yNDAwOTM_959f08a3-6923-4c64-adf4-650d06f7d458"
      unitRef="usd">14300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3ef264a2971a4d6d9632968955a88874_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzMyLTEtMS0xLTI0MDEwNQ_7d82a997-d410-4581-85c8-7c06d6f3bef2"
      unitRef="usd">90100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6c7e6db0a0f342f38f0da6050795d81e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM0LTEtMS0xLTI0MDEwNw_c461d79d-8563-483b-9792-4f265dbddf89"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i70d18d4fe82d4e3799255211fdb7c961_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM0LTMtMS0xLTIzOTAwOQ_31d164b4-45e4-4e79-af0f-90e4fc838b36"
      unitRef="usd">136800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6e527334606a4f5cb5eb429d7720b579_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM0LTUtMS0xLTIzOTAwOQ_aa5e04da-370c-4d1e-809f-1f52c6dc79c7"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i21be69bc53c046e5bc04d738798632b0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM0LTctMS0xLTIzOTAwOQ_ca0bf682-15ec-4da5-8da1-bf89e9dfc6de"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i00463fe56920430aa066d2ecd7dce5ec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM0LTktMS0xLTIzOTAwOQ_094c2850-1d37-40f6-ab0c-70af9ba9ce95"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ibc6345dbf99e4b10a664854739c10ab7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM0LTExLTEtMS0yNDAwOTU_d94b7ead-bfff-45c8-a96c-7e747839a2f0"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i09d53a5267d54e38ab69be8d99e1a128_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM1LTEtMS0xLTI0MDEwNw_43f5e70c-194d-4253-a566-635401922fb4"
      unitRef="usd">235300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i791959b335d9411682c43bc9a3d30863_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM1LTMtMS0xLTIzOTAwOQ_7c4c5770-5606-4406-8595-0da51c36bf21"
      unitRef="usd">232700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i1424fba935ab49b1bca8d99d589337e3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM1LTUtMS0xLTIzOTAwOQ_ce4fe385-f3e5-4bf8-9393-42c94992a902"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i995cc780a15a4e11a297abb46a4670e5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM1LTctMS0xLTIzOTAwOQ_a73013dc-6679-49e4-8607-bcb22ce7c3ce"
      unitRef="usd">235300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if923bd42b75741279230d2a8db22bf73_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM1LTktMS0xLTIzOTAwOQ_3b463239-b226-4bb0-909e-b8432addd5b2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ie18586de026d4b76ac4be48157ae8d1d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM1LTExLTEtMS0yNDAwOTU_e92d604e-c0e9-40c5-bd5e-549485b9b122"
      unitRef="usd">235300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i630ee0edbef7428faf2976f9c169689f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM2LTEtMS0xLTI0MDEwNw_1ebccbeb-902b-4115-a7be-187fb194d1d8"
      unitRef="usd">109800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i66776fea49f94b9a845efebd8dc9043a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM2LTMtMS0xLTIzOTAwOQ_78bcfa28-2e40-4c6e-b686-6676cc4f5dce"
      unitRef="usd">108100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i1dd7f0aa7ba940b4871022bad3341f93_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM2LTUtMS0xLTIzOTAwOQ_818ef264-e94f-4163-ae94-26559ab95b1e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iefd7992238674ff3901e725d12b4b20f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM2LTctMS0xLTIzOTAwOQ_54fe9376-18b3-46e9-9e1b-177cba98596c"
      unitRef="usd">109800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i40df2b9b5ee34ab0aa3950d2139dfd76_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM2LTktMS0xLTIzOTAwOQ_9b27edfb-e2d6-44f8-9f0d-f5eb4b0564b7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iea1803ebd97a4e4f87e68572966755b4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM2LTExLTEtMS0yNDAwOTU_b7e4892e-00d8-4066-a713-1985dbe6dd2b"
      unitRef="usd">109800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib0d644ad67b64ed896bb8c35759604a5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM3LTEtMS0xLTI0MDEwNw_bdd0e7b4-333e-4a09-af9c-9296a6e09799"
      unitRef="usd">23100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i065e0d87c04c401fae0f22c40bf7957c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM3LTMtMS0xLTIzOTAwOQ_ece92a70-0051-451c-b615-37baec668032"
      unitRef="usd">23100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id97791b6d6d4420180779511ef340d85_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM3LTUtMS0xLTIzOTAwOQ_39b78827-3ce3-4bf8-8099-c0e2cca61e0d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id9a5c2ba711e441db5517f030cff4003_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM3LTctMS0xLTIzOTAwOQ_a771235d-05a2-4004-b58c-122149120575"
      unitRef="usd">23100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i114748072ce44e029035eb08efa37d1f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM3LTktMS0xLTIzOTAwOQ_ad2568dd-ef02-41d9-bfd9-9655099e81d6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i825718d9a8af4d88a0b8aa9db37556e2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM3LTExLTEtMS0yNDAwOTU_c98c9de8-f622-4df6-9862-2c206e778a1f"
      unitRef="usd">23100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="ib5351b4419e648ebbac325c9a8f25776_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM4LTEtMS0xLTI0MDEwNw_c9fb5c06-fca2-4d2c-8906-3871a3d1f5de"
      unitRef="usd">108100000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i97a76897f7614783bbc3b95171430289_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM4LTMtMS0xLTIzOTAwOQ_0beb6541-cb76-4917-a1f5-dd350f8aa8a8"
      unitRef="usd">22200000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i08786343c67b4a868c5253051cd773cb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM4LTUtMS0xLTIzOTAwOQ_88692e76-9c04-434d-b68b-24f845f9454a"
      unitRef="usd">0</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="id0f4d070f3f34eacab1aaebe39cae662_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM4LTctMS0xLTIzOTAwOQ_98363d8f-5932-440d-bdab-edd4291ad11b"
      unitRef="usd">0</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i4762367938c14cfca0c24d191f73550c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM4LTktMS0xLTIzOTAwOQ_3605aaaf-c0bc-4925-a3ef-ce97b1f15597"
      unitRef="usd">108100000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i8e291e2320cd48a3aa360f816a7fed28_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM4LTExLTEtMS0yNDAwOTU_90829edb-8c06-4845-bdd9-9c3d347be5d6"
      unitRef="usd">108100000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="ib49d1436b4674f92b884ce9b352c35d1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM5LTEtMS0xLTI0MDEwNw_e05a2864-77ad-4c00-8461-f2d9ff6ca0c2"
      unitRef="usd">1279700000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i68ab827622544f9ea9120e5ce5dd8bab_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM5LTMtMS0xLTIzOTAwOQ_38110a80-eabd-47ca-80c7-04eb8b10966b"
      unitRef="usd">487000000.0</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="if7a8b848d1d8427c890edfad8cc5f8cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM5LTUtMS0xLTIzOTAwOQ_21f14278-5e58-40b1-af8e-b09b69daceb9"
      unitRef="usd">1279700000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="ifc8331fd4f1147f4992919b2c03cbd9c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM5LTctMS0xLTIzOTAwOQ_1b80b552-0a3e-409f-aa83-ca6836166876"
      unitRef="usd">0</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="ic7cfbaeb1387403689ac26389c2117c8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM5LTktMS0xLTIzOTAwOQ_e6a15d41-4da4-4a52-a913-4942f700c15a"
      unitRef="usd">0</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i6613a24a2ca74795845a7f065003a508_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzM5LTExLTEtMS0yNDAwOTU_c5382d00-62a1-4d2e-ab69-5357c8678a2f"
      unitRef="usd">1279700000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i3ef264a2971a4d6d9632968955a88874_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzQwLTEtMS0xLTIzOTAwOQ_da2a9448-b42d-4f99-8d50-6e85f01fed48"
      unitRef="usd">548100000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherLongTermInvestments
      contextRef="i86203110a3b4409f801853ea6da76a28_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzQxLTEtMS0xLTIzOTAwOQ_bb83ed00-347f-49df-8bac-d65e5358d855"
      unitRef="usd">771500000</us-gaap:OtherLongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i3ef264a2971a4d6d9632968955a88874_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToxMDQ1NWJjOWJiM2I0NzBhYTZkZWE4N2EwZjc0ZGJmNC90YWJsZXJhbmdlOjEwNDU1YmM5YmIzYjQ3MGFhNmRlYTg3YTBmNzRkYmY0XzQyLTEtMS0xLTI0MDEwOA_d72331f4-28b9-4eb9-b834-114a457f7ad7"
      unitRef="usd">3212600000</us-gaap:LongTermInvestments>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzI3NDg3NzkxMDIxNDg_4e9589bb-28ce-48a5-8666-6480c6314169">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes certain fair value information at December&#160;31, 2022 and 2021 for our short-term and long-term debt:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term commercial paper borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,498.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,492.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,492.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, including current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(14,740.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12,329.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12,329.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,884.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,157.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,157.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CommercialPaper
      contextRef="i05a9e0f210644523adfae49f8876648c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzMtMS0xLTEtMjM5MDkz_e967ba24-face-44a0-8dec-9b1bbbf289ac"
      unitRef="usd">1498000000</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="ib1ea8deb8e384d8cb4e5f60294c5ed92_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzMtMy0xLTEtMjM5MDkz_1f27587f-e794-465f-b943-d2a18dd7a397"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i19b69bc057c7444085abf4374f69f116_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzMtNS0xLTEtMjM5MDkz_b77d5000-2d92-4b4b-95b6-bcdc53491ab0"
      unitRef="usd">1492000000</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="iedff9c53d09a4160b981746e70812997_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzMtNy0xLTEtMjM5MDkz_83f391f0-dce0-4bf2-9b7a-e43dfbf3dbd2"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i7b78813a7f544e37b44ae5f03d274d1e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzMtOS0xLTEtMjM5MDkz_8badb64c-1769-4d52-bf1e-63744b4949a3"
      unitRef="usd">1492000000</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i7159491c93374658b5b5847e6ac5edf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzQtMS0xLTEtMjM5MDkz_6024933f-6275-4cda-8c8f-a0f5b61ed509"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="if9001871d7424666bd9d0957d8242b6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzQtMy0xLTEtMjM5MDkz_7eebe48a-e007-481a-909e-e5ddb46c7c8a"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="iab54aa3b8b47409280b75c28d3043c2f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzQtNS0xLTEtMjM5MDkz_7c45d7fb-906f-4fac-a33f-5b45b1a62da3"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i1028e48517574b909d8fcf57e1818f87_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzQtNy0xLTEtMjM5MDkz_ee9176cf-d809-45ac-95b7-0cfc3ab32e7e"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i39ef4f84d9484b978fdf61e96ab0edaa_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzQtOS0xLTEtMjM5MDkz_67133c1c-6713-4346-b352-0b29ec93b1db"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:LongTermDebt
      contextRef="ib2046b6b3eed4ac6b751298dc54b230f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzYtMS0xLTEtMjM5MDkz_07d80d4c-0ed0-4ff4-beb6-2ac0042c2427"
      unitRef="usd">14740600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4c6d39fa7dff407a9bb5b5c2e98c8f37_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzYtMy0xLTEtMjM5MDkz_6779885f-6fda-419d-ba99-3b788017e10f"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if819ebce2b824e4f956b1fc03a244870_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzYtNS0xLTEtMjM5MDkz_f95ae30d-585b-4d5f-832c-3cd25475750c"
      unitRef="usd">12329300000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6d41b93e38c04495a8c9e35a8f93a51b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzYtNy0xLTEtMjM5MDkz_9508e2bd-cbdd-4d56-a4bd-81ff50cb2483"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i7a6cadf85ae74e19b0b4b3d94566c950_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzYtOS0xLTEtMjM5MDkz_82d8d8ac-dd67-4769-a3d1-5380bf579817"
      unitRef="usd">12329300000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3ef264a2971a4d6d9632968955a88874_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzctMS0xLTEtMjM5MDkz_b7261875-8dab-4dc2-aeea-20a078542e60"
      unitRef="usd">16884700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic1d701e8a7d846deb5dfed51dc19420e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzctMy0xLTEtMjM5MDkz_f0325c5d-a072-4d5b-a7e3-ab6e79046294"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6e3bd9c97de44684a6f54ff2b763dce6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzctNS0xLTEtMjM5MDkz_cc9a720d-54b5-4756-8af2-0c7c8d9c446a"
      unitRef="usd">18157700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6543e2dc57fc4942a80a5c4b47c6a4d6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzctNy0xLTEtMjM5MDkz_39eda0fb-c067-4c36-b6be-a0b0d8279f09"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="icbf3bc2cf6f14b3e986aed5486e859be_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1ZDNjODFiYjQ0YzM0NmFiYTFiODgyMGIyMDQzOTU2ZS90YWJsZXJhbmdlOjVkM2M4MWJiNDRjMzQ2YWJhMWI4ODIwYjIwNDM5NTZlXzctOS0xLTEtMjM5MDkz_2c9b3cb5-cfff-405f-ade2-1c560dd22c14"
      unitRef="usd">18157700000</us-gaap:LongTermDebt>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE0ODY5_dd567325-5086-4c66-b89c-f909b41e439b">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions.&#160;We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their investment grade credit ratings.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE5NzkxMjA5MzMxMjc1_4bc036f3-392d-4f02-90ef-40b3ca0af179"
      unitRef="usd">422100000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE5NzkxMjA5MzMxMjgz_65bafaa3-caf0-468c-b3b4-550696d74d8f"
      unitRef="usd">550500000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE0ODUx_610af501-11f7-44b5-a2bf-03451ca588ce">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive income (loss) (see Note 17) and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive income (loss) (see Note 17). Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.&lt;/span&gt;&lt;/div&gt;We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, Chinese yuan, Japanese yen, and Swiss franc). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#x2013;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments.In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows.We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss) (see Note 17) and, upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:AverageRemainingMaturityOfForeignCurrencyDerivatives1
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzQyNDY_b17963e4-e33b-41c3-8e45-ef043016dd36">P12M</us-gaap:AverageRemainingMaturityOfForeignCurrencyDerivatives1>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzI3NDg3NzkwODYxMDA_f4deba9f-f124-4e6e-9f7b-cadd3e20d10c">At December&#160;31, 2022, we had outstanding foreign currency forward commitments as follows, all of which have settlement dates within 180 days:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.487%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sell&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,516.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,369.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,371.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,575.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chinese yuan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,139.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,212.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;British pounds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzQ3NjI_f1698e55-14db-4571-a1a6-41c94a8c660d">P180D</us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ie250a0992fc5431f969a7964f8245fdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzEtMC0xLTEtMjMzNzI4_b81f7fc1-67d4-4c6e-9069-131645d8eeaf"
      unitRef="usd">2516200000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="ie250a0992fc5431f969a7964f8245fdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzEtMi0xLTEtMjMzNzMy_654b549b-5d25-46b8-86e3-d108498b7125"
      unitRef="eur">2369200000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i7e9395f4903c4d1e8256befb608125af_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzItMC0xLTEtMjMzNjc4_82d6b93c-b1bf-473d-bf76-4cce3432e768"
      unitRef="eur">3371100000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i7e9395f4903c4d1e8256befb608125af_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzItMi0xLTEtMjMzNjkw_96c046b2-de00-4a2b-98a7-9c85c4d9ed04"
      unitRef="usd">3575300000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i3ea07b15fab64564acb30e6db85e870e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzMtMC0xLTEtMjMzNzQw_05eb8a81-9569-410c-b5e3-d32d802b99b2"
      unitRef="usd">199800000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i3ea07b15fab64564acb30e6db85e870e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzMtMi0xLTEtMjMzNzQ4_3e2c2a08-aa40-4001-9d41-8f2b80d11425"
      unitRef="cny">1396200000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i94c6020cd3ae44f998a4fa76cd815d56_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzQtMC0xLTEtMjMzNzUy_97654e94-fb8a-460e-a548-a7ac1550373e"
      unitRef="jpy">14139900000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i94c6020cd3ae44f998a4fa76cd815d56_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzQtMi0xLTEtMjMzNzYw_ef7ef507-97c1-43dd-8a5f-df0be7df894c"
      unitRef="usd">105300000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="iceee439d84744b8d804526bc0f2adeab_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzUtMC0xLTEtMjMzNzcw_901ab0f8-44cd-4682-a03f-35737561635b"
      unitRef="usd">90900000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="iceee439d84744b8d804526bc0f2adeab_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzUtMi0xLTEtMjMzNzc2_57df1571-14a9-4acf-8cc9-66a3ea12392a"
      unitRef="jpy">12212200000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i0e20eef33fbc4dec93f944ed6836a620_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzYtMC0xLTEtMjMzNzgw_b40c0de6-3abb-4d4a-b4e4-b4b7470f03aa"
      unitRef="gbp">207100000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i0e20eef33fbc4dec93f944ed6836a620_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzYtMi0xLTEtMjMzNzg0_b59c722a-ac46-4b17-b4f8-29e370d1a00e"
      unitRef="usd">254700000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i61a09d5cb8a14ccea8468a476ea53884_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzktMC0xLTEtMjM4MTQ5_c1e11e3c-7451-468a-acf8-944238a07626"
      unitRef="chf">101400000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i61a09d5cb8a14ccea8468a476ea53884_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTo1M2E2NWQxMjY5MzE0YTc1ODYzMTliMzg1MjNlODc1Yy90YWJsZXJhbmdlOjUzYTY1ZDEyNjkzMTRhNzU4NjMxOWIzODUyM2U4NzVjXzktMy0xLTEtMjM4MTU4_bf8a73cb-6cb4-4511-b763-d6ea9cfab7e5"
      unitRef="usd">109300000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:LongTermDebt
      contextRef="ibf02b938757d412587be87a02a84f028_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzQ5OTk_f63c1f66-354b-45b1-adac-995e188b94fd"
      unitRef="usd">6830000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ifd3cce905838492e986c48f76166193c_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzUwMDY_055b5f54-33e7-4878-9b13-54e48228d6a9"
      unitRef="usd">7900000000</us-gaap:LongTermDebt>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzUwNDk_16255cc8-7149-4ebc-8e08-7aa2549c984c"
      unitRef="usd">5450000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzUwNTY_a4d7b7d5-ac3e-4361-94c3-502cca17ffd9"
      unitRef="usd">5790000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i4778e0d847b8442d93aeec9ae0fcc5af_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzUyODE_ed6ad4bd-cdf6-483e-b2ae-8ddb250173ac"
      unitRef="usd">1020000000.00</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i5cef174a144b4c2b89d92be601c8cc4f_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzUzMTg_17001ad5-3e41-4aff-9f2c-80c7c739fad2"
      unitRef="usd">1000000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="if6c65f3c28a542199950c644aa1cf261_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE2NDkyNjc0NTcwMjM_db0d6aaf-d3bd-4f42-a811-e9de76094172"
      unitRef="eur">325000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i8f3aff17db1c4acb85c8851f9450065d_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzEwNDQ1MzYwNDc5ODQw_0309fa9c-057a-4930-9cb9-043e92ce790c"
      unitRef="cny">1820000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzcwOTE_d58138e3-5363-465b-93fa-813fb6fe7387"
      unitRef="number">0.10</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia85b3dcb7d4541c7aad67c44e3261dea_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzc4MDA_a8f3150d-f5a7-44d9-bafd-399424aca3d2"
      unitRef="usd">1850000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE0ODc2_8c6f02fc-a071-4fdb-a4ab-7d1cc9b9e697">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following effects of risk-management instruments were recognized in other&#x2013;net, (income) expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from hedged fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(209.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;209.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;191.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;216.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i21e6e625c3cb4498ba3bf6924f8d2408_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzItMS0xLTEtMTk3MTgy_9b20d986-0ab6-498b-a371-bb5915cd6944"
      unitRef="usd">209800000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ic7662cc39cfe4433b0594d699b335670_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzItMy0xLTEtMTk3MTgy_652668da-cedd-4c9f-8b6a-6bce84735b59"
      unitRef="usd">78500000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i6798f46f87f74360b20909f04395afc3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzItNS0xLTEtMTk3MTgy_f30b0b8c-8a13-4142-ae6b-20590ec3fd25"
      unitRef="usd">-86900000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="idbbe46ca06b34c009dcda97ccf3beb64_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzMtMS0xLTEtMTk3MTgy_5103bf7d-fa51-4d1f-9247-fe7b882f435c"
      unitRef="usd">-209800000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="if399b1d939d243708da92494b6325f95_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzMtMy0xLTEtMTk3MTgy_30b32fa4-4537-4991-8b52-44256b9df424"
      unitRef="usd">-78500000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i4cdf044d78494e7694b33040bfab47e7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzMtNS0xLTEtMTk3MTgy_3f222806-0984-4bd1-bfdb-42c59148ac95"
      unitRef="usd">86900000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="idbbe46ca06b34c009dcda97ccf3beb64_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzUtMS0xLTEtMTk3MTgy_29b26d7b-d68e-4646-8d5e-53b61628cfaf"
      unitRef="usd">16500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="if399b1d939d243708da92494b6325f95_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzUtMy0xLTEtMTk3MTgy_c265f261-db6f-4f4d-b3d1-0c6d60f77470"
      unitRef="usd">16600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i4cdf044d78494e7694b33040bfab47e7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzUtNS0xLTEtMTk3MTgy_c4c4b201-a8ad-4824-a437-6533482bef8b"
      unitRef="usd">16400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i7e9fe4a4a4094271b4b30ac4a4625c89_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzYtMS0xLTEtMTk3MTgy_84404e29-810c-4d8a-8630-d4560666cd16"
      unitRef="usd">8600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i912fb880c8bf46f58edb6cd6fdf00e0d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzYtMy0xLTEtMTk3MTgy_35ad745c-aeb7-4aa9-9b12-ef4d6f03791f"
      unitRef="usd">41800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i971ee4b6404c4ed885962afd497cc6c4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzYtNS0xLTEtMTk3MTgy_53b74e84-3f61-44a9-8402-9be2cae14aae"
      unitRef="usd">-102400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i7af19dae3f054b648cdca7471fa01367_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzctMS0xLTEtMTk3MTgy_682e6fe0-fade-4838-bb80-f9af3ff59824"
      unitRef="usd">-191300000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i7fa81b5097b2466db639a8a9b4205905_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzctMy0xLTEtMTk3MTgy_1679aaa4-e111-423d-ace6-5d8566d1c50a"
      unitRef="usd">-204600000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i9a1804ba514d421fa041c53b09e064df_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzctNS0xLTEtMTk3MTgy_0af58a56-d789-4784-884c-e5c5402873bd"
      unitRef="usd">123700000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzgtMS0xLTEtMTk3MTgy_0d9daa5d-43da-401b-8978-34c79b93981d"
      unitRef="usd">-216400000</lly:DerivativeInstrumentsGainLossRecognized>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzgtMy0xLTEtMTk3MTgy_ccd29b01-bd20-4aac-8768-54022b44356d"
      unitRef="usd">-263000000.0</lly:DerivativeInstrumentsGainLossRecognized>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZToyNWUxOTRiYTM3ODM0YWY5YTg5OTM3YjNiNWRmNDg3Yy90YWJsZXJhbmdlOjI1ZTE5NGJhMzc4MzRhZjlhODk5MzdiM2I1ZGY0ODdjXzgtNS0xLTEtMTk3MTgy_6694996a-6dc5-43b5-a9b7-abad58e521c2"
      unitRef="usd">209700000</lly:DerivativeInstrumentsGainLossRecognized>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE0ODQ0_82b80dcf-507b-4363-9544-a4b82dc4682d">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;324.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(404.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;52.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(15.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;391.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE0ODQ0_ef31cb34-ce64-419a-8db1-8134028b9837">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;324.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(404.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;52.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(15.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;391.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i544fc2f9696049b4b7cbe0345f8fde19_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzItMS0xLTEtMTk3MTgy_8a7bb25b-4a42-4a3e-8106-ad4898aa4949"
      unitRef="usd">324900000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i526dbe18caa14f808c563a07c118fdec_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzItMy0xLTEtMTk3MTgy_5921bbcc-ca77-4758-92f6-8a548ddf3172"
      unitRef="usd">435000000.0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i5ad852d92b9f48d787f3e17319eca10c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzItNS0xLTEtMTk3MTgy_45f21306-7aaa-419d-8c0f-82b71e145bed"
      unitRef="usd">-404000000.0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="idb73f5b531de4d949faf24baf79a438d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzMtMS0xLTEtMTk3MTgy_aff14e8f-b952-4a5e-8109-ebe58ff38c83"
      unitRef="usd">52000000.0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i813ae3ce219c4fb99714b7ffced341ac_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzMtMy0xLTEtMTk3MTgy_5389a8d5-a68b-46fa-ada4-6199b9b2e932"
      unitRef="usd">213700000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i2a07487d016f4962ae2b2023e270baed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzMtNS0xLTEtMTk3MTgy_c40bb61a-d282-400c-9371-dfa707041002"
      unitRef="usd">-207900000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie637e63779d34f95ab0e1211537d3d90_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzQtMS0xLTEtMjMyMDM0_4e60d0af-a7ff-4d5d-a961-f8cd0562239a"
      unitRef="usd">-15400000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3222ddf3a8ac4302b584f8b59946a14b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzQtMy0xLTEtMjMyMDcy_5c118fa0-b5f4-4f81-bb31-a6f3470905a9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ic146904e7a5d4de8860196733919670c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzQtNS0xLTEtMjMyMTIz_7be1b604-2d6c-4112-addd-e54293015bf0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i4ace96eae50846258f2aa585eca6aab7_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzUtMS0xLTEtMTk3MTgy_a20c4231-b08a-464b-8b3d-963c7e92747e"
      unitRef="usd">391500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie36116f601d041c795e77b729ac2bd12_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzUtMy0xLTEtMTk3MTgy_b3a9a56a-82fc-474a-af81-cb87de9f32b6"
      unitRef="usd">97600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i0ecf981515d64142ae2c545ec8473910_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzUtNS0xLTEtMTk3MTgy_0905c32b-fb27-44dd-9d6e-8db300af0756"
      unitRef="usd">-110900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="idb73f5b531de4d949faf24baf79a438d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzYtMS0xLTEtMTk3MTgy_670596db-b608-4e29-bfa5-b5eaf1c8862d"
      unitRef="usd">29800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i813ae3ce219c4fb99714b7ffced341ac_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzYtMy0xLTEtMTk3MTgy_19473864-0cb9-43a5-8c91-750c3b944b47"
      unitRef="usd">42300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i2a07487d016f4962ae2b2023e270baed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTphNzlkZWQ4ZDExNGI0ZTE2YjY0NDMzM2I2ZDNlMmZlMi90YWJsZXJhbmdlOmE3OWRlZDhkMTE0YjRlMTZiNjQ0MzMzYjZkM2UyZmUyXzYtNS0xLTEtMTk3MTgy_e9446d68-5bb0-4d53-948a-6565b6916f79"
      unitRef="usd">-53700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzg1NDY_b6e6069a-805e-40a8-904d-282822cdda5c"
      unitRef="usd">-16800000</us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90ZXh0cmVnaW9uOmRjZDg3ODZhNDg4YTRmMTlhNGE0OTBjNGFkYzJjZTUxXzE0ODMz_53aaae84-7268-4589-bffa-22e207b8c0fd">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes certain fair value information at December&#160;31, 2022 and 2021 for risk-management assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i5197ef213a4645978df5f719742ae403_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzctMS0xLTEtMTk3MTgy_f21d50f2-99d6-493d-b84b-f85c69f4b547"
      unitRef="usd">134300000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i50e4a751923845029648d84b7970c686_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzctMy0xLTEtMTk3MTgy_2550955a-1c69-4562-9c5e-fa592a50cc08"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ife02be8abfd44063a559e3b91d3451e8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzctNS0xLTEtMTk3MTgy_8e49c9cd-0111-43ae-af87-13e679348d7a"
      unitRef="usd">134300000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i96ba97b94ac14d2785bd7fa84c035ba6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzctNy0xLTEtMTk3MTgy_d1bddf79-4db1-4df2-88a7-3b921899076a"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i4f476c609f70478db4f2ecd35dc8eb68_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzctOS0xLTEtMTk3MTgy_ac40938d-62ac-49bf-af42-9b84e3bc0b7f"
      unitRef="usd">134300000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i22c86b90cca74ee28587fd7b463de73e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzktMS0xLTEtMTk3MTgy_df904694-1456-417b-b689-61e0ea991cac"
      unitRef="usd">162900000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i8155874edc7f4d55bd1452edf423993c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzktMy0xLTEtMTk3MTgy_ef796c2f-cf50-4b11-964c-b4dc0541117d"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i36992cb2187547dfa9f7e206d125f62d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzktNS0xLTEtMTk3MTgy_f409d366-efe9-4d6d-81c5-fd112f42ec11"
      unitRef="usd">162900000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="if2840be8f4a94f848fa12213edee040f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzktNy0xLTEtMTk3MTgy_0350c810-2fc0-49d4-af1d-1a49848ca5f8"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="if8790eb3b0704b11bbbdffca311b63b8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzktOS0xLTEtMTk3MTgy_eca9bdbe-3a44-4c55-90ed-bb48b787ba71"
      unitRef="usd">162900000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i22c86b90cca74ee28587fd7b463de73e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEwLTEtMS0xLTE5NzE4Mg_fad954fe-3840-470d-943a-ac7baaf0a188"
      unitRef="usd">246000000.0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i8155874edc7f4d55bd1452edf423993c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEwLTMtMS0xLTE5NzE4Mg_e998b429-d1f5-47a4-bff1-1508cf78d041"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i36992cb2187547dfa9f7e206d125f62d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEwLTUtMS0xLTE5NzE4Mg_a2b24393-2470-4821-a0fc-c4db09003fd5"
      unitRef="usd">246000000.0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="if2840be8f4a94f848fa12213edee040f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEwLTctMS0xLTE5NzE4Mg_b18751f0-5752-4a0b-a6ea-08d22af9e419"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="if8790eb3b0704b11bbbdffca311b63b8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEwLTktMS0xLTE5NzE4Mg_5674efe5-ed5f-4f08-bcb7-f7691cc701bf"
      unitRef="usd">246000000.0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i36c4a0d2b7e245eabd1f07bf17e8efea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEzLTEtMS0xLTE5NzE4Mg_013d0fa9-7724-48aa-9fd3-24437344b185"
      unitRef="usd">67600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i4c71c6fa987a4120a284c9b9145e27e7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEzLTMtMS0xLTE5NzE4Mg_278d17df-6d82-4061-b338-3e43b60b7709"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i3b33940746b24ac0b52755c11e6154f0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEzLTUtMS0xLTE5NzE4Mg_959b114f-eddd-4e36-af66-18020bd8e64b"
      unitRef="usd">67600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ia5b2741087f34d8badb76a8ebcb2b3fd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEzLTctMS0xLTE5NzE4Mg_7546dbb9-ca61-49cd-bd07-b936d6055953"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i7b1936dd4cad4f59a9112c82012622aa_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzEzLTktMS0xLTE5NzE4Mg_2cafc658-0c6b-4eca-a912-7f4dd43c1d69"
      unitRef="usd">67600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ic11c3f50a6ad41aaaa6ec682a1a2bf69_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzE5LTEtMS0xLTE5NzE4Mg_b5c7f65b-f516-4bb1-b66e-57dd6ab7c9d2"
      unitRef="usd">53100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i32517cdb203a46dbb43f88560fafdc6e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzE5LTMtMS0xLTE5NzE4Mg_b90c1c37-f2e5-4a06-a2ef-f1f2de9a68ee"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i233ef483a0f64f039b86216aee108bfa_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzE5LTUtMS0xLTE5NzE4Mg_65e05760-da86-4a46-9e67-6dc6982e3eab"
      unitRef="usd">53100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i2a806ed2d9564a57a182b6ed0c5fe28f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzE5LTctMS0xLTE5NzE4Mg_5f4e6dbc-dd01-455f-8b59-a1f8953fb3f8"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i2ea6da8b55e34d8189b756c1edd72ca2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzE5LTktMS0xLTE5NzE4Mg_c304611e-d914-491f-9c2c-1fac09bd57b9"
      unitRef="usd">53100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i52cdc2ce968e46748102e49a49b2747c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTEtMS0xLTIzMzAxNQ_f0247580-9f0e-4c98-ba4f-b089f0e62626"
      unitRef="usd">38300000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i5626e89be6054126b0e88da30ec22edb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTMtMS0xLTIzMzAyOA_1b9de234-0843-457a-858e-64333f86ce79"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i76ad9553f0574ea0869f164b30ead95a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTUtMS0xLTIzNDQzOA_9c0a7f7f-09ea-40c7-afa1-9462c961422e"
      unitRef="usd">38300000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ie253e8109f6b4b66b779831838983108_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTctMS0xLTIzMzAzOQ_348ea872-c381-45a4-b3b1-03b277febd44"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i4eb0b46018c54f5c946184e340c3804d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTktMS0xLTIzMzA1MQ_574d598e-32b9-41d5-9a21-107670f64248"
      unitRef="usd">38300000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i5172caf5b4c745e49a779865e4df8b6d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTEtMS0xLTE5NzE4Mg_9d38c164-dccd-4381-b0d5-35ff77071f40"
      unitRef="usd">26600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i6e87bdf692d44f63b49e30cb351f8be1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTMtMS0xLTE5NzE4Mg_12628ad2-bafd-4ab0-aeee-29bb10c6f457"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i2277951e04244daea0a2517c6b972ce4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTUtMS0xLTE5NzE4Mg_8f2a1b92-8ebc-41fe-9934-b212366b0201"
      unitRef="usd">26600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i177a13f9ceb04b04ac9f5de0f3c10743_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTctMS0xLTE5NzE4Mg_04190d2b-271b-41bc-8ba3-1994b39e1daf"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i1960642f8dbc465babdbb93b28ddece6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzIyLTktMS0xLTE5NzE4Mg_ec777679-b73f-4107-9ce2-6df9c53a788d"
      unitRef="usd">26600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i5172caf5b4c745e49a779865e4df8b6d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI0LTEtMS0xLTE5NzE4Mg_bc2ec4db-8c1c-409e-8613-b1e186de781d"
      unitRef="usd">21500000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i6e87bdf692d44f63b49e30cb351f8be1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI0LTMtMS0xLTE5NzE4Mg_a4cb39fe-70f7-428d-aa56-ca431e92b950"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i2277951e04244daea0a2517c6b972ce4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI0LTUtMS0xLTE5NzE4Mg_211102cd-d158-40e6-9b6f-3f86f8c89cb2"
      unitRef="usd">21500000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i177a13f9ceb04b04ac9f5de0f3c10743_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI0LTctMS0xLTE5NzE4Mg_cf225677-4b64-4bac-af66-6d2f00af09da"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i1960642f8dbc465babdbb93b28ddece6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI0LTktMS0xLTE5NzE4Mg_c76f1d41-1f7c-491e-a8ad-a0326151e1f9"
      unitRef="usd">21500000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ib2046b6b3eed4ac6b751298dc54b230f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI2LTEtMS0xLTE5NzE4Mg_4cf1971a-1e1e-46f6-9abe-76bc528e27e1"
      unitRef="usd">39500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i4c6d39fa7dff407a9bb5b5c2e98c8f37_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI2LTMtMS0xLTE5NzE4Mg_8452d57b-6ad0-45e3-bef9-2edd93ae7644"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="if819ebce2b824e4f956b1fc03a244870_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI2LTUtMS0xLTE5NzE4Mg_8fa3a85b-32b9-4966-8b8d-8192392e9ef3"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i6d41b93e38c04495a8c9e35a8f93a51b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI2LTctMS0xLTE5NzE4Mg_134c7548-6da4-44ef-816b-4b8262abfebd"
      unitRef="usd">39500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i7a6cadf85ae74e19b0b4b3d94566c950_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI2LTktMS0xLTE5NzE4Mg_663fbc79-1e86-4c0f-b962-1404b9b8103f"
      unitRef="usd">39500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib2046b6b3eed4ac6b751298dc54b230f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI3LTEtMS0xLTE5NzE4Mg_36a4548d-287f-4a7c-8cd4-a75788da5968"
      unitRef="usd">70600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4c6d39fa7dff407a9bb5b5c2e98c8f37_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI3LTMtMS0xLTE5NzE4Mg_9ca62ba5-a52f-4049-b851-f561e85f6f8d"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if819ebce2b824e4f956b1fc03a244870_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI3LTUtMS0xLTE5NzE4Mg_98dfd8c6-32c4-4756-8ec5-11805a1aa1ca"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6d41b93e38c04495a8c9e35a8f93a51b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI3LTctMS0xLTE5NzE4Mg_bef4defb-f3ac-411d-bc6f-24b91d91ddbf"
      unitRef="usd">70600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7a6cadf85ae74e19b0b4b3d94566c950_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzI3LTktMS0xLTE5NzE4Mg_03e26590-de5d-4348-95e8-64aebc90231d"
      unitRef="usd">70600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ia14954f687c6405ab00a4364d579fd9a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMyLTEtMS0xLTE5NzE4Mg_22320a5c-eb0b-42ef-a4c3-218a0af5fcae"
      unitRef="usd">4800000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i588da95a877d48e8954f17fe68f586a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMyLTMtMS0xLTE5NzE4Mg_ce09f582-5386-4c1b-95dd-57ab177144d2"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i96d7fb6d960d43a18ef69089fff51e0e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMyLTUtMS0xLTE5NzE4Mg_38159d67-e2cb-4aac-8db3-09f4608ce077"
      unitRef="usd">4800000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i0180c6864ed746a8b3d870461649834a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMyLTctMS0xLTE5NzE4Mg_89bbf48f-9769-4447-aaf8-0007fb78c5d0"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ia760ea075df24dcfa76244f5eb52e815_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMyLTktMS0xLTE5NzE4Mg_4c4925c0-3e8c-48fe-baf1-7b4d604f4894"
      unitRef="usd">4800000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ia14954f687c6405ab00a4364d579fd9a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMzLTEtMS0xLTE5NzE4Mg_d942b0dc-b34e-48df-968b-9f95ec4ae240"
      unitRef="usd">78300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i588da95a877d48e8954f17fe68f586a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMzLTMtMS0xLTE5NzE4Mg_27a6f7d2-a148-4763-8b7b-a94d4a286179"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i96d7fb6d960d43a18ef69089fff51e0e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMzLTUtMS0xLTE5NzE4Mg_ae7fd521-e40c-4fb6-9d85-80f920bd482a"
      unitRef="usd">78300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i0180c6864ed746a8b3d870461649834a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMzLTctMS0xLTE5NzE4Mg_e898817c-9429-412d-bdbb-038d37be23b9"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ia760ea075df24dcfa76244f5eb52e815_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzMzLTktMS0xLTE5NzE4Mg_c57f0b72-b3c0-4c0f-b264-28c7daeee5f6"
      unitRef="usd">78300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ia14954f687c6405ab00a4364d579fd9a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM1LTEtMS0xLTE5NzE4Mg_b650ab53-eace-4675-a6c9-97d22dbea44f"
      unitRef="usd">7600000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i588da95a877d48e8954f17fe68f586a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM1LTMtMS0xLTE5NzE4Mg_0524a34c-0326-4c38-8a15-f27219561238"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i96d7fb6d960d43a18ef69089fff51e0e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM1LTUtMS0xLTE5NzE4Mg_35b6d254-7b77-4094-ad5d-c2dbf7c3d403"
      unitRef="usd">7600000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i0180c6864ed746a8b3d870461649834a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM1LTctMS0xLTE5NzE4Mg_7b593424-0948-4fa2-8d2f-02cd1c3372a4"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ia760ea075df24dcfa76244f5eb52e815_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM1LTktMS0xLTE5NzE4Mg_18608297-c8eb-4937-8ab9-8a831a39f740"
      unitRef="usd">7600000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="id945978cb9e34780a08b5b17c28c3dae_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM3LTEtMS0xLTE5NzE4Mg_76e4041f-75d0-474a-87e7-9ef4f37e83db"
      unitRef="usd">49200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i377eee7df67949f38f58d5844a15b18c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM3LTMtMS0xLTE5NzE4Mg_5c130887-bd04-49f2-9444-8e4cfafb0dbd"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ib4ba21050cbf4b33a8dce7b1f2a8fba8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM3LTUtMS0xLTE5NzE4Mg_91301aee-7777-44ef-8427-fb699668c6ef"
      unitRef="usd">49200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i15f875e3e2144b5391ee55f902226825_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM3LTctMS0xLTE5NzE4Mg_c2d726b6-a8bb-4184-9ac4-2b8f79a3257e"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i1b5c16eeb8a64c579a2fa0a33daa5b36_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM3LTktMS0xLTE5NzE4Mg_757d9be9-b2cc-4b4a-a4aa-98d573ba7a24"
      unitRef="usd">49200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="id945978cb9e34780a08b5b17c28c3dae_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM4LTEtMS0xLTE5NzE4Mg_4edd3857-dada-4824-8f80-103b9796f4eb"
      unitRef="usd">31700000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i377eee7df67949f38f58d5844a15b18c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM4LTMtMS0xLTE5NzE4Mg_f543cdb6-16ee-4537-83c4-4c7dc9e2cad3"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ib4ba21050cbf4b33a8dce7b1f2a8fba8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM4LTUtMS0xLTE5NzE4Mg_d718ac06-3c9c-4839-947c-93925250642f"
      unitRef="usd">31700000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i15f875e3e2144b5391ee55f902226825_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM4LTctMS0xLTE5NzE4Mg_909c2a17-8d71-4205-b25b-f2290016a195"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i1b5c16eeb8a64c579a2fa0a33daa5b36_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzM4LTktMS0xLTE5NzE4Mg_0e45fa6b-c969-4140-9be8-8535cd1c8a35"
      unitRef="usd">31700000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i314c0f6b364b4833a2bf7dc6a7d484ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQxLTEtMS0xLTE5NzE4Mg_44a65ae8-a404-4bbd-a286-163ffab487f6"
      unitRef="usd">31300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i64c6a536ce224bd0a7d1bacbad4b9f82_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQxLTMtMS0xLTE5NzE4Mg_775335ea-f161-4240-9217-5a3c9ac9f1c0"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i85bddc6b22b045908bcc27ca039aa3f2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQxLTUtMS0xLTE5NzE4Mg_1c9e7b10-cb06-41a1-8cff-b35a73f1da24"
      unitRef="usd">31300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i233603743e32403cba2427b98f94cd71_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQxLTctMS0xLTE5NzE4Mg_b18fb8b3-281c-44a4-bdb2-2b1834a78d46"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ibb4bb153c0824966869a2e351056f2e3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQxLTktMS0xLTE5NzE4Mg_36a2a9bc-fe36-484e-960e-fcd4957f5ba2"
      unitRef="usd">31300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i314c0f6b364b4833a2bf7dc6a7d484ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQyLTEtMS0xLTE5NzE4Mg_430b7d51-1f24-42c9-934d-15a5b39ed4ba"
      unitRef="usd">1200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i64c6a536ce224bd0a7d1bacbad4b9f82_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQyLTMtMS0xLTE5NzE4Mg_955dee60-e9ab-4d08-984b-d7e065df420c"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i85bddc6b22b045908bcc27ca039aa3f2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQyLTUtMS0xLTE5NzE4Mg_bd0db6bd-5d20-44df-ad40-0be935d68705"
      unitRef="usd">1200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i233603743e32403cba2427b98f94cd71_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQyLTctMS0xLTE5NzE4Mg_3a804252-6ffb-41ed-b7a8-72c1ccf06046"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ibb4bb153c0824966869a2e351056f2e3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQyLTktMS0xLTE5NzE4Mg_94320972-ad2a-4ec7-9064-69e95983b7b9"
      unitRef="usd">1200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i9cd010e314334386addf3e1c41d3fba9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ1LTEtMS0xLTE5NzE4Mg_57a252cb-8392-433e-8445-47ca66394d28"
      unitRef="usd">33200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ifc2482a53a724280953dce9975c1774d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ1LTMtMS0xLTE5NzE4Mg_d8265275-e1e3-498f-805c-a0dfd5df8f44"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ie2d3bf8b263f4308af9996212c4ea414_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ1LTUtMS0xLTE5NzE4Mg_828a30c5-f545-4d92-ad72-700b594c9e6b"
      unitRef="usd">33200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ia46188499bcd4b979e789d0ac42002c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ1LTctMS0xLTE5NzE4Mg_8d63572c-4033-4699-b53d-89e77af4bc17"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i863c16ddfefc491d81ad6914ccd53e60_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ1LTktMS0xLTE5NzE4Mg_0bde5a6a-d649-4856-8885-39c068dde619"
      unitRef="usd">33200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i9cd010e314334386addf3e1c41d3fba9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ2LTEtMS0xLTE5NzE4Mg_9a2efa6a-7472-43ce-8195-a4244ad94bfe"
      unitRef="usd">1300000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ifc2482a53a724280953dce9975c1774d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ2LTMtMS0xLTE5NzE4Mg_4f19fc34-066c-429a-9740-48bf3e26fbf4"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ie2d3bf8b263f4308af9996212c4ea414_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ2LTUtMS0xLTE5NzE4Mg_b0b57416-9d9e-448a-9e1d-e8a3c8203ba1"
      unitRef="usd">1300000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ia46188499bcd4b979e789d0ac42002c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ2LTctMS0xLTE5NzE4Mg_3fff9f4c-addb-4d44-9597-c2e5271dd221"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i863c16ddfefc491d81ad6914ccd53e60_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ2LTktMS0xLTE5NzE4Mg_e3d2b7c7-4214-4c00-94f8-7a4cd9ff28af"
      unitRef="usd">1300000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i80d6f9b361384095856711315cacf141_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ4LTEtMS0xLTE5NzE4Mg_50cfb1c7-5344-44cd-81dd-658e35ea1172"
      unitRef="usd">9900000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="iefe9492781434d5eb9e61902a0768540_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ4LTMtMS0xLTE5NzE4Mg_c2636e80-a9f8-4608-9043-14ee99ae52f1"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i7aabc6919dd54de293fd5ab586ac3010_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ4LTUtMS0xLTE5NzE4Mg_1ec81589-6e32-4620-98ab-102a6c0c3f4d"
      unitRef="usd">9900000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i19ce6f75fe844b619eed1f83ac0c0e45_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ4LTctMS0xLTE5NzE4Mg_0e5e4bca-209a-44e5-85ac-2a23d41113ff"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i039334735ea6463da706b51515b478f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ4LTktMS0xLTE5NzE4Mg_695a8ed8-4dbb-4d22-a794-8095cedc0025"
      unitRef="usd">9900000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i80d6f9b361384095856711315cacf141_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ5LTEtMS0xLTE5NzE4Mg_a848b475-591a-4f93-ad50-a78f0639e89e"
      unitRef="usd">35300000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="iefe9492781434d5eb9e61902a0768540_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ5LTMtMS0xLTE5NzE4Mg_05870226-5fc9-4a0c-91b5-dff3914cd32b"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i7aabc6919dd54de293fd5ab586ac3010_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ5LTUtMS0xLTE5NzE4Mg_cb16cbb3-e3b3-4848-9edc-b575259751c7"
      unitRef="usd">35300000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i19ce6f75fe844b619eed1f83ac0c0e45_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ5LTctMS0xLTE5NzE4Mg_68ad1152-b744-4f8c-95a9-ab69b6f0a515"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i039334735ea6463da706b51515b478f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzQ5LTktMS0xLTE5NzE4Mg_ba085289-9eae-486d-84fb-77ef36b2035e"
      unitRef="usd">35300000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3ef264a2971a4d6d9632968955a88874_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzUxLTEtMS0xLTE5NzE4Mg_719ab64a-2e4b-4ac0-854c-dfaf2dc8a61b"
      unitRef="usd">70500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic1d701e8a7d846deb5dfed51dc19420e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzUxLTMtMS0xLTE5NzE4Mg_b9dccd67-ad75-4966-96c7-fbfc6d87e377"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6e3bd9c97de44684a6f54ff2b763dce6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzUxLTUtMS0xLTE5NzE4Mg_31739321-303f-49f7-9738-d9115f3412a0"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6543e2dc57fc4942a80a5c4b47c6a4d6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzUxLTctMS0xLTE5NzE4Mg_4b892d09-59b8-4f3a-af47-9c1af21aa1c4"
      unitRef="usd">70500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icbf3bc2cf6f14b3e986aed5486e859be_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTIvZnJhZzpkY2Q4Nzg2YTQ4OGE0ZjE5YTRhNDkwYzRhZGMyY2U1MS90YWJsZTpkMTJkYjA5MjVhZWU0YTEwODg4NzNmOTlhNzZlNTFiZS90YWJsZXJhbmdlOmQxMmRiMDkyNWFlZTRhMTA4ODg3M2Y5OWE3NmU1MWJlXzUxLTktMS0xLTE5NzE4Mg_481d3d27-e9eb-4e6e-a26d-7f877fab5d9e"
      unitRef="usd">70500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzUyODM_4567e14b-7e07-499b-b0f7-ef1d430df9d4">Goodwill and Other Intangibles&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value to its carrying value is performed to determine the amount of any impairment. The change in goodwill during 2022 was primarily related to our acquisition of Akouos. See Note 3 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No impairments occurred with respect to the carrying value of goodwill for the years ended December&#160;31, 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of intangible assets other than goodwill at December&#160;31 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketed products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,922.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,589.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,332.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,987.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,229.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,758.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,957.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,622.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,334.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,056.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,289.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,766.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,871.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,871.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,925.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,925.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,829.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,622.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,206.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,981.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,289.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,691.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction (U.S., Europe, and Japan) and capitalized milestone payments. For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other finite-lived intangible assets consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies, and customer relationships from business combinations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D consists of the fair values of acquired IPR&amp;amp;D projects acquired in business combination, adjusted for subsequent impairments, if any. The costs of acquired IPR&amp;amp;D projects acquired directly in a transaction other than a business combination are capitalized as other intangible assets if the projects have an alternative future use; otherwise, they are expensed immediately. See Note 3 for significant acquired IPR&amp;amp;D projects that had no alternative future use. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the "income method," which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, analyst expectations, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&amp;amp;D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The decrease in acquired IPR&amp;amp;D intangibles in 2022 is due to the impairment of an intangible asset for GBA1 Gene Therapy (PR001). See Note 5 for additional information. This decrease was partially offset by acquired IPR&amp;amp;D assets recognized from the acquisition of Akouos. See Note 3 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&amp;amp;D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives are capitalized and are amortized primarily to cost of sales over their estimated useful lives, ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzQ4OTk_d5717d76-4a43-4c49-bf30-1707e388a603"&gt;one&lt;/span&gt; to 20 years. As of December&#160;31, 2022, the remaining weighted-average amortization period for finite-lived intangible assets was approximately 13 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to finite-lived intangible assets was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;579.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzUyOTA_967d66f8-83da-4ada-a70e-80bd3ac68e52">Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value to its carrying value is performed to determine the amount of any impairment.For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.The costs of acquired IPR&amp;amp;D projects acquired directly in a transaction other than a business combination are capitalized as other intangible assets if the projects have an alternative future use; otherwise, they are expensed immediately. See Note 3 for significant acquired IPR&amp;amp;D projects that had no alternative future use. Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the "income method," which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, analyst expectations, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&amp;amp;D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate.ndefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&amp;amp;D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzgwNQ_355e4ed1-8def-4cea-8ed3-2705c3fabd7f"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzgwNQ_e07b8e03-c189-4e46-97ce-27c285a275b4"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzgwNQ_e8dcbf67-23d3-49e1-87b5-82a06ea1c6ba"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzUyOTg_a86b533a-bbc6-4036-a870-285ddcf31196">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of intangible assets other than goodwill at December&#160;31 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketed products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,922.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,589.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,332.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,987.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,229.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,758.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,957.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,622.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,334.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,056.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,289.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,766.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,871.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,871.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,925.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,925.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,829.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,622.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,206.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,981.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,289.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,691.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzUzMDA_5f287e23-29bd-4d24-8608-a64598dad796">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of intangible assets other than goodwill at December&#160;31 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketed products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,922.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,589.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,332.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,987.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,229.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,758.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,957.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,622.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,334.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,056.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,289.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,766.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,871.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,871.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,925.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,925.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,829.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,622.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,206.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,981.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,289.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,691.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i024cb51bbd8f473892a3c8c4eb2d1047_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzMtMS0xLTEtMTk3MTgy_26903894-b94f-477d-8b64-be42592464b8"
      unitRef="usd">7922100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i024cb51bbd8f473892a3c8c4eb2d1047_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzMtMy0xLTEtMTk3MTgy_9f8c1d8f-5428-40fe-8f77-5923bf4ac9f3"
      unitRef="usd">2589900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i024cb51bbd8f473892a3c8c4eb2d1047_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzMtNS0xLTEtMTk3MTgy_754be984-3487-4928-b215-fa4809838d05"
      unitRef="usd">5332200000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1ffb9e56119443489f2dea0c32378917_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzMtNy0xLTEtMTk3MTgy_65305e4d-15f5-457b-8457-dfee59316973"
      unitRef="usd">7987200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1ffb9e56119443489f2dea0c32378917_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzMtOS0xLTEtMTk3MTgy_9ed4fea3-f426-4b1d-96bb-e73ce6a27702"
      unitRef="usd">2229200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1ffb9e56119443489f2dea0c32378917_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzMtMTEtMS0xLTE5NzE4Mg_81fb981f-3fe4-4bf4-9f72-2fcf79f25b19"
      unitRef="usd">5758000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ifc9330205fa247e0a9d3b8796fe79d3e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzQtMS0xLTEtMTk3MTgy_a181a3b2-d0ee-444b-bf4a-bc113e3e2c15"
      unitRef="usd">35400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ifc9330205fa247e0a9d3b8796fe79d3e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzQtMy0xLTEtMTk3MTgy_4cd31321-c45a-4f7c-b84d-933499a79cc5"
      unitRef="usd">32800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ifc9330205fa247e0a9d3b8796fe79d3e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzQtNS0xLTEtMTk3MTgy_0dc5b8c8-32cf-4f88-9f77-fa4d13e8662c"
      unitRef="usd">2600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i10d20920da5045eaa6a64364e50740b4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzQtNy0xLTEtMTk3MTgy_478960dd-01c8-4cbe-a69b-33a528020fc7"
      unitRef="usd">69400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i10d20920da5045eaa6a64364e50740b4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzQtOS0xLTEtMTk3MTgy_9ab252bf-d108-473a-ba4b-41ef8bdb954f"
      unitRef="usd">60500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i10d20920da5045eaa6a64364e50740b4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzQtMTEtMS0xLTE5NzE4Mg_c07248dc-4260-4e92-9eb3-100cc3b61530"
      unitRef="usd">8900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzUtMS0xLTEtMTk3MTgy_dd785514-c5df-404e-acb6-996a6ce207c0"
      unitRef="usd">7957500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzUtMy0xLTEtMTk3MTgy_f2a6b6a2-8c45-4395-8a00-aab4fe4bb283"
      unitRef="usd">2622700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzUtNS0xLTEtMTk3MTgy_715fb403-083a-4aa2-97d1-762c1df9d3f7"
      unitRef="usd">5334800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzUtNy0xLTEtMTk3MTgy_bc9d744e-50ae-4da6-8924-1a09c5044c21"
      unitRef="usd">8056600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzUtOS0xLTEtMTk3MTgy_dc0a0d79-1530-4791-b2a2-ab988a7dc3ac"
      unitRef="usd">2289700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzUtMTEtMS0xLTE5NzE4Mg_962aa05e-c53f-4e4d-8c70-1b8b0d10baf2"
      unitRef="usd">5766900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i78739e5e4dd447ee99f90605c73e27ac_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzctMS0xLTEtMTk3MTgy_174ff15c-19c6-4c08-bfc1-c0316756b3c3"
      unitRef="usd">1871800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i78739e5e4dd447ee99f90605c73e27ac_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzctNS0xLTEtMTk3MTgy_cd45fc31-c217-4d31-892f-c0d162a8d101"
      unitRef="usd">1871800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ie1a89a2666b74590bf74ff22f798d881_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzctNy0xLTEtMTk3MTgy_d37f81f2-0b09-4c81-b121-8bef75e043d6"
      unitRef="usd">1925000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ie1a89a2666b74590bf74ff22f798d881_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzctMTEtMS0xLTE5NzE4Mg_fcb1d036-50d8-43db-b1bd-9429c5c8c81a"
      unitRef="usd">1925000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzgtMS0xLTEtMTk3MTgy_3ec36b40-2e18-4b84-b99d-452bb1fc6b57"
      unitRef="usd">9829300000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzgtMy0xLTEtMTk3MTgy_4019a388-9b30-4602-9287-33e0a6373a4b"
      unitRef="usd">2622700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzgtNS0xLTEtMTk3MTgy_86524af3-a505-4616-a775-0fc40d9181c6"
      unitRef="usd">7206600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzgtNy0xLTEtMTk3MTgy_4d8f17a4-8573-4fe7-b059-7f0f97100cfe"
      unitRef="usd">9981600000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzgtOS0xLTEtMTk3MTgy_82e66b7e-7fac-4054-84dc-7b9b142e7bc0"
      unitRef="usd">2289700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTplNjgyN2ZkZWYzMDQ0ZjdmOGUyNmQ5ZGFhMjE1YmNkYi90YWJsZXJhbmdlOmU2ODI3ZmRlZjMwNDRmN2Y4ZTI2ZDlkYWEyMTViY2RiXzgtMTEtMS0xLTE5NzE4Mg_0254dccb-1170-4848-819a-f527583227a4"
      unitRef="usd">7691900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ibb1db2575cf945c4b53c0b1c6bcbffc0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzQ5MDU_a01fc102-7262-4504-9ef5-2606c0ad5321">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzUwMjM_0b14d0ef-34e3-477f-81d9-04cdbdee4075">P13Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzUyNjY_58c7bc5e-2fac-4217-b1e4-aeb48f9fb567">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to finite-lived intangible assets was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;579.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTo3OGYxODQxZDBhMmI0MThiYjg5MzM4YTUzYjZjNmYyMi90YWJsZXJhbmdlOjc4ZjE4NDFkMGEyYjQxOGJiODkzMzhhNTNiNmM2ZjIyXzEtMS0xLTEtMTk3MTgy_4cfc7499-63b6-46f2-aa3d-70bf61ede714"
      unitRef="usd">579700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTo3OGYxODQxZDBhMmI0MThiYjg5MzM4YTUzYjZjNmYyMi90YWJsZXJhbmdlOjc4ZjE4NDFkMGEyYjQxOGJiODkzMzhhNTNiNmM2ZjIyXzEtMy0xLTEtMTk3MTgy_49cfbfb8-7808-4065-9b8a-07640c98b7de"
      unitRef="usd">628800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTo3OGYxODQxZDBhMmI0MThiYjg5MzM4YTUzYjZjNmYyMi90YWJsZXJhbmdlOjc4ZjE4NDFkMGEyYjQxOGJiODkzMzhhNTNiNmM2ZjIyXzEtNS0xLTEtMTk3MTgy_142ac77b-742d-4cd6-ab93-3992b1a3af0c"
      unitRef="usd">428200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90ZXh0cmVnaW9uOjE3ODk4MzE3MjJlNDQzZTlhMDY2M2RhNDMyNTczMDYxXzUyNzE_6d80c9fb-396c-47ba-be09-3c48c4894226">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTozYTRiZmU1M2E3N2E0YmRkOTUyOTExOGVlODkwYzYxYS90YWJsZXJhbmdlOjNhNGJmZTUzYTc3YTRiZGQ5NTI5MTE4ZWU4OTBjNjFhXzEtMS0xLTEtMTk3MTgy_6e0c8267-afc3-4664-8cbd-5004ad756ca7"
      unitRef="usd">497500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTozYTRiZmU1M2E3N2E0YmRkOTUyOTExOGVlODkwYzYxYS90YWJsZXJhbmdlOjNhNGJmZTUzYTc3YTRiZGQ5NTI5MTE4ZWU4OTBjNjFhXzEtMy0xLTEtMTk3MTgy_f2ac92a6-3b86-4e1e-89a6-7ab86097d48b"
      unitRef="usd">447700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTozYTRiZmU1M2E3N2E0YmRkOTUyOTExOGVlODkwYzYxYS90YWJsZXJhbmdlOjNhNGJmZTUzYTc3YTRiZGQ5NTI5MTE4ZWU4OTBjNjFhXzEtNS0xLTEtMTk3MTgy_05c016ff-6e26-4ed1-a127-1dce32e45c43"
      unitRef="usd">435500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTozYTRiZmU1M2E3N2E0YmRkOTUyOTExOGVlODkwYzYxYS90YWJsZXJhbmdlOjNhNGJmZTUzYTc3YTRiZGQ5NTI5MTE4ZWU4OTBjNjFhXzEtNy0xLTEtMTk3MTgy_dd1e7f67-e36f-48b0-9fac-3c5226453e12"
      unitRef="usd">424800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTUvZnJhZzoxNzg5ODMxNzIyZTQ0M2U5YTA2NjNkYTQzMjU3MzA2MS90YWJsZTozYTRiZmU1M2E3N2E0YmRkOTUyOTExOGVlODkwYzYxYS90YWJsZXJhbmdlOjNhNGJmZTUzYTc3YTRiZGQ5NTI5MTE4ZWU4OTBjNjFhXzEtOS0xLTEtMTk3MTgy_8e601a4a-c9b2-426d-a973-648b951be9af"
      unitRef="usd">422900000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzEyMTE_e3f3dc55-b8b8-4e20-bd7c-3b9e8775921b">Property and Equipment&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzI3Mg_0bc998e4-b996-4544-9f0f-ef94e39f535f"&gt;three&lt;/span&gt; to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value, and the cost basis is adjusted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;256.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,915.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,588.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,406.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,937.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,798.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,177.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,377.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,961.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10,233.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,976.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,144.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,985.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;816.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized interest costs were not material for the years ended December&#160;31, 2022, 2021, and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes long-lived assets by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,709.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,620.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,898.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,702.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,625.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,691.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,234.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,013.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment, net, operating lease assets, and certain other noncurrent assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzEyMzA_a3da989a-b164-44d0-9008-0b9b3c1feba6">Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzI3Mg_0bc998e4-b996-4544-9f0f-ef94e39f535f"&gt;three&lt;/span&gt; to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value, and the cost basis is adjusted.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i84043b4b737545c9b8356075843761af_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzI0NQ_180e6339-b271-4267-8e9b-4a9a48237f26">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ibc25faf9338644178cb1e8c7d5454052_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzI1MQ_27bdcc96-0394-4fbe-9e3e-5fc566d30d26">P50Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3c90a1dfddcc4a0b8f2e9d9ade98f0f7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzI3OA_47e8c6e9-2736-40fe-8ee4-ba883b7c3069">P25Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzEyMjg_2b207ebf-2710-4c56-ad34-5a368ff45ca1">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;256.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,915.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,588.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,406.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,937.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,798.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,177.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,377.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,961.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10,233.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,976.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,144.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,985.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;816.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:Land
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzEtMS0xLTEtMTk3MTgy_4cf58ab2-6856-4145-a2a5-020174eb6054"
      unitRef="usd">256600000</us-gaap:Land>
    <us-gaap:Land
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzEtMy0xLTEtMTk3MTgy_bd52c9b2-898c-48c8-b2d4-4b7285c70d72"
      unitRef="usd">258700000</us-gaap:Land>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzItMS0xLTEtMTk3MTgy_0bf0199e-0d41-4407-8b0e-cdcd1402999e"
      unitRef="usd">7915900000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzItMy0xLTEtMTk3MTgy_74741860-6587-40dd-84b6-03d942672bf1"
      unitRef="usd">7588100000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzMtMS0xLTEtMTk3MTgy_14ddeaa3-acbb-4dc4-a126-735469181198"
      unitRef="usd">9406300000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzMtMy0xLTEtMTk3MTgy_0e32f5ff-85bb-4a00-b4a6-35715e03e28e"
      unitRef="usd">8937200000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzUtMS0xLTEtMTk3MTgy_b2de8852-f4b8-4625-8c97-c8b73f5f1430"
      unitRef="usd">2798600000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzUtMy0xLTEtMTk3MTgy_037ed67b-9280-47eb-a2d1-fd9c624c9654"
      unitRef="usd">2177800000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzYtMS0xLTEtMTk3MTgy_94048c34-6298-4ef4-ba22-1fa234687620"
      unitRef="usd">20377400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzYtMy0xLTEtMTk3MTgy_befc2bb0-3d34-4b53-b78c-c4a86bb1896a"
      unitRef="usd">18961800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzctMS0xLTEtMTk3MTgy_a86f6cde-06c4-47f7-8fcf-4498a7f646d7"
      unitRef="usd">10233400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzctMy0xLTEtMTk3MTgy_7cdb5523-b609-4935-9045-2277ff3749ea"
      unitRef="usd">9976700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzgtMS0xLTEtMTk3MTgy_cefde9a9-9ac6-4e9a-99b5-696bbe88f969"
      unitRef="usd">10144000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZTozOWNjN2ZlOTE4NTM0NzIyYTA5OTdmZWQxYmZmODY5Zi90YWJsZXJhbmdlOjM5Y2M3ZmU5MTg1MzQ3MjJhMDk5N2ZlZDFiZmY4NjlmXzgtMy0xLTEtMTk3MTgy_7e446048-6228-445c-baf1-9c9f40ebc58f"
      unitRef="usd">8985100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToyYzc4YmY1Yzg4OWY0MGIyYTU5OTljYzVhMDlhOTU2YS90YWJsZXJhbmdlOjJjNzhiZjVjODg5ZjQwYjJhNTk5OWNjNWEwOWE5NTZhXzEtMS0xLTEtMTk3MTgy_559f6c0c-26a7-4d98-a5bd-9ae2fcfbfaee"
      unitRef="usd">816600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToyYzc4YmY1Yzg4OWY0MGIyYTU5OTljYzVhMDlhOTU2YS90YWJsZXJhbmdlOjJjNzhiZjVjODg5ZjQwYjJhNTk5OWNjNWEwOWE5NTZhXzEtMy0xLTEtMTk3MTgy_b67bfe7c-b7e6-4489-bd02-eae908d2fdb7"
      unitRef="usd">787000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToyYzc4YmY1Yzg4OWY0MGIyYTU5OTljYzVhMDlhOTU2YS90YWJsZXJhbmdlOjJjNzhiZjVjODg5ZjQwYjJhNTk5OWNjNWEwOWE5NTZhXzEtNS0xLTEtMTk3MTgy_21e0f655-9fb3-4658-ba30-7e2b7c71de06"
      unitRef="usd">765200000</us-gaap:Depreciation>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90ZXh0cmVnaW9uOmIzOGQ5YWY4ZjVkMzRlYWE5MTY1YWQwZjEzNDMyZWI4XzEyMTQ_00501e11-3fc0-487b-8ee4-85679fd0cff5">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes long-lived assets by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,709.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,620.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,898.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,702.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,625.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,691.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,234.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,013.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment, net, operating lease assets, and certain other noncurrent assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets
      contextRef="ibdc99a357f5645e68fea63babcf6e1a1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToxNTcyNzgzNGM3NmQ0N2Y3YjFkNGEzNmIwNTQ5MjEzYy90YWJsZXJhbmdlOjE1NzI3ODM0Yzc2ZDQ3ZjdiMWQ0YTM2YjA1NDkyMTNjXzMtNC0xLTEtMTk3MTgy_29ff120f-4520-46f7-bb28-fdef241f8be4"
      unitRef="usd">7709700000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i23db86fa8b8e464f9ab3b7f022c25c05_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToxNTcyNzgzNGM3NmQ0N2Y3YjFkNGEzNmIwNTQ5MjEzYy90YWJsZXJhbmdlOjE1NzI3ODM0Yzc2ZDQ3ZjdiMWQ0YTM2YjA1NDkyMTNjXzMtNi0xLTEtMTk3MTgy_ebb82039-9a29-4363-ae89-4a8b39220455"
      unitRef="usd">6620000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i4eff6ba2e6fb4744acc735827cfe6e99_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToxNTcyNzgzNGM3NmQ0N2Y3YjFkNGEzNmIwNTQ5MjEzYy90YWJsZXJhbmdlOjE1NzI3ODM0Yzc2ZDQ3ZjdiMWQ0YTM2YjA1NDkyMTNjXzQtNC0xLTEtMTk3MTgy_a2e84165-0282-46f3-b977-1b80cd8225b5"
      unitRef="usd">1898500000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="idef4bb393b97493c912842acdbb55c84_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToxNTcyNzgzNGM3NmQ0N2Y3YjFkNGEzNmIwNTQ5MjEzYy90YWJsZXJhbmdlOjE1NzI3ODM0Yzc2ZDQ3ZjdiMWQ0YTM2YjA1NDkyMTNjXzQtNi0xLTEtMTk3MTgy_bcf69752-8eea-4a6c-85a1-10cdb1aa92e7"
      unitRef="usd">1702300000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="icf3c5f0215ae42afafbd93e42ab13afc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToxNTcyNzgzNGM3NmQ0N2Y3YjFkNGEzNmIwNTQ5MjEzYy90YWJsZXJhbmdlOjE1NzI3ODM0Yzc2ZDQ3ZjdiMWQ0YTM2YjA1NDkyMTNjXzUtNC0xLTEtMTk3MTgy_e6fcec8c-e66e-4c2a-a027-4e2b36b69d51"
      unitRef="usd">1625900000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i1cd853d454b54902b5326960dc6dae46_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToxNTcyNzgzNGM3NmQ0N2Y3YjFkNGEzNmIwNTQ5MjEzYy90YWJsZXJhbmdlOjE1NzI3ODM0Yzc2ZDQ3ZjdiMWQ0YTM2YjA1NDkyMTNjXzUtNi0xLTEtMTk3MTgy_4c23bd07-6646-4f46-8411-832790656e82"
      unitRef="usd">1691000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToxNTcyNzgzNGM3NmQ0N2Y3YjFkNGEzNmIwNTQ5MjEzYy90YWJsZXJhbmdlOjE1NzI3ODM0Yzc2ZDQ3ZjdiMWQ0YTM2YjA1NDkyMTNjXzYtNC0xLTEtMTk3MTgy_a38cc748-c66a-40f7-ad31-47efddbdfd62"
      unitRef="usd">11234100000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMTgvZnJhZzpiMzhkOWFmOGY1ZDM0ZWFhOTE2NWFkMGYxMzQzMmViOC90YWJsZToxNTcyNzgzNGM3NmQ0N2Y3YjFkNGEzNmIwNTQ5MjEzYy90YWJsZXJhbmdlOjE1NzI3ODM0Yzc2ZDQ3ZjdiMWQ0YTM2YjA1NDkyMTNjXzYtNi0xLTEtMTk3MTgy_3b1da8de-6d63-4d65-a279-c277d641c53a"
      unitRef="usd">10013300000</us-gaap:NoncurrentAssets>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90ZXh0cmVnaW9uOmI1YjQwYjYwY2UzODQwZTJhZDNkM2FhNjU0MDBhYjQwXzI2MDU_2c46d43f-4297-4068-8e8d-826d226f232e">Leases&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at inception. We have leases with terms up to 14 years primarily for corporate offices, research and development facilities, vehicles, and equipment, including some of which have options to extend and/or early-terminate the leases. We determine the lease term by assuming the exercise of any renewal and/or early-termination options that are reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets are presented as other noncurrent assets in our consolidated balance sheets, and the current and long-term portions of operating lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, in our consolidated balance sheets. Short-term leases, which are deemed at inception to have a lease term of 12 months or less, are not recorded on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease assets represent our right to use an underlying asset for the lease term, and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense for operating lease assets, which is recognized on a straight-line basis over the lease term, was $148.8 million, $159.4 million, and $154.6 million during the years ended December&#160;31, 2022, 2021, and 2020, respectively. Variable lease payments, which represent non-lease components such as maintenance, insurance and taxes, and which vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the payment obligation is incurred and were not material during the years ended December&#160;31, 2022, 2021, and 2020. Short-term lease expense was not material during the years ended December&#160;31, 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases as of December&#160;31, 2022 and 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2022, 2021, and 2020 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;149.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;155.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzktMC0xLTEtMTk3MTgy_8ddc8d02-9a67-4865-bc1c-83f42fdd1643"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases are included in property and equipment, short-term borrowings and current maturities of long-term debt, and long-term debt in our consolidated balance sheets. Finance leases are not material to our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90ZXh0cmVnaW9uOmI1YjQwYjYwY2UzODQwZTJhZDNkM2FhNjU0MDBhYjQwXzI2MDY_c2e88960-8e3f-479e-93bb-cfa6fdf61897">Leases&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at inception. We have leases with terms up to 14 years primarily for corporate offices, research and development facilities, vehicles, and equipment, including some of which have options to extend and/or early-terminate the leases. We determine the lease term by assuming the exercise of any renewal and/or early-termination options that are reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets are presented as other noncurrent assets in our consolidated balance sheets, and the current and long-term portions of operating lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, in our consolidated balance sheets. Short-term leases, which are deemed at inception to have a lease term of 12 months or less, are not recorded on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease assets represent our right to use an underlying asset for the lease term, and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense for operating lease assets, which is recognized on a straight-line basis over the lease term, was $148.8 million, $159.4 million, and $154.6 million during the years ended December&#160;31, 2022, 2021, and 2020, respectively. Variable lease payments, which represent non-lease components such as maintenance, insurance and taxes, and which vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the payment obligation is incurred and were not material during the years ended December&#160;31, 2022, 2021, and 2020. Short-term lease expense was not material during the years ended December&#160;31, 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases as of December&#160;31, 2022 and 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2022, 2021, and 2020 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;149.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;155.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzktMC0xLTEtMTk3MTgy_8ddc8d02-9a67-4865-bc1c-83f42fdd1643"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases are included in property and equipment, short-term borrowings and current maturities of long-term debt, and long-term debt in our consolidated balance sheets. Finance leases are not material to our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <lly:LesseeLeaseRemainingLeaseTerm
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90ZXh0cmVnaW9uOmI1YjQwYjYwY2UzODQwZTJhZDNkM2FhNjU0MDBhYjQwXzEwOQ_7d44893b-8ba7-4992-a653-9a6758bf99b9">P14Y</lly:LesseeLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseCost
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90ZXh0cmVnaW9uOmI1YjQwYjYwY2UzODQwZTJhZDNkM2FhNjU0MDBhYjQwXzE1Mjg_f397636a-5e68-4478-857a-933aea376ae9"
      unitRef="usd">148800000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90ZXh0cmVnaW9uOmI1YjQwYjYwY2UzODQwZTJhZDNkM2FhNjU0MDBhYjQwXzE1MzI_3559d2b1-395e-4bcc-b110-2be4c42374ea"
      unitRef="usd">159400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90ZXh0cmVnaW9uOmI1YjQwYjYwY2UzODQwZTJhZDNkM2FhNjU0MDBhYjQwXzE1NDA_dff59e22-d547-400b-a814-607a9688192a"
      unitRef="usd">154600000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90ZXh0cmVnaW9uOmI1YjQwYjYwY2UzODQwZTJhZDNkM2FhNjU0MDBhYjQwXzI2MDM_417dcc33-6dc8-499c-9487-fc5e30dbd950">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases as of December&#160;31, 2022 and 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2022, 2021, and 2020 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;149.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;155.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZToxYmEzNWNhODhlOWE0NmZhODExZjE0YmU5ZGI2ZWI1Ni90YWJsZXJhbmdlOjFiYTM1Y2E4OGU5YTQ2ZmE4MTFmMTRiZTlkYjZlYjU2XzEtMi0xLTEtMTk3MTgy_63f12642-4ecc-421e-ba67-a602497c6c3a">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZToxYmEzNWNhODhlOWE0NmZhODExZjE0YmU5ZGI2ZWI1Ni90YWJsZXJhbmdlOjFiYTM1Y2E4OGU5YTQ2ZmE4MTFmMTRiZTlkYjZlYjU2XzEtMy0xLTEtMTk3MTgy_95456dfa-c39d-4d22-b2ad-6b2ea87ab79e">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZToxYmEzNWNhODhlOWE0NmZhODExZjE0YmU5ZGI2ZWI1Ni90YWJsZXJhbmdlOjFiYTM1Y2E4OGU5YTQ2ZmE4MTFmMTRiZTlkYjZlYjU2XzItMi0xLTEtMTk3MTgy_58dc5418-99c9-4521-9295-8fc9fcca7714"
      unitRef="number">0.036</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZToxYmEzNWNhODhlOWE0NmZhODExZjE0YmU5ZGI2ZWI1Ni90YWJsZXJhbmdlOjFiYTM1Y2E4OGU5YTQ2ZmE4MTFmMTRiZTlkYjZlYjU2XzItMy0xLTEtMTk3MTgy_5c046b4c-8657-4b9b-b2cd-561b38014339"
      unitRef="number">0.030</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTpiMjM1ZTk2YWRmZTY0NGJlOTE3YmNkODg5MDI4MDRkZS90YWJsZXJhbmdlOmIyMzVlOTZhZGZlNjQ0YmU5MTdiY2Q4ODkwMjgwNGRlXzEtMi0xLTEtMTk3MTgy_ae84b250-b1d9-433f-92c5-bced8679fa40"
      unitRef="usd">149700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTpiMjM1ZTk2YWRmZTY0NGJlOTE3YmNkODg5MDI4MDRkZS90YWJsZXJhbmdlOmIyMzVlOTZhZGZlNjQ0YmU5MTdiY2Q4ODkwMjgwNGRlXzEtMy0xLTEtMTk3MTgy_058b5dec-5da4-49ae-ae76-933c5f5faea5"
      unitRef="usd">156700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTpiMjM1ZTk2YWRmZTY0NGJlOTE3YmNkODg5MDI4MDRkZS90YWJsZXJhbmdlOmIyMzVlOTZhZGZlNjQ0YmU5MTdiY2Q4ODkwMjgwNGRlXzEtNC0xLTEtMTk3MTgy_91302d8e-ae57-4fd6-8a5b-e1aadff80bd6"
      unitRef="usd">160900000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTpiMjM1ZTk2YWRmZTY0NGJlOTE3YmNkODg5MDI4MDRkZS90YWJsZXJhbmdlOmIyMzVlOTZhZGZlNjQ0YmU5MTdiY2Q4ODkwMjgwNGRlXzItMi0xLTEtMTk3MTgy_6c91456a-b3a7-4f9d-a2b3-e160156c9d4d"
      unitRef="usd">155400000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTpiMjM1ZTk2YWRmZTY0NGJlOTE3YmNkODg5MDI4MDRkZS90YWJsZXJhbmdlOmIyMzVlOTZhZGZlNjQ0YmU5MTdiY2Q4ODkwMjgwNGRlXzItMy0xLTEtMTk3MTgy_10b17b7b-95d1-4ec2-9493-2befa4d696fb"
      unitRef="usd">163500000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTpiMjM1ZTk2YWRmZTY0NGJlOTE3YmNkODg5MDI4MDRkZS90YWJsZXJhbmdlOmIyMzVlOTZhZGZlNjQ0YmU5MTdiY2Q4ODkwMjgwNGRlXzItNC0xLTEtMTk3MTgy_1bc9822e-25c3-45c7-8686-b058098f80d6"
      unitRef="usd">136700000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90ZXh0cmVnaW9uOmI1YjQwYjYwY2UzODQwZTJhZDNkM2FhNjU0MDBhYjQwXzI2MDQ_50bef635-2270-4641-8131-c288c3707d4b">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzktMC0xLTEtMTk3MTgy_8ddc8d02-9a67-4865-bc1c-83f42fdd1643"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzEtMS0xLTEtMTk3MTgy_2a3a2506-16e1-4b63-85b2-76474f1029e0"
      unitRef="usd">154200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzItMS0xLTEtMTk3MTgy_5e9608cd-f671-4dbc-8670-59f554e3ef3e"
      unitRef="usd">131400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzMtMS0xLTEtMTk3MTgy_e199f799-e2d9-432f-bea0-bb9f73d1b419"
      unitRef="usd">115100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzQtMS0xLTEtMTk3MTgy_02a088bd-c829-4f1b-b7d7-1fbf6193d280"
      unitRef="usd">96100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzUtMS0xLTEtMTk3MTgy_5a80117a-b075-4c27-8d80-82dd10bd3af8"
      unitRef="usd">76300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzYtMS0xLTEtMTk3MTgy_dd1c1a3a-91b3-4f52-93e5-0c167ffff807"
      unitRef="usd">250300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzctMS0xLTEtMTk3MTgy_a4abc1b1-699a-4758-958d-3d0f8a5a08c3"
      unitRef="usd">823400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzgtMS0xLTEtMTk3MTgy_9c78d3ce-4c9b-419b-b4fb-52717323876f"
      unitRef="usd">95200000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjEvZnJhZzpiNWI0MGI2MGNlMzg0MGUyYWQzZDNhYTY1NDAwYWI0MC90YWJsZTphMjk1NzZkMDYwODk0Zjk4YjY5YzRmMDNkYmY3YTUwMC90YWJsZXJhbmdlOmEyOTU3NmQwNjA4OTRmOThiNjljNGYwM2RiZjdhNTAwXzktMS0xLTEtMTk3MTgy_2e47a54f-61fa-4c4c-8cb8-cc5c9657f896"
      unitRef="usd">728200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzQwNDk_261a1a80-bd3b-4cc2-99ab-12f0030fa369">Borrowings&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt at December&#160;31 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term commercial paper borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,498.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term notes &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,815.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,741.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(77.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustment on hedged long-term notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,238.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,884.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,501.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,538.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,737.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,346.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average effective borrowing rate on short-term commercial paper borrowings at December 31, 2022 was 4.20 percent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes long-term notes at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.179%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.35% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.00% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.00% euro denominated notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;678.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.15% Swiss franc denominated notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;649.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;654.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.125% notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;217.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;217.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.75% notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;560.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;560.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.625% euro denominated notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;799.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;847.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.5% notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;364.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;364.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.1% notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;401.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;401.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.45% Swiss franc denominated notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;433.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;436.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.375% notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;930.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;930.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.42% Japanese yen denominated notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;172.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;199.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.125% euro denominated notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;799.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;847.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.625% euro denominated notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;639.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;678.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.50% euro denominated notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;639.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;678.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.56% Japanese yen denominated notes due 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;69.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.77% notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;158.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;158.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.55% notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;444.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;444.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.95% notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;266.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;266.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.875% notes due 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;240.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;240.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.625% British pound denominated notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;301.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;337.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.65% notes due 2044&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;38.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;38.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.7% notes due 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;386.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;386.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.95% notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;347.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;347.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.95% notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;958.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;958.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.70% euro denominated notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,065.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,130.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.97% Japanese yen denominated notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;57.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.25% notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,250.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.125% euro denominated notes due 2051&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;532.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;565.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.15% notes due 2059&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;591.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;591.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.50% notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;850.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.375% euro denominated notes due 2061&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;746.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;791.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Unamortized note discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(96.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(105.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total long-term notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;14,815.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16,741.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average effective borrowing rate for each issuance of the long term-notes approximates the stated interest rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, we had a total of $7.33 billion of unused committed bank credit facilities, which consisted primarily of a $3.00 billion credit facility that expires in December 2026 and a $4.00&#160;billion 364-day facility that expires in September 2023, both of which are available to support our commercial paper program. We have not drawn against the $3.00 billion and $4.00 billion facilities as of December&#160;31, 2022. Of the remaining committed bank credit facilities, the outstanding balances as of December&#160;31, 2022 and 2021 were not material. Compensating balances and commitment fees are not material, and there are no conditions that are probable of occurring under which the lines may be withdrawn. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, we issued euro-denominated notes consisting of &#x20ac;600.0&#160;million of 0.50 percent fixed-rate notes due in September 2033, with interest to be paid annually. The net proceeds from the offering have been, and will continue to be, used to fund, in whole or in part, eligible projects designed to advance one or more of our environmental, social, and governance objectives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, we issued euro-denominated notes consisting of &#x20ac;500.0&#160;million of 1.125 percent fixed-rate notes due in September 2051 and &#x20ac;700.0&#160;million of 1.375 percent fixed-rate notes due in September 2061, with interest to be paid annually, and British pound-denominated notes consisting of &#xa3;250.0&#160;million of 1.625 percent fixed-rate notes due in September 2043, with interest to be paid annually. We paid $1.91&#160;billion of the net cash proceeds from the offering to purchase and redeem certain higher interest rate U.S. dollar-denominated notes with an aggregate principal amount of $1.50&#160;billion, resulting in a debt extinguishment loss of $405.2&#160;million. This loss was included in other-net, (income) expense in our consolidated statement of operations for the year ended December 31, 2021. The $1.50&#160;billion principal amount of higher interest rate U.S. dollar-denominated notes that were redeemed primarily included $541.8&#160;million of 3.95 percent notes due 2049, $408.7&#160;million of 4.15 percent notes due 2059, and $219.4&#160;million of 3.375 percent notes due 2029. We used the remaining net proceeds from the offering to prefund certain 2022 debt maturities and for general corporate purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, we issued $1.00&#160;billion of 2.25 percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $988.6 million for general corporate purposes, including the repayment of outstanding commercial paper. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, we issued $850.0 million of 2.50 percent fixed-rate notes due in September 2060 and an additional $250.0 million of our 2.25 percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $1.07 billion for general corporate purposes, including the repayment of outstanding commercial paper. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amounts of maturities on long-term debt for the next five years are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities on long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have converted approximately 10 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. The weighted-average effective borrowing rates based on long-term debt obligations and interest rates at December&#160;31, 2022 and 2021, including the effects of interest rate swaps for hedged debt obligations, were 2.87 percent and 2.27 percent, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments for interest on borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;323.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the requirements of derivatives and hedging guidance, the portion of our fixed-rate debt obligations that is hedged as a fair value hedge is reflected in the consolidated balance sheets as an amount equal to the sum of the debt's carrying value plus the fair value adjustment representing changes in fair value of the hedged debt attributable to movements in market interest rates subsequent to the inception of the hedge.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzQwNDg_9f36b7cc-25e4-4082-8d5f-5b8e2635972c">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt at December&#160;31 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term commercial paper borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,498.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term notes &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,815.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,741.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(77.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustment on hedged long-term notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,238.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,884.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,501.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,538.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,737.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,346.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:CommercialPaper
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzEtMS0xLTEtMjI3MTEw_ae4acb3f-57ff-4b26-8a40-3994cc496fd5"
      unitRef="usd">1498000000</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzEtMy0xLTEtMjI3MTE4_844e244c-a60b-4366-8505-a3cacca206ed"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:NotesPayable
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzEtMS0xLTEtMTk3MTgy_7ac852a6-0b0c-4524-a57a-f6e064923be9"
      unitRef="usd">14815300000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzEtMy0xLTEtMTk3MTgy_1c29cd9d-f769-4e01-8743-ba4177abf964"
      unitRef="usd">16741200000</us-gaap:NotesPayable>
    <us-gaap:OtherNotesPayable
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzItMS0xLTEtMTk3MTgy_613099e9-9363-4e22-933a-e31d8daa9f02"
      unitRef="usd">6900000</us-gaap:OtherNotesPayable>
    <us-gaap:OtherNotesPayable
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzItMy0xLTEtMTk3MTgy_3983d56c-1395-44fe-9de8-f81868b07f5c"
      unitRef="usd">10800000</us-gaap:OtherNotesPayable>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzMtMS0xLTEtMTk3MTgy_847dd41b-207f-4325-a0b5-5c87f97d0f10"
      unitRef="usd">77200000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzMtMy0xLTEtMTk3MTgy_f55fee16-5215-494c-854c-1c7b1c867b6a"
      unitRef="usd">84200000</us-gaap:UnamortizedDebtIssuanceExpense>
    <lly:LongTermDebtFairValueAdjustment
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzQtMS0xLTEtMTk3MTgy_b908fdde-f977-4583-b289-aa23f3c7c34f"
      unitRef="usd">-4400000</lly:LongTermDebtFairValueAdjustment>
    <lly:LongTermDebtFairValueAdjustment
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzQtMy0xLTEtMTk3MTgy_f115236f-14cc-4b28-8cf1-8d4126991d38"
      unitRef="usd">216900000</lly:LongTermDebtFairValueAdjustment>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzUtMS0xLTEtMTk3MTgy_e4d00767-e7a5-4881-8a3b-7ea1fd92907a"
      unitRef="usd">16238600000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzUtMy0xLTEtMTk3MTgy_3ba8112b-0064-408c-98c5-5322641adfd2"
      unitRef="usd">16884700000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtCurrent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzYtMS0xLTEtMTk3MTgy_0e173ce0-c2af-4131-b7bf-693cd5dedc79"
      unitRef="usd">1501100000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzYtMy0xLTEtMTk3MTgy_7497226a-e2f3-4cca-bbdf-64a882846b52"
      unitRef="usd">1538300000</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzctMS0xLTEtMTk3MTgy_e3177802-aad3-4105-b855-3e60e77bcd28"
      unitRef="usd">14737500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo0MmEwNTc2N2YwNWQ0MmFlYTE1YjhjYjQ5ZjdmNDVlMS90YWJsZXJhbmdlOjQyYTA1NzY3ZjA1ZDQyYWVhMTViOGNiNDlmN2Y0NWUxXzctMy0xLTEtMTk3MTgy_3bda07fa-f87a-4aee-bb16-23885b4b6c44"
      unitRef="usd">15346400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ShortTermDebtWeightedAverageInterestRate
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzEwNDQ1MzYwNDY4ODU1_fcb05a4d-a50b-45e1-9cba-f4a6fe6bce0c"
      unitRef="number">4.20</us-gaap:ShortTermDebtWeightedAverageInterestRate>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzQwNjU_4c547a22-2194-4aad-ae03-bbe34fa336dd">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes long-term notes at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.179%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.35% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.00% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.00% euro denominated notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;678.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.15% Swiss franc denominated notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;649.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;654.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.125% notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;217.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;217.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.75% notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;560.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;560.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.625% euro denominated notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;799.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;847.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.5% notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;364.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;364.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.1% notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;401.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;401.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.45% Swiss franc denominated notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;433.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;436.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.375% notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;930.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;930.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.42% Japanese yen denominated notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;172.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;199.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.125% euro denominated notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;799.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;847.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.625% euro denominated notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;639.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;678.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.50% euro denominated notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;639.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;678.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.56% Japanese yen denominated notes due 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;69.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.77% notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;158.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;158.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.55% notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;444.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;444.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.95% notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;266.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;266.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.875% notes due 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;240.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;240.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.625% British pound denominated notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;301.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;337.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.65% notes due 2044&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;38.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;38.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.7% notes due 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;386.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;386.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.95% notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;347.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;347.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.95% notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;958.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;958.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.70% euro denominated notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,065.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,130.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.97% Japanese yen denominated notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;57.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.25% notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,250.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.125% euro denominated notes due 2051&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;532.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;565.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.15% notes due 2059&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;591.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;591.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.50% notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;850.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.375% euro denominated notes due 2061&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;746.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;791.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Unamortized note discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(96.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(105.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total long-term notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;14,815.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16,741.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7296a85c804344a4b823ccbd1579e425_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246ZjQ4YmM1NjViZTk3NGMwZTlhYmYzZjNiNzc5ZmM1MjBfNA_4c93b603-f2d2-4065-bfc4-3deafc3e68c9"
      unitRef="number">0.0235</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7296a85c804344a4b823ccbd1579e425_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEtMS0xLTEtMTk3MTgy_5c93e4bd-a7e3-41a9-86e2-bd6d921d3c44"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i74a66519f1704bd5891f02b44669f2ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEtMy0xLTEtMTk3MTgy_d2102aa8-591e-444a-b5d4-9bc7d7be4b58"
      unitRef="usd">750000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iafbbc254a62f477095aad8da1c3c29cc_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzItMC0xLTEtMTk3MTgyL3RleHRyZWdpb246Y2IxYmFkZTI4YzYyNDUyNjgyOWNkOGZlNzBlYTU1MzRfNA_b34c7395-9593-472b-b0cd-566f2537aa0d"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iafbbc254a62f477095aad8da1c3c29cc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzItMS0xLTEtMTk3MTgy_33223693-9076-4985-b399-3653d057d175"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i49ed564e316641a190e2ea5bc0d13358_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzItMy0xLTEtMTk3MTgy_2d4ef707-1f60-41d9-b610-1b2cab83fa6a"
      unitRef="usd">99200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5cb67bf176ed48d699fda531feb23c5c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246ZDRhZTUxZjdjNzJkNDg4MmFmOTBiMGQ2NDczNTJkOGRfNA_3f778f31-3883-4e40-9dc9-f8873bc37f5a"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5cb67bf176ed48d699fda531feb23c5c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMtMS0xLTEtMTk3MTgy_466e2f06-6ff1-43c5-98ee-9921fb19e00c"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ieee67ef519a14645b909c395101668dd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMtMy0xLTEtMTk3MTgy_d551860a-5110-4754-a7cf-7077e3e756c8"
      unitRef="usd">678200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic91bf59cc87d4b018a72edb84c344f75_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzQtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246MjM1NWRjMTQ3ZGQ4NDk4MDkxODJhYjVjMmMyNDJhYjdfNA_56160b17-6742-47a8-a43e-d445ede21899"
      unitRef="number">0.0015</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic91bf59cc87d4b018a72edb84c344f75_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzQtMS0xLTEtMTk3MTgy_a9630d96-17f8-49c7-8abb-7fee711bd216"
      unitRef="usd">649500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5c45ef9bd50d43fd98a3d77dab23bf12_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzQtMy0xLTEtMTk3MTgy_9d9e9993-4b88-4959-8c5f-283560ecd4d8"
      unitRef="usd">654700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i61abf79406074265841d9e59afd0b927_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzUtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246NzcxODM1OGJhY2I1NDI4NGE5YmIyZWVhYzI3MGJkNDhfNA_62a742b7-c6b1-4a5e-9f81-ef194f0bc8f7"
      unitRef="number">0.07125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i61abf79406074265841d9e59afd0b927_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzUtMS0xLTEtMTk3MTgy_a2163d7b-0c29-4837-a611-b096aa9347ff"
      unitRef="usd">217500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iab38c12183ba4ea08deb88ed706456ce_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzUtMy0xLTEtMTk3MTgy_f4e1c80a-9da0-4e37-b03b-ad604170c8bc"
      unitRef="usd">217500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1b3c6352b0e54655905b05316d9d6f6e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzYtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246OTkwYTI0ZGE2OTIyNDE0MWEyMGU4MTFlZGZlMTFjM2ZfNA_b7c8acbf-396e-4840-b886-cf3f0c215c95"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1b3c6352b0e54655905b05316d9d6f6e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzYtMS0xLTEtMTk3MTgy_666f24fa-0311-401f-bdbe-b9ecc28daec1"
      unitRef="usd">560600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7460ec1a2ce645628f9b4950c383a2e7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzYtMy0xLTEtMTk3MTgy_ddfa33bb-426b-4477-bda2-e6493f6bdf29"
      unitRef="usd">560600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if91ad0b4d0f445169909fc587ad4be66_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzctMC0xLTEtMTk3MTgyL3RleHRyZWdpb246Y2VlZTdiYjkzOWRiNDA5OWFkODM5NjcxZjFmMjllMjBfNA_4cfa37a7-e18b-4c7a-ba97-64f2466905a2"
      unitRef="number">0.01625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if91ad0b4d0f445169909fc587ad4be66_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzctMS0xLTEtMTk3MTgy_8f3c8618-16a1-443e-9c33-880f25bf0dd5"
      unitRef="usd">799300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia43db658a17f4423b0dfd76ce053a30a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzctMy0xLTEtMTk3MTgy_c61a1afd-7984-4810-a357-02eb20bc8d77"
      unitRef="usd">847700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i26c8536d6b204e03856812446168bceb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzgtMC0xLTEtMTk3MTgyL3RleHRyZWdpb246ZmEzZGY3Y2Q4MDJiNGU5ODgyNmZhMDJkMDg3OTYwZTFfNA_7bbbfa6e-a72b-489b-a0cc-1b55878cca8b"
      unitRef="number">0.055</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i26c8536d6b204e03856812446168bceb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzgtMS0xLTEtMTk3MTgy_e6dfdaee-71ed-4070-a1b7-a13dee31ee2c"
      unitRef="usd">364300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i674e9d0712e3435bb2d0ecdf73d1e2f6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzgtMy0xLTEtMTk3MTgy_9a515630-7d23-403a-a11c-043d6d3a0a5f"
      unitRef="usd">364300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8f1a3b951bfe4ef2a9d50583c4bbd77c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzktMC0xLTEtMTk3MTgyL3RleHRyZWdpb246MmM1ZjQxN2M3Y2U4NGRkZGFiZTNiNzE3NDdlNDQ4MWFfNA_3f9eed45-a9df-4d37-a06e-4d36af819ead"
      unitRef="number">0.031</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8f1a3b951bfe4ef2a9d50583c4bbd77c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzktMS0xLTEtMTk3MTgy_752ebdb6-eb8f-4eca-b345-a661b2e97a9b"
      unitRef="usd">401500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0e1618d7d24c48259896e1e2026a0aed_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzktMy0xLTEtMTk3MTgy_f0c04859-d2a9-4b3c-8b0c-e2f29cd7047d"
      unitRef="usd">401500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i87bad62899d149bdaac599617b653af1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEwLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjhmMTJlYWI1ZTI5ODRjZWY5MTA1OTI2MjJjZDI5ZDY4XzQ_f40845fc-4c31-438b-bd03-6828e665f239"
      unitRef="number">0.0045</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i87bad62899d149bdaac599617b653af1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEwLTEtMS0xLTE5NzE4Mg_8db9e6a0-7f75-47d6-99de-b94f4d29cf1a"
      unitRef="usd">433000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i933751a82f6445a3b8dcbd93c8fc716a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEwLTMtMS0xLTE5NzE4Mg_a8643cf2-56b3-4405-a962-1f0a6cc6ca19"
      unitRef="usd">436400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i08a6834348314addb7e7dc8a7a6dfac1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzExLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOmYzZmQ2ZmMwYjM0NzQzNTQ4OTFmNzczMDlhNjFlY2Q3XzQ_e2981395-9ea6-4646-bfa0-9b68e07cc356"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i08a6834348314addb7e7dc8a7a6dfac1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzExLTEtMS0xLTE5NzE4Mg_8adca5db-e579-432f-8ef9-e6836a4e5621"
      unitRef="usd">930600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia61b26c361d64e2b848451ac3c78f961_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzExLTMtMS0xLTE5NzE4Mg_c82c338b-4924-4e09-b333-28e107be9c69"
      unitRef="usd">930600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie374eb8422b44d6781dd2c7369a9bbe9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEyLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjUxMWM0N2Y0NzE4NDQ2YWViOGU0ODA0MjU1ZDhmMjE1XzQ_ec5a2b1c-d0c7-4620-a0fc-f4a135c4fc0e"
      unitRef="number">0.0042</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie374eb8422b44d6781dd2c7369a9bbe9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEyLTEtMS0xLTE5NzE4Mg_2a593397-3fab-46a4-bb1a-2a143197bd72"
      unitRef="usd">172100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i53bdc5a3a83441b19c9683bb0db20458_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEyLTMtMS0xLTE5NzE4Mg_966e89cd-0862-4f5e-83bd-9d5703960c78"
      unitRef="usd">199000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i19faddcfa3a6449f9e5d54d4c7cc0a5d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEzLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjllZTNmYzAyOWQ2ZDQ2MTFiMTM5MzgxN2ZiODJlOTFhXzQ_5f4a0977-ab77-4acd-b4a3-7fc86768e8ca"
      unitRef="number">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i19faddcfa3a6449f9e5d54d4c7cc0a5d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEzLTEtMS0xLTE5NzE4Mg_503f44d3-7577-4ea7-82ce-bf6835c4529b"
      unitRef="usd">799300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i20625f40121146dbbad262af55cd252c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzEzLTMtMS0xLTE5NzE4Mg_89dfded8-2b0f-4e02-80a6-1b4713a93ceb"
      unitRef="usd">847700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0aa8cf85cde34e54833cd650ef5410b8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE0LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjMzNjVkMTAyYWFkNzQ1OTNhZDAxODY3NzI0NjkzYjczXzQ_c720d1f7-08b1-4bf5-8531-8f090315b8ae"
      unitRef="number">0.00625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0aa8cf85cde34e54833cd650ef5410b8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE0LTEtMS0xLTE5NzE4Mg_5f0d5da9-585b-4f56-ad39-74956e24924c"
      unitRef="usd">639400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie7f6d19c2b7d422585182914ccfc57a8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE0LTMtMS0xLTE5NzE4Mg_91628567-1472-416d-aa39-bb49681e758b"
      unitRef="usd">678200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8db52983c5fb45929449da08901ec208_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE1LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOmZkZTJiY2QxNDkzZTQ4YWE5ZmEyZDBiMDAwNjVlZTc5XzQ_49e7b165-8e8e-4938-87eb-dbdc7b29f74b"
      unitRef="number">0.0050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8db52983c5fb45929449da08901ec208_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE1LTEtMS0xLTE5NzE4Mg_03df2aa8-d532-4a21-8a6a-963c606ee226"
      unitRef="usd">639400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4811598343304ab1a6ac92a4d4384082_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE1LTMtMS0xLTE5NzE4Mg_2b256a63-4081-42b1-8113-796d31545a33"
      unitRef="usd">678200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i525c05f6af404e8e88124f226b94e2ce_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE2LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjU0N2M5MjA2MDkzNzQxYWU4YTRiMjZhZmU3YWZhZGUxXzQ_069bb0d5-a27d-4ca2-942d-6753af0d0421"
      unitRef="number">0.0056</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i525c05f6af404e8e88124f226b94e2ce_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE2LTEtMS0xLTE5NzE4Mg_0fcaad78-efa9-4859-bd60-e98b6dec4466"
      unitRef="usd">69700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i58706ae52cd04d5787f689decd555c79_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE2LTMtMS0xLTE5NzE4Mg_6d7d6fdf-6e33-4532-8633-0503c4ba7b69"
      unitRef="usd">80500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i62868cd48e734ea186f9dbc3ddc52276_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE3LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjk2ODc1MGQzODk5ZjQxMGQ5NWJmNzBkODllMWU5NTYyXzQ_6f78b4a7-5390-4f83-a881-6f29730faa29"
      unitRef="number">0.0677</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i62868cd48e734ea186f9dbc3ddc52276_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE3LTEtMS0xLTE5NzE4Mg_7da5f73f-93f5-41de-b967-8055f6d06db2"
      unitRef="usd">158600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i039f506220b44e9b92088ddadae4d438_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE3LTMtMS0xLTE5NzE4Mg_9cbcbb21-1ab1-4060-a571-ec428b644609"
      unitRef="usd">158600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia861290fae084d9dad2fa74b54a93f61_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE4LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjJlMDU2YzYyZTY4YjQxZWI4YWMzYTgxNmEyNWMyYjU3XzQ_0051ce5a-cf9a-4459-8404-6099c36fb130"
      unitRef="number">0.0555</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia861290fae084d9dad2fa74b54a93f61_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE4LTEtMS0xLTE5NzE4Mg_fdb263af-474c-4572-a89f-812e9ebff26d"
      unitRef="usd">444700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if0f1ac1cc9084ecbb7ec146e7a0ecf59_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE4LTMtMS0xLTE5NzE4Mg_7f6ec94f-282a-431b-8b40-21b84ea18c09"
      unitRef="usd">444700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i08e38bce3a2645658e249867cecec63c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE5LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjlhMDhiOGQ0YTI0ZDQ0MTZhMzIxNTAzZjEyN2I4MDIxXzQ_deb029cf-dc2c-4305-b09b-265a4083d13d"
      unitRef="number">0.0595</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i08e38bce3a2645658e249867cecec63c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE5LTEtMS0xLTE5NzE4Mg_5415b42c-97fe-409d-bee7-7fce072c000e"
      unitRef="usd">266800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic1a7b88a64384880b61cf8aa84d05774_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzE5LTMtMS0xLTE5NzE4Mg_d145b5ac-50d2-44e4-ba3d-38629d6643ff"
      unitRef="usd">266800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0343f767507d45eeae7ccb730acb9974_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIwLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjQwY2M4NWYwNTFkMTQxMGFhNWI4YWVmZTg2Mzc5MTFhXzQ_0097eeef-dca2-4cfb-9e35-0c261ebe064e"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0343f767507d45eeae7ccb730acb9974_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIwLTEtMS0xLTE5NzE4Mg_c5c0eb30-2848-446e-ac18-ab8d0e78e31b"
      unitRef="usd">240300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id9ce6e78973845499d30563930a6453b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIwLTMtMS0xLTE5NzE4Mg_73123ec0-afac-4f2e-bf3c-c9fbde0b189d"
      unitRef="usd">240300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ieed40c2fbef84f74b11d5910f62ad4eb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIxLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjI2NTMwNDYwYTU4ZTQwMzhiMmRkMmMzNTI4YmUzOTA1XzQ_5f6ac0f5-5aff-4e12-8dbe-077e599f1272"
      unitRef="number">0.01625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ieed40c2fbef84f74b11d5910f62ad4eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIxLTEtMS0xLTE5NzE4Mg_84d6929f-c4ba-4ad9-bbde-e357b93efc6f"
      unitRef="usd">301200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0f3c74be38f245b8b6ed35611a69d273_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIxLTMtMS0xLTE5NzE4Mg_1fe797da-29e5-4963-a1d6-487291f18e1f"
      unitRef="usd">337100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i54e0e0101a7841daae4f2106284daf1d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIyLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjM1OTYwOTVjZmIyZjRlOThhODg4YjcyMzE1NWI1YjZiXzQ_72c1eadd-914f-49ca-b4e7-07b7a582de39"
      unitRef="number">0.0465</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i54e0e0101a7841daae4f2106284daf1d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIyLTEtMS0xLTE5NzE4Mg_94f6818f-b9e5-46c4-b279-6295a32482ea"
      unitRef="usd">38300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1d2c94e9725b44148fcdb6193e2870fd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIyLTMtMS0xLTE5NzE4Mg_72b3b554-9a75-42e8-9cb2-0e8b5cac9c76"
      unitRef="usd">38300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ieeb8b7e9ed7a49e49e94f6af00648190_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIzLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjJjMWU0OWMxYTEyYzQ0MzhhZGJlNWU3NzNmNTBlZjJkXzQ_c3f66044-420f-4842-861c-1cb1c63cb8f2"
      unitRef="number">0.037</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ieeb8b7e9ed7a49e49e94f6af00648190_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIzLTEtMS0xLTE5NzE4Mg_8b003bd7-ce88-49f1-a6ee-99f81ada9197"
      unitRef="usd">386800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iea58f3bd452e4a36842dd6ec45db98a3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzIzLTMtMS0xLTE5NzE4Mg_f931d5ad-2c2f-421a-9199-56dc667696ab"
      unitRef="usd">386800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iea465f0f6ff843b3ae0b1c8b37cd87ef_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI0LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjA5NGQzZTRiOGJhNTQ5ZTRiOGNjMmI1NGEwNGM2YjQyXzQ_60ade5be-4e1f-4aed-985c-161c82b40490"
      unitRef="number">0.0395</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iea465f0f6ff843b3ae0b1c8b37cd87ef_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI0LTEtMS0xLTE5NzE4Mg_cc39c20a-3aee-40b8-8be5-df802c47a664"
      unitRef="usd">347000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i59316aeff65f444fa246fc62593bfeef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI0LTMtMS0xLTE5NzE4Mg_0c750e1a-4115-485e-9e77-6df034d59d77"
      unitRef="usd">347000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i41a65a471c734c42a6d546c096e16d1b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI1LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjU5NDlkMGQxMzZlNjQ5YTRhMDIzNTcwYTJiNzZlZjJhXzQ_1a41cea0-8f74-4bb4-b9a8-fd4baffa69ab"
      unitRef="number">0.0395</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i41a65a471c734c42a6d546c096e16d1b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI1LTEtMS0xLTE5NzE4Mg_80d7f9eb-df01-4b9e-9765-6f4862d9a505"
      unitRef="usd">958200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icd3a46888e13415cb278b164998a5c33_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI1LTMtMS0xLTE5NzE4Mg_5d5e00c0-5820-4fa5-afd8-2f3f389ef217"
      unitRef="usd">958200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibfc0c52db55940be9c4b62d052da668e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI2LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOmRmN2Q0YzMzYmVhZTQ1ZWI5NTkzNTRhNWVmODUyZjViXzQ_0fee0d7d-f0e0-43e5-8d1d-d4030132fccf"
      unitRef="number">0.0170</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibfc0c52db55940be9c4b62d052da668e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI2LTEtMS0xLTE5NzE4Mg_46fce806-ed6c-42b2-8aa8-176d8ebc17b5"
      unitRef="usd">1065700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibeb85aea19744a2ab1f156a41e098a53_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI2LTMtMS0xLTE5NzE4Mg_2eefaeeb-24b2-4b3e-a4d1-83208265d993"
      unitRef="usd">1130300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icdba7d3f60f347eca7dbb1d8296ddcdc_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI3LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOmQyZDExZTA3NGRkMjQwYzQ4ZGQxMjY3ZjM2YjBlNzJjXzQ_39472108-5679-4d92-99cd-57c5bcc6397a"
      unitRef="number">0.0097</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icdba7d3f60f347eca7dbb1d8296ddcdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI3LTEtMS0xLTE5NzE4Mg_aed4592d-f968-428f-b601-a6a5e5d2af27"
      unitRef="usd">57400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4c07500c2b6f4b61a48ebb178947c8db_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI3LTMtMS0xLTE5NzE4Mg_061d8e2d-fb99-44c9-bf14-a1c1d1edab6b"
      unitRef="usd">66300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i06e56a449d7e46f5a50fe0e1d8d8f32b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI4LTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjEzYzIyZmZiZjI0YjQzZjBiYzdhZGQ1ZTYzMDNmNmRjXzQ_a851de54-f391-4dea-8d84-5710cc9ac03c"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i06e56a449d7e46f5a50fe0e1d8d8f32b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI4LTEtMS0xLTE5NzE4Mg_7da5c66a-6946-4a2b-b7d6-2a9c8fa2947f"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i867cfd6e85ca49dc8bc5f47a7e85af14_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzI4LTMtMS0xLTE5NzE4Mg_f1a3462f-6952-4c38-a2a7-f0e4084f1296"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7e986ddd3ce54fd1b852b00b58b6aa8c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMwLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjhkODVhNmQ5MzI1ZTQxYmJhZThhMTc1NzM4M2FjMzVmXzQ_f8270979-de0a-4f40-8e85-dab83ff707f5"
      unitRef="number">0.01125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7e986ddd3ce54fd1b852b00b58b6aa8c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMwLTEtMS0xLTE5NzE4Mg_4c020fa7-bf3d-41cf-849c-e6b6cd3cbd07"
      unitRef="usd">532900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0fbb357599024d59874aed080c948903_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMwLTMtMS0xLTE5NzE4Mg_a1868b21-7e4e-491d-a011-8de5e745783f"
      unitRef="usd">565200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i60c6d92c70bb4827b8d11ed6c2927a17_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMxLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjQyNTU4Mzk0MWJhNjRiODg5MmY3MGM3MmUwZjg0YWFlXzQ_167ef358-ff2e-4713-9f01-79d5685a1c50"
      unitRef="number">0.0415</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i60c6d92c70bb4827b8d11ed6c2927a17_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMxLTEtMS0xLTE5NzE4Mg_1856d58c-d5e9-4977-a241-51f7bbcdc32f"
      unitRef="usd">591300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7ed86b00b5854fb5ad549409205591d0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMxLTMtMS0xLTE5NzE4Mg_dc51500b-f497-434a-bc88-a38f069335cc"
      unitRef="usd">591300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iedd1c12277a041ab81c0a54878416b3c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMyLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjRlNDVhMzdmMDA4YjRkODE4ZDdhMmMwNjQ3ZmEzYWExXzQ_76e7dbf4-f8c9-4085-84bc-fc73dcc5829b"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iedd1c12277a041ab81c0a54878416b3c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMyLTEtMS0xLTE5NzE4Mg_5d2505c3-4002-4cc3-9e73-29d6b7b5d8a5"
      unitRef="usd">850000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id73e022a19034845867e9f0ce636e37e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMyLTMtMS0xLTE5NzE4Mg_1e41ee1e-1ef5-436b-99ee-6289ba928dd2"
      unitRef="usd">850000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i58f74fa5874e4bab94a1ead5e6fd1e49_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMzLTAtMS0xLTE5NzE4Mi90ZXh0cmVnaW9uOjM2MmExZjM1MzM4NjQ0NjU4Zjg2MjNhN2ZiOTZhNTlhXzQ_956d6364-5bae-435a-a9ee-980046efd846"
      unitRef="number">0.01375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i58f74fa5874e4bab94a1ead5e6fd1e49_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMzLTEtMS0xLTE5NzE4Mg_d21f61ac-41c3-4d02-8276-fbef44033dbb"
      unitRef="usd">746000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9fffe809d4dc437bbf367bdf220199fd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzMzLTMtMS0xLTE5NzE4Mg_7d0f3722-4fd5-4401-bbec-b9628643d459"
      unitRef="usd">791200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzM0LTEtMS0xLTE5NzE4Mg_4ce98b37-da56-4daf-83fd-c4300ac08b51"
      unitRef="usd">96100000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzM0LTMtMS0xLTE5NzE4Mg_97d60952-4b5f-44e1-9215-b78a03ad37ae"
      unitRef="usd">105200000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzM1LTEtMS0xLTE5NzE4Mg_7e959628-b45d-4791-8572-9c3966f59a28"
      unitRef="usd">14815300000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpiNTIzODQ1YzljYzI0MWExOGJjZTE4MjJmMGE2NmJhNi90YWJsZXJhbmdlOmI1MjM4NDVjOWNjMjQxYTE4YmNlMTgyMmYwYTY2YmE2XzM1LTMtMS0xLTE5NzE4Mg_d1f7af3b-18fe-43b0-bf5e-157e62c0800f"
      unitRef="usd">16741200000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI5NA_ad756664-f0d8-43fa-b32c-61bdf88055b1"
      unitRef="usd">7330000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="icbbad28b34b342babe4bf7cc2a5134cb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzM3Mg_354d5f2b-d1b0-4552-be15-39870fc0e669"
      unitRef="usd">3000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ieb7eeafef488487ca857290e624770bd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzQyNw_fada4e91-5b86-4c4b-86d2-528f52b03ddb"
      unitRef="usd">4000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="i0c779efd9f6c4ddea6602f310141dc09_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzQzMA_adfc6e22-48d2-4a6e-a2f6-deeb6cfde601">P364D</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="icbbad28b34b342babe4bf7cc2a5134cb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzU3Ng_354d5f2b-d1b0-4552-be15-39870fc0e669"
      unitRef="usd">3000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ieb7eeafef488487ca857290e624770bd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzU4Mw_fada4e91-5b86-4c4b-86d2-528f52b03ddb"
      unitRef="usd">4000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0b321af1dafc43ccbaeaa9699581dab7_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM1MDk_d976b6a1-5e65-415f-9ad2-c2582807a9e7"
      unitRef="eur">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0b321af1dafc43ccbaeaa9699581dab7_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzU0OTc1NTgxNDMxNzk_b55646a4-5a23-4e76-90bd-8d5a59c3954c"
      unitRef="number">0.50</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i57ce917b0f0c422ca61e881f3f692344_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM1MjU_8273f2fd-887c-4cb1-9023-0f8d29862b9a"
      unitRef="eur">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i57ce917b0f0c422ca61e881f3f692344_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzU0OTc1NTgxNDMxODY_48ca812b-0123-44b8-b0ef-b2d18bcdda55"
      unitRef="number">1.125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4a5e0b9bc64e491cb66aa141907b7e5c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM1NDE_6da02cc4-97e3-401b-b3db-7aac1e36832c"
      unitRef="eur">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4a5e0b9bc64e491cb66aa141907b7e5c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzU0OTc1NTgxNDMxOTQ_8d5e6ece-2bad-42b5-b66b-aba7a0e6aad6"
      unitRef="number">1.375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i451dcfd995634628a4d966f35c25b82c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM1NTc_2c31c06c-f548-4c56-9f9d-37853b7836a2"
      unitRef="gbp">250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i451dcfd995634628a4d966f35c25b82c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzU0OTc1NTgxNDMyMDI_d12b45a1-f270-4784-93ee-0bb39b781e20"
      unitRef="number">1.625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i0b24bd1f49ea4586a8301239a10ac27e_D20210901-20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM1NzM_8d568e0e-86f1-481b-a280-5cf580678c55"
      unitRef="usd">1910000000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i0b24bd1f49ea4586a8301239a10ac27e_D20210901-20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM1ODg_2be794d1-b274-4da8-924b-cd95c8ba67dd"
      unitRef="usd">1500000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0b24bd1f49ea4586a8301239a10ac27e_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM2MDM_6c955590-d26e-4b31-a0a1-ba3ca8279096"
      unitRef="usd">-405200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i0b24bd1f49ea4586a8301239a10ac27e_D20210901-20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM2MTk_c9e2adee-16c8-4b9d-b0fa-647fd963674e"
      unitRef="usd">1500000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i7c474d66fd4941be8ee1af7f8bc945a2_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM2MzQ_c29426cd-935e-499d-b9df-cc4cd3e61c64"
      unitRef="usd">541800000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i341d1442ad9c4796ad0ad6233bebae92_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzU0OTc1NTgxNDMyMTA_3c57eb18-6f5c-4dd4-a914-cd7caf866433"
      unitRef="number">3.95</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="ied580748898946bdaf1108b103303bdd_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM2NTA_92f175c5-df18-4800-bd86-7ed59f8a6601"
      unitRef="usd">408700000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3b7e5b5013ea482e858c341d9431d76f_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzU0OTc1NTgxNDMyMTc_5cfcece4-5cbd-45e9-93e7-f045b8bdb35f"
      unitRef="number">4.15</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="ie9ac3bd2cc2c4fb7844518c2ea52b6ed_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg3NzkwNzM2NjY_4e280ac3-ef45-4c4a-84ba-9673c83e6094"
      unitRef="usd">219400000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8e29d24af5de402499fe4ebe60451143_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzU0OTc1NTgxNDMyMjQ_bbe231bd-e8bf-4f74-82fc-bc18187488a6"
      unitRef="number">3.375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ifdbadac98c4141e0b7b6c55a77240061_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI0ODk_d00c60e9-5ccc-4fba-bec8-e6452bc30de4"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifdbadac98c4141e0b7b6c55a77240061_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI0OTU_9eb3c138-582a-4efa-9ed3-a0143492ab3c"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i6441fa6a78ef4e12b30986772baa1b26_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI2MjM_4d415174-0f62-475e-bf2c-ff938a166d11"
      unitRef="usd">988600000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i06c599f0bde9445fa16d1cc4feb31a6f_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDI_80eefbaa-16e8-4d6d-b91b-e07b016c56a2"
      unitRef="usd">850000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i06c599f0bde9445fa16d1cc4feb31a6f_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI3NDg_10708b2c-ea22-48ba-852d-2bc0078a68de"
      unitRef="number">0.025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8a93a3c5ae824553bbd8a41bbef49dbb_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI4MDg_a55a9bff-00fd-4dbe-bf6f-b1bb4b71cffe"
      unitRef="usd">250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8a93a3c5ae824553bbd8a41bbef49dbb_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI4MTg_61744cdc-a78e-4619-a054-5119a73e8b00"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ic0163626092d4db6b26a6af6487a4108_D20200801-20200831"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzI5NDY_4d6a7adb-c0d0-4357-9335-01274e55272f"
      unitRef="usd">1070000000.00</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzQwMzk_d10a860f-5b2a-43df-8630-fcf9cbab2bb1">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amounts of maturities on long-term debt for the next five years are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities on long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpmZDI5ZDVmYmUwMjA0NTRjYjQ0YjE0ZWI2YzNiNTUxMi90YWJsZXJhbmdlOmZkMjlkNWZiZTAyMDQ1NGNiNDRiMTRlYjZjM2I1NTEyXzEtMS0xLTEtMTk3MTgy_2107ddb9-8f6e-4581-a9c3-7f4f279198a5"
      unitRef="usd">3100000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpmZDI5ZDVmYmUwMjA0NTRjYjQ0YjE0ZWI2YzNiNTUxMi90YWJsZXJhbmdlOmZkMjlkNWZiZTAyMDQ1NGNiNDRiMTRlYjZjM2I1NTEyXzEtMy0xLTEtMTk3MTgy_d10e9ed8-4607-410c-9097-9483f3260dc2"
      unitRef="usd">649500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpmZDI5ZDVmYmUwMjA0NTRjYjQ0YjE0ZWI2YzNiNTUxMi90YWJsZXJhbmdlOmZkMjlkNWZiZTAyMDQ1NGNiNDRiMTRlYjZjM2I1NTEyXzEtNS0xLTEtMTk3MTgy_6199602d-5db8-4e0c-9a2a-ec95fa748080"
      unitRef="usd">778100000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpmZDI5ZDVmYmUwMjA0NTRjYjQ0YjE0ZWI2YzNiNTUxMi90YWJsZXJhbmdlOmZkMjlkNWZiZTAyMDQ1NGNiNDRiMTRlYjZjM2I1NTEyXzEtNy0xLTEtMTk3MTgy_985ab90e-bcbd-4ba4-98c3-77a9090bcb6c"
      unitRef="usd">799300000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTpmZDI5ZDVmYmUwMjA0NTRjYjQ0YjE0ZWI2YzNiNTUxMi90YWJsZXJhbmdlOmZkMjlkNWZiZTAyMDQ1NGNiNDRiMTRlYjZjM2I1NTEyXzEtOS0xLTEtMTk3MTgy_7f207c14-1e75-40fe-815c-a7be555a9f92"
      unitRef="usd">765800000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <lly:DescriptionOfDerivativeActivityVolumePercent
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzMxNjc_6c4b2274-94f5-469d-9585-960b6ee02716"
      unitRef="number">0.10</lly:DescriptionOfDerivativeActivityVolumePercent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzM0NTc_2a6e0056-c529-4bdd-a48c-6f10d9d8ded0"
      unitRef="number">0.0287</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzM0NjQ_c3bd99f0-2e18-444a-8050-415a36fabf3f"
      unitRef="number">0.0227</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <lly:ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90ZXh0cmVnaW9uOmQ2NTNlMWRlNWRjMTQyYTI5NjFkYzY1YzQyNTJmNGQ0XzQwNDc_dd2564e6-d7b1-46a1-ae0a-db0afee3e57a">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments for interest on borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;323.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lly:ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock>
    <us-gaap:InterestPaidNet
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo4ZDVlNmNkNGQ4NDc0YmE4OTdmMGFiMzM1NjBhNDFhYy90YWJsZXJhbmdlOjhkNWU2Y2Q0ZDg0NzRiYTg5N2YwYWIzMzU2MGE0MWFjXzEtMS0xLTEtMTk3MTgy_18193880-e7af-4a12-a4a0-86bd5a6dc51b"
      unitRef="usd">323700000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo4ZDVlNmNkNGQ4NDc0YmE4OTdmMGFiMzM1NjBhNDFhYy90YWJsZXJhbmdlOjhkNWU2Y2Q0ZDg0NzRiYTg5N2YwYWIzMzU2MGE0MWFjXzEtMy0xLTEtMTk3MTgy_fce81304-bc37-4eab-b60a-cfd223478749"
      unitRef="usd">338000000.0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjQvZnJhZzpkNjUzZTFkZTVkYzE0MmEyOTYxZGM2NWM0MjUyZjRkNC90YWJsZTo4ZDVlNmNkNGQ4NDc0YmE4OTdmMGFiMzM1NjBhNDFhYy90YWJsZXJhbmdlOjhkNWU2Y2Q0ZDg0NzRiYTg5N2YwYWIzMzU2MGE0MWFjXzEtNS0xLTEtMTk3MTgy_2795e774-5f24-432e-aa97-0093ff83c2f6"
      unitRef="usd">345800000</us-gaap:InterestPaidNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU1ODA_5141af1b-e8b1-4744-96a7-f8beeda1297b">Stock-Based Compensation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our stock-based compensation expense consists of performance awards (PAs), shareholder value awards (SVAs), relative value awards (RVAs), and restricted stock units (RSUs). We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, RVA, and RSU shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense and the related tax benefits were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;371.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, stock-based compensation awards may be granted under the 2002 Lilly Stock Plan for not more than 50.0 million additional shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Performance Award Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain pre-established earnings-per-share targets over a two-year period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period. The fair values of PAs granted for the years ended December&#160;31, 2022, 2021, and 2020 were $234.93, $198.57, and $137.33, respectively. The number of shares ultimately issued for the PA program is dependent upon the EPS achieved during the vesting period. Pursuant to this program, approximately 0.7 million shares, 0.7 million shares, and 1.1&#160;million shares were issued during the years ended December&#160;31, 2022, 2021, and 2020, respectively. Approximately 0.5 million shares are expected to be issued in 2023. As of December&#160;31, 2022, the total remaining unrecognized compensation cost related to nonvested PAs was $38.4 million, which will be amortized over the weighted-average remaining requisite service period of 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shareholder Value Award Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SVAs are granted to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on our stock price at the end of the three-year vesting period compared to pre-established target stock prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair values of the SVA units granted during the years ended December&#160;31, 2022, 2021, and 2020 were $203.88, $230.19, and $139.14, respectively, determined using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32.99&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to this program, approximately 0.5 million shares, 1.0 million shares, and 0.8 million shares were issued during the years ended December&#160;31, 2022, 2021, and 2020, respectively. Approximately 0.3&#160;million shares are expected to be issued in 2023. As of December&#160;31, 2022, the total remaining unrecognized compensation cost related to nonvested SVAs was $43.3 million, which will be amortized over the weighted-average remaining requisite service period of 21 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Relative Value Award Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RVAs are granted to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on the growth of our stock price at the end of the three-year vesting period compared to our peers. We measure the fair value of the RVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price and our peers' stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair value of the RVA units granted during the years ended December&#160;31, 2022, 2021 and 2020 were $230.00, $286.71, and $179.90, respectively, determined using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32.86&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 0.1 million shares are expected to be issued in 2023. As of December&#160;31, 2022, the total remaining unrecognized compensation cost related to nonvested RVAs was $17.5 million, which will be amortized over the weighted-average remaining requisite service period of 22 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically three years. The weighted-average fair values of RSU awards granted during the years ended December&#160;31, 2022, 2021, and 2020 were $239.88, $196.30, and $135.42, respectively. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures. Pursuant to this program, 1.0 million, 0.7 million, and 1.1 million shares were granted and approximately 0.8 million, 0.6 million, and 0.6 million shares were issued during the years ended December&#160;31, 2022, 2021, and 2020, respectively. Approximately 0.6 million shares are expected to be issued in 2023. As of December&#160;31, 2022, the total remaining unrecognized compensation cost related to nonvested RSUs was $221.6 million, which will be amortized over the weighted-average remaining requisite service period of 25 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU1NTU_4d81b789-fc9d-4180-ad7c-418b102c2504">We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, RVA, and RSU shares.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU1NDU_38f8c5c3-c1f1-432a-bf45-e92a23bf0dea">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense and the related tax benefits were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;371.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo1MzFkYTU5NzhjM2M0NmRmYjYyYmRiNGZkMWUxM2E3OC90YWJsZXJhbmdlOjUzMWRhNTk3OGMzYzQ2ZGZiNjJiZGI0ZmQxZTEzYTc4XzEtMS0xLTEtMTk3MTgy_455b81db-4837-40ea-a0de-1081012db7b9"
      unitRef="usd">371100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo1MzFkYTU5NzhjM2M0NmRmYjYyYmRiNGZkMWUxM2E3OC90YWJsZXJhbmdlOjUzMWRhNTk3OGMzYzQ2ZGZiNjJiZGI0ZmQxZTEzYTc4XzEtMy0xLTEtMTk3MTgy_83473a63-605d-41f7-bbf6-f042e394ab56"
      unitRef="usd">342800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo1MzFkYTU5NzhjM2M0NmRmYjYyYmRiNGZkMWUxM2E3OC90YWJsZXJhbmdlOjUzMWRhNTk3OGMzYzQ2ZGZiNjJiZGI0ZmQxZTEzYTc4XzEtNS0xLTEtMTk3MTgy_1945d8de-28aa-4a77-a8da-0ab098e9d83f"
      unitRef="usd">308100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo1MzFkYTU5NzhjM2M0NmRmYjYyYmRiNGZkMWUxM2E3OC90YWJsZXJhbmdlOjUzMWRhNTk3OGMzYzQ2ZGZiNjJiZGI0ZmQxZTEzYTc4XzItMS0xLTEtMTk3MTgy_4a0ba434-1859-4816-8058-7226777e1a00"
      unitRef="usd">77900000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo1MzFkYTU5NzhjM2M0NmRmYjYyYmRiNGZkMWUxM2E3OC90YWJsZXJhbmdlOjUzMWRhNTk3OGMzYzQ2ZGZiNjJiZGI0ZmQxZTEzYTc4XzItMy0xLTEtMTk3MTgy_0ac609ba-c006-4b4c-abb4-a7bde9b5d688"
      unitRef="usd">72000000.0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo1MzFkYTU5NzhjM2M0NmRmYjYyYmRiNGZkMWUxM2E3OC90YWJsZXJhbmdlOjUzMWRhNTk3OGMzYzQ2ZGZiNjJiZGI0ZmQxZTEzYTc4XzItNS0xLTEtMTk3MTgy_7616b937-8233-49c9-809a-ac7a1d5c5cf5"
      unitRef="usd">64700000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzY5Ng_303b8ab7-7d81-4188-a5df-79ff0a6c378f"
      unitRef="shares">50000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i34e736a6ca514f689eb35288b8ec7b70_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU1Njc_8482784a-3cfe-46ab-ac0f-5661292c5b9b">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i34e736a6ca514f689eb35288b8ec7b70_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzEyMTk_0f76021d-450d-4709-8b67-9f79a15bfc73"
      unitRef="usdPerShare">234.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id89b274231544b368ef56d599d8e67f0_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzEyMjM_66b84c07-f7ed-48ff-94cb-68fc7b9e3601"
      unitRef="usdPerShare">198.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9e110f0e24e249d59282a44ccaa3721e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzEyMzE_32f50dae-7fcf-4909-bed2-7fa5083a90b1"
      unitRef="usdPerShare">137.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i34e736a6ca514f689eb35288b8ec7b70_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzE0MDk_cd2722c8-ac71-454e-8cc9-56781351acbf"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="id89b274231544b368ef56d599d8e67f0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzE0MjA_72bc02c0-e974-4f27-98a2-ec6a646798cd"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i9e110f0e24e249d59282a44ccaa3721e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzE0MzU_ad461756-6ce4-4de6-a130-f62edeebfd6d"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued
      contextRef="i34e736a6ca514f689eb35288b8ec7b70_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzE1MjQ_91934331-0344-468f-8c87-e275e66aa059"
      unitRef="shares">500000</lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ie786c6b1fada4a3dbc69ad548931dec2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzE2NTc_401ad042-25b2-4600-a64d-248c9c7651ea"
      unitRef="usd">38400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i34e736a6ca514f689eb35288b8ec7b70_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzE3NDk_613aed05-c25c-4322-995b-5cab9b23f84b">P12M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU1NDY_ef981db4-3297-4800-8439-b99cc4cf5317">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <lly:SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU1NDc_cd5003e3-837d-4bbf-b1fa-9e8d8c1d9c19">The weighted-average fair values of the SVA units granted during the years ended December&#160;31, 2022, 2021, and 2020 were $203.88, $230.19, and $139.14, respectively, determined using the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32.99&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;The weighted-average fair value of the RVA units granted during the years ended December&#160;31, 2022, 2021 and 2020 were $230.00, $286.71, and $179.90, respectively, determined using the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32.86&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</lly:SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzI4MTg_41411bfd-7bc1-4f22-a943-b3a44555f6c0"
      unitRef="usdPerShare">203.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i03b05f63c9574af38cc3b218f3d7f04c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzI4MjI_5404dac9-4039-4ce5-a359-931424154104"
      unitRef="usdPerShare">230.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i171e2f5cc14f445bbc2e02aa39c75b98_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzI4MzA_cf67c3c5-5e2e-487d-818a-29e94ef954d4"
      unitRef="usdPerShare">139.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2M2MyNjA4NDJmZGI0NWRmOWRkOWUwZTVhMTVkOWUzNC90YWJsZXJhbmdlOjYzYzI2MDg0MmZkYjQ1ZGY5ZGQ5ZTBlNWExNWQ5ZTM0XzEtMS0xLTEtMTk3MTgy_431ec3fd-c8e4-4254-b397-1dd1cd9e469b"
      unitRef="number">0.0160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i03b05f63c9574af38cc3b218f3d7f04c_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2M2MyNjA4NDJmZGI0NWRmOWRkOWUwZTVhMTVkOWUzNC90YWJsZXJhbmdlOjYzYzI2MDg0MmZkYjQ1ZGY5ZGQ5ZTBlNWExNWQ5ZTM0XzEtMy0xLTEtMTk3MTgy_112ee0f8-101e-456b-8d93-d6e88909eb3e"
      unitRef="number">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i171e2f5cc14f445bbc2e02aa39c75b98_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2M2MyNjA4NDJmZGI0NWRmOWRkOWUwZTVhMTVkOWUzNC90YWJsZXJhbmdlOjYzYzI2MDg0MmZkYjQ1ZGY5ZGQ5ZTBlNWExNWQ5ZTM0XzEtNS0xLTEtMTk3MTgy_daf78c68-2359-4438-90e9-04f92b21bfa4"
      unitRef="number">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2M2MyNjA4NDJmZGI0NWRmOWRkOWUwZTVhMTVkOWUzNC90YWJsZXJhbmdlOjYzYzI2MDg0MmZkYjQ1ZGY5ZGQ5ZTBlNWExNWQ5ZTM0XzItMS0xLTEtMTk3MTgy_682c66b8-9cea-4df9-b8ce-2e337d038d61"
      unitRef="number">0.0157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i03b05f63c9574af38cc3b218f3d7f04c_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2M2MyNjA4NDJmZGI0NWRmOWRkOWUwZTVhMTVkOWUzNC90YWJsZXJhbmdlOjYzYzI2MDg0MmZkYjQ1ZGY5ZGQ5ZTBlNWExNWQ5ZTM0XzItMy0xLTEtMTk3MTgy_cf08521a-96b0-482d-8508-b94cad3e0d19"
      unitRef="number">0.0019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i171e2f5cc14f445bbc2e02aa39c75b98_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2M2MyNjA4NDJmZGI0NWRmOWRkOWUwZTVhMTVkOWUzNC90YWJsZXJhbmdlOjYzYzI2MDg0MmZkYjQ1ZGY5ZGQ5ZTBlNWExNWQ5ZTM0XzItNS0xLTEtMTk3MTgy_867c038a-f980-4c9f-8106-41470b2e7951"
      unitRef="number">0.0138</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2M2MyNjA4NDJmZGI0NWRmOWRkOWUwZTVhMTVkOWUzNC90YWJsZXJhbmdlOjYzYzI2MDg0MmZkYjQ1ZGY5ZGQ5ZTBlNWExNWQ5ZTM0XzMtMS0xLTEtMTk3MTgy_5545dd84-be84-42bd-b821-fe62340b84b5"
      unitRef="number">0.3299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i03b05f63c9574af38cc3b218f3d7f04c_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2M2MyNjA4NDJmZGI0NWRmOWRkOWUwZTVhMTVkOWUzNC90YWJsZXJhbmdlOjYzYzI2MDg0MmZkYjQ1ZGY5ZGQ5ZTBlNWExNWQ5ZTM0XzMtMy0xLTEtMTk3MTgy_38e6f49e-11d8-4909-a3ba-26165c0c3a6d"
      unitRef="number">0.3142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i171e2f5cc14f445bbc2e02aa39c75b98_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2M2MyNjA4NDJmZGI0NWRmOWRkOWUwZTVhMTVkOWUzNC90YWJsZXJhbmdlOjYzYzI2MDg0MmZkYjQ1ZGY5ZGQ5ZTBlNWExNWQ5ZTM0XzMtNS0xLTEtMTk3MTgy_8e532a67-b791-4372-b06a-77eeff14fa46"
      unitRef="number">0.2090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzI5MzQ_6d0e7261-e6bf-4a57-bc65-b3bb870ca3e7"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i03b05f63c9574af38cc3b218f3d7f04c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzI5NDU_bf0ad94d-9a79-45a9-9a7d-46f3bfd1aba7"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i171e2f5cc14f445bbc2e02aa39c75b98_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzI5NjA_3f72a3f5-cc0e-49f6-ad8f-9f49599eac0b"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued
      contextRef="i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzMwNDk_895546e3-1c8f-4099-8ebd-8f5e753ed9bd"
      unitRef="shares">300000</lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ide30b7bea6124a16bed5fd85591c653f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzMxODM_861109a5-40fe-4d52-b23e-75b4de0b4e20"
      unitRef="usd">43300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzMyNzU_fa108418-48e8-4288-b35c-7cdd6d17e5f9">P21M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i34c6e2fee53c4d53a400e54ee5da855d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU1NTI_4d4d217c-a901-400b-999b-eba4d01b507e">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i34c6e2fee53c4d53a400e54ee5da855d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzQzNjk_7d4bbcf3-fe04-4027-940b-1ecff65e0fb0"
      unitRef="usdPerShare">230.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie9f12c5407404719932a1a7e44769cdb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzQzNzY_20decb91-f49a-4a94-920f-98d4fc49b0c0"
      unitRef="usdPerShare">286.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie4ee98787c674df09daac84147aa1690_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU0OTc1NTgxOTg2OA_7ea14d3b-a499-4459-95d9-19dda3d44fed"
      unitRef="usdPerShare">179.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i34c6e2fee53c4d53a400e54ee5da855d_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2MmJmNzJmOTQ3ZTc0NGI1ODgzYmY0MzQ1MDk3ZDY2Yy90YWJsZXJhbmdlOjYyYmY3MmY5NDdlNzQ0YjU4ODNiZjQzNDUwOTdkNjZjXzEtMS0xLTEtMTk3MTgy_03d7b4e8-de74-46b9-aee1-d6105c4715f3"
      unitRef="number">0.0160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie9f12c5407404719932a1a7e44769cdb_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2MmJmNzJmOTQ3ZTc0NGI1ODgzYmY0MzQ1MDk3ZDY2Yy90YWJsZXJhbmdlOjYyYmY3MmY5NDdlNzQ0YjU4ODNiZjQzNDUwOTdkNjZjXzEtMi0xLTEtMTk3MTgy_ce4712aa-20b5-47d4-9319-9d8fa7235a61"
      unitRef="number">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie4ee98787c674df09daac84147aa1690_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2MmJmNzJmOTQ3ZTc0NGI1ODgzYmY0MzQ1MDk3ZDY2Yy90YWJsZXJhbmdlOjYyYmY3MmY5NDdlNzQ0YjU4ODNiZjQzNDUwOTdkNjZjXzEtMy0xLTEtMjIyNTg5_4a94eb76-3612-4ae7-a82d-be2a8b0f95f6"
      unitRef="number">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i34c6e2fee53c4d53a400e54ee5da855d_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2MmJmNzJmOTQ3ZTc0NGI1ODgzYmY0MzQ1MDk3ZDY2Yy90YWJsZXJhbmdlOjYyYmY3MmY5NDdlNzQ0YjU4ODNiZjQzNDUwOTdkNjZjXzItMS0xLTEtMTk3MTgy_53f0bcd8-5c0d-423f-89e0-40af55348985"
      unitRef="number">0.0157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie9f12c5407404719932a1a7e44769cdb_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2MmJmNzJmOTQ3ZTc0NGI1ODgzYmY0MzQ1MDk3ZDY2Yy90YWJsZXJhbmdlOjYyYmY3MmY5NDdlNzQ0YjU4ODNiZjQzNDUwOTdkNjZjXzItMi0xLTEtMTk3MTgy_f152d5be-b261-422c-8ee3-f3b9fc133ab4"
      unitRef="number">0.0019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie4ee98787c674df09daac84147aa1690_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2MmJmNzJmOTQ3ZTc0NGI1ODgzYmY0MzQ1MDk3ZDY2Yy90YWJsZXJhbmdlOjYyYmY3MmY5NDdlNzQ0YjU4ODNiZjQzNDUwOTdkNjZjXzItMy0xLTEtMjIyNTg5_66dfa5b1-43c0-4d66-8437-00ec59e05405"
      unitRef="number">0.0138</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i34c6e2fee53c4d53a400e54ee5da855d_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2MmJmNzJmOTQ3ZTc0NGI1ODgzYmY0MzQ1MDk3ZDY2Yy90YWJsZXJhbmdlOjYyYmY3MmY5NDdlNzQ0YjU4ODNiZjQzNDUwOTdkNjZjXzMtMS0xLTEtMTk3MTgy_77a3af2b-6639-451a-979e-4d68fa16d25d"
      unitRef="number">0.3286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie9f12c5407404719932a1a7e44769cdb_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2MmJmNzJmOTQ3ZTc0NGI1ODgzYmY0MzQ1MDk3ZDY2Yy90YWJsZXJhbmdlOjYyYmY3MmY5NDdlNzQ0YjU4ODNiZjQzNDUwOTdkNjZjXzMtMi0xLTEtMTk3MTgy_165dd012-9f98-4a3b-962a-a1b8c4091b10"
      unitRef="number">0.3095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie4ee98787c674df09daac84147aa1690_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90YWJsZTo2MmJmNzJmOTQ3ZTc0NGI1ODgzYmY0MzQ1MDk3ZDY2Yy90YWJsZXJhbmdlOjYyYmY3MmY5NDdlNzQ0YjU4ODNiZjQzNDUwOTdkNjZjXzMtMy0xLTEtMjIyNTg5_c57785ed-4363-4a2b-bac5-843bd5885722"
      unitRef="number">0.1989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued
      contextRef="i34c6e2fee53c4d53a400e54ee5da855d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU0OTc1NTgxOTg4Mw_0c7a9d55-25f6-41b7-bb9d-e93fa777031e"
      unitRef="shares">100000</lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="if5945a2c316d46c8a331422ade10498d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzQ1MzE_44e2bd9e-7b1b-406d-ae74-5492bf12d540"
      unitRef="usd">17500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i34c6e2fee53c4d53a400e54ee5da855d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzQ2MjM_0e5ff744-8d1b-4536-b384-d92190004058">P22M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia611d9892499421694f697dc5c368ddb_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzQ5MDk_a0bbebba-00ab-478a-838c-c10fff1e6309">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia611d9892499421694f697dc5c368ddb_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzQ5OTQ_2a640fc7-10a8-477d-9ad9-877cb53bb373"
      unitRef="usdPerShare">239.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4c55e65384854a888970465b0818f479_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzQ5OTg_5b3d284c-e1f7-4f86-8f59-5cb5779d6409"
      unitRef="usdPerShare">196.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i27e6f36ed2b84f35a058e35522e9b351_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzUwMDY_f2de9144-5494-4d49-b6a8-c298253a89ef"
      unitRef="usdPerShare">135.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia611d9892499421694f697dc5c368ddb_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzUxNjE_e88b0e78-beb2-4369-a154-d7e8b47bc58d"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4c55e65384854a888970465b0818f479_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzUxNjU_6e475141-3f15-480f-894c-70abdc4a2a8f"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i27e6f36ed2b84f35a058e35522e9b351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzUxNzM_54cee153-7255-41eb-b91b-a74aff2b15de"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ia611d9892499421694f697dc5c368ddb_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzUyMTQ_02c81532-a5d1-47f9-986d-843e9215de95"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i4c55e65384854a888970465b0818f479_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzUyMTg_fd839e99-69ce-4c99-8238-769821a6e2d1"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i27e6f36ed2b84f35a058e35522e9b351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzUyMjY_8636bd95-cde8-4710-acdf-57c0fa571522"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued
      contextRef="ia611d9892499421694f697dc5c368ddb_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzUzMTU_6eed11f0-32e5-4322-be1f-0e84eb07fb75"
      unitRef="shares">600000</lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ifbf91d3e9e6846ab8570536827522ece_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU0NDk_01fdaafa-94a4-4535-b59e-2b2d542eb852"
      unitRef="usd">221600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ia611d9892499421694f697dc5c368ddb_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMjcvZnJhZzoyODBlMzliM2Y1NjE0OGU5YjA1NTQ5NGU1YjIxYjE5NC90ZXh0cmVnaW9uOjI4MGUzOWIzZjU2MTQ4ZTliMDU1NDk0ZTViMjFiMTk0XzU1NDE_5359f1c6-95bd-4890-b59b-633ce1200623">P25M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzEyMDQ_1202f42a-4620-4fb4-9f85-9b8d070be124">Shareholders' Equity&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, 2021, and 2020, we repurchased $1.50 billion, $1.25 billion, and $500.0 million, respectively, of shares associated with our share repurchase programs. As of December&#160;31, 2022, we had $3.25 billion remaining under our $5.00 billion share repurchase program that our board authorized in May 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have 5.0 million authorized shares of preferred stock. As of December&#160;31, 2022 and 2021, no preferred stock was issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have an employee benefit trust that held 50.0 million shares of our common stock at both December&#160;31, 2022 and 2021, to provide a source of funds to assist us in meeting our obligations under various employee benefit plans. The cost basis of the shares held in the trust was $3.01&#160;billion at both December&#160;31, 2022 and 2021, and is shown as a reduction of shareholders' equity. Any dividend transactions between us and the trust are eliminated. Stock held by the trust is not considered outstanding in the computation of EPS. The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended December&#160;31, 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzY5_7c62b1e3-9f2a-43fa-b17b-9700080ad39e"
      unitRef="usd">1500000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2Xzcz_7348dae8-ea46-4f0c-9cd1-fccb641b220b"
      unitRef="usd">1250000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2Xzgx_5cb8229a-1797-4d28-8066-c0792d6f1e9b"
      unitRef="usd">500000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="icf5b57373be441b6bfebc18bd3f1612c_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzQzNw_af914655-3eb4-4f4b-9ba4-9348d863fa9c"
      unitRef="usd">3250000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i15d3684123a54cc4bc7e71a64f370060_I20210531"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzQ2MA_e17e9664-e40c-4c70-ac40-5756d0751e81"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzQ5OA_4f6debf6-67e2-4644-828a-7a7b7941d681"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzU1Ng_3686d610-d539-4bb0-a401-137e384b0c4c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzU1Ng_7c1be781-c32d-4a9c-89b4-7d0066045362"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesHeldInEmployeeTrustShares
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzYzMQ_288b0258-1955-4100-bd3f-50f160ded5ba"
      unitRef="shares">50000000</us-gaap:CommonStockSharesHeldInEmployeeTrustShares>
    <us-gaap:CommonStockSharesHeldInEmployeeTrustShares
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzYzMQ_b8ba7ef8-8e3c-47a3-8634-b9eb8e9b98ac"
      unitRef="shares">50000000</us-gaap:CommonStockSharesHeldInEmployeeTrustShares>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzgzOA_8c5277a3-22b8-4b08-a646-c208d3ae664e"
      unitRef="usd">3010000000.00</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzAvZnJhZzoxZDIzYTI2ZjQ3ZTE0OGQ0YjA3YmU4ZjNhMmEyMDI3Ni90ZXh0cmVnaW9uOjFkMjNhMjZmNDdlMTQ4ZDRiMDdiZThmM2EyYTIwMjc2XzgzOA_caf06539-d285-4855-a2b9-543e1cf737fa"
      unitRef="usd">3010000000.00</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU1MzM_6d2ae9ba-16ab-4058-8350-8ef72d1d0599">Income Taxes&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Deferred taxes related to global intangible low-taxed income (GILTI) are also recognized for the future tax effects of temporary differences.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position, based on its technical merits, will be sustained upon examination by the taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is the composition of income tax expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,153.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;938.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;547.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;45.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,746.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,992.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(977.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(78.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(114.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,185.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(802.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;561.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,036.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; The 2022, 2021, and 2020 current tax expense includes $189.5 million, $64.7 million, and $144.4 million of tax benefit, respectively, from utilization of net operating loss and other tax carryforwards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of our deferred tax assets and liabilities as of December&#160;31 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,071.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,347.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;427.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;477.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax loss and other tax carryforwards and carrybacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;626.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales rebates and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,312.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Correlative tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;752.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax redeterminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;267.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;147.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,615.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;361.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,059.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,662.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(775.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(875.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,284.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,786.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings of foreign subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,226.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,583.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,387.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,516.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(639.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(596.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(546.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(560.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(433.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(215.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(130.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,579.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,030.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets - net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,705.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The deferred tax asset and related valuation allowance amounts for U.S. federal, international, and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, based on filed tax returns we have tax credit carryforwards and carrybacks of $873.6&#160;million available to reduce future income taxes; $148.8 million, if unused, will expire by 2026, and $27.1&#160;million, if unused, will expire between 2028 and 2042. The remaining portion of the tax credit carryforwards is related to federal tax credits of $68.6 million, international tax credits of $118.6&#160;million, and state tax credits of $510.5 million, all of which are fully reserved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, based on filed tax returns we had net operating losses and other carryforwards for international and U.S. federal income tax purposes of $2.52 billion: $319.1 million will expire by 2027; $1.44&#160;billion will expire between 2028 and 2042; and $762.0 million of the carryforwards will never expire. Net operating losses and other carryforwards for international and U.S. federal income tax purposes are partially reserved. Deferred tax assets related to state net operating losses and other carryforwards of $246.2&#160;million are fully reserved as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and 2021, prepaid expenses and other current assets included prepaid taxes of $2.37&#160;billion and $1.98 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic and Puerto Rican companies contributed approximately 33 percent, 28 percent, and 39 percent for the years ended December&#160;31, 2022, 2021, and 2020, respectively, to consolidated income before income taxes. We have a subsidiary operating in Puerto Rico under a tax incentive grant effective through the end of 2031, which was amended in 2022 to apply the alternate tax regime established by recently enacted Puerto Rico legislation starting in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Substantially all of the unremitted earnings of our foreign subsidiaries are considered not to be indefinitely reinvested for continued use in our foreign operations. At December&#160;31, 2022 and 2021, we accrued an immaterial amount of foreign withholding taxes and state income taxes that would be owed upon future distributions of unremitted earnings of our foreign subsidiaries that are not indefinitely reinvested. For the amount considered to be indefinitely reinvested, it is not practicable to determine the amount of the related deferred income tax liability due to the complexities in the tax laws and assumptions we would have to make.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments of U.S. federal, state, and foreign income taxes, net of refunds, were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments of income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,672.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Tax Cuts and Job Act (2017 Tax Act) was signed into law. The 2017 Tax Act included significant changes to the U.S. corporate income tax system, including a one-time repatriation transition tax (also known as the 'Toll Tax') on unremitted foreign earnings. The 2017 Tax Act provided an election to taxpayers subject to the Toll Tax to make payments over an eight-year period beginning in 2018 through 2025. Having made this election, our future cash payments relating to the Toll Tax as of December&#160;31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-3 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Tax Act Toll Tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,895.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,420.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we have additional noncurrent income tax payables of $2.28&#160;billion unrelated to the Toll Tax; we cannot reasonably estimate the timing of future cash outflows associated with these liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a reconciliation of the consolidated income tax expense applying the U.S. federal statutory rate to income before income taxes to reported consolidated income tax expense: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax at the U.S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,429.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add (deduct):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International operations, including Puerto Rico&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(299.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(447.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(297.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(155.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income deduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(287.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance release&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(116.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;561.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,036.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Includes the impact of Puerto Rico Excise Tax, GILTI tax, and other U.S. taxation of foreign income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,798.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,551.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,108.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;274.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(44.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapses of statutes of limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes related to the impact of foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(52.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance at December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,987.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,798.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,551.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was $1.70&#160;billion at both December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file U.S. federal, foreign, and various state and local income tax returns. We are no longer subject to U.S. federal income tax examination for years before 2016. In most major foreign and state jurisdictions, we are no longer subject to income tax examination for years before 2012.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. examination of tax years 2016-2018 began in 2019 and remains ongoing. While it is reasonably possible that the Internal Revenue Service examination of these tax years could conclude within the next 12 months, final resolution of certain matters is dependent upon several factors, including the potential for formal administrative proceedings. As a result, an estimate of the range of reasonably possible changes in unrecognized tax benefits cannot be made. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and penalties related to unrecognized tax benefits are recognized in income tax expense and were not material for the years ended December&#160;31, 2022, 2021, and 2020. Our accrued interest and penalties related to unrecognized tax benefits were $271.5&#160;million and $220.1&#160;million at December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU1NzE_22248e20-87b9-4fda-9bf0-6e05f4a3c2d5">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Deferred taxes related to global intangible low-taxed income (GILTI) are also recognized for the future tax effects of temporary differences.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position, based on its technical merits, will be sustained upon examination by the taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU1NDg_2dd83102-dcb2-4c3f-90d3-2dafe21a109f">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is the composition of income tax expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,153.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;938.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;547.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;45.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,746.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,992.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(977.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(78.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(114.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,185.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(802.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;561.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,036.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) The 2022, 2021, and 2020 current tax expense includes $189.5 million, $64.7 million, and $144.4 million of tax benefit, respectively, from utilization of net operating loss and other tax carryforwards.</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzItMS0xLTEtMTk3MTgy_a5f0e905-3702-4bf0-865b-add720741159"
      unitRef="usd">2153600000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzItMy0xLTEtMTk3MTgy_3d774e5d-d390-4e64-9f07-314e05625191"
      unitRef="usd">938500000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzItNS0xLTEtMTk3MTgy_a54da064-a06b-44d2-a810-0506e833486d"
      unitRef="usd">567600000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzMtMS0xLTEtMTk3MTgy_b5604c23-3a17-4b69-9152-39e933d236a0"
      unitRef="usd">547700000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzMtMy0xLTEtMTk3MTgy_2f79366e-c49c-48f7-8dba-1dc9dc6dfa76"
      unitRef="usd">466000000.0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzMtNS0xLTEtMTk3MTgy_96099319-7e3f-49c2-90ee-4045be265fbd"
      unitRef="usd">650400000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzQtMS0xLTEtMTk3MTgy_168b1a83-269d-4030-b00a-ced018f5321c"
      unitRef="usd">45500000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzQtMy0xLTEtMTk3MTgy_5a2266fa-bdf4-4d24-b6d7-0c5330d85acd"
      unitRef="usd">-28400000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzQtNS0xLTEtMTk3MTgy_b1cd9c45-e259-472a-b114-4f6b8ca74e60"
      unitRef="usd">-47300000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzUtMS0xLTEtMTk3MTgy_a8f54d4c-526f-4a7d-b8f8-cfd0be662f67"
      unitRef="usd">2746800000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzUtMy0xLTEtMTk3MTgy_78425f85-d8c0-4f3b-842a-e1f87fa50cb9"
      unitRef="usd">1376100000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzUtNS0xLTEtMTk3MTgy_0d830a03-ac4b-4e7f-8262-ec3b4d760fed"
      unitRef="usd">1170700000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzctMS0xLTEtMTk3MTgy_be25a59c-2795-4a14-954c-4d34b1a8f09d"
      unitRef="usd">-1992400000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzctMy0xLTEtMTk3MTgy_4b6fa837-b2bf-4957-8f16-cd22406d2d71"
      unitRef="usd">-977500000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzctNS0xLTEtMTk3MTgy_1e79ca39-f776-4cf6-b040-9f860b67cf43"
      unitRef="usd">-97400000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzgtMS0xLTEtMTk3MTgy_6bfd15b5-41ed-48a7-b207-6e89eaa21ea5"
      unitRef="usd">-78200000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzgtMy0xLTEtMTk3MTgy_546383f4-6f43-499e-b6f0-fbb1936a799e"
      unitRef="usd">174600000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzgtNS0xLTEtMTk3MTgy_27a1baa1-05dd-4468-a7dc-e2c1924cd78f"
      unitRef="usd">-16600000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzktMS0xLTEtMTk3MTgy_9b325236-7a88-487c-b134-4e662e7cdaa9"
      unitRef="usd">-114600000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzktMy0xLTEtMTk3MTgy_c0eaf899-9a1c-4e6c-91c5-bf0ff60a5d8f"
      unitRef="usd">600000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzktNS0xLTEtMTk3MTgy_d8665afc-90e9-4bf9-880b-7aa6f90173c0"
      unitRef="usd">-20500000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzEwLTEtMS0xLTE5NzE4Mg_ea0ee63d-3e0d-4392-a2a1-74a08967d78b"
      unitRef="usd">-2185200000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzEwLTMtMS0xLTE5NzE4Mg_6e0e04bf-a86e-45d2-b05f-298bda7a3156"
      unitRef="usd">-802300000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzEwLTUtMS0xLTE5NzE4Mg_e7b35468-58a0-4849-a458-6967a43a6de1"
      unitRef="usd">-134500000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzExLTEtMS0xLTE5NzE4Mg_dcf711c3-6d29-4c15-bf5c-f5712ad6d393"
      unitRef="usd">561600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzExLTMtMS0xLTE5NzE4Mg_339f0b33-87ad-4d9b-b2d3-9127445c753b"
      unitRef="usd">573800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2MGNjZTQzZTkzZWY0YTZkOWYxYmM1ZWI0NjA4OThmYS90YWJsZXJhbmdlOjYwY2NlNDNlOTNlZjRhNmQ5ZjFiYzVlYjQ2MDg5OGZhXzExLTUtMS0xLTE5NzE4Mg_74a60db4-cd2e-4e8c-83e4-e1037f5d5316"
      unitRef="usd">1036200000</us-gaap:IncomeTaxExpenseBenefit>
    <lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0Xzg1NQ_e45b8059-7722-46e7-a5c0-d6270a026393"
      unitRef="usd">189500000</lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward>
    <lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0Xzg1OQ_2bcd7aae-99f7-4548-88a6-8d0f2093a362"
      unitRef="usd">64700000</lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward>
    <lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0Xzg2Nw_ffdc30c1-ce5d-4e10-8674-81021b87c59f"
      unitRef="usd">144400000</lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU1NzI_720dd04f-bd22-4481-ad00-0ddb3f0560ac">&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of our deferred tax assets and liabilities as of December&#160;31 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,071.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,347.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;427.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;477.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax loss and other tax carryforwards and carrybacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;626.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales rebates and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,312.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Correlative tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;752.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax redeterminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;267.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;147.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,615.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;361.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,059.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,662.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(775.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(875.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,284.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,786.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings of foreign subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,226.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,583.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,387.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,516.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(639.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(596.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(546.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(560.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(433.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(215.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(130.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,579.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,030.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets - net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,705.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzItMS0xLTEtMTk3MTgy_6d38977f-fcf5-45db-b5d0-53d7ee746dc1"
      unitRef="usd">2071300000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzItMy0xLTEtMTk3MTgy_1d31ab87-0aa4-44b2-a298-ddd20ae52c4d"
      unitRef="usd">2347400000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzMtMS0xLTEtMTk3MTgy_b912f230-7f9c-4f7f-ad11-7191d712c71e"
      unitRef="usd">427900000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzMtMy0xLTEtMTk3MTgy_3e792e1f-2183-4b7c-b20c-7e70eeeb6ef5"
      unitRef="usd">634700000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzQtMS0xLTEtMTk3MTgy_eb64902f-b205-434a-9f01-b775706a770e"
      unitRef="usd">477600000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzQtMy0xLTEtMTk3MTgy_e9d59c69-9217-4c1e-89c1-6685e14bcfc3"
      unitRef="usd">463700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzUtMS0xLTEtMTk3MTgy_1fb4563b-ba91-48a4-8315-e2370436c7b4"
      unitRef="usd">626000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzUtMy0xLTEtMTk3MTgy_de0cee6d-bba6-462f-ac7f-59a3ab633075"
      unitRef="usd">645400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <lly:DeferredTaxAssetsSalesRebatesAndDiscounts
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzYtMS0xLTEtMTk3MTgy_48804023-3f8e-49bb-b44e-482f6912714b"
      unitRef="usd">1312900000</lly:DeferredTaxAssetsSalesRebatesAndDiscounts>
    <lly:DeferredTaxAssetsSalesRebatesAndDiscounts
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzYtMy0xLTEtMTk3MTgy_c6526476-df14-435a-ac6d-5231e1666589"
      unitRef="usd">832300000</lly:DeferredTaxAssetsSalesRebatesAndDiscounts>
    <lly:DeferredTaxAssetsCorrectiveTaxAdjustments
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzctMS0xLTEtMTk3MTgy_e2e3f656-e32a-46e8-b965-277eaaf83084"
      unitRef="usd">752500000</lly:DeferredTaxAssetsCorrectiveTaxAdjustments>
    <lly:DeferredTaxAssetsCorrectiveTaxAdjustments
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzctMy0xLTEtMTk3MTgy_b0f508df-8929-4c91-904f-d24d5c1412d7"
      unitRef="usd">560800000</lly:DeferredTaxAssetsCorrectiveTaxAdjustments>
    <lly:DeferredTaxAssetsForeignTaxRedeterminations
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzgtMS0xLTEtMTk3MTgy_c5b81b75-f773-415f-82d5-7dff5a309e33"
      unitRef="usd">267800000</lly:DeferredTaxAssetsForeignTaxRedeterminations>
    <lly:DeferredTaxAssetsForeignTaxRedeterminations
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzgtMy0xLTEtMTk3MTgy_913db604-841f-4990-a197-2ccf81629358"
      unitRef="usd">274900000</lly:DeferredTaxAssetsForeignTaxRedeterminations>
    <lly:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzktMS0xLTEtMTk3MTgy_5cc01c6f-20fe-4c34-8574-e61aefbd891c"
      unitRef="usd">147500000</lly:DeferredTaxAssetsOperatingLeaseLiability>
    <lly:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzktMy0xLTEtMTk3MTgy_63ae331d-72fa-4ce7-91bb-d38f36bff6a9"
      unitRef="usd">150000000.0</lly:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzEwLTEtMS0xLTE5NzE4Mg_3bf8a658-33d1-451f-8792-8d57b99143e6"
      unitRef="usd">1615400000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzEwLTMtMS0xLTE5NzE4Mg_55ca09c0-959a-4ae8-9ebd-03ef8cfb06d8"
      unitRef="usd">275100000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzExLTEtMS0xLTE5NzE4Mg_650e92c0-4996-498a-a085-fd734fb4ab76"
      unitRef="usd">361000000.0</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzExLTMtMS0xLTE5NzE4Mg_91624683-0def-461e-93e1-6b5d16db6926"
      unitRef="usd">477900000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzEyLTEtMS0xLTE5NzE4Mg_f0c55a64-c50c-4fe0-9f1a-03ffcb59766d"
      unitRef="usd">8059900000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzEyLTMtMS0xLTE5NzE4Mg_1aa6cbf8-10e4-4cdc-b36e-4ad2f4eb5bf4"
      unitRef="usd">6662200000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzEzLTEtMS0xLTE5NzE4Mg_53dbcffd-c6e9-4cb4-8575-45f490fa1cb6"
      unitRef="usd">775100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzEzLTMtMS0xLTE5NzE4Mg_b88b000e-7740-4c75-9caf-caf957b65fb0"
      unitRef="usd">875600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE0LTEtMS0xLTE5NzE4Mg_f87ecfff-68bd-463c-9477-4e40970aeb32"
      unitRef="usd">7284800000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE0LTMtMS0xLTE5NzE4Mg_b5e7ea97-c3e9-42c4-b5e1-e8a2bd45da6e"
      unitRef="usd">5786600000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE2LTEtMS0xLTE5NzE4Mg_182244f6-eb0b-4baa-924b-4d985b54e26c"
      unitRef="usd">1226000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE2LTMtMS0xLTE5NzE4Mg_01cb2149-9602-4f4f-9306-e67dbca9c67e"
      unitRef="usd">1583300000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE3LTEtMS0xLTE5NzE4Mg_0bd45d45-9234-4780-8869-8ff0e7a95af4"
      unitRef="usd">1387900000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE3LTMtMS0xLTE5NzE4Mg_330f02ba-dfc5-4496-8454-130d79f63793"
      unitRef="usd">1516100000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE4LTEtMS0xLTE5NzE4Mg_66a3ffbd-fbda-4a8b-bfc0-2a123478e016"
      unitRef="usd">639500000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE4LTMtMS0xLTE5NzE4Mg_325381c8-e020-47c6-9140-0c0ac8801d4e"
      unitRef="usd">596400000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE5LTEtMS0xLTE5NzE4Mg_9c51bd7a-d025-4bf2-a53a-5cf3ede2cbfa"
      unitRef="usd">546500000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzE5LTMtMS0xLTE5NzE4Mg_576a2b2a-6598-4c03-b469-69e4dd751fd2"
      unitRef="usd">560600000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzIwLTEtMS0xLTE5NzE4Mg_0524af9b-8c45-4688-a91a-8e546f9f1f90"
      unitRef="usd">433500000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzIwLTMtMS0xLTE5NzE4Mg_3a9086f1-1a92-4ddc-9ad8-b3e7adef61a9"
      unitRef="usd">338700000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesDerivatives
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzIxLTEtMS0xLTE5NzE4Mg_40794f76-34af-4865-823d-ece226c4b1e8"
      unitRef="usd">215000000.0</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredTaxLiabilitiesDerivatives
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzIxLTMtMS0xLTE5NzE4Mg_17faf3cc-4849-4006-b949-47052a04ff78"
      unitRef="usd">303000000.0</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzIyLTEtMS0xLTE5NzE4Mg_4f9b54a8-f448-4288-8811-b857e6861660"
      unitRef="usd">130700000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzIyLTMtMS0xLTE5NzE4Mg_bd93d91e-d432-4d04-a408-12d30cbcc84d"
      unitRef="usd">132600000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzIzLTEtMS0xLTE5NzE4Mg_7f81c4e9-d286-43aa-9c11-3cccf0f75d29"
      unitRef="usd">4579100000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzIzLTMtMS0xLTE5NzE4Mg_a410edf4-ef91-423e-9101-87fe41f8d86c"
      unitRef="usd">5030700000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzI0LTEtMS0xLTE5NzE4Mg_b817d386-9849-4ab1-82fe-cda7cf8695f4"
      unitRef="usd">2705700000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo1YzIwZjQxZGNlOGY0YTgwODgzZjZjNjQyN2QzMmI5Mi90YWJsZXJhbmdlOjVjMjBmNDFkY2U4ZjRhODA4ODNmNmM2NDI3ZDMyYjkyXzI0LTMtMS0xLTE5NzE4Mg_fb6bcb1a-2bc3-4fd5-a3c4-ff489d3a9237"
      unitRef="usd">755900000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i89d3a6dd2c454e45a2881b0daf36f171_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE0MDA_3d929d8a-00e5-4cf7-a371-ea65dc3afe17"
      unitRef="usd">873600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ibac57721c29548ee93eb53c76de5151c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE0NDQ_cab12370-e9f7-4d1f-a93c-e3724ce3d9bd"
      unitRef="usd">148800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i2e25213daac34fafad0267f51e54ab7e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE0ODI_462e4f31-6052-4fa1-85b2-6c6df7d100cf"
      unitRef="usd">27100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i652bcd633d9e4b988a731c9c680da3b1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE2MTk_96bbdc32-3312-445d-ba45-3b510da3477d"
      unitRef="usd">68600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i6b497353dce84fff8af5126132c7d5aa_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE2NTI_73af7c48-b134-4920-a4f3-5ac1f4278c87"
      unitRef="usd">118600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i8aaea1c0c5f449f78c245961a000b0ae_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE2ODE_bdbc433e-012d-4d4d-be57-b34cdf88c657"
      unitRef="usd">510500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i89d3a6dd2c454e45a2881b0daf36f171_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE4NjI_934023a6-bb9f-4025-80af-d9330f8edfb5"
      unitRef="usd">2520000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i8e1fc18a41da4a52b4f290bd30b05e25_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE4NjY_89abe4f0-e347-4781-bb30-19e07e97903f"
      unitRef="usd">319100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i2e25213daac34fafad0267f51e54ab7e_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE4ODg_979e4db7-b534-4b7a-ac91-8628550a815d"
      unitRef="usd">1440000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i38c21f98a7ad430e92e87e091c5eebdb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzE5MjY_c3383049-a2eb-4270-851f-1d278fcde702"
      unitRef="usd">762000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="i8aaea1c0c5f449f78c245961a000b0ae_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzIxNzg_01550da2-39f9-427e-91b9-33ef35e12990"
      unitRef="usd">246200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:PrepaidTaxes
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU0OTc1NTgyMzgxMA_ab91e71e-da44-4982-af7e-8b160db9ecc1"
      unitRef="usd">2370000000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU0OTc1NTgyMzgxOA_42b92e87-c80f-4b86-bb38-6d1d34f714ed"
      unitRef="usd">1980000000</us-gaap:PrepaidTaxes>
    <lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzIyNzI_99427c49-c42f-4658-b709-2c4707949bd2"
      unitRef="number">0.33</lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes>
    <lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzIyNzY_cb80d4f3-cf94-44b9-8251-a29fda313b4c"
      unitRef="number">0.28</lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes>
    <lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzIyODQ_33935269-e08e-4c6c-9953-85fae98d9859"
      unitRef="number">0.39</lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes>
    <lly:ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU1NjU_d19ca330-a5a2-4be8-8868-b3315319a2f8">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments of U.S. federal, state, and foreign income taxes, net of refunds, were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments of income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,672.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Having made this election, our future cash payments relating to the Toll Tax as of December&#160;31, 2022 are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-3 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Tax Act Toll Tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,895.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,420.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</lly:ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock>
    <us-gaap:IncomeTaxesPaid
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTphYmNjNWU3MmJhYTc0Y2M0OWI5N2RhN2EwMmQzZTVlYS90YWJsZXJhbmdlOmFiY2M1ZTcyYmFhNzRjYzQ5Yjk3ZGE3YTAyZDNlNWVhXzEtMS0xLTEtMTk3MTgy_5fc0ff95-a88c-4208-b7ac-1b9e5ca3a11e"
      unitRef="usd">2672900000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTphYmNjNWU3MmJhYTc0Y2M0OWI5N2RhN2EwMmQzZTVlYS90YWJsZXJhbmdlOmFiY2M1ZTcyYmFhNzRjYzQ5Yjk3ZGE3YTAyZDNlNWVhXzEtMy0xLTEtMTk3MTgy_75e055b4-19bf-4f2d-b942-9e70041d1b46"
      unitRef="usd">1598800000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTphYmNjNWU3MmJhYTc0Y2M0OWI5N2RhN2EwMmQzZTVlYS90YWJsZXJhbmdlOmFiY2M1ZTcyYmFhNzRjYzQ5Yjk3ZGE3YTAyZDNlNWVhXzEtNS0xLTEtMTk3MTgy_c24d53c8-4f63-437c-90ca-120d16613389"
      unitRef="usd">954600000</us-gaap:IncomeTaxesPaid>
    <lly:TaxCutAndJobsActTollTaxToBePaid
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTowMTQ3NmI5M2QzMDI0YTBmYTljN2E2NDhhNWRmNzEzMC90YWJsZXJhbmdlOjAxNDc2YjkzZDMwMjRhMGZhOWM3YTY0OGE1ZGY3MTMwXzEtMS0xLTEtMTk3MTgy_c8d380d6-65fa-4601-bc33-0d35b38617f5"
      unitRef="usd">1895800000</lly:TaxCutAndJobsActTollTaxToBePaid>
    <lly:TaxCutAndJobsActTollTaxToBePaidWithinOneYear
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTowMTQ3NmI5M2QzMDI0YTBmYTljN2E2NDhhNWRmNzEzMC90YWJsZXJhbmdlOjAxNDc2YjkzZDMwMjRhMGZhOWM3YTY0OGE1ZGY3MTMwXzEtMi0xLTEtMTk3MTgy_26cc5c14-0df6-4506-83ec-760346cf7436"
      unitRef="usd">475700000</lly:TaxCutAndJobsActTollTaxToBePaidWithinOneYear>
    <lly:TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTowMTQ3NmI5M2QzMDI0YTBmYTljN2E2NDhhNWRmNzEzMC90YWJsZXJhbmdlOjAxNDc2YjkzZDMwMjRhMGZhOWM3YTY0OGE1ZGY3MTMwXzEtMy0xLTEtMTk3MTgy_a32bdca8-fe8c-4538-b600-5caa6be0d089"
      unitRef="usd">1420100000</lly:TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears>
    <lly:AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzM4MTQ_25abd790-52b5-42cd-821b-6f759ba99978"
      unitRef="usd">2280000000</lly:AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU1Mzg_06922e5c-362b-45ff-8d5e-661b50ca79ed">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a reconciliation of the consolidated income tax expense applying the U.S. federal statutory rate to income before income taxes to reported consolidated income tax expense: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax at the U.S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,429.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add (deduct):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International operations, including Puerto Rico&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(299.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(447.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(297.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(155.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income deduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(287.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance release&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(116.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;561.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,036.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Includes the impact of Puerto Rico Excise Tax, GILTI tax, and other U.S. taxation of foreign income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzEtMS0xLTEtMTk3MTgy_7d543451-d616-4f8f-ab10-c03e40e8d013"
      unitRef="usd">1429300000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzEtMy0xLTEtMTk3MTgy_e2fa7bea-3b34-4314-b9cf-13f563da3b46"
      unitRef="usd">1292600000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzEtNS0xLTEtMTk3MTgy_1558863d-394d-42d9-b729-5296aec13ef5"
      unitRef="usd">1518300000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzMtMS0xLTEtMTk3MTgy_92192ea9-eddf-44ce-880e-bcee11fe83f8"
      unitRef="usd">299500000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzMtMy0xLTEtMTk3MTgy_fcc5fcd6-714d-49cf-8a54-419227d787fb"
      unitRef="usd">447500000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzMtNS0xLTEtMTk3MTgy_850113f7-70ea-4a16-b2d5-9effba0627a3"
      unitRef="usd">297200000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzQtMS0xLTEtMTk3MTgy_84f07be6-3772-439b-8a5e-40a20c717462"
      unitRef="usd">155000000.0</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzQtMy0xLTEtMTk3MTgy_92c59063-8367-4ffc-814c-60c9b7cf3047"
      unitRef="usd">100500000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzQtNS0xLTEtMTk3MTgy_f8d8b566-112f-43ea-a458-6a7e1dfddc34"
      unitRef="usd">97900000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzUtMS0xLTEtMTk3MTgy_32a389f7-56e7-45ea-9b15-1526c3b823b2"
      unitRef="usd">-287500000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzUtMy0xLTEtMTk3MTgy_4bbd0679-f3fe-443d-ab70-6698a230bb9f"
      unitRef="usd">-86700000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzUtNS0xLTEtMTk3MTgy_30c0c2bb-1314-4de8-b062-9c57b51242d2"
      unitRef="usd">-71500000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzctMS0xLTEtMjM5ODg4_24e4aef5-1004-45db-ad97-a979cf7912c5"
      unitRef="usd">-116400000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzctMy0xLTEtMjM5ODk1_ac5938ea-d0e1-4711-b72b-06828c4824ec"
      unitRef="usd">-19000000.0</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzctNS0xLTEtMjM5OTAy_e21432ad-fcf6-488e-91a6-36bd288a3d31"
      unitRef="usd">-10000000.0</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzctMS0xLTEtMTk3MTgy_8fc96519-1d6f-475a-8726-d297f9c154d0"
      unitRef="usd">-9300000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzctMy0xLTEtMTk3MTgy_1a4932fe-a480-4ee4-a26c-a770ed2b898d"
      unitRef="usd">-65100000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzctNS0xLTEtMTk3MTgy_a5482f00-5a64-4d38-8a25-edd594eb5949"
      unitRef="usd">-5500000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzgtMS0xLTEtMTk3MTgy_7a139c4b-37c4-4675-85ce-f4d31712e244"
      unitRef="usd">561600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzgtMy0xLTEtMTk3MTgy_96616586-ee43-4d10-abb9-6dea0f8e715d"
      unitRef="usd">573800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo2Nzk3ZTBlNjA5YWY0ZGJkODBkZTM4ZjQ5ZGE3NzYzOS90YWJsZXJhbmdlOjY3OTdlMGU2MDlhZjRkYmQ4MGRlMzhmNDlkYTc3NjM5XzgtNS0xLTEtMTk3MTgy_4737c0d1-dbe6-45fa-889b-091fbf2c12d3"
      unitRef="usd">1036200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU1NzQ_b5ae453e-78c7-43b1-b583-2f5deaa8dbd0">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,798.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,551.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,108.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;274.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(44.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapses of statutes of limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes related to the impact of foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(52.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance at December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,987.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,798.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,551.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzEtMS0xLTEtMTk3MTgy_06fc302e-710f-4d61-892c-9ad279ee819a"
      unitRef="usd">2798300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i68cf5a8007734a98a36e143a7305b0b7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzEtMy0xLTEtMTk3MTgy_255caf34-ae26-4f8f-a1d7-0378242e39cf"
      unitRef="usd">2551900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib66e8131e7a64596bd768a5869bc86ab_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzEtNS0xLTEtMTk3MTgy_ab0ea722-fc64-47f8-9db4-e3c05cd72337"
      unitRef="usd">2108600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzItMS0xLTEtMTk3MTgy_dee4533e-3db5-4eb6-8d8f-23a6938f0acf"
      unitRef="usd">274200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzItMy0xLTEtMTk3MTgy_a5168d71-0de1-48a4-8e9f-bd88f8c4548f"
      unitRef="usd">310300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzItNS0xLTEtMTk3MTgy_db2dbfcc-24ba-4e35-9964-04854c20f747"
      unitRef="usd">225600000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzMtMS0xLTEtMTk3MTgy_84231711-613f-4c34-bb80-5e2b5890da6b"
      unitRef="usd">34600000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzMtMy0xLTEtMTk3MTgy_571f3959-62fe-4023-8b43-7705421b50d8"
      unitRef="usd">98600000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzMtNS0xLTEtMTk3MTgy_99000abf-333e-43e8-98bb-b5f4666fd866"
      unitRef="usd">310800000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzQtMS0xLTEtMTk3MTgy_2404f3c0-9f29-4f21-959e-f44bee8b3d04"
      unitRef="usd">10900000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzQtMy0xLTEtMTk3MTgy_d9faa5ab-9328-404c-b479-1cb4495bad37"
      unitRef="usd">8100000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzQtNS0xLTEtMTk3MTgy_6bbcc308-5434-44d7-8226-30b96d9520c5"
      unitRef="usd">52400000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzUtMS0xLTEtMTk3MTgy_70eb96d1-1457-4f64-a782-ebd6204b6491"
      unitRef="usd">44800000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzUtMy0xLTEtMTk3MTgy_282130b9-7b6f-4898-85b1-bbd0520d72d1"
      unitRef="usd">38500000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzUtNS0xLTEtMTk3MTgy_0f006587-ca6c-4c9f-9b07-af675ccdf61e"
      unitRef="usd">72000000.0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzYtMS0xLTEtMTk3MTgy_c46d1bd6-5af8-40fc-8411-36ee6aa98146"
      unitRef="usd">11800000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzYtMy0xLTEtMTk3MTgy_ef3630fa-172b-4407-a802-221ae543b288"
      unitRef="usd">49700000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzYtNS0xLTEtMTk3MTgy_40e09f24-041e-4a07-8b24-dc458a9c5aad"
      unitRef="usd">41700000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzctMS0xLTEtMTk3MTgy_5f8938af-bdbf-4c6d-be6e-d51499ea0f5d"
      unitRef="usd">52600000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzctMy0xLTEtMTk3MTgy_877f7599-6bb2-4611-8212-68436dab7a7b"
      unitRef="usd">66200000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzctNS0xLTEtMTk3MTgy_d14148a4-1c43-4250-b5a8-dc0cb7545cbe"
      unitRef="usd">73000000.0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzgtMS0xLTEtMTk3MTgy_41adf140-e882-4ae3-a964-8368617429d3"
      unitRef="usd">2987000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzgtMy0xLTEtMTk3MTgy_05a493c6-5af3-4257-be55-2c30dc98a0e0"
      unitRef="usd">2798300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i68cf5a8007734a98a36e143a7305b0b7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90YWJsZTo0ZmQ0MzI1YmZlZGU0ODFmYTRjZDY2MzIxNDQyNTc4Ny90YWJsZXJhbmdlOjRmZDQzMjViZmVkZTQ4MWZhNGNkNjYzMjE0NDI1Nzg3XzgtNS0xLTEtMTk3MTgy_1334f348-feae-4338-8090-f2f0d3f4f1e7"
      unitRef="usd">2551900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzQ0NDk_92bc419f-1a36-43b9-b462-5a50531e5d0f"
      unitRef="usd">1700000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzQ0NDk_b0001d6b-2219-48ce-9efe-3b27c4586c6b"
      unitRef="usd">1700000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU0OTc1NTgyMzQ2Nw_7a75d364-0423-4189-b205-25b7f91150a5"
      unitRef="usd">271500000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzMvZnJhZzpmOTBiMjUwMDViNjU0YmVlOGRiMjU4MTIwMWM3MDkyNC90ZXh0cmVnaW9uOmY5MGIyNTAwNWI2NTRiZWU4ZGIyNTgxMjAxYzcwOTI0XzU0OTc1NTgyMzQ4NA_7b005001-e2d7-495d-8e11-ad27a0b5bc9f"
      unitRef="usd">220100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMTU4_be67f1be-9b56-401c-9b6b-eba600c67bea">Retirement Benefits&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a measurement date of December&#160;31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December&#160;31 for our defined benefit pension and retiree health benefit plans, which were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in benefit obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,565.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,225.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,663.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,753.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;351.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;398.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,158.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(564.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(395.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(608.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(630.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(86.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange rate changes and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(325.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,222.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,565.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,258.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,663.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,416.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,579.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,361.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,227.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,388.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,458.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(796.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;118.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(608.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(630.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(86.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange rate changes and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(341.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,195.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,416.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,492.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,361.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funded status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(26.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,149.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,233.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,697.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized net actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,687.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,908.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;54.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(497.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized prior service (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(62.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,669.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,770.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,226.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in the consolidated balance sheet consisted&#160;of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,208.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,383.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,910.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(70.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,163.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,749.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(141.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive (income) loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,695.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,919.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(614.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,669.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,770.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,226.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrecognized net actuarial (gain) loss and unrecognized prior service (benefit) cost have not yet been recognized in net periodic pension costs and were included in accumulated other comprehensive loss at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The $4.75&#160;billion and $750.4&#160;million declines in benefit obligation in 2022 and 2021, respectively, were both driven primarily by increases in the discount rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents our weighted-average assumptions as of December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Percents)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate for benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate for net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase for benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase for net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets for net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We annually evaluate the expected return on plan assets in our defined benefit pension and retiree health benefit plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given the design of our retiree health benefit plans, healthcare-cost trend rates do not have a material impact on our financial condition or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2028-2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension plans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,079.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retiree health benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,211.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,360.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;977.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,542.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health &lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,721.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,532.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;149.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;652.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;973.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total accumulated benefit obligation for our defined benefit pension plans was $12.01 billion and $16.44&#160;billion at December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net pension and retiree health benefit expense included the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic (benefit) cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;351.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;398.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(947.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(949.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(901.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(152.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(54.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;342.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;147.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(121.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents the amounts recognized in other comprehensive income (loss) for the years ended December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021, and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined&#160;Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree&#160;Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial gain (loss) arising during period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;823.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,072.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(663.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(552.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan amendments during period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service (benefit) cost included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(54.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial (gain) loss included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;342.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange rate changes and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;55.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income (loss) during period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,223.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(335.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(607.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have defined contribution savings plans that cover our eligible employees worldwide. The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plans are based on employee contributions and the level of our match. Expenses under the plans totaled $170.6 million, $167.3 million, and $164.3 million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide certain other postemployment benefits primarily related to disability benefits and accrue for the related cost over the service lives of employees. Expenses associated with these benefit plans for the years ended December&#160;31, 2022, 2021, and 2020 were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Benefit Plan Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. U.S. and Puerto Rico plans represent approximately 85 percent of our global investments. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control, and limit concentrations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage our portfolio to minimize concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our global benefit plans may enter into contractual arrangements (derivatives) to implement the local investment policy or manage particular portfolio risks. Derivatives are principally used to increase or decrease exposure to a particular public equity, fixed income, commodity, or currency market more rapidly or less expensively than could be accomplished through the use of the cash markets. The plans utilize both exchange-traded and over-the-counter instruments. The maximum exposure to either a market or counterparty credit loss is limited to the carrying value of the receivable, and is managed within contractual limits. We expect all of our counterparties to meet their obligations. The gross values of these derivative receivables and payables are not material to the global asset portfolio, and their values are reflected within the tables below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The defined benefit pension and retiree health benefit plan allocation for the U.S. and Puerto Rico currently comprises approximately 75 percent growth investments and 25 percent fixed-income investments. The growth investment allocation encompasses U.S. and international public equity securities, hedge funds, private equity-like investments, and real estate. These portfolio allocations are intended to reduce overall risk by providing diversification, while seeking moderate to high returns over the long term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Public equity securities are well diversified and invested in U.S. and international small-to-large companies across various asset managers and styles. The remaining portion of the growth portfolio is invested in private alternative investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed-income investments primarily consist of fixed-income securities in U.S. treasuries and agencies, emerging market debt obligations, corporate bonds, bank loans, mortgage-backed securities, commercial mortgage-backed obligations, and any related repurchase agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hedge funds are privately owned institutional investment funds that generally have moderate liquidity. Hedge funds seek specified levels of absolute return regardless of overall market conditions, and generally have low correlations to public equity and debt markets. Hedge funds often invest substantially in financial market instruments (stocks, bonds, commodities, currencies, derivatives, etc.) using a very broad range of trading activities to manage portfolio risks. Hedge fund strategies focus primarily on security selection and seek to be neutral with respect to market moves. Common groupings of hedge fund strategies include relative value, tactical, and event driven. Relative value strategies include arbitrage, when the same asset can simultaneously be bought and sold at different prices, achieving an immediate profit. Tactical strategies often take long and short positions to reduce or eliminate overall market risks while seeking a particular investment opportunity. Event strategy opportunities can evolve from specific company announcements such as mergers and acquisitions, and typically have little correlation to overall market directional movements. Our hedge fund investments are made through limited partnership interests in fund-of-funds structures and directly into hedge funds. Plan holdings in hedge funds are valued based on net asset values (NAVs) calculated by each fund or general partner, as applicable, and we have the ability to redeem these investments at NAV.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Private equity-like investment funds typically have low liquidity and are made through long-term partnerships or joint ventures that invest in pools of capital invested in primarily non-publicly traded entities. Underlying investments include venture capital (early stage investing), buyout, special situations, private debt, and private real estate investments. Private equity management firms typically acquire and then reorganize private companies to create increased long term value. Private equity-like funds usually have a limited life of approximately 10-15 years, and require a minimum investment commitment from their limited partners. Our private equity-like investments are made both directly into funds and through fund-of-funds structures to ensure broad diversification of management styles and assets across the portfolio. Plan holdings in private equity-like investments are valued using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual audited financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Real estate is composed of public holdings. Real estate investments in registered investment companies that trade on an exchange are classified as Level 1 on the fair value hierarchy. Real estate investments in funds measured at fair value on the basis of NAV provided by the fund manager are classified as such. These NAVs are developed with inputs including discounted cash flow, independent appraisal, and market comparable analyses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets include cash and cash equivalents and mark-to-market value of derivatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash value of the trust-owned insurance contract is primarily invested in investment-grade publicly traded equity and fixed-income securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than hedge funds, private equity-like investments, and a portion of the real estate holdings, which are discussed above, we determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2022 by asset category were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Asset Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in Active Markets&#160;for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Observable&#160;&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Investments Valued at Net Asset Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,445.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,058.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets - repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(706.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(713.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,014.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,988.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,261.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,195.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,335.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash value of trust owned insurance contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,492.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,514.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December&#160;31, 2022. The activity in the Level 3 investments during the year ended December&#160;31, 2022 was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2021 by asset category were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Asset Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in Active Markets&#160;for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Investments Valued at Net Asset Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,722.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;815.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,907.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,496.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,356.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets - repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,046.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,046.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,816.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,808.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,143.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,416.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,728.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,170.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash value of trust owned insurance contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,361.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,290.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December&#160;31, 2021. The activity in the Level 3 investments during the year ended December&#160;31, 2021 was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2023, we expect to contribute approximately $30 million to our defined benefit pension plans to satisfy minimum funding requirements for the year. We do not currently expect to make material discretionary contributions in 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMTE1_b989eb21-4492-49b3-9bf1-3f0f36da7497">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a measurement date of December&#160;31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December&#160;31 for our defined benefit pension and retiree health benefit plans, which were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in benefit obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,565.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,225.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,663.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,753.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;351.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;398.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,158.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(564.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(395.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(608.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(630.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(86.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange rate changes and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(325.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,222.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,565.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,258.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,663.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzMtMS0xLTEtMTk3MTgy_bf1ee576-2f15-4bdb-91e7-73d23ca8837d"
      unitRef="usd">17565000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i057f9a4808af4123bcdfdc6c3301e04b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzMtMy0xLTEtMTk3MTgy_88fe8271-2a2a-4e19-946a-21754016d5fb"
      unitRef="usd">18225500000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzMtNS0xLTEtMTk3MTgy_4e4bb330-726c-4ee8-9c1a-88e092db4f59"
      unitRef="usd">1663800000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i125b075ff711498b8733b378408d98e3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzMtNy0xLTEtMTk3MTgy_50fffef4-7cfe-497e-bd8a-19a4daf0aa46"
      unitRef="usd">1753700000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzQtMS0xLTEtMTk3MTgy_12d6bfaa-b6d8-4e3c-a02d-655480e8fc6d"
      unitRef="usd">351700000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzQtMy0xLTEtMTk3MTgy_b1a6a6e1-24d5-457b-b0ca-111209e8d20c"
      unitRef="usd">369200000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzQtNS0xLTEtMTk3MTgy_739aaee5-c226-4975-ab13-7a80d0257b59"
      unitRef="usd">46600000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzQtNy0xLTEtMTk3MTgy_5d2fe00d-66d1-4dc5-92ed-02836f516415"
      unitRef="usd">49200000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzUtMS0xLTEtMTk3MTgy_4f5fbed7-141e-4341-b274-516ea3adc153"
      unitRef="usd">398100000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzUtMy0xLTEtMTk3MTgy_9e6b9c29-5bcc-442c-9ddc-dfb22a508ca4"
      unitRef="usd">337800000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzUtNS0xLTEtMTk3MTgy_9c1c4fa1-2068-42e2-9338-4d69ec88c886"
      unitRef="usd">37800000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzUtNy0xLTEtMTk3MTgy_bcd3a7a6-5054-4200-aae9-75e83aef647e"
      unitRef="usd">32500000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzYtMS0xLTEtMTk3MTgy_7e60f945-7d8f-44b2-b5ef-49260b1c472d"
      unitRef="usd">4158900000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzYtMy0xLTEtMTk3MTgy_6e1d5dde-3e08-405d-8176-4573c2a31686"
      unitRef="usd">564300000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzYtNS0xLTEtMTk3MTgy_32538041-6430-4e26-956a-b28f6df817e4"
      unitRef="usd">395900000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzYtNy0xLTEtMTk3MTgy_bfe9e08d-1926-4728-b7db-6b77979159af"
      unitRef="usd">86100000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzctMS0xLTEtMTk3MTgy_57afa707-3d4d-449b-88d2-65884adb7b08"
      unitRef="usd">608900000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzctMy0xLTEtMTk3MTgy_5558f15f-2ef7-4b74-8cfe-8f13fa25312b"
      unitRef="usd">630100000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzctNS0xLTEtMTk3MTgy_93b026d1-8c50-422b-9aa8-08da69ac7dfe"
      unitRef="usd">86800000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzctNy0xLTEtMTk3MTgy_668488d3-db28-494c-9675-b38b74e4420d"
      unitRef="usd">79300000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzEwLTEtMS0xLTE5NzE4Mg_1c5cbcce-7728-4729-93ad-7e3a91c01d37"
      unitRef="usd">-325000000.0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzEwLTMtMS0xLTE5NzE4Mg_60d6aa91-d0a8-42d0-a1b0-91299ef33938"
      unitRef="usd">-173100000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzEwLTUtMS0xLTE5NzE4Mg_64bfde20-6e5b-4d07-89c1-1e2a12cf5bb8"
      unitRef="usd">-6700000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzEwLTctMS0xLTE5NzE4Mg_0bc800e4-4b31-43e2-b70e-97bad9f12b5d"
      unitRef="usd">-6200000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzExLTEtMS0xLTE5NzE4Mg_8a82db2b-d2d8-422f-80d1-9034a733323a"
      unitRef="usd">13222000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzExLTMtMS0xLTE5NzE4Mg_8314bc8e-45dc-4869-a8c0-d2a7c681fb95"
      unitRef="usd">17565000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzExLTUtMS0xLTE5NzE4Mg_702c6e5a-316f-4fa2-8d23-ae8d367846ff"
      unitRef="usd">1258800000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOGIyOGIzMWFiMjM0MjFjODJkY2QzMmQxMjVmZjM0Ni90YWJsZXJhbmdlOjM4YjI4YjMxYWIyMzQyMWM4MmRjZDMyZDEyNWZmMzQ2XzExLTctMS0xLTE5NzE4Mg_950e4d5d-def4-42c8-816b-16d50948a226"
      unitRef="usd">1663800000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMDcx_605d959a-66c1-4443-9b1e-5a425d5aeb54">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,416.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,579.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,361.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,227.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,388.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,458.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(796.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;118.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(608.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(630.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(86.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange rate changes and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(341.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,195.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,416.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,492.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,361.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzEtMS0xLTEtMTk3MTgy_57b46ef3-7b15-4eaa-ad10-e36cd6d68de2"
      unitRef="usd">16416000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i057f9a4808af4123bcdfdc6c3301e04b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzEtMy0xLTEtMTk3MTgy_5d5f9649-08c8-431e-86d6-01145d5ea1a3"
      unitRef="usd">14579000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzEtNS0xLTEtMTk3MTgy_021f9a18-13f0-4213-af86-905411484764"
      unitRef="usd">3361400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i125b075ff711498b8733b378408d98e3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzEtNy0xLTEtMTk3MTgy_848f1d75-94fc-490d-b114-02b53fa5b255"
      unitRef="usd">3227000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzItMS0xLTEtMTk3MTgy_592f3b4b-5486-4cd6-a4b2-969f8ce8d013"
      unitRef="usd">-2388100000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzItMy0xLTEtMTk3MTgy_884cbff1-58fa-4d03-aef8-813d3c07b2df"
      unitRef="usd">2458100000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzItNS0xLTEtMTk3MTgy_7c0dd02b-fb2a-4469-88df-e1dffa0eb50e"
      unitRef="usd">-796000000.0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzItNy0xLTEtMTk3MTgy_9a2880e2-1b0f-432b-81d1-80a32d149abf"
      unitRef="usd">202600000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzMtMS0xLTEtMTk3MTgy_a0c287f4-f079-4162-8e98-bc952781263d"
      unitRef="usd">118100000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzMtMy0xLTEtMTk3MTgy_98227f36-b9d4-4414-89f5-619ca6b067ef"
      unitRef="usd">131200000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzMtNS0xLTEtMTk3MTgy_dd219a68-5d49-4e94-8618-90c50c3d3c91"
      unitRef="usd">13900000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzMtNy0xLTEtMTk3MTgy_b3e7966c-537f-4615-8ed3-79b5068864f9"
      unitRef="usd">11100000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzQtMS0xLTEtMTk3MTgy_f2a28af4-0ad7-41d1-813b-a2c8e513ecea"
      unitRef="usd">608900000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzQtMy0xLTEtMTk3MTgy_39039af2-176a-47f8-a0b5-a63ab2d43f98"
      unitRef="usd">630100000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzQtNS0xLTEtMTk3MTgy_1a4ffa21-cc1c-40e4-891a-a6459d3c88ec"
      unitRef="usd">86800000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzQtNy0xLTEtMTk3MTgy_fd4d1f1b-d9e2-4f2d-926d-558d9bbf3f5a"
      unitRef="usd">79300000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzUtMS0xLTEtMTk3MTgy_52d8e39b-b876-4dc3-b15a-6db748409aed"
      unitRef="usd">-341300000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzUtMy0xLTEtMTk3MTgy_6327fb4e-02a3-4297-b8f1-6ade485b611d"
      unitRef="usd">-122200000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzUtNS0xLTEtMTk3MTgy_c330b8ba-f767-40b4-bee1-b160f7a2069d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzUtNy0xLTEtMTk3MTgy_f81bcc07-31b4-42de-8e98-9cd7b2bbd1c8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzYtMS0xLTEtMTk3MTgy_db506cc4-7cbc-4072-8660-382ea6868950"
      unitRef="usd">13195800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzYtMy0xLTEtMTk3MTgy_785bb8cf-d801-4677-af8b-0b9b265b4994"
      unitRef="usd">16416000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzYtNS0xLTEtMTk3MTgy_ae664107-8ec5-406d-a3e4-d6c4ac8e10de"
      unitRef="usd">2492500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozOWU3MGJjNmM2NGM0NTJkOTEyMjUxNTIzOTM3ZDZjZS90YWJsZXJhbmdlOjM5ZTcwYmM2YzY0YzQ1MmQ5MTIyNTE1MjM5MzdkNmNlXzYtNy0xLTEtMTk3MTgy_024cc0b4-312b-43ac-81dd-590cd0af86f2"
      unitRef="usd">3361400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:ScheduleOfNetFundedStatusTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMDg3_0b030c04-03a5-430f-9558-bbce09586650">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funded status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(26.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,149.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,233.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,697.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized net actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,687.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,908.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;54.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(497.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized prior service (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(62.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,669.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,770.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,226.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetFundedStatusTableTextBlock>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzAtMS0xLTEtMTk3MTgy_99cb8e11-7d01-4e36-b4d7-ddae04b0de05"
      unitRef="usd">-26200000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzAtMy0xLTEtMTk3MTgy_d7e1f5e9-b01d-4fa3-ac54-ba05788f62a5"
      unitRef="usd">-1149000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzAtNS0xLTEtMTk3MTgy_32e0c9cc-64bb-4235-9574-c2b85e6b992f"
      unitRef="usd">1233700000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzAtNy0xLTEtMTk3MTgy_0a4d1fe7-4cf8-4e47-ac8d-290a3caf1145"
      unitRef="usd">1697600000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzEtMS0xLTEtMTk3MTgy_2f5da981-b136-41c7-aae8-9fafabb5488d"
      unitRef="usd">-2687200000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzEtMy0xLTEtMTk3MTgy_a9895707-883c-4101-adde-385e3b2dc4e7"
      unitRef="usd">-3908200000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzEtNS0xLTEtMTk3MTgy_9c4d3dac-4aed-4761-bda4-c451934de1dd"
      unitRef="usd">-54500000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzEtNy0xLTEtMTk3MTgy_bb32eb12-bcb6-4a20-941c-91fcc91c1b92"
      unitRef="usd">497200000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzItMS0xLTEtMTk3MTgy_7cabf8b6-e8a0-4ee0-a71c-f35b050b3905"
      unitRef="usd">8400000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzItMy0xLTEtMTk3MTgy_46efde27-fa7d-4be1-bed2-71e3eb9b6865"
      unitRef="usd">11200000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzItNS0xLTEtMTk3MTgy_09461acc-1963-47bd-af09-0897956f2fdc"
      unitRef="usd">-62200000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzItNy0xLTEtMTk3MTgy_38467099-bdf9-4270-8f84-39e27252cd27"
      unitRef="usd">-117600000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzMtMS0xLTEtMTk3MTgy_4e1a05d1-a9a1-4efc-aa2d-8a0dfb76e428"
      unitRef="usd">2669400000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzMtMy0xLTEtMTk3MTgy_0786c1bd-ed63-4a34-b9c7-43bf960dea79"
      unitRef="usd">2770400000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzMtNS0xLTEtMTk3MTgy_db66744d-9afb-454a-b410-4b431670fbec"
      unitRef="usd">1226000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpmOWZjOWFlYzRlMDk0N2ZjYTMyYWY5MzhkNDdhYWQ2My90YWJsZXJhbmdlOmY5ZmM5YWVjNGUwOTQ3ZmNhMzJhZjkzOGQ0N2FhZDYzXzMtNy0xLTEtMTk3MTgy_01483b3e-fb2a-4bac-9718-6a1ca28b4e65"
      unitRef="usd">1082800000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMDc1_f8e4856f-8564-46a4-afcf-1b98968bad9a">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in the consolidated balance sheet consisted&#160;of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,208.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,383.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,910.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(70.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,163.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,749.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(141.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive (income) loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,695.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,919.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(614.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,669.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,770.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,226.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzEtMS0xLTEtMTk3MTgy_5cc1ce73-d503-4159-8670-faed970f4fd8"
      unitRef="usd">1208000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzEtMy0xLTEtMTk3MTgy_daf72767-1a6c-45b0-ba9c-691a8a27f69f"
      unitRef="usd">668500000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzEtNS0xLTEtMTk3MTgy_772199c6-bb2f-4719-af16-9d9774aa60ed"
      unitRef="usd">1383400000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzEtNy0xLTEtMTk3MTgy_7ade8e2c-d207-406f-b38a-1398e6a4fbbb"
      unitRef="usd">1910200000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzItMS0xLTEtMTk3MTgy_1554b65d-f6c9-443b-84fa-4565bf1b7113"
      unitRef="usd">70400000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzItMy0xLTEtMTk3MTgy_98ab0e4c-538f-43e3-a82d-8a7cb75959e2"
      unitRef="usd">68300000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzItNS0xLTEtMTk3MTgy_bc798faa-8149-481a-a9f7-b228f2fd3bdb"
      unitRef="usd">8400000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzItNy0xLTEtMTk3MTgy_b5d8e3e2-717a-4391-bd71-f480fdd2701b"
      unitRef="usd">7900000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzMtMS0xLTEtMTk3MTgy_83061b7f-1ad6-4964-bc5c-a388ac12203d"
      unitRef="usd">1163800000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzMtMy0xLTEtMTk3MTgy_116d1570-bcbb-45cd-8155-9c99b2c655b0"
      unitRef="usd">1749300000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzMtNS0xLTEtMTk3MTgy_432b4137-544f-4f73-b786-2d4be3769f51"
      unitRef="usd">141300000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzMtNy0xLTEtMTk3MTgy_22ed7b4a-f3e8-41a5-a6b0-e5b8d090948b"
      unitRef="usd">204800000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzQtMS0xLTEtMTk3MTgy_070946e5-c1bf-4a47-9430-ca115f1b2e1f"
      unitRef="usd">2695600000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzQtMy0xLTEtMTk3MTgy_41ec182f-5df1-439e-8c03-e8b66f72a222"
      unitRef="usd">3919500000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzQtNS0xLTEtMTk3MTgy_c8bc7d40-d90a-4b67-9465-ce8078a68d0a"
      unitRef="usd">-7700000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzQtNy0xLTEtMTk3MTgy_592297e2-9f89-47c1-a3ff-6153a88c6e22"
      unitRef="usd">-614700000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzUtMS0xLTEtMTk3MTgy_72c48e17-ac61-4af4-a834-62e65adb4f94"
      unitRef="usd">2669400000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzUtMy0xLTEtMTk3MTgy_176b78cb-77a9-4157-bc5d-6a557507782d"
      unitRef="usd">2770400000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzUtNS0xLTEtMTk3MTgy_4a548e7f-7346-4a3c-84aa-e4b969c1db27"
      unitRef="usd">1226000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpkNjcwMzNhNmFhMDI0YjZhOGU3ZGRkNDE5NjAwMGJkNy90YWJsZXJhbmdlOmQ2NzAzM2E2YWEwMjRiNmE4ZTdkZGQ0MTk2MDAwYmQ3XzUtNy0xLTEtMTk3MTgy_15c31197-d86b-49c2-89e5-ad845929b965"
      unitRef="usd">1082800000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzU1Mw_dc91daff-f323-4021-affd-b650eb4b0a84"
      unitRef="usd">-4750000000</us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease>
    <us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzU0OTc1NTgyNTU1NA_8e4f4607-c726-4a40-8633-e5d45c9a4a3a"
      unitRef="usd">-750400000</us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMTU1_ad8a4d6a-f62e-4d11-96e9-95f232bc2dc1">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents our weighted-average assumptions as of December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Percents)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate for benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate for net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase for benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase for net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets for net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzItMS0xLTEtMTk3MTgy_84e161e8-4e9e-4dd6-aafb-7119be178831"
      unitRef="number">0.051</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzItMy0xLTEtMTk3MTgy_cb613400-f6d5-47ed-92cf-0caa3ea0d9af"
      unitRef="number">0.028</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i057f9a4808af4123bcdfdc6c3301e04b_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzItNS0xLTEtMTk3MTgy_1b4329eb-87cd-402d-9485-0566e124dc75"
      unitRef="number">0.024</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzItNy0xLTEtMTk3MTgy_508748df-a890-44d5-8104-6ffb020eb9be"
      unitRef="number">0.052</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzItOS0xLTEtMTk3MTgy_3212120a-92f5-49c7-9c26-98a551580c5d"
      unitRef="number">0.030</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i125b075ff711498b8733b378408d98e3_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzItMTEtMS0xLTE5NzE4Mg_9b92a764-3c45-4fbe-a357-99c16b9a4e30"
      unitRef="number">0.026</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzMtMS0xLTEtMTk3MTgy_7c60c45e-f379-4579-a8ee-17c6fabcffde"
      unitRef="number">0.028</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzMtMy0xLTEtMTk3MTgy_056c9228-1b9a-4fa4-85db-9676e0ef7bf1"
      unitRef="number">0.024</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzMtNS0xLTEtMTk3MTgy_e1b08405-acf1-4287-93b6-f77b6b050fed"
      unitRef="number">0.030</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzMtNy0xLTEtMTk3MTgy_66a3e20d-7ff2-428f-81e0-0dfae58dcd44"
      unitRef="number">0.030</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzMtOS0xLTEtMTk3MTgy_f3f7733f-2b10-4897-bca6-c711d6035022"
      unitRef="number">0.026</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzMtMTEtMS0xLTE5NzE4Mg_b3cf5f09-d534-4d54-aab3-b67692b066ff"
      unitRef="number">0.033</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzQtMS0xLTEtMTk3MTgy_4bfaab60-a44c-435c-8942-1ee27324f6bc"
      unitRef="number">0.043</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzQtMy0xLTEtMTk3MTgy_caab7a89-4c1e-4c35-8963-221ba8f3c4aa"
      unitRef="number">0.035</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i057f9a4808af4123bcdfdc6c3301e04b_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzQtNS0xLTEtMTk3MTgy_192be767-d891-4ecd-b6ab-74686980c23b"
      unitRef="number">0.033</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzUtMS0xLTEtMTk3MTgy_98e97432-88c1-46e6-8b15-5920f9d81b22"
      unitRef="number">0.035</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzUtMy0xLTEtMTk3MTgy_05a4de09-6179-4057-b232-343cf11a30a4"
      unitRef="number">0.033</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzUtNS0xLTEtMTk3MTgy_6f7da3a2-b115-4eee-a30d-c43d96a1975d"
      unitRef="number">0.033</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzYtMS0xLTEtMTk3MTgy_fa50eaa7-d80f-422f-bac5-894df9c33fb4"
      unitRef="number">0.081</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzYtMy0xLTEtMTk3MTgy_8bd77c48-0894-4a7b-b11e-1dd8ae241a4f"
      unitRef="number">0.068</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzYtNS0xLTEtMTk3MTgy_679b995c-efa6-4a5d-a319-83cb108e3bf9"
      unitRef="number">0.073</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzYtNy0xLTEtMTk3MTgy_ee260a60-bc7a-4e59-9be9-1fdf4b4e13ad"
      unitRef="number">0.073</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzYtOS0xLTEtMTk3MTgy_633b7fc2-f558-455a-b4d9-b53b3d1cf43b"
      unitRef="number">0.050</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZDU2MTIwMjA0MmM0NjkwOWFjOWJhYzM1ZWYzYzI5ZS90YWJsZXJhbmdlOjVkNTYxMjAyMDQyYzQ2OTA5YWM5YmFjMzVlZjNjMjllXzYtMTEtMS0xLTE5NzE4Mg_a40ecdf6-c376-43e7-8631-9e3285809d4d"
      unitRef="number">0.060</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMTU3_d3e7271a-a53e-4e41-a112-c777101d2fe8">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2028-2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension plans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,079.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retiree health benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzEtMS0xLTEtMTk3MTgy_6d0d05c2-081a-4466-9a0d-276f81b96dea"
      unitRef="usd">648200000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzEtMy0xLTEtMTk3MTgy_f9073af4-b9e7-402b-b6c1-a6bc69236d9d"
      unitRef="usd">664500000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzEtNS0xLTEtMTk3MTgy_b80e52bc-2a34-471b-aa8c-7519282b19b7"
      unitRef="usd">682600000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzEtNy0xLTEtMTk3MTgy_39ad17bd-fed8-4288-a49c-9c2df5eb596c"
      unitRef="usd">705900000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzEtOS0xLTEtMTk3MTgy_53d000f9-7fb0-4cb1-bf2d-83bfc5332f92"
      unitRef="usd">732700000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzEtMTEtMS0xLTE5NzE4Mg_0d22029f-11a6-41d8-a7b5-061d10ea491b"
      unitRef="usd">4079400000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzItMS0xLTEtMTk3MTgy_7356fb87-5ce6-4bf1-a53a-ac1088308b7a"
      unitRef="usd">89000000.0</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzItMy0xLTEtMTk3MTgy_14d4d1b6-cf38-453c-b0ec-504350b26312"
      unitRef="usd">91600000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzItNS0xLTEtMTk3MTgy_18b93a23-60cd-44de-9d47-937947c58158"
      unitRef="usd">92400000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzItNy0xLTEtMTk3MTgy_8c1370fe-4122-46e9-b219-846b015061bb"
      unitRef="usd">92800000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzItOS0xLTEtMTk3MTgy_8635af79-1867-4a2d-92cd-a3b587cf24d2"
      unitRef="usd">93400000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTplZWEzZWVhNGNiNTI0MDFiYWJhYWY5ZmZiYzI3OTY0OS90YWJsZXJhbmdlOmVlYTNlZWE0Y2I1MjQwMWJhYmFhZjlmZmJjMjc5NjQ5XzItMTEtMS0xLTE5NzE4Mg_200eacd9-8c4a-402d-b666-3a45f3d660fa"
      unitRef="usd">468300000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMTQz_e0bab24a-46c0-4680-91d9-6a437ba6e3e1">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,211.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,360.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;977.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,542.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyZDM3MDNmNTNjYzk0NzhjYjdhYTE3N2Y1N2MzN2IwYS90YWJsZXJhbmdlOjJkMzcwM2Y1M2NjOTQ3OGNiN2FhMTc3ZjU3YzM3YjBhXzEtMS0xLTEtMTk3MTgy_8200f237-7e4a-4fce-a171-c1717a7cfb7e"
      unitRef="usd">2211200000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyZDM3MDNmNTNjYzk0NzhjYjdhYTE3N2Y1N2MzN2IwYS90YWJsZXJhbmdlOjJkMzcwM2Y1M2NjOTQ3OGNiN2FhMTc3ZjU3YzM3YjBhXzEtMy0xLTEtMTk3MTgy_cf5ba576-66e3-4fe1-b7c4-f43a892407e5"
      unitRef="usd">3360300000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="ife049f03c96e47288db50605b1356b32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyZDM3MDNmNTNjYzk0NzhjYjdhYTE3N2Y1N2MzN2IwYS90YWJsZXJhbmdlOjJkMzcwM2Y1M2NjOTQ3OGNiN2FhMTc3ZjU3YzM3YjBhXzItMS0xLTEtMTk3MTgy_de6cb23c-4f2b-478f-94b9-f44e79d2aa5f"
      unitRef="usd">977100000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="id1b649fc71124f56ae26b2e43abf1d5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyZDM3MDNmNTNjYzk0NzhjYjdhYTE3N2Y1N2MzN2IwYS90YWJsZXJhbmdlOjJkMzcwM2Y1M2NjOTQ3OGNiN2FhMTc3ZjU3YzM3YjBhXzItMy0xLTEtMTk3MTgy_93a9aa5e-fa4f-4dd4-abd0-6f76f7081dd1"
      unitRef="usd">1542800000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMDc2_c503ca8f-3505-44cd-9f33-043b1f1682af">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health &lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,721.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,532.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;149.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;652.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;973.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpjOWFjMTc5ZjU2OTg0MDM0YmZmYjZkYmNlYjk3MDRlZC90YWJsZXJhbmdlOmM5YWMxNzlmNTY5ODQwMzRiZmZiNmRiY2ViOTcwNGVkXzItMS0xLTEtMTk3MTgy_f2fb5161-ac19-4d4f-a81b-f4c208e3a87b"
      unitRef="usd">1721700000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpjOWFjMTc5ZjU2OTg0MDM0YmZmYjZkYmNlYjk3MDRlZC90YWJsZXJhbmdlOmM5YWMxNzlmNTY5ODQwMzRiZmZiNmRiY2ViOTcwNGVkXzItMy0xLTEtMTk3MTgy_baeee77b-a77e-4c93-b594-649c7f431728"
      unitRef="usd">2532000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpjOWFjMTc5ZjU2OTg0MDM0YmZmYjZkYmNlYjk3MDRlZC90YWJsZXJhbmdlOmM5YWMxNzlmNTY5ODQwMzRiZmZiNmRiY2ViOTcwNGVkXzItNS0xLTEtMTk3MTgy_17e044f3-0acf-4f85-93c1-0159a7902c16"
      unitRef="usd">149800000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpjOWFjMTc5ZjU2OTg0MDM0YmZmYjZkYmNlYjk3MDRlZC90YWJsZXJhbmdlOmM5YWMxNzlmNTY5ODQwMzRiZmZiNmRiY2ViOTcwNGVkXzItNy0xLTEtMTk3MTgy_f86ba389-cceb-4455-8a3a-fcb96915e274"
      unitRef="usd">212600000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpjOWFjMTc5ZjU2OTg0MDM0YmZmYjZkYmNlYjk3MDRlZC90YWJsZXJhbmdlOmM5YWMxNzlmNTY5ODQwMzRiZmZiNmRiY2ViOTcwNGVkXzMtMS0xLTEtMTk3MTgy_686476c1-50c3-4093-b02f-d1e1e4fefcb9"
      unitRef="usd">652700000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpjOWFjMTc5ZjU2OTg0MDM0YmZmYjZkYmNlYjk3MDRlZC90YWJsZXJhbmdlOmM5YWMxNzlmNTY5ODQwMzRiZmZiNmRiY2ViOTcwNGVkXzMtMy0xLTEtMTk3MTgy_33babdc0-d984-4b75-8e1a-119a6163be6a"
      unitRef="usd">973400000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpjOWFjMTc5ZjU2OTg0MDM0YmZmYjZkYmNlYjk3MDRlZC90YWJsZXJhbmdlOmM5YWMxNzlmNTY5ODQwMzRiZmZiNmRiY2ViOTcwNGVkXzMtNS0xLTEtMTk3MTgy_87f79d9b-94fe-4789-97a4-da160b018d56"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTpjOWFjMTc5ZjU2OTg0MDM0YmZmYjZkYmNlYjk3MDRlZC90YWJsZXJhbmdlOmM5YWMxNzlmNTY5ODQwMzRiZmZiNmRiY2ViOTcwNGVkXzMtNy0xLTEtMTk3MTgy_eb7b04f3-b5f2-4957-93ab-c302f0e3ba82"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzIwNDE_de75ac97-6ca7-48bd-9a40-43ee5e73c5a2"
      unitRef="usd">12010000000.00</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzIwNDg_3cb42574-efb1-463e-b386-4e7233b94d4f"
      unitRef="usd">16440000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMDQ3_6735bc00-4662-4193-9658-d7ffe70aa7a7">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net pension and retiree health benefit expense included the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic (benefit) cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;351.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;398.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(947.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(949.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(901.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(152.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(54.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;342.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;147.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(121.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzMtMS0xLTEtMTk3MTgy_5112051b-2529-4bab-b8ec-c1e8cbd644ff"
      unitRef="usd">351700000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzMtMy0xLTEtMTk3MTgy_e981b6d0-a7b7-43a8-aa8b-c765821e8a4e"
      unitRef="usd">369200000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzMtNS0xLTEtMTk3MTgy_87a462bf-e3ac-42de-8388-df9548d1d91a"
      unitRef="usd">325500000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzMtNy0xLTEtMTk3MTgy_1dc937e1-c2b7-4567-b33d-b617c56efb23"
      unitRef="usd">46600000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzMtOS0xLTEtMTk3MTgy_d3af3d2c-3d30-4f42-9b1e-0b557f6fc9b9"
      unitRef="usd">49200000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzMtMTEtMS0xLTE5NzE4Mg_62c28252-e348-4deb-b679-467df92b53ae"
      unitRef="usd">40800000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzQtMS0xLTEtMTk3MTgy_665b236c-db44-4bf4-8756-84591929e725"
      unitRef="usd">398100000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzQtMy0xLTEtMTk3MTgy_94764ae4-84ae-453a-a536-eec6f28830f0"
      unitRef="usd">337800000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzQtNS0xLTEtMTk3MTgy_c7cfc875-b85e-4c73-a4d8-494d004b77cc"
      unitRef="usd">425800000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzQtNy0xLTEtMTk3MTgy_821e9cf9-4a15-42c6-9184-af758f2811f8"
      unitRef="usd">37800000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzQtOS0xLTEtMTk3MTgy_48d08a41-9542-4ec5-91be-2614cd49bc4f"
      unitRef="usd">32500000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzQtMTEtMS0xLTE5NzE4Mg_27df2783-55d1-4f47-ad90-7a0a9c82343a"
      unitRef="usd">43700000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzUtMS0xLTEtMTk3MTgy_442cfb84-5bdf-424d-92c2-b1a37b18c119"
      unitRef="usd">947600000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzUtMy0xLTEtMTk3MTgy_cda9660e-240f-493f-b6f6-73e8c0f2b9b1"
      unitRef="usd">949300000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzUtNS0xLTEtMTk3MTgy_70e3e81d-daa7-4049-96ce-e2868252d364"
      unitRef="usd">901500000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzUtNy0xLTEtMTk3MTgy_0854147d-1fbf-42db-a81c-83dedf53b3fb"
      unitRef="usd">152100000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzUtOS0xLTEtMTk3MTgy_4c1ccacb-281b-41c8-8188-f9b47508606d"
      unitRef="usd">146200000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzUtMTEtMS0xLTE5NzE4Mg_cd0006a3-8a31-4f6b-a8f7-92b8cb652151"
      unitRef="usd">158100000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzYtMS0xLTEtMTk3MTgy_d508050a-c385-428e-88b4-df7c6cc4cf39"
      unitRef="usd">2400000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzYtMy0xLTEtMTk3MTgy_a8eb3858-9086-486e-8b8a-e4b4b671242f"
      unitRef="usd">4200000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzYtNS0xLTEtMTk3MTgy_40980402-6a9c-4290-a5a4-fe16fca8ad0b"
      unitRef="usd">4500000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzYtNy0xLTEtMTk3MTgy_0f60dbd3-069a-44e6-9344-ad8aaf2d257c"
      unitRef="usd">-54800000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzYtOS0xLTEtMTk3MTgy_542c5d2d-0e21-4044-b587-5bd80a59ae9e"
      unitRef="usd">-59600000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzYtMTEtMS0xLTE5NzE4Mg_fa7d99de-6cea-4fd4-8f3d-ee47f4798dc3"
      unitRef="usd">-59500000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzctMS0xLTEtMTk3MTgy_8c0d4181-87a9-4a41-ac0b-3239bdf89ff0"
      unitRef="usd">-342400000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzctMy0xLTEtMTk3MTgy_ebb44f1a-6d03-4adb-abb0-a585361c7873"
      unitRef="usd">-487700000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzctNS0xLTEtMTk3MTgy_cc9f20f4-9641-431f-ba85-08a8b32b0a79"
      unitRef="usd">-396300000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzctNy0xLTEtMTk3MTgy_5d70ee0f-89cc-41b0-8532-6ea6b01f7325"
      unitRef="usd">-900000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzctOS0xLTEtMTk3MTgy_ad5e9d29-82eb-4a72-811a-ca0927f2e442"
      unitRef="usd">-3200000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzctMTEtMS0xLTE5NzE4Mg_864a3318-7e5e-4172-9837-f4671aeac84a"
      unitRef="usd">3000000.0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzEwLTEtMS0xLTE5NzE4Mg_8d022bf3-effc-452c-b125-302c1f3dcad3"
      unitRef="usd">147000000.0</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzEwLTMtMS0xLTE5NzE4Mg_669272d5-7331-431f-9503-f4dfb81d8b05"
      unitRef="usd">249600000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzEwLTUtMS0xLTE5NzE4Mg_fcf16dd2-86a1-4c9a-a13e-8e1fbbcaa47a"
      unitRef="usd">250600000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzEwLTctMS0xLTE5NzE4Mg_3c98f622-62a8-44c8-bd81-2098f5f13007"
      unitRef="usd">-121600000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzEwLTktMS0xLTE5NzE4Mg_0e244011-e93e-47c7-8e50-b239983d54df"
      unitRef="usd">-120900000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo1ZGQwYWEyMmVhM2Y0MDZiODZmMjM3YjQwY2E4YWQ2ZS90YWJsZXJhbmdlOjVkZDBhYTIyZWEzZjQwNmI4NmYyMzdiNDBjYThhZDZlXzEwLTExLTEtMS0xOTcxODI_343bd133-b113-403e-9202-bc5b8eda7e83"
      unitRef="usd">-136100000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMTUy_98eb5e00-9f47-471c-9648-dc3a3f004c60">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents the amounts recognized in other comprehensive income (loss) for the years ended December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021, and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined&#160;Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree&#160;Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial gain (loss) arising during period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;823.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,072.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(663.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(552.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan amendments during period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service (benefit) cost included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(54.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial (gain) loss included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;342.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange rate changes and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;55.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income (loss) during period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,223.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(335.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(607.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzItMS0xLTEtMTk3MTgy_69c36391-0535-42ef-8f7b-9653722acf7e"
      unitRef="usd">823600000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzItMy0xLTEtMTk3MTgy_90b2710b-57d3-4a98-88ea-8d0dbdf6d302"
      unitRef="usd">2072400000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzItNS0xLTEtMTk3MTgy_3723285c-2493-41e6-a76b-4d0481419089"
      unitRef="usd">-663000000.0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzItNy0xLTEtMTk3MTgy_a212655f-1cae-485e-aa71-ceaf115ff040"
      unitRef="usd">-552200000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzItOS0xLTEtMTk3MTgy_15bee6a3-59a7-40a2-b8f1-fb52f1f27671"
      unitRef="usd">142500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzItMTEtMS0xLTE5NzE4Mg_bc5d2271-2a90-4015-9047-a518d6affbb4"
      unitRef="usd">238800000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzMtMS0xLTEtMTk3MTgy_9fac0324-249f-4bee-9bf1-561d61ecc7bb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzMtMy0xLTEtMTk3MTgy_7eb6de69-6c40-430f-b6c5-ac2b736954ed"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzMtNS0xLTEtMTk3MTgy_b249df60-e113-4994-adc8-594749a542e4"
      unitRef="usd">2200000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzMtNy0xLTEtMTk3MTgy_db74c448-1a17-41f2-9a23-495c7f1efbc1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzMtOS0xLTEtMTk3MTgy_835c19db-36b3-4624-b28d-bc8161b6161c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzMtMTEtMS0xLTE5NzE4Mg_24325698-37ee-4fc3-90c6-95e5454bbd92"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzUtMS0xLTEtMTk3MTgy_ff6ed148-b0cc-470e-8618-3f5753db80a9"
      unitRef="usd">2400000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzUtMy0xLTEtMTk3MTgy_de08ac5d-0bfa-4e94-9ad0-0470ef9d2187"
      unitRef="usd">4200000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzUtNS0xLTEtMTk3MTgy_7b617932-cf02-4d16-a0ae-d258f15e3c22"
      unitRef="usd">4500000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzUtNy0xLTEtMTk3MTgy_3829730e-63ce-4697-970f-54104f2953d9"
      unitRef="usd">-54800000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzUtOS0xLTEtMTk3MTgy_f9109c02-727c-49ef-a66b-9481ef41b4da"
      unitRef="usd">-59600000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzUtMTEtMS0xLTE5NzE4Mg_c1d4ea08-9d9f-4b7b-aa96-6cc0e2934ff4"
      unitRef="usd">-59500000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzYtMS0xLTEtMTk3MTgy_e6bbc0d5-db14-4e28-80f7-9e5fdad2e52b"
      unitRef="usd">342400000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzYtMy0xLTEtMTk3MTgy_3d99b073-caae-45fb-ab28-21abbd68c453"
      unitRef="usd">487700000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzYtNS0xLTEtMTk3MTgy_bcf6b2e0-0d68-4394-98f6-caef90a91b6e"
      unitRef="usd">396300000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzYtNy0xLTEtMTk3MTgy_c07e0156-457d-4519-b1ac-0547befd0e29"
      unitRef="usd">900000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzYtOS0xLTEtMTk3MTgy_58bb94fd-2940-485c-996e-07176629934d"
      unitRef="usd">3200000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzYtMTEtMS0xLTE5NzE4Mg_dcac6bd7-5b63-4c02-8d15-93828b555901"
      unitRef="usd">-3000000.0</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzctMS0xLTEtMTk3MTgy_f5862a0f-d902-4a46-b1ca-c44f9f6febe9"
      unitRef="usd">55500000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzctMy0xLTEtMTk3MTgy_dd66066d-de68-49ed-a343-da8e3d510f1f"
      unitRef="usd">47200000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzctNS0xLTEtMTk3MTgy_912331f1-2577-499d-a7ab-3b9dccf396a0"
      unitRef="usd">-71500000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzctNy0xLTEtMTk3MTgy_a2ff6f0b-6bda-4f49-8501-58a477684d37"
      unitRef="usd">-900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzctOS0xLTEtMTk3MTgy_375ae293-1dac-4828-86a0-c387ba2210f5"
      unitRef="usd">1900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzctMTEtMS0xLTE5NzE4Mg_2e8aabb9-dc24-4e40-b6a9-3a96597462db"
      unitRef="usd">2400000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzgtMS0xLTEtMTk3MTgy_1f925bc7-40d6-4117-af34-ef13d138f276"
      unitRef="usd">-1223900000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i2725f19aec1a4cfaa7860a1789b98c84_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzgtMy0xLTEtMTk3MTgy_2a6c2800-a8fd-4929-b8f8-01b92cffd37e"
      unitRef="usd">-2611500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i8b34e3397dfb42599f5afbeedaf04e44_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzgtNS0xLTEtMTk3MTgy_0ca86bb6-3e38-4cdb-b0f6-687f41701b97"
      unitRef="usd">335900000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="if520336c52c54904ba5808790e7ec324_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzgtNy0xLTEtMTk3MTgy_5ae8d82a-1602-4e04-85d3-f17a92ec1d3c"
      unitRef="usd">607000000.0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i7174925cbde4455b89ab58628d0fdb18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzgtOS0xLTEtMTk3MTgy_1eebfa4e-efa5-4c97-9d8d-a58e8f8f8a86"
      unitRef="usd">-88000000.0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i93722a85344f4f6dbbcf6de93ea58dd2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTo5ZDE2ZDI5Y2M4NWI0OTJkODUwY2UzNjJjZjRkNmM5ZC90YWJsZXJhbmdlOjlkMTZkMjljYzg1YjQ5MmQ4NTBjZTM2MmNmNGQ2YzlkXzgtMTEtMS0xLTE5NzE4Mg_9dccab36-5a03-4ee5-a153-cd1a7592362f"
      unitRef="usd">-178700000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzI2NTE_5250c117-0ad1-4d83-9cdc-109df079077d"
      unitRef="usd">170600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzI2NTU_cb8a3fa4-80c7-464c-961f-6c16b6f71af1"
      unitRef="usd">167300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzI2NjM_08a1c945-6629-49f3-9689-2d6ebe8829b1"
      unitRef="usd">164300000</us-gaap:DefinedContributionPlanCostRecognized>
    <lly:DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzMyMDI_9b5bc269-bcd1-421f-92f9-db14034465a6"
      unitRef="number">0.85</lly:DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="iad4ae6cfb47049b5bd782e22f164d8b3_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzQ4OTc_c3105c6d-d27a-4381-9b0d-8d343c2f061b"
      unitRef="number">0.75</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i8a0874db15724bfb8216d84461801c57_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzQ5MjM_624252f1-14a4-4363-ae13-313892039c0c"
      unitRef="number">0.25</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzExMDU0_517ce730-0299-4e38-a230-f04380de83a1">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2022 by asset category were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Asset Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in Active Markets&#160;for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Observable&#160;&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Investments Valued at Net Asset Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,445.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,058.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets - repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(706.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(713.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,014.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,988.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,261.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,195.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,335.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash value of trust owned insurance contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,492.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,514.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2021 by asset category were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Asset Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in Active Markets&#160;for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Investments Valued at Net Asset Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,722.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;815.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,907.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,496.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,356.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets - repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,046.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,046.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,816.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,808.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,143.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,416.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,728.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,170.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash value of trust owned insurance contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,361.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,290.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia316b6b7c534488da162855e12856aee_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzQtMS0xLTEtMTk3MTgy_1769a1fb-6ab5-48fd-b817-56267cef6191"
      unitRef="usd">1132400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if80d17ed3d7341139c95e570648359b1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzQtMy0xLTEtMTk3MTgy_99c73b70-c8de-4df8-ad1c-16caf6f68e9a"
      unitRef="usd">396600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3a731db9bce5491f98e9d3db25b05e57_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzQtNS0xLTEtMTk3MTgy_e20417e2-4075-44eb-819c-a40e55957fbe"
      unitRef="usd">100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i01910d1722ed432eac20033caa81d3e8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzQtNy0xLTEtMTk3MTgy_f17f439d-9910-4c8d-a422-4f9423affbff"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib43d57949131458885d98c8a93ecc8ff_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzQtOS0xLTEtMTk3MTgy_596f8cb4-6494-4903-b1f1-fc7b05a37af1"
      unitRef="usd">735700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9058615b4dac4d84a46d1a194938b1d0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzUtMS0xLTEtMTk3MTgy_f8d44f48-2430-42a1-9391-7d0fc3dff3c1"
      unitRef="usd">1177100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1210e6088eb043d5b57234e2c04d5495_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzUtMy0xLTEtMTk3MTgy_0a3d50da-b253-4cfb-b840-a5935a14e20a"
      unitRef="usd">369400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i304ba8d5a46e4918b1388a3aa5a0d641_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzUtNS0xLTEtMTk3MTgy_e3797b6b-96a9-4fd2-a4b9-81377e9a9c2d"
      unitRef="usd">300900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3d88291b946e4fada2d92e7be0e6c4ca_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzUtNy0xLTEtMTk3MTgy_e92831e4-f7aa-4505-ae71-fc255b45c923"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i08f9dd15c5264811a0adf0cd5ddbcd70_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzUtOS0xLTEtMTk3MTgy_2b47f7db-8b14-4c6a-8cc5-76c7a9547082"
      unitRef="usd">506800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaf36ffdc2a634608b0576bc6c10d74a6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzctMS0xLTEtMTk3MTgy_0ca04451-c765-4bd4-8893-962acd87a60f"
      unitRef="usd">2445500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie67f316541574a54a1c5e224c4068a84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzctMy0xLTEtMTk3MTgy_48e6034a-94ef-4b44-ac86-3e041a333876"
      unitRef="usd">19800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic8597a970d914e7eac33966ec50e2e45_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzctNS0xLTEtMTk3MTgy_938947cd-0dc8-453b-86e8-f6d62955ad48"
      unitRef="usd">2058200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8aa3bc29c31c46e9841c05765cc07cbb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzctNy0xLTEtMTk3MTgy_8e49e0cd-8c50-4e86-bffe-5cba4f1fdef0"
      unitRef="usd">100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0f741744892048f79ba678614ab460e9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzctOS0xLTEtMTk3MTgy_e8e7bb4c-38e6-4f7f-a571-168bd2281db2"
      unitRef="usd">367400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id53867d3f4f742a7a401891b83a35ccf_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzgtMS0xLTEtMTk3MTgy_e15bb315-fbab-4dc5-86d1-60a63e9b6dc3"
      unitRef="usd">-706600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if8d9e90e67b644c1b7eb36d3e839d86c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzgtMy0xLTEtMTk3MTgy_8efdfed4-8803-4887-a73d-1d9467a52db0"
      unitRef="usd">6400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i63893449a2d84076a10449b426a8a463_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzgtNS0xLTEtMTk3MTgy_b493a43e-26ba-4442-b06c-950d01877c9e"
      unitRef="usd">-713000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibcb0e523afe1433d98caca75025ecee4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzgtNy0xLTEtMTk3MTgy_8834a856-ce29-4f46-9f6e-ed5c09a9cc24"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i09007bccf7314e778accdfc89455e47b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzgtOS0xLTEtMTk3MTgy_1d9e0988-418f-4d03-ab1d-00a03e8b9ee5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if606ee97c9704abab603056e8b0edf59_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzktMS0xLTEtMTk3MTgy_a2e5bb37-3c0d-40f1-9e31-26e0fba4e912"
      unitRef="usd">273500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iabe7285b3fc24407971675b7ceb932de_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzktMy0xLTEtMTk3MTgy_2c5c0998-28cb-4e34-abdc-983062e789f5"
      unitRef="usd">10600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3749025b65a24fee9b938b61605247bd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzktNS0xLTEtMTk3MTgy_48ae59d5-302e-481a-bbe1-cffb43ef34a1"
      unitRef="usd">32000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i646d525b330b4affbcc9bcbad3171961_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzktNy0xLTEtMTk3MTgy_f14969f2-b52b-445a-9876-96c6a46217ac"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib5111829abe1472899906644ebdadd1d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzktOS0xLTEtMTk3MTgy_a243138e-436e-4e52-b28c-d57a9952708e"
      unitRef="usd">230900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7453fa11715a4896b1ff0f0ff5f09c00_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzExLTEtMS0xLTE5NzE4Mg_4004b510-b65e-4ce8-b69f-5fecc49a5bcd"
      unitRef="usd">3249000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i512f904a58b2427780f61c85d1dd6a60_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzExLTMtMS0xLTE5NzE4Mg_e3af4710-fb46-4511-96f9-818adc3f3a1a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6e8af31081da45808fbffb31cff06d39_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzExLTUtMS0xLTE5NzE4Mg_1055ee6e-165b-4e71-9839-e84f847e1c47"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i97fa38adcb92459287110b63f86477a0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzExLTctMS0xLTE5NzE4Mg_cdb33fa4-7cd3-42f4-8135-2144f8f9f3e1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia76c0aca32f2426babb3ee042aaa4e38_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzExLTktMS0xLTE5NzE4Mg_2a9cb174-13a7-4836-a546-dcceca186a75"
      unitRef="usd">3249000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i60107ebc9335412ca6f1bd84bb68da84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEyLTEtMS0xLTE5NzE4Mg_3ca7acf0-867c-4951-ab0e-3f62fbeb9adc"
      unitRef="usd">4014100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3068b14ed0e644b6a479187e62d04177_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEyLTMtMS0xLTE5NzE4Mg_f21b4ee7-90aa-4d49-9a02-935ba5c6fce7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0de112ae15004511bf9407f3cf72d975_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEyLTUtMS0xLTE5NzE4Mg_83bd14d3-73ef-4851-bd67-e945dbdc3731"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i09a2d55b1e1c44d2871d456003ef7230_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEyLTctMS0xLTE5NzE4Mg_29355369-c068-4a28-981b-2d5cb2a4d82c"
      unitRef="usd">25400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic04e46f294ce4c0fb14fa8b921ae66cc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEyLTktMS0xLTE5NzE4Mg_cd97584c-52a0-4859-854c-2aadf2eafc29"
      unitRef="usd">3988700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9c1c27297ae64abdb64c978fa594cbaa_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEzLTEtMS0xLTE5NzE4Mg_8bcb3f71-2e65-413e-bf46-2f2ad6dffff9"
      unitRef="usd">349100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iba64a2ba2ee54c4d8ce53c70040e9ff0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEzLTMtMS0xLTE5NzE4Mg_8433fd1c-c48c-442d-9f70-057193518868"
      unitRef="usd">234900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib078fa49932d485e98c330eba8129f3c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEzLTUtMS0xLTE5NzE4Mg_929ef952-fef3-46b8-b922-a7960591a93c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9b15966785264fd6be87c35ad8b78710_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEzLTctMS0xLTE5NzE4Mg_db0ee76d-750d-4336-964c-097fc9d57d72"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if24ea8f19b4a4e008be14e1cb7ea857b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzEzLTktMS0xLTE5NzE4Mg_16e60e70-f892-4b60-8804-ccc651305fbe"
      unitRef="usd">114200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iea985983bda74c2b82efe6e81f782028_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE0LTEtMS0xLTE5NzE4Mg_86c869f8-8085-45c1-8792-54b1c0e8eea0"
      unitRef="usd">1261700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if6bce240b92c4b78a32086372012e86c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE0LTMtMS0xLTE5NzE4Mg_3e0ccbe3-3b0b-473c-97f3-e31dc8b77a57"
      unitRef="usd">251000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9076ad0d4db44a508631c37b130697de_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE0LTUtMS0xLTE5NzE4Mg_4be98402-6826-402f-862e-d4fb225c2711"
      unitRef="usd">-131800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idfe24bf9e81d43ec9e96c7d669380b3c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE0LTctMS0xLTE5NzE4Mg_55a0a9d4-57d8-44bc-9a8c-9b9da6f8f3e4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i686e8ff5c4a8496da94e3e68008b4845_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE0LTktMS0xLTE5NzE4Mg_66fbbe6f-fd3b-4c3f-99f9-861d22a61366"
      unitRef="usd">1142500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE1LTEtMS0xLTE5NzE4Mg_64b8ae80-b764-438b-a83c-fda7660acef1"
      unitRef="usd">13195800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i343ea5fd96b643009c59bf6456fe7731_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE1LTMtMS0xLTE5NzE4Mg_81938a17-b8fd-476d-92a0-070064bb8b28"
      unitRef="usd">1288700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic6e300f5e5754a95992494e35bb4fad2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE1LTUtMS0xLTE5NzE4Mg_1cb9b91b-404e-422c-9962-7b0b2fc0864e"
      unitRef="usd">1546400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i580abbf76b7b4f58b638cef09a78edb0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE1LTctMS0xLTE5NzE4Mg_5af5cb8f-b757-48f8-a849-a4fd60c848a7"
      unitRef="usd">25500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifbf22e6860aa4abdaf439b706e4a6866_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE1LTktMS0xLTE5NzE4Mg_0852fe88-ff81-4017-87df-37a773cf309d"
      unitRef="usd">10335200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idc86bd5686bc4e3badb3c7e166fac6f4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE5LTEtMS0xLTE5NzE4Mg_1d2d2bf7-958f-44f0-8c15-657c2050dd06"
      unitRef="usd">104200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id0ff8e7d4cbb47789b98e55ac9b9b579_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE5LTMtMS0xLTE5NzE4Mg_d8c04639-d70a-4e74-8c9e-e19e51bebac2"
      unitRef="usd">35700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i57b56107f1e043c1a3ad9569212ecacb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE5LTUtMS0xLTE5NzE4Mg_00a8bfe0-530d-44e2-8c43-1c20091f7ce2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iebe855aa68c84719bddaf01cf7d20e04_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE5LTctMS0xLTE5NzE4Mg_e9d9d184-9da8-423c-834c-0512c3f2bafc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4b0a212192da4a3395f2bbeacd3c312f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzE5LTktMS0xLTE5NzE4Mg_30d2aa65-d372-4eb7-9326-92fc95e17e6b"
      unitRef="usd">68500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2f2751d7d37f4b76ad3b2e86c47f4de3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIwLTEtMS0xLTE5NzE4Mg_6cc3b3e1-a270-45d8-a2c7-3dd208fd52bf"
      unitRef="usd">72000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6b541896dac543b49b5eb351edb80e69_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIwLTMtMS0xLTE5NzE4Mg_0344aeaa-846d-4d07-9469-c9b3e22451f6"
      unitRef="usd">31900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia5150947e1ab4960a30b20610ac83cff_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIwLTUtMS0xLTE5NzE4Mg_7e6b9baa-ff3a-474b-840d-fd1deabac743"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8c5b75e2b27940d7bb2d6260640d34c3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIwLTctMS0xLTE5NzE4Mg_f1cd789f-a54c-4142-89d5-2635c3feb375"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id5a9db5d280b4dc4bfdd26c9e650a29c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIwLTktMS0xLTE5NzE4Mg_5dacfa23-b486-4dd2-b35c-d9dd3186dd92"
      unitRef="usd">40100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2bcf9c01534f47bea99586f19a3f1740_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIyLTEtMS0xLTE5NzE4Mg_bdfbd529-3c11-4196-bd30-d0a717662213"
      unitRef="usd">63100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i00e53324a4a84c8dae1e489c5b3ca7f8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIyLTMtMS0xLTE5NzE4Mg_34ec97e2-0af2-4724-a2d4-e9001f185fa2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7dd2dddf24274ba4b7eaca5d40b7c7db_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIyLTUtMS0xLTE5NzE4Mg_3510fee7-8839-4095-9fb4-fded06504310"
      unitRef="usd">63100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id68a32c29c1344a8a0b3ed2942d12fcb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIyLTctMS0xLTE5NzE4Mg_57753d67-701b-4687-afd6-96afd20f6700"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8aecc4a27cff4b94aaf8df6b2ede03a1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIyLTktMS0xLTE5NzE4Mg_5e0f6599-f19f-4ac7-aa17-8e4bcef6808b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i86e7e8e7c42c482380a28afa9ecf2c76_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIzLTEtMS0xLTE5NzE4Mg_9d3e2969-78cd-4e28-abfa-708a74d405d4"
      unitRef="usd">21000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3b8f63f573404294a870cfa838208b7e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIzLTMtMS0xLTE5NzE4Mg_091da482-57e7-486b-a13c-993bfbf4e210"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibe30650bfb8d48aca6dbadae71597e65_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIzLTUtMS0xLTE5NzE4Mg_71d1ee0f-3a0f-4f71-b014-01c7a2f8d003"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7950f077c83c4b968114ecde2e2b0bd4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIzLTctMS0xLTE5NzE4Mg_33343593-3239-4743-8ad9-453f103aa901"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i66c5b68aaa0a4c93bc23b9644ce7ffac_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzIzLTktMS0xLTE5NzE4Mg_ae3c3695-2fc0-4727-b265-1613285826ca"
      unitRef="usd">21000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i17d44c14ec1b4c2eac9a8389f7430791_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI1LTEtMS0xLTE5NzE4Mg_7b93a22b-2f3e-4f06-85ce-758b71a6a29e"
      unitRef="usd">294900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie0ee3659217840abbe55a716b6c7657a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI1LTMtMS0xLTE5NzE4Mg_46af7eb7-29a5-403c-9083-bac6eeab0901"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i27a0f7402b7543f39f6f976686d8a1b5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI1LTUtMS0xLTE5NzE4Mg_72566147-3405-4cef-8d8d-b34d47b3ee39"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i91fb865ecf4145fdb3d535b6bf576475_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI1LTctMS0xLTE5NzE4Mg_8e1e02b2-26ef-461d-a266-5c9fb8e6afde"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i27650537dca947bd9b29fafaf84048a2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI1LTktMS0xLTE5NzE4Mg_aefc68b5-0082-4332-a6d3-aceb953988a0"
      unitRef="usd">294900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id9cc9944568941598d1e56273115b999_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI2LTEtMS0xLTE5NzE4Mg_a81e23be-ee7c-4554-83ac-58abda3f044c"
      unitRef="usd">332800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icea19db21d1f4850ad503d0164f02ee0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI2LTMtMS0xLTE5NzE4Mg_da74579a-0c25-435f-bc54-aa0d8cd1abd7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i01671d18379a4457892b23355b0f63c3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI2LTUtMS0xLTE5NzE4Mg_6cf72a87-6e34-458a-9edf-9446862b6d39"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i76954bb677604e0f941a30448e281a31_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI2LTctMS0xLTE5NzE4Mg_0e78e8c2-4660-49f1-a81d-83f925f399f5"
      unitRef="usd">2400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id11b13c420a14cce9b018741905d1215_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI2LTktMS0xLTE5NzE4Mg_5b39c22f-d254-4ce8-93b8-9caf570b8b5a"
      unitRef="usd">330400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3e95f60a2ff14f7a97e13a88c47f23f9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI3LTEtMS0xLTE5NzE4Mg_9c2c5284-33f8-45f0-8a27-cbe9c1cfd917"
      unitRef="usd">1470800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i214c74f186244036ad65d031acecd8f4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI3LTMtMS0xLTE5NzE4Mg_8781c1e3-e57c-4346-b4de-be2b1f18737a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i61594b0a985e418eb0de58c665ee7a9b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI3LTUtMS0xLTE5NzE4Mg_a8860a7b-7e92-46df-b664-7f2616a7a469"
      unitRef="usd">1470800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibb8608c8404a41bc91d4b199b497742a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI3LTctMS0xLTE5NzE4Mg_fce98fde-0d78-4ce4-986a-72115568bab5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i482b293366b34226b38b20258e4f2ad2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI3LTktMS0xLTE5NzE4Mg_2c214d6b-f85a-442c-aeba-b351eddd77ff"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic00e07bcbece4f109e90289df0b99c67_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI4LTEtMS0xLTE5NzE4Mg_d37b144d-27a3-4ccb-b1b6-2718c58ad2f4"
      unitRef="usd">21600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i943b1859aecd4fa38530943834fb212b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI4LTMtMS0xLTE5NzE4Mg_33f4032c-65f8-43ff-b10b-2119a10ca6c9"
      unitRef="usd">21600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icfe4715993be47369f1c27e1cf4db3cb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI4LTUtMS0xLTE5NzE4Mg_a8100393-8411-4761-946d-8929a91b7944"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7b1abf4ee53847788edba9a69ea4a81f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI4LTctMS0xLTE5NzE4Mg_a0292649-8e02-4188-9c66-b1754b31cdee"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i538c50f08a0144988c39feeb3a4731aa_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI4LTktMS0xLTE5NzE4Mg_fc1e5eed-7c44-4f98-acce-d81c1b695a0d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib62a4aeb2d014482b292e1b7aa806e54_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI5LTEtMS0xLTE5NzE4Mg_e52ca385-bf12-43f0-b38e-b09f5010dd3b"
      unitRef="usd">112100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0b7b4fe31ce54233aefaaf027ce7e8ed_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI5LTMtMS0xLTE5NzE4Mg_7e961e6b-9178-4b7f-bbc5-56ea4f709a3a"
      unitRef="usd">24200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie2a5ae8949b04000ac5560edc4d7e9f2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI5LTUtMS0xLTE5NzE4Mg_eb91436c-ac70-4e5b-8ab1-eb2b474efabd"
      unitRef="usd">-19900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icfdcf6378ed942a7996ee1a9da26e09d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI5LTctMS0xLTE5NzE4Mg_e7e2202a-df65-412c-92cd-fac8aeb50ee0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ied4d313aab9b4f8e8034b9f72db4c6fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzI5LTktMS0xLTE5NzE4Mg_9abc11a2-4421-4d27-b373-9b5e246722e2"
      unitRef="usd">107800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i97e3f341714546fea22d7415bf7423fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzMwLTEtMS0xLTE5NzE4Mg_51edcbae-9318-4763-ad36-1ba967f97d57"
      unitRef="usd">2492500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic2c2d4e821d048eeaf50b62f405c3e71_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzMwLTMtMS0xLTE5NzE4Mg_d14d1f0f-a1d2-477d-a9cf-c87d437f3919"
      unitRef="usd">113400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0ff6377b237b439999bb2d77c5a32fec_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzMwLTUtMS0xLTE5NzE4Mg_4b372dba-d0fa-4386-95e5-c708ccf296ac"
      unitRef="usd">1514000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iee337558500947b7a15e1c6d6b59308a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzMwLTctMS0xLTE5NzE4Mg_7ad8ba04-19a5-44aa-906e-450a1d28b19d"
      unitRef="usd">2400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7c54b0e2a7354d1ebf52c04c3b53f6d5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZToyN2ZhYTkzMDQzOWI0ODgwOTcwM2M2NWI4M2Y4MjY5Yi90YWJsZXJhbmdlOjI3ZmFhOTMwNDM5YjQ4ODA5NzAzYzY1YjgzZjgyNjliXzMwLTktMS0xLTE5NzE4Mg_6c1789fa-eac7-4a89-b811-0f125cee19b1"
      unitRef="usd">862700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib132a0af29334d8a89770179f4a4c6e3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzQtMS0xLTEtMTk3MTgy_3fe780fd-2e0e-4e9b-95a1-11b61f8a7cb4"
      unitRef="usd">1325400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i20851fdc53e743b38af1e76d003c6b3a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzQtMy0xLTEtMTk3MTgy_d75ad22b-65ae-4cef-8a8a-d3364695b710"
      unitRef="usd">430400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i52ee54330e824cfdbed0febda5250fe6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzQtNS0xLTEtMTk3MTgy_cdef854e-18cd-4426-a5d4-8208f95c3272"
      unitRef="usd">100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1d7d1ea05ba24b2f993e48849a306d14_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzQtNy0xLTEtMTk3MTgy_796397b2-b7f1-4306-9495-5ac5b6f121a5"
      unitRef="usd">1200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i48bf8cce218249108f768811cdf3855e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzQtOS0xLTEtMTk3MTgy_0f4851df-d7e3-4b10-acdc-948f6d516328"
      unitRef="usd">893700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9c05e60f32ed4c1ca1330ed0411bd74e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzUtMS0xLTEtMTk3MTgy_ebde7f83-9c18-47b2-89e8-a90d36438bfc"
      unitRef="usd">2722700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1829f3c584ad46e09fa69d3bdf4dc092_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzUtMy0xLTEtMTk3MTgy_ad19cc14-767c-4b02-93fb-e81417438d45"
      unitRef="usd">815000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic042d55e713d42e19343e9d8183251f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzUtNS0xLTEtMTk3MTgy_53629ea2-70a5-44c2-b32a-7b17b7515644"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0c88f62a561a44a69856cba4e6223aaf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzUtNy0xLTEtMTk3MTgy_2f369900-e757-4f63-8f73-82ac954751d1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iebf3bab110174c6a97b925581b28f022_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzUtOS0xLTEtMTk3MTgy_3493dbb8-5a12-4234-a29e-f7bd821f335a"
      unitRef="usd">1907700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3c0f80e4c70a4dd7a7f479eb93de4798_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzctMS0xLTEtMTk3MTgy_e031ce60-fc44-415e-9192-010f7fb3d788"
      unitRef="usd">4496000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8694353f6b5944bcbe80d4ab90db02f5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzctMy0xLTEtMTk3MTgy_f282a80d-3dab-4733-af4b-15c1d92318c5"
      unitRef="usd">2600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6900b09ea625493ca6b4be8dd33fd73a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzctNS0xLTEtMTk3MTgy_df90c52d-936b-4671-a11c-0d2a651f4540"
      unitRef="usd">3356600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6bce15f7824346e9b1c4801a21ba7d71_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzctNy0xLTEtMTk3MTgy_6becca8b-ea97-4017-96b0-ba1908aa59a1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib3a21ae3393e41d2ba9480eaa0b21d70_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzctOS0xLTEtMTk3MTgy_4c97157f-753e-4e42-b084-afd0349f1780"
      unitRef="usd">1136800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if383bbdeabc347c3a143b1392643d685_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzgtMS0xLTEtMTk3MTgy_126fba34-b3d5-49c4-b2c9-3654df5cdf5a"
      unitRef="usd">-1376200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia372a081047f4dbf909c87201c2dd657_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzgtMy0xLTEtMTk3MTgy_6b0119de-cfe7-4ac6-9f90-7cd9f20827d7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6cccb32003004700acd3e2d5c3acc3ba_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzgtNS0xLTEtMTk3MTgy_d03e4c90-12ec-4a58-b1a6-1f84fe33742e"
      unitRef="usd">-1376200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7b6be538722f49cd8981ecd65c3e7940_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzgtNy0xLTEtMTk3MTgy_fa77c56b-b903-4048-bd52-edbfdaa79f0b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i436b8c7264ce4c04bb05b44bfd87ca82_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzgtOS0xLTEtMTk3MTgy_1d1f323e-03d3-47f1-a818-d2004a51a12a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7f1e4df3ea5b421eb52a4e93ecf681d3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzktMS0xLTEtMTk3MTgy_cb0a37b3-0ceb-4178-a810-b2a8327a5027"
      unitRef="usd">611000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic6ac3978756e4b5fb17fbea6da4f990d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzktMy0xLTEtMTk3MTgy_6a6976b4-4fbf-455b-bf82-3bab644efe97"
      unitRef="usd">11300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib9c29a065a0846b9ac55a37fa94c8241_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzktNS0xLTEtMTk3MTgy_a10ee009-1efe-4ef0-8267-86bf3d44d82c"
      unitRef="usd">250500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i92b5f5e714014f79bfda8cdf1d9b2a7c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzktNy0xLTEtMTk3MTgy_341e084a-6d2f-432f-834c-609cacd6b5b5"
      unitRef="usd">100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia6c67444f0284e208beac9c4be9a2f0f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzktOS0xLTEtMTk3MTgy_d7328384-9104-4283-877e-69e41c47f60f"
      unitRef="usd">349100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3dee72abed824f43841304219403a584_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzExLTEtMS0xLTE5NzE4Mg_7f0e3504-b8a2-4de6-a6b5-660f1b880c99"
      unitRef="usd">3046800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0a95086891b14aaf917d8c2716ac3e3d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzExLTMtMS0xLTE5NzE4Mg_5568f292-77e6-4ae2-8321-8b1a468c7ad7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i42734379ac9542d89b7f72f1422d85f6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzExLTUtMS0xLTE5NzE4Mg_17493d82-789e-4b96-90be-b450e0fa9c7f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0cef80ce2abe42448dfd3c31b2730530_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzExLTctMS0xLTE5NzE4Mg_593a7f83-1401-4315-ab2e-8b1a0aaee63c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i082bf7a8d7da4db2b649a2e7f798417f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzExLTktMS0xLTE5NzE4Mg_75568ad1-9bda-4af0-8fa3-a79e1196662e"
      unitRef="usd">3046800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i295f7348ee104256b1ad8f7695918565_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEyLTEtMS0xLTE5NzE4Mg_2a85b399-dd12-4ed4-9c90-802b23cf4989"
      unitRef="usd">3816400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ide75442ca7484565b7ece117ea2f7059_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEyLTMtMS0xLTE5NzE4Mg_3e349d59-5731-4864-a3f8-e089e3b47a1f"
      unitRef="usd">2100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4b695768bf7d42a3bcd05424e7e3f801_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEyLTUtMS0xLTE5NzE4Mg_b2f98595-3450-4fcf-b194-3ad99afd6452"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ieda949f586eb474d94003b25eeb0028d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEyLTctMS0xLTE5NzE4Mg_b6785422-35fe-4b66-8589-79e572addf05"
      unitRef="usd">5500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ied3619ec524f4266a7e63df4bffc201d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEyLTktMS0xLTE5NzE4Mg_49d8fe16-aadb-4731-a980-4fd35b8b3e3a"
      unitRef="usd">3808800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib5cc405af174407082725f9ad493bde7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEzLTEtMS0xLTE5NzE4Mg_d13f2a85-1663-40e5-a11e-8106ece03350"
      unitRef="usd">630300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i54dba7ed180b415fabfb7905a989ee6f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEzLTMtMS0xLTE5NzE4Mg_614b0c15-d63d-49a4-9893-1bae06e2855a"
      unitRef="usd">363800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0af2032243144ef284ce6407829b4dee_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEzLTUtMS0xLTE5NzE4Mg_7c23cb90-9314-4652-a837-829db632cfcd"
      unitRef="usd">7500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i901ab2be4c854280b4098c1694160fde_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEzLTctMS0xLTE5NzE4Mg_7565a871-a8bd-4f5f-9717-4a46411d6b67"
      unitRef="usd">10700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie3f5f72c269e4e2f8f39b493b30dee70_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzEzLTktMS0xLTE5NzE4Mg_2b7d0cc1-da56-4506-8e11-fb4c4c9c2b41"
      unitRef="usd">248300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia6e5fa70dfa147419df6887b95a1c72a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE0LTEtMS0xLTE5NzE4Mg_ace2b56a-6110-46ca-bae9-ac5ef3362e05"
      unitRef="usd">1143600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibb10e0158e6e4678aba453d3e46e07c5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE0LTMtMS0xLTE5NzE4Mg_fa91d45e-01e1-4cd0-9875-6d30f0832b8d"
      unitRef="usd">103200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i30a6b7ac42614433b9f0fa273ce3a0bb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE0LTUtMS0xLTE5NzE4Mg_69d24538-8f26-42be-83d0-71565f5df0be"
      unitRef="usd">263200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9017de5b93e24421b9baf62ead566064_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE0LTctMS0xLTE5NzE4Mg_29429a27-948d-43ab-8acd-e8c8d15937b5"
      unitRef="usd">-2100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0cfc4ac7e4a54ac497e9a40c408806fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE0LTktMS0xLTE5NzE4Mg_a1f929d3-3283-4821-9471-cd8b23da17ec"
      unitRef="usd">779300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i29379dfc9c24409c9bb7a52d0165f08f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE1LTEtMS0xLTE5NzE4Mg_d0e68794-4c7c-420a-abe9-ef4286822360"
      unitRef="usd">16416000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibad8ae81108d443a8d7b7c73c118e1b6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE1LTMtMS0xLTE5NzE4Mg_4d4133cf-5c0a-4e6b-ae20-a87dadd2a192"
      unitRef="usd">1728400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3788338e5f754c888353b212dd5956a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE1LTUtMS0xLTE5NzE4Mg_fd08c701-0e4d-4f3f-a313-6861f6893c87"
      unitRef="usd">2501700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0015f68641264909839363808c4359b0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE1LTctMS0xLTE5NzE4Mg_1e219a7d-1152-4f92-a5b8-5b0ca8a7fbd8"
      unitRef="usd">15400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i348b81fae8ab42de8c1879ac0c79e30c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE1LTktMS0xLTE5NzE4Mg_82985532-b234-4aef-b634-ac5d56067a85"
      unitRef="usd">12170500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia56272ad45124bdc80feb1442c60a30d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE5LTEtMS0xLTE5NzE4Mg_63354b14-e088-463a-87d7-201d8310d6ed"
      unitRef="usd">124700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i757f940abbe04ca0bc0b713ee02d015c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE5LTMtMS0xLTE5NzE4Mg_8138290e-5ca3-48f2-a0ed-6a2cf1df8fdc"
      unitRef="usd">40900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i345e2321a45e415d986e9e3fbe0a8b1e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE5LTUtMS0xLTE5NzE4Mg_d26ac0f3-e226-41d9-a522-2e31e506bcd0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i402b1f58d5d94b2e89c8d64936db028d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE5LTctMS0xLTE5NzE4Mg_87b5a7ad-ff57-4d80-bd47-a60e4c0a37be"
      unitRef="usd">100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6f6287de46e54474b2e7b025101c06f2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzE5LTktMS0xLTE5NzE4Mg_5210aafd-7195-4fc5-9973-9c8531f8279d"
      unitRef="usd">83700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifda53d5c5113486194c825c985c42f46_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIwLTEtMS0xLTE5NzE4Mg_010758f1-1c7b-4776-9363-90f03f228012"
      unitRef="usd">180600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i227d6a2f64bb432583256bb6d486f599_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIwLTMtMS0xLTE5NzE4Mg_b642f53c-189e-4465-82a6-a4d264371b36"
      unitRef="usd">47700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie71f4ed1e3434f8687ea6d6c4e0184d1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIwLTUtMS0xLTE5NzE4Mg_194e77db-86ec-4213-b990-18065ac2cc19"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i41aac4ca412c41fabad0761de653d3e6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIwLTctMS0xLTE5NzE4Mg_a0b0f469-6874-48ac-a205-1ce07ef903c6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibacb732d9a3e42ecb1b0d3672103ab48_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIwLTktMS0xLTE5NzE4Mg_f2d488f3-cb7a-404f-b4f5-042269bea422"
      unitRef="usd">132900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idd0e7a73c5654d22b1fb7d1f44eec75b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIyLTEtMS0xLTE5NzE4Mg_a5df6ba9-7da6-437b-9d8b-23d13e451f0e"
      unitRef="usd">102200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i143d17ad6d23439bbe5839cb7f2fa3d1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIyLTMtMS0xLTE5NzE4Mg_3c30742a-4f2e-4f86-9616-510c49e7cd47"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i82b433b6c64f411cbf07c20ec03e6cc0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIyLTUtMS0xLTE5NzE4Mg_e1b682c0-080e-4ced-9391-f2ba9448b892"
      unitRef="usd">80500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3ecc36ab470d4e41be47e03d24ef4065_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIyLTctMS0xLTE5NzE4Mg_f9d47b1c-d5df-4b62-bc55-a0028f75690d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id86c9caf6218488d8edebac267e948ff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIyLTktMS0xLTE5NzE4Mg_0e90c6ac-00a8-47fc-8365-014975541632"
      unitRef="usd">21700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifbf66898d55a4866946d2c1b7d0808c5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIzLTEtMS0xLTE5NzE4Mg_1aa51f98-f12b-4b33-9e80-6c12fbf65ec2"
      unitRef="usd">51600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic0d702f1019341bc888bc0e964569748_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIzLTMtMS0xLTE5NzE4Mg_ce29da36-aa60-4da3-9f68-ab4b6c7d3a61"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaa4a4b71cd744411915501b9954c7190_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIzLTUtMS0xLTE5NzE4Mg_df3afdcd-1c36-40ba-b98b-4456a00f3762"
      unitRef="usd">23700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i689b0515d1e94c50807ae2688713eb9a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIzLTctMS0xLTE5NzE4Mg_10c282a1-76cb-4e77-9f2c-f595569bf59b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7475b438e64f45c889b5836a9b35767c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzIzLTktMS0xLTE5NzE4Mg_3fb5097f-1a75-4037-9f5f-90ece1d0cec6"
      unitRef="usd">27900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1fba731405fa40f08f44c49bbce45751_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI1LTEtMS0xLTE5NzE4Mg_6adc1fd6-7bd5-4669-97fc-75baa0ac5d49"
      unitRef="usd">275400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iad19a6d6a32c4de3b7b3d6e7f1edf524_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI1LTMtMS0xLTE5NzE4Mg_574519dc-4022-4742-ae66-ca5d7d6ec4cd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie71ccfe9ea594f9b9006353fffcd6bd2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI1LTUtMS0xLTE5NzE4Mg_b3cd12ae-0067-48f1-b074-6460e5529d2d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i58114e11cdf547b081755beebbfc89d2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI1LTctMS0xLTE5NzE4Mg_b12cba7f-2546-4c88-bd58-f0a1ef794846"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i55c8b439a98248178a88acf2e2f0d064_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI1LTktMS0xLTE5NzE4Mg_54808306-4818-4f23-96e3-191c52c7b69f"
      unitRef="usd">275400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib8d28a152a83416bace6b87dcae9c074_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI2LTEtMS0xLTE5NzE4Mg_9c0b2662-fe1a-4e5e-a053-76bee3fb5417"
      unitRef="usd">317800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6bb519b30c624115a193843ede27be5e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI2LTMtMS0xLTE5NzE4Mg_9b147cd3-0e63-4be8-b348-6d28d1f60db8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if209ba23a08741c5a788dd9694d2de32_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI2LTUtMS0xLTE5NzE4Mg_0bec0b03-bf14-4b29-b331-52492661a95c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i29dcd560ceb84008813877608a70d4fd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI2LTctMS0xLTE5NzE4Mg_f4af29cc-1e08-4f6a-9f43-fc89cebc0519"
      unitRef="usd">500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i043b55ba16e04186b3221ade43979e4b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI2LTktMS0xLTE5NzE4Mg_2a901b00-3f0c-4fa5-a1ed-77132865b882"
      unitRef="usd">317300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic3a21e55d8164183ac65c36e858f86e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI3LTEtMS0xLTE5NzE4Mg_d089eda3-bfc6-4dd1-ac4e-167ec9cb2296"
      unitRef="usd">2166800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i905bdea6d6d74e49ba3fae3f028d50c6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI3LTMtMS0xLTE5NzE4Mg_88a1dfc7-13d0-4e87-9a08-fb3a9ae35d73"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i25b644c98bfd4c39b72d7a1615c8880e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI3LTUtMS0xLTE5NzE4Mg_36acf94b-831c-494a-a7cd-293b71df1727"
      unitRef="usd">2166800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib73e985ef58a4760a5c29be61384bb88_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI3LTctMS0xLTE5NzE4Mg_57d5b0fe-64e5-4f74-b429-e1471ca99f9c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib8bcd2b4b6ca476fadb8cce5fd37f874_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI3LTktMS0xLTE5NzE4Mg_b39f9353-46b1-43c7-bf91-48c63dd00b87"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie5e89110b5ca48398995bbf99899d921_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI4LTEtMS0xLTE5NzE4Mg_76eb7acb-9346-41df-aeb2-66c0edc49c76"
      unitRef="usd">36200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8b9ad2ac337a4df9a8bc5ff2950a967b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI4LTMtMS0xLTE5NzE4Mg_26dcaec5-9ae3-430e-8d9f-3e84e505a0ac"
      unitRef="usd">34500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia5967fb68324426389a6dc239fcdd98d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI4LTUtMS0xLTE5NzE4Mg_b46cd5f5-1553-4eb5-b983-8854b7fa5a45"
      unitRef="usd">700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i463ba1a48ccc4e9c9cb4282e58cd05a6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI4LTctMS0xLTE5NzE4Mg_cb192205-3b00-4be0-8777-c3f5ce13d489"
      unitRef="usd">1000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i299c48115d8542b08f12325d39cefe4e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI4LTktMS0xLTE5NzE4Mg_f15c6cc8-807d-4b1e-b115-59150e17d0e2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i27dc976858f044bdbd3ba64895aeb4cd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI5LTEtMS0xLTE5NzE4Mg_ea9015e8-8ec6-4bcf-95ee-eaa0293b8858"
      unitRef="usd">106100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6462a3f459994819a179b58529f573e1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI5LTMtMS0xLTE5NzE4Mg_0ec8e6f2-2b8a-440b-a20c-a03cfafe3a42"
      unitRef="usd">24400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic623b25c46754468b1e9528796093989_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI5LTUtMS0xLTE5NzE4Mg_5b22c3d8-6dc4-4f8a-9a35-aed2e420a5ed"
      unitRef="usd">18300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5a1d3b46d2544213bc3eb41e5d6e128c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI5LTctMS0xLTE5NzE4Mg_ce0a8f0d-111b-4eb1-98b7-bd29c5c76fd3"
      unitRef="usd">-100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib5ef3078b94645859a7ca03beed57c99_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzI5LTktMS0xLTE5NzE4Mg_2b49af37-1df7-4650-b8c9-8fbc30829088"
      unitRef="usd">63500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0d98baaa405f4230aa08556aee4f87ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzMwLTEtMS0xLTE5NzE4Mg_7e61c481-6b01-4092-8112-90a4b289319e"
      unitRef="usd">3361400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaf76714ef18e4ce6b454dfc623ac6be7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzMwLTMtMS0xLTE5NzE4Mg_24480fe2-ab71-4102-ab6a-d5b16ad7781e"
      unitRef="usd">147500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib0dae23a26dd4790bdef9addc65290ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzMwLTUtMS0xLTE5NzE4Mg_e4e355e6-7dd8-4aaa-bce2-6cf367e11636"
      unitRef="usd">2290000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i560967994b3c4feaa52141c4dad6145c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzMwLTctMS0xLTE5NzE4Mg_ac40aef6-fd7c-4b4e-9c7c-a68c737d3efc"
      unitRef="usd">1500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i00b75991e2e34b09b2420ae55e962bf3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90YWJsZTozNGYzNDA1NTMxODU0N2ZjOTA5ZDJkNmNlOGRmYTFiZi90YWJsZXJhbmdlOjM0ZjM0MDU1MzE4NTQ3ZmM5MDlkMmQ2Y2U4ZGZhMWJmXzMwLTktMS0xLTE5NzE4Mg_cbe3103b-97dc-4636-bc13-303b24b521f5"
      unitRef="usd">922400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="i0c073455f233450ea6806f68e460a7bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzYvZnJhZzpjZmEwZGI5MjljZGE0NDJmYTk4MmNmM2RhZTA5Y2EzZS90ZXh0cmVnaW9uOmNmYTBkYjkyOWNkYTQ0MmZhOTgyY2YzZGFlMDljYTNlXzEwODU5_561c9f06-606c-4081-ab0b-3257f0c572cb"
      unitRef="usd">30000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzI1NTM2_0e166893-9527-4f68-a946-3f7f10e9e112">Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the final outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Alimta European Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In Europe, Alimta (pemetrexed)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was protected by a patent through June 2021. A number of legal proceedings that were initiated prior to patent expiration are ongoing&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Emgality Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a named defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts seeking a ruling that various claims in three different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following a trial, in November 2022, a jury returned a verdict in favor of Teva. The parties have filed post-trial motions on which the court will rule and then enter final judgment in the case. We intend to appeal the jury verdict if necessary. Pursuant to agreement by the parties, the award, if any, will not become due until completion of the appeal process. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, we were named as a defendant in a second litigation filed by Teva in the U.S. District Court for the District of Massachusetts seeking a ruling that two of Teva's patents, which are directed toward use of the active ingredient in Emgality to treat migraine, would be infringed by our continued sales of Emgality. We challenged these two patents by filing requests for Inter Partes Review with the Patent Trial and Appeal Board (PTAB) and in October 2022, the PTAB granted our requests.The corresponding district court litigation is stayed while this PTAB proceeding is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Jardiance Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, Boehringer Ingelheim, our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court for the District of Delaware alleging infringement arising from submissions of Abbreviated New Drug Applications (ANDA) by a number of generic companies seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, the generic companies' ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. This litigation has been stayed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Taltz Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in May 2020, Lilly and Novartis Pharma AG (Novartis) had been litigating the validity and alleged infringement by Taltz of certain patents Novartis acquired from Genentech, Inc. (Genentech). As of October 2022, we had pending cases in Ireland, Italy, Switzerland, and the Netherlands where Novartis sought injunctions to stop Taltz commercialization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, we entered into a cashless (no-payment) settlement and mutual release agreement with Novartis, which resolved such disputes. Without any admission of liability or wrongdoing, we and Novartis have agreed to mutual releases for past claims and mutual covenants not to sue the other in relation to Taltz and the patents Novartis purchased from Genentech. This matter is closed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Zyprexa Canada Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the mid-2000s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trademark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgment, thereby dismissing Apotex's case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021. In August 2022, the Court dismissed the appeal and in October 2022, Apotex appealed the decision. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Byetta&#xae; Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named as a defendant in over 500 Byetta product liability lawsuits in the U.S. that were first initiated in March 2009 and involved over 800 plaintiffs. These lawsuits have been filed in various state and federal jurisdictions, including California state court (coordinated in Los Angeles County Superior Court), and various federal courts, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. The majority of these suits contained allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer). All of the MDL and state court lawsuits have been dismissed as of January 2023 and we consider these matters closed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Environmental Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than 10 sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;340B Litigation and Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies and HHS's Administrative Dispute Resolution regulations. We seek a declaratory judgment that the defendants violated the Administrative Procedure Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government's enforcement of the administrative dispute resolution process against us. In May 2021, HRSA notified us that it determined that our policy was contrary to the 340B statute. In response, in May 2021, we amended our complaint to bring claims related to HRSA's determination and filed a motion for preliminary injunction and temporary restraining order requesting that the U.S. District Court for the Southern District of Indiana enjoin defendants from taking any action against us relating to the 340B drug pricing program until after the court issues a final judgment on the aforementioned litigation. In May 2021, the court denied our motion for a temporary restraining order but deferred resolution of our motion for preliminary injunction. In June 2021, the defendants withdrew the HHS December 30, 2020 advisory opinion. In July 2021, the court held oral argument on the parties' cross motions for summary judgment, the defendants' motion to dismiss, and our motion for preliminary injunction related to HRSA's May 2021 enforcement letter. In October 2021, the court denied the defendants' motion to dismiss, and granted in part and denied in part the parties' cross motions for summary judgment. Both parties filed notices of appeal related to the court's summary judgment order. In October 2022, the U.S. Court of Appeals for the Seventh Circuit held oral argument. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administrative Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government's enforcement of this administrative dispute resolution process against us. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, we, along with Sanofi-Aventis U.S., LLC (Sanofi), Novo Nordisk Inc. (Novo Nordisk), and AstraZeneca Pharmaceuticals LP, were named as a defendant in a purported class action lawsuit filed in the U.S. District Court for the Western District of New York by Mosaic Health, Inc. alleging antitrust and unjust enrichment claims related to the defendants' 340B distribution programs. We, with Sanofi and Novo Nordisk, filed a motion to dismiss the lawsuit, which was granted in September 2022. In October 2022, the plaintiffs filed a motion for leave to amend their complaint. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received a civil investigative subpoena in February 2021 from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Branchburg Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, we received a subpoena from the U.S. Department of Justice requesting the production of certain documents relating to our manufacturing site in Branchburg, New Jersey. We are cooperating with the subpoena.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Brazil Litigation &#x2013; Cosmopolis Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Labor Attorney Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a Public Civil Action brought by the Labor Public Attorney (LPA) for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, (the Labor Court) alleging possible harm to employees and former employees caused by alleged exposure to soil and groundwater contaminants at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the Labor Court judge ruled against Lilly Brasil, ordering it to undertake several remedial and compensatory actions including health coverage for a class of individuals and certain of their children. In July 2018, the appeals court (TRT) generally affirmed our appeal of the Labor Court's ruling, which included a liquidated award of 300 million Brazilian reais, which, when adjusted for inflation and the addition of pre and post judgment interest using the current Central Bank of Brazil's special system of clearance and custody rate, is approximately one billion Brazilian reais (approximately $184&#160;million as of December&#160;31, 2022). In August 2019, Lilly Brasil filed an appeal to the superior labor court (TST) and in June 2021, the TRT published its decision on the admissibility of Lilly Brasil's appeal, allowing the majority of the elements, which were allowed to proceed in June 2021; elements not proceeding are subject to an interlocutory appeal to the TST that was filed in June 2021. In September 2019, the TRT stayed a number of elements of its trial court decision pending the determination of Lilly Brasil's appeal to the TST.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019 and September 2020, the LPA filed applications in the Labor Court for enforcement of certain remedies granted by the TRT in its July 2018 decision, requested restrictions on Lilly Brasil&#x2019;s assets in Brazil, and required Lilly Brasil and Antibi&#xf3;ticos do Brasil Ltda. (ABL) to submit a list of potential beneficiaries of the Public Civil Action. In July 2019, the Labor Court issued a ruling requiring a freeze of Lilly Brasil&#x2019;s immovable property or, alternatively, a security deposit or lien of 500 million Brazilian reais, which ruling was subsequently limited in scope and the security was reduced to 100 million Brazilian reais. ABL and LPA appealed the June 2021 Labor Court ruling to the TST, which appeal is under review. The Labor Court is currently assessing the status of Lilly Brasil&#x2019;s and ABL&#x2019;s compliance with such portion of the July 2018 TRT decision and an inspection in the industrial plant is expected. These matters are ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Individual Former Employee Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lilly Brasil is also named in various pending lawsuits filed in the Labor Court by individual former employees making related claims. These individual lawsuits are at various stages in the litigation process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Puerto Rico Tax Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2013, the Municipality of Carolina in Puerto Rico (Municipality) filed a lawsuit against us alleging noncompliance with respect to a contract with the Municipality and seeking a declaratory judgment. In December 2020, the Puerto Rico Appellate Court (AP) reversed the summary judgment previously granted by the Court of First Instance (CFI) in our favor, dismissing the Municipality's complaint in its entirety. The AP remanded the case to the CFI for trial on the merits. The trial began in May 2022; however, the Municipality filed a new motion requesting the CFI to award damages. The request was denied by the CFI in our favor and the Municipality filed for revision at the AP, which we opposed, staying the case. In February 2023, the AP denied the Municipality's motion for revision. This matter is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Average Manufacturer Price Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2014, we, along with another pharmaceutical manufacturer, were named as co-defendants in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Following a trial in August 2022, the jury returned a verdict in favor of the plaintiff. The case is proceeding with post-trial motions after which the court will enter final judgment in the case. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Health Choice Alliance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are named as a defendant in two lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively, for certain patient support programs related to our products Humalog, Humulin, and Forteo. The Texas state court action has been stayed. The New Jersey state court action was dismissed with prejudice pending an ongoing appeal before the Appellate Division of the New Jersey Superior Court. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pricing Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We, along with Sanofi, Novo Nordisk, and in some matters certain pharmacy benefit managers, have been named in lawsuits related to insulin pricing that assert various theories, including consumer protection, fraud, false advertising, unjust enrichment, civil conspiracy, federal and state RICO statutes, deceptive trade practices, and unfair competition claims. These lawsuits include In re. Insulin Pricing Litigation, a putative consumer class action (U.S. District Court for the District of New Jersey, 2017); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MSP Recovery Claims,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (U.S. District Court for the District of New Jersey, 2018); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;FWK Holdings, LLC v. Novo Nordisk Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a putative class action brought by direct purchasers of insulin (U.S. District Court for the District of New Jersey, 2020), and suits brought by the State of Minnesota (U.S. District Court for the District of New Jersey, 2018), State of Kentucky (Franklin County Circuit Court, 2019), State of Mississippi (U.S. District Court for the Southern District of Mississippi, 2021), State of Arkansas (U.S. District Court for the Eastern District of Arkansas, 2022), County of Albany, New York (U.S. District Court for the Northern District of New York, 2022), State of Montana (U.S. District Court for the District of Montana, 2022), State of Kansas (U.S. District Court for the District of Kansas, 2022), State of Illinois (U.S. District Court for the Northern District of Illinois, 2022), State of California (Los Angeles County Superior Court, 2023), Jackson County, Missouri in a putative class action on behalf of Missouri counties and municipalities (Jackson County Circuit Court, 2023), and the Government of Puerto Rico (Court of First Instance Superior Court, San Juan, 2023). These lawsuits are at various stages in the litigation process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Investigations, Subpoenas, and Inquiries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the pricing and sale of our insulin and other products, we have been subject to various investigations and received subpoenas, civil investigative demand requests, information requests, interrogatories, and other inquiries from various governmental entities. These include subpoenas from the New York and Vermont Attorney General Offices, civil investigative demands from the Washington, New Mexico, Colorado, Louisiana, Texas and Ohio Attorney General Offices, the U.S. Department of Justice and the U.S. Federal Trade Commission, as well as information requests from the Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada Attorney General Offices. In January 2022, the Michigan Attorney General filed a petition in Michigan state court seeking authorization to investigate Lilly for potential violations of the Michigan Consumer Protection Act (MCPA), and a complaint seeking a declaratory judgment that the Attorney General has authority to investigate Lilly's sale of insulin under the MCPA. The court authorized the proposed investigation and the issuance of civil investigative subpoenas. In April 2022, the parties entered into a stipulation providing that the State of Michigan will not issue any civil investigative subpoena to us under the MCPA until the declaratory judgment action is resolved. In July 2022, the court dismissed the case in its entirety. The Michigan Attorney General filed a notice of appeal to the Michigan Court of Appeals, which remains pending. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received a request in January 2019 from the House of Representatives' Committee on Oversight and Reform seeking commercial information and business records related to the pricing of insulin products, among other issues. We also received similar requests from the Senate Finance Committee and the Senate Committee on Health, Education, Labor, and Pensions, and separate requests from the House Committee on Energy and Commerce majority and minority members. In January 2021, the Senate Finance Committee released a report summarizing the findings of its investigation. In December 2021 the House of Representatives' Committee on Oversight and Reform majority and minority staffs released separate reports with findings from their investigations into drug pricing, including of insulin products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are cooperating with all of the aforementioned investigations, subpoenas, and inquiries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Research Corporation Technologies, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. In October 2021, the court issued a summary judgment decision finding in favor of RCT on certain issues, including with respect to a disputed royalty. Both parties filed motions for reconsideration, which were denied. We filed supplemental summary judgment motions. In November 2022, the court stayed proceedings so the parties can pursue mediation. A trial date has not been set. Potential damages payable under the litigation, if finally awarded after an appeal, could be material but are not currently reasonably estimable. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzI3NDg3NzkxMDIyODU_1b004409-7007-489a-babd-a885bc6b8147">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <lly:LossContingencyNumberOfPatents
      contextRef="ied91fc6d6fdd4a9db5f172426ce099f6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzMyNzE_a0dae407-b1e4-4a4e-bd66-43f914c05863"
      unitRef="patent">3</lly:LossContingencyNumberOfPatents>
    <lly:LossContingencyNumberOfPatents
      contextRef="iaead771b48fe47589b2c796815693940_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzM2MjI_985d6f3a-ba63-4f27-bcd8-17f39d105443"
      unitRef="patent">2</lly:LossContingencyNumberOfPatents>
    <lly:LossContingencyNumberOfPatents
      contextRef="i63382dd666fe46d0b3e154a58b6cfe75_I20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzE2NDkyNjc0NjcyNDg_650adb53-f904-4df1-b751-5e41bd5a2e38"
      unitRef="patent">2</lly:LossContingencyNumberOfPatents>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i31efe8055d7c4c549c6b4e3589629dce_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzcxODU_d33f24bd-c122-4f2c-b2e9-1ef020026dfc"
      unitRef="lawsuit">500</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i62bc7ea2d50e4f44a034b2205030f1c9_D20090301-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzcyOTI_56cdc529-f48f-4007-b154-72062a75aca3"
      unitRef="plaintiff">800</us-gaap:LossContingencyNumberOfPlaintiffs>
    <lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup
      contextRef="idb638f2256714679a5c385f7893d6fbf_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzk0MDI_bcd2b420-e6cf-48b4-84a5-7f38184da0e2"
      unitRef="site">10</lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i69662148bb09444d89587f00392b3075_D20180701-20180731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzE0MjEy_2660306c-6228-459d-9d3f-8d23cce1e25f"
      unitRef="brl">300000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ie6e063495e83471dbc258b40a141debf_D20220101-20221231"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzE0NDIz_9f350f2c-581d-4a18-9cc1-18899682a631"
      unitRef="brl">1000000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ie6e063495e83471dbc258b40a141debf_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzU0OTc1NTg1OTQ2Mg_29127f2b-232b-44f6-b8f0-01f46269db02"
      unitRef="usd">184000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="iad23c8f46fec4d02b0a1bcb29a2373cb_D20190701-20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzE1NDkz_b5c21ca0-ba7f-4bd3-9ccc-15038e951c94"
      unitRef="brl">500000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i63ea09a048414de7b321b1ada8f7b0a4_D20210601-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzE1NTkx_9be7e67d-cd1b-4411-a485-6545804b38f4"
      unitRef="brl">100000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ie5a9f8356a0c4d9ca2c89e981a149cb5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xMzkvZnJhZzoxYWQ1YzdlMmIzZWU0MWM2ODNmZTEzN2NjMTMyM2M0YS90ZXh0cmVnaW9uOjFhZDVjN2UyYjNlZTQxYzY4M2ZlMTM3Y2MxMzIzYzRhXzE3NTk5_97fbf8f0-ab84-439f-a41c-fcb6e67dfdec"
      unitRef="lawsuit">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90ZXh0cmVnaW9uOjdhMzRhYzM1NTIxZjRmZmJhY2M2MTc3ZDA5ZDM5ZjlkXzEwOTM_aeeed69a-98b9-4206-b3aa-447ef0d765ed">Other Comprehensive Income (Loss)&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to each component of other comprehensive income (loss):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,678.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,638.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,523.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(379.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,427.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,751.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,496.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,823.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,795.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,167.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,153.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,550.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,583.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(213.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,343.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(324.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(52.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;291.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;332.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;247.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(324.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(40.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;521.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;342.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;498.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,874.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(37.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,062.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;129.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,844.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation gains/losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(75.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized net gains/losses on securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension and retiree health benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(95.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(532.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(90.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(250.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(695.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 7), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of accumulated other comprehensive loss were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.230%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Details about Accumulated Other &lt;br/&gt;Comprehensive Loss Components&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Affected Line Item in the Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of retirement benefit items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service benefits, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(52.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2014;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;343.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2014;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;290.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(61.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2014;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications for the period, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90ZXh0cmVnaW9uOjdhMzRhYzM1NTIxZjRmZmJhY2M2MTc3ZDA5ZDM5ZjlkXzEwNzc_0a95d0e0-c817-4beb-8831-e7aaf0064872">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to each component of other comprehensive income (loss):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,678.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,638.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,523.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(379.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,427.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,751.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,496.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,823.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,795.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,167.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,153.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,550.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,583.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(213.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,343.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(324.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(52.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;291.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;332.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;247.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(324.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(40.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;521.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;342.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;498.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,874.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(37.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,062.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;129.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,844.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation gains/losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(75.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized net gains/losses on securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension and retiree health benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(95.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(532.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(90.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(250.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(695.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc973a7f9e3144daaacecbbb0e56d8b2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzItMS0xLTEtMTk3MTgy_6c76b9fb-2380-4e2a-8259-66d7a13dc9a7"
      unitRef="usd">-1678000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i782d346d63cd4661b107c0a82f9e4b82_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzItMy0xLTEtMTk3MTgy_e695553f-db2c-4f2e-8f7f-0dfa05ced034"
      unitRef="usd">4900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7be554abe40648b39a94f657bb20d919_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzItNS0xLTEtMTk3MTgy_0cf9275d-721a-4e2c-97a3-f0065e7b1f5e"
      unitRef="usd">-4638600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc3cb8d5258a4da9a5d7c9e511159aa3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzItNy0xLTEtMTk3MTgy_08ae0302-fba2-4231-b231-f530de2c08bd"
      unitRef="usd">-211900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i06509abf85c548088ad01601353119b6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzItMTEtMS0xLTE5NzE4Mg_7a797447-a909-4330-93ff-67a41851be76"
      unitRef="usd">-6523600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if9a8c569328a4f30be03a86aa6c30d95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzQtMS0xLTEtMTk3MTgy_a5281a5f-ccfd-4f0c-8595-8859d209e420"
      unitRef="usd">250500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i551c81f2cb044ba38f8c330455e4e04c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzQtMy0xLTEtMTk3MTgy_e26cc947-2d13-4a2a-9eaa-2eb8bbbdbe7b"
      unitRef="usd">6800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i17390e21b41d40f786eda486ba1ce2c7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzQtNS0xLTEtMTk3MTgy_4aff6a2e-0db2-4a4c-9900-9d51fcc065ec"
      unitRef="usd">-379700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i05873b0c5a3d432cb9d95359fb5df095_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzQtNy0xLTEtMTk3MTgy_585f6049-0087-40d3-a554-50db167da6cb"
      unitRef="usd">-133800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzQtMTEtMS0xLTE5NzE4Mg_e6fa710d-ee22-43ef-961f-486f6f7aeea9"
      unitRef="usd">-256200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if9a8c569328a4f30be03a86aa6c30d95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzUtMS0xLTEtMTk3MTgy_dab1cdbb-5e9c-44d2-9f80-1e3374debfbd"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i551c81f2cb044ba38f8c330455e4e04c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzUtMy0xLTEtMTk3MTgy_9ee00f16-7878-4b87-a968-9d92ef886a69"
      unitRef="usd">-3100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i17390e21b41d40f786eda486ba1ce2c7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzUtNS0xLTEtMTk3MTgy_84e055e8-2f68-4988-bd31-dba6e44c762b"
      unitRef="usd">-267300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i05873b0c5a3d432cb9d95359fb5df095_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzUtNy0xLTEtMTk3MTgy_218d95ec-b18b-4be4-a87e-5069d2b810a6"
      unitRef="usd">-13000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzUtMTEtMS0xLTE5NzE4Mg_88c9dd1c-a162-46bd-a2d3-393728e9958c"
      unitRef="usd">-283400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if9a8c569328a4f30be03a86aa6c30d95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzYtMS0xLTEtMTk3MTgy_abfb0712-7faf-4c10-a361-52b3e967db5e"
      unitRef="usd">250500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i551c81f2cb044ba38f8c330455e4e04c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzYtMy0xLTEtMTk3MTgy_95852712-5b41-4973-b08f-18d7a604c335"
      unitRef="usd">9900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i17390e21b41d40f786eda486ba1ce2c7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzYtNS0xLTEtMTk3MTgy_c6094f81-5e43-431e-a32f-afef7bfa1ee9"
      unitRef="usd">-112400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i05873b0c5a3d432cb9d95359fb5df095_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzYtNy0xLTEtMTk3MTgy_f657a8e9-a514-48a1-a909-606f154dddb9"
      unitRef="usd">-120800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzYtMTEtMS0xLTE5NzE4Mg_15ba3802-9ce2-4eca-bf9b-0c2f472ed8a5"
      unitRef="usd">27200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifce42ff1cd2e4bbd9d84d0fa5ad5830e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEwLTEtMS0xLTE5NzE4Mg_c055097b-5d4e-4ddd-87f9-bf562e397ce9"
      unitRef="usd">-1427500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f5a08b9d5ec477b89e3e3d1f861d631_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEwLTMtMS0xLTE5NzE4Mg_d3b0dcc3-887d-451a-ad7b-2578495e3057"
      unitRef="usd">14800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5108cbcfc4b74ce7b92ac3b0def03d6d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEwLTUtMS0xLTE5NzE4Mg_a3456d95-cdc1-458a-af10-24fba16255b2"
      unitRef="usd">-4751000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa5d7c8469594718ad1fc73143d3d064_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEwLTctMS0xLTE5NzE4Mg_ba5d6688-516d-4f63-90f0-75bf71c291e7"
      unitRef="usd">-332700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3316d423843f422793957a50410a8a36_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEwLTExLTEtMS0xOTcxODI_6d70de1e-58a0-49ea-a875-9528780cb836"
      unitRef="usd">-6496400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7653b13d4d7a4b1ea53ccf1f2894f8e0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEzLTEtMS0xLTE5NzE4Mg_d4a86c15-9c37-4d91-83e0-ab8914fff14d"
      unitRef="usd">-122700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i8d8b6b1d95db4e629430b1a90c83d5ed_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEzLTMtMS0xLTE5NzE4Mg_7e8819e9-28a2-429a-afcc-59550ce97778"
      unitRef="usd">-11900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i57369029d5994ec1a83968149ccf0c57_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEzLTUtMS0xLTE5NzE4Mg_a0554c8d-cee1-4285-9795-a9f7aaa50206"
      unitRef="usd">1823400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i223571c60a5b423f8ffc9ccfbe85991b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEzLTctMS0xLTE5NzE4Mg_45f704f2-cf84-4e7e-b994-f4ad711fe54a"
      unitRef="usd">106600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzEzLTExLTEtMS0xOTcxODI_c4ad5661-ae85-4d6a-b96c-d539e8e6c1d1"
      unitRef="usd">1795400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7653b13d4d7a4b1ea53ccf1f2894f8e0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE0LTEtMS0xLTE5NzE4Mg_86249107-a270-443d-9d8d-b6dda2e0a780"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i8d8b6b1d95db4e629430b1a90c83d5ed_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE0LTMtMS0xLTE5NzE4Mg_d39d4729-22c1-4655-86c4-3714cf66980f"
      unitRef="usd">-800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i57369029d5994ec1a83968149ccf0c57_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE0LTUtMS0xLTE5NzE4Mg_6204d94a-a43c-4d60-b397-225df2659b50"
      unitRef="usd">-344000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i223571c60a5b423f8ffc9ccfbe85991b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE0LTctMS0xLTE5NzE4Mg_be585922-10c4-42ff-a8fb-556196fa5dc1"
      unitRef="usd">-13100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE0LTExLTEtMS0xOTcxODI_0f0219ca-8136-4328-9820-1b38bc67a64d"
      unitRef="usd">-357900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7653b13d4d7a4b1ea53ccf1f2894f8e0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE1LTEtMS0xLTE5NzE4Mg_e9ea8fa4-fa95-42ea-a146-32f49b4f0f94"
      unitRef="usd">-122700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8d8b6b1d95db4e629430b1a90c83d5ed_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE1LTMtMS0xLTE5NzE4Mg_65dd5f98-5dfe-4764-9e21-05260f77aede"
      unitRef="usd">-11100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i57369029d5994ec1a83968149ccf0c57_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE1LTUtMS0xLTE5NzE4Mg_6af384e7-8d10-4829-8db7-52652ee9ffbb"
      unitRef="usd">2167400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i223571c60a5b423f8ffc9ccfbe85991b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE1LTctMS0xLTE5NzE4Mg_316c9c0c-99e0-4336-8018-69ca7b50430f"
      unitRef="usd">119700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE1LTExLTEtMS0xOTcxODI_1f453bfc-a8d9-4ada-ac42-10ff971726c1"
      unitRef="usd">2153300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i556ef38e7ad6431685ad87cfb8474525_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE3LTEtMS0xLTE5NzE4Mg_028ce19c-9e7c-4ba8-bf58-059c296710f4"
      unitRef="usd">-1550200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66b44aaa3e8a45e08cb1bf413d8b0659_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE3LTMtMS0xLTE5NzE4Mg_82e0f518-4dac-48ca-8b76-f16b8596b34c"
      unitRef="usd">3700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i17c04e1ff996458393a87969564ad1fc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE3LTUtMS0xLTE5NzE4Mg_0e6acf46-f501-43b5-9913-74ea15e1194a"
      unitRef="usd">-2583600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i972702fe45444acb9e6640afa709e559_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE3LTctMS0xLTE5NzE4Mg_36459c6f-ce99-4300-aafe-71b5a2eb17aa"
      unitRef="usd">-213000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i555a212b77e94fec899486cbaa76fc01_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE3LTExLTEtMS0xOTcxODI_732cb8d2-446c-46ed-a925-9f5b8a652caf"
      unitRef="usd">-4343100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2aa5e5ddf4514d70abb39fde1aef3c0c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE5LTEtMS0xLTE5NzE4Mg_96484811-d050-4da2-8247-0331c8c378eb"
      unitRef="usd">-324400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i9c2f066479d04e8a991d5d71e2aa8bac_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE5LTMtMS0xLTE5NzE4Mg_632c3bad-4027-43f5-96e7-2083f0bc5c7f"
      unitRef="usd">-52200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i66b74eb9d22141c790775d44d424fc2f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE5LTUtMS0xLTE5NzE4Mg_d09b379a-d390-4b04-84d3-2f9064e3dddb"
      unitRef="usd">291500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ib6f1b84d8e0044fba3da52e09503d7ef_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE5LTctMS0xLTE5NzE4Mg_5f5963ba-d589-4f11-9849-a3188487f03b"
      unitRef="usd">332800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzE5LTExLTEtMS0xOTcxODI_37f1a871-1a54-4754-872b-06482443285b"
      unitRef="usd">247700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i2aa5e5ddf4514d70abb39fde1aef3c0c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIwLTEtMS0xLTE5NzE4Mg_8519654e-3378-4608-9d91-1b35892d6970"
      unitRef="usd">-400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i9c2f066479d04e8a991d5d71e2aa8bac_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIwLTMtMS0xLTE5NzE4Mg_e6a9c7b2-2b23-4d84-b508-10c31a5d1213"
      unitRef="usd">-11400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i66b74eb9d22141c790775d44d424fc2f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIwLTUtMS0xLTE5NzE4Mg_6d187392-82d4-4979-828a-525ca6db2cbe"
      unitRef="usd">-229800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ib6f1b84d8e0044fba3da52e09503d7ef_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIwLTctMS0xLTE5NzE4Mg_721bd12a-629d-49a8-80f0-7713d19e79bb"
      unitRef="usd">-9200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIwLTExLTEtMS0xOTcxODI_b14214f3-759e-4e10-abcf-2fa99d40740f"
      unitRef="usd">-250800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2aa5e5ddf4514d70abb39fde1aef3c0c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIxLTEtMS0xLTE5NzE4Mg_a2f135ee-3c6f-4fe3-961b-408fd008e100"
      unitRef="usd">-324000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9c2f066479d04e8a991d5d71e2aa8bac_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIxLTMtMS0xLTE5NzE4Mg_46d755ad-c50d-4ada-a14b-3128f7ef0fea"
      unitRef="usd">-40800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i66b74eb9d22141c790775d44d424fc2f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIxLTUtMS0xLTE5NzE4Mg_fe564505-d03f-43fd-be06-6fe84ae1be42"
      unitRef="usd">521300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib6f1b84d8e0044fba3da52e09503d7ef_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIxLTctMS0xLTE5NzE4Mg_066dcf29-9084-4e09-9beb-a62df3685d9c"
      unitRef="usd">342000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIxLTExLTEtMS0xOTcxODI_e75150a6-3719-4af6-b6c6-e7e24dfe1717"
      unitRef="usd">498500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie3ab662330354f1d9f630d917b2b9226_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIzLTEtMS0xLTE5NzE4Mg_a5a82191-03fa-4abc-8c4a-e91ee8341a13"
      unitRef="usd">-1874200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie36998435f274cd5b1ef204d97105cbd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIzLTMtMS0xLTE5NzE4Mg_29327494-0343-45bb-939d-5680860773ab"
      unitRef="usd">-37100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia343b309a27649efbcdc14994affb7a6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIzLTUtMS0xLTE5NzE4Mg_4668156c-b9bd-4acc-a75a-86d493dba333"
      unitRef="usd">-2062300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i463002f84e9c4e7ba72e5b39ba3391e7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIzLTctMS0xLTE5NzE4Mg_77b6471a-f848-4a75-8206-d344538e680a"
      unitRef="usd">129000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib916975408c44e2c89551e919105a31d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplYzgwYzY2NTI0NTE0NzNjOGIzNWJkYjYzMTIyMzMxOC90YWJsZXJhbmdlOmVjODBjNjY1MjQ1MTQ3M2M4YjM1YmRiNjMxMjIzMzE4XzIzLTExLTEtMS0xOTcxODI_44f45736-1f10-4b6e-ab7a-9be44be528d0"
      unitRef="usd">-3844600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i2aa5e5ddf4514d70abb39fde1aef3c0c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzEtMS0xLTEtMTk3MTgy_98946bd5-4ba4-43ea-9b30-ad031815bff3"
      unitRef="usd">75900000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i7653b13d4d7a4b1ea53ccf1f2894f8e0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzEtMy0xLTEtMTk3MTgy_0e55065c-de55-443c-be81-9379fb1826d6"
      unitRef="usd">136200000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="if9a8c569328a4f30be03a86aa6c30d95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzEtNS0xLTEtMTk3MTgy_88e146b3-9e33-4fc0-a2af-428630e1e3b2"
      unitRef="usd">-128300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i9c2f066479d04e8a991d5d71e2aa8bac_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzItMS0xLTEtMTk3MTgy_032c327b-3eca-4f87-8bbf-c672736fbeeb"
      unitRef="usd">-12400000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i8d8b6b1d95db4e629430b1a90c83d5ed_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzItMy0xLTEtMTk3MTgy_db5c552a-820a-458f-9fb6-ff9429d6c7a7"
      unitRef="usd">-4700000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i551c81f2cb044ba38f8c330455e4e04c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzItNS0xLTEtMTk3MTgy_c82e23eb-7c00-4451-b3b9-d6c2ff373f64"
      unitRef="usd">4300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i66b74eb9d22141c790775d44d424fc2f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzMtMS0xLTEtMTk3MTgy_ae3958b9-6557-4335-bd9e-202cd44d2934"
      unitRef="usd">95600000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i57369029d5994ec1a83968149ccf0c57_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzMtMy0xLTEtMTk3MTgy_108d4222-2734-4d6c-99c0-c63a5716e92f"
      unitRef="usd">532000000.0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i17390e21b41d40f786eda486ba1ce2c7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzMtNS0xLTEtMTk3MTgy_08439e0a-1b3c-42ec-9711-76716bcd0af6"
      unitRef="usd">-44800000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ib6f1b84d8e0044fba3da52e09503d7ef_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzQtMS0xLTEtMTk3MTgy_23a08ab4-552a-4a82-b9d7-1dffec48d580"
      unitRef="usd">90900000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i223571c60a5b423f8ffc9ccfbe85991b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzQtMy0xLTEtMTk3MTgy_edc92e1d-4e22-458c-8365-a5352b38746a"
      unitRef="usd">31800000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i05873b0c5a3d432cb9d95359fb5df095_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzQtNS0xLTEtMTk3MTgy_b502da06-7d32-473a-9546-ccd5f6b49731"
      unitRef="usd">-32100000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzUtMS0xLTEtMTk3MTgy_2998a4fd-393b-43fe-be55-8d8811982aba"
      unitRef="usd">250000000.0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzUtMy0xLTEtMTk3MTgy_689140d7-2582-4226-ada8-77bc777ff11e"
      unitRef="usd">695300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTphOTdiMDA4MzkxOWE0ZWI3OTIwZGI2ZTgwMmFmZmYyOS90YWJsZXJhbmdlOmE5N2IwMDgzOTE5YTRlYjc5MjBkYjZlODAyYWZmZjI5XzUtNS0xLTEtMTk3MTgy_f2c4e9ee-1b7c-40ca-8a35-95159a41f328"
      unitRef="usd">-200900000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90ZXh0cmVnaW9uOjdhMzRhYzM1NTIxZjRmZmJhY2M2MTc3ZDA5ZDM5ZjlkXzEwNzM_c7846259-1d68-49a4-8b76-7e6c53e6df59">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of accumulated other comprehensive loss were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.230%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Details about Accumulated Other &lt;br/&gt;Comprehensive Loss Components&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Affected Line Item in the Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of retirement benefit items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service benefits, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(52.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2014;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;343.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2014;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;290.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(61.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2014;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications for the period, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6fb8bb210d8244f89d422fb23165a4e3_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzMtMS0xLTEtMTk3MTgy_f73304af-c996-4db6-8ad9-a737caed5b10"
      unitRef="usd">-52400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i023d933f184447ddac5d72ebf87e0336_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzMtMy0xLTEtMTk3MTgy_8b3c569e-80ba-4c3f-a31e-2df9ab8d5885"
      unitRef="usd">-55400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i472a66eae4d2427ba823727867f6c0f9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzMtNS0xLTEtMTk3MTgy_3cf4534d-7e4e-4893-bbcf-dc7566482409"
      unitRef="usd">-55000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i84dd851668914a6db57dd7071efd43cf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzQtMS0xLTEtMTk3MTgy_23ce4b39-5a24-4cc9-ae03-0bd200290a64"
      unitRef="usd">343300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i514b258fa8244695bafee3af86f5baa4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzQtMy0xLTEtMTk3MTgy_71826d29-fac3-4610-9b8d-83e29c54251d"
      unitRef="usd">490900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic9961583d4b548ebbcb37171c99e617d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzQtNS0xLTEtMTk3MTgy_cf6a8100-1167-4df8-8e38-780474724bcf"
      unitRef="usd">393300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i344999926eb8490985eec925cad19570_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzUtMS0xLTEtMTk3MTgy_04d368d9-9693-4395-bc53-483f62c41dba"
      unitRef="usd">290900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4d7c5f720a834207b54353c4bd105eba_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzUtMy0xLTEtMTk3MTgy_7866748c-2ea4-45fd-bbb2-3474abfa3107"
      unitRef="usd">435500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i18678afeadcd4e3d83ea294339141d26_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzUtNS0xLTEtMTk3MTgy_c208e4ff-2ed6-4b88-b29d-b0747c492873"
      unitRef="usd">338300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i344999926eb8490985eec925cad19570_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzYtMS0xLTEtMTk3MTgy_1d2d1ecb-177b-45bd-96ce-82107c69a0b1"
      unitRef="usd">61100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4d7c5f720a834207b54353c4bd105eba_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzYtMy0xLTEtMTk3MTgy_666482a3-dee9-4113-80b3-f3452ee2d6f6"
      unitRef="usd">91500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i18678afeadcd4e3d83ea294339141d26_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzYtNS0xLTEtMTk3MTgy_016bb354-7ff2-4b35-b7b8-00cc581e54f1"
      unitRef="usd">71000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i344999926eb8490985eec925cad19570_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzctMS0xLTEtMTk3MTgy_1f383320-441d-4953-864b-ee777e32ea02"
      unitRef="usd">229800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4d7c5f720a834207b54353c4bd105eba_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzctMy0xLTEtMTk3MTgy_edeeda4c-d507-463c-909b-aeed2fb96168"
      unitRef="usd">344000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i18678afeadcd4e3d83ea294339141d26_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzctNS0xLTEtMTk3MTgy_c552122f-4e9c-48ac-934a-38a2ee908dd5"
      unitRef="usd">267300000</us-gaap:ProfitLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9b856402e0234773bcad0e3fc79b8715_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzktMS0xLTEtMTk3MTgy_dcb9c177-28f1-4bd9-817b-fbcc089686ab"
      unitRef="usd">21000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia960d127a0284a50a7e9041cfc5cc3ff_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzktMy0xLTEtMTk3MTgy_7314f096-574d-47ce-9291-ef11ae72e29d"
      unitRef="usd">13900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib01471a2ae8e487caadc07f6eb55dd21_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzktNS0xLTEtMTk3MTgy_2851bea4-4ec5-4f4a-bace-d9bc3896222c"
      unitRef="usd">16100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="if3a0343f9166479e970860fc345fb4c5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzEyLTEtMS0xLTE5NzE4Mg_ce5d27a1-8cec-4f56-8091-bfc570f427a4"
      unitRef="usd">250800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1a4ec401a8f24eeda71c72518a06d67d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzEyLTMtMS0xLTE5NzE4Mg_39affce1-d377-4f3b-86c0-522de3725d66"
      unitRef="usd">357900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iefbc11fe7e2b4373988b6e83dcf18945_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDIvZnJhZzo3YTM0YWMzNTUyMWY0ZmZiYWNjNjE3N2QwOWQzOWY5ZC90YWJsZTplOTdhZTc1YThkNjg0ZjAzOTMzZTZhZWE1NGZhNDQ4OS90YWJsZXJhbmdlOmU5N2FlNzVhOGQ2ODRmMDM5MzNlNmFlYTU0ZmE0NDg5XzEyLTUtMS0xLTE5NzE4Mg_81f452e0-0d12-4344-9fff-46e41595da22"
      unitRef="usd">283400000</us-gaap:ProfitLoss>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90ZXh0cmVnaW9uOjZmNWEzYzJjYTM2NTQ2ZDFhNzRmZTZkZTFkZWRlZDZlXzk5_2dee57ff-0eae-4595-a098-0d843b15f84e">Other&#x2013;Net, (Income) Expense&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&#x2013;net, (income) expense consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;331.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(62.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment (gains) losses on equity securities (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;410.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,442.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt extinguishment loss (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(372.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(289.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(251.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;320.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,171.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90ZXh0cmVnaW9uOjZmNWEzYzJjYTM2NTQ2ZDFhNzRmZTZkZTFkZWRlZDZlXzEwMg_8ae14efc-5dfa-4d10-b071-0b0882f450e8">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&#x2013;net, (income) expense consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;331.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(62.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment (gains) losses on equity securities (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;410.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,442.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt extinguishment loss (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(372.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(289.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(251.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;320.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,171.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InterestExpense
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzEtMS0xLTEtMTk3MTgy_753a56d9-3634-4a4d-9294-d0412294897a"
      unitRef="usd">331600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzEtMy0xLTEtMTk3MTgy_6a386a27-cb9c-4eab-b37d-13a0a00097b8"
      unitRef="usd">339800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzEtNS0xLTEtMTk3MTgy_a69beaf1-e4a9-445e-8c61-b8a722bfa586"
      unitRef="usd">359600000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzItMS0xLTEtMTk3MTgy_8c837135-1bb6-404c-9b51-85265c771796"
      unitRef="usd">62800000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzItMy0xLTEtMTk3MTgy_a2d864e4-17d6-42be-98ad-bd58e26635a3"
      unitRef="usd">25400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzItNS0xLTEtMTk3MTgy_8dba20b7-31c6-42bf-8753-c13b35676af9"
      unitRef="usd">33000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzMtMS0xLTEtMTk3MTgy_9552f222-c655-4f7a-83cb-31912d57cef9"
      unitRef="usd">-410700000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzMtMy0xLTEtMTk3MTgy_30c351bf-3c4a-4302-898e-615e97d82620"
      unitRef="usd">176900000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzMtNS0xLTEtMTk3MTgy_3e44f26d-065b-4a9c-975d-7d991cd0ac9b"
      unitRef="usd">1442200000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzQtMS0xLTEtMTk3MTgy_9b59edee-6a17-4561-bd3d-b4bbdf8b3169"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzQtMy0xLTEtMTk3MTgy_96d772e1-8c81-4067-89e4-988474312348"
      unitRef="usd">-405200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzQtNS0xLTEtMTk3MTgy_e68387c1-98e7-4a6d-a7a8-0b05ef09589c"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzYtMS0xLTEtMTk3MTgy_00d5eece-8559-4d91-8765-7d7fee01fce3"
      unitRef="usd">-372900000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzYtMy0xLTEtMTk3MTgy_ea278574-9582-48fc-b30f-90da43fa2020"
      unitRef="usd">-289700000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzYtNS0xLTEtMTk3MTgy_ad281757-096a-47c9-b5f7-691c86163026"
      unitRef="usd">-251800000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzctMS0xLTEtMTk3MTgy_17e95600-da3f-4720-a5a8-72d67f6a6abb"
      unitRef="usd">-14300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzctMy0xLTEtMTk3MTgy_742f85a8-ba51-4f8a-801a-3bac81837bc9"
      unitRef="usd">51400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzctNS0xLTEtMTk3MTgy_5823e245-3113-40c6-8f24-554bc6abf8c2"
      unitRef="usd">-195500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzgtMS0xLTEtMTk3MTgy_82a7c708-983b-424d-aba5-680bf57fa323"
      unitRef="usd">-320900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzgtMy0xLTEtMTk3MTgy_633422de-f95b-4be3-bba9-c86dc2c9751c"
      unitRef="usd">-201600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2e718011c2b0434bb67e4bb0cbf4dc15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDUvZnJhZzo2ZjVhM2MyY2EzNjU0NmQxYTc0ZmU2ZGUxZGVkZWQ2ZS90YWJsZTo1ZWNlNmEyZTUyYzI0ZWUyODU2NDZjZmI5NWIzYTQyYi90YWJsZXJhbmdlOjVlY2U2YTJlNTJjMjRlZTI4NTY0NmNmYjk1YjNhNDJiXzgtNS0xLTEtMTk3MTgy_844213a2-7366-44ae-81c9-28cdf5b354ea"
      unitRef="usd">1171900000</us-gaap:NonoperatingIncomeExpense>
    <dei:AuditorFirmId
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNDgvZnJhZzo4YWEwYjY1ZTg2NDE0MDQ5YWM1ZWZmMjU4YzQ5NzI2OS90ZXh0cmVnaW9uOjhhYTBiNjVlODY0MTQwNDlhYzVlZmYyNThjNDk3MjY5XzE1ODM_4a0f09f2-d247-4711-8977-296f2d67bde9">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNTEvZnJhZzo5YzA2ZDg0NTEwMWY0OGU0YmFkZWQ1ZDk0MzE3ZDA5Yy90ZXh0cmVnaW9uOjljMDZkODQ1MTAxZjQ4ZTRiYWRlZDVkOTQzMTdkMDljXzM1NzI_a58897d7-b537-436f-87d5-0acebc7f09b5">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwOWI3MDJmN2RiMDQ0MDc4YThlM2UxNTA1MDM3ODhkL3NlYzo5MDliNzAyZjdkYjA0NDA3OGE4ZTNlMTUwNTAzNzg4ZF8xNTEvZnJhZzo5YzA2ZDg0NTEwMWY0OGU0YmFkZWQ1ZDk0MzE3ZDA5Yy90ZXh0cmVnaW9uOjljMDZkODQ1MTAxZjQ4ZTRiYWRlZDVkOTQzMTdkMDljXzM1NzM_d22bef63-634f-4ba5-81e6-c07b96351d64">Indianapolis, Indiana</dei:AuditorLocation>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>123
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M84^:2C^)]@MT^<RL7B8JY;ZH];[X<X"R1FG!NF!#P"CW(WGK[N$X )\)P%T
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M-^I*)AQTW>&RC0PX'Z%I69TW@O/FZ+(GY+4 '7,!.N/&[XTJ:VN"^?9H5S3
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M(\[Z1K*B.O2[8U*RK+K<$9P0K@'J]WNF-OGF1O]!>]"\^1]02P,$%     @
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MF:VCN-SSV?+''U ,?_8Y]T:3C5PE!U=):/;E-5,;P.H<K.T+_N^NV+/2^*[
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M B@MA-*BGL;=W*D8$$$Q><T.M@O5VRXCMX7U-)L?3,0OXE(?=+0 H2X+E!9
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M&<QQ3F*Q Y?&P@&)6?6^7_6ED(?R#;BM+ J9E)=[X8<B4P;P_YV$35_]1?U
M\];E^O]02P,$%     @ 5E-65I%.:=L1"P  "!P  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&ULQ5E;4R.Y%?XK*B>U@2IC;,\EJ5V@"AAV,\E,AL)#
M]B&5![E;MK6HI1Y);</^^GSG2'TQ \PF#]D7<+>EHW/]SG?DDYWS=V&C5!3W
ME;'A=+2)L?[^^#@4&U7),'&ULOAFY7PE(Q[]^CC47LF2-U7F>#Z=OCVNI+:C
MLQ-^=^W/3EP3C;;JVHO05)7T#Q?*N-WI:#9J7]SH]2;2B^.SDUJNU4+%V_K:
MX^FXDU+J2MF@G15>K4Y'Y[/O+U[3>E[P3ZUV8?!9D"5+Y^[HX7UY.IJ20LJH
M(I($B7];=:F,(4%0XTN6.>J.I(W#SZWT']EVV+*405TZ\[,NX^9T])>1*-5*
M-B;>N-U?5;;G#<DKG G\5^SRVNE(%$V(KLJ;H4&E;?HO[[,??LN&>=XP9[W3
M0:SE.QGEV8EW.^%I-:31!S:5=T,Y;2DHB^CQK<:^>+9(P1!N)19Z;?5*%])&
M<5X4KK%1V[6X=D876@4A;2G>5[51B$F4[%/L^@<<_Z.VTA9:FN&^1<0&Z<MP
M<ARA*!UW7&2E+I)2\V>4FLW%1V?C)H@K6ZIR7\ Q+.S,G+=F7LQ?E/A.%1/Q
M:C86\^E\_H*\5YW;7K&\5\_(>\H__SI?ANB19O]^RN(D[_73\JCTO@^U+-3I
M"+45E-^JT=EW?YB]G?[P@K:O.VU?OR3]]PKR[ZZ4N)!!!UI[34YM]W[>**!!
MX:I:V@?:4#@;<%8IHRK%JA,9L)Z/#$+;PC2E$E=&BP_:F ?6Z3*)X,_28$.S
M#+K4TK=*;^16B:525B"JM?00KRV?[4L<HE#L<<//6?7:XR0-2X-8*ZN\Y*.*
M0M4Q[8W0_=9J>EJ0>D$<_'1^?GTX$3\KMD.7R@,@?G%>QP>Q=2Q6VZC@@1C&
M0@:Q P;2?[5:*09%H;#35;H0S@N'(SR)BAYHY+9XD%; "R1OMX$MI2I@)<3B
MB1=CEW511#?T9+^+=>O-*1VO9M^TQRP?1*6D#?GTN,'FQ[I##+Y3PC4X<0=I
M8:-K"NY>^/9B@.##E2')FTVGHE:^@%)C]J-U-I]OZ*"P08 VSL"!X4_]L0)O
MJ?U0'X%\^$V*0,$D&RF)G(5$TD-]:=C:<[B7M^<40]LP%.V4$X (&R3WI#!(
M$&4TX)U,F'""IH3IDOV9K"3;J3-S;"B7*!F@+32!\L@#B\Y*BRDXE;Q#J$/4
M%2<.9VU -ZZ3+G!2%))S@MT#!9QGDRM*3ZXCK%>414;+I38ZPLEC+-PJV] G
M=0^R$.@3"??*<$A*'0KC0D,:R22;$P3RZ/.3IM'^LO$4EUX7KA#EM8./SHO8
M8 MDHO\&^*$Q=!+4]V+E785M+@S,Y234,!<*408]>2K2<*4Y&=B9=/)"%5 C
MMA5]=5\@E]:*:K^". K/P>+J\K"O=[65INER$:$@]Y.+<$!34R!(+M0:>(#/
MY">D[+FU9-H-VRQP /$/I._1WR?B4OD(J@6["X-@,&H^3J5* JEP#, $E9D<
M%EKP^#;6<5X,X1'5"NM3=5.R]<Z!:SQ95P_@E1T-TLCUD:H%0DS[CBM-K3DG
ME5TC/3M<HSPAO'D8 V*VX(MUQ;6*+&Y6J!A.!WKT=RKR1U(U2$)+^*Y&_59H
MH4V$3PQT<F53P![00E."52DDC5@;MTQIHZ0O-BG/^L, 96MI]:^I[M@3B&)=
M [80=^BY_STC0Z@)=I>P$,[Y;PQA[9-PJ$])V>H\0?#7. &:(@X5D(1B-#P[
M9#>,Z;#H];*)*DLD=(^,(*TPPI-E@S 0%B+!I F.3T[UC:S/;D%?PCL*'/)A
M!=1I; *JB?@$]4H%4&.4(NL9+W9/Q[J-L ZI*85(3UW>]'FG;1HL$L=?-T9Z
MN .( OJ=5.,\VVBU&B00=2 N/8(TSWZO&Z@>4B;D"LQPP0< ?L?4HUV1WB-L
M<'A!4 5$RXV&6H/>)E0'CF4SI5\SYI%S:P"YI<7T ,&JD($WDPJK!I%5;<%1
M# =)]FZ09%<9)OF+\X+!&@S''EU[5U",GMUY\/[ZYCM9U3^\._SJNX\:A1#1
MC1[M'Z9WX=J.EJ&:&QHLIT(N)]_:F&/)/FYM:#=3%6=O9P<_+8GGL-PY$JVB
MY<A?9@74!2DGHQOOAX'$+,$A5IIB@2K*[8>_H&+;8"1MM<)>("K# &H#?_/[
M%#:%7;74988TYNR]OGM5-AF$I_7\5Q95O>-;GDA)"P6BYJ(*J7FJ>Y2/31PH
M;=\3BWK]!;V7,JT]L\3?(F(]L<8A<QCR)-G7-CRVS.4Y3O4Y)%NTUK *G.4Y
M79M P%B6.C+@&(!69Q#<])!@<6GT.@-/V]93(X-3]QA-8A%>]7F1VA!6I_J.
M#J1?UK!V2YBVRET)/*HAN!VF)K--^IJ[)X5RO58^E=] )>YU,B%%K[HK<#X"
M>"4]56P0UW#8@CB>.+BZ7APR34/"'C'O:TG.6#26*2,[>*>#XO;7]:B5<Y'[
MX9A5S8V/. 4%HM2F842EN2-1<FD*,EKQNT+@9+Y%X TD<,?W!JH\0H0\NJ&P
M3;4D3KUBZ,<JU@\*-3'08,.H9IJ0')/H&A;#W3[-1Z;=P32H=@2]E(>@D^B,
MNFY[<,MK'NG9VO!_UY0:($)7W!VE8_?*'^FR]K*"LB!#4,2*2^8>Q8/X3.EG
MTK)/J450(E*S)HG#>8 TT[D\'TU1MY/%Y#!W=!K/!B'/39!*N3V3JED"+#KI
M-!IIO$##:[MD:E\R-[,VTY7=:N\L5]6.YYG'@E OZ.T:59]FII:K<UF R*'E
M;%)/;\FOZWHC&4ZMZ&7+82I;&K/GB E2!+ZVE(<HB_KB/24F)>G!8D/+R]N<
M$&U.=!YB2M 2HHZT\_C U@PFB,>Z].+3/OB,K,_$VR<V_[DU)"F5\ZO#'RK<
M- :TV9%%6A7S%),C@H7[<_NC%&CGX0JUOJ';R"UCFP-]/\!4$PX)/6%]U*QV
MU]LO4ZL-P8'HD%EIUA\L?:X-)]Z9()2Z":LQ8+W$\#H"*4ND&E' !.IM6]Y7
MJI_+V X=$BSG-",_*(,L#=PWO"PUNB]=1:"W*?@EG<0C+;NOEXPNXU#'I#,A
M^CW/6A#YQ]ED*A!?PQ+Q-.^?2!;>S-HW9!U=R_'EW"Q]CT_3,7/K=$-!72D5
MV$X.9_HW[41/1N0Y-!74 [HY6"L'[UOW2\1M4YC#8.7P6J:[B4)42A4*$.X>
M((!F& TXHN0$.(YROYN:?M/4-?G?+KB>?'E;\WA]<+ZX/62?'LW@S)^()"7<
M01EJ0NA"B3%-R!*M-&P89GCR[ ?V]BHA3894SFDN)%^D2@-8N+7^E0=.*8#1
M/$0E7D532;IZ[[2L7*D,"UKW^LA>GR&7X,8D2\=W7^3%D$VD8H%__H9QB@ S
M7^LF3.#U=&@)@D?41T-?:CQ/S_S#RPG4S.*64^]H^GH,+KQ2A&5*W) [\4BS
M+]^@K1K/Z0)KD"T)Z//>V=%TEGA]>IX?3=]2,;DMX#>Y$"?3E$5WGW6&6RK0
M4G?C-\!.U5T;DS0B\CUE'K?YDF= 7E'7&U6N$^U.G9#NQO+,DJGBD*2E6YY^
MON(OF0"V=R?,"]N>]<'9$E^])P!82GLG/M$U"[:S8PX^O+_X='/(";#/,'WG
M00+M%)\NAC0:)GL,\T%4F*0A>F@772"J-%O@]9(BH!Z%_<WS6=+V;^TQLGS!
MGIC8R@O)DGBR(!3CN:%-GL0EOEW%3UW6'P]^G<$HO^;?H/C&RL;T0TWWMON9
MZSS]NM,O3[^1?<0LJBT!X I;IY,_OQD)GWYW2@_1U?Q;S]+%Z"K^2'.1\K0
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M S9<J* (YE!6F,(29SQ1?DF/0> ^3E+L<DG,V<0C/!@$Z2(4YNU@,#USM#U
MM4,*[W(8ATOC)/ZB-T@<^J,O6@F E?[L',$.?&&T-YL/'! WPNR@-:4K8=2'
MQ9:P2).><-&+[$E^;4OI H1!U%THMF;.MA\P#4<N,]M;3J\\/UY (:J/ P=
MI.VY9I$@@PBD]Z"2@#92OQ@D=Z.K(H](M,#'#=P)#EPV]?X9"=<-\#@,$$<
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MY@;N69"W3_LECY/++"1Q4HP^-FVCPGN:MC1;./&_G +Q'&=9C'*M?GYHUX-
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M</W_MQ,3%W5RMH$"K13VLVA]G/Z.4$3D[=HZ+&1I*7 !Q*7M#6W(3LY0C?I
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M^!P]'D?K:WKC#9^L!OCA2CPN6\CW;'5-\T1S=JI?3=\V=LL;HB_4C]5>ER-
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M+*[D"(G_TC5'_I<#FZ8#07QY,+#,EA[ [[NFZ?P76B#\#XJ7_PM02P,$%
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M*;-("5-:D5L3EU$A<ITKVG4 HE%2QCI;8%6SZT# 3!,Y,U:&SSJ[5:X@\OA
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MSXK^J-#R!EJ?&^.W R;8_:.-_@%02P,$%     @ 5E-65KB-DVI_ P  UP<
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MU\H$_X^58N=]2$Y(NNHH2P(6F<^GY=8GF%A"KK0@5MKW/%2"_V2PX(I3I==
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M^$^:]=MV$!BA2\ZYF$_GXP@^E_-Q"!_A-!Q/X#.83.DS#*;C0+RTL;TUE*U
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M8-K@(JOCP=QSIPJJ&-*R%\;9S(GMVO0)9 U1=.A-!3 T8ZRKB 5HLL[4':5
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M2%G9TC@:>K>GYHH>-Y3*45.52U!JU'T+6:O@UPD!AB 8[N$82,QLN\/^_AP
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MT?)Z<#M^^6K&\V7"GX;N_-:]8D\6UG[FP2_9]6#$@*B@-+ &C<N:7E-1L"+
M^-+J'/0F67#[OM/^5GR'+POMZ;4M/IDLY->#BX'*:*F;(GRP=S]3ZX\ 3&WA
MY5_=Q;EC3$X;'VS9"@-!::IXU?=M'+8$+D9?$9BT A/!'0T)RC<ZZ)LK9^^4
MX]G0QC?BJD@#G*DX*1^#PUL#N7#SCN"2OQH&Z.(GP[25>Q7E)E^1&T_4K[8*
MN5<_51EENPJ& -$CF71(7DT.:GQ#::*FXQ,U&4TF!_1->\^FHF]ZT#/UU^W"
M!X?D__V4DU'%V=,JN"%>^EJG=#U Q7MR:QK<_/#=>#[Z\0# LQ[@V2'M!T+_
M'#GUB5!]@1R*@I19*HT2=TY7*T+/!&6\TJK@J4IC5*54<QLD+)?K-<5W'N46
M<L5JO&IJ%:P:GZD-:>=5[0SZU!0;A=Y7J76U=3J0LLNE2<F?* Z)=FD.TQFP
MK-'AM=A>ZM04)AB>M*;<I 7?\2SZTAB9<\*0BB8SU4IY6[)6=8>9>01G!:QG
M/'0?")*0'@(&#!:;T^@V@PEYYTFR&Y'^A3BG%ANE/9B'[?$KNB>7&B]V=;6!
M+Q7=Z>)I,TP?/:(<X=2.(*&]K?2BB)H=98GZK2:$B&U$TXXYX=0N3QM.@_<4
MO,A*-56!X)97%GB<JFR5-LYQ^-J)!D8;#GSE;6$RS=,7NM!(I9*&;V/*[O2B
M&!>V6@ETA81%T'#2[D$KC%ZT21)(,1TPP68%4:=S9R;T/\*[-4&*HB:AVF)S
M\@P?$O4Q!\P(.&;RI*T$AI41RCG;*6$N"BD2O9U@N A.*B,G(8,H.8X/5%0V
M !7JE[UC<8[7(4#[66SSX:A-F[@DJ64HDMI*-:!!U Q+R7QIFMTBC.DZE(A=
M$W91F)7N7"[UYTY9K3?<0YPXXUG3TMGRP=A7/9#JV,L[1V95F7]BD%-;0G,:
M*82C(TM>'[8.W5H7C;3.'AZ[IGVG$W7KD18?I @;U_%.9B4QM;-KDTD$35D7
M)C5(%NRB!DA"RR)(O1-(:-"%=>!9=LT]@F>JN$N1Y7ZM38'NI*?=0F%V7-%1
MPG\XER@A7C '-D2X<G[W<QGCW-6O\=O194R*ER+A!"9U!F^>#!HT@!A>C,\N
MD@NL^D4!CTXPGETF9P]C3B>>G27S[IG*&M>Y$TF<>'566%NI7,!,M[[*_SBJ
MP-UHMV\3]2<J2X*W&X/.LX<Z!0V<QCF(<6TK*0/?</<B[=@4@KRYN9@*0)+2
M9T):^KY;$Z+*-;:$@$]<ZFG.RY@P():2(/V<&I<VI0^L 0]2)A]IMF5HP_<X
MR9&IP-AM]2(]V&AR:@,VEI$=VG0*[\DD<L;**.**@N+^=D,:1B<$F$4GJ&4:
ME!\TH%"_-16/";$O.2Z*_\M&4]=%WU/;!+C318X*H4@D9:_6O2Q=R\>V.B-C
M@8O?TA;8^ON7\:V\^22;9<I.0>..4X+VUK$3MRC]O'6JNSZ2RHQ/;5-%QE!3
M],'W^!_A?\>]5/M<+8'AV:Y]:UP/N"RO'WBYQ^0C>3^"\ (;L<ODG*^S>;S.
M1\FE^O#$EL(N J(7:YCN8_<(/V%/<W"]&<]F()3Q?)K,U'C*9G[/N3^K!F%C
M:BR;\A''1QH_N)_X2F5(D^R%9RH>GB42)F"9CH$(MP TGB42M[FZG,>[<W4^
M3Z;J5GI>QI/9" ]^MYSG/: 7DRE4O<,^@)>6)DA\($A8BRYG,!BE7JCSR05&
M;XT055_=>WLB+%3P.&SVM['^H5G[I2FNM-WV"/6&<I+ \*+2[\XR6H23O1T;
M/WO6IND)M#O,P%6]KV,I,OP6-!HHKFH'#C*S_B S^\:#S'/DC@>9XT'F>) Y
M'F2.!YGC0>9XD#D>9(X'F>-!YGB0.1YD_H^#S'#KPUA);B6?_[R27HO?R/JG
M_1?&V_AA[6%Z_#SYJW8K,#]P+B$Z2LYQMG'QDU\<!%O+9[:%#<&6<IN3QEZ*
M)^#]TMK0#=A _]WUYE]02P,$%     @ 5E-65HD[:]U>"@  6QT  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C N>&ULS5E;;]O(%?XK ZUVFP RQ3NIQ#80
M)[MHB@TV6&^:AZ(/(W$D,>%M9X:6W5_?[\Q0E$19MERT0%]&%#GG_IW+D)>;
M6GY7:R$TNR^+2EV-UEHW;Z93M5B+DBNG;D2%)\M:EESCKUQ-52,%SPQ164Q]
MUXVG)<^KT?6EN?=97E_6K2[R2GR63+5ER>7#C2CJS=7(&VUO_)ZOUIIN3*\O
M&[X2MT)_:3Y+_)OV7+*\%)7*ZXI)L;P:O?/>W(2TWVSX>RXV:N^:D27SNOY.
M?SYF5R.7%!*%6&CBP/%S)]Z+HB!&4.//CN>H%TF$^]=;[K\8VV'+G"OQOBZ^
MYIE>7XW2$<O$DK>%_KW>_%5T]D3$;U$7RJQL8_?ZR8@M6J7KLB.&!F5>V5]^
MW_EACR!U3Q#X'8%O]+:"C)8?N.;7E[+>,$F[P8TNC*F&&LKE%07E5DL\S4&G
MKV]J"8J\6JG+J08_NCM==+0WEM8_0>OY[%-=Z;5B/U>9R X93,&VU\;?:G/C
M/\GQ@U@X+/ FS'=]_PE^06]=8/@%)_G--?N0JT51JU8*]H]W<Z4ED/#/QZRU
MO,+'>5%VO%$-7XBK$>"OA+P3H^N??O!B]^T3FH:]IN%3W)^)P[FTS!C,8;-8
MB'(N))S)%C522&F1L7K)]%JP95T49O\;XV=:/':[KJ6^T$*6("A+(1<Y+UC#
M&S"9[P2,F3<)9ZGCXNJG'U+?\]^R7^MJ92FK6@O%O'"2>I$3,"^>)*'G^.PW
MB)6LZ/=EI&;LS)CG.BG[4O$2PO-_047S)%>JY=5"0!.E%7N5)([_FKU*0_KY
MA>>2W?&B%8QGWY A*!&:(<'7(EN!0S'0YE7HA*^9[Y&X/VH-HXP,Z.8'J1/3
M10K."?M5*(64DY+X-:00F+[R)I'K.=YK<P6"X/6>O8;3F Q.@L2)Z#*:!&'L
MA.P/.'IC:H+(+OB=D"AQ3"R7PI2AG4N9Y%J0^NJ\ !P&UV8*VW#%X!R78?,"
MZCM&?!]GIOF\$%WAA9O5D9,.N>[CPG>"Z,=N5P:?FR>[V(]9$KE 0^"X[M&V
M[:;9#!CPS [1RAINJVK4,DZ8/$$2)REH7,>#\-L- ,&6$I X31JR.)PA!'%$
ML4P<SQ^J'0$$%*1N=9+C#5'L A%V]9R86#RM<,P2&!>P-$P@-7*&+!,6Q"&>
M=ZOC'3T/@:ZH6UTG/-?<E(4!?(Z5P!8XP9$U,S8+R Z[@K7_(_L;;WB%VL4>
M1'6:-](R\1V/>3#-A:.\9_T0N =^<,]P'0I3',R@^S;2T7/H"((A17RF10%H
M9M K=0D@3I(<NBI L"-3"LR** Y\&2!,(<'*KI$S.][@QS%*F5T#)QV&(Y@Q
M/W3A(;MVX+J1N<[5&M6FK;*3ZH= CDME-$"1\9#H\8!Y" 2DA"^S. /SP@@/
MC%IV/=(^!$H1-W>['F\ EB+RN5T])WDN5J#P)FX<P5O>Q O(9->9)6?&"]11
M0H&.R6'.,),C%TQ]4W;ZWS- &GDL"GQT@0AZ^7"C-^2+1S,/(NWJ&TCN;XA=
MEAIQ:2?49-V30F./)>@'E!\4P?U61]M8AN$$P:<N-XMMFW$C:G.V50WK]'C7
M7,>[]OJR7H-)G@F^6._:;#<7D#!&PBZZIM TLK[/,?KB#VU0VMB75]@DE#;L
M'/;ND8XT@3YLS3/&F3:&0,0X<9#"\[PHJ+'B1ENU"NRHV^6:&,]Y]9TMI,AR
MS99\D1?(#J' :YU#W=T<T\B<&EGQ0%PX&U/SZ1D?TC] <30W<=_D4!FJ[W0U
MY9M7I.,XW.> 8GV1\8?3+&Y%HWL>P00.UFM2Q>K),6CR.YX7INGJ&GVWH7&"
MU:T\;NUP\4KRTF%?R6&(%GS/,LDW.+&L<*B"F\GUAS:2UH<Z[]S%, M EZ.0
M..PW&V8IZ+!&<'C>\[0?1SD$OLJ(8LX+0LQ)(48S,S=L !%C"\%'PEZ'O:]+
MG"45UX><JBT$S""W%'1O0#LQNVB(%-TS0@.4A>G*AH=NPY=SXW2H5B]HE"-)
M**W0T,;&P!SCLP+K!S9'VN1Z;;SML(^#P'H&Q)0D<! E^<5QDG>8)#&0B>$%
MV'D;NU0=RAW0J;EM1S.VS.^1I283=X5B *H H"+-=JD&&$';AN> :U6UO"@>
M[)!7X> .NQ="9#0TU*6-&9+?&&\@-1>BLB[<0"E2&AJWPC*=,).%N%["4Q-2
M9;.NR8F2KALN]82)(E_EY%F(^H:R JV%RE>5)>39G:TCE:%"A;,A -Y%=9?+
MNJ+04AA5O>C#N:I1J2I+./]F:Y7Z+X8A&H;!-(D7Q0$M@S3M&";'#-$ 7L0P
M]LX(K'7/P6QPALU>'+RUS?! P_B%)H?G0>]K=V?L.3-OOZCK#I,+3KJ?!B:X
M-JU<K#EF 3(7M4<(''V$U*A.;(UN)N1AJV%?G%N'93C5</F(0XS6G,KF2HH5
M[4>?J!9Y@UJ+KMO2*7%)"D=]V9Q K&H+XT0(Y?9 )^[I1@OGFXI4U,H4NW%(
MG7GK7<J^7-F'=/R"I*+-3'=D-56J"WAAPE[A?EV*U]0^4/N,NVT?J%1=Y)G1
MW_15>XQ%UB!:W!8VZM3DM ?!*9.(^[#B>K8*'%CUJ-W_@4--735UW ;GH//V
M]HXCS"#I/NAH@.PQ=SC73<B+*:;"O>TTB#VZ/9K93!C['HW]!Q+V$^_P\&*P
M:4O:0;-[IE 2'J6@$MACT#0T@PCTH59VW14;*"XK42%.5$PEFKM!6XLKU96P
M3V@OH'?WB]?8V^_8,(-&VV>3TW**W"?24HDROSC(S=[^<U*1L#U+Z>BS=?'3
M!DZZX!NW&1\W_*&'[]ZT,!QVC&?>M:L6ZA\Y)QW6+O^E71/CN1GGD,B9G0T@
M>'Q4$RG]_H\\#U DNS'N?^5X*A*[PFC+@JEJ>]"&_,$KNFT!JE 2X:8[6XKL
M?,95]X))F==%@7T)8]^ST&1MWFY\>HK[F%Z(8+4O;L8LP;F>_MM7"?C%.2WM
MYV)43,P+5)WVSB4H1-X.)%UP=V*.(DM33E';"51VYQI9MRL[&2)VQ..P1JH-
M;Y3SLC.6,E\*LD=LKN>8I+KR3F ]D'7B[=YVIAZ&WTI7)U0VP>O>B0Y%3VQ9
M]YTTZ9UGI#A^?\/TQL::MQTVAP@BT1;C%H=6:*\,S-^]N9R8C# $38YAT)R!
MMULGCT%J^P82E8*]/U,*@<H/T&#P&]C7U$%(,/I(7X"04ID9.$U"VQ3ZL\6Q
MSK*%<C@JY'?<C*+&(^1 \C?& 4-ICT3;M\,=X/9@=A1DTT0Q*'21@(D<)ZS^
M%;:Y3<_1>^A+E1T@2,;!A-"=EICYT&-.7U3E; Q@ ?(<R#9']+;<3F&DRE\P
M)W(I'\@$*[ I6GN87S[Z'ATEA3YN5"9#,)U5*WODW=O=L=^'%M=:YO-6;T^\
M)49[ZU*08F#XCL@/D*[:N8+F)+-3'>!&,=\;(XT$Y[&/*].]#UXH="OS68]&
M8OC#?OOJ[_9?#M_9#V:[[?:SXR<N$6 ,<F()4M=)HA&3]E.>_:/KQGP^PR%?
MUZ6Y7 L.G- &/%_6J"S='Q+0?T^]_C=02P,$%     @ 5E-65J4TJ0Q!"
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MV/[U[2?>-.'%HY*@]S,,*_I@0<L':']CJ/$/$W8P?@*M_P-02P,$%     @
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M)AJ5;+:J[495L: ["4N++?)$IQJKA,07!]44.,+J1N^,*<D>:T6,8VG%K+&
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MXFB,^#C,O)5((U(MY< "I\'L,[%%G)&KQVGD%GU+3_P?WUG+XDLKTI## K&
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MGY[L/K+5=+I-EEDA:OR+=N,G4)Q0SL[SM-M0.<DCF/."I2NW)#<CG/8F?<F
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M)5>BL6\7V8O.'/B-'D!<9_;\<Z=@XH86X/^-@3.Z"SI@?,7K];\ 4$L#!!0
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MFV6<8S]B7CL'PV!8;^ PUOB(60I3U#3%VD("*AX"Q\#KV<]KV'<52I*6<FG
MYL* ?;0,C#,]W\ ]S%W#0C4INJ&6/\QZ#2:PU'G;]S4?#T2W,WI4H/?=7?)M
M"^\6C9L[+-O3%/S]K2UF%M)U0QP8Z@J?<#X[SV*WV PFIGDJZ\O.S2P]#"]Y
M3$H:)B'UV54QZ-7MTI5+6HYF:,P*H[%I."3;5(:M';Z_=?T2KKC 6;J>&:8#
MY#F2";. Z_8]+;0J;MRB[:!D]>:XN(#4^J)I^V+=>N]F-8AI,1"$PQ$)9> I
M*,,*O,?MLYR$%;%KF@>HP;>-F=6;@FP)\8!G@3]SJV&%=4A7B"LX5K'*S%8(
M#!\JZ7P@!5:;V6 _0R78'$#,!MYW678#N '$@O4W.U2]*);M+5C;3?+#XL/K
M=V33U#7L!1@=Q//6X1O:S-)@E,D.LL*46,7.YY#(@H8/'6M26[L*3U7,K8;T
ME+;A9 D84/?OP550H F,8J]2H_O<@+ZT!-B_,Z?(.#, 2*U330!C>.LX)K"#
M^.*B_D"D73#DPBRHP)91B5K-=HE.45A3\YKA\')U[ZPH_(PM5T=?S EZX2%:
MIEAT=&  4) IR&DV/T]O/!205--Z4F@@M1K\V,?$F:EY0<8\T,^/$/$PC#A$
MA.[:)G4OL+4=-@B^TH(=S1?D?_ L#W*LF0@1 6G#03!]6,I^9ON./S>\[1GL
M'*T_(T[PUG:DGGX@),F<H3G@'!AA\H'<&%<;5;;!LRT0<IB:$D2#WKMW"%](
M>ZQ8EDA.YZ[&IS&UHI(TX6J@(V5;J53:I)NB.8X.P/="2JZW).PPOW"67O<#
M!P:'Y6J2O&+IX''AT2!-2AL]W3E+IT>,P7G2N@O35>+@9$N#A]<(=I?M%,$#
MHD"MO6QG9M->P1#(2*-(GXS>R-[N,HNM1SD"1G1XX=QOEW!!7W:2Q\5+6YK!
M!V[!%/=LN&"K !A6 (4P)J78;Z*"\ I;UF15U6^,_<4P^UTENC8=C%\SK&;B
M'V%J*K8>:=(M+QP4-<J$&.N!*#LN7@TL7*: OFY(=7J<$JF<H@T6M#K9B#1W
M5/=)\".(K^:/^6M5E[WCB-U@,5ODNA:=3IK8D.#8&\=^1VE@81)^'1=7@J$R
MLS6MW0K"\WKH8/0@R;M/7#3ZZR0\?+B&2^\[^]E61\4M;! 6Z$6<9J B(+5^
M"0>X6!8_#3">"$).CXNI,I]X?P?<O;4,JK&^$=H=>:XV3 K!=9TJ. E'LVA)
MY(^+URM,1RS:W8$B=:/./7IV.LZ,RZ+?V,$'>V.*JY',>; !OJ,Q*BT_7KY\
MR_S>^^QOU]-B@A$(P X15];)#M/C1T&,?CN^/J; B:4&\=30B<30;_%K<.H2
M)M:4RX&0E8>@V$\,-Q1]"=L"IL\%M;. )PY>E.1#*!4NPOFJAD0XS1LG<:K-
MT)0"9D6M28T%1H.4R.5 )\D;00UQ\BNWZ Q!&G*;%;G3X^(-&-#>"L5]Q]@:
MO_X"'\>20-$I'&/Q^\ J!,5JR)>02E6T?SP[-S<MBPQM07"O1BSB9.3@8 7Z
MQ[Q L6K%>;<!W!&E)?.740<89X,O!O"ADU4 ]OM0+31*DT&PQFRN'1YJV%P*
MU.5?F>9(*(%C@E (SZ!I",\&DC$:L<!)\*S@<9^HG_ '<PNS/:'A !J3!(O4
M?%6P,80Z:H[":IMA_4 *ZY $@,XKOB*[J,IQ3"H<E9 -#BM9A+IFK!*&0JD6
MF[U3-_X?Y+>_;<,)/_)!3"=Z?(RS71<\%C&LR!R%)*1 %?A<.3V]**GDL.%O
M^BB<DWND_QZ19S% 4 1UYA'BMXGNH%28 WRB+77VWX,E/TOL8,L!LP20Y(OW
M,,^482//2K2KM?H@R!=,G\J9OFQIDX=7'Z8OCS0>+'XM^S:I#(_&SP"$.#C"
M0* _+'S\@26^(SC72GA2A1,11<@.%Z+B>[-A=^W8C>(;GCI9YY$\_41 @['C
M7G>1Z?;I\PFV8I?,96+%PM8 0JL)4TMZT)"L-EEXSH!&@E;6&1Q!7&^2>0:6
M/O4*^6;^G&R^@H._9>^ <UWP1K,$ R=?Z,MYUZX(2:R<]V):YL5T-B-GR\3\
M@C-]U0T+.KX:3D#LS^'TEU?3(W&*R?$!)P&\E:S/IB$K%E5B3>D3B4\4082'
M*20*"V?L^+'>?#:KF9/0XGK3_([?-JS%B%:ZB@\I"AL?9\6@&[I(T69@%]-^
MU5$&YUR3/>QB,6F04 2KD%Y"HHH<A(&GWSY_5AS2'&]-7RX??S2?5X9_/3IF
MH7<ED'$'/'*[%5]DVZ#A.VQY5!#[A#M_FC4). A:CZA!;0: '4P-0=I@:CAX
M(B%0'!D#A/! 2H[A6T^VF1_7LQ87LUHC1*QTS"0D"&$_*@I0Q>Z(<4^VYS@
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M965T,C8N>&ULK5AM<]LV$OXK.ZJG)\^HE B^2')LS]A.VN:F33QQTIN;F_L
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MW(>Y3TQEMD@5L:WM1T@2%O:]'(5#)WLCTEN@:!K3Y^&P"QW>"U,221+&7:"
MZ?R)8#0:+'16-'A,%TIE#!J@=XZ/&V%?P&"^T<(*VNS<*(LPZ$+*XG  '3;H
MAR,B9,=IRD/>A0N<N^C<I=@(4WAB1]A8,M8%7PQ^ FG<"WFKW:$5&CU^CA*7
MPL*ZS"09)@/N??#A*!SX')C+Q1?VWVJR-$R@0Q#*DXUZ8>\=':"J\3@<D>1Q
M74U*B T8N=UWX:*=&5&A7OE):*B/&VGK<='NML/VM)XQ?^#UI+[.](J*#B4N
MR91*V@M U].O5JQ:^XDS5Y;FEU\6],- [0!TOE14UD9Q#MI?T.PW4$L#!!0
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M+D#U N^G6L!=\8D9?VRSHA&QKLT5F<],*20P6&3+KNV@"%VPX+(H'%>1N-G
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MU;FZC2Q/9]+1&?C1?O<;V+'#%R[ [<'](#Q0+^$$L-\5L6UT K:^<KZIQ>'
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M?6B;2O[D&W#6\P'\SK>#T@<>T+\*_?1?4$L#!!0    ( %935E9\PPT-9 @
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MQQB./Q$.LX=?,.?CGX?;Y>/_FS^T7Z,.L<9<0Q3=$FCX\9_(^!#<-OZ'6+J
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MC^FV^;4;JVK7<+;*8OMRRP+_%T"3 -[OE++'#1GH_T!6_P%02P,$%     @
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MK)2EF>./)0UYU$Z OJ^5LKN+(^A_&]EO4$L#!!0    ( %935E8R#5L0NP(
M ,L%   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;(64VV[;, R&7X7P
MBJ$% A]S7F*@:5<LP(H5;;=>#+M0;"86*DN>)#?MVX^R$R\#TNS&U('\]%,R
M.=LJ_6P*1 NOI9!F[A765M,@,%F!)3.^JE#2SEKIDEF:ZDU@*HTL;X)*$<1A
M. Q*QJ67SIJU.YW.5&T%EWBGP=1ER?3; H7:SKW(VR_<\TUAW4*0SBJVP0>T
MWZL[3;.@H^2\1&FXDJ!Q/?<NH^FB[_P;AQ\<M^9@#"Z3E5+/;K+,YU[H!*'
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M;H/M+J>,\XL7>W<K[D3^<7^3(G5>M>('D8BS((E9*C8O1Y?\^2MN4059XI=
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M9]=ND+)?W/ @ND8\B*E[Q!^ +B=JL37I0:$%P;_1+P'W-.!1 W@"X$$3N$_
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M!D-#?.NCB<##TJ.<P.Z";1QLD .$^KWLO&VO*S?;,?'; 8%-J (X<T(KD+,
MX_2K(:\+N0!]^\W2Y.9WU?.[':QPEHLT:@[XX^QNQK;)O4ACY02RV%;$WD-S
MO;,,4!L7CF6M2M6=U'?RT562[I,4D[2U<CH6P.#'J:K(G$9"FNEL[7J?8%JM
M+BVQ]%\6/KW_6?I3[VP)O98_93%K!?Q\A>YE=K=5:.+;-.%_2F+B&]GE=QF-
M0\S))7QNR2BA3'?933WK-YS)+4B2:3G 50U:YC53B&7R+<!TV(_+Q8G/N69]
ME==,]=G?H>7/,77?&9IM9:+E VM%AK9LK9;%.;RU7%"^?*IFB]06XGG>,.-\
M::&(O20E5O=E.^55Y;Y1-74_'H-\A\TJHQUM$#[ IN1J;(JHIUI;,*.L";,7
M2SB@:"42J.DW&J,RBR7QOYL6M$Q,5P:'?T[G,.^;P^;46A 93^[F7 632YE1
M<Z0L]$<GL^FH5<V1X4R1ZB*E?-3/2=O"8_E35FDG!OA(\8FAL>_TOH^'%'+/
MM;*G]RT.(ABWU,\I=>HGO5* ,*K/Y5^@!):296[-I7*6Z4XED,\&E  :8.'7
MU$RM\IJI(24P5H#!C26&5IE"YC53O4ILH:+\J;L\3;2](+LS3<U;=6_T2/T.
MB@&?F@N*GNPEV:A,M9HK\O^H)#@V 7I$$A8DI[V28$V!"-.,@H7KI#-8/?'O
MM A>,N:KXPF8/A4R#$;K%.749?]V$MW,I*[\*C?;6>##_BZ"HUVPW6&H88"!
M^"UK(*PJMN/%WBT5@D7JF(<V2[1=EL$Q=>T3(5%J?TB]G9L)BL'7%'<UY6W&
M/L@=OXJW4#$3C7[=_3Y-/@?H%Y:NK3Z3%M6V/7YU0(,ZV*/'24YU0\1+TE_
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M+59M!%I4L3S[)R80":D:&U.EB=H:;>B%01,$R4&I?[!&?8;6US3,$;I9AM6
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M:W)67G=2[-[5>$56L-*:&0V;)_B=8:5IN^<EK/#.UZ=D=A[VR[$ZP-AK9>@
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M+*!V&VB]4<H^*L[!]/NQ_@]02P,$%     @ 5E-65K[C0'&F!0  G@\  !D
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MUOE1\R,P)Z!:*U&)!(MXL@,>@0$9\<L/?,>]*,:$-ZL=]ZR/P%+D+5B-^PO
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MMHJ3N1CYCNWL:X=:J5.(6Q#14-A;6-,,]J\H3#9[%.9SC9."\#:K-8&$E0,
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M >VW.=Q4_4(3M/^E/?\/4$L#!!0    ( %935E9A2KS31@8  !T0   9
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;*U8VV[;.!#]E8$;% H@R!(IR7*:
M&$C2=IM%+T&2[F*QV =:HFVADNB2="[]^IVAY%OC. ':EXB2R>&9,S-GR!S?
M*?W-S*2T<%]7C3GIS:R='_7[)I_)6IA S66#OTR4KH7%5SWMF[F6HG"+ZJK/
MPC#MUZ)L>J-C]^U2CX[5PE9E(R\UF$5="_UP)BMU=]*+>LL/5^5T9NE#?W0\
M%U-Y+>W7^:7&M_[*2E'6LC&E:D#+R4GO-#HZ2VB^F_!7*>_,QAC(D[%2W^CE
MHCCIA01(5C*W9$'@XU:>RZHB0PCC>V>SM]J2%FZ.E];?.]_1E[$P\EQ5?Y>%
MG9WTLAX4<B(6E;U2=Q]DYX\#F*O*N+]PU\Y-ACW(%\:JNEN,".JR:9_BON-A
M8T$6/K& =0N8P]UNY%"^%5:,CK6Z TVST1H-G*MN-8(K&PK*M=7X:XGK[.B+
MG4D-YZK&D,Z(ZUL)%TVN:@G>1V7,(7@W8EQ)<WC<M[@?K>KGG>VSUC9[PG;$
MX)-J[,S NZ:0Q;:!/@)=H65+M&=LK\6W,@^ 1SZPD+$]]OC*>^[L\2?LO?N^
M*.T#_'LZ-E9C@ORWR\G61+S;!!7-D9F+7)[TD$(C]:WLC5Z_BM+PS1Z \0I@
MO,_ZZ!J+L%A4$M0$3O-\42\J864!SX9MER-[M]KMR,U,PD156+IE,P5+F=#5
M;_E#&D 4;5T1BUJVV*P"*?(9()JY:F1C";QR@/,MP&4'N"+ 1^"=UFK16 -N
M^X9,-=(MMN(>$Q"P#+'(&CA?:"V;_ %NM&@,;DKE_0<*D&F=I[E?&Y2H"D$6
M\!F-_/0KSK^6^4*7MD0OWLH)<E' F6QP9.&RTQS1%' E;:FEA ]HS<[64RK<
M&=Y-)M*I"EPJ[5 @V'-A9O >&<,UQ13-/Q<W H6&IV73$,EC@;9SY-7"GZ)9
MH%)"F_ A'( 7^>D@"\)#',?!D+[$?LJS(*4O'HNB8.A&J9\P3E^_/$<\C"5J
MN\3PY94PIIR4N6/4 $O"(($TR,#C@V$P0"V(. \R?+(D#=BAHU:XJ&TL1S<G
M6M68&&N_=X6?=H?7KS(6L3? @PA8.@@X1#P(@64\B)WY9Q.G@SE$-KPH8D%,
M,%E(,-D@8'"VYA/E0]9C-,>7C"*?,<Y*#B&*R<_8'R01T>MQSIS'J1\/4S+Z
M"T0BGM98&Y[(SQBY%X5ID.+;8)ATSOX>+M%WX'&,-$9$*T\&R,W+N-Q$&B&!
M?H0Q0:01AI_>$HX1VL-H1(PF&!!,#HY+/.8GF<M#S$WNB(U]'G,R_BN$<A:[
M0">,=F+#"#. (I8!BP>X[Z^3&3JW\0]C0S0[Q$RB1,M>2B0A=.ZZ3$Q8A,3Q
MF&%0XF&&:+$E_E3M/W/)VGK/!C'Y>$!%2+11F?MAR@).XPC1.6'@?H8A1Z))
MLE$P03IQ,J1U)-,DI;])JK$C:&?S00IM0%)SWT9_)S%LPG2MPQS!#0(:=]KI
MR7L\4AIYV#KILL85XU+?\Z6^VPU]GY*"]RLGX.3O(.F4+N)IRT_$,N1X0_C)
MY:UE:,:L99^T D44DS0F+I==8 ESOM$%=-<%9FT76$UQ7<##\J4$3S#_,.(Q
M"<FZ,\S7G2&GSC"ASC!K.X,W#,D)CT>4([@\6C:8OC?7ZK8D "W=70!<)P2!
MK.;+ #X?KM+*VG%&"1RV[0$QN_S!PSN*PYZ32K(ZJ20O/ZETC?Q*YFK:N%B4
MS9.];]=19>]>NX\J5X]4 N\@A.9%Y?XH8]]**\H*N1Z3F<<]_!_,_?9<NYWZ
MIR[R^/4C@H8+I)Y\IVHY1TRJ*@MGY-KB R\W5* 3^#*7>METMVL"J<3\^2&6
M.=1F(BU<9:$+[Q%<ZA+SA,@H44^Z'XWOJN# *67L0I\DZT'8J7#7.7"J#UZ;
M/(?0E2GZ;O$44HH*NC(B_>8H8Y0Y?$CCYXW<*(L&.D$G>6)N><P3I]Q4N5L:
MD;K^XY&PXV/@>O+%9@U\7AT-.X5N.UY[AG!X_(WC(Z#^NG8XA"C%,GLIX,>M
M9ZE]&+%2%5M[''0=XJ!KN0?=,697=?4WKFRUU%-W,368F5@X[>UM]75U]SUM
MKWSKZ>W%^9/04SK=5G*"2\-@@,6CV\MH^V+5W%T Q\KB==(-4<@*J6D"_CY1
MRBY?:(/5?P1&_P-02P,$%     @ 5E-65L;LKX(, P  BP8  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#,N>&ULA55-;]LX$/TK [4H+""51$K^2FP#2=/%
M]M!LD.RVA\4>:&EL$95(EZ3B]-_OD%+4%)MX+R*'G'GSWI <K8[:?+,UHH/'
MME%V'=7.'<[3U)8UML(F^H"*=G;:M,*1:?:I/1@450AJFY1GV2QMA5319A76
M;LUFI3O72(6W!FS7ML+\N,)&']<1BYX6[N2^=GXAW:P.8H_WZ/XZW!JRTA&E
MDBTJ*[4"@[MU=,G.KPKO'QR^2#S:9W/P2K9:?_/&IVH=99X0-E@ZCR!H>, /
MV#0>B&A\'S"C,:4/?#Y_0O\M:"<M6V'Q@VZ^RLK5ZV@1084[T37N3A]_QT'/
MU..5NK'A"\?>MR#GLK-.MT,P,6BEZD?Q.-3A6< B>R6 #P$\\.X3!9;7PHG-
MRN@C&.]-:'X2I(9H(B>5/Y1[9VA74IS;_.%J-/ >;M"=P>23*G6+,7Q\I$.W
M"),_Q;9!&Z]21[E\1%H.N%<]+G\%EW'XK)6K+7Q4%5:_ J1$<F3*GYA>\9.(
MUU@FD+,SX!GG)_#R47D>\/)7\&ZTHJMMA)-J#[UPF S"8_C[<FN=H3OSSTO:
M>^3B963_CL[M092XCNBA6#0/&&W>O6&S[.($[V+D79Q"W]S3NZRZ!D'OH#^]
MDTI>HG\Z00!]]V;!&;M0X5K(X5K@<"U*38_2.JP\!_*&G6[H=5/Z\W Z_L/\
M)R,Z#JD&;HQ]"WG.DED8E\G"C],EV:.C' 3,>+*(8<*G24%#GB=9[&\I[3^0
M&_4%!Y,]=1T;0Z.M10OTR/%[)]T/L%AV1CI)BY,;[1#F,10L2^8P8?-9LB1
M=E84/.$Q7./6L_/%ZZ2M [ ''"(9BR$4@U] D4T3/EIWZ*3!X+]%A3OIX- (
M18'YG(<<?+%,YD$#\UKZT_I/-5F1Y# A%]+)EM-D"O]_ E0UGB5+&GG65Y,$
ML3FCM"]=L?19@VC1[$,;M'2.G7)]KQA7QTY[V3>8G^Y]F_XLS)Z*#@WN*)1*
M.HW ]*VO-YP^A':SU8Z:5YC6]+= XQUH?Z>IK(/A$XS_G\V_4$L#!!0    (
M %935E8V;+&=NP(  *X'   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM
M;*U574_;,!3]*U:&)I!8\]$6)M9&:LD0/#!55&P/TQ[<Y":Q<.S,=EOV[^>/
M-*0H99W$2V,[]YR<>VY][V3+Q9,L 11ZKBB34Z]4JK[R?9F64&$YX#4P_2;G
MHL)*;T7ARUH SBRHHGX4!!=^A0GSXHD]6XAXPM>*$@8+@>2ZJK#X,P?*MU,O
M]'8'#Z0HE3GPXTF-"UB">JP70N_\EB4C%3!).$,"\JDW"Z^2L8FW =\);&5G
MC4PF*\Z?S.8NFWJ!$0044F48L'YLX!HH-41:QN^&TVL_:8#=]8[]QN:N<UEA
M"=><_B"9*J?>9P]ED.,U50]\>PM-/E9@RJFTOVC;Q 8>2M=2\:H!:P458>Z)
MGQL?.H#PX@ @:@#1:\#H &#8 (;' D8-8&2=<:E8'Q*L<#P1?(N$B=9L9F'-
MM&B=/F&F[$LE]%NB<2I>NG(CGJ,E*1C)28J90K,TY6NF""O0@E.2$I (LPS=
M534%776%;=4TZILN[0UAF*4$TRYNJ30 BTRBTP04)E2>H4_H<9F@TY,S=(((
M0W-"J::1$U_I5(P@/VUDSYWLZ(#L,$+WG*E2HJ\L@VR?P-<>M$9$.R/FT9N,
M":0#- S/411$48^@Z^/A80\\.1X>O)'-L"WKT/(-#_#UU>_G;"65T!?M5Y_?
MCF_4SV>:SY6L<0I33W<7"6(#7OSQ0W@1?.GSZCW)DG<BV_-QU/HX>HL]GF4;
M$(I(8R0\ZUXKH<\\1S*V)*;1;F+]']AT'7$1E]V(0;0?D_3%O/#LZ1^W^L?_
MJ_\<U2!2<X4+,!=8P ;8NC<MQQT&'47!(!B_2NVHJ.1?42X]O]/)*A"%G0@2
MV3^SN\OM:3MT9K;7OCJ?ZV'D9L<+C9MD]U@4A$E$(=>4P>!2*Q-N.KB-XK7M
MERNN=/>URU(/5! F0+_/.5>[C?E .Z+COU!+ P04    " !64U96&!Q$6ZT#
M  #N$   &0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6RU6%UOVS84_2N$
M5@P)T%G?LIS9!IIHPPHT0Y"@V\.P!T:ZEHA*I$?2=KM?/Y*2%<F1A:137BR1
MNN>0YY!7XO7RP/@740!(]+4JJ5A9A93;*]L6:0$5%C.V!:J>;!BOL%1-GMMB
MRP%G!E25MN<XD5UA0JWUTO3=\?62[61)*-QQ)'95A?FW:RC9866YUK'CGN2%
MU!WV>KG%.3R _+R]XZIEMRP9J8 *PBCBL%E9']RKQ/4UP$3\0> @.O=(2WED
M[(MN?,Q6EJ-G!"6D4E-@==G##92E9E+S^*<AM=HQ-;![?V3_U8A78AZQ@!M6
M_DDR6:RLV$(9;/"NE/?L\!LT@D+-E[)2F%]T:&(="Z4[(5G5@-4,*D+K*_[:
M&-$!N-$9@-< O%- < ;@-P#_I8"@ 03&F5J*\2'!$J^7G!T0U]&*3=\8,PU:
MR2=4K_N#Y.HI43BYOH<]T!V@BX=ZX1';H&/?/:0LI^1?R"[110(2DU)<HI_0
MYX<$7;R[1.\0H>B6E*5:0+&TI9J.)K739NCK>FCOS-"NAVX9E85 O] ,LCZ!
MK72T8KRCF&MOE#&!=(9\]SWR',\;F-#-R^'N #QY.=P94>.W2^,;/O\<'Q$X
MSSGDV&1(9V'^^J1"T4<)E?A[R/>:-QCFU6^2*['%*:PL]:H0P/=@K7_\P8V<
MGX<\FY(LF8BLYV?0^AF,L1^W^N!.K9%S@]2OROW:B\/ G05+>]\U8RC.=^/3
MN&0@+@C]Q2QNXWH2PE9"."KA=_4AV'*6[5*I7KI&SI":49+7KO^49,E$9#WS
MHM:\Z(WR*9K2SRG)DHG(>G[.6S_GWYU/-3+N[O\PB+S._J_-&(I;A//9XB2?
M!N*\:!&<RZ>XE1"/2E"GA1(_,E[O"$PSQ&0!?"RW1@E?NQ>F)$LF(NL9N6B-
M7+Q1;BVF]'-*LF0BLIZ?KO-T+G.^.[L::#<=?&<>SZ*3[!J(\_S(F84GV=7$
M19TX-P["X=QR.T=+]_]D%\)"L)1@"9DZ],I"?=D(XV@+ZI(AR3$5&^!";R9"
MI:H,5*FPPZ7^ *H8^6W0F=$9O78[3<J63,767PWO:36\-TK1AG@J4Z=D2Z9B
MZYOZ=$1W1T^LXUGJ/SL$NI'_[$C9A(7=L/FS#!W@\L-.PM?SMSN%8 4\-P6U
M0"G;45F746UO6[1_,*7J2?^U+N9-@?E$4_\3<(MY3JA )6P4I3.;JXGSNKBN
M&Y)M3;GYR*0J7LUM 3@#K@/4\PUC\MC0 [1_<:S_ U!+ P04    " !64U96
MD>N?%'H%  !+(@  &0   'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6R]6FUO
MVS80_BN$!PPI$,22[#@O2PPT5H<5:(8B6=</PS[0TMDF(I$:2=M)T1^_(R5+
MEJ<P=LKL2R+)=X^.S_&.?"1=K85\4 L 31[SC*OKWD+KXK+?5\D"<JI.1 $<
M?YD)F5.-IW+>5X4$FEJG/.M'03#JYY3QWOC*7OLLQU=BJ3/&X;,D:IGG5#[=
M0";6U[VPM[EPQ^8+;2[TQU<%G<,]Z"_%9XEG_1HE93EPQ00G$F;7O??A91R=
M&@=K\2>#M=HZ)F8H4R$>S,G']+H7F(@@@T0;"(K_5C"!+#-(&,<_%6BOOJ=Q
MW#[>H/]J!X^#F5(%$Y%]9:E>7/?.>R2%&5UF^DZL?X-J0#; 1&3*_B7KRC;H
MD62IM,@K9XP@9[S\3Q\K(K8<PM$S#E'E$.TZ#)]Q&%0.@WT=AI7#T#)3#L7R
M$%--QU=2K(DTUHAF#BR9UAN'S[C)^[V6^"M#/SV^@Q7P)9"CWZF4U.3@'3F*
M05.6J7=7?8VW,(;]I(*[*>&B9^#"B-P*KA>*?. II&V /L96!QAM KR)G(@Q
M)"=D$!Z3*(BBCH F^[N''>[Q_NZ!8S2#FNZ!Q1L\@S=94#X'PCAYGR1BR37C
M<_)!:88S&,A?G]"<?-20J[^[N"^QA]W8ID-<JH(F<-W#%J! KJ W_OFG<!3\
MTL6;3[#8$UB+TV'-Z="%OIG"QZ0 :1LA3X"(:<;FU+06O$Z?L%-IHD'FZIBD
M]$F1F10Y'B'I8D;4@A7&XMA4&,N7>1?Y[B &@<7M(MKI>"C1GL!:1)_61)_^
M?T33Q^>(=@=Q]CS13L=#B?8$UB)Z5!,]\DKTC'$T,:TD$7DAN&48?9E(R13T
M&H 3+2E7,Y F#0FV:(E+#>5I#24A 59H<B0DR4!U-W]WV"%Y BJ[,N/T.S0S
MGL!:F3FK,W/V8YE1%,E#,J=FQF^XK5)QM"R(%IW$NN\Z(KE=5+NH=7H>2JTG
ML!:UYS6UYWZHU4O)<=(74J3+1!-X+)BT)K;-=+'KOG$T=-#K=#V47D]@+7HO
M:GHOO-)+5R"IW:J@GQ;R";O""C)W?W"'$)8\=]'L=#R49D]@+9K#H-E0!W[G
M,<@$&39<8VOF8%IQM2<W/!.-6\;NG7@91UAN[8W 6XV#DP WR:MM:O<SBU\T
M:].QI2]")QU?3NY/R'=RWQYTV2#--,,E*&7*[H6["O#&#7_HIM<K6NP+K4UM
MU% ;O:&8J,!]$>L3+?:%UB:V$6FA4Z\T)<QX^63%+"Y+!2DNWR0%L^LRW&[J
M%+=.8L[9-TB/25+GA#8Y@2HG=;&[NV@5G:G([5(,=PM[+[/X1;,V28WJ"MV*
MYX^%!""?J)SC\,C7A<#QV"+_3C8/%6Z )XN<R@>\=ELJ*SR:V*<:N!.="&[(
MJ!;O.Z8>.MGPJ9\F7M%B7VCM%#1Z+#Q]RP;@4R]-O*+%OM#:Q#;Z*W0KF?;,
ME#@SM]?I3C)'7546CG9K=B^S^$6S]K@:]1*ZA<2A-5N*]%?4K$]5,O&*%OM"
M:Z>@43GA^5O6K$\],O&*%OM":Q/;Z)O0K2Y>4;,77546_6>=W<LL?M&L_?B[
MT1.16T\X:K::00J+-P&VHM,,?F2E=0=RZ.3RBA;[0FLGH5$Q4?B&51MYU3!>
MT6)?:&UB&PT3.;?RKZC:"G!W;3S?J=K]S&)W>*\=?J,T(K?2.+RX7[LDNP,Y
M> YZ?7OD"ZV=A$;)1,.W+&ZO^L0K6NP+K4ULHT\B][N:5Q3W:><B>K%;W'N9
MQ>[P#AU^?^LM.];=W'ZMH(B=,>7[[/IJ_47$>_L=P,[UF_ R+K]K:&#*SRQN
ML1$PKD@&,X0,3LYP ++\<J$\T:*P[_*G0F/QV\,%T!2D,<#?9T+HS8FY0?W]
MR/A?4$L#!!0    ( %935E:Q+4<S*@(  !L%   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;*U476_;(!3]*XA54RIUP1]MNF6VI=;1M$FM%"7J]C#M
M@3C7,2H&#TC<_?L!=KQ4<K<^[,7FPCV'>PY<DE:J1UT!&/14<Z%37!G3S G1
M104UU5/9@+ KI50U-394.Z(;!73K034G41#,2$V9P%GBYY8J2^3><"9@J9#>
MUS55OVZ!RS;%(3Y.K-BN,FZ"9$E#=[ &\] LE8W(P+)E-0C-I$ *RA3?A/,\
M=OD^X2N#5I^,D5.RD?+1!5^V*0Y<0<"A,(Z!VM\!<N#<$=DR?O:<>-C2 4_'
M1_9/7KO5LJ$:<LF_L:VI4OP>HRV4=,_-2K:?H==SY?@*R;7_HK;+G5UA5.RU
MD74/MA743'1_^M3[< ((+U\ 1#T@>BT@[@'>.=)5YF4MJ*%9HF2+E,NV;&[@
MO?%HJX8)=XIKH^PJLSB3K>  8@]HDDMAE#45W3&Z89P9!OH<319@*.-V] X]
MK!=H<G:.SA 3Z)YQ;H]!)\38*AP7*?H=;[L=HQ=V7$ Q17%X@:(@BD;@^>OA
MX7,XL=H' Z+!@,CSQ?\PH%2R1H,)+3,5RKW]H-#WFXWV\S_&Y';\E^/\K@OG
MNJ$%I-BVF09U )R]?1/.@H]CXO\3V3,KXL&*^&_LV:">_[D"8X([EFO/XEZ)
M0Q:%'Z;V+ ^G2D:R9M%T-F1U)9*3J^N>C7NJ=DQHQ*&TN&!Z;1M-=:W8!48V
M_C9OI+&'XX>5?;U N02[7DIICH%KD.$]S'X#4$L#!!0    ( %935E9A;.G&
M-A0   #C   9    >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;+6=[6\;1Y+&
M_Q5"MSAL@%MINJ>G9\8K"XC966P.EW.0MP/N<!]H:2SQPA<?2=E1L'_\DA*E
M?JF::@WSC#\DEESS,Z?4Y7Y8K.GG\LMZ\^OVKNMVD]^6B]7V[=G=;O?IS<7%
M]OJN6\ZVY^M/W6K_)Q_7F^5LM_]R<WNQ_;3I9C>/%RT7%[HH[,5R-E^=75T^
M?N_[S=7E^GZWF*^Z[S>3[?UR.=L\O.L6ZR]OS]39\S=^F-_>[0[?N+BZ_#2[
M[7[L=C]_^GZS_^KBA7(S7W:K[7R]FFRZCV_/OE9OG&K;PQ6/(;_,NR_;X/>3
MP[U\6*]_/7SQ[<W;L^+PDKI%=[T[,&;[_WWNIMUB<4#M7\C_'ZEG+W_IX<+P
M]\_TOSW>_?YN/LRVW72]^*_YS>[N[5ES-KGI/L[N%[L?UE_^WAWOJ#KPKM>+
M[>-_)U^.L<79Y/I^NULOCQ?O7\%ROGKZ_^RW8R:""Y3MN4 ?+]#I!:;G@O)X
M0?G:"\SQ O.8F:=;><R#F^UF5Y>;]9?)YA"]IQU^\YC,QZOWMS]?'7[P/^XV
M^S^=[Z_;7?W0?>Y6]]WDSVZ^G=W>;KK;V>//8_UQ\OQ''QXFWV_6-_?7NZ_V
M8=UN-E]LOYK\9?+SCV[RYS]]-?G39+Z:?#=?+/;7;2\O=OM7=6!?7!]?P;NG
M5Z![7H'2D^_6J]W==O+-ZJ:[B0$7^]MYN2?]?$_OM$ATW?7YI%3_-M&%ULP+
MFK[^<L5<[EY_>2'<3?GR$RH?>64?K_<'\S__L0^=?+OKEMO_Y?+^Q#4\]_ O
MRIOMI]EU]_9L_T_&MMM\[LZN_O5?E"W^RN4,"7,@6)1/\Y)/(]&?5SR[4I^N
MK!^O//R3^?E*-Y51Y^;RXG.8#"ZN5$T:YY@X4Y7M>?,2%]U"]7(+E7@+/Y__
M>,Z]?/&JH3]P),R!8%&V[$NV[$@%9)'Y1,(<"!;ELW[)9WUR 3U=:8,%KQK5
M%DGY,%&V42HIGJ>H)HPR6K?G)5\\S<O+;\27__Y^MYW?=).^(A*O'OI#1\(<
M"!9EK7W)6CM2$;7(?")A#@2+\JD*+[R*D\OH>&FT]HNR4L':?\H'%ZBJHB8[
M$4]4Q7G%5Y,*!*02[\/-9Q^Z7;>=_*.WI&3"T#4 I3D4+<Z>]MG3(]75$8Q*
M*I+F4+0XJ5XQ*U% RJ55DD)H6Z7.55I9-*ZI57NN6_\KK3%Z2=T6;8".[\<K
M5B5+UJ#$<KN73!J\*I TAZ+%6?2B655CE1I46$-I#D6+D^JUM1*EIEQJEM2#
MJ:KRO$Y+C8DSM@G>)1UOE<:5K:[Z!*'R@E;)BO:GS?UB?CW?/>P34YN_2CN9
M"!J\$I TAZ+%2?2R6C5CE1=4<D-I#D6+D^I5MQ)%J%Q>+2F'RC:D;*9,G&F5
MH1*1QI5-69VW?'EIKW2UK'1I>>5V,1DX=$5 :0Y%BY/IY;96(Y69AJIP*,VA
M:'%2O0K7HB 5R^QX:?3.J:Z*\T3]3;FXJJK/;5)F7)PN];GN*3.O>K6L>O]]
MMKF9SU;7W5.9L?<";0E#:0Y%B[/G-;8V8]455')#:0Y%BY/J);>6&]5B756D
M"Z@+:].JJI@N8%L0;<C%J;W6[.FT:R]PM2QPDZH2M*$,&KP.H/UB%"U.HA?8
MNAZKN*""&TIS*%J<5"^XM=S(%HNK8<JA-4&W[Y@0&M<4==IF=$R8U45O<7EY
MJV5Y2XLKJPRA[60HS:%H\<?$7F:7Q5@?%$/E-I3F4+0XJ5YNEW)W6RJRXZ5)
MBY#4&!-FFS(-<\>P<#^LRI[61NF5;2DKV[_?+V>+]6UV\Y(Q@Y< M)N,HL4I
M#.8O1AO P$Y@8$<PQI#;I9?;Y>E3&,=+D\U+D7=<7%RYWY;JM+*8.--4P3NS
M^":\O"UE>9L65V[SDG&#UP.TCXRBQ:GT,KL<:TBCA,IN*,VA:'%2O>PN3Y_4
M*.EX16,;TIMGPM2^R(A"9.-,T=>;+[W*+665NZ^Q^_WW\AL8M(D,I3D4+4ZA
M5]GE6+,;)51M0VD.18N'"+W:-J>/;Q@Z;%&71=#A>\H'$];L2RO]6)D+LS9H
MW\=WX*6MD:5M6EFYW4O&#5T,4)I#T>)4>I5MQIKB,%#=#:4Y%"U.JM?=YO0I
M#D-'+733T@JC8>4^+&W)<V%MV=>1-\&DL2QRW\WVRV(QV_0WY&7 X!\_M'>,
MHL7)\^+:C#6N8: R&TIS*%J<5"^SS>GC&H:.5]2VH+/O-*QI-6EG,&%*:=.[
M;7E1:V11&Q>5H AESN!E &T=HVAQ#KVH-F/-:ABHS(;2'(H6)]7+;'/ZK(9A
M9C!JTJF8,F%5TY W6TQ88W3?>ZW*:]I*UK2DM'*24.8-?N($VCA&T>)<>G5=
MC36G44%U-I3F4+0XJ5YG5Z?/:51TKN(@"=,28\+*PJ3*T;$TW3?*6WE16\FB
M]KOU_>K_9IMU=O>2.8-7 ;1WC*+%.?2RNAIK5*."RFTHS:%H<5*#1PI/']6H
MZ'!%:6WZ-FI:T8F.(BTK*21^Y5[35K*F)265W;6@'6,HS:%H<2Z]N*[&&M2H
MH&H;2G,H6IQ4K[:KTP<U*FY0HR(?=1W#Q-*20N)7[B5M)4O:][N[;C.YR3_A
M)7,&__2AC6(4+7[XV(MJ.]98AH6J:RC-H6AQ4KVZMJ>/95@Z;Z$M>39_RH55
M%?GPF UK^H2@]5+6RE*6E%9NUY)Y@U<#M%.,HL6Y]*+:CC6A8:$J&TIS*%J<
M5*^R[>D3&I9.5)2V)D^>,&&F4*3]SM&,Z7LRV7I):V5)^WYUO5ZL;Q^$?4LF
M#/[Y0UO%*%J<O>#4C-&.S<">FX$].&,,?6V]OK:G3V18.D)1:M60)Y.YN$+3
MQR69.%VWO3T,Z_6LS9R@X>LJNVE!V\50FD/1XBQZ;6W'FLJP4+$-I3D4+3Z9
MQHOM^O2IC)K.46AC:'UQ<;6BGW!Q<96N^SXVKKVXK65Q^TNW^;U;S?,]0IDS
M="% :0Y%BW/HY74]UD1&#=794)I#T>*D>IU=GSZ14=,9"F6KDHQD,'%-:<C0
M$Q-F]WMA7VUY55O+JI;45FX'DWF#EP.T98RBQ;GT^KH>:T*CALIN*,VA:'%2
MO>RN3Y_0J)G1B[(@AT(=PZ(G2139O2A+M[WC&75P.)RL<*</F]GR]UE^[X+V
MBZ$TAZ+%*?3ZNAYK.J.&RFTHS:%H<5*]W*Y/G\ZHF9,O*GKJ)QM&]*/CPAK5
M=XQ&X[5M(VO;M+*R!QE"V\=0FD/1XE1ZA=V,-9S10"4WE.90M#BI7G(WIP]G
M'"\-MR2KTV-!&SIS86M#^AI<6-7[,'+CU6TCJ]NO%_/E+K]QR93!*P#:,D;1
MX@QZ<=V,-9C10%4VE.90M#BI7F4WIP]F-'0PHS+T@#4F3.FR)&^ZV#C;>\!:
MXT5M(XO:I+2R.Q>T@0RE.10MSJ27U\U8 QH-5'!#:0Y%BY,:G A]^H!&0\<J
MRB95A@USC(:N2<>0"5.%-4&]QC?@Q6TCB]MO-A_FN_O?\GL7M',,I3D4+3[>
MVJOK=JPQC1:JLZ$TAZ+%2?4ZNSU]3*.E@Q5549!N/!-F]N^F4E'(AA5]GW6U
M7M2VLJA-*RNW=<FXP8L!VCU&T>)4>GW=CC6ET4(E-Y3F4+0XJ5YRMZ=/:;1T
MKN+PW' 1_"+5-O@2QUQ2V3[)V'K9V\JR]Z>'SP^[_@<GY:L'+PEH!QE%BS/G
MQ78[UN!&"]7=4)I#T>*D>MW=GCZXT3*#%FU)VO),F*'C'8X)*XNF3R.V7N2V
MLL@-"DI0B#)D\!* =I!1M#B!@0/*:!8H6 \4K G*."XHH0W*'_%!*<B[K[1K
M^(H8)\<D+SUP/BED>1N75-::0:8-7098G(/ADFSJ()NC6:$46"\4*,[!<$EF
M SN4X@_XH13,41K,[L7%<=L7%R?L7ZH(7% *6>L^C<RO\U.]&=#P]0#M)\-P
M22(#(Y1B-">4 FN% L4Y&"[);."&4OP!.Y2".1+#TB>4V3A-.B..BS.V[U1#
M501V*(4L=DFAY;<VK"\*%.=@N"2A@35*,9HW2H$U1X'B' R79#;P1RG^@$%*
M02<Q=&6HU1<7I^@YHER<JGK/W5"A%V#&#/#;Y?)^E=W69,C@M0#%.1@N26)H
M1#C65(=".Q2"+0I'D>:A2:%LV"=7F6(,30XG0A$?(C:0Z>6S@64M%%H@A3/6
M@%&A9;<U&39\64 [SS!<DLQ D*NQYCT4V*<0;%0XCE-A:%4HV_9E"H[S1*E(
M'4V? R.C95,3VTJ.5T3')";W$>CAC#W@3[/%[O=LTS%#&;X:H)UG&"[)8J#'
MU5A#'PIL6 AV+!S'LC#T+)3]^S)UQHQKU-J0<V_8P,IHZK#'!>JFZ3=A#H1P
MQBDPKK3\S@9M26-Q#H9+3)D#/:['F@916.]"+,[!<$EF Y$N6_G)%:?I%$==
M$3/S*1=G:W)4J7N.BYZ$*?H:_X%=H,KX!;Y?W"_GLY7P^72&,'P9@/VY1VE)
M!UZ%2H\U#**P)H98G(/ADLP&HESV],L4&!W6.#Q!EEH6<7'J<"X5Z4$R@;9L
M^AYV48%UH,IX!\8U)JE'&31\06![TBA<DLA @^NQYD$4UM(0BW,P7)+90)?+
M#G^94F,<44Q#GH?FXDI-FI2.B[.]_I8JL!%4&1]!4FA9\2@#AR\+;$\:A4L2
M&DAQ/=:@B,+:&V)Q#H:+,QLX'"K9[4\NN)*>QV$;XE0T?8X+16'=DG)CHJJZ
M[WU:X">H,H:"3Y^MS5_5[Y=1@U<#%.=@N"25@0HO1QL8P=H=8G$.ADLR&ZAS
MV?TO4V<EJ0SR*.=S4-P2(0?99UC)ZP\T<,9=D"FR[*8F(X<O"6Q'&H5+4AK(
M\7*TF1&L[2$6YV"X)+.!/I== #/%QLV"T$^PN;":'+3(AIG>/G]@-*@R3H/_
MV=UOUMOK>;>Z[L0=#=N.AN(<#)>D,9#BY6AS(EC_0RS.P7!)9@--+ML!9HJ,
MSG581=KW4SZ.'E# Q9FF[OWX.C =5!G7P:3.LIN:C!N\*J X!\,EZ0S$N!EM
M8@3KAHC%.1@NR6R@S65S0+G>#)WO:,N2?G[-Q.W?W9/S#=QS8/1!=VEZSK)2
M@06ARG@0?K.\G2WFNX=\$U(&#5\/V*XT"I<D,E#D9K11$:Q'(A;G8+@DLX$P
MERT#,Y5&1SN,94:SN+C2D ,,N+A25[WM_L"84&6<"4FEY?<V;',:BG,P7)+0
M0)*;T89&L,Z)6)R#X9+,!BI=-A+,5!PSXM'00X;9.*.9K8TY?Z3O69K JU!E
MS K_^V&?G-_RIUUE.,/7 K8CC<+%>0P<$U4UVJ (UCP1BW,P7)+90)O+7H)R
ME55T *2D5K5L&+5_YL*,[3L[1 5VA2KC5YA6679/DWG#UP2V+XW")?D,Y'@U
MVM0(UD\1BW,P7)+90)_+]H*9:J-#'F5AZ=0(%]<RS]%P<;;HG8(,3 Q5QL5P
M^K#\,%N\XA3'#&CX>L VI5&X))&!'*]&&QK!VBMB<0Z&2S(;Z'+9;3!3:<PP
M"#W/D0UKF#IC3ASI]7]1@:&ARC@:DC++;VS8]C04YV"X)*&!'*]&&QG!6B]B
M<0Z&BS,;N"\JV8E0+C?+6<(0@3CEX@[S_:3QS\35NNK]@"WP.U09P\.G3[17
MK_R8388-7A-0G(/ADF0&LMR.-CABL0(=BG,P7)+90*#+IH29:F.L7RJJ(BV=
M"5%%ZL_.P>JRSQ]&!;:'*N-[R%9:=G^3H</7!;9)C<(E20UTN1UM>@1KT8C%
M.1@NR6P@U&7'PDS%,?,>#;>_,68P!3V_F(W316_[/_!%5!ECQ*>JD[8T;$\:
MBG,P7)*_0)';T29'L!Z-6)R#X9+,!M)<MBS,%!AWP@AUD9[R@8>C54F),6>,
MV,B^.KZ3P!M19<P1GVLLNYG)G,$K HIS,%R2QT"+UZ--C6 =&[$X!\,EF0V$
MN6Q@*-=:38<\6DM:_C4S,U+9DNYE7*#1O0YH*K!)5!F?Q.G[7[YU?U'M9+;:
MS3^L;^9]=X3M24-Q#H9+TA@H\7JTF1&L:R,6YV"X)+.!')=-##-U1D\-T06=
M\.?"M"$GK]9T8J2I5>\;M< H466<$IDJDP2D3!N^)+!M:10NR68@P.O1QD6P
M5HY8G(/ADLP&TEQV-LP4&QT#T471I-9,T^? J"O2UJ0#R80U5=\3-8%[HLK8
M)_+%EE>2V.8T%.=@N#BK@:.C:D:;'L&Z.V)Q#H9+,AMH=-GL4"ZZALY[*$/?
MLS%AVA);4,?&]>]P@:&BRC@J_FV]V75Y&_@,9OA:P#:E4;@DC8$<;T:;&L&:
M/6)Q#H9+,ALH=-G[,%-EW)1'39_'9N*,471*BXFK5-'[5$W@L*@R%HM)G65W
M-1DW?%5@6](H7)+.0)@WH\V.8)T?L3@'PR69#42Z;(28J3?&AL94=-:?B3M,
M7Y%GLX]QT0D(9=]'V8'9HLJX+4[GL\5\^XI=#=N7AN(<#)>D,5#DS6@C(U@;
M2"S.P7!Q9@,G2"6[(LI5UM(1C[*BI_HP8?N]BNQI3)A5O8?Z!,:+*N.\F!19
M=DN3<8.7!!3G8+@DG8$2;T>;&,$Z0F)Q#H9+,AN(<]D@,5-L=,BCJICC#YBX
MNJB)OS7+VV^1?2W_P(9197P8LY]?R]</7P;8CC0*E^0OD.#M: ,B6"M(+,[!
M<$EF S4N.R-F"HP[$,0PVQD35UIZ2!T3IXWM+[! ^F8,&%_]X;7,&;X<L-UH
M%"[)8Z"^V]$&1;#>D%B<@^&2S :"7+9*S!3:T[5U]+&THLT0)DZ7);.3T;A2
M4^5XL;WKNIV;[697E\MN<]M-N\5B.[E>WZ_VUQWTS\MW)YONX^$NWWRMSR[(
M]]^I-TX=OG_A,5>7GV:WW7>SS>U\M9TLNH][9'%^^,!O,[^]>_EBM_ZT3^39
MY,-ZMULO'W][U\UNNLTA8/_G']?KW?,7A[_@RWKSZ^/+OOHG4$L#!!0    (
M %935E: =8BL%P0  "H7   9    >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM
M;+58:V_;-A3]*X16# VP22(EZY'9!A*KW5HT6) @VX=A'QB;EH1*HD?2=OOO
M1SVLATT+<4%_L?6XY_C>0U[I^$[WE'WE"2$"?,NS@L^,1(C-K67Q94)RS$VZ
M(86\LZ8LQT*>LMCB&T;PJ@+EF85LV[-RG!;&?%I=>V3S*=V*+"W((P-\F^>8
M?;\G&=W/#&@<+CRE<2+*"]9\NL$Q>2;B9?/(Y)G5LJS2G!0\I05@9#TS[N!M
M!,,24$7\E9(][QV#LI172K^6)Y]6,\,N,R(968J2 LNO'5F0+"N99![_-:1&
M^YLEL']\8/]8%2^+><6<+&CV=[H2R<P(#+ B:[S-Q!/=_T&:@B8EWY)FO/H$
M^R;6-L!RRP7-&[#,($^+^AM_:X3H :!W!H : #H&N&< 3@-PW@IP&X!;*5.7
M4ND088'G4T;W@)71DJT\J,2LT++\M"C7_5DP>3>5.#%_(CM2; EX'Z4<QS$C
M,:[6@Z[!X=;K=_ [H3'#FR1=X@S<R?UU(P%$X#3C-^!7\/(<@??O;L [D!;@
M(<TRR<"GEI#YE;]B+9M<[NM<T)E<( (/M! )!Q^*%5D-"2Q96%L=.E1WCT89
M([(T@0-_ <A&2)'0XNUPJ(!';X?;(]4X[5HY%9]SCN_L$OWS18:"3X+D_%^5
M[C6OJ^8M'RVW?(.79&;(9P<G;$>,^<\_0<_^3:693K)($]E 3[?5TQUC/^Q]
MY4ZMD7Z%+)^=NSD*)BXTW:FUZXNABG-@<!P7*>+<B1.:01LW*&'2EC 9+>'%
M?#95Z8^B+EUPG621)K*!6EZKEG>E!O)TZJF3+-)$-M#3;_7T?[B!:J37V_ P
M@*%]U#Z**"^ \*AYZJB@'^4B%)J.NGF"-OU@-/T/6R;]DRKY4=RERZV3+-)$
M-M K;/4*K]0^H4X]=9)%FL@&>D*[,U_V#S=0 ^WO>A>%H8F.6D@5Y_M>[\U2
M5ZJ*@X%O^NHF@CT'"4>+^(PWN%!6,(J[=-FULD6ZV(::H4XS=*56:HAUB:J3
M+=+%-A2UL\=PU"V.=Y-S^@[Q7;_W"FD$<4[>2,CQ_.->.F5#D\ QX9E>ZAPI
M'+>DBR0ML#+_4=S%RZZ3+=+%-M2LL\!P<JU>TFJ3M;)%NMB&HG9.&8X:Q_%>
M\A1^;(*.WS@+59SGG?R'BE1Q$'IF>*:;.GL*Q_WIGR(A#*PI(VE<@"7=%H*E
M9VH:9;IX*^ADBW2Q#57L7#(,KM5?6GVT5K9(%]M0U,Y*PU%G.=Y?-70R'#Z<
M^+[P=*3@V^C8'T:J./GOZ<3W6;TA8DY87 UC>=TU]<2MO=H.?.^J,>?1]?MR
M$%P-)SN:>HK\@%F<%AQD9"TI;=.7);)Z,%N?"+JI1I6O5 B:5X<)P2O"R@!Y
M?TVI.)R4/]".Q^?_ U!+ P04    " !64U96#@LFJP4)   %8@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970U,"YX;6R]G5MOVS@:AO\*X1T,6B!C2Y2/F21
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M<Z#<R.)]L2#]0YQE<5B\W'&VX4E>0+S_&,?9RT:>X/CDAYO_ 5!+ P04
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M=;N5H%J*W3+%[MX4SZFB"T[E;N?NQ;]T-QHBJTGME5)[K^W<7I.U:HBL5JO
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M&0S?8SE4W33K@9&5:R,K:; IN<<"OS- 60"^7TMI'@=V@?;+9?8/4$L#!!0
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M($R _K[F7+T.S 3M-3']#E!+ P04    " !64U96C'3\E*,'  #P.P  &0
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MRE+_+8<K^D*B=@&TOU3*/DU<$VZ^N?$_4$L#!!0    ( %935E::BR65\ (
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M7CMLP6;VG9I]Q\I^C!C[H<A>9+3(11-'*\"N2\L1F#'7;CW7[B&69M>E?H[
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ME&"F N3O4TK%RX%Z1:=^)6OT'U!+ P04    " !64U962ZDDX7<&  #*00
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M(M,7J,]7:2KO3_17X?<_WS#]'U!+ P04    " !64U96O/"Q:BT&  "%)P
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M09;DY3=^K8AH-8#3(PU0U0!U&P1'&OA5 __4!D'5("B8*8=2\!!B@9?7C!X
M4]$231T49!:MY?"37,W[DV#RUT2V$\N[),=YE. 4W.=<L+V<4L'!Q9/,KWB?
M$D#7X,-Z+2=)'3TF_"MXP+E,"!5W"2Y"(G"2\DLP!%^>0G#Q[A*\ TD.'I(T
ME=/*K\="=E+=:AQ5';HM.X2.= @B\$!SL>7@0QZ36 <8R]'50T1O0[Q%5L20
M1"/@P]\ \A R=&AU>G-H:!Z>WMRSC,:O)\PO\/PC>"O,MV MY0KD#&T(OS)1
M7$($9@CU*+GB.QR1FX%\5G#"7LA@^>LO<.K];J+')5CH"$RC+JBI"VSHRS^H
MP*F)KK+9K&BF'I0O2P2GH^!Z_-+FH8R:M*.FOAX3]I&&R%N,9G68UO%)W?&)
MM>,?U4S'X"YYE7\?L2 @),_"-!(KSKD3[Q(L= 2F\3>M^9M^OV:F+JES"18Z
M M.HF]74S:RI5S[\Y=(,=I05*[5<!YA<!X99O0[(!WZS=(@M%N" N2P*(KK)
MDW]DRLH%@8HM82"BF>SC5I4-$C')Y3D!%RGE_-(T)677YBTU^2@8+3JZ+*.F
MK:C GW1TV8\9!EY@5N6\IF9NI6;%9+^'T9XQDD??Y&@$D?P+P)1 ^0'OC*N?
M%?/<-',)%CH"T[A<U%PNOE^A"Y?4N00+'8%IU$&O*>&\GU>C5=_:TIJ@CD*K
MF+FVP/JM5;%DT1 F5\]92_ Z0:T:%_[$!,'^X!>C>9>B?E2 1MWRPA UG/C'
MR@N(&H*0E2!IH:1!RL&'UVB+\PT!*UF",^G)C .R8IVK0Z=HH2LTG<>F-H<.
MBG/HM#IWBA:Z0M/Y:PIT:*_0?ZQ0@[ZXX*1G ZJP]@//Z\K4%J)3TU@ :/<
M4J('S.(A%U@RDV].K3?LL&=GFU-/X I-I[1Q!="!+8!.?8%3M- 5FLY?8PW@
M3^P-H,$<+.!HTE5K/VPQ&TT6[4]7O?TF0PB]HV5(XQ>@W3"$A,M%5JHU!I(#
M9>J5CIOW;N!?<+K3M]_K[+QTZB1<H>D\-UX"VLW$'4X8>,'IGEB%[=1..$4+
M7:'I[TL;0X%.,11@S6A6,AB#M<K(8;'4Q$<R$AG+]WZI:XJ;S;O*#0UA\^EH
MX;4^T*Q(U!@#9#<&)RCR_FV9+=1HJXOM]SHWH9RBA:[0=)X;?X&0 T4BI\;"
M*5KH"DTGL#$6R%IX:XK4"[^HRDAC\5>A:M[3I,A^F$F0_:CAJ8IL'  *OK\F
M0U87<7:BN$0+7:'I_#4V =EM@K$F4T44X4">',D=59"EF/-DG:AGO<HR'$7[
M;)\6ST93@:8PC7,SZ64)G/;*,G/4M)MQQJ@CKVU14_<C:UU\RE/__[W;M=_W
M[+QTZA5<H>F<-UX!S1SHVNHWSN;/)5KH"DWGK_$.R.X=?KRNY_URK"O8E2$H
M@-WE)C1$#:&'C@J[*?R1M2Y>?J("G"#NL]YVVF]Y=DXZM0FNT/2-"(U-\#T'
M6Q&L5N/LO0@NT4)7:#I_C?OP[>[C$Q'@8H.3G%^VI+RNLK->?,A;FC:RSF6B
MQUJB;ZM$;[UN,<X&[&U0@ O8_3_#RA"&O*"W/AO"AA#U_Q\Q;NU/R@C;%/N\
MN!S//A?E/I[Z:KV7['VQ@ZIS_19>A>6.L :FW*#V@)D</P<I64M(;S23I0,K
M]WR5)X+NBEU0SU0(FA6'6X)CPE2 _'U-J7@[43>H=]XM_P-02P,$%     @
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MS@;Z^B"*9*VH*)[9]&7&E4Z&;'&E$UP0IH-^O^!<;2MF@"IEGOP#4$L#!!0
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M&7A^U"DXN2("QPD_!6?@R]T5.'ES"MZ . .?Y6WY<OG"$C(VQ= *RS@^'.)
M/7%<D= $,_@.(!LAC?OEZ]UAV]V2&:W2BJJTH@)OUH/72E5<9P4763G7Q7<
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M*GHAJ3"":\%UH>"2YYCO$OA&82<SVLB<1J\RIICUH!]^@"B(HCT)71P.#_?
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MX22H".5>EKJU)YFE8J,9Y? DD=I4%9&_;H")9N:-O+>%9[HNM5T(LK0F:UB
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M4ZGC5NJX.9_W'W6.T8QB)4M3I-\7*AQ-)23B3UNI!7>OG5L_GZ<BPQ&,#?4
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M'RG =8"ZOF!,/B[T&%Q]]H1_ 5!+ P04    " !64U96B(@"UIP"  "U!P
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M T]?#O>.5!-VMQ!:OO#X+?R\7"@M\5?XU2=Q0Q'U4YCV<*%JFL'4P?]?@=R
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M@09=Q-WF(N@%+8UM-I2HDK2=]NDSE!35!]K9B]S8HC3S\_M'0U+3O9"?U09
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M8-$M6-0'BRYADXD;],/B#A;?@L5]L/CBQ.(H=,?_P;RS"VK>NB656U8IPJ%
MW<"-<8-D\WXT'2UJ>V<W0N,+8)L[?')!F@4X7PBA3QWS#'2/>/H'4$L#!!0
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M[_/YCH_/&>ZX>)8Y@$+[@C(Y<G*EUO>N*Y,<"BP[? U,[V1<%%CIJ5BY<BT
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M6%(>LJ"./3L* L^4\+KE/K$Z-F7*$9C!U'#+U-":XW>MK]2R(VO*E5[,ZU]
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ML&U?+BH9KY11E?UE;GN6G%4O;<8]1HYW8.2_-GHE% P&_3^1> T2;QB)7 :
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MZP;($H1IH']?<:Y>+XR#_0'FQ?]02P,$%     @ 5E-65B9CU(>+ @  N@8
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M=M^PU3.R?+E@RCUAU^8&'N0;I475@DT%%>7-F]RU?>@!PO$S@*@%1(\!\3.
M80L8OA80MP#7:K^1XOJ0$4W21(H=2)MMV.S -=.AC7S*[;8OM#1?J<'I])+G
MHD+X3NY0P?'"G*IBPQ#$"F9$E3 G]V:/M;*!?NH'.,Y0$\K,Z!/<+#(X/OH
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M<@ND@'*+4U(Z\ 6<SY&XD.8"SD"4\""DM*=NDI"L2Z<59JVCF\81.^)HCMD
MAO$G8!%C\+R<P_G9Q=\TH2VRJY1UE3+/.SS"RZ)XXJS"=4:=[SY[#<VHG\8U
MR96I>(:SP':!0;W#(/WX(;Z,OIXP.>Q,#D^QIT^*N.PSU< F'N8:;9?&TR_C
MP30)=SURHTYN=%+N.QIC[Y&7$,,OY+I/N6&8'BB/)N/!I%]XW F/3PK'GX=>
ML/?_&/]?ZXA%@_@?R?#@KW</R /76U$:D+BQP&@PL3RZ:<HF(%7Y1E@ILFWE
MI[E]QU"[!+N_48K> ]=;W<N8_@%02P,$%     @ 5E-65DL%/03A P  %@T
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M9+:%G$B7[Z#07]9<Y$3IH=AX<B> K$JGG'F![\=>3FCA3$;EN[F8C/A>,5K
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M*^'9?%^U7!!-Y1K/_Y1S$1<BV$IFOZV2&1U7,MWCGLS21]3S_KZ@]]^JZ+?
M189;,"FRNCV!+57;%7\VT2);:$W^]D<!?_"Q"=QYU#B96IMHD2VT)K7[DXG_
MQM'D] 1N/8H$+Q+8ZEG$%EK)DGMP"Y4 QFQN\Q26)7FJR[N<NK>^,?Q<W),=
M]5^;F\3B=FL/4UY#XN=[S5)%.*P0T@B<0V1YLU<VM,B*NZZ%T%HDQ>,&*)YU
MC0&^7PFAGQMF@/I^=?8_4$L#!!0    ( %935E;5<F)OV0,  $<1   9
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M,@$: U<&^'S+F#S?J FJ;R>+OP%02P,$%     @ 5E-65FJ_<-P&"@  5D8
M !D   !X;"]W;W)K<VAE971S+W-H965T.3DN>&ULS9QM;Z-($H#_2LNW.B72
MV*;? .<22TF8T8YT<QLENW<?3O>!X([-+H8LX"2SO_X:3-Q ->W8T]%,/LSX
MI;KHJNJ7AZHVY\]9_D>Q$J)$+^LD+2Y&J[)\/)M.BV@EUF$QR1Y%*K]YR/)U
M6,JW^7):/.8B7-2-ULF4.(X[78=Q.IJ?UY_=Y//S;%,F<2IN<E1LUNLP_WHE
MDNSY8H1'KQ_<QLM567TPG9\_ADMQ)\K?'F]R^6ZZT[*(UR(MXBQ%N7BX&%WB
ML\"E58-:XM^Q>"Y:KU%ERGV6_5&]^;RX&#E5CT0BHK)2$<K_GL2U2))*D^S'
MGXW2T>Z:5</VZU?MGVKCI3'W82&NL^0_\:)<78S\$5J(AW"3E+?9\\^B,8A7
M^J(L*>I_T7,CZXQ0M"G*;-TTECU8Q^GV__"E<42K 78'&I"F >DW8 ,-:-.
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MRF9Z3;:OW6G9[OQR^>FR^+\B^@.358V='$@Q Q*S1K-['<TNC[79(8<?*69
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M4GL\$E3+$]09=@5@_3P^^.BI"CTV0ZG9B1L1L,W$I-A"40^J9E!J=@[($Y2
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M,S Y)Q$$]S32TZA]3^.;1BAOR_!-C6]V9.L_ESX077+_"65IGK)B=PU$8<A
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M->RO7QQT<S':OP9=TKB9QC5;+@MNUE8-/&B'_[[01_"Z+E:<U"M_A+T,VV_
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M(W,79;[E-2]HL<DV4+X(K464':XI":E,*YCK2R'TOI V4&X\GOX/4$L#!!0
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M:*.\8E7@>0CV?W:::V (<@X*54W7%$(TU#3%G1L!9LGX>(G%&GV''!^I7'1
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M.$I"SLF&1&&>-PX^[T7^P2J*]ND^"06.@0JSP@JP"$DBKR[ E_L G'TX!Q\
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MN8'\?$.I>+G)7U ?S"[_ U!+ P04    " !64U96G:KT':(#  "4"P  &@
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !64U9624G+#>T    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !6
M4U96F5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( %935E9,D8_1BPL  #5O   8
M  " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !6
M4U96G;?G83@"  "]!0  &               @('-$P  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ 5E-65O)@PIEX!0  =!8  !@
M         ("!.Q8  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( %935E8,MCL^4P0  &4/   8              " @>D;  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !64U96B#S&+B$(   .(P
M&               @(%R(   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ 5E-65LD@ZR*9 @  I 8  !@              ("!R2@  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( %935E;,(/+CV L
M  M_   8              " @9@K  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " !64U96JC_LK(X"  #)!@  &               @(&F
M-P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 5E-65NFJ
MDS#E"   @2D  !@              ("!:CH  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( %935E:13FG;$0L   @<   9
M  " @85#  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M5E-65JHCWR(D&   CT(  !D              ("!S4X  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " !64U96O'^P[- 0  #E6@  &0
M            @($H9P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( %935E88P<J2S0P  -0G   9              " @2]X  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 5E-65HA7=<SS P
MKPD  !D              ("!,X4  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " !64U96N(V3:G\#  #7!P  &0              @(%=
MB0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( %935E9+
M$B%A,1D  +Y9   9              " @1.-  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ 5E-65K:3/_9""0  6QH  !D
M     ("!>Z8  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %935E8D#U05V ,   X)   9              "
M@2/.  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 5E-6
M5M+3M2"1#@  [B4  !D              ("!,M(  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " !64U960Z)2N)48  !!20  &0
M        @('ZX   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( %935E9>,MXFR1\   A=   9              " @<;Y  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 5E-65NE$'ZPC!P  ^!$
M !D              ("!QAD! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " !64U96G.%@G_8"  ".!@  &0              @($@(0$
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( %935E:TA$%T
MQ!,  !8]   9              " @4TD 0!X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ 5E-65GS##0UD"   I!(  !D
M ("!2#@! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !6
M4U96:NFP]/8&  !/$0  &0              @('C0 $ >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( %935E8\-DJ8O ,  (T(   9
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M970S-2YX;6Q02P$"% ,4    " !64U96J-YUL+<#  "."   &0
M    @(&K8@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M %935E;,24T^B@,  (H(   9              " @9EF 0!X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ 5E-65K[C0'&F!0  G@\  !D
M             ("!6FH! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    " !64U96?^F_B74#   S"   &0              @($W< $ >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( %935E9^,.J"_ <
M (03   9              " @>-S 0!X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ 5E-65I-F[UTH#0  5RL  !D              ("!
M%GP! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !64U96
M84J\TT8&   =$   &0              @(%UB0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( %935E;&[*^"# ,  (L&   9
M      " @?*/ 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ 5E-65C9LL9V[ @  K@<  !D              ("!-9,! 'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " !64U96&!Q$6ZT#  #N$
M&0              @($GE@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    ( %935E:1ZY\4>@4  $LB   9              " @0N: 0!X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ 5E-65K$M1S,J
M @  &P4  !D              ("!O)\! 'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    " !64U9686SIQC84    XP  &0
M@($=H@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( %93
M5E: =8BL%P0  "H7   9              " @8JV 0!X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#%     @ 5E-65@X+)JL%"0  !6(  !D
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M=#4T+GAM;%!+ 0(4 Q0    ( %935E8S9?U2I04  .PI   9
M  " @9[8 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @
M5E-65OV281$: P  Q0@  !D              ("!>MX! 'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6Q02P$"% ,4    " !64U96DSGF'/P"   &"   &0
M            @('+X0$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4
M Q0    ( %935E;.>/]B6@,  #(*   9              " @?[D 0!X;"]W
M;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ 5E-65HQT_)2C!P
M\#L  !D              ("!C^@! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6Q02P$"% ,4    " !64U96H+6"-8D"   L!@  &0              @(%I
M\ $ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( %935E9T
M'+30P (  '\'   9              " @2GS 0!X;"]W;W)K<VAE971S+W-H
M965T-C$N>&UL4$L! A0#%     @ 5E-65IJ+)97P @  ?P@  !D
M     ("!(/8! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %935E9PL^;*<@T  %6<   9              "
M@9P; @!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ 5E-6
M5KDNU*@Q P  /@\  !D              ("!12D" 'AL+W=O<FMS:&5E=',O
M<VAE970V."YX;6Q02P$"% ,4    " !64U96KD*9:JT$  #G%P  &0
M        @(&M+ ( >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0
M   ( %935E:@ Q>ME@(  ,P&   9              " @9$Q @!X;"]W;W)K
M<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ 5E-65K)('65< @  ]P4
M !D              ("!7C0" 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q0
M2P$"% ,4    " !64U96-S":B[X"   _"P  &0              @('Q-@(
M>&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( %935E:$)X)K
M"P,  "P)   9              " @>8Y @!X;"]W;W)K<VAE971S+W-H965T
M-S,N>&UL4$L! A0#%     @ 5E-65CFQ%%6) @  M@8  !D
M ("!*#T" 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " !6
M4U964S6M*"<#   "#0  &0              @('H/P( >&PO=V]R:W-H965T
M<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( %935E:(B +6G (  +4'   9
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M970X,"YX;6Q02P$"% ,4    " !64U96EL7]/YL/  #FQ@  &0
M    @($_7P( >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    (
M %935E:"@LU;30(  - %   9              " @1%O @!X;"]W;W)K<VAE
M971S+W-H965T.#(N>&UL4$L! A0#%     @ 5E-65J6<.?N- @  Q 8  !D
M             ("!E7$" 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q02P$"
M% ,4    " !64U96;&9Y/;D"  "<!P  &0              @(%9= ( >&PO
M=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( %935E9>P:,_?P8
M #8M   9              " @4EW @!X;"]W;W)K<VAE971S+W-H965T.#4N
M>&UL4$L! A0#%     @ 5E-65E)0_1-Z P  SPX  !D              ("!
M_WT" 'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q02P$"% ,4    " !64U96
MB^5^J>(#   3$P  &0              @(&P@0( >&PO=V]R:W-H965T<R]S
M:&5E=#@W+GAM;%!+ 0(4 Q0    ( %935E8'*+48!00  /4.   9
M      " @<F% @!X;"]W;W)K<VAE971S+W-H965T.#@N>&UL4$L! A0#%
M  @ 5E-65NVGVRQ"!0  /10  !D              ("!!8H" 'AL+W=O<FMS
M:&5E=',O<VAE970X.2YX;6Q02P$"% ,4    " !64U96QP?MIHH&  #,+
M&0              @(%^CP( >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;%!+
M 0(4 Q0    ( %935E8F8]2'BP(  +H&   9              " @3^6 @!X
M;"]W;W)K<VAE971S+W-H965T.3$N>&UL4$L! A0#%     @ 5E-65D7KIV)-
M @  )04  !D              ("! 9D" 'AL+W=O<FMS:&5E=',O<VAE970Y
M,BYX;6Q02P$"% ,4    " !64U962P4]!.$#   6#0  &0
M@(&%FP( >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+ 0(4 Q0    ( %93
M5E:TZTK"&00  '(.   9              " @9V? @!X;"]W;W)K<VAE971S
M+W-H965T.30N>&UL4$L! A0#%     @ 5E-65FK0!09+!P  $RT  !D
M         ("![:," 'AL+W=O<FMS:&5E=',O<VAE970Y-2YX;6Q02P$"% ,4
M    " !64U96W1(Y1 \$  "V$   &0              @(%OJP( >&PO=V]R
M:W-H965T<R]S:&5E=#DV+GAM;%!+ 0(4 Q0    ( %935E:R1JR*700  &L5
M   9              " @;6O @!X;"]W;W)K<VAE971S+W-H965T.3<N>&UL
M4$L! A0#%     @ 5E-65M5R8F_9 P  1Q$  !D              ("!2;0"
M 'AL+W=O<FMS:&5E=',O<VAE970Y."YX;6Q02P$"% ,4    " !64U96:K]P
MW 8*  !61@  &0              @(%9N ( >&PO=V]R:W-H965T<R]S:&5E
M=#DY+GAM;%!+ 0(4 Q0    ( %935E8"U?-4;1L  ,J6 0 :
M  " @9;" @!X;"]W;W)K<VAE971S+W-H965T,3 P+GAM;%!+ 0(4 Q0    (
M %935E9(++]8D04  (0L   :              " @3O> @!X;"]W;W)K<VAE
M971S+W-H965T,3 Q+GAM;%!+ 0(4 Q0    ( %935E:J3PGPB0<  /0L   :
M              " @03D @!X;"]W;W)K<VAE971S+W-H965T,3 R+GAM;%!+
M 0(4 Q0    ( %935E9$!)E88@0  (T6   :              " @<7K @!X
M;"]W;W)K<VAE971S+W-H965T,3 S+GAM;%!+ 0(4 Q0    ( %935E82ZZU:
M%P4  *0=   :              " @5_P @!X;"]W;W)K<VAE971S+W-H965T
M,3 T+GAM;%!+ 0(4 Q0    ( %935E:=JO0=H@,  )0+   :
M  " @:[U @!X;"]W;W)K<VAE971S+W-H965T,3 U+GAM;%!+ 0(4 Q0    (
M %935E9,:D\XQ ,  $P=   -              "  8CY @!X;"]S='EL97,N
M>&UL4$L! A0#%     @ 5E-65I>*NQS     $P(   L              ( !
M=_T" %]R96QS+RYR96QS4$L! A0#%     @ 5E-65KW5-[(/!P  NT0   \
M             ( !8/X" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %93
M5E;B50\<^ (  + ]   :              "  9P% P!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( %935E8.2"\Y:@(  '4[   3
M          "  <P( P!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !Q '$
*%!\  &<+ P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>925</ContextCount>
  <ElementCount>517</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>204</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>15</UnitCount>
  <MyReports>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards</Role>
      <ShortName>Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Collaborations and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangements</Role>
      <ShortName>Collaborations and Other Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Goodwill and Other Intangibles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/GoodwillandOtherIntangibles</Role>
      <ShortName>Goodwill and Other Intangibles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Retirement Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefits</Role>
      <ShortName>Retirement Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLoss</Role>
      <ShortName>Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Other-Net, (Income) Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpense</Role>
      <ShortName>Other-Net, (Income) Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Revenue</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Acquisitions</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Collaborations and Other Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</Role>
      <ShortName>Collaborations and Other Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Inventories</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstruments</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Goodwill and Other Intangibles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/GoodwillandOtherIntangiblesTables</Role>
      <ShortName>Goodwill and Other Intangibles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/GoodwillandOtherIntangibles</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/PropertyandEquipment</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Leases</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Borrowings</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/StockBasedCompensation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Retirement Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsTables</Role>
      <ShortName>Retirement Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefits</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</Role>
      <ShortName>Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLoss</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Other - Net, (Income) Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpenseTables</Role>
      <ShortName>Other - Net, (Income) Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails</Role>
      <ShortName>Revenue (Summary of Revenue Recognized) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Revenue (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueNarrativeDetails</Role>
      <ShortName>Revenue (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Revenue (Contract Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueContractLiabilitiesDetails</Role>
      <ShortName>Revenue (Contract Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails</Role>
      <ShortName>Revenue (Disaggregation of Revenue by Product) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails</Role>
      <ShortName>Revenue (Disaggregation of Revenue by Geographical Area) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Acquisitions (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Acquisitions (Assets Acquired and Liabilities Assumed) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions (Assets Acquired and Liabilities Assumed) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Acquisitions (Asset Acquisitions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails</Role>
      <ShortName>Acquisitions (Asset Acquisitions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Collaborations and Other Arrangements (Net Product Revenue) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Net Product Revenue) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Collaborations and Other Arrangements (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges - Schedule of Other Operating Cost and Expense, by Component (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges - Schedule of Other Operating Cost and Expense, by Component (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/InventoriesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Financial Instruments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Financial Instruments (Schedule of Contractual Maturities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails</Role>
      <ShortName>Financial Instruments (Schedule of Contractual Maturities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Financial Instruments (Unrealized Gains and Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails</Role>
      <ShortName>Financial Instruments (Unrealized Gains and Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Financial Instruments (Realized Gains and Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails</Role>
      <ShortName>Financial Instruments (Realized Gains and Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Financial Instruments (Schedule of Fair Value Measurement) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails</Role>
      <ShortName>Financial Instruments (Schedule of Fair Value Measurement) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails</Role>
      <ShortName>Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Financial Instruments (Schedule of Foreign Currency Forward Commitments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails</Role>
      <ShortName>Financial Instruments (Schedule of Foreign Currency Forward Commitments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Financial Instruments (Schedule of Effect of Risk Management) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails</Role>
      <ShortName>Financial Instruments (Schedule of Effect of Risk Management) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Financial Instruments (Schedule of Risk Management Instruments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Schedule of Risk Management Instruments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Goodwill and Other Intangibles (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangibles (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/GoodwillandOtherIntangiblesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Goodwill and Other Intangibles (Schedule of Finite-lived and Indefinite-lived Intangible Assets other than Goodwill) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails</Role>
      <ShortName>Goodwill and Other Intangibles (Schedule of Finite-lived and Indefinite-lived Intangible Assets other than Goodwill) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/GoodwillandOtherIntangiblesTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Goodwill and Other Intangibles (Schedule of Amortization Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Other Intangibles (Schedule of Amortization Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/GoodwillandOtherIntangiblesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Goodwill and Other Intangibles (Schedule of Estimated Amortization Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Other Intangibles (Schedule of Estimated Amortization Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/GoodwillandOtherIntangiblesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Property and Equipment (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Property and Equipment (Schedule of Depreciation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails</Role>
      <ShortName>Property and Equipment (Schedule of Depreciation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Property and Equipment (Schedule of Geographic Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails</Role>
      <ShortName>Property and Equipment (Schedule of Geographic Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/LeasesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Leases (Impact of Leases to Consolidated Condensed Financial Statements) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails</Role>
      <ShortName>Leases (Impact of Leases to Consolidated Condensed Financial Statements) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/LeasesTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases (Maturities of Operating Lease Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/LeasesTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Borrowings (Schedule of Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BorrowingsScheduleofDebtDetails</Role>
      <ShortName>Borrowings (Schedule of Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/BorrowingsTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Borrowings (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/BorrowingsTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Borrowings (Summary of Long-term Notes) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails</Role>
      <ShortName>Borrowings (Summary of Long-term Notes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/BorrowingsTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Borrowings (Schedule of Debt Maturities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails</Role>
      <ShortName>Borrowings (Schedule of Debt Maturities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/BorrowingsTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Borrowings (Schedule of Cash Payments for Interest on Borrowings) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails</Role>
      <ShortName>Borrowings (Schedule of Cash Payments for Interest on Borrowings) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/BorrowingsTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/StockBasedCompensationTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Stock-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/StockBasedCompensationTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Stock-Based Compensation (Schedule of Assumptions Used) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails</Role>
      <ShortName>Stock-Based Compensation (Schedule of Assumptions Used) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/StockBasedCompensationTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/ShareholdersEquity</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Income Taxes (Schedule of Composition of Income Tax Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes (Schedule of Composition of Income Tax Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Income Taxes (Schedule of Deferred Tax Asset and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails</Role>
      <ShortName>Income Taxes (Schedule of Deferred Tax Asset and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - Income Taxes (Schedule of Cash Payments of Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Schedule of Cash Payments of Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - Income Taxes (Schedule of Future Cash Payments Relating to the Toll Tax) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails</Role>
      <ShortName>Income Taxes (Schedule of Future Cash Payments Relating to the Toll Tax) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - Income Taxes (Schedule of Reconciliation of Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Schedule of Reconciliation of Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - Retirement Benefits (Schedule of Benefit Obligations and Plan Assets and Funded Status) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails</Role>
      <ShortName>Retirement Benefits (Schedule of Benefit Obligations and Plan Assets and Funded Status) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails</Role>
      <ShortName>Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0000097 - Disclosure - Retirement Benefits (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsNarrativeDetails</Role>
      <ShortName>Retirement Benefits (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>0000098 - Disclosure - Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails</Role>
      <ShortName>Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>0000099 - Disclosure - Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails</Role>
      <ShortName>Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>0000100 - Disclosure - Retirement Benefits (Schedule of Fair Value Disclosures) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails</Role>
      <ShortName>Retirement Benefits (Schedule of Fair Value Disclosures) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>0000101 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Contingencies</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>0000102 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Component of Other Comprehensive Income (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Schedule of Component of Other Comprehensive Income (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>0000103 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Tax Effects) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Schedule of Tax Effects) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>0000104 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>104</Position>
    </Report>
    <Report instance="lly-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>0000105 - Disclosure - Other - Net, (Income) Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpenseDetails</Role>
      <ShortName>Other - Net, (Income) Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherNetIncomeExpenseTables</ParentRole>
      <Position>105</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentAnnualReport, dei:DocumentTransitionReport, us-gaap:FiniteLivedIntangibleAssetUsefulLife, us-gaap:PropertyPlantAndEquipmentUsefulLife -  lly-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="lly-20221231.htm">lly-20221231.htm</File>
    <File>lly-20221231.xsd</File>
    <File>lly-20221231_cal.xml</File>
    <File>lly-20221231_def.xml</File>
    <File>lly-20221231_lab.xml</File>
    <File>lly-20221231_pre.xml</File>
    <File>lly-20221231x10kexhibit102.htm</File>
    <File>lly-20221231x10kexhibit103.htm</File>
    <File>lly-20221231x10kexhibit104.htm</File>
    <File>lly-20221231x10kexhibit105.htm</File>
    <File>lly-20221231x10kexhibit21.htm</File>
    <File>lly-20221231x10kexhibit23.htm</File>
    <File>lly-20221231x10kexhibit311.htm</File>
    <File>lly-20221231x10kexhibit312.htm</File>
    <File>lly-20221231x10kexhibit32.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>lly-20221231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2068">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="67">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>129
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lly-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 35,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 2068,
    "http://xbrl.sec.gov/dei/2022": 67
   },
   "contextCount": 925,
   "dts": {
    "calculationLink": {
     "local": [
      "lly-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lly-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lly-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lly-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lly-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lly-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 897,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 5,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 11
   },
   "keyCustom": 49,
   "keyStandard": 468,
   "memberCustom": 124,
   "memberStandard": 76,
   "nsprefix": "lly",
   "nsuri": "http://www.lilly.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.lilly.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards",
     "shortName": "Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i0c073455f233450ea6806f68e460a7bc_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000100 - Disclosure - Retirement Benefits (Schedule of Fair Value Disclosures) (Details)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
     "shortName": "Retirement Benefits (Schedule of Fair Value Disclosures) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ia316b6b7c534488da162855e12856aee_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "idb638f2256714679a5c385f7893d6fbf_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup",
      "reportCount": 1,
      "unitRef": "site",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000101 - Disclosure - Contingencies (Details)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://www.lilly.com/role/ContingenciesDetails",
     "shortName": "Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i62bc7ea2d50e4f44a034b2205030f1c9_D20090301-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNumberOfPlaintiffs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plaintiff",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "id1b649fc71124f56ae26b2e43abf1d5d_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000102 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Component of Other Comprehensive Income (Loss)) (Details)",
     "menuCat": "Details",
     "order": "102",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
     "shortName": "Other Comprehensive Income (Loss) (Schedule of Component of Other Comprehensive Income (Loss)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000103 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Tax Effects) (Details)",
     "menuCat": "Details",
     "order": "103",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails",
     "shortName": "Other Comprehensive Income (Loss) (Schedule of Tax Effects) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000104 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss) (Details)",
     "menuCat": "Details",
     "order": "104",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails",
     "shortName": "Other Comprehensive Income (Loss) (Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "if3a0343f9166479e970860fc345fb4c5_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000105 - Disclosure - Other - Net, (Income) Expense (Details)",
     "menuCat": "Details",
     "order": "105",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpenseDetails",
     "shortName": "Other - Net, (Income) Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Revenue",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.lilly.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Acquisitions",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.lilly.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Collaborations and Other Arrangements",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangements",
     "shortName": "Collaborations and Other Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.lilly.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Financial Instruments",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.lilly.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Goodwill and Other Intangibles",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.lilly.com/role/GoodwillandOtherIntangibles",
     "shortName": "Goodwill and Other Intangibles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.lilly.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.lilly.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.lilly.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Borrowings",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.lilly.com/role/Borrowings",
     "shortName": "Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.lilly.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Shareholders' Equity",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.lilly.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.lilly.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Retirement Benefits",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.lilly.com/role/RetirementBenefits",
     "shortName": "Retirement Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Contingencies",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.lilly.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Other Comprehensive Income (Loss)",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLoss",
     "shortName": "Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Other-Net, (Income) Expense",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpense",
     "shortName": "Other-Net, (Income) Expense",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpensePolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Policies)",
     "menuCat": "Policies",
     "order": "28",
     "role": "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies",
     "shortName": "Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpensePolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Revenue (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.lilly.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.lilly.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Acquisitions (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.lilly.com/role/AcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Collaborations and Other Arrangements (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsTables",
     "shortName": "Collaborations and Other Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.lilly.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.lilly.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Goodwill and Other Intangibles (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.lilly.com/role/GoodwillandOtherIntangiblesTables",
     "shortName": "Goodwill and Other Intangibles (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.lilly.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.lilly.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Borrowings (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.lilly.com/role/BorrowingsTables",
     "shortName": "Borrowings (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.lilly.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.lilly.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Retirement Benefits (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.lilly.com/role/RetirementBenefitsTables",
     "shortName": "Retirement Benefits (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Other Comprehensive Income (Loss) (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables",
     "shortName": "Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Other - Net, (Income) Expense (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpenseTables",
     "shortName": "Other - Net, (Income) Expense (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsDetails",
     "shortName": "Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails",
     "shortName": "Revenue (Summary of Revenue Recognized) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ie555d2f92f6542cc95e629676af2b0dc_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lly:RevenuefromContractPaymentTermMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Revenue (Narrative) (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.lilly.com/role/RevenueNarrativeDetails",
     "shortName": "Revenue (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lly:RevenuefromContractPaymentTermMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Revenue (Contract Liabilities) (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.lilly.com/role/RevenueContractLiabilitiesDetails",
     "shortName": "Revenue (Contract Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
     "shortName": "Revenue (Disaggregation of Revenue by Product) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i1e3a4aa6df1d471499e619affd59a81c_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
     "shortName": "Revenue (Disaggregation of Revenue by Geographical Area) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "icb29b5e537384747850aedf57eea8ac5_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.lilly.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Acquisitions (Narrative) (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
     "shortName": "Acquisitions (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i24ac34b561704aaf9cdc8cf15d9421c4_D20221201-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "right",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Acquisitions (Assets Acquired and Liabilities Assumed) (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisitions (Assets Acquired and Liabilities Assumed) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "iceb5a7f2472e4bb0a0f8c4fe22cd2d24_I20221201",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:PaymentsForAssetAcquisitions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Acquisitions (Asset Acquisitions) (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
     "shortName": "Acquisitions (Asset Acquisitions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i22bda1e261ac4b2488c77f767678e525_D20220201-20220228",
      "decimals": "-5",
      "lang": "en-US",
      "name": "lly:PaymentsForAssetAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ib72f8530223f4b8b9206e3912e939d05_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:CollaborativeArrangementRightsAndObligationsRightsObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
     "shortName": "Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ib72f8530223f4b8b9206e3912e939d05_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:CollaborativeArrangementRightsAndObligationsRightsObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Collaborations and Other Arrangements (Net Product Revenue) (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
     "shortName": "Collaborations and Other Arrangements (Net Product Revenue) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i540e1253ab844a0bbc43a8cfb3ee0920_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Collaborations and Other Arrangements (Narrative) (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
     "shortName": "Collaborations and Other Arrangements (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i81b687c200704d14b8cd74e649ddccdc_D20220101-20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "lly:CollaborativeArrangementRightsAndObligationsPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges - Schedule of Other Operating Cost and Expense, by Component (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges - Schedule of Other Operating Cost and Expense, by Component (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ibbb1e2ae2a934a25bce4c0807ac76d40_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "id1b649fc71124f56ae26b2e43abf1d5d_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Inventories (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.lilly.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "id1b649fc71124f56ae26b2e43abf1d5d_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Financial Instruments (Narrative) (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Financial Instruments (Schedule of Contractual Maturities) (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails",
     "shortName": "Financial Instruments (Schedule of Contractual Maturities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Financial Instruments (Unrealized Gains and Losses) (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails",
     "shortName": "Financial Instruments (Unrealized Gains and Losses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Financial Instruments (Realized Gains and Losses) (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails",
     "shortName": "Financial Instruments (Realized Gains and Losses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Financial Instruments (Schedule of Fair Value Measurement) (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
     "shortName": "Financial Instruments (Schedule of Fair Value Measurement) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ib2046b6b3eed4ac6b751298dc54b230f_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommercialPaper",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails",
     "shortName": "Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ib2046b6b3eed4ac6b751298dc54b230f_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ie250a0992fc5431f969a7964f8245fdc_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilityNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Financial Instruments (Schedule of Foreign Currency Forward Commitments) (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails",
     "shortName": "Financial Instruments (Schedule of Foreign Currency Forward Commitments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ie250a0992fc5431f969a7964f8245fdc_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilityNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:DerivativeInstrumentsGainLossRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Financial Instruments (Schedule of Effect of Risk Management) (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
     "shortName": "Financial Instruments (Schedule of Effect of Risk Management) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:DerivativeInstrumentsGainLossRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ib2046b6b3eed4ac6b751298dc54b230f_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Financial Instruments (Schedule of Risk Management Instruments) (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
     "shortName": "Financial Instruments (Schedule of Risk Management Instruments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ib2046b6b3eed4ac6b751298dc54b230f_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Goodwill and Other Intangibles (Narrative) (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
     "shortName": "Goodwill and Other Intangibles (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Goodwill and Other Intangibles (Schedule of Finite-lived and Indefinite-lived Intangible Assets other than Goodwill) (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails",
     "shortName": "Goodwill and Other Intangibles (Schedule of Finite-lived and Indefinite-lived Intangible Assets other than Goodwill) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i356b319ab866417988ad019b9794d8cb_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Shareholders' Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity",
     "shortName": "Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i356b319ab866417988ad019b9794d8cb_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Goodwill and Other Intangibles (Schedule of Amortization Expense) (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails",
     "shortName": "Goodwill and Other Intangibles (Schedule of Amortization Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Goodwill and Other Intangibles (Schedule of Estimated Amortization Expense) (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails",
     "shortName": "Goodwill and Other Intangibles (Schedule of Estimated Amortization Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i84043b4b737545c9b8356075843761af_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Property and Equipment (Narrative) (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
     "shortName": "Property and Equipment (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i84043b4b737545c9b8356075843761af_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Schedule of Property and Equipment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Property and Equipment (Schedule of Depreciation Expense) (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails",
     "shortName": "Property and Equipment (Schedule of Depreciation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Property and Equipment (Schedule of Geographic Information) (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails",
     "shortName": "Property and Equipment (Schedule of Geographic Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lly:LesseeLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Leases (Narrative) (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.lilly.com/role/LeasesNarrativeDetails",
     "shortName": "Leases (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lly:LesseeLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Leases (Impact of Leases to Consolidated Condensed Financial Statements) (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails",
     "shortName": "Leases (Impact of Leases to Consolidated Condensed Financial Statements) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases (Maturities of Operating Lease Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommercialPaper",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Borrowings (Schedule of Debt) (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails",
     "shortName": "Borrowings (Schedule of Debt) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Borrowings (Narrative) (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.lilly.com/role/BorrowingsNarrativeDetails",
     "shortName": "Borrowings (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Borrowings (Summary of Long-term Notes) (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
     "shortName": "Borrowings (Summary of Long-term Notes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Borrowings (Schedule of Debt Maturities) (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails",
     "shortName": "Borrowings (Schedule of Debt Maturities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lly:ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Borrowings (Schedule of Cash Payments for Interest on Borrowings) (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails",
     "shortName": "Borrowings (Schedule of Cash Payments for Interest on Borrowings) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lly:ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Stock-Based Compensation (Narrative) (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Stock-Based Compensation (Schedule of Assumptions Used) (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails",
     "shortName": "Stock-Based Compensation (Schedule of Assumptions Used) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i0dcedd244b5e446596bc5ca545f26167_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockValueAcquiredCostMethod",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Shareholders' Equity (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.lilly.com/role/ShareholdersEquityDetails",
     "shortName": "Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Income Taxes (Schedule of Composition of Income Tax Expense) (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails",
     "shortName": "Income Taxes (Schedule of Composition of Income Tax Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Income Taxes (Schedule of Deferred Tax Asset and Liabilities) (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails",
     "shortName": "Income Taxes (Schedule of Deferred Tax Asset and Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - Income Taxes (Narrative) (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.lilly.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lly:ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - Income Taxes (Schedule of Cash Payments of Income Taxes) (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails",
     "shortName": "Income Taxes (Schedule of Cash Payments of Income Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lly:ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:TaxCutAndJobsActTollTaxToBePaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - Income Taxes (Schedule of Future Cash Payments Relating to the Toll Tax) (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails",
     "shortName": "Income Taxes (Schedule of Future Cash Payments Relating to the Toll Tax) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:TaxCutAndJobsActTollTaxToBePaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - Income Taxes (Schedule of Reconciliation of Income Taxes) (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails",
     "shortName": "Income Taxes (Schedule of Reconciliation of Income Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "id1b649fc71124f56ae26b2e43abf1d5d_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ib66e8131e7a64596bd768a5869bc86ab_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i29379dfc9c24409c9bb7a52d0165f08f_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - Retirement Benefits (Schedule of Benefit Obligations and Plan Assets and Funded Status) (Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
     "shortName": "Retirement Benefits (Schedule of Benefit Obligations and Plan Assets and Funded Status) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i75692be42e8645c782c2d9d44c4b1814_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanActuarialGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
     "shortName": "Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i0c073455f233450ea6806f68e460a7bc_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000097 - Disclosure - Retirement Benefits (Narrative) (Details)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
     "shortName": "Retirement Benefits (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i095cf5e171c244d4957ecbd3f0e77a2d_D20220101-20221231",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i0c073455f233450ea6806f68e460a7bc_I20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000098 - Disclosure - Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails",
     "shortName": "Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "i0c073455f233450ea6806f68e460a7bc_I20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000099 - Disclosure - Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
     "shortName": "Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20221231.htm",
      "contextRef": "ife049f03c96e47288db50605b1356b32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 204,
   "tag": {
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRAZIL",
        "terseLabel": "Brazil"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IRELAND",
        "terseLabel": "Ireland"
       }
      }
     },
     "localname": "IE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "verboseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "verboseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r844",
      "r845",
      "r846"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r844",
      "r845",
      "r846"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r844",
      "r845",
      "r846"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r844",
      "r845",
      "r846"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r847"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r848"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r849"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r844",
      "r845",
      "r846"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lly_A015SwissFrancDenominatedNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.15% Swiss Franc-denominated Notes Due 2024",
        "label": "0.15% Swiss Franc-denominated Notes Due 2024 [Member]",
        "terseLabel": "0.15% Swiss franc denominated notes due 2024"
       }
      }
     },
     "localname": "A015SwissFrancDenominatedNotesDue2024Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A045SwissFrancDenominatedNotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.45% Swiss Franc Denominated Notes Due 2028",
        "label": "0.45% Swiss Franc Denominated Notes Due 2028 [Member]",
        "terseLabel": "0.45% Swiss franc denominated notes due 2028"
       }
      }
     },
     "localname": "A045SwissFrancDenominatedNotesDue2028Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.625NotesDueJune22026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Notes Due June 2, 2026 [Member]",
        "label": "1.625% Notes Due June 2, 2026 [Member]",
        "terseLabel": "1.625% Notes due 2026"
       }
      }
     },
     "localname": "A1.625NotesDueJune22026Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.700Notesdue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.700% Notes due 2049 [Member]",
        "label": "1.700% Notes due 2049 [Member]",
        "terseLabel": "1.700% Notes due 2049"
       }
      }
     },
     "localname": "A1.700Notesdue2049Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A10EuroDenominatedNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.0% Euro-denominated Notes Due 2022",
        "label": "1.0% Euro-denominated Notes Due 2022 [Member]",
        "terseLabel": "1.00% euro denominated notes due 2022"
       }
      }
     },
     "localname": "A10EuroDenominatedNotesDue2022Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1125NotesDue2051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.125% Notes Due 2051",
        "label": "1.125% Notes Due 2051 [Member]",
        "terseLabel": "1.125% Notes due 2051",
        "verboseLabel": "1.125% euro denominated notes due 2051"
       }
      }
     },
     "localname": "A1125NotesDue2051Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1375NotesDue2061Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.375% Notes Due 2061",
        "label": "1.375% Notes Due 2061 [Member]",
        "terseLabel": "1.375% Notes due 2061",
        "verboseLabel": "1.375% euro denominated notes due 2061"
       }
      }
     },
     "localname": "A1375NotesDue2061Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1625BritishPoundDenominatedNotesDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% British Pound Denominated Notes Due 2043",
        "label": "1.625% British Pound Denominated Notes Due 2043 [Member]",
        "terseLabel": "1.625% Notes due 2043"
       }
      }
     },
     "localname": "A1625BritishPoundDenominatedNotesDue2043Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1625EuroDenominatedNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Euro-denominated Notes Due 2026",
        "label": "1.625% Euro-denominated Notes Due 2026 [Member]",
        "terseLabel": "1.625% euro denominated notes due 2026"
       }
      }
     },
     "localname": "A1625EuroDenominatedNotesDue2026Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A17EuroDenominatedNotesDue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.7% Euro-deonominated Notes Due 2049 [Member]",
        "label": "1.7% Euro-denominated Notes Due 2049 [Member]",
        "terseLabel": "1.70% euro denominated notes due 2049"
       }
      }
     },
     "localname": "A17EuroDenominatedNotesDue2049Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A2.125NotesDueJune32030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.125% Notes Due June 3, 2030 [Member]",
        "label": "2.125% Notes Due June 3, 2030 [Member]",
        "terseLabel": "2.125% Notes due 2030"
       }
      }
     },
     "localname": "A2.125NotesDueJune32030Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A2125EuroDenominatedNotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.125% Euro-denominated Notes Due 2030",
        "label": "2.125% Euro-denominated Notes Due 2030 [Member]",
        "terseLabel": "2.125% euro denominated notes due 2030"
       }
      }
     },
     "localname": "A2125EuroDenominatedNotesDue2030Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A225NotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.25% Notes Due 2050 [Member]",
        "label": "2.25% Notes Due 2050 [Member]",
        "terseLabel": "2.25% notes due 2050"
       }
      }
     },
     "localname": "A225NotesDue2050Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A235NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.35% Notes Due 2022",
        "label": "2.35% Notes Due 2022 [Member]",
        "terseLabel": "2.35% notes due 2022"
       }
      }
     },
     "localname": "A235NotesDue2022Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A25NotesDue2060Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.5% Notes Due 2060",
        "label": "2.5% Notes Due 2060 [Member]",
        "terseLabel": "2.50% notes due 2060"
       }
      }
     },
     "localname": "A25NotesDue2060Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A275NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.75% Notes Due 2025",
        "label": "2.75% Notes Due 2025 [Member]",
        "terseLabel": "2.75% notes due 2025"
       }
      }
     },
     "localname": "A275NotesDue2025Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A30NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.0% Notes Due 2022",
        "label": "3.0% Notes Due 2022 [Member]",
        "terseLabel": "3.00% notes due 2022"
       }
      }
     },
     "localname": "A30NotesDue2022Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A31NotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.1% Notes Due 2027",
        "label": "3.1% Notes Due 2027 [Member]",
        "terseLabel": "3.1% notes due 2027"
       }
      }
     },
     "localname": "A31NotesDue2027Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A3375NotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.375% Notes Due 2029",
        "label": "3.375% Notes Due 2029 [Member]",
        "terseLabel": "3.375% notes due 2029"
       }
      }
     },
     "localname": "A3375NotesDue2029Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A37NotesDue2045Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.7% Notes Due 2045",
        "label": "3.7% Notes Due 2045 [Member]",
        "terseLabel": "3.7% notes due 2045"
       }
      }
     },
     "localname": "A37NotesDue2045Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A3875NotesDue2039Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2039 [Member]",
        "label": "3.875% Notes Due 2039 [Member]",
        "terseLabel": "3.875% notes due 2039"
       }
      }
     },
     "localname": "A3875NotesDue2039Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A395NotesDue2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.95% Notes Due 2047",
        "label": "3.95% Notes Due 2047 [Member]",
        "terseLabel": "3.95% notes due 2047"
       }
      }
     },
     "localname": "A395NotesDue2047Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A395NotesDue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.95% Notes Due 2049 [Member]",
        "label": "3.95% Notes Due 2049 [Member]",
        "terseLabel": "3.95% notes due 2049"
       }
      }
     },
     "localname": "A395NotesDue2049Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A415NotesDue2059Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.15% Notes Due 2059 [Member]",
        "label": "4.15% Notes Due 2059 [Member]",
        "terseLabel": "4.15% notes due 2059"
       }
      }
     },
     "localname": "A415NotesDue2059Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A42YenDenominatedNotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".42% Yen-denominated Notes Due 2029 [Member]",
        "label": ".42% Yen-denominated Notes Due 2029 [Member]",
        "terseLabel": "0.42% Japanese yen denominated notes due 2029"
       }
      }
     },
     "localname": "A42YenDenominatedNotesDue2029Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A465NotesDue2044Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.65% Notes Due 2044",
        "label": "4.65% Notes Due 2044 [Member]",
        "terseLabel": "4.65% notes due 2044"
       }
      }
     },
     "localname": "A465NotesDue2044Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A5000NotesDue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".5000% Notes Due 2033",
        "label": ".5000% Notes Due 2033 [Member]",
        "terseLabel": "0.500% Notes due 2033",
        "verboseLabel": "0.50% euro denominated notes due 2033"
       }
      }
     },
     "localname": "A5000NotesDue2033Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A555NotesDue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.55% Notes Due 2037",
        "label": "5.55% Notes Due 2037 [Member]",
        "terseLabel": "5.55% notes due 2037"
       }
      }
     },
     "localname": "A555NotesDue2037Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A55NotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.5% Notes Due 2027",
        "label": "5.5% Notes Due 2027 [Member]",
        "terseLabel": "5.5% notes due 2027"
       }
      }
     },
     "localname": "A55NotesDue2027Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A56YenDenominatedNotesDue2034Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".56% Yen-denominated Notes Due 2034 [Member]",
        "label": ".56% Yen-denominated Notes Due 2034 [Member]",
        "terseLabel": "0.56% Japanese yen denominated notes due 2034"
       }
      }
     },
     "localname": "A56YenDenominatedNotesDue2034Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A595NotesDue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.95% Notes Due 2037",
        "label": "5.95% Notes Due 2037 [Member]",
        "terseLabel": "5.95% notes due 2037"
       }
      }
     },
     "localname": "A595NotesDue2037Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A6.77NotesDueJanuary12036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "label": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "terseLabel": "6.77%\u00a0Notes due 2036"
       }
      }
     },
     "localname": "A6.77NotesDueJanuary12036Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A625EuroDenominatedNotesDue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".625% Euro-deonominated Notes Due 2031 [Member]",
        "label": ".625% Euro-denominated Notes Due 2031 [Member]",
        "terseLabel": "0.625% euro denominated notes due 2031"
       }
      }
     },
     "localname": "A625EuroDenominatedNotesDue2031Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A625Notesdue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".625% Notes due 2031 [Member]",
        "label": ".625% Notes due 2031 [Member]",
        "terseLabel": "0.625% Notes due 2031"
       }
      }
     },
     "localname": "A625Notesdue2031Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A677NotesDue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.77% Notes Due 2036",
        "label": "6.77% Notes Due 2036 [Member]",
        "terseLabel": "6.77% notes due 2036"
       }
      }
     },
     "localname": "A677NotesDue2036Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A7125NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7.125% Notes Due 2025",
        "label": "7.125% Notes Due 2025 [Member]",
        "terseLabel": "7.125% notes due 2025"
       }
      }
     },
     "localname": "A7125NotesDue2025Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A718NotesDueJune12025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "label": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "terseLabel": "7 1/8% Notes due 2025"
       }
      }
     },
     "localname": "A718NotesDueJune12025Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A97YenDenominatedNotesDue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".97% Yen-denominated Notes Due 2049",
        "label": ".97% Yen-denominated Notes Due 2049 [Member]",
        "terseLabel": "0.97% Japanese yen denominated notes due 2049"
       }
      }
     },
     "localname": "A97YenDenominatedNotesDue2049Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible",
        "label": "Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible",
        "terseLabel": "Long-term income taxes payable, estimated timing of future cash outflows not possible"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Other, net of tax"
       }
      }
     },
     "localname": "AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AcquiredInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense related to research and development that are acquired directly in a transaction other than a business combination, that do not have an alternative future use and are therefore written off in the period of acquisition.",
        "label": "Acquired in-process research and development",
        "verboseLabel": "Acquired in-process research and development and development milestones (Note 3)"
       }
      }
     },
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired In-Process Research And Development And Development Milestones",
        "label": "Acquired In-Process Research And Development And Development Milestones",
        "terseLabel": "Acquired in-process research and development and development milestones",
        "verboseLabel": "Acquired in-process research and development and development milestones (Note 3)"
       }
      }
     },
     "localname": "AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AddDeductAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Add (Deduct) [Abstract]",
        "label": "Add (Deduct) [Abstract]",
        "terseLabel": "Add (deduct):"
       }
      }
     },
     "localname": "AddDeductAbstract",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_AdvertisingExpensePercentageOfRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advertising Expense, Percentage Of Revenue",
        "label": "Advertising Expense, Percentage Of Revenue",
        "terseLabel": "Advertising expense, percentage of revenue"
       }
      }
     },
     "localname": "AdvertisingExpensePercentageOfRevenue",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_AkouosAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Akouos Acquisition [Member]",
        "label": "Akouos Acquisition [Member]",
        "terseLabel": "Akouos Acquisition"
       }
      }
     },
     "localname": "AkouosAcquisitionMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AlimtaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alimta [Member]",
        "label": "Alimta [Member]",
        "terseLabel": "Alimta\u00ae"
       }
      }
     },
     "localname": "AlimtaMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Impairment Charges (Recoveries) And Other Special Charges",
        "label": "Asset Impairment Charges (Recoveries) And Other Special Charges",
        "terseLabel": "Asset impairment (gain) and other special charges"
       }
      }
     },
     "localname": "AssetImpairmentChargesRecoveriesAndOtherSpecialCharges",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.lilly.com/20221231",
     "xbrltype": "stringItemType"
    },
    "lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for Sale Securities and Equity Securities, FV-NI, Realized Gain",
        "label": "Available for Sale Securities and Equity Securities, FV-NI, Realized Gain",
        "terseLabel": "Realized gross gains on sales"
       }
      }
     },
     "localname": "AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale Securities and Equity Securities, FV-NI, Realized Loss",
        "label": "Available for sale Securities and Equity Securities, FV-NI, Realized Loss",
        "terseLabel": "Realized gross losses on sales"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_BasaglarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basaglar [Member]",
        "label": "Basaglar [Member]",
        "verboseLabel": "Basaglar\u00ae"
       }
      }
     },
     "localname": "BasaglarMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BioMarinPharmaceuticalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioMarin Pharmaceutical Inc",
        "label": "BioMarin Pharmaceutical Inc [Member]",
        "terseLabel": "BioMarin Pharmaceutical Inc."
       }
      }
     },
     "localname": "BioMarinPharmaceuticalIncMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Contingent Value Right, Additional Price Per Share",
        "label": "Business Acquisition, Contingent Value Right, Additional Price Per Share",
        "terseLabel": "Contingent value right, additional price per share (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentValueRightAdditionalPricePerShare",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs",
        "label": "Business Acquisition, Contingent Value Right, Regulatory Approval Delay, Monthly Reduction",
        "terseLabel": "Contingent value right, monthly reduction"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Number Of Contingent Value Rights",
        "label": "Business Combination, Consideration Transferred, Number Of Contingent Value Rights",
        "terseLabel": "Consideration transferred, number of contingent value rights"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredNumberOfContingentValueRights",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net",
        "terseLabel": "Other assets and liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_BuyEuroSellUsDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Forward Commitment to Buy euro Sell US dollar",
        "label": "Buy Euro Sell Us Dollar [Member]",
        "terseLabel": "Buy Euro Sell USD"
       }
      }
     },
     "localname": "BuyEuroSellUsDollarMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyGBPSellUSDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy GBP Sell USD",
        "label": "Buy GBP Sell USD [Member]",
        "terseLabel": "Buy GBP Sell USD"
       }
      }
     },
     "localname": "BuyGBPSellUSDMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyJapaneseYenSellUSDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy Japanese Yen Sell US Dollar",
        "label": "Buy Japanese Yen Sell US Dollar [Member]",
        "terseLabel": "Buy Japanese Yen Sell US Dollar"
       }
      }
     },
     "localname": "BuyJapaneseYenSellUSDollarMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuySwissFrancSellUSDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy Swiss Franc Sell US Dollar",
        "label": "Buy Swiss Franc Sell US Dollar [Member]",
        "terseLabel": "Buy Swiss Franc Sell US Dollar"
       }
      }
     },
     "localname": "BuySwissFrancSellUSDollarMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyUSDollarSellChineseYuanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy US Dollar Sell Chinese Yuan",
        "label": "Buy US Dollar Sell Chinese Yuan [Member]",
        "terseLabel": "Buy US Dollar Sell Chinese Yuan"
       }
      }
     },
     "localname": "BuyUSDollarSellChineseYuanMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyUSdollarSellJapaneseYenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy US dollar Sell Japanese Yen [Member]",
        "label": "Buy US dollar Sell Japanese Yen [Member]",
        "terseLabel": "Buy USD Sell Japanese Yen"
       }
      }
     },
     "localname": "BuyUSdollarSellJapaneseYenMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyUsdSellEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy USD Sell Euro [Member]",
        "label": "Buy USD Sell Euro [Member]",
        "terseLabel": "Buy USD Sell Euro"
       }
      }
     },
     "localname": "BuyUsdSellEuroMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ByettaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Byetta",
        "label": "Byetta [Member]",
        "terseLabel": "Byetta"
       }
      }
     },
     "localname": "ByettaMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_COVID19AntibodiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Antibodies",
        "label": "COVID-19 Antibodies [Member]",
        "terseLabel": "COVID-19 Antibodies",
        "verboseLabel": "COVID-19 antibodies"
       }
      }
     },
     "localname": "COVID19AntibodiesMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Carryforward [Member]",
        "label": "Carryforward [Member]",
        "terseLabel": "Carryforward"
       }
      }
     },
     "localname": "CarryforwardMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CashFlowHedgeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow Hedge [Abstract]",
        "label": "Cash Flow Hedge [Abstract]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "CashFlowHedgeAbstract",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_CialisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cialis [Member]",
        "label": "Cialis [Member]",
        "terseLabel": "Cialis\u00ae"
       }
      }
     },
     "localname": "CialisMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CollaborationandOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and Other Revenue [Member]",
        "label": "Collaboration and Other Revenue [Member]",
        "verboseLabel": "Collaboration and other revenue"
       }
      }
     },
     "localname": "CollaborationandOtherRevenueMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CollaborativeArrangementRightsAndObligationsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.",
        "label": "Collaborative Arrangement, Rights and Obligations Percent",
        "terseLabel": "Collaborative arrangement, rights and obligations percent (up to)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPercent",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_CollaborativeArrangementRightsAndObligationsRightsObligations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Rights (Obligations)",
        "label": "Collaborative Arrangement, Rights and Obligations, Rights (Obligations)",
        "terseLabel": "Potential achievements"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsRightsObligations",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CostOfSalesOperatingExpensesAndOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of sales, operating expenses, and other-net",
        "label": "Cost of sales, operating expenses, and other-net",
        "totalLabel": "Costs, expenses, and other"
       }
      }
     },
     "localname": "CostOfSalesOperatingExpensesAndOtherNet",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward",
        "label": "Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward",
        "terseLabel": "Current federal tax expense, utilization of net operating loss carryforward"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CymbaltaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cymbalta [Member]",
        "label": "Cymbalta [Member]",
        "terseLabel": "Cymbalta\u00ae"
       }
      }
     },
     "localname": "CymbaltaMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CyramzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cyramza [Member]",
        "label": "Cyramza [Member]",
        "terseLabel": "Cyramza\u00ae"
       }
      }
     },
     "localname": "CyramzaMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, Unrealized Gain Position",
        "label": "Debt Securities, Available-for-sale, Unrealized Gain Position",
        "terseLabel": "Fair value of securities in an unrealized gain position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforsaleUnrealizedGainPosition",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DeferredTaxAssetsCorrectiveTaxAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Corrective Tax Adjustments",
        "label": "Deferred Tax Assets, Corrective Tax Adjustments",
        "terseLabel": "Correlative tax adjustments"
       }
      }
     },
     "localname": "DeferredTaxAssetsCorrectiveTaxAdjustments",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DeferredTaxAssetsForeignTaxRedeterminations": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Foreign Tax Redeterminations",
        "label": "Deferred Tax Assets, Foreign Tax Redeterminations",
        "terseLabel": "Foreign tax redeterminations"
       }
      }
     },
     "localname": "DeferredTaxAssetsForeignTaxRedeterminations",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease, Liability",
        "label": "Deferred Tax Assets, Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DeferredTaxAssetsSalesRebatesAndDiscounts": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Sales Rebates And Discounts",
        "label": "Deferred Tax Assets, Sales Rebates And Discounts",
        "terseLabel": "Sales rebates and discounts"
       }
      }
     },
     "localname": "DeferredTaxAssetsSalesRebatesAndDiscounts",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DefineBenefitPlanOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Define Benefit Plan, Other [Member]",
        "label": "Define Benefit Plan, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DefineBenefitPlanOtherMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage description of US defined benefit and other postretirement plan assets as compared to the total global investment balance",
        "label": "Defined Benefit Plan, Percentage of Global Investments in Plan Assets",
        "terseLabel": "Percentage of global investments in plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_DerivativeInstrumentsGainLossRecognized": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instruments, Gain (Loss) Recognized",
        "label": "Derivative Instruments, Gain (Loss) Recognized",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossRecognized",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DermiraInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dermira, Inc. [Member]",
        "label": "Dermira, Inc. [Member]",
        "terseLabel": "Dermira"
       }
      }
     },
     "localname": "DermiraInc.Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DescriptionOfDerivativeActivityVolumePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of Derivative Activity Volume Percent",
        "label": "Description of Derivative Activity Volume Percent",
        "terseLabel": "Description of derivative activity volume percent"
       }
      }
     },
     "localname": "DescriptionOfDerivativeActivityVolumePercent",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_DesignatedUnusableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Those operating loss/tax credit carryforwards/carrybacks included that have been designated to be unusable and therefore, is fully reserved.",
        "label": "Designated Unusable [Member]",
        "terseLabel": "Designated Unusable"
       }
      }
     },
     "localname": "DesignatedUnusableMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diabetes",
        "label": "Diabetes [Member]",
        "terseLabel": "Diabetes"
       }
      }
     },
     "localname": "DiabetesMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DisarmTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disarm Therapeutics, Inc.",
        "label": "Disarm Therapeutics, Inc. [Member]",
        "terseLabel": "Disarm Therapeutics, Inc."
       }
      }
     },
     "localname": "DisarmTherapeuticsIncMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent contribution of most significant (domestic, including Puerto Rico) areas that contributed to the consolidated income (loss) before income taxes.",
        "label": "Domestic and Puerto Rican Contribution to Income before Income Taxes",
        "terseLabel": "Domestic and Puerto Rican companies contribution"
       }
      }
     },
     "localname": "DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_EmgalityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emgality [Member]",
        "label": "Emgality [Member]",
        "terseLabel": "Emgality\u00ae"
       }
      }
     },
     "localname": "EmgalityMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmgalityPatentLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emgality Patent Litigation [Member]",
        "label": "Emgality Patent Litigation [Member]",
        "terseLabel": "Emgality Patent Litigation"
       }
      }
     },
     "localname": "EmgalityPatentLitigationMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmployeeLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Litigation [Member]",
        "label": "Employee Litigation [Member]",
        "terseLabel": "Employee Litigation"
       }
      }
     },
     "localname": "EmployeeLitigationMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EquityMethodAndOtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method and Other Investments [Member]",
        "label": "Equity Method And Other Investments [Member]",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodAndOtherInvestmentsMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ErbituxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Erbitux [Member]",
        "label": "Erbitux [Member]",
        "terseLabel": "Erbitux\u00ae"
       }
      }
     },
     "localname": "ErbituxMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ExpirationBetween2028And2042Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Between 2028 and 2042 [Member]",
        "label": "Expiration Between 2028 and 2042 [Member]",
        "terseLabel": "Expiration Between 2028 and 2042"
       }
      }
     },
     "localname": "ExpirationBetween2028And2042Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ExpirationBy2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration By 2026 [Member]",
        "label": "Expiration By 2026 [Member]",
        "terseLabel": "Expiration By 2026"
       }
      }
     },
     "localname": "ExpirationBy2026Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ExpirationBy2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration By 2027 [Member]",
        "label": "Expiration By 2027 [Member]",
        "terseLabel": "Expiration By 2027"
       }
      }
     },
     "localname": "ExpirationBy2027Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_FairValueHedgeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Hedge [Abstract]",
        "label": "Fair Value Hedge [Abstract]",
        "terseLabel": "Fair value hedges:"
       }
      }
     },
     "localname": "FairValueHedgeAbstract",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period",
        "label": "Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period",
        "terseLabel": "Unfunded commitments to invest in venture capital funds, anticipated payment period"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_FixedIncomeFundsEmergingMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An investment that pools funds from many investors to invest in a combination of underlying investments, primarily fixed income investments in EMERGING MARKETS.",
        "label": "Fixed Income Funds Emerging Markets [Member]",
        "terseLabel": "Emerging markets"
       }
      }
     },
     "localname": "FixedIncomeFundsEmergingMarketsMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_FixedIncomeFundsRepurchasedAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Income Funds - Repurchased Agreements [Member]",
        "label": "Fixed Income Funds - Repurchased Agreements [Member]",
        "terseLabel": "Developed markets - repurchase agreements"
       }
      }
     },
     "localname": "FixedIncomeFundsRepurchasedAgreementsMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_FoghornTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foghorn Therapeutics Inc.",
        "label": "Foghorn Therapeutics Inc. [Member]",
        "terseLabel": "Foghorn Therapeutics Inc."
       }
      }
     },
     "localname": "FoghornTherapeuticsIncMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ForeignCurrencyDenominatedDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Denominated Debt [Member]",
        "label": "Foreign Currency Denominated Debt [Member]",
        "terseLabel": "Foreign Currency Denominated Debt"
       }
      }
     },
     "localname": "ForeignCurrencyDenominatedDebtMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ForteoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forteo [Member]",
        "label": "Forteo [Member]",
        "terseLabel": "Forteo\u00ae"
       }
      }
     },
     "localname": "ForteoMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HedgedFixedRateDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedged Fixed-Rate Debt [Member]",
        "label": "Hedged Fixed Rate Debt [Member]",
        "terseLabel": "Hedged Fixed Rate Debt"
       }
      }
     },
     "localname": "HedgedFixedRateDebtMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumalogHumulinAndForteoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humalog, Humulin, And Forteo",
        "label": "Humalog, Humulin, And Forteo [Member]",
        "terseLabel": "Humalog, Humulin and Forteo"
       }
      }
     },
     "localname": "HumalogHumulinAndForteoMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumalogMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humalog [Member]",
        "label": "Humalog [Member]",
        "terseLabel": "Humalog\u00ae"
       }
      }
     },
     "localname": "HumalogMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumulinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humulin [Member]",
        "label": "Humulin [Member]",
        "terseLabel": "Humulin\u00ae"
       }
      }
     },
     "localname": "HumulinMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunology [Member]",
        "label": "Immunology [Member]",
        "terseLabel": "Immunology"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_InnoventBiologicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovent Biologics, Inc.",
        "label": "Innovent Biologics, Inc. [Member]",
        "terseLabel": "Innovent Biologics, Inc. (Innovent)"
       }
      }
     },
     "localname": "InnoventBiologicsIncMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_JardianceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jardiance [Member]",
        "label": "Jardiance [Member]",
        "verboseLabel": "Jardiance\u00ae"
       }
      }
     },
     "localname": "JardianceMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LebrikizumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lebrikizumab [Member]",
        "label": "Lebrikizumab [Member]",
        "terseLabel": "Lebrikizumab"
       }
      }
     },
     "localname": "LebrikizumabMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LesseeLeaseRemainingLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Lease, Remaining Lease Term",
        "label": "Lessee, Lease, Remaining Lease Term",
        "terseLabel": "Lessee, lease, remaining lease term (up to)"
       }
      }
     },
     "localname": "LesseeLeaseRemainingLeaseTerm",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_LongTermDebtFairValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value adjustment to carrying value of long term debt to arrive at total fair value.",
        "label": "Long-term Debt, Fair Value Adjustment",
        "terseLabel": "Fair value adjustment on hedged long-term notes"
       }
      }
     },
     "localname": "LongTermDebtFairValueAdjustment",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_LossContingencyNumberOfPatents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Patents",
        "label": "Loss Contingency, Number Of Patents",
        "terseLabel": "Number of patents"
       }
      }
     },
     "localname": "LossContingencyNumberOfPatents",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup",
        "label": "Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup",
        "terseLabel": "Number of sites jointly and severally liable for cleanup (fewer than)"
       }
      }
     },
     "localname": "LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities [Member]",
        "label": "Marketable Securities [Member]",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MaturityDate2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity Date, 2019 [Member]",
        "label": "Maturity Date, 2023 [Member]",
        "terseLabel": "Maturity Date, 2019"
       }
      }
     },
     "localname": "MaturityDate2023Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MaturityDate2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity Date, 2026",
        "label": "Maturity Date, 2026 [Member]",
        "terseLabel": "Maturity Date, 2023"
       }
      }
     },
     "localname": "MaturityDate2026Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_May2021ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "May 2021 Share Repurchase Program",
        "label": "May 2021 Share Repurchase Program [Member]",
        "terseLabel": "May 2021 Share Repurchase Program"
       }
      }
     },
     "localname": "May2021ShareRepurchaseProgramMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsDevelopmentAndRegulatoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Development and Regulatory [Member]",
        "label": "Milestone Payments, Development and Regulatory [Member]",
        "terseLabel": "Milestone Payments, Development and Regulatory"
       }
      }
     },
     "localname": "MilestonePaymentsDevelopmentAndRegulatoryMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]",
        "label": "Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member]",
        "terseLabel": "Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative"
       }
      }
     },
     "localname": "MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsSalesBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Sales-based [Member]",
        "label": "Milestone Payments, Sales-based [Member]",
        "terseLabel": "Milestone Payments, Sales-based"
       }
      }
     },
     "localname": "MilestonePaymentsSalesBasedMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MounjaroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mounjaro",
        "label": "Mounjaro [Member]",
        "terseLabel": "Mounjaro\u00ae"
       }
      }
     },
     "localname": "MounjaroMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue to unaffiliated customers, Neuroscience",
        "label": "Neuroscience [Member]",
        "terseLabel": "Neuroscience"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_NoExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Those operating loss/tax credit carryforwards/carrybacks included that have no expiration.",
        "label": "No Expiration [Member]",
        "terseLabel": "No Expiration"
       }
      }
     },
     "localname": "NoExpirationMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OlumiantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Olumiant [Member]",
        "label": "Olumiant [Member]",
        "terseLabel": "Olumiant\u00ae"
       }
      }
     },
     "localname": "OlumiantMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue to unaffiliated customers, Oncology",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherDiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Diabetes",
        "label": "Other Diabetes [Member]",
        "terseLabel": "Other diabetes"
       }
      }
     },
     "localname": "OtherDiabetesMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Equity Securities [Member]",
        "label": "Other Equity Securities [Member]",
        "terseLabel": "Other securities, noncurrent investments"
       }
      }
     },
     "localname": "OtherEquitySecuritiesMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherForeignCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Foreign Countries [Member]",
        "label": "Other Foreign Countries [Member]",
        "terseLabel": "Other foreign countries",
        "verboseLabel": "Other foreign countries"
       }
      }
     },
     "localname": "OtherForeignCountriesMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Immunology",
        "label": "Other Immunology [Member]",
        "terseLabel": "Other immunology"
       }
      }
     },
     "localname": "OtherImmunologyMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherNeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Neuroscience [Member]",
        "label": "Other Neuroscience [Member]",
        "terseLabel": "Other neuroscience"
       }
      }
     },
     "localname": "OtherNeuroscienceMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Oncology [Member]",
        "label": "Other Oncology [Member]",
        "terseLabel": "Other oncology"
       }
      }
     },
     "localname": "OtherOncologyMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Product [Member]",
        "label": "Other Product [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherProductTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Product, Total [Member]",
        "label": "Other Product, Total [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductTotalMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PaymentsForAssetAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Asset Acquisitions",
        "label": "Payments for Asset Acquisitions",
        "terseLabel": "Acquired IPR&amp;D Expense"
       }
      }
     },
     "localname": "PaymentsForAssetAcquisitions",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_PetraPharmaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Petra Pharma Corporation",
        "label": "Petra Pharma Corporation [Member]",
        "terseLabel": "Petra Pharma Corporation (Petra)"
       }
      }
     },
     "localname": "PetraPharmaCorporationMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PrecisionBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Precision Biosciences, Inc.",
        "label": "Precision Biosciences, Inc. [Member]",
        "terseLabel": "Precision Biosciences, Inc."
       }
      }
     },
     "localname": "PrecisionBiosciencesIncMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PrevailTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prevail Therapeutics Inc.",
        "label": "Prevail Therapeutics Inc. [Member]",
        "terseLabel": "Prevail Therapeutics Inc."
       }
      }
     },
     "localname": "PrevailTherapeuticsIncMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Sale of Equity and Available for Sale Securities",
        "label": "Proceeds from Sale of Equity and Available for Sale Securities",
        "terseLabel": "Proceeds from sales"
       }
      }
     },
     "localname": "ProceedsfromSaleofEquityandAvailableforSaleSecurities",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_ProductLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability",
        "label": "Product Liability [Member]",
        "terseLabel": "Product Liability"
       }
      }
     },
     "localname": "ProductLiabilityMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PurchasedInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).",
        "label": "Purchased in-process research and development",
        "negatedTerseLabel": "Purchases of in-process research and development"
       }
      }
     },
     "localname": "PurchasedInProcessResearchAndDevelopment",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_RelativeValueAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relative Value Awards",
        "label": "Relative Value Awards [Member]",
        "terseLabel": "Relative Value Awards"
       }
      }
     },
     "localname": "RelativeValueAwardsMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent",
        "label": "Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent",
        "terseLabel": "Revenue, information used to determine revenue recognized, change in accounting estimate, percent (or less)"
       }
      }
     },
     "localname": "RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt",
        "label": "Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt",
        "terseLabel": "Revenue, performance obligation, payment terms, financing component, period between transfer of control and payment receipt (or less)"
       }
      }
     },
     "localname": "RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_RevenuePerformanceObligationSalesRebatePaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Sales Rebate Payment Period",
        "label": "Revenue, Performance Obligation, Sales Rebate Payment Period",
        "terseLabel": "Revenue, performance obligation, sales rebate payment period (up to)"
       }
      }
     },
     "localname": "RevenuePerformanceObligationSalesRebatePaymentPeriod",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Sales Returns, Average Inventory Level",
        "label": "Revenue, Performance Obligation, Sales Returns, Average Inventory Level",
        "terseLabel": "Revenue, performance obligation, sales returns, average inventory level (or less)"
       }
      }
     },
     "localname": "RevenuePerformanceObligationSalesReturnsAverageInventoryLevel",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue",
        "label": "Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue",
        "terseLabel": "Revenue, performance obligation, sales returns, percentage of net revenue (less than)"
       }
      }
     },
     "localname": "RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Sales Returns, Product Expiration Date",
        "label": "Revenue, Performance Obligation, Sales Returns, Product Expiration Date",
        "terseLabel": "Revenue, performance obligation, sales returns, product expiration date"
       }
      }
     },
     "localname": "RevenuePerformanceObligationSalesReturnsProductExpirationDate",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_RevenuefromContractPaymentTermMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from Contract, Payment Term, Maximum",
        "label": "Revenue from Contract, Payment Term, Maximum",
        "terseLabel": "Revenue, performance obligation, payment terms, days from date of shipment, maximum"
       }
      }
     },
     "localname": "RevenuefromContractPaymentTermMaximum",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_RevenuefromContractPaymentTermMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from Contract, Payment Term",
        "label": "Revenue from Contract, Payment Term, Minimum",
        "terseLabel": "Revenue, performance obligation, payment terms, days from date of shipment, minimum"
       }
      }
     },
     "localname": "RevenuefromContractPaymentTermMinimum",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_RigelPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rigel Pharmaceuticals, Inc.",
        "label": "Rigel Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Rigel Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "RigelPharmaceuticalsIncMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_RocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche [Member]",
        "label": "Roche [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "RocheMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SalesRebatesAndDiscounts": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales rebates and discounts",
        "label": "Sales rebates and discounts",
        "terseLabel": "Sales rebates and discounts"
       }
      }
     },
     "localname": "SalesRebatesAndDiscounts",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Additional Borrowings Disclosures [Table Text Block]",
        "label": "Schedule of Additional Borrowings Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Additional Borrowings Disclosures"
       }
      }
     },
     "localname": "ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Additional Income Tax Disclosures [Table Text Block]",
        "label": "Schedule of Additional Income Tax Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Cash Payments Relating to Income Taxes and Tax Act Toll Tax"
       }
      }
     },
     "localname": "ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]",
        "label": "Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Additional Stock-Based Compensation Disclosures"
       }
      }
     },
     "localname": "ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lly_SellChineseYuanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sell Chinese Yuan",
        "label": "Sell Chinese Yuan [Member]",
        "terseLabel": "Sell Chinese Yuan"
       }
      }
     },
     "localname": "SellChineseYuanMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SellEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sell Euro [Member]",
        "label": "Sell Euro [Member]",
        "terseLabel": "Sell Euro"
       }
      }
     },
     "localname": "SellEuroMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SeniorNotesDueMay2050AndSeptember2060Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due May 2050 And September 2060",
        "label": "Senior Notes Due May 2050 And September 2060 [Member]",
        "terseLabel": "Senior Notes Due May 2050 and September 2060"
       }
      }
     },
     "localname": "SeniorNotesDueMay2050AndSeptember2060Member",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares expected to be issued in the next twelve months under the plan.",
        "label": "Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued",
        "terseLabel": "Shares expected to be issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]",
        "label": "Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]",
        "terseLabel": "Share-based Compensation Awards, Fair Value Assumptions Used"
       }
      }
     },
     "localname": "SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lly_ShareholderValueAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder Value Awards are granted to officers and management and are payable in shares of common stock at the end of a 3 yr period.",
        "label": "Shareholder Value Awards [Member]",
        "terseLabel": "Shareholder Value Awards"
       }
      }
     },
     "localname": "ShareholderValueAwardsMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SwapSwissFrancsToU.S.DollarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap Swiss Francs To U.S. Dollars [Member]",
        "label": "Swap Swiss Francs To U.S. Dollars [Member]",
        "terseLabel": "Swap Swiss Francs to USD"
       }
      }
     },
     "localname": "SwapSwissFrancsToU.S.DollarsMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SwapUSDollarsToEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap U.S. Dollars To Euro",
        "label": "Swap U.S. Dollars To Euro [Member]",
        "terseLabel": "Swap U.S Dollars To Euro"
       }
      }
     },
     "localname": "SwapUSDollarsToEuroMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TYVYTMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TYVYT",
        "label": "TYVYT [Member]",
        "terseLabel": "Tyvyt\u00ae"
       }
      }
     },
     "localname": "TYVYTMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TaltzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taltz [Member]",
        "label": "Taltz [Member]",
        "terseLabel": "Taltz\u00ae"
       }
      }
     },
     "localname": "TaltzMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TaxCutAndJobsActTollTaxPaymentDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cut And Jobs Act, Toll Tax, Payment, Due",
        "label": "Tax Cut And Jobs Act, Toll Tax, Payment, Due [Abstract]",
        "terseLabel": "2017 Tax Act Toll Tax"
       }
      }
     },
     "localname": "TaxCutAndJobsActTollTaxPaymentDueAbstract",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_TaxCutAndJobsActTollTaxToBePaid": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cut And Jobs Act, Toll Tax, To Be Paid",
        "label": "Tax Cut And Jobs Act, Toll Tax, To Be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "TaxCutAndJobsActTollTaxToBePaid",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails": {
       "order": 2.0,
       "parentTag": "lly_TaxCutAndJobsActTollTaxToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years",
        "label": "Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years",
        "terseLabel": "1-3 Years"
       }
      }
     },
     "localname": "TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails": {
       "order": 1.0,
       "parentTag": "lly_TaxCutAndJobsActTollTaxToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year",
        "label": "Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year",
        "terseLabel": "Less than 1 Year"
       }
      }
     },
     "localname": "TaxCutAndJobsActTollTaxToBePaidWithinOneYear",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_ThreeLargestWholesalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Largest Wholesales [Member]",
        "label": "Three Largest Wholesales [Member]",
        "terseLabel": "Three Largest Wholesales"
       }
      }
     },
     "localname": "ThreeLargestWholesalesMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TrajentaBIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trajenta (BI) [Member]",
        "label": "Trajenta (BI) [Member]",
        "verboseLabel": "Trajenta\u00ae"
       }
      }
     },
     "localname": "TrajentaBIMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TrulicityMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trulicity [Member] [Member]",
        "label": "Trulicity [Member] [Member]",
        "terseLabel": "Trulicity\u00ae"
       }
      }
     },
     "localname": "TrulicityMemberMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_UNITEDSTATESAndPUERTORICOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UNITED STATES And PUERTO RICO [Member]",
        "label": "UNITED STATES And PUERTO RICO [Member]",
        "verboseLabel": "U.S. and Puerto Rico"
       }
      }
     },
     "localname": "UNITEDSTATESAndPUERTORICOMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_VerzenioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verzenio [Member]",
        "label": "Verzenio [Member]",
        "terseLabel": "Verzenio\u00ae"
       }
      }
     },
     "localname": "VerzenioMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ZyprexaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zyprexa [Member]",
        "label": "Zyprexa [Member]",
        "terseLabel": "Zyprexa\u00ae"
       }
      }
     },
     "localname": "ZyprexaMember",
     "nsuri": "http://www.lilly.com/20221231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r376",
      "r813",
      "r905",
      "r950"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r423",
      "r570",
      "r745",
      "r766",
      "r790",
      "r791",
      "r810",
      "r828",
      "r839",
      "r902",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r423",
      "r570",
      "r745",
      "r766",
      "r790",
      "r791",
      "r810",
      "r828",
      "r839",
      "r902",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r376",
      "r813",
      "r905",
      "r950"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r373",
      "r747",
      "r811",
      "r837",
      "r897",
      "r898",
      "r905",
      "r949"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r373",
      "r747",
      "r811",
      "r837",
      "r897",
      "r898",
      "r905",
      "r949"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r423",
      "r517",
      "r570",
      "r601",
      "r602",
      "r603",
      "r721",
      "r745",
      "r766",
      "r790",
      "r791",
      "r810",
      "r828",
      "r839",
      "r893",
      "r902",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r423",
      "r517",
      "r570",
      "r601",
      "r602",
      "r603",
      "r721",
      "r745",
      "r766",
      "r790",
      "r791",
      "r810",
      "r828",
      "r839",
      "r893",
      "r902",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r374",
      "r375",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r812",
      "r838",
      "r905"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r374",
      "r375",
      "r774",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r812",
      "r838",
      "r905"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r23",
      "r836"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r377",
      "r378"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowances of $16.0 (2022)\u00a0and $22.5 (2021)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r10",
      "r241",
      "r261"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term income taxes payable (Note 14)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r42",
      "r49",
      "r193",
      "r861",
      "r862",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Defined Benefit Pension and Retiree\u00a0Health Benefit Plans",
        "verboseLabel": "Amortization of retirement benefit items"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r41",
      "r49",
      "r193",
      "r311",
      "r862",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Actuarial losses"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r44",
      "r49",
      "r193",
      "r311",
      "r862",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Prior service benefits, net"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r113",
      "r281"
     ],
     "calculation": {
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r40",
      "r49",
      "r193",
      "r311",
      "r862",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign Currency Translation Gains\u00a0(Losses)"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
     "auth_ref": [
      "r302",
      "r311",
      "r666",
      "r862",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
        "terseLabel": "Effective Portion of Cash\u00a0Flow Hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r302",
      "r311",
      "r862",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized Net Gains (Losses) on\u00a0Securities"
       }
      }
     },
     "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r46",
      "r48",
      "r49",
      "r291",
      "r761",
      "r771",
      "r772"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss (Note 17)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r311",
      "r312",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r45",
      "r49",
      "r193",
      "r714",
      "r767",
      "r768",
      "r861",
      "r862",
      "r863",
      "r875",
      "r876",
      "r877"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r610",
      "r611",
      "r612",
      "r875",
      "r876",
      "r877",
      "r928"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Expenses"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r616"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r605"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r292",
      "r379",
      "r391"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, allowances"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r76",
      "r98",
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r45",
      "r49",
      "r193",
      "r861",
      "r862",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r921"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r921"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "auth_ref": [
      "r921"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for asset acquisition.",
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "AssetAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r818",
      "r881"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r238",
      "r260",
      "r284",
      "r326",
      "r364",
      "r367",
      "r371",
      "r389",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r662",
      "r667",
      "r689",
      "r836",
      "r900",
      "r901",
      "r939"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r275",
      "r295",
      "r326",
      "r389",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r662",
      "r667",
      "r689",
      "r836",
      "r900",
      "r901",
      "r939"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized gross gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Unrealized gross losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r94",
      "r383",
      "r758"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "6-10 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r94",
      "r382",
      "r757"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "1-5 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r94",
      "r384",
      "r759"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "More Than 10 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r94",
      "r381",
      "r756"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Less Than 1 Year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r91",
      "r380",
      "r397",
      "r751"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r89",
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r89",
      "r279",
      "r397"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Noncurrent investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the percentage of nonperforming assets that the underlying assets in the security represent and which were considered as one of the potential factors in reaching a conclusion that the available-for-sale investments are not other-than-temporarily impaired.",
        "label": "Available-for-Sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets",
        "terseLabel": "Percentage of nonperforming assets"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average period remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Average Remaining Maturity of Foreign Currency Derivatives",
        "terseLabel": "Average remaining maturity of foreign currency derivatives"
       }
      }
     },
     "localname": "AverageRemainingMaturityOfForeignCurrencyDerivatives1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r655",
      "r822",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r655",
      "r822",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business acquisition, share price (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r181",
      "r182",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Contingent value right, additional price per share, aggregate amount"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r180",
      "r183",
      "r657"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "negatedTerseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r180",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "negatedTerseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r187",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": {
     "auth_ref": [
      "r176",
      "r177"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability",
        "negatedTerseLabel": "Fair value of CVR liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt",
        "terseLabel": "Long-term debt assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Acquisition date fair value of consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r226",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "negatedTerseLabel": "Cash acquired"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r78",
      "r278",
      "r793"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents (Note 7)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r72",
      "r78",
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and Cash Equivalents at End of Year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r72",
      "r230"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash flow hedges"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r83",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Change in Accounting Estimate [Line Items]",
        "terseLabel": "Change in Accounting Estimate [Line Items]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r83",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": 2.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "negatedTerseLabel": "Effect from interest rate contracts"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": 1.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "negatedTerseLabel": "Effect from hedged fixed-rate debt"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r326",
      "r346",
      "r347",
      "r349",
      "r351",
      "r355",
      "r356",
      "r389",
      "r424",
      "r426",
      "r427",
      "r428",
      "r431",
      "r432",
      "r463",
      "r464",
      "r466",
      "r470",
      "r477",
      "r689",
      "r792",
      "r851",
      "r870",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations and Other Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaper": {
     "auth_ref": [
      "r5",
      "r239",
      "r262"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.",
        "label": "Commercial Paper",
        "negatedTerseLabel": "Short-term commercial paper borrowings",
        "terseLabel": "Short-term commercial paper borrowings"
       }
      }
     },
     "localname": "CommercialPaper",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r33",
      "r248",
      "r267"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 16)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r119",
      "r417",
      "r418",
      "r776",
      "r899"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Stock (no par value)"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividend declared per share (in usd per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r875",
      "r876",
      "r928"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesHeldInEmployeeTrust": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.",
        "label": "Common Stock, Shares Held in Employee Trust",
        "negatedTerseLabel": "Employee benefit trust",
        "terseLabel": "Employee benefit trust"
       }
      }
     },
     "localname": "CommonStockSharesHeldInEmployeeTrust",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockSharesHeldInEmployeeTrustShares": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock held in a trust that has been set up specifically to accumulate stock for the sole purpose of distribution to participating employees but not yet earned.",
        "label": "Common Stock, Shares Held in Employee Trust, Shares",
        "terseLabel": "Shares held in employee trust (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesHeldInEmployeeTrustShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14",
      "r836"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock\u2014no par value Authorized shares: 3,200,000 Issued shares: 950,632 (2022)\u00a0and 954,116 (2021)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r51",
      "r307",
      "r309",
      "r317",
      "r753",
      "r763"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r62",
      "r316",
      "r752",
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r85",
      "r86",
      "r228",
      "r229",
      "r376",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r85",
      "r86",
      "r228",
      "r229",
      "r376",
      "r773",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r85",
      "r86",
      "r228",
      "r229",
      "r376",
      "r775",
      "r952"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r255",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration Risk, Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r85",
      "r86",
      "r228",
      "r229",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r85",
      "r86",
      "r228",
      "r229",
      "r376",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r904"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recorded for Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r479",
      "r480",
      "r490"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r818",
      "r820",
      "r951"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r55",
      "r747"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs, expenses, and other:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "auth_ref": [
      "r907",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "terseLabel": "Cross-currency interest rate swaps"
       }
      }
     },
     "localname": "CrossCurrencyInterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r873",
      "r918",
      "r920"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r873",
      "r918"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r172",
      "r639",
      "r647",
      "r873"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r873",
      "r918",
      "r920"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r84",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "negatedLabel": "Less current portion",
        "terseLabel": "Short-term borrowings and current maturities of long-term debt (Note 11)"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails",
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r128",
      "r324",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r449",
      "r456",
      "r457",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/Borrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r240",
      "r243",
      "r257",
      "r330",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r439",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r703",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r8",
      "r243",
      "r257",
      "r460"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Long-term notes, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r232",
      "r234",
      "r433",
      "r703",
      "r806",
      "r807"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r30",
      "r232",
      "r462",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument, interest rate, effective percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r30",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "verboseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r31",
      "r330",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r439",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r703",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r31",
      "r130",
      "r131",
      "r132",
      "r133",
      "r231",
      "r232",
      "r234",
      "r254",
      "r330",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r439",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r703",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r231",
      "r234",
      "r903"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Unamortized note discounts"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
        "label": "Debt, Long-Term and Short-Term, Combined Amount",
        "totalLabel": "Total debt"
       }
      }
     },
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r387",
      "r398",
      "r802"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Fair value of securities in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r873",
      "r919",
      "r920"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r172",
      "r873",
      "r919"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r620",
      "r621"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets (Note 14)"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r76",
      "r172",
      "r640",
      "r646",
      "r647",
      "r873"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r11",
      "r12",
      "r242",
      "r256",
      "r634"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r620",
      "r621"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities (Note 14)"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r873",
      "r919",
      "r920"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Purchases of intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r170",
      "r917"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r916"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r916"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r170",
      "r917"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Tax loss and other tax carryforwards and carrybacks"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r170",
      "r917"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Deferred tax assets related to state net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r170",
      "r917"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r168",
      "r170",
      "r917"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r170",
      "r917"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Compensation and benefits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r636"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowances"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts": {
     "auth_ref": [
      "r170",
      "r917"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.",
        "label": "Deferred Tax Liabilities, Inventory",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDerivatives": {
     "auth_ref": [
      "r170",
      "r917"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from derivatives.",
        "label": "Deferred Tax Liabilities, Derivatives",
        "negatedLabel": "Financial instruments"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": {
     "auth_ref": [
      "r170",
      "r917"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets",
        "negatedLabel": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r170",
      "r917"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid employee benefits"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r170",
      "r917"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": {
     "auth_ref": [
      "r917"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.",
        "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings",
        "negatedLabel": "Earnings of foreign subsidiaries"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": {
     "auth_ref": [
      "r526"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.",
        "label": "Defined Benefit Plan, Accumulated Benefit Obligation",
        "terseLabel": "Total accumulated benefit obligation for our defined benefit pension plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": {
     "auth_ref": [
      "r43",
      "r49",
      "r909"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax",
        "terseLabel": "Accumulated other comprehensive (income) loss before income taxes"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": {
     "auth_ref": [
      "r49",
      "r538"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax",
        "negatedTerseLabel": "Unrecognized net actuarial (gain) loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r49",
      "r538"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax",
        "terseLabel": "Unrecognized prior service (benefit) cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "auth_ref": [
      "r508",
      "r820"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "terseLabel": "Actual return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "negatedTerseLabel": "Actuarial (gain) loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r495",
      "r533",
      "r558",
      "r820",
      "r821"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedTerseLabel": "Recognized actuarial (gain) loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r495",
      "r534",
      "r559",
      "r820",
      "r821"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service (benefit) cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": {
     "auth_ref": [
      "r142",
      "r145"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.",
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position",
        "totalLabel": "Net amount recognized"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]",
        "terseLabel": "Amounts recognized in the consolidated balance sheet consisted\u00a0of:"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax": {
     "auth_ref": [
      "r41",
      "r46",
      "r149"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax",
        "terseLabel": "Amortization of net actuarial (gain) loss included in net income"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r237",
      "r259",
      "r493",
      "r494",
      "r516",
      "r820"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "terseLabel": "Discount rate for benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "terseLabel": "Rate of compensation increase for benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "terseLabel": "Discount rate for net benefit costs"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "auth_ref": [
      "r542",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets",
        "terseLabel": "Expected return on plan assets for net benefit costs"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "terseLabel": "Rate of compensation increase for net benefit costs"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "periodEndLabel": "Benefit obligation at end of year",
        "periodStartLabel": "Benefit obligation at beginning of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "auth_ref": [
      "r503",
      "r566"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "negatedLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease)",
        "negatedLabel": "Defined benefit obligation, period decrease"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "auth_ref": [
      "r517",
      "r518",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r545",
      "r818",
      "r819",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "terseLabel": "Change in benefit obligation:"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "terseLabel": "Change in plan assets:"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r510",
      "r520",
      "r562",
      "r818",
      "r819",
      "r820",
      "r821"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Employer contribution"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": {
     "auth_ref": [
      "r818",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities [Member]",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember": {
     "auth_ref": [
      "r818",
      "r819",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity, not domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities, Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesNonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember": {
     "auth_ref": [
      "r818",
      "r819",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity, domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities, US [Member]",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]",
        "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "verboseLabel": "2028-2032"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "auth_ref": [
      "r528",
      "r821"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year",
        "terseLabel": "Expected future employer contributions, next fiscal year"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r495",
      "r532",
      "r557",
      "r820",
      "r821"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r507",
      "r518",
      "r520",
      "r521",
      "r818",
      "r819",
      "r820"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "netLabel": "Fair value of plan assets",
        "periodEndLabel": "Fair value of plan assets at end of year",
        "periodStartLabel": "Fair value of plan assets at beginning of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "auth_ref": [
      "r502"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency exchange rate changes and other adjustments"
       }
      }
     },
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "auth_ref": [
      "r493",
      "r516",
      "r820"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "terseLabel": "Funded status"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r495",
      "r499",
      "r531",
      "r556",
      "r820",
      "r821"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r529",
      "r554",
      "r820",
      "r821"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic (benefit) cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]",
        "terseLabel": "Components of net periodic (benefit) cost:"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]",
        "terseLabel": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": {
     "auth_ref": [
      "r552",
      "r553",
      "r820"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation",
        "terseLabel": "Accumulated benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": {
     "auth_ref": [
      "r552",
      "r553",
      "r820"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "terseLabel": "Fair value of plan assets",
        "verboseLabel": "Fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": {
     "auth_ref": [
      "r911"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "terseLabel": "Projected benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "auth_ref": [
      "r512",
      "r913"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "negatedLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r509"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency exchange rate changes and other adjustments"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "auth_ref": [
      "r517",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "terseLabel": "Plan assets, target allocation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]",
        "terseLabel": "Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanRealEstateMember": {
     "auth_ref": [
      "r818",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property composed of building, land and land improvement; in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Real Estate [Member]",
        "terseLabel": "Real estate"
       }
      }
     },
     "localname": "DefinedBenefitPlanRealEstateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r497",
      "r530",
      "r555",
      "r820",
      "r821"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost",
        "verboseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPostretirementHealthCoverageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide postretirement health benefits to retiree or beneficiary. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Postretirement Health Coverage [Member]",
        "terseLabel": "Retiree Health Benefit Plans"
       }
      }
     },
     "localname": "DefinedBenefitPostretirementHealthCoverageMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r567"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Expense under the plans"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r76",
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r76",
      "r362"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotionalAmount": {
     "auth_ref": [
      "r923",
      "r924",
      "r925"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative asset.",
        "label": "Derivative Asset, Notional Amount",
        "terseLabel": "Derivative asset, notional amount"
       }
      }
     },
     "localname": "DerivativeAssetNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "DerivativeAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative, Name [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r204",
      "r206",
      "r210",
      "r211",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r202",
      "r204",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "negatedLabel": "Other current liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "negatedLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r923",
      "r924",
      "r925"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Derivative liability, notional amount"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r924",
      "r925"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r202",
      "r203",
      "r207",
      "r210",
      "r212",
      "r214",
      "r216",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r196",
      "r197",
      "r202",
      "r203",
      "r213",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Marketed products"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r489",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r905"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r575",
      "r606",
      "r607",
      "r609",
      "r614",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r134",
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "negatedLabel": "Cash dividends declared"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r318",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r344",
      "r346",
      "r349",
      "r350",
      "r351",
      "r352",
      "r678",
      "r679",
      "r754",
      "r764",
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r318",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r346",
      "r349",
      "r350",
      "r351",
      "r352",
      "r678",
      "r679",
      "r754",
      "r764",
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r81",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share (EPS)"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r692"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r608"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition of the compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r605"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefit"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r129",
      "r272",
      "r311",
      "r312",
      "r313",
      "r331",
      "r332",
      "r333",
      "r335",
      "r341",
      "r343",
      "r354",
      "r390",
      "r478",
      "r610",
      "r611",
      "r612",
      "r642",
      "r643",
      "r677",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r700",
      "r714",
      "r767",
      "r768",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityFundsMember": {
     "auth_ref": [
      "r907"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An investment that pools funds from many investors to invest in a combination of underlying investments, primarily equity investments.",
        "label": "Equity Funds [Member]",
        "terseLabel": "Equity-like funds"
       }
      }
     },
     "localname": "EquityFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFVNINoncurrent": {
     "auth_ref": [
      "r686"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFVNINoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r886"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedLabel": "Net investment (gains) losses on equity securities (Note 7)",
        "terseLabel": "Net investment gains on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r447",
      "r688",
      "r806",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Extinguishment of debt, amount"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r681",
      "r682",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Information, Assets"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r218",
      "r226",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r218",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, by Balance Sheet Grouping"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r447",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r682",
      "r718",
      "r719",
      "r720",
      "r806",
      "r807",
      "r818",
      "r819",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r218",
      "r222",
      "r447",
      "r806",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r447",
      "r806",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair value hedges"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r447",
      "r520",
      "r525",
      "r682",
      "r718",
      "r818",
      "r819",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r447",
      "r520",
      "r525",
      "r682",
      "r719",
      "r806",
      "r807",
      "r818",
      "r819",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r447",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r682",
      "r720",
      "r806",
      "r807",
      "r818",
      "r819",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments).",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments",
        "terseLabel": "Unfunded commitments to invest in venture capital funds"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Fair Value Information, Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {
     "auth_ref": [
      "r520",
      "r680",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Measured at Net Asset Value Per Share [Member]",
        "terseLabel": "Investments Valued at Net Asset Value"
       }
      }
     },
     "localname": "FairValueMeasuredAtNetAssetValuePerShareMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r447",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r718",
      "r719",
      "r720",
      "r806",
      "r807",
      "r818",
      "r819",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r224",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Investment"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r385",
      "r386",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r399",
      "r400",
      "r401",
      "r458",
      "r475",
      "r675",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r802",
      "r883",
      "r884",
      "r885",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-lived intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r283",
      "r413"
     ],
     "calculation": {
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Finite-lived Intangible Assets Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r410",
      "r412",
      "r413",
      "r415",
      "r748",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated amortization expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r105",
      "r749"
     ],
     "calculation": {
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Carrying Amount, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-lived intangible assets:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r99",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r105",
      "r748"
     ],
     "calculation": {
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Carrying Amount, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Remaining amortization period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FixedIncomeFundsMember": {
     "auth_ref": [
      "r907"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment that pools funds from investors to invest in a combination of underlying investments, primarily fixed income investments.",
        "label": "Fixed Income Funds [Member]",
        "terseLabel": "Developed markets"
       }
      }
     },
     "localname": "FixedIncomeFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r797",
      "r818",
      "r833"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contract"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r204",
      "r209"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": 3.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "negatedTerseLabel": "Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r59",
      "r90",
      "r850"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedTerseLabel": "Net investment (gains) losses"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Schedule of Activity Related to Our Available-for-Sale Securities"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r76",
      "r126",
      "r127"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Debt extinguishment loss (Note 11)",
        "negatedTerseLabel": "Debt extinguishment loss (Note 11)"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r282",
      "r406",
      "r750",
      "r804",
      "r836",
      "r890",
      "r891"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "netLabel": "Goodwill",
        "terseLabel": "Goodwill (Note 8)",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Other Intangibles"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangibles"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r76",
      "r407",
      "r408",
      "r409",
      "r804"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill, impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgeFundsMember": {
     "auth_ref": [
      "r907"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in registered hedge funds.",
        "label": "Hedge Funds [Member]",
        "terseLabel": "Hedge funds"
       }
      }
     },
     "localname": "HedgeFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r202",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset.",
        "label": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of indefinite-lived intangible asset excluding goodwill.",
        "label": "Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r869",
      "r892"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment of intangible assets, finite-lived"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r869",
      "r892"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets, indefinite-lived"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r53",
      "r236",
      "r249",
      "r270",
      "r364",
      "r366",
      "r370",
      "r372",
      "r755",
      "r801"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Total before tax",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r327",
      "r624",
      "r632",
      "r638",
      "r644",
      "r648",
      "r652",
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r328",
      "r342",
      "r343",
      "r363",
      "r622",
      "r645",
      "r650",
      "r765"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Tax benefit",
        "terseLabel": "Income taxes (Note 14)",
        "totalLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations",
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails",
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r310",
      "r618",
      "r619",
      "r632",
      "r633",
      "r637",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r914"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowance release"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r914"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign-derived intangible income deduction"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r623"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "verboseLabel": "Income tax at the U.S. federal statutory tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r914"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r914"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedLabel": "General business credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": {
     "auth_ref": [
      "r914"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount",
        "negatedLabel": "International operations, including Puerto Rico"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r73",
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash payments of income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Receivables\u2014(increase) decrease"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other liabilities\u2014increase (decrease)"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable\u2014increase (decrease)"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Change in deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories\u2014(increase) decrease"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Other changes in operating assets and liabilities, net of acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets\u2014(increase) decrease"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r411",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r100",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Carrying Amount, Gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r97",
      "r103"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Other intangibles, net (Note 8)",
        "totalLabel": "Carrying Amount, Net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "terseLabel": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r233",
      "r251",
      "r314",
      "r361",
      "r702"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r319",
      "r322",
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "verboseLabel": "Cash payments for interest on borrowings"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": {
     "auth_ref": [
      "r217"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.",
        "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "negatedTerseLabel": "Losses expected to be reclassified in the next 12 months"
       }
      }
     },
     "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r797",
      "r818",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest Rate Contract"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Forward-starting interest rate swaps"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS)"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r854"
     ],
     "calculation": {
      "http://www.lilly.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r858"
     ],
     "calculation": {
      "http://www.lilly.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total (approximates replacement cost)"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLIFOReserve": {
     "auth_ref": [
      "r857"
     ],
     "calculation": {
      "http://www.lilly.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.",
        "label": "Inventory, LIFO Reserve",
        "negatedTerseLabel": "Increase to LIFO cost"
       }
      }
     },
     "localname": "InventoryLIFOReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r294",
      "r794",
      "r836"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.lilly.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories (Note 6)",
        "totalLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r277",
      "r293",
      "r353",
      "r402",
      "r404",
      "r405",
      "r746",
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r856"
     ],
     "calculation": {
      "http://www.lilly.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r855"
     ],
     "calculation": {
      "http://www.lilly.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r58",
      "r360"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summary of the Contractual Maturities of Our Investments in Debt Securities Measured at Fair Value"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LIFOInventoryAmount": {
     "auth_ref": [
      "r796"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of LIFO (last in first out) inventory present at the reporting date when inventory is also valued using different valuation methods.",
        "label": "LIFO Inventory Amount",
        "terseLabel": "LIFO inventory amount"
       }
      }
     },
     "localname": "LIFOInventoryAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r853"
     ],
     "calculation": {
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Impact of Leases to Consolidated Condensed Financial Statements"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r935"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r712"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r712"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "After 2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r712"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r712"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r712"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r712"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r712"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r712"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r245",
      "r265",
      "r836",
      "r872",
      "r887",
      "r930"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r276",
      "r326",
      "r389",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r663",
      "r667",
      "r668",
      "r689",
      "r836",
      "r900",
      "r939",
      "r940"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r8",
      "r9",
      "r326",
      "r389",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r663",
      "r667",
      "r668",
      "r689",
      "r900",
      "r939",
      "r940"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total other liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Line of credit facility, remaining borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Long-lived Assets by Geographic Areas"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r8",
      "r243",
      "r262",
      "r446",
      "r461",
      "r806",
      "r807"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "negatedLabel": "Long-term debt, including current portion",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total long-term notes"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Maturities on long-term debt"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r124",
      "r330",
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r124",
      "r330",
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r124",
      "r330",
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r124",
      "r330",
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r124",
      "r330",
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt (Note 11)",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails",
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.",
        "label": "Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingVariableInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Investments (Note 7)",
        "totalLabel": "Noncurrent investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r31",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r120",
      "r121",
      "r419",
      "r420",
      "r421",
      "r895",
      "r896"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r120",
      "r121",
      "r419",
      "r420",
      "r421",
      "r895",
      "r896"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r894",
      "r895",
      "r896"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded, value"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r120",
      "r121",
      "r419",
      "r420",
      "r421",
      "r895",
      "r896"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [
      "r895",
      "r896"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r895",
      "r896"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of pending lawsuits"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maximum Remaining Maturity of Foreign Currency Derivatives",
        "terseLabel": "Maximum remaining maturity of foreign currency derivatives"
       }
      }
     },
     "localname": "MaximumRemainingMaturityOfForeignCurrencyDerivatives1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r36",
      "r244",
      "r264",
      "r326",
      "r389",
      "r424",
      "r426",
      "r427",
      "r428",
      "r431",
      "r432",
      "r689"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r818",
      "r819",
      "r820",
      "r880",
      "r951"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by mortgage loans.",
        "label": "Collateralized Mortgage-Backed Securities [Member]",
        "terseLabel": "Mortgage-backed securities"
       }
      }
     },
     "localname": "MortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Used for Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Used for Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r72",
      "r74",
      "r77"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Provided by Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r54",
      "r77",
      "r250",
      "r269",
      "r274",
      "r305",
      "r308",
      "r313",
      "r326",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r342",
      "r343",
      "r348",
      "r364",
      "r366",
      "r370",
      "r372",
      "r389",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r679",
      "r689",
      "r801",
      "r900"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net investment hedges"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.",
        "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component",
        "terseLabel": "Retirement benefit plans"
       }
      }
     },
     "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Implementation of New Financial Accounting Standard"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Outside U.S."
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r188",
      "r478",
      "r875",
      "r876",
      "r877"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncurrentAssets": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
        "label": "Long-Lived Assets",
        "verboseLabel": "Long-lived assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": -1.0
      },
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "Other\u2014net, (income) expense (Note 18)",
        "negatedTotalLabel": "Other\u2013net, (income) expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r8",
      "r243",
      "r262"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Long-term notes"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Offsetting Assets [Line Items]",
        "terseLabel": "Offsetting Assets [Line Items]"
       }
      }
     },
     "localname": "OffsettingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsTable": {
     "auth_ref": [
      "r37",
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.",
        "label": "Offsetting Assets [Table]",
        "terseLabel": "Offsetting Assets [Table]"
       }
      }
     },
     "localname": "OffsettingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r707",
      "r835"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r704"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability.",
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r706",
      "r708"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r711",
      "r835"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r710",
      "r835"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r44",
      "r46",
      "r537"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax",
        "negatedTerseLabel": "Plan amendments during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r39",
      "r46",
      "r690",
      "r691",
      "r693"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Change in foreign currency translation gains (losses)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r46",
      "r50",
      "r304",
      "r537"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax",
        "terseLabel": "Amortization of prior service (benefit) cost included in net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": {
     "auth_ref": [
      "r298",
      "r299",
      "r301"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax",
        "terseLabel": "Change in net unrealized gains (losses) on securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r49",
      "r52",
      "r312",
      "r694",
      "r696",
      "r700",
      "r861"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), before Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": {
     "auth_ref": [
      "r190",
      "r191",
      "r192"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive income (loss) before income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax": {
     "auth_ref": [
      "r297",
      "r301"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax",
        "terseLabel": "Change in effective portion of cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r297",
      "r301",
      "r669",
      "r670",
      "r674"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r301",
      "r303",
      "r671"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": 4.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "auth_ref": [
      "r39",
      "r46"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax",
        "terseLabel": "Foreign currency exchange rate changes and other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r672"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r52",
      "r129",
      "r306",
      "r309",
      "r316",
      "r694",
      "r699",
      "r700",
      "r752",
      "r762",
      "r861",
      "r862"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income, net of tax (Note 17)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r306",
      "r309"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive income, net of tax (Note 17)",
        "verboseLabel": "Other comprehensive income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]",
        "terseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": {
     "auth_ref": [
      "r43",
      "r46",
      "r820",
      "r908"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
       "weight": -1.0
      },
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax",
        "negatedLabel": "Change in defined benefit pension and retiree health benefit plans (Note 15)",
        "negatedTotalLabel": "Total other comprehensive income (loss) during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r41",
      "r46",
      "r149"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax",
        "terseLabel": "Actuarial gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r47",
      "r311",
      "r316",
      "r622",
      "r649",
      "r651",
      "r694",
      "r697",
      "r700",
      "r752",
      "r762"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "negatedLabel": "Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": {
     "auth_ref": [
      "r190",
      "r191",
      "r192"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent",
        "negatedNetLabel": "Benefit (provision) for income taxes related to other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherContractMember": {
     "auth_ref": [
      "r797",
      "r818",
      "r834"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is classified as other.",
        "label": "Other Contract [Member]",
        "terseLabel": "Cash value of trust owned insurance contract"
       }
      }
     },
     "localname": "OtherContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "auth_ref": [
      "r882",
      "r888",
      "r907",
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as other.",
        "label": "Other Debt Obligations [Member]",
        "terseLabel": "Other securities"
       }
      }
     },
     "localname": "OtherDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r139",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other-Net, (Income) Expense"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r28",
      "r836"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r268",
      "r852"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-Term Investments",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income) expense",
        "terseLabel": "Other, net (income) expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNotesPayable": {
     "auth_ref": [
      "r8",
      "r243",
      "r262"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term notes payable classified as other.",
        "label": "Other Notes Payable",
        "terseLabel": "Other long-term debt"
       }
      }
     },
     "localname": "OtherNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other non-cash operating activities, net"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivables": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from parties in nontrade transactions, classified as other.",
        "label": "Other Receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r864",
      "r865"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other investing activities, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "terseLabel": "Payment for debt extinguishment"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Cash paid for acquisitions, net of cash acquired (Note 3)",
        "terseLabel": "Cash paid, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedLabel": "Purchases of noncurrent investments"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Payments to Acquire Other Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-Term Investments",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r517",
      "r519",
      "r525",
      "r544",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r564",
      "r565",
      "r567",
      "r572",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Retirement Benefits"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "auth_ref": [
      "r7",
      "r493",
      "r494",
      "r516",
      "r820"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.",
        "label": "Liability, Defined Benefit Plan, Current",
        "negatedLabel": "Other current liabilities"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r10",
      "r493",
      "r494",
      "r516",
      "r820"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "negatedNetLabel": "Accrued retirement benefits",
        "terseLabel": "Accrued retirement benefits (Note 15)"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r140",
      "r493",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r540",
      "r542",
      "r543",
      "r545",
      "r548",
      "r551",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r567",
      "r568",
      "r571",
      "r820",
      "r821",
      "r825",
      "r826",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Defined Benefit Pension Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "auth_ref": [
      "r517",
      "r518",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r545",
      "r818",
      "r819",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]"
       }
      }
     },
     "localname": "PlanAssetCategoriesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not measured at fair value.",
        "label": "Portion at Other than Fair Value Measurement [Member]",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "PortionAtOtherThanFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r860"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidTaxes": {
     "auth_ref": [
      "r795",
      "r803",
      "r889"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Taxes",
        "terseLabel": "Prepaid taxes"
       }
      }
     },
     "localname": "PrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r866"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r867",
      "r868"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from (Repayments of) Short-Term Debt",
        "terseLabel": "Net change in short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "terseLabel": "Proceeds from sales of noncurrent investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-Term Investments",
        "terseLabel": "Proceeds from sales and maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenue"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r274",
      "r305",
      "r308",
      "r320",
      "r326",
      "r334",
      "r342",
      "r343",
      "r364",
      "r366",
      "r370",
      "r372",
      "r389",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r661",
      "r664",
      "r665",
      "r679",
      "r689",
      "r755",
      "r801",
      "r830",
      "r831",
      "r863",
      "r900"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "verboseLabel": "Total reclassifications for the period, net of tax"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r115",
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r112",
      "r280"
     ],
     "calculation": {
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r114",
      "r266",
      "r760",
      "r836"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net (Note 9)",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r778",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r49",
      "r52",
      "r312",
      "r694",
      "r698",
      "r700",
      "r861"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Net amount reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recognized in Other Comprehensive Loss"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayments of long-term debt",
        "terseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r159",
      "r271",
      "r947"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense and Acquired In-Process Research and Development (IPR&amp;D)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]",
        "terseLabel": "Asset Impairment, Restructuring, And Other Special Charges"
       }
      }
     },
     "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringSettlementAndImpairmentProvisions": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of restructuring charges, remediation cost, and asset impairment loss.",
        "label": "Restructuring, Settlement and Impairment Provisions",
        "terseLabel": "Asset impairment, restructuring, and other special charges (Note 5)",
        "totalLabel": "Total asset impairment, restructuring, and other special charges"
       }
      }
     },
     "localname": "RestructuringSettlementAndImpairmentProvisions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails",
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r134",
      "r263",
      "r770",
      "r772",
      "r836"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r272",
      "r331",
      "r332",
      "r333",
      "r335",
      "r341",
      "r343",
      "r390",
      "r610",
      "r611",
      "r612",
      "r642",
      "r643",
      "r677",
      "r767",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r140",
      "r141",
      "r493",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r540",
      "r542",
      "r543",
      "r545",
      "r548",
      "r551",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r567",
      "r568",
      "r569",
      "r571",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r140",
      "r141",
      "r493",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r540",
      "r542",
      "r543",
      "r545",
      "r548",
      "r551",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r567",
      "r568",
      "r569",
      "r571",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r315",
      "r326",
      "r358",
      "r359",
      "r365",
      "r368",
      "r369",
      "r373",
      "r374",
      "r376",
      "r389",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r689",
      "r755",
      "r900"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "verboseLabel": "Revenue (Note 2)"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r709",
      "r835"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyAgreementTermsMember": {
     "auth_ref": [
      "r160",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the royalty agreement under research and development arrangements.",
        "label": "Royalty Agreement Terms [Member]",
        "terseLabel": "Royalty Payments Received"
       }
      }
     },
     "localname": "RoyaltyAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Collaboration and other revenue associated with prior period transfers of intellectual property"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Sales returns, rebates, and discounts"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r376",
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r820",
      "r911",
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r49",
      "r932",
      "r933"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Allocation of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.",
        "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recognized in Balance Sheet"
       }
      }
     },
     "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.",
        "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r820",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r174",
      "r175",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.",
        "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Effective Portion of Risk-Management Instruments that was Recognized in Other Comprehensive Income (Loss), Cash Flow Hedges"
       }
      }
     },
     "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfChangeInAccountingEstimateTable": {
     "auth_ref": [
      "r83",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summarization of the nature of changes in accounting estimates, including changes that occur in interim periods. Changes in accounting estimate have the effect of adjusting the carrying amounts of existing assets or liabilities or altering the subsequent accounting for existing or future assets or liabilities. Changes in accounting estimates are a necessary consequence of assessments, in conjunction with the periodic presentation of financial statements, of the present status and expected future benefits and obligations associated with assets and liabilities. Changes in accounting estimates result from new or better information. Examples of items for which estimates are necessary are uncollectible receivables, inventory obsolescence, service lives and salvage values of depreciable assets, warranty obligations, and regulatory reviews.",
        "label": "Schedule of Change in Accounting Estimate [Table]",
        "terseLabel": "Schedule of Change in Accounting Estimate [Table]"
       }
      }
     },
     "localname": "ScheduleOfChangeInAccountingEstimateTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in the accumulated postemployment benefit obligation from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits.",
        "label": "Schedule of Changes in Accumulated Postemployment Benefit Obligations [Table Text Block]",
        "terseLabel": "Schedule of Changes in Accumulated Postemployment Benefit Obligations"
       }
      }
     },
     "localname": "ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.",
        "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Changes in Fair Value of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Arrangements"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r31",
      "r130",
      "r131",
      "r132",
      "r133",
      "r231",
      "r232",
      "r234",
      "r254",
      "r806",
      "r808",
      "r874"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Summary of Long-term Notes"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r202",
      "r203",
      "r207",
      "r210",
      "r212",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Schedule of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Effects of Risk-Management Instruments Were Recognized in Other\u2013Net, (Income) Expense"
       }
      }
     },
     "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "terseLabel": "Schedule of Expected Benefit Payments"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r99",
      "r104",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r99",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-lived Intangible Assets other than Goodwill"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r108",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r108",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite-lived Intangible Assets other than Goodwill"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r20",
      "r21",
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Schedule of Net Benefit Costs"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetFundedStatusTableTextBlock": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of net funded status of pension plans and/or other employee benefit plans.",
        "label": "Schedule of Net Funded Status [Table Text Block]",
        "terseLabel": "Schedule of Net Funded Status"
       }
      }
     },
     "localname": "ScheduleOfNetFundedStatusTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r926"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Effective Portion of Risk-Management Instruments that was Recognized in Other Comprehensive Income (Loss), Net Investment Hedges"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of Other Nonoperating Income (Expense)"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.",
        "label": "Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block]",
        "terseLabel": "Schedule of Research and Development Assets Acquired Other than Through Business Combination"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r116",
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of Other Operating Cost and Expense, by Component"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r573",
      "r574",
      "r576",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.",
        "label": "Schedule of Subsidiary or Equity Method Investee [Table]",
        "terseLabel": "Schedule of Equity [Table]"
       }
      }
     },
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Marketing, selling, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Grants in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r579",
      "r598",
      "r599",
      "r600",
      "r601",
      "r604",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Compensation, Option and Incentive Plans"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermDebtWeightedAverageInterestRate": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time.",
        "label": "Short-Term Debt, Weighted Average Interest Rate, at Point in Time",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "ShortTermDebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r246",
      "r247",
      "r258",
      "r859"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments (Note 7)"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r326",
      "r346",
      "r347",
      "r349",
      "r351",
      "r355",
      "r356",
      "r389",
      "r424",
      "r426",
      "r427",
      "r428",
      "r431",
      "r432",
      "r463",
      "r464",
      "r466",
      "r470",
      "r477",
      "r689",
      "r792",
      "r851",
      "r870",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r34",
      "r129",
      "r272",
      "r311",
      "r312",
      "r313",
      "r331",
      "r332",
      "r333",
      "r335",
      "r341",
      "r343",
      "r354",
      "r390",
      "r478",
      "r610",
      "r611",
      "r612",
      "r642",
      "r643",
      "r677",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r700",
      "r714",
      "r767",
      "r768",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r354",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r13",
      "r14",
      "r129",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of stock under employee stock plans, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r13",
      "r14",
      "r129",
      "r134"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "netLabel": "Issuance of stock under employee stock plans, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r134",
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r17",
      "r18",
      "r88",
      "r836",
      "r872",
      "r887",
      "r930"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Eli Lilly and Company shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r188",
      "r189",
      "r194",
      "r272",
      "r273",
      "r312",
      "r331",
      "r332",
      "r333",
      "r335",
      "r341",
      "r390",
      "r478",
      "r610",
      "r611",
      "r612",
      "r642",
      "r643",
      "r677",
      "r694",
      "r695",
      "r700",
      "r714",
      "r768",
      "r769",
      "r872",
      "r887",
      "r930"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Eli Lilly and Company Shareholders' Equity (Notes 12 and 13)"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r138",
      "r325",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r476",
      "r478",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary or Equity Method Investee [Line Items]",
        "terseLabel": "Schedule of Equity [Line Items]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r163",
      "r165",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Summary of Income Tax Contingencies"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable (Note 14)"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.",
        "label": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized",
        "terseLabel": "Accounts receivable derecognized"
       }
      }
     },
     "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r385",
      "r386",
      "r458",
      "r475",
      "r675",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r883",
      "r884",
      "r885",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax": {
     "auth_ref": [
      "r931"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of cumulative translation adjustment attributable to gain (loss) on foreign currency derivatives that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax",
        "terseLabel": "Foreign currency-denominated notes, designated as hedge"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Common Stock in Treasury"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r35",
      "r136",
      "r137"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedLabel": "Cost of common stock in treasury"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r14",
      "r129",
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of treasury shares"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r14",
      "r129",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Purchase of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "auth_ref": [
      "r14",
      "r129",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period.",
        "label": "Treasury Stock, Shares, Retired",
        "negatedTerseLabel": "Retirement of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesRetired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r129",
      "r134",
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Purchase of treasury shares",
        "terseLabel": "Purchase for treasury"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrustForBenefitOfEmployeesMember": {
     "auth_ref": [
      "r910",
      "r936",
      "r937",
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trust created by the entity that exists for the benefit of its employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management.",
        "label": "Trust for Benefit of Employees [Member]",
        "terseLabel": "Employee Benefit Trust"
       }
      }
     },
     "localname": "TrustForBenefitOfEmployeesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r799",
      "r818",
      "r948"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "negatedLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnfavorableRegulatoryActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A enacted or proposed action, ruling or regulation that is likely to or possibly will have an adverse effect on the entity's financial position or results of operations, excluding tax matters.",
        "label": "Unfavorable Regulatory Action [Member]",
        "terseLabel": "Unfavorable Regulatory Action"
       }
      }
     },
     "localname": "UnfavorableRegulatoryActionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Summary of the Fair Value of Available-for-Sale Securities in an Unrealized Gain or Loss Position"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r617",
      "r626"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation": {
     "auth_ref": [
      "r915"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from foreign currency translation.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation",
        "negatedLabel": "Changes related to the impact of foreign currency translation"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r627"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reductions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r629"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r625"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accruals for the payment of interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r628"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation": {
     "auth_ref": [
      "r915"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from foreign currency translation.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation",
        "terseLabel": "Changes related to the impact of foreign currency translation"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r627"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r630"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Lapses of statutes of limitation"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r631"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r345",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Shares used in calculation of earnings per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r344",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 15
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "https://asc.fasb.org/topic&trid=49130413",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=109244457&loc=d3e16701-113920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "https://asc.fasb.org/topic&trid=2122503",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126972413&loc=SL7495116-110257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r792": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e777-108305",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r841": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r842": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r843": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r844": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r845": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r846": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r847": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r848": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r849": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r933": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r934": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r935": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r943": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r944": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r945": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r946": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r947": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r948": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r949": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r950": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r951": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r952": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r953": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r954": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r955": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r956": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r957": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r958": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r959": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>130
<FILENAME>0000059478-23-000082-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000059478-23-000082-xbrl.zip
M4$L#!!0    ( %=35E9S:POJ*64% !'%/0 0    ;&QY+3(P,C(Q,C,Q+FAT
M;>R]:9==1:XM^OW^"A[OZ\LB&D6$Q*CB#H,-E[JD36.@["\U)(7"WG8V/MF
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MFY_O/_+<P%'S' -\X&;/ ]R/DT=]V!,B1\U'YAZ-,/9L$%@FO^S%1>#K_*<
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M_S!P_,OSIS^^SN__]67?=?B\\1(?O?GI_VB4_8D5XOE)\H8*O('[GXM;;\X
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MQI03AI&2T@*D[;]'[IW>XO?+O^^>G%\\[V6MXAKM @4T)T@;.JK+5:.8550
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MK#;CD+'\=9O5T62>DZ!S:$E:0AX=8N]<-(JFTHG3:&7YK3BOEB:K+TU3X&@
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MM2+*/&M L?2L;+52@3@=(=I#HFK04^Z#EK)==#OF9_\L*1>I06,ZFCHQJ/&
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MW\%"_/WK=45.]*PS>0XJ)770%B0H-XDCCQR$4)8?.:\ N5EB9F\TC;14*S)
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M-6EI3B02BVEWP?@#&_5!HG!P[82QQ&(5(LP:60L,1T5H(Q*'W47A#VS4AUE
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M,2: &BN*NBP<(\J/DT3;%P"G"PFU@9.%45=[AEQ$DHVRP7K+%CWU#9\-.&L
M3MB-KT?.0B5*=_">F*R$@EE!Q%I;>?<AQ_T"<+H($#S6B-;F'0+ 5 BI>KS+
MFAS85]YNV#, )XP 3=B&0"2R""3&K(6HQC9*Q<Q]PR>_?WTA&7YU(1GWA<7I
MX@+EW$ID'$7 D(\C1Z#I/-"IV+7%NK)8.#\L3MB9"+EBGLUM<@0VD^;-%+EQ
MM<ZZ<K28P/\( =H7 B=<1JA1AG#,-5H%3X* ,"*%9FW81^)8.#+L&X$3MD/.
M0S<.PZ=Y5M5JPVB6M.5*3"*^X3LOOXH I/_TRW<GA9WA<,*S"%E,1XW (S-
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M:HO@/:+#O#4&!:S/JH2UBK>#\&V6TUOA1X*Q#UA2-8-&0<P[L9G6H<B"+]"
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M/;N\O1YQZ)O[BCX1/PKM_:+/BZ?^X>@SWOLGX"YNKB#%-G[//_]FYKSZ$!Q
MQ3%#BR::1ND+@2-$\Q%U/I_.$N*&D^&9,3="US#&!\AX/VF-G;)BAZ&2%"PD
M&82(2B).N665N]A$KV(3';'IP3F)]/ZQB?Y(;/J)G'8.Q $0(I@WR2E*9&/L
M;3 #=_$DAOHBGBRXV+$[3EZLI;Q?//G)LLL?X,0+4\=<*H<13T@Y*9(3QI%X
M2*5LM]K]9<WSIV??\Y.K1^.?9T\N+C^YM"^OKF_]:KNU[-L:1*EE;IT\QU&
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M37M$@I7ZR^X:COM/*__[XA\?C_QX]>Q:_>;%NX^=[>Z'MXL?_O7_C+]>JNU
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MSI.N4DR>5C_4+ ST^VF:$PL'@0%"E@PMCDL!!2)-4-SF/D#QGY)A'N,S@\W
ME/H: 1%SN/S_DNSC%27JP9+*)!+,H\R#G86&7(.>Z_D6Z%G#T.TQ?QB,>K8_
MM /'ZGE^U_E\3-RDW[5V@(7Z\(HX_Y\=L[_,4MZ0LO\J3EG1Y"A).36#M##E
M[3L&KAUNM7XM_C(_@^=_[K+!L!LX0]/CE#7H6:8W# +3!T;NC%P[]/QPYX4S
M<#M=U^D 8>#_%)]1 'VQG-3T\!0'3- #:0S8G$] 02*$ER214T5O6A9D^J.J
M(NCA%?<R0.&Y+)(8= Q MNXS8RW^BB<OH'!OX/<=W^7,&;JN;_$1Z[K6H.LP
MWG6&ON<3"G<MT)YT%#X^?;6BR(#62P7([^A59_6:6Z1>B=3GQ_//(Z?K^[VP
M!ZC,0&CZH]!D@U'7''@]$)Z]X: ?!#LO1CVKXXSZ'=L>+B'T%N+S'>I@1ZE?
MDN%PG(!9,4LI\OS'_*T2,N?PHC]B0,)?"YG0[.]]MD=.Z'._:^(_V!">F4-W
M9)EA&(2ATQ_Q@=W;,3C0VPR.DYPC+]Z@%TLFGR[)TC<@&N?&.V6M505,R!6,
M@R0I09*><$[^*;B?"'\"0ALMJPD#.XM*HR(-5$V-($I )W@#DM@X/CZN"A.D
M"^M&O\0CRD8=#?='UNWR1F6H45T@"4M0\.H D-RXW(HS(\4I"@Q%W2OC9*N=
M\ MO=?%<9JGP7S\# YFA]5P?!RY:NTNNP*IO81XL!33!M;=HP2K4V'@F^=2+
M__:RWQ= KO\_/H((?&2-O('EA(/ LUP07D,VY%UN]ZR>U1T,A\'GP8ZZ9U(=
MZHR-N>EEG%V UHIJ((NOV#S?^;W)0 $_](-8MP>-T8XJ1KM^ [?8_4]R:=NZ
M50>.EW%DO(ZP_ C]YH<+ <=KQ$F_&65\@*6_ GW"L"WS/VN7^^#K(T;YD;/,
M>$F!H",P25#-$QI;UR:-S;FQ$DK2E UD_7RK0'!.O!=X]B&*=Y#(M\&<WIIE
MWR\C'XWVAR)]^WOY^'#?LN\B]7UH_=A3KUOKH+\_ZCF/9;'[ _MVZWDLJ3@_
MEY4B*.,N4S=N)G,0=&))8*FA]H8"G8*=>!5HCFS,-Y30>FV.TG6Y 6'X$QM>
ME:QRW8;_FSWP"HQ)AC;4OVY6>NPNP@?UZO_^G2UJ(8^ (I95U26-V.Y=HQ)O
MYT:^?\\M+6T!+?5W7AR# 6S8^W=-3"TX[P><*M]Z"^'Y _9+"^GUD.ZM 7'+
M7[<'3"/%7P]:!OM$X/DVRB^,5\POTJQELD\>VH[;<MEMAY/C*"[[1\MEGP@\
MWR<9S],8<Q_?%2Q$5^QT*ERQ6P?@EN5N%/3=EN5N/YQZDN4Z+<=](N!\DZ4S
M/%+>LM@G#^N6Q3X". TEB^VV+/:)@/,U'[,8,\]\3IUH6T[[Y$'><MKMAU/7
MEIS6;3GM$P'G"=QBO&,A+^;&493[<9J76:O9/GW W\1OVTR+EBD]"&ZZ*FNI
M35O:HHT\&#&)Z=,M)?T )0VDMM9KM;4G LX348RM2K :=5JB^-)X2?73'?@M
MIEHKJL84]5C&"?9%RO(.U7J((9K&FS+S)RP7!:?B9FW"YY8@3L4$6B5PH_C4
MO9_4J):'_RB0W*[DX?V6AS\1</Z_;SDLX)('_]^60+1EKG<#Z.Z@9:[;#225
MU#]HF>L3 >>)WN43_9EEGD>R*>B!UDP.>' 9B\Y^9S,N7IK35:^J5GR':1)0
M!?N6($?+I^\&9^Z)3[>T_1-P&EB*5;?U 4\%GO^+_32C@MJ)$.N%+V+UMQ:+
M,@Z\M"P,Z?O JH(MQ("6)V\4-WIMS=;VPTGY)H8M2WXBX*R5WW=U=V9DS>_*
MV2RFOUDVI[GD6PCRE@=O%!EZ_=9_L=5 LGLJPC=J.?!3@><A=5+'V2/$>$$/
M9N.,2U9,@V(.Q#P01I,)$O4GM85M^"]J%7I+D*-U8-P1SMAVMU67MQY2?>7#
M&+4^C"<#4&Q\F $<B/=2P4+0YL_^$I!OF>ZC@)1R4HS:E@=/!J!G-+CH.!$3
M!;8G0M>RV[N#><MN'P6D5$K%Z+!EMT\%H+4C 3..648C:%ZE&;PK,?Y=9E$>
M1'*T'TWR>Y/Q2YP4<9SD,SGS;PMQH670F\62&QET6P33\K"'P<Y155+6UI1M
MT49:<GJ4Y#2HN@A:K8[W5 !Z%.%XYA2+PUY6$Y+/Y(3DCAP.) =X&7_B:&0,
M,VU+9*G5Z^X.,VR[[<SR"""E^@S:[82")P/0FA,?:L/NMQ"\+<_=+.#OB^>V
MN5<_#B;5==!N.[L^&8#*Q@=SX^PJ ;UW$LUHN"$<,XL2XP^><%"(,;=*_$YJ
M<5UR1G]>TW=A2]"D3<.Z(^RQ[;9J8?LA-51-#.VV7^R3 :ABT<1],> $K#MO
M\./S#);)1#2J(U-KA<O#.(:W@G8=\-:A\2O@2LNF'P6D7,6FVV:S3P:@;[(H
M\:,9*-!U$8/QBG-99,:SR\AODV=_ 41H>?"C@)2J+[/;%I)/!J OOTXB+RH6
MN]U4!;_&.W_"@S)N^? O@ RV?3]%OBW9_M1XS6KZ>-L&\LD ]%6:80J-^1_C
M73F=LFR^A9!MV>UF86[;U_8:^[U@7LS5]]KYR\6X/5CM+,VI*]VSC'Q=E_SY
M5104$UII$VH"DL^L^A;FY6E<%NMO^0Y PT%M\)@=7(FS<##:_^,:H^!_=FYQ
MT-:.NFF2U30PYJ:7<79ALA"V]8S%5VR>[_S>V/TT2DS]J->=$E#K&"XMTMFS
M$5&?6+67_;X(6K7VS9SB4)TB/>=95 "D_,:Y#E:>*[":*Y8%YNLTO<#<_;JY
M2W.YJ[?8K[9X/UAP/HERXR!)2M!*W_)9FA78YJ!FEZBWIF5FI%0%-BL].(1X
M;K!+%L5(/T:0^J7HEQ E?EP&'!NFTP'$\@#RNKL-ME2($FJG/N4LP5_3$#N@
M(\$8SN  _\1?ZZ;HQH%?X+?VJ-N5C@MYM?URQ=4OO_K4TT&[S35V]6_WA$.:
M9=S(2^\+/,TH4GI,SD)N3%CFI9GA _JB)QNWS;VY05R(KGJ319>8EZ>]]#7\
M,R9N!6>(=7+UVT>]?>,X,68,V7X9LZP#YU25TAEL-N,LPW,0+]CYH\P!1GG>
MV3%V])GN\#>N>N=.>F[N*-CEUP!OWWBU'K *]BR.]:^I0B5(C20M#.*@<,AI
MS &!X,@!\V!G* P-// RR] @"F&_,F8PY@FL/(:K?2 'CP-/@BNB, *X $@0
M&&7.<8M7:1;D $Y_8K#< 'J:X_EY/([X)<>/5U$<X[_\*Q;)X*=9EGZ1'WE>
M1  /NC "/IP$^ G[Y:'[3'P_BUF"__HI=O\H\3M8=!X!(;+,@,=FG "1X]=A
M66#]#NY*'3%L$D2_!Z>XC5S@6L@B!20%0"%*+G'VM3%ER=S( #D%0I6)+P)"
M1 L$<C\M8U"/&(('X(G,)9,("8 /HC $7,<CQZ7#D\,LG<*=*5PNCQ) #(SB
M.FS\@.OJB-8M\_57=HRKZJ%PI2$P0% ? (AP)$2L@85)N*FEPL]46P7H&!4&
MT)7'<%UPXU2G0H6YB"+B1+1WP+V-'8W3-  <Q]8R>*5$T8#H@6%K1G@[RP%?
MD+?"^R+8Z5_I%5R3T4Z0$L:8I):DL.B\S# Q6!PZ'@.1P.HM(@G(K>&W]*>'
MX)F(%<!WS/?3Z2R.\@D/D&U=<J307#!!.&&@W@E!%ND9M@MO!K95XHG%$2TD
MO1YFYQ,4#W&<7N$OBFGDZ13V6A;T6.0@DJV'@O7=B%(5G&Y$KIJF@V>WH<,N
MJH!"HS=1?1=: >EM$88PBV<F?G.OM/I?_QHZ3O^Y6OY]O7CA'-Q]*H$AL0D*
M+#!E'\,+?IH7J[B"%/HSD*Y30)N2;" $($@_7Y!" #",TQEYQ6;8VR-'NB,4
M062A;DQPPTP3V,"V52<F>0>B3NKA:_&'C(]!Y (.S5'09NDEB_/G+=PW!/=H
M.@-"E!IBX2,1P^DS_Y\R$A:00 1/:C0- !=:@@!=E<G, 92_8Z&N"&1JX;4I
M>(%8B.3) ISPH..8"TXZ$U/6Y_BAD/HUSCV2)$Q4!48 _!J4OB1P%!6\B,2U
MR&))78M\_/%W%#M1JM0C=5\+RTW $B'!O"C&U$E@A!)D0O% TP+$,$HXU4U4
M6&XKP=W"8Q/P\.LF@N+<C9A=H5(BQ0_Q.,7?4$-A!8,K_0M0(8$H0<#ET674
M0F-#T%!L"71D3>( +8!>Z%/GQDIAU]D9\;=HQO$M+20V 8FIZ"%?S@IV0:I!
MQGUA2,8,M$.P,5K!L-$#UQU+(!(F":Q@##;A/,=P5I2P@/]3,A_T\8Z![ED
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M7?6VMA9MYT7_4=>BW:OOZ83&E2DKZTB-;0(@;^/LH0]RK-=4#OYJS):BH6
M'$ZSVEC 9@5=,*VV. 4S.PVDHBQN YUJ-F&2KBY9%E'6KAH.A9KIE/-"E"^
M8I8#(8!*EW N'T.37N=:C8,A)TK?JG3@ON=WK<8!5""W%-HX33V50\1$_%$?
MK$=SPU#[56/%@ MRG.J*(4I,&T*V)HI=>#)&TT<8,Y-Y'OD12P0(17[TA(,!
M,<&!R_B*4%@F+,X%,N$P9FP7ABI_\\I++-_/<4)P633Q44,H\0ID+[IA(S:'
MGS!DF5""-R8W)3S.._4(-;P@C@HT^Y2LR!G.%\[U"N5ZQ%JJ;; C6PU2N9\T
M\FB\'.5'$570F&4#-0.12'7%10.T GL3+CU=&'VQ&G>7EU/<O08+:?;)OCIX
M[Q7W0&QP_;"I'TZU5P&5* $).!4F7GV:3: 3,.JT,+H""#A.YYQ+X,-#? EG
M:J(($E;^DF9CEE1M3&'],=J<B!7X&, 8^,>7R\PH35X="L6<I34-&T+JWU:"
MJ4X]IY2\N)XYB7[.62YL[>PRPD.:I' N<#89X(D</SE''9R'$8YB3.!L\"?Q
MB5K8\>8I=L13<?*CCUP4YX(O_$ZSV0E8>*[U-$5Z6)3D1524\EIEZ$NLK2:0
M<_@G5@ND07^P4=(JX $X3504!4ZU9GP3GB\L5=(J+A$U+1K/6,KI\!GW:.J@
MG.AXZ]&;#S,H7B.UE7*0B6&7<OYB4#%'#=S"]X!XP+5S[7P?9^PT^@,+-B)\
M'>@B%;_")PM]'QG7T*U>7=KD'7(>ZHG_'W@) *.1ZWH G"82-/H'N4&:/].L
M66R@B-3Z%RU9E$3)APJ"]@GHTIV"<UG'210"-\2662+;GOB!.%'D;UB72)%&
MBL67H%N<JHJ:2AMH/G6*:?QPOHEA6V"M]$%M%D^^[K'DQ<,IXZ'$77+8889_
MIG,AC4=V 'Q<#*(?=HR=5]A7G0C^73UH',_D79U$F\V-(U8P>2"G*%>=9\9;
MN;&=QZ&LG)5%CJU[%<YL(XV>Z_-H21323.#&8%3R9"Y0[B6"B"(H0@.54I8^
MXG33YLY)5.L*DJX"K%12KE>3:HI7@IE(FGA,K1&C0)]$0$OP\G1&ONA.0]Q7
MPW27A6X'I!'V8S9RH!OMF?41K1P66TRB#!1VEA7$I.AF.+IJ&533*Q2\FMLU
M#EHJ_*AMX5^:O-C*A(#:*#O4ZP"V<ASLH2I?7"&%!%"%8WQ92 M<6QA[+4:"
MDY!_12G]I.D*K12 N*KMOH _=OY./7@"&X.P(84#R$ .7%XQ;YD9(#N*$!AQ
MJ@^<J#:@*^KG&?N"=-(ZR6YRDOT;CRDH>=$Z%&\^*S6#HV/\&<\!T;VH/;2;
M#NW='"<A!&T;]1M/ZCR+VI.Z38K0__-66 ]J;O2M:\3N5<[>M27@/EM0-N@>
MD9IXH"M,C\1.. 1%@A?1MGJRSW1=R:>U<JG!*'?RE S"54J2[F+$B!+<X:OM
M7BJUZ_;]0N_7?S%%O0L-;GW)<LR!U+E FP^IJ1-8ICQ'E9^%O)A+9R:-30@Q
M!8)Z<DQ+:M(TB^%\1*?Q61:A4)VQ.=HRJ73R";=>-/7*+!?Z(=HNTHL1\"F@
M/);.HY\++!ZSL8+GRJM/W8(H@X3%\&T=6EBX7+PL!R/>G\@7D"):=4_A5YJF
M"9\PU82+XELLGHC4PF"7 ,@3M,'T>PS1-D$Z<J[0?U#03QRK98H*HS1%&VMA
M QZ #18!?P9XLHRJ9JDJ!_.%*LT]SC@+YH;HC5E99IEX%^KU<! \4UL2R3,*
MF#BKPO@PX8G^C;:ZYL9+VC,E],1P=G"XHG-3[<;+V(RPGE)P\!2H@11Z:1H:
M.JQ +@?_PI?H!]DP3#P<0X=>9.\+IB^1D>!CPP8>2)OU,HW+*1=P&:MB)T(J
M,3-$VK*P(FR#NIUD]H'#1N,(SH1VK_E=-:K+2TIQ,L2L)/)_DE\4(*$B@MJI
M[O)(=)*!A_&J0\=2G3IA6[Y'^54^%G*+ $>27C+1(Z-)7KJYSPKEK% 3D0)8
M?8'PRIO##L32"&<,($51WD4$KYS'<$)14J9E#LQ1/(SZQ=6>F>@R*N;*;!6>
M#!)[:*NNXJH\N8RRE%S9^\;Y!+/5?("F1^W$6)Z7F1@A@+N@N$0(*R9;-XYE
MVIQL."*M4'B^!$!8QAI14&>2 I/!0)$2^6?50VNO$C[5XX2%\C,>$Y!4TN"K
MZ$PJHBF=#_U+':SE<F#S2PRE0=7"75E3=IM;\&+0YA;<5@7[4TJ6-PWM92N]
M6&<)E[YW$(]C$"Y-]<2? +ER4(')5PG*"D?R).*JQ&=SD^0ZK3VU+[$6EJ/-
M#UOJ:*[6+V46Y4&D9 H-HUI6-92&()A@\TW&KG@2A1P\V0Y.5Q)WU9?YWAY.
MG9O.X$NY[%RYFW-*-\7*(V 2IHCLTI02F?9J%'C(N1"7E:Z$ZXTRJ9X)[2S$
M<(J/NIIJR:A."/39,A0)3UDN!G#%E9:QXA$*(%)VU&'@?>.@9F*=-<^7Q<;(
M_9-+A&?(,B/D5UP/]=*9 42#E$X6V9U4DQHZ]EI-CB0-2Z1R( ZCNE$++L$J
MX# 4D%:]!O;D^RF&K\8Q'-X5:E"LN@H;+"@H+AH#<8IL.X(72DV-?\5Z4!)O
M'10D"1J*>!"(MZ2+\217"HU?FTE-?$;-.E<@D*OL2)\[;KF6:'@!+$*DES=#
M:IC))N(<VE-^RQM1+T/H?1.XELK'TX"N!S1$O3?CJ(WH<>1\10"ABN2KU7.,
M_"<B%!)DM?X&B.V+ *8>7N &G&6=7QY*#=#T2"E$V@.<(H![41 HU4BE,C 0
M_;>?5'R_3H,R$X5%L]*+L2\'Q4%P] 27VA)VMI=I[1PTAY).D4Y$6%D5GT"]
MH<ZPIX,E[#03!J (LG*L0KG18LB8"@GVC=?LJIFU4Y,H\8J.ZLE&AJ_/<HI1
M42N@*CTAR@5,07L7F0,UR,42ZB:Q'@<2$@9=F6"Q@Y:*0.PT0+#1/D"YRS$0
M)I0R?"7P7!E!8(O;)/.&NA-Y5?("2@-8=4!<FXB.K# /K2=09LLD1N8M:(#G
M?A9YE/^CHNU LM14@>9#98!C2,\D050.1(WJZ5(4$ D:I!,P/L'U@8@*ZJ56
MR+[($4HM=E%GYBQ9B.H,R<C"4'86@K*/E"E(93&XH]2Z6!(N@I :DL<,],\'
M-XE6JR-_5';O5JH@!T924KW(4B2-,GT+@9_"ML4,+NKV+N.M2DJ;.>4OS*(9
M.57)6*^D_X)*H@I2I+H!#ZNNE 1#5_" NGE@J\&.Z#-(F19I/J6&'P<H%?#"
M-X+#B,P+XYU,,:*?B:RGTO>(B*^G2!J'N@0"!'P-ULS\-WTU4X9928!A:#+6
MM3J5<@0')AI FVFM :$AA5E[%PD&HUFNN3U0V&I_(GTP(F>@?*1ZB?8DSY*Z
M8*C60RI1C-RFH[J+1 0K%L^%7";=0&E/\E5H<:(AUM!JU-,ZU4;5&X7\H?BU
MP3RP)RY%U3OP&0;\V[\0S!HX7H:VOLA Q\G<4JD"N[*NHI2L-%A6J]0"X%C4
MD6KE4#B=="J&UVE^ N+1TFO7G"\ #.%*F-JP+J%0ZR>](TUK^=6..H\TB\:4
MNZ,2<RFYB(;IZ;57(&X3>#I:S$$$"$%]-*46N_(Q*'"X5&64&W%69I%R)Q)E
M^?.M%-]_2G^P3/32=2 2<;6MKF.'9C]@^QTT/$F0":S2Z0#)HJ(<NJA""E/S
M ]045<,9S[KJ/6V\(>5*IV0\VF/I]($_@0\@ !S+&AF[=.^;P^.#O88ZH#-
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M)WUUJE3$ANJWC:8)R;\WTC!_QVD Y-$<3$X0KMN(YQK;K?P).2V[HZ4W*ST
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M-0Y$]A*\KIG;0(XPZGWU5E^"@-\!Y?K(]Z#J?&,F;5,6WH\I\H:\9#GFC[.
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M,;/4Z&O?>(\UN'7]ZQ67-8IZ ]3EU-2%,U2S_F"W+;UL@%Z.TH0E?,H\.9J
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MN^)S9.>(/:LOU#J>UM@& /.CS"^GEUQT=X=3N.+L HTM,>O>DZL4TQ!P*%&
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M2V@Z5\"32!K8\I=FZDQ'&-"-:Z-$-V%T*QT3FA.N#?+!K_+:Y;9@TB]94VI
MT%*^BX@D*C[!9V51&;A )!T*-L*5PH=[E99QL!1):-@8]>RU)6T^:UA_,E(?
M98$P7M0:!!DBVI0"7P@-ZP'C.3>:9O[*)94-HUB-IM2>2F=7NR_@FU*"@H 2
M)<T#;5B6E'%>:1[[Q@'-3,/XCU+W-=,*BP^7&)L<)ASQ%9RJNB'@@"R19(%K
M]MDP[YH@W$X=XX,8FBC4S)K6F2A1$3KT+5P^FE\&?UKAC*D9U7HC%@6I=I!
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M?^&G:18HK6\Q&K] ,55:LDH9%](E!QU-I!_KR0 J_M_1\[BDS]=/LUE*E;9
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MB<GHT>T:@T]$&QX#,R:E_QM\)F]08B6]S:RLSZS<O[F9E6]=LO'6ZE+0/P&
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MPQT[S9!U)C'OG43H.L3R.*_=FK-.] M+I8@%"4DF(LNKQGE:?+>IBF=""*M
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M %/0BG+U'35RG'<BPD:[^@I_3=IMI.WROC8DHJ$^O/(-$7@UW2"D6XD 891
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MZ_#9%IQ"T%=/B]%&2H4/!"Z%ZZMX%J#-"/$5XPU()C-00$[I>*%!6@+=,):
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MFA!W0_0^? !2PFUX>R_P-F0@*"I9A 5S0H.QPV69G?4HKMZQVM=_%VT6E%B
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MM,%))3F2@:)AY-Z=CX59E\;L%,H@>8>(1 C=P%2DT?:,,.YQ9/3'_*1HQEL
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MWRQ]1WQP6YX?L2_"L<R.V;H@7O1@%AH[+<X(!5I1J>,A6D=&:G+8>L2:F_]
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MT :!]?IX09U $5)UU[>=$TI@S!R#4JLR*;FG2T3"&.%MPB9%P%P?R^:+)E>
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MMFP4>P%%$ H5<G%WLZ*AWRU:7T,0H&Z2E8GYFX:+HJ2N=WX7N=S=$^!J7K\
M$*(V$8]O:[@^_G$,U[W--5Q?4FS]*/1"W-#+QQ5'W-Z%V9H)NQW@R)J4["1M
M#>E,C ^1Z$R<20K+0)4WOEO&C#. $JOD5Y@/X]J/!1?%XOH*F,9D*^DOSY2R
M3Z0"Q$XF %.34U!OA%X235Y4E\X;7LOUW-OY<:[G_<V]GJ]@Y;YCTLMG(;R[
MB9?4'5[30^<VCGG_.N*8>_<W/XXI6[.S>_VW^=R[>X0:P</#*TNP1WT2++J&
MCW:[(NO15YCD5436@PT665P:*[V(@7ZA^ ?5$2 T"QY:@D2DGISO74CI:FT
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MB=B?$SE!2O.^@ O &_^4 SW65)KSS7"R8BS7'-7Y'/D%.NI(P I]8%MP2 ?
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M *9GA#WN)0F3NZ2AWC[@;RIUK5_DQ=^+Q>U-Z-]DZ7E+5S4BY9:$#^X:&R@
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MI]G[#,]\-)2M5G5H4L7/TQ$Z[ECW-4S>(@09 $0E1UTO-34"T]+!UW.6(;B
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M*K'V\-!A6>2[U6K53_;G<O;&5WEZ6+[*620F/[<\X. 9%<KR&I[%8J/=;>Z
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M9%N][+96670S]U9WODF)+C/I=#15@X0@!Z] [CL$"@X&\!JX!?@#2F!6F;P
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M80L^_,F/:\J):5 X'8QSR^?Y'(H@7%$O&/.*BA+4FNIN8JF9;AVT/,/*X(U
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M"_A#J>HI&+-1(KX#AI-Z&,0J)IR%U>!\$5BH 'K4NS0O (T+?1H@&$8R8Q/
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M#:9-FJD\X0R, 5*?+T=>S/7'E!\ ]F*$OM2Y[@W9.TD(XW94+YHR7NPE"ZH
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M;+AS5%; :RG.W"0-4U"B.>3F#EX!:H1H0V2=P?-OU"]CGR0@@(I!*W\,^8!
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M"]_H9*RTN=X0"Y%4T )?8(Z+0[LBTE9'U,+7,VJO>8;40P,0-A^^2Q KI!
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MY8$$9+A/R"$W*29SX^U%CALCQW-7MXL<+T6.:PJX)R1:0Q0X304PXRW8Q.)
M,V&B( +';'#DFTS1+=H@.9Z3BMUL1>9-Z ?3J_(2OVN-ME!5^T>(-F$2&X)H
MS=-IQHN7X&SWV]*]&%I."JC-"]0.GM?5&HM\4"A$H,XC8)YKT$F7 9R6.)H0
M")4ZDQ.LT2JJ-3^ LD71H?4&C^:I-04\E@4>-<U&,1Y\B!PH00H2#4IDB*@
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M8:.T1X;F6F)H#I%K16"7(K"_/*:Z\@-!+=%J<Y/BFMIB"=$^L2\(1N4X=L+
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M5L^ 4M0#HE%+&1 *GF8>A;?JK5**=#=1NI>L+SW ?E+D?.%R7M.7)+;8.85
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M$U VEYI7R!O/!?9!;VS+34GYA(B> KL%=@OLKJQMK\#NDF#W\#:_]DIH05"
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M 9W$F+#(A0E$6!(8-39BSWT%@/=QU!< 7#( UO)&%#4N8JK!<<J!24W ",Z
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M*9G>+++23T^77DTHA#Q>TZH^SO.;*SJL%_@J+>M!&!S&(W-=H&]^T#>AO&C
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M?/[BT_Z[/]'AT=]GA^_^2L_T6[JOE^V3LS<?JGMZJ;X<_OF/")1X)6U26%P
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MB. JM]'$2-&87H6DP!"I$P-V01'LE%\V1)0L__GA1\W,RS'C&!D& 1&2248
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M5P\+); !BGO--[8)WL2<;LGO3B*T0J$5"B]7*-PE-,DIQB3D[C+.<1."!<#
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MS]\?WZ;]+L:_UUE:A_"WP]V]#]Q'98UR*'MT$4\2?J)2(NZIT0P3PY/.Q7=
MV"W]D-[<6\+1L^_Z_OP0;SDAGC/B+7^CNPQ=<HY$:N'_&\8M%<['W*01JQS4
M"KR::DL:Q",MXCT=XM%YQ!.> +%"0B1*BSCG%EFF)!))6&6=R@.Q-[;%IM!D
M2RT@7HL_+?X\/?[0J(C&!/0MASGCSDD5X5_L7>+!$U'P!S?X@UO\>3K\X0L:
M%TY4"YF08R[FUC<1&<M<;O#+N Z@,'N5-2YBV%KAS[<ZE)8]6VTIL99VW$[X
M>#X:5W'#\:#S-@+;^6XO=K(97'%(_OMMO$P_W<?-M HO1GN/6]RC'<^QRH$.
MZ[?@-=RNN[L%*S7,K*4>MAO/AJ 9E E\'=L/'7N:L_&^//S0R&<Q:/$9>-MF
M*0@_]V+)I>R'G1E"MBKAJE3"@R5.."<9-U1;1(2C53=$YYU!1(-%RCP36-F-
M;;(I*%V2T]XZX;XW#%D__U6+(8^,(0MN+6XDI5H+E+A1B.=Z&..,0UC@9$((
M@N>:2, 0KI:D9;<<_<PY>N4>H9:C'YFC%QQ%RBHIN%5(RB@R1W,$RH!'P.41
M4Z43M3IS-*-LRZP11Z_24;2V1H\;=V!5L-SS[N@D^XLZO<%HU/GA8#".'4)N
ME;;YS<Z.KTXB6MS,-<&X];-\?K/=_BA[O./HL/_Z"CD/4Z;Q58!+W7]B0%_B
M<-!BVUVP[7+1XB&,>4,-1YI:L'BL=Z"MI(2P\S0P)271*ML9&JCX\_.S>+Z"
M: \VY>Y%8\<Z6#S7] 6X!8BT8'$7L%@P;9C0)#FO$.,A(2YU1#IQA6BDB3 J
M3"1F8YMCL:3=7\NXSYQQ5V[8M$+_D?AXP:"1.% <DD2!R0!"WUED*8^(&<%B
MGBL9L;U>Z#\=)W\'49Q7)[9_''/A68@I#H<QU$G?G;']YQLK)EZVQV8%@U57
M;<[L]7WN.A=W8_7?O?YN3<PJ<^$HD[+UV:P*X@Y?+=HU0EA,G$XHT=P0@X'H
MT)P*9('&U'.L=2[<IYM$+U-6[MR=J'7 /BPLWH6=5QY3N24[MQQ[%XY=,"Z<
M(5%9K%#4HJ3CZ=Q&DB!)E%8A44XLV]C6F&ZQEE]?$K^NW+!H^?4!^'7!B C2
MIDBP01[(!Q+6)V0U#BC(I+CS7*9(-[8)XZOH_M>&0V[%=J4U&W)PYO,KGI[%
M_JC*!XO_Y)^_K7+T9?M%UB\84MI3_Y)I^&J&A"U>W06OWBU:!-(:J3Q E9+>
M(9 L'EE/"'+&TA@H3L[&C6VFR,-.NFWC',\"%M8ASM'"PNIA8<'L\)12'CU!
MG!.%.&88.0 !1!TQ"2L5#0$UAG&ZI.JZ9=)GSJ0K-SU:)ET%DR[8&I$88U22
M2-J($3>)(QL=0RQY'ZWGB4H-3(KU$MG=ABL>O"G-YUB5ZG5^.,XQO1]+"E8;
MK%A3:^,KZ1,Y&GO8WYL0M/62W*G(^&AG?/!J;DBB4,E%;Q,RV@%T$4Z1#9HA
M,#V(UX0$FMV:G.*M!QV2TQ:4/ M\6,/H1XL+*\&%[APN>""(UL&AK&J"W8$Q
MTHI'9+6@D?K  +PWMHG22W"A#7<\8P9]D#RJ)0S:9A>LCGL/YZ6ZXSX0:3B2
M.C#$O9'(I.@05Y$9ZRR3).22$,YT&_YX-#;<\?\Y[U8I4^AL./!Q-.H,XRC:
MH3\I)?$A?HZ]P5EEJY0*$=86B*RGE5)A7 _6WE!UK_^FHNG;FJ0[_; [)6@+
M:G<"M=>+I@HG)'%I(HI4&,2S<F*52<@:(1)31'*N*E-EL<IM[4V5UOFZ;L[7
ME5DJ+4@\($C,VRT,D$ G11" 0@Z:& ,_&?@I!!65)9XDL%O E+E_*6S+LNO&
MLBNS75J6?3B673!6E*0@S+%%4N&4QP0R9$S \ \.B6I+68Z>2(FW^!JQ['<0
M/3D<G\1A![8;^=S'<#!I7F@GS0LW._TX;@,I:VRB-&Z80LQ)_\EI^\G<HC)W
MJ)P,PFL![4Z MK=HJ"ABN1"2(R$X!<TC*:23TT@S)VFT%#N;<CBX[93?0L4Z
M&2HM5#PX5,R;*PE+(PGCB 7!$+?!(0/@@6QB,;BH8V1\8UL0<G_=IV7<=6/<
ME8=:6L9]*,9=,%JLEDHZ'1'GN1PL,8*TL!CAI*)-A EB',AXUK;<>A*CQ9<Z
M]3(A=<9L&8WB>%0B+;VN==W>U(3)PY]M-OBKV>#5ET(WQRN[X_-AVZ7]>=QC
ME48Y%4\_?&#Y$7\;?>Q^SA/$1W43C!^Z=4WACUD^E)]:H_QYMF+8\1YV<SS:
MZ8<"93/$;J7VG:3V'XN6.54Q:*X)(EAQQ)T(R$J,D>5:6ZVB8A2D-C5F2>O;
M-JMIS33M-6NZ\%7&;;.=5LC5"[F*)BA.74+, D-SH2TR'E,4+8Y"8T.2BSG;
MB2K=-F=X67S]",T96KY^)+Y># QR2GBB!E%0LQ"W@B*M*454@?*%G>1PUDMC
M:X'7I4G2*@WL]35 <B)O?SP8=E=N@+SL!(=G88#,$+>%L#M!V)^+!D?2+F4!
MA!2S&G%)!#),!T2X8R&:I)D$"!-@<"R.<+P]@+692&NGF#R"P=$RZCT8=<&&
M2)0+Y8%1O26(QQ"0,80@HXGC26$ON-C8IDPL\>>WC/J,&?41+(B64;^=41>,
M@MQH 2LJP1Y( G%C7!Z0;'((CN-DN!(V@$1E;$G$_$D8]?N(251AMRK"U@8E
M7II-,)=84*C<0MF=H.S]HG' 6.(&1X*L]1[Q/(5/"\W@)R ?5]0'S#:VE6'K
M4J/9<NRZ).Q=TR3EMIS;NBU7R-;SIH3*C6>CPDAXBQ$'ZP$YG1(*+IK("<-<
MF3)ADX@VJ^^9</>:612M/%X!XRZ8%A+C&'04R'K,P;Y@!FFCX5<0S21X[AF7
M&]M<J"5MW-IHPP-&&Z8#9CIG]C*'WFH3H[$P.C\T%D;;+^$Y%",MC;(.SZ]T
MP']34;J%M3O!FE\T,YQP3' 7$?6&(IX20Y81@I*01G,X#-*7%K)R2=+3VI<C
MM1[5M=-_'M.\:6%C9; Q;\;PF!,B)4-:&8DXL_"3S09-\E$8$KUFN8I1M*'+
M9\"_ZV6^M%R[*JY=L&&8QCYXX9$QN>N)M10Y'1VRV#@5G,8\*>!:2I?T;7P9
MS136UY!I,@D;(Z84&0U*X&2F'FG%ILW+]M8\$].FD+W&N)U^J/'O]RG16Y?L
MZE#Q>-$$DBYB;Z1%-"B&.&$9%;%&AA+OG"<\9L\.V62,+-%FUMX(:IW W[L1
M= N :3'D;A@R;P^!,FP5-PHQ!\C!'3?($BR0TBQH)2TERN4V57Q=O,,M*S\C
M>ZC5$!Z5NQ?M)D=!*Z 8*9M[-A&ID!5$(Q^C<UIB*XRI:LC(DAJR9]_1X4FM
MI>5*?)[=DQN7=-X,!Y^[(8:.N^Q,8IZ=:7>3IX[XN,$PQ"$:#\Y^RE0<#7K=
MT,F[LHYPN'X&$] YD[FA\B^7?XZR:VA)&YL6 E<'@9^6I*-91W7.K&7%S6N\
M1UJDA%P@V'O*I%1J8UMM8LV7Y*VLO9%T)VY])!_TS8OY;H!I';+J6F!:"V":
MM[QD2%PP0G-/;Y,[>3-D/)A?B@0-4LA(3TP&)BKQ$N]-"Q,M3#RD.=?"Q-/
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M")^_8BLC.G1^.!B,8X>UXU'7VG"XU@ORR_D(5C@" _$@C@]3)G_]26@![DX
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MV<-GNZ'6&\8YQ#)=[Q6YL98:P_00-^=S89-/)\=S8D5GR0![,NX6R36J]'A
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M=Q:+Q&GNN3FMQ\M/RS^!&IL=(QGMX)!,#\MLM<FD*FDT^=/T&%7M#\J+W^)
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M>:\/6!#Y;*'F2V\)*1!!A1XJ>VX5T"6(B!YH-J];!/FL[>US+Y+$9E-J:P8
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MRD8(Q=# 9.'26U55&_P6<D^6EU6_^NR0%]GMX^NC4S[8._K-V^4WL>OMQG+
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M8OS0 .@%Y,X'K+=W%74;B..=/YCKM?'__DB/Y(;O$Y2HMKCT2#5&2,&RH+J
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MB81;=]5;7N<@_<&<'G,=>W@76[!C$E[M/(YIV/O#G__YCS^^8:OSO3S]W:O
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M/C8?&.%*\'D2^%2GP8=II@AS*9(VU6#OR<3S*OAD!.*DB1VA%GOP(3/LO67
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MZD13S!F.8:'$?"6*RM+'7B-%Y;CW7%)4/F-_;"*JOZ8I_ $I*M>6YC="47G
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M#%]Y)FS.$AI/AS_X=>.:';? 6GK9C6BZC$[X?YZ/G[Z165MW:ZU6^B-K5<%
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MQZ&9P,3:U!HA-75I/!4<\K,K5WX-7L2H\JR?K][%&IE\H[@6X+=8N'W?> X
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M;FN7[F ZQTK2>>+#]E(#;XQD8*"1R"8)BR+/@&),2I.4I<XJ+A^+$Y0#O^+
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M_\]X>491<H"'7U&ZTZI#'\[]RE1Z\%JG2L(G^G'DOY?M84KSA4.Z[=0U4E[
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M/S8,/Z(# Q5KLMZ"S :K3MZ;I+.NE4]?)QD;@A,K 1U,08;L1:Z)!$A3&"+
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M%J0*UE!R)7F7KI^.-%PS_/MD_^UK5O OSDY(5^LW4^M_7J+6$8.A9DH9\%5
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M<S:+5[D""J,A$[($X,,<<B3#7VHTR2KLO.I;HLU%7A6M#*P=^$!B*0UMG$C
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MMYZKJ#V)RB0""A0Q428BA5=,<1.RRUL[3"U1@*L)757NNS>A*Y6TA4KF;>G
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MJ9 T&$8)SP&EJHU 7&:1, <6ES$XF1]RI,"CQZW1EB8O?"D"CRJ5]S[F')S
M?RKAK^$\KU+U)OA<<)JGX*R//A'A  @$*0DN6"3>@_'::._TQDC5%GG.V^Q:
MFPF%GJ2'>V 50UKK8*N'?=?DK1=?&LZ:<)?<^_8"=C^\SRY:"1F9"U5# II&
M8D$XX@*2ELO4,8.:!0>U36NJ_H<&T=ORLM6HH%N [NX\=).UQ@.W)+(L$;H.
M2M971IBD)F1M2M'(M1D%%;QM ^]MN=JJ?+T!2-_,@]1QST%803C*5@*(1>)H
M#B1 ]-12*G*45;X^4(C>EK^MRM=;@&Z8AZXOS,HR)5)+3L!13YQ*CE 3.7?9
M)F"VRM>'"]Y;<KI5^7H#D'Z:!ZE4:+_D)$F*,A/(U! ?O"99*\M"T)3YO"GR
MM6:AJ$^V):JQG4'+WZW;?%D,<ZEMU>U_QN>:]'(W"62^ZCE5;:.VT<I YDT]
M;;EI(/,#UE.%"FB;1.YUXB"3\Q%M%NTST\F@9N3JX?"=*JG?EARR4"8BS<X2
MK3D0,,X1FV/Q"8'0 M"Z,')K1^EMU7H=M9J1*\(3@F9!X>(;[8!QZKB!8+UE
MB%6NDZXQ5VV![<(!"]<F,ATS4=%P E0QXH4P1"007E&O-:T.H(>+7(&+;8%J
M4)Z#"]1+KJ4,C"7%)&1:!>M=(W3A=,5*ZQF#3%*,D4 2BKBL%&&&<NJC2:J4
M8:V"]2'"TTG/-3!J=!80C7?1:^5,\L%S+_+-KQI4P;HFV"Z<K&@)*GIO27 H
M4Z$D)?*1:N*M4%%1*:T45; ^6.1JS\I"1P@N0I;66<9X,)PRKCAWU6*]<X0N
M'*OPX$KE<T-H4!X%:W $5XF3$B<60006E=T0P5I/5>J3=0/4)^L&J$_6<]4U
MGJNN)S?4YA[=U3;:V4:E^_ID/5.O-QAO[*<(C 61)77*16 ._Z=24(8[YKC/
MRM8(T+MV5<@EA^M>!IV5]"1+I@AXSXA7*A&I8U3.ZV CW]J18INUWE51/8FK
M'M%QR72(GM-2I2AZ#R(;(Q7-+L>@UG+'N!X#K FY"^?KY7(X,JPFF2=9+E@H
MXGC*)+/,8[).F93J,<"#!2\7(F4PPM&L(%-AO5&<*9<2H\;G:Q\#5/%Z Y N
M'+$KF:C4BI+H#(I7I%EBD])$(;]:PY-(SE?Q^D 1Z@Q5*?)HI0(GM6.&>_P!
M#3(G;NK]Q38A=^&4769(J!,%$B-E!*3,Q'AIB6/96"FR%VM,&E;!VSKP)J>0
ML[V4J<3',&.]EBJP%*/FP?$J7N\!I L'[4%04(PE$BT# I9E8@,/A&47J/51
M:F\W1+Q6OVM]LAZS?8^]?QL,\=M^)WT-!Z[_X?*CM7*@AF/J=/NC\?"X7%NL
MIVNUC5:TT9[#%6Z6@+SYOMN/")FGI)R^W#_J)Z<MIT<MO?.R98_BO&6EDO,\
M1%1^DE4F@=)@&.4)K -;0KWU-?+1S12)J]&AUU%:7YZ<'[F\_+;[[=G7O3_>
M9\I!2T.)S301"-80[R 33TWYB>+X9VM'F!N5B*L69=LL2HG+FM",3*I4\N#*
MTV1,=(*FP'F*?CWPK ZA-<%V=Q:V)Z^>O6?>QL0%$&I $)#:$2--(@J$$-FH
MD'2]S[AA\%U%O&I5DOU*D:G4D!PURF:FP". RR^N<>!2Q>L:</KF#*=[S__X
MACBU@3J==2;4)D> !DU<=HQ84#Q8Q0#9MHK7S<#G"O!,7(J$*J_-RH-7RFMM
MC6!&F/(7O5F)Y"I>UPW;,"M>O[WZX[T DYS1G 1ARGE+R<<L/"-4H/6B<_(1
MH(K7S8+O2B7.DZ<>%&4F2,@R(%VS4C,;"5P8"M>XD%S%ZQIP^FD6IVSWC_>H
M_$1I4>\5W%L"+$IB'6>$4:UTB47A8-HO7JNS_?K.]OY@7!WNM8W-:*,]#O=6
MWV:H&0(O]]NQ$O"1I8>@01:'>K$L%/XK9N-5+<IZ;Q[U\T1&49C %) 80B10
M# A/43$1,F>MJ689Z-8.5QN0;Z$:#BO"4R6C?<S*<C00LQ(>;!(T>"$9PC.Q
MFLBH+;!=N,%0$M88%SGQ+B-LG:?$I90(M]XS&E0&J:O)_V"1RSD*4LD219,1
MHDN.NN9"DO(6)6Z"*ECORY=^AE"3N6/><E(2PZ&QGQ.Q5@#Q95F4\I135@7K
MPX0GT]HQD6U(G@+^YX+-,B::16!4@ZB"M2VP7;B[0('9DM.<<,T\PA:Q:[P3
MA%D+7MC$HLM5L#Y<Y%I%%?!LH@^@I'>^I(L4GIN(0$VJ"M;[\J*?5Q\-6FNE
M+?%:9$0HU02)EA,5D7"E<-J8N"&"M5Y<J$^VY2RES2[6=84P+QE_JP772B',
M:_>UUD/@FXHONBQK3."IU. E)C"T"ZE-Q"@FB&>)&163-JR(+[8M;W (_!V@
MWY9B>=7SI8>$SWOUM=88JUN$[8+#U0&NE<V):)HU ;0'B'-2D>! L&2YMY*N
MS2ZL\&V=>%V_Q[6*US7@=,'MRAECE(=((I,&Q6M2Q'J52;EFD$TP-GA>Q>MF
MX/->/:Y5O-XB;!?<KB%S+I5&R>H5X!<7)O645.294I>IC:Z*U\V"[RKB=?U^
MURI>UX#3Q:PQ6F46@1&6=2A98Q)QQJ$N3 57#/4CEFW[Q6N+(AO;&<+\*SZ!
M72T^-X3IJ!O3T#40GO' 72],^:KG3[6-VD8KPY2K#_WA:B&>4U!>>9%21!-"
M>2T9MR8&"9X+>N6TD[\<C[ ?H]&O@T/?[3?,><ZHO\X2ZJF6<E)UE&OI*'R)
MAQU"9E8S1U ;20145L0ZGXA6/DAN2O%KMK4C;+MUE&I#K%SO7$5AL],Q9Z#:
M6>^EEX$G:X+)XLKUSF\"WA\X"&@%]15!O>!_-R!YR4E)E(N4@$R"^)0MX2E&
M*US2:HUWG"NXVP;N;)A-/B3N#8<$V4KE60Y4. Y@])5+HE=PMP#<2V*EG7!&
M^NG%:*L4,=Y$@HO.A44&3WE]99DKN%NG=ZL(S%N1A D4P$IG@DT"_\I([9)=
M.;]7U;OO$,4+/GPF(&@)AJCH@ "DC  N19R1LQ5WOB0BJ7KWPT.O=BJXF(U$
M+0P2LR49B1?1@E0J6'DGLKFB=T7T+GCVE1+9!VW1:B[E5@+-Q%O%"0,*WGK#
MJ,CM1V^+//MM=@;.5&"L:8%;Z0^LE+8:I8DECD"A'* ^$@DW.A-P.A 3(A"G
M9;DDXJ159FM'TR4W15J4;ZG>X=H<1V!U$JP-S0L>0!N<XMY)XB1'-%.PQ!O)
M2)8*51:952[WONK-S >*ZGOT %94KPW5"ZX_U*9R-$$1P0,0T%(1DX(DC!DJ
M'7..A?4%_E54MT[%OD?77U6Q5X;O@L_/IPPQ94^R<"7+"8O$!Y4)!V]9Q/^B
MSU7%?GBPO4>?7X7MRK!=</91D;B2EI*89,GZ!X98F0Q1X%#'LA37+;8?MFMQ
M]IT^<@H%:(#>[LRLM8W:QBT#XZ=QR6B+?\?NYYU3$M@[/D31$B;?AX:GCQMR
MWOD[/C:')) H=8X&HVYYX.DP]9IK&3]_Z<;QP:GY-_.I">"?TO./.#\:](['
MEW]DAD,"BHLTO"MQR4M/##UCPLD<S7P].*.5(_<A$3],[A-Q&;OXU/6^N)/1
MUD\71G+8[9/9:;MLQ(=N^ $?'0^.GMIF$TPZX(?8W)+.S*W21%S:)!G-:$0'
M;4&@&)=.TQ0#E!NM%OQ$TN-G4GQ63%XAN0&17 PL0M;4F,B-EE(:U-!MII?V
M4#4]7-H':IPP'EAD,D#&W@3+5$@F -?&45X8N.R_\\TQ1#V@ *+GCD;IZ>D_
M?C[=O]U^LT#-AWZ>]F&ZH^1B+<9FXTQ^/9UJ:[>5966VI\<_TQ=/%V*[68@Y
MB3?Y'=!M(R__-=UFE_[N>\W:;6.OU^KW?R>UJ'VM?;V5OIJKMGK7![=S*NA=
M'LOJ*YE>R_U8WQG)%92 'S[*Y%4F:")9[W**]/*J&JX[[/S;]8Y39S>YT?$P
M-<4R.F_0@/QP.S.W^=OE=L,A)D)Y*F:+:8?Z6C=V3@>]BM)[Q:9:O#]_=</A
M2=F*11E[=H@*_/@J%R3O;@ZGOR^:V49.\!_'@U(SYU]H@*11I]OO/ O%H.CL
MNN&GA$20!\/.RU)^N_2R,TF[V2S&W_Z9/J?>!#-LP7UQ6S-95VSG3WQM-V,7
M$ IE(9K8H\F_/+;8U$QIOGW9/SI>LEB\+M;]+=:;_N 'B]01ZUB?QR4EBA;3
M3&&CR=R[!+^BS_9>XQB73^3S%-*A3\..8$\ZG')6LQ'4-EK01BNR$;0P[OAU
M=_2)'+J^^]#8;;/U#FNYP]I&"]IHA:1M<U*@ET6%2J-Q9^C&LT5-+Q8TS<5/
M\[GQTY3:IC5/4&VC'6VT0C*W_VK0=\J9KC+6I9%.+1GH_]QH8&T,W5HA<LLQ
ML!*R,CHHH-)Y2AT(!5%JFZ-U3>06JQ5N[B8Z:W=935;.!:=.!I(\]01XRL1!
M$(0SXZC+,@>'O 3;YN&E0J@4\P H1I;+=2646^L()IG"-TSGI$R61CE]8XJI
M>9C71#T+EZQ"HA87B1,IFEO@S!,K8R12.\^T9@"1/^!,+)5^'@#]6!5U]BI:
M12,(QTS*RE)C<9RE@$.J&LY=T\S"K2]AF+11:9)X0 W'N4!,]((@^8"B!EE(
MZZKA5(II*\509FA01D&*&I0S7D2C*2BFP!H!-S>BJH:S)NI9N+%FK/<93"96
M*TL 0!/GLB&XHU!J:!-D?,B%G"K]/ #Z<5K1Y*B6,7.((>/W'"#+Y"5/*%JK
MAG/7-+-PPPX"6"X#)2*90)!O$O$N,Z(]1$4!&<C"9F@X+3H7:[/??":EEIO$
M'CZ&;%HM<#SOG4U\Y:W5>.O;$M]SM, ]C8%X 0EY*Z*BI(PG-EN9 KC$ =4C
M;;9%3<;QT!!Z6W[;6816PV9-R%UPW7+M5-:1$R1:0T K08S7GC@+$1PWBFE;
M,^D\6/#>EM>SBM<;@'3!\>F2SE%R1A)0- MPP8B-1A)#L^74(^UR5\7KPT3H
M;3D-JWB]!>0N^ U1'3*&Z4!00;8$&(^DU"@E5)@HM$]<^"I>'RYX;\OE5L7K
M#4"Z6)Y6ZDR]YFB]!CI-8L\5$&Z"CBZE)+/:$/%ZJVZWFS5>GVS_DX\F7GF-
MI0RN>@36%O&U2L+&]7M?9PJL5R%V72'&EKA@O9+4>2E(<J'4+]62.!4LL3IR
M'GURJ'>@$+M1;L;V'4P_2(3>J_/U$H#67.9K NZ"!Y9*#DY 0)N0E^!988AQ
M3)+,-6=6*EP\\X!#2QXD@E>1L>MWP589NQZH+@:@2EPG+H%HKS4!:H&X*'&7
MHH#-.H@(5%09NQ$(O5</[/5D; 7N58&[X(;57EH!' A"UA#(CA,3>2:4A\B"
M$)J[6@=\PQ"\DAV[=C]LE;'K@>J",Y8910VWF@23/ $K-*K#WN(7(Y@3-NLF
ME*C=,K9%T8^;G!4DN-%!)_<&7VI2D-I&B]JH3O8[#&[>-+UD!;6D5#ZRV@1O
MDP!MJ*/&2\]TX :-25>CK^Y<(UE6$%BK!!18)J@^4@(:'#$Z:6)3ABQT,B+Z
MK1VPV[Q:#@\-H4+KE)*.66D+-HOB5H_2 #B&0#6A1E^U"+D+KG49F*#&:.(C
M!;0E,B<6 (A)@#9@]A0%?S7['RQX/7C'&94T^ Q>"&=B2-JSS)W)WIDJ7N\!
MI(NU?!&CS*5$M"Y.=4B9&.":9*^L5<H$E7(5KP\3H4QFHV42B3, +X5E*4F9
M+>6<*\/7$A]9Q>N:D+O@50\\:JZ\(LYX3X 9(-8%(-R;K*T37.I4Q>O#!:]'
M_4JEY(U3$"2N.,^..H&6JY->J"I>[P&D"_YT+76T/EGB>0@$/%JO#IPC%NT8
M+;S3CL.&B-<6>=4WQ.UVT]C63;N:L<J9X/J=;_5,< T<!DL\<)!B%$9J$EUT
M! Q'$SX;2A@5WFJK,B2_M2/8MFYSX?%Z>^K>G6\U\.9VD;O@@<L21(AH(A1%
MD8 LI_D"300(.@:;>'!1U/N/FX7@583L^EUP5<BN!ZH+?KBHF7&!*B*"+;G'
MA"46RLUE8;GDDBK@N0K9S8#HO;K@JI"]7>0N^.$LM8$[AJ(5,4R 4XG&OO0D
M<VXI9<HQ*ZN0W2P$KR)DU^^(JT)V/5!=\,;1!#([Y4FP)8\P TJL3X88*60)
M13=.R/8+V1;%O[4SO/77X6 T(A/<A)-.]TK1KOU4"EQ^QN>:6I<W"7F]ZLE%
M;:.VT8*0U_8EPJA/UL.7FM#Y5IRZK"184JB6@@<CA.,^ZQB4*PD,(.5Z:GS'
M>NH?7Y>=N(!3TJ%BZJ!$3GH?24D&2Y@2.3M<.%U28J&>VOZ46-6>7!&A:$,J
M)X4*B7/PD2(R&4Z =Q&\S8;7H*P6(7?AQ$5K*81,CF2FBC.H6)B<:2*="-8%
MFUE87Z6:"MZV@==('U&:>LX]!6FI\2%P'1P5UCF1UP+>"M(50;IPUL*"+:=@
ME 1/%0'F&#$A9^*%=%ID%IN@K"I>'R)"N1"*"@TB"21G@7*5 ]?>FFPA1,VJ
M>&T1<A?.6CPSV1LO"#<L$%23H21TYH3C+P0X;2*H*EX?+'B]1UN(21&HX5!N
MIRCK>!*24:DR_J.*UWL Z<(IBU"..^L#R4F@>#60B%4TD1PB6*FS1,[=$/':
MHJ.6-KO=:C+?^_"\S1P3UR*0UV*ODV6^-T&]CI(1ECF@!5^2^ J(A,ERFF]3
M!.^V=MB2"QLMRH!4;U/=N]=M&3JK8; FU"[XW:R4,25%2;+.$XC4$&O DZ@3
M53)FX#34RY";!=]5I.OZ'6]5NJX!IPNN-Z36Z)6/1$9.T8"/F2#%4D)]LD)&
M93255;IN!#SOU>E6I>LMHG;![2:<H< E)RKGDFH I]9K9XCF@860J:)K=+M5
M^+9.NJ[?[U:EZQIPNN!YLR XM9JC3.6.0 J:6*J *)NLM$9X7>H=MERZUEC'
M^F1;8AT?4'Q[S>9<VVAC&_6(I69S7H>-:4.DC";!0 @01N$0LT@L (LB>V?K
MV?!=:ZC+ZB1*[=".#)X883G!I4K$ $@".CBEA(7(S=:.$!N0#ZN:D2LB- <.
MACLIG.; #;52Q)"LU3(PK2'6T*L6(7?AA"4:KB37DB26! %K,C%4!N)HS%'&
M;#+4(DX/%[R)1^&S\5R)#((:EZVU"M<Z0'+ H(K7>P#IPO&*X<8)&B3)L@C5
M:(LK2'.B*?720K!)^2I>'R9"'2AF#%CK0PE:T#9I8R-U 3BE"-,J7EN$W(4C
M%A.5D)H' E2@>%76$H_Z$3&XC-IE\*@C5?'Z8,%KE A,H<F:<@#+HF$N*LL@
MA"A%4K2*UWL Z6+^&!^3=,J1J, 2,%(18XPDP@:J3(Q),;LAXK453O8K>]MB
M]_-IV],F2'G^*=>GC73[$3?Y4V(;6KE'[]RR&&CL_@._Q+%2R?6U>^IJPJPU
M$!Y?XJXKQ_RY$)X&7=QU(1'#K"0..("+%GQ.Y4!Y\29'B_)EU6M6]^ZHJTDI
M;Q>X"]XZR,SF((!0I="FX-81JX&BSN*1:[G*/J_/6U<1W#H9NWYW796QZX'J
M8D@T]5(#4\1&FPB 0:@F%DDR3@3#J?".51F[$0B]5V]=E;&W"]S%J&BTT&V&
M0'![ECM' ,1*JTG@27+-8N2<51F[60A>Z<[1VGUV5<:N!ZH+CKLD(O<Z:-2$
M62E_0BFQD W1#D*T.7-4D%HO8UL4*=?.N-C?!D/\MM])7\.!ZW^8C87M#\9S
M\; E"A;'U>GV1^/A<<GY7+,]US9:T48K?//M#XD=II!0</K>(RFON(IJ0J/*
MU@O%A %JI9%*,R:8#"YD!M?.<E;O:EU+)5E655'2D#U#E40*-!P ]1!BT&8@
M2II4,H@RIOG6CMVVU7)X:.A,.5FP7!L& J),WI:#8\H=U<I(N/9A?[T)O6[4
M+OC5 U=")4.)LV@^@"IY1B@(PB E:QT:_KG:_ \7N=HY']#&MS%*B(E;D:-T
M7AKE@J#LYLBM"%T1H8O)?5,P3!I+5!(<$<K1U#?.$X;\J@(-(D.L<O5!HI/9
MD%36,B<#X%&DIA19-L+ALI?27U6NM@6U"[YTFF0"'QSAU#K4AI,D1KI N.,B
M D/;)><J5Q\L<JFP0H N=H\"):+35'G)\(\';?*U$_M6N7I=A"ZXT)65SJ2(
M2F_TY;2+<^*T!5+"@T**@5(N-T.NMLB/WF;W6DWJ>Q]^MIH8Z:;D)9<XVYP!
M@Y)$$FD9JA?9"N*B1"L>A0M5PB9C$>!"WN@ L-ZJ:9M:L7Y'6\T[>(NP7?"V
M46DTY5P1F8,EX&@@EGE)8LZB!%I$P7V]%+=9\%U%O*[?W5;%ZQIPNN!S"YZI
MX+T@2> 70&%++)H$Q$LMN;1:LJ"K>-T,?-ZKOZV*UUN$[8+331D7&9.<>%V.
MH+-!\2J=)<XKZU6F3C)9Q>MFP7<5\;I^KUL5KVO Z8+KS3MJ)#<6A:I+*%Y5
M) :R)UJG+)3G%%>P_>*U15%M[0Q?_16?P*X6GQO"=-2-:>@:",]XX&K6UMI&
M&]JH/O1UY(6HBLBT-E[*7('C5C,'446K!+?*6"F=,49?^3+<+\<C[,=H].O@
MT'?[#7F>D^JOLYQZJJB<5/UD)?WDS=<EWG7-+)H,X A/X F@^4>,A$!B=IG'
M8)QB?FM'TVW99OVDV@\KFO^!14U9,DY' RHF+V-.4;(8F 5.TZVBMGH%UH3F
M!:>[MS&$J'3)'"E)*?="K J:9)^#BD8GH6LFNH>+:I6$CS98'1. ,N!4EI S
M]UJ5+#"JHGH34+W@HA=,"RLX(X**C*C.FE@M#(F6,9D%,.YH1?5FH7H5%5M)
M$ F5,:G+977@SE G WC0016=NZK8;8+O@JL>O+$\4DND]89 %HZX#(CAP%#'
M9LZQ %7%?GBP#3X+'WC(*C/P(EFC'.K88%0RN!5N5\>NL%T1M@N>>S LBL@U
M23:A99Q4(HZK2'0V6F>'%E.).VL[;-?@[/MI7.YI[S2C#,W&.VYVVVERU)D$
MKX=N^*';)^/!T5-U=\E<>4'FZ^[H$SET??<AE800L[DA.LX//J>.&Z8.#C+T
M!J,4.XA=U_E0JK%UO!MU1]N=_8,TG#SUV0V[@^-1IYGU46>0.Z,T'N1<RC<-
M0K=)0_&E.S[H!%P0U^V7)\8'"9__41_&!V[<O&)T[#^F,.Z,!YW41]4YI#+)
MG4,W&A??8QH7?..3PY(,8]+"8-@9=7&^W+#C/@S3Y*?;G6>]\<'@^,/!=WK=
MCZLWC)\XZ:2OW=%X,M0ROFX?U[H;CUT/-]!Q*5UWY(;%*UJ&<:4)>#+31N_D
M2?G0*'4RTEH?Y[5WVO<R0R7M!QH4J6R-[;ETO L[L1U[\.]S_9IPKY#<H +G
M8F 1LJ;&1&ZTE-)8X6RF5SL]Z@Q3K]0(Q)D>' \O_ ;7?31)AU(^WD\3R72V
M:K_^^_6HTQV-CB?)4QRV-#KNC<L&00:9///LT^!X,&IVRK^&Z;/K]CHN_/<8
MVRUM3<#1R:X[Q%W6.TZCTQV/;5_HRI<"H30:=P\;D!PW_7(-[)H-$V=J&>(V
MZ9T@\IJW_C-]3KV.P#$<'8]'99N$WG'AQ,[1</!Q,J0R!T?8>9RGYL2Z=,+A
M'AE^2N-.LQ-#%]=Z_/]&G<_=].6TC^GK$7[^]-5'[F2Z'^>P7!YMMC]V^PCG
M;Y@^'..,#X8G'=P@.";DQ88K)N2!W?+GXRZO2N&@7]@9L1T"RFO<W8@J',&T
M'T>#,;ZX[/*S]CHXZM(7)(#FD3 X/"KB 3];)N5\(D\GL*D3B<OQ9TJ=/6P/
M9ZQ\MHB/,D/8=K<_,<2[S1!ZS:>GZ"R+=0'XY:/-%EA<_NU%D'4N@O!'D-OY
MNQ_^M%,_TX+/3$D*)++8T6""Z:?-YD 4_?RE&\<'I\ZFF4]-U(NG]/PCSH\&
MO>/QY1^9T5A"*O+A3NG7L#DQ,?.U=+)A8TNMUY1G'3T%H-HXDT1BDDHJ-%+S
M>U8"IZ:?.AB>]OP(11KQP^0^H?&& WOJ>E_<R6CKIXN+@RLS.]F7S=/,(MKO
M+N+]:%AZZ?06OIDXD\S3SM0.VD/A/NR&N=@D*T.6B6D6.$ $*W4*/HI,2ST4
M'M\_1\.'4T89*?^86$ 7;9[?!X/XI=OK/>O'E\CV_0]=U(XF]P*?3U2XXV':
MQS?^TAN$3_=NY+R9&CF#K_@S^>KY+O[]\N3=/KZ'OT$CYQG?^[CW"0V?;[L?
MWXC=;\]X,7+>_>> AL-_]]U?]OC5QQ?X_D^P^^V%V/WXC][>\S^^O4,#9_?Y
M6[[+BY&T>[*W'[[A]U_18#G!=[P'J71"TY+H1#4I^4B)IQD-EHR*AJ QVP@3
MFQ0Y/,5GQ3EK  "7D]K,.20/3D=(0).P:-MH@?9B0M/QJ&!Y>(QVP.E"-+)A
M<C!^OB"C4\MGN@WF-N]2;>C'';C88<M]#!8"R_A81(TI1*^T J=,$+(<9[0$
M'J<SM1ISWYUB>C]H_=>@UPTGCQJI^\_>6Z6C4MD0(Z(CX/"+TS010W&B75 F
M23Z_\3//D2DI@S$9M[_R62KCI ?.DDK*7HK4B7J/VMUP<%CR*:(J.F=6=(OM
MZZ=NI:)TGOJ5.FBB3331<UV_J*_=4J"EF[N-C8HVY+2.\<1&&*:XW3E[>W>2
ML-$=#E ?_X;*IS\>EQ^B6HDZ.7Y?E,[NX1&VWYB(: _W$AJG2##]J5&(#^"G
ML0_#]-]C?*9WTNGFV<\4&S(4U7QB*4YM@B<=?X*FY' TZ=ZHL3W^BVUVI^9"
M=J'Y#*K#,:$,1VF=.E\.4L-JW::7S7M[W4\)WXFV>K\92V.TSTT*/MLKD]<\
MU!V7&NW#X4EC[1P617V[\S*C-50FOA@RZ4;M-Z;!Q?;10"ACPU69#FY<JL@W
M+14C J=E--\D#OM"1\]>=)2&Q6:8& KG,],81,W+&D.K?S*S!-OSS-\8B-/4
MG;B]/IQNAW@\+.\JS-'Y@M;GT1 MFB'RVJQQ4@S:&7.SO&YBD5S1T-EN,>=>
M*9C[.A1\[C)^N??;98S\\FS%_CD8C3;@D/:N^?G#E[T_W@LI$Z3(B(DI$PC)
M$9.B(%Q3&41V/NJ\TH)Z[UGB#O^S AR7/B0(U%#M@E81:+.@['1!%\X ZH+>
M<$%1'_8F44$",Y:@XJB(U2'A@@9NI.,:Q>A*"\J39H8RQ"=:C0(\JJ )O]+@
M,\3 9+.@]'1!:5W0=2^HB3C52A,N8JE@G1"KVDMBN*,J.1:4=\5"73B*^?$/
M9J3:J#,(3<SOU"6(0O1HZJ2_((+/]*(S,7?JP#M)#A6,U(_8Q/,4TJ%/PXG-
M+-B31@HV7]G$OU>VRCW+KN6VS!)#;\ZPNT5KXL]PD.)Q+[W*OW41D>F?J-XL
MV!7[115]W&9%28VAO!3"$>^#*M5G%7%&4X(<%V/(@C&[8-#?V>*]1!#DNH"7
M+2#^_>R]S-SHQ%'3L#Z6Q$Q 3,E+ZA1(:Z*+>LD"MD.]W3\]KNA/B!,-M+,5
M/C4/!PV--";,&5.B@3)/C)-3(U?.(WJ]P9>9BU(_I,3F:/K<83U$$[<<K??<
MT2@]/?W'SZ='V]U^,X[F0S]/VYIZN8NW=NYXO7%F3WX]=>1:NZTL*[K]] +,
M],53-^]VH_;/G?E/?L?5ME;BTE_3;7;I[[[7+*/;%.2UFOW^[Z2^E<X:9C>G
MLQLULQO56:5@<SI+Y=4Z^X.+<=<MG[P&1C=7"FU;'B=\-A(FKS*4R:G?70YF
M08%M!E/4DRM<M_UA[.+&C9I=&/45]^15+IY.9&N1O"5 ;33H=6/G=!@;,#6_
M3FVWYHSUV=2%VGSS>XD!N\K5[*O,P".8R6=H(A\>-[[;T\DLGO[&$5NG<0T;
M<B^-UT%=CV&J*G8K=ENU(>>QNWKJ$U/^_'S=&6I)!H6)XX[TBN-GT2]PS40H
M*\S,]3)IU!?4%]07M/@%CZ .ZFX3S8ZL>30<Q.,P7M!N;GR5[LX'NER&_L^-
M!G:_=P.7CVB5@ \.P4OF?309M#"6.Q%,@.1Y9!1T<S5P(<YC\6K@=P[(&M7X
MXG%R__B0Q,&83%O<^#/EZ27!WM['#R=[_-VG=W^]_5;ZAN\\?/7[FY.]PS_D
MN]]_.]C]^(*]/<3/=^<O";[AKYZ_%.\.7_?>?=S]LO?\-8[O+?;Q)7_WO/?I
M[5\O3G;W_]U]BV/^S[>S9!OCW?U/8G?_P\E[KBS%Q0/B+60"6D=BO,)O$W!I
M.2CP9FM'/[&<;[,E)]$3 -P=N6Q\*H!*?FTEOY5RE]X^^\T8NK,V;N7#M?+A
MR1P?VFP"PT4E$K@A0',B)FM-D N%S^""S6)KAS^19EFMH1;=FJ[$]&"(J5V\
MM)?&E8/6R4%[\SJ9EN"3-4 $F'(I"HG(<R9Q2X&AU@@3J=S:D4^$X-N\ZF2/
MD?J6+\0F4]_-RT'D[&V2BC$+@,BQF<?D:!!<:&.9OFJNFFJ0WBGYS2M@2@HJ
M$T3"9)8$I/;$X%<2<TK2"J:L%HU!:O02\JM45*GHED:TBGEX!UQ4S<,[8*=7
M\ZJ931%R<H)DX(J 9Y%8Y3U)6H2D'->:\F(><FZ7L%,U#^\?Q@^/F-K%2]4\
M7+>+:C'CO6&XC/B%B)P 62@#L5ESPG/(&M=4>F:+@:BEV:8MTI&N&TJR08>?
MS;6S:U786#+6EN01O;%7*@<K!.549L=!)^IL%-YHJW+2^,^TOK/"RBTK<,L?
MB\>!CAGFA.<DTI0( 'A2O-[$!\9$$HF'DEI*R&W8/+_3=\CDMG2JN5=>*[_P
MIO'"*G;2'1##I792I8K5J&+>45/J7[.2TC^ +$7M=2#> -I#0H"U3ML0"E7P
M;7,#.ZAB]A'*\L:$J/!<"9X+AT@T!NE-,$3PD$MU75-L!%T.D2**<J,4#UL[
M?%M50?[H2>'F?@4:.;6<1B<IR.2<<@J$@B2I!NJO7$&O*OCKIH4%J:V-531&
M0AER P2?B%/6$R&<Y 9Y/0>]M:/L$@6_HK2-*%WI6.+V85K5[?4 =_'DP7DN
MN<\D,HK U25ECBOU+EG*QD=O)60$[LUJ>53,/D+)6M7M:UC#BT[Y0#4'$P,!
MKBB!9#FQR0N"2QZ"\(I)0;=VS)*HT?L3K(_@-M+^8.QZG?S=VYPWJ8A]Y6NN
M+6&DFSL $@6;J0A6)=#<F.@E551Z)J3R@M>+/^TCK#>+GOX8M9&2 0DR9@(4
MT! (7A%K4<*$Q*D.M(FSDGJ)2M%Z'\&JZ+RCZ(J;W4A]-'2TTAG"[?-1C;6Z
M"X::=U5D[I17CA,30!(05A+C*"7.><@E=3$WS54<Q?FVOGFL5:6*C:2*=C%%
MC7Y:,RLL7HYA,GN@@E C2AT2Y >K(R-:\<!*O2"1]>1R#"PY>:QZ2R6C=CAV
M(O,*V2AHQCADJ5SBRO,$POG,HHSUNDHKZ6A>2?'!1@UH/$GJ$H'H%#&6 V&.
MVB I0.!L:\<\H5(M.6JMY/"(R&$5H^8.V*$:-7? %PO'.#%01Z.VI+B#"6C+
MB.>HPSAOC7$Z!N%"<X'$V&K4/%JJ:!=35*-FW:Z.Q=,CJ[AS5"82I,BEW%,D
M)FA*F#>>1D:]R[RYTJ'4S4^0[HH<UG3?HX6G2N>586XE0^@Z<A/6-FH;]]+&
M(SA4?C8M&MMY^:_7_]<='OW\_"9'R"U42V[L:]5&"YM*(H<(H%.R-MOB:PU:
M)*Y=N*JO]0<EN%Y\+:5I<?).:Q%6165]BDI8/#5F&G)F,A!F2[FV0 WQ.3 2
MJ&!*%R]Z$%L[[(G1;(.]KRVZ=O\@>>3__A^#T/^Y;H>Z':I8>81B9>%0+T20
M.0B4(YQI A'_92S/*%8B0\/8H ',JEBI/+(VKUEBSEC'E5)>@[34YZ+8<)ZU
M1;O&L*MZS2J/W"N/S)_&1:&S89D3ZJE%]=0PXAE',O$I:YDHB*@*CU@N6Y48
MI:+Z>US;*(MU<=JX.)5R'QGE+CFZR,&S6 JW2QH-08KU2+H^$@O<!AD,LK!K
M(^D^W-.))@G5S)'$U2OP7*QK-"TLSA<.AVYVRKIQB>+7/BL;;H6O*Y!V:<!:
M)?!;)/ /BRY=D8)0'BCAB2%]>U-J =E(0'+O60[*2[VU8Y\8;K?%YMG>Z\;N
M'=V'7DM_KYS#M=+^HZ7]>M7J$<J A:PPE%DG2HHH7Z(2%>7$<J.)$(DZ);1P
MX-=QU:J2<27C2L:MUL'WTKAJX+?*O@NG7T9)#BX+XB25R+Y,$:>U)#0'H-$R
MPX(J5_$Y77:'I&K@E?3;2OHW+<'PP$B_-<'^U?%R#[2_H'1'DYEV0(S4@D!.
MFG@J+=&99JM+VJB<BN/%&G;SJX.5A"L)5Q*NES,K(Y\S\L+E3,-3.9U.2,$N
M$* 2N1EB(-I;SX G[4M.K)M?SJQD7,FXDG&K->+J!KEU)_1B) GE$NDV>,*8
MI@0,&&*8=21+KJ41G*.V7!PARK*UI5&]=Q)NPE!^&CO<>OAW['[>.1W9WO$A
MXB<L?H\/G8[KT T_=/M-]U3#JW>"4EY0NNN&GQ(J*)VCX2 >A_&H('/4'8T[
M@]P9'Z2.FV@NJ4B9\Y\V4S+JC ?3B[(==WJ9KMOO^.,1OF=4FCKTW7ZC]. 3
M_=AQ1_B:<M,6,=@Y;%Z-,U\^XSHCG-5NQAGNCSL?>@/O>IV/Q\/N*'8G_/&W
M-]M_;C_IO#@>#H[2DZ:Y?SB<I_]M_AG<47>,*U,ZBI.31N-!/W6.W,EAZH]'
MVYW"1H5SNOWCIC\3>&>>(U-2!F,R!*8\DH]QT@-G225E)SR%GT$-KC"&<8H*
M"39%Y0$L-=)GBJ8>%3J:1,/6SF\XL/$0%V2RGT>=01/&,SYP98S+9N9)YTN:
MZ?Z2WN/\A.-AF5R'"S#LN#QNFDRGB]8Y</@B/W;8>.P,TX>B= Z&)]/Y+JES
M9^=[N]F+L[-QYG^<;-UV;,U) -3W+VB?[=:C(?+W$%]]^;[M=4/JC\I6Q]DI
M0J S3N&@CV/XT$VCLD1E(C_C1WLXOV5Q\-_Y>'P\3)WC42K+@',[2FX8#IH]
M%]/GU!L<E35Z@K/;/T:%$Y\N.WJVY<E>#<>XJ A];*(W0<1!]VC4R</!X7+
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MQ-*K3RFMW;;KK!M;\YU5%[PQE@F5A.0B2IVBE<Q9YY.,Q))YZ_%K_3-_.1@
M*QF'Y;]$529\OK^&:XUJNU56ZQW@&FVP1N?+:6T70O+>'GS6@:A">-ZXGLRJ
M[9!:;L )G],8>=K</F PWG;UZ  WZE4*XR:U[5,(Y6N=K.97^V,RJV92@G Y
M(2XHQ/<R*>0<U2B%F"@G2;O(L]:PPF;&Z:F5WW-=O>.9ZP=VK]U'6#VP>_U6
M 0M.RV2UTY%+GHQUS*D$ .>I\%C,6XY>@MV;@EU[ NRB<YIBE@\<48,XDPS9
MJ.$[F$AF*,5<B(TM^4E2_/J=T;<^+SI'O+A6;',O1V/3[0A?<C[V@VDNOYJ;
M\9B2=)9&F1Q7G%OO%1.:*I^BC,:4W&SY<'4PS<U@PC0G,G?[TS1S,X:<40H1
MI[$/FE+A *[()VWTIE@_;E9JLZ\:K0'.SQUX0@;+C!OF#:&:4^N#<T)XS4M:
MLQ(X,4EK<HAME*!Y9]8"F9$>:6$)(H 2CEAK:,QB-Q##T1D]'%9,D?VC)='V
M+UIQD-<__/(,;O/R[&+0CH]+G?^ZRC^OICD^,2\@""/"1H"M9),+AN5O'6$V
M^9+F+!^^#J=I#K!2'[WV*$H9$??4(HNI0CQ2QZ23)@B2X4O2LD=>B1,+H#D$
MR+-@@0ON!#>8.L&H-!('+P,@ARQISDK@Q"3- 61@+F"%I.02\01?(#PB2#.J
M#)9"1DT+G##D(V9O5I#;/+J7O\B@;,[-VX^B'%/JA*VF3E@)]F\']HT9N2^F
MO5=<(R\EQ+0X*60#([D?1@K!A11D!GORB3(^0RYFY5GAJ@C4E-I@*^)+?UF$
M7QEML!+AWQ3A)^D\<R18'2*203+$@Q3( I%'GBH5)"=>,%NH/V+"%I:V7#K>
MSA8$6XAEB4TZQ[F8QZI?Z:9^HOJULD"G.ED3/OL$SU1\D0U_V!Y>5/KI$86R
M0FKX4R7_"6[N[*32C7 /-V\?GS3S\"[;/JOTB\SLV9W5W[QH<Z+D=N) 7OXY
MPT_[[-*.J<93IYVV_L<-_K7UZ#FBFSOF.7T]/3=WAWW^Z^&YJIL5C'^\Q3I8
MK9<7C[]EJNC_74]C:3[Q7.]]S8,L0-1@XQ2F206'.<=*6QU9) (+S!10]V-"
MR<;MNUJ#'\<;3B)R@VA/D4UP8[_9[I6]'F[\Z^'DP,S<?]B//:=[DVA^.HG+
MT?.;BHB*QUOK7\0Q)!+\VPTVOO'QR0CF$K^TS^R9C__.5C9<F<.2^7-N?&+M
M:"^?4:;577C=Z 2^/[QN'!V,FMNU5J/> !_U^:J17S-]6)(TBC/*C:L&/1SM
M;Q]<->MPS>W::95^:=4ZAS#FWUOY-?\[@NMO'QY3SV7@+"%.C8*@16JDHPY(
M4QDHE8DR&L?D!= CAL\712F9QIYP%A/#/%)M0YZ!1!51-D:GI@Y7OL>L[M_"
M9SFOU>W&L:=1:R,QS&:>7&4B,LPYY).5*21)M%&3\^J-=YJ9Z*C3/%E KR@]
M#Y%Q)BRS;')>QT]ZIKMY\//$^>C[KF@\.4\NJ$?>]^2 5^5<[U$$&@\H#W@>
M*^T$/KUB!P-[=A(+B=+VL&)OO3[\!.!TGF]RLP+O:]F_X_AOP\I5^Z)5R9<9
M5B[/L^3I&UE6%VY[;%7%%'^-/2 ?MZ95A\]_$&? 0_&_A<M!/CS_RUG;SM7^
MP;$*6;"&.:1=U@ SAB(K!4/&2B6T2\:XK K/)TWC1F_@?-#.)[R[UX4.@>\/
MSOL 91$88VK["!1P$(?P0M\JN&"(?\=N?ZQMFZQO=X%+Y1?]'5MMWXTWC/$>
MNX3UU+W,40#$!KU\U<H5O+(U7EG]8J4-\V*"E1/AG?#N?\$PX .[UVB\9O-@
MLCS">!D6R_+'<K[[0[$R\XET(*67O>( ._PI?H\#WQX6GVO/KN%>SN)5/JD^
MZV.R9=^-J 6V8 =9XM<.^V<0?HRO/(AA<_X3[N]GX_L3_+V(K% _H<L[,E_<
MSGF>S;.+(D!XC-#G#O/]RT$1.^1XKI X=K:;>4MEV(IW@4%^PG=OA9\+A8!B
M'LYSFY_\'.&Y3X86W;9U-^NF&-)XA11"&3<CNKWF@U?"]:?&>^\%Q3H]CSX'
M =WK3W/<PV;E/RT8YGC X\7UZ69QYF&%"/ 8'D!B7J?%NK7WUQS<(J&5'DQ1
M"^YW '\:YN=SH_(QB#Z'R##XL_'S^MF UF%EW:R10;Q92L5C+I9;?CS%<LO9
MIQ#!M/*[BM??:9S\>&[C)?2SQ?'P(_H.(C%[.PT]>WI[L7-[G:$F+Z;V,%\I
M#?J]'Q^V67GD#HH5.[$6\VR=G!6R+38+MO3@RG[L)O.,57)\?S>5MZ/[VW8O
M"X29&$__[SAYTYN5ST-8*N. /-_5C6\-_6*Q0(C^=SL43[#=.^^V?1L6$'PN
MK,M8/-K\%EB.@V)(@&.N/QB,Y3H&4\-KGXW=9'YB]F_;[A9R&S-O"XSE%E)O
MD?.)FUO-M5I0A#MU]KSF'LMKC.V\/;P_X_DYP3@'ML#.?/7\0-LS)_)3H>S^
M?Y:II/HPYO@#%M6:)&#?GR:1:N?D.#&C)),6Y<.6B',%P:90%B(39J-E2MI8
M\"0]HUEK!99H%[[Y]*PI7[CJ8SGESYCRT=XQ$\($Z@AB1D3$G??($8(1=3 1
MG#+%<ZL[(LR,EI8_ICP[BN=,^\)U\<IIGW_:X3K'(25A(J4H")[32M@AJPE'
M$BS/2*V)H<6T\QFJR+?37H&8\M87/E^8[2$;W:Q\ VY2N-^'7O36#_U@.C 4
M-'X->.GS_EE!)(:7F9,"<;!92Z[('V:""]%(P1X+*FZ_WP9?XTO^;0?7< \Q
MDR7?RL%^P>LA9KLH6*IO#_QE;WB1KP"_\)E2%W0MYX-OF.HD31CS;PB-;O@/
M.%-[4I"#BW8OCCGOC?,MV'SQ(O#D_>*G\;C&;RQN_SZE:^?1%;0^C&]B2B7O
M5?,QS?7O6$+VXPO\H'<5Y+N%@]52WEM*TK%ZS(D*WC.&9/ ZYT$\,EPKE+R(
M# <7C, KJKSWG\OS\^X=I[\?%#Y@\??:#4WPVJ+)$-CA[$5ZNSK)K]".2&Z"
M[YU7^VU^I:KY5>+XIIFSO<YS+RL>__/+[FMQ,G7SZWNMA[3:<_3D5OM.YFGO
M\X*U\5%[XAP5/\2 +(PELYO![?[#O>C_A8]T44_R9X]QQ2J.9U*?YY08_RP2
MNIVKS^.IFMXI(A]MJ^BV"*W1VQG5CFHM^/SN_M$.KO6:\/W.]V9G!S=ZAZ()
MUVL>[9':5%/*+^U&O4H:=(?O[QZ*1OV -GL[O%K_TJO6O[:;]2Z,O=EM= YI
MT2EAL@A-LD2HY!3Q",$TIR0B9Z5"5F+*C?+2YR(T-7NOZ36G'=;$&'Y:G#G3
M&)Y3C5D:PU*-8;)MB!%<R) L\LP$Q .ER%$;4)X_JY5URL37&,,K*-L:.5BX
MR^*4=[&%L0#/NIZ'-)]Y;N?L,H=Y"SFZPYZ%*]LWL_45)NNO.,A$]R[?B&B)
M)',@R=ZT6Q4Z>,&)1L9XDZ4%"3+4"*23!]?@K5*$;VRQ=>SBMIB#H>]G<O_U
M* 2M)[ \\[C(3&!YV8F1$EC>'U@F*8KPF$O'/=)2*,2=<4!1?$!"$L<T)IPQ
MDX%E1<Y_OY\!/&[F<_"O56Q0_R"'[.VP54G=_M7<^>-7[7K\"GGE9[6Y?XN\
M\MJU2EFKP<XWM67"O&S \LS<^H>[:?R<KC,?=9O@1TWIG:L=C@M/)SWKRS,:
MCS]"E_^=,R6Z&F?X7ZW2\JQ;7L6X<G5*1?^ZJ3Y:^SJQ<71UWJYVJJ19/Z6-
MHZ^]9KV!:[M_=O?K.ZS1JYWFUJG5[3U>W?YZVIQLL=K;NZZ.OL%KFZWF;K-;
MZQP4T5BU'MH->L#WMT^OJIV3J]KNU^[,W1 ;-7=48.1(R/KH+"%#O4#.QZ!S
MOT?+<2XI7<M6$,\RN66WJ5Y\C^H5!-&W;E"]2B#Z:I63-RZ^+D'TI2 ZF:+"
M0CL!#QZ)8#GBQD9DHY*Y+M^+))*--JNV"SD#1!?<I[J$M!+25AC2WOA@00EI
M+X2T*3$^0QBF06<@RUGW%"325C@4B;4A)8U=D !I$L_09UY%2%O[HH.O,XY#
M]UU6-1J?5(C?QV<DBC.#9_'J9^=2%UJBL((;AJL7OA:SMY\.A[$0FMN_F;B]
MLYV;:?O2'SR$LG_?3-=UB67/PK(9I0G2&\*%M,BQ+"^13$"6.@98)C&0,F\"
M#YF>B1EGZ%8LQGT[=K>8).\:4I*%1UFEK;^CK4^&8@0[HIQRR(A <HDO188;
MEL_+)LN#-#*YS%O83]IGE5;R#L2]M)+WLY(I=D^<-YK2B*CP#''A%=)22^2P
MT-AHH/<%NV>S$A;3>V</:TDFY<O>7[SN;J%4[<7E /Y?'B[=/C@6&"!0,H$H
M5;GM,R=($T:0IUI[IK *W*WHX=)Z*Q\1/[NTW4K6=^E=]J:$:L9:-#\5:OK9
M\=+BL/;'+O]1<A/+N8]?SGU92C85G^^R-S'X[0ONIGC\'!?E;Q^\]!?=VX<U
MS1:6?_DUTZX?+?.ZJ*8H/W6XM_G7[<M8@T^N7\7NW[%:Z,I]%-+6JG9.26W4
M/*UN-ZZ :.%FYY2#'Q:-T==>%?QOH]=@#?C,N_?<D;:=Z_WZ85;<OZIU/O/]
M^M?>?KW5KG6ZG=INXZH*]PKC;\%8KXI=IO],D#9J&82G6"(B(X0V3C*DA:-(
M2:YX(IB:B,>:,/2M4[+OE)6=MT9[!8$(C(G_VL<PE@]!C6@']:M^B3S/0IZ]
M:>01T4BL?4!)*D">X/)A# @BA$E"\)AUIV,.%\F,!.J*->%[1E>ZE087\2)P
M^<"-S)<"+JU!C"6\/ M>JM/P$HDQ21F#(BUJ$&E"+EJ,G(-?LT <)UG6DH@9
M7=]6K)7Y1^$NLN0NRX>7+_W+08DNST*7@VETP=1BK1TL4DT!71)QR*F@$$DN
M26)8H!K")B-?#RXE=YD/7%3)758 7-I_E]3E>>!R.",RLGE35%GDL!*(>ZH0
M+%*,- V!8!>837IC2\F%=3,LF<O/;.YS(?W[8H@I^<O"(*:8B1)G7H0SC6F<
M 33QQ#*+#'$,2(R@R+ H$/9$JKQH-5;@6P5^/="4+&8.RZOWLT;%PTWHU[":
MUVV^E7CT)!Z5$/0L"/+3$&2Y=9XX@J0Q%G$E-#)"!\0"3MH*"+(\V]C2E+T^
M"5QN/[W6$K-9Y 9,EQ?%Z0#PQ7%X47*B)6#0X=FM.F0,.]\]O/1S+_]4 M*S
M .ED&I",5SHP'R'L,@YQDH7!>')(Y+ZGC#*M9-K8,N+UV^$E)9K'\.Y_5-;F
M1>WOJ-4.(9[]5B[NGR[NTXOJ9(6N#L'K@&G1 Q5Q+;,D _%(L\1I@G! <G9#
M0^^6\8N\ZTWU(9URL+]T/=@"GDKI'&<<T/UP-?SOAQ!3Y6 P+5;PA"1)P,=]
M5LCT3B/O!<R94$D;N;$%,[?H<K#7V\:KG.?/3QNL1L'ZEW;1XNRNL]%$C^#S
M02Y4O[B>[#0]_-'AZZXMZKC+ZVV[X-[X1$.N9\\-3>^Z%8?H+CY-=##.OYNK
MB?",T3YH)Y;%-B>OD8KWY+\.+^ 7XXZJ#ZOF_S71<W[6;^Y-U\T#Y+D._KP_
M;.<7_%;H?;;_CC_*W__KX:F$F\6(?[S%.A@EQ#V/OF5*D^Y=EX86$T_IWM<\
MR (,#39.89I4<)ASK+35D44BL,!, 10?$\HW;M_5NJNH/[<G$;E!M*>H:(+W
MF^U>V>OAQK\>V@48Q?V'_=ASNF<_YLY^MO['#?ZU->L6WMORI@YY%X^WUK^(
M%4)^J[SQN:-M,*ZL]]SMYX[JJW.VZ.#6F9W6.H>C9OW+:;/^[;0QVL'5PN$T
MOC=WJ[1V5,75SB%<\^MI;>ILT0&MY6L??>W6CKYVJO6#ZT9]3]0Z7^ Z#=(8
M'5S7ZC#^W0/\OR-P7MNGQU022ZS&"!XBA&(^G[HTUB%"$\8,)\ND&?,+,/T8
M/N<&'IY*:V%M<TTPITIH;J7 5 C,A:4L3)Y%^OT.$:= ?[)AX7V,&4_(TQ_V
M<' A61=UXEH;P5W@5C.A(+I4W!)@0_CG#5$6L+[^XULQ7';C?LHK;<4.L"UC
MD9T<F\2D4]XC*B)''&N*=! )":<CE4P81?V*'F#+<YC[ED^>/BM\:GN8'6IN
M0=J*-P?0,E'ZB$?0V"9GJI1JYO,]@\5)-:^'+&\IP/R"]. 3$I<S0J\53-/<
M:VU<]&P>%)'%.0#YX%XD]$92NRN1OBK5A9>0F_KC;JW]E9?:NK2D?QG]NFGD
MDE\#U_.T1AM7M2,86^]+MU'?(8U.J]/H' @80Z^V_:U;G12=Z&2*]IG41@W6
M['PFS6WX^>A;JUK_UM[?K;5KVUVXWP:N'1U^?W!^L0//HKYS=6PCM]XQ(&PJ
M)<0=S9)R'"-F#$0,W,@4LDKF)V[TC&8N*R;$M.IBP\]P"_.+<ZX$K-;;O3BL
MU.)5Y6N_9\_>;7]@N0"[T+M^!M2^K&_6,Z$VM;_'@$9QL$IG-=<$9:\?H"P_
MUIQ'RKG/_6P=XDP"R@HLD&7>>F\IEC%D;-/@'__[U1L#[X%Y'[A*YRY7?]:_
M //^8 4Z*\/S<E)X^)>]SBF/DN2]"<F[W954UFM!K43889_;@')DA;(HR8C!
MD5#F8C[+R3]I(F;4*J\\RUM@*= +X6R.S,=+('$-2Q06Q4U*>'AS=G(G/.BI
M\<$$E)0TB$=,D%:<(6<Y40KFS4B>Y3D_*4YFU"TL)%>V^KQ@_Z(5!Q,[^2\[
M73!]QR4WF*A/RL_Z(0*41OX,(Y\A%R,)P\9$@PR3#(R<YL-*S*+(2-#!6I@V
MNK$E9W0.6'GW/QM"WB.5\Z3[7T\<6!D24.+ JW%@TMDSHUD0TB/"C$"<IXA,
MB!HE3;34#JLD/#A[O*D7E(<HLPT_,ZI#6/!]&,0HAIO:P.'PLBC\\_WA"X\O
MKEORX1]+8!CWGGNN ]F[>>H[W\_CV;"$F>?!S SY*,U5")PX1 %1LGR40!8[
M@837*AD5<")X8TNI&?'$/S]"W+^>]CD;HYYCGXOR_*5]+M8^)VE $B+%2"02
ME  -,/F@@H OQ"M'O);*2;NQI6?)UB[%/C]N7N&+;0\J?]ON9:S8T+D<7N2R
M_0I862N&DWC_[$"Q'_%+I!S>AQ$,X>[@NUOHZ<+@\^9/'9YUQIP\,=_RO'R^
MFY82=YZ%.S.$WYS!.H40$9  A;C0##FJ#;*6LL2\\HRGC2T^0ZY@?M@I\P$?
M+1]0FN8;F.84)2!$4"83(MS[7 JFD?:)( T\GDIC2&!Z8XN263G",C7P5G)&
M+]YFN+G/=1,Q6ID]B(PS&7,R]?I\%HIJZ/S]'_V>RTW1;A5#RJW)16'2#"G'
MR /&2BH4E84P16N (\L<4M&2% PU6-EB:Y(RO2G7;^OBN4;Z3NF-%Y6H?F14
M6CH#*E%IB:@TM8?BK(:Y<@AC61QZ],AH+Y!@E$I.;$B!%JBD-9_1K'%%,>+C
MIE@*X;5;M8;SG%;LGY5YE#?D37^,GW4)0XN#H1GZLS@2Q7S$R%.;$,]]0YUR
M"4G#/+B4&+S*99V?!"8S=/3+?,J*L8EE;+.4QOI6QCK)&10W"MB!19$FEM4X
M+'(N@+%RJS757#I!"V.%0&:Z!'LIQOIQ4RO__FD5YYQ,[*.(]+WVE//"G\HJ
M,JEE*-C>2WC7^F>^A.E%P_0,0>W(B%(:4V1M )@F6""GA4 LRJP3Y'R@NC@J
MHYC:%.N><%J>:N#+$E*O&^_<9ZH_)LZ_]K#U!\/YE4GIE3C_#C@_G<(+%JMD
M4=+*(FYC!#I.)*),:^&XDY[G,T_B$^-R80UTEXZZ:Z/56F_%RO@%,2 +]V1/
M8B6F%'T6'OTA/U09V(N8BZ6&<XD5W9=[JS#R*7>EHI4K.ZP\:O=@>2Y+(RR
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M39)?:R3#P4A$5-*(&Z^0MLXAE6)4A+A B03_Q\VRSPF7>>#UH;[" [8FXX+
M@;,4C+8L*!4LA,,0)M.2^B[#]">IKPDF&I.W1YW.IB\,TEXD1#43$D<?>,C4
M5RQ._6W%J>]'3@1+8EU2AF.)@0=)H7/>/PIC4\#.4%52WZ6;Z.&3U+<V\D!S
MJP0^N]6@>Z2VO<=KNSNBT=N#UWQKP=A8=3<GB%N9^DIJ8:Z=0EXZ@K@5$9FD
M"8J)&)ZP\SJIC2VU2>B3A>*B3/S.<G0OLZK2T;VM%4UQ7."PP#\<PIX:Q#53
MR$I"D,-&6FL85REE3?BE:^&4Z=WUX;C6,>T))9HYRZ/%.D2@43$H++F0/I8<
M=QFF/]4.@D?B-;;(!(L1CV#Z#C.';)"8$X6]=OXQTU\'0RS3N_=,DCCF)1/4
MX2BX%,)@X;!@1 839)*QY+A+-]'&DQQWOWX*K]_#3?B\_?K>=6U[)X_ENKI[
MR*OU+]WF;A.N^Z53I<VBT%=Y;;U+B!D9P;=SC "&)?*))7#W1'@C\EE(]:84
M=W5S.:^FN"\SJM+/O:T1335&SW7M/%F$&1!;CDE"X(PB<B9Z3W6PT9.-+2'Q
MLON+E&G<]:&XBN<T(+'4Q\QIJ4[&<2.P9YI9&E5)<9=A^E,5#"%+!#F'.)7P
MA2N@N,%2!'-F6)(N)&H>,_UU,,0RC7M?L\\0&[#C 2?.!9'&8).\T,H&[J*4
M)<5=NHGZ.<ZR?>LVZZ'=Z)R.]H^^MN&>Q?[1E]/][:JH=?SW9N=+K]KI=N_D
M/L# E54H$@T&[I5%SAJ%) >7+R40,IM%]S?ES#3NSPMZ)[7O/D9RY]6D]V5F
M5GJ^MS6K2=*K$_-:$HV(M$!Z<U6/\8PAK7&BPB4< L1^RI@9O2A6GO26>=TE
MY74Y"TX*;8D"VZ?,X9""DCY"T&L9MB7I78;I3Y)>+XDE-@6DC.:(:X*194(A
M3*.C>6<S*+6QI;EZ?>U"F===-NFETFO!9) PM3QBIH74A'(NB=3.1U>2WJ6;
MZ,G3A]AZ.Z/F;H,UZ &'9]6N[1Z*_>V3ZUJOV8*?3ZO;)PSNY0KN+Y->Y9Q+
M5D9DLW8#U\8AB[U'Q F@8=I[JQU$M3.V;2;2NJI,Z\YR<R^SJ=+-O:T-337R
MD4 ^<EL'16) '"MP<\0I^,)"C(S$2/W&%I-\'1ENF=9=#L.5BD<3L"(T,LZ$
M<S3D:L^D6""1)EDRW&68_E1UKA5$2(:1"I2!Z3,+5D\\PA"?R, LMB(]9OKK
M8(AE6O>>2>I$+'-&$)<BCXE:$P06FGGN'$0RI4S#\DWT].F#:;TJ:<(U:K0*
M+/>0UW:_GC9WO[3AGN%9[+#:=NC6MH']'GT9RS28& ,7""8[(1YR52+.-0R!
M29LT,=$6$F7338\7R'!7-Y'S:H;[,ILJW=S;VM DPU6"1EB!$D6GP0IB[BC,
MLE%(21R-1ED#<1['I*S-+7.X\YH^CD02'8 Y<<\U%48;&8';8BJ!-\52>F$I
MIC]5FXL]YEH8% ";$7?,(^VPS[W%J?%!8:["8Z:_#H98YG#O>V/E;)!4&Q,(
M-RY8ZX4QDB@G!;.)E QWZ2:Z<_7O^N=;#RV L?)J>Z*Y6:?5J];_[#:.]DBS
MOB?VM[]VFD<-487GLU_?HS"63G-[3S2W&_Q_1P?'B6/-1?*(>Y:5E;1#+F"&
MI*8Z2BD2987V G^Q]H(NL[LSN>^+K*UT@&]L73L/K>OD6 =G(G 2I)(2"/R=
M1#!EN6R7)Q[ "T(, RZ0L1D*]2O/?LO\[G+8KV%,"6(U39)S 3&P#MX%P[S.
M;;YE6<&P'..O3AJ_U9(SGRC*W981YSBG@B1%)&$KO9?>$I.-?W&MNU><_W[D
M#"_65FK&&=>,<+A!IZ(*7EME94C6E_QW!8ST^Y/\-_?CZQW09J]ZU>A4<6UT
M,*K5#_A^_4NO-O(C>":M6N=+MT$/6.:_D1I-BBX4T4K$)9?()?#VQDD=L?*>
M"9E3O.SITVFF3/+.S/2\R*Q*7_?&9C1-=&WP5@2'HE &(D&:D([)H BS)RV/
M0E*RL6786IY/*].\2RK5S5L$TC-)@N21.LTU!^+KF5<Z0;1;$MVE&/\4T?6:
M>I:3/]Q0CGC$!CG&&*(Z$JQ<-%Z:QXQ_'4RQ3/3>E[UFBD<P19K;(0:I- F!
M>L6DL<;!7)=$=_E&>OUTHO?P>Q7&6*,-G/]>VSZ@C:-O[?W=0[R__3F/G32W
M6[UJ9X<41-<+2QWQ*&"O@.A2C"Q.'B5N"1.>)X]CD>B=%M'^K\J?%I9R',;*
M=3Q[/-/[&@*\NLF>5Q/@EYE;Z0/?V+RF"#"UPC!F%&+)@B,$SHN<(Q912S@C
M1KF@\B%.16?4^ZP\ 2XSO4O2V64N /(R"R$P)XX8;R"><@Z'7-5?]EM;DO%/
M$6 C9=3&!X2UI(@G$1%,4T F"(69D> T-1B_,:]O1%QF>I=-@(E)<%OYS+Z5
MG)MDH@B"!^Z5]]B*4!+@Y1OIZ&D"W.W"_?4:<-_[1P>T"02X6O_2KM:KHCHZ
M^5ZCS?;^]I_=_?J75B;  I@N-DHAZ^ +MV#KCEN&5/):*JFC]C;+D,V6VOVI
M1@/#9>IWIC#9B^RL='YO;%=3S%=@EB T 5L0V32B54A3'Y%+P%5RIP":*WQ+
ME88R]?N<XZM84L!<3(#><AF<LX%*:I,0/E!!?<E\EV+\4\Q7FY!"#!I1AW-Y
M/Z9(8RL1<5P19@WST94Z#1^$^6)KM4\:3# R'@77C/D@!8Y)<(*=+IGO\HT4
M/\U\JZ-:Y]MIM?[YNG'TY;0V.B#[]5JKN?WY^_YV@]5@;+7.Z:C1\:/,?+VB
M.)"D(+;-329<$D@+1I!.V&!&A-.V2/V^0)V,D3+G.[/HX45V5CJ_-[:K:>:;
M<!#!&B2T<#GM(Y$-S"#%C9"1YMU0O[$EF9E1X+?RS+?,^2ZIK;!*,A#CJ5.!
M4PI+BVAJ"/<^>:%LF?-=CO%/YWR)I%I(A0A7%'$B [(6C-\Y;J0F48DL8+20
MQL)ESG?9S%<')ZC1S(ODN##4<)X;CFB#2?04E\QW!8R4/%W=VX1Q_]ENT(/O
MM>U3N(\#WCC:$4VXA^;V[_#</E\!,^XVZUYDYLM-5(Y(X+M11\0-TTBKZ! L
M<Z\<-4EQEYFOF-[4>8KXLC+E._-8VXO,K/1];VQ64\07LY H!"DH" :^SU((
M!ZVTR$CF)98Q4BK7EOB6*=_E$%^NX2TF%_LSS*TCL*"\H98'SC3'NFPJO!SC
MGR*^U%$AK<R:99H@3AT8/R$,*2,#(R*?2&0+(KYERG?9Q%=0X;%(TB:..= @
MG45$$\"[,SQ27[9<6P$CI7-4^^(:K8IJYS.M O&MC>!Z1X?PG."9=9JM9N^0
M-8[@_[N'WS/QQ=+D&C.!+%4!<6\I,IP&)%46%\ !\WR8!XCO=#G_G-6^C)>9
MWYD%?R\RM]('OK%Y31/@Y*T-2J.8LK11%CER06(4C782)H9SF0FPF;'KN?+\
MMTS\+JG85RLL;134 \ &H;1*4AM83$$(X94I^>]2;'^*_\J@@DPA(1D9D. <
M 6L)WV&!L_:D52Z?=M/X]:IF:Y+WY?G?CTE_)=52^\!U5(Q'2[1,)CC/0O""
M4E6V8UL!&V5/T]]3NK_M277W ,9S*K*&+WPO:D?PW$:_G^YO=[O5HT-1JS>N
M,_V526G'K4*"&8QXT@Q9(&)()FH4P\G:W'!1;JIIY_Y0U(&]JOO:M%FMB*=[
M-<M]F565GNZ-K6B*Y:I@15(L(<.20)P4PF52(8T%Q"@!R^#RF3:AUU+48:;;
M6A&:N[K&_WKM7F:2P))2[#B/QAF*M0[!!AN+5&])<Y=B_-/U#=YYYRA!Q.:Z
M/PS1K16*( AN*02Y$.%B\YCQKX,IEFG>^THK6A)J@-I$K'DP8(TT6<6=X#;W
MF"[5RU; 2/G3//?/;G7[D#9&C>MFO<$;<+WFT1YO'%5'C?K)]QK<"]S#=:-S
M6*B782R(C\(BGXQ%G N#-,<<@6$;SV1RA.&B!=M3XF6L[,$V6[_H1595NKHW
MMJ(IGIN QTIF$^**>\2%HA#PF80TH=%$EQ*56:B>\S*=6Z9SYVXQCA.QGGAO
MP/@C4"D5/>$R*HNC3Z),YR['^*=XKDHR>L,3HIJ"%V3$(>TX1I0X720G?.:Y
MLXU_'4RQS.<^D!.-++<_999*+J30^92&ELI'^%>RL@_;"ABIF$.[H57=;K7W
M=P]PH[Z'F_DYU9NMZF@O/Z-1LP,\E^[QZO9>4<X0HL-9:A\%3\&],RR0P\8A
M*H7E6+- 6,@\U[PISUW=E,X"1'I?8E6EJWMC*YH^K\:)<!QLP*@4$<<F(!>C
MRB(F$2OJ81F!VZ!2;NKUX[EE/G<Y/-<3JYS65N8R7:VQD\0G;2U$O%@HQ4N>
MNQ3CG^*Y@7#AA/5(X$ 1YY$C9UE 3$MJ@H3I2^DQXU\'4RSSN0\V66 ZE50"
MJ\!%C#8J[YUBV'IGS(U1ECQWF4:Z-T<WMH.K!H7K'37@_KZ<5NNY;N%+JU;D
M=+_UFO436AUY4;W1*,/8J!ACYKD6+-PGATQD F%/)8DN8LEC[D:AG^Q&P4HQ
MWD?V+E]B5J6O>V,SFB*Z7G@<'<.( B4!7R<CLIYH9)T.."H(5X@#7\?Q.DJ2
ME0G=Y1#=8'R4L'B, J(KN#&!82&9 >N'J)>YDN@NQ?BG$[H,YB!ZC&P"MLL3
MS5*$S"-OD@L1.Z)->,SXU\$42V&&^VHI,7#@-\G%I'D^D$]($(;@)*D-/+J2
MZ"[?2)]NN];9H[5Z]:JVG=]W"/=Z<%4=M=K5WM?3:J\Z@G'"M0]'^_"\QF*\
MTGJ<!!(V9=%!0I$.+B*L5!3&)$(+K?U'),E^'[0OVL-6Y3S;R*,GU'@IT3!;
MGNA%!E=ZP3<VL.F&;#Q(0TU"^4@*XC9D9:(0$02$RAD6DY<)@D%,9IS27GD*
M7$HT+*EV%W@4F'QD.E$NG'8R!B8D(5::0!4K*?!2C'^* I,4E5'!(FJB0-Q(
MABP)$G&MJ"&)Z$BR\3,UHQG-.IABF>N]?VZ41QPQP<0JS4FP-D+,0["DX )L
M(F4_BA4PTCD:LE4)C/5JO_ZMT^SMY7%V]^NMUO[V"6]T_'5UM$-J1WNDT6FV
M,P56U),(JQD9PH$"&V^1XU$!!7;*"DU#9+EJ:5,^E>KEI1+#[-/8+[*JTM6]
ML15-\5S#D]1$)^0*5R<]1XXJ@R0UPC+*-8T67)TN,[UEIG?NSC.!>L.C450X
MS@G7R0<G"41-5"N<0DESEV+[TYE>ZI@3@B-C%=@^C1H9[RC"43OAK3=>R4=L
M?QTLL4ST/L@[0;BIHHE!66XB_)>1WR:,)=?$X)+E+M]&Y^BZ]F>G>G2(]X^J
M^3K7C1$\IU&KU=S]LUL[.F2U4:U7J__>;7;^/"UZ3[ D)5!4L.W<74;S++5"
M/"+>D5Q8ZG2BN:+A*2$&+LID[NQD[DN,JG1T;VQ$T\E<AS%S02$?M89H+Q%D
M98S(F*2)#=80H[*C6\_"W3*9NYQ&$U;H!*N*"QJY91+0-009/1?!&6W+9.YR
MC'^*Y2;#2! V(.HI.$%*+ )[-TC(X*54TDCK'C/^=3#%,IG[P"BY% DGF9+F
MS#&;"U:\=DSYH%5,)<U=OI'.T6+MLZCM'L#XO[;A\UNU^H$8?P_7AL^J[>Y<
MU> ^&IV#L> 8MB$*%W,I UBXC0$9+8#F M?5U'',#<XT]\D#:KP48GC$U;W$
MJDI7]\96-%VWZYGQ%%L$,Y0/J#F-M(L"A:0Q]5Q9*3D8 E>;TRU75I[GEMG<
M)>GJ G^2-J8$$, Y3Y9RF;RD\'N7XHWQESSWO8U_BN=BKP2.P&XY3''6U(;X
M-BJ%9$B8\2!,4.HQXU\'4RS3N?>;O1";3]\KXA7CGE,K@^#28R,CD8&4=;LK
M8*1/-U3K'(K:=O>TNGOPO3IJ=FN= ]&H?VU5M_=&M;J':_T)SZ29T[G% 35B
M.?'18J23XH@[QY$S5J,4N+,I66F*2'8.GON:\VFKF])Y-<]]F565KNZ-K6@Z
MGXN#2B:W$DPX]]0VX.J4%$@FKB4-Q@HL-K:,F-5":>5Y;IG/79(00V 0YFJM
M(V&<".^HTHY(;HRVPK,RG[L<XY_BN2*(B+''2&B:Y>6M0#8%C6ABB6D3$R7J
M,>-?!U,L\[GWC-(EC[V@P0EA.';1>.X X3'\RDJIR_YI*V"D3_=/ZWV%YW.
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M?".=HV]'E<)XOS<[55(=P74[!QCNAS<[)[3:J;5JM-G>KS=;M7JW$'HS0@8
M78Z$LQ$L7%ADLX4;C3&7,07-<R'6)E//KF20KZED6-TDS^O[U;W(SDKG]\9V
M-<5\ R5)$NMS$0/0WP#T5U,E46ZHS3EF+#@( 167Z\A\RPSO<C*\!FXL:FR
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MK9_U"'DY\+S-*BB!YVG@N:YN[QT'("=<6((251AQI<'[L!@1=HX9F'H2*<[
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MBBLI8$=DL+A,5_ZO^_PJD+E",#=6H!)S.)"7UH^W_^^\-;R\H0 =[,.KZ!^
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MKF)N>Y'"='78I!BFR1F"$C<6<6LX,A0G9'3@R7/C<$$#J.66FNW'\7CFM@A
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M#__LON[.ZL_HW)6ON\*8Y3!F3DMT)R3FGC+$+%'@OTF##!$49:I*Q@)ETF+
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M<!:+M@"2S,N+6WLSI@JM_&YFS..1I *+!<%BIH63$-YBXS$RPH!18Z-&)KJ
M,(M)^^2P#$6416R1*LKRS%&67.Q3Q5.>JY8GO^T*419#E'F-/J7 T5! %&Z,
MA!_:(HNU0"DHQI/CUBDP/Y@D5>%.%4-98^.C H3' <*,B6&(I%QJAG"("7%)
M(C(L$B2="$0&)PV5)?G TALY:QHW(68M#8R#WM"V:_ 4@\$\!OYE B;+M9BL
M[)()ELD\/57,9(48=3G':$G8"V$E1U[@S.,6P2%*Q((;E))WPB@IP\:VWL3"
MO."ZG;7ICKO(>):)MKPT&%I?:ZB"H2> H1E3B5@KO4L:$1PYXCYXY)B,B-M
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M".(K^7A"^6CL?FQZ<(Y@X<0H&A -'DA"UC"/(E.4^PCBX_(&'M=S6+QK(]$
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MY>]LU;Z.4L+L31?7RPD/N-6=6!![(*G@=\-WLPL-UX%APRUKQWT+XX\IE4.
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M!=>E'7\410EY$L<Y56U[4;Y8.QB<=\[*EP2S5+[/,CVX5^O8;W$**6_EHJ_
MJ;FQ2CY[ /7S=NREG1!:9:SWVO+8;0U\NS> B1T<Y!=U '?]L]WSWUZ=H?&%
MP+6; 'C>,H:1%9:"2QXS99+,G*V,"$:,I4E/ Q_@G))&&)6DYI)2K8R3GBHC
M7<2,V@U87;T]RPL1:.HZP&"Q+OUE!R>U,WM9$/AD1;A=-E @0VD%C=5X$B8V
MRV!^ M5)8+<,,A;U,WT:?#L7)0S>U!X>C"C*,FX6^*(4!!Z^;<\&\<WXES\
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MJ5M*T34/Z2ND=&>XM [029/.@2]1C<'@ =DF"?SZ=]6V(<3;)!@;LPVETX>
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M29Y='IYXL[4'\KCU?G!6W?/NPZ]&-8\$?\\NL>UJ\G*UELOG>-$+E^OS8OS
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M_ZK3HIJ0R>3,F)!;;N4;9^9:--$<[O0F3EL6-V^Q5^X4^_0XIZN60%$V4-E
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M& ,*7!>%:\TBP*A@&G.")&<8\4@E,D):Y*A.,B2 ;LSV.R/*Z=HDN"Y^NJY
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MI>(\(&.30["V%CE.,.*.,R(53BYW(23/*)U5L[)(Y.4$:.H)4"3R=<F[+"?
M*D^ FD1.N&:.190<M<#[UB.CB$;2$F^I=CQ6/O)G6-,9Q=37E(]O5QMP=44
M?P*!4A3PI2<?D\Z=S61"\(,C+BU'-OF$B#/:2""G8&PI"KCNI>O*8$M1P/L1
M=B8D>\UMV6KW6J.CF(F].F.RF[_EQL3;&F;FK=YJ#^'U\4G73\]OC,E>1BA'
MN49SKK'4]ME-[3=51;6T0,@9M] >3;I-+9+OT0S];TD6P :I<$UVJU\V]<M_
M3%X?[EYMJB>APIWL'OLO.Q>[1[O=UT<[+[?QP3$(M&_>L\,W[T!]>R5VCU]\
MV7GSU\EN385[2V&,%SOT%3WX\.K+SO&[]FXWCS&<'(+Z!JH:W7GYXLM!]RV;
M66E">$]\5 P%@1GB1!BDI<*PRV(P"B>>@JZ,>%BOL1&O01FBZ\>&2[*&-8@-
MF^QB_AD;%L*;C_!J54UM4C2W1296>L2%P\A9XQ'HWE9;JI(T:6-+2CTC(;Z0
M3Q'%'EX4NT=_:A'%5L=,-7^J4I08XR5RCB;$%3'()B*1 4%,<6LECB&+8DRS
M-8YP+&Q81+$U\2T6-EPA&]9:HMH0=:0>!8I5[G:8D&/:(L*,CM+RY)S+;&BR
M?;I!DMJ3Z#0_MOQ=FOTZ;>O:G?:H'1?JE]/ /,.'[(KS/3W]G=,&^[T7O7$N
MX=_]X6@01^U![,(*U+EK^.=X;?[S;6D*)<U%23,*C! AN),BH"2]09PSAS1/
M%I1("<(W<8H0MK$U,_JXY HW3,)837.;@N&'QO"T6&&T=3ARCP33H&2QR)#5
M51J9\DX)(TRD&UM2;[*"X>9@^"$K>A0,/S"&:X82YY71R5JD"8=S6!.+K$D*
M.4IU+MC!7'"S"WT5"*_Q,;PL3;] >/40KA44%4%'%G,Y+04"-#.Y*K$B*'&-
M4PA480(05INF&1!^$N$\+[P?G,70^@:&UJ2@Z-/HS;(.:OTU$BJ6R/O@JAF5
M)S3#$I3[A(@-$G$C.7)>>&29UM832C&K_#)$LAE9#@]2_KA4,U]OS;_ _/YA
M/BV2$"(#$0KG&N<YG=4'T"^$0+#JQE$OA7 XPUQQLY!QH,"\<:?Y0QD';H!Y
M0?)<2*[9!SBCCA.FD. \(9X40TYIB6C@+C(E31($D,Q)P7&3<+R^%H*"XZ7@
M>/I$IC0&Y;A%B46-.+$"6>DPBL+I@ TV7+N-+8IY4\3N)^'[OU;6MM4?QP%<
M+VS;^J5=E;8=-W5MN:J0;6O\6FMDOSZ1&(%FI-;\O +QTVJRN"(N>ULW(F"5
M*XU'@3QQ()-8KI#A#"-O"1&).!I)JLI7&C&C#G'C@SN+NZ1I<9$/VJ"DL,K]
ML$JM20F)GFB:D B)9#=*1-ICAJ)V4B9%09&E5>M68A9/9RD8?T2&BV5V,7AT
MS0I6!NB:Z<)KYU7@& 6#<T4EF<4$"5)#U%AID P#MMDOJIKA%RTX?FC#1<%Q
M(W \?3 +0RF0,T4F:8.X\@19EA*21#"KM9<Q'\R2\*8@^4E$.#QL_Y$&YI,]
M=*GC)F6B-=F.4ZI<KHK+W\_H*TL]UY$H9+T$)<LFCJQF'$D:I;#!\63X$^X\
MLE9%CE=?X;B!K/_0Y8V;Q/I-MK,5UE\AZ]?"@91T2GN'E+(F%\92.>HO(&F%
M4 (KI6EH3+>1PL'KQL%%\EZ/BCB%@U?'P?5 +BM \E8)@5XE<\<GCS2W%D7N
MC#2>!%>U;GVJ'48*ZZ\;ZQ?)>STJ_Q367R'KUR1OX1DA1J&@I4,<%"ND313(
M!LV%H0:XOSE=15;84N3R(2:])?)89,6D*T$GS>C</XJ R&M%\'O9HNY'9S9?
MN_7+)]ON30+_;"]\_]'3W.B^-1QWNF_],DDM_!4P/1RUCNSGV.KU1ZWSF+,.
M8V^JTGZ^SRF,N1_:'GZIPG.K;XYO]"6.8PP[9V'\>?N3(,7Q$$>ME]''KHN#
M\:YAY%DK2XK5-3-Y;%[MHVH1\M)D"FKWSNQ8Q+BV+).)XMGU<=H?MO,'G@\B
MC %N^/ME+X6*XZY]:[+C\+>O6 >[ZVQT\U>N[2T?@0\'*]T"ADW-R;6?1X/+
M,9S:3Q&Y0;0GR"88XG/;^6+/AQN_?;^381M?G[:;GOC:CC=7.W[K?]W@MZU9
M@YE:I3$-VQ 9]U$#@7"NO37$T924L\XY!<K"^'"![\3P(C,[:!'*VN1"P(E[
M'.&825XS"BI%5#*Q&T?X$)C\GWF.S;LT'[IV?JHYG,Z37_<<[-9J+?ZN,+S=
M\[ UAA'05_U[NP/5K.F!>O?F1>_)SI>/P1L2;$HH,<H0!U8"2*6 G!0X.NZP
MU7QCBV^JFP*\7+O3R7LBD]H\&P6 02*U\)]AW%+A? 0@: RBE9*!XVJCD,N-
MLEATPE(WRKI*7@ML%+RW[\DNO+>[_Y[LOOBH00;F$BOD%<V:,\=(2\90%($+
M;RSHTCF.2-QLN^Q.=@U,;N:<83Y5)V=VJW^U3/G5[T[,9W!P#T^CSX=>Y_S9
M^&2&0^ZH%0;P4B^+ 4"60'XM=YZ/[&I=AY?==$)[Z,?^>3BZAU/'[\HZJ@V'
M9]W3_'C#]\,82@<UV%,?0?JV/$B+DJ01\4 (,C(:9+*_FSI/@R>U#FK-.2%3
MO]/I?P%!'?8GR('#F+LY]<\&K?$W8T @@0Y :LE-;"Y7'WYO]5--2'S^_;;\
MT4.NMH4<2$Z;>"P]S=U#3FQ2JI;>/$QL"G:[WF'S-CJ[VS?+6,M8']%8^>W:
M_?TDN.\!V^_I!>SJ5T]"Q&T>9:PKK_)A9ONU)L)O:R+R5EKL).&X5643WZ))
MX$\#J==K2MY5R=6Q]7_1=D9'U8Q,9F?&C*S/9KXAOP-4FSSQPUJ<[RP_S!S=
MC)NXLEG87M9CWJ9)X_I/%RG3-<]TX66PY:.:D8*W@K=5X>VN!2_FF8AFIY2\
MO&ZPRM;)&4:R10I>W'JF&I(+-V<L5^\L&U:6DDC!;M71Y[IA[T_;\=E'"%-8
MLS]?KNL[6-8KPS*B:VK]&_OT^^3PY7NZL[_]90?NL]/=P;O5>%\?[WWXZ^C@
M8H<<?CBX.+C8%E??N?3I'_][LKM_\!6^=P[/='YP\9;NY>M_V!$'W=?'.Q?_
M=@Z/=X]A+)V9K3,TCT227,4GFFP]#!)EYQI2A!@7B=(:%G-+;)+UB^*Z*Z4U
M,NCR_RW2H7ZQ8_(1DN&<(4XSR?!N^06%#!M$AM,!3MY)PF!OH"2#0%S%@ SU
M"6%O+8L6!V-S+:#%@YO6E)IFPZ904].H"0N5C.4::YLX,)#S(04O/6.81,Q=
M14VX4%-SJ:D6<4\<9]1$A[3R(0>; #5Q+1 64D9">?!*9&I:...I4%.AIGM4
M(>^6$52HJ4'45"NI@K7B.B1DM<&(<Q"=-,$<R90<'#/1@2*95<AZ,]BB0A85
M<EW)<"ERVIT290H9-H<,]Z;E- 9G%Z'8@N*81,Z14<AX*I'15@@B-/8B;&RQ
M&5F13X.:BIRV'M1$J'!8B904(1Q82BO&'%.:8PVD%5E1(9M.33N9EL;T)'8O
M7O&=3Q^-,]0JR1'S',@IN8@L$\!0QA/IC.61X:Q$UNM<%W*ZLV=U'>OQU9VG
MO7C5='"<WO<D.@_.QYE*2$-=Y#1JR857FGH:3.#<<T<TX3])X%J(/'?CZ.])
M&N;D\W_"*A4&O3N#SF@XJ+S$P)P1):8,X@)^6!TC(O!&LLZG%.)L_T#C-=W2
M-*F!0AA55"1B;/3$<I^L55IB2Y2&@UQ[S7^2Z%<(I6F$,FTZPT)Z0ZE&!*0O
M$,@L1UH$AXQ4,N*8E$MD*5;] N\&PEL[!A(W,RHDQZDP)@D+,GD,-F$>^1C>
M^!+>RU6V"KR7#^^:TRX2AT%C%LCZW 6$:E"UF),H*>6DPP*GN!QC4(%W ]6!
M)"AF3'I!O> &<V>%QEH9'%7TC!9U8-W@/7UZ2VE9I#@@E1+-\$Y(DX@1#LE&
MH8,'U6\VO(LZ\-0(91GR@B**&RJ\"R <".&TL4YH277 *3BBBSJP7H12<QXE
M!I(!8PE11S#BVN32QE8BKP@)$C.!<W.2)=AG"[P;"&_#%*56"\9YXDD&YSS\
MC(9%$!Q"H$4=6"]XSW# ..:32-B@ *N,>! <6>L8<J#O&^JPE"EEB:'>_OSA
M /XD>B?G'9XKRN1BA+$WO"RA-"Z"= _98PVDL,>2():7<B_]>6TA+XN5%0J;
MC\)F=$OF+@%A28PLYQYQ)CS2AE-$8J0*=-HDG<\U[^H$UGB5IW1?;*!,U(0D
MJT(H2R246LH5T(FRN16C)Q%^, &$(AF"4\)9G9CGUF:)J#1)?HSP;D*B4H'W
M\N!=3UO* 3%*YI+QAB >?2Z/:QU27&II-/:PYDM1>!H,[W*-Y5SC243>_5P1
M+9%XZQB)5TZ999TR,QK!&AV-XHPBK3V<,C)*I!T12!B*DPF:N&PWGR5$-EXK
M+9;Z!HJMS8O+*_2R1'JI1^E9'B(V2)(<]HMSQU$*;,,X\XD0R[#E3;/:%[ _
MWBB] O;E@;VFL<JD@F66(D= @N QYAPI#'N=LV"D)4:-$S@?,]C+-99SC2?A
M.GWU-7>5B:$UB*.S0:\%A'H*I);;=<31<(DJ:W--H8]39;U<V/_T>Y_VXZ#[
MKEK?O7P=6-ARU,QWU!S4U=9DLXO<9N,H3HA3FA#L^NP X2$9SQ@('!M;>HUK
M;S;1'+N>%/,XU=9",4NFF&G55;N@E.<:82 5Q*UR6:Z-B(2@;:0<-D+:V))+
MJVA9 -\DP#=/=2V 7R[@Z^JK C(WPJ.8;.XO*0*HK\0@S;PC6$?FDMG84H_:
MX;J>@'^<*6<%\$L&_/0)'R,%(4YBY+RRB$=AD''1())"XHY'PFR8#?BB1#PU
MBGF<26B%8I9+,;6T-,F84\E3E(30"!;=(L>#04XPQP+QB><@+K&TFH8%\$T"
M?//2T@K@EVPUJ">J68ZC#TDBSQ2H$2RJW*:>(!,9U2!3FL!#MALT"?*5M^6W
MJD?WUJ0#^&_?=:9O2MOS#[%E>[TSV^F<M^)GVSG+,7^CH]B*/W:EM'M58_0P
MZ5-[Z5$YG?2HM;WJBU7#UJ.J8>NWC^1FK9NM[=[E_7*_]>_O.(D['-_Y6>M+
MS"PP;(<X:'5M[[R58'W[@R&\TX8+V];I   ^.(>[VL[YL%WU8_=G@T'LC:J1
MG [ZQ^-+P\=.8G;\]$*[ OGOXP>:W&M8?7S\"DQ)W]O+#\'+>8R?V_%+=?E.
MM'F3M.#Q;<_#,K1L^-R&11A?(L(=^MWV< 1/"E/<M3"XSK /M\E7J*;N"-[M
M#_(.^JZ;? ZVM ,8ZOC9_ C6!KXV/.N,X('M$&:CD[]1#>>[-O1YB/#(X_D;
MMLY&[0YL!%B;\]:P#1O&#L9S#]-V% ?PY=/3#MP>MNAFZ_;-ZE>W-=^T/\=>
M]9@A#@%B>=KSQ/UH7SV;O.IA"E%V[WTW):'?ZO5'K2/[&9X>%F44\RA;;9AQ
M/\H[/%_^VXI>[9)6?W"Y!-4@3N-@O#$VOY^W[Q ^E5U@A$\B$D5R]E#@1H 6
M[ )+H XK2\-,;?C[P^H??Q3#62?NI<M#Y_+<LN?=W"MX/Z_E/MSR#]BY)VMZ
MX!S^]PC[[K\]^\&<[<'[!_M_P+U.SO<^[)X<[,,8NX='>R )'M"#B\,WKSLP
MIN,#N/]_+UY]A3&PCP$."*J(15:P"$HH)\B"Z(^\4@JF-] 4]48KPL%\"I,[
M&IS%C:;L^/VC'%8-O/,E4\O5QIXL;\9MVQ_!3DP=6/YO?)G.@+MB"V[ZN>UC
M11* [4$?:!&V./P]N$:NHSY<&*[9SCPWN=OP^>WQ7YUI5V?HN*@NS$K'G@[C
M\\M??@_M(>#Q_'F[5SUE]:7?)]<:GY3/<P3!U!E:G;'CMW^?M+;'>!./!<5)
M[,+DSI.W-_&-O>VIV628W/@VWKSYO1]=UFQJ(>]TU1^_)U09:QGKDQ^KY+>Z
MZD^BF>:(HEJ/CLILN1W,U^.A^5-\:/$4'UH^Q8=63_&A-:@WC*Z\/WP#8U5?
MWF ZJ?38>^MN,=,8W) 9^9_[>^JU,GV?#<-2:ADA\7-[]Z4IX76E0TX9%'9A
M /M?8N=SW('1''TS9\LU-2Z,K=FGG<,/\/>'?X]VW^RV=_>W86ROVP?9DOWA
M0!QV#]L'%]ML;_\ [TU;L[O_=K*Q ;Z/#^@VV3E^^V4G?Z_[^NCPN-,][/YU
MO'/LQ>[Q6_'?BU?U,%L9<,#"4X0UL8AS*9&Q.""J9-+$&1FBW=B27,_H4-B\
MOC<KZY!5Z*_0W^KI[R#:P?Z7?F&]>5EO.BXH&5@_FSAR)JK<,-HA)SU!5CHO
M#64RF.S!DWQII94*ZQ76*ZQW=]8[&L18>&].WJL%0#N-HZ#.(VISB5U%'+)6
M>Z0$,5131XQ3P'MZ/;H<%MXKO/?(>>]U_VQ0:&]>VIL6]YBQ@2@74(I!YUXD
M&EEN?&X^'9*(3ACI-[84%INFT%ZAO4)[#TY[[<]%VIN7]FJAZ8(%V$+)()4<
M1MP[@ERB 6GFDA>,T60HT!ZCFZK07J&]0GL/27N9\EZW,^5E ASNYXA8FT8Y
MXR#U!UT[@J%]'3WOG751Z(_0Y,Z%).<U!=;#^7&@L*(F(4)R5C !$1'662 L
M22"P_MP0M['%GV%E%N\UNRJB7%(]X 8RU[L?1%L_LFJ_"W.949$EQHDB7'"9
MHJ4T*$Z$2XI3EHJ;MI$LM5UWTRHF9'):(>$C<)1+)$>36V0]P5HSK)VR&UO:
ME&ZY!<3%V?BPV)VV/A$>>"!.(I]8SA!F'CD</1*8,X$=E8R &F9(Z5Q9L%M<
M9@^,WGJ3%NT,LY0AB7U G(>(3."Y5[TR7'FAB=" 7KJX:E#06]!;'#\+@;=6
MX<\3IG"*H-53FGM?&.1H+OC%I<-$@(;O7 7>A4O\%? 6\!;WQ2+@K;DOM&3"
M)F40T5(A;FE AOI<LL\)K7RB/&2YF963MX#W_HWP!<WS:<%U.SO%.%H?X/3U
MW.:@V]SN4$K$+!>)!2EQLAM;7.I&M8^X1>&<5579J'7G'&[#=O9Q.-Q+KVU[
M\*_MG,'')E6C8JF_\75G_^W%QXB==31O.>DQ_- 8&0+;4%K.E+,RLD@:6G_C
M11=V]6C8&L3.I"Q1_\8*1Y4#9%RDYUMYH<L/];_MF5PI*5:[)I>.N5Y"Z4M5
MA.>J!D?+CEHOHX^Y[%F+D<=8DD.!\,#4TLL&$+))N5B3&@?58&\W![<L<O
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MD@A.L3RLUEM34I 8FQMN^X;7Z$WPNQGO8P2;/4CS'B\/?3KG?9V'QLY#6^Y
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M\*;E:$T%C";,6LJ6<0Z#*H;"![6Z5A'9O]-\UHGHOD1T6_>IJH7$QB(B+ZB
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MLI+6$K']K9QMQU1>M1.J*"A #>!)9? =R7N+Y.@KFL;9*6JP40>OE$S.U.#
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MEGX9#G6'ZR<!UR_NDZM1HT4*$6*2W)K$;*V35#(4WA?U#\[.%SPZ?M6!^[&
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M1["3VO*=<CKE?("LW9K(@C&2@H9<2Z(B*Z6"5EM^X3KE/"[E?'];S\F%:K!
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M0'3=@;9_8 XN@FD93I.- "DG"K( IBA+DKK:[NY^9+S>-K"K9E.:UTB8@DF
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MM/52P7C_O&A_QU*J 78C/';<*;0+?@^F@ .;&H:?-WLOTSE8GY7O3EE7OD\
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M#.?/*V+=S,?4;SW*S_S':-K]KL-P:7R'<\E^=S3(XSJ!NPU*5'8\30O-WE'
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M@<*<3[GK=,9W&D=4%1NNNE?73?;FY[N8SNK74=TW?]YHJYIDUVDR"\)60@<
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MN%&P5@_!"%_M779](;;;Z[E_7+GC_WG_9#CXU,U.^ZKJM:Z#'=O/<=2QO=[
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M*#G7B.W;BB.[CN[)AF8$,@$E2[8<Q0M-.R2ZAL$:36D(UK3>]%H?;6[([?S
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M@2CCJA%?G,_)A88A9[6YF7.74YNK(<)LRU__3 V4;S27))0)5Q#+\;AF^,V
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M,,0=5MJ%S"'G@D29@V0,FZG<DXVOX?1%4X!1C5)Q77 3B2?H<6,'R$)-(WZ
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M*'4IMA&4&M]@ VQ@*2!$!:-&O9^QC5B5^0T;@%3##J)3,'64.Q_;B$KL(6R
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M@IV03D8D^':/?#3=\0I2+Q]4!;W<M'E5B(N4 1.\4"LK=8]_$9\\+@K)[E0
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M7(>]GL3=M^$[+: 8$-N2!T%*L&WY ;!NJ/V.R70FKHV]8(:F6#$L[VHPPR6
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MU'R17NM.W,7?VO91(?7#-YJ7T?*7RZ'P=#P_7H&7-HJD!JB^_>G\#^QO=A5
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M(^G0:)<]65E&$ P+X)S3P.EG(D>IO76-5<\5 (>NID_Q)RZ+<"A!:T7BCRI
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MK1,>UR ,*4-Q!,*T$$1_5GAC),?^UO*6#SG8JCT$K)'U.7_,M^JWA6B305M
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M%%R H#WYK]I)(Z)%)5JG&?8&.Z3@I#73CB/!MA/0;]L#(2*S+!E 5ALS>2O
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MDI)'Z*9!*&$81"X%%!Y]<%U%;1_)S7M!#>H&:T_L.%06_5F459/5#^$K7AF
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MQOI8RA!.*8;"VN-SX]&)_M<PGBYJ[R!<7*Y .VYC(/\:ZV$0N=L(P80",?J
MGH(W;8Y@:?;&/[ QM$^!TP?3X'&\W&X*U[3F[,?3%^3,S2;C7%>ZN9\].;<[
M/;I7GW;_37@T5S9[89RP$KQF%+Z%*"!(7I5E,CP5+F,?/>2.Z\J^K:]8UQJK
M>^_>DJ687TCQ)IK%>G3#9D49RUQ$0_N22VV=9&I+9U>/%YPILH[6DK;UE<;#
M4>_H!@]-^^Y"S>O:]\@B;^8\[(I[\_;H;)I6JQB%+)PHO$XX-G7<N8I0&YV#
M4R(DDURPSCPR6V\%/J@CS&$3]G#!/Z[#>^G;&%4;JB8'* 1"[=X!=3(K.*D4
MQ:=&,-=#_XP#$ _I./2X)#VBI/MDYWEWF?K-N1.W\1)E9YV6@H$NKLY'I/C1
MY]JH1"KGLZ5WB/5PB6,WD$,Z]WQT#C:4Y^,$3_5()2TO%[4N7:<08G7G=YT=
M/WAT<WL,O893#;:EM[BJ9I]P/I[E<5K_M":@ZCCP$J0F+U'Y",H6 =$Z!PDQ
MDN8+7ND>KN]LA:V](MW(O(UHU<7(@""RKQ-V!.GV@!%LMLF8S)#I'F[?W@UH
MV$< #=CSL%[<5SP]FM[7TR7.<;%:K:$%>EXB1');ZZVI6JTG#*!,.L9@,Q/]
M.WZ;B(:=@#\*9_864(^D.3<#9"I.Y],WTTN;/Q+1^=KE EB2G&)TPNJD8_7>
M'V=2<!-%_]FKN_$-//U]%$8UDEZ?\<"GV7PY_N>J +W<?J8TPL(-&E>'YM1-
M413%>)D+:5$MO<7""O;0GFD/I,..#(Y"N>8"/1KY-@Y_1B$)PA,<6%;?#JT"
M.(&FMNRWR'G*21V;<1OP!E41.0B>[2N[9N2Z*P%3,=V;7MS,*UY>OKG,VY F
M9FBM!V.TKV7#$0+2MU%ABEPQ*YJGD_M:RR#VF,CY^S2LR(.Y\J;^\^?S<6TQ
M\//IG/Y<D?=2!,Y1#!^\AR)S!L5C)E=,&C"BA,1DCM:T;I[U2$L=U*'5(%ZI
MZXKH*7"P=Z5VN\J_U=3?NZ@8G' Z*2!G,]<2(02G780DM%.)9\.;7X#I>4E#
MBF*?U/OS&)0ZBO%?W]U8G7&G;Q_FM*DAK:>%==^M"7++1KL@?4RV.Z1)=4QZ
M'9A.K[\QPGEF4PBE=83=TU(&%8P_J1?CF!PZR@NQZ;A? GY%4GK^YL7KK?>?
M]F2+(M2$R7NA+(3$16U79\$Y)2"5HKV7)M\83M7K&W3,M>^8B_B?5^YIL+3?
M=,CUD^/[MFA=+UN_W)"'<[DP"KXQ1))'L!DBUQQ8#D[Y)$)NWL>DEX4,*L4R
MR+?G\?G37[W ?;!OJ3B>E?O^P?XE [W .+AJH/_-:50X\ #YWI1*.!D5TZ86
M[#%2P$K528I.:WH/LA0H GIL77"T#:X^/;#5VT:OZ20L%N,R3JLKH!=;PHT/
M1C(#67()M<$]Q!(1I+9<68F(HO5 @@/@#JG8H#GC=G%96HJUF9=Q'4[G03U<
MM[@N"5]%]Q<K<-PD60HY1H;I>B4H@.=DL[3FAFO!%9>M"WQ:XA]4A77O5'TT
MR??L%A"F%=*#*P+O_;@V9GHKL(W,[6^SZ>Q\D.B5AXXBCT44:2 $SVNO)DT>
M)J\3+:(2PB6'K/4%GCO!'-X.956D<[ZV@DS*S 3$Q.L(!9V G-8 0DGA%'(N
M<OM.8E<@#.K0I@T);O8JV7_3&S;".<-5 +5:V#FH$=E/+Y E$(*%.MU-@-<F
M0[9:HTHBE>;WA._",J3SA[ZHT$ *S3BQ47?P9OKR:UWJZ7AQ4N&]*3]C7(X,
MIZBU% XQ< IHF:" UB@&A0)O;;1. ELG1!X$-:1+-/VPI*U<FM%EHS+F:OID
ML5[T.SS#^2),WI3U#UY^39/33/ WTX?GH?6(,_*'?)"$6OG:_RE S,$#9X%Y
MPWB])M_:L+9=PJ"RU/UP\3&%WO9$Y^[]J6>LGFD%O@Z_4TI&B.@U&"63<BS*
MZ%NW#[P?T9#&-?5#JX82:<:2.EEL^>T]IM-Y=SOVU=EOX_,<[TAX"GR,( ,M
M:S IJX&V+H"3A@=I,6K96EG=AV=(_?WZ84@S:6P94:]_7O^(88%_^</_!U!+
M P04    " !74U965XP[O*ZD  #4*@< %    &QL>2TR,#(R,3(S,5]D968N
M>&UL[+U;=ULWLB[ZOG]%3O;K08+[I<?JM8<O<2_W3FP?V^FU>[]P%(""S!6*
M]"(I)^Y??PJ4J"LE37)B4A*=[C$<7:B)#_75!*H*585_^U]_'$^^^X+SQ7@V
M_>OWX@?^_7<X3;,\GA[]]?M?/[YB_OO_]>__XW_\V__#V/]Y_O[G[U[.TLDQ
M3I??O9@C+#%_]_MX^>F[_\RX^.V[,I\=?_>?L_EOXR_ V+^O_NC%[//7^?CH
MT_([R:6Z_MOY7U*""! **]Q'IA,6YE,RS$9A2Y)%>.G_WZ._>*$C:*69<]8S
M+0QG,0?'G%'"F.PP&[]ZZ&0\_>TO]9\("_R.)C==K+[]Z_>?ELO/?_GQQ]]_
M__V'/^)\\L-L?O2CY%S]N/[T]V<?_^/&YW]7JT^+$,*/J]^>?W0QWO1!>JSX
M\?_\\O.'] F/@8VGBR5,T\4 -'Q>GO_A933FQ]-?TD<7X[\L5G__\RS!<D7/
MO5/X[M9/U._8^F.L_H@)R93XX8]%_O[?_\=WWYU*#N9I/IO@>RS?G7WYZ_O7
M-Y&.I\L?\_CXQ[//_ B3"2%>/6'Y]3/^]?O%^/CS!-<_^S3'<BOZ]90K*%/A
M_,_ZM!][8_I$0.;I)"*CG^*T*GA#C)N>WA_S^;-8Q@(GDV5#Q#>?W13O[!C&
M+05\X]$-T*X>Q([Q..*\)=0KS[V$<PWR.L+ZR,EX,OGZ0YH=_[C"]F)&B_ [
M.,+[<='?T=A2"GGZ^O[/B[^]-#:1/)Z.Z[KQ,WU[]H ZU XH\(\E3C/F[[\;
MY[]^/RY<@T&$Y%S4D5M01147$_<H'8(:73RFXEDCFLS2E:=.ZKHV.R=B A$G
MJY^.,HY'ZXWF];3,YL=P-A%\O<3CQ4A%]!SK-J%S9EJZ2-M!!"9 NT2@E,SJ
M)IF+M7(L,/UP-/OR(XWS8Y5D_6(ETE,Z[QG]5,K]9O61/CN*1NIL>61&BL T
M]YEFX34S%IR!4I1%VV06=;2KJ"^TX]E\C?_L-=GQ/:J;_P#L+6<-A'?*#,'_
M_KO9/./\K]_S%B2^P_EXEG^:YI=D"8VXB+RX8IAP6=.LBF10HF%!.K)O8LG(
M4Q,VKPQ[0+3N+LZ;_(H^_+XXF<\)SZOQ(L'DGPCS-::@I5&!+$W@CJS00A84
M<*UHFAJ2RM$:W>^%O6WD V"YB5!O$BW[$/W3=#E>?GTUGN";DRJ.$621G5.<
M<?J7:>O)&W'6,9ZE"I'^,:![$7Q]Q ,@MI<0;Q*J^A/Z'H_&B^4<ILLW<(PC
M+ (E%X0GF;I3&,=BD<!"DC(!!@E*-B#UZJ@'0VP/8=XD5_<G]_4TS>:?9_/5
M)#\L:05Y,3N9+N=?7\PRCD G'83ES'$E*CS-/$)DR6?22:/I:]^ ZSM!' SU
M[41]4Q-,?TWX"'^\SC3S<1F?!DC.UI^@G?0ED6?N:!O1,68&I+,L9(Q*2ZM#
M[+=+WSG\P;#?0KPW>;?]>7^6\QP7B[/_U.F*D3.%.YX]X]$6IA5-%70)K&B/
MMI0@A(T-.-\P],'PW5>L-[EVS;A^05^^G7^<_3X=I12U0[(I<BED+LHL"%(N
M+$3@1D@G8NKG^M\R\*'QO*-(;[+LF[&\VF+>SM_-9U_&TT0[C/3H3+1,@2-;
M0W!@T7K).( (*L4"LB'5UT8_-+[["/<FZ:$9Z>]FBR5,_N_X\\JH\-*F"(E,
MB6!X/>>AS45DSF1&3,(0*&BQ=V\:^] (WUVP&\(IO>)E=:EY-D=8 5$Z<MI'
M$LW-D]XE A*\M_2M0F&4T<7V>ZDOCW8 G.XLO TL]HJ*U6/(R;M/L^G:SY<:
M1<1LF,^A&@=H&;@4&5G^BDL?DD7>B\GK(QX F[V$N('17N&O#YA.YJ1>0L:/
MX^4$1]H9PIX",S)J@I ="Y(;EH7WQ6<I=2R]&+T^X@$PVDN(&QCM%?_Z.(>:
MN?'AZW&<34:Y@$I9%H;:TYK/P9))%Q5+@7,E#7*(HA>=5X8[ "YW%]\&(GO%
MNM9:]=,?Z1-,CW 5>Z,]W-/BX)G0-5=&*&3!RLP$3<IC+-SHW.3UO#SJ =#:
M6Y@;V&T0O_I/G$S^]Y0<L \("]H1\NO%XH2V!*5] 9N!I4A;.YEJA@5-^X)$
ME:#D;%PP#6S@6X8_ +[;B7<#\0T"6/^834ZF2YBO#DWFBY$0DH,B'"8&P;0K
M@7G-:<8V6EEXS*[GR?'&80^&Z#[BW$!P@ZC5V5GG>_P\FR_KAD*^]\EB%%TF
MU0/'C,JD>9F4+A@AF2TEFZS)/^N9[W'7Z =#=P/A;F"]013K]72)<TC+\1=\
M"4LXPSGB/!B/PC&>M",S0FD6C4E,H"3KOA0TUC4YDMHT^L&PWD"X&UAO$,9:
M+3HO8(E'L_G7$;>0 ! 9&D-6A>.2T2Z#+!<1A,_HH^WG06T8]& XWEV4&_)"
M>D6L3O%\.(;)Y/G)@J:W6(R0;/[LZKF7=S4A*1H6=406"Z(B@Y%<]Q;O\95!
M#X;:W46Y@=I>8:Q3/#\=X_R(-H^_S6>_+S^]F!U_ABFI'&T;7CG#0(G"=-*%
M@8?,N+ AB*3HGQ;I/QL'/QBJ^XMV ^6]XERO4YD_.\EC^L2SY1(7R]5\7TW@
M:.2T+!%\H FN<I5R85X6PY+G1H&C_]M^OM;M8Q\ X8T$NX'O!EE@'SZ1 [A6
M/TGR=:I:![K6#P6;"(XD;>2A&&-1<=TB+^CRF ? ;T]!;N"U00+8NY,X&:=7
MDQF0^9>=407)W@LU>JXCV0B%7#TCE YD,N2B6BS8EX8\&%9W%>,&4AO$PDB]
MCFN.V2S]]N$3S''Q]F19B^9J.'84R!"4$ ,+0'/4/F8R\CW9#)&\/$,*EUT+
MEN_"<#"T-Q/T!CWH%1I;SWEQD76(^?G7]UB0/+V$'_&/Y7/Z\&\CI5P./F66
ME>.T!#G/?,AI94HH3-I$U:;0XEXH!Z 5PXA]@W+T"JNM43Z;3D]@<AKZ&67M
MG4K>L6!7!VTN,2A:L!1YT9D7VHSZ+0N;1CT@RG<6Y@9V>X7/SNNZYC!=K*1Y
M!HKS&MM1@I&'8$GE%!D;405FP3@4UD;+^[G<MXU\0"SW$NH&IGN%S)X1HEQ1
MK7P$BUP)$2/+/-= ?4HLIAR9B$5+R"AR[G>>>66X ^!T=_%MJ+-I4@)Y4<[U
MBGZR&/$4 )'T*I-_1\J%D8$CY=*U5A.-$DYNJ++>X8V]-O !D-M"I!MH[A4L
MNXKIM$#S%%7(V6<HA4ER%VKY;34:?:W6+!*T#=S8?@[UK4,?'-6[BG4#V0VJ
M(5\0KCE,7D\S_O&_\>LH^!**US7MI99G6E-3U9QC"KC*W@?%1;\LOXW#'@#)
M_<6Y@>!><;$-T_P(<8(C&I06%V59<D"@8A$LTA;"HO?6>@<BR#:6]/61&])\
MJ07-'M_@7J+<5+;^W6ESD;^DR6R!^:_?+^<G>/'#V71)_MA/$ZQC__7[!1X=
MWSCD[:X3)PMV!/!YM"H-J ]Z,8'%XFU910>>_3%>C*1TQ7M25&XCF1@@+*,9
MD)UADQ">2U/N[+-18!%79)V-=*H=.%DNUC^Y4)-[P334E3M: ]VK.SO0/!M"
MW U['JR!7<;S<K5J=D(TNM:KJ)$BW$33<E.XK='2!?^-Z9H-(NO]: &@SY@-
M:;L4DFEOZWEM+DP%IZW, %S<54'_F-F_TK;J <G?1L1#D+X*"Z]P/?L%3]LX
M2*ET2(*9D#G3.7!&FV)FJ(T %3TD%UJ3?@/%_NS 5MQ<I[J?8!MV+II,OHZ>
M.>'?S):X>'F"?S^9HB *S!FL@L8XRQ4KQ@)YEZY6B-&DN>%%N!"$E->J!6XT
M(KMGB"=+9DO1-7QY5[#$#U::R\ D ;-K55,0<R)/TG+KF!8A,,CT;4(%TL<@
M-%==.+UKD*?-:C/Q-6Q-M (F?Q!7@2G)%3\#1FYCUK;4J%\DMP4, >.QU.P*
M<B:U<3SH+KS>-<C3YK69^!IV*%H!6ZM;/D%"),X0(=<A^$0XK#),([DF$*H?
MFJ0$R=%&"UT(W?CTI\UD?X$U[$.T0F0XYVO5(DCJ#)(II%>*!Q:PMD8"+9E'
MHU=%G2Z[4!6P"X>;'_^T26P@LH8]A$[UZ@?GSA<(F)[ _"OMZ6J]]A,R1!T,
MHST<::'(B7F5+ LI1JZ"RB5W6F+O'N9IL]I0A T[!9WNZ[1L/)^3+!>?WLU.
MIODE3F?'XVG-;KC00WVNA\A#<$"&N,"::ZX4\S(K6EQL0(F:<]OIU=UJU*?-
M_7 ";MA(Z,S$<V>+SVH+T6%M!101N7&._#!=6V*L$EIH']$(0@>NA73W=5Z^
MZ_E/G-X&0FO8*^@4TR633G*S-@5$43$7KY@MRM6M@^9HM6,8LA,RT6J33"<>
M-S[^B=/87V0-F_^<0E+N$B2[AJ1 !%(AS0)(Q71RM7Y/ ^E9\D;(8,WU#.U;
M6-SX^"?.8G^1W=[3Y]]^O":3G^G;'7O83Q>SR3C7/> \<+J8E56BZ:?9A(9=
M_/3?)^/EUZNH.C:Y[_SP_EWP=YO'M3;YEM,2"MX9*:+VTGGB1D2ER;2U2J;:
M)K_S.(T.^'X^/_@$C1Q"$$QQ6;/ K&1@/#!/6$7"H)*\JQ:YU\G>.8J^4>O7
MTS1'6.!+//WOZ]/$YBNB>S^;3%[-YK_#/(^45SF#)U>1W!&FLZRM61QG0@#)
M0[J<5>N0]I80][].]=2-Z_'N(2EI& R_&IZ_E Z_:A*11S31C HU\]'7\B5%
M2VL&QQQ*\EHDIFQ:'WS? F7_&C$HA1N/1_K)?X#CL(]UXB?SKRM@9QA7\$:F
M)*5#(9\6ZKM!KP193@Z9];1168&F^+L:S>ZB&+>".6S5:,-!P[#\Q8IY?<HD
MELE)K:!Y5UM2$ '+Y7P<3Y8U5>3C[,UL6A-W2,[TQ*-5(P-<+$>J.,6]-LQ!
MT$R#XBP&4G',T=KHM/.B_0[< OEAJ]T#L-OPB&$]BW?S61DO?YXM%J/,(PTO
M@=5C9Z:ES,Q;&YBU3D7O.>@[,W5WT;.+T0];5W:4<L/SB#62M\M/.*\UNN0X
MU-26+UCKN8ZQ8GN#R[?E(_RQ47W?P:J/B@C1)(Z262=K^8_D!#\KEK00* J6
MC'?5P>^B)#TA'[9F[9//A@<K:_@OQU_&F7SAQ<C97%"FPBQBIKTZ"Q:C0*:R
MBQ*,\N#NZD&YBV*=#W[8*K*;C!N>LVPTU$Y-M/>X',_)C*]1?QXM9RG4!(ID
M/?.UL,%Z761&FFMI[4;=CN:PU:$1"PT/7S8B.\/T8K98_H++3[/\[+C>*3/B
MPA8)7K*L:^EY"IF$0/NGCU%ZI9TQ=U[2U%M3;L'U#>E,"V8:GOC<H=?/$DFA
M*K:.(5GN'$N"!*!%Y QRT8SSVIXW2H7YKFK#1LO+&LXWI"L]>&AXG+01VC]@
M<H)K9!?*/ J%UVO"R2(/1M8<35LQUH0^;DWVCM]=;-Q;5V[!]0TI30MF6EY-
M<<7C/XT[OCR95S]_59!YJN,_'7^>S+XBKC[T[F2>/I'(WDU@NAC9[#47) YI
M:P=I,(Z!C)8A&@[HD7"WWK)VA'K82K8/_EI>IG$/[M5K<BOLD5>$.Z!@UM3>
MB<I[%A0 XUHH5VKM?VQ?DK<#T&]2YQIRU_*RCRZH5Z_+<T*::]@!IXM5M>-(
MUFO=I5Y=S"O(MTR27A)NF5-2<Q5+2;GUD>GV*+]=76O 6LL[2&X/HJ\"6M43
M1>G1,!3D4.@"D453%"NH/2 (3,T+"6^!\@VH3$_YM[S2Y+[C7A\R\$@K(2KR
M(G1(F?E<ZMT<HF JX!!;1PD[';>W/#GF6LI$\V$6:P=<4\C<J,E;/D@P0D*1
M;M (Q^TGQP]V!%H4#]XKTD3@](\B'P 2D!M9()E$ A&B]:G#$$>@/1*R3KL)
MB."D0QF8*]'7PT)#JF&!07$JZLQ-":V3"JXB&+H/QT#)1CW$^.AZ;YPJ8]W%
M9].:!K@J,G<<G"T@&6W;R'0"S2+MZTP:ZSVM&@E*^Q?D#D#[[L'1@NC;=*:W
MP ?(.[J&Z2QON NH@9IP; 3TP'TX^A,W&TKJ>U,)8Q/7*"3+GG#I$BV+J=[>
MJWV]"]1:]*TCWWM4A:Y-.?:D"=L(>[#>'"O#95U8![$ DB\0::Y,2]HS?0F*
M.9E,KBZ>%'?=,M/37'ZHBHH&Y-R>?;J#9 =(1WZ6\TJ(,'D'X_QZ^@(^CY<P
M.0,7M)=<I7K,0I:R#E"8-THS1]^CMV =OZM-VRZTWPGH$%2@G<0'>//?XY+F
MA_DGF$_)^UB<U^!E<)X 21M#;2"S4E++LHWH")H2I;4GN1G)(2A  QD/D&/\
M<7ZR6+Z:S9_CE*2Z?%O60>4U/D3G:9L++&I:GK2VE@%HPXK-'$DYR9ENG=5Y
M'Z9#T(:F<A\@K_=92B?')Y-:,79;BN!Z)TM.%NT$*]Y@O=/#DTN-L5Z/J&+2
MR09]5^_TG3:+KN .05.&86* U. -0< S8-IH$0R0!TX[&],FTAH'9#C;X),/
M=I4J.GQ$\G!4HHVD!TC'W1S$/,,6+;=HP+-<O& :/:FGT8&A#C:#U!(1&FO!
M77@.01&:R?O6;-UV1=OO\0M.3_##R?$QS+_.RMGW[S'-CJ;C?V%^60VDR>(J
MI$XEVYT?W;=@>[<Y7"O7%I!R0A&5<T*G8,%(+Y.5!0,7+I11YU'ZYLXOX.AH
MCD>KH]RWZV$N(N9*!V<$[2*"O%&FP17R5E4]ZS60+!:'S9LRWX>IOZ.S>MYB
M!&C]JFXA^!AI1@EK\*:>!J(T.GF7[NQ$OIMK<SKV_A>>IDS?]&MV$.D (8U;
M)GD:R+=1)F6+9K)F7VF=(XM1:Y9L<=):&26TIOLN//LZ!AN4^&8"?^@CLL5\
M62OL\DE:OIU_P/F7<<)5A-<[T*Z@9B[6C'0E$@O1%V82S\KHDG7IE)-$ US2
M&/KN0EMN&_NA#L#:D3IK*-R&(:]+>!;/IOD,T>+,&.L":IL3L&[,WP2RWY.O
M-AS=)+R1@/?&?B /*:6,C'NAR'L2R+R6GEE!KK5(+BG=Z;CC<;%^RR'7'DG?
M1JX#1+?/@)VY1=RE+#7/K$CA:FI:35DTY!8E,L85\B2;)YI> ; _\Z\A*3?K
MT7>4:.,^\R_(\X58+Q.M1RO3TPC9V9ZU;D&'&*0B_8V04KUP$IBW23#2Z^14
M\0#73[ W]GN[?Z2G3.P LASBF&KV%2;+K^M6GU"<!R692L!)[32M4Y;43M:D
M/INT5KJY"W<9P%/FN[]$;SV+:AXQ>@/SJI-?L'> Z,:3&L6#[D9X+?P#R7GK
MI/11*9U4!D](M77D<7&(R8UN>VC/Y(Y/,#W"U]-G*=5JV_'TZ*?%<GP,RTO>
M8"A<T_Y.+CMR8-K2D@XVD3>8E"C1<F^:ERYV@-5G?SB397V57M1 *:3E._BZ
M2O##^?$OQ/CQR?$(9 J1U]JL& WI?4 6U&H#D]FA22:+W&&+Z#38 S0(;<S\
MY3VCO7P;&PCW (0_5@ S]\HX1RN=QE07OLA"RH()84P@IS=*T>7ZDDZ#?5,*
ML(-\&]];<P;P'<Y7-^M-$[Z-D_%I>.,2TL6K,=D\B61S?CYS6OWT')>_(TY7
MMUL7G+\M+TX/7&@?/OOS]YAP_'DY2E$'B$XP(VJ?:A6!@9:6<4!RJ! S3UT:
M^>\-\$$JXB/C>8",'<*55G>]KJY:'R]^(_SU!W"$8F1T-LKQVC3#JMHK7;$
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M7"9<K&;Y'S3+43;66V$<RZZ>VX) !C+73$#.%<8HDNAT*+F#Q=1F!@>@E(^
MVL9]C3J^8N_QZ&12'_/UV>?/\]D7F+S$"7S]A3[Z:?+U/=8* OK3$3>TC,52
M/8VL:OD 9^!Y9DG[PI5Q06K9;O7KB.H %.^!J6K8FNGN5VBCJ2!&.B4/Y)RP
MH BAUC)55Q:8Y<X8PS').T//[=:^S?@.0,$&IZ5A7]TUUK_-9OGW\60R$BZK
M6"+M[-[5C5Z30U*35'S6T8 &;TSK"-QZ[ .B?B=QWJ35#[ RO,<T.YJ._X7Y
M=:;%;ES&-27I&;FGR\7:+7TVS3_3C\<3$@DNZ'<GQS5VMJ1-=WS^X550_^,G
MF)Y/%G,(/G'%5)&NGJMI%CA$9A!$\<&[&V6<0RPMPTWP@!3T\2K&S;<@/*:W
MX"6>KM@?X8]+OQRE8#+6**"IV1RZ>,%B=9><-LX*B#4;X!&K_N99_:GO0ZG
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M:%UST7X6^SJG>W -?B2*\%A._C[2Y]Z62]-:Q;"+]9+\W\"LYI'IVG28'-_
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M:Y%U[1I7F%;"L^C(ORP%$2R$*+1M/,6[\.S??._+^_5P4C-I#] "Y16,Y_^
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MJK?>0?H-\PUT9.-B,!"83;7Q5*3EW%L$LF8,N2R^7OW=VC&X&]$WK$<-J1K
MM5Q=O'D+M!! VR@$+8VEU.O*$HN\2"8+UYY,ANQ%ZPOG[H#S#:M0*Y(&<$17
MF0X;5TB1HDJQ*)94[7:C16*A +!42-,%INB;-PV\%<PWK#MM"&I8ZE9;,J]
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MNKCTFY_^D(O3;MQ=7I,:2&R(W/!/,#W"U]-?IW.$R?A?F/]&@OEYMEB\G:Z
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M>>V[EK?_<SE>7-V::O,/BZ\X^_PU3#Y\KX^8+[_3^?O):J'_@>,O7Q>87_W
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MF'9&BIA!RDC'&R8)@7D-+EHC@G*)Z>;&Y0N\4#^(ST=1]FE>J.L8O)'(H<1
M*TC+Z^!8*[J%=2[8R%UL3-<SNU#?B0./7JCOHHOG<B'994V_+M1WNE#?B29#
MW$SNH^/GPE]GO;"BCN6PA=8F3 2O0P$6BD1/'[OG@S<0.!G>[G2A?G*TW46U
MC6^_'KV5TQ992B%#D4+5N6T<HDL*>$S.9D2N.S62>0&7HCMIL.NEZ"[B;WQ7
MOOUN#HM(GF<$[6K/'<$2^")R[5NEO396%-=E;.VY7XKN2X@V@M^Z232\QKIE
M[GR5LW[ 3=769QU\&=4-Y;W[IF"*S9G,Y6""BI%[925*PUA1(G%G1ML?>Z#A
M<!GGXSP.LZL/L]5S_XF+K]/\?E5*@[=>IPE)L\P,I% 8V?H\D)FO,X@<LM):
M8FX?T.H*[E#SZ?,,P_QR=K6\U5M]"(G>-ZL?Z'RQ>NFH6&.SU @ET-I5KGY.
MX>1[:V,D$[5DJ+6[V 77$;:O7CASW^YIKI,^+E0JMD_X_7*6OM)6_7$V_3(+
MWSYA%>-X\N75)8&<U3*SVW_SZMOT<K+@(\<TLI(#T*8M0)62(=AD0-,B4C3<
M:"=:?TY[HSU7C@VDOSX<OHW(;P&O86;+HF!2 )(+ HK)2!8=V0<2B^(Y6;2F
M^<5T-V@OBU.':::'J/]'4C;.9M<)3*N,V5N0(RN5Y5P8<-[6R%ZL0_VL 26%
M+C%;7JQNS)O'$9TK71KJH6$SE<?07;?0R"%FIVV E&J10$))&$N!9 LY#2E'
M<W_&8B\,.5H[E*.Q8P_Y]]#"A#S7;]/)'5C_AA>T^'6A_N?9Y7RQ^HN1]])Q
MQ3D0QMI\@CS*X.ILR9A<P$)G96QM.'='=Z[,Z4D_/30'Z8)T9'.*19H"VM:9
M\#8%"(09A$^%IR3)<\Y'X-!+9L]..NFC2\;M->83,EE=5A977,@Q@V6U#CT6
M,KC0)2B12\FS4;8T;W"Z&\3!<A"&,81[U,^I)!0L/XZ'QGZ]\_&9!X>2/@PC
M4AU:Y<![3""MDZA*5(SW4HZZ$<T)I!JTY\"FB[+#=='7[>P#9-=Q^R[8^LP2
MV(+K.+?]K738B1H'*&!HDG KT1>A@=4>XTJK!'3(,N N>)&4C]KTTI9X4'(\
M<:5^#&[L(O?&]^3_#%>D$[X9WGHXN/5T)&L.Q6L#BEL%M'UF((L]L$"R(-9V
MN!KM\*HC79(VT<NT/Z%NO5-H=^WY?D*_I./Q;YPWF,/RV-,.O?KLC/3^Q!6=
MG2-ET@^G>-1>%QES+F@28PYQ]-B##]MT/Y M$VHC_-^G\_D;>O95F<Z6=^!W
M;&"94HC1@5BZQR9ZB):88;PI&*TL++<.A7: =?"59_C[S0SS>''W\:O8]$CH
M('(MB]?5]%?9%G#+ GG#A;%"V)Q;YW$_ F?XK:<U*QY<;3:2?0\WFMN7/K*6
M1>NYH,5F\@6CH'W1U6IY(12+@6-J7CJZ'<WYD:*1Y'NP3'^[CD$3;5_-Y[B8
M;X?ZYR(L:F[2[_30BU$2F#PM&J(L"I2B,W7YJQ*TLM$*97AIS)A]L9X?GP;1
M6C\7D]_#."]/^U&*M/=Y&X S1P+@68+G <'HI*PD>03LX9+IYOWGQXJ]I=MX
M4@/9\74"40J3_/$29XOII_KK-]/)8C:.EU7&B^G*[(M($L [)N!(,L6]SV3\
MJV#K2-HZ+U$P8([;F#@=F>$I,_A ".?#BR%UT? 6<CE3,Z79<N[(K7,PG:1+
MVO,FB[>TGF]UT/CG\3<2VH?R[G)Q.<,W8?[UP^6B7$S_1?]X\9%D.:YA1Q&2
MB"0E<#$'4,ES</0E@#92D>"4D*[3_-)FB,Z+8$?25 ]WE7]-9C>MXVDAKW%"
MJEG,/W\-B_^87E[D]]^^A[1X6PJFZJ32/UE6^"8775$\@2BR5OBB@)!4!"ET
M=%YG:;"U"[D?TO/AW8 :Z^%N<POJFR_H(T["Q6*,<[+:UIT5KK^RD8J,6:L8
M6(.<O 49P6,1X$M,3N50.Q@-0[8N<%\,XYKKKH?>^MM%L[J>L]YH)ERLK0DB
MP2.7-$K"6#2S15DG'&OMT#T!::@K\^-Y_[M+_E0NQS>'N>I]33%:Y<(\!%T=
MCQ!JQA$3H)VW1://EK>^SMH*YEA7XTTUWBG N*OD>P@E;01VIXBM"[R>+L.?
M@':<^_!&BNQ"CP.U< 2R")Y-S.0+^,C(]ZP.:.0U+"H]=P9%X*YU0M=12/+$
MO?AQ.+*+\!O?C-]%='UGF\A,Y^2- XNUFW.)$AR+9#PE96P1B479)23T\,G#
MFZ=-!3]M)K7&Y=YO__X^GBW+GE_7&WFS[L/L,],I<+!69%"N1 B<?M!_%!=6
ME6*[U'IO?OKYZ+*!]!I_DW<0X>)?B!."Y<C!J9,EUXWX4\K)N@*&O!A"YR4$
M= Q2S#R+S&*R9C?=;GG36>JYA50;WM8LX\8X'W^9U-C=7Y/+>35:U_VOO?(\
M"0$A)$GGCJ=?:5& *X6TU114G=*2MCW_?/3;1(*-;V;N[2UVS3-'%H/)M5=M
M;5(H4!,B*X#'[((,6BNVQ\YLSTVC#:37^)KDC^DMIG6;EY+0YNS !NMJ]IR$
MR%2 J(44)C$;>9?1(P^??#YZ/%!J/5P]W,0/KZM#%U=+&]]F.M8+K4@(PJ(,
MK3(&PVJ^4$BA!,%D:R=H,Y)SC*,TD'D/&1(/45V3O0NNGJ(GVS =)VS20F]/
M4N$ H?<0+-F*SV&JVU0 Z;!V<3(>0G&&+(MH"T=GG6X=LQ^6#$^$1X;DPBZR
M[H4#"YQ-PL4G_(&3R_6P]/>?_EQ;E5QDC3D#6D%K]CZ *\J!82AB9D&7YB7[
M3T :WF!HH[L'A&@G^!Z2>M]-9TA^QIN:8#R[NL8D<F'6Q 0R5TR12_!DIH*V
M/+)(+F1LWMUS$XXS8<#!(NZE1]"=M,[_=SD;S_,XW3%H;>;>,8_$2D*F-*W<
M$Q^A!$]_H4S.S4^&)R"="1E:"GZK_=BNPN@3+L:S5>_YZUR%VSE6UW_R(5Z,
MORR=H7E8=9Y<Y133;]Y=UE*>NN3+^?YU2>TQ'%K-U+-4[@\<BTS;J+6():B0
MF M>)53%\J1"*7+4'L[!10'C">;K5]>7U7R6#XNO./LXG2]F]^$N_\72(_M,
M2W]-C_KOWV\R)Y+E)MCJEFM=:B)R)-?::1"8(_,\ZF1:GT4M\3<HL+B'Y<W7
MV@KV_>2!9C]-+R[>K?S;$7)=#/T'&%>,1!=KCII64)SG#CG/MOG^O1_2X;?U
MH[%S0Q5&WZKMP6!\B/H!VA'SRAK#&22OZ^5R+!!ST*"5*5*CM3JW'O75 =8I
M4*V]AI\DU6'JZ:=F[![$:Z>H-F\=J>559*UE,X*#2MR"JU5M15DO$R?DNG4W
MIT<!O5#6[*N2'F*:#\&M4V.7Z#AZPZ-DX)74M>XQ0R C&F)06+RQK/#^"7,7
MT0MES-Y*Z:$WY4-TK]+B,LS&X>(?)-!Z'3#BV4DG@@"?+-+1K10X3[M@X"'0
M%AAX#OT?4@]@O5#R'*:>'GI8=CA'U\[6QS#.(\>=+3X24F9KKH7+X QWX%F1
M0K-D?&C=R')'B"^46>W4UL/%[4.XZV#AL@(N7;W].RU%5@N/5L*;/[3G$B.4
M.6?PO%YDV^!J7P@.!H5U5I $6>L2LB; 7R@C^U9Q#S5G7;P*'JUB*@5@R&MO
M)&_I*ZJC@KR)W&ICW/W,KN&=OI;QEYLIKA_*;3SM+FM\O40,J,%&)T A_0A%
M1TB6Q2Q<C+[(P6(P3Z$]A6_QY.(P354\B">]$?&HL!PQ1?HJO:N93BBJ(<Z
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MN=<Z7-,$^"^>]J7E4TEHN+V:1L.<,&3@N&3I0Q,A@V-!+#/DT B/& 8XR'=
M_%+(.:!>3R+E0-O(C(F%-GM'/\@G!L\LUK32$+U.+I?^<]&?0<K!D;C74'LG
MFU^@.;>)C%\(/M0.E(C@)%G).J0D(SHKL/\<X9>27]#6T>Y;W2>>7^ $,X6'
M2"(4$923D3YVID&X9+#HH(QIS=QSS"_8B1'=\@MVT<R05\E=<+WD_(*=]-;U
M3GD?H0])"HN$ E.!P)@C?-F2T:@T6.DY(ZNQ1-?:!GL.^06]<&$761\CO\ Q
M;6T0#"33",K3HFGU'#(YN%S9H#"V3K9\1OD%.VEOU_R"741_"OD%/CFT]#$
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MWWWFL(=P(Q%/&\BGL1'U;Y??PL7T"_W7)?TUK>_==+; Z;K6L:1B"!Q9=\Z
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ML02UNG2_"^GFTN]I4 T#?%N!#!_@:Z2H:5]2;OWA;P7' ]DRSF>PG@P9A=F
M$T*#U:)PE0HRWJD:[;14_TB4;TC-[R+<AAI/T\O)8G8U>OUII(-T410)F.L\
M55>'+:220 2)B@X<GNXWG/I)O7-,_^?+],?_O7[B2L/7O[E5\.W[A@T;-1+\
M]""I;;7AVA7T7#?(^/9]AE\KPW_@JA]2/;QNIP_6?S"=D#RFY;'_P?X%0;W
M.+2@J'_9W"M(LBQZ5F@_<&B5<):8QI6PVG)R *4)HUX0'>84O$K_O[TKZVTC
M1\+O^U\*R_MX62 S<!8##)( DW>#Q6-&NXD5Z)CU_/LM2CXR/F2U1';+D1'
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MOMZJ84P$5Z,KM(GHD2JPYM'!CU@RZ8KJ4]!]WX+@$>GQ8%5ACA=@">F@0:G
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M'6S?33* >B^0*#.ITWC8UJ2KB;.'W#Y^]DK48,,2KX&(< ?Q]@U[K8'(]0)
M) RQF62N.5(SE9^+"9@WH@I3&5?42CH]5-BO(,\2R+[M_M$&)I%:"]9LZ#D*
M#[GOSC.=L&NVDCBXW?OPI*/LUX4: 2!ERY=$+-"F!GJ"G"2 <"ZP<"3Q&^5W
MJFX VUX@?5D&OJC@KA, ;4P"?S4R%*LZ,8KD-JJ, & 4TZ$0^LP!B# VWXF*
MIX7%-:Y@!$OZAQMFGR/Y8G.K>U>G72]ZI^NS9EMUBW!&+J_XA4^_[XM*G8&@
M(S'?9KP"'BZ/?+3LNLU7IUEA;^&WSLRC39Q5W&#>+:3J]U6TWC:ZL  (0H8
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MQ(K3CC'/*Z[>>O%I]\<%7>3=NR'N):+9G.2)$-K8LQQ'L#4(YX?2X.)"WH_
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MOSQ%V,-*Y2:I4+^VO,X\"G?SK9/H"XQCBS[D"8#E,&XJ40"LV.]H'L8]QQ
MM_2YL;M_GI/Y Z+*UQ8 EYI3!0"A1 !L,:EV^=L+OUREJ!>,YF^1%P #T_0%
MI4 G7+0 >+<$PR/W"( "!['.7ZWN+UJ*(TIMIW[EF/%CW952&> W$61P$6K
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M(UK0[1I6 1%](%=9Q;J(=L!4LPSKE=__U?FOO. O:]A^Y :UX(^T  C<ZR(
M?N0&MG^6_2?+_NAT;?_;?&*4^7W]?TA8@3>%U?^0L"(N[<^2_UW)_XQ;7OW$
MFAU)]E7^8>8RKQ2(1R:5CL6O>V"D\O:Y^)82\"$6M<"D/G3LC_5A6AXP8%I#
MF6-"\E&MV>(I=9A_"?OZ_U=9(2;AF]2$ /BZ 'Y1<%=Z')#[H0A;=..1SH59
M+^.W6=N/'GQXYHM2R4_5?U]7_5^D/9!(V.D?I4S^+/M+97_B/C^"G6]L:(_-
MP)[TC22S4QO-UAF?]FG1OD]6%.I_\7_(Q@[@Y(AQVZ%;J;AX"^N;G;Z^@5?&
M[^;<+L/=M 269;3<<N\&U4[WQKD=F<1J/S\^YD=Y4E-GXY3U8<_#Q$U>#Q=\
M<\>^T"7@<69<_ H6M8LB,:RN'_9Y0[!$5_O#AB_I) %0F:$1W_+E72EPYS;\
MA)U]V?Y,0S@JZIS/BD<I<^Z:E2,;\25.FO=$(^VM7VQ(E?5S.!:NG"=S_7KM
MX>4-T8O*,+<%P*8R*01R'-? YA"P%O!A_C"'\9=-5/\X'1QEJEOQ]]/!_WH%
M43_SE"Y(S[!H1V?(E4=$RV;_P=^GK9J_[^*^![9:X([A:6%=H#@UL.I-7+>:
M; +K 4,GWJ@.)3E$K'AXW_.!U^FTZQ_R3K(6L>9VM)7+FCY:DWZE(X'=HR@$
MNT(1;)OOOU -MKJ2<*S];!MX$)IK00R&_'W_*;:RBGORU1<D-,S#.S4W1T^_
MS][>]]J$MLI57H>SC2%_(!KK;JLSU9T,'L*_V<]T3M!A43I2WSP8Q<7772E.
M,*I+CA@=R3D;9MZMUJEZ]D9T'KLK_ES(1D>'C8N:CN@3EP^_LTIH>M+<*7Q*
MLWB!$AX)D,/Y3ZF0#6$120/1JHGDQ:LR"1Y,&C6AMLL$M/.7"8!8_(TWQ.-/
MGCZO"] -XG)*#:WOVB^U@(<[JN4Z;P^*O*+6F4T?X!#Y/4AH;AC EPQ&6,X3
M:.!<8Y!9!RA).T91)<O#W>Y!^APW=Q/'FE>!<Z:_C>6LW!Z?L!:0MCJE]TD
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MF\@O;OG'6J;4;AG/'=ADE*7>3J92Q\"37&"0R$8PE."Y+ C1(5JMK!!HGO&
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M(W=F>$CGTFCMO9R"^3C0V\*FM'-Q)M'IQ NS'<5G@I^J)9>4MF27[SX0#F0
M&21XZNMZ7."-"4<1-PPS%DN9RH75F?D?9N3]2<6/1U09_=:/^A9:!AQ53LN=
M5*)<%PE#PJ05^!?,]L.8D3D9&AZ\RSM_A^UY>KB ;%!K TH,HYX/S;22U+H7
M763,RE/F[7J7G)JJJ\JO29:W;2\3SX_CV70W'/@>BOU(@#:[LZ2\*&26U!YT
M7$A_'4($94S%1[MJN@A8TJ4F6$'7UBI;59D*&GNHN-U_,E'J4G0HY<15'&A-
M@+;OC(<)OY,DP;ZMOXFY$7,,>CV.EPFR'V_:Y8%<6S%1\[RJ-,Y-,)GV_NOC
M%*N[:T6B-X<;O'E(.LR.@H]UWI@,\A(RH9NUA=[*6L\[/E\_L\5/=XF?[M[4
M+JRP8[^Y2HJJ=.'&#6]HA]Z\;$)/.4_.B<#K<ZL7H\4\!A$8A]DQN#/S2IR.
M40THC&\=QIS0$)*82W@,^7_BSZD,;4NQ=WJ83=ADR"QZ$*\:%XY V[C"_))O
MX;L$8LG!?R=@MO76!H+]AOVLO<0@6]?,0_3Y\%K4V1W^.)&+R6%,K[ME(5_M
MZAO/7!O\_)G$_CUV^K+OJ2Q&&,>W]VEY>1WFL-_.R+(^Q'W4(@ZJ4:*N$:I9
M1[L^$&T\=S]#WCJ8SUOQL+:?(Q]1OQ*M) :BXI9FV2U=BW)"! QI6"P$2;W(
M\NT+ MMGZ;Y".A:)7DY1(N23=3M6.@0>V[AZ,5"#-?"'NSP)TC%*?!&6)?CE
M NHI%[C9R06$W&FYI>WQ.(\1[\:PB<Y+&TM;2\Z_9GGP=CG>EJPI@=F-U:H2
M?V(<>6VM7G(QR["S.#VD=6>.+(XYJ8N\?:60J8[95>NK%C>O-1=V[;6WNW/&
M(:N"#_;5BZAK9(%:9,1CEE;G[;0OKW?$'1GG\%$(?>&[OG"!B\3K4[LKNK28
MQ?:^7&"[YLN=P>8KB@^L)FU@&V"%?J&X%98#[O/2+NY?#/*$3N:$7I^@S[LF
M>KI[GEE355J9)-MJ1C-\@N0Y;BW02*Z8Q6H1:,WO7XZ3X6-W=F0ZH.2=8LQ+
MB_#D)VNB5(^)[;ZW(K\PR(QFQ$ 2;O3J1HE&;U_%I\33CA4SSWD&KR9VDG0'
M/VQ8XG/O0> QGF -3:!QIK^4'ABIL4-(F^^=H =AY)R</<+(4%9JF@N4!N"#
M"S"!I>2J0V[=LT_=GZEDV\K%N'/XE?O%*.V19''L3Z./\3<P:L$!+N%[MV\Z
M:Q5PDWHBS#(LDJG'6E,*;:+&;GS^+&G&@;QM,''X])SL^P_=^G/.62$I5S\#
M @\Z_[G[BK_E%./J SF*H[CZT"(<)2UY>(H+@#%#GD;&:/$)'P--W;N#\U,?
MOQT^-3?#(-XA6WRO4/AHH,$*A%28!D&.+%_Z^+A )$LFQ_3^(#%N:2;,8"PI
MY^W]7G.&@"9/;R>*+XC,$55EQR[-2SBS#-AQ)"66+?M1K8T/YT0&NIX C+@.
M#KW^\"YT?[.0Z?";*&->PJEW7" 2UKH$UF/[$1J-A(%)RO)L.;4M*X/0I!A6
MZTC33& /*%>7"WLDF6[6;3$]=$478 NDF%$3<S.,#QMO2D\"> LVD^S8N4A*
M-0ZT0 ^86N-$6$?81-;>?"C<8J*5BN(W6V'D+J1>$ZSN[K./?4T1#! U5=&:
M@&FKGO<2Y\"K%WDLR3&.D!2]G!$1K. _&9E+YP'[(S\>.*;Y4BO-/:]MUSBO
MU!)JMIW)BVU&E9*R[B#+EF=K* 2^%ZT?20\>>H@_GFU+P#(^1^@/^Z8%:/)\
M); .N'&$S)DVN(?P) >0%+RK=L319UP CT-P.N4K#"1+$D./5BED34]OGEY[
M27##> <7B Z QYXE7R2/<88)H/US X1'/X*^1+$:"&UT,Y.(Z#$M=EU=.]4B
MMV8>]4#36J 5 2 IU\9 "XWP4UR I9;">2=-$-=W4KWNU"Z+<21G-E4O[Q5-
MU1E*IYH+N'2V1.OW]Z^XWG[\.>22O$%L[M# H--AE:K*RDBW)%5>'KL30+9H
M8USI_\#)%G18D@X<(758S8"/TII EN,\9(&D;N? R*='SR+.,S4&R%.CWDQ2
M)^>]=F [XFC_)S1K ZP-:(9R/B'8+1T\7$!"B@OT9N$^'>0"\V&V,"2%:C7K
M95+)!:(.+^@<_>H#:S>PK!N^BH= K6_EQ@ V'==DC%MR)WR[B6..H7+M6._Z
M%T5H&D,+##6P:GX.-4BH>^L0Y:0A<="O;N6L]%5#I9?&F*$"7+T3%S@=[Y2:
M-X60^Z*56=K5;PR2<BZ_6U0>\_Q>+$IF'>"M.U6M!+#OD'2A;)WA5&,(O36!
M?<I\/>^8),]BK]2"!DM[><Z4"*OBUV#QT@U%7+$:AO&+=RKKPB%W56V!:1<V
MX_A-Z!JL:\BS!+X@K\"1[[^G[7>=76$GK\8) 2L7X[YE,E4X0G,T5W0M"E1I
MW*UC-3N"M*M-%R#?.[1^D9;*D<OC"&G1-#*;X--H4V.Y;>_R'$8/+&N:G-I.
MK,6>^ LJ.BR]&5K22UB6P'LM:37NTN'CXB?B([(%T;!OB'<PE:-HSM2]2/YJ
MK1](U_FNA#ER 4%$D\)S6 FK+;O%LZ@6@PFCH 1781S&+=6. N?N&]G$;1"#
M%(0H+&,FFM.J)/6J'WD1R6,RL_PPOMF^[)5!@4(Y]G9K4"A'$-Y"/@[X6N0,
M4]O3MD1W1\%%F;1@ PZF/>,+2X^IB'V=M:XQZ"KC/"B5DY1J2E5'[N4P=W]!
MW@>"/U7#ZW,.EL@XC]2PFYR.@.7RU!L11SKFO\03#,]>2UMZ@@ 78:U9GLA*
MY0+P*LO6.M:P42P5LNA.U07DR(*<^N=WZQLX\F /TAV<C+[D!]$3[]C'BK?F
M2@J]-$3LQ34&LX+Z6[XWDN8;@\JO$F"!+;AN< I)N#L79\0T_'X?M&G+-280
MA&N<QDZ0E*''7KZM!4[G^,+4IYYLX?UT"3YUKK46G=A501=6+^VO_/@&M^4=
M LS&47*QJI.N;+*^'I4RAM409>VL>C[>H=5VW>!EX50&#(F"3L_C,T N$,<%
M.$)&]%.3R%".1*?7(X[K*6UUWE8":$P<4!\_\.0#IS-K!Q1/W\\O^Q6#HS'(
MMEFULOV(*/49^#4+U30!EGP_C'X$W3@9%XT3PJ# ,?N?(FAB ,:P9\>7ES$6
MZ6KA;E7*4I,K:):X%Z.7?7?GL<=,!>P(9Q4][)::]J@T^P%)8.I4Z97]Z-ZY
M'!FWCKF#,WWD$_G98N\U1#D]*- 1/2"[!@OKN/6R^CSC<]K#9V>:D>6FB<74
MGT3IG@Z?=SYN/RWK]F#&!1F%I(P3(+6D^\7UE/G!3 OH,1,)70_XD*'10H[:
M'W6GF8G7ELR04CPVZ2_+*IR_^("&$PI"M0RJ<N3HA*A9K3#MJ8#AJ97[&<X'
M]ZQH^@B5K,!6WWJ8 )*Q';A5. _R4%XK4IS$PW(#VQ,6]:#%O/)>S-[B^M"U
M#_P*-2]I'FW<-OVF[FO1(_$URF0DO D(1225#T()-'B++OCDT1+8Y6Z8SI,/
MOG&RW,X<Z#%37Y%DYR,IX4CP\'S,Y:#X<?=FU(!*XZAXRF"#BZD#7>U&9>'(
M*L7]6S:.;'H5]29H+F<P.<WMH_BQ3Z=/IN!24(-6+4K\].I6C?6P^!8D8DPU
M(M:?>AY=[TE[9T?46N-W.YWS-O6(8=NW<^L 8*_X 3.!#V/@42Z01 #OLS0(
M5.WGP36V(,F@]27)\Y(SBX#:49;UQDUJY?S?6!9>8 U#$/I&00_D,*I JV9B
M'$<")QZDW7XJ#B'O83-B*>PZ=?QFVK9BX9Q8*<'D777!R;E7]H@Q]C+W<>IP
M)<C&=X&-N(JTV4GPS:A>6G?S<E2MD2?-VV1ZJ_?3XO3#^>7.^CY$OE:^ FJ]
M[#Y-GD7%OPY'88S@LYC*CL3![&]0SPY29SICFQQ>\+<V$P9F6ASDYZ-8NVD%
M;[65-E8^3U*M*?.\PG=\7W6,^EYERK/1&U$(M$,3$G0@),)<RAHQH-&*6HWT
MTAB(:!Q5IA,;4$)!25\0>,):EDKVT.AT2%*ZOL?-L;JU%P*D!^Z_,?E<DV#,
M,?P2CE# U1^ F?Y3)#]6@65)7Y[]GB]@R4[0/P@.,FEB<SK%8Q^@B*8,8U(E
M=8=:TY7B"N]<[8>KFY]'1J],''J2*G A4=!MQ8EY%:9E7;)[.[2E&']#?ROS
MV#"4:@/FW5C*ZU4#+Z03S<_G>77/V27Z\\>+Z?O>=#RQ!_/VBIDJHOE?T0]P
M<>N#J6CCSDN+;L$[6@=VN$7/K:]R=7DB<U5I8EQMN$/@4R!+H9ZJ(1PD,,X%
MY@8H:%[H2JMIIQ]ZD&!7UN5W?T_O3U5E5;&/S:AQFCQNQL9"3P  X+^*JA"H
M1T+J_3%(RDN".,Y3X\,8(P0\NM\G$[2U!!UN<#:QSKUX824V-*1?,BUC,JJP
M?=C9.>S!IQA@5:ZJQLTV@B5\SN19!O3YZSC/]J'"XW3"=:TPY2%G=L%2_(CT
M^(GN\]66AP8>95X"->/X2N\E[/]X+*2+];UN+0W;,P;"X- 69%(%>:CQ>W-_
M?RXP0&A^87=[K $=8[ :5$&U4N.?=;"?-!YG*LL%FLTR'9<52P^?./-Q=[@K
M.XY,R455I44AT=]E917\SD+,1M DEJ[@"O8,<H%&I")K][/GWL+- 3=CY8/N
MZ#T\'^=G=@$;,''H6Z+ G:XK2-"K2M^!N97E WTL)MZG:2ARNDGJ/94S4[IW
M''=[W;@P;;A#A>?#J]'*:"9R^#LQ7Z_&U;O7?K]"0 %$UVO(!.E04+-L2K'M
M43 ZAN7[P"+7!6IW[#F3->JXH_CC*JLR4\F):)6H&[P1&P]_))]'#YJT<M8(
MTOO'R;.%S#.LC?19E+ ^FNY@35^N)\9PI,"P/F+>2'U^T2'+S;:7BCJ&#YV-
M/53R+?.M6^6IS9?%3'YK[5?_I"E+HIR*:L$E$:K$YF"NR(^!QL!0%Y"_NB6^
M6-T8<J%J2#EF>A\7$_6LFA$:=:Z[<D9G\[X-&P^X)4=-!(V0C3\#3\7@4W(
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MYE\VD\_H8O]-SNC_YSHF5X4!*M,D"=OVD1:KBV]B<[)T^+XG2TM$0&N\+H.
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MGMW@ZR&01]+:TN<)#II+'6@HR<:O\R@R?^,=NS! ADZ"G"N=#9AY9="3VAW
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M2GOJ-02KO=OY'\CMZK/7Q-_R&^6UC]Q^O)C'%Y "IA$24:(33QRWUN $%8F
M\,3'UR@I6L;H;NKASBY[KMV SFW"H;H?$_GZ">]>+-@HFXH IN/(U2.2.I%$
M54B\>IE*C9ML^ZM5*T)>NSR_(\2ID0=\_?_F^SG!I\5K<A'PDTSZ5BL"RGL
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M83"'Z"3=&=\Z^B^55A$PALS+\(;2C>(?18 'O;L=7FW&N\*9&A<!BQ>1/!'
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MSR^1]Q5AK;>(XH5KZ 74&Z5E42+@ F:IK59XXR3!0J(N=R;D_F_$("X$Y8H
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MH4OFNT,9VC+ON6^)<:TV@)( L>[51XD[2.\M6+(1(<)/>W!=S+D!A87WML)
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MOU:3]YS3]Q^^.9Z@]_00L7MCTSZT6NZU/R]*9$S_-QC&OTF3!HZY^/Y[8B)
M/TD$##L6_;D/WS^>TOFO@FIS_ZJHS3_G_N>&X0>0JLT1TTV"-@Y%7@7%X6[*
M\GQ+]Z?XP"-)?-OVU'J7['1%IZT9SO=3:GZB36Z>/][X]DQP;\($Y=*3Z]:
M"+A]BL2*Q,QX@//)!&0RFG9\*D%0]!D2*^H*/GO,GM1%VL:XF(B@ VG]NF\K
M#Q\F%1?AGIC\/C$Z0'!@@Y!I(+PLE855\LXPYP2/>U[.'ETP?2S#N_^\A^#
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MHF&IQWQC4K4]09WJ@Y,<Z*P$!R@H7!QFC<"2F_UP2PD5_2WI@S(^>-O&CTG
MZ/X/AJ^=3CC,/ .48KC:[+EHZ\V0RC$H>&#X6;C9B=)M;EM6WKMR*Z)6-CJV
M]\EU7:\>Q^R(K!ZOT-#7-S_TF&O*=J^5WYV/#;R^^=/B8 ED;OIB%)T)P1#I
M/UFP^/]9Z$!J/0WD?NW[1M3:<?AI!O96DNX!?VV5DR?Z+)]L6 (X?KTT56R(
MFF'VSO'X0@J=E4XOJA^:4./O'0VN/6PW7"Q4V]>:MW<AJNSYAU7UYWWESZ-U
MEU[[<=_1(>TVT((J:<4!D#XL?7\@ (6OK3&EE#$%"ND#J>-S;/1MU6)5W"VB
M)I0_VC%WR+6QX4S$T5\'&Y]5/KR^_MC-5:5?G<[S%_XW^3ZHS=@>#UCZ&1?#
M5ID8&A0!76HL%8$"=D"_ 2LGL&R_VBO\/]K[\G"HWK__L90L-79*C$+*D@^1
ML@T5*FFD(L1\2K8F)-N4,6/)3J(B^3!)I;),&"0RQEHA:W9FD92E.:.:3LV9
M\1S?W[^_Z_D^SY_/=7W_N,]<<UTSY[[/^_V^W^_7ZYQSOVY_.-!>=R"D8WHL
M<7=O=PSNVYEXK?K3G=Q]LW'H0U\H?3/ZPBV[AH@*X!K"%FB %#%"R2EN*2]R
M ,(\WT5^C/_597%Q^DO0M1EY]KR25?'-7"5>?&/"0W]4Z6B#V]CHX.S$>4?3
M?0X:6Q]=?;_H<%CT@.8M.T41G?]--G3O1M6K0$H<)U"![TQ9MN8;$=\7FX._
MN.F,(\Z^/@ YX7,#E0H(,I*,WY%BKQ*:_&];77EQYM/1F_<8JC%KB)=ED%(9
M?0U11^G&R F[U]_P":!L)2B 'UG!.I$X3@KQH-S14.IG/VS]N9E#A*97]PH.
MRZIP_*(W7'R(.G\**TL<( ,>P>[M-.I".OH2:3R1MYW+6=G,9J2\A!FR?)65
M[K/)H#_8E$MWE9T<FQIU_%Y/JO[6D]![KUIS]/DR%L!@P-WY]&QP=W];[.GN
M-83,#_68=L^%I+JO5",-/+*3MW/,'1@M5_G3@[M?$[98M45-7+WJ5KH(A_KO
MGCV[SP>TDL #?%ZJX#E!0;>#,=$DW%3"S>^:5<MV+6[%/=C8%&S6=/Z(;:YU
M&[+9?*_C*TJD(!W-?$66H 7U3YH2.VD:L#6R4\D(H?'TN;K/V<SL= N7AFW3
M4A6]H^YBHM>4U%^>,M<S/L3W"I28&EE_<-T'&8*G6:C$675RFU Z.8+Z:J3*
MZ+&*0H':AX)?C>]6BA/K(M;UC)5^KX3#67."6]:%40&?HD!=$J1PFIW=S=D
MZGL4'A]KT0KT+,HK>#+CW=X[^+6+F3^R_U-LZ^-OKB)N#G\C!Q[HMY&8Q?\2
M&(F#CZ[H^"$H"-12KG[:\P2G\&76 ""G+1-[7H Q9U(T@HM&+._KQ[VW$T]
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M->MO9TS #%I84H$W:G?IJ='.95'^SL!D-:Z.U!7]HQT7M1 E^2%VKI,,A/6
MW7:- &.Y (;%Q8)RJPMS3<\\3-5U?4#/B!GT!RVI7^Y[K/H4;6][)&B(O/,I
M%>,%P(&L T6'@EHIW9QX%-4Q-8+%_<Y[T/S1RGO.J=KB3=VMAGV5?45W>C3.
MYNC:#EF$2/U2$-_[XDF<52*3U(',A-,K9IG_E#B&W49C?F9($?:";]@S.\SZ
MD*SN%,B/U1,J WI]L#.L+XPIZ]N3R\HY;M!RX;M<AO[UBB3R )4#'M!G?UQ#
M0+*W.+SI:H"8&,MM&>O& N7LFNJ=WGI+G1N/2%Y7=6OO&*UJL!,+-EH5>YE,
MD17\8W,0]HT.C'TFL@^#2GP"B;XEH%KPB*#RT/[1DH9L"B\TXQ2Y\T\2]:)2
M,[7YUDS)?6\E#YE,9DA.>H$*KJ$"NK2NU20<0]=)0++^AD;MI&JC=F0"0Y4*
M4YU1F@)D#L2PRE(<[N"T1V_:*YJ?,JU 4R_5RIST(/HE[)*KJ1] .G+7]]S)
M%TH' 5AF+XJ:TLH!]26R6G0(T</"'M(+R)QKEE>(3(Q<,#&:C  U(],,9?4/
M>#3L"#7X^] Y4U*4'=^#H Q$93T)(E%U.QFB>.DNUR^C^3::P*W:N0QQLE-C
MGF(.4^>)6ENMDKQ(7:N,R29*8HLAB4[7T 0;@2W8F^1JE>5X;A;MLN&-#^KH
MDV D&Y7L?K63E77<0=*P4]#99OBJ/E'^KVOCP>7-#D_>QRJP.;"GE^WY9Y^F
M<;-Y0L%]2 V&!QEC/BK#AH1P]BO[C\WF8X"GHV*E3)#)S8P;+^V[#LT=M!J0
M*!&.HVJ,_B5XML%:4$SM3T++$G<NN9.1E)]-P3X@7,[0 8D=48,&+PS*7B7:
M!)?6)D<ZN'IJ[[A;A6.C06US.BV)7+L J3CQYD$C --Z(S392I_%V )9U0U&
M&.X<MP_%R0[>2SVK?NQB;^^UWM[>CEIYTO$6&6@;Z,NW)NP=M)&"5('8^GA6
MZ!8/:6L%A]H 8T];R1V*C?Y=QQ8QGJ"34%( \+M?(R&5*=X2=[:)F>73<WC,
ME":R-Z-BYFM-=] S56J$A[B"R<U\7T(EM:@L,1W!KYT+Z%Q#B K[:1+-I[EC
M[*AR'FH+:-G^Z\&'ALC,^RO!)4&/]=!I]25M/[7C+,9:L8 M-M'&&OP9-$<&
M#8U6G)XH@_?XARZ;D#=-3JO/M=ML3O#.VZ_\FY^FFZ>M3:HXNC(-]<Z_1H$'
M[T-!7%U(GG$65 -TVV[,5E80,-P/2:R8>P/4=U5/ZJFY"RO[CB_)YU;+7=:*
M.N!=<QO3APV#=,$@%C81)4V ([(U3QKW"'_:MG;P1\P9Q*;*X)*C%VTE'NW,
M;HNS^'<2<&@C$G,0^_M(,XWG9F4'K2SM$VZA#$5P4E"U:XA6[)1YF]OS8*X8
M*W]%NJ0AV2S572'5_Q8[*#AQR_'FO+QO[B6KKZ_A/E/ '1A(";-> 'V%'0K"
M7AI591G%=[YLHXE57YQLF"3H NE.A8<WT#/^1IH.U'-N?PKN/ND<0^J0)%VF
M@0?0O&K0^NDBNIK<891(J^&TH;8=GL/(+I*4?^0\72PV&:FD*]>_]/@6.G/A
M2>9KRV?'/E]<9!\8%X,3;4(1B7Z(J TN"*6<2TET Z(*<5JX5?"@6;\4W$IP
MYP:P/]<]&_>ZK"!YZ6S]X(^QELCT@P4^>SQ&.)/+[?-)N3Y:+*.5*39I7%HH
MA00">/@!.,=66#BN8 '27#%5N+78VKW3PJV2C=Z(RYJO_.?S9WJ#<W"809K&
M!.)L>\YWA(\1J*>[7,O,GB@52OU:7Z:L(W@*%P!C+H>ITH%.<<&'=H=-X;<9
MR9T'==WK SNV%=1&^'ZB_M6]]5Y8O'8KU*:=AYEH[Z!54U;<^01HO?8Q[]$
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MXRKS:DIS2/LU"TL$,>/?K?+^#>/%C>EKB/<Z\W">K&8C%T(]R$ D\4X9X8"
M+!053K3(USF%IJ)D:('>FYN-*PZ]^N>P:;2"TQ75:V<_41NNO4'>&[Z#-2/1
MI4C,%S>0D **ITGF^0D>TN"Z.HD[Q14%.6X?6X99Z)NNYR=5]\IX(:X_36H@
MI&B%6%S#30DUG?AGX3RP_C EF[YB?DJ0*=Q!4!?D$V7!(=0V?,IIL.%QEOD9
M;MZ3D$UU=0G]X<2ES09^@S.',/M4W.6Z6M5AX+@DE%+@ZG:C ==@-:&D+]#$
M6P#ZES^RO%&M/6Q:!EK%K-*A;<KEOM/.ROKLIV^^5YSJ?<\]_J&,..:/,C#(
MY:(D22$,!6$K%G A):)KN]9W9+LPA+X,I^LUQ/:?94 O=[%ESU!=J!RX[WRH
MX94%\_V;7^-P:9>.\MZ*5FW/OB_*)=%/H?W(XC#[!-R;2. >HQ5SOF1V-@G1
ML@.R2&PG6MZ::AW$IR_0+=[4.FB.]!66HG1*D@_TEF=*[I+X+*==0_R@H2/(
M(EVF32VPB-EPJ:Z$TY,Y9%8'7F?%.O%#V=AN]';"1HN=7X9LOQH^]C3-?(F>
MZGA^NQ.%,PU1N1+"%&L:$>X4PDD<< \%=S=T<29*F2DK&6QL/%8<'5#.QR"7
MMN6W3YU3P7+=:'I'_46_G?4-ED$J/K_)C-^JUW7H(H\SCEM_T)I"[*(I$W4)
M>H(FH;4GP0Y4*@WB/<AOQ]SRV3?R8VGSR5TY.;K#9DJ.KGP/H5>:HJ@+Q&@^
M-_>[J0VK9)8-[FB %)MXV=SL%6,@NNM/=BMC$M41-6L*4#H8$GC/.;?ZP9_>
MM6I3TN#*O6+EH%VQ*1+Z\K<W1:\*,GB!8#LW0RBMQ@UG=Z9T&4T,K2$P@LQ0
M*_V@4KS[$3"-%131=[KK1LVTH]5D@FB/B8=NWAFQN.[WFLD>.;8V'4#_BC2,
M:ZXTDUF,>!MK4+]C+'_4M>+UR7CVDE=A?F*(]@[-NZ\0&N<B^D_Y')X+W4:B
MVZ"92:B7I3WJ1>1V3K*-/.[I &09'&LV,UL2&V[:L&MH;,6D><Q<_OVJDNNG
MG9]R<QR.CX >L'O:84O!-=F"\I,\V<.+$=PV[=^,FU4%NDJL&H3;G)H*OQHJ
M;\P-O)#VA&0\X]OJ8M*-B*2\):WO+R$EPJ+<8M3[/('#3!P^S6MA.Y:ZD-5\
MZB%.7I>.21)N!P\;+B1!R+^EJ-$B(;M25MP_Q9V@:(@Y:,\WER DOM @M5_\
M@X08@!QG8T*<9E#)<9^ @#1T$"5=Q68_%=C^PLT9>2(JI]+U;UM]R[3'_N(;
M)^:517KTH/4N]\)=GA>^)P$G&<K$;@L*/4O%;93@QZ9-^;;)@_UL3):9PTB=
MX ;&>KPPHTQ,NNGSZMR90[87I0D?_V#Y"!+=T49CG>%020I+-@A0C(MK#6+A
M"L^%E(#E3'KI.WR QU;/<<G'W\\2'JERJ34_^PAP;MGP9QWX:N"'>7\5M@HW
M??QY=W -<04MR5CD//Y:,RVM=B2G8?J$[^GY(V]F7I8VPDC+XM_<=;21AN=G
M$7I^(UF=MC0,1^Y(R@G*\S7$Q>S?^S WR;P3$3#HL\.:P6-]2Y3BYG=@P)W=
M78R-$!K(*ZM:4JE_K5H[1,5)[JT*T*=\_3"U,\NC4*JB&\'<8[T!'[W\"Z;"
M6R 4Z,&W M58]@Q(X0ZO::2.L06_[\20?\-PBW3RK<^+LT.[SSGT14FZ?KEZ
M/#&;U:^(Z$_S/%D$2 NWC("X&*#MHRF72^'=H&%3E7GE=:%/J?SPSG#-[<I:
MSK7.W>29R$]CA7@,;X6K BDY\6Z"%#8C%0UX5.KSSH#VP!JBVYVH!$8R:3+X
M'H=!R(Z]JV[J\Y+*'0:Z\--1CRB'%[YH$QG3DZO\4$C!B =7B34$#LX^*IEH
M)A7;X-C:Q$EZ,2N#V0C)@UC*L:8S0U3R7^\,YR=O5XI7>?ZM%>G6-_W;_FP:
M^1,GGB2&OL  M;N[.!F,VA1(J5PH61XT9R2SA)(+A8X!I+D2T+1%MVZ$FE'Y
MQ/3=YUN2EY+QQQ/G9:^N]A25SS?'H4Z1Z,8PE7JA80"0N]8UJJL=5XSYYT#<
M7!<9P+16SC$DH"#@+N]:2Q/K&=NM,9FS'#)06.Z?N[M'K+''AGVU8KI_V6E]
MYX-U%)$@*"J! S49.@X?R2"?^0#/_O9GB85M)R7QE)\_#?0DN,O30\:$%SDC
M3E2_]TVB+L]GS:]D/X1_'DK8!I!6[KP@#OAH@NLO<C4!$LM+ +K+1J090+=3
M5)')T@_![H[17P/BS:\*E.[&)MXP2"WVY-A@>OL4"_$44-<(4A(=%DKNX>\(
M0@$G8126LCS&]74 [P%57BNZ[0P@'2_ZW>TE]TU!XP.<![7GOGO/M;=L*TO-
M]Z+GY+_$H:[ <QJ>)4'8)&P-,25@_8*XV'BKS=S]PVYOAJ;<7W'="H.#V3&!
M6PE%#F;'CH0UY[SFI$7=\S.L^8LE$<W-9I&6U^GB05"N$I($4Y[C0]DI\49[
M5V@-$0PDV/C R&*/,OYP7]FT02I]\/SF.4L[.J4([8^=0';2@#/]$_L<P?5]
M$6F"/"OT,WQRJ,KBZ^XXJ\W//9R"PEG6\@OOO7!>)3*IGE\>>_W3HJKO4/5B
MD?U(4!.!O8D&#F% W89L*]@-XN\%F4>Y 6EUECAK9+N/\A E4O7S1S^'HYP0
M7[<<Z-F.8]J:?Q\\DGF/\0JQ/ERZH!E2XJ.)?:]3EM4 ][;V+KB MAP +R^U
M8;>TJ'RY6C$FO6%9WO,=*4R5+7W.-TA5I:W)P7%3;G-LV7(.W-\]<,>ZZKKV
M.M$E3Z:T1<W"**E5ZT)5H$7"8O0INS(P_:#-P)C<IL=V%HZ6-0_O>1S?_?Z:
M/1$F0WMIH8P)<YY6AJO@D8V-L(-6K]NQODE,=[5T=AI6Z2<YH>WZB2H1W&:K
M-^/[>4<//91Z=DGN^=\OJCM51K" >S:HOX980;(XH"XJCJA%I*-J&9W!^SH9
MVT.,#*]\X[2@,'LIS#<FDW9*,].CMW]G*$VIV(DVQ1VFQGVV<MD0"AI15C:1
MZT>+D)!L(<]R> 7RY?JR0\J>]LTM%?I]O](L4C(Y.S5K_1,JSY%)>I0B1R;[
M:HB]$WWWQQ=8HN>1MMB@ K%(TZ5W5<$_U+>-G4Q@,S\?<]V4I^./GMUA9_-Y
M7:/M'Q+@REB_JZ-PFF4@W BNW\[]*JB)S%98&I9FH"#[,:%4Q61W>J2HDW5?
M;]\-KQ#>M1RQ.G/CWT5%#)Y3ZZQ!'7<A(8*T??QK_J@+SO/L&VB_9Q'M7GC(
M'8>:3?,GBG)W7S'YQ$PP"11S^]^J/_RG_:?]I_VG_1]IR+6)_P)02P,$%
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M\%CLINF(O-2_>*_^U4RC!^HATVJ>AKH[HHKOI5AQ4;/EWM @X__^@_K78E/
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M-J,N,7!'RE=DR:HVBA]$647551??B+S*S/MM)3<K+KAN;9O5-S<5\^KZ*HM
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M,$H)1%0*J$S+  KJ!VI[B0B-C$J8/QUX;AQ:RV9N*NV!=-YL'*KZR"]R+=8
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MH82H+:+P8)Q(WT.4>!Q9I8@<GV9N5HN6$NS$-*EB9P.J:>#,I5"-'B]CC=*
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MTR1&&:(Z01K4.4EFD_1D")E-BI/ID/915U_(LOQGFU2/.*8L#"'&RD9$21C
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MAV6/KT6>?:WR =[M:MJKG>-K4:BK-(U>%[I*==5O;GO!(HD2/XF1#WW$$AT
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MD=S;;"D^;*J#7Y9&,J%JZY$R_8FFL7KO)/9A&/D^3_Q L-3XO7LZ^-Q>O>9
M20L(:@EM#]PZP)F>L@V#8YJC-1,D!ARG':I\P1E:9[")#\X.U3@\+3MRC7V
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MK-GB?L66.Z[K$URJT_)!Z;A>;96^:IB'LA^A*+;UII=DG,1JFP:C'*>*@O(
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MH3;IPBP/,J,=\,V9IL:8^L!*'SO6"5IED_BJ53S8QRY5*KPX1GA<!]V,#[U
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MR/)<0L1Q"JF4.8PCEF:($H&E4>,&P_FF9M;N7QC=IG/9.KAQ]-'>@MN.=#R
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M+Y5=HPP?\':UT.@U_GC--7S <-1VP\N KN'J3T_KU9?MFOV[K%,[CS 5F:X
MFX:I,FMC*B#&,8%A'@2"RS2*I)59>SK!U#X_E7R@T +^Y4^Y>B+_NEKK.OW@
MFQ87W.VVC^M-^2:530"*_Q?$,R7B+ @"<%\4N]8_X"28I7$$7NE'^Z>J9:9^
M2W&"9F&8EK\/+>L6G"V0F97<!_;!M^TEXJ5LLZ8T=X6DSSCWR_I[BVX_&7[D
MF/;+RIU'LE^YSO5$AFX/B6X?U!+7!25Q*AG2I4HRFH6ZMD .2< 4<? X1$F<
M(Y1;E8Z^-M'4N*/LJ'H0= :TJ([.O:O@FAZ;](=L\/,0)[0<CCNZH?!VCG%E
MFI$/*+J5/3]YN'&]&S6\KF/2[PZAX'=5T'KS&(=ISAE'!*91F$#$XA221/U5
M1H'(<)IF46+5FOOFC%,CBT9@T))X!AJ9'5GC-NYF].$5S8%YI"^0UH1B#(XG
M9KD]WZ@48ZS^*=>8W^A&.E_$:K'>E#T*F][-3"H+FTFU6Y$4(IE%,(\I@2R)
MDD#D(0X"JPS;LQFF1BJ5@%5_3#OF. ?/C"EZ03(P,[31&,#A?E5U3^_]^?BC
MON=7U3M]KZ]?Z.Z#6&R;\[RC8+)/Z^6"O7P5W[>OE:C_GE,A:,!DKE[K)(.(
M!QG,&4.0(YH$,I-44JOF[.933^W-;TE>>@*/9+=W,1CB;^Y\\(_J"&Z)JX#.
M0"4X^+W^K]8 E"IX)!A[W#RZ,PPG'MW180?()1>(Y0B.Q@A[%'RW%!_E&U(\
MOENN_]#E?T1Q7S88U3F:K82?,AY%B?:\$8\Z25<7$-)E(+5#]ZOV!!_>.)[F
M#.,,P9@KGD,9H9"$,H!9CDB4)&F4A59AK /).35Z;-34^<F_2"E8&>[S2>=3
M55UC/R^*?\-?R8K4(4*M"DY5DO0?I#R_7S^L2N?O8E5'$1W!T517?:41^6D&
M-*:Z%L\?H$+5TB8;Z!DRM.Q^_),QM'W8>BA.5PHT:NJ5;J=YWEQU\'NI\#"?
MA($7Q9?E.I"4X]J_PT)]9D4//)W;9^R3'KU,/BVG_+16K"BV:LNNF?$\;+EX
ML]MLU+^TBA?/XRBGC.8<9D0WD@P"!/,DR&&(>,B").$<9W:]$OH+941"H[92
MJ&B%59*V"YS;?3(\K)?9UV&D-1@I@:R6ZD7G[5_*TJBE]\?C_N#S1-D>!!J5
MG?T!>$K$'D?VE>E6BU1.]Z_%]K'U):BO:O6FOU_]\ET7?_DH]?55MXJ[AX=-
M26-==\ZS+$MY'H20!9D^DT$88J*8.A9Y*#DE.N:C7XK<.(I,;?/1-A_KWJU@
MO9>V;];=2 ^'Z;GS])=\\'/M2U\0_2?X0^E_M)EHKCDHHK<;%09Z5U+>U;0'
MZKYQR/S <==PL,3"D=3XP1F)XR[6[53&D>5Q+$5Q^'K7W_,[JK[[A&WG:<3#
M(,I3B(.,Z4C]$!*24IAP$<N8QCRP*]-[?:JI?;=J\=I]@BS+3UQ'U>QSX@>K
MD78/Y;E @]GOC: ^RT_<1,-7^8GK$XU;?N*FPF?E)V[?X480^[Y,V@>\8FJ.
MDG;*+<(=_Y]=41TJS 7!:1!0!&42"(A(F$(B<@(3I"QIK'[,XGC^36SHVI0O
M#&>V>2':\P_LTK C#%.4S=AC .0&II+#T42K3=MG]<$#QRK,:C=T2XN9+C*X
M\^FCL(3/$_>8SCHJ$5E"<<I*MK>[4=1OJTV="-+T'/FXNE]]$_7H)X= >9Y)
M$48$"D3+"EO*P,D2#E&6!)S&**.A51<DJ]FG9NE\V3T]D<V+WG+I6L;OR&)3
M92+HW^SS<:!<;^"7D[0K78-Y!0[: ZV^6K<RT0I\6E>!;G8T:+>29F0XV/H,
M3(FGR-:';&JGW))^T#,W)^0\L:'=W*-RHA,LI\SH-H@;/W[>>W'UWO*K&J2.
MB:8$<TPD49N[B$+$=6FP6!#(42Q9)D+$96I#A=<FFAKK'>2L'$U:4L? \ZO8
MFI&3#\0&YB$WL*S)YA82GGCEZC2C4L@M94_9XN;UKL3 EJ0H%G+!*KMLM_TH
M#4[;ZT#I(! )R_(,QBC&$ 6*2' 6AU#D4H&28F5)6:6R]!-G>B1SK U8[\K>
M%V8Q-;8LU&LA3;EJK.49G-'ZK,P  ?5^D/7&D+V$&9E'?0!WSK9>1G5/+C[L
MLO9;L'?KC=Z '<Q&;3(VFZQYG!&:4$EA$B4"HB@C,,<)A4'&<9H'24Y39)MX
M;"O$U/BWW,M^:_:RQ>G&=7?87NE2.^#9:</JM%JF)\K#KL'@I\%T>U2/Y=R;
M,&M[#\R\!DY)T*XH>DR0MA9A].1I5Y N)58[CV7?"?A.&<5<&\;OEN1!\: 0
M$6<Q3)A$NA8AA32E.L,ZB21+*,I#HP(,9R-/C=SVP@$MG7GSWV.XNHFH%P@#
MLXNA_E;]?B_JZM3K]WBDT?K\7E2@W>/W\@5N=LJ[Q6JQ%>^5\</O5UNU-@OU
MEI=Q"[\50NZ6[Q=2S$D<YLHP2: ,=5=N@1.U0Q02AIBGF21Q$MO5GC>9=&JO
M:B4S7&JAE>W12%TU-YSI1H-*<+!4DMN9'D8+8&9J^(9UX)>_1K24%QP$KN+%
ME%%1(?J^"U%K.\(&(D]V@]&4H]H)-B"<V@56]SH4)<79?XO56[%:/^E6H(*7
M:=EO=R(*$*[=' G+I) XAS0+=?UVDD(JL=!.JXP$0<@"9N2O,IQO:D04_(RS
M/X-_D&>R$H4 +V(%^$%^L"JK!7"U7=(J6!2U-$"^FX8&P'-@!BJ15/+"-H!5
MN86W-8 .;<5,D+0H NH7T9%*?1H@ZZF(ISD\7:4Z#489KR"GN4I'93<M;G.S
M%3\^"]UG8/7P7I!"Z+[R\RP)$,=!#)4=B'09+*S+8*4P3#*6)42F$L4VEN'Y
M%%.CWU(P(+X_BU5A:>I=P,_,L.N'RL DNA<.E-+-@);/G\5V77=/]MF%"4:U
MQJXK>&I[=5SIN/DCBTT9)J13==6X]<=)%YU*<(IAQF6@:^822'B"8103A)(@
MC?+(JD'.Y6FF]F*W',V/#L4.KF!IN'/KC=#0>[5#1%DMX@#G9]TH^-J.79YD
MW U8IZ)G6Z[NJWW[?8K/0L<DJ(F.^C6+S6+-PWD0$<)23F&4A00B1!C$B<S5
M7ZD@.OU2Q';<X";'U,AC+RL@+6'!<RFM+X=0]\KT]1%YP_M'NHT*W2F@68JV
M'N!3]U)X]"09 3FX<ZE;BHGXFXR@,G=!F0WGN/GI*%GR06P_RJ_D^SR*9("2
M7$"&=3AFGJ<P#[!4ZY9$.!(\#'(QWZZW9&FX'3*8U(H*]U,/N!^H*H$<A=PL
M2JEG8"7*")TM^0Y>Z>TI"#/+_@%&RV"XJ_(,[M#[K-OENCY4\"JY/>Z_+%#R
MM2,SF7+</9H%"&>[-IM[[3WF35/5=^M-R8&MZL3%/,UBB@(6PSA5+(10D$-"
M.8<X),I>BPF-<V-7>==$4S/'ZKK,RC[X]/DOY.GYKV_+1L7&'IN;P-[VA/N"
M:V!6:<0L6S*5@K;KD%LTQ>J$R]S=[0NVD?S<KO!9^;A-,.EP;G?>/II7VT2)
MMCO;Z/J>;J]6MO6O@A0[Q1@?5Y]UU--&V9"O2;$H#FEJ$HN(!0+#-"*ZXV&<
MPSS$.10Y(9': @<IM4HX=))B:D3;2CQLN8CN5^IU>*HS?9VK+[@MDZ7#;2CP
M1_/''0$,&AUT?N%>"U"J,6B.82\\?7OVK&3X,8X_%YBN^@6=!K.W-#^+;V*U
M$UHK77A:%Z6H2?JKV#S]2KXOGG9/\Y FZG\8081% E&0Q!!G-(8$A3(B28Q#
M9E32WGC&J5%B+?1,._]*&E1/1JM<FOI]I0)0PCP5,\#)BS(?E(KJIVT5Y/ZX
M>*Y:2CU5*II;869K=-MZ]8[\P'Q8RUOAV$@\ [7,0 L] [\.@Z:Y<>L=U9&L
M7"_H6IF\5DAUV+YFXXQF!%NIU;:&[6YTB+N+\RPY!(S$39R2R$*>)TD.TUP?
M!;-<L7D>93"1)*$Q1P('1I&_'7-,C;_CGY68?SZ*HXMMXNBN('F;<SW@,S#+
MUM"TX[ABIPBY*QA91,7UQVHD[CQJXF2.F5T07#<:78%O5^X<+]BM6_2C +<;
ME[HY TY3FTX2GP[IHG_;K(OBN-[':]WB6M=%FDN<)@A'">2(,\63+(,TQQ'D
MDDL2YC'/(ZL<>B]238U96VF"#UIL\*"DM70*^%DN,R?!Z(LP,'T;Y7*VL^=+
MO4YK0\T +77S>\SD%6M/#@4_,HWJ8/ *XZG#P>_@??M25>4"BT-/H_N510^A
M'"&2DS"!.=>UXJGZ ],@AUF4,!RAE(H0N_6AZB77U"B[W6*H5LRVBY1KSZA^
MZVO&\#]@U0;F> \+-E(#*"^(>V_XU$^J']3@R0N4UQLZ^1G>C>__ME[S/Q;+
MY=WJ+-CK[:)@R[5V=^^K<HLDQS3#&+*<9A#E*85$5U%) Q2PB!"<Q=2&U:UF
MGQIW-\*7[3_/ B7!00&38M\>%L>,D@>#?&#B]8JV-:TZH>:)/.WF'I4BG6 Y
M)4*W0>Q]L&\5?Q;;!5,/T*>=V&S7G_7/I;MW07?:2[5=5RQ;;<#V59EUDSHF
MDXR)$$9(!WH%/('*I,4PS&/*PCA!,C;*P^LIQ]0HL%&E?"DK94"I31F?2E;Z
MR)RU%#-W8?99K-NNX)&68&A_PU7TVYH ]=O:_JP="X?:\:8A(WU7Q-SQ/-+*
MC!6^)M1 J^W1.Z!W#D_K8@N*A;+V=/$\=<$K7NL]T['<RQW7826')5W_!(C:
M[=>MAO>CJ0V'^G==D5S]JE@O%[QT*RWJW<:RW&W4BU[_<JN1^MF/6]S#6G6X
MSON,/II[W0,$;1>\C^'<]@&O=\5B)8I"[3FH3F]74[7V(UP]Q.I1)?L/<Q,
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M8TF29YS"+(@E1%&((8E%#(7$*459D@4LLSM,,9]\:FQ_D!U4PL^ =ON]VBL
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M7:GYT[JJDC!/D,0Y1@G$/%*V.-6IP D-H&0\IRS*XYP8Q9"["C U6_L=66S
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M42^HCCFF1G"5F* EIT7(W148;^^(/8 S\*M[CHM+3.(5@"QB$OL#-5:A$@?
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MEN*/'PY[A-K(L;#5W),,A#V"Q34*]G@0YTK)NJYV759;5]5^\ZB>,G&_VB>
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MH!%5%V37P@(E+=#BFCWQ%Y#M?_K=X34R$PR%ROCA-D/BQ(->"O;;7?[T;VJ
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MJ@?SM;E 9Y WW ^/@.?(5'$Z#^AL]V/PJJ[==CX3P4$N4#]HHV4"G9GVA?.
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M\O^UH)HS*L1&J&AK@(DC:ZUOIDF--0.5#VTUDUN&%(D)HK/9OV'[W18TI8E
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M-L(\2%B*(0E8&$N<"AX+NQ+<!K/.C?INV?]N,IT4\?'KM[^0A\>_OK/=6YI
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MOP]F3/HRJSPRWYY*8*W5:IS2-X<>ZYNNR_H&'"HY3DZK>^P=T;A#P28E>_>
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M4]E<_(4NL[OZ!4>PI"%7VQWD"Z1+7G.(N9?"& <B]BG''K;R@3B1:FXDTJ@
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M952E7QU;^+.;B@Z6P]U3T\'T29-5=; TK5O7P?;6L<[M2P]M.@4M4B:01&D
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M\4K%O_Z;1;3&&6K#)Z$W8>%[*\.K8\D*!O![JZ!-^,H9(!:1*[< ,]&AH"U
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M!SR1B[K!_=<MV6P-UR43FF#S*9X:XG'B;IL)L).^#+HM&A6/Q6JES\K7LFH
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MQHA8'49?M+KGW/GX^LF.F"^JV3U-OGR!'=LPS52;E\7#NT6.F$AR$4%%*/I
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M;FN^'(N=(X:T%C\I)XX%YY0%1S]G9+R3CJ?Z(K:[S4I'4=TOE^L_B#*XK7Y
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M,PE^>O-P!]X*N@4'C>_ WAJH-(;:GCOP-S5N^[:O1*IW"!Q,ZS:"G:;1ZRC
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MA$,H8XJB+$[SU*R=0;^8N7'6PYOW7T"C*NCH"K2RYE5&>G#MYS1W:'GFMG%
M614:&<9A5*61GL=.5FIDV+1NK1&#JT?ER[?)/W7:X94ZK0N:2)20/(,LRBA$
M24QA'B<)##**PSBD>18:$8&-T+G1PJ%2\5+K"9:'="FK%&LSQ(>7/3YP]$P8
M1TF"M=)]%: ]P&J5INX<WHE65*Y@MDT?M\*K/U?<[%%3)H9;&7>2!6YW[SA7
MU1NRV;RHAWX1S[J8"J][#K\GQ>:_R'(G#NVSVCCB) DI"@1,:99"%,0QQ"P.
M89(*A 43.)"AC>_*4O[<V+U5?ZA7LQ/LS7Q;'A'US/.MQJ!2%/RJWO-=4^G"
M?9G*D3 Y<G[92I_4&S82FE/WV-C'C".RJD?3LIHB#Z>.[]>;JAUJ6RSC/P1_
MU U2/TD=&H )HH2R2"U/N3XBQ!DD44P@HHCB/$Y9*JP:E-BK,#<Z:_O2URY,
M]@*Y6*V?BI4NI@%6.N#Z3M>K49=4OR$E^*[-L:.]$2-EQGQ^\?>^R&U3JTNP
MJWM#-ZVD]W5[*M7OJM^NI=MPC/'0.2+$$0I,RHGC 3JEQ1N>-#)D0B>959&Z
M.GY#K,I:]J&]W2\OATN:\-[[/\B&U^<;#ZMRNZGV'V7E0/SVG:P^5>6JRK^I
M1U0%B*H:IB>I;M4?WRJ>V#.^(ER>9%)P&!.I"!>A#&**&&0XS .=3ALPJT#>
MV5@V-Q[?YY62)J_T4:L,N-(92*4T^%&ML'0>+]<]#S<E4+N+.J?7,J5W-F-@
M&GTR%WUG-/=4!L/*8M!%Y:CU*GT!W>L::$"%S1UH#JH[\'1[M38(W8$:HZK4
M8(72'3A+@:XN 1HJH+&J-P,.XVGF-OZN G9F8]>T$4&S,?M:R-'L%+1W^'\6
MVPWYK+1\(F_6F^>J0>YZU7@E<O4JJJF<P#1F6 =:,D@#M8MB>1:P0*(\QD8=
M!88$S6V.K70%M;*@HRWXJ?J+X30Z".^P1]\5:)XGF:MXV4<W] )F[JMW!=QD
M-6,O ^C&$6\"1H_SO??VR1SN)D9TG>Q&UX]LX<28KE.N_23G!5T[@?%JDZ?3
M+W0<_<.*+7>Z"LCG]:::)+;;34%WVRHT=5WU)U]M%11*ZN/#2G&<VBPV+SU+
MPSR1NJ5#B@5$81A!C',)PY3'B8P2C,S*D+^*]G-C]GNVW9%-09:@SF2R;"PU
MZ<";;7IF.YR>YYR.W>!25?3R*,]).]8ZJ5!@#P%H, !=$'25[6,80(N#CZY:
MKS&"KKIT3:K[M%V_7F-8SKJ(O8H2XZ;%SYOF7/OK=LW^4=>_NM]MOZ\W.H-T
M0<* (**F,!JE!")=>@\C]1,.",89#B3FPF8>ZQ<WMXEGKRTHM;IW39$]0/8:
MCR^]-P"\V3SB#D[?FXT]DE]K))MR>@=EW5&S&2B.N'1 V*3D9V;X*5L9WC6.
M7O;>CDY5\B:.@']:?=&I&AM%:;^0LBA_6ZUI*38_-.<]K)YW6_5G9;BZJ]H%
M5!EA"XQUWD6<09K(%")$.<P9H3!2K!3'F?ZM50=XUPK.C<(.+MN[;CW_-IB#
MZZ( >RM!9>8=Z!H**DO!L:E-AJ5EM1/G+X,92;[F$'NFU5<:76M*]C4$CDC<
MN7J3TKXO<$\G"F]R1M1696RS$WS?[%N4ASR_=^6V>-)K[V_%DU+GDWR_T\5M
MWI#R^Z?=5B[7?ZB+MY_5HKO0'(+")$UD@"!/4JDF%)E BH,,8L[2G"1<1,2X
MA* [M>8VC7Q8KQZA$O0$BLHXL-76@6?RHD?R#HC6.K"MS-,!,;(R$#!E(5@W
M)NJ@)=TUJS+2HGJIN_$>]M^_SBCZ][QHHT!M%:C,ZB8MWX&]::"V#7R2H+8.
M:/- :Y^NI0H^O^806E2K?96AG.C\8>HAM:N%ZQSYOL*Y[H1-5V77.4!')7G=
M/]U^EOYE]_+UCZ(LWV_(BGT5R^5O7]]6T4V-KURD2*0X(9!CG$"4YA22- HA
MYV%*(LI%*HR<2P:RYC:?*G5!I2^H% 9:8]UJLM;9G%6'(!Z>[1P"YWD*Z\=L
MQ+'U$'CF\XQ#$">:/$:^@%9S@"$J/<0^](3)V-K0E"X%F]XRSK'V\/2LMF/Z
M1=&UD[9J:#59UYEI[XM5L17+XH?@BQ#GG&*,("&A@$@HHL4\SR$E0O(4A2)/
MK<JN&<J=&]\>U-8[DV*O>-.M]P[(2G=8*6_GU3(="3-GE0=\/=/R,;0'G?<I
MJ[7:\$,OM-8N)4N@''F*3*5.Z@"RA.+4KV-[^ZV%(L\3*\J'5>?,M*^TY4F!
M0QEG(LZH5'3&F';>A!!GDD&9((;3+,HIBL85E72GY-RHL%L[\9V4@E7=.MN(
M"O7++T7Y#_@K69$FT+P;0[[]3K;@#U)6'N/'574$6JR:T/(C.-IM:5O&]E+N
ME&4DCY=7R(R67_O%\,SAW7?BXD#I0>X&[PP.^$0U.-V/AO-ZG0Y5?*7:GNY!
MOEX'U(.LD848UD]/1:5%>;_BAUKYA2@/F=('&J$XX!D+8YBS2$*4$@%S76DG
M37&8QY3B*.)6=1BLQ,]MCCG2U[((@QWN9O3M#TW/Q-Q1') 5!T>J@X/NBFY]
M$.TXW%S59+ 3/FU)AE' G%5D&/>4,9[8LEB)LKQG_[,KRD*O]/;2MM69[A>=
MK73/>?4WLOR\*9CX+#95.- "Y1RII;9BLX#%$+&40\RB5/T48(98C(E9-/OM
MJLR6Z+9-"N]&*W\'R%Y]\*SU/Z3SWI3DZV L33S"4XV0=X=Q;0CH6'('.D-6
MU[7Y4@_9P1Y0&:0S8NLPQ<G&QL;A/-483>:/]CQ6EIYK%_#V.K9O$C"AW]L%
M$,=N<2=/'!OMOF9"\/*],O*A+'=$ ?!)ZN"6;V+SI'OS+#A+<1S'*:0H%Q"1
M5$(<B1C*.!!J*<]D(JV*$ V+G-N<UFH,]*L BD9G[1I8[J. N-+;-MY]$'JS
MM;Q;0#U/0<=8/G2PK"*JM,952RB7T>^F\#B+@!\4.'$4O"D YY'PQG>.]RFL
M5YTX>RU%\$6<YTF(402S-(X@RO1Q'8LIE((&$N<\3X65&_N*G+D13:WF<6[-
M744XMR367 ,Y(EA(&@N8Y0%1Q)XG>A,30<'C%*>*Z D/%\]5[8:O6[+93@;U
MJ4R/BRSQ6*Q6.A",DF5%1,Y1SD,2XQQG,$I%HE .$<P#2B&+$L9"H2;7+&I0
M?K?B$V/<2O2'L)+@%5YS=]>-@$W@UU*?_E$RV!VHU73KONK!P:&?ZI*4R1U2
M/:9>\CSU73XB)#_.DX^Z(N7;G8@"E+4Q5(1RDK $YDB[CG3'/QJ*#*:,<8%0
MP,+4N!K-91%SF]7BG_/DG^OBG("K+:O6U"),^C*,PUZ;V\'Q_,G7N%0J@K<-
M+B."]JZ]9^8QX3<#-9%+Y!)@CH*S>R'H"[2^?.-T0=.]BA\%0/=?.;*&C(Z)
MZ3@N#L=0>8340IVED"0$J16\4,L>S!A4VXDP(2SG,K1*2[TJ:6YLU]'1MB[+
M53#-%CE.(/+,>96.79>FIW.Z02Q<50ZY*F?:*A]#YIY5Y!B\86RWAO+[^^7Z
M#QVHH-;]S5Q$!>5(;79@FB=$KWDRM=.D"(9Q*K$B HD"*Q?B12ES(X(JH4@G
MC]0ER&U/_2\":;C;N14>WWL=C8Q6$#0:>NF>T(.!LQX)EV1,W FAQ\SS?@=]
M%X_[X-O3"[5_HKH,O^*20R3D U>+PD(69!\^6U'.1O#[%>\D3:N_J?4C/V1D
M=?YVY!"GBBQ8FJ4P3GBJ5A6)A"3$" 94R%P$84@S:4,DDVH_-X+Z<'1XH0/_
MM1EV-#7M\)O1WVP'U3.M[D^,.X;?=>.2N[8WR0B@M;X*INI6S&@ Z.;/=O]^
MY^V\YE6&S]&,,*WND\XTKS(LIS/8ZRAQ8Z6G1I<C'2Z4"5$7*)4V1U5#/BAK
M'[;BJ5P@DK&(1@&,180A$HC"G& ,91ZEB0QC$7"KF<^I=G.;V;I5@!J>.Z6W
MRP6!]%5=,^L*0>!W;2FH3!U;X<G)2V V_[W:T'J>WUYE5,=7=G*)ONNR3DYT
M>YV:3BYAO5K0R:F0<=/'1['5^[7/F_6/@@O^R\MOI2Y?4>>":-DZ3:U2;,&I
M;EA.D3ZYCR%*LPSFF*801TP@Q&6(4[[8KK=D:38WF(NV(OZ] OXH0J=J5=X%
MK3&0ZPW8*PT.6MM1N,5 F/&S'W@]D^\>V59MW6[GI]_J/G!_M8/9FE/M$7-$
MF!:")V5#>T!.J6[$$\;QV'G!Y[K-9ME9N*_ZDM@Z1:%_$>J3UM5[%EE*,:8H
MA2D1%*(H4,MAEC 812&/11JC@*<VRV$O6LYM6:Q,VFR+_R5M7O-*?=-DWTK@
MIT>BOV3=44#7M%ON>)W*K*^J:]S9\::?@3>CV%<?3L]L;)!>?JF;P%VW>\ =
M(%*]=7J=O"1EJ3;.K.FIUNDX0"OCW;;R]#HXCHC?CXZ3SA%>83Z=3OP*&SOS
MT.VA5,-[]275.BUB$>8A4ZMDG!+=$"R6D!"10Q(@SG)&4&Q7P_^:H+GQO]93
M47FKZ!V0ZCI 1C2&OPJM*3W?#IAGAJVP>NA@I;4$]_U8C:#"?B"<L=D5,1,3
M4K^QYYPR</W(0F&Z6\B*++^('V*U$U_%YD?!Q,.7K\T9>ZC6EFF>1C#2M<%0
M()'B"2Y@3**(I#%!E%H%*PS(FQM)M.J"1E_0* Q^4BI;!FT/06W&%@X!]$P:
M_=AYB'(PA,95K:\!:=/6^#(S_:RVE^%M(VMZZ?CQ.G+\[4Z[!.O6IY5/\=W3
M\W+](D1US6?URGTGI= KI45&2$)IA&"61P0B25*8<Y;"B,@X1)@&E,4+M0TS
MXYM1.AA]1'G]$;6:>/R..FF!53(4V*W4( #1J-_\\EEWC[K3&U3+LEFC1LF,
MK/RA/U'AJPK9V@!06[#OA-V<O;1FU,DJH#6DVF$Z+&EU"Y"N:E:-TF':HE2W
MP'16=>JFAXU. 3W=#ZJ]X">IG3V4\BQ.1 "S))00Q1A!BF4$ Y%A]?\A04%F
M<[#1(VMN)QG'OITQ_K<^8,VXS!%<GAEKL,BBFD24QG=GO3$_$QW\X32Y;@@N
M=PEV5R5-G60W9/*%1+O!6^R8I-QL%Q^*;?%8N2_?*%JZ_[,H%RS/)1(\AVIU
MQ2!B3,(\1"%DF"<T$T&4D=AD'W?Y\7/;MATTU,=T ORNE30,5KD"8#])W Z+
M9UZP1,3X<^\WO.\+5W=VOF[UK\.7?>6ADWS,_0:UW^_ 5?;YL6]>GBA9;DF;
M(Y+%.,J$@%E$ XB$#NWFZNO%:8K"(,&1"(EI7NSQH^?VJ;;:_>6?P@S]NWFB
MYPE@_9_G;3#XGK(;Q49DNYZ 8)[E.AZ,B;);S4&Q2FV];'=/2NO)#9.ELEY6
MM)O">N4*.^KAHEB\6VV+[<N;.OKWBWC6Q^*KQZ]JA'?E D6I8%&0P;C:=.0!
M4NL&FL,P#1 +D)0L#DV(:$C0W&BIUA4TRH*]MJ!6U^P3'42WG[5<8N:9P\;"
M9?SQFF)Q8<51"O;SX_K'OZI'U L.]<-AK3'XX$D^>5/S6@(POMY^)?*^^+/M
M#/9^M^+ENR>QJ1+DR.8?8ENV4PT2&8_5+D($(H>(L!AB3E(HLB!.,L1B3HP+
M=QA)G!U!-$J"IUI+\TG;#.#A!8USV#QS1*5OZY*H- 9[$!N=1RR!#%]7XY61
M<U2G:O>X L6A+4/5B.-YO5Z60%9(5P4&G\CJI;EJO2FUUZ?^APYL(X =THBT
MEZ@Z9%B^Z-$Y/+B\TP6+U2M?+%^ K :TZ?C:N48_[MVO[[[\[>'CW\"O]U_^
MOW??OO[L9OUF-3H]RSJSYTRVVK,RJ[L(M+MQG$^Z"E3JA/XW,\XBIV'" Y9#
M*F2L*^;I6FYI F/!,T9P$F?<:(\Z(&=NQ%]'&[9)H,N#OG8.Z6NHFCFC'6#E
MF>UKF(YR9!LEW?F8!U!PY%^^)F52W_* J:=^Y:'+QS%!-Q_TEY=?U4)SHU:@
M][3<;@C;+J*0A1'*U"*0ZF)N2<H@B1&"ZE^8ABC)0F95I[1?W-QXH=%/)]ZI
M"?266L@#,)LQA#OP?'NFCS+G=3_ DI$E^+L@&]"J#7YO%7<8+F2&D",2&1 V
M*9>8&7Y**89W.6C_IU<R@M<;V=..?@))A*14 .-,44R00B*B% 8Q8Q)3D=/8
M*EC94.[<N.:T(5NMN95ORA9Y,];Q@*=G^NF%<KHV=<-8^>@\UR/U]9K)#4/1
MVQ_.X/:1L3F;==DLI-A+%3FI-KQ?R%;H!A6: ]N^]20G"8TQY'&"( JR".(X
MC6' 4R%D)@FE5L4I#.7.C:,JM2%K]-9-E2O%P49I#LH_R+-M#3A#^,V(R@.H
MOH\)M<:@51FT.@.M-&BU]E$[S@XI5T$]AE*G#?"Q@^(LV,?R]I&)7D5)'A\W
MH@Y-^"2;V.Z*"A><!&D<H1CRC.CB"#* . I3&&*":!PD(HB85;)7C["Y$=*Q
MKE4KXR8QH9[E+8O9].)L1D*NT//,/..!LT\!,T#$51I8GZAI4\$,C#Y+!S.Y
MQXY F$XGV[PL_O/S0L24X9A%,(F8[C@3A##G.5<;+DX)RE,9YNGBA]C0]1!1
M'!YJ\T)W'^WOO?Y/\MP3HW\-F_Y/>YR]GC_@_[S_?/_Q]H_TW+:>T_;FXOI+
M;/YQ^ @[CYKD4SM7O?V@+OS%:;93W3_C:KY J5OBA&F.$8QPKEM#ZU)%&68P
MY'$6B@B1-++RFH[48VZSM776T_AN.F-'SM EXG\\?+M(>K*@VMX\?6E0#FL?
MW0BFWTRH02WFD ME"I5A-I3QXV[U"Y]7-A7<H*[IB1>3TCS$*6%0+6]2B/(L
M@#1,0TAR3"/U)Y3&5OL?Q_K-C82[SM$+I9/5CX:%D\?ZI-V,NJWO>O*QG-#'
M?=,P3N0/=XJ_<[^Y&^U>R;_N%-KK?GBW8L96/-H4/]3V^$?K^^)Q%.2!@"F*
M-/<G,:049S"6<9BHWS/)+*OD'3U_;MQ]4&^D?^L$/D.7UGA0?'NQS/$84;GH
MHM7."A8=/WWB.D4733LO3W3YLAOVTM_72W5'^4[QQ?:E"FA:)"R-)4+J$\ZJ
MJ/,TU]DHNOA[$F4Y"I(XS18K[1137&*Y93X79_3R[LN G CU]R)7NHW8X5[
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M:K460,$ES7,21CA+QD2MNE!N;I32C76LK8.5>>!@7^.HO .UB>"H$VACY+B
M52>C;<9>KS6&GFG/T?!-$JCJ$GK'4:I.5'N5$%67H%Z+3W4JP]GYY<'SK'XJ
M"]XXG[KGK%_T3Y_DI]U65_PKJU8T_U$\?E^$D@01#1,8B@!#%*<AQ%1P*'*>
M4D9RC*55S0FWZLUMCNB</]6GDANEI-IF$<X+;1-9ZBJ73 "U_*]3RM3?FFS;
M<2U"'0_WZ'/*B0;Q58XE.Z-Z9%PWU$6[A"O'L9I>6@OWK;RTE5Z/(1V@[^_4
M\1;E7ON0T0&P!F>*+J2,K>GQ0XE;\7(1A8K/41Y C(,0(JF=!"&+8!I0'L4T
MPASMXU+,J'[_[!'!([YY6I_.\%8_P'5O]HUM,MD!.S/6M,-CJ@H<C4XN*VV<
MF.FLK$;[W(EK:)R8<UXPX_0"%WW4OP@NGIXU"]3IL&_73Z18+5C(42 R#FF(
M=)F=,-,;=JS^@QE*$Y&&=CG])D+GML@ZZQE^4/NN21\'O]>J6V<F&0R!X<?N
M&%C?/. "TQO[LO>#Y*5'^Q61K]BOO1^$_M[M _?>4*3]XWJUKF,65H]U4?AF
MZ[J@N<099PA&240A"J(<8AYCF"*:4IYPDMCE/O:+FQL55=KNBX1H1?\*Q!@_
MWP#*84!D%G !6:1/<&B(U3(M#F&F5F4Y";&,U"[<:G'F .=)5VQU)H%7D,V(
MW=T+ZIG2:\2ZFNZ[MC;*7@]+&%<P?Q 5EW7SKPN;OGS^H.$7J^@/WW5[,?V%
M) %+@DQ 'C/%SZG:X.6Q#& 8A#G%-$E$9E67I/OPN;'Q!T>E\1=!$(@D4% 1
MD>IBX+F A L)18:2 "%,22#LZ-8:MDG)]1BX.]UY9[GCFC':;B15#["U84V[
MBYBR/)51$J<PESIN26UC((E%#CE'5%+"U*L8V\0MC7X1)XA3^J9E=#HUK-9;
MVRXN1]B9S4QC$?$\#QVW8?#39<%UA$'WT:_60>%J3,&E:\9-%?>,[9YV2TTQ
MU91TH6NX[O"^;VBOOM( Q4D$A0QBB!C2C8/S&&**\RR/1$:H5;*SI?RY33@=
M]<&Z[M[4-4 Q0%DV,:!A9AD$:CLT9ASA$7#/--+%NE[:'NF^7]MJ]?]:!3;J
MHQAE@SO&&0F>(U*RE3XI;XV$YI3:QCYF;!V(IZ?UZLV2E.5]4^.?Y22@0:B6
M>E*WGD.8P#Q* ACC.!9!FD4(6;DSSD7,C<-J#9OJFC^MUN"9-"FUEH1U 4TS
M3KH-(\^TT\!3:0?N?71!N&J]L\H#9P(FKA]PS<#S*@!7KQQ[I"*+E>"_B)7Z
M8:NCK:M<S,I%6OY6ZA29)=-TH[8ZBE-JKVG!FNO?K,NMWI'K7)IVS?5%;'>;
MU:=5'=&SR/(\PF$4PDP&NB,+R2')U/:&BE1R0F,D1&YW'.-7X;F13ZLMV%1J
MZH0[77<9D#KA6ZXWE6^5UO:IU55IFS+I_14P/0Z:S\!Z/TJJ3 6-[E7>R1WH
MF NTO:!C<+58:TW>WZ>-O@/[-^2PC:Q3,W7!T?:=T2*:X$V7AU/3#)FS@RW/
MZDY\*#8-^.<':A/)';E?KQ[2=O3%"<MXAKA:HM(,(L(E))R&,")9$G/,:, "
M&Y?:T=/GZ5-K_9&D_V,W ,]POSP6$M^[X292W7GGXXL&N]K!'CU[VOWI);/.
M=I\7+QKWI:K=J2@_DQ<=VMV^<D'.2! )!FE*B3Z+01#3*(.!X%E,$YR$$;=9
M+5Z0,;<%7N.5V6I-U<ZR4K7UB"'+#>8E2,V^XAN!\OPM5]J!1CT/GW2/]8X^
M[$L2)OV\>TP\_<C[+K7[U)?+E_H@]^'I:;=:+]>/+XW?(PD201*:0)%C"A'.
MU2>?J_]DDHA$Y 0)&IA\Z%<ES.TSKQVRQ5Y+LP_[.H#]G[436#Q_U#4B!P6'
M/4>&T/ UJX*]J@AQOQ =B9H.JMN9;]#ZFO?49167A5$<5GQV_;Y)V&Q0[9;+
MAB^T8S(NBL6[U;;8OGQ](LMEFZ&P(#F*LS 0,.!A!%$N$X@Y2B -XAB'1$8T
M,8HVOO+\N;%8K2*H= 2MDF;?ZS4$^XG, 2Z>:<P.$N,/=,#PGNY_ZLYZ1:)^
M."Q$KCUODL]VP)CVHQVZ;-P^0U= K9*!?E$40,K=IDH7^H6417G_9U$N\BA*
MN%Z $!''$&4"0X*D_J+C-,@CA/+,JO;'@+RY?=(='4&E)/A=JVF9%S $LMDN
MQ"%TGK]Z:]2L]R2&6#C:GPQ)FW2O8FCZZ;[%]+:1545T+K)ZF"Y3^J2#4$\3
M$']Y.5RB=D_Z5_=_D$W3IJ]NW_?0Y!TLDEP(FN@NOPE'4*TA**0I26&. A0E
M24YU-Q6;LB(NM9L;1=4Z@J+N@EFL=&ZX3K<9WW74Z5B:<=NKC9!G)JS4@Y76
MH&O949<#^@*ZUS7F@<J^MI%IV^54#6IMI,.J(3ZP=U4VQ*ENT]8-\0'K6>$0
M+T)N"8>J H'V.:WJP96DMTV&]"),>"I2B6 <)Q0BE&%((ZJ9/J<BYBD*8FP?
M(-4O=&Z,?90]OD\>/]3TJ*A[5W9^,RJ4:F DS(C9-;Z>^;8;C78']AI7.:@U
MDZK?#F7KCXS!,@/):536@,A7B-,R ^%RY);AO2,WNM<+*^FBK6DF),%Q .,J
M0S)0ZTZ2TAPR+L,@2G&8!]SF++Q?W-P.Q]^0S>9%1]+4)0;[Z[J.@==PA^L,
M-,\T,U0 SFE97#-47&UU^X5-N],U,OQLHVMVE_U9W5>Q*M8;??9<OMV)7\E+
M%"3!_8I_5:94WO,H2(/FE"7D08I9$$"F5C00Z6TLEHA!25$49$&.<89,3_ L
MY,YMI5.K#BK=@5(>*.V!5K^J([TW &@+S ^V; 9B^"30$[R^-Y97D;T_0W;$
MV:$-Q.8GBIZ@GNB<T09R-V>0(_#J.9FT>=IDYY4C3.R>8HZY_<:#DGHJ:7RH
M_)-NZ+3;;-3BJ?*E'JKERHAS)I(8HDA6!=%22$..84B3+!6(,)):I0+9*C"[
MN:!;0%?WW:N,4:LGN=X\-942!V*PW0R,Y6F+![A]KT[WZ+:(@E9]'>V^-Z ]
MF_%8D7@LBJX/;DS%O\Y)CB4X5X]V;)\SLFW<T_-R_2+$5['Y43!QV07Y<;WZ
M(<JMX)6WL:RBK[M_UZ'NBK;_+K:'AGB+D(J0YX$FRA1!E*<YQ+G(M)M0I"0+
MJ.!6U>F\:3HW;FV"V[L'##K721>. "]B"S9[S2T;QGD;:C,2GL4 3GA$M#_Z
M.3CP[\#>OO9$2!NDEZ'5T!YLNG/>B\,[_*XZPWG3<]K^<+[A/NL2YUW@V+S;
M3?&C;M:M9S3U]*KV>=-$!Z4!9S2*H909@RA%!)(DD% @1%$2LY!G1M'11M+F
MQO0'9>L<ICO-\75E^#'EW_N1-B-I9_AY)MH.=/<U=*VJSHG3"!)GB9M]LB;.
MNC0P^SQETN0FQTTGWQ8E6Z[U,KG3S"@)4(A("D4<$(AP+"#!:C$JLBR5(J=I
MR*V:&=D(GQO-''5*W"ONJ$GB)?#-J,87I)Z9I[>)(CCHKK;B/C;A8U#SW6?Q
MDNAY]%WL <6X#V/?,QPSV3?UO*:R.$F19"G/8!YRIF.U$XC3K%HG94+@G&:Y
M5=BD@<RY\M:5=J5:\9&UW4T&X$82&P>K9^ZJZF;4!]W?CHZY/=1SMT#&-S]U
M),Z#ELXA,&:C"[?:GW[?)TE[S*)0S)JS/QS3/&64P20*8[5F"A)(,YG"+)<X
M5-<QGAIY[*Y*F!O!)#\G_US78P5\)X!6U/Q4]3*&PT?4-R/CF2,J4 [GHEK'
M$6?.E]$Q/UV^&:6)SI$OH.7FN+@7@)Z#X<OW378$W*MV]["W_T(777,^%"OQ
ML!5/Y0+CG*,P#J",LQ0BR4.($Q+"+$!YFO$\$#E>_! ;NA[7*F<OR>8%[<KS
MZ2<YZN4"?M>Z@DK9F_KA',#- \DSDF8PQ+F B,0QI"A%,$O#($TC&=+ JJB\
M VA?H?&0!V!-'78WP^7=53<"J1O;!YWAX*5CT$'**S8).C.UOR_0^>7.6LNJ
M96JUF;AG:K%:5CU.[ZF22YBI]]GNH3-ZQR_U"JWVJ_7NJJ,\^+U5W^'+/PXW
M?UT^^X2_=A=/ V ,NG2:/&5DCZVV#<P'0=0L5A!:+(OMRX(%DJBIE,",5WFT
MC$(<91C*+,TCD@E.96BWB+DB:7Z+F.J8TK*]TQ44S7C( 3*>"6>O(:A4O -[
M)1WV<>I'P54#IRM2INW<U&_J6<NF@<O'??F_??W;6GU0JRJO\U&L6*&V1VKR
M_JHCOQ3%B++91DN41#(.U1J;2 (1XA02Q&/((Q1E+*,!QE:^85/!<UN#__;S
MUY_!XU[U:L(E6O\74.Y5M^,-XS$P(Q(?R'IFEM^^@H/.H%6ZZM<##FI[*'YO
MBY4C_C$6.RDAV8)QRE#6]]L[D=^O-Z)X7-5U$]G+6[%:/^G5D>!:4/.94)2$
M5$0,"MVH&/$T@CB/(_7/E"8ISB261BGBI@+G1E&-SJ!5&G2T[N^!-0[O8?^S
M:Q0]T]$@@".<TT9(FONJ72,ZD>O: ;)6'FT;F'H<W$:/F<S?;6-4U_UM==_(
MUI]J.;2(TS@,::@6B%FDEHIQ3"%-XAA&641#$;(X(G8M/]5#Y\:Q6B?+AHH:
M&K,5G*W!GNFPUU;[MHD=XURU2]2/G+9-8L>(L_:(W;^YK(;VZ;GQ CTH'5<Z
MX%&?U)>?U\N"O2Q2R644!A$,XX!!)"C1/6,Q%"P,8RG"E(96Z8(C=)C;1UIG
M1M"SXEEWH#:CVKSM#:DB?BRW;F,&RHP#/,/OF3(&<E+ [[7&?G(&;X#.:]6Q
M?@UF4%O,""*S"F)FCQI;B>=/79I#-W9XOUOQUCL2RU2(((RA9*%:=D2* '%&
M$LADIGX1!Y&45KW0+HN9&\>]%3_$<OVLOK,GLOF'??+S92S-..IVA'QOY+2"
M;6?62D4//J1^%)R5U;DH9.)R.GV&GI?1Z;W:>1&N^R?=(OY_*_;1/;!6I?B[
M()MO?ZP7,J(\)B* J=#%=% 80HJ2 $8R)R*-4HXCHV(Z-VDQ-^)0KQAR5J*K
M!WQ3*O$,J7>FZ2GHU>DBV#7F#F@[@#)DDEI?PSCZ+P'6H\-<*H,-PV11,,S@
M8:XZRS:] I70YI?E9U+P!0N"%&$>PSRDH5H510*2("<P8X&0E(J(I.%B)1ZU
M&\B,_4Q%&WV=>?UU=A7P&#'3: >>E7JWMG&]@K<9W3G%\#7;JG8ZG]Z!/;Z?
M^_!UT BU'RQO#4VOB'WEQJ3]8 PW&!VX?V0MY^]ZK_^PNF=,I^$6J\=WY;9X
M(IHGVV#3.$LPBG$(6:S/Z42,89Z%"20R3!$)&$>I56L0 YES6X35*NNB[ >E
M0:OU#?&])O";,95C4#V3E ,\[8LWFR/DJG:S@<1I2S>;0W!6N=GBUM%+);'9
M"/Z-_+FOXKJ/$8Y)FM,H4^NA" F( A$I^I$42D["-)()3VQK@5P7-C?R:775
MW5&;AL;_9KTJN@ZM\4K("6#^5S\U5DK/;I5F+Z'5)IBX6^1<%S7UPF;0Z N+
MF>%[1G8Z9VSWI!NMZ]/QTR53><__>U=N]5&&;L*^*=:;I@32PXHM=URQV&>]
M\5NO[K?;34%W6UTA\=OZHX)BO=HJ6)3D1[59%.H=;8,_6(98@'2R6$(#B*@@
M,)<D@UF8RC"BB*3(BHHFMV!N_%99!<K:+$";Q>T=6-G6II_^73#CSEF/L&="
M[M@.+FU-2W"POV;J^G5H, ![$$"# NC" +9K< P$:)'P<(+P:N/H:!*97O])
M9Z97&Y[3Z>[U%!DWARK!&YVL\%;4__NPJIH&[S,9ZCE[03,:TR0@D.8\@4AF
M"<1Y%, T#],P0WE"663GHC03/#\'9=V)NEZ*_^6?<!1&__Y3T=CR5]WHJ?K)
M;O(R' 2S&<<AL--,$ZW"X*=6Y;]J[T -]"&A::!NN#6CV^'DB(8-A4[*G79
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ME,^&@'3,<8.>U8_WS.'B@ZG]9TZPUKQ,,-(BZ%^\R:58FK*K1")-92F *4H
MY#$#A,D0B"B)8IRD$8S3YLS/CN:NCMGCD&]D5ON+MF5-T62V*[3]:\J15Y*Z
M,=UUL.UHS0^ $Y4.4JHN]EE)7=;\-#N X+GP-^4?*OG+,[Z=SPAP:\0\\=;U
M\28E*6OUCQG)_L8>;;7T0W9;;<S]=<.*6[Z]VZQ,">HZ2.;M3NX+VZ%,*B$(
M!313 D#)E;:SPAB$%(4QC%4:4JN02*=1YV98Q6&$JH*Y?!L8J<T_'!I46:/=
MS4&C83@R#Y7LLML&6NK B&U@O-GC>-,$$MX$6GSG6HQN #OT!QL#Z*FZASD
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M2Q0],^0+)XA>!N%Z8FC'O?T8Z)M^@3;Y=OE_4I0G+T6Q,Z>^38HC0RI-4HI
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M^]3KU?M)7S:_)6LJY(& Y2O]W5'40F7#(FC!*:!B+A/=3H$VP>I0BC1X6KW
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M^&/YFO[RWT=2VNQ=RI"E960I5VT'<EIY6A*3TE&V>8'W*"F'(>KEI&:[T<%
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MG\U-\Y?E+/W]?#8AH2^JG5S^O!:-4<Y3&,C!&?I%:18A1B-!1#*:Q;H016N
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M\?AYCN1G:\__9*D/("GQ9G9Q,5X_<UJU8YLNQ],SG"9B:E28""EA %>'DJM
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MVMD?X\7(LF!-H2!6*(:@4E 0G5 @M'$N:)Y"\YF4>PD:"):.T/1#H#E9[ /
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MM^Z@TX3PTV>[7ROM.V[I:M?>"DF*() \4_2VMF<H0+^M,@I>9DL,YM9S(IY
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M-2"+7OF^<B^+$B:'6*"H5/F,&8)B!IPF"1OE.6VXQN [@LS#</C2<OQ=ZVL
MD+Q^2'5W:QDA"_<D*-I9')26%#X+U" =\U)KQEENG?QZB);#P/72$OI-)#\
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M'>>B%%U !%-'O95:W64U9&);I>RD;MZ9I<,Y\#? OEYD_8!S>?="(A:K"_/
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M;>O5&0J[T,P@8]G/N!S/5\UL-G[P\2'M@Y]J,0#Z$"H;!;BW$AMU4L/5VCM
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M=78W>*0S0W8"?@Z*8CI2W0!.5/(;-M.Z-V;Y<GD0YW>XEIJA3"Q!QOK4J [
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M<! 5DP];T-<_O](WUGE [9AE%&O;$LE%2MK64C\!NCZ^9$H;7@ZZY'M*YO0
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MI'IG7<IZV.!97Q&-,G-26^M!*$SU36L$GS)Y"UQK'T6*@LO3P;->K.=RF_[
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MMP^^[#DN:X>MM*L+VAR801XUE&!L5=L:8F$!R%(L008T[<<-_ZP7M"8K49.
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M_DX(.:PX?P=Q]83%+:7@,9B (C,HH2:"FL1K-\ $7&!6,GBNTVC(>^'%^;N
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M 71UXD&V ,)#(&LEE0Z0]G&Q7(OF>C[]PQ/"-9/.9.G &4-+8[6,5PH'R&-
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M8;#)1A:YR,&U-@GWI_;EW[6T0>\SR7OZAK<'+/C(%AEY2 P4JPF)3#,RF5D
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M#*V+D_:EL:MS=3#P':N<[L#W/GQ?GQT3JWW.ALS+&)!$%EP 'X2$XEUV E-
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M]'D_8X%O7^6<$?A>%'KG#9.TA'QQM06 TF38*F+2&Q*KSRIP[I4GQWTD!/Y
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MV >S#^;0CJ+^#JR,*\JOYSZ3WZIU\AHDMQJ4EQE<* &8CBI;DQUGJ;5M>Y>
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MN9@N\S3=,>ELYMXQC[0":J,^39+RA'THP=,/E,FY^5'V#$F=9#"T!%)+)72
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MZ%A\/.'C7OX.A<(M;8Q/K.,.3(=;:59V/M+?6D^?DL2!<T$!EU'7GKN\<I'
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M\#%"<4-3*7:PPOS/90G?AV5=@__$\ZN+^N,_?TN_Y/C)N^0L+Z ->7R5K("
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M$4YEEWCKR03C$&5?)Z+::&#T#00/1KP_6_.Z_D9]B6&%__EO_P=02P,$%
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MY.1]!/=&>[!(*L5]<@HA[!_2CGW'%-6=8!7<TU9:55$VQY@MB!M:Y@Q_XI%
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M!1UNB; 8EQ:O!H4N\JP,N'<<M15*CA1!K<G!ASPM9N:HSRFL78B%Y&"$K":
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M@8?-3<&NX?BG0WL73$"B#BG5PKKYQDATG$/!;%VF9T0W"#;3PZ6L.;0V0<]
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MY?YEQ;!?_SOVWQ7>:J/%N&,ZZ)-Q'?3!I$Q7\+]9,\]__O]02P,$%     @
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M0/W4<?1)SW6:Z3JFNL4C.#%N2(N.=36OI9BQX$^W_I#;SN=;-AM@LVVMP=^
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MDRJ;P#G =KD$$RPL+Y?1#GRXG&4@*1(0BP./[<I9?P7P\AO"CASL/5Y']1=
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M,8O[!$TR(:P="01*]])QFB8B5BT<O6JDC D=J#;/+TN*7U^*N1R2N9[DTI6
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MCX459@7%.*&HWE3MI/7 ,[-:+$,>&2)"'<L=R2I* V6BNX[C=V_ OW(:ORD
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MLJW0LO8GU=P*+,\+ZM?Q=M+KH/_7FBP:Z<KJ$/&/KL.JR17Z=14 [?@%MD
MQ SPA1$/9UF@HATH6X$WESM1'0D)G=2F9#Q#)*4-L<!\CB>D?L_R\WBFS(&Y
MB>/%%9SBC%F[QA0CQ?Y=3$S%Z(8^OOIP^$_N"L(B V,"GS/G&)*9U>Z'.[RK
MD)\%M80CGES4P&*>^X%3FCF$T_/,-)9<@]K 1WOBBT2]BMZTH!=!QM)D'G9_
MS'C W9[(R]62*I%DWL% I4EGX/Q72I;K#IIUL&[F)5DWJ !>P084BO !/B%<
M9:;%0CAR6&/'-I'[RMK-%]BSZR)^KU<5XE>*UL&SNZ()\V\+VU(2@'7W)^+9
MB6E.VA)K>\W^UM/Q*II!EHY%4H)&U+"QWVL2[9FKUBCUVTP)!3TU/A0%?(LI
ME_YU"A_%JL-%F<(1/ 2T2CTP 0\^D&3/4N=P6CO[![O1'/9U!K;^'%D-+L[1
M9\GSTD:,!+WCG%?N],AQ?]SN  PMREJN*)2Y(H7Y*^;(W;*L\G2)_6*2&]+%
M"0;-2<%87\"MD6Q]*D!;#S!WCABXOE,S1N7 'V5URNTJ*CW+$-.%\PO4*T>H
ME 7/UHD]J O&?6SS1C%R>F=@M.G58\P7ILB8:RU>D66?L6=U_S.BL##3JX5*
MJ):T*>D(HAVU:YKM:O;CMX494ICQ?%N8<3,*,S82#C\:R LKIE<B$,F817=4
M5<D,8X_ EN6"TX[ Q6#-LM7-$Y6HCMN;1X^5VN8RK]E9W'=F;%)CICM.D>[!
MV?52<B7#M ?N,;8N6H3FF?64""A:'&_84L:?[T.(DW#LX8)U.(A610,J#A,B
M6-H]Z8H>V312O$[.29BB9A74T+A4 WK2Z*X&[S_P(B;Z#=$SXXKF]:"^QH/*
M0/#'45NATDD1>YQB@WB0,5.$/J6,>"'.E0-4LD8$>E"#)@M^NQO4/)KN[K*J
M$9AT$OP]P9P7FA^82<>>MM@1$%] (\OJV%. -;-'-[*#U\"IE'.Z'$S:5)Y(
ML,I5IX]!2(U(9CDS-F0T]%H<G'1+#>"@S(0.ODG@KZ.R4AQ7_ H#M+\,=*,-
M,@K>*QM IHHY=N_/9J:XVYK;<J2.^S5BFWJ,99YOS*D)@3?@TE "HB;4V95K
M].4-_6OM]FFC]5PFEUX/> H_FQ4,#NXV6N+6\3ZXP\AJ+AFV8.A9E=Y'WEA)
M)W5B ,Z&0=XX.B)%U1I=CJ0KA\V!V8>"H<FP<ACDP4'+?.&?)2PC7]WPT_BM
M!WDPM&W6"5MO+!NH"0K4B]5\M,N%YVJN?0B*1'Y"DUC;(C'E$GQ @8,%#@%W
ML*_E"A^RV1<HS;*,=L EQ,ENH4>X0(<YO9!'R!J9!E^1U"<3+;;-9-3,)?8;
M*8HB8Y/ U)</O;7<\]6N0'ZQC<$%_9Z9L>:GK_FG+/3]:O;*"1O_5ILMZ(V\
MI&VEMM?NZ"\8C.VE;.%2<M!,=DIZX>E![0*EZ,%_&HS]13L!/9NO3$>5Z[C:
MM2WN=KCE;[N>9CJ7<BH6$W;<6E1E]6D_1I%GIT@%7 \"FP3NMIK !Q3!K6QS
M&2\0UU?IIO:7-1J^6"N\HZC+<A2S1D\305",K4H(IG)V-#L.4><6!)?,0)8(
M,$KMYT1H)P(^6F/7)D[\I,TP<*H]^Q?WP=[>H4&Z*#/F37MKKVD SLQV(@Y
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M<K.Z,X"&Y*\4</&!^V%/4[(50D88+;>C@LB.6PL1@8-G(H(QP;,1NMB5*$%
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MT3LKD 1U>(QQ)![(A1[3NPUWN1@'R[2"@U,2F\'5.'DXF%X-C(-A79J"3CO
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MHF[*Y#1:Y%0W93OFRJI?N&2GJ@=@BNX%@I&<%UV^^9U!9N)11#E-%7,[*"]
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MGJ0J5U%<E/.B5"@41]$BK:=16E?1O$SS.)VK#)@);DX5I?:6>9&EU<@.8"9
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MBT7KQC\[0C@X9&*H83IU8IXL/Q_03X_JI/O;B\<'AR?/!W\^/#@:_&W5L"=
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M;J6.=3RH8_76 &_]L8#M*^"U2'%159&#C;@$<E0QVL&HXDR*# @/.1$Q#6
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MB3_L1U*(ZPC?I,:KLL1'SB33#WM]W%[K>#,/VC8ED#[XZ>VDS2"Q>K_.3+D
M9=8+T*>P+A5CMC]R;+ITR?S9[&P8F^ASU4KTUCE8?->-,-!2"WP?N>Q]PW6P
M?0?AAZJ$$R"P0XL_YVL2.8H#C0N<H@M";WIB;Y>']\G@.?VD:S@@M/1W/3P^
M[+=\,V#F]I:*&6>,3VK*-2CQNI*PFPA.>EZ((H8^)L$GJ-(O0&Y[3P_W*<5Q
MU$H\6F^=WU[>^I<]CWX3)52EJJ#)EN4_(/;WTOV--W$S6\2>$"[ \*?"JK2I
M;4&/5JVI4BPO\H=_4MXE(JDDR _QBMCON^SILO8%#E^<.ATST;8QX/O_CEZ;
M0?SFS6&KKY;^G!3:6H>BVKNL4 <M$/L.>U=_YZ)NHI28B?UV\.D GD/)"&CC
M7PA><^7YS>E%SMZ>N7:%)!B&]@5G@;A)>YY?=DR=!<4W9OVH^.$;^E+WS0.U
M*K.4G',.MKV_5E9_01A-EG;V_2L-HDBT1%2H*M8Q5R_N\"FPXP:7?+(/<<O<
M>U@]_<#-D.L0O3*^KYR<LY $FMSSL_I[C:U:4,*;'0EZQ"#?"]DA<$O@E?N"
M5*KR'#29LB+(K:&DK]ZE&3F0>=^"ZRU9ELK"X/J@:XR5KGMJ_WX #@SKNU?B
MR5=@RM<O66W0X J.A'5L?X@A ZWF2>O>3KPBR"DQK')_9!E-WRH)5;9>==V;
MALQID$3DW.]_9X;A$^3@W#;D(P'#/MK_+KR%U^UX0^YRUUG%<#+J*=, 9S-.
MD*4:"\0O(PQ,R2>C-?;T9/(-7N$&.OL^^(G=.7*XL5$&^9Y,#INH*D:_02W)
MY?V338OZ&Y(D:4V<4.'DE-ZWADW 9M>@_?AN! 4JC#+IW30=":+*M]1%N:W)
MH=N8(5=M 4-/@I_-;QRFC?L66GRZ"RW>HM#BMO+BX48/IQZ8[!70& D?HTZS
M4 LR)-\NHFZQ\I#\);5^ L8R:'H"B3'R^[$6:$J@,X]<><@7@R[*AL=XV!G(
M-R5=U7!.\G$R]Y2D##4#CD0* MUN]:LAH_,7E9;1KYRS\J\> W3CO W7H8E!
M/(RAU*<OLVF1)T'&BW=/:RBU9K!X57/INW'6A_LOM!/6:#W)T OUM)%OOOHQ
M)3+QW$&A[NY"+IY/>M(2K'?2H?QT<)4_XM5M/,H[?N9N"[+D^R+LQ45;=8/U
M5;UBV_HI1>L,E%%40!$%V!XRY<.DNPX[+)T8KA5EFS29ZGU@6HD-PB#7PLXQ
M_Y#T[R00([KMH;C[986W!6423O=Y"6O&&%L=@#T^,K_EE8ZQ[]C!39S[*'HO
ME36]P<]<8NO*EM?TJE*#,5-R)94-G]$888HU);PV56T@$#_#01+J(R)JU[5[
M@6(K 8V*5%C[T]<N5D])Y8BDQDL>Q9E*9T&C[@N=ZQ*+;BH@P<HYAJY4UW:[
M1.>S07+Z4!;3=,QE3J>R2.?">+X6=/MD&[* @M.FUITUPX#SY&\_/'[VJBCY
M]'G%(7S:T-$@D'(^>Y:<97)5) U7F&,?0?CIHH'[L-^?G#.,&77<=%):J@9U
M.DQ\H]($ S/J*M@SM:!70)V1@!BH4RK6*(P;/XDMYS*95OYV6)?41U= N0XV
MT;P_E[*-0(AEV2B:@QSST^P)GZO'?T1K2B64B)PSI=>NIMJX;ZS+!],E>.F=
M?6@K*DMK;TA:14LXCJ2P<LFB6-7HFN*J0U-^!_-6Z-#G>0?.+LM$$,?U;C*#
MY\-Z-#5 KE*!",&0YKGZLAY]_Y8K&\.J]$=] ;1 Z/TBRT1,6G>081>4&<=1
M"?B@/FM&NL34I;F)\DC9*$40X@+SV]07'_AYHC%N#/1$+&(DX*AXFC&83T%O
MN&,??B]BK!-'Z$Q*KL-VV,NR@('A]U$T0<>#-A5N%7]IB*9@ =_D'BX&SH.\
MF>@&!W*I[*>!*@]TC*1Q.E=&9R"O Q4PYHC,?F&P90V3:D783%(!G"[6C^%1
M;_'!0;3>!>3BSWFQ(&*M7$"KR4#-)CR55'DG%M>W,R[%D:C+^ QE7.]+E>'I
MI^8SP)B0MVM.;1#W#9R!AEX0=WBJL["]DG\21.LQ[S%I2EKO[OLX]V)PD# <
M-X/#A#''4L]AAMBEEE,=R!^68..,SY2O6=)9-0$FUS!"#F[/DO2DRU/&'1U8
MW]_5;M]^09URY(H^^X:W[U(01==>:+DO+@ :0#Z -HL/OI!$]]R^$\F3/N^3
M-_.>VUQO++/@* ["YTF6(@+']>J=K/#;J&522)H+>AB9V!,RYUB,P?858^!Y
M-BD$568X125;FNAVM(JH+&XYM!FLPA"R!R(P"2B.[CW2(65TCP ^)9ZF^E(S
M. >1=9,IPQ(P[1+!S?G<SHJ2\3P"Q40C*PO"V;U'#6_F6#G"MOW1E&F5I%ZM
MQ6I:M^F@ QQWC_!HRQG\*;'ALM61=M]H&3Z<-1$PF/&\$,P5^U=JY1O<];CJ
ML#7^P???^_Q>?6%(:#Y)9ITIZ??2A W]=L'^$6 =#!WP")^ [$\E6#F*EJ7+
M]X8CYX-EPQS6".5";ECVBXCK<ZIL;^W.NE2:(5]5;^IB-P;BLVI+SP8+OMJ$
MD$<B0=/2:$XX&W6!^SW"/FN[**U$:9_MHK2W*$H[Q!*^,P-@R@I:C'E<$>T3
MIZ7TR\'Q,F#FMK$@L0+1C_NX1:]V1BCR9H2V[K)0%^PU$/A$?$"0O=SWF!8(
MV "7N==%FE_%Z9U_K)VG@VIORZ=4 <.'^2X8W*% E)6RR72(?/,4"^1$KS5
M#8C&-R@]5DKWM7*C]^1C(Q>K M[$01QQ/QA6:FP*N;%&3(\^RB&7N!"UY?/2
MUP++8"_$CK)O,-:@44W8)NE'Q&<P+GJ9MKECML "6I%;C=<B_$T%=G6?OBW)
M=DY90\ ,CG=332/F/Y3%9TV=-HL23:>)>2*M"J\%MVY%A3#A3(7N)L*3T&RO
MN(F(W#ZB;CGV8G>NG=>2K,\>CT6_%3CR-Q9[Y3!^$W'2F@$388$HJ\7GFKU
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M_'TXCQ>#YU&B62X<1H:A=)<12^6;G5FC0ZBJA4X(AY0TE:X/DV=3V18>8?S
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MJQV,0>;EF""![J0Y^WW(A*&;[J.[9+B"9ALH=*WT_B25$=^TJ]R5F8IOB/N
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M'[0+@;.ML,X4.ZO28ABPTX[%B.M@AW=PD\ZCC#'2SMPK:N$UM>63/?@UY/D
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MH1E*?09B1!3Y0U, Z8U7+8%9S")8!+#,TFHJ,.8&S;\#S./GAC#4C_+1>^X
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MDYP9EV.&//GMBU32Y:;% G>Y'>:E"K:JHAR\\5(J>O*@MH!3>&)3<=;W")G
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MU2DMC5XZFTD[@=T;F:(PL],CX,.=LH6.9-*7B9ZDI[0[?-MMZO[1X&"?]K4
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MTLIKSX54%B7LGAFW6(@_S0CVI'J\<^,&XMNP$OL;:27>!';YPMOE'HCG3,7
M_![M#: NE](0-^0(V0VE?#5_6#/RZ>)QLK]!XB$[Q>,\!_.7HOE@!X^P)#0*
ME4:9$02\] CA%P=?0$7?JHA>/&#SUF;=IK+P%G)550.32_:!L8A!:R<D&+Y$
M8R!+8]0C.VL)<;ZR=P0^P&S .U,)QBF*4,GA JQL3(91@W#I%$B>\2+A!MC3
M% G:K@ (6$D8\-Q/V0!)Q)6Y2F#J[>'^CI@!RZ> >&8HR? P4#PV"2S?>P&%
M5J?-,@7+W6:,DSA+:L%?F70GA'@KOJ3&1S4OYL P--<BUA;V@ID'0N=^ZPE8
ML!1S8Y-XCAYF)',$9[61)=?&%KY>1&TCVU'W??5@N/=D@Q1!=RH"YC9QF\$H
MQ7<Z5ST!DP&#>L@)(7,2QPDY6>?C%/(9E:=,"C!L_#)<(F<SAR$JGTX^T@EJ
MCS@N&.)KW,!DT7^K**^+9E)F,@)?V0/Y)<:+;;E# ZQX4][ &,<#9PS14C3M
MB5C!@":;$:$P?UQ&C-MS\/E$7JQ1ID:E=^S2/X8W'94(B3QYK)5X#[P\+A24
M"60LU[ ] *1 S8BZU3&ZZ"(B +%,4J('V%R.@<?@RV-/,OZ4FR1N$HP(:A'8
M!]&BLT=/*;+8'G4PC>Q(O4.\3I O4ID*@+C+RP9I=<)/#S(V3"^Z%>.RU:K@
M]F@0U)XH+2I)C""S0.'&[>NQ'*A;9"9?\E:FB@')&B(B;;6\>'<'7U69(O:@
MIA46Y,18T"&0Q<;O%;3KW ^W7'++$#\2N#BU*I$HXYU5!;=]>_4K<@0K!UE<
M>>5K9\L/#P8@0U\G6[[$Q.$1"6I[!GTDH]N)-64:]YWTCND_+_ZG>YA8WUJ?
MNNE*-(?_3FV=M)^H_@C\YVU?C@ME3V4RA_ANZV-K2??6O0LY&UDM/R^#3UF:
M*^]+OD"F]LM1=4E:^/#$7"-"V4>S<73_M-^GF>(',KR9M$6JT(15;HX-FC6W
M=+D&&#D[\1R\:H:.-2W(=N$S90XKH\<AR(J=A<RR1,,UAM(^>>$<8AV)5]YM
MQ0P#F ;44YM6-I9 SE1G!(KK09I1/%IE&.CC$?\J"> ^,#NJ4XX!E+9-,O!]
M<C8A3PC7]-8-:PBW1!*B@(13FK&5<TPZLO=* -P4[/"(=[#-L$F ^F,]7KB4
M1S1US/PIKWET+WJ^*(XX>;A<=A#H1;>IF2<JGKB$2QCYU77)>@,TX6E&7 K3
M.=K&?=2%!421J1H#M)#6127P;)7J[KFTT4SB@P#J '1'R[C0;T\U'4!V3=*/
M/0XEH%9^\$\#!"2+1\G[YYA?*RW $I6WL2E(JZ\+,WPR?J: EL\+]!Z0&=OG
M.Q2]YIB?1.3I8I/(K1*OC<N4\Q2@TLNI1XB-;Q4'^>N45#AA+H#V,.-;S(W8
MWM\1"XAUFCD!L $@G1^1$^  9OO7'0>7*>_;<Y$]QI>J(IH0=JHY@@(_R=T\
M+2MV8U[PF#XD(S4-H[(UKU[RJ^Q]@ME,D%,-A[H?05=ND7/T?VC,JV>WU?M(
M96&^!_4='J0X7&0RS]G7@/<K:)HR0X.^_W>?D<[*$80GL ,0(G":*(+]PFS&
M#L\.J__QA\.3,XP5G^\$#G*]S. C;+V )/!,F%BR.K]=SD\E^A;W?V[*! -T
M=:<1QBY$F2L7TD8)J"Z3A]19+ D&1'6FKM9Z$;%L%B)0 \HF: ST750/XEAM
M&_KX&> +G4'H MJN<W2MZ %3CHIS-4$.(Z(P,\JV,R<D\ &33BN9 I3T:G@?
M\&%@&"4EJ0(6#U=(A_%AM*DKMC2M&6>X,FNX2ZKF\M@"]ABING!#GJ!'^HP7
M4:&14R N.2W;I(E+ ?BE\DJ#A2+)Y#U:F$5O F7W7W?'1O7J!&8 G7A@D&J3
MW'%>Y\-Y(N:6ZLH !<D5-V>N.1^"REQI"R=OW (;R8_&[0^LZE$ZT@#$@$%T
MA? :SM1HAIF#O*Y3J1-E)E9FH! BCTRFZC2J51.#LE.5HW%[.<-+60(<-E68
MJ$:<,X'Y013ES*"0DATB70"MP%F#1. (,:7?<2ZND+[6RXC(YL#/"7"A)=V"
MZE>KW<XGF""DO3U#5KM*4LT[;8M2<FO!8HZFLS*^E*$C/6/&Z9P610H*L7O@
MB_'A)LVN7%J 2W0QP<H:.HD?B)>L,* E:6A+[K1):/ @&][:5T")*$GU7%R1
M3GN."$ $S!\R5Q(".9PRHO4C5GWOP.YH08,G*IU@8G7<P!,KT$127P53YS.V
M'Z#PL>OANF B@%T@Z#;OJ/]V%Y7:C/%2+66D(G1U$!SHF:OMX(HA(N'!UBI&
M4Q1OU8)2H/!CF>IW93.S+N,[V"^ 2H.P:);D9CT/EG2:ZZ6=.=2/H)96#S^!
M=).4Z[1$9B-X23AY;DTYF9JRH)=':F%<+=[ =B+\K002:,FH8C40YVGHY=:M
M###&E*Q7 *24O%/K0GD8 J #3KTJ!;'"D!*;!,@<=8_"D,%[O$:F9*ETP$67
MO*LW(:B*%%/#TEF9,6]86Z8'6,-8$0S%%+0"7F (2<B-88$#D:JW##;Y38N"
MRK7-]OV^%RD>3ZQ3+N15%5)C?BK2ILR9M9R8]U=Z@"\Q>S,);#E:KU7XQ] 5
M1LQ5T+'!#C/OJBDONT%PCP8?L:IVM8O S09^HZE#WL=TJA'(X42S.:CWG7)=
M,+UK9(@-0&2T[G2D@FJH(L]4A&TTZ-I+!I=D[2E-O=YN42VJRROXDB^("\&)
MNFD& P"+<J^:G33(J[")!CG5[2B^0K5D;?;V>X;__U.&_^"OSO!O!JZIXHMQ
M:<F\K8DSM(O,)%8!2TIF.7C'&NXC.8U>CE/DF$<U:!'*- @TX.DR=7E2NC!V
M*5)^)@C,.1&.SIW2WZ[?EQ)<:++8G??"F >,C.R%[J0*@IRE61#5ED&ORSZM
MX-6>C[?;UM>.I6-,#*#+0^^&Z1U3.P0$+C"+BM>-.$5404]C&B8':SL>HUO(
MD).%ZS206$&)B&F)G+-/1X9JD#7PK3BWJX,0:.0HSH^$-ZKT-(!X(+$B%T::
M [D0@E@."P+OOQ0CACM70OA@EZA">+4@;UVP/P+CS[ZG@]MA%F Y;4PK8<3A
M?6;/41T4/:KW81DS>:L0O'R0S,<8DMPTF:/SJF#1$:H;KKJY5GT*\<%'PS6
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M+Y.B*\3CZ;=K@T$%N/9R\4[EB2EB3]CPF!'E,_#<0^$1$1*0LF(YVCST 6!
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MIZM7J)F KO4IP"ST 9"P0"FIO;SN;UIFVEC1:793M=2J]YC,IG;KJ+1V-4S
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M$?61_76"12.>T@FHZ+ZYV[= &'^<E+*GS^FC>I_\7?'U7[;^7@CX7@CX>H6
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M'_/44Z+NL%AS6FNC!#99CV)H[1FX;181/6]TDK0KJ*)WUE =GB?*R_!LS?>
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M &QL>2TR,#(R,3(S,2YX<V102P$"% ,4    " !74U96516WY-TV   ^-P(
M%               @ %-@P4 ;&QY+3(P,C(Q,C,Q7V-A;"YX;6Q02P$"% ,4
M    " !74U965XP[O*ZD  #4*@< %               @ %<N@4 ;&QY+3(P
M,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4    " !74U96("%$C[+K  "WD $ $P
M            @ $\7P8 ;&QY+3(P,C(Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    (
M %=35E9GA8;>6ZX! /-]$0 4              "  1]+!P!L;'DM,C R,C$R
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( %=35E8XN<W][/T  'J4"P 4
M      "  :SY" !L;'DM,C R,C$R,S%?<')E+GAM;%!+ 0(4 Q0    ( %=3
M5E:X A][]4,  #R^ 0 >              "  <KW"0!L;'DM,C R,C$R,S%X
M,3!K97AH:6)I=#$P,BYH=&U02P$"% ,4    " !74U963M4,[ Y!  !LJ@$
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M,2YH=&U02P$"% ,4    " !74U96>>T1 R,#  ":"   '0
M@ %4Y H ;&QY+3(P,C(Q,C,Q>#$P:V5X:&EB:70R,RYH=&U02P$"% ,4
M" !74U96_%P7C/@'    *   '@              @ &RYPH ;&QY+3(P,C(Q
M,C,Q>#$P:V5X:&EB:70S,3$N:'1M4$L! A0#%     @ 5U-65O*-))GW!P
MP2<  !X              ( !YN\* &QL>2TR,#(R,3(S,7@Q,&ME>&AI8FET
M,S$R+FAT;5!+ 0(4 Q0    ( %=35E:PA,"OSP0  ,H;   =
M  "  1GX"@!L;'DM,C R,C$R,S%X,3!K97AH:6)I=#,R+FAT;5!+!08
..$  0 &X$   C_0H    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
